-DOCSTART- -X- -X- O

Identification NN O O
of NN O O
APC2 NN O O
, NN O O
a NN O O
homologue NN O O
of NN O O
the NN O O
adenomatous NN O B-Disease
polyposis NN O I-Disease
coli NN O I-Disease
tumour NN O I-Disease
suppressor NN O O
. NN O O

The NN O O
adenomatous NN O B-Disease
polyposis NN O I-Disease
coli NN O I-Disease
( NN O I-Disease
APC NN O I-Disease
) NN O I-Disease
tumour NN O I-Disease
- NN O O
suppressor NN O O
protein NN O O
controls NN O O
the NN O O
Wnt NN O O
signalling NN O O
pathway NN O O
by NN O O
forming NN O O
a NN O O
complex NN O O
with NN O O
glycogen NN O O
synthase NN O O
kinase NN O O
3beta NN O O
( NN O O
GSK NN O O
- NN O O
3beta NN O O
) NN O O
, NN O O
axin NN O O
/ NN O O
conductin NN O O
and NN O O
betacatenin NN O O
. NN O O

Complex NN O O
formation NN O O
induces NN O O
the NN O O
rapid NN O O
degradation NN O O
of NN O O
betacatenin NN O O
. NN O O

In NN O O
colon NN O B-Disease
carcinoma NN O I-Disease
cells NN O O
, NN O O
loss NN O O
of NN O O
APC NN O O
leads NN O O
to NN O O
the NN O O
accumulation NN O O
of NN O O
betacatenin NN O O
in NN O O
the NN O O
nucleus NN O O
, NN O O
where NN O O
it NN O O
binds NN O O
to NN O O
and NN O O
activates NN O O
the NN O O
Tcf NN O O
- NN O O
4 NN O O
transcription NN O O
factor NN O O
( NN O O
reviewed NN O O
in NN O O
[ NN O O
1 NN O O
] NN O O
[ NN O O
2 NN O O
] NN O O
) NN O O
. NN O O

Here NN O O
, NN O O
we NN O O
report NN O O
the NN O O
identification NN O O
and NN O O
genomic NN O O
structure NN O O
of NN O O
APC NN O O
homologues NN O O
. NN O O

Mammalian NN O O
APC2 NN O O
, NN O O
which NN O O
closely NN O O
resembles NN O O
APC NN O O
in NN O O
overall NN O O
domain NN O O
structure NN O O
, NN O O
was NN O O
functionally NN O O
analyzed NN O O
and NN O O
shown NN O O
to NN O O
contain NN O O
two NN O O
SAMP NN O O
domains NN O O
, NN O O
both NN O O
of NN O O
which NN O O
are NN O O
required NN O O
for NN O O
binding NN O O
to NN O O
conductin NN O O
. NN O O

Like NN O O
APC NN O O
, NN O O
APC2 NN O O
regulates NN O O
the NN O O
formation NN O O
of NN O O
active NN O O
betacatenin NN O O
- NN O O
Tcf NN O O
complexes NN O O
, NN O O
as NN O O
demonstrated NN O O
using NN O O
transient NN O O
transcriptional NN O O
activation NN O O
assays NN O O
in NN O O
APC NN O O
- NN O O
/ NN O O
- NN O O
colon NN O B-Disease
carcinoma NN O I-Disease
cells NN O O
. NN O O

Human NN O O
APC2 NN O O
maps NN O O
to NN O O
chromosome NN O O
19p13 NN O O
. NN O O

3 NN O O
. NN O O

APC NN O O
and NN O O
APC2 NN O O
may NN O O
therefore NN O O
have NN O O
comparable NN O O
functions NN O O
in NN O O
development NN O O
and NN O O
cancer NN O B-Disease
. NN O O

A NN O O
common NN O O
MSH2 NN O O
mutation NN O O
in NN O O
English NN O O
and NN O O
North NN O O
American NN O O
HNPCC NN O B-Disease
families NN O O
: NN O O
origin NN O O
, NN O O
phenotypic NN O O
expression NN O O
, NN O O
and NN O O
sex NN O O
specific NN O O
differences NN O O
in NN O O
colorectal NN O B-Disease
cancer NN O I-Disease
. NN O O

The NN O O
frequency NN O O
, NN O O
origin NN O O
, NN O O
and NN O O
phenotypic NN O O
expression NN O O
of NN O O
a NN O O
germline NN O O
MSH2 NN O O
gene NN O O
mutation NN O O
previously NN O O
identified NN O O
in NN O O
seven NN O O
kindreds NN O O
with NN O O
hereditary NN O B-Disease
non NN O I-Disease
- NN O I-Disease
polyposis NN O I-Disease
cancer NN O I-Disease
syndrome NN O I-Disease
( NN O O
HNPCC NN O B-Disease
) NN O O
was NN O O
investigated NN O O
. NN O O

The NN O O
mutation NN O O
( NN O O
A NN O O
- NN O O
- NN O O
> NN O O
T NN O O
at NN O O
nt943 NN O O
+ NN O O
3 NN O O
) NN O O
disrupts NN O O
the NN O O
3 NN O O
splice NN O O
site NN O O
of NN O O
exon NN O O
5 NN O O
leading NN O O
to NN O O
the NN O O
deletion NN O O
of NN O O
this NN O O
exon NN O O
from NN O O
MSH2 NN O O
mRNA NN O O
and NN O O
represents NN O O
the NN O O
only NN O O
frequent NN O O
MSH2 NN O O
mutation NN O O
so NN O O
far NN O O
reported NN O O
. NN O O

Although NN O O
this NN O O
mutation NN O O
was NN O O
initially NN O O
detected NN O O
in NN O O
four NN O O
of NN O O
33 NN O O
colorectal NN O B-Disease
cancer NN O I-Disease
families NN O O
analysed NN O O
from NN O O
eastern NN O O
England NN O O
, NN O O
more NN O O
extensive NN O O
analysis NN O O
has NN O O
reduced NN O O
the NN O O
frequency NN O O
to NN O O
four NN O O
of NN O O
52 NN O O
( NN O O
8 NN O O
% NN O O
) NN O O
English NN O O
HNPCC NN O B-Disease
kindreds NN O O
analysed NN O O
. NN O O

In NN O O
contrast NN O O
, NN O O
the NN O O
MSH2 NN O O
mutation NN O O
was NN O O
identified NN O O
in NN O O
10 NN O O
of NN O O
20 NN O O
( NN O O
50 NN O O
% NN O O
) NN O O
separately NN O O
identified NN O O
colorectal NN O B-Disease
families NN O O
from NN O O
Newfoundland NN O O
. NN O O

To NN O O
investigate NN O O
the NN O O
origin NN O O
of NN O O
this NN O O
mutation NN O O
in NN O O
colorectal NN O B-Disease
cancer NN O I-Disease
families NN O O
from NN O O
England NN O O
( NN O O
n NN O O
= NN O O
4 NN O O
) NN O O
, NN O O
Newfoundland NN O O
( NN O O
n NN O O
= NN O O
10 NN O O
) NN O O
, NN O O
and NN O O
the NN O O
United NN O O
States NN O O
( NN O O
n NN O O
= NN O O
3 NN O O
) NN O O
, NN O O
haplotype NN O O
analysis NN O O
using NN O O
microsatellite NN O O
markers NN O O
linked NN O O
to NN O O
MSH2 NN O O
was NN O O
performed NN O O
. NN O O

Within NN O O
the NN O O
English NN O O
and NN O O
US NN O O
families NN O O
there NN O O
was NN O O
little NN O O
evidence NN O O
for NN O O
a NN O O
recent NN O O
common NN O O
origin NN O O
of NN O O
the NN O O
MSH2 NN O O
splice NN O O
site NN O O
mutation NN O O
in NN O O
most NN O O
families NN O O
. NN O O

In NN O O
contrast NN O O
, NN O O
a NN O O
common NN O O
haplotype NN O O
was NN O O
identified NN O O
at NN O O
the NN O O
two NN O O
flanking NN O O
markers NN O O
( NN O O
CA5 NN O O
and NN O O
D2S288 NN O O
) NN O O
in NN O O
eight NN O O
of NN O O
the NN O O
Newfoundland NN O O
families NN O O
. NN O O

These NN O O
findings NN O O
suggested NN O O
a NN O O
founder NN O O
effect NN O O
within NN O O
Newfoundland NN O O
similar NN O O
to NN O O
that NN O O
reported NN O O
by NN O O
others NN O O
for NN O O
two NN O O
MLH1 NN O O
mutations NN O O
in NN O O
Finnish NN O O
HNPCC NN O B-Disease
families NN O O
. NN O O

We NN O O
calculated NN O O
age NN O O
related NN O O
risks NN O O
of NN O O
all NN O O
, NN O O
colorectal NN O B-Disease
, NN O I-Disease
endometrial NN O I-Disease
, NN O I-Disease
and NN O I-Disease
ovarian NN O I-Disease
cancers NN O I-Disease
in NN O O
nt943 NN O O
+ NN O O
3 NN O O
A NN O O
- NN O O
- NN O O
> NN O O
T NN O O
MSH2 NN O O
mutation NN O O
carriers NN O O
( NN O O
n NN O O
= NN O O
76 NN O O
) NN O O
for NN O O
all NN O O
patients NN O O
and NN O O
for NN O O
men NN O O
and NN O O
women NN O O
separately NN O O
. NN O O

For NN O O
both NN O O
sexes NN O O
combined NN O O
, NN O O
the NN O O
penetrances NN O O
at NN O O
age NN O O
60 NN O O
years NN O O
for NN O O
all NN O O
cancers NN O B-Disease
and NN O O
for NN O O
colorectal NN O B-Disease
cancer NN O I-Disease
were NN O O
0 NN O O
. NN O O

86 NN O O
and NN O O
0 NN O O
. NN O O

57 NN O O
, NN O O
respectively NN O O
. NN O O

The NN O O
risk NN O O
of NN O O
colorectal NN O B-Disease
cancer NN O I-Disease
was NN O O
significantly NN O O
higher NN O O
( NN O O
p NN O O
< NN O O
0 NN O O
. NN O O
01 NN O O
) NN O O
in NN O O
males NN O O
than NN O O
females NN O O
( NN O O
0 NN O O
. NN O O
63 NN O O
v NN O O
0 NN O O
. NN O O
30 NN O O
and NN O O
0 NN O O
. NN O O
84 NN O O
v NN O O
0 NN O O
. NN O O
44 NN O O
at NN O O
ages NN O O
50 NN O O
and NN O O
60 NN O O
years NN O O
, NN O O
respectively NN O O
) NN O O
. NN O O

For NN O O
females NN O O
there NN O O
was NN O O
a NN O O
high NN O O
risk NN O O
of NN O O
endometrial NN O B-Disease
cancer NN O I-Disease
( NN O O
0 NN O O
. NN O O
5 NN O O
at NN O O
age NN O O
60 NN O O
years NN O O
) NN O O
and NN O O
premenopausal NN O B-Disease
ovarian NN O I-Disease
cancer NN O I-Disease
( NN O O
0 NN O O
. NN O O
2 NN O O
at NN O O
50 NN O O
years NN O O
) NN O O
. NN O O

These NN O O
intersex NN O O
differences NN O O
in NN O O
colorectal NN O B-Disease
cancer NN O I-Disease
risks NN O O
have NN O O
implications NN O O
for NN O O
screening NN O O
programmes NN O O
and NN O O
for NN O O
attempts NN O O
to NN O O
identify NN O O
colorectal NN O B-Disease
cancer NN O I-Disease
susceptibility NN O O
modifiers NN O O
. NN O O

Age NN O O
of NN O O
onset NN O O
in NN O O
Huntington NN O B-Disease
disease NN O I-Disease
: NN O O
sex NN O O
specific NN O O
influence NN O O
of NN O O
apolipoprotein NN O O
E NN O O
genotype NN O O
and NN O O
normal NN O O
CAG NN O O
repeat NN O O
length NN O O
. NN O O

Age NN O O
of NN O O
onset NN O O
( NN O O
AO NN O O
) NN O O
of NN O O
Huntington NN O B-Disease
disease NN O I-Disease
( NN O O
HD NN O B-Disease
) NN O O
is NN O O
known NN O O
to NN O O
be NN O O
correlated NN O O
with NN O O
the NN O O
length NN O O
of NN O O
an NN O O
expanded NN O O
CAG NN O O
repeat NN O O
in NN O O
the NN O O
HD NN O B-Disease
gene NN O O
. NN O O

Apolipoprotein NN O O
E NN O O
( NN O O
APOE NN O O
) NN O O
genotype NN O O
, NN O O
in NN O O
turn NN O O
, NN O O
is NN O O
known NN O O
to NN O O
influence NN O O
AO NN O O
in NN O O
Alzheimer NN O B-Disease
disease NN O I-Disease
, NN O O
rendering NN O O
the NN O O
APOE NN O O
gene NN O O
a NN O O
likely NN O O
candidate NN O O
to NN O O
affect NN O O
AO NN O O
in NN O O
other NN O O
neurological NN O B-Disease
diseases NN O I-Disease
too NN O O
. NN O O

We NN O O
therefore NN O O
determined NN O O
APOE NN O O
genotype NN O O
and NN O O
normal NN O O
CAG NN O O
repeat NN O O
length NN O O
in NN O O
the NN O O
HD NN O B-Disease
gene NN O O
for NN O O
138 NN O O
HD NN O B-Disease
patients NN O O
who NN O O
were NN O O
previously NN O O
analysed NN O O
with NN O O
respect NN O O
to NN O O
CAG NN O O
repeat NN O O
length NN O O
. NN O O

Genotyping NN O O
for NN O O
APOE NN O O
was NN O O
performed NN O O
blind NN O O
to NN O O
clinical NN O O
information NN O O
. NN O O

In NN O O
addition NN O O
to NN O O
highlighting NN O O
the NN O O
effect NN O O
of NN O O
the NN O O
normal NN O O
repeat NN O O
length NN O O
upon NN O O
AO NN O O
in NN O O
maternally NN O O
inherited NN O O
HD NN O B-Disease
and NN O O
in NN O O
male NN O O
patients NN O O
, NN O O
we NN O O
show NN O O
that NN O O
the NN O O
APOE NN O O
epsilon2epsilon3 NN O O
genotype NN O O
is NN O O
associated NN O O
with NN O O
significantly NN O O
earlier NN O O
AO NN O O
in NN O O
males NN O O
than NN O O
in NN O O
females NN O O
. NN O O

Such NN O O
a NN O O
sex NN O O
difference NN O O
in NN O O
AO NN O O
was NN O O
not NN O O
apparent NN O O
for NN O O
any NN O O
of NN O O
the NN O O
other NN O O
APOE NN O O
genotypes NN O O
. NN O O

Our NN O O
findings NN O O
suggest NN O O
that NN O O
subtle NN O O
differences NN O O
in NN O O
the NN O O
course NN O O
of NN O O
the NN O O
neurodegeneration NN O B-Disease
in NN O O
HD NN O B-Disease
may NN O O
allow NN O O
interacting NN O O
genes NN O O
to NN O O
exert NN O O
gender NN O O
specific NN O O
effects NN O O
upon NN O O
AO NN O O
. NN O O

Familial NN O B-Disease
deficiency NN O I-Disease
of NN O I-Disease
the NN O I-Disease
seventh NN O I-Disease
component NN O I-Disease
of NN O I-Disease
complement NN O I-Disease
associated NN O O
with NN O O
recurrent NN O O
bacteremic NN O B-Disease
infections NN O I-Disease
due NN O I-Disease
to NN O I-Disease
Neisseria NN O I-Disease
. NN O O

The NN O O
serum NN O O
of NN O O
a NN O O
29 NN O O
- NN O O
year NN O O
old NN O O
woman NN O O
with NN O O
a NN O O
recent NN O O
episode NN O O
of NN O O
disseminated NN O B-Disease
gonococcal NN O I-Disease
infection NN O I-Disease
and NN O O
a NN O O
history NN O O
of NN O O
meningococcal NN O B-Disease
meningitis NN O I-Disease
and NN O O
arthritis NN O B-Disease
as NN O O
a NN O O
child NN O O
was NN O O
found NN O O
to NN O O
lack NN O O
serum NN O O
hemolytic NN O O
complement NN O O
activity NN O O
. NN O O

The NN O O
seventh NN O O
component NN O O
of NN O O
complement NN O O
( NN O O
C7 NN O O
) NN O O
was NN O O
not NN O O
detected NN O O
by NN O O
functional NN O O
or NN O O
immunochemical NN O O
assays NN O O
, NN O O
whereas NN O O
other NN O O
components NN O O
were NN O O
normal NN O O
by NN O O
hemolytic NN O O
and NN O O
immunochemical NN O O
assessment NN O O
. NN O O

Her NN O O
fresh NN O O
serum NN O O
lacked NN O O
complement NN O O
- NN O O
mediated NN O O
bactericidal NN O O
activity NN O O
against NN O O
Neisseria NN O O
gonorrhoeae NN O O
, NN O O
but NN O O
the NN O O
addition NN O O
of NN O O
fresh NN O O
normal NN O O
serum NN O O
or NN O O
purified NN O O
C7 NN O O
restored NN O O
bactericidal NN O O
activity NN O O
as NN O O
well NN O O
as NN O O
hemolytic NN O O
activity NN O O
. NN O O

The NN O O
absence NN O B-Disease
of NN O I-Disease
functional NN O I-Disease
C7 NN O I-Disease
activity NN O O
could NN O O
not NN O O
be NN O O
accounted NN O O
for NN O O
on NN O O
the NN O O
basis NN O O
of NN O O
an NN O O
inhibitor NN O O
. NN O O

Opsonization NN O O
and NN O O
generation NN O O
of NN O O
chemotactic NN O O
activity NN O O
functioned NN O O
normally NN O O
. NN O O

Complete NN O B-Disease
absence NN O I-Disease
of NN O I-Disease
C7 NN O I-Disease
was NN O O
also NN O O
found NN O O
in NN O O
one NN O O
sibling NN O O
who NN O O
had NN O O
the NN O O
clinical NN O O
syndrome NN O O
of NN O O
meningococcal NN O B-Disease
meningitis NN O I-Disease
and NN O O
arthritis NN O B-Disease
as NN O O
a NN O O
child NN O O
and NN O O
in NN O O
this NN O O
siblings NN O O
clinically NN O O
well NN O O
eight NN O O
- NN O O
year NN O O
- NN O O
old NN O O
son NN O O
. NN O O

HLA NN O O
histocompatibility NN O O
typing NN O O
of NN O O
the NN O O
family NN O O
members NN O O
did NN O O
not NN O O
demonstrate NN O O
evidence NN O O
for NN O O
genetic NN O O
linkage NN O O
of NN O O
C7 NN O B-Disease
deficiency NN O I-Disease
with NN O O
the NN O O
major NN O O
histocompatibility NN O O
loci NN O O
. NN O O

This NN O O
report NN O O
represents NN O O
the NN O O
first NN O O
cases NN O O
of NN O O
C7 NN O B-Disease
deficiency NN O I-Disease
associated NN O O
with NN O O
infectious NN O O
complications NN O O
and NN O O
suggests NN O O
that NN O O
bactericidal NN O O
activity NN O O
may NN O O
be NN O O
important NN O O
in NN O O
host NN O O
defense NN O O
against NN O O
bacteremic NN O B-Disease
neisseria NN O I-Disease
infections NN O I-Disease
. NN O O

Increased NN O O
incidence NN O O
of NN O O
cancer NN O B-Disease
in NN O O
patients NN O O
with NN O O
cartilage NN O B-Disease
- NN O I-Disease
hair NN O I-Disease
hypoplasia NN O I-Disease
. NN O O

OBJECTIVE NN O O
Previous NN O O
reports NN O O
have NN O O
suggested NN O O
an NN O O
increased NN O O
risk NN O O
of NN O O
cancer NN O B-Disease
among NN O O
patients NN O O
with NN O O
cartilage NN O B-Disease
- NN O I-Disease
hair NN O I-Disease
hypoplasia NN O I-Disease
( NN O O
CHH NN O B-Disease
) NN O O
. NN O O

This NN O O
study NN O O
was NN O O
carried NN O O
out NN O O
to NN O O
further NN O O
evaluate NN O O
this NN O O
risk NN O O
among NN O O
patients NN O O
with NN O O
CHH NN O B-Disease
and NN O O
their NN O O
first NN O O
- NN O O
degree NN O O
relatives NN O O
. NN O O

STUDY NN O O
DESIGN NN O O
One NN O O
hundred NN O O
twenty NN O O
- NN O O
two NN O O
patients NN O O
with NN O O
CHH NN O B-Disease
were NN O O
identified NN O O
through NN O O
2 NN O O
countrywide NN O O
epidemiologic NN O O
surveys NN O O
in NN O O
1974 NN O O
and NN O O
in NN O O
1986 NN O O
. NN O O

Their NN O O
parents NN O O
and NN O O
nonaffected NN O O
siblings NN O O
were NN O O
identified NN O O
through NN O O
the NN O O
Population NN O O
Register NN O O
Center NN O O
. NN O O

This NN O O
cohort NN O O
underwent NN O O
follow NN O O
- NN O O
up NN O O
for NN O O
cancer NN O B-Disease
incidence NN O O
through NN O O
the NN O O
Finnish NN O O
Cancer NN O O
Registry NN O O
to NN O O
the NN O O
end NN O O
of NN O O
1995 NN O O
. NN O O

RESULTS NN O O
A NN O O
statistically NN O O
significant NN O O
excess NN O O
risk NN O O
of NN O O
cancer NN O B-Disease
was NN O O
seen NN O O
among NN O O
the NN O O
patients NN O O
with NN O O
CHH NN O B-Disease
( NN O O
standardized NN O O
incidence NN O O
ratio NN O O
6 NN O O
. NN O O
9 NN O O
, NN O O
95 NN O O
% NN O O
confidence NN O O
interval NN O O
2 NN O O
. NN O O
3 NN O O
to NN O O
16 NN O O
) NN O O
, NN O O
which NN O O
was NN O O
mainly NN O O
attributable NN O O
to NN O O
non NN O B-Disease
- NN O I-Disease
Hodgkins NN O I-Disease
lymphoma NN O I-Disease
( NN O O
standardized NN O O
incidence NN O O
ratio NN O O
90 NN O O
, NN O O
95 NN O O
% NN O O
confidence NN O O
interval NN O O
18 NN O O
to NN O O
264 NN O O
) NN O O
. NN O O

In NN O O
addition NN O O
, NN O O
a NN O O
significant NN O O
excess NN O O
risk NN O O
of NN O O
basal NN O B-Disease
cell NN O I-Disease
carcinoma NN O I-Disease
was NN O O
seen NN O O
( NN O O
standardized NN O O
incidence NN O O
ratio NN O O
35 NN O O
, NN O O
95 NN O O
% NN O O
confidence NN O O
interval NN O O
7 NN O O
. NN O O
2 NN O O
to NN O O
102 NN O O
) NN O O
. NN O O

The NN O O
cancer NN O B-Disease
incidence NN O O
among NN O O
the NN O O
siblings NN O O
or NN O O
the NN O O
parents NN O O
did NN O O
not NN O O
differ NN O O
from NN O O
the NN O O
average NN O O
cancer NN O B-Disease
incidence NN O O
in NN O O
the NN O O
Finnish NN O O
population NN O O
. NN O O

CONCLUSIONS NN O O
This NN O O
study NN O O
confirms NN O O
an NN O O
increased NN O O
risk NN O O
of NN O O
cancer NN O B-Disease
, NN O O
especially NN O O
non NN O B-Disease
- NN O I-Disease
Hodgkins NN O I-Disease
lymphoma NN O I-Disease
, NN O O
probably NN O O
attributable NN O O
to NN O O
defective NN O O
immunity NN O O
, NN O O
among NN O O
patients NN O O
with NN O O
CHH NN O B-Disease
. NN O O

Genotype NN O O
and NN O O
phenotype NN O O
in NN O O
patients NN O O
with NN O O
dihydropyrimidine NN O B-Disease
dehydrogenase NN O I-Disease
deficiency NN O I-Disease
. NN O O

Dihydropyrimidine NN O B-Disease
dehydrogenase NN O I-Disease
( NN O I-Disease
DPD NN O I-Disease
) NN O I-Disease
deficiency NN O I-Disease
is NN O O
an NN O O
autosomal NN O B-Disease
recessive NN O I-Disease
disease NN O I-Disease
characterised NN O O
by NN O O
thymine NN O O
- NN O O
uraciluria NN O O
in NN O O
homozygous NN O O
deficient NN O O
patients NN O O
and NN O O
has NN O O
been NN O O
associated NN O O
with NN O O
a NN O O
variable NN O O
clinical NN O O
phenotype NN O O
. NN O O

In NN O O
order NN O O
to NN O O
understand NN O O
the NN O O
genetic NN O O
and NN O O
phenotypic NN O O
basis NN O O
for NN O O
DPD NN O B-Disease
deficiency NN O I-Disease
, NN O O
we NN O O
have NN O O
reviewed NN O O
17 NN O O
families NN O O
presenting NN O O
22 NN O O
patients NN O O
with NN O O
complete NN O O
deficiency NN O B-Disease
of NN O I-Disease
DPD NN O I-Disease
. NN O O

In NN O O
this NN O O
group NN O O
of NN O O
patients NN O O
, NN O O
7 NN O O
different NN O O
mutations NN O O
have NN O O
been NN O O
identified NN O O
, NN O O
including NN O O
2 NN O O
deletions NN O O
[ NN O O
295 NN O O
- NN O O
298delTCAT NN O O
, NN O O
1897delC NN O O
] NN O O
, NN O O
1 NN O O
splice NN O O
- NN O O
site NN O O
mutation NN O O
[ NN O O
IVS14 NN O O
+ NN O O
1G NN O O
> NN O O
A NN O O
) NN O O
] NN O O
and NN O O
4 NN O O
missense NN O O
mutations NN O O
( NN O O
85T NN O O
> NN O O
C NN O O
, NN O O
703C NN O O
> NN O O
T NN O O
, NN O O
2658G NN O O
> NN O O
A NN O O
, NN O O
2983G NN O O
> NN O O
T NN O O
) NN O O
. NN O O

Analysis NN O O
of NN O O
the NN O O
prevalence NN O O
of NN O O
the NN O O
various NN O O
mutations NN O O
among NN O O
DPD NN O B-Disease
patients NN O O
has NN O O
shown NN O O
that NN O O
the NN O O
G NN O O
- NN O O
- NN O O
> NN O O
A NN O O
point NN O O
mutation NN O O
in NN O O
the NN O O
invariant NN O O
splice NN O O
donor NN O O
site NN O O
is NN O O
by NN O O
far NN O O
the NN O O
most NN O O
common NN O O
( NN O O
52 NN O O
% NN O O
) NN O O
, NN O O
whereas NN O O
the NN O O
other NN O O
six NN O O
mutations NN O O
are NN O O
less NN O O
frequently NN O O
observed NN O O
. NN O O

A NN O O
large NN O O
phenotypic NN O O
variability NN O O
has NN O O
been NN O O
observed NN O O
, NN O O
with NN O O
convulsive NN O B-Disease
disorders NN O I-Disease
, NN O O
motor NN O B-Disease
retardation NN O I-Disease
and NN O O
mental NN O B-Disease
retardation NN O I-Disease
being NN O O
the NN O O
most NN O O
abundant NN O O
manifestations NN O O
. NN O O

A NN O O
clear NN O O
correlation NN O O
between NN O O
the NN O O
genotype NN O O
and NN O O
phenotype NN O O
has NN O O
not NN O O
been NN O O
established NN O O
. NN O O

An NN O O
altered NN O O
beta NN O O
- NN O O
alanine NN O O
, NN O O
uracil NN O O
and NN O O
thymine NN O O
homeostasis NN O O
might NN O O
underlie NN O O
the NN O O
various NN O O
clinical NN O B-Disease
abnormalities NN O I-Disease
encountered NN O O
in NN O O
patients NN O O
with NN O O
DPD NN O B-Disease
deficiency NN O I-Disease
. NN O O

Fibroblast NN O O
growth NN O O
factor NN O O
homologous NN O O
factor NN O O
2 NN O O
( NN O O
FHF2 NN O O
) NN O O
: NN O O
gene NN O O
structure NN O O
, NN O O
expression NN O O
and NN O O
mapping NN O O
to NN O O
the NN O O
Borjeson NN O B-Disease
- NN O I-Disease
Forssman NN O I-Disease
- NN O I-Disease
Lehmann NN O I-Disease
syndrome NN O I-Disease
region NN O O
in NN O O
Xq26 NN O O
delineated NN O O
by NN O O
a NN O O
duplication NN O O
breakpoint NN O O
in NN O O
a NN O O
BFLS NN O B-Disease
- NN O O
like NN O O
patient NN O O
. NN O O

Borjeson NN O B-Disease
- NN O I-Disease
Forssman NN O I-Disease
- NN O I-Disease
Lehmann NN O I-Disease
syndrome NN O I-Disease
( NN O O
BFLS NN O B-Disease
) NN O O
is NN O O
a NN O O
syndromal NN O O
X NN O B-Disease
- NN O I-Disease
linked NN O I-Disease
mental NN O I-Disease
retardation NN O I-Disease
, NN O O
which NN O O
maps NN O O
by NN O O
linkage NN O O
to NN O O
the NN O O
q26 NN O O
region NN O O
of NN O O
the NN O O
human NN O O
X NN O O
chromosome NN O O
. NN O O

We NN O O
have NN O O
identified NN O O
a NN O O
male NN O O
patient NN O O
with NN O O
BFLS NN O B-Disease
- NN O O
like NN O O
features NN O O
and NN O O
a NN O O
duplication NN O O
, NN O O
46 NN O O
, NN O O
Y NN O O
, NN O O
dup NN O O
( NN O O
X NN O O
) NN O O
( NN O O
q26q28 NN O O
) NN O O
, NN O O
inherited NN O O
from NN O O
his NN O O
phenotypically NN O O
normal NN O O
mother NN O O
. NN O O

Fluorescence NN O O
in NN O O
situ NN O O
hybridisation NN O O
using NN O O
yeast NN O O
artificial NN O O
chromosome NN O O
clones NN O O
from NN O O
Xq26 NN O O
localised NN O O
the NN O O
duplication NN O O
breakpoint NN O O
to NN O O
an NN O O
approximately NN O O
400 NN O O
- NN O O
kb NN O O
interval NN O O
in NN O O
the NN O O
Xq26 NN O O
. NN O O

3 NN O O
region NN O O
between NN O O
DXS155 NN O O
and NN O O
DXS294 NN O O
/ NN O O
DXS730 NN O O
. NN O O

Database NN O O
searches NN O O
and NN O O
analysis NN O O
of NN O O
available NN O O
genomic NN O O
DNA NN O O
sequence NN O O
from NN O O
the NN O O
region NN O O
revealed NN O O
the NN O O
presence NN O O
of NN O O
the NN O O
fibroblast NN O O
growth NN O O
factor NN O O
homologous NN O O
factor NN O O
gene NN O O
, NN O O
FHF2 NN O O
, NN O O
within NN O O
the NN O O
duplication NN O O
breakpoint NN O O
interval NN O O
. NN O O

The NN O O
gene NN O O
structure NN O O
of NN O O
FHF2 NN O O
was NN O O
determined NN O O
and NN O O
two NN O O
new NN O O
exons NN O O
were NN O O
identified NN O O
, NN O O
including NN O O
a NN O O
new NN O O
5 NN O O
end NN O O
exon NN O O
, NN O O
1B NN O O
. NN O O

FHF2 NN O O
is NN O O
a NN O O
large NN O O
gene NN O O
extending NN O O
over NN O O
approximately NN O O
200 NN O O
kb NN O O
in NN O O
Xq26 NN O O
. NN O O

3 NN O O
and NN O O
is NN O O
composed NN O O
of NN O O
at NN O O
least NN O O
seven NN O O
exons NN O O
. NN O O

It NN O O
shows NN O O
tissue NN O O
- NN O O
specific NN O O
alternative NN O O
splicing NN O O
and NN O O
alternative NN O O
transcription NN O O
starts NN O O
. NN O O

Northern NN O O
blot NN O O
hybridisation NN O O
showed NN O O
highest NN O O
expression NN O O
in NN O O
brain NN O O
and NN O O
skeletal NN O O
muscle NN O O
. NN O O

The NN O O
FHF2 NN O O
gene NN O O
localisation NN O O
and NN O O
tissue NN O O
- NN O O
specific NN O O
expression NN O O
pattern NN O O
suggest NN O O
it NN O O
to NN O O
be NN O O
a NN O O
candidate NN O O
gene NN O O
for NN O O
familial NN O O
cases NN O O
of NN O O
the NN O O
BFLS NN O B-Disease
syndrome NN O I-Disease
and NN O O
other NN O O
syndromal NN O O
and NN O O
non NN O O
- NN O O
specific NN O O
forms NN O O
of NN O O
X NN O B-Disease
- NN O I-Disease
linked NN O I-Disease
mental NN O I-Disease
retardation NN O I-Disease
mapping NN O O
to NN O O
the NN O O
region NN O O
. NN O O

Germline NN O O
E NN O O
- NN O O
cadherin NN O O
gene NN O O
( NN O O
CDH1 NN O O
) NN O O
mutations NN O O
predispose NN O O
to NN O O
familial NN O B-Disease
gastric NN O I-Disease
cancer NN O I-Disease
and NN O O
colorectal NN O B-Disease
cancer NN O I-Disease
. NN O O

Inherited NN O O
mutations NN O O
in NN O O
the NN O O
E NN O O
- NN O O
cadherin NN O O
gene NN O O
( NN O O
CDH1 NN O O
) NN O O
were NN O O
described NN O O
recently NN O O
in NN O O
three NN O O
Maori NN O O
kindreds NN O O
with NN O O
familial NN O B-Disease
gastric NN O I-Disease
cancer NN O I-Disease
. NN O O

Familial NN O B-Disease
gastric NN O I-Disease
cancer NN O I-Disease
is NN O O
genetically NN O O
heterogeneous NN O O
and NN O O
it NN O O
is NN O O
not NN O O
clear NN O O
what NN O O
proportion NN O O
of NN O O
gastric NN O B-Disease
cancer NN O I-Disease
susceptibility NN O O
in NN O O
non NN O O
- NN O O
Maori NN O O
populations NN O O
is NN O O
due NN O O
to NN O O
germline NN O O
CDH1 NN O O
mutations NN O O
. NN O O

Therefore NN O O
, NN O O
we NN O O
screened NN O O
eight NN O O
familial NN O B-Disease
gastric NN O I-Disease
cancer NN O I-Disease
kindreds NN O O
of NN O O
British NN O O
and NN O O
Irish NN O O
origin NN O O
for NN O O
germline NN O O
CDH1 NN O O
mutations NN O O
, NN O O
by NN O O
SSCP NN O O
analysis NN O O
of NN O O
all NN O O
16 NN O O
exons NN O O
and NN O O
flanking NN O O
sequences NN O O
. NN O O

Each NN O O
family NN O O
contained NN O O
( NN O O
i NN O O
) NN O O
two NN O O
cases NN O O
of NN O O
gastric NN O B-Disease
cancer NN O I-Disease
in NN O O
first NN O O
degree NN O O
relatives NN O O
with NN O O
one NN O O
affected NN O O
before NN O O
age NN O O
50 NN O O
years NN O O
; NN O O
or NN O O
( NN O O
ii NN O O
) NN O O
three NN O O
or NN O O
more NN O O
cases NN O O
of NN O O
gastric NN O B-Disease
cancer NN O I-Disease
. NN O O

Novel NN O O
germline NN O O
CDH1 NN O O
mutations NN O O
( NN O O
a NN O O
nonsense NN O O
and NN O O
a NN O O
splice NN O O
site NN O O
) NN O O
were NN O O
detected NN O O
in NN O O
two NN O O
families NN O O
( NN O O
25 NN O O
% NN O O
) NN O O
. NN O O

Both NN O O
mutations NN O O
were NN O O
predicted NN O O
to NN O O
truncate NN O O
the NN O O
E NN O O
- NN O O
cadherin NN O O
protein NN O O
in NN O O
the NN O O
signal NN O O
peptide NN O O
domain NN O O
. NN O O

In NN O O
one NN O O
family NN O O
there NN O O
was NN O O
evidence NN O O
of NN O O
non NN O O
- NN O O
penetrance NN O O
and NN O O
susceptibility NN O O
to NN O O
both NN O O
gastric NN O B-Disease
and NN O I-Disease
colorectal NN O I-Disease
cancer NN O I-Disease
; NN O O
thus NN O O
, NN O O
in NN O O
addition NN O O
to NN O O
six NN O O
cases NN O O
of NN O O
gastric NN O B-Disease
cancer NN O I-Disease
, NN O O
a NN O O
CDH1 NN O O
mutation NN O O
carrier NN O O
developed NN O O
colorectal NN O B-Disease
cancer NN O I-Disease
at NN O O
age NN O O
30 NN O O
years NN O O
. NN O O

We NN O O
have NN O O
confirmed NN O O
that NN O O
germline NN O O
mutations NN O O
in NN O O
the NN O O
CDH1 NN O O
gene NN O O
cause NN O O
familial NN O B-Disease
gastric NN O I-Disease
cancer NN O I-Disease
in NN O O
non NN O O
- NN O O
Maori NN O O
populations NN O O
. NN O O

However NN O O
, NN O O
only NN O O
a NN O O
minority NN O O
of NN O O
familial NN O O
gastric NN O B-Disease
cancers NN O I-Disease
can NN O O
be NN O O
accounted NN O O
for NN O O
by NN O O
CDH1 NN O O
mutations NN O O
. NN O O

Loss NN O O
of NN O O
E NN O O
- NN O O
cadherin NN O O
function NN O O
has NN O O
been NN O O
implicated NN O O
in NN O O
the NN O O
pathogenesis NN O O
of NN O O
sporadic NN O O
colorectal NN O B-Disease
and NN O I-Disease
other NN O I-Disease
cancers NN O I-Disease
, NN O O
and NN O O
our NN O O
findings NN O O
provide NN O O
evidence NN O O
that NN O O
germline NN O O
CDH1 NN O O
mutations NN O O
predispose NN O O
to NN O O
early NN O O
onset NN O O
colorectal NN O B-Disease
cancer NN O I-Disease
. NN O O

Thus NN O O
, NN O O
CDH1 NN O O
should NN O O
be NN O O
investigated NN O O
as NN O O
a NN O O
cause NN O O
of NN O O
inherited NN O O
susceptibility NN O O
to NN O O
both NN O O
gastric NN O B-Disease
and NN O I-Disease
colorectal NN O I-Disease
cancers NN O I-Disease
. NN O O

A NN O O
zinc NN O O
finger NN O O
truncation NN O O
of NN O O
murine NN O O
WT1 NN O O
results NN O O
in NN O O
the NN O O
characteristic NN O O
urogenital NN O B-Disease
abnormalities NN O I-Disease
of NN O O
Denys NN O B-Disease
- NN O I-Disease
Drash NN O I-Disease
syndrome NN O I-Disease
. NN O O

The NN O O
Wilms NN O B-Disease
tumor NN O I-Disease
- NN O O
suppressor NN O O
gene NN O O
, NN O O
WT1 NN O O
, NN O O
plays NN O O
a NN O O
key NN O O
role NN O O
in NN O O
urogenital NN O O
development NN O O
, NN O O
and NN O O
WT1 NN O B-Disease
dysfunction NN O I-Disease
is NN O O
implicated NN O O
in NN O O
both NN O O
neoplastic NN O B-Disease
( NN O O
Wilms NN O B-Disease
tumor NN O I-Disease
, NN O O
mesothelioma NN O B-Disease
, NN O O
leukemias NN O B-Disease
, NN O O
and NN O O
breast NN O B-Disease
cancer NN O I-Disease
) NN O O
and NN O O
nonneoplastic NN O B-Disease
( NN O O
glomerulosclerosis NN O B-Disease
) NN O O
disease NN O O
. NN O O

The NN O O
analysis NN O O
of NN O O
diseases NN O O
linked NN O O
specifically NN O O
with NN O O
WT1 NN O O
mutations NN O O
, NN O O
such NN O O
as NN O O
Denys NN O B-Disease
- NN O I-Disease
Drash NN O I-Disease
syndrome NN O I-Disease
( NN O O
DDS NN O B-Disease
) NN O O
, NN O O
can NN O O
provide NN O O
valuable NN O O
insight NN O O
concerning NN O O
the NN O O
role NN O O
of NN O O
WT1 NN O O
in NN O O
development NN O O
and NN O O
disease NN O O
. NN O O

DDS NN O B-Disease
is NN O O
a NN O O
rare NN O O
childhood NN O O
disease NN O O
characterized NN O O
by NN O O
a NN O O
nephropathy NN O B-Disease
involving NN O O
mesangial NN O B-Disease
sclerosis NN O I-Disease
, NN O O
XY NN O O
pseudohermaphroditism NN O B-Disease
, NN O O
and NN O O
/ NN O O
or NN O O
Wilms NN O B-Disease
tumor NN O I-Disease
( NN O O
WT NN O B-Disease
) NN O O
. NN O O

DDS NN O B-Disease
patients NN O O
are NN O O
constitutionally NN O O
heterozygous NN O O
for NN O O
exonic NN O O
point NN O O
mutations NN O O
in NN O O
WT1 NN O O
, NN O O
which NN O O
include NN O O
mutations NN O O
predicted NN O O
to NN O O
truncate NN O O
the NN O O
protein NN O O
within NN O O
the NN O O
C NN O O
- NN O O
terminal NN O O
zinc NN O O
finger NN O O
( NN O O
ZF NN O O
) NN O O
region NN O O
. NN O O

We NN O O
report NN O O
that NN O O
heterozygosity NN O O
for NN O O
a NN O O
targeted NN O O
murine NN O O
Wt1 NN O O
allele NN O O
, NN O O
Wt1 NN O O
( NN O O
tmT396 NN O O
) NN O O
, NN O O
which NN O O
truncates NN O O
ZF3 NN O O
at NN O O
codon NN O O
396 NN O O
, NN O O
induces NN O O
mesangial NN O B-Disease
sclerosis NN O I-Disease
characteristic NN O O
of NN O O
DDS NN O B-Disease
in NN O O
adult NN O O
heterozygous NN O O
and NN O O
chimeric NN O O
mice NN O O
. NN O O

Male NN O B-Disease
genital NN O I-Disease
defects NN O I-Disease
also NN O O
were NN O O
evident NN O O
and NN O O
there NN O O
was NN O O
a NN O O
single NN O O
case NN O O
of NN O O
Wilms NN O B-Disease
tumor NN O I-Disease
in NN O O
which NN O O
the NN O O
transcript NN O O
of NN O O
the NN O O
nontargeted NN O O
allele NN O O
showed NN O O
an NN O O
exon NN O O
9 NN O O
skipping NN O O
event NN O O
, NN O O
implying NN O O
a NN O O
causal NN O O
link NN O O
between NN O O
Wt1 NN O B-Disease
dysfunction NN O I-Disease
and NN O O
Wilms NN O B-Disease
tumorigenesis NN O I-Disease
in NN O O
mice NN O O
. NN O O

However NN O O
, NN O O
the NN O O
mutant NN O O
WT1 NN O O
( NN O O
tmT396 NN O O
) NN O O
protein NN O O
accounted NN O O
for NN O O
only NN O O
5 NN O O
% NN O O
of NN O O
WT1 NN O O
in NN O O
both NN O O
heterozygous NN O O
embryonic NN O O
stem NN O O
cells NN O O
and NN O O
the NN O O
WT NN O B-Disease
. NN O O

This NN O O
has NN O O
implications NN O O
regarding NN O O
the NN O O
mechanism NN O O
by NN O O
which NN O O
the NN O O
mutant NN O O
allele NN O O
exerts NN O O
its NN O O
effect NN O O
. NN O O

Mechanism NN O O
of NN O O
increased NN O O
iron NN O O
absorption NN O O
in NN O O
murine NN O O
model NN O O
of NN O O
hereditary NN O B-Disease
hemochromatosis NN O I-Disease
: NN O O
increased NN O O
duodenal NN O O
expression NN O O
of NN O O
the NN O O
iron NN O O
transporter NN O O
DMT1 NN O O
. NN O O

Hereditary NN O B-Disease
hemochromatosis NN O I-Disease
( NN O O
HH NN O B-Disease
) NN O O
is NN O O
a NN O O
common NN O O
autosomal NN O B-Disease
recessive NN O I-Disease
disorder NN O I-Disease
characterized NN O O
by NN O O
tissue NN O O
iron NN O O
deposition NN O O
secondary NN O O
to NN O O
excessive NN O O
dietary NN O O
iron NN O O
absorption NN O O
. NN O O

We NN O O
recently NN O O
reported NN O O
that NN O O
HFE NN O O
, NN O O
the NN O O
protein NN O O
defective NN O O
in NN O O
HH NN O B-Disease
, NN O O
was NN O O
physically NN O O
associated NN O O
with NN O O
the NN O O
transferrin NN O O
receptor NN O O
( NN O O
TfR NN O O
) NN O O
in NN O O
duodenal NN O O
crypt NN O O
cells NN O O
and NN O O
proposed NN O O
that NN O O
mutations NN O O
in NN O O
HFE NN O O
attenuate NN O O
the NN O O
uptake NN O O
of NN O O
transferrin NN O O
- NN O O
bound NN O O
iron NN O O
from NN O O
plasma NN O O
by NN O O
duodenal NN O O
crypt NN O O
cells NN O O
, NN O O
leading NN O O
to NN O O
up NN O O
- NN O O
regulation NN O O
of NN O O
transporters NN O O
for NN O O
dietary NN O O
iron NN O O
. NN O O

Here NN O O
, NN O O
we NN O O
tested NN O O
the NN O O
hypothesis NN O O
that NN O O
HFE NN O O
- NN O O
/ NN O O
- NN O O
mice NN O O
have NN O O
increased NN O O
duodenal NN O O
expression NN O O
of NN O O
the NN O O
divalent NN O O
metal NN O O
transporter NN O O
( NN O O
DMT1 NN O O
) NN O O
. NN O O

By NN O O
4 NN O O
weeks NN O O
of NN O O
age NN O O
, NN O O
the NN O O
HFE NN O O
- NN O O
/ NN O O
- NN O O
mice NN O O
demonstrated NN O O
iron NN O O
loading NN O O
when NN O O
compared NN O O
with NN O O
HFE NN O O
+ NN O O
/ NN O O
+ NN O O
littermates NN O O
, NN O O
with NN O O
elevated NN O O
transferrin NN O O
saturations NN O O
( NN O O
68 NN O O
. NN O O
4 NN O O
% NN O O
vs NN O O
. NN O O
49 NN O O
. NN O O
8 NN O O
% NN O O
) NN O O
and NN O O
elevated NN O O
liver NN O O
iron NN O O
concentrations NN O O
( NN O O
985 NN O O
micrograms NN O O
vs NN O O
. NN O O
381 NN O O
micrograms NN O O
) NN O O
. NN O O

By NN O O
using NN O O
Northern NN O O
blot NN O O
analyses NN O O
, NN O O
we NN O O
quantitated NN O O
duodenal NN O O
expression NN O O
of NN O O
both NN O O
classes NN O O
of NN O O
DMT1 NN O O
transcripts NN O O
one NN O O
containing NN O O
an NN O O
iron NN O O
responsive NN O O
element NN O O
( NN O O
IRE NN O O
) NN O O
, NN O O
called NN O O
DMT1 NN O O
( NN O O
IRE NN O O
) NN O O
, NN O O
and NN O O
one NN O O
containing NN O O
no NN O O
IRE NN O O
, NN O O
called NN O O
DMT1 NN O O
( NN O O
non NN O O
- NN O O
IRE NN O O
) NN O O
. NN O O

The NN O O
positive NN O O
control NN O O
for NN O O
DMT1 NN O O
up NN O O
- NN O O
regulation NN O O
was NN O O
a NN O O
murine NN O O
model NN O O
of NN O O
dietary NN O B-Disease
iron NN O I-Disease
deficiency NN O I-Disease
that NN O O
demonstrated NN O O
greatly NN O O
increased NN O O
levels NN O O
of NN O O
duodenal NN O O
DMT1 NN O O
( NN O O
IRE NN O O
) NN O O
mRNA NN O O
. NN O O

HFE NN O O
- NN O O
/ NN O O
- NN O O
mice NN O O
also NN O O
demonstrated NN O O
an NN O O
increase NN O O
in NN O O
duodenal NN O O
DMT1 NN O O
( NN O O
IRE NN O O
) NN O O
mRNA NN O O
( NN O O
average NN O O
7 NN O O
. NN O O
7 NN O O
- NN O O
fold NN O O
) NN O O
, NN O O
despite NN O O
their NN O O
elevated NN O O
transferrin NN O O
saturation NN O O
and NN O O
hepatic NN O O
iron NN O O
content NN O O
. NN O O

Duodenal NN O O
expression NN O O
of NN O O
DMT1 NN O O
( NN O O
non NN O O
- NN O O
IRE NN O O
) NN O O
was NN O O
not NN O O
increased NN O O
, NN O O
nor NN O O
was NN O O
hepatic NN O O
expression NN O O
of NN O O
DMT1 NN O O
increased NN O O
. NN O O

These NN O O
data NN O O
support NN O O
the NN O O
model NN O O
for NN O O
HH NN O O
in NN O O
which NN O O
HFE NN O O
mutations NN O O
lead NN O O
to NN O O
inappropriately NN O O
low NN O O
crypt NN O O
cell NN O O
iron NN O O
, NN O O
with NN O O
resultant NN O O
stabilization NN O O
of NN O O
DMT1 NN O O
( NN O O
IRE NN O O
) NN O O
mRNA NN O O
, NN O O
up NN O O
- NN O O
regulation NN O O
of NN O O
DMT1 NN O O
, NN O O
and NN O O
increased NN O O
absorption NN O O
of NN O O
dietary NN O O
iron NN O O
. NN O O

Neurophysiologic NN O O
follow NN O O
- NN O O
up NN O O
of NN O O
long NN O O
- NN O O
term NN O O
dietary NN O O
treatment NN O O
in NN O O
adult NN O O
- NN O O
onset NN O O
adrenoleukodystrophy NN O B-Disease
. NN O O

OBJECTIVE NN O O
To NN O O
monitor NN O O
the NN O O
effects NN O O
of NN O O
dietary NN O O
treatment NN O O
in NN O O
adult NN O O
- NN O O
onset NN O O
adrenoleukodystrophy NN O B-Disease
( NN O O
ALD NN O B-Disease
) NN O O
by NN O O
means NN O O
of NN O O
somatosensory NN O O
evoked NN O O
potentials NN O O
( NN O O
SEPs NN O O
) NN O O
and NN O O
motor NN O O
evoked NN O O
potentials NN O O
( NN O O
MEPs NN O O
) NN O O
. NN O O

BACKGROUND NN O O
SEPs NN O O
and NN O O
MEPs NN O O
have NN O O
proved NN O O
useful NN O O
in NN O O
revealing NN O O
signs NN O O
of NN O O
progressively NN O O
severe NN O O
, NN O O
central NN O O
dying NN O B-Disease
- NN O I-Disease
back NN O I-Disease
axonopathy NN O I-Disease
in NN O O
early NN O O
stages NN O O
of NN O O
adult NN O O
- NN O O
onset NN O O
ALD NN O B-Disease
. NN O O

METHODS NN O O
Eight NN O O
patients NN O O
with NN O O
adult NN O O
- NN O O
onset NN O O
ALD NN O B-Disease
underwent NN O O
clinical NN O O
examination NN O O
, NN O O
brain NN O O
and NN O O
spine NN O O
MRI NN O O
, NN O O
and NN O O
SEP NN O O
and NN O O
MEP NN O O
studies NN O O
before NN O O
and NN O O
after NN O O
3 NN O O
years NN O O
of NN O O
Lorenzos NN O O
oil NN O O
dietary NN O O
therapy NN O O
. NN O O

RESULTS NN O O
Before NN O O
treatment NN O O
, NN O O
brain NN O O
MRI NN O O
was NN O O
normal NN O O
in NN O O
five NN O O
patients NN O O
. NN O O

Three NN O O
of NN O O
these NN O O
patients NN O O
had NN O O
pure NN O O
spinal NN O B-Disease
SEP NN O I-Disease
abnormalities NN O I-Disease
and NN O O
in NN O O
the NN O O
remaining NN O O
two NN O O
patients NN O O
SEPs NN O O
showed NN O O
signs NN O O
of NN O O
involvement NN O O
of NN O O
both NN O O
the NN O O
spinal NN O O
and NN O O
cerebral NN O O
somatosensory NN O O
tracts NN O O
. NN O O

After NN O O
treatment NN O O
, NN O O
the NN O O
three NN O O
patients NN O O
with NN O O
pure NN O O
spinal NN O B-Disease
abnormalities NN O I-Disease
showed NN O O
clinical NN O O
and NN O O
neurophysiologic NN O O
worsening NN O O
, NN O O
whereas NN O O
the NN O O
two NN O O
patients NN O O
with NN O O
a NN O O
more NN O O
advanced NN O O
stage NN O O
of NN O O
disease NN O O
( NN O O
exhibited NN O O
by NN O O
SEPs NN O O
) NN O O
showed NN O O
substantially NN O O
unchanged NN O O
clinical NN O O
and NN O O
neurophysiologic NN O O
features NN O O
. NN O O

The NN O O
patients NN O O
with NN O O
abnormal NN O O
brain NN O O
MRI NN O O
at NN O O
the NN O O
onset NN O O
of NN O O
treatment NN O O
showed NN O O
clinical NN O O
and NN O O
neurophysiologic NN O O
worsening NN O O
. NN O O

CONCLUSIONS NN O O
Lorenzos NN O O
oil NN O O
therapy NN O O
had NN O O
no NN O O
effect NN O O
on NN O O
patients NN O O
with NN O O
evidence NN O O
of NN O O
inflammatory NN O B-Disease
brain NN O I-Disease
lesions NN O I-Disease
. NN O O

Moreover NN O O
, NN O O
in NN O O
patients NN O O
without NN O O
clear NN O O
signs NN O O
of NN O O
inflammatory NN O O
damage NN O O
, NN O O
this NN O O
treatment NN O O
does NN O O
not NN O O
modify NN O O
significantly NN O O
the NN O O
natural NN O O
course NN O O
of NN O O
the NN O O
disease NN O O
. NN O O

However NN O O
, NN O O
because NN O O
effective NN O O
treatments NN O O
should NN O O
begin NN O O
before NN O O
the NN O O
onset NN O O
of NN O O
severe NN O O
neurologic NN O O
symptoms NN O O
, NN O O
SEPs NN O O
and NN O O
MEPs NN O O
should NN O O
be NN O O
considered NN O O
to NN O O
evaluate NN O O
the NN O O
effectiveness NN O O
of NN O O
other NN O O
experimental NN O O
treatments NN O O
in NN O O
the NN O O
patient NN O O
with NN O O
a NN O O
negative NN O O
brain NN O O
MRI NN O O
. NN O O

GCH1 NN O O
mutation NN O O
in NN O O
a NN O O
patient NN O O
with NN O O
adult NN O O
- NN O O
onset NN O O
oromandibular NN O B-Disease
dystonia NN O I-Disease
. NN O O

The NN O O
authors NN O O
report NN O O
a NN O O
mutation NN O O
in NN O O
exon NN O O
5 NN O O
of NN O O
GCH1 NN O O
in NN O O
a NN O O
patient NN O O
with NN O O
adult NN O O
- NN O O
onset NN O O
oromandibular NN O B-Disease
dystonia NN O I-Disease
and NN O O
no NN O O
obvious NN O O
family NN O O
history NN O O
of NN O O
dystonia NN O B-Disease
. NN O O

The NN O O
patient NN O O
responded NN O O
positively NN O O
to NN O O
treatment NN O O
with NN O O
L NN O O
- NN O O
dopa NN O O
. NN O O

These NN O O
findings NN O O
demonstrate NN O O
that NN O O
GCH1 NN O O
mutations NN O O
must NN O O
be NN O O
considered NN O O
even NN O O
in NN O O
patients NN O O
with NN O O
dystonic NN O B-Disease
symptoms NN O O
not NN O O
typical NN O O
of NN O O
dopa NN O B-Disease
- NN O I-Disease
responsive NN O I-Disease
dystonia NN O I-Disease
. NN O O

Germline NN O O
mutations NN O O
of NN O O
the NN O O
APC NN O B-Disease
gene NN O O
in NN O O
Korean NN O O
familial NN O B-Disease
adenomatous NN O I-Disease
polyposis NN O I-Disease
patients NN O O
. NN O O

We NN O O
extensively NN O O
analyzed NN O O
genomic NN O O
DNA NN O O
and NN O O
messenger NN O O
RNA NN O O
( NN O O
mRNA NN O O
) NN O O
from NN O O
62 NN O O
unrelated NN O O
Korean NN O O
patients NN O O
with NN O O
familial NN O B-Disease
adenomatous NN O I-Disease
polyposis NN O I-Disease
( NN O O
FAP NN O B-Disease
) NN O O
for NN O O
identification NN O O
of NN O O
germline NN O O
adenomatous NN O B-Disease
polyposis NN O I-Disease
coli NN O I-Disease
( NN O O
APC NN O B-Disease
) NN O O
gene NN O O
mutations NN O O
. NN O O

We NN O O
adopted NN O O
both NN O O
single NN O O
- NN O O
strand NN O O
conformation NN O O
polymorphism NN O O
( NN O O
SSCP NN O O
) NN O O
analysis NN O O
and NN O O
a NN O O
method NN O O
of NN O O
analysis NN O O
involving NN O O
the NN O O
reverse NN O O
transcription NN O O
- NN O O
polymerase NN O O
chain NN O O
reaction NN O O
( NN O O
RT NN O O
- NN O O
PCR NN O O
) NN O O
followed NN O O
by NN O O
a NN O O
protein NN O O
truncation NN O O
test NN O O
( NN O O
PTT NN O O
) NN O O
. NN O O

DNA NN O O
sequencing NN O O
confirmed NN O O
all NN O O
alterations NN O O
represented NN O O
by NN O O
aberrant NN O O
bands NN O O
. NN O O

Germline NN O O
mutations NN O O
were NN O O
identified NN O O
in NN O O
38 NN O O
patients NN O O
( NN O O
61 NN O O
% NN O O
) NN O O
. NN O O

Nineteen NN O O
of NN O O
the NN O O
detected NN O O
mutations NN O O
were NN O O
presumed NN O O
to NN O O
be NN O O
novel NN O O
, NN O O
thus NN O O
emphasizing NN O O
the NN O O
heterogeneity NN O O
of NN O O
the NN O O
mutational NN O O
spectrum NN O O
in NN O O
Korean NN O O
FAP NN O B-Disease
patients NN O O
. NN O O

In NN O O
the NN O O
initial NN O O
48 NN O O
patients NN O O
, NN O O
SSCP NN O O
analysis NN O O
was NN O O
followed NN O O
by NN O O
PTT NN O O
for NN O O
those NN O O
patients NN O O
for NN O O
whom NN O O
no NN O O
detectable NN O O
mutations NN O O
were NN O O
found NN O O
by NN O O
SSCP NN O O
. NN O O

Using NN O O
this NN O O
combined NN O O
approach NN O O
, NN O O
we NN O O
identified NN O O
germline NN O O
APC NN O B-Disease
gene NN O O
mutations NN O O
in NN O O
29 NN O O
of NN O O
the NN O O
48 NN O O
FAP NN O B-Disease
patients NN O O
( NN O O
60 NN O O
% NN O O
) NN O O
, NN O O
including NN O O
6 NN O O
patients NN O O
in NN O O
whom NN O O
SSCP NN O O
analysis NN O O
failed NN O O
to NN O O
distinguish NN O O
the NN O O
mutant NN O O
allele NN O O
. NN O O

In NN O O
the NN O O
14 NN O O
later NN O O
patients NN O O
, NN O O
we NN O O
identified NN O O
truncating NN O O
mutations NN O O
in NN O O
9 NN O O
patients NN O O
( NN O O
64 NN O O
% NN O O
) NN O O
using NN O O
PTT NN O O
only NN O O
. NN O O

Our NN O O
results NN O O
confirm NN O O
that NN O O
the NN O O
mutation NN O O
detection NN O O
rate NN O O
with NN O O
PTT NN O O
was NN O O
superior NN O O
to NN O O
that NN O O
with NN O O
SSCP NN O O
, NN O O
and NN O O
suggest NN O O
that NN O O
PTT NN O O
would NN O O
be NN O O
a NN O O
more NN O O
practical NN O O
screening NN O O
method NN O O
to NN O O
detect NN O O
germline NN O O
mutations NN O O
of NN O O
the NN O O
APC NN O B-Disease
gene NN O O
in NN O O
FAP NN O B-Disease
patients NN O O
. NN O O

Molecular NN O O
epidemiology NN O O
of NN O O
C9 NN O B-Disease
deficiency NN O I-Disease
heterozygotes NN O O
with NN O O
an NN O O
Arg95Stop NN O O
mutation NN O O
of NN O O
the NN O O
C9 NN O O
gene NN O O
in NN O O
Japan NN O O
. NN O O

Deficiency NN O B-Disease
of NN O I-Disease
the NN O I-Disease
ninth NN O I-Disease
component NN O I-Disease
of NN O I-Disease
human NN O I-Disease
complement NN O I-Disease
( NN O O
C9 NN O O
) NN O O
is NN O O
the NN O O
most NN O O
common NN O O
complement NN O B-Disease
deficiency NN O I-Disease
in NN O O
Japan NN O O
, NN O O
with NN O O
an NN O O
incidence NN O O
of NN O O
approximately NN O O
one NN O O
homozygote NN O O
in NN O O
1000 NN O O
, NN O O
but NN O O
is NN O O
very NN O O
rare NN O O
in NN O O
other NN O O
countries NN O O
. NN O O

Genetic NN O O
analyses NN O O
of NN O O
Japanese NN O O
C9 NN O B-Disease
deficiency NN O I-Disease
have NN O O
shown NN O O
that NN O O
a NN O O
C NN O O
- NN O O
to NN O O
- NN O O
T NN O O
transition NN O O
leading NN O O
to NN O O
TGA NN O O
stop NN O O
codon NN O O
for NN O O
Arg95 NN O O
in NN O O
exon NN O O
4 NN O O
of NN O O
the NN O O
C9 NN O O
gene NN O O
( NN O O
Arg95Stop NN O O
) NN O O
is NN O O
common NN O O
in NN O O
Japanese NN O O
C9 NN O B-Disease
deficiency NN O I-Disease
. NN O O

To NN O O
determine NN O O
the NN O O
prevalence NN O O
of NN O O
heterozygous NN O O
carriers NN O O
of NN O O
the NN O O
Arg95Stop NN O O
mutation NN O O
in NN O O
a NN O O
Japanese NN O O
population NN O O
, NN O O
we NN O O
collected NN O O
DNA NN O O
samples NN O O
from NN O O
300 NN O O
individuals NN O O
in NN O O
two NN O O
of NN O O
the NN O O
four NN O O
main NN O O
islands NN O O
of NN O O
Japan NN O O
. NN O O

Heterozygote NN O O
detection NN O O
was NN O O
performed NN O O
with NN O O
an NN O O
allele NN O O
- NN O O
specific NN O O
polymerase NN O O
chain NN O O
reaction NN O O
( NN O O
PCR NN O O
) NN O O
system NN O O
designed NN O O
to NN O O
detect NN O O
exclusively NN O O
only NN O O
one NN O O
of NN O O
the NN O O
normal NN O O
and NN O O
mutant NN O O
alleles NN O O
, NN O O
followed NN O O
by NN O O
confirmation NN O O
with NN O O
PCR NN O O
/ NN O O
single NN O O
- NN O O
strand NN O O
conformation NN O O
polymorphism NN O O
( NN O O
SSCP NN O O
) NN O O
analysis NN O O
and NN O O
direct NN O O
sequencing NN O O
. NN O O

Twenty NN O O
individuals NN O O
were NN O O
heterozygous NN O O
for NN O O
the NN O O
Arg95Stop NN O O
mutation NN O O
. NN O O

None NN O O
was NN O O
homozygous NN O O
. NN O O

The NN O O
prevalence NN O O
of NN O O
carriers NN O O
of NN O O
the NN O O
Arg95Stop NN O O
mutation NN O O
was NN O O
6 NN O O
. NN O O

7 NN O O
% NN O O
( NN O O
20 NN O O
/ NN O O
300 NN O O
) NN O O
. NN O O

An NN O O
estimated NN O O
frequency NN O O
( NN O O
0 NN O O
. NN O O
12 NN O O
% NN O O
) NN O O
of NN O O
complete NN O O
C9 NN O B-Disease
deficiency NN O I-Disease
due NN O O
to NN O O
homozygous NN O O
Arg95Stop NN O O
mutation NN O O
was NN O O
consistent NN O O
with NN O O
frequencies NN O O
determined NN O O
by NN O O
serological NN O O
studies NN O O

The NN O O
hereditary NN O B-Disease
hemochromatosis NN O I-Disease
protein NN O O
, NN O O
HFE NN O O
, NN O O
specifically NN O O
regulates NN O O
transferrin NN O O
- NN O O
mediated NN O O
iron NN O O
uptake NN O O
in NN O O
HeLa NN O O
cells NN O O
. NN O O

HFE NN O O
is NN O O
the NN O O
protein NN O O
product NN O O
of NN O O
the NN O O
gene NN O O
mutated NN O O
in NN O O
the NN O O
autosomal NN O B-Disease
recessive NN O I-Disease
disease NN O I-Disease
hereditary NN O B-Disease
hemochromatosis NN O I-Disease
( NN O O
Feder NN O O
, NN O O
J NN O O
. NN O O

N NN O O
. NN O O
, NN O O
Gnirke NN O O
, NN O O
A NN O O
. NN O O
, NN O O
Thomas NN O O
, NN O O
W NN O O
. NN O O
, NN O O
Tsuchihashi NN O O
, NN O O
Z NN O O
. NN O O
, NN O O
Ruddy NN O O
, NN O O
D NN O O
. NN O O

A NN O O
. NN O O
, NN O O
Basava NN O O
, NN O O
A NN O O
. NN O O
, NN O O
Dormishian NN O O
, NN O O
F NN O O
. NN O O
, NN O O
Domingo NN O O
, NN O O
R NN O O
. NN O O

J NN O O
. NN O O
, NN O O
Ellis NN O O
, NN O O
M NN O O
. NN O O

C NN O O
. NN O O
, NN O O
Fullan NN O O
, NN O O
A NN O O
. NN O O
, NN O O
Hinton NN O O
, NN O O
L NN O O
. NN O O

M NN O O
. NN O O
, NN O O
Jones NN O O
, NN O O
N NN O O
. NN O O

L NN O O
. NN O O
, NN O O
Kimmel NN O O
, NN O O
B NN O O
. NN O O

E NN O O
. NN O O
, NN O O
Kronmal NN O O
, NN O O
G NN O O
. NN O O

S NN O O
. NN O O
, NN O O
Lauer NN O O
, NN O O
P NN O O
. NN O O
, NN O O
Lee NN O O
, NN O O
V NN O O
. NN O O

K NN O O
. NN O O
, NN O O
Loeb NN O O
, NN O O
D NN O O
. NN O O

B NN O O
. NN O O
, NN O O
Mapa NN O O
, NN O O
F NN O O
. NN O O

A NN O O
. NN O O
, NN O O
McClelland NN O O
, NN O O
E NN O O
. NN O O
, NN O O
Meyer NN O O
, NN O O
N NN O O
. NN O O

C NN O O
. NN O O
, NN O O
Mintier NN O O
, NN O O
G NN O O
. NN O O

A NN O O
. NN O O
, NN O O
Moeller NN O O
, NN O O
N NN O O
. NN O O
, NN O O
Moore NN O O
, NN O O
T NN O O
. NN O O
, NN O O
Morikang NN O O
, NN O O
E NN O O
. NN O O
, NN O O
Prasss NN O O
, NN O O
C NN O O
. NN O O

E NN O O
. NN O O
, NN O O
Quintana NN O O
, NN O O
L NN O O
. NN O O
, NN O O
Starnes NN O O
, NN O O
S NN O O
. NN O O

M NN O O
. NN O O
, NN O O
Schatzman NN O O
, NN O O
R NN O O
. NN O O

C NN O O
. NN O O
, NN O O
Brunke NN O O
, NN O O
K NN O O
. NN O O

J NN O O
. NN O O
, NN O O
Drayna NN O O
, NN O O
D NN O O
. NN O O

T NN O O
. NN O O
, NN O O
Risch NN O O
, NN O O
N NN O O
. NN O O

J NN O O
. NN O O
, NN O O
Bacon NN O O
, NN O O
B NN O O
. NN O O

R NN O O
. NN O O
, NN O O
and NN O O
Wolff NN O O
, NN O O
R NN O O
. NN O O

R NN O O
. NN O O

( NN O O
1996 NN O O
) NN O O
Nat NN O O
. NN O O

Genet NN O O
. NN O O

13 NN O O
, NN O O
399 NN O O
- NN O O
408 NN O O
) NN O O
. NN O O

At NN O O
the NN O O
cell NN O O
surface NN O O
, NN O O
HFE NN O O
complexes NN O O
with NN O O
transferrin NN O O
receptor NN O O
( NN O O
TfR NN O O
) NN O O
, NN O O
increasing NN O O
the NN O O
dissociation NN O O
constant NN O O
of NN O O
transferrin NN O O
( NN O O
Tf NN O O
) NN O O
for NN O O
its NN O O
receptor NN O O
10 NN O O
- NN O O
fold NN O O
( NN O O
Gross NN O O
, NN O O
C NN O O
. NN O O

N NN O O
. NN O O
, NN O O
Irrinki NN O O
, NN O O
A NN O O
. NN O O
, NN O O
Feder NN O O
, NN O O
J NN O O
. NN O O
N NN O O
. NN O O
, NN O O
and NN O O
Enns NN O O
, NN O O
C NN O O
. NN O O
A NN O O
. NN O O
( NN O O
1998 NN O O
) NN O O
J NN O O
. NN O O
Biol NN O O
. NN O O
Chem NN O O
. NN O O
273 NN O O
, NN O O
22068 NN O O
- NN O O
22074 NN O O
; NN O O
Feder NN O O
, NN O O
J NN O O
. NN O O
N NN O O
. NN O O
, NN O O
Penny NN O O
, NN O O
D NN O O
. NN O O
M NN O O
. NN O O
, NN O O
Irrinki NN O O
, NN O O
A NN O O
. NN O O
, NN O O
Lee NN O O
, NN O O
V NN O O
. NN O O
K NN O O
. NN O O
, NN O O
Lebron NN O O
, NN O O
J NN O O
. NN O O
A NN O O
. NN O O
, NN O O
Watson NN O O
, NN O O
N NN O O
. NN O O
, NN O O
Tsuchihashi NN O O
, NN O O
Z NN O O
. NN O O
, NN O O
Sigal NN O O
, NN O O
E NN O O
. NN O O
, NN O O
Bjorkman NN O O
, NN O O
P NN O O
. NN O O
J NN O O
. NN O O
, NN O O
and NN O O
Schatzman NN O O
, NN O O
R NN O O
. NN O O
C NN O O
. NN O O
( NN O O
1998 NN O O
) NN O O
Proc NN O O
. NN O O
Natl NN O O
. NN O O

Acad NN O O
. NN O O

Sci NN O O
. NN O O

U NN O O
S NN O O
A NN O O
95 NN O O
, NN O O
1472 NN O O
- NN O O
1477 NN O O
) NN O O
. NN O O

HFE NN O O
does NN O O
not NN O O
remain NN O O
at NN O O
the NN O O
cell NN O O
surface NN O O
, NN O O
but NN O O
traffics NN O O
with NN O O
TfR NN O O
to NN O O
Tf NN O O
- NN O O
positive NN O O
internal NN O O
compartments NN O O
( NN O O
Gross NN O O
et NN O O
al NN O O
. NN O O
, NN O O
1998 NN O O
) NN O O
. NN O O

Using NN O O
a NN O O
HeLa NN O O
cell NN O O
line NN O O
in NN O O
which NN O O
the NN O O
expression NN O O
of NN O O
HFE NN O O
is NN O O
controlled NN O O
by NN O O
tetracycline NN O O
, NN O O
we NN O O
show NN O O
that NN O O
the NN O O
expression NN O O
of NN O O
HFE NN O O
reduces NN O O
55Fe NN O O
uptake NN O O
from NN O O
Tf NN O O
by NN O O
33 NN O O
% NN O O
but NN O O
does NN O O
not NN O O
affect NN O O
the NN O O
endocytic NN O O
or NN O O
exocytic NN O O
rates NN O O
of NN O O
TfR NN O O
cycling NN O O
. NN O O

Therefore NN O O
, NN O O
HFE NN O O
appears NN O O
to NN O O
reduce NN O O
cellular NN O O
acquisition NN O O
of NN O O
iron NN O O
from NN O O
Tf NN O O
within NN O O
endocytic NN O O
compartments NN O O
. NN O O

HFE NN O O
specifically NN O O
reduces NN O O
iron NN O O
uptake NN O O
from NN O O
Tf NN O O
, NN O O
as NN O O
non NN O O
- NN O O
Tf NN O O
- NN O O
mediated NN O O
iron NN O O
uptake NN O O
from NN O O
Fe NN O O
- NN O O
nitrilotriacetic NN O O
acid NN O O
is NN O O
not NN O O
altered NN O O
. NN O O

These NN O O
results NN O O
explain NN O O
the NN O O
decreased NN O O
ferritin NN O O
levels NN O O
seen NN O O
in NN O O
our NN O O
HeLa NN O O
cell NN O O
system NN O O
and NN O O
demonstrate NN O O
the NN O O
specific NN O O
control NN O O
of NN O O
HFE NN O O
over NN O O
the NN O O
Tf NN O O
- NN O O
mediated NN O O
pathway NN O O
of NN O O
iron NN O O
uptake NN O O
. NN O O

These NN O O
results NN O O
also NN O O
have NN O O
implications NN O O
for NN O O
the NN O O
understanding NN O O
of NN O O
cellular NN O O
iron NN O O
homeostasis NN O O
in NN O O
organs NN O O
such NN O O
as NN O O
the NN O O
liver NN O O
, NN O O
pancreas NN O O
, NN O O
heart NN O O
, NN O O
and NN O O
spleen NN O O
that NN O O
are NN O O
iron NN O O
loaded NN O O
in NN O O
hereditary NN O B-Disease
hemochromatotic NN O I-Disease
individuals NN O O
lacking NN O O
functional NN O O
HFE NN O O
. NN O O

Mutation NN O O
and NN O O
haplotype NN O O
studies NN O O
of NN O O
familial NN O B-Disease
Mediterranean NN O I-Disease
fever NN O I-Disease
reveal NN O O
new NN O O
ancestral NN O O
relationships NN O O
and NN O O
evidence NN O O
for NN O O
a NN O O
high NN O O
carrier NN O O
frequency NN O O
with NN O O
reduced NN O O
penetrance NN O O
in NN O O
the NN O O
Ashkenazi NN O O
Jewish NN O O
population NN O O
. NN O O

Familial NN O B-Disease
Mediterranean NN O I-Disease
fever NN O I-Disease
( NN O O
FMF NN O B-Disease
) NN O O
is NN O O
a NN O O
recessive NN O B-Disease
disorder NN O I-Disease
characterized NN O O
by NN O O
episodes NN O O
of NN O O
fever NN O O
with NN O O
serositis NN O B-Disease
or NN O O
synovitis NN O B-Disease
. NN O O

The NN O O
FMF NN O B-Disease
gene NN O O
( NN O O
MEFV NN O O
) NN O O
was NN O O
cloned NN O O
recently NN O O
, NN O O
and NN O O
four NN O O
missense NN O O
mutations NN O O
were NN O O
identified NN O O
. NN O O

Here NN O O
we NN O O
present NN O O
data NN O O
from NN O O
non NN O O
- NN O O
Ashkenazi NN O O
Jewish NN O O
and NN O O
Arab NN O O
patients NN O O
in NN O O
whom NN O O
we NN O O
had NN O O
not NN O O
originally NN O O
found NN O O
mutations NN O O
and NN O O
from NN O O
a NN O O
new NN O O
, NN O O
more NN O O
ethnically NN O O
diverse NN O O
panel NN O O
. NN O O

Among NN O O
90 NN O O
symptomatic NN O O
mutation NN O O
- NN O O
positive NN O O
individuals NN O O
, NN O O
11 NN O O
mutations NN O O
accounted NN O O
for NN O O
79 NN O O
% NN O O
of NN O O
carrier NN O O
chromosomes NN O O
. NN O O

Of NN O O
the NN O O
two NN O O
mutations NN O O
that NN O O
are NN O O
novel NN O O
, NN O O
one NN O O
alters NN O O
the NN O O
same NN O O
residue NN O O
( NN O O
680 NN O O
) NN O O
as NN O O
a NN O O
previously NN O O
known NN O O
mutation NN O O
, NN O O
and NN O O
the NN O O
other NN O O
( NN O O
P369S NN O O
) NN O O
is NN O O
located NN O O
in NN O O
exon NN O O
3 NN O O
. NN O O

Consistent NN O O
with NN O O
another NN O O
recent NN O O
report NN O O
, NN O O
the NN O O
E148Q NN O O
mutation NN O O
was NN O O
observed NN O O
in NN O O
patients NN O O
of NN O O
several NN O O
ethnicities NN O O
and NN O O
on NN O O
multiple NN O O
microsatellite NN O O
haplotypes NN O O
, NN O O
but NN O O
haplotype NN O O
data NN O O
indicate NN O O
an NN O O
ancestral NN O O
relationships NN O O
between NN O O
non NN O O
- NN O O
Jewish NN O O
Italian NN O O
and NN O O
Ashkenazi NN O O
Jewish NN O O
patients NN O O
with NN O O
FMF NN O B-Disease
and NN O O
other NN O O
affected NN O O
populations NN O O
. NN O O

Among NN O O
approximately NN O O
200 NN O O
anonymous NN O O
Ashkenazi NN O O
Jewish NN O O
DNA NN O O
samples NN O O
, NN O O
the NN O O
MEFV NN O O
carrier NN O O
frequency NN O O
was NN O O
21 NN O O
% NN O O
, NN O O
with NN O O
E148Q NN O O
the NN O O
most NN O O
common NN O O
mutation NN O O
. NN O O

Several NN O O
lines NN O O
of NN O O
evidence NN O O
indicate NN O O
reduced NN O O
penetrance NN O O
among NN O O
Ashkenazi NN O O
Jews NN O O
, NN O O
especially NN O O
for NN O O
E148Q NN O O
, NN O O
P369S NN O O
, NN O O
and NN O O
K695R NN O O
. NN O O

Nevertheless NN O O
, NN O O
E148Q NN O O
helps NN O O
account NN O O
for NN O O
recessive NN O O
inheritance NN O O
in NN O O
an NN O O
Ashkenazi NN O O
family NN O O
previously NN O O
reported NN O O
as NN O O
an NN O O
unusual NN O O
case NN O O
of NN O O
dominantly NN O O
inherited NN O O
FMF NN O B-Disease
. NN O O

The NN O O
presence NN O O
of NN O O
three NN O O
frequent NN O O
MEFV NN O O
mutations NN O O
in NN O O
multiple NN O O
Mediterranean NN O O
populations NN O O
strongly NN O O
suggests NN O O
a NN O O
heterozygote NN O O
advantage NN O O
in NN O O
this NN O O
geographic NN O O
region NN O O
. NN O O

Autoimmune NN O B-Disease
lymphoproliferative NN O I-Disease
syndrome NN O I-Disease
with NN O O
defective NN O O
Fas NN O O
: NN O O
genotype NN O O
influences NN O O
penetrance NN O O
. NN O O

Autoimmune NN O B-Disease
lymphoproliferative NN O I-Disease
syndrome NN O I-Disease
( NN O O
ALPS NN O B-Disease
) NN O O
is NN O O
a NN O O
disorder NN O B-Disease
of NN O I-Disease
lymphocyte NN O I-Disease
homeostasis NN O I-Disease
and NN O I-Disease
immunological NN O I-Disease
tolerance NN O I-Disease
. NN O O

Most NN O O
patients NN O O
have NN O O
a NN O O
heterozygous NN O O
mutation NN O O
in NN O O
the NN O O
APT1 NN O O
gene NN O O
, NN O O
which NN O O
encodes NN O O
Fas NN O O
( NN O O
CD95 NN O O
, NN O O
APO NN O O
- NN O O
1 NN O O
) NN O O
, NN O O
mediator NN O O
of NN O O
an NN O O
apoptotic NN O O
pathway NN O O
crucial NN O O
to NN O O
lymphocyte NN O O
homeostasis NN O O
. NN O O

Of NN O O
17 NN O O
unique NN O O
APT1 NN O O
mutations NN O O
in NN O O
unrelated NN O O
ALPS NN O B-Disease
probands NN O O
, NN O O
12 NN O O
( NN O O
71 NN O O
% NN O O
) NN O O
occurred NN O O
in NN O O
exons NN O O
7 NN O O
- NN O O
9 NN O O
, NN O O
which NN O O
encode NN O O
the NN O O
intracellular NN O O
portion NN O O
of NN O O
Fas NN O O
. NN O O

In NN O O
vitro NN O O
, NN O O
activated NN O O
lymphocytes NN O O
from NN O O
all NN O O
17 NN O O
patients NN O O
showed NN O O
apoptotic NN O O
defects NN O O
when NN O O
exposed NN O O
to NN O O
an NN O O
anti NN O O
- NN O O
Fas NN O O
agonist NN O O
monoclonal NN O O
antibody NN O O
. NN O O

Similar NN O O
defects NN O O
were NN O O
found NN O O
in NN O O
a NN O O
Fas NN O O
- NN O O
negative NN O O
cell NN O O
line NN O O
transfected NN O O
with NN O O
cDNAs NN O O
bearing NN O O
each NN O O
of NN O O
the NN O O
mutations NN O O
. NN O O

In NN O O
cotransfection NN O O
experiments NN O O
, NN O O
Fas NN O O
constructs NN O O
with NN O O
either NN O O
intra NN O O
- NN O O
or NN O O
extracellular NN O O
mutations NN O O
caused NN O O
dominant NN O O
inhibition NN O O
of NN O O
apoptosis NN O O
mediated NN O O
by NN O O
wild NN O O
- NN O O
type NN O O
Fas NN O O
. NN O O

Two NN O O
missense NN O O
Fas NN O O
variants NN O O
, NN O O
not NN O O
restricted NN O O
to NN O O
patients NN O O
with NN O O
ALPS NN O B-Disease
, NN O O
were NN O O
identified NN O O
. NN O O

Variant NN O O
A NN O O
( NN O O
- NN O O
1 NN O O
) NN O O
T NN O O
at NN O O
the NN O O
Fas NN O O
signal NN O O
- NN O O
sequence NN O O
cleavage NN O O
site NN O O
, NN O O
which NN O O
mediates NN O O
apoptosis NN O O
less NN O O
well NN O O
than NN O O
wild NN O O
- NN O O
type NN O O
Fas NN O O
and NN O O
is NN O O
partially NN O O
inhibitory NN O O
, NN O O
was NN O O
present NN O O
in NN O O
13 NN O O
% NN O O
of NN O O
African NN O O
American NN O O
alleles NN O O
. NN O O

Among NN O O
the NN O O
ALPS NN O B-Disease
- NN O O
associated NN O O
Fas NN O O
mutants NN O O
, NN O O
dominant NN O O
inhibition NN O O
of NN O O
apoptosis NN O O
was NN O O
much NN O O
more NN O O
pronounced NN O O
in NN O O
mutants NN O O
affecting NN O O
the NN O O
intracellular NN O O
, NN O O
versus NN O O
extracellular NN O O
, NN O O
portion NN O O
of NN O O
the NN O O
Fas NN O O
receptor NN O O
. NN O O

Mutations NN O O
causing NN O O
disruption NN O O
of NN O O
the NN O O
intracellular NN O O
Fas NN O O
death NN O O
domain NN O O
also NN O O
showed NN O O
a NN O O
higher NN O O
penetrance NN O O
of NN O O
ALPS NN O B-Disease
phenotype NN O O
features NN O O
in NN O O
mutation NN O O
- NN O O
bearing NN O O
relatives NN O O
. NN O O

Significant NN O O
ALPS NN O B-Disease
- NN O O
related NN O O
morbidity NN O O
occurred NN O O
in NN O O
44 NN O O
% NN O O
of NN O O
relatives NN O O
with NN O O
intracellular NN O O
mutations NN O O
, NN O O
versus NN O O
0 NN O O
% NN O O
of NN O O
relatives NN O O
with NN O O
extracellular NN O O
mutations NN O O
. NN O O

Thus NN O O
, NN O O
the NN O O
location NN O O
of NN O O
mutations NN O O
within NN O O
APT1 NN O O
strongly NN O O
influences NN O O
the NN O O
development NN O O
and NN O O
the NN O O
severity NN O O
of NN O O
ALPS NN O B-Disease
. NN O O

Multicentric NN O O
origin NN O O
of NN O O
hemochromatosis NN O B-Disease
gene NN O O
( NN O O
HFE NN O O
) NN O O
mutations NN O O
. NN O O

Genetic NN O B-Disease
hemochromatosis NN O I-Disease
( NN O O
GH NN O B-Disease
) NN O O
is NN O O
believed NN O O
to NN O O
be NN O O
a NN O O
disease NN O O
restricted NN O O
to NN O O
those NN O O
of NN O O
European NN O O
ancestry NN O O
. NN O O

In NN O O
northwestern NN O O
Europe NN O O
, NN O O
> NN O O
80 NN O O
% NN O O
of NN O O
GH NN O B-Disease
patients NN O O
are NN O O
homozygous NN O O
for NN O O
one NN O O
mutation NN O O
, NN O O
the NN O O
substitution NN O O
of NN O O
tyrosine NN O O
for NN O O
cysteine NN O O
at NN O O
position NN O O
282 NN O O
( NN O O
C282Y NN O O
) NN O O
in NN O O
the NN O O
unprocessed NN O O
protein NN O O
. NN O O

In NN O O
a NN O O
proportion NN O O
of NN O O
GH NN O B-Disease
patients NN O O
, NN O O
two NN O O
mutations NN O O
are NN O O
present NN O O
, NN O O
C282Y NN O O
and NN O O
H63D NN O O
. NN O O

The NN O O
clinical NN O O
significance NN O O
of NN O O
this NN O O
second NN O O
mutation NN O O
is NN O O
such NN O O
that NN O O
it NN O O
appears NN O O
to NN O O
predispose NN O O
1 NN O O
% NN O O
- NN O O
2 NN O O
% NN O O
of NN O O
compound NN O O
heterozygotes NN O O
to NN O O
expression NN O O
of NN O O
the NN O O
disease NN O O
. NN O O

The NN O O
distribution NN O O
of NN O O
the NN O O
two NN O O
mutations NN O O
differ NN O O
, NN O O
C282Y NN O O
being NN O O
limited NN O O
to NN O O
those NN O O
of NN O O
northwestern NN O O
European NN O O
ancestry NN O O
and NN O O
H63D NN O O
being NN O O
found NN O O
at NN O O
allele NN O O
frequencies NN O O
> NN O O
5 NN O O
% NN O O
, NN O O
in NN O O
Europe NN O O
, NN O O
in NN O O
countries NN O O
bordering NN O O
the NN O O
Mediterranean NN O O
, NN O O
in NN O O
the NN O O
Middle NN O O
East NN O O
, NN O O
and NN O O
in NN O O
the NN O O
Indian NN O O
subcontinent NN O O
. NN O O

The NN O O
C282Y NN O O
mutation NN O O
occurs NN O O
on NN O O
a NN O O
haplotype NN O O
that NN O O
extends NN O O
< NN O O
/ NN O O
= NN O O
6 NN O O
Mb NN O O
, NN O O
suggesting NN O O
that NN O O
this NN O O
mutation NN O O
has NN O O
arisen NN O O
during NN O O
the NN O O
past NN O O
2 NN O O
, NN O O
000 NN O O
years NN O O
. NN O O

The NN O O
H63D NN O O
mutation NN O O
is NN O O
older NN O O
and NN O O
does NN O O
not NN O O
occur NN O O
on NN O O
such NN O O
a NN O O
large NN O O
extended NN O O
haplotype NN O O
, NN O O
the NN O O
haplotype NN O O
in NN O O
this NN O O
case NN O O
extending NN O O
< NN O O
/ NN O O
= NN O O
700 NN O O
kb NN O O
. NN O O

Here NN O O
we NN O O
report NN O O
the NN O O
finding NN O O
of NN O O
the NN O O
H63D NN O O
and NN O O
C282Y NN O O
mutations NN O O
on NN O O
new NN O O
haplotypes NN O O
. NN O O

In NN O O
Sri NN O O
Lanka NN O O
we NN O O
have NN O O
found NN O O
H63D NN O O
on NN O O
three NN O O
new NN O O
haplotypes NN O O
and NN O O
have NN O O
found NN O O
C282Y NN O O
on NN O O
one NN O O
new NN O O
haplotype NN O O
, NN O O
demonstrating NN O O
that NN O O
these NN O O
mutations NN O O
have NN O O
arisen NN O O
independently NN O O
on NN O O
this NN O O
island NN O O
. NN O O

These NN O O
results NN O O
suggest NN O O
that NN O O
the NN O O
HFE NN O O
gene NN O O
has NN O O
been NN O O
the NN O O
subject NN O O
of NN O O
selection NN O O
pressure NN O O
. NN O O

These NN O O
selection NN O O
pressures NN O O
could NN O O
be NN O O
due NN O O
to NN O O
infectious NN O B-Disease
diseases NN O I-Disease
, NN O O
environmental NN O O
conditions NN O O
, NN O O
or NN O O
other NN O O
genetic NN O B-Disease
disorders NN O I-Disease
such NN O O
as NN O O
anemia NN O B-Disease
. NN O O

A NN O O
retrospective NN O O
anonymous NN O O
pilot NN O O
study NN O O
in NN O O
screening NN O O
newborns NN O O
for NN O O
HFE NN O O
mutations NN O O
in NN O O
Scandinavian NN O O
populations NN O O
. NN O O

We NN O O
have NN O O
retrospectively NN O O
analyzed NN O O
837 NN O O
random NN O O
anonymized NN O O
dried NN O O
blood NN O O
spot NN O O
( NN O O
DBS NN O O
) NN O O
samples NN O O
from NN O O
neonatal NN O O
screening NN O O
programs NN O O
in NN O O
Scandinavia NN O O
for NN O O
mutations NN O O
in NN O O
HFE NN O O
, NN O O
the NN O O
candidate NN O O
gene NN O O
for NN O O
hemochromatosis NN O B-Disease
. NN O O

We NN O O
have NN O O
found NN O O
C282Y NN O O
allele NN O O
frequencies NN O O
of NN O O
2 NN O O
. NN O O

3 NN O O
% NN O O
( NN O O
+ NN O O
2 NN O O
. NN O O
0 NN O O
% NN O O
) NN O O
( NN O O
- NN O O
1 NN O O
. NN O O
3 NN O O
% NN O O
) NN O O
in NN O O
Greenland NN O O
, NN O O
4 NN O O
. NN O O

5 NN O O
% NN O O
+ NN O O
/ NN O O
- NN O O
1 NN O O
. NN O O

9 NN O O
% NN O O
in NN O O
Iceland NN O O
, NN O O
5 NN O O
. NN O O

1 NN O O
% NN O O
+ NN O O
/ NN O O
- NN O O
2 NN O O
. NN O O

3 NN O O
% NN O O
in NN O O
the NN O O
Faeroe NN O O
Islands NN O O
, NN O O
and NN O O
8 NN O O
. NN O O

2 NN O O
% NN O O
+ NN O O
/ NN O O
- NN O O
2 NN O O
. NN O O

7 NN O O
% NN O O
in NN O O
Denmark NN O O
. NN O O

The NN O O
high NN O O
prevalence NN O O
of NN O O
HFE NN O O
mutations NN O O
in NN O O
Denmark NN O O
suggests NN O O
that NN O O
population NN O O
screening NN O O
for NN O O
the NN O O
C282Y NN O O
mutation NN O O
could NN O O
be NN O O
highly NN O O
advantageous NN O O
in NN O O
terms NN O O
of NN O O
preventive NN O O
health NN O O
care NN O O
. NN O O

Long NN O O
- NN O O
term NN O O
follow NN O O
- NN O O
up NN O O
evaluation NN O O
of NN O O
C282Y NN O O
homozygotes NN O O
and NN O O
H63D NN O O
/ NN O O
C282Y NN O O
compound NN O O
heterozygotes NN O O
will NN O O
give NN O O
an NN O O
indication NN O O
of NN O O
the NN O O
penetrance NN O O
of NN O O
the NN O O
mutations NN O O
. NN O O

Identification NN O O
of NN O O
the NN O O
mutation NN O O
in NN O O
the NN O O
alkaptonuria NN O B-Disease
mouse NN O O
model NN O O
. NN O O

Alkaptonuria NN O B-Disease
( NN O O
aku NN O B-Disease
) NN O O
, NN O O
an NN O O
inborn NN O B-Disease
error NN O I-Disease
of NN O I-Disease
metabolism NN O I-Disease
caused NN O O
by NN O O
the NN O O
loss NN O O
of NN O O
homogentisate NN O O
1 NN O O
, NN O O
2 NN O O
- NN O O
dioxygenase NN O O
( NN O O
HGD NN O O
) NN O O
, NN O O
has NN O O
been NN O O
described NN O O
in NN O O
a NN O O
mouse NN O O
model NN O O
created NN O O
by NN O O
ethylnitrosourea NN O O
mutagenesis NN O O
but NN O O
the NN O O
mutation NN O O
in NN O O
these NN O O
mice NN O O
has NN O O
not NN O O
previously NN O O
been NN O O
identified NN O O
. NN O O

We NN O O
used NN O O
RT NN O O
- NN O O
PCR NN O O
to NN O O
amplify NN O O
the NN O O
Hgd NN O O
cDNA NN O O
from NN O O
Hgd NN O O
( NN O O
aku NN O O
) NN O O
/ NN O O
Hgd NN O O
( NN O O
aku NN O O
) NN O O
mice NN O O
. NN O O

Two NN O O
products NN O O
shorter NN O O
than NN O O
the NN O O
wild NN O O
- NN O O
type NN O O
product NN O O
were NN O O
amplified NN O O
. NN O O

Restriction NN O O
mapping NN O O
and NN O O
DNA NN O O
sequencing NN O O
were NN O O
then NN O O
used NN O O
to NN O O
identify NN O O
the NN O O
Hgd NN O O
( NN O O
aku NN O O
) NN O O
mouse NN O O
mutation NN O O
, NN O O
found NN O O
to NN O O
be NN O O
a NN O O
single NN O O
base NN O O
change NN O O
in NN O O
a NN O O
splice NN O O
donor NN O O
consensus NN O O
sequence NN O O
, NN O O
causing NN O O
exon NN O O
skipping NN O O
and NN O O
frame NN O O
- NN O O
shifted NN O O
products NN O O
. NN O O

This NN O O
base NN O O
change NN O O
allowed NN O O
us NN O O
to NN O O
create NN O O
a NN O O
non NN O O
- NN O O
radioactive NN O O
genotyping NN O O
assay NN O O
for NN O O
this NN O O
allele NN O O
. NN O O

Non NN O B-Disease
- NN O I-Disease
syndromic NN O I-Disease
hearing NN O I-Disease
loss NN O I-Disease
associated NN O O
with NN O O
enlarged NN O B-Disease
vestibular NN O I-Disease
aqueduct NN O I-Disease
is NN O O
caused NN O O
by NN O O
PDS NN O B-Disease
mutations NN O O
. NN O O

Enlarged NN O B-Disease
vestibular NN O I-Disease
aqueduct NN O I-Disease
( NN O O
EVA NN O B-Disease
) NN O O
, NN O O
known NN O O
as NN O O
the NN O O
most NN O O
common NN O O
form NN O O
of NN O O
inner NN O B-Disease
ear NN O I-Disease
abnormality NN O I-Disease
, NN O O
has NN O O
recently NN O O
been NN O O
of NN O O
particular NN O O
genetic NN O O
interest NN O O
because NN O O
this NN O O
anomaly NN O O
is NN O O
inherited NN O O
in NN O O
a NN O O
recessive NN O O
manner NN O O
. NN O O

The NN O O
locus NN O O
for NN O O
non NN O B-Disease
- NN O I-Disease
syndromic NN O I-Disease
sensorineural NN O I-Disease
hearing NN O I-Disease
loss NN O I-Disease
with NN O O
EVA NN O B-Disease
has NN O O
been NN O O
mapped NN O O
to NN O O
the NN O O
same NN O O
chromosomal NN O O
region NN O O
, NN O O
7q31 NN O O
, NN O O
as NN O O
the NN O O
Pendred NN O B-Disease
syndrome NN O I-Disease
locus NN O O
. NN O O

In NN O O
the NN O O
present NN O O
study NN O O
, NN O O
seven NN O O
mutations NN O O
in NN O O
the NN O O
PDS NN O B-Disease
gene NN O O
( NN O O
PDS NN O O
) NN O O
, NN O O
the NN O O
gene NN O O
responsible NN O O
for NN O O
Pendred NN O B-Disease
syndrome NN O I-Disease
, NN O O
have NN O O
been NN O O
found NN O O
in NN O O
families NN O O
of NN O O
non NN O B-Disease
- NN O I-Disease
syndromic NN O I-Disease
sensorineural NN O I-Disease
hearing NN O I-Disease
loss NN O I-Disease
with NN O O
EVA NN O B-Disease
. NN O O

One NN O O
family NN O O
is NN O O
homozygous NN O O
, NN O O
three NN O O
families NN O O
are NN O O
compound NN O O
heterozygotes NN O O
, NN O O
and NN O O
two NN O O
families NN O O
are NN O O
heterozygous NN O O
but NN O O
with NN O O
no NN O O
other NN O O
mutation NN O O
detected NN O O
. NN O O

The NN O O
present NN O O
results NN O O
provide NN O O
evidence NN O O
that NN O O
mutations NN O O
in NN O O
PDS NN O O
cause NN O O
both NN O O
syndromic NN O B-Disease
and NN O I-Disease
non NN O I-Disease
- NN O I-Disease
syndromic NN O I-Disease
hearing NN O I-Disease
loss NN O I-Disease
. NN O O
. NN O O

Mutational NN O O
analysis NN O O
and NN O O
genotype NN O O
- NN O O
phenotype NN O O
correlation NN O O
of NN O O
29 NN O O
unrelated NN O O
Japanese NN O O
patients NN O O
with NN O O
X NN O B-Disease
- NN O I-Disease
linked NN O I-Disease
adrenoleukodystrophy NN O I-Disease
. NN O O

BACKGROUND NN O O
X NN O B-Disease
- NN O I-Disease
linked NN O I-Disease
adrenoleukodystrophy NN O I-Disease
( NN O O
ALD NN O B-Disease
) NN O O
is NN O O
an NN O O
inherited NN O B-Disease
disease NN O I-Disease
characterized NN O O
by NN O O
progressive NN O O
neurologic NN O B-Disease
dysfunction NN O I-Disease
, NN O O
occasionally NN O O
associated NN O O
with NN O O
adrenal NN O B-Disease
insufficiency NN O I-Disease
. NN O O

The NN O O
classic NN O O
form NN O O
of NN O O
ALD NN O B-Disease
usually NN O O
has NN O O
onset NN O O
in NN O O
childhood NN O O
( NN O O
childhood NN O B-Disease
cerebral NN O I-Disease
ALD NN O I-Disease
) NN O O
, NN O O
with NN O O
rapid NN O O
neurologic NN O B-Disease
deterioration NN O I-Disease
leading NN O O
to NN O O
a NN O O
vegetative NN O O
state NN O O
. NN O O

Adult NN O O
- NN O O
onset NN O O
cerebral NN O B-Disease
ALD NN O I-Disease
also NN O O
presents NN O O
with NN O O
rapidly NN O O
progressive NN O O
neurologic NN O B-Disease
dysfunction NN O I-Disease
. NN O O

Milder NN O O
phenotypes NN O O
such NN O O
as NN O O
adrenomyeloneuropathy NN O B-Disease
and NN O O
Addison NN O B-Disease
disease NN O I-Disease
only NN O O
also NN O O
have NN O O
been NN O O
recognized NN O O
. NN O O

Despite NN O O
discovery NN O O
of NN O O
the NN O O
causative NN O O
gene NN O O
, NN O O
a NN O O
molecular NN O O
basis NN O O
for NN O O
the NN O O
diverse NN O O
clinical NN O O
presentations NN O O
remains NN O O
to NN O O
be NN O O
elucidated NN O O
. NN O O

OBJECTIVES NN O O
To NN O O
conduct NN O O
mutational NN O O
analyses NN O O
in NN O O
29 NN O O
Japanese NN O O
patients NN O O
with NN O O
ALD NN O B-Disease
from NN O O
29 NN O O
unrelated NN O O
families NN O O
, NN O O
to NN O O
obtain NN O O
knowledge NN O O
of NN O O
the NN O O
spectrum NN O O
of NN O O
mutations NN O O
in NN O O
this NN O O
gene NN O O
, NN O O
and NN O O
to NN O O
study NN O O
genotype NN O O
- NN O O
phenotype NN O O
correlations NN O O
in NN O O
Japanese NN O O
patients NN O O
. NN O O

METHODS NN O O
The NN O O
29 NN O O
patients NN O O
comprised NN O O
13 NN O O
patients NN O O
with NN O O
childhood NN O B-Disease
cerebral NN O I-Disease
ALD NN O I-Disease
, NN O O
11 NN O O
patients NN O O
with NN O O
adult NN O O
- NN O O
onset NN O O
cerebral NN O B-Disease
ALD NN O I-Disease
, NN O O
and NN O O
5 NN O O
patients NN O O
with NN O O
adrenomyeloneuropathy NN O B-Disease
. NN O O

We NN O O
conducted NN O O
detailed NN O O
mutational NN O O
analyses NN O O
of NN O O
29 NN O O
unrelated NN O O
Japanese NN O O
patients NN O O
with NN O O
ALD NN O B-Disease
by NN O O
genomic NN O O
Southern NN O O
blot NN O O
analysis NN O O
and NN O O
direct NN O O
nucleotide NN O O
sequence NN O O
analysis NN O O
of NN O O
reverse NN O O
transcriptase NN O O
- NN O O
polymerase NN O O
chain NN O O
reaction NN O O
products NN O O
derived NN O O
from NN O O
total NN O O
RNA NN O O
that NN O O
was NN O O
extracted NN O O
from NN O O
cultured NN O O
skin NN O O
fibroblasts NN O O
, NN O O
lymphoblastoid NN O O
cells NN O O
, NN O O
or NN O O
peripheral NN O O
blood NN O O
leukocytes NN O O
. NN O O

RESULTS NN O O
Three NN O O
patients NN O O
with NN O O
adult NN O O
- NN O O
onset NN O O
cerebral NN O B-Disease
ALD NN O I-Disease
were NN O O
identified NN O O
as NN O O
having NN O O
large NN O O
genomic NN O O
rearrangements NN O O
. NN O O

The NN O O
remaining NN O O
26 NN O O
patients NN O O
were NN O O
identified NN O O
as NN O O
having NN O O
21 NN O O
independent NN O O
mutations NN O O
, NN O O
including NN O O
12 NN O O
novel NN O O
mutations NN O O
resulting NN O O
in NN O O
small NN O O
nucleotide NN O O
alterations NN O O
in NN O O
the NN O O
ALD NN O B-Disease
gene NN O O
. NN O O

Eighteen NN O O
( NN O O
69 NN O O
% NN O O
) NN O O
of NN O O
26 NN O O
mutations NN O O
were NN O O
missense NN O O
mutations NN O O
. NN O O

Most NN O O
missense NN O O
mutations NN O O
involved NN O O
amino NN O O
acids NN O O
conserved NN O O
in NN O O
homologous NN O O
gene NN O O
products NN O O
, NN O O
including NN O O
PMP70 NN O O
, NN O O
mALDRP NN O O
, NN O O
and NN O O
Pxa1p NN O O
. NN O O

The NN O O
AG NN O O
dinucleotide NN O O
deletion NN O O
at NN O O
position NN O O
1081 NN O O
- NN O O
1082 NN O O
, NN O O
which NN O O
has NN O O
been NN O O
reported NN O O
previously NN O O
to NN O O
be NN O O
the NN O O
most NN O O
common NN O O
mutation NN O O
in NN O O
white NN O O
patients NN O O
( NN O O
12 NN O O
% NN O O
- NN O O
17 NN O O
% NN O O
) NN O O
, NN O O
was NN O O
also NN O O
identified NN O O
as NN O O
the NN O O
most NN O O
common NN O O
mutation NN O O
in NN O O
Japanese NN O O
patients NN O O
( NN O O
12 NN O O
% NN O O
) NN O O
. NN O O

All NN O O
phenotypes NN O O
were NN O O
associated NN O O
with NN O O
mutations NN O O
resulting NN O O
in NN O O
protein NN O O
truncation NN O O
or NN O O
subtle NN O O
amino NN O O
acid NN O O
changes NN O O
. NN O O

There NN O O
were NN O O
no NN O O
differences NN O O
in NN O O
phenotypic NN O O
expressions NN O O
between NN O O
missense NN O O
mutations NN O O
involving NN O O
conserved NN O O
amino NN O O
acids NN O O
and NN O O
those NN O O
involving NN O O
nonconserved NN O O
amino NN O O
acids NN O O
. NN O O

CONCLUSIONS NN O O
There NN O O
are NN O O
no NN O O
obvious NN O O
correlations NN O O
between NN O O
the NN O O
phenotypes NN O O
of NN O O
patients NN O O
with NN O O
ALD NN O B-Disease
and NN O O
their NN O O
genotypes NN O O
, NN O O
suggesting NN O O
that NN O O
other NN O O
genetic NN O O
or NN O O
environmental NN O O
factors NN O O
modify NN O O
the NN O O
phenotypic NN O O
expressions NN O O
of NN O O
ALD NN O B-Disease
. NN O O
. NN O O

A NN O O
common NN O O
human NN O O
skin NN O B-Disease
tumour NN O I-Disease
is NN O O
caused NN O O
by NN O O
activating NN O O
mutations NN O O
in NN O O
beta NN O O
- NN O O
catenin NN O O
. NN O O

WNT NN O O
signalling NN O O
orchestrates NN O O
a NN O O
number NN O O
of NN O O
developmental NN O O
programs NN O O
. NN O O

In NN O O
response NN O O
to NN O O
this NN O O
stimulus NN O O
, NN O O
cytoplasmic NN O O
beta NN O O
- NN O O
catenin NN O O
( NN O O
encoded NN O O
by NN O O
CTNNB1 NN O O
) NN O O
is NN O O
stabilized NN O O
, NN O O
enabling NN O O
downstream NN O O
transcriptional NN O O
activation NN O O
by NN O O
members NN O O
of NN O O
the NN O O
LEF NN O O
/ NN O O
TCF NN O O
family NN O O
. NN O O

One NN O O
of NN O O
the NN O O
target NN O O
genes NN O O
for NN O O
beta NN O O
- NN O O
catenin NN O O
/ NN O O
TCF NN O O
encodes NN O O
c NN O O
- NN O O
MYC NN O O
, NN O O
explaining NN O O
why NN O O
constitutive NN O O
activation NN O O
of NN O O
the NN O O
WNT NN O O
pathway NN O O
can NN O O
lead NN O O
to NN O O
cancer NN O B-Disease
, NN O O
particularly NN O O
in NN O O
the NN O O
colon NN O O
. NN O O

Most NN O O
colon NN O B-Disease
cancers NN O I-Disease
arise NN O O
from NN O O
mutations NN O O
in NN O O
the NN O O
gene NN O O
encoding NN O O
adenomatous NN O B-Disease
polyposis NN O I-Disease
coli NN O I-Disease
( NN O O
APC NN O B-Disease
) NN O O
, NN O O
a NN O O
protein NN O O
required NN O O
for NN O O
ubiquitin NN O O
- NN O O
mediated NN O O
degradation NN O O
of NN O O
beta NN O O
- NN O O
catenin NN O O
, NN O O
but NN O O
a NN O O
small NN O O
percentage NN O O
of NN O O
colon NN O B-Disease
and NN O I-Disease
some NN O I-Disease
other NN O I-Disease
cancers NN O I-Disease
harbour NN O O
beta NN O O
- NN O O
catenin NN O O
- NN O O
stabilizing NN O O
mutations NN O O
. NN O O

Recently NN O O
, NN O O
we NN O O
discovered NN O O
that NN O O
transgenic NN O O
mice NN O O
expressing NN O O
an NN O O
activated NN O O
beta NN O O
- NN O O
catenin NN O O
are NN O O
predisposed NN O O
to NN O O
developing NN O O
skin NN O B-Disease
tumours NN O I-Disease
resembling NN O O
pilomatricomas NN O B-Disease
. NN O O

Given NN O O
that NN O O
the NN O O
skin NN O O
of NN O O
these NN O O
adult NN O O
mice NN O O
also NN O O
exhibits NN O O
signs NN O O
of NN O O
de NN O O
novo NN O O
hair NN O O
- NN O O
follicle NN O O
morphogenesis NN O O
, NN O O
we NN O O
wondered NN O O
whether NN O O
human NN O O
pilomatricomas NN O B-Disease
might NN O O
originate NN O O
from NN O O
hair NN O O
matrix NN O O
cells NN O O
and NN O O
whether NN O O
they NN O O
might NN O O
possess NN O O
beta NN O O
- NN O O
catenin NN O O
- NN O O
stabilizing NN O O
mutations NN O O
. NN O O

Here NN O O
, NN O O
we NN O O
explore NN O O
the NN O O
cell NN O O
origin NN O O
and NN O O
aetiology NN O O
of NN O O
this NN O O
common NN O O
human NN O O
skin NN O B-Disease
tumour NN O I-Disease
. NN O O

We NN O O
found NN O O
nuclear NN O O
LEF NN O O
- NN O O
1 NN O O
in NN O O
the NN O O
dividing NN O O
tumour NN O B-Disease
cells NN O O
, NN O O
providing NN O O
biochemical NN O O
evidence NN O O
that NN O O
pilomatricomas NN O B-Disease
are NN O O
derived NN O O
from NN O O
hair NN O O
matrix NN O O
cells NN O O
. NN O O

At NN O O
least NN O O
75 NN O O
% NN O O
of NN O O
these NN O O
tumours NN O B-Disease
possess NN O O
mutations NN O O
affecting NN O O
the NN O O
amino NN O O
- NN O O
terminal NN O O
segment NN O O
, NN O O
normally NN O O
involved NN O O
in NN O O
phosphorylation NN O O
- NN O O
dependent NN O O
, NN O O
ubiquitin NN O O
- NN O O
mediated NN O O
degradation NN O O
of NN O O
the NN O O
protein NN O O
. NN O O

This NN O O
percentage NN O O
of NN O O
CTNNB1 NN O O
mutations NN O O
is NN O O
greater NN O O
than NN O O
in NN O O
all NN O O
other NN O O
human NN O O
tumours NN O B-Disease
examined NN O O
thus NN O O
far NN O O
, NN O O
and NN O O
directly NN O O
implicates NN O O
beta NN O O
- NN O O
catenin NN O O
/ NN O O
LEF NN O O
misregulation NN O O
as NN O O
the NN O O
major NN O O
cause NN O O
of NN O O
hair NN O O
matrix NN O O
cell NN O O
tumorigenesis NN O O
in NN O O
humans NN O O
. NN O O
. NN O O

The NN O O
Pendred NN O B-Disease
syndrome NN O I-Disease
gene NN O O
encodes NN O O
a NN O O
chloride NN O O
- NN O O
iodide NN O O
transport NN O O
protein NN O O
. NN O O

Pendred NN O B-Disease
syndrome NN O I-Disease
is NN O O
the NN O O
most NN O O
common NN O O
form NN O O
of NN O O
syndromic NN O B-Disease
deafness NN O I-Disease
and NN O O
characterized NN O O
by NN O O
congenital NN O O
sensorineural NN O B-Disease
hearing NN O I-Disease
loss NN O I-Disease
and NN O O
goitre NN O B-Disease
. NN O O

This NN O O
disorder NN O O
was NN O O
mapped NN O O
to NN O O
chromosome NN O O
7 NN O O
and NN O O
the NN O O
gene NN O O
causing NN O O
Pendred NN O B-Disease
syndrome NN O I-Disease
( NN O O
PDS NN O B-Disease
) NN O O
was NN O O
subsequently NN O O
identified NN O O
by NN O O
positional NN O O
cloning NN O O
. NN O O

PDS NN O O
encodes NN O O
a NN O O
putative NN O O
transmembrane NN O O
protein NN O O
designated NN O O
pendrin NN O O
. NN O O

Pendrin NN O O
is NN O O
closely NN O O
related NN O O
to NN O O
a NN O O
family NN O O
of NN O O
sulfate NN O O
transport NN O O
proteins NN O O
that NN O O
includes NN O O
the NN O O
rat NN O O
sulfate NN O O
- NN O O
anion NN O O
transporter NN O O
( NN O O
encoded NN O O
by NN O O
Sat NN O O
- NN O O
1 NN O O
; NN O O
29 NN O O
% NN O O
amino NN O O
acid NN O O
sequence NN O O
identity NN O O
) NN O O
, NN O O
the NN O O
human NN O O
diastrophic NN O B-Disease
dysplasia NN O I-Disease
sulfate NN O O
transporter NN O O
( NN O O
encoded NN O O
by NN O O
DTD NN O O
; NN O O
32 NN O O
% NN O O
) NN O O
and NN O O
the NN O O
human NN O O
sulfate NN O O
transporter NN O O
downregulated NN O O
in NN O O
adenoma NN O B-Disease
( NN O O
encoded NN O O
by NN O O
DRA NN O O
; NN O O
45 NN O O
% NN O O
) NN O O
. NN O O

On NN O O
the NN O O
basis NN O O
of NN O O
this NN O O
homology NN O O
and NN O O
the NN O O
presence NN O O
of NN O O
a NN O O
slightly NN O O
modified NN O O
sulfate NN O O
- NN O O
transporter NN O O
signature NN O O
sequence NN O O
comprising NN O O
its NN O O
putative NN O O
second NN O O
transmembrane NN O O
domain NN O O
, NN O O
pendrin NN O O
has NN O O
been NN O O
proposed NN O O
to NN O O
function NN O O
as NN O O
a NN O O
sulfate NN O O
transporter NN O O
. NN O O

We NN O O
were NN O O
unable NN O O
to NN O O
detect NN O O
evidence NN O O
of NN O O
sulfate NN O O
transport NN O O
following NN O O
the NN O O
expression NN O O
of NN O O
pendrin NN O O
in NN O O
Xenopus NN O O
laevis NN O O
oocytes NN O O
by NN O O
microinjection NN O O
of NN O O
PDS NN O O
cRNA NN O O
or NN O O
in NN O O
Sf9 NN O O
cells NN O O
following NN O O
infection NN O O
with NN O O
PDS NN O O
- NN O O
recombinant NN O O
baculovirus NN O O
. NN O O

The NN O O
rates NN O O
of NN O O
transport NN O O
for NN O O
iodide NN O O
and NN O O
chloride NN O O
were NN O O
significantly NN O O
increased NN O O
following NN O O
the NN O O
expression NN O O
of NN O O
pendrin NN O O
in NN O O
both NN O O
cell NN O O
systems NN O O
. NN O O

Our NN O O
results NN O O
demonstrate NN O O
that NN O O
pendrin NN O O
functions NN O O
as NN O O
a NN O O
transporter NN O O
of NN O O
chloride NN O O
and NN O O
iodide NN O O
, NN O O
but NN O O
not NN O O
sulfate NN O O
, NN O O
and NN O O
may NN O O
provide NN O O
insight NN O O
into NN O O
thyroid NN O O
physiology NN O O
and NN O O
the NN O O
pathophysiology NN O O
of NN O O
Pendred NN O B-Disease
syndrome NN O I-Disease
. NN O O
. NN O O

HFE NN O O
mutations NN O O
analysis NN O O
in NN O O
711 NN O O
hemochromatosis NN O B-Disease
probands NN O O
: NN O O
evidence NN O O
for NN O O
S65C NN O O
implication NN O O
in NN O O
mild NN O O
form NN O O
of NN O O
hemochromatosis NN O B-Disease
. NN O O

Hereditary NN O B-Disease
hemochromatosis NN O I-Disease
( NN O O
HH NN O B-Disease
) NN O O
is NN O O
a NN O O
common NN O O
autosomal NN O B-Disease
recessive NN O I-Disease
genetic NN O I-Disease
disorder NN O I-Disease
of NN O O
iron NN O O
metabolism NN O O
. NN O O

The NN O O
HFE NN O O
candidate NN O O
gene NN O O
encoding NN O O
an NN O O
HLA NN O O
class NN O O
I NN O O
- NN O O
like NN O O
protein NN O O
involved NN O O
in NN O O
HH NN O B-Disease
was NN O O
identified NN O O
in NN O O
1996 NN O O
. NN O O

Two NN O O
missense NN O O
mutations NN O O
have NN O O
been NN O O
described NN O O
C282Y NN O O
, NN O O
accounting NN O O
for NN O O
80 NN O O
% NN O O
to NN O O
90 NN O O
% NN O O
of NN O O
HH NN O B-Disease
chromosomes NN O O
, NN O O
and NN O O
H63D NN O O
, NN O O
which NN O O
is NN O O
associated NN O O
with NN O O
a NN O O
milder NN O O
form NN O O
of NN O O
the NN O O
disease NN O O
representing NN O O
40 NN O O
% NN O O
to NN O O
70 NN O O
% NN O O
of NN O O
non NN O O
- NN O O
C282Y NN O O
HH NN O B-Disease
chromosomes NN O O
. NN O O

We NN O O
report NN O O
here NN O O
on NN O O
the NN O O
analysis NN O O
of NN O O
C282Y NN O O
, NN O O
H63D NN O O
, NN O O
and NN O O
the NN O O
193A NN O O
- NN O O
- NN O O
> NN O O
T NN O O
substitution NN O O
leading NN O O
to NN O O
the NN O O
S65C NN O O
missense NN O O
substitution NN O O
in NN O O
a NN O O
large NN O O
series NN O O
of NN O O
probands NN O O
and NN O O
controls NN O O
. NN O O

The NN O O
results NN O O
confirm NN O O
that NN O O
the NN O O
C282Y NN O O
substitution NN O O
was NN O O
the NN O O
main NN O O
mutation NN O O
involved NN O O
in NN O O
hemochromatosis NN O B-Disease
, NN O O
accounting NN O O
for NN O O
85 NN O O
% NN O O
of NN O O
carrier NN O O
chromosomes NN O O
, NN O O
whereas NN O O
the NN O O
H63D NN O O
substitution NN O O
represented NN O O
39 NN O O
% NN O O
of NN O O
the NN O O
HH NN O B-Disease
chromosomes NN O O
that NN O O
did NN O O
not NN O O
carry NN O O
the NN O O
C282Y NN O O
mutation NN O O
. NN O O

In NN O O
addition NN O O
, NN O O
our NN O O
screening NN O O
showed NN O O
that NN O O
the NN O O
S65C NN O O
substitution NN O O
was NN O O
significantly NN O O
enriched NN O O
in NN O O
probands NN O O
with NN O O
at NN O O
least NN O O
one NN O O
chromosome NN O O
without NN O O
an NN O O
assigned NN O O
mutation NN O O
. NN O O

This NN O O
substitution NN O O
accounted NN O O
for NN O O
7 NN O O
. NN O O

8 NN O O
% NN O O
of NN O O
HH NN O B-Disease
chromosomes NN O O
that NN O O
were NN O O
neither NN O O
C282Y NN O O
nor NN O O
H63D NN O O
. NN O O

This NN O O
enrichment NN O O
of NN O O
S65C NN O O
among NN O O
HH NN O B-Disease
chromosomes NN O O
suggests NN O O
that NN O O
the NN O O
S65C NN O O
substitution NN O O
is NN O O
associated NN O O
with NN O O
the NN O O
mild NN O O
form NN O O
of NN O O
hemochromatosis NN O B-Disease
. NN O O

Germline NN O O
BRCA1 NN O O
alterations NN O O
in NN O O
a NN O O
population NN O O
- NN O O
based NN O O
series NN O O
of NN O O
ovarian NN O B-Disease
cancer NN O I-Disease
cases NN O O
. NN O O

The NN O O
objective NN O O
of NN O O
this NN O O
study NN O O
was NN O O
to NN O O
provide NN O O
more NN O O
accurate NN O O
frequency NN O O
estimates NN O O
of NN O O
breast NN O B-Disease
cancer NN O I-Disease
susceptibility NN O O
gene NN O O
1 NN O O
( NN O O
BRCA1 NN O O
) NN O O
germline NN O O
alterations NN O O
in NN O O
the NN O O
ovarian NN O B-Disease
cancer NN O I-Disease
population NN O O
. NN O O

To NN O O
achieve NN O O
this NN O O
, NN O O
we NN O O
determined NN O O
the NN O O
prevalence NN O O
of NN O O
BRCA1 NN O O
alterations NN O O
in NN O O
a NN O O
population NN O O
- NN O O
based NN O O
series NN O O
of NN O O
consecutive NN O O
ovarian NN O B-Disease
cancer NN O I-Disease
cases NN O O
. NN O O

This NN O O
is NN O O
the NN O O
first NN O O
population NN O O
- NN O O
based NN O O
ovarian NN O B-Disease
cancer NN O I-Disease
study NN O O
reporting NN O O
BRCA1 NN O O
alterations NN O O
derived NN O O
from NN O O
a NN O O
comprehensive NN O O
screen NN O O
of NN O O
the NN O O
entire NN O O
coding NN O O
region NN O O
. NN O O

One NN O O
hundred NN O O
and NN O O
seven NN O O
ovarian NN O B-Disease
cancer NN O I-Disease
cases NN O O
were NN O O
analyzed NN O O
for NN O O
BRCA1 NN O O
alterations NN O O
using NN O O
the NN O O
RNase NN O O
mismatch NN O O
cleavage NN O O
assay NN O O
followed NN O O
by NN O O
direct NN O O
sequencing NN O O
. NN O O

Two NN O O
truncating NN O O
mutations NN O O
, NN O O
962del4 NN O O
and NN O O
3600del11 NN O O
, NN O O
were NN O O
identified NN O O
. NN O O

Both NN O O
patients NN O O
had NN O O
a NN O O
family NN O O
history NN O O
of NN O O
breast NN O B-Disease
or NN O I-Disease
ovarian NN O I-Disease
cancer NN O I-Disease
. NN O O

Several NN O O
novel NN O O
as NN O O
well NN O O
as NN O O
previously NN O O
reported NN O O
uncharacterized NN O O
variants NN O O
were NN O O
also NN O O
identified NN O O
, NN O O
some NN O O
of NN O O
which NN O O
were NN O O
associated NN O O
with NN O O
a NN O O
family NN O O
history NN O O
of NN O O
cancer NN O B-Disease
. NN O O

The NN O O
frequency NN O O
distribution NN O O
of NN O O
common NN O O
polymorphisms NN O O
was NN O O
determined NN O O
in NN O O
the NN O O
91 NN O O
Caucasian NN O O
cancer NN O B-Disease
cases NN O O
in NN O O
this NN O O
series NN O O
and NN O O
24 NN O O
sister NN O O
controls NN O O
using NN O O
allele NN O O
- NN O O
specific NN O O
amplification NN O O
. NN O O

The NN O O
rare NN O O
form NN O O
of NN O O
the NN O O
Q356R NN O O
polymorphism NN O O
was NN O O
significantly NN O O
( NN O O
P NN O O
= NN O O
0 NN O O
. NN O O
03 NN O O
) NN O O
associated NN O O
with NN O O
a NN O O
family NN O O
history NN O O
of NN O O
ovarian NN O B-Disease
cancer NN O I-Disease
, NN O O
suggesting NN O O
that NN O O
this NN O O
polymorphism NN O O
may NN O O
influence NN O O
ovarian NN O B-Disease
cancer NN O I-Disease
risk NN O O
. NN O O

In NN O O
summary NN O O
, NN O O
our NN O O
data NN O O
suggest NN O O
a NN O O
role NN O O
for NN O O
some NN O O
uncharacterized NN O O
variants NN O O
and NN O O
rare NN O O
forms NN O O
of NN O O
polymorphisms NN O O
in NN O O
determining NN O O
ovarian NN O B-Disease
cancer NN O I-Disease
risk NN O O
, NN O O
and NN O O
highlight NN O O
the NN O O
necessity NN O O
to NN O O
screen NN O O
for NN O O
missense NN O O
alterations NN O O
as NN O O
well NN O O
as NN O O
truncating NN O O
mutations NN O O
in NN O O
this NN O O
population NN O O
. NN O O

Adrenoleukodystrophy NN O O
- NN O O
related NN O O
protein NN O O
can NN O O
compensate NN O O
functionally NN O O
for NN O O
adrenoleukodystrophy NN O B-Disease
protein NN O I-Disease
deficiency NN O I-Disease
( NN O O
X NN O B-Disease
- NN O I-Disease
ALD NN O I-Disease
) NN O O
: NN O O
implications NN O O
for NN O O
therapy NN O O
. NN O O

Inherited NN O B-Disease
defects NN O I-Disease
in NN O O
the NN O O
peroxisomal NN O O
ATP NN O O
- NN O O
binding NN O O
cassette NN O O
( NN O O
ABC NN O O
) NN O O
transporter NN O O
adrenoleukodystrophy NN O B-Disease
protein NN O O
( NN O O
ALDP NN O O
) NN O O
lead NN O O
to NN O O
the NN O O
lethal NN O O
peroxisomal NN O B-Disease
disorder NN O I-Disease
X NN O B-Disease
- NN O I-Disease
linked NN O I-Disease
adrenoleukodystrophy NN O I-Disease
( NN O O
X NN O B-Disease
- NN O I-Disease
ALD NN O I-Disease
) NN O O
, NN O O
for NN O O
which NN O O
no NN O O
efficient NN O O
treatment NN O O
has NN O O
been NN O O
established NN O O
so NN O O
far NN O O
. NN O O

Three NN O O
other NN O O
peroxisomal NN O O
ABC NN O O
transporters NN O O
currently NN O O
are NN O O
known NN O O
adrenoleukodystrophy NN O O
- NN O O
related NN O O
protein NN O O
( NN O O
ALDRP NN O O
) NN O O
, NN O O
70 NN O O
kDa NN O O
peroxisomal NN O O
membrane NN O O
protein NN O O
( NN O O
PMP70 NN O O
) NN O O
and NN O O
PMP70 NN O O
- NN O O
related NN O O
protein NN O O
. NN O O

By NN O O
using NN O O
transient NN O O
and NN O O
stable NN O O
overexpression NN O O
of NN O O
human NN O O
cDNAs NN O O
encoding NN O O
ALDP NN O O
and NN O O
its NN O O
closest NN O O
relative NN O O
ALDRP NN O O
, NN O O
we NN O O
could NN O O
restore NN O O
the NN O O
impaired NN O O
peroxisomal NN O O
beta NN O O
- NN O O
oxidation NN O O
in NN O O
fibroblasts NN O O
of NN O O
X NN O B-Disease
- NN O I-Disease
ALD NN O I-Disease
patients NN O O
. NN O O

The NN O O
pathognomonic NN O O
accumulation NN O O
of NN O O
very NN O O
long NN O O
chain NN O O
fatty NN O O
acids NN O O
could NN O O
also NN O O
be NN O O
prevented NN O O
by NN O O
overexpression NN O O
of NN O O
ALDRP NN O O
in NN O O
immortalized NN O O
X NN O O
- NN O O
ALD NN O O
cells NN O O
. NN O O

Immunofluorescence NN O O
analysis NN O O
demonstrated NN O O
that NN O O
the NN O O
functional NN O O
replacement NN O O
of NN O O
ALDP NN O O
by NN O O
ALDRP NN O O
was NN O O
not NN O O
due NN O O
to NN O O
stabilization NN O O
of NN O O
the NN O O
mutated NN O O
ALDP NN O O
itself NN O O
. NN O O

Moreover NN O O
, NN O O
we NN O O
were NN O O
able NN O O
to NN O O
restore NN O O
the NN O O
peroxisomal NN O O
beta NN O O
- NN O O
oxidation NN O O
defect NN O O
in NN O O
the NN O O
liver NN O O
of NN O O
ALDP NN O O
- NN O O
deficient NN O O
mice NN O O
by NN O O
stimulation NN O O
of NN O O
ALDRP NN O O
and NN O O
PMP70 NN O O
gene NN O O
expression NN O O
through NN O O
a NN O O
dietary NN O O
treatment NN O O
with NN O O
the NN O O
peroxisome NN O O
proliferator NN O O
fenofibrate NN O O
. NN O O

These NN O O
results NN O O
suggest NN O O
that NN O O
a NN O O
correction NN O O
of NN O O
the NN O O
biochemical NN O O
defect NN O O
in NN O O
X NN O B-Disease
- NN O I-Disease
ALD NN O I-Disease
could NN O O
be NN O O
possible NN O O
by NN O O
drug NN O O
- NN O O
induced NN O O
overexpression NN O O
or NN O O
ectopic NN O O
expression NN O O
of NN O O
ALDRP NN O O
. NN O O
. NN O O

Centrosome NN O O
amplification NN O O
and NN O O
a NN O O
defective NN O O
G2 NN O O
- NN O O
M NN O O
cell NN O O
cycle NN O O
checkpoint NN O O
induce NN O O
genetic NN O O
instability NN O O
in NN O O
BRCA1 NN O O
exon NN O O
11 NN O O
isoform NN O O
- NN O O
deficient NN O O
cells NN O O
. NN O O

Germline NN O O
mutations NN O O
of NN O O
the NN O O
Brca1 NN O O
tumor NN O B-Disease
suppressor NN O O
gene NN O O
predispose NN O O
women NN O O
to NN O O
breast NN O B-Disease
and NN O I-Disease
ovarian NN O I-Disease
cancers NN O I-Disease
. NN O O

To NN O O
study NN O O
mechanisms NN O O
underlying NN O O
BRCA1 NN O O
- NN O O
related NN O O
tumorigenesis NN O O
, NN O O
we NN O O
derived NN O O
mouse NN O O
embryonic NN O O
fibroblast NN O O
cells NN O O
carrying NN O O
a NN O O
targeted NN O O
deletion NN O O
of NN O O
exon NN O O
11 NN O O
of NN O O
the NN O O
Brca1 NN O O
gene NN O O
. NN O O

We NN O O
show NN O O
that NN O O
the NN O O
mutant NN O O
cells NN O O
maintain NN O O
an NN O O
intact NN O O
G1 NN O O
- NN O O
S NN O O
cell NN O O
cycle NN O O
checkpoint NN O O
and NN O O
proliferate NN O O
poorly NN O O
. NN O O

However NN O O
, NN O O
a NN O O
defective NN O O
G2 NN O O
- NN O O
M NN O O
checkpoint NN O O
in NN O O
these NN O O
cells NN O O
is NN O O
accompanied NN O O
by NN O O
extensive NN O O
chromosomal NN O B-Disease
abnormalities NN O I-Disease
. NN O O

Mutant NN O O
fibroblasts NN O O
contain NN O O
multiple NN O O
, NN O O
functional NN O O
centrosomes NN O O
, NN O O
which NN O O
lead NN O O
to NN O O
unequal NN O O
chromosome NN O O
segregation NN O O
, NN O O
abnormal NN O O
nuclear NN O O
division NN O O
, NN O O
and NN O O
aneuploidy NN O B-Disease
. NN O O

These NN O O
data NN O O
uncover NN O O
an NN O O
essential NN O O
role NN O O
of NN O O
BRCA1 NN O O
in NN O O
maintaining NN O O
genetic NN O O
stability NN O O
through NN O O
the NN O O
regulation NN O O
of NN O O
centrosome NN O O
duplication NN O O
and NN O O
the NN O O
G2 NN O O
- NN O O
M NN O O
checkpoint NN O O
and NN O O
provide NN O O
a NN O O
molecular NN O O
basis NN O O
for NN O O
the NN O O
role NN O O
of NN O O
BRCA1 NN O O
in NN O O
tumorigenesis NN O O
. NN O O
. NN O O

Defective NN O O
CD95 NN O O
/ NN O O
APO NN O O
- NN O O
1 NN O O
/ NN O O
Fas NN O O
signal NN O O
complex NN O O
formation NN O O
in NN O O
the NN O O
human NN O O
autoimmune NN O B-Disease
lymphoproliferative NN O I-Disease
syndrome NN O I-Disease
, NN O I-Disease
type NN O I-Disease
Ia NN O I-Disease
. NN O O

Heterozygous NN O O
mutations NN O O
in NN O O
the NN O O
CD95 NN O O
( NN O O
APO NN O O
- NN O O
1 NN O O
/ NN O O
Fas NN O O
) NN O O
receptor NN O O
occur NN O O
in NN O O
most NN O O
individuals NN O O
with NN O O
autoimmune NN O B-Disease
lymphoproliferative NN O I-Disease
syndrome NN O I-Disease
( NN O O
ALPS NN O B-Disease
) NN O O
and NN O O
dominantly NN O O
interfere NN O O
with NN O O
apoptosis NN O O
by NN O O
an NN O O
unknown NN O O
mechanism NN O O
. NN O O

We NN O O
show NN O O
that NN O O
local NN O O
or NN O O
global NN O O
alterations NN O O
in NN O O
the NN O O
structure NN O O
of NN O O
the NN O O
cytoplasmic NN O O
death NN O O
domain NN O O
from NN O O
nine NN O O
independent NN O O
ALPS NN O B-Disease
CD95 NN O O
death NN O O
- NN O O
domain NN O O
mutations NN O O
result NN O O
in NN O O
a NN O O
failure NN O O
to NN O O
bind NN O O
the NN O O
FADD NN O O
/ NN O O
MORT1 NN O O
signaling NN O O
protein NN O O
. NN O O

Despite NN O O
heterozygosity NN O O
for NN O O
the NN O O
abnormal NN O O
allele NN O O
, NN O O
lymphocytes NN O O
from NN O O
ALPS NN O B-Disease
patients NN O O
showed NN O O
markedly NN O O
decreased NN O O
FADD NN O O
association NN O O
and NN O O
a NN O O
loss NN O O
of NN O O
caspase NN O O
recruitment NN O O
and NN O O
activation NN O O
after NN O O
CD95 NN O O
crosslinking NN O O
. NN O O

These NN O O
data NN O O
suggest NN O O
that NN O O
intracytoplasmic NN O O
CD95 NN O O
mutations NN O O
in NN O O
ALPS NN O B-Disease
impair NN O O
apoptosis NN O O
chiefly NN O O
by NN O O
disrupting NN O O
death NN O O
- NN O O
domain NN O O
interactions NN O O
with NN O O
the NN O O
signaling NN O O
protein NN O O
FADD NN O O
/ NN O O
MORT1 NN O O
. NN O O
. NN O O

Analysis NN O O
of NN O O
alkaptonuria NN O B-Disease
( NN O O
AKU NN O B-Disease
) NN O O
mutations NN O O
and NN O O
polymorphisms NN O O
reveals NN O O
that NN O O
the NN O O
CCC NN O O
sequence NN O O
motif NN O O
is NN O O
a NN O O
mutational NN O O
hot NN O O
spot NN O O
in NN O O
the NN O O
homogentisate NN O O
1 NN O O
, NN O O
2 NN O O
dioxygenase NN O O
gene NN O O
( NN O O
HGO NN O O
) NN O O
. NN O O

We NN O O
recently NN O O
showed NN O O
that NN O O
alkaptonuria NN O B-Disease
( NN O O
AKU NN O B-Disease
) NN O O
is NN O O
caused NN O O
by NN O O
loss NN O O
- NN O O
of NN O O
- NN O O
function NN O O
mutations NN O O
in NN O O
the NN O O
homogentisate NN O O
1 NN O O
, NN O O
2 NN O O
dioxygenase NN O O
gene NN O O
( NN O O
HGO NN O O
) NN O O
. NN O O

Herein NN O O
we NN O O
describe NN O O
haplotype NN O O
and NN O O
mutational NN O O
analyses NN O O
of NN O O
HGO NN O O
in NN O O
seven NN O O
new NN O O
AKU NN O B-Disease
pedigrees NN O O
. NN O O

These NN O O
analyses NN O O
identified NN O O
two NN O O
novel NN O O
single NN O O
- NN O O
nucleotide NN O O
polymorphisms NN O O
( NN O O
INV4 NN O O
+ NN O O
31A NN O O
- NN O O
- NN O O
> NN O O
G NN O O
and NN O O
INV11 NN O O
+ NN O O
18A NN O O
- NN O O
- NN O O
> NN O O
G NN O O
) NN O O
and NN O O
six NN O O
novel NN O O
AKU NN O B-Disease
mutations NN O O
( NN O O
INV1 NN O O
- NN O O
1G NN O O
- NN O O
- NN O O
> NN O O
A NN O O
, NN O O
W60G NN O O
, NN O O
Y62C NN O O
, NN O O
A122D NN O O
, NN O O
P230T NN O O
, NN O O
and NN O O
D291E NN O O
) NN O O
, NN O O
which NN O O
further NN O O
illustrates NN O O
the NN O O
remarkable NN O O
allelic NN O O
heterogeneity NN O O
found NN O O
in NN O O
AKU NN O B-Disease
. NN O O

Reexamination NN O O
of NN O O
all NN O O
29 NN O O
mutations NN O O
and NN O O
polymorphisms NN O O
thus NN O O
far NN O O
described NN O O
in NN O O
HGO NN O O
shows NN O O
that NN O O
these NN O O
nucleotide NN O O
changes NN O O
are NN O O
not NN O O
randomly NN O O
distributed NN O O
; NN O O
the NN O O
CCC NN O O
sequence NN O O
motif NN O O
and NN O O
its NN O O
inverted NN O O
complement NN O O
, NN O O
GGG NN O O
, NN O O
are NN O O
preferentially NN O O
mutated NN O O
. NN O O

These NN O O
analyses NN O O
also NN O O
demonstrated NN O O
that NN O O
the NN O O
nucleotide NN O O
substitutions NN O O
in NN O O
HGO NN O O
do NN O O
not NN O O
involve NN O O
CpG NN O O
dinucleotides NN O O
, NN O O
which NN O O
illustrates NN O O
important NN O O
differences NN O O
between NN O O
HGO NN O O
and NN O O
other NN O O
genes NN O O
for NN O O
the NN O O
occurrence NN O O
of NN O O
mutation NN O O
at NN O O
specific NN O O
short NN O O
- NN O O
sequence NN O O
motifs NN O O
. NN O O

Because NN O O
the NN O O
CCC NN O O
sequence NN O O
motifs NN O O
comprise NN O O
a NN O O
significant NN O O
proportion NN O O
( NN O O
34 NN O O
. NN O O
5 NN O O
% NN O O
) NN O O
of NN O O
all NN O O
mutated NN O O
bases NN O O
that NN O O
have NN O O
been NN O O
observed NN O O
in NN O O
HGO NN O O
, NN O O
we NN O O
conclude NN O O
that NN O O
the NN O O
CCC NN O O
triplet NN O O
is NN O O
a NN O O
mutational NN O O
hot NN O O
spot NN O O
in NN O O
HGO NN O O
. NN O O

Fabry NN O B-Disease
disease NN O I-Disease
: NN O O
identification NN O O
of NN O O
novel NN O O
alpha NN O O
- NN O O
galactosidase NN O O
A NN O O
mutations NN O O
and NN O O
molecular NN O O
carrier NN O O
detection NN O O
by NN O O
use NN O O
of NN O O
fluorescent NN O O
chemical NN O O
cleavage NN O O
of NN O O
mismatches NN O O
. NN O O

Fabry NN O B-Disease
disease NN O I-Disease
( NN O O
FD NN O B-Disease
) NN O O
( NN O O
angiokeratoma NN O B-Disease
corporis NN O I-Disease
diffusum NN O I-Disease
) NN O O
is NN O O
an NN O O
X NN O B-Disease
- NN O I-Disease
linked NN O I-Disease
inborn NN O I-Disease
error NN O I-Disease
of NN O I-Disease
glycosphingolipid NN O I-Disease
metabolism NN O I-Disease
caused NN O O
by NN O O
defects NN O O
in NN O O
the NN O O
lysosomal NN O O
alpha NN O O
- NN O O
galactosidase NN O O
A NN O O
gene NN O O
( NN O O
GLA NN O O
) NN O O
. NN O O

The NN O O
enzymatic NN O O
defect NN O O
leads NN O O
to NN O O
the NN O O
systemic NN O O
accumulation NN O O
of NN O O
neutral NN O O
glycosphingolipids NN O O
with NN O O
terminal NN O O
alpha NN O O
- NN O O
galactosyl NN O O
moieties NN O O
. NN O O

Clinically NN O O
, NN O O
affected NN O O
hemizygous NN O O
males NN O O
have NN O O
angiokeratoma NN O B-Disease
, NN O O
severe NN O B-Disease
acroparesthesia NN O I-Disease
, NN O O
renal NN O B-Disease
failure NN O I-Disease
, NN O O
and NN O O
vasculopathy NN O B-Disease
of NN O I-Disease
the NN O I-Disease
heart NN O I-Disease
and NN O I-Disease
brain NN O I-Disease
. NN O O

While NN O O
demonstration NN O O
of NN O O
alpha NN O B-Disease
- NN O I-Disease
galactosidase NN O I-Disease
deficiency NN O I-Disease
in NN O O
leukocytes NN O O
is NN O O
diagnostic NN O O
in NN O O
affected NN O O
males NN O O
, NN O O
enzymatic NN O O
detection NN O O
of NN O O
female NN O O
carriers NN O O
is NN O O
often NN O O
inconclusive NN O O
, NN O O
due NN O O
to NN O O
random NN O O
X NN O O
- NN O O
chromosomal NN O O
inactivation NN O O
, NN O O
underlining NN O O
the NN O O
need NN O O
of NN O O
molecular NN O O
investigations NN O O
for NN O O
accurate NN O O
genetic NN O O
counseling NN O O
. NN O O

By NN O O
use NN O O
of NN O O
chemical NN O O
cleavage NN O O
of NN O O
mismatches NN O O
adapted NN O O
to NN O O
fluorescence NN O O
- NN O O
based NN O O
detection NN O O
systems NN O O
, NN O O
we NN O O
have NN O O
characterized NN O O
the NN O O
mutations NN O O
underlying NN O O
alpha NN O B-Disease
- NN O I-Disease
Gal NN O I-Disease
A NN O I-Disease
deficiency NN O I-Disease
in NN O O
16 NN O O
individuals NN O O
from NN O O
six NN O O
unrelated NN O O
families NN O O
with NN O O
FD NN O B-Disease
. NN O O

The NN O O
mutational NN O O
spectrum NN O O
included NN O O
five NN O O
missense NN O O
mutations NN O O
( NN O O
C202W NN O O
, NN O O
C223G NN O O
, NN O O
N224D NN O O
, NN O O
R301Q NN O O
, NN O O
and NN O O
Q327K NN O O
) NN O O
and NN O O
one NN O O
splice NN O O
- NN O O
site NN O O
mutation NN O O
[ NN O O
IVS3 NN O O
G NN O O
( NN O O
- NN O O
1 NN O O
) NN O O
- NN O O
- NN O O
> NN O O
C NN O O
] NN O O
. NN O O

Studies NN O O
at NN O O
the NN O O
mRNA NN O O
level NN O O
showed NN O O
that NN O O
the NN O O
latter NN O O
led NN O O
to NN O O
altered NN O O
pre NN O O
- NN O O
mRNA NN O O
splicing NN O O
with NN O O
consequent NN O O
alteration NN O O
of NN O O
the NN O O
mRNA NN O O
translational NN O O
reading NN O O
frame NN O O
and NN O O
generation NN O O
of NN O O
a NN O O
premature NN O O
termination NN O O
codon NN O O
of NN O O
translation NN O O
. NN O O

By NN O O
use NN O O
of NN O O
this NN O O
strategy NN O O
, NN O O
carrier NN O O
status NN O O
was NN O O
accurately NN O O
assessed NN O O
in NN O O
all NN O O
seven NN O O
at NN O O
- NN O O
risk NN O O
females NN O O
tested NN O O
, NN O O
whereas NN O O
enzymatic NN O O
dosages NN O O
failed NN O O
to NN O O
diagnose NN O O
or NN O O
exclude NN O O
heterozygosity NN O O
. NN O O
. NN O O

Prenatal NN O O
diagnosis NN O O
by NN O O
FISH NN O O
in NN O O
a NN O O
family NN O O
with NN O O
Pelizaeus NN O B-Disease
- NN O I-Disease
Merzbacher NN O I-Disease
disease NN O I-Disease
caused NN O O
by NN O O
duplication NN O O
of NN O O
PLP NN O O
gene NN O O
. NN O O

A NN O O
diagnosis NN O O
of NN O O
Pelizaeus NN O B-Disease
- NN O I-Disease
Merzbacher NN O I-Disease
disease NN O I-Disease
( NN O O
MIM NN O O
312080 NN O O
) NN O O
was NN O O
made NN O O
in NN O O
a NN O O
young NN O O
boy NN O O
. NN O O

No NN O O
mutation NN O O
in NN O O
the NN O O
coding NN O O
region NN O O
of NN O O
the NN O O
proteolipid NN O O
protein NN O O
( NN O O
PLP NN O O
) NN O O
gene NN O O
had NN O O
been NN O O
found NN O O
. NN O O

The NN O O
boys NN O O
maternal NN O O
aunt NN O O
came NN O O
for NN O O
prenatal NN O O
diagnosis NN O O
when NN O O
16 NN O O
+ NN O O
weeks NN O O
pregnant NN O O
and NN O O
carrying NN O O
a NN O O
male NN O O
fetus NN O O
. NN O O

Samples NN O O
were NN O O
tested NN O O
for NN O O
duplication NN O O
of NN O O
the NN O O
PLP NN O O
gene NN O O
, NN O O
by NN O O
interphase NN O O
FISH NN O O
, NN O O
in NN O O
lymphocyte NN O O
preparations NN O O
from NN O O
the NN O O
proband NN O O
, NN O O
his NN O O
aunt NN O O
and NN O O
an NN O O
amniotic NN O O
fluid NN O O
cell NN O O
preparation NN O O
from NN O O
the NN O O
fetus NN O O
. NN O O

The NN O O
proband NN O O
was NN O O
found NN O O
to NN O O
carry NN O O
the NN O O
duplication NN O O
, NN O O
thus NN O O
confirming NN O O
the NN O O
diagnosis NN O O
of NN O O
Pelizaeus NN O B-Disease
Merzbacher NN O I-Disease
disease NN O I-Disease
, NN O O
but NN O O
neither NN O O
the NN O O
aunt NN O O
nor NN O O
the NN O O
fetus NN O O
carried NN O O
a NN O O
duplication NN O O
. NN O O
. NN O O

Dominant NN O O
negative NN O O
effect NN O O
of NN O O
the NN O O
APC1309 NN O O
mutation NN O O
: NN O O
a NN O O
possible NN O O
explanation NN O O
for NN O O
genotype NN O O
- NN O O
phenotype NN O O
correlations NN O O
in NN O O
familial NN O B-Disease
adenomatous NN O I-Disease
polyposis NN O I-Disease
. NN O O

Inactivation NN O O
of NN O O
the NN O O
adenomatous NN O B-Disease
polyposis NN O I-Disease
coli NN O I-Disease
( NN O O
APC NN O B-Disease
) NN O O
gene NN O O
product NN O O
initiates NN O O
colorectal NN O O
tumorigenesis NN O O
. NN O O

Patients NN O O
with NN O O
familial NN O B-Disease
APC NN O I-Disease
( NN O O
FAP NN O B-Disease
) NN O O
carry NN O O
germ NN O O
- NN O O
line NN O O
mutations NN O O
in NN O O
the NN O O
APC NN O B-Disease
gene NN O O
and NN O O
develop NN O O
multiple NN O O
colorectal NN O B-Disease
adenomas NN O I-Disease
and NN O O
subsequent NN O O
carcinomas NN O B-Disease
early NN O O
in NN O O
life NN O O
. NN O O

The NN O O
severity NN O O
of NN O O
the NN O O
disease NN O O
correlates NN O O
with NN O O
the NN O O
position NN O O
of NN O O
the NN O O
inherited NN O O
APC NN O B-Disease
mutation NN O O
( NN O O
genotype NN O O
- NN O O
phenotype NN O O
correlation NN O O
) NN O O
. NN O O

Together NN O O
with NN O O
the NN O O
fact NN O O
that NN O O
both NN O O
germ NN O O
- NN O O
line NN O O
and NN O O
sporadic NN O O
APC NN O B-Disease
mutations NN O O
cluster NN O O
in NN O O
the NN O O
central NN O O
region NN O O
of NN O O
the NN O O
APC NN O B-Disease
gene NN O O
, NN O O
this NN O O
points NN O O
to NN O O
a NN O O
dominant NN O O
negative NN O O
effect NN O O
of NN O O
certain NN O O
APC NN O B-Disease
mutants NN O O
. NN O O

Loss NN O O
of NN O O
APC NN O B-Disease
function NN O O
was NN O O
recently NN O O
shown NN O O
to NN O O
result NN O O
in NN O O
enhanced NN O O
beta NN O O
- NN O O
catenin NN O O
- NN O O
/ NN O O
Tcf NN O O
- NN O O
mediated NN O O
transcription NN O O
in NN O O
colon NN O O
epithelial NN O O
cells NN O O
. NN O O

Here NN O O
, NN O O
we NN O O
provide NN O O
experimental NN O O
evidence NN O O
for NN O O
a NN O O
dominant NN O O
negative NN O O
effect NN O O
of NN O O
APC NN O B-Disease
gene NN O O
products NN O O
associated NN O O
with NN O O
severe NN O O
polyposis NN O B-Disease
. NN O O

Wild NN O O
- NN O O
type NN O O
APC NN O B-Disease
activity NN O O
in NN O O
beta NN O O
- NN O O
catenin NN O O
- NN O O
/ NN O O
Tcf NN O O
- NN O O
mediated NN O O
transcription NN O O
was NN O O
strongly NN O O
inhibited NN O O
by NN O O
a NN O O
mutant NN O O
APC NN O B-Disease
that NN O O
is NN O O
truncated NN O O
at NN O O
codon NN O O
1309 NN O O
. NN O O

In NN O O
contrast NN O O
, NN O O
mutant NN O O
APC NN O B-Disease
gene NN O O
products NN O O
that NN O O
are NN O O
associated NN O O
with NN O O
attenuated NN O B-Disease
polyposis NN O I-Disease
( NN O O
codon NN O O
386 NN O O
or NN O O
1465 NN O O
) NN O O
interfered NN O O
only NN O O
weakly NN O O
with NN O O
wild NN O O
- NN O O
type NN O O
APC NN O B-Disease
activity NN O O
. NN O O

These NN O O
results NN O O
suggest NN O O
a NN O O
molecular NN O O
explanation NN O O
for NN O O
the NN O O
genotype NN O O
- NN O O
phenotype NN O O
correlation NN O O
in NN O O
FAP NN O B-Disease
patients NN O O
and NN O O
support NN O O
the NN O O
idea NN O O
that NN O O
colorectal NN O B-Disease
tumor NN O I-Disease
growth NN O O
might NN O O
be NN O O
, NN O O
in NN O O
part NN O O
, NN O O
driven NN O O
by NN O O
selection NN O O
for NN O O
a NN O O
mutation NN O O
in NN O O
the NN O O
mutation NN O O
cluster NN O O
region NN O O
. NN O O
. NN O O

BRCA1 NN O O
interacts NN O O
with NN O O
components NN O O
of NN O O
the NN O O
histone NN O O
deacetylase NN O O
complex NN O O
. NN O O

Germ NN O O
- NN O O
line NN O O
mutations NN O O
in NN O O
the NN O O
BRCA1 NN O O
tumor NN O O
- NN O O
suppressor NN O O
gene NN O O
are NN O O
associated NN O O
with NN O O
an NN O O
increased NN O O
susceptibility NN O O
to NN O O
breast NN O B-Disease
and NN O I-Disease
ovarian NN O I-Disease
cancer NN O I-Disease
. NN O O

BRCA1 NN O O
contains NN O O
a NN O O
carboxyl NN O O
- NN O O
terminal NN O O
domain NN O O
( NN O O
BRCT NN O O
) NN O O
that NN O O
is NN O O
shared NN O O
with NN O O
several NN O O
other NN O O
proteins NN O O
involved NN O O
in NN O O
maintaining NN O O
genome NN O O
integrity NN O O
. NN O O

In NN O O
an NN O O
effort NN O O
to NN O O
understand NN O O
the NN O O
function NN O O
of NN O O
BRCA1 NN O O
, NN O O
we NN O O
sought NN O O
to NN O O
isolate NN O O
proteins NN O O
that NN O O
interact NN O O
with NN O O
the NN O O
BRCT NN O O
domain NN O O
. NN O O

Purified NN O O
BRCT NN O O
polypeptide NN O O
was NN O O
used NN O O
as NN O O
a NN O O
probe NN O O
to NN O O
screen NN O O
a NN O O
human NN O O
placenta NN O O
cDNA NN O O
expression NN O O
library NN O O
by NN O O
Far NN O O
Western NN O O
analysis NN O O
. NN O O

Here NN O O
we NN O O
report NN O O
that NN O O
BRCA1 NN O O
interacts NN O O
in NN O O
vivo NN O O
and NN O O
in NN O O
vitro NN O O
with NN O O
the NN O O
Rb NN O O
- NN O O
binding NN O O
proteins NN O O
, NN O O
RbAp46 NN O O
and NN O O
RbAp48 NN O O
, NN O O
as NN O O
well NN O O
as NN O O
with NN O O
Rb NN O O
. NN O O

Moreover NN O O
, NN O O
the NN O O
BRCT NN O O
domain NN O O
associates NN O O
with NN O O
the NN O O
histone NN O O
deacetylases NN O O
HDAC1 NN O O
and NN O O
HDAC2 NN O O
. NN O O

These NN O O
results NN O O
demonstrate NN O O
that NN O O
BRCA1 NN O O
interacts NN O O
with NN O O
components NN O O
of NN O O
the NN O O
histone NN O O
deacetylase NN O O
complex NN O O
, NN O O
and NN O O
therefore NN O O
may NN O O
explain NN O O
the NN O O
involvement NN O O
of NN O O
BRCA1 NN O O
in NN O O
multiple NN O O
processes NN O O
such NN O O
as NN O O
transcription NN O O
, NN O O
DNA NN O O
repair NN O O
, NN O O
and NN O O
recombination NN O O
. NN O O
. NN O O

Combined NN O B-Disease
genetic NN O I-Disease
deficiency NN O I-Disease
of NN O I-Disease
C6 NN O I-Disease
and NN O I-Disease
C7 NN O I-Disease
in NN O O
man NN O O
. NN O O

By NN O O
routine NN O O
screening NN O O
of NN O O
sera NN O O
, NN O O
a NN O O
subject NN O O
was NN O O
discovered NN O O
who NN O O
showed NN O O
a NN O O
sub NN O B-Disease
- NN O I-Disease
total NN O I-Disease
deficiency NN O I-Disease
of NN O I-Disease
C6 NN O I-Disease
and NN O I-Disease
C7 NN O I-Disease
. NN O O

No NN O O
clinical NN O O
disease NN O O
was NN O O
associated NN O O
with NN O O
this NN O O
deficiency NN O O
which NN O O
was NN O O
transmitted NN O O
through NN O O
the NN O O
subjects NN O O
family NN O O
as NN O O
a NN O O
single NN O O
genetic NN O O
characteristic NN O O
, NN O O
the NN O O
C6 NN O B-Disease
deficiency NN O I-Disease
being NN O O
associated NN O O
with NN O O
a NN O O
silent NN O O
allele NN O O
at NN O O
the NN O O
structural NN O O
locus NN O O
. NN O O

The NN O O
propositus NN O O
was NN O O
found NN O O
to NN O O
have NN O O
low NN O O
quantities NN O O
of NN O O
an NN O O
abnormal NN O O
C6 NN O O
which NN O O
was NN O O
both NN O O
antigenically NN O O
deficient NN O O
and NN O O
smaller NN O O
in NN O O
size NN O O
than NN O O
normal NN O O
C6 NN O O
( NN O O
110 NN O O
, NN O O
000 NN O O
daltons NN O O
compared NN O O
with NN O O
140 NN O O
, NN O O
000 NN O O
daltons NN O O
) NN O O
and NN O O
small NN O O
quantities NN O O
of NN O O
apparently NN O O
normal NN O O
C7 NN O O
. NN O O

It NN O O
is NN O O
concluded NN O O
that NN O O
the NN O O
most NN O O
likely NN O O
explanation NN O O
for NN O O
this NN O O
defect NN O O
is NN O O
that NN O O
the NN O O
subject NN O O
has NN O O
a NN O O
structural NN O O
mutation NN O O
in NN O O
his NN O O
C6 NN O O
gene NN O O
which NN O O
produces NN O O
hyopsynthesis NN O O
not NN O O
only NN O O
of NN O O
C6 NN O O
but NN O O
also NN O O
of NN O O
the NN O O
closely NN O O
linked NN O O
gene NN O O
for NN O O
C7 NN O O
. NN O O

These NN O O
findings NN O O
suggest NN O O
the NN O O
possibility NN O O
that NN O O
C6 NN O O
and NN O O
C7 NN O O
may NN O O
function NN O O
as NN O O
a NN O O
single NN O O
genetic NN O O
unit NN O O
and NN O O
that NN O O
the NN O O
primary NN O O
transcript NN O O
copied NN O O
from NN O O
the NN O O
genome NN O O
includes NN O O
information NN O O
for NN O O
both NN O O
proteins NN O O
. NN O O
. NN O O

Changes NN O O
at NN O O
P183 NN O O
of NN O O
emerin NN O O
weaken NN O O
its NN O O
protein NN O O
- NN O O
protein NN O O
interactions NN O O
resulting NN O O
in NN O O
X NN O B-Disease
- NN O I-Disease
linked NN O I-Disease
Emery NN O I-Disease
- NN O I-Disease
Dreifuss NN O I-Disease
muscular NN O I-Disease
dystrophy NN O I-Disease
. NN O O

Emery NN O B-Disease
- NN O I-Disease
Dreifuss NN O I-Disease
muscular NN O I-Disease
dystrophy NN O I-Disease
( NN O O
EDMD NN O B-Disease
) NN O O
is NN O O
an NN O O
X NN O B-Disease
- NN O I-Disease
linked NN O I-Disease
recessive NN O I-Disease
muscular NN O I-Disease
dystrophy NN O I-Disease
characterized NN O O
by NN O O
early NN O O
contractures NN O B-Disease
of NN O I-Disease
the NN O I-Disease
elbows NN O I-Disease
, NN O I-Disease
Achilles NN O I-Disease
tendons NN O I-Disease
and NN O I-Disease
spine NN O I-Disease
, NN O O
slowly NN O O
progressive NN O O
muscle NN O B-Disease
wasting NN O I-Disease
and NN O O
weakness NN O B-Disease
, NN O O
and NN O O
cardiomyopathy NN O B-Disease
associated NN O O
with NN O O
cardiac NN O B-Disease
conduction NN O I-Disease
defects NN O I-Disease
. NN O O

The NN O O
emerin NN O O
gene NN O O
has NN O O
been NN O O
mapped NN O O
to NN O O
Xq28 NN O O
and NN O O
encodes NN O O
a NN O O
34 NN O O
- NN O O
kDa NN O O
serine NN O O
- NN O O
rich NN O O
protein NN O O
, NN O O
emerin NN O O
, NN O O
which NN O O
has NN O O
been NN O O
localized NN O O
to NN O O
the NN O O
nuclear NN O O
envelope NN O O
in NN O O
a NN O O
wide NN O O
variety NN O O
of NN O O
tissues NN O O
, NN O O
including NN O O
skeletal NN O O
and NN O O
cardiac NN O O
muscle NN O O
. NN O O

Mutations NN O O
spanning NN O O
the NN O O
emerin NN O O
gene NN O O
have NN O O
been NN O O
identified NN O O
in NN O O
patients NN O O
with NN O O
EDMD NN O B-Disease
. NN O O

We NN O O
present NN O O
here NN O O
the NN O O
effect NN O O
, NN O O
on NN O O
emerin NN O O
protein NN O O
expression NN O O
, NN O O
of NN O O
two NN O O
missense NN O O
mutations NN O O
identified NN O O
in NN O O
unrelated NN O O
EDMD NN O B-Disease
patients NN O O
. NN O O

These NN O O
alterations NN O O
predict NN O O
the NN O O
replacement NN O O
of NN O O
a NN O O
proline NN O O
residue NN O O
at NN O O
position NN O O
183 NN O O
with NN O O
either NN O O
a NN O O
histidine NN O O
or NN O O
a NN O O
threonine NN O O
. NN O O

Biochemical NN O O
analysis NN O O
has NN O O
demonstrated NN O O
that NN O O
the NN O O
mobility NN O O
and NN O O
expression NN O O
levels NN O O
of NN O O
the NN O O
mutant NN O O
forms NN O O
of NN O O
emerin NN O O
are NN O O
indistinguishable NN O O
from NN O O
that NN O O
of NN O O
wild NN O O
- NN O O
type NN O O
emerin NN O O
, NN O O
but NN O O
that NN O O
they NN O O
have NN O O
weakened NN O O
interactions NN O O
with NN O O
nuclear NN O O
lamina NN O O
components NN O O
. NN O O

In NN O O
comparison NN O O
with NN O O
the NN O O
usual NN O O
EDMD NN O B-Disease
phenotype NN O O
, NN O O
patients NN O O
with NN O O
P183 NN O O
missense NN O O
mutations NN O O
have NN O O
a NN O O
later NN O O
age NN O O
at NN O O
onset NN O O
of NN O O
first NN O O
symptoms NN O O
, NN O O
elbow NN O B-Disease
contractures NN O I-Disease
, NN O O
ankle NN O B-Disease
contractures NN O I-Disease
, NN O O
upper NN O B-Disease
limb NN O I-Disease
weakness NN O I-Disease
and NN O O
lower NN O B-Disease
limb NN O I-Disease
weakness NN O I-Disease
, NN O O
but NN O O
there NN O O
is NN O O
no NN O O
difference NN O O
for NN O O
the NN O O
age NN O O
at NN O O
onset NN O O
of NN O O
cardiac NN O B-Disease
involvement NN O I-Disease
. NN O O

This NN O O
is NN O O
the NN O O
first NN O O
report NN O O
of NN O O
protein NN O O
studies NN O O
on NN O O
patients NN O O
with NN O O
missense NN O O
mutations NN O O
resulting NN O O
in NN O O
the NN O O
clinical NN O O
features NN O O
of NN O O
EDMD NN O B-Disease
. NN O O

These NN O O
studies NN O O
demonstrate NN O O
the NN O O
importance NN O O
of NN O O
proline NN O O
183 NN O O
for NN O O
the NN O O
proper NN O O
structure NN O O
/ NN O O
function NN O O
of NN O O
emerin NN O O
. NN O O
. NN O O

Microdeletions NN O O
at NN O O
chromosome NN O O
bands NN O O
1q32 NN O O
- NN O O
q41 NN O O
as NN O O
a NN O O
cause NN O O
of NN O O
Van NN O B-Disease
der NN O I-Disease
Woude NN O I-Disease
syndrome NN O I-Disease
. NN O O

Van NN O B-Disease
der NN O I-Disease
Woude NN O I-Disease
syndrome NN O I-Disease
( NN O O
VWS NN O B-Disease
) NN O O
is NN O O
an NN O O
autosomal NN O B-Disease
dominant NN O I-Disease
disorder NN O I-Disease
comprising NN O O
cleft NN O B-Disease
lip NN O I-Disease
and NN O O
/ NN O O
or NN O O
cleft NN O B-Disease
palate NN O I-Disease
and NN O O
lip NN O B-Disease
pits NN O I-Disease
. NN O O

We NN O O
reported NN O O
previously NN O O
a NN O O
family NN O O
whose NN O O
underlying NN O O
mutation NN O O
is NN O O
a NN O O
500 NN O O
- NN O O
800 NN O O
kb NN O O
deletion NN O O
localized NN O O
to NN O O
chromosome NN O O
bands NN O O
1q32 NN O O
- NN O O
q41 NN O O
[ NN O O
Sander NN O O
et NN O O
al NN O O
. NN O O
, NN O O
1994 NN O O
Hum NN O O
Mol NN O O
Genet NN O O
3 NN O O
576 NN O O
- NN O O
578 NN O O
] NN O O
. NN O O

Along NN O O
with NN O O
cleft NN O B-Disease
lip NN O I-Disease
/ NN O I-Disease
palate NN O I-Disease
and NN O O
lip NN O B-Disease
pits NN O I-Disease
, NN O O
affected NN O O
relatives NN O O
exhibit NN O O
developmental NN O B-Disease
delays NN O I-Disease
, NN O O
suggesting NN O O
that NN O O
the NN O O
function NN O O
of NN O O
a NN O O
gene NN O O
nearby NN O O
may NN O O
also NN O O
be NN O O
disrupted NN O O
. NN O O

To NN O O
further NN O O
localize NN O O
the NN O O
VWS NN O B-Disease
gene NN O O
we NN O O
searched NN O O
for NN O O
other NN O O
deletions NN O O
that NN O O
cause NN O O
VWS NN O B-Disease
. NN O O

An NN O O
allele NN O O
loss NN O O
assay NN O O
was NN O O
performed NN O O
using NN O O
a NN O O
novel NN O O
highly NN O O
polymorphic NN O O
marker NN O O
, NN O O
D1S3753 NN O O
. NN O O

From NN O O
a NN O O
panel NN O O
of NN O O
37 NN O O
unrelated NN O O
individuals NN O O
, NN O O
we NN O O
detected NN O O
an NN O O
allele NN O O
loss NN O O
in NN O O
one NN O O
family NN O O
, NN O O
indicating NN O O
the NN O O
presence NN O O
of NN O O
a NN O O
deletion NN O O
. NN O O

In NN O O
this NN O O
family NN O O
, NN O O
the NN O O
phenotype NN O O
in NN O O
three NN O O
generations NN O O
of NN O O
affected NN O O
individuals NN O O
was NN O O
confined NN O O
to NN O O
the NN O O
cardinal NN O O
signs NN O O
of NN O O
VWS NN O B-Disease
. NN O O

Surprisingly NN O O
, NN O O
mapping NN O O
of NN O O
the NN O O
new NN O O
deletion NN O O
showed NN O O
that NN O O
it NN O O
extended NN O O
0 NN O O
. NN O O

2 NN O O
- NN O O
1 NN O O
Mb NN O O
beyond NN O O
the NN O O
proximal NN O O
breakpoint NN O O
for NN O O
the NN O O
deletion NN O O
described NN O O
previously NN O O
. NN O O

No NN O O
deletions NN O O
were NN O O
detected NN O O
in NN O O
seven NN O O
cases NN O O
of NN O O
popliteal NN O B-Disease
pterygia NN O I-Disease
syndrome NN O I-Disease
, NN O O
76 NN O O
cases NN O O
of NN O O
mixed NN O O
syndromic NN O B-Disease
forms NN O I-Disease
of NN O I-Disease
cleft NN O I-Disease
lip NN O I-Disease
and NN O I-Disease
palate NN O I-Disease
, NN O O
and NN O O
178 NN O O
cases NN O O
of NN O O
nonsyndromic NN O B-Disease
cleft NN O I-Disease
lip NN O I-Disease
and NN O I-Disease
palate NN O I-Disease
. NN O O

Splicing NN O O
defects NN O O
in NN O O
the NN O O
ataxia NN O B-Disease
- NN O I-Disease
telangiectasia NN O I-Disease
gene NN O O
, NN O O
ATM NN O O
: NN O O
underlying NN O O
mutations NN O O
and NN O O
consequences NN O O
. NN O O

Mutations NN O O
resulting NN O O
in NN O O
defective NN O O
splicing NN O O
constitute NN O O
a NN O O
significant NN O O
proportion NN O O
( NN O O
30 NN O O
/ NN O O
62 NN O O
[ NN O O
48 NN O O
% NN O O
] NN O O
) NN O O
of NN O O
a NN O O
new NN O O
series NN O O
of NN O O
mutations NN O O
in NN O O
the NN O O
ATM NN O O
gene NN O O
in NN O O
patients NN O O
with NN O O
ataxia NN O B-Disease
- NN O I-Disease
telangiectasia NN O I-Disease
( NN O O
AT NN O B-Disease
) NN O O
that NN O O
were NN O O
detected NN O O
by NN O O
the NN O O
protein NN O O
- NN O O
truncation NN O O
assay NN O O
followed NN O O
by NN O O
sequence NN O O
analysis NN O O
of NN O O
genomic NN O O
DNA NN O O
. NN O O

Fewer NN O O
than NN O O
half NN O O
of NN O O
the NN O O
splicing NN O O
mutations NN O O
involved NN O O
the NN O O
canonical NN O O
AG NN O O
splice NN O O
- NN O O
acceptor NN O O
site NN O O
or NN O O
GT NN O O
splice NN O O
- NN O O
donor NN O O
site NN O O
. NN O O

A NN O O
higher NN O O
percentage NN O O
of NN O O
mutations NN O O
occurred NN O O
at NN O O
less NN O O
stringently NN O O
conserved NN O O
sites NN O O
, NN O O
including NN O O
silent NN O O
mutations NN O O
of NN O O
the NN O O
last NN O O
nucleotide NN O O
of NN O O
exons NN O O
, NN O O
mutations NN O O
in NN O O
nucleotides NN O O
other NN O O
than NN O O
the NN O O
conserved NN O O
AG NN O O
and NN O O
GT NN O O
in NN O O
the NN O O
consensus NN O O
splice NN O O
sites NN O O
, NN O O
and NN O O
creation NN O O
of NN O O
splice NN O O
- NN O O
acceptor NN O O
or NN O O
splice NN O O
- NN O O
donor NN O O
sites NN O O
in NN O O
either NN O O
introns NN O O
or NN O O
exons NN O O
. NN O O

These NN O O
splicing NN O O
mutations NN O O
led NN O O
to NN O O
a NN O O
variety NN O O
of NN O O
consequences NN O O
, NN O O
including NN O O
exon NN O O
skipping NN O O
and NN O O
, NN O O
to NN O O
a NN O O
lesser NN O O
degree NN O O
, NN O O
intron NN O O
retention NN O O
, NN O O
activation NN O O
of NN O O
cryptic NN O O
splice NN O O
sites NN O O
, NN O O
or NN O O
creation NN O O
of NN O O
new NN O O
splice NN O O
sites NN O O
. NN O O

In NN O O
addition NN O O
, NN O O
5 NN O O
of NN O O
12 NN O O
nonsense NN O O
mutations NN O O
and NN O O
1 NN O O
missense NN O O
mutation NN O O
were NN O O
associated NN O O
with NN O O
deletion NN O O
in NN O O
the NN O O
cDNA NN O O
of NN O O
the NN O O
exons NN O O
in NN O O
which NN O O
the NN O O
mutations NN O O
occurred NN O O
. NN O O

No NN O O
ATM NN O O
protein NN O O
was NN O O
detected NN O O
by NN O O
western NN O O
blotting NN O O
in NN O O
any NN O O
AT NN O B-Disease
cell NN O O
line NN O O
in NN O O
which NN O O
splicing NN O O
mutations NN O O
were NN O O
identified NN O O
. NN O O

Several NN O O
cases NN O O
of NN O O
exon NN O O
skipping NN O O
in NN O O
both NN O O
normal NN O O
controls NN O O
and NN O O
patients NN O O
for NN O O
whom NN O O
no NN O O
underlying NN O O
defect NN O O
could NN O O
be NN O O
found NN O O
in NN O O
genomic NN O O
DNA NN O O
were NN O O
also NN O O
observed NN O O
, NN O O
suggesting NN O O
caution NN O O
in NN O O
the NN O O
interpretation NN O O
of NN O O
exon NN O O
deletions NN O O
observed NN O O
in NN O O
ATM NN O O
cDNA NN O O
when NN O O
there NN O O
is NN O O
no NN O O
accompanying NN O O
identification NN O O
of NN O O
genomic NN O O
mutations NN O O
. NN O O
. NN O O

Alpha NN O O
- NN O O
cardiac NN O O
actin NN O O
is NN O O
a NN O O
novel NN O O
disease NN O O
gene NN O O
in NN O O
familial NN O B-Disease
hypertrophic NN O I-Disease
cardiomyopathy NN O I-Disease
. NN O O

We NN O O
identified NN O O
the NN O O
alpha NN O O
- NN O O
cardiac NN O O
actin NN O O
gene NN O O
( NN O O
ACTC NN O O
) NN O O
as NN O O
a NN O O
novel NN O O
disease NN O O
gene NN O O
in NN O O
a NN O O
pedigree NN O O
suffering NN O O
from NN O O
familial NN O B-Disease
hypertrophic NN O I-Disease
cardiomyopathy NN O I-Disease
( NN O O
FHC NN O B-Disease
) NN O O
. NN O O

Linkage NN O O
analyses NN O O
excluded NN O O
all NN O O
the NN O O
previously NN O O
reported NN O O
FHC NN O B-Disease
loci NN O O
as NN O O
possible NN O O
disease NN O O
loci NN O O
in NN O O
the NN O O
family NN O O
studied NN O O
, NN O O
with NN O O
lod NN O O
scores NN O O
varying NN O O
between NN O O
- NN O O
2 NN O O
. NN O O

5 NN O O
and NN O O
- NN O O
6 NN O O
. NN O O

0 NN O O
0 NN O O
. NN O O

Further NN O O
linkage NN O O
analyses NN O O
of NN O O
plausible NN O O
candidate NN O O
genes NN O O
highly NN O O
expressed NN O O
in NN O O
the NN O O
adult NN O O
human NN O O
heart NN O O
identified NN O O
ACTC NN O O
as NN O O
the NN O O
most NN O O
likely NN O O
disease NN O O
gene NN O O
, NN O O
showing NN O O
a NN O O
maximal NN O O
lod NN O O
score NN O O
of NN O O
3 NN O O
. NN O O

6 NN O O
6 NN O O
. NN O O

Mutation NN O O
analysis NN O O
of NN O O
ACTC NN O O
revealed NN O O
an NN O O
Ala295Ser NN O O
mutation NN O O
in NN O O
exon NN O O
5 NN O O
close NN O O
to NN O O
2 NN O O
missense NN O O
mutations NN O O
recently NN O O
described NN O O
to NN O O
cause NN O O
the NN O O
inherited NN O O
form NN O O
of NN O O
idiopathic NN O B-Disease
dilated NN O I-Disease
cardiomyopathy NN O I-Disease
( NN O O
IDC NN O B-Disease
) NN O O
. NN O O

Overgrowth NN O B-Disease
of NN O I-Disease
oral NN O I-Disease
mucosa NN O I-Disease
and NN O I-Disease
facial NN O I-Disease
skin NN O I-Disease
, NN O O
a NN O O
novel NN O O
feature NN O O
of NN O O
aspartylglucosaminuria NN O B-Disease
. NN O O

Aspartylglucosaminuria NN O B-Disease
( NN O O
AGU NN O B-Disease
) NN O O
is NN O O
a NN O O
lysosomal NN O B-Disease
storage NN O I-Disease
disorder NN O I-Disease
caused NN O O
by NN O O
deficiency NN O B-Disease
of NN O I-Disease
aspartylglucosaminidase NN O I-Disease
( NN O O
AGA NN O O
) NN O O
. NN O O

The NN O O
main NN O O
symptom NN O O
is NN O O
progressive NN O O
mental NN O B-Disease
retardation NN O I-Disease
. NN O O

A NN O O
spectrum NN O O
of NN O O
different NN O O
mutations NN O O
has NN O O
been NN O O
reported NN O O
in NN O O
this NN O O
disease NN O O
, NN O O
one NN O O
missense NN O O
mutation NN O O
( NN O O
Cys163Ser NN O O
) NN O O
being NN O O
responsible NN O O
for NN O O
the NN O O
majority NN O O
of NN O O
Finnish NN O O
cases NN O O
. NN O O

We NN O O
were NN O O
able NN O O
to NN O O
examine NN O O
66 NN O O
Finnish NN O O
AGU NN O B-Disease
patients NN O O
for NN O O
changes NN O O
in NN O O
the NN O O
oral NN O O
mucosa NN O O
and NN O O
44 NN O O
of NN O O
these NN O O
for NN O O
changes NN O O
in NN O O
facial NN O O
skin NN O O
. NN O O

Biopsy NN O O
specimens NN O O
of NN O O
16 NN O O
oral NN O O
lesions NN O O
, NN O O
12 NN O O
of NN O O
them NN O O
associated NN O O
with NN O O
the NN O O
teeth NN O O
, NN O O
plus NN O O
two NN O O
facial NN O B-Disease
lesions NN O I-Disease
were NN O O
studied NN O O
histologically NN O O
. NN O O

Immunohistochemical NN O O
staining NN O O
for NN O O
AGA NN O O
was NN O O
performed NN O O
on NN O O
15 NN O O
oral NN O O
specimens NN O O
. NN O O

Skin NN O O
was NN O O
seborrhoeic NN O O
in NN O O
adolescent NN O O
and NN O O
adult NN O O
patients NN O O
, NN O O
with NN O O
erythema NN O B-Disease
of NN O I-Disease
the NN O I-Disease
facial NN O I-Disease
skin NN O I-Disease
already NN O O
common NN O O
in NN O O
childhood NN O O
. NN O O

Of NN O O
44 NN O O
patients NN O O
, NN O O
nine NN O O
( NN O O
20 NN O O
% NN O O
) NN O O
had NN O O
facial NN O B-Disease
angiofibromas NN O I-Disease
, NN O O
tumours NN O B-Disease
primarily NN O O
occurring NN O O
in NN O O
association NN O O
with NN O O
tuberous NN O B-Disease
sclerosis NN O I-Disease
. NN O O

Oedemic NN O B-Disease
buccal NN O I-Disease
mucosa NN O I-Disease
( NN O O
leucoedema NN O B-Disease
) NN O O
and NN O O
gingival NN O B-Disease
overgrowths NN O I-Disease
were NN O O
more NN O O
frequent NN O O
in NN O O
AGU NN O B-Disease
patients NN O O
than NN O O
in NN O O
controls NN O O
( NN O O
p NN O O
< NN O O
0 NN O O
. NN O O
001 NN O O
) NN O O
. NN O O

Of NN O O
16 NN O O
oral NN O B-Disease
mucosal NN O I-Disease
lesions NN O I-Disease
studied NN O O
histologically NN O O
, NN O O
15 NN O O
represented NN O O
fibroepithelial NN O B-Disease
or NN O I-Disease
epithelial NN O I-Disease
hyperplasias NN O I-Disease
and NN O O
were NN O O
reactive NN O O
in NN O O
nature NN O O
. NN O O

Cytoplasmic NN O O
vacuolisation NN O O
was NN O O
evident NN O O
in NN O O
four NN O O
. NN O O

Immunohistochemically NN O O
, NN O O
expression NN O O
of NN O O
AGA NN O O
in NN O O
AGU NN O B-Disease
patients NN O O
mucosal NN O B-Disease
lesions NN O I-Disease
did NN O O
not NN O O
differ NN O O
from NN O O
that NN O O
seen NN O O
in NN O O
corresponding NN O O
lesions NN O O
of NN O O
normal NN O O
subjects NN O O
. NN O O

Thus NN O O
, NN O O
the NN O O
high NN O O
frequency NN O O
of NN O O
mucosal NN O B-Disease
overgrowth NN O I-Disease
in NN O O
AGU NN O B-Disease
patients NN O O
does NN O O
not NN O O
appear NN O O
to NN O O
be NN O O
directly NN O O
associated NN O O
with NN O O
lysosomal NN O O
storage NN O O
or NN O O
with NN O O
alterations NN O O
in NN O O
the NN O O
level NN O O
of NN O O
AGA NN O O
expression NN O O
. NN O O

Characterization NN O O
of NN O O
a NN O O
germline NN O O
mosaicism NN O O
in NN O O
families NN O O
with NN O O
Lowe NN O B-Disease
syndrome NN O I-Disease
, NN O O
and NN O O
identification NN O O
of NN O O
seven NN O O
novel NN O O
mutations NN O O
in NN O O
the NN O O
OCRL1 NN O O
gene NN O O
. NN O O

The NN O O
oculocerebrorenal NN O B-Disease
syndrome NN O I-Disease
of NN O I-Disease
Lowe NN O I-Disease
( NN O O
OCRL NN O B-Disease
) NN O O
is NN O O
an NN O O
X NN O B-Disease
- NN O I-Disease
linked NN O I-Disease
disorder NN O I-Disease
characterized NN O O
by NN O O
major NN O O
abnormalities NN O B-Disease
of NN O I-Disease
eyes NN O I-Disease
, NN O I-Disease
nervous NN O I-Disease
system NN O I-Disease
, NN O I-Disease
and NN O I-Disease
kidneys NN O I-Disease
. NN O O

Mutations NN O O
in NN O O
the NN O O
OCRL1 NN O O
gene NN O O
have NN O O
been NN O O
associated NN O O
with NN O O
the NN O O
disease NN O O
. NN O O

OCRL1 NN O O
encodes NN O O
a NN O O
phosphatidylinositol NN O O
4 NN O O
, NN O O
5 NN O O
- NN O O
biphosphate NN O O
( NN O O
PtdIns NN O O
[ NN O O
4 NN O O
, NN O O
5 NN O O
] NN O O
P2 NN O O
) NN O O
5 NN O O
- NN O O
phosphatase NN O O
. NN O O

We NN O O
have NN O O
examined NN O O
the NN O O
OCRL1 NN O O
gene NN O O
in NN O O
eight NN O O
unrelated NN O O
patients NN O O
with NN O O
OCRL NN O B-Disease
and NN O O
have NN O O
found NN O O
seven NN O O
new NN O O
mutations NN O O
and NN O O
one NN O O
recurrent NN O O
in NN O O
- NN O O
frame NN O O
deletion NN O O
. NN O O

Among NN O O
the NN O O
new NN O O
mutations NN O O
, NN O O
two NN O O
nonsense NN O O
mutations NN O O
( NN O O
R317X NN O O
and NN O O
E558X NN O O
) NN O O
and NN O O
three NN O O
other NN O O
frameshift NN O O
mutations NN O O
caused NN O O
premature NN O O
termination NN O O
of NN O O
the NN O O
protein NN O O
. NN O O

A NN O O
missense NN O O
mutation NN O O
, NN O O
R483G NN O O
, NN O O
was NN O O
located NN O O
in NN O O
the NN O O
highly NN O O
conserved NN O O
PtdIns NN O O
( NN O O
4 NN O O
, NN O O
5 NN O O
) NN O O
P2 NN O O
5 NN O O
- NN O O
phosphatase NN O O
domain NN O O
. NN O O

Finally NN O O
, NN O O
one NN O O
frameshift NN O O
mutation NN O O
, NN O O
2799delC NN O O
, NN O O
modifies NN O O
the NN O O
C NN O O
- NN O O
terminal NN O O
part NN O O
of NN O O
OCRL1 NN O O
, NN O O
with NN O O
an NN O O
extension NN O O
of NN O O
six NN O O
amino NN O O
acids NN O O
. NN O O

Altogether NN O O
, NN O O
70 NN O O
% NN O O
of NN O O
missense NN O O
mutations NN O O
are NN O O
located NN O O
in NN O O
exon NN O O
15 NN O O
, NN O O
and NN O O
52 NN O O
% NN O O
of NN O O
all NN O O
mutations NN O O
cluster NN O O
in NN O O
exons NN O O
11 NN O O
- NN O O
15 NN O O
. NN O O

We NN O O
also NN O O
identified NN O O
two NN O O
new NN O O
microsatellite NN O O
markers NN O O
for NN O O
the NN O O
OCRL1 NN O O
locus NN O O
, NN O O
and NN O O
we NN O O
detected NN O O
a NN O O
germline NN O O
mosaicism NN O O
in NN O O
one NN O O
family NN O O
. NN O O

This NN O O
observation NN O O
has NN O O
direct NN O O
implications NN O O
for NN O O
genetic NN O O
counseling NN O O
of NN O O
Lowe NN O B-Disease
syndrome NN O I-Disease
families NN O O
. NN O O
. NN O O

MEFV NN O O
- NN O O
Gene NN O O
analysis NN O O
in NN O O
armenian NN O O
patients NN O O
with NN O O
Familial NN O B-Disease
Mediterranean NN O I-Disease
fever NN O I-Disease
: NN O O
diagnostic NN O O
value NN O O
and NN O O
unfavorable NN O O
renal NN O O
prognosis NN O O
of NN O O
the NN O O
M694V NN O O
homozygous NN O O
genotype NN O O
- NN O O
genetic NN O O
and NN O O
therapeutic NN O O
implications NN O O
. NN O O

Familial NN O B-Disease
Mediterranean NN O I-Disease
fever NN O I-Disease
( NN O O
FMF NN O B-Disease
) NN O O
is NN O O
a NN O O
recessively NN O B-Disease
inherited NN O I-Disease
disorder NN O I-Disease
that NN O O
is NN O O
common NN O O
in NN O O
patients NN O O
of NN O O
Armenian NN O O
ancestry NN O O
. NN O O

To NN O O
date NN O O
, NN O O
its NN O O
diagnosis NN O O
, NN O O
which NN O O
can NN O O
be NN O O
made NN O O
only NN O O
retrospectively NN O O
, NN O O
is NN O O
one NN O O
of NN O O
exclusion NN O O
, NN O O
based NN O O
entirely NN O O
on NN O O
nonspecific NN O O
clinical NN O O
signs NN O O
that NN O O
result NN O O
from NN O O
serosal NN O B-Disease
inflammation NN O I-Disease
and NN O O
that NN O O
may NN O O
lead NN O O
to NN O O
unnecessary NN O O
surgery NN O O
. NN O O

Renal NN O B-Disease
amyloidosis NN O I-Disease
, NN O O
prevented NN O O
by NN O O
colchicine NN O O
, NN O O
is NN O O
the NN O O
most NN O O
severe NN O O
complication NN O O
of NN O O
FMF NN O B-Disease
, NN O O
a NN O O
disorder NN O O
associated NN O O
with NN O O
mutations NN O O
in NN O O
the NN O O
MEFV NN O O
gene NN O O
. NN O O

To NN O O
evaluate NN O O
the NN O O
diagnostic NN O O
and NN O O
prognostic NN O O
value NN O O
of NN O O
MEFV NN O O
- NN O O
gene NN O O
analysis NN O O
, NN O O
we NN O O
investigated NN O O
90 NN O O
Armenian NN O O
FMF NN O B-Disease
patients NN O O
from NN O O
77 NN O O
unrelated NN O O
families NN O O
that NN O O
were NN O O
not NN O O
selected NN O O
through NN O O
genetic NN O O
- NN O O
linkage NN O O
analysis NN O O
. NN O O

Eight NN O O
mutations NN O O
, NN O O
one NN O O
of NN O O
which NN O O
( NN O O
R408Q NN O O
) NN O O
is NN O O
new NN O O
, NN O O
were NN O O
found NN O O
to NN O O
account NN O O
for NN O O
93 NN O O
% NN O O
of NN O O
the NN O O
163 NN O O
independent NN O O
FMF NN O B-Disease
alleles NN O O
, NN O O
with NN O O
both NN O O
FMF NN O B-Disease
alleles NN O O
identified NN O O
in NN O O
89 NN O O
% NN O O
of NN O O
the NN O O
patients NN O O
. NN O O

In NN O O
several NN O O
instances NN O O
, NN O O
family NN O O
studies NN O O
provided NN O O
molecular NN O O
evidence NN O O
for NN O O
pseudodominant NN O O
transmission NN O O
and NN O O
incomplete NN O O
penetrance NN O O
of NN O O
the NN O O
disease NN O O
phenotype NN O O
. NN O O

The NN O O
M694V NN O O
homozygous NN O O
genotype NN O O
was NN O O
found NN O O
to NN O O
be NN O O
associated NN O O
with NN O O
a NN O O
higher NN O O
prevalence NN O O
of NN O O
renal NN O B-Disease
amyloidosis NN O I-Disease
and NN O O
arthritis NN O B-Disease
, NN O O
compared NN O O
with NN O O
other NN O O
genotypes NN O O
( NN O O
P NN O O
= NN O O
. NN O O
0002 NN O O
and NN O O
P NN O O
= NN O O
. NN O O
006 NN O O
, NN O O
respectively NN O O
) NN O O
. NN O O

The NN O O
demonstration NN O O
of NN O O
both NN O O
the NN O O
diagnostic NN O O
and NN O O
prognostic NN O O
value NN O O
of NN O O
MEFV NN O O
analysis NN O O
and NN O O
particular NN O O
modes NN O O
of NN O O
inheritance NN O O
should NN O O
lead NN O O
to NN O O
new NN O O
ways NN O O
for NN O O
management NN O O
of NN O O
FMF NN O O
- NN O O
including NN O O
genetic NN O O
counseling NN O O
and NN O O
therapeutic NN O O
decisions NN O O
in NN O O
affected NN O O
families NN O O
. NN O O

Noninvasive NN O O
test NN O O
for NN O O
fragile NN O B-Disease
X NN O I-Disease
syndrome NN O I-Disease
, NN O O
using NN O O
hair NN O O
root NN O O
analysis NN O O
. NN O O

Identification NN O O
of NN O O
the NN O O
FMR1 NN O O
gene NN O O
and NN O O
the NN O O
repeat NN O O
- NN O O
amplification NN O O
mechanism NN O O
causing NN O O
fragile NN O B-Disease
X NN O I-Disease
syndrome NN O I-Disease
led NN O O
to NN O O
development NN O O
of NN O O
reliable NN O O
DNA NN O O
- NN O O
based NN O O
diagnostic NN O O
methods NN O O
, NN O O
including NN O O
Southern NN O O
blot NN O O
hybridization NN O O
and NN O O
PCR NN O O
. NN O O

Both NN O O
methods NN O O
are NN O O
performed NN O O
on NN O O
DNA NN O O
isolated NN O O
from NN O O
peripheral NN O O
blood NN O O
cells NN O O
and NN O O
measure NN O O
the NN O O
repeat NN O O
size NN O O
in NN O O
FMR1 NN O O
. NN O O

Using NN O O
an NN O O
immunocytochemical NN O O
technique NN O O
on NN O O
blood NN O O
smears NN O O
, NN O O
we NN O O
recently NN O O
developed NN O O
a NN O O
novel NN O O
test NN O O
for NN O O
identification NN O O
of NN O O
patients NN O O
with NN O O
fragile NN O B-Disease
X NN O I-Disease
syndrome NN O I-Disease
. NN O O

This NN O O
method NN O O
, NN O O
also NN O O
called NN O O
" NN O O
antibody NN O O
test NN O O
, NN O O
" NN O O
uses NN O O
monoclonal NN O O
antibodies NN O O
against NN O O
the NN O O
FMR1 NN O O
gene NN O O
product NN O O
( NN O O
FMRP NN O O
) NN O O
and NN O O
is NN O O
based NN O O
on NN O O
absence NN O O
of NN O O
FMRP NN O O
in NN O O
patients NN O O
cells NN O O
. NN O O

Here NN O O
we NN O O
describe NN O O
a NN O O
new NN O O
diagnostic NN O O
test NN O O
to NN O O
identify NN O O
male NN O O
patients NN O O
with NN O O
fragile NN O B-Disease
X NN O I-Disease
syndrome NN O I-Disease
, NN O O
on NN O O
the NN O O
basis NN O O
of NN O O
lack NN O O
of NN O O
FMRP NN O O
in NN O O
their NN O O
hair NN O O
roots NN O O
. NN O O

Expression NN O O
of NN O O
FMRP NN O O
in NN O O
hair NN O O
roots NN O O
was NN O O
studied NN O O
by NN O O
use NN O O
of NN O O
an NN O O
FMRP NN O O
- NN O O
specific NN O O
antibody NN O O
test NN O O
, NN O O
and NN O O
the NN O O
percentage NN O O
of NN O O
FMRP NN O O
- NN O O
expressing NN O O
hair NN O O
roots NN O O
in NN O O
controls NN O O
and NN O O
in NN O O
male NN O O
fragile NN O B-Disease
X NN O I-Disease
patients NN O O
was NN O O
determined NN O O
. NN O O

Control NN O O
individuals NN O O
showed NN O O
clear NN O O
expression NN O O
of NN O O
FMRP NN O O
in NN O O
nearly NN O O
every NN O O
hair NN O O
root NN O O
, NN O O
whereas NN O O
male NN O O
fragile NN O B-Disease
X NN O I-Disease
patients NN O O
lacked NN O O
expression NN O O
of NN O O
FMRP NN O O
in NN O O
almost NN O O
all NN O O
their NN O O
hair NN O O
roots NN O O
. NN O O

Mentally NN O B-Disease
retarded NN O I-Disease
female NN O O
patients NN O O
with NN O O
a NN O O
full NN O O
mutation NN O O
showed NN O O
FMRP NN O O
expression NN O O
in NN O O
only NN O O
some NN O O
of NN O O
their NN O O
hair NN O O
roots NN O O
( NN O O
< NN O O
55 NN O O
% NN O O
) NN O O
, NN O O
and NN O O
no NN O O
overlap NN O O
with NN O O
normal NN O O
female NN O O
controls NN O O
was NN O O
observed NN O O
. NN O O

The NN O O
advantages NN O O
of NN O O
this NN O O
test NN O O
are NN O O
( NN O O
1 NN O O
) NN O O
plucking NN O O
of NN O O
hair NN O O
follicles NN O O
does NN O O
no NN O O
appreciable NN O O
harm NN O O
to NN O O
the NN O O
mentally NN O B-Disease
retarded NN O I-Disease
patient NN O O
, NN O O
( NN O O
2 NN O O
) NN O O
hairs NN O O
can NN O O
be NN O O
sent NN O O
in NN O O
a NN O O
simple NN O O
envelope NN O O
to NN O O
a NN O O
diagnostic NN O O
center NN O O
, NN O O
and NN O O
( NN O O
3 NN O O
) NN O O
the NN O O
result NN O O
of NN O O
the NN O O
test NN O O
is NN O O
available NN O O
within NN O O
5 NN O O
h NN O O
of NN O O
plucking NN O O
. NN O O

In NN O O
addition NN O O
, NN O O
this NN O O
test NN O O
enabled NN O O
us NN O O
to NN O O
identify NN O O
two NN O O
fragile NN O B-Disease
X NN O I-Disease
patients NN O O
who NN O O
did NN O O
not NN O O
show NN O O
the NN O O
full NN O O
mutation NN O O
by NN O O
analysis NN O O
of NN O O
DNA NN O O
isolated NN O O
from NN O O
blood NN O O
cells NN O O
. NN O O
. NN O O

In NN O O
Swedish NN O O
families NN O O
with NN O O
hereditary NN O B-Disease
prostate NN O I-Disease
cancer NN O I-Disease
, NN O O
linkage NN O O
to NN O O
the NN O O
HPC1 NN O O
locus NN O O
on NN O O
chromosome NN O O
1q24 NN O O
- NN O O
25 NN O O
is NN O O
restricted NN O O
to NN O O
families NN O O
with NN O O
early NN O O
- NN O O
onset NN O O
prostate NN O B-Disease
cancer NN O I-Disease
. NN O O

Prostate NN O B-Disease
cancer NN O I-Disease
clusters NN O O
in NN O O
some NN O O
families NN O O
, NN O O
and NN O O
an NN O O
estimated NN O O
5 NN O O
% NN O O
- NN O O
10 NN O O
% NN O O
of NN O O
all NN O O
cases NN O O
are NN O O
estimated NN O O
to NN O O
result NN O O
from NN O O
inheritance NN O O
of NN O O
prostate NN O O
cancer NN O O
- NN O O
susceptibility NN O O
genes NN O O
. NN O O

We NN O O
previously NN O O
reported NN O O
evidence NN O O
of NN O O
linkage NN O O
to NN O O
the NN O O
1q24 NN O O
- NN O O
25 NN O O
region NN O O
( NN O O
HPC1 NN O O
) NN O O
in NN O O
91 NN O O
North NN O O
American NN O O
and NN O O
Swedish NN O O
families NN O O
each NN O O
with NN O O
multiple NN O O
cases NN O O
of NN O O
prostate NN O B-Disease
cancer NN O I-Disease
( NN O O
Smith NN O O
et NN O O
al NN O O
. NN O O
1996 NN O O
) NN O O
. NN O O

In NN O O
the NN O O
present NN O O
report NN O O
we NN O O
analyze NN O O
40 NN O O
( NN O O
12 NN O O
original NN O O
and NN O O
28 NN O O
newly NN O O
identified NN O O
) NN O O
Swedish NN O O
families NN O O
with NN O O
hereditary NN O B-Disease
prostate NN O I-Disease
cancer NN O I-Disease
( NN O O
HPC NN O B-Disease
) NN O O
that NN O O
, NN O O
on NN O O
the NN O O
basis NN O O
of NN O O
40 NN O O
markers NN O O
spanning NN O O
a NN O O
25 NN O O
- NN O O
cM NN O O
interval NN O O
within NN O O
1q24 NN O O
- NN O O
25 NN O O
, NN O O
have NN O O
evidence NN O O
of NN O O
linkage NN O O
. NN O O

In NN O O
the NN O O
complete NN O O
set NN O O
of NN O O
families NN O O
, NN O O
a NN O O
maximum NN O O
two NN O O
- NN O O
point NN O O
LOD NN O O
score NN O O
of NN O O
1 NN O O
. NN O O

10 NN O O
was NN O O
observed NN O O
at NN O O
D1S413 NN O O
( NN O O
at NN O O
a NN O O
recombination NN O O
fraction NN O O
[ NN O O
theta NN O O
] NN O O
of NN O O
. NN O O
1 NN O O
) NN O O
, NN O O
with NN O O
a NN O O
maximum NN O O
NPL NN O O
( NN O O
nonparametric NN O O
linkage NN O O
) NN O O
Z NN O O
score NN O O
of NN O O
1 NN O O
. NN O O

64 NN O O
at NN O O
D1S202 NN O O
( NN O O
P NN O O
= NN O O
. NN O O
05 NN O O
) NN O O
. NN O O

The NN O O
evidence NN O O
of NN O O
linkage NN O O
to NN O O
this NN O O
region NN O O
originated NN O O
almost NN O O
exclusively NN O O
from NN O O
the NN O O
subset NN O O
of NN O O
12 NN O O
early NN O O
- NN O O
onset NN O O
( NN O O
age NN O O
< NN O O
65 NN O O
years NN O O
) NN O O
families NN O O
, NN O O
which NN O O
yielded NN O O
a NN O O
maximum NN O O
LOD NN O O
score NN O O
of NN O O
2 NN O O
. NN O O

38 NN O O
at NN O O
D1S413 NN O O
( NN O O
straight NN O O
theta NN O O
= NN O O
0 NN O O
) NN O O
and NN O O
an NN O O
NPL NN O O
Z NN O O
score NN O O
of NN O O
1 NN O O
. NN O O

95 NN O O
at NN O O
D1S422 NN O O
( NN O O
P NN O O
= NN O O
. NN O O
03 NN O O
) NN O O
. NN O O

Estimates NN O O
from NN O O
heterogeneity NN O O
tests NN O O
suggest NN O O
that NN O O
, NN O O
within NN O O
Sweden NN O O
, NN O O
as NN O O
many NN O O
as NN O O
50 NN O O
% NN O O
of NN O O
early NN O O
- NN O O
onset NN O O
families NN O O
had NN O O
evidence NN O O
of NN O O
linkage NN O O
to NN O O
the NN O O
HPC1 NN O O
region NN O O
. NN O O

These NN O O
results NN O O
are NN O O
consistent NN O O
with NN O O
the NN O O
hypothesis NN O O
of NN O O
linkage NN O O
to NN O O
HPC1 NN O O
in NN O O
a NN O O
subset NN O O
of NN O O
families NN O O
with NN O O
prostate NN O B-Disease
cancer NN O I-Disease
, NN O O
particularly NN O O
those NN O O
with NN O O
an NN O O
early NN O O
age NN O O
at NN O O
diagnosis NN O O
. NN O O

Molecular NN O O
basis NN O O
of NN O O
feline NN O O
beta NN O B-Disease
- NN O I-Disease
glucuronidase NN O I-Disease
deficiency NN O I-Disease
: NN O O
an NN O O
animal NN O O
model NN O O
of NN O O
mucopolysaccharidosis NN O B-Disease
VII NN O I-Disease
. NN O O

A NN O O
family NN O O
of NN O O
domestic NN O O
cats NN O O
was NN O O
found NN O O
that NN O O
exhibited NN O O
clinical NN O O
and NN O O
biochemical NN O O
abnormalities NN O O
consistent NN O O
with NN O O
mucopolysaccharidosis NN O B-Disease
VII NN O I-Disease
, NN O O
an NN O O
autosomal NN O B-Disease
recessive NN O I-Disease
lysosomal NN O I-Disease
storage NN O I-Disease
disorder NN O I-Disease
caused NN O O
by NN O O
beta NN O B-Disease
- NN O I-Disease
glucuronidase NN O I-Disease
deficiency NN O I-Disease
. NN O O

beta NN O O
- NN O O
Glucuronidase NN O O
activity NN O O
was NN O O
undetectable NN O O
in NN O O
affected NN O O
cat NN O O
fibroblasts NN O O
and NN O O
restored NN O O
by NN O O
retroviral NN O O
gene NN O O
transfer NN O O
of NN O O
rat NN O O
beta NN O O
- NN O O
glucuronidase NN O O
cDNA NN O O
. NN O O

beta NN O O
- NN O O
Glucuronidase NN O O
mRNA NN O O
was NN O O
normal NN O O
in NN O O
affected NN O O
cat NN O O
testis NN O O
by NN O O
Northern NN O O
blot NN O O
analysis NN O O
. NN O O

Normal NN O O
feline NN O O
beta NN O O
- NN O O
glucuronidase NN O O
cDNA NN O O
was NN O O
cloned NN O O
and NN O O
characterized NN O O
, NN O O
and NN O O
amplified NN O O
from NN O O
affected NN O O
cat NN O O
fibroblasts NN O O
by NN O O
reverse NN O O
transcription NN O O
coupled NN O O
polymerase NN O O
chain NN O O
reaction NN O O
. NN O O

There NN O O
was NN O O
a NN O O
G NN O O
- NN O O
to NN O O
- NN O O
A NN O O
transition NN O O
in NN O O
the NN O O
affected NN O O
cat NN O O
cDNA NN O O
that NN O O
predicted NN O O
an NN O O
E351K NN O O
substitution NN O O
, NN O O
destroyed NN O O
a NN O O
BssSI NN O O
site NN O O
, NN O O
and NN O O
eliminated NN O O
GUSB NN O O
enzymatic NN O O
activity NN O O
in NN O O
expression NN O O
studies NN O O
. NN O O

Multiple NN O O
species NN O O
comparison NN O O
and NN O O
the NN O O
crystal NN O O
structure NN O O
of NN O O
human NN O O
beta NN O O
- NN O O
glucuronidase NN O O
indicated NN O O
that NN O O
E351 NN O O
is NN O O
a NN O O
highly NN O O
conserved NN O O
residue NN O O
most NN O O
likely NN O O
essential NN O O
in NN O O
maintenance NN O O
of NN O O
the NN O O
enzymes NN O O
conformation NN O O
. NN O O

BssSI NN O O
digestion NN O O
of NN O O
polymerase NN O O
chain NN O O
reaction NN O O
products NN O O
amplified NN O O
from NN O O
genomic NN O O
DNA NN O O
indicated NN O O
that NN O O
affected NN O O
cats NN O O
were NN O O
homozygous NN O O
and NN O O
cats NN O O
with NN O O
half NN O O
- NN O O
normal NN O O
beta NN O O
- NN O O
glucuronidase NN O O
activity NN O O
were NN O O
heterozygous NN O O
for NN O O
the NN O O
missense NN O O
mutation NN O O
. NN O O

Carriers NN O O
identified NN O O
in NN O O
this NN O O
manner NN O O
produced NN O O
affected NN O O
kittens NN O O
in NN O O
prospective NN O O
breedings NN O O
, NN O O
and NN O O
a NN O O
feline NN O O
MPS NN O B-Disease
VII NN O I-Disease
breeding NN O O
colony NN O O
has NN O O
been NN O O
established NN O O
. NN O O
. NN O O

A NN O O
common NN O O
molecular NN O O
basis NN O O
for NN O O
rearrangement NN O B-Disease
disorders NN O I-Disease
on NN O O
chromosome NN O O
22q11 NN O O
. NN O O

The NN O O
chromosome NN O O
22q11 NN O O
region NN O O
is NN O O
susceptible NN O O
to NN O O
rearrangements NN O O
that NN O O
are NN O O
associated NN O O
with NN O O
congenital NN O B-Disease
anomaly NN O I-Disease
disorders NN O I-Disease
and NN O O
malignant NN O B-Disease
tumors NN O I-Disease
. NN O O

Three NN O O
congenital NN O B-Disease
anomaly NN O I-Disease
disorders NN O I-Disease
, NN O O
cat NN O B-Disease
- NN O I-Disease
eye NN O I-Disease
syndrome NN O I-Disease
, NN O O
der NN O B-Disease
( NN O I-Disease
) NN O I-Disease
syndrome NN O I-Disease
and NN O O
velo NN O B-Disease
- NN O I-Disease
cardio NN O I-Disease
- NN O I-Disease
facial NN O I-Disease
syndrome NN O I-Disease
/ NN O O
DiGeorge NN O B-Disease
syndrome NN O I-Disease
( NN O O
VCFS NN O B-Disease
/ NN O O
DGS NN O B-Disease
) NN O O
are NN O O
associated NN O O
with NN O O
tetrasomy NN O O
, NN O O
trisomy NN O O
or NN O O
monosomy NN O O
, NN O O
respectively NN O O
, NN O O
for NN O O
part NN O O
of NN O O
chromosome NN O O
22q11 NN O O
. NN O O

VCFS NN O B-Disease
/ NN O O
DGS NN O B-Disease
is NN O O
the NN O O
most NN O O
common NN O O
syndrome NN O O
associated NN O O
with NN O O
22q11 NN O O
rearrangements NN O O
. NN O O

In NN O O
order NN O O
to NN O O
determine NN O O
whether NN O O
there NN O O
are NN O O
particular NN O O
regions NN O O
on NN O O
22q11 NN O O
that NN O O
are NN O O
prone NN O O
to NN O O
rearrangements NN O O
, NN O O
the NN O O
deletion NN O O
end NN O O
- NN O O
points NN O O
in NN O O
a NN O O
large NN O O
number NN O O
of NN O O
VCFS NN O B-Disease
/ NN O O
DGS NN O B-Disease
patients NN O O
were NN O O
defined NN O O
by NN O O
haplotype NN O O
analysis NN O O
. NN O O

Most NN O O
VCFS NN O B-Disease
/ NN O O
DGS NN O B-Disease
patients NN O O
have NN O O
a NN O O
similar NN O O
3 NN O O
Mb NN O O
deletion NN O O
, NN O O
some NN O O
have NN O O
a NN O O
nested NN O O
distal NN O O
deletion NN O O
breakpoint NN O O
resulting NN O O
in NN O O
a NN O O
1 NN O O
. NN O O

5 NN O O
Mb NN O O
deletion NN O O
and NN O O
a NN O O
few NN O O
rare NN O O
patients NN O O
have NN O O
unique NN O O
deletions NN O O
or NN O O
translocations NN O O
. NN O O

The NN O O
high NN O O
prevalence NN O O
of NN O O
the NN O O
disorder NN O O
in NN O O
the NN O O
population NN O O
and NN O O
the NN O O
fact NN O O
that NN O O
most NN O O
cases NN O O
occur NN O O
sporadically NN O O
suggest NN O O
that NN O O
sequences NN O O
at NN O O
or NN O O
near NN O O
the NN O O
breakpoints NN O O
confer NN O O
susceptibility NN O O
to NN O O
chromosome NN O O
rearrangements NN O O
. NN O O

To NN O O
investigate NN O O
this NN O O
hypothesis NN O O
, NN O O
we NN O O
developed NN O O
hamster NN O O
- NN O O
human NN O O
somatic NN O O
hybrid NN O O
cell NN O O
lines NN O O
from NN O O
VCFS NN O B-Disease
/ NN O O
DGS NN O B-Disease
patients NN O O
with NN O O
all NN O O
three NN O O
classes NN O O
of NN O O
deletions NN O O
and NN O O
we NN O O
now NN O O
show NN O O
that NN O O
the NN O O
breakpoints NN O O
occur NN O O
within NN O O
similar NN O O
low NN O O
copy NN O O
repeats NN O O
, NN O O
termed NN O O
LCR22s NN O O
. NN O O

To NN O O
support NN O O
this NN O O
idea NN O O
further NN O O
, NN O O
we NN O O
identified NN O O
a NN O O
family NN O O
that NN O O
carries NN O O
an NN O O
interstitial NN O O
duplication NN O O
of NN O O
the NN O O
same NN O O
3 NN O O
Mb NN O O
region NN O O
that NN O O
is NN O O
deleted NN O O
in NN O O
VCFS NN O B-Disease
/ NN O O
DGS NN O B-Disease
patients NN O O
. NN O O

We NN O O
present NN O O
models NN O O
to NN O O
explain NN O O
how NN O O
the NN O O
LCR22s NN O O
can NN O O
mediate NN O O
different NN O O
homologous NN O O
recombination NN O O
events NN O O
, NN O O
thereby NN O O
generating NN O O
a NN O O
number NN O O
of NN O O
rearrangements NN O O
that NN O O
are NN O O
associated NN O O
with NN O O
congenital NN O B-Disease
anomaly NN O I-Disease
disorders NN O I-Disease
. NN O O

We NN O O
identified NN O O
five NN O O
additional NN O O
copies NN O O
of NN O O
the NN O O
LCR22 NN O O
on NN O O
22q11 NN O O
that NN O O
may NN O O
mediate NN O O
other NN O O
rearrangements NN O O
leading NN O O
to NN O O
disease NN O O
. NN O O

Functional NN O O
consequences NN O O
of NN O O
mutations NN O O
in NN O O
the NN O O
early NN O O
growth NN O O
response NN O O
2 NN O O
gene NN O O
( NN O O
EGR2 NN O O
) NN O O
correlate NN O O
with NN O O
severity NN O O
of NN O O
human NN O O
myelinopathies NN O B-Disease
. NN O O

The NN O O
early NN O O
growth NN O O
response NN O O
2 NN O O
gene NN O O
( NN O O
EGR2 NN O O
) NN O O
is NN O O
a NN O O
Cys2His2zinc NN O O
finger NN O O
transcription NN O O
factor NN O O
which NN O O
is NN O O
thought NN O O
to NN O O
play NN O O
a NN O O
role NN O O
in NN O O
the NN O O
regulation NN O O
of NN O O
peripheral NN O O
nervous NN O O
system NN O O
myelination NN O O
. NN O O

This NN O O
idea NN O O
is NN O O
based NN O O
partly NN O O
on NN O O
the NN O O
phenotype NN O O
of NN O O
homozygous NN O O
Krox20 NN O O
( NN O O
Egr2 NN O O
) NN O O
knockout NN O O
mice NN O O
, NN O O
which NN O O
display NN O O
hypomyelination NN O B-Disease
of NN O I-Disease
the NN O I-Disease
PNS NN O I-Disease
and NN O O
a NN O O
block NN O O
of NN O O
Schwann NN O O
cells NN O O
at NN O O
an NN O O
early NN O O
stage NN O O
of NN O O
differentiation NN O O
. NN O O

Mutations NN O O
in NN O O
the NN O O
human NN O O
EGR2 NN O O
gene NN O O
have NN O O
recently NN O O
been NN O O
associated NN O O
with NN O O
the NN O O
inherited NN O B-Disease
peripheral NN O I-Disease
neuropathies NN O I-Disease
Charcot NN O B-Disease
- NN O I-Disease
Marie NN O I-Disease
- NN O I-Disease
Tooth NN O I-Disease
type NN O I-Disease
1 NN O I-Disease
, NN O O
Dejerine NN O B-Disease
- NN O I-Disease
Sottas NN O I-Disease
syndrome NN O I-Disease
and NN O O
congenital NN O B-Disease
hypomyelinating NN O I-Disease
neuropathy NN O I-Disease
. NN O O

Three NN O O
of NN O O
the NN O O
four NN O O
EGR2 NN O O
mutations NN O O
are NN O O
dominant NN O O
and NN O O
occur NN O O
within NN O O
the NN O O
zinc NN O O
finger NN O O
DNA NN O O
- NN O O
binding NN O O
domain NN O O
. NN O O

The NN O O
fourth NN O O
mutation NN O O
is NN O O
recessive NN O O
and NN O O
affects NN O O
the NN O O
inhibitory NN O O
domain NN O O
( NN O O
R1 NN O O
) NN O O
that NN O O
binds NN O O
the NN O O
NAB NN O O
transcriptional NN O O
co NN O O
- NN O O
repressors NN O O
. NN O O

A NN O O
combination NN O O
of NN O O
DNA NN O O
- NN O O
binding NN O O
assays NN O O
and NN O O
transcriptional NN O O
analysis NN O O
was NN O O
used NN O O
to NN O O
determine NN O O
the NN O O
functional NN O O
consequences NN O O
of NN O O
these NN O O
mutations NN O O
. NN O O

The NN O O
zinc NN O O
finger NN O O
mutations NN O O
affect NN O O
DNA NN O O
binding NN O O
and NN O O
the NN O O
amount NN O O
of NN O O
residual NN O O
binding NN O O
directly NN O O
correlates NN O O
with NN O O
disease NN O O
severity NN O O
. NN O O

The NN O O
R1 NN O O
domain NN O O
mutation NN O O
prevents NN O O
interaction NN O O
of NN O O
EGR2 NN O O
with NN O O
the NN O O
NAB NN O O
co NN O O
- NN O O
repressors NN O O
and NN O O
thereby NN O O
increases NN O O
transcriptional NN O O
activity NN O O
. NN O O

These NN O O
data NN O O
provide NN O O
insight NN O O
into NN O O
the NN O O
possible NN O O
disease NN O O
mechanisms NN O O
underlying NN O O
EGR2 NN O O
mutations NN O O
and NN O O
the NN O O
reason NN O O
for NN O O
varying NN O O
severity NN O O
and NN O O
differences NN O O
in NN O O
inheritance NN O O
patterns NN O O
. NN O O
. NN O O

Autosomal NN O B-Disease
recessive NN O I-Disease
familial NN O I-Disease
neurohypophyseal NN O I-Disease
diabetes NN O I-Disease
insipidus NN O I-Disease
with NN O O
continued NN O O
secretion NN O O
of NN O O
mutant NN O O
weakly NN O O
active NN O O
vasopressin NN O O
. NN O O

Familial NN O B-Disease
neurohypophyseal NN O I-Disease
diabetes NN O I-Disease
insipidus NN O I-Disease
is NN O O
an NN O O
autosomal NN O B-Disease
dominant NN O I-Disease
disorder NN O I-Disease
characterized NN O O
by NN O O
post NN O O
- NN O O
natal NN O O
development NN O O
of NN O O
arginine NN O B-Disease
vasopressin NN O I-Disease
( NN O I-Disease
AVP NN O I-Disease
) NN O I-Disease
deficiency NN O I-Disease
due NN O O
to NN O O
mutations NN O O
in NN O O
the NN O O
AVP NN O O
gene NN O O
. NN O O

All NN O O
published NN O O
mutations NN O O
affect NN O O
the NN O O
signal NN O O
peptide NN O O
or NN O O
the NN O O
neurophysin NN O O
- NN O O
II NN O O
carrier NN O O
protein NN O O
and NN O O
are NN O O
presumed NN O O
to NN O O
interfere NN O O
with NN O O
processing NN O O
of NN O O
the NN O O
preprohormone NN O O
, NN O O
leading NN O O
to NN O O
neuronal NN O B-Disease
damage NN O I-Disease
. NN O O

We NN O O
studied NN O O
an NN O O
unusual NN O O
Palestinian NN O O
family NN O O
consisting NN O O
of NN O O
asymptomatic NN O O
first NN O O
cousin NN O O
parents NN O O
and NN O O
three NN O O
children NN O O
affected NN O O
with NN O O
neurohypophyseal NN O B-Disease
diabetes NN O I-Disease
insipidus NN O I-Disease
, NN O O
suggesting NN O O
autosomal NN O O
recessive NN O O
inheritance NN O O
. NN O O

All NN O O
three NN O O
affected NN O O
children NN O O
were NN O O
homozygous NN O O
and NN O O
the NN O O
parents NN O O
heterozygous NN O O
for NN O O
a NN O O
single NN O O
novel NN O O
mutation NN O O
( NN O O
C301 NN O O
- NN O O
> NN O O
T NN O O
) NN O O
in NN O O
exon NN O O
1 NN O O
, NN O O
replacing NN O O
Pro7 NN O O
of NN O O
mature NN O O
AVP NN O O
with NN O O
Leu NN O O
( NN O O
Leu NN O O
- NN O O
AVP NN O O
) NN O O
. NN O O

Leu NN O O
- NN O O
AVP NN O O
was NN O O
a NN O O
weak NN O O
agonist NN O O
with NN O O
approximately NN O O
30 NN O O
- NN O O
fold NN O O
reduced NN O O
binding NN O O
to NN O O
the NN O O
human NN O O
V2 NN O O
receptor NN O O
. NN O O

Measured NN O O
by NN O O
radioimmunoassay NN O O
with NN O O
a NN O O
synthetic NN O O
Leu NN O O
- NN O O
AVP NN O O
standard NN O O
, NN O O
serum NN O O
Leu NN O O
- NN O O
AVP NN O O
levels NN O O
were NN O O
elevated NN O O
in NN O O
all NN O O
three NN O O
children NN O O
and NN O O
further NN O O
increased NN O O
during NN O O
water NN O O
deprivation NN O O
to NN O O
as NN O O
high NN O O
as NN O O
30 NN O O
times NN O O
normal NN O O
. NN O O

The NN O O
youngest NN O O
child NN O O
( NN O O
2 NN O O
years NN O O
old NN O O
) NN O O
was NN O O
only NN O O
mildly NN O O
affected NN O O
but NN O O
had NN O O
Leu NN O O
- NN O O
AVP NN O O
levels NN O O
similar NN O O
to NN O O
her NN O O
severely NN O O
affected NN O O
8 NN O O
- NN O O
year NN O O
- NN O O
old NN O O
brother NN O O
, NN O O
suggesting NN O O
that NN O O
unknown NN O O
mechanisms NN O O
may NN O O
partially NN O O
compensate NN O O
for NN O O
a NN O O
deficiency NN O B-Disease
of NN O I-Disease
active NN O I-Disease
AVP NN O I-Disease
in NN O O
very NN O O
young NN O O
children NN O O
. NN O O
. NN O O

X NN O O
inactivation NN O O
and NN O O
somatic NN O O
cell NN O O
selection NN O O
rescue NN O O
female NN O O
mice NN O O
carrying NN O O
a NN O O
Piga NN O O
- NN O O
null NN O O
mutation NN O O
. NN O O

A NN O O
somatic NN O O
mutation NN O O
in NN O O
the NN O O
X NN O O
linked NN O O
PIGA NN O O
gene NN O O
is NN O O
responsible NN O O
for NN O O
the NN O O
deficiency NN O B-Disease
of NN O I-Disease
glycosyl NN O I-Disease
phosphatidylinositol NN O I-Disease
( NN O I-Disease
GPI NN O I-Disease
) NN O I-Disease
- NN O I-Disease
anchored NN O I-Disease
proteins NN O I-Disease
on NN O O
blood NN O O
cells NN O O
from NN O O
patients NN O O
with NN O O
paroxysmal NN O B-Disease
nocturnal NN O I-Disease
hemoglobinuria NN O I-Disease
. NN O O

No NN O O
inherited NN O O
form NN O O
of NN O O
GPI NN O B-Disease
- NN O I-Disease
anchor NN O I-Disease
deficiency NN O I-Disease
has NN O O
been NN O O
described NN O O
. NN O O

Because NN O O
conventional NN O O
Piga NN O O
gene NN O O
knockout NN O O
is NN O O
associated NN O O
with NN O O
high NN O O
embryonic NN O B-Disease
lethality NN O I-Disease
in NN O O
chimeric NN O O
mice NN O O
, NN O O
we NN O O
used NN O O
the NN O O
Cre NN O O
/ NN O O
loxP NN O O
system NN O O
. NN O O

We NN O O
generated NN O O
mice NN O O
in NN O O
which NN O O
two NN O O
loxP NN O O
sites NN O O
flank NN O O
part NN O O
of NN O O
Piga NN O O
exon NN O O
2 NN O O
. NN O O

After NN O O
crossbreeding NN O O
with NN O O
female NN O O
mice NN O O
of NN O O
the NN O O
EIIa NN O O
- NN O O
cre NN O O
strain NN O O
, NN O O
the NN O O
floxed NN O O
allele NN O O
undergoes NN O O
Cre NN O O
- NN O O
mediated NN O O
recombination NN O O
with NN O O
high NN O O
efficiency NN O O
during NN O O
early NN O O
embryonic NN O O
development NN O O
. NN O O

Because NN O O
of NN O O
X NN O O
chromosome NN O O
inactivation NN O O
, NN O O
female NN O O
offspring NN O O
are NN O O
mosaic NN O O
for NN O O
cells NN O O
that NN O O
express NN O O
or NN O O
lack NN O O
GPI NN O O
- NN O O
linked NN O O
proteins NN O O
. NN O O

Analysis NN O O
of NN O O
mosaic NN O O
mice NN O O
showed NN O O
that NN O O
in NN O O
heart NN O O
, NN O O
lung NN O O
, NN O O
kidney NN O O
, NN O O
brain NN O O
, NN O O
and NN O O
liver NN O O
, NN O O
mainly NN O O
wild NN O O
- NN O O
type NN O O
Piga NN O O
is NN O O
active NN O O
, NN O O
suggesting NN O O
that NN O O
these NN O O
tissues NN O O
require NN O O
GPI NN O O
- NN O O
linked NN O O
proteins NN O O
. NN O O

The NN O O
salient NN O O
exceptions NN O O
were NN O O
spleen NN O O
, NN O O
thymus NN O O
, NN O O
and NN O O
red NN O O
blood NN O O
cells NN O O
, NN O O
which NN O O
had NN O O
almost NN O O
equal NN O O
numbers NN O O
of NN O O
cells NN O O
expressing NN O O
the NN O O
wild NN O O
- NN O O
type NN O O
or NN O O
the NN O O
recombined NN O O
allele NN O O
, NN O O
implying NN O O
that NN O O
GPI NN O O
- NN O O
linked NN O O
proteins NN O O
are NN O O
not NN O O
essential NN O O
for NN O O
the NN O O
derivation NN O O
of NN O O
these NN O O
tissues NN O O
. NN O O

PIGA NN O O
( NN O O
- NN O O
) NN O O
cells NN O O
had NN O O
no NN O O
growth NN O O
advantage NN O O
, NN O O
suggesting NN O O
that NN O O
other NN O O
factors NN O O
are NN O O
needed NN O O
for NN O O
their NN O O
clonal NN O O
dominance NN O O
in NN O O
patients NN O O
with NN O O
paroxysmal NN O B-Disease
nocturnal NN O I-Disease
hemoglobinuria NN O I-Disease
. NN O O
. NN O O

The NN O O
C282Y NN O O
mutation NN O O
causing NN O O
hereditary NN O B-Disease
hemochromatosis NN O I-Disease
does NN O O
not NN O O
produce NN O O
a NN O O
null NN O O
allele NN O O
. NN O O

Targeted NN O O
mutagenesis NN O O
was NN O O
used NN O O
to NN O O
produce NN O O
two NN O O
mutations NN O O
in NN O O
the NN O O
murine NN O O
hemochromatosis NN O B-Disease
gene NN O O
( NN O O
Hfe NN O O
) NN O O
locus NN O O
. NN O O

The NN O O
first NN O O
mutation NN O O
deletes NN O O
a NN O O
large NN O O
portion NN O O
of NN O O
the NN O O
coding NN O O
sequence NN O O
, NN O O
generating NN O O
a NN O O
null NN O O
allele NN O O
. NN O O

The NN O O
second NN O O
mutation NN O O
introduces NN O O
a NN O O
missense NN O O
mutation NN O O
( NN O O
C282Y NN O O
) NN O O
into NN O O
the NN O O
Hfe NN O O
locus NN O O
, NN O O
but NN O O
otherwise NN O O
leaves NN O O
the NN O O
gene NN O O
intact NN O O
. NN O O

This NN O O
mutation NN O O
is NN O O
identical NN O O
to NN O O
the NN O O
disease NN O O
- NN O O
causing NN O O
mutation NN O O
in NN O O
patients NN O O
with NN O O
hereditary NN O B-Disease
hemochromatosis NN O I-Disease
. NN O O

Mice NN O O
carrying NN O O
each NN O O
of NN O O
the NN O O
two NN O O
mutations NN O O
were NN O O
bred NN O O
and NN O O
analyzed NN O O
. NN O O

Homozygosity NN O O
for NN O O
either NN O O
mutation NN O O
results NN O O
in NN O O
postnatal NN O O
iron NN O O
loading NN O O
. NN O O

The NN O O
effects NN O O
of NN O O
the NN O O
null NN O O
mutation NN O O
are NN O O
more NN O O
severe NN O O
than NN O O
the NN O O
effects NN O O
of NN O O
the NN O O
C282Y NN O O
mutation NN O O
. NN O O

Mice NN O O
heterozygous NN O O
for NN O O
either NN O O
mutation NN O O
accumulate NN O O
more NN O O
iron NN O O
than NN O O
normal NN O O
controls NN O O
. NN O O

Interestingly NN O O
, NN O O
although NN O O
liver NN O O
iron NN O O
stores NN O O
are NN O O
greatly NN O O
increased NN O O
, NN O O
splenic NN O O
iron NN O O
is NN O O
decreased NN O O
. NN O O

We NN O O
conclude NN O O
that NN O O
the NN O O
C282Y NN O O
mutation NN O O
does NN O O
not NN O O
result NN O O
in NN O O
a NN O O
null NN O O
allele NN O O
. NN O O
. NN O O

Genotype NN O O
- NN O O
phenotype NN O O
analysis NN O O
in NN O O
X NN O B-Disease
- NN O I-Disease
linked NN O I-Disease
Emery NN O I-Disease
- NN O I-Disease
Dreifuss NN O I-Disease
muscular NN O I-Disease
dystrophy NN O I-Disease
and NN O O
identification NN O O
of NN O O
a NN O O
missense NN O O
mutation NN O O
associated NN O O
with NN O O
a NN O O
milder NN O O
phenotype NN O O
. NN O O

Direct NN O O
sequencing NN O O
of NN O O
the NN O O
emerin NN O O
gene NN O O
in NN O O
22 NN O O
families NN O O
with NN O O
Emery NN O B-Disease
- NN O I-Disease
Dreifuss NN O I-Disease
muscular NN O I-Disease
dystrophy NN O I-Disease
( NN O O
EMD NN O B-Disease
) NN O O
revealed NN O O
mutations NN O O
in NN O O
21 NN O O
( NN O O
95 NN O O
% NN O O
) NN O O
, NN O O
confirming NN O O
that NN O O
emerin NN O O
mutations NN O O
can NN O O
be NN O O
identified NN O O
in NN O O
the NN O O
majority NN O O
of NN O O
families NN O O
with NN O O
X NN O B-Disease
- NN O I-Disease
linked NN O I-Disease
EMD NN O I-Disease
. NN O O

Most NN O O
emerin NN O O
mutations NN O O
result NN O O
in NN O O
absence NN O O
of NN O O
the NN O O
protein NN O O
. NN O O

In NN O O
this NN O O
study NN O O
three NN O O
mutations NN O O
( NN O O
a NN O O
missense NN O O
mutation NN O O
Pro183Thr NN O O
and NN O O
two NN O O
in NN O O
- NN O O
frame NN O O
deletions NN O O
removing NN O O
residues NN O O
95 NN O O
- NN O O
99 NN O O
and NN O O
236 NN O O
- NN O O
241 NN O O
, NN O O
respectively NN O O
) NN O O
were NN O O
unusual NN O O
in NN O O
being NN O O
associated NN O O
with NN O O
expression NN O O
of NN O O
mutant NN O O
protein NN O O
. NN O O

The NN O O
phenotype NN O O
in NN O O
these NN O O
families NN O O
was NN O O
compared NN O O
in NN O O
detail NN O O
with NN O O
the NN O O
clinical NN O O
features NN O O
in NN O O
cases NN O O
with NN O O
typical NN O O
null NN O O
mutations NN O O
. NN O O

For NN O O
the NN O O
in NN O O
- NN O O
frame NN O O
deletions NN O O
there NN O O
were NN O O
no NN O O
significant NN O O
differences NN O O
. NN O O

In NN O O
the NN O O
family NN O O
with NN O O
the NN O O
missense NN O O
mutation NN O O
the NN O O
phenotype NN O O
was NN O O
milder NN O O
. NN O O

Age NN O O
at NN O O
onset NN O O
was NN O O
later NN O O
for NN O O
first NN O O
symptoms NN O O
and NN O O
for NN O O
development NN O O
of NN O O
ankle NN O B-Disease
contractures NN O I-Disease
and NN O O
muscle NN O B-Disease
weakness NN O I-Disease
. NN O O

These NN O O
findings NN O O
have NN O O
diagnostic NN O O
implications NN O O
as NN O O
well NN O O
as NN O O
pointing NN O O
to NN O O
functionally NN O O
important NN O O
regions NN O O
of NN O O
the NN O O
emerin NN O O
protein NN O O
. NN O O
. NN O O

Severe NN O O
clinical NN O O
expression NN O O
in NN O O
X NN O B-Disease
- NN O I-Disease
linked NN O I-Disease
Emery NN O I-Disease
- NN O I-Disease
Dreifuss NN O I-Disease
muscular NN O I-Disease
dystrophy NN O I-Disease
. NN O O

X NN O B-Disease
- NN O I-Disease
linked NN O I-Disease
Emery NN O I-Disease
- NN O I-Disease
Dreifuss NN O I-Disease
muscular NN O I-Disease
dystrophy NN O I-Disease
( NN O O
EDMD NN O B-Disease
) NN O O
is NN O O
a NN O O
relatively NN O O
rare NN O O
benign NN O B-Disease
neuromuscular NN O I-Disease
disorder NN O I-Disease
which NN O O
can NN O O
vary NN O O
remarkably NN O O
in NN O O
onset NN O O
, NN O O
course NN O O
and NN O O
severity NN O O
. NN O O

In NN O O
the NN O O
present NN O O
study NN O O
, NN O O
a NN O O
TCTAC NN O O
deletion NN O O
spanning NN O O
the NN O O
nucleotides NN O O
631 NN O O
- NN O O
635 NN O O
of NN O O
the NN O O
emerin NN O O
gene NN O O
caused NN O O
an NN O O
unusually NN O O
severe NN O O
disease NN O O
phenotype NN O O
including NN O O
loss NN O B-Disease
of NN O I-Disease
ambulation NN O I-Disease
and NN O O
severe NN O O
muscle NN O B-Disease
wasting NN O I-Disease
in NN O O
two NN O O
affected NN O O
brothers NN O O
. NN O O

The NN O O
same NN O O
mutation NN O O
has NN O O
been NN O O
reported NN O O
previously NN O O
in NN O O
an NN O O
unrelated NN O O
family NN O O
showing NN O O
a NN O O
significantly NN O O
milder NN O O
phenotype NN O O
. NN O O

The NN O O
interfamilial NN O O
heterogeneity NN O O
in NN O O
distribution NN O O
and NN O O
in NN O O
severity NN O O
of NN O O
the NN O O
features NN O O
in NN O O
the NN O O
two NN O O
families NN O O
point NN O O
to NN O O
environmental NN O O
or NN O O
genetic NN O O
modification NN O O
as NN O O
the NN O O
cause NN O O
of NN O O
clinical NN O O
variability NN O O
in NN O O
Emery NN O B-Disease
- NN O I-Disease
Dreifuss NN O I-Disease
muscular NN O I-Disease
dystrophy NN O I-Disease
. NN O O
. NN O O

Common NN O O
mutations NN O O
in NN O O
BRCA1 NN O O
and NN O O
BRCA2 NN O O
do NN O O
not NN O O
contribute NN O O
to NN O O
early NN O O
prostate NN O B-Disease
cancer NN O I-Disease
in NN O O
Jewish NN O O
men NN O O
. NN O O

BACKGROUND NN O O
Families NN O O
with NN O O
a NN O O
high NN O O
incidence NN O O
of NN O O
hereditary NN O B-Disease
breast NN O I-Disease
cancer NN O I-Disease
, NN O O
and NN O O
subsequently NN O O
shown NN O O
to NN O O
have NN O O
terminating NN O O
mutations NN O O
in NN O O
BRCA1 NN O O
or NN O O
BRCA2 NN O O
, NN O O
appear NN O O
to NN O O
have NN O O
a NN O O
higher NN O O
incidence NN O O
of NN O O
prostate NN O B-Disease
cancer NN O I-Disease
among NN O O
male NN O O
relatives NN O O
. NN O O

We NN O O
aimed NN O O
to NN O O
determine NN O O
whether NN O O
the NN O O
common NN O O
germline NN O O
mutations NN O O
of NN O O
BRCA1 NN O O
or NN O O
BRCA2 NN O O
in NN O O
Ashkenazi NN O O
Jewish NN O O
men NN O O
predisposed NN O O
them NN O O
to NN O O
prostate NN O B-Disease
cancer NN O I-Disease
. NN O O

METHODS NN O O
We NN O O
examined NN O O
genomic NN O O
DNA NN O O
from NN O O
83 NN O O
( NN O O
for NN O O
BRCA1 NN O O
185delAG NN O O
) NN O O
or NN O O
82 NN O O
( NN O O
for NN O O
BRCA2 NN O O
6174delT NN O O
) NN O O
Ashkenazi NN O O
Jewish NN O O
prostate NN O B-Disease
cancer NN O I-Disease
patients NN O O
, NN O O
most NN O O
of NN O O
whom NN O O
were NN O O
treated NN O O
at NN O O
a NN O O
relatively NN O O
young NN O O
age NN O O
, NN O O
for NN O O
the NN O O
most NN O O
common NN O O
germline NN O O
mutation NN O O
in NN O O
each NN O O
gene NN O O
seen NN O O
in NN O O
the NN O O
Ashkenazi NN O O
population NN O O
. NN O O

RESULTS NN O O
Our NN O O
study NN O O
should NN O O
have NN O O
been NN O O
able NN O O
to NN O O
detect NN O O
a NN O O
4 NN O O
- NN O O
5 NN O O
- NN O O
fold NN O O
increase NN O O
in NN O O
the NN O O
risk NN O O
of NN O O
prostate NN O B-Disease
cancer NN O I-Disease
due NN O O
to NN O O
mutation NN O O
of NN O O
BRCA1 NN O O
or NN O O
BRCA2 NN O O
. NN O O

However NN O O
, NN O O
only NN O O
one NN O O
( NN O O
1 NN O O
. NN O O
15 NN O O
% NN O O
; NN O O
95 NN O O
% NN O O
confidence NN O O
interval NN O O
, NN O O
0 NN O O
- NN O O
3 NN O O
. NN O O
6 NN O O
% NN O O
) NN O O
of NN O O
the NN O O
patients NN O O
was NN O O
heterozygous NN O O
for NN O O
the NN O O
BRCA1 NN O O
mutant NN O O
allele NN O O
, NN O O
and NN O O
only NN O O
two NN O O
were NN O O
heterozygous NN O O
for NN O O
the NN O O
BRCA2 NN O O
mutation NN O O
( NN O O
2 NN O O
. NN O O
4 NN O O
% NN O O
; NN O O
95 NN O O
% NN O O
confidence NN O O
interval NN O O
, NN O O
0 NN O O
- NN O O
6 NN O O
. NN O O
2 NN O O
% NN O O
) NN O O
. NN O O

CONCLUSIONS NN O O
The NN O O
incidence NN O O
of NN O O
each NN O O
of NN O O
the NN O O
germline NN O O
mutations NN O O
in NN O O
these NN O O
prostate NN O B-Disease
cancer NN O I-Disease
patients NN O O
closely NN O O
matched NN O O
their NN O O
incidence NN O O
( NN O O
about NN O O
1 NN O O
% NN O O
) NN O O
in NN O O
the NN O O
general NN O O
Ashkenazi NN O O
Jewish NN O O
population NN O O
. NN O O

This NN O O
suggests NN O O
that NN O O
unlike NN O O
cases NN O O
of NN O O
breast NN O B-Disease
and NN O I-Disease
ovarian NN O I-Disease
cancers NN O I-Disease
, NN O O
mutations NN O O
in NN O O
BRCA1 NN O O
or NN O O
BRCA2 NN O O
do NN O O
not NN O O
significantly NN O O
predispose NN O O
men NN O O
to NN O O
prostate NN O B-Disease
cancer NN O I-Disease

Beta NN O O
- NN O O
catenin NN O O
accumulation NN O O
and NN O O
mutation NN O O
of NN O O
the NN O O
CTNNB1 NN O O
gene NN O O
in NN O O
hepatoblastoma NN O B-Disease
. NN O O

Hepatoblastoma NN O B-Disease
is NN O O
a NN O O
rare NN O O
malignant NN O B-Disease
tumor NN O I-Disease
of NN O I-Disease
the NN O I-Disease
liver NN O I-Disease
that NN O O
occurs NN O O
in NN O O
children NN O O
at NN O O
an NN O O
average NN O O
age NN O O
of NN O O
2 NN O O
to NN O O
3 NN O O
years NN O O
. NN O O

Epidemiologic NN O O
studies NN O O
have NN O O
shown NN O O
an NN O O
increased NN O O
frequency NN O O
of NN O O
this NN O O
tumor NN O B-Disease
type NN O O
in NN O O
families NN O O
affected NN O O
by NN O O
adenomatous NN O B-Disease
polyposis NN O I-Disease
coli NN O I-Disease
. NN O O

In NN O O
addition NN O O
to NN O O
the NN O O
epidemiologic NN O O
data NN O O
, NN O O
molecular NN O O
genetic NN O O
studies NN O O
suggest NN O O
that NN O O
inactivation NN O O
of NN O O
the NN O O
APC NN O B-Disease
tumor NN O I-Disease
suppressor NN O O
may NN O O
be NN O O
involved NN O O
in NN O O
hepatoblastoma NN O B-Disease
tumorigenesis NN O O
. NN O O

A NN O O
major NN O O
function NN O O
of NN O O
APC NN O O
is NN O O
the NN O O
downregulation NN O O
of NN O O
beta NN O O
- NN O O
catenin NN O O
, NN O O
a NN O O
transcription NN O O
- NN O O
activating NN O O
protein NN O O
with NN O O
oncogenic NN O O
potential NN O O
. NN O O

In NN O O
an NN O O
ongoing NN O O
immunohistochemical NN O O
study NN O O
of NN O O
beta NN O O
- NN O O
catenin NN O O
expression NN O O
in NN O O
sporadic NN O O
cases NN O O
of NN O O
tumor NN O B-Disease
types NN O O
that NN O O
are NN O O
associated NN O O
with NN O O
adenomatous NN O B-Disease
polyposis NN O I-Disease
coli NN O I-Disease
, NN O O
we NN O O
observed NN O O
increased NN O O
beta NN O O
- NN O O
catenin NN O O
levels NN O O
in NN O O
the NN O O
cytoplasm NN O O
and NN O O
in NN O O
the NN O O
nuclei NN O O
of NN O O
three NN O O
investigated NN O O
hepatoblastomas NN O B-Disease
. NN O O

Sequencing NN O O
of NN O O
exon NN O O
3 NN O O
of NN O O
the NN O O
beta NN O O
- NN O O
catenin NN O O
gene NN O O
( NN O O
CTNNB1 NN O O
) NN O O
revealed NN O O
an NN O O
activating NN O O
mutation NN O O
in NN O O
one NN O O
of NN O O
the NN O O
tumor NN O B-Disease
samples NN O O
. NN O O

Our NN O O
data NN O O
indicate NN O O
for NN O O
the NN O O
first NN O O
time NN O O
that NN O O
beta NN O O
- NN O O
catenin NN O O
accumulation NN O O
may NN O O
play NN O O
a NN O O
role NN O O
in NN O O
the NN O O
development NN O O
of NN O O
hepatoblastoma NN O B-Disease
and NN O O
that NN O O
activating NN O O
mutations NN O O
of NN O O
the NN O O
beta NN O O
- NN O O
catenin NN O O
gene NN O O
may NN O O
substitute NN O O
biallelic NN O O
APC NN O O
inactivation NN O O
in NN O O
this NN O O
tumor NN O B-Disease
type NN O O
. NN O O

Genes NN O O
Chromosomes NN O O
Cancer NN O O
25 NN O O
399 NN O O
- NN O O
402 NN O O
, NN O O
1999 NN O O
. NN O O
. NN O O

Decrease NN O O
in NN O O
GTP NN O O
cyclohydrolase NN O O
I NN O O
gene NN O O
expression NN O O
caused NN O O
by NN O O
inactivation NN O O
of NN O O
one NN O O
allele NN O O
in NN O O
hereditary NN O B-Disease
progressive NN O I-Disease
dystonia NN O I-Disease
with NN O O
marked NN O O
diurnal NN O O
fluctuation NN O O
. NN O O

Hereditary NN O B-Disease
progressive NN O I-Disease
dystonia NN O I-Disease
with NN O O
marked NN O O
diurnal NN O O
fluctuation NN O O
( NN O O
HPD NN O B-Disease
; NN O O
dopa NN O B-Disease
- NN O I-Disease
responsive NN O I-Disease
dystonia NN O I-Disease
, NN O O
DRD NN O B-Disease
) NN O O
have NN O O
been NN O O
recently NN O O
found NN O O
to NN O O
be NN O O
caused NN O O
by NN O O
a NN O O
genetic NN O B-Disease
defect NN O I-Disease
in NN O O
the NN O O
GTP NN O O
cyclohydrolase NN O O
I NN O O
( NN O O
GCH1 NN O O
) NN O O
gene NN O O
. NN O O

In NN O O
this NN O O
study NN O O
, NN O O
we NN O O
quantified NN O O
the NN O O
mRNA NN O O
level NN O O
of NN O O
GCH1 NN O O
in NN O O
phytohemagglutinin NN O O
( NN O O
PHA NN O O
) NN O O
- NN O O
stimulated NN O O
mononuclear NN O O
blood NN O O
cells NN O O
from NN O O
one NN O O
Japanese NN O O
family NN O O
that NN O O
do NN O O
not NN O O
have NN O O
a NN O O
mutation NN O O
in NN O O
the NN O O
coding NN O O
region NN O O
or NN O O
splice NN O O
junctions NN O O
of NN O O
the NN O O
gene NN O O
. NN O O

The NN O O
results NN O O
showed NN O O
that NN O O
the NN O O
amounts NN O O
of NN O O
the NN O O
GCH1 NN O O
mRNA NN O O
were NN O O
decreased NN O O
to NN O O
about NN O O
40 NN O O
% NN O O
of NN O O
the NN O O
normal NN O O
level NN O O
in NN O O
both NN O O
patients NN O O
and NN O O
carriers NN O O
. NN O O

In NN O O
addition NN O O
, NN O O
we NN O O
found NN O O
that NN O O
the NN O O
GCH1 NN O O
mRNA NN O O
was NN O O
transcribed NN O O
from NN O O
only NN O O
one NN O O
allele NN O O
, NN O O
indicating NN O O
that NN O O
the NN O O
other NN O O
allele NN O O
was NN O O
in NN O O
an NN O O
inactive NN O O
state NN O O
. NN O O

These NN O O
results NN O O
suggest NN O O
that NN O O
some NN O O
novel NN O O
mutations NN O O
should NN O O
exist NN O O
on NN O O
one NN O O
of NN O O
the NN O O
alleles NN O O
in NN O O
some NN O O
unknown NN O O
region NN O O
of NN O O
the NN O O
GCH1 NN O O
gene NN O O
, NN O O
and NN O O
may NN O O
decrease NN O O
the NN O O
GCH1 NN O O
mRNA NN O O
causing NN O O
the NN O O
HPD NN O B-Disease
/ NN O O
DRD NN O B-Disease
symptoms NN O O
. NN O O
. NN O O

Sulfate NN O O
transport NN O O
is NN O O
not NN O O
impaired NN O O
in NN O O
pendred NN O B-Disease
syndrome NN O I-Disease
thyrocytes NN O O
. NN O O

Pendred NN O B-Disease
syndrome NN O I-Disease
is NN O O
the NN O O
most NN O O
common NN O O
form NN O O
of NN O O
syndromic NN O B-Disease
deafness NN O I-Disease
, NN O O
characterized NN O O
by NN O O
dyshormonogenic NN O B-Disease
goiter NN O I-Disease
associated NN O O
with NN O O
sensory NN O B-Disease
- NN O I-Disease
neural NN O I-Disease
deafness NN O I-Disease
. NN O O

The NN O O
gene NN O O
responsible NN O O
for NN O O
the NN O O
disease NN O O
( NN O O
PDS NN O B-Disease
) NN O O
has NN O O
been NN O O
cloned NN O O
, NN O O
but NN O O
its NN O O
function NN O O
is NN O O
as NN O O
yet NN O O
unknown NN O O
and NN O O
the NN O O
connection NN O O
between NN O O
thyroid NN O B-Disease
goiter NN O I-Disease
and NN O O
sensory NN O B-Disease
- NN O I-Disease
neural NN O I-Disease
deafness NN O I-Disease
remains NN O O
an NN O O
enigma NN O O
. NN O O

PDS NN O O
codes NN O O
for NN O O
a NN O O
novel NN O O
protein NN O O
, NN O O
pendrin NN O O
, NN O O
which NN O O
is NN O O
closely NN O O
related NN O O
to NN O O
a NN O O
number NN O O
of NN O O
sufate NN O O
transporters NN O O
. NN O O

Mechanisms NN O O
by NN O O
which NN O O
abnormal NN O O
sulfate NN O O
transport NN O O
could NN O O
deleteriously NN O O
affect NN O O
iodide NN O O
organification NN O O
have NN O O
been NN O O
proposed NN O O
. NN O O

We NN O O
tested NN O O
sulfate NN O O
transport NN O O
in NN O O
thyrocytes NN O O
obtained NN O O
from NN O O
Pendred NN O B-Disease
syndrome NN O I-Disease
patients NN O O
and NN O O
found NN O O
that NN O O
it NN O O
was NN O O
not NN O O
defective NN O O
. NN O O

This NN O O
suggests NN O O
that NN O O
pendrin NN O O
in NN O O
fact NN O O
may NN O O
not NN O O
be NN O O
a NN O O
sulfate NN O O
transporter NN O O
, NN O O
and NN O O
emphasizes NN O O
the NN O O
importance NN O O
of NN O O
functional NN O O
studies NN O O
on NN O O
this NN O O
novel NN O O
protein NN O O
. NN O O
. NN O O

Small NN O O
deletions NN O O
in NN O O
the NN O O
type NN O O
II NN O O
collagen NN O O
triple NN O O
helix NN O O
produce NN O O
kniest NN O B-Disease
dysplasia NN O I-Disease
. NN O O

Kniest NN O B-Disease
dysplasia NN O I-Disease
is NN O O
a NN O O
moderately NN O O
severe NN O O
type NN O B-Disease
II NN O I-Disease
collagenopathy NN O I-Disease
, NN O O
characterized NN O O
by NN O O
short NN O O
trunk NN O O
and NN O O
limbs NN O O
, NN O O
kyphoscoliosis NN O B-Disease
, NN O O
midface NN O B-Disease
hypoplasia NN O I-Disease
, NN O O
severe NN O O
myopia NN O B-Disease
, NN O O
and NN O O
hearing NN O B-Disease
loss NN O I-Disease
. NN O O

Mutations NN O O
in NN O O
the NN O O
gene NN O O
that NN O O
encodes NN O O
type NN O O
II NN O O
collagen NN O O
( NN O O
COL2A1 NN O O
) NN O O
, NN O O
the NN O O
predominant NN O O
protein NN O O
of NN O O
cartilage NN O O
, NN O O
have NN O O
been NN O O
identified NN O O
in NN O O
a NN O O
number NN O O
of NN O O
individuals NN O O
with NN O O
Kniest NN O B-Disease
dysplasia NN O I-Disease
. NN O O

All NN O O
but NN O O
two NN O O
of NN O O
these NN O O
previously NN O O
described NN O O
mutations NN O O
cause NN O O
in NN O O
- NN O O
frame NN O O
deletions NN O O
in NN O O
type NN O O
II NN O O
collagen NN O O
, NN O O
either NN O O
by NN O O
small NN O O
deletions NN O O
in NN O O
the NN O O
gene NN O O
or NN O O
splice NN O O
site NN O O
alterations NN O O
. NN O O

Furthermore NN O O
, NN O O
all NN O O
but NN O O
one NN O O
of NN O O
these NN O O
mutations NN O O
is NN O O
located NN O O
between NN O O
exons NN O O
12 NN O O
and NN O O
24 NN O O
in NN O O
the NN O O
COL2A1 NN O O
gene NN O O
. NN O O

We NN O O
used NN O O
heteroduplex NN O O
analysis NN O O
to NN O O
identify NN O O
sequence NN O O
anomalies NN O O
in NN O O
five NN O O
individuals NN O O
with NN O O
Kniest NN O B-Disease
dysplasia NN O I-Disease
. NN O O

Sequencing NN O O
of NN O O
the NN O O
index NN O O
patients NN O O
genomic NN O O
DNA NN O O
identified NN O O
four NN O O
new NN O O
dominant NN O O
mutations NN O O
in NN O O
COL2A1 NN O O
that NN O O
result NN O O
in NN O O
Kniest NN O B-Disease
dysplasia NN O I-Disease
a NN O O
21 NN O O
- NN O O
bp NN O O
deletion NN O O
in NN O O
exon NN O O
16 NN O O
, NN O O
an NN O O
18 NN O O
- NN O O
bp NN O O
deletion NN O O
in NN O O
exon NN O O
19 NN O O
, NN O O
and NN O O
4 NN O O
- NN O O
bp NN O O
deletions NN O O
in NN O O
the NN O O
splice NN O O
donor NN O O
sites NN O O
of NN O O
introns NN O O
14 NN O O
and NN O O
20 NN O O
. NN O O

A NN O O
previously NN O O
described NN O O
28 NN O O
- NN O O
bp NN O O
deletion NN O O
at NN O O
the NN O O
COL2A1 NN O O
exon NN O O
12 NN O O
- NN O O
intron NN O O
12 NN O O
junction NN O O
, NN O O
deleting NN O O
the NN O O
splice NN O O
donor NN O O
site NN O O
, NN O O
was NN O O
identified NN O O
in NN O O
the NN O O
fifth NN O O
case NN O O
. NN O O

The NN O O
latter NN O O
three NN O O
mutations NN O O
are NN O O
predicted NN O O
to NN O O
result NN O O
in NN O O
exon NN O O
skipping NN O O
in NN O O
the NN O O
mRNA NN O O
encoded NN O O
from NN O O
the NN O O
mutant NN O O
allele NN O O
. NN O O

These NN O O
data NN O O
suggest NN O O
that NN O O
Kniest NN O B-Disease
dysplasia NN O I-Disease
results NN O O
from NN O O
shorter NN O O
type NN O O
II NN O O
collagen NN O O
monomers NN O O
, NN O O
and NN O O
support NN O O
the NN O O
hypothesis NN O O
that NN O O
alteration NN O O
of NN O O
a NN O O
specific NN O O
COL2A1 NN O O
domain NN O O
, NN O O
which NN O O
may NN O O
span NN O O
from NN O O
exons NN O O
12 NN O O
to NN O O
24 NN O O
, NN O O
leads NN O O
to NN O O
the NN O O
Kniest NN O B-Disease
dysplasia NN O I-Disease
phenotype NN O O
. NN O O
. NN O O

Classical NN O B-Disease
galactosemia NN O I-Disease
and NN O O
mutations NN O O
at NN O O
the NN O O
galactose NN O O
- NN O O
1 NN O O
- NN O O
phosphate NN O O
uridyl NN O O
transferase NN O O
( NN O O
GALT NN O O
) NN O O
gene NN O O
. NN O O

Classical NN O B-Disease
galactosemia NN O I-Disease
is NN O O
caused NN O O
by NN O O
a NN O O
deficiency NN O O
in NN O O
activity NN O O
of NN O O
the NN O O
enzyme NN O O
galactose NN O O
- NN O O
1 NN O O
- NN O O
phosphate NN O O
uridyl NN O O
transferase NN O O
( NN O O
GALT NN O O
) NN O O
, NN O O
which NN O O
, NN O O
in NN O O
turn NN O O
, NN O O
is NN O O
caused NN O O
by NN O O
mutations NN O O
at NN O O
the NN O O
GALT NN O O
gene NN O O
. NN O O

The NN O O
disorder NN O O
exhibits NN O O
considerable NN O O
allelic NN O O
heterogeneity NN O O
and NN O O
, NN O O
at NN O O
the NN O O
end NN O O
of NN O O
1998 NN O O
, NN O O
more NN O O
than NN O O
150 NN O O
different NN O O
base NN O O
changes NN O O
were NN O O
recorded NN O O
in NN O O
24 NN O O
different NN O O
populations NN O O
and NN O O
ethnic NN O O
groups NN O O
in NN O O
15 NN O O
countries NN O O
worldwide NN O O
. NN O O

The NN O O
mutations NN O O
most NN O O
frequently NN O O
cited NN O O
are NN O O
Q188R NN O O
, NN O O
K285N NN O O
, NN O O
S135L NN O O
, NN O O
and NN O O
N314D NN O O
. NN O O

Q188R NN O O
is NN O O
the NN O O
most NN O O
common NN O O
mutation NN O O
in NN O O
European NN O O
populations NN O O
or NN O O
in NN O O
those NN O O
predominantly NN O O
of NN O O
European NN O O
descent NN O O
. NN O O

Overall NN O O
, NN O O
it NN O O
accounts NN O O
for NN O O
60 NN O O
- NN O O
70 NN O O
% NN O O
of NN O O
mutant NN O O
chromosomes NN O O
, NN O O
but NN O O
there NN O O
are NN O O
significant NN O O
differences NN O O
in NN O O
its NN O O
relative NN O O
frequency NN O O
in NN O O
individual NN O O
populations NN O O
. NN O O

Individuals NN O O
homoallelic NN O O
for NN O O
Q188R NN O O
tend NN O O
to NN O O
have NN O O
a NN O O
severe NN O O
phenotype NN O O
and NN O O
this NN O O
is NN O O
in NN O O
keeping NN O O
with NN O O
the NN O O
virtually NN O O
complete NN O O
loss NN O O
of NN O O
enzyme NN O O
activity NN O O
observed NN O O
in NN O O
in NN O O
vitro NN O O
expression NN O O
systems NN O O
. NN O O

Globally NN O O
, NN O O
K285N NN O O
is NN O O
rarer NN O O
, NN O O
but NN O O
in NN O O
many NN O O
European NN O O
populations NN O O
it NN O O
can NN O O
be NN O O
found NN O O
on NN O O
25 NN O O
- NN O O
40 NN O O
% NN O O
of NN O O
mutant NN O O
chromosomes NN O O
. NN O O

It NN O O
is NN O O
invariably NN O O
associated NN O O
with NN O O
a NN O O
severe NN O O
phenotype NN O O
. NN O O

S135L NN O O
is NN O O
found NN O O
almost NN O O
exclusively NN O O
in NN O O
African NN O O
Americans NN O O
. NN O O

In NN O O
vitro NN O O
expression NN O O
results NN O O
are NN O O
discrepant NN O O
, NN O O
but NN O O
some NN O O
individuals NN O O
carrying NN O O
S135L NN O O
appear NN O O
to NN O O
exhibit NN O O
GALT NN O O
activity NN O O
in NN O O
some NN O O
tissues NN O O
. NN O O

Duarte NN O O
1 NN O O
( NN O O
or NN O O
Los NN O O
Angeles NN O O
) NN O O
and NN O O
Duarte NN O O
2 NN O O
( NN O O
or NN O O
Duarte NN O O
) NN O O
variants NN O O
carry NN O O
the NN O O
same NN O O
amino NN O O
acid NN O O
substitution NN O O
, NN O O
N314D NN O O
, NN O O
even NN O O
though NN O O
D1 NN O O
is NN O O
associated NN O O
with NN O O
increased NN O O
erythrocyte NN O O
GALT NN O O
activity NN O O
and NN O O
D2 NN O O
with NN O O
reduced NN O O
activity NN O O
. NN O O

N314D NN O O
is NN O O
in NN O O
linkage NN O O
disequilibrium NN O O
with NN O O
other NN O O
base NN O O
changes NN O O
that NN O O
differ NN O O
on NN O O
the NN O O
D1 NN O O
and NN O O
D2 NN O O
alleles NN O O
. NN O O

N314D NN O O
does NN O O
not NN O O
impair NN O O
GALT NN O O
activity NN O O
in NN O O
in NN O O
vitro NN O O
expression NN O O
systems NN O O
. NN O O

However NN O O
, NN O O
there NN O O
are NN O O
differences NN O O
in NN O O
the NN O O
abundance NN O O
of NN O O
GALT NN O O
protein NN O O
in NN O O
lymphoblastoid NN O O
cells NN O O
lines NN O O
from NN O O
D2 NN O O
and NN O O
D1 NN O O
individuals NN O O
. NN O O

It NN O O
is NN O O
unclear NN O O
whether NN O O
the NN O O
specific NN O O
molecular NN O O
changes NN O O
that NN O O
distinguish NN O O
the NN O O
D1 NN O O
and NN O O
D2 NN O O
alleles NN O O
account NN O O
for NN O O
the NN O O
different NN O O
activities NN O O
. NN O O

The NN O O
considerable NN O O
genetic NN O O
heterogeneity NN O O
documented NN O O
to NN O O
date NN O O
undoubtedly NN O O
contributes NN O O
to NN O O
the NN O O
phenotypic NN O O
heterogeneity NN O O
that NN O O
is NN O O
observed NN O O
in NN O O
galactosemia NN O B-Disease
. NN O O

The NN O O
additional NN O O
effects NN O O
of NN O O
nonallelic NN O O
variation NN O O
and NN O O
other NN O O
constitutional NN O O
factors NN O O
on NN O O
phenotypic NN O O
variability NN O O
remain NN O O
to NN O O
be NN O O
elucidated NN O O
. NN O O
. NN O O

Mutations NN O O
of NN O O
the NN O O
VHL NN O B-Disease
gene NN O O
in NN O O
sporadic NN O B-Disease
renal NN O I-Disease
cell NN O I-Disease
carcinoma NN O I-Disease
: NN O O
definition NN O O
of NN O O
a NN O O
risk NN O O
factor NN O O
for NN O O
VHL NN O B-Disease
patients NN O O
to NN O O
develop NN O O
an NN O O
RCC NN O B-Disease
. NN O O

To NN O O
investigate NN O O
the NN O O
nature NN O O
of NN O O
somatic NN O O
von NN O B-Disease
Hippel NN O I-Disease
- NN O I-Disease
Lindau NN O I-Disease
( NN O O
VHL NN O B-Disease
) NN O O
mutations NN O O
, NN O O
we NN O O
analyzed NN O O
173 NN O O
primary NN O O
sporadic NN O O
human NN O O
renal NN O B-Disease
cell NN O I-Disease
carcinomas NN O I-Disease
for NN O O
mutations NN O O
of NN O O
the NN O O
VHL NN O B-Disease
tumor NN O I-Disease
suppressor NN O O
gene NN O O
, NN O O
using NN O O
polymerase NN O O
chain NN O O
reaction NN O O
( NN O O
PCR NN O O
) NN O O
and NN O O
single NN O O
- NN O O
strand NN O O
conformational NN O O
polymorphism NN O O
analysis NN O O
( NN O O
SSCP NN O O
) NN O O
of NN O O
DNA NN O O
. NN O O

We NN O O
detected NN O O
abnormal NN O O
SSCP NN O O
pattern NN O O
in NN O O
73 NN O O
samples NN O O
. NN O O

After NN O O
sequencing NN O O
, NN O O
we NN O O
identified NN O O
microdeletions NN O O
in NN O O
58 NN O O
% NN O O
of NN O O
cases NN O O
, NN O O
microinsertions NN O O
in NN O O
17 NN O O
% NN O O
, NN O O
nonsense NN O O
mutations NN O O
in NN O O
8 NN O O
% NN O O
, NN O O
and NN O O
missense NN O O
mutations NN O O
in NN O O
17 NN O O
% NN O O
. NN O O

Among NN O O
these NN O O
mutations NN O O
, NN O O
50 NN O O
% NN O O
correspond NN O O
to NN O O
new NN O O
mutations NN O O
. NN O O

VHL NN O B-Disease
mutations NN O O
were NN O O
found NN O O
only NN O O
in NN O O
the NN O O
nonpapillary NN O B-Disease
renal NN O I-Disease
cell NN O I-Disease
carcinoma NN O I-Disease
( NN O O
RCC NN O B-Disease
) NN O O
subtype NN O O
, NN O O
as NN O O
previously NN O O
reported NN O O
. NN O O

To NN O O
compare NN O O
somatic NN O O
and NN O O
germline NN O O
mutations NN O O
, NN O O
we NN O O
used NN O O
the NN O O
VHL NN O B-Disease
database NN O O
, NN O O
which NN O O
includes NN O O
507 NN O O
mutations NN O O
. NN O O

The NN O O
study NN O O
of NN O O
mutational NN O O
events NN O O
revealed NN O O
a NN O O
significant NN O O
difference NN O O
between NN O O
somatic NN O O
and NN O O
germline NN O O
mutations NN O O
with NN O O
mutations NN O O
leading NN O O
to NN O O
truncated NN O O
proteins NN O O
observed NN O O
in NN O O
78 NN O O
% NN O O
of NN O O
somatic NN O O
mutations NN O O
vs NN O O
only NN O O
37 NN O O
% NN O O
in NN O O
germline NN O O
mutations NN O O
( NN O O
P NN O O
< NN O O
0 NN O O
. NN O O
001 NN O O
) NN O O
. NN O O

We NN O O
postulated NN O O
that NN O O
a NN O O
specific NN O O
pattern NN O O
of NN O O
VHL NN O B-Disease
mutations NN O O
is NN O O
associated NN O O
with NN O O
sporadic NN O B-Disease
RCC NN O I-Disease
. NN O O

This NN O O
pattern NN O O
corresponds NN O O
to NN O O
mutations NN O O
leading NN O O
mainly NN O O
to NN O O
truncated NN O O
proteins NN O O
with NN O O
few NN O O
specific NN O O
missense NN O O
mutations NN O O
. NN O O

We NN O O
then NN O O
analyzed NN O O
the NN O O
occurrence NN O O
of NN O O
RCC NN O B-Disease
in NN O O
VHL NN O B-Disease
families NN O O
, NN O O
based NN O O
on NN O O
the NN O O
nature NN O O
of NN O O
mutations NN O O
. NN O O

We NN O O
observed NN O O
RCC NN O B-Disease
in NN O O
at NN O O
least NN O O
one NN O O
member NN O O
of NN O O
the NN O O
VHL NN O B-Disease
families NN O O
in NN O O
77 NN O O
% NN O O
of NN O O
cases NN O O
with NN O O
mutations NN O O
leading NN O O
to NN O O
truncated NN O O
proteins NN O O
versus NN O O
55 NN O O
% NN O O
in NN O O
cases NN O O
with NN O O
missense NN O O
mutations NN O O
( NN O O
P NN O O
< NN O O
0 NN O O
. NN O O
05 NN O O
) NN O O
. NN O O

Thus NN O O
, NN O O
mutations NN O O
resulting NN O O
in NN O O
truncated NN O O
proteins NN O O
may NN O O
lead NN O O
to NN O O
a NN O O
higher NN O O
risk NN O O
of NN O O
RCC NN O B-Disease
in NN O O
VHL NN O B-Disease
patients NN O O

Defective NN O O
CTLA NN O O
- NN O O
4 NN O O
cycling NN O O
pathway NN O O
in NN O O
Chediak NN O B-Disease
- NN O I-Disease
Higashi NN O I-Disease
syndrome NN O I-Disease
: NN O O
a NN O O
possible NN O O
mechanism NN O O
for NN O O
deregulation NN O O
of NN O O
T NN O O
lymphocyte NN O O
activation NN O O
. NN O O

Cytotoxic NN O O
T NN O O
lymphocyte NN O O
- NN O O
associated NN O O
antigen NN O O
4 NN O O
( NN O O
CTLA NN O O
- NN O O
4 NN O O
, NN O O
also NN O O
known NN O O
as NN O O
CD152 NN O O
) NN O O
has NN O O
been NN O O
shown NN O O
to NN O O
play NN O O
a NN O O
major NN O O
role NN O O
in NN O O
the NN O O
regulation NN O O
of NN O O
T NN O O
cell NN O O
activation NN O O
. NN O O

Its NN O O
membrane NN O O
expression NN O O
is NN O O
highly NN O O
regulated NN O O
by NN O O
endocytosis NN O O
and NN O O
trafficking NN O O
through NN O O
the NN O O
secretory NN O O
lysosome NN O O
pathway NN O O
. NN O O

Chediak NN O B-Disease
- NN O I-Disease
Higashi NN O I-Disease
syndrome NN O I-Disease
( NN O O
CHS NN O B-Disease
) NN O O
is NN O O
an NN O O
inherited NN O B-Disease
disorder NN O I-Disease
caused NN O O
by NN O O
mutations NN O O
in NN O O
the NN O O
lysosomal NN O O
trafficking NN O O
regulator NN O O
gene NN O O
, NN O O
LYST NN O O
. NN O O

It NN O O
results NN O O
in NN O O
defective NN O O
membrane NN O O
targeting NN O O
of NN O O
the NN O O
proteins NN O O
present NN O O
in NN O O
secretory NN O O
lysosomes NN O O
, NN O O
and NN O O
it NN O O
is NN O O
associated NN O O
with NN O O
a NN O O
variety NN O O
of NN O O
features NN O O
, NN O O
including NN O O
a NN O O
lymphoproliferative NN O B-Disease
syndrome NN O I-Disease
with NN O O
hemophagocytosis NN O B-Disease
. NN O O

The NN O O
murine NN O O
equivalent NN O O
of NN O O
CHS NN O B-Disease
, NN O O
beige NN O O
mice NN O O
, NN O O
present NN O O
similar NN O O
characteristics NN O O
but NN O O
do NN O O
not NN O O
develop NN O O
the NN O O
lymphoproliferative NN O B-Disease
syndrome NN O I-Disease
. NN O O

We NN O O
show NN O O
herein NN O O
that NN O O
CTLA NN O O
- NN O O
4 NN O O
is NN O O
present NN O O
in NN O O
enlarged NN O O
, NN O O
abnormal NN O O
vesicles NN O O
in NN O O
CHS NN O B-Disease
T NN O O
cells NN O O
and NN O O
is NN O O
not NN O O
properly NN O O
expressed NN O O
at NN O O
the NN O O
cell NN O O
surface NN O O
after NN O O
T NN O O
cell NN O O
activation NN O O
, NN O O
whereas NN O O
its NN O O
surface NN O O
expression NN O O
is NN O O
not NN O O
impaired NN O O
. NN O O

It NN O O
is NN O O
therefore NN O O
proposed NN O O
that NN O O
the NN O O
defective NN O O
surface NN O O
expression NN O O
of NN O O
CTLA NN O O
- NN O O
4 NN O O
by NN O O
CHS NN O B-Disease
T NN O O
cells NN O O
is NN O O
involved NN O O
in NN O O
the NN O O
generation NN O O
of NN O O
lymphoproliferative NN O B-Disease
disease NN O I-Disease
. NN O O

This NN O O
observation NN O O
may NN O O
provide NN O O
insight NN O O
into NN O O
the NN O O
role NN O O
of NN O O
CTLA NN O O
- NN O O
4 NN O O
in NN O O
humans NN O O
. NN O O
. NN O O

Proteolipoprotein NN O O
gene NN O O
analysis NN O O
in NN O O
82 NN O O
patients NN O O
with NN O O
sporadic NN O O
Pelizaeus NN O B-Disease
- NN O I-Disease
Merzbacher NN O I-Disease
Disease NN O I-Disease
: NN O O
duplications NN O O
, NN O O
the NN O O
major NN O O
cause NN O O
of NN O O
the NN O O
disease NN O O
, NN O O
originate NN O O
more NN O O
frequently NN O O
in NN O O
male NN O O
germ NN O O
cells NN O O
, NN O O
but NN O O
point NN O O
mutations NN O O
do NN O O
not NN O O
. NN O O

The NN O O
Clinical NN O O
European NN O O
Network NN O O
on NN O O
Brain NN O B-Disease
Dysmyelinating NN O I-Disease
Disease NN O I-Disease
. NN O O

Pelizaeus NN O B-Disease
- NN O I-Disease
Merzbacher NN O I-Disease
Disease NN O I-Disease
( NN O O
PMD NN O B-Disease
) NN O O
is NN O O
an NN O O
X NN O B-Disease
- NN O I-Disease
linked NN O I-Disease
developmental NN O I-Disease
defect NN O I-Disease
of NN O I-Disease
myelination NN O I-Disease
affecting NN O O
the NN O O
central NN O O
nervous NN O O
system NN O O
and NN O O
segregating NN O O
with NN O O
the NN O O
proteolipoprotein NN O O
( NN O O
PLP NN O O
) NN O O
locus NN O O
. NN O O

Investigating NN O O
82 NN O O
strictly NN O O
selected NN O O
sporadic NN O O
cases NN O O
of NN O O
PMD NN O B-Disease
, NN O O
we NN O O
found NN O O
PLP NN O O
mutations NN O O
in NN O O
77 NN O O
% NN O O
; NN O O
complete NN O O
PLP NN O O
- NN O O
gene NN O O
duplications NN O O
were NN O O
the NN O O
most NN O O
frequent NN O O
abnormality NN O O
( NN O O
62 NN O O
% NN O O
) NN O O
, NN O O
whereas NN O O
point NN O O
mutations NN O O
in NN O O
coding NN O O
or NN O O
splice NN O O
- NN O O
site NN O O
regions NN O O
of NN O O
the NN O O
gene NN O O
were NN O O
involved NN O O
less NN O O
frequently NN O O
( NN O O
38 NN O O
% NN O O
) NN O O
. NN O O

We NN O O
analyzed NN O O
the NN O O
maternal NN O O
status NN O O
of NN O O
56 NN O O
cases NN O O
to NN O O
determine NN O O
the NN O O
origin NN O O
of NN O O
both NN O O
types NN O O
of NN O O
PLP NN O O
mutation NN O O
, NN O O
since NN O O
this NN O O
is NN O O
relevant NN O O
to NN O O
genetic NN O O
counseling NN O O
. NN O O

In NN O O
the NN O O
22 NN O O
point NN O O
mutations NN O O
, NN O O
68 NN O O
% NN O O
of NN O O
mothers NN O O
were NN O O
heterozygous NN O O
for NN O O
the NN O O
mutation NN O O
, NN O O
a NN O O
value NN O O
identical NN O O
to NN O O
the NN O O
two NN O O
- NN O O
thirds NN O O
of NN O O
carrier NN O O
mothers NN O O
that NN O O
would NN O O
be NN O O
expected NN O O
if NN O O
there NN O O
were NN O O
an NN O O
equal NN O O
mutation NN O O
rate NN O O
in NN O O
male NN O O
and NN O O
female NN O O
germ NN O O
cells NN O O
. NN O O

In NN O O
sharp NN O O
contrast NN O O
, NN O O
among NN O O
the NN O O
34 NN O O
duplicated NN O O
cases NN O O
, NN O O
91 NN O O
% NN O O
of NN O O
mothers NN O O
were NN O O
carriers NN O O
, NN O O
a NN O O
value NN O O
significantly NN O O
( NN O O
chi2 NN O O
= NN O O
9 NN O O
. NN O O
20 NN O O
, NN O O
P NN O O
< NN O O
. NN O O
01 NN O O
) NN O O
in NN O O
favor NN O O
of NN O O
a NN O O
male NN O O
bias NN O O
, NN O O
with NN O O
an NN O O
estimation NN O O
of NN O O
the NN O O
male NN O O
/ NN O O
female NN O O
mutation NN O O
frequency NN O O
( NN O O
k NN O O
) NN O O
of NN O O
9 NN O O
. NN O O

3 NN O O
3 NN O O
. NN O O

Moreover NN O O
, NN O O
we NN O O
observed NN O O
the NN O O
occurrence NN O O
of NN O O
de NN O O
novo NN O O
mutations NN O O
between NN O O
parental NN O O
and NN O O
grandparental NN O O
generations NN O O
in NN O O
17 NN O O
three NN O O
- NN O O
generation NN O O
families NN O O
, NN O O
which NN O O
allowed NN O O
a NN O O
direct NN O O
estimation NN O O
of NN O O
the NN O O
k NN O O
value NN O O
( NN O O
k NN O O
= NN O O
11 NN O O
) NN O O
. NN O O

Again NN O O
, NN O O
a NN O O
significant NN O O
male NN O O
mutation NN O O
imbalance NN O O
was NN O O
observed NN O O
only NN O O
for NN O O
the NN O O
duplications NN O O
. NN O O

Chromosome NN O O
breakage NN O O
in NN O O
the NN O O
Prader NN O B-Disease
- NN O I-Disease
Willi NN O I-Disease
and NN O I-Disease
Angelman NN O I-Disease
syndromes NN O I-Disease
involves NN O O
recombination NN O O
between NN O O
large NN O O
, NN O O
transcribed NN O O
repeats NN O O
at NN O O
proximal NN O O
and NN O O
distal NN O O
breakpoints NN O O
. NN O O

Prader NN O B-Disease
- NN O I-Disease
Willi NN O I-Disease
syndrome NN O I-Disease
( NN O O
PWS NN O B-Disease
) NN O O
and NN O O
Angelman NN O B-Disease
syndrome NN O I-Disease
( NN O O
AS NN O B-Disease
) NN O O
are NN O O
distinct NN O O
neurobehavioral NN O B-Disease
disorders NN O I-Disease
that NN O O
most NN O O
often NN O O
arise NN O O
from NN O O
a NN O O
4 NN O O
- NN O O
Mb NN O O
deletion NN O O
of NN O O
chromosome NN O O
15q11 NN O O
- NN O O
q13 NN O O
during NN O O
paternal NN O O
or NN O O
maternal NN O O
gametogenesis NN O O
, NN O O
respectively NN O O
. NN O O

At NN O O
a NN O O
de NN O O
novo NN O O
frequency NN O O
of NN O O
approximately NN O O
. NN O O

67 NN O O
- NN O O
1 NN O O
/ NN O O
10 NN O O
, NN O O
000 NN O O
births NN O O
, NN O O
these NN O O
deletions NN O O
represent NN O O
a NN O O
common NN O O
structural NN O O
chromosome NN O O
change NN O O
in NN O O
the NN O O
human NN O O
genome NN O O
. NN O O

To NN O O
elucidate NN O O
the NN O O
mechanism NN O O
underlying NN O O
these NN O O
events NN O O
, NN O O
we NN O O
characterized NN O O
the NN O O
regions NN O O
that NN O O
contain NN O O
two NN O O
proximal NN O O
breakpoint NN O O
clusters NN O O
and NN O O
a NN O O
distal NN O O
cluster NN O O
. NN O O

Novel NN O O
DNA NN O O
sequences NN O O
potentially NN O O
associated NN O O
with NN O O
the NN O O
breakpoints NN O O
were NN O O
positionally NN O O
cloned NN O O
from NN O O
YACs NN O O
within NN O O
or NN O O
near NN O O
these NN O O
regions NN O O
. NN O O

Analyses NN O O
of NN O O
rodent NN O O
- NN O O
human NN O O
somatic NN O O
- NN O O
cell NN O O
hybrids NN O O
, NN O O
YAC NN O O
contigs NN O O
, NN O O
and NN O O
FISH NN O O
of NN O O
normal NN O O
or NN O O
rearranged NN O O
chromosomes NN O O
15 NN O O
identified NN O O
duplicated NN O O
sequences NN O O
( NN O O
the NN O O
END NN O O
repeats NN O O
) NN O O
at NN O O
or NN O O
near NN O O
the NN O O
breakpoints NN O O
. NN O O

The NN O O
END NN O O
- NN O O
repeat NN O O
units NN O O
are NN O O
derived NN O O
from NN O O
large NN O O
genomic NN O O
duplications NN O O
of NN O O
a NN O O
novel NN O O
gene NN O O
( NN O O
HERC2 NN O O
) NN O O
, NN O O
many NN O O
copies NN O O
of NN O O
which NN O O
are NN O O
transcriptionally NN O O
active NN O O
in NN O O
germline NN O O
tissues NN O O
. NN O O

One NN O O
of NN O O
five NN O O
PWS NN O B-Disease
/ NN O O
AS NN O B-Disease
patients NN O O
analyzed NN O O
to NN O O
date NN O O
has NN O O
an NN O O
identifiable NN O O
, NN O O
rearranged NN O O
HERC2 NN O O
transcript NN O O
derived NN O O
from NN O O
the NN O O
deletion NN O O
event NN O O
. NN O O

We NN O O
postulate NN O O
that NN O O
the NN O O
END NN O O
repeats NN O O
flanking NN O O
15q11 NN O O
- NN O O
q13 NN O O
mediate NN O O
homologous NN O O
recombination NN O O
resulting NN O O
in NN O O
deletion NN O O
. NN O O

Furthermore NN O O
, NN O O
we NN O O
propose NN O O
that NN O O
active NN O O
transcription NN O O
of NN O O
these NN O O
repeats NN O O
in NN O O
male NN O O
and NN O O
female NN O O
germ NN O O
cells NN O O
may NN O O
facilitate NN O O
the NN O O
homologous NN O O
recombination NN O O
process NN O O
. NN O O

Linkage NN O O
analysis NN O O
in NN O O
a NN O O
large NN O O
Brazilian NN O O
family NN O O
with NN O O
van NN O B-Disease
der NN O I-Disease
Woude NN O I-Disease
syndrome NN O I-Disease
suggests NN O O
the NN O O
existence NN O O
of NN O O
a NN O O
susceptibility NN O O
locus NN O O
for NN O O
cleft NN O B-Disease
palate NN O I-Disease
at NN O O
17p11 NN O O
. NN O O
2 NN O O
- NN O O
11 NN O O
. NN O O
1 NN O O
. NN O O

van NN O B-Disease
der NN O I-Disease
Woude NN O I-Disease
syndrome NN O I-Disease
( NN O O
VWS NN O B-Disease
) NN O O
, NN O O
which NN O O
has NN O O
been NN O O
mapped NN O O
to NN O O
1q32 NN O O
- NN O O
41 NN O O
, NN O O
is NN O O
characterized NN O O
by NN O O
pits NN O B-Disease
and NN O I-Disease
/ NN O I-Disease
or NN O I-Disease
sinuses NN O I-Disease
of NN O I-Disease
the NN O I-Disease
lower NN O I-Disease
lip NN O I-Disease
, NN O O
cleft NN O B-Disease
lip NN O I-Disease
/ NN O I-Disease
palate NN O I-Disease
( NN O O
CL NN O B-Disease
/ NN O I-Disease
P NN O I-Disease
) NN O O
, NN O O
cleft NN O B-Disease
palate NN O I-Disease
( NN O O
CP NN O B-Disease
) NN O O
, NN O O
bifid NN O B-Disease
uvula NN O I-Disease
, NN O O
and NN O O
hypodontia NN O B-Disease
( NN O O
H NN O B-Disease
) NN O O
. NN O O

The NN O O
expression NN O O
of NN O O
VWS NN O B-Disease
, NN O O
which NN O O
has NN O O
incomplete NN O O
penetrance NN O O
, NN O O
is NN O O
highly NN O O
variable NN O O
. NN O O

Both NN O O
the NN O O
occurrence NN O O
of NN O O
CL NN O B-Disease
/ NN O I-Disease
P NN O I-Disease
and NN O O
CP NN O B-Disease
within NN O O
the NN O O
same NN O O
genealogy NN O O
and NN O O
a NN O O
recurrence NN O O
risk NN O O
< NN O O
40 NN O O
% NN O O
for NN O O
CP NN O B-Disease
among NN O O
descendants NN O O
with NN O O
VWS NN O B-Disease
have NN O O
suggested NN O O
that NN O O
the NN O O
development NN O O
of NN O O
clefts NN O B-Disease
in NN O O
this NN O O
syndrome NN O O
is NN O O
influenced NN O O
by NN O O
modifying NN O O
genes NN O O
at NN O O
other NN O O
loci NN O O
. NN O O

To NN O O
test NN O O
this NN O O
hypothesis NN O O
, NN O O
we NN O O
have NN O O
conducted NN O O
linkage NN O O
analysis NN O O
in NN O O
a NN O O
large NN O O
Brazilian NN O O
kindred NN O O
with NN O O
VWS NN O B-Disease
, NN O O
considering NN O O
as NN O O
affected NN O O
the NN O O
individuals NN O O
with NN O O
CP NN O B-Disease
, NN O O
regardless NN O O
of NN O O
whether NN O O
it NN O O
is NN O O
associated NN O O
with NN O O
other NN O O
clinical NN O O
signs NN O O
of NN O O
VWS NN O B-Disease
. NN O O

Our NN O O
results NN O O
suggest NN O O
that NN O O
a NN O O
gene NN O O
at NN O O
17p11 NN O O
. NN O O

2 NN O O
- NN O O
11 NN O O
2 NN O O
- NN O O
11 NN O O
. NN O O

1 NN O O
, NN O O
together NN O O
with NN O O
the NN O O
VWS NN O B-Disease
gene NN O O
at NN O O
1p32 NN O O
- NN O O
41 NN O O
, NN O O
enhances NN O O
the NN O O
probability NN O O
of NN O O
CP NN O B-Disease
in NN O O
an NN O O
individual NN O O
carrying NN O O
the NN O O
two NN O O
at NN O O
- NN O O
risk NN O O
genes NN O O
. NN O O

If NN O O
this NN O O
hypothesis NN O O
is NN O O
confirmed NN O O
in NN O O
other NN O O
VWS NN O B-Disease
pedigrees NN O O
, NN O O
it NN O O
will NN O O
represent NN O O
one NN O O
of NN O O
the NN O O
first NN O O
examples NN O O
of NN O O
a NN O O
gene NN O O
, NN O O
mapped NN O O
through NN O O
linkage NN O O
analysis NN O O
, NN O O
which NN O O
modifies NN O O
the NN O O
expression NN O O
of NN O O
a NN O O
major NN O O
gene NN O O
. NN O O

New NN O O
mutations NN O O
, NN O O
polymorphisms NN O O
, NN O O
and NN O O
rare NN O O
variants NN O O
in NN O O
the NN O O
ATM NN O O
gene NN O O
detected NN O O
by NN O O
a NN O O
novel NN O O
SSCP NN O O
strategy NN O O
. NN O O

The NN O O
gene NN O O
for NN O O
ataxia NN O B-Disease
- NN O I-Disease
telangiectasia NN O I-Disease
, NN O O
ATM NN O O
, NN O O
spans NN O O
about NN O O
150 NN O O
kb NN O O
of NN O O
genomic NN O O
DNA NN O O
. NN O O

ATM NN O O
mutations NN O O
are NN O O
found NN O O
along NN O O
the NN O O
entire NN O O
gene NN O O
, NN O O
with NN O O
no NN O O
evidence NN O O
of NN O O
a NN O O
mutational NN O O
hot NN O O
spot NN O O
. NN O O

Using NN O O
DNA NN O O
as NN O O
the NN O O
starting NN O O
material NN O O
, NN O O
we NN O O
screened NN O O
the NN O O
ATM NN O O
gene NN O O
in NN O O
92 NN O O
A NN O B-Disease
- NN O I-Disease
T NN O I-Disease
patients NN O O
, NN O O
using NN O O
an NN O O
optimized NN O O
single NN O O
- NN O O
strand NN O O
conformation NN O O
polymorphism NN O O
( NN O O
SSCP NN O O
) NN O O
technique NN O O
that NN O O
detected NN O O
all NN O O
previously NN O O
known NN O O
mutations NN O O
in NN O O
the NN O O
polymerase NN O O
chain NN O O
reaction NN O O
( NN O O
PCR NN O O
) NN O O
segments NN O O
being NN O O
analyzed NN O O
. NN O O

To NN O O
expedite NN O O
screening NN O O
, NN O O
we NN O O
sequentially NN O O
loaded NN O O
the NN O O
SSCP NN O O
gels NN O O
with NN O O
three NN O O
different NN O O
sets NN O O
of NN O O
PCR NN O O
products NN O O
that NN O O
were NN O O
pretested NN O O
to NN O O
avoid NN O O
overlapping NN O O
patterns NN O O
. NN O O

Many NN O O
of NN O O
the NN O O
DNA NN O O
changes NN O O
we NN O O
detected NN O O
were NN O O
intragenic NN O O
polymorphisms NN O O
. NN O O

Of NN O O
an NN O O
expected NN O O
177 NN O O
unknown NN O O
mutations NN O O
, NN O O
we NN O O
detected NN O O
approximately NN O O
70 NN O O
% NN O O
, NN O O
mostly NN O O
protein NN O O
truncating NN O O
mutations NN O O
( NN O O
that NN O O
would NN O O
have NN O O
been NN O O
detectable NN O O
by NN O O
protein NN O O
truncation NN O O
testing NN O O
if NN O O
RNA NN O O
starting NN O O
material NN O O
had NN O O
been NN O O
available NN O O
) NN O O
. NN O O

Mutations NN O O
have NN O O
now NN O O
been NN O O
defined NN O O
for NN O O
every NN O O
exon NN O O
of NN O O
the NN O O
ATM NN O O
gene NN O O
. NN O O

Herein NN O O
, NN O O
we NN O O
present NN O O
35 NN O O
new NN O O
mutations NN O O
and NN O O
34 NN O O
new NN O O
intragenic NN O O
polymorphisms NN O O
or NN O O
rare NN O O
variants NN O O
within NN O O
the NN O O
ATM NN O O
gene NN O O
. NN O O

This NN O O
is NN O O
the NN O O
most NN O O
comprehensive NN O O
compilation NN O O
of NN O O
ATM NN O O
polymorphisms NN O O
assembled NN O O
to NN O O
date NN O O
. NN O O

Defining NN O O
polymorphic NN O O
sites NN O O
as NN O O
well NN O O
as NN O O
mutations NN O O
in NN O O
the NN O O
ATM NN O O
gene NN O O
will NN O O
be NN O O
of NN O O
great NN O O
importance NN O O
in NN O O
designing NN O O
automated NN O O
methods NN O O
for NN O O
detecting NN O O
mutations NN O O
. NN O O
. NN O O

A NN O O
novel NN O O
frameshift NN O O
mutation NN O O
in NN O O
the NN O O
McLeod NN O B-Disease
syndrome NN O I-Disease
gene NN O O
in NN O O
a NN O O
Japanese NN O O
family NN O O
. NN O O

We NN O O
report NN O O
a NN O O
novel NN O O
mutation NN O O
in NN O O
the NN O O
XK NN O O
gene NN O O
( NN O O
XK NN O O
) NN O O
in NN O O
a NN O O
Japanese NN O O
patient NN O O
with NN O O
McLeod NN O B-Disease
syndrome NN O I-Disease
. NN O O

A NN O O
50 NN O O
- NN O O
year NN O O
- NN O O
old NN O O
man NN O O
showed NN O O
progressive NN O O
muscular NN O B-Disease
atrophy NN O I-Disease
, NN O O
choreic NN O B-Disease
movement NN O I-Disease
, NN O O
elevated NN O O
level NN O O
of NN O O
serum NN O O
creatinine NN O O
kinase NN O O
, NN O O
and NN O O
acanthocytosis NN O B-Disease
. NN O O

The NN O O
expression NN O O
level NN O O
of NN O O
all NN O O
the NN O O
Kell NN O O
antigens NN O O
in NN O O
erythrocyte NN O O
was NN O O
decreased NN O O
and NN O O
molecular NN O O
analysis NN O O
revealed NN O O
a NN O O
single NN O O
- NN O O
base NN O O
( NN O O
T NN O O
) NN O O
deletion NN O O
at NN O O
the NN O O
nucleotide NN O O
position NN O O
1095 NN O O
in NN O O
XK NN O O
. NN O O

This NN O O
deletion NN O O
caused NN O O
a NN O O
frameshift NN O O
in NN O O
translation NN O O
, NN O O
leading NN O O
to NN O O
a NN O O
premature NN O O
stop NN O O
codon NN O O
at NN O O
the NN O O
amino NN O O
acid NN O O
position NN O O
408 NN O O
. NN O O

We NN O O
conclude NN O O
this NN O O
single NN O O
- NN O O
base NN O O
deletion NN O O
causes NN O O
defective NN O O
Kx NN O O
protein NN O O
, NN O O
which NN O O
is NN O O
responsible NN O O
for NN O O
the NN O O
McLeod NN O B-Disease
phenotype NN O O
in NN O O
this NN O O
patient NN O O
. NN O O
. NN O O

Association NN O O
of NN O O
BRCA1 NN O O
with NN O O
the NN O O
hRad50 NN O O
- NN O O
hMre11 NN O O
- NN O O
p95 NN O O
complex NN O O
and NN O O
the NN O O
DNA NN O O
damage NN O O
response NN O O
. NN O O

BRCA1 NN O O
encodes NN O O
a NN O O
tumor NN O B-Disease
suppressor NN O O
that NN O O
is NN O O
mutated NN O O
in NN O O
familial NN O B-Disease
breast NN O I-Disease
and NN O I-Disease
ovarian NN O I-Disease
cancers NN O I-Disease
. NN O O

Here NN O O
, NN O O
it NN O O
is NN O O
shown NN O O
that NN O O
BRCA1 NN O O
interacts NN O O
in NN O O
vitro NN O O
and NN O O
in NN O O
vivo NN O O
with NN O O
hRad50 NN O O
, NN O O
which NN O O
forms NN O O
a NN O O
complex NN O O
with NN O O
hMre11 NN O O
and NN O O
p95 NN O O
/ NN O O
nibrin NN O O
. NN O O

Upon NN O O
irradiation NN O O
, NN O O
BRCA1 NN O O
was NN O O
detected NN O O
in NN O O
discrete NN O O
foci NN O O
in NN O O
the NN O O
nucleus NN O O
, NN O O
which NN O O
colocalize NN O O
with NN O O
hRad50 NN O O
. NN O O

Formation NN O O
of NN O O
irradiation NN O O
- NN O O
induced NN O O
foci NN O O
positive NN O O
for NN O O
BRCA1 NN O O
, NN O O
hRad50 NN O O
, NN O O
hMre11 NN O O
, NN O O
or NN O O
p95 NN O O
was NN O O
dramatically NN O O
reduced NN O O
in NN O O
HCC NN O O
/ NN O O
1937 NN O O
breast NN O B-Disease
cancer NN O I-Disease
cells NN O O
carrying NN O O
a NN O O
homozygous NN O O
mutation NN O O
in NN O O
BRCA1 NN O O
but NN O O
was NN O O
restored NN O O
by NN O O
transfection NN O O
of NN O O
wild NN O O
- NN O O
type NN O O
BRCA1 NN O O
. NN O O

Ectopic NN O O
expression NN O O
of NN O O
wild NN O O
- NN O O
type NN O O
, NN O O
but NN O O
not NN O O
mutated NN O O
, NN O O
BRCA1 NN O O
in NN O O
these NN O O
cells NN O O
rendered NN O O
them NN O O
less NN O O
sensitive NN O O
to NN O O
the NN O O
DNA NN O O
damage NN O O
agent NN O O
, NN O O
methyl NN O O
methanesulfonate NN O O
. NN O O

These NN O O
data NN O O
suggest NN O O
that NN O O
BRCA1 NN O O
is NN O O
important NN O O
for NN O O
the NN O O
cellular NN O O
responses NN O O
to NN O O
DNA NN O O
damage NN O O
that NN O O
are NN O O
mediated NN O O
by NN O O
the NN O O
hRad50 NN O O
- NN O O
hMre11 NN O O
- NN O O
p95 NN O O
complex NN O O
. NN O O
. NN O O

Relationship NN O O
among NN O O
genotype NN O O
, NN O O
biochemical NN O O
phenotype NN O O
, NN O O
and NN O O
cognitive NN O O
performance NN O O
in NN O O
females NN O O
with NN O O
phenylalanine NN O B-Disease
hydroxylase NN O I-Disease
deficiency NN O I-Disease
: NN O O
report NN O O
from NN O O
the NN O O
Maternal NN O B-Disease
Phenylketonuria NN O I-Disease
Collaborative NN O O
Study NN O O
. NN O O

OBJECTIVE NN O O
To NN O O
examine NN O O
the NN O O
relationship NN O O
of NN O O
phenylalanine NN O O
hydroxylase NN O O
( NN O O
PAH NN O O
) NN O O
genotypes NN O O
to NN O O
biochemical NN O O
phenotype NN O O
and NN O O
cognitive NN O O
development NN O O
in NN O O
maternal NN O B-Disease
phenylketonuria NN O I-Disease
( NN O O
PKU NN O B-Disease
) NN O O
. NN O O

METHODOLOGY NN O O
PAH NN O O
gene NN O O
mutations NN O O
were NN O O
examined NN O O
in NN O O
222 NN O O
hyperphenylalaninemic NN O B-Disease
females NN O O
enrolled NN O O
in NN O O
the NN O O
Maternal NN O B-Disease
PKU NN O I-Disease
Collaborative NN O O
Study NN O O
( NN O O
MPKUCS NN O O
) NN O O
. NN O O

A NN O O
total NN O O
of NN O O
84 NN O O
different NN O O
mutations NN O O
were NN O O
detected NN O O
, NN O O
and NN O O
complete NN O O
genotype NN O O
was NN O O
obtained NN O O
in NN O O
199 NN O O
individuals NN O O
. NN O O

Based NN O O
on NN O O
previous NN O O
knowledge NN O O
about NN O O
mutation NN O O
- NN O O
phenotype NN O O
associations NN O O
, NN O O
78 NN O O
of NN O O
the NN O O
mutations NN O O
could NN O O
be NN O O
assigned NN O O
to NN O O
one NN O O
of NN O O
four NN O O
classes NN O O
of NN O O
severity NN O O
( NN O O
severe NN O O
PKU NN O B-Disease
, NN O O
moderate NN O O
PKU NN O B-Disease
, NN O O
mild NN O O
PKU NN O B-Disease
, NN O O
and NN O O
mild NN O B-Disease
hyperphenylalaninemia NN O I-Disease
[ NN O O
MHP NN O B-Disease
] NN O O
) NN O O
. NN O O

Then NN O O
, NN O O
189 NN O O
MPKUCS NN O O
subjects NN O O
were NN O O
grouped NN O O
according NN O O
to NN O O
the NN O O
various NN O O
combinations NN O O
of NN O O
mutation NN O O
classifications NN O O
. NN O O

The NN O O
sample NN O O
sizes NN O O
were NN O O
large NN O O
enough NN O O
for NN O O
statistical NN O O
testing NN O O
in NN O O
four NN O O
groups NN O O
with NN O O
at NN O O
least NN O O
one NN O O
mutation NN O O
that NN O O
completely NN O O
abolishes NN O O
enzyme NN O O
activity NN O O
. NN O O

These NN O O
patients NN O O
are NN O O
considered NN O O
functionally NN O O
hemizygous NN O O
. NN O O

RESULTS NN O O
The NN O O
biochemical NN O O
phenotype NN O O
predicted NN O O
from NN O O
the NN O O
genotype NN O O
in NN O O
functionally NN O O
hemizygous NN O O
patients NN O O
was NN O O
related NN O O
significantly NN O O
to NN O O
the NN O O
assigned NN O O
phenylalanine NN O O
level NN O O
. NN O O

Cognitive NN O O
performance NN O O
( NN O O
IQ NN O O
) NN O O
was NN O O
also NN O O
significantly NN O O
related NN O O
to NN O O
genotype NN O O
. NN O O

The NN O O
IQ NN O O
of NN O O
PAH NN O B-Disease
- NN O I-Disease
deficient NN O I-Disease
mothers NN O O
with NN O O
a NN O O
severe NN O O
PKU NN O B-Disease
mutation NN O O
in NN O O
combination NN O O
with NN O O
a NN O O
MHP NN O B-Disease
mutation NN O O
or NN O O
a NN O O
mild NN O O
PKU NN O B-Disease
mutation NN O O
was NN O O
99 NN O O
and NN O O
96 NN O O
, NN O O
respectively NN O O
, NN O O
whereas NN O O
the NN O O
IQ NN O O
of NN O O
PKU NN O B-Disease
mothers NN O O
with NN O O
two NN O O
severe NN O O
PKU NN O B-Disease
mutations NN O O
or NN O O
with NN O O
one NN O O
severe NN O O
and NN O O
one NN O O
moderate NN O O
PKU NN O B-Disease
mutation NN O O
was NN O O
83 NN O O
and NN O O
84 NN O O
, NN O O
respectively NN O O
. NN O O

Of NN O O
the NN O O
patients NN O O
with NN O O
PKU NN O B-Disease
, NN O O
92 NN O O
% NN O O
had NN O O
been NN O O
treated NN O O
during NN O O
childhood NN O O
. NN O O

Those NN O O
who NN O O
were NN O O
untreated NN O O
or NN O O
treated NN O O
late NN O O
had NN O O
lower NN O O
than NN O O
average NN O O
IQ NN O O
scores NN O O
for NN O O
their NN O O
group NN O O
of NN O O
mutation NN O O
combinations NN O O
. NN O O

Females NN O O
with NN O O
moderate NN O O
or NN O O
mild NN O O
PKU NN O B-Disease
who NN O O
were NN O O
treated NN O O
early NN O O
and NN O O
treated NN O O
for NN O O
> NN O O
6 NN O O
years NN O O
showed NN O O
IQ NN O O
scores NN O O
10 NN O O
points NN O O
above NN O O
average NN O O
for NN O O
their NN O O
group NN O O
. NN O O

CONCLUSIONS NN O O
The NN O O
reproductive NN O O
outcome NN O O
in NN O O
maternal NN O B-Disease
phenylketonuria NN O I-Disease
is NN O O
dependent NN O O
on NN O O
prenatal NN O O
metabolic NN O O
control NN O O
and NN O O
postnatal NN O O
environmental NN O O
circumstances NN O O
. NN O O

Both NN O O
factors NN O O
depend NN O O
on NN O O
the NN O O
intellectual NN O O
resources NN O O
of NN O O
the NN O O
mother NN O O
with NN O O
PKU NN O B-Disease
. NN O O

The NN O O
significant NN O O
relationship NN O O
among NN O O
genotype NN O O
, NN O O
biochemical NN O O
phenotype NN O O
, NN O O
and NN O O
cognitive NN O O
performance NN O O
observed NN O O
in NN O O
the NN O O
present NN O O
study NN O O
is NN O O
of NN O O
importance NN O O
for NN O O
the NN O O
development NN O O
of NN O O
an NN O O
optimal NN O O
strategy NN O O
for NN O O
future NN O O
treatment NN O O
of NN O O
females NN O O
with NN O O
PKU NN O B-Disease
who NN O O
plan NN O O
pregnancy NN O O
. NN O O
. NN O O

Spinal NN O B-Disease
xanthomatosis NN O I-Disease
: NN O O
a NN O O
variant NN O O
of NN O O
cerebrotendinous NN O B-Disease
xanthomatosis NN O I-Disease
. NN O O

We NN O O
describe NN O O
seven NN O O
Dutch NN O O
patients NN O O
from NN O O
six NN O O
families NN O O
with NN O O
a NN O O
slowly NN O O
progressive NN O O
, NN O O
mainly NN O O
spinal NN O B-Disease
cord NN O I-Disease
syndrome NN O I-Disease
that NN O O
remained NN O O
for NN O O
many NN O O
years NN O O
the NN O O
sole NN O O
expression NN O O
of NN O O
cerebrotendinous NN O B-Disease
xanthomatosis NN O I-Disease
( NN O O
CTX NN O B-Disease
) NN O O
. NN O O

MRI NN O O
demonstrated NN O O
white NN O B-Disease
matter NN O I-Disease
abnormalities NN O I-Disease
in NN O O
the NN O O
lateral NN O O
and NN O O
dorsal NN O O
columns NN O O
of NN O O
the NN O O
spinal NN O O
cord NN O O
. NN O O

Post NN O O
- NN O O
mortem NN O O
examination NN O O
of NN O O
one NN O O
of NN O O
the NN O O
patients NN O O
showed NN O O
extensive NN O O
myelin NN O O
loss NN O O
in NN O O
these NN O O
columns NN O O
. NN O O

An NN O O
array NN O O
of NN O O
genotypes NN O O
was NN O O
found NN O O
in NN O O
these NN O O
patients NN O O
. NN O O

We NN O O
conclude NN O O
that NN O O
spinal NN O B-Disease
xanthomatosis NN O I-Disease
is NN O O
a NN O O
clinical NN O O
and NN O O
radiological NN O O
separate NN O O
entity NN O O
of NN O O
CTX NN O B-Disease
that NN O O
should NN O O
be NN O O
included NN O O
in NN O O
the NN O O
differential NN O O
diagnosis NN O O
of NN O O
chronic NN O B-Disease
myelopathy NN O I-Disease
. NN O O
. NN O O

A NN O O
transgene NN O O
insertion NN O O
creating NN O O
a NN O O
heritable NN O O
chromosome NN O O
deletion NN O O
mouse NN O O
model NN O O
of NN O O
Prader NN O B-Disease
- NN O I-Disease
Willi NN O I-Disease
and NN O I-Disease
angelman NN O I-Disease
syndromes NN O I-Disease
. NN O O

Prader NN O B-Disease
- NN O I-Disease
Willi NN O I-Disease
syndrome NN O I-Disease
( NN O O
PWS NN O B-Disease
) NN O O
and NN O O
Angelman NN O B-Disease
syndrome NN O I-Disease
( NN O O
AS NN O B-Disease
) NN O O
result NN O O
from NN O O
the NN O O
loss NN O O
of NN O O
function NN O O
of NN O O
imprinted NN O O
genes NN O O
in NN O O
human NN O O
chromosome NN O O
15q11 NN O O
- NN O O
q13 NN O O
. NN O O

The NN O O
central NN O O
part NN O O
of NN O O
mouse NN O O
chromosome NN O O
7 NN O O
is NN O O
homologous NN O O
to NN O O
human NN O O
15q11 NN O O
- NN O O
q13 NN O O
, NN O O
with NN O O
conservation NN O O
of NN O O
both NN O O
gene NN O O
order NN O O
and NN O O
imprinted NN O O
features NN O O
. NN O O

We NN O O
report NN O O
here NN O O
the NN O O
characterization NN O O
of NN O O
a NN O O
transgene NN O O
insertion NN O O
( NN O O
Epstein NN O O
- NN O O
Barr NN O O
virus NN O O
Latent NN O O
Membrane NN O O
Protein NN O O
2A NN O O
, NN O O
LMP2A NN O O
) NN O O
into NN O O
mouse NN O O
chromosome NN O O
7C NN O O
, NN O O
which NN O O
has NN O O
resulted NN O O
in NN O O
mouse NN O O
models NN O O
for NN O O
PWS NN O B-Disease
and NN O O
AS NN O B-Disease
dependent NN O O
on NN O O
the NN O O
sex NN O O
of NN O O
the NN O O
transmitting NN O O
parent NN O O
. NN O O

Epigenotype NN O O
( NN O O
allelic NN O O
expression NN O O
and NN O O
DNA NN O O
methylation NN O O
) NN O O
and NN O O
fluorescence NN O O
in NN O O
situ NN O O
hybridization NN O O
analyses NN O O
indicate NN O O
that NN O O
the NN O O
transgene NN O O
- NN O O
induced NN O O
mutation NN O O
has NN O O
generated NN O O
a NN O O
complete NN O O
deletion NN O O
of NN O O
the NN O O
PWS NN O B-Disease
/ NN O O
AS NN O B-Disease
- NN O O
homologous NN O O
region NN O O
but NN O O
has NN O O
not NN O O
deleted NN O O
flanking NN O O
loci NN O O
. NN O O

Because NN O O
the NN O O
intact NN O O
chromosome NN O O
7 NN O O
, NN O O
opposite NN O O
the NN O O
deleted NN O O
homolog NN O O
, NN O O
maintains NN O O
the NN O O
correct NN O O
imprint NN O O
in NN O O
somatic NN O O
cells NN O O
of NN O O
PWS NN O B-Disease
and NN O O
AS NN O B-Disease
mice NN O O
and NN O O
establishes NN O O
the NN O O
correct NN O O
imprint NN O O
in NN O O
male NN O O
and NN O O
female NN O O
germ NN O O
cells NN O O
of NN O O
AS NN O B-Disease
mice NN O O
, NN O O
homologous NN O O
association NN O O
and NN O O
replication NN O O
asynchrony NN O O
are NN O O
not NN O O
part NN O O
of NN O O
the NN O O
imprinting NN O O
mechanism NN O O
. NN O O

This NN O O
heritable NN O O
- NN O O
deletion NN O O
mouse NN O O
model NN O O
will NN O O
be NN O O
particularly NN O O
useful NN O O
for NN O O
the NN O O
identification NN O O
of NN O O
the NN O O
etiological NN O O
genes NN O O
and NN O O
mechanisms NN O O
, NN O O
phenotypic NN O O
basis NN O O
, NN O O
and NN O O
investigation NN O O
of NN O O
therapeutic NN O O
approaches NN O O
for NN O O
PWS NN O B-Disease
. NN O O
. NN O O

Linkage NN O O
analysis NN O O
of NN O O
5 NN O O
novel NN O O
van NN O B-Disease
der NN O I-Disease
Woude NN O I-Disease
syndrome NN O I-Disease
kindreds NN O O
to NN O O
1q32 NN O O
- NN O O
q41 NN O O
markers NN O O
further NN O O
supports NN O O
locus NN O O
homogeneity NN O O
of NN O O
the NN O O
disease NN O O
trait NN O O
. NN O O

van NN O B-Disease
der NN O I-Disease
Woude NN O I-Disease
syndrome NN O I-Disease
( NN O O
vWS NN O B-Disease
, NN O O
MIM NN O O
119300 NN O O
) NN O O
is NN O O
a NN O O
rare NN O O
autosomal NN O B-Disease
dominant NN O I-Disease
clefting NN O I-Disease
condition NN O I-Disease
with NN O O
cardinal NN O O
features NN O O
of NN O O
mucous NN O B-Disease
cysts NN O I-Disease
( NN O O
lower NN O B-Disease
- NN O I-Disease
lip NN O I-Disease
pits NN O I-Disease
) NN O O
and NN O O
clefts NN O B-Disease
to NN O I-Disease
the NN O I-Disease
lip NN O I-Disease
and NN O I-Disease
/ NN O I-Disease
or NN O I-Disease
palate NN O I-Disease
. NN O O

The NN O O
vWS NN O B-Disease
gene NN O O
has NN O O
been NN O O
assigned NN O O
to NN O O
a NN O O
locus NN O O
in NN O O
1q32 NN O O
- NN O O
q41 NN O O
by NN O O
linkage NN O O
analysis NN O O
and NN O O
physical NN O O
mapping NN O O
. NN O O

We NN O O
have NN O O
investigated NN O O
5 NN O O
novel NN O O
vWS NN O B-Disease
families NN O O
through NN O O
probands NN O O
attended NN O O
for NN O O
cleft NN O B-Disease
lip NN O I-Disease
and NN O I-Disease
/ NN O I-Disease
or NN O I-Disease
palate NN O I-Disease
repair NN O O
at NN O O
the NN O O
Department NN O O
of NN O O
Maxillofacial NN O O
Surgery NN O O
of NN O O
Hopital NN O O
Trousseau NN O O
, NN O O
Paris NN O O
, NN O O
in NN O O
order NN O O
to NN O O
tentatively NN O O
refine NN O O
the NN O O
genetic NN O O
map NN O O
of NN O O
the NN O O
vWS NN O B-Disease
region NN O O
in NN O O
1q32 NN O O
- NN O O
q41 NN O O
and NN O O
possibly NN O O
identify NN O O
unlinked NN O O
pedigrees NN O O
. NN O O

Linkage NN O O
analysis NN O O
was NN O O
carried NN O O
out NN O O
to NN O O
6 NN O O
microsatellite NN O O
markers NN O O
( NN O O
D1S249 NN O O
, NN O O
D1S425 NN O O
, NN O O
D1S491 NN O O
, NN O O
D1S205 NN O O
, NN O O
D1S414 NN O O
, NN O O
D1S425 NN O O
) NN O O
, NN O O
yielding NN O O
a NN O O
maximum NN O O
cumulative NN O O
LOD NN O O
score NN O O
of NN O O
Z NN O O
= NN O O
3 NN O O
. NN O O

27 NN O O
at NN O O
theta NN O O
= NN O O
0 NN O O
. NN O O

00 NN O O
for NN O O
D1S245 NN O O
. NN O O

The NN O O
innermost NN O O
four NN O O
markers NN O O
were NN O O
found NN O O
to NN O O
be NN O O
tightly NN O O
linked NN O O
to NN O O
one NN O O
another NN O O
, NN O O
with NN O O
no NN O O
evidence NN O O
for NN O O
recombination NN O O
. NN O O

Our NN O O
results NN O O
support NN O O
linkage NN O O
of NN O O
vWS NN O B-Disease
within NN O O
a NN O O
region NN O O
of NN O O
tightly NN O O
linked NN O O
markers NN O O
and NN O O
do NN O O
not NN O O
favour NN O O
locus NN O O
heterogeneity NN O O
of NN O O
the NN O O
disease NN O O
trait NN O O
. NN O O

Null NN O O
mutation NN O O
of NN O O
the NN O O
murine NN O O
ATP7B NN O O
( NN O O
Wilson NN O B-Disease
disease NN O I-Disease
) NN O O
gene NN O O
results NN O O
in NN O O
intracellular NN O B-Disease
copper NN O I-Disease
accumulation NN O I-Disease
and NN O O
late NN O B-Disease
- NN O I-Disease
onset NN O I-Disease
hepatic NN O I-Disease
nodular NN O I-Disease
transformation NN O I-Disease
. NN O O

The NN O O
Atp7b NN O O
protein NN O O
is NN O O
a NN O O
copper NN O O
- NN O O
transporting NN O O
ATPase NN O O
expressed NN O O
predominantly NN O O
in NN O O
the NN O O
liver NN O O
and NN O O
to NN O O
a NN O O
lesser NN O O
extent NN O O
in NN O O
most NN O O
other NN O O
tissues NN O O
. NN O O

Mutations NN O O
in NN O O
the NN O O
ATP7B NN O O
gene NN O O
lead NN O O
to NN O O
Wilson NN O B-Disease
disease NN O I-Disease
, NN O O
a NN O O
copper NN O B-Disease
toxicity NN O I-Disease
disorder NN O I-Disease
characterized NN O O
by NN O O
dramatic NN O O
build NN O O
- NN O O
up NN O O
of NN O O
intracellular NN O O
hepatic NN O O
copper NN O O
with NN O O
subsequent NN O O
hepatic NN O B-Disease
and NN O I-Disease
neuro NN O I-Disease
- NN O I-Disease
logical NN O I-Disease
abnormalities NN O I-Disease
. NN O O

Using NN O O
homologous NN O O
recombination NN O O
to NN O O
disrupt NN O O
the NN O O
normal NN O O
translation NN O O
of NN O O
ATP7B NN O O
, NN O O
we NN O O
have NN O O
generated NN O O
a NN O O
strain NN O O
of NN O O
mice NN O O
that NN O O
are NN O O
homozygous NN O O
mutants NN O O
( NN O O
null NN O O
) NN O O
for NN O O
the NN O O
Wilson NN O B-Disease
disease NN O I-Disease
gene NN O O
. NN O O

The NN O O
ATP7B NN O O
null NN O O
mice NN O O
display NN O O
a NN O O
gradual NN O O
accumulation NN O O
of NN O O
hepatic NN O O
copper NN O O
that NN O O
increases NN O O
to NN O O
a NN O O
level NN O O
60 NN O O
- NN O O
fold NN O O
greater NN O O
than NN O O
normal NN O O
by NN O O
5 NN O O
months NN O O
of NN O O
age NN O O
. NN O O

An NN O O
increase NN O O
in NN O O
copper NN O O
concentration NN O O
was NN O O
also NN O O
observed NN O O
in NN O O
the NN O O
kidney NN O O
, NN O O
brain NN O O
, NN O O
placenta NN O O
and NN O O
lactating NN O O
mammary NN O O
glands NN O O
of NN O O
homo NN O O
- NN O O
zygous NN O O
mutants NN O O
, NN O O
although NN O O
milk NN O O
from NN O O
the NN O O
mutant NN O O
glands NN O O
was NN O O
copper NN O B-Disease
deficient NN O I-Disease
. NN O O

Morphological NN O B-Disease
abnormalities NN O I-Disease
resembling NN O O
cirrhosis NN O B-Disease
developed NN O O
in NN O O
the NN O O
majority NN O O
of NN O O
the NN O O
livers NN O O
from NN O O
homozygous NN O O
mutants NN O O
older NN O O
than NN O O
7 NN O O
months NN O O
of NN O O
age NN O O
. NN O O

Progeny NN O O
of NN O O
the NN O O
homozygous NN O O
mutant NN O O
females NN O O
demonstrated NN O O
neurological NN O B-Disease
abnormalities NN O I-Disease
and NN O O
growth NN O B-Disease
retardation NN O I-Disease
characteristic NN O O
of NN O O
copper NN O B-Disease
deficiency NN O I-Disease
. NN O O

Copper NN O O
concentration NN O O
in NN O O
the NN O O
livers NN O O
of NN O O
the NN O O
newborn NN O O
homozygous NN O O
null NN O O
mutants NN O O
was NN O O
decreased NN O O
dramatically NN O O
. NN O O

In NN O O
summary NN O O
, NN O O
inactivation NN O O
of NN O O
the NN O O
murine NN O O
ATP7B NN O O
gene NN O O
produces NN O O
a NN O O
form NN O O
of NN O O
cirrhotic NN O B-Disease
liver NN O I-Disease
disease NN O I-Disease
that NN O O
resembles NN O O
Wilson NN O B-Disease
disease NN O I-Disease
in NN O O
humans NN O O
and NN O O
the NN O O
toxic NN O O
milk NN O O
phenotype NN O O
in NN O O
the NN O O
mouse NN O O
. NN O O
. NN O O

French NN O O
Machado NN O B-Disease
- NN O I-Disease
Joseph NN O I-Disease
disease NN O I-Disease
patients NN O O
do NN O O
not NN O O
exhibit NN O O
gametic NN O O
segregation NN O O
distortion NN O O
: NN O O
a NN O O
sperm NN O O
typing NN O O
analysis NN O O
. NN O O

Segregation NN O O
distortion NN O O
has NN O O
been NN O O
reported NN O O
to NN O O
occur NN O O
in NN O O
a NN O O
number NN O O
of NN O O
the NN O O
trinucleotide NN O B-Disease
repeat NN O I-Disease
disorders NN O I-Disease
. NN O O

On NN O O
the NN O O
basis NN O O
of NN O O
a NN O O
sperm NN O O
typing NN O O
study NN O O
performed NN O O
in NN O O
patients NN O O
of NN O O
Japanese NN O O
descent NN O O
with NN O O
Machado NN O B-Disease
- NN O I-Disease
Joseph NN O I-Disease
disease NN O I-Disease
( NN O O
MJD NN O B-Disease
) NN O O
, NN O O
it NN O O
was NN O O
reported NN O O
that NN O O
disease NN O O
alleles NN O O
are NN O O
preferentially NN O O
transmitted NN O O
during NN O O
meiosis NN O O
. NN O O

We NN O O
performed NN O O
a NN O O
sperm NN O O
typing NN O O
study NN O O
of NN O O
five NN O O
MJD NN O B-Disease
patients NN O O
of NN O O
French NN O O
descent NN O O
and NN O O
analysis NN O O
of NN O O
the NN O O
pooled NN O O
data NN O O
shows NN O O
a NN O O
ratio NN O O
of NN O O
mutant NN O O
to NN O O
normal NN O O
alleles NN O O
of NN O O
379 NN O O
436 NN O O
( NN O O
46 NN O O
. NN O O
5 NN O O
53 NN O O
. NN O O
5 NN O O
% NN O O
) NN O O
, NN O O
which NN O O
does NN O O
not NN O O
support NN O O
meiotic NN O O
segregation NN O O
distortion NN O O
. NN O O

To NN O O
confirm NN O O
these NN O O
results NN O O
, NN O O
sperm NN O O
typing NN O O
analysis NN O O
was NN O O
also NN O O
performed NN O O
using NN O O
a NN O O
polymorphic NN O O
marker NN O O
, NN O O
D14S1050 NN O O
, NN O O
closely NN O O
linked NN O O
to NN O O
the NN O O
MJD1 NN O O
gene NN O O
. NN O O

Among NN O O
910 NN O O
sperm NN O O
analyzed NN O O
, NN O O
the NN O O
allele NN O O
linked NN O O
to NN O O
the NN O O
disease NN O O
chromosome NN O O
was NN O O
detected NN O O
in NN O O
50 NN O O
. NN O O

3 NN O O
% NN O O
of NN O O
the NN O O
samples NN O O
and NN O O
the NN O O
allele NN O O
linked NN O O
to NN O O
the NN O O
normal NN O O
chromosome NN O O
was NN O O
found NN O O
in NN O O
49 NN O O
. NN O O

6 NN O O
% NN O O
of NN O O
the NN O O
sperm NN O O
. NN O O

The NN O O
difference NN O O
in NN O O
frequency NN O O
of NN O O
these NN O O
two NN O O
alleles NN O O
is NN O O
not NN O O
significant NN O O
( NN O O
P NN O O
= NN O O
0 NN O O
. NN O O
8423 NN O O
) NN O O
. NN O O

Likelihood NN O O
- NN O O
based NN O O
analysis NN O O
of NN O O
segregation NN O O
distortion NN O O
in NN O O
the NN O O
single NN O O
sperm NN O O
data NN O O
using NN O O
the NN O O
SPERMSEG NN O O
program NN O O
also NN O O
showed NN O O
no NN O O
support NN O O
for NN O O
segregation NN O O
distortion NN O O
at NN O O
the NN O O
gamete NN O O
level NN O O
in NN O O
this NN O O
patient NN O O
population NN O O
. NN O O

The NN O O
previous NN O O
report NN O O
on NN O O
the NN O O
Japanese NN O O
patients NN O O
also NN O O
suggested NN O O
that NN O O
disease NN O O
allele NN O O
stability NN O O
may NN O O
be NN O O
influenced NN O O
by NN O O
a NN O O
trans NN O O
effect NN O O
of NN O O
an NN O O
intragenic NN O O
polymorphism NN O O
( NN O O
987 NN O O
G NN O O
/ NN O O
C NN O O
) NN O O
in NN O O
the NN O O
wild NN O O
- NN O O
type NN O O
allele NN O O
. NN O O

All NN O O
of NN O O
the NN O O
French NN O O
patients NN O O
were NN O O
heterozygous NN O O
for NN O O
this NN O O
polymorphism NN O O
. NN O O

However NN O O
, NN O O
analysis NN O O
of NN O O
the NN O O
variance NN O O
in NN O O
repeat NN O O
number NN O O
in NN O O
sperm NN O O
from NN O O
the NN O O
French NN O O
MJD NN O B-Disease
patients NN O O
overlapped NN O O
significantly NN O O
with NN O O
the NN O O
variance NN O O
in NN O O
repeat NN O O
number NN O O
observed NN O O
in NN O O
the NN O O
C NN O O
/ NN O O
C NN O O
homozygous NN O O
Japanese NN O O
patients NN O O
. NN O O

Missense NN O O
mutation NN O O
in NN O O
the NN O O
alternative NN O O
splice NN O O
region NN O O
of NN O O
the NN O O
PAX6 NN O O
gene NN O O
in NN O O
eye NN O B-Disease
anomalies NN O I-Disease
. NN O O

The NN O O
PAX6 NN O O
gene NN O O
is NN O O
involved NN O O
in NN O O
ocular NN O O
morphogenesis NN O O
, NN O O
and NN O O
PAX6 NN O O
mutations NN O O
have NN O O
been NN O O
detected NN O O
in NN O O
various NN O O
types NN O O
of NN O O
ocular NN O B-Disease
anomalies NN O I-Disease
, NN O O
including NN O O
aniridia NN O B-Disease
, NN O O
Peters NN O B-Disease
anomaly NN O I-Disease
, NN O O
corneal NN O B-Disease
dystrophy NN O I-Disease
, NN O O
congenital NN O B-Disease
cataract NN O I-Disease
, NN O O
and NN O O
foveal NN O B-Disease
hypoplasia NN O I-Disease
. NN O O

The NN O O
gene NN O O
encodes NN O O
a NN O O
transcriptional NN O O
regulator NN O O
that NN O O
recognizes NN O O
target NN O O
genes NN O O
through NN O O
its NN O O
paired NN O O
- NN O O
type NN O O
DNA NN O O
- NN O O
binding NN O O
domain NN O O
. NN O O

The NN O O
paired NN O O
domain NN O O
is NN O O
composed NN O O
of NN O O
two NN O O
distinct NN O O
DNA NN O O
- NN O O
binding NN O O
subdomains NN O O
, NN O O
the NN O O
N NN O O
- NN O O
terminal NN O O
subdomain NN O O
( NN O O
NTS NN O O
) NN O O
and NN O O
the NN O O
C NN O O
- NN O O
terminal NN O O
subdomain NN O O
( NN O O
CTS NN O O
) NN O O
, NN O O
which NN O O
bind NN O O
respective NN O O
consensus NN O O
DNA NN O O
sequences NN O O
. NN O O

The NN O O
human NN O O
PAX6 NN O O
gene NN O O
produces NN O O
two NN O O
alternative NN O O
splice NN O O
isoforms NN O O
that NN O O
have NN O O
the NN O O
distinct NN O O
structure NN O O
of NN O O
the NN O O
paired NN O O
domain NN O O
. NN O O

The NN O O
insertion NN O O
, NN O O
into NN O O
the NN O O
NTS NN O O
, NN O O
of NN O O
14 NN O O
additional NN O O
amino NN O O
acids NN O O
encoded NN O O
by NN O O
exon NN O O
5a NN O O
abolishes NN O O
the NN O O
DNA NN O O
- NN O O
binding NN O O
activity NN O O
of NN O O
the NN O O
NTS NN O O
and NN O O
unmasks NN O O
the NN O O
DNA NN O O
- NN O O
binding NN O O
ability NN O O
of NN O O
the NN O O
CTS NN O O
. NN O O

Thus NN O O
, NN O O
exon NN O O
5a NN O O
appears NN O O
to NN O O
function NN O O
as NN O O
a NN O O
molecular NN O O
switch NN O O
that NN O O
specifies NN O O
target NN O O
genes NN O O
. NN O O

We NN O O
ascertained NN O O
a NN O O
novel NN O O
missense NN O O
mutation NN O O
in NN O O
four NN O O
pedigrees NN O O
with NN O O
Peters NN O B-Disease
anomaly NN O I-Disease
, NN O O
congenital NN O B-Disease
cataract NN O I-Disease
, NN O O
Axenfeldt NN O B-Disease
anomaly NN O I-Disease
, NN O O
and NN O O
/ NN O O
or NN O O
foveal NN O B-Disease
hypoplasia NN O I-Disease
, NN O O
which NN O O
, NN O O
to NN O O
our NN O O
knowledge NN O O
, NN O O
is NN O O
the NN O O
first NN O O
mutation NN O O
identified NN O O
in NN O O
the NN O O
splice NN O O
- NN O O
variant NN O O
region NN O O
. NN O O

A NN O O
T NN O O
- NN O O
- NN O O
> NN O O
A NN O O
transition NN O O
at NN O O
the NN O O
20th NN O O
nucleotide NN O O
position NN O O
of NN O O
exon NN O O
5a NN O O
results NN O O
in NN O O
a NN O O
Val NN O O
- NN O O
- NN O O
> NN O O
Asp NN O O
( NN O O
GTC NN O O
- NN O O
- NN O O
> NN O O
GAC NN O O
) NN O O
substitution NN O O
at NN O O
the NN O O
7th NN O O
codon NN O O
of NN O O
the NN O O
alternative NN O O
splice NN O O
region NN O O
. NN O O

Functional NN O O
analyses NN O O
demonstrated NN O O
that NN O O
the NN O O
V54D NN O O
mutation NN O O
slightly NN O O
increased NN O O
NTS NN O O
binding NN O O
and NN O O
decreased NN O O
CTS NN O O
transactivation NN O O
activity NN O O
to NN O O
almost NN O O
half NN O O
. NN O O
. NN O O

Penetrances NN O O
of NN O O
BRCA1 NN O O
1675delA NN O O
and NN O O
1135insA NN O O
with NN O O
respect NN O O
to NN O O
breast NN O B-Disease
cancer NN O I-Disease
and NN O O
ovarian NN O B-Disease
cancer NN O I-Disease
. NN O O

For NN O O
genetic NN O O
counseling NN O O
and NN O O
predictive NN O O
testing NN O O
in NN O O
families NN O O
with NN O O
inherited NN O B-Disease
breast NN O I-Disease
- NN O I-Disease
ovarian NN O I-Disease
cancer NN O I-Disease
, NN O O
penetrances NN O O
and NN O O
expressions NN O O
of NN O O
the NN O O
underlying NN O O
mutations NN O O
should NN O O
be NN O O
known NN O O
. NN O O

We NN O O
have NN O O
previously NN O O
reported NN O O
two NN O O
BRCA1 NN O O
founder NN O O
mutations NN O O
in NN O O
the NN O O
Norwegian NN O O
population NN O O
. NN O O

Index NN O O
cases NN O O
for NN O O
the NN O O
present NN O O
study NN O O
were NN O O
found NN O O
two NN O O
different NN O O
ways NN O O
through NN O O
a NN O O
series NN O O
of NN O O
consecutive NN O O
ovarian NN O B-Disease
cancers NN O I-Disease
( NN O O
n NN O O
= NN O O
16 NN O O
) NN O O
and NN O O
through NN O O
our NN O O
family NN O O
cancer NN O B-Disease
clinic NN O O
( NN O O
n NN O O
= NN O O
14 NN O O
) NN O O
. NN O O

Altogether NN O O
, NN O O
20 NN O O
of NN O O
the NN O O
patients NN O O
had NN O O
BRCA1 NN O O
1675delA NN O O
, NN O O
and NN O O
10 NN O O
had NN O O
1135insA NN O O
. NN O O

Their NN O O
relatives NN O O
were NN O O
described NN O O
with NN O O
respect NN O O
to NN O O
absence NN O O
/ NN O O
presence NN O O
of NN O O
breast NN O B-Disease
and NN O I-Disease
/ NN O I-Disease
or NN O I-Disease
ovarian NN O I-Disease
cancer NN O I-Disease
. NN O O

Of NN O O
133 NN O O
living NN O O
female NN O O
relatives NN O O
, NN O O
83 NN O O
( NN O O
62 NN O O
% NN O O
) NN O O
were NN O O
tested NN O O
for NN O O
the NN O O
presence NN O O
of NN O O
a NN O O
mutation NN O O
. NN O O

No NN O O
difference NN O O
, NN O O
in NN O O
penetrance NN O O
and NN O O
expression NN O O
, NN O O
between NN O O
the NN O O
two NN O O
mutations NN O O
were NN O O
found NN O O
, NN O O
whereas NN O O
differences NN O O
according NN O O
to NN O O
method NN O O
of NN O O
ascertainment NN O O
were NN O O
seen NN O O
. NN O O

The NN O O
overall NN O O
findings NN O O
were NN O O
that NN O O
disease NN O O
started NN O O
to NN O O
occur NN O O
at NN O O
age NN O O
30 NN O O
years NN O O
and NN O O
that NN O O
by NN O O
age NN O O
50 NN O O
years NN O O
48 NN O O
% NN O O
of NN O O
the NN O O
mutation NN O O
- NN O O
carrying NN O O
women NN O O
had NN O O
experienced NN O O
breast NN O B-Disease
and NN O I-Disease
/ NN O I-Disease
or NN O I-Disease
ovarian NN O I-Disease
cancer NN O I-Disease
. NN O O

More NN O O
ovarian NN O B-Disease
cancers NN O I-Disease
than NN O O
breast NN O B-Disease
cancers NN O I-Disease
were NN O O
recorded NN O O
. NN O O

Both NN O O
penetrance NN O O
and NN O O
expression NN O O
( NN O O
breast NN O B-Disease
cancer NN O I-Disease
vs NN O O
. NN O O
ovarian NN O B-Disease
cancer NN O I-Disease
) NN O O
were NN O O
different NN O O
from NN O O
those NN O O
in NN O O
reports NN O O
of NN O O
the NN O O
Ashkenazi NN O O
founder NN O O
mutations NN O O
. NN O O

Whether NN O O
the NN O O
reported NN O O
differences NN O O
reflect NN O O
true NN O O
differences NN O O
and NN O O
/ NN O O
or NN O O
methodological NN O O
problems NN O O
is NN O O
discussed NN O O
. NN O O

An NN O O
observed NN O O
excess NN O O
of NN O O
mutation NN O O
carriers NN O O
could NN O O
not NN O O
be NN O O
accounted NN O O
for NN O O
by NN O O
methodological NN O O
problems NN O O
; NN O O
possible NN O O
explanations NN O O
were NN O O
a NN O O
" NN O O
true NN O O
" NN O O
low NN O O
penetrance NN O O
or NN O O
preferential NN O O
segregation NN O O
. NN O O
. NN O O

The NN O O
dermatofibrosarcoma NN O B-Disease
protuberans NN O I-Disease
- NN O O
associated NN O O
collagen NN O O
type NN O O
Ialpha1 NN O O
/ NN O O
platelet NN O O
- NN O O
derived NN O O
growth NN O O
factor NN O O
( NN O O
PDGF NN O O
) NN O O
B NN O O
- NN O O
chain NN O O
fusion NN O O
gene NN O O
generates NN O O
a NN O O
transforming NN O O
protein NN O O
that NN O O
is NN O O
processed NN O O
to NN O O
functional NN O O
PDGF NN O O
- NN O O
BB NN O O
. NN O O

Dermatofibrosarcoma NN O B-Disease
protuberans NN O I-Disease
( NN O O
DFSP NN O B-Disease
) NN O O
displays NN O O
chromosomal NN O O
rearrangements NN O O
involving NN O O
chromosome NN O O
17 NN O O
and NN O O
22 NN O O
, NN O O
which NN O O
fuse NN O O
the NN O O
collagen NN O O
type NN O O
Ialpha1 NN O O
( NN O O
COLIA1 NN O O
) NN O O
gene NN O O
to NN O O
the NN O O
platelet NN O O
- NN O O
derived NN O O
growth NN O O
factor NN O O
( NN O O
PDGF NN O O
) NN O O
B NN O O
- NN O O
chain NN O O
( NN O O
PDGFB NN O O
) NN O O
gene NN O O
. NN O O

To NN O O
characterize NN O O
the NN O O
functional NN O O
and NN O O
structural NN O O
properties NN O O
of NN O O
the NN O O
COLIA1 NN O O
/ NN O O
PDGFB NN O O
fusion NN O O
protein NN O O
, NN O O
we NN O O
generated NN O O
a NN O O
stable NN O O
NIH3T3 NN O O
cell NN O O
line NN O O
that NN O O
contained NN O O
a NN O O
tumor NN O O
- NN O O
derived NN O O
chimeric NN O O
gene NN O O
resulting NN O O
from NN O O
a NN O O
COIA1 NN O O
intron NN O O
7 NN O O
- NN O O
PDGFB NN O O
intron NN O O
1 NN O O
fusion NN O O
. NN O O

Expression NN O O
of NN O O
the NN O O
fusion NN O O
protein NN O O
led NN O O
to NN O O
morphological NN O O
transformation NN O O
and NN O O
increased NN O O
growth NN O O
rate NN O O
of NN O O
these NN O O
cells NN O O
. NN O O

The NN O O
PDGF NN O O
receptor NN O O
kinase NN O O
inhibitor NN O O
CGP57148B NN O O
reversed NN O O
the NN O O
transformed NN O O
phenotype NN O O
and NN O O
reduced NN O O
the NN O O
growth NN O O
rate NN O O
of NN O O
COLIA1 NN O O
/ NN O O
PDGFB NN O O
- NN O O
expressing NN O O
cells NN O O
but NN O O
had NN O O
no NN O O
effects NN O O
on NN O O
control NN O O
cells NN O O
. NN O O

The NN O O
presence NN O O
of NN O O
dimeric NN O O
COLIA1 NN O O
/ NN O O
PDGFB NN O O
precursors NN O O
was NN O O
demonstrated NN O O
through NN O O
PDGFB NN O O
immunoprecipitations NN O O
of NN O O
metabolically NN O O
labeled NN O O
cells NN O O
and NN O O
also NN O O
by NN O O
PDGFB NN O O
immunoprecipitations NN O O
followed NN O O
by NN O O
immunoblotting NN O O
with NN O O
COLIA1 NN O O
antibodies NN O O
. NN O O

Pulse NN O O
- NN O O
chase NN O O
studies NN O O
demonstrated NN O O
that NN O O
the NN O O
COLIA1 NN O O
/ NN O O
PDGFB NN O O
precursor NN O O
was NN O O
processed NN O O
to NN O O
an NN O O
end NN O O
product NN O O
that NN O O
was NN O O
indistinguishable NN O O
from NN O O
wild NN O O
- NN O O
type NN O O
PDGF NN O O
- NN O O
BB NN O O
. NN O O

Finally NN O O
, NN O O
COLIA1 NN O O
/ NN O O
PDGFB NN O O
- NN O O
expressing NN O O
cells NN O O
generated NN O O
tumors NN O B-Disease
after NN O O
s NN O O
. NN O O

c NN O O
c NN O O
. NN O O
injection NN O O
into NN O O
nude NN O O
mice NN O O
, NN O O
and NN O O
tumor NN O B-Disease
growth NN O O
was NN O O
reduced NN O O
by NN O O
treatment NN O O
with NN O O
CGP57148B NN O O
. NN O O

We NN O O
conclude NN O O
that NN O O
the NN O O
COLIA1 NN O O
/ NN O O
PDGFB NN O O
fusion NN O O
associated NN O O
with NN O O
DFSP NN O B-Disease
contributes NN O O
to NN O O
tumor NN O B-Disease
development NN O O
through NN O O
ectopic NN O O
production NN O O
of NN O O
PDGF NN O O
- NN O O
BB NN O O
and NN O O
the NN O O
formation NN O O
of NN O O
an NN O O
autocrine NN O O
loop NN O O
. NN O O

Our NN O O
findings NN O O
, NN O O
thus NN O O
, NN O O
suggest NN O O
that NN O O
PDGF NN O O
receptors NN O O
could NN O O
be NN O O
a NN O O
target NN O O
for NN O O
pharmacological NN O O
treatment NN O O
of NN O O
DFSP NN O B-Disease
and NN O O
giant NN O B-Disease
cell NN O I-Disease
fibroblastoma NN O I-Disease
, NN O O
e NN O O
. NN O O
g NN O O
. NN O O
, NN O O
through NN O O
the NN O O
use NN O O
of NN O O
PDGF NN O O
receptor NN O O
kinase NN O O
inhibitors NN O O
such NN O O
as NN O O
CGP57148B NN O O
. NN O O

Identification NN O O
of NN O O
a NN O O
common NN O O
PEX1 NN O O
mutation NN O O
in NN O O
Zellweger NN O B-Disease
syndrome NN O I-Disease
. NN O O

The NN O O
Zellweger NN O B-Disease
spectrum NN O I-Disease
of NN O I-Disease
disease NN O I-Disease
, NN O O
encompassing NN O O
Zellweger NN O B-Disease
syndrome NN O I-Disease
and NN O O
the NN O O
progressively NN O O
milder NN O O
phenotypes NN O O
of NN O O
neonatal NN O B-Disease
adrenoleukodystrophy NN O I-Disease
and NN O O
infantile NN O B-Disease
Refsum NN O I-Disease
disease NN O I-Disease
, NN O O
is NN O O
due NN O O
to NN O O
a NN O O
failure NN O O
to NN O O
form NN O O
functional NN O O
peroxisomes NN O O
. NN O O

Cell NN O O
fusion NN O O
complementation NN O O
studies NN O O
demonstrated NN O O
that NN O O
these NN O O
diseases NN O O
are NN O O
genetically NN O O
heterogeneous NN O O
, NN O O
with NN O O
two NN O O
- NN O O
thirds NN O O
of NN O O
all NN O O
patients NN O O
lying NN O O
within NN O O
a NN O O
single NN O O
complementation NN O O
group NN O O
, NN O O
CG1 NN O O
. NN O O

Molecular NN O O
genetic NN O O
and NN O O
cell NN O O
biology NN O O
studies NN O O
have NN O O
shown NN O O
that NN O O
PEX1 NN O O
is NN O O
deficient NN O O
in NN O O
many NN O O
CG1 NN O O
patients NN O O
. NN O O

However NN O O
, NN O O
previous NN O O
studies NN O O
have NN O O
focused NN O O
on NN O O
mildly NN O O
affected NN O O
patients NN O O
and NN O O
there NN O O
is NN O O
still NN O O
no NN O O
report NN O O
of NN O O
two NN O O
mutant NN O O
PEX1 NN O O
alleles NN O O
in NN O O
any NN O O
Zellweger NN O B-Disease
syndrome NN O I-Disease
patient NN O O
. NN O O

Furthermore NN O O
, NN O O
mutations NN O O
in NN O O
the NN O O
PMP70 NN O O
gene NN O O
have NN O O
also NN O O
been NN O O
identified NN O O
in NN O O
two NN O O
Zellweger NN O B-Disease
syndrome NN O I-Disease
patients NN O O
from NN O O
CG1 NN O O
, NN O O
raising NN O O
the NN O O
possibility NN O O
that NN O O
CG1 NN O O
patients NN O O
may NN O O
represent NN O O
a NN O O
mixture NN O O
of NN O O
PEX1 NN O O
- NN O O
deficient NN O O
and NN O O
PMP70 NN O O
- NN O O
deficient NN O O
individuals NN O O
. NN O O

To NN O O
address NN O O
the NN O O
molecular NN O O
basis NN O O
of NN O O
disease NN O O
in NN O O
Zellweger NN O B-Disease
syndrome NN O I-Disease
patients NN O O
from NN O O
CG1 NN O O
, NN O O
we NN O O
examined NN O O
all NN O O
24 NN O O
PEX1 NN O O
exons NN O O
in NN O O
four NN O O
patients NN O O
, NN O O
including NN O O
both NN O O
patients NN O O
that NN O O
have NN O O
mutations NN O O
in NN O O
PMP70 NN O O
. NN O O

PEX1 NN O O
mutations NN O O
were NN O O
detected NN O O
in NN O O
all NN O O
four NN O O
patients NN O O
, NN O O
including NN O O
a NN O O
1 NN O O
- NN O O
bp NN O O
insertion NN O O
( NN O O
c NN O O
. NN O O
2097insT NN O O
) NN O O
in NN O O
exon NN O O
13 NN O O
that NN O O
was NN O O
present NN O O
in NN O O
three NN O O
of NN O O
the NN O O
four NN O O
patients NN O O
. NN O O

Subsequent NN O O
studies NN O O
demonstrated NN O O
that NN O O
this NN O O
mutation NN O O
is NN O O
present NN O O
in NN O O
one NN O O
- NN O O
half NN O O
of NN O O
all NN O O
CG1 NN O O
patients NN O O
and NN O O
correlates NN O O
with NN O O
the NN O O
Zellweger NN O B-Disease
syndrome NN O I-Disease
phenotype NN O O
. NN O O

As NN O O
this NN O O
mutation NN O O
leads NN O O
to NN O O
a NN O O
loss NN O O
of NN O O
protein NN O O
function NN O O
its NN O O
frequency NN O O
makes NN O O
it NN O O
the NN O O
most NN O O
common NN O O
cause NN O O
of NN O O
Zellweger NN O B-Disease
syndrome NN O I-Disease
, NN O O
helping NN O O
to NN O O
explain NN O O
the NN O O
high NN O O
percentage NN O O
of NN O O
patients NN O O
that NN O O
belong NN O O
to NN O O
CG1 NN O O
. NN O O

Novel NN O O
mutations NN O O
in NN O O
the NN O O
Wiskott NN O B-Disease
- NN O I-Disease
Aldrich NN O I-Disease
syndrome NN O I-Disease
protein NN O O
gene NN O O
and NN O O
their NN O O
effects NN O O
on NN O O
transcriptional NN O O
, NN O O
translational NN O O
, NN O O
and NN O O
clinical NN O O
phenotypes NN O O
. NN O O

Wiskott NN O B-Disease
- NN O I-Disease
Aldrich NN O I-Disease
syndrome NN O I-Disease
( NN O O
WAS NN O B-Disease
) NN O O
is NN O O
an NN O O
X NN O B-Disease
- NN O I-Disease
linked NN O I-Disease
recessive NN O I-Disease
immunodeficiency NN O I-Disease
characterized NN O O
by NN O O
thrombocytopenia NN O B-Disease
, NN O O
eczema NN O B-Disease
, NN O O
and NN O O
recurrent NN O O
infections NN O O
, NN O O
and NN O O
caused NN O O
by NN O O
mutations NN O O
in NN O O
the NN O O
WAS NN O B-Disease
protein NN O O
( NN O O
WASP NN O O
) NN O O
gene NN O O
. NN O O

WASP NN O O
contains NN O O
several NN O O
functional NN O O
domains NN O O
through NN O O
which NN O O
it NN O O
interacts NN O O
with NN O O
proteins NN O O
involved NN O O
in NN O O
intracellular NN O O
signaling NN O O
and NN O O
regulation NN O O
of NN O O
the NN O O
actin NN O O
cytoskeleton NN O O
. NN O O

In NN O O
this NN O O
report NN O O
, NN O O
17 NN O O
WASP NN O O
gene NN O O
mutations NN O O
were NN O O
identified NN O O
, NN O O
12 NN O O
of NN O O
which NN O O
are NN O O
novel NN O O
. NN O O

DNA NN O O
of NN O O
affected NN O O
males NN O O
and NN O O
obligate NN O O
carriers NN O O
was NN O O
PCR NN O O
amplified NN O O
and NN O O
analyzed NN O O
by NN O O
SSCA NN O O
, NN O O
heteroduplex NN O O
analysis NN O O
, NN O O
and NN O O
direct NN O O
sequencing NN O O
. NN O O

The NN O O
effects NN O O
of NN O O
the NN O O
mutations NN O O
at NN O O
the NN O O
mRNA NN O O
and NN O O
protein NN O O
level NN O O
were NN O O
ascertained NN O O
by NN O O
RT NN O O
- NN O O
PCR NN O O
and NN O O
Western NN O O
blot NN O O
analyses NN O O
. NN O O

All NN O O
missense NN O O
mutations NN O O
were NN O O
located NN O O
in NN O O
exons NN O O
1 NN O O
- NN O O
4 NN O O
. NN O O

Most NN O O
of NN O O
the NN O O
nonsense NN O O
, NN O O
frameshift NN O O
and NN O O
splice NN O O
site NN O O
mutations NN O O
were NN O O
found NN O O
in NN O O
exons NN O O
6 NN O O
- NN O O
11 NN O O
. NN O O

Mutations NN O O
that NN O O
alter NN O O
splice NN O O
sites NN O O
led NN O O
to NN O O
the NN O O
synthesis NN O O
of NN O O
several NN O O
types NN O O
of NN O O
mRNAs NN O O
, NN O O
a NN O O
fraction NN O O
of NN O O
which NN O O
represented NN O O
the NN O O
normally NN O O
spliced NN O O
product NN O O
. NN O O

The NN O O
presence NN O O
of NN O O
normally NN O O
spliced NN O O
transcripts NN O O
was NN O O
correlated NN O O
with NN O O
a NN O O
milder NN O O
phenotype NN O O
. NN O O

When NN O O
one NN O O
such NN O O
case NN O O
was NN O O
studied NN O O
by NN O O
Western NN O O
blotting NN O O
, NN O O
reduced NN O O
amounts NN O O
of NN O O
normal NN O O
- NN O O
size NN O O
WASP NN O O
were NN O O
present NN O O
. NN O O

In NN O O
other NN O O
cases NN O O
as NN O O
well NN O O
, NN O O
a NN O O
correlation NN O O
was NN O O
found NN O O
between NN O O
the NN O O
amount NN O O
of NN O O
normal NN O O
or NN O O
mutant NN O O
WASP NN O O
present NN O O
and NN O O
the NN O O
phenotypes NN O O
of NN O O
the NN O O
affected NN O O
individuals NN O O
. NN O O

No NN O O
protein NN O O
was NN O O
detected NN O O
in NN O O
two NN O O
individuals NN O O
with NN O O
severe NN O O
WAS NN O B-Disease
. NN O O

Reduced NN O O
levels NN O O
of NN O O
a NN O O
normal NN O O
- NN O O
size NN O O
WASP NN O O
with NN O O
a NN O O
missense NN O O
mutation NN O O
were NN O O
seen NN O O
in NN O O
two NN O O
individuals NN O O
with NN O O
XLT NN O B-Disease
. NN O O

It NN O O
is NN O O
concluded NN O O
that NN O O
mutation NN O O
analysis NN O O
at NN O O
the NN O O
DNA NN O O
level NN O O
is NN O O
not NN O O
sufficient NN O O
for NN O O
predicting NN O O
clinical NN O O
course NN O O
. NN O O

Studies NN O O
at NN O O
the NN O O
transcript NN O O
and NN O O
protein NN O O
level NN O O
are NN O O
needed NN O O
for NN O O
a NN O O
better NN O O
assessment NN O O
. NN O O
. NN O O

Aminoglycoside NN O O
antibiotics NN O O
restore NN O O
dystrophin NN O O
function NN O O
to NN O O
skeletal NN O O
muscles NN O O
of NN O O
mdx NN O O
mice NN O O
. NN O O

Duchenne NN O B-Disease
muscular NN O I-Disease
dystrophy NN O I-Disease
( NN O O
DMD NN O B-Disease
) NN O O
is NN O O
caused NN O O
by NN O O
mutations NN O O
in NN O O
the NN O O
dystrophin NN O O
gene NN O O
, NN O O
leading NN O O
to NN O O
the NN O O
absence NN O O
of NN O O
the NN O O
dystrophin NN O O
protein NN O O
in NN O O
striated NN O O
muscle NN O O
. NN O O

A NN O O
significant NN O O
number NN O O
of NN O O
these NN O O
mutations NN O O
are NN O O
premature NN O O
stop NN O O
codons NN O O
. NN O O

On NN O O
the NN O O
basis NN O O
of NN O O
the NN O O
observation NN O O
that NN O O
aminoglycoside NN O O
treatment NN O O
can NN O O
suppress NN O O
stop NN O O
codons NN O O
in NN O O
cultured NN O O
cells NN O O
, NN O O
we NN O O
tested NN O O
the NN O O
effect NN O O
of NN O O
gentamicin NN O O
on NN O O
cultured NN O O
muscle NN O O
cells NN O O
from NN O O
the NN O O
mdx NN O O
mouse NN O O
- NN O O
an NN O O
animal NN O O
model NN O O
for NN O O
DMD NN O B-Disease
that NN O O
possesses NN O O
a NN O O
premature NN O O
stop NN O O
codon NN O O
in NN O O
the NN O O
dystrophin NN O O
gene NN O O
. NN O O

Exposure NN O O
of NN O O
mdx NN O O
myotubes NN O O
to NN O O
gentamicin NN O O
led NN O O
to NN O O
the NN O O
expression NN O O
and NN O O
localization NN O O
of NN O O
dystrophin NN O O
to NN O O
the NN O O
cell NN O O
membrane NN O O
. NN O O

We NN O O
then NN O O
evaluated NN O O
the NN O O
effects NN O O
of NN O O
differing NN O O
dosages NN O O
of NN O O
gentamicin NN O O
on NN O O
expression NN O O
and NN O O
functional NN O O
protection NN O O
of NN O O
the NN O O
muscles NN O O
of NN O O
mdx NN O O
mice NN O O
. NN O O

We NN O O
identified NN O O
a NN O O
treatment NN O O
regimen NN O O
that NN O O
resulted NN O O
in NN O O
the NN O O
presence NN O O
of NN O O
dystrophin NN O O
in NN O O
the NN O O
cell NN O O
membrane NN O O
in NN O O
all NN O O
striated NN O O
muscles NN O O
examined NN O O
and NN O O
that NN O O
provided NN O O
functional NN O O
protection NN O O
against NN O O
muscular NN O B-Disease
injury NN O I-Disease
. NN O O

To NN O O
our NN O O
knowledge NN O O
, NN O O
our NN O O
results NN O O
are NN O O
the NN O O
first NN O O
to NN O O
demonstrate NN O O
that NN O O
aminoglycosides NN O O
can NN O O
suppress NN O O
stop NN O O
codons NN O O
not NN O O
only NN O O
in NN O O
vitro NN O O
but NN O O
also NN O O
in NN O O
vivo NN O O
. NN O O

Furthermore NN O O
, NN O O
these NN O O
results NN O O
raise NN O O
the NN O O
possibility NN O O
of NN O O
a NN O O
novel NN O O
treatment NN O O
regimen NN O O
for NN O O
muscular NN O B-Disease
dystrophy NN O I-Disease
and NN O O
other NN O O
diseases NN O O
caused NN O O
by NN O O
premature NN O O
stop NN O O
codon NN O O
mutations NN O O
. NN O O

This NN O O
treatment NN O O
could NN O O
prove NN O O
effective NN O O
in NN O O
up NN O O
to NN O O
15 NN O O
% NN O O
of NN O O
patients NN O O
with NN O O
DMD NN O B-Disease
. NN O O
. NN O O

Loss NN O O
of NN O O
the NN O O
ataxia NN O B-Disease
- NN O I-Disease
telangiectasia NN O I-Disease
gene NN O O
product NN O O
causes NN O O
oxidative NN O O
damage NN O O
in NN O O
target NN O O
organs NN O O
. NN O O

Ataxia NN O B-Disease
- NN O I-Disease
telangiectasia NN O I-Disease
( NN O O
A NN O B-Disease
- NN O I-Disease
T NN O I-Disease
) NN O O
is NN O O
characterized NN O O
by NN O O
a NN O O
markedly NN O O
increased NN O O
sensitivity NN O O
to NN O O
ionizing NN O O
radiation NN O O
, NN O O
increased NN O O
incidence NN O O
of NN O O
cancer NN O B-Disease
, NN O O
and NN O O
neurodegeneration NN O B-Disease
, NN O O
especially NN O O
of NN O O
the NN O O
cerebellar NN O O
Purkinje NN O O
cells NN O O
. NN O O

Ionizing NN O O
radiation NN O O
oxidizes NN O O
macromolecules NN O O
and NN O O
causes NN O O
tissue NN O O
damage NN O O
through NN O O
the NN O O
generation NN O O
of NN O O
reactive NN O O
oxygen NN O O
species NN O O
( NN O O
ROS NN O O
) NN O O
. NN O O

We NN O O
therefore NN O O
hypothesized NN O O
that NN O O
A NN O B-Disease
- NN O I-Disease
T NN O I-Disease
is NN O O
due NN O O
to NN O O
oxidative NN O O
damage NN O O
resulting NN O O
from NN O O
loss NN O O
of NN O O
function NN O O
of NN O O
the NN O O
A NN O B-Disease
- NN O I-Disease
T NN O I-Disease
gene NN O O
product NN O O
. NN O O

To NN O O
assess NN O O
this NN O O
hypothesis NN O O
, NN O O
we NN O O
employed NN O O
an NN O O
animal NN O O
model NN O O
of NN O O
A NN O B-Disease
- NN O I-Disease
T NN O I-Disease
, NN O O
the NN O O
mouse NN O O
with NN O O
a NN O O
disrupted NN O O
Atm NN O O
gene NN O O
. NN O O

We NN O O
show NN O O
that NN O O
organs NN O O
which NN O O
develop NN O O
pathologic NN O O
changes NN O O
in NN O O
the NN O O
Atm NN O O
- NN O O
deficient NN O O
mice NN O O
are NN O O
targets NN O O
of NN O O
oxidative NN O O
damage NN O O
, NN O O
and NN O O
that NN O O
cerebellar NN O O
Purkinje NN O O
cells NN O O
are NN O O
particularly NN O O
affected NN O O
. NN O O

These NN O O
observations NN O O
provide NN O O
a NN O O
mechanistic NN O O
basis NN O O
for NN O O
the NN O O
A NN O B-Disease
- NN O I-Disease
T NN O I-Disease
phenotype NN O O
and NN O O
lay NN O O
a NN O O
rational NN O O
foundation NN O O
for NN O O
therapeutic NN O O
intervention NN O O
. NN O O
. NN O O

Recessively NN O O
inherited NN O O
multiple NN O B-Disease
epiphyseal NN O I-Disease
dysplasia NN O I-Disease
with NN O O
normal NN O O
stature NN O O
, NN O O
club NN O B-Disease
foot NN O I-Disease
, NN O O
and NN O O
double NN O B-Disease
layered NN O I-Disease
patella NN O I-Disease
caused NN O O
by NN O O
a NN O O
DTDST NN O O
mutation NN O O
. NN O O

We NN O O
have NN O O
observed NN O O
over NN O O
25 NN O O
different NN O O
mutations NN O O
in NN O O
the NN O O
diastrophic NN O B-Disease
dysplasia NN O I-Disease
sulphate NN O O
transporter NN O O
gene NN O O
( NN O O
DTDST NN O O
) NN O O
in NN O O
association NN O O
with NN O O
the NN O O
recessive NN O B-Disease
disorders NN O I-Disease
achondrogenesis NN O B-Disease
1B NN O I-Disease
, NN O O
atelosteogenesis NN O B-Disease
2 NN O I-Disease
, NN O O
and NN O O
diastrophic NN O B-Disease
dysplasia NN O I-Disease
. NN O O

The NN O O
c862t NN O O
( NN O O
R279W NN O O
) NN O O
transition NN O O
is NN O O
the NN O O
most NN O O
common NN O O
mutation NN O O
in NN O O
non NN O O
- NN O O
Finnish NN O O
patients NN O O
, NN O O
but NN O O
in NN O O
these NN O O
disorders NN O O
it NN O O
is NN O O
usually NN O O
combined NN O O
with NN O O
other NN O O
DTDST NN O O
mutations NN O O
. NN O O

We NN O O
had NN O O
not NN O O
seen NN O O
a NN O O
case NN O O
of NN O O
homozygosity NN O O
for NN O O
c862t NN O O
( NN O O
R279W NN O O
) NN O O
until NN O O
we NN O O
analysed NN O O
DNA NN O O
from NN O O
a NN O O
36 NN O O
year NN O O
old NN O O
male NN O O
with NN O O
tall NN O O
- NN O O
normal NN O O
stature NN O O
( NN O O
180 NN O O
cm NN O O
) NN O O
who NN O O
asked NN O O
for NN O O
genetic NN O O
counselling NN O O
for NN O O
suspected NN O O
multiple NN O B-Disease
epiphyseal NN O I-Disease
dysplasia NN O I-Disease
. NN O O

He NN O O
was NN O O
treated NN O O
for NN O O
club NN O B-Disease
foot NN O I-Disease
and NN O O
hip NN O B-Disease
dysplasia NN O I-Disease
at NN O O
birth NN O O
. NN O O

Skeletal NN O O
changes NN O O
consistent NN O O
with NN O O
multiple NN O B-Disease
epiphyseal NN O I-Disease
dysplasia NN O I-Disease
, NN O O
with NN O O
the NN O O
peculiar NN O O
finding NN O O
of NN O O
a NN O O
double NN O B-Disease
layered NN O I-Disease
patella NN O I-Disease
, NN O O
were NN O O
recognised NN O O
during NN O O
childhood NN O O
. NN O O

Cleft NN O B-Disease
palate NN O I-Disease
, NN O O
swelling NN O B-Disease
of NN O I-Disease
the NN O I-Disease
ear NN O I-Disease
pinna NN O I-Disease
, NN O O
and NN O O
hitch NN O B-Disease
hiker NN O I-Disease
thumb NN O I-Disease
were NN O O
absent NN O O
. NN O O

He NN O O
was NN O O
found NN O O
to NN O O
be NN O O
homozygous NN O O
, NN O O
and NN O O
both NN O O
healthy NN O O
parents NN O O
heterozygous NN O O
, NN O O
for NN O O
the NN O O
R279W NN O O
mutation NN O O
in NN O O
DTDST NN O O
, NN O O
and NN O O
his NN O O
fibroblasts NN O O
showed NN O O
a NN O O
sulphate NN O O
incorporation NN O O
defect NN O O
typical NN O O
of NN O O
DTDST NN O B-Disease
disorders NN O I-Disease
. NN O O

Counselling NN O O
was NN O O
given NN O O
for NN O O
a NN O O
recessive NN O B-Disease
disorder NN O I-Disease
, NN O O
thereby NN O O
considerably NN O O
reducing NN O O
the NN O O
probability NN O O
of NN O O
affected NN O O
offspring NN O O
. NN O O

Multiple NN O B-Disease
epiphyseal NN O I-Disease
dysplasia NN O I-Disease
is NN O O
more NN O O
frequently NN O O
caused NN O O
by NN O O
dominant NN O O
mutations NN O O
in NN O O
the NN O O
COMP NN O O
( NN O O
EDM1 NN O B-Disease
, NN O O
McKusick NN O O
132400 NN O O
) NN O O
and NN O O
COL9A2 NN O O
genes NN O O
( NN O O
EDM2 NN O B-Disease
, NN O O
McKusick NN O O
600204 NN O O
) NN O O
. NN O O

A NN O O
few NN O O
other NN O O
patients NN O O
and NN O O
families NN O O
with NN O O
features NN O O
similar NN O O
to NN O O
our NN O O
proband NN O O
have NN O O
been NN O O
described NN O O
previously NN O O
and NN O O
considered NN O O
to NN O O
have NN O O
autosomal NN O O
recessive NN O O
MED NN O B-Disease
( NN O O
EDM4 NN O B-Disease
, NN O O
McKusick NN O O
226900 NN O O
) NN O O
. NN O O

This NN O O
observation NN O O
confirms NN O O
the NN O O
existence NN O O
of NN O O
this NN O O
entity NN O O
and NN O O
assigns NN O O
it NN O O
to NN O O
the NN O O
phenotypic NN O O
spectrum NN O O
associated NN O O
with NN O O
mutations NN O O
at NN O O
the NN O O
DTDST NN O O
locus NN O O
. NN O O
. NN O O

Homozygosity NN O O
for NN O O
a NN O O
novel NN O O
DTDST NN O O
mutation NN O O
in NN O O
a NN O O
child NN O O
with NN O O
a NN O O
' NN O O
broad NN O O
bone NN O O
- NN O O
platyspondylic NN O O
' NN O O
variant NN O O
of NN O O
diastrophic NN O B-Disease
dysplasia NN O I-Disease
. NN O O

Atypical NN O O
or NN O O
variant NN O O
forms NN O O
of NN O O
well NN O O
- NN O O
known NN O O
chondrodysplasias NN O B-Disease
may NN O O
pose NN O O
diagnostic NN O O
problems NN O O
. NN O O

We NN O O
report NN O O
on NN O O
a NN O O
girl NN O O
with NN O O
clinical NN O O
features NN O O
suggesting NN O O
diastrophic NN O B-Disease
dysplasia NN O I-Disease
but NN O O
with NN O O
unusual NN O O
radiographic NN O O
features NN O O
including NN O O
severe NN O O
platyspondyly NN O B-Disease
, NN O O
wide NN O O
metaphyses NN O O
, NN O O
and NN O O
fibular NN O O
overgrowth NN O O
, NN O O
which NN O O
are NN O O
partially NN O O
reminiscent NN O O
of NN O O
metatropic NN O B-Disease
dysplasia NN O I-Disease
. NN O O

The NN O O
diagnosis NN O O
was NN O O
clarified NN O O
by NN O O
molecular NN O O
analysis NN O O
of NN O O
the NN O O
DTDST NN O O
gene NN O O
, NN O O
which NN O O
revealed NN O O
homozygosity NN O O
for NN O O
a NN O O
previously NN O O
undescribed NN O O
mutation NN O O
leading NN O O
to NN O O
a NN O O
Q454P NN O O
substitution NN O O
in NN O O
the NN O O
10th NN O O
transmembrane NN O O
domain NN O O
of NN O O
the NN O O
DTDST NN O O
sulfate NN O O
transporter NN O O
. NN O O

Molecular NN O O
analysis NN O O
may NN O O
be NN O O
of NN O O
particular NN O O
value NN O O
in NN O O
such NN O O
atypical NN O O
cases NN O O
. NN O O
. NN O O

The NN O O
type NN O O
of NN O O
somatic NN O O
mutation NN O O
at NN O O
APC NN O O
in NN O O
familial NN O B-Disease
adenomatous NN O I-Disease
polyposis NN O I-Disease
is NN O O
determined NN O O
by NN O O
the NN O O
site NN O O
of NN O O
the NN O O
germline NN O O
mutation NN O O
: NN O O
a NN O O
new NN O O
facet NN O O
to NN O O
Knudson NN O O
' NN O O
s NN O O
' NN O O
two NN O O
- NN O O
hit NN O O
' NN O O
hypothesis NN O O
. NN O O

APC NN O O
is NN O O
often NN O O
cited NN O O
as NN O O
a NN O O
prime NN O O
example NN O O
of NN O O
a NN O O
tumor NN O B-Disease
suppressor NN O O
gene NN O O
. NN O O

Truncating NN O O
germline NN O O
and NN O O
somatic NN O O
mutations NN O O
( NN O O
or NN O O
, NN O O
infrequently NN O O
, NN O O
allelic NN O O
loss NN O O
) NN O O
occur NN O O
in NN O O
tumors NN O B-Disease
in NN O O
FAP NN O B-Disease
( NN O O
familial NN O B-Disease
adenomatous NN O I-Disease
polyposis NN O I-Disease
) NN O O
. NN O O

Most NN O O
sporadic NN O B-Disease
colorectal NN O I-Disease
cancers NN O I-Disease
also NN O O
have NN O O
two NN O O
APC NN O B-Disease
mutations NN O O
. NN O O

Clues NN O O
from NN O O
attenuated NN O B-Disease
polyposis NN O I-Disease
, NN O O
missense NN O O
germline NN O O
variants NN O O
with NN O O
mild NN O O
disease NN O O
and NN O O
the NN O O
somatic NN O O
mutation NN O O
cluster NN O O
region NN O O
( NN O O
codons NN O O
1 NN O O
, NN O O
250 NN O O
- NN O O
1 NN O O
, NN O O
450 NN O O
) NN O O
indicate NN O O
, NN O O
however NN O O
, NN O O
that NN O O
APC NN O B-Disease
mutations NN O O
might NN O O
not NN O O
result NN O O
in NN O O
simple NN O O
loss NN O O
of NN O O
protein NN O O
function NN O O
. NN O O

We NN O O
have NN O O
found NN O O
that NN O O
FAP NN O B-Disease
patients NN O O
with NN O O
germline NN O O
APC NN O B-Disease
mutations NN O O
within NN O O
a NN O O
small NN O O
region NN O O
( NN O O
codons NN O O
1 NN O O
, NN O O
194 NN O O
- NN O O
1 NN O O
, NN O O
392 NN O O
at NN O O
most NN O O
) NN O O
mainly NN O O
show NN O O
allelic NN O O
loss NN O O
in NN O O
their NN O O
colorectal NN O B-Disease
adenomas NN O I-Disease
, NN O O
in NN O O
contrast NN O O
to NN O O
other NN O O
FAP NN O B-Disease
patients NN O O
, NN O O
whose NN O O
second NN O O
hits NN O O
tend NN O O
to NN O O
occur NN O O
by NN O O
truncating NN O O
mutations NN O O
in NN O O
the NN O O
mutation NN O O
cluster NN O O
region NN O O
. NN O O

Our NN O O
results NN O O
indicate NN O O
that NN O O
different NN O O
APC NN O B-Disease
mutations NN O O
provide NN O O
cells NN O O
with NN O O
different NN O O
selective NN O O
advantages NN O O
, NN O O
with NN O O
mutations NN O O
close NN O O
to NN O O
codon NN O O
1 NN O O
, NN O O
300 NN O O
providing NN O O
the NN O O
greatest NN O O
advantage NN O O
. NN O O

Allelic NN O O
loss NN O O
is NN O O
selected NN O O
strongly NN O O
in NN O O
cells NN O O
with NN O O
one NN O O
mutation NN O O
near NN O O
codon NN O O
1 NN O O
, NN O O
300 NN O O
. NN O O

A NN O O
different NN O O
germline NN O O
- NN O O
somatic NN O O
APC NN O B-Disease
mutation NN O O
association NN O O
exists NN O O
in NN O O
FAP NN O B-Disease
desmoids NN O I-Disease
. NN O O

APC NN O O
is NN O O
not NN O O
, NN O O
therefore NN O O
, NN O O
a NN O O
classical NN O O
tumor NN O B-Disease
suppressor NN O O
. NN O O

Our NN O O
findings NN O O
also NN O O
indicate NN O O
a NN O O
new NN O O
mechanism NN O O
for NN O O
disease NN O O
severity NN O O
if NN O O
a NN O O
broader NN O O
spectrum NN O O
of NN O O
mutations NN O O
is NN O O
selected NN O O
in NN O O
tumors NN O B-Disease
, NN O O
the NN O O
somatic NN O O
mutation NN O O
rate NN O O
is NN O O
effectively NN O O
higher NN O O
and NN O O
more NN O O
tumors NN O B-Disease
grow NN O O
. NN O O
. NN O O

Mxi1 NN O O
mutations NN O O
in NN O O
human NN O O
neurofibrosarcomas NN O B-Disease
. NN O O

Mxi1 NN O O
is NN O O
thought NN O O
to NN O O
negatively NN O O
regulate NN O O
Myc NN O O
function NN O O
and NN O O
may NN O O
therefore NN O O
be NN O O
a NN O O
potential NN O O
tumor NN O B-Disease
suppressor NN O O
gene NN O O
. NN O O

Little NN O O
effort NN O O
has NN O O
yet NN O O
been NN O O
made NN O O
to NN O O
find NN O O
alterations NN O O
involving NN O O
this NN O O
gene NN O O
in NN O O
human NN O O
solid NN O B-Disease
tumors NN O I-Disease
. NN O O

We NN O O
screened NN O O
31 NN O O
human NN O O
gastric NN O B-Disease
cancers NN O I-Disease
, NN O O
7 NN O O
esophageal NN O B-Disease
cancers NN O I-Disease
, NN O O
85 NN O O
bone NN O B-Disease
and NN O I-Disease
soft NN O I-Disease
tissue NN O I-Disease
tumors NN O I-Disease
of NN O O
various NN O O
types NN O O
, NN O O
including NN O O
4 NN O O
neurofibrosarcomas NN O B-Disease
. NN O O

We NN O O
also NN O O
examined NN O O
29 NN O O
human NN O O
tumor NN O B-Disease
cell NN O O
lines NN O O
consisting NN O O
of NN O O
12 NN O O
esophageal NN O B-Disease
cancers NN O I-Disease
, NN O O
7 NN O O
glioma NN O B-Disease
/ NN O O
glioblastomas NN O B-Disease
and NN O O
10 NN O O
others NN O O
for NN O O
Mxi1 NN O O
mutations NN O O
in NN O O
exons NN O O
1 NN O O
, NN O O
2 NN O O
, NN O O
4 NN O O
( NN O O
HLH NN O O
domain NN O O
) NN O O
, NN O O
5 NN O O
and NN O O
6 NN O O
. NN O O

Polymerase NN O O
chain NN O O
reaction NN O O
- NN O O
single NN O O
- NN O O
strand NN O O
conformation NN O O
polymorphism NN O O
( NN O O
PCR NN O O
- NN O O
SSCP NN O O
) NN O O
and NN O O
subsequent NN O O
sequencing NN O O
revealed NN O O
three NN O O
distinct NN O O
polymorphisms NN O O
in NN O O
the NN O O
intron NN O O
- NN O O
exon NN O O
boundary NN O O
upstream NN O O
from NN O O
exon NN O O
6 NN O O
. NN O O

We NN O O
discovered NN O O
a NN O O
missense NN O O
mutation NN O O
, NN O O
GCA NN O O
to NN O O
GTA NN O O
( NN O O
Ala NN O O
54 NN O O
Val NN O O
) NN O O
, NN O O
in NN O O
exon NN O O
2 NN O O
in NN O O
a NN O O
neurofibrosarcoma NN O B-Disease
patient NN O O
( NN O O
case NN O O
1 NN O O
) NN O O
, NN O O
two NN O O
missense NN O O
mutations NN O O
, NN O O
AAA NN O O
to NN O O
CAA NN O O
( NN O O
Lys NN O O
118 NN O O
Gln NN O O
) NN O O
and NN O O
GAA NN O O
to NN O O
GGA NN O O
( NN O O
Glu NN O O
154 NN O O
Gly NN O O
) NN O O
in NN O O
exon NN O O
5 NN O O
of NN O O
another NN O O
neurofibrosarcoma NN O B-Disease
patient NN O O
( NN O O
case NN O O
2 NN O O
) NN O O
, NN O O
and NN O O
3 NN O O
amino NN O O
acid NN O O
substitutions NN O O
, NN O O
GTG NN O O
to NN O O
GCG NN O O
( NN O O
Val NN O O
179 NN O O
Ala NN O O
) NN O O
, NN O O
GTT NN O O
to NN O O
GCT NN O O
( NN O O
Val NN O O
181 NN O O
Ala NN O O
) NN O O
and NN O O
TTC NN O O
to NN O O
CTC NN O O
( NN O O
Phe NN O O
186 NN O O
Leu NN O O
) NN O O
, NN O O
in NN O O
a NN O O
third NN O O
neurofibrosarcoma NN O B-Disease
patient NN O O
( NN O O
case NN O O
3 NN O O
) NN O O
. NN O O

In NN O O
case NN O O
3 NN O O
, NN O O
loss NN O O
of NN O O
heterozygosity NN O O
was NN O O
also NN O O
demonstrated NN O O
by NN O O
informative NN O O
( NN O O
TTC NN O O
) NN O O
3 NN O O
/ NN O O
( NN O O
TTC NN O O
) NN O O
2 NN O O
polymorphism NN O O
. NN O O

Our NN O O
data NN O O
demonstrate NN O O
that NN O O
mutations NN O O
occur NN O O
in NN O O
the NN O O
Mxi1 NN O O
gene NN O O
in NN O O
neurofibrosarcoma NN O B-Disease
. NN O O

Missense NN O O
mutations NN O O
in NN O O
the NN O O
functional NN O O
domain NN O O
of NN O O
Mxi1 NN O O
in NN O O
these NN O O
cases NN O O
may NN O O
be NN O O
involved NN O O
in NN O O
the NN O O
pathogenesis NN O O
of NN O O
neurofibrosarcoma NN O B-Disease
. NN O O
. NN O O

A NN O O
population NN O O
- NN O O
based NN O O
study NN O O
of NN O O
the NN O O
clinical NN O O
expression NN O O
of NN O O
the NN O O
hemochromatosis NN O B-Disease
gene NN O O
. NN O O

BACKGROUND NN O O
AND NN O O
METHODS NN O O
Hereditary NN O B-Disease
hemochromatosis NN O I-Disease
is NN O O
associated NN O O
with NN O O
homozygosity NN O O
for NN O O
the NN O O
C282Y NN O O
mutation NN O O
in NN O O
the NN O O
hemochromatosis NN O B-Disease
( NN O O
HFE NN O O
) NN O O
gene NN O O
on NN O O
chromosome NN O O
6 NN O O
, NN O O
elevated NN O O
serum NN O O
transferrin NN O O
saturation NN O O
, NN O O
and NN O O
excess NN O B-Disease
iron NN O I-Disease
deposits NN O I-Disease
throughout NN O O
the NN O O
body NN O O
. NN O O

To NN O O
assess NN O O
the NN O O
prevalence NN O O
and NN O O
clinical NN O O
expression NN O O
of NN O O
the NN O O
HFE NN O O
gene NN O O
, NN O O
we NN O O
conducted NN O O
a NN O O
population NN O O
- NN O O
based NN O O
study NN O O
in NN O O
Busselton NN O O
, NN O O
Australia NN O O
. NN O O

In NN O O
1994 NN O O
, NN O O
we NN O O
obtained NN O O
blood NN O O
samples NN O O
for NN O O
the NN O O
determination NN O O
of NN O O
serum NN O O
transferrin NN O O
saturation NN O O
and NN O O
ferritin NN O O
levels NN O O
and NN O O
the NN O O
presence NN O O
or NN O O
absence NN O O
of NN O O
the NN O O
C282Y NN O O
mutation NN O O
and NN O O
the NN O O
H63D NN O O
mutation NN O O
( NN O O
which NN O O
may NN O O
contribute NN O O
to NN O O
increased NN O O
hepatic NN O O
iron NN O O
levels NN O O
) NN O O
in NN O O
3011 NN O O
unrelated NN O O
white NN O O
adults NN O O
. NN O O

We NN O O
evaluated NN O O
all NN O O
subjects NN O O
who NN O O
had NN O O
persistently NN O O
elevated NN O O
transferrin NN O O
- NN O O
saturation NN O O
values NN O O
( NN O O
45 NN O O
percent NN O O
or NN O O
higher NN O O
) NN O O
or NN O O
were NN O O
homozygous NN O O
for NN O O
the NN O O
C282Y NN O O
mutation NN O O
. NN O O

We NN O O
recommended NN O O
liver NN O O
biopsy NN O O
for NN O O
subjects NN O O
with NN O O
serum NN O O
ferritin NN O O
levels NN O O
of NN O O
300 NN O O
ng NN O O
per NN O O
milliliter NN O O
or NN O O
higher NN O O
. NN O O

The NN O O
subjects NN O O
were NN O O
followed NN O O
for NN O O
up NN O O
to NN O O
four NN O O
years NN O O
. NN O O

RESULTS NN O O
Sixteen NN O O
of NN O O
the NN O O
subjects NN O O
( NN O O
0 NN O O
. NN O O
5 NN O O
percent NN O O
) NN O O
were NN O O
homozygous NN O O
for NN O O
the NN O O
C282Y NN O O
mutation NN O O
, NN O O
and NN O O
424 NN O O
( NN O O
14 NN O O
. NN O O
1 NN O O
percent NN O O
) NN O O
were NN O O
heterozygous NN O O
. NN O O

The NN O O
serum NN O O
transferrin NN O O
saturation NN O O
was NN O O
45 NN O O
percent NN O O
or NN O O
higher NN O O
in NN O O
15 NN O O
of NN O O
the NN O O
16 NN O O
who NN O O
were NN O O
homozygous NN O O
; NN O O
in NN O O
1 NN O O
subject NN O O
it NN O O
was NN O O
43 NN O O
percent NN O O
. NN O O

Four NN O O
of NN O O
the NN O O
homozygous NN O O
subjects NN O O
had NN O O
previously NN O O
been NN O O
given NN O O
a NN O O
diagnosis NN O O
of NN O O
hemochromatosis NN O B-Disease
, NN O O
and NN O O
12 NN O O
had NN O O
not NN O O
. NN O O

Seven NN O O
of NN O O
these NN O O
12 NN O O
patients NN O O
had NN O O
elevated NN O O
serum NN O O
ferritin NN O O
levels NN O O
in NN O O
1994 NN O O
; NN O O
6 NN O O
of NN O O
the NN O O
7 NN O O
had NN O O
further NN O O
increases NN O O
in NN O O
1998 NN O O
, NN O O
and NN O O
1 NN O O
had NN O O
a NN O O
decrease NN O O
, NN O O
although NN O O
the NN O O
value NN O O
remained NN O O
elevated NN O O
. NN O O

The NN O O
serum NN O O
ferritin NN O O
levels NN O O
in NN O O
the NN O O
four NN O O
other NN O O
homozygous NN O O
patients NN O O
remained NN O O
in NN O O
the NN O O
normal NN O O
range NN O O
. NN O O

Eleven NN O O
of NN O O
the NN O O
16 NN O O
homozygous NN O O
subjects NN O O
underwent NN O O
liver NN O O
biopsy NN O O
; NN O O
3 NN O O
had NN O O
hepatic NN O B-Disease
fibrosis NN O I-Disease
, NN O O
and NN O O
1 NN O O
, NN O O
who NN O O
had NN O O
a NN O O
history NN O O
of NN O O
excessive NN O B-Disease
alcohol NN O I-Disease
consumption NN O I-Disease
, NN O O
had NN O O
cirrhosis NN O B-Disease
and NN O O
mild NN O O
microvesicular NN O B-Disease
steatosis NN O I-Disease
. NN O O

Eight NN O O
of NN O O
the NN O O
16 NN O O
homozygous NN O O
subjects NN O O
had NN O O
clinical NN O O
findings NN O O
that NN O O
were NN O O
consistent NN O O
with NN O O
the NN O O
presence NN O O
of NN O O
hereditary NN O B-Disease
hemochromatosis NN O I-Disease
, NN O O
such NN O O
as NN O O
hepatomegaly NN O B-Disease
, NN O O
skin NN O B-Disease
pigmentation NN O I-Disease
, NN O O
and NN O O
arthritis NN O B-Disease
. NN O O

CONCLUSIONS NN O O
In NN O O
a NN O O
population NN O O
of NN O O
white NN O O
adults NN O O
of NN O O
northern NN O O
European NN O O
ancestry NN O O
, NN O O
0 NN O O
. NN O O

5 NN O O
percent NN O O
were NN O O
homozygous NN O O
for NN O O
the NN O O
C282Y NN O O
mutation NN O O
in NN O O
the NN O O
HFE NN O O
gene NN O O
. NN O O

However NN O O
, NN O O
only NN O O
half NN O O
of NN O O
those NN O O
who NN O O
were NN O O
homozygous NN O O
had NN O O
clinical NN O O
features NN O O
of NN O O
hemochromatosis NN O B-Disease
, NN O O
and NN O O
one NN O O
quarter NN O O
had NN O O
serum NN O O
ferritin NN O O
levels NN O O
that NN O O
remained NN O O
normal NN O O
over NN O O
a NN O O
four NN O O
- NN O O
year NN O O
period NN O O
. NN O O

Large NN O O
heterozygous NN O O
deletion NN O O
masquerading NN O O
as NN O O
homozygous NN O O
missense NN O O
mutation NN O O
: NN O O
a NN O O
pitfall NN O O
in NN O O
diagnostic NN O O
mutation NN O O
analysis NN O O
. NN O O

The NN O O
clinical NN O O
use NN O O
of NN O O
molecular NN O O
analyses NN O O
in NN O O
recessive NN O B-Disease
disorders NN O I-Disease
relies NN O O
on NN O O
the NN O O
exact NN O O
characterization NN O O
of NN O O
both NN O O
mutant NN O O
alleles NN O O
in NN O O
the NN O O
affected NN O O
patient NN O O
. NN O O

This NN O O
can NN O O
be NN O O
problematic NN O O
when NN O O
only NN O O
part NN O O
of NN O O
the NN O O
gene NN O O
is NN O O
examined NN O O
or NN O O
when NN O O
relevant NN O O
DNA NN O O
alterations NN O O
are NN O O
not NN O O
recognized NN O O
by NN O O
standard NN O O
methods NN O O
. NN O O

We NN O O
present NN O O
a NN O O
child NN O O
in NN O O
whom NN O O
phenylketonuria NN O B-Disease
was NN O O
apparently NN O O
caused NN O O
by NN O O
homozygosity NN O O
for NN O O
the NN O O
mutation NN O O
E390G NN O O
in NN O O
exon NN O O
11 NN O O
of NN O O
the NN O O
phenylalanine NN O O
hydroxylase NN O O
( NN O O
PAH NN O O
) NN O O
gene NN O O
. NN O O

However NN O O
, NN O O
the NN O O
clinical NN O O
severity NN O O
of NN O O
the NN O O
disease NN O O
was NN O O
not NN O O
quite NN O O
as NN O O
mild NN O O
as NN O O
expected NN O O
, NN O O
the NN O O
mutation NN O O
was NN O O
not NN O O
identified NN O O
in NN O O
the NN O O
father NN O O
despite NN O O
confirmed NN O O
paternity NN O O
, NN O O
and NN O O
the NN O O
paternal NN O O
allele NN O O
showed NN O O
a NN O O
highly NN O O
unusual NN O O
pattern NN O O
of NN O O
polymorphic NN O O
markers NN O O
in NN O O
the NN O O
PAH NN O O
gene NN O O
. NN O O

Presence NN O O
of NN O O
a NN O O
large NN O O
deletion NN O O
involving NN O O
exons NN O O
9 NN O O
, NN O O
10 NN O O
and NN O O
11 NN O O
of NN O O
the NN O O
phenylalanine NN O O
hydroxylase NN O O
gene NN O O
was NN O O
confirmed NN O O
by NN O O
long NN O O
- NN O O
range NN O O
PCR NN O O
. NN O O

Diagnostic NN O O
DNA NN O O
analyses NN O O
should NN O O
include NN O O
a NN O O
comprehensive NN O O
examination NN O O
of NN O O
the NN O O
whole NN O O
relevant NN O O
gene NN O O
in NN O O
the NN O O
patient NN O O
and NN O O
confirmation NN O O
of NN O O
carrier NN O O
status NN O O
in NN O O
both NN O O
parents NN O O
. NN O O
. NN O O

Early NN O O
onset NN O O
of NN O O
X NN O B-Disease
- NN O I-Disease
linked NN O I-Disease
Emery NN O I-Disease
- NN O I-Disease
Dreifuss NN O I-Disease
muscular NN O I-Disease
dystrophy NN O I-Disease
in NN O O
a NN O O
boy NN O O
with NN O O
emerin NN O O
gene NN O O
deletion NN O O
. NN O O

A NN O O
boy NN O O
developed NN O O
contractures NN O B-Disease
of NN O I-Disease
the NN O I-Disease
Achilles NN O I-Disease
tendons NN O I-Disease
at NN O O
3 NN O O
years NN O O
and NN O O
of NN O O
the NN O O
postcervical NN O O
muscles NN O O
at NN O O
7 NN O O
years NN O O
, NN O O
although NN O O
neither NN O O
contractures NN O B-Disease
of NN O I-Disease
the NN O I-Disease
elbows NN O I-Disease
nor NN O O
cardiac NN O B-Disease
abnormality NN O I-Disease
were NN O O
recognized NN O O
by NN O O
the NN O O
age NN O O
of NN O O
9 NN O O
years NN O O
. NN O O

Muscle NN O O
computed NN O O
tomography NN O O
scanning NN O O
revealed NN O O
changes NN O O
characteristic NN O O
of NN O O
muscle NN O O
involvement NN O O
. NN O O

Emerin NN O O
was NN O O
not NN O O
detected NN O O
in NN O O
the NN O O
biopsied NN O O
muscle NN O O
, NN O O
and NN O O
RT NN O O
- NN O O
PCR NN O O
and NN O O
PCR NN O O
- NN O O
based NN O O
genomic NN O O
DNA NN O O
analyses NN O O
of NN O O
the NN O O
emerin NN O O
gene NN O O
demonstrated NN O O
no NN O O
amplification NN O O
product NN O O
in NN O O
the NN O O
patient NN O O
. NN O O

These NN O O
results NN O O
confirmed NN O O
the NN O O
diagnosis NN O O
of NN O O
X NN O B-Disease
- NN O I-Disease
linked NN O I-Disease
Emery NN O I-Disease
- NN O I-Disease
Dreifuss NN O I-Disease
muscular NN O I-Disease
dystrophy NN O I-Disease
( NN O O
EDMD NN O B-Disease
) NN O O
, NN O O
and NN O O
reinforce NN O O
the NN O O
necessity NN O O
of NN O O
molecular NN O O
genetic NN O O
diagnosis NN O O
of NN O O
the NN O O
membrane NN O O
protein NN O O
emerin NN O O
in NN O O
younger NN O O
patients NN O O
with NN O O
possible NN O O
EDMD NN O B-Disease
before NN O O
appearance NN O O
of NN O O
the NN O O
typical NN O O
symptoms NN O O
, NN O O
to NN O O
avoid NN O O
sudden NN O B-Disease
cardiac NN O I-Disease
death NN O I-Disease
. NN O O
. NN O O

Duchenne NN O B-Disease
/ NN O I-Disease
Becker NN O I-Disease
muscular NN O I-Disease
dystrophy NN O I-Disease
: NN O O
correlation NN O O
of NN O O
phenotype NN O O
by NN O O
electroretinography NN O O
with NN O O
sites NN O O
of NN O O
dystrophin NN O O
mutations NN O O
. NN O O

The NN O O
dark NN O O
- NN O O
adapted NN O O
electroretinogram NN O O
( NN O O
ERG NN O O
) NN O O
of NN O O
patients NN O O
with NN O O
Duchenne NN O B-Disease
and NN O I-Disease
Becker NN O I-Disease
muscular NN O I-Disease
dystrophy NN O I-Disease
( NN O O
DMD NN O B-Disease
/ NN O O
BMD NN O B-Disease
) NN O O
shows NN O O
a NN O O
marked NN O O
reduction NN O O
in NN O O
b NN O O
- NN O O
wave NN O O
amplitude NN O O
. NN O O

Genotype NN O O
- NN O O
phenotype NN O O
studies NN O O
of NN O O
mouse NN O O
models NN O O
for NN O O
DMD NN O B-Disease
show NN O O
position NN O O
- NN O O
specific NN O O
effects NN O O
of NN O O
the NN O O
mutations NN O O
upon NN O O
the NN O O
phenotype NN O O
mice NN O O
with NN O O
5 NN O O
defects NN O O
of NN O O
dystrophin NN O O
have NN O O
normal NN O O
ERGs NN O O
, NN O O
those NN O O
with NN O O
defects NN O O
in NN O O
the NN O O
central NN O O
region NN O O
have NN O O
a NN O O
normal NN O O
b NN O O
- NN O O
wave NN O O
amplitude NN O O
associated NN O O
with NN O O
prolonged NN O O
implicit NN O O
times NN O O
for NN O O
both NN O O
the NN O O
b NN O O
- NN O O
wave NN O O
and NN O O
oscillatory NN O O
potentials NN O O
, NN O O
and NN O O
mice NN O O
with NN O O
3 NN O O
defects NN O O
have NN O O
a NN O O
phenotype NN O O
similar NN O O
to NN O O
that NN O O
seen NN O O
in NN O O
DMD NN O B-Disease
/ NN O O
BMD NN O B-Disease
patients NN O O
. NN O O

The NN O O
mouse NN O O
studies NN O O
suggest NN O O
a NN O O
key NN O O
role NN O O
for NN O O
the NN O O
carboxyl NN O O
terminal NN O O
dystrophin NN O O
isoform NN O O
, NN O O
Dp260 NN O O
, NN O O
in NN O O
retinal NN O O
electrophysiology NN O O
. NN O O

We NN O O
have NN O O
undertaken NN O O
a NN O O
systematic NN O O
evaluation NN O O
of NN O O
DMD NN O B-Disease
/ NN O O
BMD NN O B-Disease
patients NN O O
through NN O O
clinical NN O O
examination NN O O
and NN O O
review NN O O
of NN O O
the NN O O
literature NN O O
in NN O O
order NN O O
to NN O O
determine NN O O
whether NN O O
the NN O O
position NN O O
- NN O O
specific NN O O
effects NN O O
of NN O O
mutations NN O O
noted NN O O
in NN O O
the NN O O
mouse NN O O
are NN O O
present NN O O
in NN O O
man NN O O
. NN O O

We NN O O
have NN O O
found NN O O
that NN O O
, NN O O
in NN O O
man NN O O
, NN O O
a NN O O
wider NN O O
variation NN O O
of NN O O
DMD NN O B-Disease
defects NN O I-Disease
correlate NN O O
with NN O O
reductions NN O O
in NN O O
the NN O O
b NN O O
- NN O O
wave NN O O
amplitude NN O O
. NN O O

Individuals NN O O
with NN O O
normal NN O O
ERGs NN O O
have NN O O
mutations NN O O
predominantly NN O O
located NN O O
5 NN O O
of NN O O
the NN O O
transcript NN O O
initiation NN O O
site NN O O
of NN O O
Dp260 NN O O
. NN O O

Our NN O O
results NN O O
suggest NN O O
that NN O O
the NN O O
most NN O O
important NN O O
determinant NN O O
in NN O O
the NN O O
ERG NN O O
b NN O O
- NN O O
wave NN O O
phenotype NN O O
is NN O O
the NN O O
mutation NN O O
position NN O O
, NN O O
rather NN O O
than NN O O
muscle NN O B-Disease
disease NN O I-Disease
severity NN O O
. NN O O

Forty NN O O
- NN O O
six NN O O
per NN O O
cent NN O O
of NN O O
patients NN O O
with NN O O
mutations NN O O
5 NN O O
of NN O O
the NN O O
Dp260 NN O O
transcript NN O O
start NN O O
site NN O O
have NN O O
abnormal NN O O
ERGs NN O O
, NN O O
as NN O O
opposed NN O O
to NN O O
94 NN O O
% NN O O
with NN O O
more NN O O
distal NN O O
mutations NN O O
. NN O O

The NN O O
human NN O O
genotype NN O O
- NN O O
phenotype NN O O
correlations NN O O
are NN O O
consistent NN O O
with NN O O
a NN O O
role NN O O
for NN O O
Dp260 NN O O
in NN O O
normal NN O O
retinal NN O O
electrophysiology NN O O
and NN O O
may NN O O
also NN O O
reflect NN O O
the NN O O
expression NN O O
of NN O O
other NN O O
C NN O O
- NN O O
terminal NN O O
dystrophin NN O O
isoforms NN O O
and NN O O
their NN O O
contributions NN O O
to NN O O
retinal NN O O
signal NN O O
transmission NN O O
. NN O O
. NN O O

Cis NN O O
and NN O O
trans NN O O
effects NN O O
of NN O O
the NN O O
myotonic NN O B-Disease
dystrophy NN O I-Disease
( NN O O
DM NN O B-Disease
) NN O O
mutation NN O O
in NN O O
a NN O O
cell NN O O
culture NN O O
model NN O O
. NN O O

The NN O O
mutation NN O O
causing NN O O
myotonic NN O B-Disease
dystrophy NN O I-Disease
( NN O O
DM NN O B-Disease
) NN O O
has NN O O
been NN O O
identified NN O O
as NN O O
a NN O O
CTG NN O O
expansion NN O O
in NN O O
the NN O O
3 NN O O
- NN O O
untranslated NN O O
region NN O O
( NN O O
3 NN O O
- NN O O
UTR NN O O
) NN O O
of NN O O
the NN O O
DM NN O B-Disease
protein NN O O
kinase NN O O
gene NN O O
( NN O O
DMPK NN O O
) NN O O
, NN O O
but NN O O
the NN O O
mechanism NN O O
( NN O O
s NN O O
) NN O O
of NN O O
pathogenesis NN O O
remain NN O O
unknown NN O O
. NN O O

Studies NN O O
using NN O O
DM NN O B-Disease
patient NN O O
materials NN O O
have NN O O
often NN O O
produced NN O O
confusing NN O O
results NN O O
. NN O O

Therefore NN O O
, NN O O
to NN O O
study NN O O
the NN O O
effects NN O O
of NN O O
the NN O O
DM NN O B-Disease
mutation NN O O
in NN O O
a NN O O
controlled NN O O
environment NN O O
, NN O O
we NN O O
have NN O O
established NN O O
a NN O O
cell NN O O
culture NN O O
model NN O O
system NN O O
using NN O O
C2C12 NN O O
mouse NN O O
myoblasts NN O O
. NN O O

By NN O O
expressing NN O O
chimeric NN O O
reporter NN O O
constructs NN O O
containing NN O O
a NN O O
reporter NN O O
gene NN O O
fused NN O O
to NN O O
a NN O O
human NN O O
DMPK NN O O
3 NN O O
- NN O O
UTR NN O O
, NN O O
we NN O O
identified NN O O
both NN O O
cis NN O O
and NN O O
trans NN O O
effects NN O O
that NN O O
are NN O O
mediated NN O O
by NN O O
the NN O O
DM NN O B-Disease
mutation NN O O
. NN O O

Our NN O O
data NN O O
show NN O O
that NN O O
a NN O O
mutant NN O O
DMPK NN O O
3 NN O O
- NN O O
UTR NN O O
, NN O O
with NN O O
as NN O O
few NN O O
as NN O O
57 NN O O
CTGs NN O O
, NN O O
had NN O O
a NN O O
negative NN O O
cis NN O O
effect NN O O
on NN O O
protein NN O O
expression NN O O
and NN O O
resulted NN O O
in NN O O
the NN O O
aggregation NN O O
of NN O O
reporter NN O O
transcripts NN O O
into NN O O
discrete NN O O
nuclear NN O O
foci NN O O
. NN O O

We NN O O
determined NN O O
by NN O O
deletion NN O O
analysis NN O O
that NN O O
an NN O O
expanded NN O O
( NN O O
CTG NN O O
) NN O O
( NN O O
n NN O O
) NN O O
tract NN O O
alone NN O O
was NN O O
sufficient NN O O
to NN O O
mediate NN O O
these NN O O
cis NN O O
effects NN O O
. NN O O

Furthermore NN O O
, NN O O
in NN O O
contrast NN O O
to NN O O
the NN O O
normal NN O O
DMPK NN O O
3 NN O O
- NN O O
UTR NN O O
mRNA NN O O
, NN O O
a NN O O
mutant NN O O
DMPK NN O O
3 NN O O
- NN O O
UTR NN O O
mRNA NN O O
with NN O O
( NN O O
CUG NN O O
) NN O O
( NN O O
200 NN O O
) NN O O
selectively NN O O
inhibited NN O O
myogenic NN O O
differentiation NN O O
of NN O O
C2C12 NN O O
myoblasts NN O O
. NN O O

Genetic NN O O
analysis NN O O
and NN O O
the NN O O
Cre NN O O
- NN O O
loxP NN O O
system NN O O
were NN O O
used NN O O
to NN O O
clearly NN O O
demonstrate NN O O
that NN O O
the NN O O
myoblast NN O O
fusion NN O O
defect NN O O
could NN O O
be NN O O
rescued NN O O
by NN O O
eliminating NN O O
the NN O O
expression NN O O
of NN O O
the NN O O
mutant NN O O
DMPK NN O O
3 NN O O
- NN O O
UTR NN O O
transcript NN O O
. NN O O

Characterization NN O O
of NN O O
spontaneous NN O O
deletion NN O O
events NN O O
mapped NN O O
the NN O O
inhibitory NN O O
effect NN O O
to NN O O
the NN O O
( NN O O
CTG NN O O
) NN O O
( NN O O
n NN O O
) NN O O
expansion NN O O
and NN O O
/ NN O O
or NN O O
the NN O O
3 NN O O
end NN O O
of NN O O
the NN O O
DMPK NN O O
3 NN O O
- NN O O
UTR NN O O
. NN O O

These NN O O
results NN O O
provide NN O O
evidence NN O O
that NN O O
the NN O O
DM NN O B-Disease
mutation NN O O
acts NN O O
in NN O O
cis NN O O
to NN O O
reduce NN O O
protein NN O O
production NN O O
( NN O O
consistent NN O O
with NN O O
DMPK NN O B-Disease
haploinsufficiency NN O I-Disease
) NN O O
and NN O O
in NN O O
trans NN O O
as NN O O
a NN O O
riboregulator NN O O
to NN O O
inhibit NN O O
myogenesis NN O O
. NN O O
. NN O O

Coats NN O B-Disease
' NN O I-Disease
disease NN O I-Disease
of NN O O
the NN O O
retina NN O O
( NN O O
unilateral NN O B-Disease
retinal NN O I-Disease
telangiectasis NN O I-Disease
) NN O O
caused NN O O
by NN O O
somatic NN O O
mutation NN O O
in NN O O
the NN O O
NDP NN O O
gene NN O O
: NN O O
a NN O O
role NN O O
for NN O O
norrin NN O O
in NN O O
retinal NN O O
angiogenesis NN O O
. NN O O

Coats NN O B-Disease
disease NN O I-Disease
is NN O O
characterized NN O O
by NN O O
abnormal NN O B-Disease
retinal NN O I-Disease
vascular NN O I-Disease
development NN O I-Disease
( NN O O
so NN O O
- NN O O
called NN O O
retinal NN O B-Disease
telangiectasis NN O I-Disease
) NN O O
which NN O O
results NN O O
in NN O O
massive NN O O
intraretinal NN O B-Disease
and NN O I-Disease
subretinal NN O I-Disease
lipid NN O I-Disease
accumulation NN O I-Disease
( NN O O
exudative NN O B-Disease
retinal NN O I-Disease
detachment NN O I-Disease
) NN O O
. NN O O

The NN O O
classical NN O O
form NN O O
of NN O O
Coats NN O B-Disease
disease NN O I-Disease
is NN O O
almost NN O O
invariably NN O O
isolated NN O O
, NN O O
unilateral NN O O
and NN O O
seen NN O O
in NN O O
males NN O O
. NN O O

A NN O O
female NN O O
with NN O O
a NN O O
unilateral NN O O
variant NN O O
of NN O O
Coats NN O B-Disease
disease NN O I-Disease
gave NN O O
birth NN O O
to NN O O
a NN O O
son NN O O
affected NN O O
by NN O O
Norrie NN O B-Disease
disease NN O I-Disease
. NN O O

Both NN O O
carried NN O O
a NN O O
missense NN O O
mutation NN O O
within NN O O
the NN O O
NDP NN O O
gene NN O O
on NN O O
chromosome NN O O
Xp11 NN O O
. NN O O

2 NN O O
2 NN O O
. NN O O

Subsequently NN O O
analysis NN O O
of NN O O
the NN O O
retinas NN O O
of NN O O
nine NN O O
enucleated NN O O
eyes NN O O
from NN O O
males NN O O
with NN O O
Coats NN O B-Disease
disease NN O I-Disease
demonstrated NN O O
in NN O O
one NN O O
a NN O O
somatic NN O O
mutation NN O O
in NN O O
the NN O O
NDP NN O O
gene NN O O
which NN O O
was NN O O
not NN O O
present NN O O
within NN O O
non NN O O
- NN O O
retinal NN O O
tissue NN O O
. NN O O

We NN O O
suggest NN O O
that NN O O
Coats NN O B-Disease
telangiectasis NN O I-Disease
is NN O O
secondary NN O O
to NN O O
somatic NN O O
mutation NN O O
in NN O O
the NN O O
NDP NN O O
gene NN O O
which NN O O
results NN O O
in NN O O
a NN O O
deficiency NN O B-Disease
of NN O I-Disease
norrin NN O I-Disease
( NN O O
the NN O O
protein NN O O
product NN O O
of NN O O
the NN O O
NDP NN O O
gene NN O O
) NN O O
within NN O O
the NN O O
developing NN O O
retina NN O O
. NN O O

This NN O O
supports NN O O
recent NN O O
observations NN O O
that NN O O
the NN O O
protein NN O O
is NN O O
critical NN O O
for NN O O
normal NN O O
retinal NN O O
vasculogenesis NN O O
. NN O O

Hereditary NN O O
TP53 NN O O
codon NN O O
292 NN O O
and NN O O
somatic NN O O
P16INK4A NN O O
codon NN O O
94 NN O O
mutations NN O O
in NN O O
a NN O O
Li NN O B-Disease
- NN O I-Disease
Fraumeni NN O I-Disease
syndrome NN O I-Disease
family NN O O
. NN O O

Li NN O B-Disease
- NN O I-Disease
Fraumeni NN O I-Disease
syndrome NN O I-Disease
is NN O O
an NN O O
autosomal NN O B-Disease
dominant NN O I-Disease
disorder NN O I-Disease
that NN O O
is NN O O
characterized NN O O
by NN O O
various NN O O
types NN O O
of NN O O
cancer NN O B-Disease
in NN O O
childhood NN O O
and NN O O
adult NN O O
cases NN O O
. NN O O

Although NN O O
hereditary NN O O
TP53 NN O O
mutation NN O O
is NN O O
very NN O O
rare NN O O
in NN O O
different NN O O
human NN O O
cancers NN O B-Disease
, NN O O
it NN O O
has NN O O
been NN O O
frequently NN O O
reported NN O O
in NN O O
Li NN O B-Disease
- NN O I-Disease
Fraumeni NN O I-Disease
syndrome NN O I-Disease
. NN O O

On NN O O
the NN O O
other NN O O
hand NN O O
, NN O O
hereditary NN O O
mutations NN O O
of NN O O
TP57KIP2 NN O O
, NN O O
P15INK4B NN O O
, NN O O
and NN O O
P16INK4A NN O O
, NN O O
which NN O O
affect NN O O
the NN O O
cell NN O O
cycle NN O O
similar NN O O
to NN O O
TP53 NN O O
, NN O O
were NN O O
observed NN O O
in NN O O
some NN O O
types NN O O
of NN O O
cancer NN O B-Disease
. NN O O

In NN O O
a NN O O
Turkish NN O O
family NN O O
with NN O O
the NN O O
diagnosis NN O O
of NN O O
Li NN O B-Disease
- NN O I-Disease
Fraumeni NN O I-Disease
syndrome NN O I-Disease
, NN O O
we NN O O
analyzed NN O O
the NN O O
mutation NN O O
pattern NN O O
of NN O O
TP53 NN O O
, NN O O
P57KIP2 NN O O
, NN O O
P15INK4B NN O O
, NN O O
and NN O O
P16INK4A NN O O
in NN O O
the NN O O
peripheral NN O O
blood NN O O
, NN O O
and NN O O
loss NN O O
of NN O O
heterozygosity NN O O
( NN O O
homo NN O O
/ NN O O
hemizygous NN O O
deletion NN O O
) NN O O
pattern NN O O
of NN O O
TP53 NN O O
and NN O O
P15INK4B NN O O
/ NN O O
P16INK4A NN O O
in NN O O
two NN O O
tumor NN O B-Disease
tissues NN O O
. NN O O

The NN O O
propositus NN O O
had NN O O
a NN O O
seminoma NN O B-Disease
, NN O O
his NN O O
daughter NN O O
a NN O O
medulloblastoma NN O B-Disease
, NN O O
and NN O O
one NN O O
of NN O O
his NN O O
healthy NN O O
cousins NN O O
, NN O O
a NN O O
TP53 NN O O
codon NN O O
292 NN O O
missense NN O O
point NN O O
mutation NN O O
( NN O O
AAA NN O O
- NN O O
- NN O O
> NN O O
ATA NN O O
; NN O O
Lys NN O O
- NN O O
- NN O O
> NN O O
Ile NN O O
) NN O O
in NN O O
the NN O O
peripheral NN O O
blood NN O O
cells NN O O
. NN O O

Tumor NN O O
tissue NN O O
obtained NN O O
from NN O O
the NN O O
propositus NN O O
with NN O O
the NN O O
seminoma NN O B-Disease
revealed NN O O
loss NN O O
of NN O O
heterozygosity NN O O
in NN O O
the NN O O
TP53 NN O O
gene NN O O
. NN O O

In NN O O
the NN O O
analyses NN O O
of NN O O
tumor NN O B-Disease
tissues NN O O
from NN O O
the NN O O
propositus NN O O
and NN O O
his NN O O
daughter NN O O
, NN O O
a NN O O
P16INK4A NN O O
codon NN O O
94 NN O O
missense NN O O
point NN O O
mutation NN O O
( NN O O
GCG NN O O
- NN O O
- NN O O
> NN O O
GAG NN O O
; NN O O
Ala NN O O
- NN O O
- NN O O
> NN O O
Glu NN O O
) NN O O
was NN O O
observed NN O O
with NN O O
the NN O O
hereditary NN O O
TP53 NN O O
mutation NN O O
. NN O O

P16INK4A NN O O
codon NN O O
94 NN O O
mutation NN O O
observed NN O O
in NN O O
our NN O O
family NN O O
is NN O O
a NN O O
novel NN O O
mutation NN O O
in NN O O
Li NN O B-Disease
- NN O I-Disease
Fraumeni NN O I-Disease
syndrome NN O I-Disease
. NN O O

No NN O O
other NN O O
gene NN O O
alteration NN O O
in NN O O
TP53 NN O O
, NN O O
P57KIP2 NN O O
, NN O O
P15INK4B NN O O
, NN O O
and NN O O
P16INK4A NN O O
was NN O O
observed NN O O
. NN O O

Existence NN O O
of NN O O
the NN O O
P16INK4A NN O O
mutation NN O O
and NN O O
the NN O O
hereditary NN O O
TP53 NN O O
mutation NN O O
with NN O O
or NN O O
without NN O O
loss NN O O
of NN O O
heterozygosity NN O O
in NN O O
the NN O O
TP53 NN O O
gene NN O O
( NN O O
seminoma NN O B-Disease
/ NN O O
medulloblastoma NN O B-Disease
) NN O O
may NN O O
be NN O O
evidence NN O O
for NN O O
a NN O O
common NN O O
mechanism NN O O
involved NN O O
in NN O O
tumorogenesis NN O B-Disease
. NN O O

The NN O O
gene NN O O
alterations NN O O
in NN O O
TP53 NN O O
and NN O O
P16INK4A NN O O
genes NN O O
may NN O O
be NN O O
used NN O O
as NN O O
tumor NN O B-Disease
markers NN O O
in NN O O
our NN O O
family NN O O
. NN O O
. NN O O

A NN O O
novel NN O O
mutation NN O O
in NN O O
the NN O O
sodium NN O O
/ NN O O
iodide NN O O
symporter NN O O
gene NN O O
in NN O O
the NN O O
largest NN O O
family NN O O
with NN O O
iodide NN O B-Disease
transport NN O I-Disease
defect NN O I-Disease
. NN O O

We NN O O
previously NN O O
reported NN O O
nine NN O O
children NN O O
with NN O O
an NN O O
autosomally NN O O
recessive NN O O
form NN O O
of NN O O
congenital NN O B-Disease
hypothyroidism NN O I-Disease
due NN O O
to NN O O
an NN O O
iodide NN O B-Disease
transport NN O I-Disease
defect NN O I-Disease
in NN O O
a NN O O
large NN O O
Hutterite NN O O
family NN O O
with NN O O
extensive NN O O
consanguinity NN O O
living NN O O
in NN O O
central NN O O
Canada NN O O
. NN O O

Since NN O O
the NN O O
original NN O O
report NN O O
, NN O O
we NN O O
have NN O O
diagnosed NN O O
congenital NN O B-Disease
hypothyroidism NN O I-Disease
by NN O O
newborn NN O O
TSH NN O O
screening NN O O
in NN O O
9 NN O O
additional NN O O
children NN O O
from NN O O
the NN O O
family NN O O
. NN O O

We NN O O
performed NN O O
direct NN O O
sequencing NN O O
of NN O O
the NN O O
PCR NN O O
products NN O O
of NN O O
each NN O O
NIS NN O O
( NN O O
sodium NN O O
/ NN O O
iodide NN O O
symporter NN O O
) NN O O
gene NN O O
exon NN O O
with NN O O
flanking NN O O
introns NN O O
amplified NN O O
from NN O O
genomic NN O O
DNA NN O O
extracted NN O O
from NN O O
peripheral NN O O
blood NN O O
cells NN O O
of NN O O
the NN O O
patients NN O O
. NN O O

We NN O O
identified NN O O
a NN O O
novel NN O O
NIS NN O O
gene NN O O
mutation NN O O
, NN O O
G395R NN O O
( NN O O
Gly395 NN O O
- NN O O
- NN O O
> NN O O
Arg NN O O
; NN O O
GGA NN O O
- NN O O
- NN O O
> NN O O
AGA NN O O
) NN O O
, NN O O
in NN O O
10 NN O O
patients NN O O
examined NN O O
in NN O O
the NN O O
present NN O O
study NN O O
. NN O O

All NN O O
of NN O O
the NN O O
parents NN O O
tested NN O O
were NN O O
heterozygous NN O O
for NN O O
the NN O O
mutation NN O O
, NN O O
suggesting NN O O
that NN O O
the NN O O
patients NN O O
were NN O O
homozygous NN O O
. NN O O

The NN O O
mutation NN O O
was NN O O
located NN O O
in NN O O
the NN O O
10th NN O O
transmembrane NN O O
helix NN O O
. NN O O

Expression NN O O
experiments NN O O
by NN O O
transfection NN O O
of NN O O
the NN O O
mutant NN O O
NIS NN O O
complimentary NN O O
DNA NN O O
into NN O O
COS NN O O
- NN O O
7 NN O O
cells NN O O
showed NN O O
no NN O O
perchlorate NN O O
- NN O O
sensitive NN O O
iodide NN O O
uptake NN O O
, NN O O
confirming NN O O
that NN O O
the NN O O
mutation NN O O
is NN O O
the NN O O
direct NN O O
cause NN O O
of NN O O
the NN O O
iodide NN O B-Disease
transport NN O I-Disease
defect NN O I-Disease
in NN O O
these NN O O
patients NN O O
. NN O O

A NN O O
patient NN O O
who NN O O
showed NN O O
an NN O O
intermediate NN O O
saliva NN O O
/ NN O O
serum NN O O
technetium NN O O
ratio NN O O
( NN O O
14 NN O O
. NN O O
0 NN O O
; NN O O
normal NN O O
, NN O O
> NN O O
or NN O O
= NN O O
20 NN O O
) NN O O
and NN O O
was NN O O
considered NN O O
to NN O O
have NN O O
a NN O O
partial NN O O
or NN O O
less NN O O
severe NN O O
defect NN O O
in NN O O
the NN O O
previous NN O O
report NN O O
( NN O O
IX NN O O
- NN O O
24 NN O O
) NN O O
did NN O O
not NN O O
have NN O O
a NN O O
NIS NN O O
gene NN O O
mutation NN O O
. NN O O

It NN O O
is NN O O
now NN O O
possible NN O O
to NN O O
use NN O O
gene NN O O
diagnostics NN O O
of NN O O
this NN O O
unique NN O O
NIS NN O O
mutation NN O O
to NN O O
identify NN O O
patients NN O O
with NN O O
congenital NN O B-Disease
hypothyroidism NN O I-Disease
due NN O O
to NN O O
an NN O O
iodide NN O B-Disease
transport NN O I-Disease
defect NN O I-Disease
in NN O O
this NN O O
family NN O O
and NN O O
to NN O O
determine NN O O
the NN O O
carrier NN O O
state NN O O
of NN O O
potential NN O O
parents NN O O
for NN O O
genetic NN O O
counseling NN O O
and NN O O
arranging NN O O
rapid NN O O
and NN O O
early NN O O
diagnosis NN O O
of NN O O
their NN O O
infants NN O O
. NN O O

Molecular NN O O
analysis NN O O
in NN O O
familial NN O B-Disease
neurohypophyseal NN O I-Disease
diabetes NN O I-Disease
insipidus NN O I-Disease
: NN O O
early NN O O
diagnosis NN O O
of NN O O
an NN O O
asymptomatic NN O O
carrier NN O O
. NN O O

Familial NN O B-Disease
neurohypophyseal NN O I-Disease
diabetes NN O I-Disease
insipidus NN O I-Disease
( NN O O
FNDI NN O B-Disease
) NN O O
is NN O O
an NN O O
inherited NN O O
deficiency NN O B-Disease
of NN O I-Disease
the NN O I-Disease
hormone NN O I-Disease
arginine NN O I-Disease
vasopressin NN O I-Disease
( NN O O
AVP NN O O
) NN O O
and NN O O
is NN O O
transmitted NN O O
as NN O O
an NN O O
autosomal NN O O
dominant NN O O
trait NN O O
. NN O O

In NN O O
the NN O O
present NN O O
study NN O O
we NN O O
have NN O O
analyzed NN O O
the NN O O
AVP NN O O
- NN O O
neurophysin NN O O
II NN O O
( NN O O
AVP NN O O
- NN O O
NPII NN O O
) NN O O
gene NN O O
in NN O O
a NN O O
Spanish NN O O
kindred NN O O
. NN O O

Studies NN O O
were NN O O
performed NN O O
on NN O O
seven NN O O
members NN O O
( NN O O
four NN O O
clinically NN O O
affected NN O O
) NN O O
of NN O O
the NN O O
family NN O O
. NN O O

Patients NN O O
were NN O O
diagnosed NN O O
at NN O O
the NN O O
Hospital NN O O
Universitario NN O O
Gregorio NN O O
Maranon NN O O
( NN O O
Madrid NN O O
, NN O O
Spain NN O O
) NN O O
. NN O O

The NN O O
entire NN O O
coding NN O O
region NN O O
of NN O O
the NN O O
AVP NN O O
- NN O O
NPII NN O O
gene NN O O
of NN O O
all NN O O
family NN O O
members NN O O
was NN O O
amplified NN O O
by NN O O
PCR NN O O
and NN O O
sequenced NN O O
. NN O O

All NN O O
affected NN O O
individuals NN O O
presented NN O O
a NN O O
missense NN O O
mutation NN O O
( NN O O
G1757 NN O O
- NN O O
- NN O O
> NN O O
A NN O O
) NN O O
that NN O O
replaces NN O O
glycine NN O O
at NN O O
position NN O O
23 NN O O
with NN O O
arginine NN O O
within NN O O
the NN O O
NPII NN O O
domain NN O O
. NN O O

The NN O O
substitution NN O O
was NN O O
confirmed NN O O
by NN O O
restriction NN O O
endonuclease NN O O
analysis NN O O
and NN O O
was NN O O
present NN O O
in NN O O
heterozygosis NN O O
. NN O O

Additionally NN O O
, NN O O
one NN O O
of NN O O
the NN O O
asymptomatic NN O O
relatives NN O O
( NN O O
a NN O O
girl NN O O
8 NN O O
months NN O O
old NN O O
at NN O O
the NN O O
time NN O O
of NN O O
study NN O O
) NN O O
was NN O O
identified NN O O
as NN O O
carrier NN O O
of NN O O
the NN O O
same NN O O
mutation NN O O
and NN O O
developed NN O O
the NN O O
disease NN O O
3 NN O O
months NN O O
later NN O O
. NN O O

The NN O O
alteration NN O O
found NN O O
in NN O O
the NN O O
second NN O O
exon NN O O
of NN O O
the NN O O
gene NN O O
in NN O O
this NN O O
family NN O O
seems NN O O
to NN O O
be NN O O
responsible NN O O
for NN O O
the NN O O
disease NN O O
, NN O O
as NN O O
all NN O O
individuals NN O O
harboring NN O O
the NN O O
mutation NN O O
had NN O O
been NN O O
previously NN O O
diagnosed NN O O
or NN O O
have NN O O
eventually NN O O
developed NN O O
FNDI NN O B-Disease
. NN O O

Identification NN O O
of NN O O
the NN O O
molecular NN O O
defect NN O O
underlying NN O O
FNDI NN O B-Disease
in NN O O
affected NN O O
families NN O O
is NN O O
a NN O O
powerful NN O O
tool NN O O
for NN O O
early NN O O
asymptomatic NN O O
diagnosis NN O O
in NN O O
infants NN O O
. NN O O
. NN O O

Deficit NN O O
of NN O O
in NN O O
vivo NN O O
mitochondrial NN O O
ATP NN O O
production NN O O
in NN O O
patients NN O O
with NN O O
Friedreich NN O B-Disease
ataxia NN O I-Disease
. NN O O

Friedreich NN O B-Disease
ataxia NN O I-Disease
( NN O O
FRDA NN O B-Disease
) NN O O
, NN O O
the NN O O
most NN O O
common NN O O
of NN O O
the NN O O
inherited NN O B-Disease
ataxias NN O I-Disease
, NN O O
is NN O O
an NN O O
autosomal NN O B-Disease
recessive NN O I-Disease
degenerative NN O I-Disease
disorder NN O I-Disease
, NN O O
characterized NN O O
clinically NN O O
by NN O O
onset NN O O
before NN O O
the NN O O
age NN O O
of NN O O
25 NN O O
of NN O O
progressive NN O B-Disease
gait NN O I-Disease
and NN O I-Disease
limb NN O I-Disease
ataxia NN O I-Disease
, NN O O
absence NN O B-Disease
of NN O I-Disease
deep NN O I-Disease
tendon NN O I-Disease
reflexes NN O I-Disease
, NN O O
extensor NN O B-Disease
plantar NN O I-Disease
responses NN O I-Disease
, NN O O
and NN O O
loss NN O B-Disease
of NN O I-Disease
position NN O I-Disease
and NN O I-Disease
vibration NN O I-Disease
sense NN O I-Disease
in NN O O
the NN O O
lower NN O O
limbs NN O O
. NN O O

FRDA NN O B-Disease
is NN O O
caused NN O O
by NN O O
a NN O O
GAA NN O O
triplet NN O O
expansion NN O O
in NN O O
the NN O O
first NN O O
intron NN O O
of NN O O
the NN O O
FRDA NN O B-Disease
gene NN O O
on NN O O
chromosome NN O O
9q13 NN O O
in NN O O
97 NN O O
% NN O O
of NN O O
patients NN O O
. NN O O

The NN O O
FRDA NN O B-Disease
gene NN O O
encodes NN O O
a NN O O
widely NN O O
expressed NN O O
210 NN O O
- NN O O
aa NN O O
protein NN O O
, NN O O
frataxin NN O O
, NN O O
which NN O O
is NN O O
located NN O O
in NN O O
mitochondria NN O O
and NN O O
is NN O O
severely NN O O
reduced NN O O
in NN O O
FRDA NN O B-Disease
patients NN O O
. NN O O

Frataxin NN O O
function NN O O
is NN O O
still NN O O
unknown NN O O
but NN O O
the NN O O
knockout NN O O
of NN O O
the NN O O
yeast NN O O
frataxin NN O O
homologue NN O O
gene NN O O
( NN O O
YFH1 NN O O
) NN O O
showed NN O O
a NN O O
severe NN O O
defect NN O O
of NN O O
mitochondrial NN O O
respiration NN O O
and NN O O
loss NN O O
of NN O O
mtDNA NN O O
associated NN O O
with NN O O
elevated NN O O
intramitochondrial NN O O
iron NN O O
. NN O O

Here NN O O
we NN O O
report NN O O
in NN O O
vivo NN O O
evidence NN O O
of NN O O
impaired NN O O
mitochondrial NN O O
respiration NN O O
in NN O O
skeletal NN O O
muscle NN O O
of NN O O
FRDA NN O B-Disease
patients NN O O
. NN O O

Using NN O O
phosphorus NN O O
magnetic NN O O
resonance NN O O
spectroscopy NN O O
we NN O O
demonstrated NN O O
a NN O O
maximum NN O O
rate NN O O
of NN O O
muscle NN O O
mitochondrial NN O O
ATP NN O O
production NN O O
( NN O O
V NN O O
( NN O O
max NN O O
) NN O O
) NN O O
below NN O O
the NN O O
normal NN O O
range NN O O
in NN O O
all NN O O
12 NN O O
FRDA NN O B-Disease
patients NN O O
and NN O O
a NN O O
strong NN O O
negative NN O O
correlation NN O O
between NN O O
mitochondrial NN O O
V NN O O
( NN O O
max NN O O
) NN O O
and NN O O
the NN O O
number NN O O
of NN O O
GAA NN O O
repeats NN O O
in NN O O
the NN O O
smaller NN O O
allele NN O O
. NN O O

Our NN O O
results NN O O
show NN O O
that NN O O
FRDA NN O B-Disease
is NN O O
a NN O O
nuclear NN O O
- NN O O
encoded NN O O
mitochondrial NN O B-Disease
disorder NN O I-Disease
affecting NN O O
oxidative NN O O
phosphorylation NN O O
and NN O O
give NN O O
a NN O O
rationale NN O O
for NN O O
treatments NN O O
aimed NN O O
to NN O O
improve NN O O
mitochondrial NN O O
function NN O O
in NN O O
this NN O O
condition NN O O
. NN O O
. NN O O

Identification NN O O
of NN O O
a NN O O
novel NN O O
R21X NN O O
mutation NN O O
in NN O O
the NN O O
liver NN O O
- NN O O
type NN O O
arginase NN O O
gene NN O O
( NN O O
ARG1 NN O O
) NN O O
in NN O O
four NN O O
Portuguese NN O O
patients NN O O
with NN O O
argininemia NN O B-Disease
. NN O O

Argininemia NN O B-Disease
is NN O O
a NN O O
rare NN O O
autossomal NN O B-Disease
recessive NN O I-Disease
disorder NN O I-Disease
caused NN O O
by NN O O
deficiency NN O B-Disease
in NN O I-Disease
the NN O I-Disease
cytosolic NN O I-Disease
liver NN O I-Disease
- NN O I-Disease
type NN O I-Disease
arginase NN O I-Disease
enzyme NN O I-Disease
( NN O O
L NN O O
- NN O O
arginine NN O O
urea NN O O
- NN O O
hydrolase NN O O
; NN O O
E NN O O
. NN O O
C NN O O
. NN O O
3 NN O O
. NN O O
5 NN O O
. NN O O
3 NN O O
. NN O O
1 NN O O
) NN O O
. NN O O

In NN O O
order NN O O
to NN O O
investigate NN O O
the NN O O
molecular NN O O
basis NN O O
for NN O O
argininemia NN O B-Disease
in NN O O
four NN O O
unrelated NN O O
Portuguese NN O O
patients NN O O
( NN O O
two NN O O
from NN O O
northern NN O O
Portugal NN O O
and NN O O
two NN O O
from NN O O
Madeira NN O O
Island NN O O
) NN O O
we NN O O
performed NN O O
a NN O O
DNA NN O O
sequence NN O O
analysis NN O O
of NN O O
all NN O O
the NN O O
exons NN O O
and NN O O
exon NN O O
/ NN O O
intron NN O O
boundaries NN O O
of NN O O
the NN O O
liver NN O O
- NN O O
type NN O O
arginase NN O O
gene NN O O
( NN O O
ARG1 NN O O
) NN O O
. NN O O

All NN O O
patients NN O O
were NN O O
found NN O O
to NN O O
be NN O O
homozygous NN O O
for NN O O
a NN O O
newly NN O O
identified NN O O
C NN O O
- NN O O
> NN O O
T NN O O
transition NN O O
in NN O O
codon NN O O
21 NN O O
( NN O O
exon NN O O
2 NN O O
) NN O O
substituting NN O O
arginine NN O O
for NN O O
a NN O O
premature NN O O
stop NN O O
codon NN O O
( NN O O
R21X NN O O
CGA NN O O
to NN O O
TGA NN O O
) NN O O
and NN O O
generating NN O O
a NN O O
NlaIII NN O O
restriction NN O O
site NN O O
. NN O O

Restriction NN O O
digestion NN O O
following NN O O
PCR NN O O
amplification NN O O
of NN O O
ARG1 NN O O
exon NN O O
2 NN O O
confirmed NN O O
the NN O O
presence NN O O
of NN O O
the NN O O
mutation NN O O
. NN O O

Mutation NN O O
of NN O O
the NN O O
sterol NN O O
27 NN O O
- NN O O
hydroxylase NN O O
gene NN O O
( NN O O
CYP27 NN O O
) NN O O
results NN O O
in NN O O
truncation NN O O
of NN O O
mRNA NN O O
expressed NN O O
in NN O O
leucocytes NN O O
in NN O O
a NN O O
Japanese NN O O
family NN O O
with NN O O
cerebrotendinous NN O B-Disease
xanthomatosis NN O I-Disease
. NN O O

OBJECTIVES NN O O
A NN O O
Japanese NN O O
family NN O O
with NN O O
cerebrotendinous NN O B-Disease
xanthomatosis NN O I-Disease
( NN O O
CTX NN O B-Disease
) NN O O
was NN O O
investigated NN O O
for NN O O
a NN O O
sequence NN O O
alteration NN O O
in NN O O
the NN O O
sterol NN O O
27 NN O O
- NN O O
hydroxylase NN O O
gene NN O O
( NN O O
CYP27 NN O O
) NN O O
. NN O O

The NN O O
expression NN O O
of NN O O
CYP27 NN O O
has NN O O
been NN O O
mostly NN O O
explored NN O O
using NN O O
cultured NN O O
fibroblasts NN O O
, NN O O
prompting NN O O
the NN O O
examination NN O O
of NN O O
the NN O O
transcripts NN O O
from NN O O
blood NN O O
leucocytes NN O O
as NN O O
a NN O O
simple NN O O
and NN O O
rapid NN O O
technique NN O O
. NN O O

METHODS NN O O
An NN O O
alteration NN O O
in NN O O
CYP27 NN O O
of NN O O
the NN O O
proband NN O O
was NN O O
searched NN O O
for NN O O
by NN O O
polymerase NN O O
chain NN O O
reaction NN O O
- NN O O
single NN O O
strand NN O O
conformation NN O O
polymorphism NN O O
( NN O O
PCR NN O O
- NN O O
SSCP NN O O
) NN O O
analysis NN O O
and NN O O
subsequent NN O O
sequencing NN O O
. NN O O

Samples NN O O
of NN O O
RNA NN O O
were NN O O
subjected NN O O
to NN O O
reverse NN O O
transcription NN O O
PCR NN O O
( NN O O
RT NN O O
- NN O O
PCR NN O O
) NN O O
and NN O O
the NN O O
product NN O O
of NN O O
the NN O O
proband NN O O
was NN O O
amplified NN O O
with NN O O
nested NN O O
primers NN O O
and NN O O
sequenced NN O O
. NN O O

RESULTS NN O O
A NN O O
homozygous NN O O
G NN O O
to NN O O
A NN O O
transition NN O O
at NN O O
the NN O O
5 NN O O
end NN O O
of NN O O
intron NN O O
7 NN O O
was NN O O
detected NN O O
in NN O O
the NN O O
patient NN O O
. NN O O

In NN O O
RT NN O O
- NN O O
PCR NN O O
analysis NN O O
, NN O O
only NN O O
a NN O O
truncated NN O O
transcript NN O O
was NN O O
detected NN O O
in NN O O
the NN O O
patient NN O O
, NN O O
whereas NN O O
both NN O O
normal NN O O
and NN O O
truncated NN O O
transcripts NN O O
were NN O O
detected NN O O
in NN O O
the NN O O
siblings NN O O
. NN O O

The NN O O
sequencing NN O O
of NN O O
the NN O O
patients NN O O
cDNA NN O O
fragment NN O O
disclosed NN O O
a NN O O
direct NN O O
conjuction NN O O
of NN O O
exon NN O O
6 NN O O
and NN O O
exon NN O O
8 NN O O
. NN O O

CONCLUSION NN O O
The NN O O
mutation NN O O
at NN O O
splice NN O O
donor NN O O
site NN O O
and NN O O
the NN O O
truncation NN O O
of NN O O
mRNA NN O O
were NN O O
identical NN O O
with NN O O
those NN O O
of NN O O
a NN O O
recently NN O O
reported NN O O
Italian NN O O
patient NN O O
, NN O O
although NN O O
different NN O O
in NN O O
symptomatology NN O O
. NN O O

The NN O O
application NN O O
of NN O O
blood NN O O
leucocytes NN O O
can NN O O
be NN O O
a NN O O
simple NN O O
technique NN O O
on NN O O
analysing NN O O
a NN O O
constructive NN O O
abnormality NN O B-Disease
of NN O I-Disease
CYP27 NN O I-Disease
mRNA NN O O
. NN O O
. NN O O

Clinical NN O O
and NN O O
molecular NN O O
genetic NN O O
analysis NN O O
of NN O O
19 NN O O
Wolfram NN O B-Disease
syndrome NN O I-Disease
kindreds NN O O
demonstrating NN O O
a NN O O
wide NN O O
spectrum NN O O
of NN O O
mutations NN O O
in NN O O
WFS1 NN O O
. NN O O

Wolfram NN O B-Disease
syndrome NN O I-Disease
is NN O O
an NN O O
autosomal NN O B-Disease
recessive NN O I-Disease
neurodegenerative NN O I-Disease
disorder NN O I-Disease
characterized NN O O
by NN O O
juvenile NN O B-Disease
- NN O I-Disease
onset NN O I-Disease
diabetes NN O I-Disease
mellitus NN O I-Disease
and NN O O
progressive NN O O
optic NN O B-Disease
atrophy NN O I-Disease
. NN O O

mtDNA NN O O
deletions NN O O
have NN O O
been NN O O
described NN O O
, NN O O
and NN O O
a NN O O
gene NN O O
( NN O O
WFS1 NN O O
) NN O O
recently NN O O
has NN O O
been NN O O
identified NN O O
, NN O O
on NN O O
chromosome NN O O
4p16 NN O O
, NN O O
encoding NN O O
a NN O O
predicted NN O O
890 NN O O
amino NN O O
acid NN O O
transmembrane NN O O
protein NN O O
. NN O O

Direct NN O O
DNA NN O O
sequencing NN O O
was NN O O
done NN O O
to NN O O
screen NN O O
the NN O O
entire NN O O
coding NN O O
region NN O O
of NN O O
the NN O O
WFS1 NN O O
gene NN O O
in NN O O
30 NN O O
patients NN O O
from NN O O
19 NN O O
British NN O O
kindreds NN O O
with NN O O
Wolfram NN O B-Disease
syndrome NN O I-Disease
. NN O O

DNA NN O O
was NN O O
also NN O O
screened NN O O
for NN O O
structural NN O O
rearrangements NN O O
( NN O O
deletions NN O O
and NN O O
duplications NN O O
) NN O O
and NN O O
point NN O O
mutations NN O O
in NN O O
mtDNA NN O O
. NN O O

No NN O O
pathogenic NN O O
mtDNA NN O O
mutations NN O O
were NN O O
found NN O O
in NN O O
our NN O O
cohort NN O O
. NN O O

We NN O O
identified NN O O
24 NN O O
mutations NN O O
in NN O O
the NN O O
WFS1 NN O O
gene NN O O
8 NN O O
nonsense NN O O
mutations NN O O
, NN O O
8 NN O O
missense NN O O
mutations NN O O
, NN O O
3 NN O O
in NN O O
- NN O O
frame NN O O
deletions NN O O
, NN O O
1 NN O O
in NN O O
- NN O O
frame NN O O
insertion NN O O
, NN O O
and NN O O
4 NN O O
frameshift NN O O
mutations NN O O
. NN O O

Of NN O O
these NN O O
, NN O O
23 NN O O
were NN O O
novel NN O O
mutations NN O O
, NN O O
and NN O O
most NN O O
occurred NN O O
in NN O O
exon NN O O
8 NN O O
. NN O O

The NN O O
majority NN O O
of NN O O
patients NN O O
were NN O O
compound NN O O
heterozygotes NN O O
for NN O O
two NN O O
mutations NN O O
, NN O O
and NN O O
there NN O O
was NN O O
no NN O O
common NN O O
founder NN O O
mutation NN O O
. NN O O

The NN O O
data NN O O
were NN O O
also NN O O
analyzed NN O O
for NN O O
genotype NN O O
- NN O O
phenotype NN O O
relationships NN O O
. NN O O

Although NN O O
some NN O O
interesting NN O O
cases NN O O
were NN O O
noted NN O O
, NN O O
consideration NN O O
of NN O O
the NN O O
small NN O O
sample NN O O
size NN O O
and NN O O
frequency NN O O
of NN O O
each NN O O
mutation NN O O
indicated NN O O
no NN O O
clear NN O O
- NN O O
cut NN O O
correlations NN O O
between NN O O
any NN O O
of NN O O
the NN O O
observed NN O O
mutations NN O O
and NN O O
disease NN O O
severity NN O O
. NN O O

There NN O O
were NN O O
no NN O O
obvious NN O O
mutation NN O O
hot NN O O
spots NN O O
or NN O O
clusters NN O O
. NN O O

Hence NN O O
, NN O O
molecular NN O O
screening NN O O
for NN O O
Wolfram NN O B-Disease
syndrome NN O I-Disease
in NN O O
affected NN O O
families NN O O
and NN O O
for NN O O
Wolfram NN O B-Disease
syndrome NN O I-Disease
- NN O O
carrier NN O O
status NN O O
in NN O O
subjects NN O O
with NN O O
psychiatric NN O B-Disease
disorders NN O I-Disease
or NN O O
diabetes NN O B-Disease
mellitus NN O I-Disease
will NN O O
require NN O O
complete NN O O
analysis NN O O
of NN O O
exon NN O O
8 NN O O
and NN O O
upstream NN O O
exons NN O O
. NN O O
. NN O O

Late NN O O
- NN O O
onset NN O O
familial NN O B-Disease
Mediterranean NN O I-Disease
fever NN O I-Disease
( NN O O
FMF NN O B-Disease
) NN O O
: NN O O
a NN O O
subset NN O O
with NN O O
distinct NN O O
clinical NN O O
, NN O O
demographic NN O O
, NN O O
and NN O O
molecular NN O O
genetic NN O O
characteristics NN O O
. NN O O

To NN O O
determine NN O O
the NN O O
prevalence NN O O
and NN O O
characterize NN O O
demographic NN O O
, NN O O
clinical NN O O
, NN O O
and NN O O
genetic NN O O
features NN O O
of NN O O
familial NN O B-Disease
Mediterranean NN O I-Disease
fever NN O I-Disease
( NN O O
FMF NN O B-Disease
) NN O O
of NN O O
late NN O O
onset NN O O
, NN O O
all NN O O
patients NN O O
experiencing NN O O
their NN O O
first NN O O
FMF NN O B-Disease
attack NN O O
at NN O O
age NN O O
40 NN O O
years NN O O
or NN O O
more NN O O
were NN O O
identified NN O O
using NN O O
the NN O O
computerized NN O O
registry NN O O
of NN O O
our NN O O
FMF NN O B-Disease
clinic NN O O
, NN O O
and NN O O
then NN O O
thoroughly NN O O
interviewed NN O O
and NN O O
examined NN O O
. NN O O

The NN O O
control NN O O
group NN O O
consisted NN O O
of NN O O
40 NN O O
consecutive NN O O
FMF NN O B-Disease
patients NN O O
, NN O O
who NN O O
arrived NN O O
at NN O O
the NN O O
FMF NN O B-Disease
clinic NN O O
for NN O O
their NN O O
regular NN O O
follow NN O O
- NN O O
up NN O O
visit NN O O
and NN O O
were NN O O
40 NN O O
years NN O O
of NN O O
age NN O O
or NN O O
older NN O O
at NN O O
the NN O O
time NN O O
of NN O O
the NN O O
examination NN O O
. NN O O

The NN O O
severity NN O O
of NN O O
the NN O O
disease NN O O
in NN O O
patients NN O O
and NN O O
controls NN O O
was NN O O
determined NN O O
using NN O O
a NN O O
modified NN O O
score NN O O
, NN O O
developed NN O O
previously NN O O
. NN O O

Mutational NN O O
analysis NN O O
in NN O O
the NN O O
FMF NN O B-Disease
gene NN O O
was NN O O
performed NN O O
using NN O O
a NN O O
commercial NN O O
kit NN O O
. NN O O

Only NN O O
20 NN O O
of NN O O
4000 NN O O
( NN O O
0 NN O O
. NN O O
5 NN O O
% NN O O
) NN O O
patients NN O O
had NN O O
late NN O O
- NN O O
onset NN O O
FMF NN O B-Disease
. NN O O

These NN O O
patients NN O O
were NN O O
mostly NN O O
men NN O O
, NN O O
of NN O O
non NN O O
- NN O O
North NN O O
African NN O O
origin NN O O
, NN O O
P NN O O
< NN O O
0 NN O O
. NN O O

05 NN O O
compared NN O O
to NN O O
controls NN O O
. NN O O

All NN O O
had NN O O
abdominal NN O O
attacks NN O O
and NN O O
in NN O O
most NN O O
these NN O O
were NN O O
the NN O O
only NN O O
manifestation NN O O
of NN O O
their NN O O
disease NN O O
, NN O O
P NN O O
< NN O O
0 NN O O
. NN O O

001 NN O O
001 NN O O
. NN O O

None NN O O
had NN O O
chronic NN O O
or NN O O
prolonged NN O O
manifestations NN O O
of NN O O
FMF NN O B-Disease
, NN O O
for NN O O
example NN O O
, NN O O
amyloidosis NN O B-Disease
, NN O O
chronic NN O B-Disease
arthritis NN O I-Disease
, NN O O
or NN O O
protracted NN O O
myalgia NN O B-Disease
, NN O O
P NN O O
< NN O O
0 NN O O
. NN O O

001 NN O O
. NN O O

The NN O O
response NN O O
to NN O O
treatment NN O O
was NN O O
good NN O O
despite NN O O
using NN O O
low NN O O
colchicine NN O O
dose NN O O
, NN O O
P NN O O
< NN O O
0 NN O O
. NN O O

05 NN O O
. NN O O

The NN O O
overall NN O O
severity NN O O
score NN O O
indicated NN O O
a NN O O
mild NN O O
disease NN O O
, NN O O
P NN O O
< NN O O
0 NN O O
. NN O O

001 NN O O
. NN O O

Mutational NN O O
analysis NN O O
revealed NN O O
absence NN O O
of NN O O
M694V NN O O
homozygosity NN O O
, NN O O
P NN O O
< NN O O
0 NN O O
. NN O O

01 NN O O
, NN O O
compared NN O O
to NN O O
our NN O O
regular NN O O
FMF NN O B-Disease
population NN O O
. NN O O

We NN O O
conclude NN O O
that NN O O
the NN O O
onset NN O O
of NN O O
FMF NN O B-Disease
in NN O O
a NN O O
late NN O O
age NN O O
defines NN O O
a NN O O
milder NN O O
form NN O O
of NN O O
disease NN O O
with NN O O
typical NN O O
clinical NN O O
, NN O O
demographic NN O O
, NN O O
and NN O O
molecular NN O O
genetic NN O O
characteristics NN O O

A NN O O
highly NN O O
accurate NN O O
, NN O O
low NN O O
cost NN O O
test NN O O
for NN O O
BRCA1 NN O O
mutations NN O O
. NN O O

The NN O O
hereditary NN O B-Disease
breast NN O I-Disease
and NN O I-Disease
ovarian NN O I-Disease
cancer NN O I-Disease
syndrome NN O I-Disease
is NN O O
associated NN O O
with NN O O
a NN O O
high NN O O
frequency NN O O
of NN O O
BRCA1 NN O O
mutations NN O O
. NN O O

However NN O O
, NN O O
the NN O O
widespread NN O O
use NN O O
of NN O O
BRCA1 NN O O
testing NN O O
has NN O O
been NN O O
limited NN O O
to NN O O
date NN O O
by NN O O
three NN O O
principal NN O O
concerns NN O O
the NN O O
fear NN O O
of NN O O
loss NN O O
of NN O O
health NN O O
and NN O O
life NN O O
insurance NN O O
, NN O O
the NN O O
uncertain NN O O
clinical NN O O
value NN O O
of NN O O
a NN O O
positive NN O O
test NN O O
result NN O O
, NN O O
and NN O O
the NN O O
current NN O O
lack NN O O
of NN O O
an NN O O
inexpensive NN O O
and NN O O
sensitive NN O O
screening NN O O
test NN O O
for NN O O
BRCA1 NN O O
mutations NN O O
. NN O O

We NN O O
have NN O O
developed NN O O
an NN O O
inexpensive NN O O
system NN O O
for NN O O
gene NN O O
mutational NN O O
scanning NN O O
, NN O O
based NN O O
on NN O O
a NN O O
combination NN O O
of NN O O
extensive NN O O
multiplex NN O O
PCR NN O O
amplification NN O O
and NN O O
two NN O O
dimensional NN O O
electrophoresis NN O O
. NN O O

The NN O O
efficiency NN O O
of NN O O
this NN O O
system NN O O
, NN O O
as NN O O
a NN O O
screening NN O O
test NN O O
for NN O O
BRCA1 NN O O
mutations NN O O
, NN O O
was NN O O
evaluated NN O O
in NN O O
a NN O O
panel NN O O
of NN O O
60 NN O O
samples NN O O
from NN O O
high NN O O
risk NN O O
women NN O O
, NN O O
14 NN O O
of NN O O
which NN O O
contained NN O O
a NN O O
previously NN O O
identified NN O O
mutation NN O O
in NN O O
BRCA1 NN O O
. NN O O

All NN O O
14 NN O O
mutations NN O O
were NN O O
identified NN O O
, NN O O
as NN O O
well NN O O
as NN O O
an NN O O
additional NN O O
five NN O O
that NN O O
had NN O O
previously NN O O
escaped NN O O
detection NN O O
. NN O O

In NN O O
addition NN O O
to NN O O
the NN O O
19 NN O O
mutations NN O O
, NN O O
a NN O O
total NN O O
of NN O O
15 NN O O
different NN O O
polymorphic NN O O
variants NN O O
were NN O O
scored NN O O
, NN O O
most NN O O
of NN O O
which NN O O
were NN O O
recurring NN O O
. NN O O

All NN O O
were NN O O
confirmed NN O O
by NN O O
nucleotide NN O O
sequencing NN O O
. NN O O

The NN O O
cost NN O O
of NN O O
screening NN O O
per NN O O
sample NN O O
was NN O O
calculated NN O O
to NN O O
be NN O O
approximately NN O O
US NN O O
$ NN O O
70 NN O O
for NN O O
the NN O O
manual NN O O
technique NN O O
used NN O O
in NN O O
this NN O O
study NN O O
, NN O O
and NN O O
may NN O O
be NN O O
reduced NN O O
to NN O O
approximately NN O O
US NN O O
$ NN O O
10 NN O O
with NN O O
the NN O O
introduction NN O O
of NN O O
commercially NN O O
available NN O O
PCR NN O O
robotics NN O O
and NN O O
fluorescent NN O O
imaging NN O O
. NN O O

Implementation NN O O
of NN O O
this NN O O
method NN O O
of NN O O
mutation NN O O
screening NN O O
in NN O O
the NN O O
research NN O O
and NN O O
clinical NN O O
setting NN O O
should NN O O
permit NN O O
rapid NN O O
accrual NN O O
of NN O O
quantitative NN O O
data NN O O
on NN O O
genotype NN O O
- NN O O
phenotype NN O O
associations NN O O
for NN O O
the NN O O
evaluation NN O O
of NN O O
diagnostic NN O O
testing NN O O
. NN O O
. NN O O

Maternal NN O B-Disease
uniparental NN O I-Disease
disomy NN O I-Disease
for NN O I-Disease
chromosome NN O I-Disease
14 NN O I-Disease
in NN O O
a NN O O
boy NN O O
with NN O O
a NN O O
normal NN O O
karyotype NN O O
. NN O O

We NN O O
report NN O O
on NN O O
a NN O O
boy NN O O
with NN O O
a NN O O
maternal NN O B-Disease
uniparental NN O I-Disease
disomy NN O I-Disease
for NN O I-Disease
chromosome NN O I-Disease
14 NN O I-Disease
( NN O O
UPD NN O B-Disease
( NN O O
14 NN O O
) NN O O
) NN O O
. NN O O

At NN O O
7 NN O O
years NN O O
of NN O O
age NN O O
he NN O O
was NN O O
referred NN O O
to NN O O
us NN O O
by NN O O
the NN O O
paediatrician NN O O
because NN O O
of NN O O
symptoms NN O O
of NN O O
Prader NN O B-Disease
- NN O I-Disease
Willi NN O I-Disease
syndrome NN O I-Disease
( NN O O
PWS NN O B-Disease
) NN O O
. NN O O

He NN O O
showed NN O O
short NN O B-Disease
stature NN O I-Disease
, NN O O
obesity NN O B-Disease
, NN O O
mild NN O O
developmental NN O B-Disease
delay NN O I-Disease
, NN O O
cryptorchidism NN O B-Disease
, NN O O
and NN O O
some NN O O
mild NN O O
dysmorphic NN O B-Disease
features NN O I-Disease
. NN O O

The NN O O
history NN O O
further NN O O
indicated NN O O
intrauterine NN O B-Disease
growth NN O I-Disease
retardation NN O I-Disease
at NN O O
the NN O O
end NN O O
of NN O O
the NN O O
pregnancy NN O O
. NN O O

His NN O O
mother NN O O
was NN O O
44 NN O O
years NN O O
of NN O O
age NN O O
at NN O O
the NN O O
time NN O O
of NN O O
his NN O O
birth NN O O
. NN O O

After NN O O
birth NN O O
he NN O O
showed NN O O
hypotonia NN O B-Disease
with NN O O
poor NN O O
sucking NN O O
, NN O O
for NN O O
which NN O O
gavage NN O O
feeding NN O O
was NN O O
needed NN O O
. NN O O

Motor NN O O
development NN O O
was NN O O
delayed NN O O
. NN O O

After NN O O
1 NN O O
year NN O O
he NN O O
became NN O O
obese NN O B-Disease
despite NN O O
a NN O O
normal NN O O
appetite NN O O
. NN O O

Recurrent NN O O
middle NN O B-Disease
ear NN O I-Disease
infections NN O I-Disease
, NN O O
a NN O O
high NN O O
pain NN O O
threshold NN O O
, NN O O
and NN O O
a NN O O
great NN O O
skill NN O O
with NN O O
jigsaw NN O O
puzzles NN O O
were NN O O
reported NN O O
. NN O O

There NN O O
were NN O O
no NN O O
behavioural NN O O
problems NN O O
or NN O O
sleep NN O O
disturbance NN O O
. NN O O

Chromosomal NN O O
analysis NN O O
was NN O O
normal NN O O
( NN O O
46 NN O O
, NN O O
XY NN O O
) NN O O
. NN O O

DNA NN O O
analysis NN O O
for NN O O
Prader NN O B-Disease
- NN O I-Disease
Willi NN O I-Disease
syndrome NN O I-Disease
showed NN O O
no NN O O
abnormalities NN O O
. NN O O

Two NN O O
years NN O O
later NN O O
he NN O O
was NN O O
re NN O O
- NN O O
examined NN O O
because NN O O
we NN O O
thought NN O O
his NN O O
features NN O O
fitted NN O O
the NN O O
PWS NN O B-Disease
- NN O O
like NN O O
phenotype NN O O
associated NN O O
with NN O O
maternal NN O O
UPD NN O B-Disease
( NN O O
14 NN O O
) NN O O
. NN O O

At NN O O
that NN O O
time NN O O
precocious NN O O
puberty NN O O
was NN O O
evident NN O O
. NN O O

DNA NN O O
analysis NN O O
showed NN O O
maternal NN O B-Disease
heterodisomy NN O I-Disease
for NN O O
chromosome NN O O
14 NN O O
. NN O O

In NN O O
all NN O O
the NN O O
previously NN O O
described NN O O
11 NN O O
cases NN O O
with NN O O
maternal NN O O
UPD NN O B-Disease
( NN O O
14 NN O O
) NN O O
, NN O O
a NN O O
Robertsonian NN O O
translocation NN O O
involving NN O O
chromosome NN O O
14 NN O O
was NN O O
detected NN O O
cytogenetically NN O O
before NN O O
DNA NN O O
analysis NN O O
. NN O O

This NN O O
is NN O O
the NN O O
first NN O O
report NN O O
of NN O O
diagnosis NN O O
of NN O O
maternal NN O O
UPD NN O B-Disease
( NN O O
14 NN O O
) NN O O
based NN O O
on NN O O
clinical NN O O
features NN O O
. NN O O

This NN O O
finding NN O O
underlines NN O O
the NN O O
importance NN O O
of NN O O
DNA NN O O
analysis NN O O
for NN O O
maternal NN O O
UPD NN O O
( NN O O
14 NN O O
) NN O O
in NN O O
patients NN O O
with NN O O
a NN O O
similar NN O O
PWS NN O B-Disease
- NN O O
like NN O O
phenotype NN O O
even NN O O
without NN O O
previous NN O O
identification NN O O
of NN O O
a NN O O
Robertsonian NN O O
translocation NN O O
involving NN O O
chromosome NN O O
14 NN O O
. NN O O
. NN O O

Clinical NN O O
and NN O O
genetic NN O O
study NN O O
of NN O O
Friedreich NN O B-Disease
ataxia NN O I-Disease
in NN O O
an NN O O
Australian NN O O
population NN O O
. NN O O

Friedreich NN O B-Disease
ataxia NN O I-Disease
is NN O O
an NN O O
autosomal NN O B-Disease
recessive NN O I-Disease
disorder NN O I-Disease
caused NN O O
by NN O O
mutations NN O O
in NN O O
the NN O O
FRDA NN O B-Disease
gene NN O O
that NN O O
encodes NN O O
a NN O O
210 NN O O
- NN O O
amino NN O O
acid NN O O
protein NN O O
called NN O O
frataxin NN O O
. NN O O

An NN O O
expansion NN O O
of NN O O
a NN O O
GAA NN O O
trinucleotide NN O O
repeat NN O O
in NN O O
intron NN O O
1 NN O O
of NN O O
the NN O O
gene NN O O
is NN O O
present NN O O
in NN O O
more NN O O
than NN O O
95 NN O O
% NN O O
of NN O O
mutant NN O O
alleles NN O O
. NN O O

Of NN O O
the NN O O
83 NN O O
people NN O O
we NN O O
studied NN O O
who NN O O
have NN O O
mutations NN O O
in NN O O
FRDA NN O O
, NN O O
78 NN O O
are NN O O
homozygous NN O O
for NN O O
an NN O O
expanded NN O O
GAA NN O O
repeat NN O O
; NN O O
the NN O O
other NN O O
five NN O O
patients NN O O
have NN O O
an NN O O
expansion NN O O
in NN O O
one NN O O
allele NN O O
and NN O O
a NN O O
point NN O O
mutation NN O O
in NN O O
the NN O O
other NN O O
. NN O O

Here NN O O
we NN O O
present NN O O
a NN O O
detailed NN O O
clinical NN O O
and NN O O
genetic NN O O
study NN O O
of NN O O
a NN O O
subset NN O O
of NN O O
51 NN O O
patients NN O O
homozygous NN O O
for NN O O
an NN O O
expansion NN O O
of NN O O
the NN O O
GAA NN O O
repeat NN O O
. NN O O

We NN O O
found NN O O
a NN O O
correlation NN O O
between NN O O
the NN O O
size NN O O
of NN O O
the NN O O
smaller NN O O
of NN O O
the NN O O
two NN O O
expanded NN O O
alleles NN O O
and NN O O
age NN O O
at NN O O
onset NN O O
, NN O O
age NN O O
into NN O O
wheelchair NN O O
, NN O O
scoliosis NN O B-Disease
, NN O O
impaired NN O O
vibration NN O O
sense NN O O
, NN O O
and NN O O
the NN O O
presence NN O O
of NN O O
foot NN O B-Disease
deformity NN O I-Disease
. NN O O

There NN O O
was NN O O
no NN O O
significant NN O O
correlation NN O O
between NN O O
the NN O O
size NN O O
of NN O O
the NN O O
smaller NN O O
allele NN O O
and NN O O
cardiomyopathy NN O B-Disease
, NN O O
diabetes NN O B-Disease
mellitus NN O I-Disease
, NN O O
loss NN O B-Disease
of NN O I-Disease
proprioception NN O I-Disease
, NN O O
or NN O O
bladder NN O B-Disease
symptoms NN O I-Disease
. NN O O

The NN O O
larger NN O O
allele NN O O
size NN O O
correlated NN O O
with NN O O
bladder NN O B-Disease
symptoms NN O I-Disease
and NN O O
the NN O O
presence NN O O
of NN O O
foot NN O B-Disease
deformity NN O I-Disease
. NN O O

The NN O O
duration NN O O
of NN O O
disease NN O O
is NN O O
correlated NN O O
with NN O O
wheelchair NN O O
use NN O O
and NN O O
the NN O O
presence NN O O
of NN O O
diabetes NN O B-Disease
, NN O O
scoliosis NN O B-Disease
, NN O O
bladder NN O B-Disease
symptoms NN O I-Disease
and NN O O
impaired NN O B-Disease
proprioception NN O I-Disease
, NN O O
and NN O O
vibration NN O O
sense NN O O
but NN O O
no NN O O
other NN O O
complications NN O O
studied NN O O
. NN O O
. NN O O

Novel NN O O
mutations NN O O
in NN O O
XLRS1 NN O O
causing NN O O
retinoschisis NN O B-Disease
, NN O O
including NN O O
first NN O O
evidence NN O O
of NN O O
putative NN O O
leader NN O O
sequence NN O O
change NN O O
. NN O O

Juvenile NN O B-Disease
retinoschisis NN O I-Disease
is NN O O
an NN O O
X NN O B-Disease
- NN O I-Disease
linked NN O I-Disease
recessive NN O I-Disease
disease NN O I-Disease
caused NN O O
by NN O O
mutations NN O O
in NN O O
the NN O O
XLRS1 NN O O
gene NN O O
. NN O O

We NN O O
screened NN O O
31 NN O O
new NN O O
unrelated NN O O
patients NN O O
and NN O O
families NN O O
for NN O O
XLRS1 NN O O
mutations NN O O
in NN O O
addition NN O O
to NN O O
previously NN O O
reported NN O O
mutations NN O O
for NN O O
60 NN O O
of NN O O
our NN O O
families NN O O
( NN O O
Retinoschisis NN O B-Disease
Consortium NN O O
, NN O O
Hum NN O O
Mol NN O O
Genet NN O O
1998 NN O O
; NN O O
7 NN O O
1185 NN O O
- NN O O
1192 NN O O
) NN O O
. NN O O

Twenty NN O O
- NN O O
three NN O O
different NN O O
mutations NN O O
including NN O O
12 NN O O
novel NN O O
ones NN O O
were NN O O
identified NN O O
in NN O O
28 NN O O
patients NN O O
. NN O O

Mutations NN O O
identified NN O O
in NN O O
this NN O O
study NN O O
include NN O O
19 NN O O
missense NN O O
mutations NN O O
, NN O O
two NN O O
nonsense NN O O
mutations NN O O
, NN O O
one NN O O
intragenic NN O O
deletion NN O O
, NN O O
four NN O O
microdeletions NN O O
, NN O O
one NN O O
insertion NN O O
, NN O O
and NN O O
one NN O O
intronic NN O O
sequence NN O O
substitution NN O O
that NN O O
is NN O O
likely NN O O
to NN O O
result NN O O
in NN O O
a NN O O
splice NN O O
site NN O O
defect NN O O
. NN O O

Two NN O O
novel NN O O
mutations NN O O
, NN O O
c NN O O
. NN O O

38T NN O O
- NN O O
- NN O O
> NN O O
C NN O O
( NN O O
L13P NN O O
) NN O O
and NN O O
c NN O O
. NN O O

667T NN O O
- NN O O
- NN O O
> NN O O
C NN O O
( NN O O
C223R NN O O
) NN O O
, NN O O
respectively NN O O
, NN O O
present NN O O
the NN O O
first NN O O
genetic NN O O
evidence NN O O
for NN O O
the NN O O
functional NN O O
significance NN O O
of NN O O
the NN O O
putative NN O O
leader NN O O
peptide NN O O
sequence NN O O
and NN O O
for NN O O
the NN O O
functional NN O O
significance NN O O
at NN O O
the NN O O
carboxyl NN O O
terminal NN O O
of NN O O
the NN O O
XLRS1 NN O O
protein NN O O
beyond NN O O
the NN O O
discoidin NN O O
domain NN O O
. NN O O

Mutations NN O O
in NN O O
25 NN O O
of NN O O
the NN O O
families NN O O
were NN O O
localized NN O O
to NN O O
exons NN O O
4 NN O O
- NN O O
6 NN O O
, NN O O
emphasizing NN O O
the NN O O
critical NN O O
functional NN O O
significance NN O O
of NN O O
the NN O O
discoidin NN O O
domain NN O O
of NN O O
the NN O O
XLRS1 NN O O
protein NN O O

Growth NN O O
hormone NN O O
treatment NN O O
increases NN O O
CO NN O O
( NN O O
2 NN O O
) NN O O
response NN O O
, NN O O
ventilation NN O O
and NN O O
central NN O O
inspiratory NN O O
drive NN O O
in NN O O
children NN O O
with NN O O
Prader NN O B-Disease
- NN O I-Disease
Willi NN O I-Disease
syndrome NN O I-Disease
. NN O O

We NN O O
studied NN O O
whether NN O O
the NN O O
beneficial NN O O
effects NN O O
of NN O O
growth NN O O
hormone NN O O
( NN O O
GH NN O O
) NN O O
treatment NN O O
on NN O O
growth NN O O
and NN O O
body NN O O
composition NN O O
in NN O O
PWS NN O B-Disease
are NN O O
accompanied NN O O
by NN O O
an NN O O
improvement NN O O
in NN O O
respiratory NN O O
function NN O O
. NN O O

We NN O O
measured NN O O
resting NN O O
ventilation NN O O
, NN O O
airway NN O O
occlusion NN O O
pressure NN O O
( NN O O
P NN O O
( NN O O
0 NN O O
. NN O O
1 NN O O
) NN O O
) NN O O
and NN O O
ventilatory NN O O
response NN O O
to NN O O
CO NN O O
( NN O O
2 NN O O
) NN O O
in NN O O
nine NN O O
children NN O O
, NN O O
aged NN O O
7 NN O O
- NN O O
14 NN O O
years NN O O
, NN O O
before NN O O
and NN O O
6 NN O O
- NN O O
9 NN O O
months NN O O
after NN O O
the NN O O
start NN O O
of NN O O
GH NN O O
treatment NN O O
. NN O O

During NN O O
GH NN O O
treatment NN O O
, NN O O
resting NN O O
ventilation NN O O
increased NN O O
by NN O O
26 NN O O
% NN O O
, NN O O
P NN O O
( NN O O
0 NN O O
. NN O O
1 NN O O
) NN O O
by NN O O
72 NN O O
% NN O O
and NN O O
the NN O O
response NN O O
to NN O O
CO NN O O
( NN O O
2 NN O O
) NN O O
by NN O O
65 NN O O
% NN O O
( NN O O
P NN O O
< NN O O
0 NN O O
. NN O O
002 NN O O
, NN O O
< NN O O
0 NN O O
. NN O O
04 NN O O
and NN O O
< NN O O
0 NN O O
. NN O O
02 NN O O
, NN O O
respectively NN O O
) NN O O
. NN O O

This NN O O
observed NN O O
increase NN O O
in NN O O
ventilatory NN O O
output NN O O
was NN O O
not NN O O
correlated NN O O
to NN O O
changes NN O O
in NN O O
body NN O O
mass NN O O
index NN O O
. NN O O

CONCLUSION NN O O
Treatment NN O O
of NN O O
children NN O O
with NN O O
Prader NN O B-Disease
- NN O I-Disease
Willi NN O I-Disease
syndrome NN O I-Disease
( NN O O
PWS NN O B-Disease
) NN O O
seems NN O O
to NN O O
have NN O O
a NN O O
stimulatory NN O O
effect NN O O
on NN O O
central NN O O
respiratory NN O O
structures NN O O
. NN O O

The NN O O
observed NN O O
increase NN O O
in NN O O
ventilation NN O O
and NN O O
inspiratory NN O O
drive NN O O
may NN O O
contribute NN O O
to NN O O
the NN O O
improved NN O O
activity NN O O
level NN O O
reported NN O O
by NN O O
parents NN O O
of NN O O
PWS NN O B-Disease
children NN O O
during NN O O
growth NN O O
hormone NN O O
therapy NN O O

G130V NN O O
, NN O O
a NN O O
common NN O O
FRDA NN O B-Disease
point NN O O
mutation NN O O
, NN O O
appears NN O O
to NN O O
have NN O O
arisen NN O O
from NN O O
a NN O O
common NN O O
founder NN O O
. NN O O

Friedreich NN O B-Disease
ataxia NN O I-Disease
( NN O O
FRDA NN O B-Disease
) NN O O
is NN O O
the NN O O
most NN O O
common NN O O
inherited NN O B-Disease
ataxia NN O I-Disease
. NN O O

About NN O O
98 NN O O
% NN O O
of NN O O
mutant NN O O
alleles NN O O
have NN O O
an NN O O
expansion NN O O
of NN O O
a NN O O
GAA NN O O
trinucleotide NN O O
repeat NN O O
in NN O O
intron NN O O
1 NN O O
of NN O O
the NN O O
affected NN O O
gene NN O O
, NN O O
FRDA NN O O
. NN O O

The NN O O
other NN O O
2 NN O O
% NN O O
are NN O O
point NN O O
mutations NN O O
. NN O O

Of NN O O
the NN O O
17 NN O O
point NN O O
mutations NN O O
so NN O O
far NN O O
described NN O O
, NN O O
three NN O O
appear NN O O
to NN O O
be NN O O
more NN O O
common NN O O
. NN O O

One NN O O
of NN O O
these NN O O
is NN O O
the NN O O
G130V NN O O
mutation NN O O
in NN O O
exon NN O O
4 NN O O
of NN O O
FRDA NN O O
. NN O O

G130V NN O O
, NN O O
when NN O O
present NN O O
with NN O O
an NN O O
expanded NN O O
GAA NN O O
repeat NN O O
on NN O O
the NN O O
other NN O O
allele NN O O
, NN O O
is NN O O
associated NN O O
with NN O O
an NN O O
atypical NN O O
FRDA NN O B-Disease
phenotype NN O O
. NN O O

Haplotype NN O O
analysis NN O O
was NN O O
undertaken NN O O
on NN O O
the NN O O
four NN O O
families NN O O
who NN O O
have NN O O
been NN O O
described NN O O
with NN O O
this NN O O
mutation NN O O
. NN O O

The NN O O
results NN O O
suggest NN O O
a NN O O
common NN O O
founder NN O O
for NN O O
this NN O O
mutation NN O O
. NN O O

Although NN O O
marked NN O O
differences NN O O
in NN O O
extragenic NN O O
marker NN O O
haplotypes NN O O
were NN O O
seen NN O O
in NN O O
one NN O O
family NN O O
, NN O O
similar NN O O
intragenic NN O O
haplotyping NN O O
suggests NN O O
the NN O O
same NN O O
mutation NN O O
founder NN O O
for NN O O
this NN O O
family NN O O
with NN O O
the NN O O
differences NN O O
explicable NN O O
by NN O O
two NN O O
recombination NN O O
events NN O O
. NN O O
. NN O O

Synergistic NN O O
effect NN O O
of NN O O
histone NN O O
hyperacetylation NN O O
and NN O O
DNA NN O O
demethylation NN O O
in NN O O
the NN O O
reactivation NN O O
of NN O O
the NN O O
FMR1 NN O O
gene NN O O
. NN O O

Most NN O O
fragile NN O B-Disease
X NN O I-Disease
syndrome NN O I-Disease
patients NN O O
have NN O O
expansion NN O O
of NN O O
a NN O O
( NN O O
CGG NN O O
) NN O O
( NN O O
n NN O O
) NN O O
sequence NN O O
with NN O O
> NN O O
200 NN O O
repeats NN O O
( NN O O
full NN O O
mutation NN O O
) NN O O
in NN O O
the NN O O
FMR1 NN O O
gene NN O O
responsible NN O O
for NN O O
this NN O O
condition NN O O
. NN O O

Hypermethylation NN O O
of NN O O
the NN O O
expanded NN O O
repeat NN O O
and NN O O
of NN O O
the NN O O
FMR1 NN O O
promoter NN O O
is NN O O
almost NN O O
always NN O O
present NN O O
and NN O O
apparently NN O O
suppresses NN O O
transcription NN O O
, NN O O
resulting NN O O
in NN O O
absence NN O O
of NN O O
the NN O O
FMR1 NN O O
protein NN O O
. NN O O

We NN O O
recently NN O O
showed NN O O
that NN O O
transcriptional NN O O
reactivation NN O O
of NN O O
FMR1 NN O O
full NN O O
mutations NN O O
can NN O O
be NN O O
achieved NN O O
by NN O O
inducing NN O O
DNA NN O O
demethylation NN O O
with NN O O
5 NN O O
- NN O O
azadeoxycytidine NN O O
( NN O O
5 NN O O
- NN O O
azadC NN O O
) NN O O
. NN O O

The NN O O
level NN O O
of NN O O
histone NN O O
acetylation NN O O
is NN O O
another NN O O
important NN O O
factor NN O O
in NN O O
regulating NN O O
gene NN O O
expression NN O O
; NN O O
therefore NN O O
, NN O O
we NN O O
treated NN O O
lymphoblastoid NN O O
cell NN O O
lines NN O O
of NN O O
non NN O O
- NN O O
mosaic NN O O
full NN O O
mutation NN O O
patients NN O O
with NN O O
three NN O O
drugs NN O O
capable NN O O
of NN O O
inducing NN O O
histone NN O O
hyperacetylation NN O O
. NN O O

We NN O O
observed NN O O
a NN O O
consistent NN O O
, NN O O
although NN O O
modest NN O O
, NN O O
reactivation NN O O
of NN O O
the NN O O
FMR1 NN O O
gene NN O O
with NN O O
4 NN O O
- NN O O
phenylbutyrate NN O O
, NN O O
sodium NN O O
butyrate NN O O
and NN O O
trichostatin NN O O
A NN O O
, NN O O
as NN O O
shown NN O O
by NN O O
RT NN O O
- NN O O
PCR NN O O
. NN O O

However NN O O
, NN O O
we NN O O
report NN O O
that NN O O
combining NN O O
these NN O O
drugs NN O O
with NN O O
5 NN O O
- NN O O
azadC NN O O
results NN O O
in NN O O
a NN O O
2 NN O O
- NN O O
to NN O O
5 NN O O
- NN O O
fold NN O O
increase NN O O
in NN O O
FMR1 NN O O
mRNA NN O O
levels NN O O
obtained NN O O
with NN O O
5 NN O O
- NN O O
azadC NN O O
alone NN O O
, NN O O
thus NN O O
showing NN O O
a NN O O
marked NN O O
synergistic NN O O
effect NN O O
of NN O O
histone NN O O
hyperacetylation NN O O
and NN O O
DNA NN O O
demethylation NN O O
in NN O O
the NN O O
reactivation NN O O
of NN O O
FMR1 NN O O
full NN O O
mutations NN O O
. NN O O
. NN O O

Constitutional NN O O
von NN O B-Disease
Hippel NN O I-Disease
- NN O I-Disease
Lindau NN O I-Disease
( NN O O
VHL NN O B-Disease
) NN O O
gene NN O O
deletions NN O O
detected NN O O
in NN O O
VHL NN O B-Disease
families NN O O
by NN O O
fluorescence NN O O
in NN O O
situ NN O O
hybridization NN O O
. NN O O

von NN O B-Disease
Hippel NN O I-Disease
- NN O I-Disease
Lindau NN O I-Disease
( NN O I-Disease
VHL NN O I-Disease
) NN O I-Disease
disease NN O I-Disease
is NN O O
an NN O O
autosomal NN O B-Disease
dominantly NN O I-Disease
inherited NN O I-Disease
cancer NN O I-Disease
syndrome NN O I-Disease
predisposing NN O O
to NN O O
a NN O O
variety NN O O
of NN O O
tumor NN O B-Disease
types NN O O
that NN O O
include NN O O
retinal NN O O
hemangioblastomas NN O B-Disease
, NN O O
hemangioblastomas NN O B-Disease
of NN O O
the NN O O
central NN O O
nervous NN O O
system NN O O
, NN O O
renal NN O B-Disease
cell NN O I-Disease
carcinomas NN O I-Disease
, NN O O
pancreatic NN O B-Disease
cysts NN O I-Disease
and NN O I-Disease
tumors NN O I-Disease
, NN O O
pheochromocytomas NN O B-Disease
, NN O O
endolymphatic NN O B-Disease
sac NN O I-Disease
tumors NN O I-Disease
, NN O O
and NN O O
epididymal NN O B-Disease
cystadenomas NN O I-Disease
[ NN O O
W NN O O
. NN O O

M NN O O
. NN O O

Linehan NN O O
et NN O O
al NN O O
. NN O O
, NN O O
J NN O O
. NN O O

Am NN O O
. NN O O
Med NN O O
. NN O O
Assoc NN O O
. NN O O
, NN O O
273 NN O O
564 NN O O
- NN O O
570 NN O O
, NN O O
1995 NN O O
; NN O O
E NN O O
. NN O O
A NN O O
. NN O O
Maher NN O O
and NN O O
W NN O O
. NN O O
G NN O O
. NN O O
Kaelin NN O O
, NN O O
Jr NN O O
. NN O O
, NN O O
Medicine NN O O
( NN O O
Baltimore NN O O
) NN O O
, NN O O
76 NN O O
381 NN O O
- NN O O
391 NN O O
, NN O O
1997 NN O O
; NN O O
W NN O O
. NN O O
M NN O O
. NN O O
Linehan NN O O
and NN O O
R NN O O
. NN O O
D NN O O
. NN O O
Klausner NN O O
, NN O O
In NN O O
B NN O O
. NN O O
Vogelstein NN O O
and NN O O
K NN O O
. NN O O
Kinzler NN O O
( NN O O
eds NN O O
. NN O O
) NN O O
, NN O O
The NN O O
Genetic NN O O
Basis NN O O
of NN O O
Human NN O O
Cancer NN O O
, NN O O
pp NN O O
. NN O O

455 NN O O
- NN O O
473 NN O O
, NN O O
McGraw NN O O
- NN O O
Hill NN O O
, NN O O
1998 NN O O
] NN O O
. NN O O

The NN O O
VHL NN O B-Disease
gene NN O O
was NN O O
localized NN O O
to NN O O
chromosome NN O O
3p25 NN O O
- NN O O
26 NN O O
and NN O O
cloned NN O O
[ NN O O
F NN O O
. NN O O
Latif NN O O
et NN O O
al NN O O
. NN O O
, NN O O
Science NN O O
( NN O O
Washington NN O O
DC NN O O
) NN O O
, NN O O
260 NN O O
1317 NN O O
- NN O O
1320 NN O O
, NN O O
1993 NN O O
] NN O O
. NN O O

Germline NN O O
mutations NN O O
in NN O O
the NN O O
VHL NN O B-Disease
gene NN O O
have NN O O
been NN O O
detected NN O O
in NN O O
the NN O O
majority NN O O
of NN O O
VHL NN O B-Disease
kindreds NN O O
. NN O O

The NN O O
reported NN O O
frequency NN O O
of NN O O
detection NN O O
of NN O O
VHL NN O B-Disease
germline NN O O
mutations NN O O
has NN O O
varied NN O O
from NN O O
39 NN O O
to NN O O
80 NN O O
% NN O O
( NN O O
J NN O O
. NN O O
M NN O O
. NN O O
Whaley NN O O
et NN O O
al NN O O
. NN O O
, NN O O
Am NN O O
. NN O O
J NN O O
. NN O O
Hum NN O O
. NN O O
Genet NN O O
. NN O O
, NN O O
55 NN O O
1092 NN O O
- NN O O
1102 NN O O
, NN O O
1994 NN O O
; NN O O
Clinical NN O O
Research NN O O
Group NN O O
for NN O O
Japan NN O O
, NN O O
Hum NN O O
. NN O O
Mol NN O O
. NN O O
Genet NN O O
. NN O O
, NN O O
4 NN O O
2233 NN O O
- NN O O
2237 NN O O
, NN O O
1995 NN O O
; NN O O
F NN O O
. NN O O
Chen NN O O
et NN O O
al NN O O
. NN O O
, NN O O
Hum NN O O
. NN O O
Mutat NN O O
. NN O O
, NN O O
5 NN O O
66 NN O O
- NN O O
75 NN O O
, NN O O
1995 NN O O
; NN O O
E NN O O
. NN O O
R NN O O
. NN O O
Maher NN O O
et NN O O
al NN O O
. NN O O
, NN O O
J NN O O
. NN O O
Med NN O O
. NN O O
Genet NN O O
. NN O O
, NN O O
33 NN O O
328 NN O O
- NN O O
332 NN O O
, NN O O
1996 NN O O
; NN O O
B NN O O
. NN O O
Zbar NN O O
, NN O O
Cancer NN O O
Surv NN O O
. NN O O
, NN O O
25 NN O O
219 NN O O
- NN O O
232 NN O O
, NN O O
1995 NN O O
) NN O O
. NN O O

Recently NN O O
a NN O O
quantitative NN O O
Southern NN O O
blotting NN O O
procedure NN O O
was NN O O
found NN O O
to NN O O
improve NN O O
this NN O O
frequency NN O O
( NN O O
C NN O O
. NN O O
Stolle NN O O
et NN O O
al NN O O
. NN O O
, NN O O
Hum NN O O
. NN O O
Mutat NN O O
. NN O O
, NN O O
12 NN O O
417 NN O O
- NN O O
423 NN O O
, NN O O
1998 NN O O
) NN O O
. NN O O

In NN O O
the NN O O
present NN O O
study NN O O
, NN O O
we NN O O
report NN O O
the NN O O
use NN O O
of NN O O
fluorescence NN O O
in NN O O
situ NN O O
hybridization NN O O
( NN O O
FISH NN O O
) NN O O
as NN O O
a NN O O
method NN O O
to NN O O
detect NN O O
and NN O O
characterize NN O O
VHL NN O B-Disease
germline NN O O
deletions NN O O
. NN O O

We NN O O
reexamined NN O O
a NN O O
group NN O O
of NN O O
VHL NN O B-Disease
patients NN O O
shown NN O O
previously NN O O
by NN O O
single NN O O
- NN O O
strand NN O O
conformation NN O O
and NN O O
sequencing NN O O
analysis NN O O
not NN O O
to NN O O
harbor NN O O
point NN O O
mutations NN O O
in NN O O
the NN O O
VHL NN O B-Disease
locus NN O O
. NN O O

We NN O O
found NN O O
constitutional NN O O
deletions NN O O
in NN O O
29 NN O O
of NN O O
30 NN O O
VHL NN O B-Disease
patients NN O O
in NN O O
this NN O O
group NN O O
using NN O O
cosmid NN O O
and NN O O
P1 NN O O
probes NN O O
that NN O O
cover NN O O
the NN O O
VHL NN O B-Disease
locus NN O O
. NN O O

We NN O O
then NN O O
tested NN O O
six NN O O
phenotypically NN O O
normal NN O O
offspring NN O O
from NN O O
four NN O O
of NN O O
these NN O O
VHL NN O B-Disease
families NN O O
two NN O O
were NN O O
found NN O O
to NN O O
carry NN O O
the NN O O
deletion NN O O
and NN O O
the NN O O
other NN O O
four NN O O
were NN O O
deletion NN O O
- NN O O
free NN O O
. NN O O

In NN O O
addition NN O O
, NN O O
germline NN O O
mosaicism NN O O
of NN O O
the NN O O
VHL NN O B-Disease
gene NN O O
was NN O O
identified NN O O
in NN O O
one NN O O
family NN O O
. NN O O

In NN O O
sum NN O O
, NN O O
FISH NN O O
was NN O O
found NN O O
to NN O O
be NN O O
a NN O O
simple NN O O
and NN O O
reliable NN O O
method NN O O
to NN O O
detect NN O O
VHL NN O B-Disease
germline NN O O
deletions NN O O
and NN O O
practically NN O O
useful NN O O
in NN O O
cases NN O O
where NN O O
other NN O O
methods NN O O
of NN O O
screening NN O O
have NN O O
failed NN O O
to NN O O
detect NN O O
a NN O O
VHL NN O B-Disease
gene NN O I-Disease
abnormality NN O I-Disease

Spectrum NN O O
of NN O O
hSNF5 NN O O
/ NN O O
INI1 NN O O
somatic NN O O
mutations NN O O
in NN O O
human NN O O
cancer NN O B-Disease
and NN O O
genotype NN O O
- NN O O
phenotype NN O O
correlations NN O O
. NN O O

The NN O O
hSNF5 NN O O
/ NN O O
INI1 NN O O
gene NN O O
which NN O O
encodes NN O O
a NN O O
member NN O O
of NN O O
the NN O O
SWI NN O O
/ NN O O
SNF NN O O
chromatin NN O O
ATP NN O O
- NN O O
dependent NN O O
remodeling NN O O
complex NN O O
, NN O O
is NN O O
a NN O O
new NN O O
tumor NN O B-Disease
suppressor NN O O
gene NN O O
localized NN O O
on NN O O
chromosome NN O O
22q11 NN O O
. NN O O

2 NN O O
and NN O O
recently NN O O
shown NN O O
to NN O O
be NN O O
mutated NN O O
in NN O O
malignant NN O B-Disease
rhabdoid NN O I-Disease
tumors NN O I-Disease
. NN O O

We NN O O
have NN O O
searched NN O O
for NN O O
hSNF5 NN O O
/ NN O O
INI1 NN O O
mutations NN O O
in NN O O
229 NN O O
tumors NN O B-Disease
of NN O O
various NN O O
origins NN O O
using NN O O
a NN O O
screening NN O O
method NN O O
based NN O O
on NN O O
denaturing NN O O
high NN O O
- NN O O
performance NN O O
liquid NN O O
chromatography NN O O
. NN O O

A NN O O
total NN O O
of NN O O
31 NN O O
homozygous NN O O
deletions NN O O
and NN O O
36 NN O O
point NN O O
alterations NN O O
were NN O O
identified NN O O
. NN O O

Point NN O O
mutations NN O O
were NN O O
scattered NN O O
along NN O O
the NN O O
coding NN O O
sequence NN O O
and NN O O
included NN O O
15 NN O O
nonsense NN O O
, NN O O
15 NN O O
frameshift NN O O
, NN O O
three NN O O
splice NN O O
site NN O O
, NN O O
two NN O O
missense NN O O
and NN O O
one NN O O
editing NN O O
mutations NN O O
. NN O O

Mutations NN O O
were NN O O
retrieved NN O O
in NN O O
most NN O O
rhabdoid NN O B-Disease
tumors NN O I-Disease
, NN O O
whatever NN O O
their NN O O
sites NN O O
of NN O O
occurrence NN O O
, NN O O
indicating NN O O
the NN O O
common NN O O
pathogenetic NN O O
origin NN O O
of NN O O
these NN O O
tumors NN O B-Disease
. NN O O

Recurrent NN O O
hSNF5 NN O O
/ NN O O
INI1 NN O O
alterations NN O O
were NN O O
also NN O O
observed NN O O
in NN O O
choroid NN O B-Disease
plexus NN O I-Disease
carcinomas NN O I-Disease
and NN O O
in NN O O
a NN O O
subset NN O O
of NN O O
central NN O O
primitive NN O O
neuroectodermal NN O B-Disease
tumors NN O I-Disease
( NN O O
cPNETs NN O O
) NN O O
and NN O O
medulloblastomas NN O B-Disease
. NN O O

In NN O O
contrast NN O O
, NN O O
hSNF5 NN O O
/ NN O O
INI1 NN O O
point NN O O
mutations NN O O
were NN O O
not NN O O
detected NN O O
in NN O O
breast NN O B-Disease
cancers NN O I-Disease
, NN O O
Wilms NN O B-Disease
tumors NN O I-Disease
, NN O O
gliomas NN O B-Disease
, NN O O
ependymomas NN O B-Disease
, NN O O
sarcomas NN O B-Disease
and NN O O
other NN O O
tumor NN O B-Disease
types NN O O
, NN O O
even NN O O
though NN O O
most NN O O
analyzed NN O O
cases NN O O
harbored NN O O
loss NN O O
of NN O O
heterozygosity NN O O
at NN O O
22q11 NN O O
. NN O O

2 NN O O
loci NN O O
. NN O O

These NN O O
results NN O O
suggest NN O O
that NN O O
rhabdoid NN O B-Disease
tumors NN O I-Disease
, NN O O
choroid NN O B-Disease
plexus NN O I-Disease
carcinomas NN O I-Disease
and NN O O
a NN O O
subset NN O O
of NN O O
medulloblastomas NN O B-Disease
and NN O O
cPNETs NN O O
share NN O O
common NN O O
pathways NN O O
of NN O O
oncogenesis NN O O
related NN O O
to NN O O
hSNF5 NN O O
/ NN O O
INI1 NN O O
alteration NN O O
and NN O O
that NN O O
hSNF5 NN O O
/ NN O O
INI1 NN O O
mutations NN O O
define NN O O
a NN O O
genetically NN O O
homogeneous NN O O
family NN O O
of NN O O
highly NN O O
aggressive NN O O
cancers NN O B-Disease
mainly NN O O
occurring NN O O
in NN O O
young NN O O
children NN O O
and NN O O
frequently NN O O
, NN O O
but NN O O
not NN O O
always NN O O
, NN O O
exhibiting NN O O
a NN O O
rhabdoid NN O B-Disease
phenotype NN O O

Ataxin NN O O
- NN O O
3 NN O O
with NN O O
an NN O O
altered NN O O
conformation NN O O
that NN O O
exposes NN O O
the NN O O
polyglutamine NN O O
domain NN O O
is NN O O
associated NN O O
with NN O O
the NN O O
nuclear NN O O
matrix NN O O
. NN O O

Spinocerebellar NN O B-Disease
ataxia NN O I-Disease
type NN O I-Disease
- NN O I-Disease
3 NN O I-Disease
or NN O O
Machado NN O B-Disease
- NN O I-Disease
Joseph NN O I-Disease
disease NN O I-Disease
( NN O O
SCA3 NN O B-Disease
/ NN O O
MJD NN O B-Disease
) NN O O
is NN O O
a NN O O
member NN O O
of NN O O
the NN O O
CAG NN O B-Disease
/ NN O I-Disease
polyglutamine NN O I-Disease
repeat NN O I-Disease
disease NN O I-Disease
family NN O O
. NN O O

In NN O O
this NN O O
family NN O O
of NN O O
disorders NN O O
, NN O O
a NN O O
normally NN O O
polymorphic NN O O
CAG NN O O
repeat NN O O
becomes NN O O
expanded NN O O
, NN O O
resulting NN O O
in NN O O
expression NN O O
of NN O O
an NN O O
expanded NN O O
polyglutamine NN O O
domain NN O O
in NN O O
the NN O O
disease NN O O
gene NN O O
product NN O O
. NN O O

Experimental NN O O
models NN O O
of NN O O
polyglutamine NN O B-Disease
disease NN O I-Disease
implicate NN O O
the NN O O
nucleus NN O O
in NN O O
pathogenesis NN O O
; NN O O
however NN O O
, NN O O
the NN O O
link NN O O
between NN O O
intranuclear NN O O
expression NN O O
of NN O O
expanded NN O O
polyglutamine NN O O
and NN O O
neuronal NN O B-Disease
dysfunction NN O I-Disease
remains NN O O
unclear NN O O
. NN O O

Here NN O O
we NN O O
demonstrate NN O O
that NN O O
ataxin NN O O
- NN O O
3 NN O O
, NN O O
the NN O O
disease NN O O
protein NN O O
in NN O O
SCA3 NN O B-Disease
/ NN O O
MJD NN O B-Disease
, NN O O
adopts NN O O
a NN O O
unique NN O O
conformation NN O O
when NN O O
expressed NN O O
within NN O O
the NN O O
nucleus NN O O
of NN O O
transfected NN O O
cells NN O O
. NN O O

The NN O O
monoclonal NN O O
antibody NN O O
1C2 NN O O
is NN O O
known NN O O
preferentially NN O O
to NN O O
bind NN O O
expanded NN O O
polyglutamine NN O O
, NN O O
but NN O O
we NN O O
find NN O O
that NN O O
it NN O O
also NN O O
binds NN O O
a NN O O
fragment NN O O
of NN O O
ataxin NN O O
- NN O O
3 NN O O
containing NN O O
a NN O O
normal NN O O
glutamine NN O O
repeat NN O O
. NN O O

In NN O O
addition NN O O
, NN O O
expression NN O O
of NN O O
ataxin NN O O
- NN O O
3 NN O O
within NN O O
the NN O O
nucleus NN O O
exposes NN O O
the NN O O
glutamine NN O O
domain NN O O
of NN O O
the NN O O
full NN O O
- NN O O
length NN O O
non NN O O
- NN O O
pathological NN O O
protein NN O O
, NN O O
allowing NN O O
it NN O O
to NN O O
bind NN O O
the NN O O
monoclonal NN O O
antibody NN O O
1C2 NN O O
. NN O O

Fractionation NN O O
and NN O O
immunochemical NN O O
experiments NN O O
indicate NN O O
that NN O O
this NN O O
novel NN O O
conformation NN O O
of NN O O
intranuclear NN O O
ataxin NN O O
- NN O O
3 NN O O
is NN O O
not NN O O
due NN O O
to NN O O
proteolysis NN O O
, NN O O
suggesting NN O O
instead NN O O
that NN O O
association NN O O
with NN O O
nuclear NN O O
protein NN O O
( NN O O
s NN O O
) NN O O
alters NN O O
the NN O O
structure NN O O
of NN O O
full NN O O
- NN O O
length NN O O
ataxin NN O O
- NN O O
3 NN O O
which NN O O
exposes NN O O
the NN O O
polyglutamine NN O O
domain NN O O
. NN O O

This NN O O
conformationally NN O O
altered NN O O
ataxin NN O O
- NN O O
3 NN O O
is NN O O
bound NN O O
to NN O O
the NN O O
nuclear NN O O
matrix NN O O
. NN O O

The NN O O
pathological NN O O
form NN O O
of NN O O
ataxin NN O O
- NN O O
3 NN O O
with NN O O
an NN O O
expanded NN O O
polyglutamine NN O O
domain NN O O
also NN O O
associates NN O O
with NN O O
the NN O O
nuclear NN O O
matrix NN O O
. NN O O

These NN O O
data NN O O
suggest NN O O
that NN O O
an NN O O
early NN O O
event NN O O
in NN O O
the NN O O
pathogenesis NN O O
of NN O O
SCA3 NN O B-Disease
/ NN O O
MJD NN O B-Disease
may NN O O
be NN O O
an NN O O
altered NN O O
conformation NN O O
of NN O O
ataxin NN O O
- NN O O
3 NN O O
within NN O O
the NN O O
nucleus NN O O
that NN O O
exposes NN O O
the NN O O
polyglutamine NN O O
domain NN O O
. NN O O
. NN O O

The NN O O
human NN O O
MAGEL2 NN O O
gene NN O O
and NN O O
its NN O O
mouse NN O O
homologue NN O O
are NN O O
paternally NN O O
expressed NN O O
and NN O O
mapped NN O O
to NN O O
the NN O O
Prader NN O B-Disease
- NN O I-Disease
Willi NN O I-Disease
region NN O O
. NN O O

Prader NN O B-Disease
- NN O I-Disease
Willi NN O I-Disease
syndrome NN O I-Disease
( NN O O
PWS NN O B-Disease
) NN O O
is NN O O
a NN O O
complex NN O O
neurogenetic NN O B-Disease
disorder NN O I-Disease
. NN O O

The NN O O
phenotype NN O O
is NN O O
likely NN O O
to NN O O
be NN O O
a NN O O
contiguous NN O B-Disease
gene NN O I-Disease
syndrome NN O I-Disease
involving NN O O
genes NN O O
which NN O O
are NN O O
paternally NN O O
expressed NN O O
only NN O O
, NN O O
located NN O O
in NN O O
the NN O O
human NN O O
15q11 NN O O
- NN O O
q13 NN O O
region NN O O
. NN O O

Four NN O O
mouse NN O O
models NN O O
of NN O O
PWS NN O B-Disease
have NN O O
been NN O O
reported NN O O
but NN O O
these NN O O
do NN O O
not NN O O
definitively NN O O
allow NN O O
the NN O O
delineation NN O O
of NN O O
the NN O O
critical NN O O
region NN O O
and NN O O
the NN O O
associated NN O O
genes NN O O
involved NN O O
in NN O O
the NN O O
aetiology NN O O
of NN O O
PWS NN O B-Disease
. NN O O

Moreover NN O O
, NN O O
targeted NN O O
mutagenesis NN O O
of NN O O
mouse NN O O
homologues NN O O
of NN O O
the NN O O
human NN O O
candidate NN O O
PWS NN O B-Disease
genes NN O O
does NN O O
not NN O O
appear NN O O
to NN O O
result NN O O
in NN O O
any NN O O
of NN O O
the NN O O
features NN O O
of NN O O
PWS NN O B-Disease
. NN O O

Therefore NN O O
, NN O O
the NN O O
isolation NN O O
of NN O O
new NN O O
genes NN O O
in NN O O
this NN O O
region NN O O
remains NN O O
crucial NN O O
for NN O O
a NN O O
better NN O O
understanding NN O O
of NN O O
the NN O O
molecular NN O O
basis NN O O
of NN O O
PWS NN O B-Disease
. NN O O

In NN O O
this NN O O
manuscript NN O O
, NN O O
we NN O O
report NN O O
the NN O O
characterization NN O O
of NN O O
MAGEL2 NN O O
and NN O O
its NN O O
mouse NN O O
homologue NN O O
Magel2 NN O O
. NN O O

These NN O O
are NN O O
located NN O O
in NN O O
the NN O O
human NN O O
15q11 NN O O
- NN O O
q13 NN O O
and NN O O
mouse NN O O
7C NN O O
regions NN O O
, NN O O
in NN O O
close NN O O
proximity NN O O
to NN O O
NDN NN O O
/ NN O O
Ndn NN O O
. NN O O

By NN O O
northern NN O O
blot NN O O
analysis NN O O
we NN O O
did NN O O
not NN O O
detect NN O O
any NN O O
expression NN O O
of NN O O
MAGEL2 NN O O
/ NN O O
Magel2 NN O O
but NN O O
by NN O O
RT NN O O
- NN O O
PCR NN O O
analysis NN O O
, NN O O
specific NN O O
expression NN O O
was NN O O
detected NN O O
in NN O O
fetal NN O O
and NN O O
adult NN O O
brain NN O O
and NN O O
in NN O O
placenta NN O O
. NN O O

Both NN O O
genes NN O O
are NN O O
intronless NN O O
with NN O O
tandem NN O O
direct NN O O
repeat NN O O
sequences NN O O
contained NN O O
within NN O O
a NN O O
CpG NN O O
island NN O O
in NN O O
the NN O O
5 NN O O
- NN O O
untranscribed NN O O
region NN O O
. NN O O

The NN O O
transcripts NN O O
encode NN O O
putative NN O O
proteins NN O O
that NN O O
are NN O O
homologous NN O O
to NN O O
the NN O O
MAGE NN O O
proteins NN O O
and NN O O
NDN NN O O
. NN O O

Moreover NN O O
, NN O O
MAGEL2 NN O O
/ NN O O
Magel2 NN O O
are NN O O
expressed NN O O
only NN O O
from NN O O
the NN O O
paternal NN O O
allele NN O O
in NN O O
brain NN O O
, NN O O
suggesting NN O O
a NN O O
potential NN O O
role NN O O
in NN O O
the NN O O
aetiology NN O O
of NN O O
PWS NN O B-Disease
and NN O O
its NN O O
mouse NN O O
model NN O O
, NN O O
respectively NN O O
. NN O O
. NN O O

cDNA NN O O
microarrays NN O O
detect NN O O
activation NN O O
of NN O O
a NN O O
myogenic NN O O
transcription NN O O
program NN O O
by NN O O
the NN O O
PAX3 NN O O
- NN O O
FKHR NN O O
fusion NN O O
oncogene NN O O
. NN O O

Alveolar NN O B-Disease
rhabdomyosarcoma NN O I-Disease
is NN O O
an NN O O
aggressive NN O O
pediatric NN O B-Disease
cancer NN O I-Disease
of NN O I-Disease
striated NN O I-Disease
muscle NN O I-Disease
characterized NN O O
in NN O O
60 NN O O
% NN O O
of NN O O
cases NN O O
by NN O O
a NN O O
t NN O O
( NN O O
2 NN O O
; NN O O
13 NN O O
) NN O O
( NN O O
q35 NN O O
; NN O O
q14 NN O O
) NN O O
. NN O O

This NN O O
results NN O O
in NN O O
the NN O O
fusion NN O O
of NN O O
PAX3 NN O O
, NN O O
a NN O O
developmental NN O O
transcription NN O O
factor NN O O
required NN O O
for NN O O
limb NN O O
myogenesis NN O O
, NN O O
with NN O O
FKHR NN O O
, NN O O
a NN O O
member NN O O
of NN O O
the NN O O
forkhead NN O O
family NN O O
of NN O O
transcription NN O O
factors NN O O
. NN O O

The NN O O
resultant NN O O
PAX3 NN O O
- NN O O
FKHR NN O O
gene NN O O
possesses NN O O
transforming NN O O
properties NN O O
; NN O O
however NN O O
, NN O O
the NN O O
effects NN O O
of NN O O
this NN O O
chimeric NN O O
oncogene NN O O
on NN O O
gene NN O O
expression NN O O
are NN O O
largely NN O O
unknown NN O O
. NN O O

To NN O O
investigate NN O O
the NN O O
actions NN O O
of NN O O
these NN O O
transcription NN O O
factors NN O O
, NN O O
both NN O O
Pax3 NN O O
and NN O O
PAX3 NN O O
- NN O O
FKHR NN O O
were NN O O
introduced NN O O
into NN O O
NIH NN O O
3T3 NN O O
cells NN O O
, NN O O
and NN O O
the NN O O
resultant NN O O
gene NN O O
expression NN O O
changes NN O O
were NN O O
analyzed NN O O
with NN O O
a NN O O
murine NN O O
cDNA NN O O
microarray NN O O
containing NN O O
2 NN O O
, NN O O
225 NN O O
elements NN O O
. NN O O

We NN O O
found NN O O
that NN O O
PAX3 NN O O
- NN O O
FKHR NN O O
but NN O O
not NN O O
PAX3 NN O O
activated NN O O
a NN O O
myogenic NN O O
transcription NN O O
program NN O O
including NN O O
the NN O O
induction NN O O
of NN O O
transcription NN O O
factors NN O O
MyoD NN O O
, NN O O
Myogenin NN O O
, NN O O
Six1 NN O O
, NN O O
and NN O O
Slug NN O O
as NN O O
well NN O O
as NN O O
a NN O O
battery NN O O
of NN O O
genes NN O O
involved NN O O
in NN O O
several NN O O
aspects NN O O
of NN O O
muscle NN O O
function NN O O
. NN O O

Notable NN O O
among NN O O
this NN O O
group NN O O
were NN O O
the NN O O
growth NN O O
factor NN O O
gene NN O O
Igf2 NN O O
and NN O O
its NN O O
binding NN O O
protein NN O O
Igfbp5 NN O O
. NN O O

Relevance NN O O
of NN O O
this NN O O
model NN O O
was NN O O
suggested NN O O
by NN O O
verification NN O O
that NN O O
three NN O O
of NN O O
these NN O O
genes NN O O
( NN O O
IGFBP5 NN O O
, NN O O
HSIX1 NN O O
, NN O O
and NN O O
Slug NN O O
) NN O O
were NN O O
also NN O O
expressed NN O O
in NN O O
alveolar NN O B-Disease
rhabdomyosarcoma NN O I-Disease
cell NN O O
lines NN O O
. NN O O

This NN O O
study NN O O
utilizes NN O O
cDNA NN O O
microarrays NN O O
to NN O O
elucidate NN O O
the NN O O
pattern NN O O
of NN O O
gene NN O O
expression NN O O
induced NN O O
by NN O O
an NN O O
oncogenic NN O O
transcription NN O O
factor NN O O
and NN O O
demonstrates NN O O
the NN O O
profound NN O O
myogenic NN O O
properties NN O O
of NN O O
PAX3 NN O O
- NN O O
FKHR NN O O
in NN O O
NIH NN O O
3T3 NN O O
cells NN O O
. NN O O
. NN O O

Experimental NN O O
hemochromatosis NN O B-Disease
due NN O O
to NN O O
MHC NN O O
class NN O O
I NN O O
HFE NN O B-Disease
deficiency NN O I-Disease
: NN O O
immune NN O O
status NN O O
and NN O O
iron NN O O
metabolism NN O O
. NN O O

The NN O O
puzzling NN O O
linkage NN O O
between NN O O
genetic NN O O
hemochromatosis NN O B-Disease
and NN O O
histocompatibility NN O O
loci NN O O
became NN O O
even NN O O
more NN O O
so NN O O
when NN O O
the NN O O
gene NN O O
involved NN O O
, NN O O
HFE NN O O
, NN O O
was NN O O
identified NN O O
. NN O O

Indeed NN O O
, NN O O
within NN O O
the NN O O
well NN O O
defined NN O O
, NN O O
mainly NN O O
peptide NN O O
- NN O O
binding NN O O
, NN O O
MHC NN O O
class NN O O
I NN O O
family NN O O
of NN O O
molecules NN O O
, NN O O
HFE NN O O
seems NN O O
to NN O O
perform NN O O
an NN O O
unusual NN O O
yet NN O O
essential NN O O
function NN O O
. NN O O

As NN O O
yet NN O O
, NN O O
our NN O O
understanding NN O O
of NN O O
HFE NN O O
function NN O O
in NN O O
iron NN O O
homeostasis NN O O
is NN O O
only NN O O
partial NN O O
; NN O O
an NN O O
even NN O O
more NN O O
open NN O O
question NN O O
is NN O O
its NN O O
possible NN O O
role NN O O
in NN O O
the NN O O
immune NN O O
system NN O O
. NN O O

To NN O O
advance NN O O
on NN O O
both NN O O
of NN O O
these NN O O
avenues NN O O
, NN O O
we NN O O
report NN O O
the NN O O
deletion NN O O
of NN O O
HFE NN O O
alpha1 NN O O
and NN O O
alpha2 NN O O
putative NN O O
ligand NN O O
binding NN O O
domains NN O O
in NN O O
vivo NN O O
. NN O O

HFE NN O B-Disease
- NN O I-Disease
deficient NN O I-Disease
animals NN O O
were NN O O
analyzed NN O O
for NN O O
a NN O O
comprehensive NN O O
set NN O O
of NN O O
metabolic NN O O
and NN O O
immune NN O O
parameters NN O O
. NN O O

Faithfully NN O O
mimicking NN O O
human NN O O
hemochromatosis NN O B-Disease
, NN O O
mice NN O O
homozygous NN O O
for NN O O
this NN O O
deletion NN O O
develop NN O O
iron NN O O
overload NN O O
, NN O O
characterized NN O O
by NN O O
a NN O O
higher NN O O
plasma NN O O
iron NN O O
content NN O O
and NN O O
a NN O O
raised NN O O
transferrin NN O O
saturation NN O O
as NN O O
well NN O O
as NN O O
an NN O O
elevated NN O O
hepatic NN O O
iron NN O O
load NN O O
. NN O O

The NN O O
primary NN O O
defect NN O O
could NN O O
, NN O O
indeed NN O O
, NN O O
be NN O O
traced NN O O
to NN O O
an NN O O
augmented NN O O
duodenal NN O O
iron NN O O
absorption NN O O
. NN O O

In NN O O
parallel NN O O
, NN O O
measurement NN O O
of NN O O
the NN O O
gut NN O O
mucosal NN O O
iron NN O O
content NN O O
as NN O O
well NN O O
as NN O O
iron NN O O
regulatory NN O O
proteins NN O O
allows NN O O
a NN O O
more NN O O
informed NN O O
evaluation NN O O
of NN O O
various NN O O
hypotheses NN O O
regarding NN O O
the NN O O
precise NN O O
role NN O O
of NN O O
HFE NN O O
in NN O O
iron NN O O
homeostasis NN O O
. NN O O

Finally NN O O
, NN O O
an NN O O
extensive NN O O
phenotyping NN O O
of NN O O
primary NN O O
and NN O O
secondary NN O O
lymphoid NN O O
organs NN O O
including NN O O
the NN O O
gut NN O O
provides NN O O
no NN O O
compelling NN O O
evidence NN O O
for NN O O
an NN O O
obvious NN O O
immune NN O O
- NN O O
linked NN O O
function NN O O
for NN O O
HFE NN O O
. NN O O
. NN O O

Somatic NN O O
rearrangement NN O O
of NN O O
chromosome NN O O
14 NN O O
in NN O O
human NN O O
lymphocytes NN O O
. NN O O

Ataxia NN O B-Disease
- NN O I-Disease
telangiectasia NN O I-Disease
is NN O O
a NN O O
rare NN O O
genetic NN O B-Disease
disorder NN O I-Disease
associated NN O O
with NN O O
immune NN O B-Disease
deficiency NN O I-Disease
, NN O O
chromosome NN O B-Disease
instability NN O I-Disease
, NN O O
and NN O O
a NN O O
predisposition NN O O
to NN O O
lymphoid NN O B-Disease
malignancy NN O I-Disease
. NN O O

We NN O O
have NN O O
detected NN O O
chromosomally NN O O
anomalous NN O O
clones NN O O
of NN O O
lymphocytes NN O O
in NN O O
eight NN O O
patients NN O O
with NN O O
this NN O O
disorder NN O O
. NN O O

Chromosome NN O O
banding NN O O
disclosed NN O O
that NN O O
the NN O O
clones NN O O
are NN O O
consistently NN O O
marked NN O O
by NN O O
structural NN O O
rearrangement NN O O
of NN O O
the NN O O
long NN O O
arm NN O O
( NN O O
q NN O O
) NN O O
of NN O O
chromosome NN O O
14 NN O O
. NN O O

A NN O O
translocation NN O O
involving NN O O
14q NN O O
was NN O O
found NN O O
in NN O O
clones NN O O
obtained NN O O
from NN O O
seven NN O O
of NN O O
the NN O O
eight NN O O
patients NN O O
whereas NN O O
a NN O O
ring NN O O
14 NN O O
chromosome NN O O
was NN O O
found NN O O
in NN O O
a NN O O
clone NN O O
obtained NN O O
from NN O O
the NN O O
other NN O O
. NN O O

These NN O O
findings NN O O
as NN O O
well NN O O
as NN O O
data NN O O
obtained NN O O
by NN O O
others NN O O
for NN O O
patients NN O O
with NN O O
ataxia NN O B-Disease
- NN O I-Disease
telangiectasia NN O I-Disease
suggest NN O O
that NN O O
structural NN O O
rearrangement NN O O
of NN O O
14q NN O O
is NN O O
the NN O O
initial NN O O
chromosomal NN O O
change NN O O
in NN O O
lymphocyte NN O O
clones NN O O
of NN O O
patients NN O O
with NN O O
this NN O O
disorder NN O O
. NN O O

Chromosomes NN O O
of NN O O
lymphocytes NN O O
from NN O O
one NN O O
of NN O O
the NN O O
patients NN O O
were NN O O
studied NN O O
before NN O O
and NN O O
after NN O O
the NN O O
onset NN O O
of NN O O
chronic NN O B-Disease
lymphocytic NN O I-Disease
leukemia NN O I-Disease
. NN O O

Before NN O O
leukemia NN O B-Disease
was NN O O
diagnosed NN O O
, NN O O
the NN O O
patient NN O O
had NN O O
a NN O O
lymphocyte NN O O
clone NN O O
with NN O O
a NN O O
14q NN O O
translocation NN O O
. NN O O

This NN O O
clone NN O O
appears NN O O
to NN O O
have NN O O
given NN O O
rise NN O O
to NN O O
the NN O O
leukemic NN O B-Disease
cells NN O O
. NN O O

We NN O O
hypothesize NN O O
that NN O O
structural NN O O
rearrangement NN O O
of NN O O
14q NN O O
is NN O O
directly NN O O
related NN O O
to NN O O
abnormal NN O O
growth NN O O
of NN O O
lymphocytes NN O O
and NN O O
that NN O O
it NN O O
may NN O O
be NN O O
a NN O O
step NN O O
toward NN O O
the NN O O
development NN O O
of NN O O
lymphoid NN O B-Disease
malignancies NN O I-Disease
. NN O O

Increasing NN O O
evidence NN O O
, NN O O
provided NN O O
by NN O O
others NN O O
, NN O O
for NN O O
the NN O O
nonrandom NN O O
involvement NN O O
of NN O O
14q NN O O
in NN O O
African NN O O
- NN O O
type NN O O
Burkitts NN O B-Disease
lymphoma NN O I-Disease
and NN O O
other NN O O
lymphoid NN O B-Disease
neoplasms NN O I-Disease
further NN O O
strengthens NN O O
this NN O O
hypothesis NN O O
. NN O O
. NN O O

Exon NN O O
9 NN O O
mutations NN O O
in NN O O
the NN O O
WT1 NN O O
gene NN O O
, NN O O
without NN O O
influencing NN O O
KTS NN O O
splice NN O O
isoforms NN O O
, NN O O
are NN O O
also NN O O
responsible NN O O
for NN O O
Frasier NN O B-Disease
syndrome NN O I-Disease
. NN O O

We NN O O
report NN O O
new NN O O
mutations NN O O
in NN O O
exon NN O O
9 NN O O
of NN O O
the NN O O
WT1 NN O O
gene NN O O
that NN O O
did NN O O
not NN O O
alter NN O O
the NN O O
ratio NN O O
of NN O O
+ NN O O
/ NN O O
- NN O O
KTS NN O O
splice NN O O
isoforms NN O O
in NN O O
two NN O O
unrelated NN O O
patients NN O O
with NN O O
Frasier NN O B-Disease
syndrome NN O I-Disease
( NN O O
FS NN O B-Disease
) NN O O
. NN O O

The NN O O
mutation NN O O
of NN O O
intron NN O O
9 NN O O
inducing NN O O
defective NN O O
alternative NN O O
splicing NN O O
was NN O O
reported NN O O
to NN O O
be NN O O
responsible NN O O
for NN O O
this NN O O
syndrome NN O O
. NN O O

The NN O O
mutations NN O O
found NN O O
in NN O O
our NN O O
cases NN O O
occurred NN O O
in NN O O
the NN O O
same NN O O
exon NN O O
of NN O O
the NN O O
WT1 NN O O
gene NN O O
as NN O O
detected NN O O
in NN O O
Denys NN O B-Disease
- NN O I-Disease
Drash NN O I-Disease
syndrome NN O I-Disease
( NN O O
DDS NN O B-Disease
) NN O O
and NN O O
could NN O O
not NN O O
be NN O O
explained NN O O
by NN O O
the NN O O
previously NN O O
proposed NN O O
mechanism NN O O
. NN O O

The NN O O
results NN O O
suggest NN O O
that NN O O
the NN O O
two NN O O
syndromes NN O O
originate NN O O
from NN O O
the NN O O
same NN O O
WT1 NN O B-Disease
gene NN O I-Disease
abnormality NN O I-Disease
. NN O O

From NN O O
a NN O O
molecular NN O O
biological NN O O
point NN O O
of NN O O
view NN O O
, NN O O
we NN O O
concluded NN O O
that NN O O
the NN O O
two NN O O
diseases NN O O
were NN O O
not NN O O
separable NN O O
, NN O O
and NN O O
that NN O O
FS NN O B-Disease
should NN O O
be NN O O
included NN O O
as NN O O
an NN O O
atypical NN O O
form NN O O
of NN O O
DDS NN O B-Disease
. NN O O
. NN O O

Splice NN O O
- NN O O
site NN O O
mutation NN O O
in NN O O
the NN O O
PDS NN O B-Disease
gene NN O O
may NN O O
result NN O O
in NN O O
intrafamilial NN O O
variability NN O O
for NN O O
deafness NN O B-Disease
in NN O O
Pendred NN O B-Disease
syndrome NN O I-Disease
. NN O O

Pendred NN O B-Disease
syndrome NN O I-Disease
is NN O O
a NN O O
recessive NN O B-Disease
inherited NN O I-Disease
disorder NN O I-Disease
that NN O O
consists NN O O
of NN O O
developmental NN O B-Disease
abnormalities NN O I-Disease
of NN O I-Disease
the NN O I-Disease
cochlea NN O I-Disease
, NN O O
sensorineural NN O B-Disease
hearing NN O I-Disease
loss NN O I-Disease
, NN O O
and NN O O
diffuse NN O B-Disease
thyroid NN O I-Disease
enlargement NN O I-Disease
( NN O O
goiter NN O B-Disease
) NN O O
. NN O O

This NN O O
disorder NN O O
may NN O O
account NN O O
for NN O O
up NN O O
to NN O O
10 NN O O
% NN O O
of NN O O
cases NN O O
of NN O O
hereditary NN O B-Disease
deafness NN O I-Disease
. NN O O

The NN O O
disease NN O O
gene NN O O
( NN O O
PDS NN O B-Disease
) NN O O
has NN O O
been NN O O
mapped NN O O
to NN O O
chromosome NN O O
7q22 NN O O
- NN O O
q31 NN O O
, NN O O
and NN O O
encodes NN O O
a NN O O
chloride NN O O
- NN O O
iodide NN O O
transport NN O O
protein NN O O
. NN O O

We NN O O
performed NN O O
mutation NN O O
analysis NN O O
of NN O O
individual NN O O
exons NN O O
of NN O O
the NN O O
PDS NN O B-Disease
gene NN O O
in NN O O
one NN O O
Spanish NN O O
family NN O O
that NN O O
shows NN O O
intrafamilial NN O O
variability NN O O
of NN O O
the NN O O
deafness NN O B-Disease
phenotype NN O O
( NN O O
two NN O O
patients NN O O
with NN O O
profound NN O O
and NN O O
one NN O O
with NN O O
moderate NN O O
- NN O O
severe NN O O
deafness NN O B-Disease
) NN O O
. NN O O

We NN O O
identified NN O O
a NN O O
new NN O O
splice NN O O
- NN O O
site NN O O
mutation NN O O
affecting NN O O
intron NN O O
4 NN O O
of NN O O
the NN O O
PDS NN O B-Disease
gene NN O O
, NN O O
at NN O O
nucleotide NN O O
position NN O O
639 NN O O
+ NN O O
7 NN O O
. NN O O

RNA NN O O
analysis NN O O
from NN O O
lymphocytes NN O O
of NN O O
the NN O O
affected NN O O
patients NN O O
showed NN O O
that NN O O
mutation NN O O
639 NN O O
+ NN O O
7A NN O O
- NN O O
- NN O O
> NN O O
G NN O O
generates NN O O
a NN O O
new NN O O
donor NN O O
splice NN O O
site NN O O
, NN O O
leading NN O O
to NN O O
an NN O O
mRNA NN O O
with NN O O
an NN O O
insertion NN O O
of NN O O
six NN O O
nucleotides NN O O
from NN O O
intron NN O O
4 NN O O
of NN O O
PDS NN O O
. NN O O

Since NN O O
the NN O O
newly NN O O
created NN O O
donor NN O O
splice NN O O
site NN O O
is NN O O
likely NN O O
to NN O O
compete NN O O
with NN O O
the NN O O
normal NN O O
one NN O O
, NN O O
variations NN O O
of NN O O
the NN O O
levels NN O O
of NN O O
normal NN O O
and NN O O
aberrant NN O O
transcripts NN O O
of NN O O
the NN O O
PDS NN O B-Disease
gene NN O O
in NN O O
the NN O O
cochlea NN O O
may NN O O
explain NN O O
the NN O O
variability NN O O
in NN O O
the NN O O
deafness NN O B-Disease
presentation NN O O
. NN O O
. NN O O

The NN O O
molecular NN O O
basis NN O O
of NN O O
Sjogren NN O B-Disease
- NN O I-Disease
Larsson NN O I-Disease
syndrome NN O I-Disease
: NN O O
mutation NN O O
analysis NN O O
of NN O O
the NN O O
fatty NN O O
aldehyde NN O O
dehydrogenase NN O O
gene NN O O
. NN O O

Sjogren NN O B-Disease
- NN O I-Disease
Larsson NN O I-Disease
syndrome NN O I-Disease
( NN O O
SLS NN O B-Disease
) NN O O
is NN O O
an NN O O
autosomal NN O B-Disease
recessive NN O I-Disease
disorder NN O I-Disease
characterized NN O O
by NN O O
ichthyosis NN O B-Disease
, NN O O
mental NN O B-Disease
retardation NN O I-Disease
, NN O O
spasticity NN O B-Disease
, NN O O
and NN O O
deficient NN O B-Disease
activity NN O I-Disease
of NN O I-Disease
fatty NN O I-Disease
aldehyde NN O I-Disease
dehydrogenase NN O I-Disease
( NN O O
FALDH NN O O
) NN O O
. NN O O

To NN O O
define NN O O
the NN O O
molecular NN O O
defects NN O O
causing NN O O
SLS NN O B-Disease
, NN O O
we NN O O
performed NN O O
mutation NN O O
analysis NN O O
of NN O O
the NN O O
FALDH NN O O
gene NN O O
in NN O O
probands NN O O
from NN O O
63 NN O O
kindreds NN O O
with NN O O
SLS NN O B-Disease
. NN O O

Among NN O O
these NN O O
patients NN O O
, NN O O
49 NN O O
different NN O O
mutations NN O O
- NN O O
including NN O O
10 NN O O
deletions NN O O
, NN O O
2 NN O O
insertions NN O O
, NN O O
22 NN O O
amino NN O O
acid NN O O
substitutions NN O O
, NN O O
3 NN O O
nonsense NN O O
mutations NN O O
, NN O O
9 NN O O
splice NN O O
- NN O O
site NN O O
defects NN O O
, NN O O
and NN O O
3 NN O O
complex NN O O
mutations NN O O
- NN O O
were NN O O
found NN O O
. NN O O

All NN O O
of NN O O
the NN O O
patients NN O O
with NN O O
SLS NN O B-Disease
were NN O O
found NN O O
to NN O O
carry NN O O
mutations NN O O
. NN O O

Nineteen NN O O
of NN O O
the NN O O
missense NN O O
mutations NN O O
resulted NN O O
in NN O O
a NN O O
severe NN O O
reduction NN O O
of NN O O
FALDH NN O O
enzyme NN O O
catalytic NN O O
activity NN O O
when NN O O
expressed NN O O
in NN O O
mammalian NN O O
cells NN O O
, NN O O
but NN O O
one NN O O
mutation NN O O
( NN O O
798G NN O O
- NN O O
- NN O O
> NN O O
C NN O O
[ NN O O
K266N NN O O
] NN O O
) NN O O
seemed NN O O
to NN O O
have NN O O
a NN O O
greater NN O O
effect NN O O
on NN O O
mRNA NN O O
stability NN O O
. NN O O

The NN O O
splice NN O O
- NN O O
site NN O O
mutations NN O O
led NN O O
to NN O O
exon NN O O
skipping NN O O
or NN O O
utilization NN O O
of NN O O
cryptic NN O O
acceptor NN O O
- NN O O
splice NN O O
sites NN O O
. NN O O

Thirty NN O O
- NN O O
seven NN O O
mutations NN O O
were NN O O
private NN O O
, NN O O
and NN O O
12 NN O O
mutations NN O O
were NN O O
seen NN O O
in NN O O
two NN O O
or NN O O
more NN O O
probands NN O O
of NN O O
European NN O O
or NN O O
Middle NN O O
Eastern NN O O
descent NN O O
. NN O O

Four NN O O
single NN O O
- NN O O
nucleotide NN O O
polymorphisms NN O O
( NN O O
SNPs NN O O
) NN O O
were NN O O
found NN O O
in NN O O
the NN O O
FALDH NN O O
gene NN O O
. NN O O

At NN O O
least NN O O
four NN O O
of NN O O
the NN O O
common NN O O
mutations NN O O
( NN O O
551C NN O O
- NN O O
- NN O O
> NN O O
T NN O O
, NN O O
682C NN O O
- NN O O
- NN O O
> NN O O
T NN O O
, NN O O
733G NN O O
- NN O O
- NN O O
> NN O O
A NN O O
, NN O O
and NN O O
798 NN O O
+ NN O O
1delG NN O O
) NN O O
were NN O O
associated NN O O
with NN O O
multiple NN O O
SNP NN O O
haplotypes NN O O
, NN O O
suggesting NN O O
that NN O O
these NN O O
mutations NN O O
originated NN O O
independently NN O O
on NN O O
more NN O O
than NN O O
one NN O O
occasion NN O O
or NN O O
were NN O O
ancient NN O O
SLS NN O B-Disease
genes NN O O
that NN O O
had NN O O
undergone NN O O
intragenic NN O O
recombination NN O O
. NN O O

Our NN O O
results NN O O
demonstrate NN O O
that NN O O
SLS NN O B-Disease
is NN O O
caused NN O O
by NN O O
a NN O O
strikingly NN O O
heterogeneous NN O O
group NN O O
of NN O O
mutations NN O O
in NN O O
the NN O O
FALDH NN O O
gene NN O O
and NN O O
provide NN O O
a NN O O
framework NN O O
for NN O O
understanding NN O O
the NN O O
genetic NN O O
basis NN O O
of NN O O
SLS NN O B-Disease
and NN O O
the NN O O
development NN O O
of NN O O
DNA NN O O
- NN O O
based NN O O
diagnostic NN O O
tests NN O O
. NN O O
. NN O O

Loss NN O O
- NN O O
of NN O O
- NN O O
function NN O O
mutations NN O O
in NN O O
the NN O O
cathepsin NN O O
C NN O O
gene NN O O
result NN O O
in NN O O
periodontal NN O B-Disease
disease NN O I-Disease
and NN O O
palmoplantar NN O B-Disease
keratosis NN O I-Disease
. NN O O

Papillon NN O B-Disease
- NN O I-Disease
Lefevre NN O I-Disease
syndrome NN O I-Disease
, NN O O
or NN O O
keratosis NN O B-Disease
palmoplantaris NN O I-Disease
with NN O O
periodontopathia NN O B-Disease
( NN O O
PLS NN O B-Disease
, NN O O
MIM NN O O
245000 NN O O
) NN O O
, NN O O
is NN O O
an NN O O
autosomal NN O B-Disease
recessive NN O I-Disease
disorder NN O I-Disease
that NN O O
is NN O O
mainly NN O O
ascertained NN O O
by NN O O
dentists NN O O
because NN O O
of NN O O
the NN O O
severe NN O O
periodontitis NN O B-Disease
that NN O O
afflicts NN O O
patients NN O O
. NN O O

Both NN O O
the NN O O
deciduous NN O O
and NN O O
permanent NN O O
dentitions NN O O
are NN O O
affected NN O O
, NN O O
resulting NN O O
in NN O O
premature NN O O
tooth NN O B-Disease
loss NN O I-Disease
. NN O O

Palmoplantar NN O B-Disease
keratosis NN O I-Disease
, NN O O
varying NN O O
from NN O O
mild NN O O
psoriasiform NN O O
scaly NN O O
skin NN O O
to NN O O
overt NN O O
hyperkeratosis NN O B-Disease
, NN O O
typically NN O O
develops NN O O
within NN O O
the NN O O
first NN O O
three NN O O
years NN O O
of NN O O
life NN O O
. NN O O

Keratosis NN O B-Disease
also NN O O
affects NN O O
other NN O O
sites NN O O
such NN O O
as NN O O
elbows NN O O
and NN O O
knees NN O O
. NN O O

Most NN O O
PLS NN O B-Disease
patients NN O O
display NN O O
both NN O O
periodontitis NN O B-Disease
and NN O O
hyperkeratosis NN O B-Disease
. NN O O

Some NN O O
patients NN O O
have NN O O
only NN O O
palmoplantar NN O B-Disease
keratosis NN O I-Disease
or NN O O
periodontitis NN O B-Disease
, NN O O
and NN O O
in NN O O
rare NN O O
individuals NN O O
the NN O O
periodontitis NN O B-Disease
is NN O O
mild NN O O
and NN O O
of NN O O
late NN O O
onset NN O O
. NN O O

The NN O O
PLS NN O O
locus NN O O
has NN O O
been NN O O
mapped NN O O
to NN O O
chromosome NN O O
11q14 NN O O
- NN O O
q21 NN O O
( NN O O
refs NN O O
7 NN O O
, NN O O
8 NN O O
, NN O O
9 NN O O
) NN O O
. NN O O

Using NN O O
homozygosity NN O O
mapping NN O O
in NN O O
eight NN O O
small NN O O
consanguineous NN O O
families NN O O
, NN O O
we NN O O
have NN O O
narrowed NN O O
the NN O O
candidate NN O O
region NN O O
to NN O O
a NN O O
1 NN O O
. NN O O

2 NN O O
- NN O O
cM NN O O
interval NN O O
between NN O O
D11S4082 NN O O
and NN O O
D11S931 NN O O
. NN O O

The NN O O
gene NN O O
( NN O O
CTSC NN O O
) NN O O
encoding NN O O
the NN O O
lysosomal NN O O
protease NN O O
cathepsin NN O O
C NN O O
( NN O O
or NN O O
dipeptidyl NN O O
aminopeptidase NN O O
I NN O O
) NN O O
lies NN O O
within NN O O
this NN O O
interval NN O O
. NN O O

We NN O O
defined NN O O
the NN O O
genomic NN O O
structure NN O O
of NN O O
CTSC NN O O
and NN O O
found NN O O
mutations NN O O
in NN O O
all NN O O
eight NN O O
families NN O O
. NN O O

In NN O O
two NN O O
of NN O O
these NN O O
families NN O O
we NN O O
used NN O O
a NN O O
functional NN O O
assay NN O O
to NN O O
demonstrate NN O O
an NN O O
almost NN O O
total NN O O
loss NN O O
of NN O O
cathepsin NN O O
C NN O O
activity NN O O
in NN O O
PLS NN O B-Disease
patients NN O O
and NN O O
reduced NN O O
activity NN O O
in NN O O
obligate NN O O
carriers NN O O
. NN O O

Confirmation NN O O
of NN O O
linkage NN O O
of NN O O
Van NN O B-Disease
der NN O I-Disease
Woude NN O I-Disease
syndrome NN O I-Disease
to NN O O
chromosome NN O O
1q32 NN O O
: NN O O
evidence NN O O
of NN O O
association NN O O
with NN O O
STR NN O O
alleles NN O O
suggests NN O O
possible NN O O
unique NN O O
origin NN O O
of NN O O
the NN O O
disease NN O O
mutation NN O O
. NN O O

Van NN O B-Disease
der NN O I-Disease
Woude NN O I-Disease
syndrome NN O I-Disease
( NN O O
VWS NN O B-Disease
) NN O O
is NN O O
an NN O O
autosomal NN O B-Disease
dominant NN O I-Disease
craniofacial NN O I-Disease
disorder NN O I-Disease
with NN O O
high NN O O
penetrance NN O O
and NN O O
variable NN O O
expression NN O O
. NN O O

Its NN O O
clinical NN O O
features NN O O
are NN O O
variably NN O O
expressed NN O O
, NN O O
but NN O O
include NN O O
cleft NN O B-Disease
lip NN O I-Disease
and NN O O
/ NN O O
or NN O O
cleft NN O B-Disease
palate NN O I-Disease
, NN O O
lip NN O B-Disease
pits NN O I-Disease
and NN O O
hypodontia NN O B-Disease
. NN O O

All NN O O
VWS NN O B-Disease
families NN O O
studied NN O O
to NN O O
date NN O O
map NN O O
the NN O O
disease NN O O
gene NN O O
to NN O O
a NN O O
< NN O O
2 NN O O
cM NN O O
region NN O O
of NN O O
chromosome NN O O
1q32 NN O O
, NN O O
with NN O O
no NN O O
evidence NN O O
of NN O O
locus NN O O
heterogeneity NN O O
. NN O O

The NN O O
aim NN O O
of NN O O
this NN O O
study NN O O
is NN O O
to NN O O
refine NN O O
the NN O O
localization NN O O
of NN O O
the NN O O
VWS NN O B-Disease
gene NN O O
and NN O O
to NN O O
further NN O O
assess NN O O
possible NN O O
heterogeneity NN O O
. NN O O

We NN O O
analyzed NN O O
four NN O O
multiplex NN O O
VWS NN O B-Disease
families NN O O
. NN O O

All NN O O
available NN O O
members NN O O
were NN O O
clinically NN O O
assessed NN O O
and NN O O
genotyped NN O O
for NN O O
19 NN O O
short NN O O
tandem NN O O
repeat NN O O
markers NN O O
on NN O O
chromosome NN O O
1 NN O O
in NN O O
the NN O O
VWS NN O B-Disease
candidate NN O O
gene NN O O
region NN O O
. NN O O

We NN O O
performed NN O O
two NN O O
- NN O O
point NN O O
and NN O O
multipoint NN O O
limit NN O O
of NN O O
detection NN O O
( NN O O
LOD NN O O
) NN O O
score NN O O
analyses NN O O
using NN O O
a NN O O
high NN O O
penetrance NN O O
autosomal NN O O
dominant NN O O
model NN O O
. NN O O

All NN O O
families NN O O
showed NN O O
positive NN O O
LOD NN O O
scores NN O O
without NN O O
any NN O O
recombination NN O O
in NN O O
the NN O O
candidate NN O O
region NN O O
. NN O O

The NN O O
largest NN O O
two NN O O
- NN O O
point NN O O
LOD NN O O
score NN O O
was NN O O
5 NN O O
. NN O O

87 NN O O
87 NN O O
. NN O O

Our NN O O
assay NN O O
method NN O O
for NN O O
short NN O O
tandem NN O O
repeat NN O O
( NN O O
STR NN O O
) NN O O
markers NN O O
provided NN O O
highly NN O O
accurate NN O O
size NN O O
estimation NN O O
of NN O O
marker NN O O
allele NN O O
fragment NN O O
sizes NN O O
, NN O O
and NN O O
therefore NN O O
enabled NN O O
us NN O O
to NN O O
determine NN O O
the NN O O
specific NN O O
alleles NN O O
segregating NN O O
with NN O O
the NN O O
VWS NN O B-Disease
gene NN O O
in NN O O
each NN O O
of NN O O
our NN O O
four NN O O
families NN O O
. NN O O

We NN O O
observed NN O O
a NN O O
striking NN O O
pattern NN O O
of NN O O
STR NN O O
allele NN O O
sharing NN O O
at NN O O
several NN O O
closely NN O O
linked NN O O
loci NN O O
among NN O O
our NN O O
four NN O O
Caucasian NN O O
VWS NN O B-Disease
families NN O O
recruited NN O O
at NN O O
three NN O O
different NN O O
locations NN O O
in NN O O
the NN O O
US NN O O
. NN O O

These NN O O
results NN O O
suggest NN O O
the NN O O
possibility NN O O
of NN O O
a NN O O
unique NN O O
origin NN O O
for NN O O
a NN O O
mutation NN O O
responsible NN O O
for NN O O
many NN O O
or NN O O
most NN O O
cases NN O O
of NN O O
VWS NN O B-Disease
. NN O O

A NN O O
point NN O O
mutation NN O O
Thr NN O O
( NN O O
799 NN O O
) NN O O
Met NN O O
on NN O O
the NN O O
alpha NN O O
( NN O O
2 NN O O
) NN O O
integrin NN O O
leads NN O O
to NN O O
the NN O O
formation NN O O
of NN O O
new NN O O
human NN O O
platelet NN O O
alloantigen NN O O
Sit NN O O
( NN O O
a NN O O
) NN O O
and NN O O
affects NN O O
collagen NN O O
- NN O O
induced NN O O
aggregation NN O O
. NN O O

A NN O O
new NN O O
platelet NN O O
- NN O O
specific NN O O
alloantigen NN O O
, NN O O
termed NN O O
Sit NN O O
( NN O O
a NN O O
) NN O O
, NN O O
was NN O O
identified NN O O
in NN O O
a NN O O
severe NN O O
case NN O O
of NN O O
neonatal NN O B-Disease
alloimmune NN O I-Disease
thrombocytopenia NN O I-Disease
. NN O O

The NN O O
Sit NN O O
( NN O O
a NN O O
) NN O O
alloantigen NN O O
is NN O O
of NN O O
low NN O O
frequency NN O O
( NN O O
1 NN O O
/ NN O O
400 NN O O
) NN O O
in NN O O
the NN O O
German NN O O
population NN O O
. NN O O

Immunochemical NN O O
studies NN O O
demonstrated NN O O
that NN O O
the NN O O
Sit NN O O
( NN O O
a NN O O
) NN O O
epitopes NN O O
reside NN O O
on NN O O
platelet NN O O
glycoprotein NN O O
( NN O O
GP NN O O
) NN O O
Ia NN O O
. NN O O

Nucleotide NN O O
sequence NN O O
analysis NN O O
of NN O O
GPIa NN O O
cDNA NN O O
derived NN O O
from NN O O
Sit NN O O
( NN O O
a NN O O
) NN O O
- NN O O
positive NN O O
platelets NN O O
showed NN O O
C NN O O
( NN O O
2531 NN O O
) NN O O
- NN O O
- NN O O
> NN O O
T NN O O
( NN O O
2531 NN O O
) NN O O
point NN O O
mutation NN O O
, NN O O
resulting NN O O
in NN O O
Thr NN O O
( NN O O
799 NN O O
) NN O O
Met NN O O
dimorphism NN O O
. NN O O

Analysis NN O O
of NN O O
genomic NN O O
DNA NN O O
from NN O O
22 NN O O
Sit NN O O
( NN O O
a NN O O
) NN O O
- NN O O
negative NN O O
normal NN O O
individuals NN O O
showed NN O O
that NN O O
the NN O O
Thr NN O O
( NN O O
799 NN O O
) NN O O
is NN O O
encoded NN O O
by NN O O
ACG NN O O
( NN O O
2532 NN O O
) NN O O
( NN O O
90 NN O O
. NN O O
9 NN O O
% NN O O
) NN O O
or NN O O
ACA NN O O
( NN O O
2532 NN O O
) NN O O
( NN O O
9 NN O O
. NN O O
1 NN O O
% NN O O
) NN O O
. NN O O

To NN O O
establish NN O O
a NN O O
DNA NN O O
typing NN O O
technique NN O O
, NN O O
we NN O O
elucidated NN O O
the NN O O
organization NN O O
of NN O O
the NN O O
GPIa NN O O
gene NN O O
adjacent NN O O
to NN O O
the NN O O
polymorphic NN O O
bases NN O O
. NN O O

The NN O O
introns NN O O
( NN O O
421 NN O O
bp NN O O
and NN O O
1 NN O O
. NN O O
2 NN O O
kb NN O O
) NN O O
encompass NN O O
a NN O O
142 NN O O
- NN O O
bp NN O O
exon NN O O
with NN O O
the NN O O
2 NN O O
polymorphic NN O O
bases NN O O
2531 NN O O
and NN O O
2532 NN O O
. NN O O

Polymerase NN O O
chain NN O O
reaction NN O O
- NN O O
restriction NN O O
fragment NN O O
length NN O O
polymorphism NN O O
analysis NN O O
on NN O O
DNA NN O O
derived NN O O
from NN O O
100 NN O O
donors NN O O
using NN O O
the NN O O
restriction NN O O
enzyme NN O O
Mae NN O O
III NN O O
showed NN O O
that NN O O
the NN O O
Met NN O O
( NN O O
799 NN O O
) NN O O
form NN O O
of NN O O
GPIa NN O O
is NN O O
restricted NN O O
to NN O O
Sit NN O O
( NN O O
a NN O O
) NN O O
( NN O O
+ NN O O
) NN O O
phenotype NN O O
. NN O O

Analysis NN O O
of NN O O
stable NN O O
Chinese NN O O
hamster NN O O
ovary NN O O
transfectants NN O O
expressing NN O O
allele NN O O
- NN O O
specific NN O O
recombinant NN O O
forms NN O O
of NN O O
GPIa NN O O
showed NN O O
that NN O O
anti NN O O
- NN O O
Sit NN O O
( NN O O
a NN O O
) NN O O
exclusively NN O O
reacted NN O O
with NN O O
the NN O O
Glu NN O O
( NN O O
505 NN O O
) NN O O
Met NN O O
( NN O O
799 NN O O
) NN O O
, NN O O
but NN O O
not NN O O
with NN O O
the NN O O
Glu NN O O
( NN O O
505 NN O O
) NN O O
Thr NN O O
( NN O O
799 NN O O
) NN O O
and NN O O
the NN O O
Lys NN O O
( NN O O
505 NN O O
) NN O O
Thr NN O O
( NN O O
799 NN O O
) NN O O
isoforms NN O O
. NN O O

In NN O O
contrast NN O O
, NN O O
anti NN O O
- NN O O
Br NN O O
( NN O O
a NN O O
) NN O O
( NN O O
HPA NN O O
- NN O O
5b NN O O
) NN O O
only NN O O
recognized NN O O
the NN O O
Lys NN O O
( NN O O
505 NN O O
) NN O O
Thr NN O O
( NN O O
799 NN O O
) NN O O
form NN O O
, NN O O
whereas NN O O
anti NN O O
- NN O O
Br NN O O
( NN O O
b NN O O
) NN O O
( NN O O
HPA NN O O
- NN O O
5a NN O O
) NN O O
reacted NN O O
with NN O O
both NN O O
Glu NN O O
( NN O O
505 NN O O
) NN O O
Thr NN O O
( NN O O
799 NN O O
) NN O O
and NN O O
Glu NN O O
( NN O O
505 NN O O
) NN O O
Met NN O O
( NN O O
799 NN O O
) NN O O
isoforms NN O O
. NN O O

These NN O O
results NN O O
demonstrated NN O O
that NN O O
the NN O O
Met NN O O
( NN O O
799 NN O O
) NN O O
is NN O O
responsible NN O O
for NN O O
formation NN O O
of NN O O
the NN O O
Sit NN O O
( NN O O
a NN O O
) NN O O
alloantigenic NN O O
determinants NN O O
, NN O O
whereas NN O O
amino NN O O
acid NN O O
505 NN O O
( NN O O
Lys NN O O
or NN O O
Glu NN O O
) NN O O
specifically NN O O
controls NN O O
the NN O O
expression NN O O
of NN O O
Br NN O O
( NN O O
a NN O O
) NN O O
and NN O O
Br NN O O
( NN O O
b NN O O
) NN O O
epitopes NN O O
, NN O O
respectively NN O O
. NN O O

Platelet NN O O
aggregation NN O O
responses NN O O
of NN O O
Sit NN O O
( NN O O
a NN O O
) NN O O
( NN O O
+ NN O O
) NN O O
individuals NN O O
were NN O O
diminished NN O O
in NN O O
response NN O O
to NN O O
collagen NN O O
, NN O O
indicating NN O O
that NN O O
the NN O O
Thr NN O O
( NN O O
799 NN O O
) NN O O
Met NN O O
mutation NN O O
affects NN O O
the NN O O
function NN O O
of NN O O
the NN O O
GPIa NN O O
/ NN O O
IIa NN O O
complex NN O O

Mutations NN O O
of NN O O
the NN O O
cathepsin NN O O
C NN O O
gene NN O O
are NN O O
responsible NN O O
for NN O O
Papillon NN O B-Disease
- NN O I-Disease
Lefevre NN O I-Disease
syndrome NN O I-Disease
. NN O O

Papillon NN O B-Disease
- NN O I-Disease
Lefevre NN O I-Disease
syndrome NN O I-Disease
( NN O O
PLS NN O B-Disease
) NN O O
is NN O O
an NN O O
autosomal NN O B-Disease
recessive NN O I-Disease
disorder NN O I-Disease
characterised NN O O
by NN O O
palmoplantar NN O B-Disease
hyperkeratosis NN O I-Disease
and NN O O
severe NN O O
early NN O O
onset NN O O
periodontitis NN O B-Disease
that NN O O
results NN O O
in NN O O
the NN O O
premature NN O O
loss NN O O
of NN O O
the NN O O
primary NN O O
and NN O O
secondary NN O O
dentitions NN O O
. NN O O

A NN O O
major NN O O
gene NN O O
locus NN O O
for NN O O
PLS NN O B-Disease
has NN O O
been NN O O
mapped NN O O
to NN O O
a NN O O
2 NN O O
. NN O O

8 NN O O
cM NN O O
interval NN O O
on NN O O
chromosome NN O O
11q14 NN O O
. NN O O

Correlation NN O O
of NN O O
physical NN O O
and NN O O
genetic NN O O
maps NN O O
of NN O O
this NN O O
interval NN O O
indicate NN O O
it NN O O
includes NN O O
at NN O O
least NN O O
40 NN O O
ESTs NN O O
and NN O O
six NN O O
known NN O O
genes NN O O
including NN O O
the NN O O
lysosomal NN O O
protease NN O O
cathepsin NN O O
C NN O O
gene NN O O
( NN O O
CTSC NN O O
) NN O O
. NN O O

The NN O O
CTSC NN O O
message NN O O
is NN O O
expressed NN O O
at NN O O
high NN O O
levels NN O O
in NN O O
a NN O O
variety NN O O
of NN O O
immune NN O O
cells NN O O
including NN O O
polymorphonuclear NN O O
leucocytes NN O O
, NN O O
macrophages NN O O
, NN O O
and NN O O
their NN O O
precursors NN O O
. NN O O

By NN O O
RT NN O O
- NN O O
PCR NN O O
, NN O O
we NN O O
found NN O O
CTSC NN O O
is NN O O
also NN O O
expressed NN O O
in NN O O
epithelial NN O O
regions NN O O
commonly NN O O
affected NN O O
by NN O O
PLS NN O B-Disease
, NN O O
including NN O O
the NN O O
palms NN O O
, NN O O
soles NN O O
, NN O O
knees NN O O
, NN O O
and NN O O
oral NN O O
keratinised NN O O
gingiva NN O O
. NN O O

The NN O O
4 NN O O
. NN O O

7 NN O O
kb NN O O
CTSC NN O O
gene NN O O
consists NN O O
of NN O O
two NN O O
exons NN O O
. NN O O

Sequence NN O O
analysis NN O O
of NN O O
CTSC NN O O
from NN O O
subjects NN O O
affected NN O O
with NN O O
PLS NN O B-Disease
from NN O O
five NN O O
consanguineous NN O O
Turkish NN O O
families NN O O
identified NN O O
four NN O O
different NN O O
mutations NN O O
. NN O O

An NN O O
exon NN O O
1 NN O O
nonsense NN O O
mutation NN O O
( NN O O
856C NN O O
- NN O O
- NN O O
> NN O O
T NN O O
) NN O O
introduces NN O O
a NN O O
premature NN O O
stop NN O O
codon NN O O
at NN O O
amino NN O O
acid NN O O
286 NN O O
. NN O O

Three NN O O
exon NN O O
2 NN O O
mutations NN O O
were NN O O
identified NN O O
, NN O O
including NN O O
a NN O O
single NN O O
nucleotide NN O O
deletion NN O O
( NN O O
2692delA NN O O
) NN O O
of NN O O
codon NN O O
349 NN O O
introducing NN O O
a NN O O
frameshift NN O O
and NN O O
premature NN O O
termination NN O O
codon NN O O
, NN O O
a NN O O
2 NN O O
bp NN O O
deletion NN O O
( NN O O
2673 NN O O
- NN O O
2674delCT NN O O
) NN O O
that NN O O
results NN O O
in NN O O
introduction NN O O
of NN O O
a NN O O
stop NN O O
codon NN O O
at NN O O
amino NN O O
acid NN O O
343 NN O O
, NN O O
and NN O O
a NN O O
G NN O O
- NN O O
- NN O O
> NN O O
A NN O O
substitution NN O O
in NN O O
codon NN O O
429 NN O O
( NN O O
2931G NN O O
- NN O O
- NN O O
> NN O O
A NN O O
) NN O O
introducing NN O O
a NN O O
premature NN O O
termination NN O O
codon NN O O
. NN O O

All NN O O
PLS NN O B-Disease
patients NN O O
were NN O O
homozygous NN O O
for NN O O
cathepsin NN O O
C NN O O
mutations NN O O
inherited NN O O
from NN O O
a NN O O
common NN O O
ancestor NN O O
. NN O O

Parents NN O O
and NN O O
sibs NN O O
heterozygous NN O O
for NN O O
cathepsin NN O O
C NN O O
mutations NN O O
do NN O O
not NN O O
show NN O O
either NN O O
the NN O O
palmoplantar NN O B-Disease
hyperkeratosis NN O I-Disease
or NN O O
severe NN O O
early NN O O
onset NN O O
periodontitis NN O B-Disease
characteristic NN O O
of NN O O
PLS NN O B-Disease
. NN O O

A NN O O
more NN O O
complete NN O O
understanding NN O O
of NN O O
the NN O O
functional NN O O
physiology NN O O
of NN O O
cathepsin NN O O
C NN O O
carries NN O O
significant NN O O
implications NN O O
for NN O O
understanding NN O O
normal NN O O
and NN O O
abnormal NN O O
skin NN O O
development NN O O
and NN O O
periodontal NN O B-Disease
disease NN O I-Disease
susceptibility NN O O

Mutational NN O O
analysis NN O O
of NN O O
the NN O O
HGO NN O O
gene NN O O
in NN O O
Finnish NN O O
alkaptonuria NN O B-Disease
patients NN O O
. NN O O

Alkaptonuria NN O B-Disease
( NN O O
AKU NN O B-Disease
) NN O O
, NN O O
the NN O O
prototypic NN O O
inborn NN O B-Disease
error NN O I-Disease
of NN O I-Disease
metabolism NN O I-Disease
, NN O O
has NN O O
recently NN O O
been NN O O
shown NN O O
to NN O O
be NN O O
caused NN O O
by NN O O
loss NN O O
of NN O O
function NN O O
mutations NN O O
in NN O O
the NN O O
homogentisate NN O O
- NN O O
1 NN O O
, NN O O
2 NN O O
- NN O O
dioxygenase NN O O
gene NN O O
( NN O O
HGO NN O O
) NN O O
. NN O O

So NN O O
far NN O O
17 NN O O
mutations NN O O
have NN O O
been NN O O
characterised NN O O
in NN O O
AKU NN O B-Disease
patients NN O O
of NN O O
different NN O O
ethnic NN O O
origin NN O O
. NN O O

We NN O O
describe NN O O
three NN O O
novel NN O O
mutations NN O O
( NN O O
R58fs NN O O
, NN O O
R330S NN O O
, NN O O
and NN O O
H371R NN O O
) NN O O
and NN O O
one NN O O
common NN O O
AKU NN O B-Disease
mutation NN O O
( NN O O
M368V NN O O
) NN O O
, NN O O
detected NN O O
by NN O O
mutational NN O O
and NN O O
polymorphism NN O O
analysis NN O O
of NN O O
the NN O O
HGO NN O O
gene NN O O
in NN O O
five NN O O
Finnish NN O O
AKU NN O B-Disease
pedigrees NN O O
. NN O O

The NN O O
three NN O O
novel NN O O
AKU NN O B-Disease
mutations NN O O
are NN O O
most NN O O
likely NN O O
specific NN O O
for NN O O
the NN O O
Finnish NN O O
population NN O O
and NN O O
have NN O O
originated NN O O
recently NN O O
. NN O O
. NN O O

The NN O O
identical NN O O
5 NN O O
' NN O O
splice NN O O
- NN O O
site NN O O
acceptor NN O O
mutation NN O O
in NN O O
five NN O O
attenuated NN O B-Disease
APC NN O I-Disease
families NN O O
from NN O O
Newfoundland NN O O
demonstrates NN O O
a NN O O
founder NN O O
effect NN O O
. NN O O

Inherited NN O O
mutations NN O O
of NN O O
the NN O O
APC NN O B-Disease
gene NN O O
predispose NN O O
carriers NN O O
to NN O O
multiple NN O O
adenomatous NN O B-Disease
polyps NN O I-Disease
of NN O I-Disease
the NN O I-Disease
colon NN O I-Disease
and NN O I-Disease
rectum NN O I-Disease
and NN O O
to NN O O
colorectal NN O B-Disease
cancer NN O I-Disease
. NN O O

Mutations NN O O
located NN O O
at NN O O
the NN O O
extreme NN O O
5 NN O O
end NN O O
of NN O O
the NN O O
APC NN O B-Disease
gene NN O O
, NN O O
however NN O O
, NN O O
are NN O O
associated NN O O
with NN O O
a NN O O
less NN O O
severe NN O O
disease NN O O
known NN O O
as NN O O
attenuated NN O B-Disease
adenomatous NN O I-Disease
polyposis NN O I-Disease
coli NN O I-Disease
( NN O O
AAPC NN O B-Disease
) NN O O
. NN O O

Many NN O O
individuals NN O O
with NN O O
AAPC NN O B-Disease
develop NN O O
relatively NN O O
few NN O O
colorectal NN O B-Disease
polyps NN O I-Disease
but NN O O
are NN O O
still NN O O
at NN O O
high NN O O
risk NN O O
for NN O O
colorectal NN O B-Disease
cancer NN O I-Disease
. NN O O

We NN O O
report NN O O
here NN O O
the NN O O
identification NN O O
of NN O O
a NN O O
5 NN O O
APC NN O B-Disease
germline NN O O
mutation NN O O
in NN O O
five NN O O
separately NN O O
ascertained NN O O
AAPC NN O B-Disease
families NN O O
from NN O O
Newfoundland NN O O
, NN O O
Canada NN O O
. NN O O

This NN O O
disease NN O O
- NN O O
causing NN O O
mutation NN O O
is NN O O
a NN O O
single NN O O
basepair NN O O
change NN O O
( NN O O
G NN O O
to NN O O
A NN O O
) NN O O
in NN O O
the NN O O
splice NN O O
- NN O O
acceptor NN O O
region NN O O
of NN O O
APC NN O B-Disease
intron NN O O
3 NN O O
that NN O O
creates NN O O
a NN O O
mutant NN O O
RNA NN O O
without NN O O
exon NN O O
4 NN O O
of NN O O
APC NN O O
. NN O O

The NN O O
observation NN O O
of NN O O
the NN O O
same NN O O
APC NN O B-Disease
mutation NN O O
in NN O O
five NN O O
families NN O O
from NN O O
the NN O O
same NN O O
geographic NN O O
area NN O O
demonstrates NN O O
a NN O O
founder NN O O
effect NN O O
. NN O O

Furthermore NN O O
, NN O O
the NN O O
identification NN O O
of NN O O
this NN O O
germline NN O O
mutation NN O O
strengthens NN O O
the NN O O
correlation NN O O
between NN O O
the NN O O
5 NN O O
location NN O O
of NN O O
an NN O O
APC NN O B-Disease
disease NN O O
- NN O O
causing NN O O
mutation NN O O
and NN O O
the NN O O
attenuated NN O B-Disease
polyposis NN O I-Disease
phenotype NN O O
. NN O O
. NN O O

Alstrom NN O B-Disease
syndrome NN O I-Disease
: NN O O
further NN O O
evidence NN O O
for NN O O
linkage NN O O
to NN O O
human NN O O
chromosome NN O O
2p13 NN O O
. NN O O

Alstrom NN O B-Disease
syndrome NN O I-Disease
is NN O O
a NN O O
rare NN O O
autosomal NN O B-Disease
recessive NN O I-Disease
disorder NN O I-Disease
characterized NN O O
by NN O O
retinal NN O B-Disease
degeneration NN O I-Disease
, NN O O
sensorineural NN O B-Disease
hearing NN O I-Disease
loss NN O I-Disease
, NN O O
early NN O O
- NN O O
onset NN O O
obesity NN O B-Disease
, NN O O
and NN O O
non NN O B-Disease
- NN O I-Disease
insulin NN O I-Disease
- NN O I-Disease
dependent NN O I-Disease
diabetes NN O I-Disease
mellitus NN O I-Disease
. NN O O

The NN O O
gene NN O O
for NN O O
Alstrom NN O B-Disease
syndrome NN O I-Disease
( NN O O
ALMS1 NN O O
) NN O O
has NN O O
been NN O O
previously NN O O
localized NN O O
to NN O O
human NN O O
chromosome NN O O
2p13 NN O O
by NN O O
homozygosity NN O O
mapping NN O O
in NN O O
two NN O O
distinct NN O O
isolated NN O O
populations NN O O
- NN O O
French NN O O
Acadian NN O O
and NN O O
North NN O O
African NN O O
. NN O O

Pair NN O O
- NN O O
wise NN O O
analyses NN O O
resulted NN O O
in NN O O
maximum NN O O
lod NN O O
( NN O O
logarithm NN O O
of NN O O
the NN O O
odds NN O O
ratio NN O O
) NN O O
scores NN O O
of NN O O
3 NN O O
. NN O O

84 NN O O
and NN O O
2 NN O O
. NN O O

9 NN O O
, NN O O
respectively NN O O
. NN O O

To NN O O
confirm NN O O
these NN O O
findings NN O O
, NN O O
a NN O O
large NN O O
linkage NN O O
study NN O O
was NN O O
performed NN O O
in NN O O
twelve NN O O
additional NN O O
families NN O O
segregating NN O O
for NN O O
Alstrom NN O B-Disease
syndrome NN O I-Disease
. NN O O

A NN O O
maximum NN O O
two NN O O
- NN O O
point NN O O
lod NN O O
score NN O O
of NN O O
7 NN O O
. NN O O

13 NN O O
( NN O O
theta NN O O
= NN O O
0 NN O O
. NN O O
00 NN O O
) NN O O
for NN O O
marker NN O O
D2S2110 NN O O
and NN O O
a NN O O
maximum NN O O
cumulative NN O O
multipoint NN O O
lod NN O O
score NN O O
of NN O O
9 NN O O
. NN O O

16 NN O O
for NN O O
marker NN O O
D2S2110 NN O O
were NN O O
observed NN O O
, NN O O
further NN O O
supporting NN O O
linkage NN O O
to NN O O
chromosome NN O O
2p13 NN O O
. NN O O

No NN O O
evidence NN O O
of NN O O
genetic NN O O
heterogeneity NN O O
was NN O O
observed NN O O
in NN O O
these NN O O
families NN O O
. NN O O

Meiotic NN O O
recombination NN O O
events NN O O
have NN O O
localized NN O O
the NN O O
critical NN O O
region NN O O
containing NN O O
ALMS1 NN O O
to NN O O
a NN O O
6 NN O O
. NN O O

1 NN O O
- NN O O
cM NN O O
interval NN O O
flanked NN O O
by NN O O
markers NN O O
D2S327 NN O O
and NN O O
D2S286 NN O O
. NN O O

A NN O O
fine NN O O
resolution NN O O
radiation NN O O
hybrid NN O O
map NN O O
of NN O O
31 NN O O
genes NN O O
and NN O O
markers NN O O
has NN O O
been NN O O
constructed NN O O
. NN O O

Pendred NN O B-Disease
syndrome NN O I-Disease
: NN O O
phenotypic NN O O
variability NN O O
in NN O O
two NN O O
families NN O O
carrying NN O O
the NN O O
same NN O O
PDS NN O B-Disease
missense NN O O
mutation NN O O
. NN O O

Pendred NN O B-Disease
syndrome NN O I-Disease
comprises NN O O
congenital NN O B-Disease
sensorineural NN O I-Disease
hearing NN O I-Disease
loss NN O I-Disease
, NN O O
thyroid NN O B-Disease
goiter NN O I-Disease
, NN O O
and NN O O
positive NN O O
perchlorate NN O O
discharge NN O O
test NN O O
. NN O O

Recently NN O O
, NN O O
this NN O O
autosomal NN O B-Disease
recessive NN O I-Disease
disorder NN O I-Disease
was NN O O
shown NN O O
to NN O O
be NN O O
caused NN O O
by NN O O
mutations NN O O
in NN O O
the NN O O
PDS NN O B-Disease
gene NN O O
, NN O O
which NN O O
encodes NN O O
an NN O O
anion NN O O
transporter NN O O
called NN O O
pendrin NN O O
. NN O O

Molecular NN O O
analysis NN O O
of NN O O
the NN O O
PDS NN O B-Disease
gene NN O O
was NN O O
performed NN O O
in NN O O
two NN O O
consanguineous NN O O
large NN O O
families NN O O
from NN O O
Southern NN O O
Tunisia NN O O
comprising NN O O
a NN O O
total NN O O
of NN O O
23 NN O O
individuals NN O O
affected NN O O
with NN O O
profound NN O O
congenital NN O B-Disease
deafness NN O I-Disease
; NN O O
the NN O O
same NN O O
missense NN O O
mutation NN O O
, NN O O
L445W NN O O
, NN O O
was NN O O
identified NN O O
in NN O O
all NN O O
affected NN O O
individuals NN O O
. NN O O

A NN O O
widened NN O B-Disease
vestibular NN O I-Disease
aqueduct NN O I-Disease
was NN O O
found NN O O
in NN O O
all NN O O
patients NN O O
who NN O O
underwent NN O O
computed NN O O
tomography NN O O
( NN O O
CT NN O O
) NN O O
scan NN O O
exploration NN O O
of NN O O
the NN O O
inner NN O O
ear NN O O
. NN O O

In NN O O
contrast NN O O
, NN O O
goiter NN O B-Disease
was NN O O
present NN O O
in NN O O
only NN O O
11 NN O O
affected NN O O
individuals NN O O
, NN O O
who NN O O
interestingly NN O O
had NN O O
a NN O O
normal NN O O
result NN O O
of NN O O
the NN O O
perchlorate NN O O
discharge NN O O
test NN O O
whenever NN O O
performed NN O O
. NN O O

The NN O O
present NN O O
results NN O O
question NN O O
the NN O O
sensitivity NN O O
of NN O O
the NN O O
perchlorate NN O O
test NN O O
for NN O O
the NN O O
diagnosis NN O O
of NN O O
Pendred NN O B-Disease
syndrome NN O I-Disease
and NN O O
support NN O O
the NN O O
use NN O O
of NN O O
a NN O O
molecular NN O O
analysis NN O O
of NN O O
the NN O O
PDS NN O B-Disease
gene NN O O
in NN O O
the NN O O
assessment NN O O
of NN O O
individuals NN O O
with NN O O
severe NN O O
to NN O O
profound NN O O
congenital NN O B-Disease
hearing NN O I-Disease
loss NN O I-Disease
associated NN O O
with NN O O
inner NN O B-Disease
ear NN O I-Disease
morphological NN O I-Disease
anomaly NN O I-Disease
even NN O O
in NN O O
the NN O O
absence NN O O
of NN O O
a NN O O
thyroid NN O B-Disease
goiter NN O I-Disease
. NN O O
. NN O O

Knobloch NN O B-Disease
syndrome NN O I-Disease
involving NN O O
midline NN O B-Disease
scalp NN O I-Disease
defect NN O I-Disease
of NN O I-Disease
the NN O I-Disease
frontal NN O I-Disease
region NN O I-Disease
. NN O O

We NN O O
report NN O O
on NN O O
a NN O O
4 NN O O
- NN O O
year NN O O
- NN O O
old NN O O
boy NN O O
with NN O O
Knobloch NN O B-Disease
syndrome NN O I-Disease
. NN O O

He NN O O
has NN O O
vitreoretinal NN O B-Disease
degeneration NN O I-Disease
, NN O O
high NN O B-Disease
myopia NN O I-Disease
, NN O O
cataract NN O B-Disease
, NN O O
telecanthus NN O B-Disease
, NN O O
hypertelorism NN O B-Disease
, NN O O
and NN O O
a NN O O
high NN O B-Disease
- NN O I-Disease
arched NN O I-Disease
palate NN O I-Disease
. NN O O

He NN O O
also NN O O
has NN O O
a NN O O
defect NN O B-Disease
of NN O I-Disease
the NN O I-Disease
anterior NN O I-Disease
midline NN O I-Disease
scalp NN O I-Disease
with NN O O
involvement NN O O
of NN O O
the NN O O
frontal NN O O
bone NN O O
as NN O O
documented NN O O
by NN O O
a NN O O
computed NN O O
tomography NN O O
( NN O O
CT NN O O
) NN O O
scan NN O O
. NN O O

The NN O O
brain NN O O
was NN O O
normal NN O O
on NN O O
CT NN O O
scan NN O O
and NN O O
magnetic NN O O
resonance NN O O
imaging NN O O
. NN O O

We NN O O
present NN O O
a NN O O
review NN O O
of NN O O
the NN O O
23 NN O O
published NN O O
cases NN O O
with NN O O
this NN O O
syndrome NN O O
. NN O O

Our NN O O
patient NN O O
illustrates NN O O
the NN O O
importance NN O O
of NN O O
investigating NN O O
for NN O O
underlying NN O O
ocular NN O O
and NN O O
central NN O O
nervous NN O O
system NN O O
pathology NN O O
whenever NN O O
midline NN O B-Disease
scalp NN O I-Disease
defects NN O I-Disease
are NN O O
present NN O O
. NN O O
. NN O O

The NN O O
DNA NN O O
double NN O O
- NN O O
strand NN O O
break NN O O
repair NN O O
gene NN O O
hMRE11 NN O O
is NN O O
mutated NN O O
in NN O O
individuals NN O O
with NN O O
an NN O O
ataxia NN O B-Disease
- NN O I-Disease
telangiectasia NN O I-Disease
- NN O I-Disease
like NN O I-Disease
disorder NN O I-Disease
. NN O O

We NN O O
show NN O O
that NN O O
hypomorphic NN O O
mutations NN O O
in NN O O
hMRE11 NN O O
, NN O O
but NN O O
not NN O O
in NN O O
ATM NN O O
, NN O O
are NN O O
present NN O O
in NN O O
certain NN O O
individuals NN O O
with NN O O
an NN O O
ataxia NN O B-Disease
- NN O I-Disease
telangiectasia NN O I-Disease
- NN O I-Disease
like NN O I-Disease
disorder NN O I-Disease
( NN O O
ATLD NN O B-Disease
) NN O O
. NN O O

The NN O O
cellular NN O O
features NN O O
resulting NN O O
from NN O O
these NN O O
hMRE11 NN O O
mutations NN O O
are NN O O
similar NN O O
to NN O O
those NN O O
seen NN O O
in NN O O
A NN O B-Disease
- NN O I-Disease
T NN O I-Disease
as NN O O
well NN O O
as NN O O
NBS NN O B-Disease
and NN O O
include NN O O
hypersensitivity NN O B-Disease
to NN O I-Disease
ionizing NN O I-Disease
radiation NN O I-Disease
, NN O O
radioresistant NN O O
DNA NN O O
synthesis NN O O
, NN O O
and NN O O
abrogation NN O O
of NN O O
ATM NN O O
- NN O O
dependent NN O O
events NN O O
, NN O O
such NN O O
as NN O O
the NN O O
activation NN O O
of NN O O
Jun NN O O
kinase NN O O
following NN O O
exposure NN O O
to NN O O
gamma NN O O
irradiation NN O O
. NN O O

Although NN O O
the NN O O
mutant NN O O
hMre11 NN O O
proteins NN O O
retain NN O O
some NN O O
ability NN O O
to NN O O
interact NN O O
with NN O O
hRad50 NN O O
and NN O O
Nbs1 NN O O
, NN O O
formation NN O O
of NN O O
ionizing NN O O
radiation NN O O
- NN O O
induced NN O O
hMre11 NN O O
and NN O O
Nbs1 NN O O
foci NN O O
was NN O O
absent NN O O
in NN O O
hMRE11 NN O O
mutant NN O O
cells NN O O
. NN O O

These NN O O
data NN O O
demonstrate NN O O
that NN O O
ATM NN O O
and NN O O
the NN O O
hMre11 NN O O
/ NN O O
hRad50 NN O O
/ NN O O
Nbs1 NN O O
protein NN O O
complex NN O O
act NN O O
in NN O O
the NN O O
same NN O O
DNA NN O O
damage NN O O
response NN O O
pathway NN O O
and NN O O
link NN O O
hMre11 NN O O
to NN O O
the NN O O
complex NN O O
pathology NN O O
of NN O O
A NN O B-Disease
- NN O I-Disease
T NN O I-Disease
. NN O O
. NN O O

Mutations NN O O
in NN O O
TNFRSF11A NN O O
, NN O O
affecting NN O O
the NN O O
signal NN O O
peptide NN O O
of NN O O
RANK NN O O
, NN O O
cause NN O O
familial NN O B-Disease
expansile NN O I-Disease
osteolysis NN O I-Disease
. NN O O

Familial NN O B-Disease
expansile NN O I-Disease
osteolysis NN O I-Disease
( NN O O
FEO NN O B-Disease
, NN O O
MIM NN O O
174810 NN O O
) NN O O
is NN O O
a NN O O
rare NN O O
, NN O O
autosomal NN O B-Disease
dominant NN O I-Disease
bone NN O I-Disease
disorder NN O I-Disease
characterized NN O O
by NN O O
focal NN O O
areas NN O O
of NN O O
increased NN O B-Disease
bone NN O I-Disease
remodelling NN O I-Disease
. NN O O

The NN O O
osteolytic NN O B-Disease
lesions NN O I-Disease
, NN O O
which NN O O
develop NN O O
usually NN O O
in NN O O
the NN O O
long NN O O
bones NN O O
during NN O O
early NN O O
adulthood NN O O
, NN O O
show NN O O
increased NN O O
osteoblast NN O O
and NN O O
osteoclast NN O O
activity NN O O
. NN O O

Our NN O O
previous NN O O
linkage NN O O
studies NN O O
mapped NN O O
the NN O O
gene NN O O
responsible NN O O
for NN O O
FEO NN O B-Disease
to NN O O
an NN O O
interval NN O O
of NN O O
less NN O O
than NN O O
5 NN O O
cM NN O O
between NN O O
D18S64 NN O O
and NN O O
D18S51 NN O O
on NN O O
chromosome NN O O
18q21 NN O O
. NN O O

2 NN O O
- NN O O
21 NN O O
2 NN O O
- NN O O
21 NN O O
. NN O O

3 NN O O
in NN O O
a NN O O
large NN O O
Northern NN O O
Irish NN O O
family NN O O
. NN O O

The NN O O
gene NN O O
encoding NN O O
receptor NN O O
activator NN O O
of NN O O
nuclear NN O O
factor NN O O
- NN O O
kappa NN O O
B NN O O
( NN O O
RANK NN O O
; NN O O
ref NN O O
. NN O O
5 NN O O
) NN O O
, NN O O
TNFRSF11A NN O O
, NN O O
maps NN O O
to NN O O
this NN O O
region NN O O
. NN O O

RANK NN O O
is NN O O
essential NN O O
in NN O O
osteoclast NN O O
formation NN O O
. NN O O

We NN O O
identified NN O O
two NN O O
heterozygous NN O O
insertion NN O O
mutations NN O O
in NN O O
exon NN O O
1 NN O O
of NN O O
TNFRSF11A NN O O
in NN O O
affected NN O O
members NN O O
of NN O O
four NN O O
families NN O O
with NN O O
FEO NN O B-Disease
or NN O O
familial NN O B-Disease
Paget NN O I-Disease
disease NN O I-Disease
of NN O I-Disease
bone NN O I-Disease
( NN O O
PDB NN O B-Disease
) NN O O
. NN O O

One NN O O
was NN O O
a NN O O
duplication NN O O
of NN O O
18 NN O O
bases NN O O
and NN O O
the NN O O
other NN O O
a NN O O
duplication NN O O
of NN O O
27 NN O O
bases NN O O
, NN O O
both NN O O
of NN O O
which NN O O
affected NN O O
the NN O O
signal NN O O
peptide NN O O
region NN O O
of NN O O
the NN O O
RANK NN O O
molecule NN O O
. NN O O

Expression NN O O
of NN O O
recombinant NN O O
forms NN O O
of NN O O
the NN O O
mutant NN O O
RANK NN O O
proteins NN O O
revealed NN O O
perturbations NN O O
in NN O O
expression NN O O
levels NN O O
and NN O O
lack NN O O
of NN O O
normal NN O O
cleavage NN O O
of NN O O
the NN O O
signal NN O O
peptide NN O O
. NN O O

Both NN O O
mutations NN O O
caused NN O O
an NN O O
increase NN O O
in NN O O
RANK NN O O
- NN O O
mediated NN O O
nuclear NN O O
factor NN O O
- NN O O
kappaB NN O O
( NN O O
NF NN O O
- NN O O
kappaB NN O O
) NN O O
signalling NN O O
in NN O O
vitro NN O O
, NN O O
consistent NN O O
with NN O O
the NN O O
presence NN O O
of NN O O
an NN O O
activating NN O O
mutation NN O O
. NN O O

Cardiac NN O O
Na NN O O
( NN O O
+ NN O O
) NN O O
channel NN O O
dysfunction NN O O
in NN O O
Brugada NN O B-Disease
syndrome NN O I-Disease
is NN O O
aggravated NN O O
by NN O O
beta NN O O
( NN O O
1 NN O O
) NN O O
- NN O O
subunit NN O O
. NN O O

BACKGROUND NN O O
Mutations NN O O
in NN O O
the NN O O
gene NN O O
encoding NN O O
the NN O O
human NN O O
cardiac NN O O
Na NN O O
( NN O O
+ NN O O
) NN O O
channel NN O O
alpha NN O O
- NN O O
subunit NN O O
( NN O O
hH1 NN O O
) NN O O
are NN O O
responsible NN O O
for NN O O
chromosome NN O O
3 NN O O
- NN O O
linked NN O O
congenital NN O B-Disease
long NN O I-Disease
- NN O I-Disease
QT NN O I-Disease
syndrome NN O I-Disease
( NN O O
LQT3 NN O B-Disease
) NN O O
and NN O O
idiopathic NN O B-Disease
ventricular NN O I-Disease
fibrillation NN O I-Disease
( NN O O
IVF NN O B-Disease
) NN O O
. NN O O

An NN O O
auxiliary NN O O
beta NN O O
( NN O O
1 NN O O
) NN O O
- NN O O
subunit NN O O
, NN O O
widely NN O O
expressed NN O O
in NN O O
excitable NN O O
tissues NN O O
, NN O O
shifts NN O O
the NN O O
voltage NN O O
dependence NN O O
of NN O O
steady NN O O
- NN O O
state NN O O
inactivation NN O O
toward NN O O
more NN O O
negative NN O O
potentials NN O O
and NN O O
restores NN O O
normal NN O O
gating NN O O
kinetics NN O O
of NN O O
brain NN O O
and NN O O
skeletal NN O O
muscle NN O O
Na NN O O
( NN O O
+ NN O O
) NN O O
channels NN O O
expressed NN O O
in NN O O
Xenopus NN O O
oocytes NN O O
but NN O O
has NN O O
little NN O O
if NN O O
any NN O O
functional NN O O
effect NN O O
on NN O O
the NN O O
cardiac NN O O
isoform NN O O
. NN O O

Here NN O O
, NN O O
we NN O O
characterize NN O O
the NN O O
altered NN O O
effects NN O O
of NN O O
a NN O O
human NN O O
beta NN O O
( NN O O
1 NN O O
) NN O O
- NN O O
subunit NN O O
( NN O O
hbeta NN O O
( NN O O
1 NN O O
) NN O O
) NN O O
on NN O O
the NN O O
heterologously NN O O
expressed NN O O
hH1 NN O O
mutation NN O O
( NN O O
T1620M NN O O
) NN O O
previously NN O O
associated NN O O
with NN O O
IVF NN O B-Disease
. NN O O

METHODS NN O O
AND NN O O
RESULTS NN O O
When NN O O
expressed NN O O
alone NN O O
in NN O O
Xenopus NN O O
oocytes NN O O
, NN O O
T1620M NN O O
exhibited NN O O
no NN O O
persistent NN O O
currents NN O O
, NN O O
in NN O O
contrast NN O O
to NN O O
the NN O O
LQT3 NN O B-Disease
mutant NN O O
channels NN O O
, NN O O
but NN O O
the NN O O
midpoint NN O O
of NN O O
steady NN O O
- NN O O
state NN O O
inactivation NN O O
( NN O O
V NN O O
( NN O O
1 NN O O
/ NN O O
2 NN O O
) NN O O
) NN O O
was NN O O
significantly NN O O
shifted NN O O
toward NN O O
more NN O O
positive NN O O
potentials NN O O
than NN O O
for NN O O
wild NN O O
- NN O O
type NN O O
hH1 NN O O
. NN O O

Coexpression NN O O
of NN O O
hbeta NN O O
( NN O O
1 NN O O
) NN O O
did NN O O
not NN O O
significantly NN O O
alter NN O O
current NN O O
decay NN O O
or NN O O
recovery NN O O
from NN O O
inactivation NN O O
of NN O O
wild NN O O
- NN O O
type NN O O
hH1 NN O O
; NN O O
however NN O O
, NN O O
it NN O O
further NN O O
shifted NN O O
the NN O O
V NN O O
( NN O O
1 NN O O
/ NN O O
2 NN O O
) NN O O
and NN O O
accelerated NN O O
the NN O O
recovery NN O O
from NN O O
inactivation NN O O
of NN O O
T1620M NN O O
. NN O O

Oocyte NN O O
macropatch NN O O
analysis NN O O
revealed NN O O
that NN O O
the NN O O
activation NN O O
kinetics NN O O
of NN O O
T1620M NN O O
were NN O O
normal NN O O
. NN O O

CONCLUSIONS NN O O
It NN O O
is NN O O
suggested NN O O
that NN O O
coexpression NN O O
of NN O O
hbeta NN O O
( NN O O
1 NN O O
) NN O O
exposes NN O O
a NN O O
more NN O O
severe NN O O
functional NN O O
defect NN O O
that NN O O
results NN O O
in NN O O
a NN O O
greater NN O O
overlap NN O O
in NN O O
the NN O O
relationship NN O O
between NN O O
channel NN O O
inactivation NN O O
and NN O O
activation NN O O
( NN O O
window NN O O
current NN O O
) NN O O
in NN O O
T1620M NN O O
, NN O O
which NN O O
is NN O O
proposed NN O O
to NN O O
be NN O O
a NN O O
potential NN O O
pathophysiological NN O O
mechanism NN O O
of NN O O
IVF NN O B-Disease
in NN O O
vivo NN O O
. NN O O

One NN O O
possible NN O O
explanation NN O O
for NN O O
our NN O O
finding NN O O
is NN O O
an NN O O
altered NN O O
alpha NN O O
- NN O O
/ NN O O
beta NN O O
( NN O O
1 NN O O
) NN O O
- NN O O
subunit NN O O
association NN O O
in NN O O
the NN O O
mutant NN O O
. NN O O
. NN O O

Meiotic NN O O
segregation NN O O
analysis NN O O
of NN O O
RB1 NN O O
alleles NN O O
in NN O O
retinoblastoma NN O B-Disease
pedigrees NN O O
by NN O O
use NN O O
of NN O O
single NN O O
- NN O O
sperm NN O O
typing NN O O
. NN O O

In NN O O
hereditary NN O B-Disease
retinoblastoma NN O I-Disease
, NN O O
different NN O O
epidemiological NN O O
studies NN O O
have NN O O
indicated NN O O
a NN O O
preferential NN O O
paternal NN O O
transmission NN O O
of NN O O
mutant NN O O
retinoblastoma NN O B-Disease
alleles NN O O
to NN O O
offspring NN O O
, NN O O
suggesting NN O O
the NN O O
occurrence NN O O
of NN O O
a NN O O
meiotic NN O O
drive NN O O
. NN O O

To NN O O
investigate NN O O
this NN O O
mechanism NN O O
, NN O O
we NN O O
analyzed NN O O
sperm NN O O
samples NN O O
from NN O O
six NN O O
individuals NN O O
from NN O O
five NN O O
unrelated NN O O
families NN O O
affected NN O O
with NN O O
hereditary NN O B-Disease
retinoblastoma NN O I-Disease
. NN O O

Single NN O O
- NN O O
sperm NN O O
typing NN O O
techniques NN O O
were NN O O
performed NN O O
for NN O O
each NN O O
sample NN O O
by NN O O
study NN O O
of NN O O
two NN O O
informative NN O O
short NN O O
tandem NN O O
repeats NN O O
located NN O O
either NN O O
in NN O O
or NN O O
close NN O O
to NN O O
the NN O O
retinoblastoma NN O B-Disease
gene NN O O
( NN O O
RB1 NN O O
) NN O O
. NN O O

The NN O O
segregation NN O O
probability NN O O
of NN O O
mutant NN O O
RB1 NN O O
alleles NN O O
in NN O O
sperm NN O O
samples NN O O
was NN O O
assessed NN O O
by NN O O
use NN O O
of NN O O
the NN O O
SPERMSEG NN O O
program NN O O
, NN O O
which NN O O
includes NN O O
experimental NN O O
parameters NN O O
, NN O O
recombination NN O O
fractions NN O O
between NN O O
the NN O O
markers NN O O
, NN O O
and NN O O
segregation NN O O
parameters NN O O
. NN O O

A NN O O
total NN O O
of NN O O
2 NN O O
, NN O O
952 NN O O
single NN O O
sperm NN O O
from NN O O
the NN O O
six NN O O
donors NN O O
were NN O O
analyzed NN O O
. NN O O

We NN O O
detected NN O O
a NN O O
significant NN O O
segregation NN O O
distortion NN O O
in NN O O
the NN O O
data NN O O
as NN O O
a NN O O
whole NN O O
( NN O O
P NN O O
= NN O O
. NN O O
0099 NN O O
) NN O O
and NN O O
a NN O O
significant NN O O
heterogeneity NN O O
in NN O O
the NN O O
segregation NN O O
rate NN O O
across NN O O
donors NN O O
( NN O O
. NN O O
0092 NN O O
) NN O O
. NN O O

Further NN O O
analysis NN O O
shows NN O O
that NN O O
this NN O O
result NN O O
can NN O O
be NN O O
explained NN O O
by NN O O
segregation NN O O
distortion NN O O
in NN O O
favor NN O O
of NN O O
the NN O O
normal NN O O
allele NN O O
in NN O O
one NN O O
donor NN O O
only NN O O
and NN O O
that NN O O
it NN O O
does NN O O
not NN O O
provide NN O O
evidence NN O O
of NN O O
a NN O O
significant NN O O
segregation NN O O
distortion NN O O
in NN O O
the NN O O
other NN O O
donors NN O O
. NN O O

The NN O O
segregation NN O O
distortion NN O O
favoring NN O O
the NN O O
mutant NN O O
RB1 NN O O
allele NN O O
does NN O O
not NN O O
seem NN O O
to NN O O
occur NN O O
during NN O O
spermatogenesis NN O O
, NN O O
and NN O O
, NN O O
thus NN O O
, NN O O
meiotic NN O O
drive NN O O
may NN O O
result NN O O
either NN O O
from NN O O
various NN O O
mechanisms NN O O
, NN O O
including NN O O
a NN O O
fertilization NN O O
advantage NN O O
or NN O O
a NN O O
better NN O O
mobility NN O O
in NN O O
sperm NN O O
bearing NN O O
a NN O O
mutant NN O O
RB1 NN O O
gene NN O O
, NN O O
or NN O O
from NN O O
the NN O O
existence NN O O
of NN O O
a NN O O
defectively NN O O
imprinted NN O O
gene NN O O
located NN O O
on NN O O
the NN O O
human NN O O
X NN O O
chromosome NN O O
. NN O O

Friedreich NN O B-Disease
ataxia NN O I-Disease
: NN O O
an NN O O
overview NN O O
. NN O O

Friedreich NN O B-Disease
ataxia NN O I-Disease
, NN O O
an NN O O
autosomal NN O B-Disease
recessive NN O I-Disease
neurodegenerative NN O I-Disease
disease NN O I-Disease
, NN O O
is NN O O
the NN O O
most NN O O
common NN O O
of NN O O
the NN O O
inherited NN O B-Disease
ataxias NN O I-Disease
. NN O O

The NN O O
recent NN O O
discovery NN O O
of NN O O
the NN O O
gene NN O O
that NN O O
is NN O O
mutated NN O O
in NN O O
this NN O O
condition NN O O
, NN O O
FRDA NN O O
, NN O O
has NN O O
led NN O O
to NN O O
rapid NN O O
advances NN O O
in NN O O
the NN O O
understanding NN O O
of NN O O
the NN O O
pathogenesis NN O O
of NN O O
Friedreich NN O B-Disease
ataxia NN O I-Disease
. NN O O

About NN O O
98 NN O O
% NN O O
of NN O O
mutant NN O O
alleles NN O O
have NN O O
an NN O O
expansion NN O O
of NN O O
a NN O O
GAA NN O O
trinucleotide NN O O
repeat NN O O
in NN O O
intron NN O O
1 NN O O
of NN O O
the NN O O
gene NN O O
. NN O O

This NN O O
leads NN O O
to NN O O
reduced NN O O
levels NN O O
of NN O O
the NN O O
protein NN O O
, NN O O
frataxin NN O O
. NN O O

There NN O O
is NN O O
mounting NN O O
evidence NN O O
to NN O O
suggest NN O O
that NN O O
Friedreich NN O B-Disease
ataxia NN O I-Disease
is NN O O
the NN O O
result NN O O
of NN O O
accumulation NN O O
of NN O O
iron NN O O
in NN O O
mitochondria NN O O
leading NN O O
to NN O O
excess NN O O
production NN O O
of NN O O
free NN O O
radicals NN O O
, NN O O
which NN O O
then NN O O
results NN O O
in NN O O
cellular NN O O
damage NN O O
and NN O O
death NN O O
. NN O O

Currently NN O O
there NN O O
is NN O O
no NN O O
known NN O O
treatment NN O O
that NN O O
alters NN O O
the NN O O
natural NN O O
course NN O O
of NN O O
the NN O O
disease NN O O
. NN O O

The NN O O
discovery NN O O
of NN O O
the NN O O
FRDA NN O B-Disease
gene NN O O
and NN O O
its NN O O
possible NN O O
function NN O O
has NN O O
raised NN O O
hope NN O O
that NN O O
rational NN O O
therapeutic NN O O
strategies NN O O
will NN O O
be NN O O
developed NN O O
. NN O O
. NN O O

X NN O B-Disease
- NN O I-Disease
linked NN O I-Disease
retinoschisis NN O I-Disease
with NN O O
point NN O O
mutations NN O O
in NN O O
the NN O O
XLRS1 NN O O
gene NN O O
. NN O O

BACKGROUND NN O O
X NN O B-Disease
- NN O I-Disease
linked NN O I-Disease
retinoschisis NN O I-Disease
( NN O O
XLRS NN O B-Disease
) NN O O
is NN O O
a NN O O
relatively NN O O
rare NN O O
vitreoretinal NN O B-Disease
dystrophy NN O I-Disease
that NN O O
causes NN O O
visual NN O B-Disease
loss NN O I-Disease
in NN O O
young NN O O
men NN O O
. NN O O

Recently NN O O
, NN O O
a NN O O
gene NN O O
responsible NN O O
for NN O O
this NN O O
disease NN O O
, NN O O
designated NN O O
XLRS1 NN O O
, NN O O
was NN O O
identified NN O O
, NN O O
and NN O O
several NN O O
deleterious NN O O
gene NN O O
mutations NN O O
were NN O O
reported NN O O
. NN O O

OBJECTIVE NN O O
To NN O O
analyze NN O O
Japanese NN O O
patients NN O O
clinically NN O O
diagnosed NN O O
as NN O O
having NN O O
XLRS NN O B-Disease
formutational NN O O
changes NN O O
in NN O O
the NN O O
XLRS1 NN O O
gene NN O O
. NN O O

METHODS NN O O
Ten NN O O
patients NN O O
with NN O O
XLRS NN O B-Disease
underwent NN O O
full NN O O
ophthalmologic NN O O
examination NN O O
, NN O O
including NN O O
slitlamp NN O O
biomicroscopy NN O O
and NN O O
dilated NN O O
funduscopy NN O O
. NN O O

Genomic NN O O
DNA NN O O
was NN O O
isolated NN O O
from NN O O
leukocytes NN O O
, NN O O
and NN O O
all NN O O
exons NN O O
of NN O O
the NN O O
XLRS1 NN O O
gene NN O O
were NN O O
amplified NN O O
by NN O O
polymerase NN O O
chain NN O O
reaction NN O O
and NN O O
analyzed NN O O
using NN O O
a NN O O
direct NN O O
sequencing NN O O
method NN O O
. NN O O

RESULTS NN O O
Point NN O O
mutations NN O O
in NN O O
the NN O O
XLRS1 NN O O
gene NN O O
were NN O O
identified NN O O
in NN O O
all NN O O
10 NN O O
patients NN O O
. NN O O

The NN O O
mutations NN O O
were NN O O
identical NN O O
in NN O O
each NN O O
of NN O O
2 NN O O
pairs NN O O
of NN O O
brothers NN O O
. NN O O

Six NN O O
of NN O O
the NN O O
point NN O O
mutations NN O O
represented NN O O
missense NN O O
mutations NN O O
, NN O O
1 NN O O
was NN O O
a NN O O
nonsense NN O O
mutation NN O O
, NN O O
and NN O O
1 NN O O
was NN O O
a NN O O
frameshift NN O O
mutation NN O O
. NN O O

Five NN O O
of NN O O
the NN O O
mutations NN O O
are NN O O
newly NN O O
reported NN O O
herein NN O O
. NN O O

CONCLUSIONS NN O O
The NN O O
discovery NN O O
of NN O O
new NN O O
point NN O O
mutations NN O O
in NN O O
this NN O O
study NN O O
increases NN O O
the NN O O
available NN O O
information NN O O
regarding NN O O
the NN O O
spectrum NN O O
of NN O O
genetic NN O B-Disease
abnormalities NN O I-Disease
and NN O O
clinical NN O O
manifestations NN O O
of NN O O
XLRS NN O B-Disease
. NN O O

However NN O O
, NN O O
the NN O O
limited NN O O
data NN O O
failed NN O O
to NN O O
reveal NN O O
a NN O O
correlation NN O O
between NN O O
mutation NN O O
and NN O O
disease NN O O
phenotype NN O O
. NN O O

CLINICAL NN O O
RELEVANCE NN O O
Identification NN O O
of NN O O
mutations NN O O
in NN O O
the NN O O
XLRS1 NN O O
gene NN O O
and NN O O
expanded NN O O
information NN O O
on NN O O
clinical NN O O
manifestations NN O O
will NN O O
facilitate NN O O
early NN O O
diagnosis NN O O
, NN O O
appropriate NN O O
early NN O O
therapy NN O O
, NN O O
and NN O O
genetic NN O O
counseling NN O O
regarding NN O O
the NN O O
prognosis NN O O
of NN O O
XLRS NN O B-Disease
. NN O O
. NN O O

Atm NN O O
and NN O O
Bax NN O O
cooperate NN O O
in NN O O
ionizing NN O O
radiation NN O O
- NN O O
induced NN O O
apoptosis NN O O
in NN O O
the NN O O
central NN O O
nervous NN O O
system NN O O
. NN O O

Ataxia NN O B-Disease
- NN O I-Disease
telangiectasia NN O I-Disease
is NN O O
a NN O O
hereditary NN O B-Disease
multisystemic NN O I-Disease
disease NN O I-Disease
resulting NN O O
from NN O O
mutations NN O O
of NN O O
ataxia NN O B-Disease
telangiectasia NN O I-Disease
, NN O O
mutated NN O O
( NN O O
ATM NN O O
) NN O O
and NN O O
is NN O O
characterized NN O O
by NN O O
neurodegeneration NN O B-Disease
, NN O O
cancer NN O B-Disease
, NN O O
immune NN O B-Disease
defects NN O I-Disease
, NN O O
and NN O O
hypersensitivity NN O B-Disease
to NN O I-Disease
ionizing NN O I-Disease
radiation NN O I-Disease
. NN O O

The NN O O
molecular NN O O
details NN O O
of NN O O
ATM NN O O
function NN O O
in NN O O
the NN O O
nervous NN O O
system NN O O
are NN O O
unclear NN O O
, NN O O
although NN O O
the NN O O
neurological NN O B-Disease
lesion NN O I-Disease
in NN O O
ataxia NN O B-Disease
- NN O I-Disease
telangiectasia NN O I-Disease
becomes NN O O
apparent NN O O
early NN O O
in NN O O
life NN O O
, NN O O
suggesting NN O O
a NN O O
developmental NN O O
origin NN O O
. NN O O

The NN O O
central NN O O
nervous NN O O
system NN O O
( NN O O
CNS NN O O
) NN O O
of NN O O
Atm NN O O
- NN O O
null NN O O
mice NN O O
shows NN O O
a NN O O
pronounced NN O O
defect NN O O
in NN O O
apoptosis NN O O
induced NN O O
by NN O O
genotoxic NN O O
stress NN O O
, NN O O
suggesting NN O O
ATM NN O O
functions NN O O
to NN O O
eliminate NN O O
neurons NN O O
with NN O O
excessive NN O O
genomic NN O O
damage NN O O
. NN O O

Here NN O O
, NN O O
we NN O O
report NN O O
that NN O O
the NN O O
death NN O O
effector NN O O
Bax NN O O
is NN O O
required NN O O
for NN O O
a NN O O
large NN O O
proportion NN O O
of NN O O
Atm NN O O
- NN O O
dependent NN O O
apoptosis NN O O
in NN O O
the NN O O
developing NN O O
CNS NN O O
after NN O O
ionizing NN O O
radiation NN O O
( NN O O
IR NN O O
) NN O O
. NN O O

Although NN O O
many NN O O
of NN O O
the NN O O
same NN O O
regions NN O O
of NN O O
the NN O O
CNS NN O O
in NN O O
both NN O O
Bax NN O O
- NN O O
/ NN O O
- NN O O
and NN O O
Atm NN O O
- NN O O
/ NN O O
- NN O O
mice NN O O
were NN O O
radioresistant NN O O
, NN O O
mice NN O O
nullizygous NN O O
for NN O O
both NN O O
Bax NN O O
and NN O O
Atm NN O O
showed NN O O
additional NN O O
reduction NN O O
in NN O O
IR NN O O
- NN O O
induced NN O O
apoptosis NN O O
in NN O O
the NN O O
CNS NN O O
. NN O O

Therefore NN O O
, NN O O
although NN O O
the NN O O
major NN O O
IR NN O O
- NN O O
induced NN O O
apoptotic NN O O
pathway NN O O
in NN O O
the NN O O
CNS NN O O
requires NN O O
Atm NN O O
and NN O O
Bax NN O O
, NN O O
a NN O O
p53 NN O O
- NN O O
dependent NN O O
collateral NN O O
pathway NN O O
exists NN O O
that NN O O
has NN O O
both NN O O
Atm NN O O
- NN O O
and NN O O
Bax NN O O
- NN O O
independent NN O O
branches NN O O
. NN O O

Further NN O O
, NN O O
Atm NN O O
- NN O O
and NN O O
Bax NN O O
- NN O O
dependent NN O O
apoptosis NN O O
in NN O O
the NN O O
CNS NN O O
also NN O O
required NN O O
caspase NN O O
- NN O O
3 NN O O
activation NN O O
. NN O O

These NN O O
data NN O O
implicate NN O O
Bax NN O O
and NN O O
caspase NN O O
- NN O O
3 NN O O
as NN O O
death NN O O
effectors NN O O
in NN O O
neurodegenerative NN O O
pathways NN O O
. NN O O
. NN O O

Haim NN O B-Disease
- NN O I-Disease
Munk NN O I-Disease
syndrome NN O I-Disease
and NN O O
Papillon NN O B-Disease
- NN O I-Disease
Lefevre NN O I-Disease
syndrome NN O I-Disease
are NN O O
allelic NN O O
mutations NN O O
in NN O O
cathepsin NN O O
C NN O O
. NN O O

Of NN O O
the NN O O
many NN O O
palmoplantar NN O B-Disease
keratoderma NN O I-Disease
( NN O I-Disease
PPK NN O I-Disease
) NN O I-Disease
conditions NN O I-Disease
, NN O O
only NN O O
Papillon NN O B-Disease
- NN O I-Disease
Lefevre NN O I-Disease
syndrome NN O I-Disease
( NN O O
PLS NN O B-Disease
) NN O O
and NN O O
Haim NN O B-Disease
- NN O I-Disease
Munk NN O I-Disease
syndrome NN O I-Disease
( NN O O
HMS NN O B-Disease
) NN O O
are NN O O
associated NN O O
with NN O O
premature NN O O
periodontal NN O O
destruction NN O O
. NN O O

Although NN O O
both NN O O
PLS NN O B-Disease
and NN O O
HMS NN O B-Disease
share NN O O
the NN O O
cardinal NN O O
features NN O O
of NN O O
PPK NN O B-Disease
and NN O O
severe NN O O
periodontitis NN O B-Disease
, NN O O
a NN O O
number NN O O
of NN O O
additional NN O O
findings NN O O
are NN O O
reported NN O O
in NN O O
HMS NN O B-Disease
including NN O O
arachnodactyly NN O B-Disease
, NN O O
acro NN O B-Disease
- NN O I-Disease
osteolysis NN O I-Disease
, NN O O
atrophic NN O B-Disease
changes NN O I-Disease
of NN O I-Disease
the NN O I-Disease
nails NN O I-Disease
, NN O O
and NN O O
a NN O O
radiographic NN O B-Disease
deformity NN O I-Disease
of NN O I-Disease
the NN O I-Disease
fingers NN O I-Disease
. NN O O

While NN O O
PLS NN O B-Disease
cases NN O O
have NN O O
been NN O O
identified NN O O
throughout NN O O
the NN O O
world NN O O
, NN O O
HMS NN O B-Disease
has NN O O
only NN O O
been NN O O
described NN O O
among NN O O
descendants NN O O
of NN O O
a NN O O
religious NN O O
isolate NN O O
originally NN O O
from NN O O
Cochin NN O O
, NN O O
India NN O O
. NN O O

Parental NN O O
consanguinity NN O O
is NN O O
a NN O O
characteristic NN O O
of NN O O
many NN O O
cases NN O O
of NN O O
both NN O O
conditions NN O O
. NN O O

Although NN O O
autosomal NN O O
recessive NN O O
transmission NN O O
of NN O O
PLS NN O B-Disease
is NN O O
evident NN O O
, NN O O
a NN O O
more NN O O
" NN O O
complex NN O O
" NN O O
autosomal NN O O
recessive NN O O
pattern NN O O
of NN O O
inheritance NN O O
with NN O O
phenotypic NN O O
influences NN O O
from NN O O
a NN O O
closely NN O O
linked NN O O
modifying NN O O
locus NN O O
has NN O O
been NN O O
hypothesised NN O O
for NN O O
HMS NN O B-Disease
. NN O O

Recently NN O O
, NN O O
mutations NN O O
of NN O O
the NN O O
cathepsin NN O O
C NN O O
gene NN O O
have NN O O
been NN O O
identified NN O O
as NN O O
the NN O O
underlying NN O O
genetic NN O B-Disease
defect NN O I-Disease
in NN O O
PLS NN O B-Disease
. NN O O

To NN O O
determine NN O O
if NN O O
a NN O O
cathepsin NN O O
C NN O O
mutation NN O O
is NN O O
also NN O O
responsible NN O O
for NN O O
HMS NN O B-Disease
, NN O O
we NN O O
sequenced NN O O
the NN O O
gene NN O O
in NN O O
affected NN O O
and NN O O
unaffected NN O O
subjects NN O O
from NN O O
the NN O O
Cochin NN O O
isolate NN O O
in NN O O
which NN O O
both NN O O
the NN O O
PLS NN O B-Disease
and NN O O
HMS NN O B-Disease
phenotypes NN O O
appear NN O O
. NN O O

Here NN O O
we NN O O
report NN O O
identification NN O O
of NN O O
a NN O O
mutation NN O O
of NN O O
cathepsin NN O O
C NN O O
( NN O O
exon NN O O
6 NN O O
, NN O O
2127A NN O O
- NN O O
- NN O O
> NN O O
G NN O O
) NN O O
that NN O O
changes NN O O
a NN O O
highly NN O O
conserved NN O O
amino NN O O
acid NN O O
in NN O O
the NN O O
cathepsin NN O O
C NN O O
peptide NN O O
. NN O O

This NN O O
mutation NN O O
segregates NN O O
with NN O O
HMS NN O B-Disease
in NN O O
four NN O O
nuclear NN O O
families NN O O
. NN O O

Additionally NN O O
, NN O O
the NN O O
existence NN O O
of NN O O
a NN O O
shared NN O O
common NN O O
haplotype NN O O
for NN O O
genetic NN O O
loci NN O O
flanking NN O O
the NN O O
cathepsin NN O O
C NN O O
gene NN O O
suggests NN O O
that NN O O
affected NN O O
subjects NN O O
descended NN O O
from NN O O
the NN O O
Cochin NN O O
isolate NN O O
are NN O O
homozygous NN O O
for NN O O
a NN O O
mutation NN O O
inherited NN O O
" NN O O
identical NN O O
by NN O O
descent NN O O
" NN O O
from NN O O
a NN O O
common NN O O
ancestor NN O O
. NN O O

This NN O O
finding NN O O
supports NN O O
simple NN O O
autosomal NN O O
recessive NN O O
inheritance NN O O
for NN O O
HMS NN O B-Disease
in NN O O
these NN O O
families NN O O
. NN O O

We NN O O
also NN O O
report NN O O
a NN O O
mutation NN O O
of NN O O
the NN O O
same NN O O
exon NN O O
6 NN O O
CTSC NN O O
codon NN O O
( NN O O
2126C NN O O
- NN O O
- NN O O
> NN O O
T NN O O
) NN O O
in NN O O
a NN O O
Turkish NN O O
family NN O O
with NN O O
classical NN O O
PLS NN O B-Disease
. NN O O

These NN O O
findings NN O O
provide NN O O
evidence NN O O
that NN O O
PLS NN O B-Disease
and NN O O
HMS NN O B-Disease
are NN O O
allelic NN O O
variants NN O O
of NN O O
cathepsin NN O O
C NN O O
gene NN O O
mutations NN O O
. NN O O
. NN O O

ATM NN O O
- NN O O
heterozygous NN O O
germline NN O O
mutations NN O O
contribute NN O O
to NN O O
breast NN O B-Disease
cancer NN O I-Disease
- NN O O
susceptibility NN O O
. NN O O

Approximately NN O O
0 NN O O
. NN O O

5 NN O O
% NN O O
- NN O O
1 NN O O
% NN O O
of NN O O
the NN O O
general NN O O
population NN O O
has NN O O
been NN O O
estimated NN O O
to NN O O
be NN O O
heterozygous NN O O
for NN O O
a NN O O
germline NN O O
mutation NN O O
in NN O O
the NN O O
ATM NN O O
gene NN O O
. NN O O

Mutations NN O O
in NN O O
the NN O O
ATM NN O O
gene NN O O
are NN O O
responsible NN O O
for NN O O
the NN O O
autosomal NN O B-Disease
recessive NN O I-Disease
disorder NN O I-Disease
ataxia NN O B-Disease
- NN O I-Disease
telangiectasia NN O I-Disease
( NN O O
A NN O B-Disease
- NN O I-Disease
T NN O I-Disease
) NN O O
( NN O O
MIM NN O O
208900 NN O O
) NN O O
. NN O O

The NN O O
finding NN O O
that NN O O
ATM NN O O
- NN O O
heterozygotes NN O O
have NN O O
an NN O O
increased NN O O
relative NN O O
risk NN O O
for NN O O
breast NN O B-Disease
cancer NN O I-Disease
was NN O O
supported NN O O
by NN O O
some NN O O
studies NN O O
but NN O O
not NN O O
confirmed NN O O
by NN O O
others NN O O
. NN O O

In NN O O
view NN O O
of NN O O
this NN O O
discrepancy NN O O
, NN O O
we NN O O
examined NN O O
the NN O O
frequency NN O O
of NN O O
ATM NN O O
germline NN O O
mutations NN O O
in NN O O
a NN O O
selected NN O O
group NN O O
of NN O O
Dutch NN O O
patients NN O O
with NN O O
breast NN O B-Disease
cancer NN O I-Disease
. NN O O

We NN O O
have NN O O
analyzed NN O O
ATM NN O O
germline NN O O
mutations NN O O
in NN O O
normal NN O O
blood NN O O
lymphocytes NN O O
, NN O O
using NN O O
the NN O O
protein NN O O
- NN O O
truncation NN O O
test NN O O
followed NN O O
by NN O O
genomic NN O O
- NN O O
sequence NN O O
analysis NN O O
. NN O O

A NN O O
high NN O O
percentage NN O O
of NN O O
ATM NN O O
germline NN O O
mutations NN O O
was NN O O
demonstrated NN O O
among NN O O
patients NN O O
with NN O O
sporadic NN O B-Disease
breast NN O I-Disease
cancer NN O I-Disease
. NN O O

The NN O O
82 NN O O
patients NN O O
included NN O O
in NN O O
this NN O O
study NN O O
had NN O O
developed NN O O
breast NN O B-Disease
cancer NN O I-Disease
at NN O O
age NN O O
< NN O O
45 NN O O
and NN O O
had NN O O
survived NN O O
> NN O O
/ NN O O
= NN O O
5 NN O O
years NN O O
( NN O O
mean NN O O
15 NN O O
years NN O O
) NN O O
, NN O O
and NN O O
in NN O O
33 NN O O
( NN O O
40 NN O O
% NN O O
) NN O O
of NN O O
the NN O O
patients NN O O
a NN O O
contralateral NN O O
breast NN O O
tumor NN O O
had NN O O
been NN O O
diagnosed NN O O
. NN O O

Among NN O O
these NN O O
patients NN O O
we NN O O
identified NN O O
seven NN O O
( NN O O
8 NN O O
. NN O O
5 NN O O
% NN O O
) NN O O
ATM NN O O
germline NN O O
mutations NN O O
, NN O O
of NN O O
which NN O O
five NN O O
are NN O O
distinct NN O O
. NN O O

One NN O O
splice NN O O
- NN O O
site NN O O
mutation NN O O
( NN O O
IVS10 NN O O
- NN O O
6T NN O O
- NN O O
- NN O O
> NN O O
G NN O O
) NN O O
was NN O O
detected NN O O
three NN O O
times NN O O
in NN O O
our NN O O
series NN O O
. NN O O

Four NN O O
heterozygous NN O O
carriers NN O O
were NN O O
patients NN O O
with NN O O
bilateral NN O O
breast NN O O
cancer NN O O
. NN O O

Our NN O O
results NN O O
indicate NN O O
that NN O O
the NN O O
mutations NN O O
identified NN O O
in NN O O
this NN O O
study NN O O
are NN O O
" NN O O
A NN O O
- NN O O
T NN O O
disease NN O O
- NN O O
causing NN O O
" NN O O
mutations NN O O
that NN O O
might NN O O
be NN O O
associated NN O O
with NN O O
an NN O O
increased NN O O
risk NN O O
of NN O O
breast NN O O
cancer NN O O
in NN O O
heterozygotes NN O O
. NN O O

We NN O O
conclude NN O O
that NN O O
ATM NN O O
heterozygotes NN O O
have NN O O
an NN O O
approximately NN O O
ninefold NN O O
- NN O O
increased NN O O
risk NN O O
of NN O O
developing NN O O
a NN O O
type NN O O
of NN O O
breast NN O O
cancer NN O O
characterized NN O O
by NN O O
frequent NN O O
bilateral NN O O
occurrence NN O O
, NN O O
early NN O O
age NN O O
at NN O O
onset NN O O
, NN O O
and NN O O
long NN O O
- NN O O
term NN O O
survival NN O O
. NN O O

The NN O O
specific NN O O
characteristics NN O O
of NN O O
our NN O O
population NN O O
of NN O O
patients NN O O
may NN O O
explain NN O O
why NN O O
such NN O O
a NN O O
high NN O O
frequency NN O O
was NN O O
not NN O O
found NN O O
in NN O O
other NN O O
series NN O O
. NN O O

Human NN O O
mutations NN O O
in NN O O
glucose NN O O
6 NN O O
- NN O O
phosphate NN O O
dehydrogenase NN O O
reflect NN O O
evolutionary NN O O
history NN O O
. NN O O

Glucose NN O O
6 NN O O
- NN O O
phosphate NN O O
dehydrogenase NN O O
( NN O O
G6PD NN O O
) NN O O
is NN O O
a NN O O
cytosolic NN O O
enzyme NN O O
encoded NN O O
by NN O O
a NN O O
housekeeping NN O O
X NN O O
- NN O O
linked NN O O
gene NN O O
whose NN O O
main NN O O
function NN O O
is NN O O
to NN O O
produce NN O O
NADPH NN O O
, NN O O
a NN O O
key NN O O
electron NN O O
donor NN O O
in NN O O
the NN O O
defense NN O O
against NN O O
oxidizing NN O O
agents NN O O
and NN O O
in NN O O
reductive NN O O
biosynthetic NN O O
reactions NN O O
. NN O O

Inherited NN O O
G6PD NN O B-Disease
deficiency NN O I-Disease
is NN O O
associated NN O O
with NN O O
either NN O O
episodic NN O B-Disease
hemolytic NN O I-Disease
anemia NN O I-Disease
( NN O O
triggered NN O O
by NN O O
fava NN O O
beans NN O O
or NN O O
other NN O O
agents NN O O
) NN O O
or NN O O
life NN O B-Disease
- NN O I-Disease
long NN O I-Disease
hemolytic NN O I-Disease
anemia NN O I-Disease
. NN O O

We NN O O
show NN O O
here NN O O
that NN O O
an NN O O
evolutionary NN O O
analysis NN O O
is NN O O
a NN O O
key NN O O
to NN O O
understanding NN O O
the NN O O
biology NN O O
of NN O O
a NN O O
housekeeping NN O O
gene NN O O
. NN O O

From NN O O
the NN O O
alignment NN O O
of NN O O
the NN O O
amino NN O O
acid NN O O
( NN O O
aa NN O O
) NN O O
sequence NN O O
of NN O O
52 NN O O
glucose NN O O
6 NN O O
- NN O O
phosphate NN O O
dehydrogenase NN O O
( NN O O
G6PD NN O O
) NN O O
species NN O O
from NN O O
42 NN O O
different NN O O
organisms NN O O
, NN O O
we NN O O
found NN O O
a NN O O
striking NN O O
correlation NN O O
between NN O O
the NN O O
aa NN O O
replacements NN O O
that NN O O
cause NN O O
G6PD NN O B-Disease
deficiency NN O I-Disease
in NN O O
humans NN O O
and NN O O
the NN O O
sequence NN O O
conservation NN O O
of NN O O
G6PD NN O O
two NN O O
- NN O O
thirds NN O O
of NN O O
such NN O O
replacements NN O O
are NN O O
in NN O O
highly NN O O
and NN O O
moderately NN O O
conserved NN O O
( NN O O
50 NN O O
- NN O O
99 NN O O
% NN O O
) NN O O
aa NN O O
; NN O O
relatively NN O O
few NN O O
are NN O O
in NN O O
fully NN O O
conserved NN O O
aa NN O O
( NN O O
where NN O O
they NN O O
might NN O O
be NN O O
lethal NN O O
) NN O O
or NN O O
in NN O O
poorly NN O O
conserved NN O O
aa NN O O
, NN O O
where NN O O
presumably NN O O
they NN O O
simply NN O O
would NN O O
not NN O O
cause NN O O
G6PD NN O B-Disease
deficiency NN O I-Disease
. NN O O

This NN O O
is NN O O
consistent NN O O
with NN O O
the NN O O
notion NN O O
that NN O O
all NN O O
human NN O O
mutants NN O O
have NN O O
residual NN O O
enzyme NN O O
activity NN O O
and NN O O
that NN O O
null NN O O
mutations NN O O
are NN O O
lethal NN O O
at NN O O
some NN O O
stage NN O O
of NN O O
development NN O O
. NN O O

Comparing NN O O
the NN O O
distribution NN O O
of NN O O
mutations NN O O
in NN O O
a NN O O
human NN O O
housekeeping NN O O
gene NN O O
with NN O O
evolutionary NN O O
conservation NN O O
is NN O O
a NN O O
useful NN O O
tool NN O O
for NN O O
pinpointing NN O O
amino NN O O
acid NN O O
residues NN O O
important NN O O
for NN O O
the NN O O
stability NN O O
or NN O O
the NN O O
function NN O O
of NN O O
the NN O O
corresponding NN O O
protein NN O O
. NN O O

In NN O O
view NN O O
of NN O O
the NN O O
current NN O O
explosive NN O O
increase NN O O
in NN O O
full NN O O
genome NN O O
sequencing NN O O
projects NN O O
, NN O O
this NN O O
tool NN O O
will NN O O
become NN O O
rapidly NN O O
available NN O O
for NN O O
numerous NN O O
other NN O O
genes NN O O
. NN O O
. NN O O

Constitutive NN O O
and NN O O
regulated NN O O
modes NN O O
of NN O O
splicing NN O O
produce NN O O
six NN O O
major NN O O
myotonic NN O B-Disease
dystrophy NN O I-Disease
protein NN O O
kinase NN O O
( NN O O
DMPK NN O O
) NN O O
isoforms NN O O
with NN O O
distinct NN O O
properties NN O O
. NN O O

Myotonic NN O B-Disease
dystrophy NN O I-Disease
( NN O O
DM NN O B-Disease
) NN O O
is NN O O
the NN O O
most NN O O
prevalent NN O O
inherited NN O B-Disease
neuromuscular NN O I-Disease
disease NN O I-Disease
in NN O O
adults NN O O
. NN O O

The NN O O
genetic NN O B-Disease
defect NN O I-Disease
is NN O O
a NN O O
CTG NN O O
triplet NN O O
repeat NN O O
expansion NN O O
in NN O O
the NN O O
3 NN O O
- NN O O
untranslated NN O O
region NN O O
of NN O O
the NN O O
myotonic NN O B-Disease
dystrophy NN O I-Disease
protein NN O O
kinase NN O O
( NN O O
DMPK NN O O
) NN O O
gene NN O O
, NN O O
consisting NN O O
of NN O O
15 NN O O
exons NN O O
. NN O O

Using NN O O
a NN O O
transgenic NN O O
DMPK NN O O
- NN O O
overexpressor NN O O
mouse NN O O
model NN O O
, NN O O
we NN O O
demonstrate NN O O
here NN O O
that NN O O
the NN O O
endogenous NN O O
mouse NN O O
DMPK NN O O
gene NN O O
and NN O O
the NN O O
human NN O O
DMPK NN O O
transgene NN O O
produce NN O O
six NN O O
major NN O O
alternatively NN O O
spliced NN O O
mRNAs NN O O
which NN O O
have NN O O
almost NN O O
identical NN O O
cell NN O O
type NN O O
- NN O O
dependent NN O O
distribution NN O O
frequencies NN O O
and NN O O
expression NN O O
patterns NN O O
. NN O O

Use NN O O
of NN O O
a NN O O
cryptic NN O O
5 NN O O
splice NN O O
site NN O O
in NN O O
exon NN O O
8 NN O O
, NN O O
which NN O O
results NN O O
in NN O O
absence NN O O
or NN O O
presence NN O O
of NN O O
15 NN O O
nucleotides NN O O
specifying NN O O
a NN O O
VSGGG NN O O
peptide NN O O
motif NN O O
, NN O O
and NN O O
/ NN O O
or NN O O
use NN O O
of NN O O
a NN O O
cryptic NN O O
3 NN O O
splice NN O O
site NN O O
in NN O O
exon NN O O
14 NN O O
, NN O O
which NN O O
leads NN O O
to NN O O
a NN O O
frameshift NN O O
in NN O O
the NN O O
mRNA NN O O
reading NN O O
frame NN O O
, NN O O
occur NN O O
as NN O O
independent NN O O
stochastic NN O O
events NN O O
in NN O O
all NN O O
tissues NN O O
examined NN O O
. NN O O

In NN O O
contrast NN O O
, NN O O
the NN O O
excision NN O O
of NN O O
exons NN O O
13 NN O O
/ NN O O
14 NN O O
that NN O O
causes NN O O
a NN O O
frameshift NN O O
and NN O O
creates NN O O
a NN O O
C NN O O
- NN O O
terminally NN O O
truncated NN O O
protein NN O O
is NN O O
clearly NN O O
cell NN O O
type NN O O
dependent NN O O
and NN O O
occurs NN O O
predominantly NN O O
in NN O O
smooth NN O O
muscle NN O O
. NN O O

We NN O O
generated NN O O
all NN O O
six NN O O
full NN O O
- NN O O
length NN O O
mouse NN O O
cDNAs NN O O
that NN O O
result NN O O
from NN O O
combinations NN O O
of NN O O
these NN O O
three NN O O
major NN O O
splicing NN O O
events NN O O
and NN O O
show NN O O
that NN O O
their NN O O
transfection NN O O
into NN O O
cells NN O O
in NN O O
culture NN O O
leads NN O O
to NN O O
production NN O O
of NN O O
four NN O O
different NN O O
approximately NN O O
74 NN O O
kDa NN O O
full NN O O
- NN O O
length NN O O
( NN O O
heart NN O O
- NN O O
, NN O O
skeletal NN O O
muscle NN O O
- NN O O
or NN O O
brain NN O O
- NN O O
specific NN O O
) NN O O
and NN O O
two NN O O
C NN O O
- NN O O
terminally NN O O
truncated NN O O
approximately NN O O
68 NN O O
kDa NN O O
( NN O O
smooth NN O O
muscle NN O O
- NN O O
specific NN O O
) NN O O
isoforms NN O O
. NN O O

Information NN O O
on NN O O
DMPK NN O O
mRNA NN O O
and NN O O
protein NN O O
isoform NN O O
expression NN O O
patterns NN O O
will NN O O
be NN O O
useful NN O O
for NN O O
recognizing NN O O
differential NN O O
effects NN O O
of NN O O
( NN O O
CTG NN O O
) NN O O
( NN O O
n NN O O
) NN O O
expansion NN O O
in NN O O
DM NN O B-Disease
manifestation NN O O
. NN O O
. NN O O

Genetic NN O O
analysis NN O O
, NN O O
phenotypic NN O O
diagnosis NN O O
, NN O O
and NN O O
risk NN O O
of NN O O
venous NN O B-Disease
thrombosis NN O I-Disease
in NN O O
families NN O O
with NN O O
inherited NN O O
deficiencies NN O B-Disease
of NN O I-Disease
protein NN O I-Disease
S NN O I-Disease
. NN O O

Protein NN O B-Disease
S NN O I-Disease
deficiency NN O I-Disease
is NN O O
a NN O O
recognized NN O O
risk NN O O
factor NN O O
for NN O O
venous NN O B-Disease
thrombosis NN O I-Disease
. NN O O

Of NN O O
all NN O O
the NN O O
inherited NN O O
thrombophilic NN O B-Disease
conditions NN O I-Disease
, NN O O
it NN O O
remains NN O O
the NN O O
most NN O O
difficult NN O O
to NN O O
diagnose NN O O
because NN O O
of NN O O
phenotypic NN O O
variability NN O O
, NN O O
which NN O O
can NN O O
lead NN O O
to NN O O
inconclusive NN O O
results NN O O
. NN O O

We NN O O
have NN O O
overcome NN O O
this NN O O
problem NN O O
by NN O O
studying NN O O
a NN O O
cohort NN O O
of NN O O
patients NN O O
from NN O O
a NN O O
single NN O O
center NN O O
where NN O O
the NN O O
diagnosis NN O O
was NN O O
confirmed NN O O
at NN O O
the NN O O
genetic NN O O
level NN O O
. NN O O

Twenty NN O O
- NN O O
eight NN O O
index NN O O
patients NN O O
with NN O O
protein NN O B-Disease
S NN O I-Disease
deficiency NN O I-Disease
and NN O O
a NN O O
PROS1 NN O B-Disease
gene NN O I-Disease
defect NN O I-Disease
were NN O O
studied NN O O
, NN O O
together NN O O
with NN O O
109 NN O O
first NN O O
- NN O O
degree NN O O
relatives NN O O
. NN O O

To NN O O
avoid NN O O
selection NN O O
bias NN O O
, NN O O
we NN O O
confined NN O O
analysis NN O O
of NN O O
total NN O O
and NN O O
free NN O O
protein NN O O
S NN O O
levels NN O O
and NN O O
thrombotic NN O O
risk NN O O
to NN O O
the NN O O
patients NN O O
relatives NN O O
. NN O O

In NN O O
this NN O O
group NN O O
of NN O O
relatives NN O O
, NN O O
a NN O O
low NN O O
free NN O O
protein NN O O
S NN O O
level NN O O
was NN O O
the NN O O
most NN O O
reliable NN O O
predictor NN O O
of NN O O
a NN O O
PROS1 NN O B-Disease
gene NN O I-Disease
defect NN O I-Disease
( NN O O
sensitivity NN O O
97 NN O O
. NN O O
7 NN O O
% NN O O
, NN O O
specificity NN O O
100 NN O O
% NN O O
) NN O O
. NN O O

First NN O O
- NN O O
degree NN O O
relatives NN O O
with NN O O
a NN O O
PROS1 NN O B-Disease
gene NN O I-Disease
defect NN O I-Disease
had NN O O
a NN O O
5 NN O O
. NN O O

0 NN O O
- NN O O
fold NN O O
higher NN O O
risk NN O O
of NN O O
thrombosis NN O B-Disease
( NN O O
95 NN O O
% NN O O
confidence NN O O
interval NN O O
, NN O O
1 NN O O
. NN O O
5 NN O O
- NN O O
16 NN O O
. NN O O
8 NN O O
) NN O O
than NN O O
those NN O O
with NN O O
a NN O O
normal NN O O
PROS1 NN O O
gene NN O O
and NN O O
no NN O O
other NN O O
recognized NN O O
thrombophilic NN O B-Disease
defect NN O I-Disease
. NN O O

Although NN O O
pregnancy NN O O
/ NN O O
puerperium NN O O
and NN O O
immobility NN O O
/ NN O O
trauma NN O B-Disease
were NN O O
important NN O O
precipitating NN O O
factors NN O O
for NN O O
thrombosis NN O B-Disease
, NN O O
almost NN O O
half NN O O
of NN O O
the NN O O
events NN O O
were NN O O
spontaneous NN O O
. NN O O

Relatives NN O O
with NN O O
splice NN O O
- NN O O
site NN O O
or NN O O
major NN O O
structural NN O O
defects NN O B-Disease
in NN O I-Disease
the NN O I-Disease
PROS1 NN O I-Disease
gene NN O I-Disease
were NN O O
more NN O O
likely NN O O
to NN O O
have NN O O
had NN O O
a NN O O
thrombotic NN O O
event NN O O
and NN O O
had NN O O
significantly NN O O
lower NN O O
total NN O O
and NN O O
free NN O O
protein NN O O
S NN O O
levels NN O O
than NN O O
those NN O O
relatives NN O O
having NN O O
missense NN O O
mutations NN O O
. NN O O

We NN O O
conclude NN O O
that NN O O
persons NN O O
with NN O O
PROS1 NN O B-Disease
gene NN O I-Disease
defects NN O I-Disease
and NN O O
protein NN O B-Disease
S NN O I-Disease
deficiency NN O I-Disease
are NN O O
at NN O O
increased NN O O
risk NN O O
of NN O O
thrombosis NN O B-Disease
and NN O O
that NN O O
free NN O O
protein NN O O
S NN O O
estimation NN O O
offers NN O O
the NN O O
most NN O O
reliable NN O O
way NN O O
of NN O O
diagnosing NN O O
the NN O O
deficiency NN O O
. NN O O

( NN O O
Blood NN O O
. NN O O
2000 NN O O
; NN O O
95 NN O O
1935 NN O O
- NN O O
1941 NN O O
) NN O O
. NN O O

Autoimmune NN O B-Disease
lymphoproliferative NN O I-Disease
syndrome NN O I-Disease
( NN O O
ALPS NN O B-Disease
) NN O O
in NN O O
a NN O O
child NN O O
from NN O O
consanguineous NN O O
parents NN O O
: NN O O
a NN O O
dominant NN O O
or NN O O
recessive NN O O
disease NN O O
? NN O O

Autoimmune NN O B-Disease
lymphoproliferative NN O I-Disease
syndrome NN O I-Disease
( NN O O
ALPS NN O B-Disease
) NN O O
is NN O O
characterized NN O O
by NN O O
autoimmune NN O O
features NN O O
and NN O O
lymphoproliferations NN O O
and NN O O
is NN O O
generally NN O O
caused NN O O
by NN O O
defective NN O O
Fas NN O O
- NN O O
mediated NN O O
apoptosis NN O O
. NN O O

This NN O O
report NN O O
describes NN O O
a NN O O
child NN O O
with NN O O
clinical NN O O
features NN O O
of NN O O
ALPS NN O B-Disease
without NN O O
detectable NN O O
Fas NN O O
expression NN O O
on NN O O
freshly NN O O
isolated NN O O
blood NN O O
leukocytes NN O O
. NN O O

Detection NN O O
of NN O O
FAS NN O O
transcripts NN O O
via NN O O
real NN O O
- NN O O
time NN O O
quantitative NN O O
PCR NN O O
made NN O O
a NN O O
severe NN O O
transcriptional NN O O
defect NN O O
unlikely NN O O
. NN O O

Sequencing NN O O
of NN O O
the NN O O
FAS NN O O
gene NN O O
revealed NN O O
a NN O O
20 NN O O
- NN O O
nucleotide NN O O
duplication NN O O
in NN O O
the NN O O
last NN O O
exon NN O O
affecting NN O O
the NN O O
cytoplasmic NN O O
signaling NN O O
domain NN O O
. NN O O

The NN O O
patient NN O O
was NN O O
homozygous NN O O
for NN O O
this NN O O
mutation NN O O
, NN O O
whereas NN O O
the NN O O
consanguineous NN O O
parents NN O O
and NN O O
the NN O O
siblings NN O O
were NN O O
heterozygous NN O O
. NN O O

The NN O O
patient NN O O
reported NN O O
here NN O O
is NN O O
a NN O O
human NN O O
homologue NN O O
of NN O O
the NN O O
Fas NN O O
- NN O O
null NN O O
mouse NN O O
, NN O O
inasmuch NN O O
as NN O O
she NN O O
carries NN O O
an NN O O
autosomal NN O O
homozygous NN O O
mutation NN O O
in NN O O
the NN O O
FAS NN O O
gene NN O O
and NN O O
she NN O O
shows NN O O
the NN O O
severe NN O O
and NN O O
accelerated NN O O
ALPS NN O B-Disease
phenotype NN O O
. NN O O

The NN O O
heterozygous NN O O
family NN O O
members NN O O
did NN O O
not NN O O
have NN O O
the NN O O
ALPS NN O B-Disease
phenotype NN O O
, NN O O
indicating NN O O
that NN O O
the NN O O
disease NN O O
- NN O O
causing NN O O
FAS NN O O
mutation NN O O
in NN O O
this NN O O
family NN O O
is NN O O
autosomal NN O O
recessive NN O O
. NN O O
. NN O O

Identification NN O O
of NN O O
novel NN O O
imprinted NN O O
transcripts NN O O
in NN O O
the NN O O
Prader NN O B-Disease
- NN O I-Disease
Willi NN O I-Disease
syndrome NN O I-Disease
and NN O O
Angelman NN O B-Disease
syndrome NN O I-Disease
deletion NN O O
region NN O O
: NN O O
further NN O O
evidence NN O O
for NN O O
regional NN O O
imprinting NN O O
control NN O O
. NN O O

Deletions NN O O
and NN O O
other NN O O
abnormalities NN O O
of NN O O
human NN O O
chromosome NN O O
15q11 NN O O
- NN O O
q13 NN O O
are NN O O
associated NN O O
with NN O O
two NN O O
developmental NN O O
disorders NN O O
, NN O O
Prader NN O B-Disease
- NN O I-Disease
Willi NN O I-Disease
syndrome NN O I-Disease
( NN O O
PWS NN O B-Disease
) NN O O
and NN O O
Angelman NN O B-Disease
syndrome NN O I-Disease
( NN O O
AS NN O B-Disease
) NN O O
. NN O O

Loss NN O O
of NN O O
expression NN O O
of NN O O
imprinted NN O O
, NN O O
paternally NN O O
expressed NN O O
genes NN O O
has NN O O
been NN O O
implicated NN O O
in NN O O
PWS NN O B-Disease
. NN O O

However NN O O
, NN O O
the NN O O
number NN O O
of NN O O
imprinted NN O O
genes NN O O
that NN O O
contribute NN O O
to NN O O
PWS NN O B-Disease
, NN O O
and NN O O
the NN O O
range NN O O
over NN O O
which NN O O
the NN O O
imprinting NN O O
signal NN O O
acts NN O O
to NN O O
silence NN O O
one NN O O
copy NN O O
of NN O O
the NN O O
gene NN O O
in NN O O
a NN O O
parent NN O O
- NN O O
of NN O O
- NN O O
origin NN O O
- NN O O
specific NN O O
manner NN O O
, NN O O
are NN O O
unknown NN O O
. NN O O

To NN O O
identify NN O O
additional NN O O
imprinted NN O O
genes NN O O
that NN O O
could NN O O
contribute NN O O
to NN O O
the NN O O
PWS NN O B-Disease
phenotype NN O O
and NN O O
to NN O O
understand NN O O
the NN O O
regional NN O O
control NN O O
of NN O O
imprinting NN O O
in NN O O
15q11 NN O O
- NN O O
q13 NN O O
, NN O O
we NN O O
have NN O O
constructed NN O O
an NN O O
imprinted NN O O
transcript NN O O
map NN O O
of NN O O
the NN O O
PWS NN O O
- NN O O
AS NN O O
deletion NN O O
interval NN O O
. NN O O

The NN O O
imprinting NN O O
status NN O O
of NN O O
22 NN O O
expressed NN O O
sequence NN O O
tags NN O O
derived NN O O
from NN O O
the NN O O
radiation NN O O
- NN O O
hybrid NN O O
human NN O O
transcript NN O O
maps NN O O
or NN O O
physical NN O O
maps NN O O
was NN O O
determined NN O O
in NN O O
a NN O O
reverse NN O O
transcriptase NN O O
- NN O O
PCR NN O O
assay NN O O
and NN O O
correlated NN O O
with NN O O
the NN O O
position NN O O
of NN O O
the NN O O
transcripts NN O O
on NN O O
the NN O O
physical NN O O
map NN O O
. NN O O

Seven NN O O
new NN O O
paternally NN O O
expressed NN O O
transcripts NN O O
localize NN O O
to NN O O
an NN O O
approximately NN O O
1 NN O O
. NN O O

5 NN O O
- NN O O
Mb NN O O
domain NN O O
surrounding NN O O
the NN O O
SNRPN NN O O
- NN O O
associated NN O O
imprinting NN O O
center NN O O
, NN O O
which NN O O
already NN O O
includes NN O O
four NN O O
imprinted NN O O
, NN O O
paternally NN O O
expressed NN O O
genes NN O O
. NN O O

All NN O O
other NN O O
tested NN O O
new NN O O
transcripts NN O O
in NN O O
the NN O O
deletion NN O O
region NN O O
were NN O O
expressed NN O O
from NN O O
both NN O O
alleles NN O O
. NN O O

A NN O O
domain NN O O
of NN O O
exclusive NN O O
paternal NN O O
expression NN O O
surrounding NN O O
the NN O O
imprinting NN O O
center NN O O
suggests NN O O
strong NN O O
regional NN O O
control NN O O
of NN O O
the NN O O
imprinting NN O O
process NN O O
. NN O O

This NN O O
study NN O O
provides NN O O
the NN O O
means NN O O
for NN O O
further NN O O
investigation NN O O
of NN O O
additional NN O O
genes NN O O
that NN O O
cause NN O O
or NN O O
modify NN O O
the NN O O
phenotypes NN O O
associated NN O O
with NN O O
rearrangements NN O O
of NN O O
15q11 NN O O
- NN O O
q13 NN O O
. NN O O

Combined NN O O
analysis NN O O
of NN O O
hereditary NN O B-Disease
prostate NN O I-Disease
cancer NN O I-Disease
linkage NN O O
to NN O O
1q24 NN O O
- NN O O
25 NN O O
: NN O O
results NN O O
from NN O O
772 NN O O
hereditary NN O B-Disease
prostate NN O I-Disease
cancer NN O I-Disease
families NN O O
from NN O O
the NN O O
International NN O O
Consortium NN O O
for NN O O
Prostate NN O B-Disease
Cancer NN O I-Disease
Genetics NN O O
. NN O O

A NN O O
previous NN O O
linkage NN O O
study NN O O
provided NN O O
evidence NN O O
for NN O O
a NN O O
prostate NN O B-Disease
cancer NN O I-Disease
- NN O O
susceptibility NN O O
locus NN O O
at NN O O
1q24 NN O O
- NN O O
25 NN O O
. NN O O

Subsequent NN O O
reports NN O O
in NN O O
additional NN O O
collections NN O O
of NN O O
families NN O O
have NN O O
yielded NN O O
conflicting NN O O
results NN O O
. NN O O

In NN O O
addition NN O O
, NN O O
evidence NN O O
for NN O O
locus NN O O
heterogeneity NN O O
has NN O O
been NN O O
provided NN O O
by NN O O
the NN O O
identification NN O O
of NN O O
other NN O O
putative NN O O
hereditary NN O B-Disease
prostate NN O I-Disease
cancer NN O I-Disease
loci NN O O
on NN O O
Xq27 NN O O
- NN O O
28 NN O O
, NN O O
1q42 NN O O
- NN O O
43 NN O O
, NN O O
and NN O O
1p36 NN O O
. NN O O

The NN O O
present NN O O
study NN O O
describes NN O O
a NN O O
combined NN O O
analysis NN O O
for NN O O
six NN O O
markers NN O O
in NN O O
the NN O O
1q24 NN O O
- NN O O
25 NN O O
region NN O O
in NN O O
772 NN O O
families NN O O
affected NN O O
by NN O O
hereditary NN O B-Disease
prostate NN O I-Disease
cancer NN O I-Disease
and NN O O
ascertained NN O O
by NN O O
the NN O O
members NN O O
of NN O O
the NN O O
International NN O O
Consortium NN O O
for NN O O
Prostate NN O B-Disease
Cancer NN O I-Disease
Genetics NN O O
( NN O O
ICPCG NN O O
) NN O O
from NN O O
North NN O O
America NN O O
, NN O O
Australia NN O O
, NN O O
Finland NN O O
, NN O O
Norway NN O O
, NN O O
Sweden NN O O
, NN O O
and NN O O
the NN O O
United NN O O
Kingdom NN O O
. NN O O

Overall NN O O
, NN O O
there NN O O
was NN O O
some NN O O
evidence NN O O
for NN O O
linkage NN O O
, NN O O
with NN O O
a NN O O
peak NN O O
parametric NN O O
multipoint NN O O
LOD NN O O
score NN O O
assuming NN O O
heterogeneity NN O O
( NN O O
HLOD NN O O
) NN O O
of NN O O
1 NN O O
. NN O O

40 NN O O
( NN O O
P NN O O
= NN O O
. NN O O
01 NN O O
) NN O O
at NN O O
D1S212 NN O O
. NN O O

The NN O O
estimated NN O O
proportion NN O O
of NN O O
families NN O O
( NN O O
alpha NN O O
) NN O O
linked NN O O
to NN O O
the NN O O
locus NN O O
was NN O O
. NN O O

06 NN O O
( NN O O
1 NN O O
- NN O O
LOD NN O O
support NN O O
interval NN O O
. NN O O
01 NN O O
- NN O O
. NN O O
12 NN O O
) NN O O
. NN O O

This NN O O
evidence NN O O
was NN O O
not NN O O
observed NN O O
by NN O O
a NN O O
nonparametric NN O O
approach NN O O
, NN O O
presumably NN O O
because NN O O
of NN O O
the NN O O
extensive NN O O
heterogeneity NN O O
. NN O O

Further NN O O
parametric NN O O
analysis NN O O
revealed NN O O
a NN O O
significant NN O O
effect NN O O
of NN O O
the NN O O
presence NN O O
of NN O O
male NN O O
- NN O O
to NN O O
- NN O O
male NN O O
disease NN O O
transmission NN O O
within NN O O
the NN O O
families NN O O
. NN O O

In NN O O
the NN O O
subset NN O O
of NN O O
491 NN O O
such NN O O
families NN O O
, NN O O
the NN O O
peak NN O O
HLOD NN O O
was NN O O
2 NN O O
. NN O O

In NN O O
the NN O O
subset NN O O
of NN O O
491 NN O O
such NN O O
families NN O O
, NN O O
the NN O O
peak NN O O
HLOD NN O O
was NN O O
2 NN O O
. NN O O

56 NN O O
( NN O O
P NN O O
= NN O O
. NN O O
0006 NN O O
) NN O O
and NN O O
alpha NN O O
= NN O O
. NN O O

11 NN O O
( NN O O
1 NN O O
- NN O O
LOD NN O O
support NN O O
interval NN O O
. NN O O
04 NN O O
- NN O O
. NN O O
19 NN O O
) NN O O
, NN O O
compared NN O O
with NN O O
HLODs NN O O
of NN O O
0 NN O O
in NN O O
the NN O O
remaining NN O O
281 NN O O
families NN O O
. NN O O

Within NN O O
the NN O O
families NN O O
with NN O O
male NN O O
- NN O O
to NN O O
- NN O O
male NN O O
disease NN O O
transmission NN O O
, NN O O
alpha NN O O
increased NN O O
with NN O O
the NN O O
early NN O O
mean NN O O
age NN O O
at NN O O
diagnosis NN O O
( NN O O
< NN O O
65 NN O O
years NN O O
, NN O O
alpha NN O O
= NN O O
. NN O O
19 NN O O
, NN O O
with NN O O
1 NN O O
- NN O O
LOD NN O O
support NN O O
interval NN O O
. NN O O
06 NN O O
- NN O O
. NN O O
34 NN O O
) NN O O
and NN O O
the NN O O
number NN O O
of NN O O
affected NN O O
family NN O O
members NN O O
( NN O O
five NN O O
or NN O O
more NN O O
family NN O O
members NN O O
, NN O O
alpha NN O O
= NN O O
. NN O O
15 NN O O
, NN O O
with NN O O
1 NN O O
- NN O O
LOD NN O O
support NN O O
interval NN O O
. NN O O
04 NN O O
- NN O O
. NN O O
28 NN O O
) NN O O
. NN O O

The NN O O
highest NN O O
value NN O O
of NN O O
alpha NN O O
was NN O O
observed NN O O
for NN O O
the NN O O
48 NN O O
families NN O O
that NN O O
met NN O O
all NN O O
three NN O O
criteria NN O O
( NN O O
peak NN O O
HLOD NN O O
= NN O O
2 NN O O
. NN O O
25 NN O O
, NN O O
P NN O O
= NN O O
. NN O O
001 NN O O
, NN O O
alpha NN O O
= NN O O
. NN O O
29 NN O O
, NN O O
with NN O O
1 NN O O
- NN O O
LOD NN O O
support NN O O
interval NN O O
. NN O O
08 NN O O
- NN O O
. NN O O
53 NN O O
) NN O O
. NN O O

These NN O O
results NN O O
support NN O O
the NN O O
finding NN O O
of NN O O
a NN O O
prostate NN O B-Disease
cancer NN O I-Disease
- NN O O
susceptibility NN O O
gene NN O O
linked NN O O
to NN O O
1q24 NN O O
- NN O O
25 NN O O
, NN O O
albeit NN O O
in NN O O
a NN O O
defined NN O O
subset NN O O
of NN O O
prostate NN O B-Disease
cancer NN O I-Disease
families NN O O
. NN O O

Although NN O O
HPC1 NN O O
accounts NN O O
for NN O O
only NN O O
a NN O O
small NN O O
proportion NN O O
of NN O O
all NN O O
families NN O O
affected NN O O
by NN O O
hereditary NN O B-Disease
prostate NN O I-Disease
cancer NN O I-Disease
, NN O O
it NN O O
appears NN O O
to NN O O
play NN O O
a NN O O
more NN O O
prominent NN O O
role NN O O
in NN O O
the NN O O
subset NN O O
of NN O O
families NN O O
with NN O O
several NN O O
members NN O O
affected NN O O
at NN O O
an NN O O
early NN O O
age NN O O
and NN O O
with NN O O
male NN O O
- NN O O
to NN O O
- NN O O
male NN O O
disease NN O O
transmission NN O O
. NN O O

A NN O O
recurrent NN O O
expansion NN O O
of NN O O
a NN O O
maternal NN O O
allele NN O O
with NN O O
36 NN O O
CAG NN O O
repeats NN O O
causes NN O O
Huntington NN O B-Disease
disease NN O I-Disease
in NN O O
two NN O O
sisters NN O O
. NN O O

Large NN O O
intergenerational NN O O
repeat NN O O
expansions NN O O
of NN O O
the NN O O
CAG NN O O
trinucleotide NN O O
repeat NN O O
in NN O O
the NN O O
HD NN O B-Disease
gene NN O O
have NN O O
been NN O O
well NN O O
documented NN O O
for NN O O
the NN O O
male NN O O
germline NN O O
. NN O O

We NN O O
describe NN O O
a NN O O
recurrent NN O O
large NN O O
expansion NN O O
of NN O O
a NN O O
maternal NN O O
allele NN O O
with NN O O
36 NN O O
CAG NN O O
repeats NN O O
( NN O O
to NN O O
66 NN O O
and NN O O
57 NN O O
repeats NN O O
, NN O O
respectively NN O O
, NN O O
in NN O O
two NN O O
daughters NN O O
) NN O O
associated NN O O
with NN O O
onset NN O O
of NN O O
Huntington NN O B-Disease
disease NN O I-Disease
( NN O O
HD NN O B-Disease
) NN O O
in NN O O
the NN O O
second NN O O
and NN O O
third NN O O
decade NN O O
in NN O O
a NN O O
family NN O O
without NN O O
history NN O O
of NN O O
HD NN O B-Disease
. NN O O

Our NN O O
findings NN O O
give NN O O
evidence NN O O
of NN O O
a NN O O
gonadal NN O O
mosaicism NN O O
in NN O O
the NN O O
unaffected NN O O
mother NN O O
. NN O O

We NN O O
hypothesize NN O O
that NN O O
large NN O O
expansions NN O O
also NN O O
occur NN O O
in NN O O
the NN O O
female NN O O
germline NN O O
and NN O O
that NN O O
a NN O O
negative NN O O
selection NN O O
of NN O O
oocytes NN O O
with NN O O
long NN O O
repeats NN O O
might NN O O
explain NN O O
the NN O O
different NN O O
instability NN O O
behavior NN O O
of NN O O
the NN O O
male NN O O
and NN O O
the NN O O
female NN O O
germlines NN O O
. NN O O
. NN O O

Abnormal NN O O
development NN O O
of NN O O
Purkinje NN O O
cells NN O O
and NN O O
lymphocytes NN O O
in NN O O
Atm NN O O
mutant NN O O
mice NN O O
. NN O O

Motor NN O B-Disease
incoordination NN O I-Disease
, NN O O
immune NN O B-Disease
deficiencies NN O I-Disease
, NN O O
and NN O O
an NN O O
increased NN O O
risk NN O O
of NN O O
cancer NN O B-Disease
are NN O O
the NN O O
characteristic NN O O
features NN O O
of NN O O
the NN O O
hereditary NN O B-Disease
disease NN O I-Disease
ataxia NN O B-Disease
- NN O I-Disease
telangiectasia NN O I-Disease
( NN O O
A NN O B-Disease
- NN O I-Disease
T NN O I-Disease
) NN O O
, NN O O
which NN O O
is NN O O
caused NN O O
by NN O O
mutations NN O O
in NN O O
the NN O O
ATM NN O O
gene NN O O
. NN O O

Through NN O O
gene NN O O
targeting NN O O
, NN O O
we NN O O
have NN O O
generated NN O O
a NN O O
line NN O O
of NN O O
Atm NN O O
mutant NN O O
mice NN O O
, NN O O
Atm NN O O
( NN O O
y NN O O
/ NN O O
y NN O O
) NN O O
mice NN O O
. NN O O

In NN O O
contrast NN O O
to NN O O
other NN O O
Atm NN O O
mutant NN O O
mice NN O O
, NN O O
Atm NN O O
( NN O O
y NN O O
/ NN O O
y NN O O
) NN O O
mice NN O O
show NN O O
a NN O O
lower NN O O
incidence NN O O
of NN O O
thymic NN O B-Disease
lymphoma NN O I-Disease
and NN O O
survive NN O O
beyond NN O O
a NN O O
few NN O O
months NN O O
of NN O O
age NN O O
. NN O O

Atm NN O O
( NN O O
y NN O O
/ NN O O
y NN O O
) NN O O
mice NN O O
exhibit NN O O
deficits NN O O
in NN O O
motor NN O O
learning NN O O
indicative NN O O
of NN O O
cerebellar NN O B-Disease
dysfunction NN O I-Disease
. NN O O

Even NN O O
though NN O O
we NN O O
found NN O O
no NN O O
gross NN O O
cerebellar NN O B-Disease
degeneration NN O I-Disease
in NN O O
older NN O O
Atm NN O O
( NN O O
y NN O O
/ NN O O
y NN O O
) NN O O
animals NN O O
, NN O O
ectopic NN O O
and NN O O
abnormally NN O O
differentiated NN O O
Purkinje NN O O
cells NN O O
were NN O O
apparent NN O O
in NN O O
mutant NN O O
mice NN O O
of NN O O
all NN O O
ages NN O O
. NN O O

These NN O O
findings NN O O
establish NN O O
that NN O O
some NN O O
neuropathological NN O B-Disease
abnormalities NN O I-Disease
seen NN O O
in NN O O
A NN O B-Disease
- NN O I-Disease
T NN O I-Disease
patients NN O O
also NN O O
are NN O O
present NN O O
in NN O O
Atm NN O O
mutant NN O O
mice NN O O
. NN O O

In NN O O
addition NN O O
, NN O O
we NN O O
report NN O O
a NN O O
previously NN O O
unrecognized NN O O
effect NN O O
of NN O O
Atm NN O B-Disease
deficiency NN O I-Disease
on NN O O
development NN O O
or NN O O
maintenance NN O O
of NN O O
CD4 NN O O
( NN O O
+ NN O O
) NN O O
8 NN O O
( NN O O
+ NN O O
) NN O O
thymocytes NN O O
. NN O O

We NN O O
discuss NN O O
these NN O O
findings NN O O
in NN O O
the NN O O
context NN O O
of NN O O
the NN O O
hypothesis NN O O
that NN O O
abnormal NN O O
development NN O O
of NN O O
Purkinje NN O O
cells NN O O
and NN O O
lymphocytes NN O O
contributes NN O O
to NN O O
the NN O O
pathogenesis NN O O
of NN O O
A NN O B-Disease
- NN O I-Disease
T NN O I-Disease
. NN O O
. NN O O

Novel NN O O
mutations NN O O
of NN O O
the NN O O
ATP7B NN O O
gene NN O O
in NN O O
Japanese NN O O
patients NN O O
with NN O O
Wilson NN O B-Disease
disease NN O I-Disease
. NN O O

Wilson NN O B-Disease
disease NN O I-Disease
( NN O O
WD NN O B-Disease
) NN O O
is NN O O
an NN O O
autosomal NN O B-Disease
recessive NN O I-Disease
disorder NN O I-Disease
characterized NN O O
by NN O O
copper NN O O
accumulation NN O O
in NN O O
the NN O O
liver NN O O
, NN O O
brain NN O O
, NN O O
kidneys NN O O
, NN O O
and NN O O
corneas NN O O
, NN O O
and NN O O
culminating NN O O
in NN O O
copper NN O O
toxication NN O O
in NN O O
these NN O O
organs NN O O
. NN O O

In NN O O
this NN O O
study NN O O
, NN O O
we NN O O
analyzed NN O O
mutations NN O O
of NN O O
the NN O O
responsible NN O O
gene NN O O
, NN O O
ATP7B NN O O
, NN O O
in NN O O
four NN O O
Japanese NN O O
patients NN O O
with NN O O
WD NN O B-Disease
. NN O O

By NN O O
direct NN O O
sequencing NN O O
, NN O O
we NN O O
identified NN O O
five NN O O
mutations NN O O
, NN O O
of NN O O
which NN O O
two NN O O
were NN O O
novel NN O O
, NN O O
and NN O O
16 NN O O
polymorphisms NN O O
, NN O O
of NN O O
which NN O O
6 NN O O
were NN O O
novel NN O O
. NN O O

The NN O O
mutations NN O O
2871delC NN O O
and NN O O
2513delA NN O O
shift NN O O
the NN O O
reading NN O O
frame NN O O
so NN O O
that NN O O
truncated NN O O
abnormal NN O O
protein NN O O
is NN O O
expected NN O O
. NN O O

In NN O O
contrast NN O O
to NN O O
these NN O O
mutations NN O O
found NN O O
in NN O O
patients NN O O
with NN O O
hepatic NN O O
- NN O O
type NN O O
of NN O O
early NN O O
onset NN O O
, NN O O
the NN O O
mutations NN O O
A874V NN O O
, NN O O
R778L NN O O
, NN O O
and NN O O
3892delGTC NN O O
were NN O O
either NN O O
missense NN O O
mutations NN O O
or NN O O
in NN O O
frame NN O O
1 NN O O
- NN O O
amino NN O O
acid NN O O
deletion NN O O
, NN O O
and NN O O
occurred NN O O
in NN O O
the NN O O
patients NN O O
with NN O O
hepato NN O O
- NN O O
neurologic NN O O
type NN O O
of NN O O
late NN O O
onset NN O O
. NN O O

The NN O O
mutations NN O O
2871delC NN O O
and NN O O
R778L NN O O
have NN O O
been NN O O
previously NN O O
reported NN O O
in NN O O
a NN O O
relatively NN O O
large NN O O
number NN O O
of NN O O
Japanese NN O O
patients NN O O
. NN O O

In NN O O
particular NN O O
, NN O O
R778L NN O O
is NN O O
known NN O O
to NN O O
be NN O O
more NN O O
prevalent NN O O
in NN O O
Asian NN O O
countries NN O O
than NN O O
in NN O O
other NN O O
countries NN O O
of NN O O
the NN O O
world NN O O
. NN O O

Our NN O O
data NN O O
are NN O O
compatible NN O O
with NN O O
the NN O O
hypothesis NN O O
that NN O O
the NN O O
mutations NN O O
tend NN O O
to NN O O
occur NN O O
in NN O O
a NN O O
population NN O O
- NN O O
specific NN O O
manner NN O O
. NN O O

Therefore NN O O
, NN O O
the NN O O
accumulation NN O O
of NN O O
the NN O O
types NN O O
of NN O O
mutations NN O O
in NN O O
Japanese NN O O
patients NN O O
with NN O O
WD NN O B-Disease
will NN O O
facilitate NN O O
the NN O O
fast NN O O
and NN O O
effective NN O O
genetic NN O O
diagnosis NN O O
of NN O O
WD NN O B-Disease
in NN O O
Japanese NN O O
patients NN O O
. NN O O
. NN O O

Autoinhibition NN O O
and NN O O
activation NN O O
mechanisms NN O O
of NN O O
the NN O O
Wiskott NN O B-Disease
- NN O I-Disease
Aldrich NN O I-Disease
syndrome NN O I-Disease
protein NN O O
. NN O O

The NN O O
Rho NN O O
- NN O O
family NN O O
GTPase NN O O
, NN O O
Cdc42 NN O O
, NN O O
can NN O O
regulate NN O O
the NN O O
actin NN O O
cytoskeleton NN O O
through NN O O
activation NN O O
of NN O O
Wiskott NN O B-Disease
- NN O I-Disease
Aldrich NN O I-Disease
syndrome NN O I-Disease
protein NN O O
( NN O O
WASP NN O O
) NN O O
family NN O O
members NN O O
. NN O O

Activation NN O O
relieves NN O O
an NN O O
autoinhibitory NN O O
contact NN O O
between NN O O
the NN O O
GTPase NN O O
- NN O O
binding NN O O
domain NN O O
and NN O O
the NN O O
carboxy NN O O
- NN O O
terminal NN O O
region NN O O
of NN O O
WASP NN O O
proteins NN O O
. NN O O

Here NN O O
we NN O O
report NN O O
the NN O O
autoinhibited NN O O
structure NN O O
of NN O O
the NN O O
GTPase NN O O
- NN O O
binding NN O O
domain NN O O
of NN O O
WASP NN O O
, NN O O
which NN O O
can NN O O
be NN O O
induced NN O O
by NN O O
the NN O O
C NN O O
- NN O O
terminal NN O O
region NN O O
or NN O O
by NN O O
organic NN O O
co NN O O
- NN O O
solvents NN O O
. NN O O

In NN O O
the NN O O
autoinhibited NN O O
complex NN O O
, NN O O
intramolecular NN O O
interactions NN O O
with NN O O
the NN O O
GTPase NN O O
- NN O O
binding NN O O
domain NN O O
occlude NN O O
residues NN O O
of NN O O
the NN O O
C NN O O
terminus NN O O
that NN O O
regulate NN O O
the NN O O
Arp2 NN O O
/ NN O O
3 NN O O
actin NN O O
- NN O O
nucleating NN O O
complex NN O O
. NN O O

Binding NN O O
of NN O O
Cdc42 NN O O
to NN O O
the NN O O
GTPase NN O O
- NN O O
binding NN O O
domain NN O O
causes NN O O
a NN O O
dramatic NN O O
conformational NN O O
change NN O O
, NN O O
resulting NN O O
in NN O O
disruption NN O O
of NN O O
the NN O O
hydrophobic NN O O
core NN O O
and NN O O
release NN O O
of NN O O
the NN O O
C NN O O
terminus NN O O
, NN O O
enabling NN O O
its NN O O
interaction NN O O
with NN O O
the NN O O
actin NN O O
regulatory NN O O
machinery NN O O
. NN O O

These NN O O
data NN O O
show NN O O
that NN O O
intrinsically NN O O
unstructured NN O O
peptides NN O O
such NN O O
as NN O O
the NN O O
GTPase NN O O
- NN O O
binding NN O O
domain NN O O
of NN O O
WASP NN O O
can NN O O
be NN O O
induced NN O O
into NN O O
distinct NN O O
structural NN O O
and NN O O
functional NN O O
states NN O O
depending NN O O
on NN O O
context NN O O
. NN O O
. NN O O

hCds1 NN O O
- NN O O
mediated NN O O
phosphorylation NN O O
of NN O O
BRCA1 NN O O
regulates NN O O
the NN O O
DNA NN O O
damage NN O O
response NN O O
. NN O O

Mutations NN O O
in NN O O
the NN O O
BRCA1 NN O O
( NN O O
ref NN O O
. NN O O
1 NN O O
) NN O O
tumour NN O B-Disease
suppressor NN O O
gene NN O O
are NN O O
found NN O O
in NN O O
almost NN O O
all NN O O
of NN O O
the NN O O
families NN O O
with NN O O
inherited NN O B-Disease
breast NN O I-Disease
and NN O I-Disease
ovarian NN O I-Disease
cancers NN O I-Disease
and NN O O
about NN O O
half NN O O
of NN O O
the NN O O
families NN O O
with NN O O
only NN O O
breast NN O B-Disease
cancer NN O I-Disease
. NN O O

Although NN O O
the NN O O
biochemical NN O O
function NN O O
of NN O O
BRCA1 NN O O
is NN O O
not NN O O
well NN O O
understood NN O O
, NN O O
it NN O O
is NN O O
important NN O O
for NN O O
DNA NN O O
damage NN O O
repair NN O O
and NN O O
cell NN O O
- NN O O
cycle NN O O
checkpoint NN O O
. NN O O

BRCA1 NN O O
exists NN O O
in NN O O
nuclear NN O O
foci NN O O
but NN O O
is NN O O
hyperphosphorylated NN O O
and NN O O
disperses NN O O
after NN O O
DNA NN O O
damage NN O O
. NN O O

It NN O O
is NN O O
not NN O O
known NN O O
whether NN O O
BRCA1 NN O O
phosphorylation NN O O
and NN O O
dispersion NN O O
and NN O O
its NN O O
function NN O O
in NN O O
DNA NN O O
damage NN O O
response NN O O
are NN O O
related NN O O
. NN O O

In NN O O
yeast NN O O
the NN O O
DNA NN O O
damage NN O O
response NN O O
and NN O O
the NN O O
replication NN O O
- NN O O
block NN O O
checkpoint NN O O
are NN O O
mediated NN O O
partly NN O O
through NN O O
the NN O O
Cds1 NN O O
kinase NN O O
family NN O O
. NN O O

Here NN O O
we NN O O
report NN O O
that NN O O
the NN O O
human NN O O
Cds1 NN O O
kinase NN O O
( NN O O
hCds1 NN O O
/ NN O O
Chk2 NN O O
) NN O O
regulates NN O O
BRCA1 NN O O
function NN O O
after NN O O
DNA NN O O
damage NN O O
by NN O O
phosphorylating NN O O
serine NN O O
988 NN O O
of NN O O
BRCA1 NN O O
. NN O O

We NN O O
show NN O O
that NN O O
hCds1 NN O O
and NN O O
BRCA1 NN O O
interact NN O O
and NN O O
co NN O O
- NN O O
localize NN O O
within NN O O
discrete NN O O
nuclear NN O O
foci NN O O
but NN O O
separate NN O O
after NN O O
gamma NN O O
irradiation NN O O
. NN O O

Phosphorylation NN O O
of NN O O
BRCA1 NN O O
at NN O O
serine NN O O
988 NN O O
is NN O O
required NN O O
for NN O O
the NN O O
release NN O O
of NN O O
BRCA1 NN O O
from NN O O
hCds1 NN O O
. NN O O

This NN O O
phosphorylation NN O O
is NN O O
also NN O O
important NN O O
for NN O O
the NN O O
ability NN O O
of NN O O
BRCA1 NN O O
to NN O O
restore NN O O
survival NN O O
after NN O O
DNA NN O O
damage NN O O
in NN O O
the NN O O
BRCA1 NN O O
- NN O O
mutated NN O O
cell NN O O
line NN O O
HCC1937 NN O O
. NN O O
. NN O O

Characterization NN O O
of NN O O
the NN O O
rat NN O O
spinocerebellar NN O O
ataxia NN O O
type NN O O
3 NN O O
gene NN O O
. NN O O

Machado NN O B-Disease
- NN O I-Disease
Joseph NN O I-Disease
disease NN O I-Disease
( NN O O
MJD NN O B-Disease
) NN O O
belongs NN O O
to NN O O
a NN O O
group NN O O
of NN O O
clinically NN O O
and NN O O
genetically NN O O
heterogeneous NN O O
neurodegenerative NN O B-Disease
disorders NN O I-Disease
characterized NN O O
by NN O O
progressive NN O B-Disease
cerebellar NN O I-Disease
ataxia NN O I-Disease
. NN O O

The NN O O
disease NN O O
- NN O O
causing NN O O
mutation NN O O
has NN O O
recently NN O O
been NN O O
identified NN O O
as NN O O
an NN O O
unstable NN O O
and NN O O
expanded NN O O
( NN O O
CAG NN O O
) NN O O
n NN O O
trinucleotide NN O O
repeat NN O O
in NN O O
a NN O O
novel NN O O
gene NN O O
of NN O O
unknown NN O O
function NN O O
. NN O O

In NN O O
Caucasians NN O O
, NN O O
repeat NN O O
expansions NN O O
in NN O O
the NN O O
MJD1 NN O O
gene NN O O
have NN O O
also NN O O
been NN O O
found NN O O
in NN O O
patients NN O O
with NN O O
the NN O O
clinically NN O O
distinct NN O O
autosomal NN O O
dominant NN O O
spinocerebellar NN O B-Disease
ataxia NN O I-Disease
type NN O I-Disease
3 NN O I-Disease
( NN O O
SCA3 NN O B-Disease
) NN O O
. NN O O

In NN O O
order NN O O
to NN O O
gain NN O O
insight NN O O
into NN O O
the NN O O
biology NN O O
of NN O O
the NN O O
MJD1 NN O O
/ NN O O
SCA3 NN O O
gene NN O O
we NN O O
cloned NN O O
the NN O O
rat NN O O
homologue NN O O
and NN O O
studied NN O O
its NN O O
expression NN O O
. NN O O

The NN O O
rat NN O O
and NN O O
human NN O O
ataxin NN O O
- NN O O
3 NN O O
genes NN O O
are NN O O
highly NN O O
homologous NN O O
with NN O O
an NN O O
overall NN O O
sequence NN O O
identity NN O O
of NN O O
approximately NN O O
88 NN O O
% NN O O
. NN O O

However NN O O
, NN O O
the NN O O
C NN O O
- NN O O
terminal NN O O
end NN O O
of NN O O
the NN O O
putative NN O O
protein NN O O
differs NN O O
strongly NN O O
from NN O O
the NN O O
published NN O O
human NN O O
sequence NN O O
. NN O O

The NN O O
( NN O O
CAG NN O O
) NN O O
n NN O O
block NN O O
in NN O O
the NN O O
rat NN O O
cDNA NN O O
consists NN O O
of NN O O
just NN O O
three NN O O
interrupted NN O O
units NN O O
suggesting NN O O
that NN O O
a NN O O
long NN O O
polyglutamine NN O O
stretch NN O O
is NN O O
not NN O O
essential NN O O
for NN O O
the NN O O
normal NN O O
function NN O O
of NN O O
the NN O O
ataxin NN O O
- NN O O
3 NN O O
protein NN O O
in NN O O
rodents NN O O
. NN O O

The NN O O
expression NN O O
pattern NN O O
of NN O O
the NN O O
SCA3 NN O O
gene NN O O
in NN O O
various NN O O
rat NN O O
and NN O O
human NN O O
tissues NN O O
was NN O O
investigated NN O O
by NN O O
Northern NN O O
blot NN O O
analyses NN O O
. NN O O

The NN O O
mature NN O O
transcript NN O O
is NN O O
approximately NN O O
6 NN O O
kb NN O O
in NN O O
length NN O O
. NN O O

In NN O O
rat NN O O
testis NN O O
, NN O O
a NN O O
smaller NN O O
transcript NN O O
of NN O O
1 NN O O
. NN O O

3 NN O O
kb NN O O
was NN O O
identified NN O O
. NN O O

Transcription NN O O
of NN O O
rsca3 NN O O
was NN O O
detected NN O O
in NN O O
most NN O O
rat NN O O
tissues NN O O
including NN O O
brain NN O O
. NN O O

Analyzing NN O O
the NN O O
expression NN O O
level NN O O
of NN O O
the NN O O
SCA3 NN O O
gene NN O O
in NN O O
several NN O O
human NN O O
brain NN O O
sections NN O O
revealed NN O O
no NN O O
significant NN O O
higher NN O O
mRNA NN O O
level NN O O
in NN O O
regions NN O O
predominantly NN O O
affected NN O O
in NN O O
MJD NN O B-Disease
. NN O O

Thus NN O O
additional NN O O
molecules NN O O
and NN O O
/ NN O O
or NN O O
regulatory NN O O
events NN O O
are NN O O
necessary NN O O
to NN O O
explain NN O O
the NN O O
exclusive NN O O
degeneration NN O B-Disease
of NN O I-Disease
certain NN O I-Disease
brain NN O I-Disease
areas NN O I-Disease
. NN O O

Emerin NN O B-Disease
, NN O I-Disease
deficiency NN O I-Disease
of NN O O
which NN O O
causes NN O O
Emery NN O B-Disease
- NN O I-Disease
Dreifuss NN O I-Disease
muscular NN O I-Disease
dystrophy NN O I-Disease
, NN O O
is NN O O
localized NN O O
at NN O O
the NN O O
inner NN O O
nuclear NN O O
membrane NN O O
. NN O O

X NN O B-Disease
- NN O I-Disease
linked NN O I-Disease
recessive NN O I-Disease
Emery NN O I-Disease
- NN O I-Disease
Dreifuss NN O I-Disease
muscular NN O I-Disease
dystrophy NN O I-Disease
( NN O O
EDMD NN O B-Disease
) NN O O
is NN O O
an NN O O
inherited NN O B-Disease
muscle NN O I-Disease
disorder NN O I-Disease
characterized NN O O
by NN O O
the NN O O
clinical NN O O
triad NN O O
of NN O O
progressive NN O O
wasting NN O B-Disease
of NN O I-Disease
humero NN O I-Disease
- NN O I-Disease
peroneal NN O I-Disease
muscles NN O I-Disease
, NN O O
early NN O O
contractures NN O B-Disease
of NN O I-Disease
the NN O I-Disease
elbows NN O I-Disease
, NN O I-Disease
Achilles NN O I-Disease
tendons NN O I-Disease
and NN O I-Disease
postcervical NN O I-Disease
muscles NN O I-Disease
, NN O O
and NN O O
cardiac NN O B-Disease
conduction NN O I-Disease
block NN O I-Disease
with NN O O
a NN O O
high NN O O
risk NN O O
of NN O O
sudden NN O B-Disease
death NN O I-Disease
. NN O O

The NN O O
gene NN O O
for NN O O
EDMD NN O B-Disease
on NN O O
Xq28 NN O O
encodes NN O O
a NN O O
novel NN O O
protein NN O O
named NN O O
emerin NN O O
that NN O O
localizes NN O O
at NN O O
the NN O O
nuclear NN O O
membrane NN O O
of NN O O
skeletal NN O O
, NN O O
cardiac NN O O
and NN O O
smooth NN O O
muscles NN O O
and NN O O
some NN O O
other NN O O
non NN O O
- NN O O
muscle NN O O
tissues NN O O
. NN O O

To NN O O
investigate NN O O
a NN O O
possible NN O O
physiological NN O O
role NN O O
for NN O O
emerin NN O O
, NN O O
we NN O O
examined NN O O
the NN O O
ultrastructural NN O O
localization NN O O
of NN O O
the NN O O
protein NN O O
in NN O O
human NN O O
skeletal NN O O
muscle NN O O
and NN O O
HeLa NN O O
cells NN O O
, NN O O
using NN O O
ultrathin NN O O
cryosections NN O O
. NN O O

We NN O O
found NN O O
that NN O O
the NN O O
immune NN O O
- NN O O
labeled NN O O
colloidal NN O O
gold NN O O
particles NN O O
were NN O O
localized NN O O
on NN O O
the NN O O
nucleoplasmic NN O O
surface NN O O
of NN O O
the NN O O
inner NN O O
nuclear NN O O
membrane NN O O
, NN O O
but NN O O
not NN O O
on NN O O
the NN O O
nuclear NN O O
pore NN O O
. NN O O

Emerin NN O O
stayed NN O O
on NN O O
the NN O O
cytoplasmic NN O O
surface NN O O
of NN O O
the NN O O
nuclear NN O O
lamina NN O O
, NN O O
even NN O O
after NN O O
detergent NN O O
treatment NN O O
that NN O O
solubilizes NN O O
membrane NN O O
lipids NN O O
and NN O O
washes NN O O
out NN O O
membrane NN O O
proteins NN O O
. NN O O

These NN O O
results NN O O
suggest NN O O
that NN O O
emerin NN O O
anchors NN O O
at NN O O
the NN O O
inner NN O O
nuclear NN O O
membrane NN O O
through NN O O
the NN O O
hydrophobic NN O O
stretch NN O O
, NN O O
and NN O O
protrudes NN O O
from NN O O
the NN O O
hydrophilic NN O O
region NN O O
to NN O O
the NN O O
nucleoplasm NN O O
where NN O O
it NN O O
interacts NN O O
with NN O O
the NN O O
nuclear NN O O
lamina NN O O
. NN O O

We NN O O
speculate NN O O
that NN O O
emerin NN O O
contributes NN O O
to NN O O
maintain NN O O
the NN O O
nuclear NN O O
structure NN O O
and NN O O
stability NN O O
, NN O O
as NN O O
well NN O O
as NN O O
nuclear NN O O
functions NN O O
, NN O O
particularly NN O O
in NN O O
muscle NN O O
tissues NN O O
that NN O O
have NN O O
severe NN O O
stress NN O O
with NN O O
rigorous NN O O
contraction NN O O
- NN O O
relaxation NN O O
movements NN O O
and NN O O
calcium NN O O
flux NN O O
. NN O O
. NN O O

Locus NN O O
heterogeneity NN O O
in NN O O
Friedreich NN O B-Disease
ataxia NN O I-Disease
. NN O O

Friedreich NN O B-Disease
ataxia NN O I-Disease
( NN O O
FRDA NN O B-Disease
) NN O O
is NN O O
the NN O O
most NN O O
common NN O O
form NN O O
of NN O O
autosomal NN O B-Disease
recessive NN O I-Disease
ataxia NN O I-Disease
. NN O O

The NN O O
disease NN O O
locus NN O O
was NN O O
assigned NN O O
to NN O O
chromosome NN O O
9 NN O O
and NN O O
the NN O O
disease NN O O
gene NN O O
, NN O O
STM7 NN O O
/ NN O O
X25 NN O O
, NN O O
has NN O O
been NN O O
isolated NN O O
. NN O O

To NN O O
date NN O O
most NN O O
data NN O O
suggest NN O O
locus NN O O
homogeneity NN O O
in NN O O
FRDA NN O B-Disease
. NN O O

We NN O O
now NN O O
provide NN O O
strong NN O O
evidence NN O O
of NN O O
a NN O O
second NN O O
FRDA NN O B-Disease
locus NN O O
. NN O O

Studying NN O O
two NN O O
siblings NN O O
with NN O O
FRDA NN O B-Disease
from NN O O
two NN O O
families NN O O
we NN O O
did NN O O
not NN O O
detect NN O O
a NN O O
mutation NN O O
in NN O O
STM7 NN O O
/ NN O O
X25 NN O O
. NN O O

Haplotype NN O O
analysis NN O O
of NN O O
the NN O O
STM7 NN O O
/ NN O O
X25 NN O O
region NN O O
of NN O O
chromosome NN O O
9 NN O O
demonstrated NN O O
that NN O O
the NN O O
relevant NN O O
portion NN O O
of NN O O
chromosome NN O O
9 NN O O
differs NN O O
in NN O O
the NN O O
patients NN O O
. NN O O

Although NN O O
the NN O O
patients NN O O
studied NN O O
had NN O O
typical NN O O
FRDA NN O B-Disease
, NN O O
one NN O O
sibpair NN O O
had NN O O
the NN O O
uncommon NN O O
symptom NN O O
of NN O O
retained NN O O
tendon NN O O
reflexes NN O O
. NN O O

In NN O O
order NN O O
to NN O O
investigate NN O O
whether NN O O
retained NN O O
tendon NN O O
reflexes NN O O
are NN O O
characteristic NN O O
of NN O O
FRDA NN O B-Disease
caused NN O O
by NN O O
the NN O O
second NN O O
locus NN O O
, NN O O
FRDA2 NN O O
, NN O O
we NN O O
studied NN O O
an NN O O
unrelated NN O O
FRDA NN O B-Disease
patient NN O O
with NN O O
retained NN O O
tendon NN O O
reflexes NN O O
. NN O O

The NN O O
observation NN O O
of NN O O
typical NN O O
mutations NN O O
in NN O O
STM7 NN O O
/ NN O O
X25 NN O O
( NN O O
GAA NN O O
expansions NN O O
) NN O O
in NN O O
this NN O O
patient NN O O
demonstrates NN O O
that NN O O
the NN O O
two NN O O
genetically NN O O
different NN O O
forms NN O O
of NN O O
FRDA NN O B-Disease
cannot NN O O
be NN O O
distinguished NN O O
clinically NN O O
. NN O O
. NN O O

Glycerol NN O O
as NN O O
a NN O O
correlate NN O O
of NN O O
impaired NN O B-Disease
glucose NN O I-Disease
tolerance NN O I-Disease
: NN O O
dissection NN O O
of NN O O
a NN O O
complex NN O O
system NN O O
by NN O O
use NN O O
of NN O O
a NN O O
simple NN O O
genetic NN O O
trait NN O O
. NN O O

Glycerol NN O O
kinase NN O O
( NN O O
GK NN O O
) NN O O
represents NN O O
the NN O O
primary NN O O
entry NN O O
of NN O O
glycerol NN O O
into NN O O
glucose NN O O
and NN O O
triglyceride NN O O
metabolism NN O O
. NN O O

Impaired NN O B-Disease
glucose NN O I-Disease
tolerance NN O I-Disease
( NN O O
IGT NN O B-Disease
) NN O O
and NN O O
hypertriglyceridemia NN O B-Disease
are NN O O
associated NN O O
with NN O O
an NN O O
increased NN O O
risk NN O O
of NN O O
diabetes NN O B-Disease
mellitus NN O I-Disease
and NN O O
cardiovascular NN O B-Disease
disease NN O I-Disease
. NN O O

The NN O O
relationship NN O O
between NN O O
glycerol NN O O
and NN O O
the NN O O
risk NN O O
of NN O O
IGT NN O B-Disease
, NN O O
however NN O O
, NN O O
is NN O O
poorly NN O O
understood NN O O
. NN O O

We NN O O
therefore NN O O
undertook NN O O
the NN O O
study NN O O
of NN O O
fasting NN O O
plasma NN O O
glycerol NN O O
levels NN O O
in NN O O
a NN O O
cohort NN O O
of NN O O
1 NN O O
, NN O O
056 NN O O
unrelated NN O O
men NN O O
and NN O O
women NN O O
of NN O O
French NN O O
- NN O O
Canadian NN O O
descent NN O O
. NN O O

Family NN O O
screening NN O O
in NN O O
the NN O O
initial NN O O
cohort NN O O
identified NN O O
18 NN O O
men NN O O
from NN O O
five NN O O
families NN O O
with NN O O
severe NN O O
hyperglycerolemia NN O B-Disease
( NN O O
values NN O O
above NN O O
2 NN O O
. NN O O
0 NN O O
mmol NN O O
/ NN O O
liter NN O O
) NN O O
and NN O O
demonstrated NN O O
an NN O O
X NN O O
- NN O O
linked NN O O
pattern NN O O
of NN O O
inheritance NN O O
. NN O O

Linkage NN O O
analysis NN O O
of NN O O
the NN O O
data NN O O
from NN O O
12 NN O O
microsatellite NN O O
markers NN O O
surrounding NN O O
the NN O O
Xp21 NN O O
. NN O O

3 NN O O
GK NN O O
gene NN O O
resulted NN O O
in NN O O
a NN O O
peak NN O O
LOD NN O O
score NN O O
of NN O O
3 NN O O
. NN O O

46 NN O O
, NN O O
centered NN O O
around NN O O
marker NN O O
DXS8039 NN O O
. NN O O

In NN O O
addition NN O O
, NN O O
since NN O O
all NN O O
of NN O O
the NN O O
families NN O O
originated NN O O
in NN O O
a NN O O
population NN O O
with NN O O
a NN O O
proven NN O O
founder NN O O
effect NN O O
- NN O O
the NN O O
Saguenay NN O O
Lac NN O O
- NN O O
St NN O O
. NN O O

- NN O O
Jean NN O O
region NN O O
of NN O O
Quebec NN O O
- NN O O
a NN O O
common NN O O
disease NN O O
haplotype NN O O
was NN O O
sought NN O O
. NN O O

Indeed NN O O
, NN O O
a NN O O
six NN O O
- NN O O
marker NN O O
haplotype NN O O
extending NN O O
over NN O O
a NN O O
region NN O O
of NN O O
5 NN O O
. NN O O

5 NN O O
cM NN O O
was NN O O
observed NN O O
in NN O O
all NN O O
families NN O O
. NN O O

Resequencing NN O O
of NN O O
the NN O O
GK NN O O
gene NN O O
in NN O O
family NN O O
members NN O O
led NN O O
to NN O O
the NN O O
discovery NN O O
of NN O O
a NN O O
N288D NN O O
missense NN O O
mutation NN O O
in NN O O
exon NN O O
10 NN O O
, NN O O
which NN O O
resulted NN O O
in NN O O
the NN O O
substitution NN O O
of NN O O
a NN O O
highly NN O O
conserved NN O O
asparagine NN O O
residue NN O O
by NN O O
a NN O O
negatively NN O O
charged NN O O
aspartic NN O O
acid NN O O
. NN O O

Clinical NN O O
and NN O O
molecular NN O O
genetics NN O O
of NN O O
primary NN O B-Disease
dystonias NN O I-Disease
. NN O O

Primary NN O B-Disease
dystonias NN O I-Disease
are NN O O
movement NN O B-Disease
disorders NN O I-Disease
with NN O O
dystonia NN O B-Disease
as NN O O
a NN O O
major NN O O
symptom NN O O
. NN O O

They NN O O
are NN O O
frequently NN O O
inherited NN O O
as NN O O
Mendelian NN O O
traits NN O O
. NN O O

There NN O O
are NN O O
at NN O O
least NN O O
eight NN O O
clinically NN O O
distinct NN O O
autosomal NN O O
dominant NN O O
and NN O O
two NN O O
X NN O O
- NN O O
linked NN O O
recessive NN O O
forms NN O O
. NN O O

In NN O O
addition NN O O
, NN O O
pedigree NN O O
analyses NN O O
suggest NN O O
the NN O O
occurrence NN O O
of NN O O
an NN O O
autosomal NN O O
recessive NN O O
variant NN O O
. NN O O

The NN O O
clinical NN O O
classification NN O O
is NN O O
increasingly NN O O
being NN O O
replaced NN O O
by NN O O
a NN O O
genetic NN O O
one NN O O
. NN O O

To NN O O
date NN O O
gene NN O O
loci NN O O
have NN O O
been NN O O
identified NN O O
in NN O O
at NN O O
least NN O O
six NN O O
autosomal NN O O
dominant NN O O
forms NN O O
, NN O O
i NN O O
. NN O O
e NN O O
. NN O O
, NN O O
in NN O O
idiopathic NN O B-Disease
torsion NN O I-Disease
dystonia NN O I-Disease
( NN O O
9q34 NN O O
) NN O O
, NN O O
focal NN O B-Disease
dystonia NN O I-Disease
( NN O O
18p NN O O
) NN O O
, NN O O
adult NN O O
- NN O O
onset NN O O
idiopathic NN O B-Disease
torsion NN O I-Disease
dystonia NN O I-Disease
of NN O O
mixed NN O O
type NN O O
( NN O O
8p21 NN O O
- NN O O
q22 NN O O
) NN O O
, NN O O
dopa NN O B-Disease
- NN O I-Disease
responsive NN O I-Disease
dystonia NN O I-Disease
( NN O O
14q22 NN O O
. NN O O
1 NN O O
- NN O O
q22 NN O O
. NN O O
2 NN O O
) NN O O
, NN O O
and NN O O
paroxysmal NN O B-Disease
dystonic NN O I-Disease
choreoathetosis NN O I-Disease
( NN O O
2q25 NN O O
- NN O O
q33 NN O O
; NN O O
1p21 NN O O
- NN O O
p13 NN O O
. NN O O
3 NN O O
) NN O O
. NN O O

Gene NN O O
loci NN O O
in NN O O
the NN O O
X NN O O
- NN O O
linked NN O O
recessive NN O O
forms NN O O
have NN O O
been NN O O
assigned NN O O
to NN O O
Xq13 NN O O
. NN O O

1 NN O O
in NN O O
the NN O O
X NN O B-Disease
- NN O I-Disease
linked NN O I-Disease
dystonia NN O I-Disease
parkinsonism NN O I-Disease
syndrome NN O I-Disease
and NN O O
to NN O O
Xq22 NN O O
in NN O O
X NN O B-Disease
- NN O I-Disease
linked NN O I-Disease
sensorineural NN O I-Disease
deafness NN O I-Disease
, NN O O
dystonia NN O B-Disease
, NN O O
and NN O O
mental NN O B-Disease
retardation NN O I-Disease
. NN O O

The NN O O
disease NN O O
genes NN O O
have NN O O
been NN O O
identified NN O O
in NN O O
two NN O O
autosomal NN O O
dominant NN O O
forms NN O O
and NN O O
in NN O O
one NN O O
X NN O O
- NN O O
linked NN O O
recessive NN O O
form NN O O
. NN O O

Mutations NN O O
in NN O O
a NN O O
gene NN O O
coding NN O O
for NN O O
an NN O O
ATP NN O O
- NN O O
binding NN O O
protein NN O O
were NN O O
detected NN O O
in NN O O
idiopathic NN O B-Disease
torsion NN O I-Disease
dystonia NN O I-Disease
( NN O O
DYT1 NN O O
) NN O O
, NN O O
and NN O O
the NN O O
GTP NN O O
cyclohydrolase NN O O
1 NN O O
gene NN O O
is NN O O
mutated NN O O
in NN O O
dopa NN O B-Disease
- NN O I-Disease
responsive NN O I-Disease
dystonia NN O I-Disease
( NN O O
DYT5 NN O O
) NN O O
. NN O O

In NN O O
sensorineural NN O B-Disease
deafness NN O I-Disease
, NN O O
dystonia NN O B-Disease
, NN O O
and NN O O
mental NN O B-Disease
retardation NN O I-Disease
, NN O O
mutations NN O O
were NN O O
found NN O O
in NN O O
the NN O O
gene NN O O
DDP NN O O
coding NN O O
for NN O O
a NN O O
polypeptide NN O O
of NN O O
unknown NN O O
function NN O O
. NN O O

This NN O O
article NN O O
reviews NN O O
the NN O O
clinical NN O O
and NN O O
molecular NN O O
genetics NN O O
of NN O O
primary NN O B-Disease
dystonias NN O I-Disease
, NN O O
critically NN O O
discusses NN O O
present NN O O
findings NN O O
, NN O O
and NN O O
proposes NN O O
referring NN O O
to NN O O
the NN O O
known NN O O
forms NN O O
, NN O O
most NN O O
of NN O O
which NN O O
can NN O O
be NN O O
distinguished NN O O
by NN O O
genetic NN O O
criteria NN O O
, NN O O
as NN O O
dystonias NN O B-Disease
1 NN O I-Disease
- NN O I-Disease
12 NN O I-Disease
. NN O O

Determination NN O O
of NN O O
30 NN O O
X NN O B-Disease
- NN O I-Disease
linked NN O I-Disease
adrenoleukodystrophy NN O I-Disease
mutations NN O O
, NN O O
including NN O O
15 NN O O
not NN O O
previously NN O O
described NN O O
. NN O O

X NN O B-Disease
- NN O I-Disease
linked NN O I-Disease
Adrenoleukodystrophy NN O I-Disease
( NN O O
X NN O B-Disease
- NN O I-Disease
ALD NN O I-Disease
) NN O O
is NN O O
the NN O O
most NN O O
frequent NN O O
peroxisomal NN O B-Disease
disease NN O I-Disease
. NN O O

It NN O O
mainly NN O O
involves NN O O
the NN O O
nervous NN O O
system NN O O
white NN O O
matter NN O O
, NN O O
adrenal NN O O
cortex NN O O
and NN O O
testes NN O O
. NN O O

Several NN O O
distinct NN O O
clinical NN O O
phenotypes NN O O
are NN O O
known NN O O
. NN O O

The NN O O
principal NN O O
biochemical NN O O
abnormality NN O O
is NN O O
the NN O O
accumulation NN O O
of NN O O
saturated NN O O
very NN O O
- NN O O
long NN O O
- NN O O
chain NN O O
fatty NN O O
acids NN O O
( NN O O
VLCFAs NN O O
> NN O O
C22 NN O O
0 NN O O
, NN O O
mainly NN O O
C26 NN O O
0 NN O O
) NN O O
, NN O O
which NN O O
is NN O O
due NN O O
to NN O O
impaired NN O O
capacity NN O O
for NN O O
beta NN O O
- NN O O
oxidation NN O O
in NN O O
peroxisomes NN O O
. NN O O

Diagnosis NN O O
is NN O O
usually NN O O
based NN O O
on NN O O
the NN O O
VLCFA NN O O
levels NN O O
in NN O O
plasma NN O O
or NN O O
cultured NN O O
skin NN O O
fibroblasts NN O O
in NN O O
both NN O O
patients NN O O
and NN O O
carriers NN O O
. NN O O

In NN O O
0 NN O O
. NN O O

1 NN O O
% NN O O
of NN O O
affected NN O O
males NN O O
, NN O O
however NN O O
, NN O O
the NN O O
plasma NN O O
C26 NN O O
0 NN O O
level NN O O
is NN O O
borderline NN O O
normal NN O O
, NN O O
and NN O O
15 NN O O
% NN O O
of NN O O
obligate NN O O
female NN O O
carriers NN O O
have NN O O
normal NN O O
results NN O O
. NN O O

Effective NN O O
mutation NN O O
detection NN O O
in NN O O
these NN O O
families NN O O
is NN O O
therefore NN O O
fundamental NN O O
to NN O O
unambiguously NN O O
determine NN O O
the NN O O
genetic NN O O
status NN O O
of NN O O
each NN O O
individual NN O O
at NN O O
risk NN O O
. NN O O

Of NN O O
particular NN O O
concern NN O O
are NN O O
female NN O O
members NN O O
of NN O O
kindreds NN O O
segregating NN O O
X NN O B-Disease
- NN O I-Disease
ALD NN O I-Disease
mutations NN O O
, NN O O
because NN O O
normal NN O O
VLCFA NN O O
levels NN O O
do NN O O
not NN O O
guarantee NN O O
lack NN O O
of NN O O
carrier NN O O
status NN O O
. NN O O

We NN O O
describe NN O O
a NN O O
fast NN O O
method NN O O
for NN O O
detection NN O O
of NN O O
X NN O B-Disease
- NN O I-Disease
ALD NN O I-Disease
mutations NN O O
. NN O O

The NN O O
method NN O O
is NN O O
based NN O O
on NN O O
SSCP NN O O
analysis NN O O
of NN O O
nested NN O O
PCR NN O O
fragments NN O O
followed NN O O
by NN O O
sequence NN O O
- NN O O
determination NN O O
reactions NN O O
. NN O O

Using NN O O
this NN O O
methodology NN O O
we NN O O
have NN O O
found NN O O
X NN O B-Disease
- NN O I-Disease
ALD NN O I-Disease
mutations NN O O
in NN O O
30 NN O O
kindreds NN O O
, NN O O
including NN O O
15 NN O O
not NN O O
previously NN O O
reported NN O O
. NN O O

beta NN O O
- NN O O
galactosidase NN O O
gene NN O O
mutations NN O O
affecting NN O O
the NN O O
lysosomal NN O O
enzyme NN O O
and NN O O
the NN O O
elastin NN O O
- NN O O
binding NN O O
protein NN O O
in NN O O
GM1 NN O B-Disease
- NN O I-Disease
gangliosidosis NN O I-Disease
patients NN O O
with NN O O
cardiac NN O B-Disease
involvement NN O I-Disease
. NN O O

GM1 NN O B-Disease
- NN O I-Disease
gangliosidosis NN O I-Disease
is NN O O
a NN O O
lysosomal NN O B-Disease
storage NN O I-Disease
disorder NN O I-Disease
caused NN O O
by NN O O
deficiency NN O B-Disease
of NN O I-Disease
acid NN O I-Disease
beta NN O I-Disease
- NN O I-Disease
galactosidase NN O I-Disease
( NN O O
GLB1 NN O O
) NN O O
. NN O O

We NN O O
report NN O O
five NN O O
new NN O O
beta NN O O
- NN O O
galactosidase NN O O
gene NN O O
mutations NN O O
in NN O O
nine NN O O
Italian NN O O
patients NN O O
and NN O O
one NN O O
fetus NN O O
, NN O O
segregating NN O O
in NN O O
seven NN O O
unrelated NN O O
families NN O O
. NN O O

Six NN O O
of NN O O
the NN O O
eight NN O O
patients NN O O
with NN O O
the NN O O
infantile NN O O
, NN O O
severe NN O O
form NN O O
of NN O O
the NN O O
disease NN O O
presented NN O O
cardiac NN O B-Disease
involvement NN O I-Disease
, NN O O
a NN O O
feature NN O O
rarely NN O O
associated NN O O
with NN O O
GM1 NN O B-Disease
- NN O I-Disease
gangliosidosis NN O I-Disease
. NN O O

Molecular NN O O
analysis NN O O
of NN O O
the NN O O
patients NN O O
RNA NN O O
and NN O O
DNA NN O O
identified NN O O
two NN O O
new NN O O
RNA NN O O
splicing NN O O
defects NN O O
, NN O O
three NN O O
new NN O O
and NN O O
three NN O O
previously NN O O
described NN O O
amino NN O O
acid NN O O
substitutions NN O O
. NN O O

Interestingly NN O O
, NN O O
all NN O O
patients NN O O
with NN O O
cardiac NN O B-Disease
involvement NN O I-Disease
were NN O O
homozygous NN O O
for NN O O
one NN O O
of NN O O
these NN O O
mutations NN O O
R59H NN O O
, NN O O
Y591C NN O O
, NN O O
Y591N NN O O
, NN O O
or NN O O
IVS14 NN O O
- NN O O
2A NN O O
> NN O O
G NN O O
. NN O O

In NN O O
contrast NN O O
, NN O O
all NN O O
other NN O O
patients NN O O
were NN O O
compound NN O O
heterozygous NN O O
for NN O O
one NN O O
of NN O O
the NN O O
following NN O O
mutations NN O O
R201H NN O O
, NN O O
R482H NN O O
, NN O O
G579D NN O O
, NN O O
IVS8 NN O O
+ NN O O
2T NN O O
> NN O O
C NN O O
. NN O O

Although NN O O
we NN O O
could NN O O
not NN O O
directly NN O O
correlate NN O O
the NN O O
presence NN O O
of NN O O
cardiac NN O B-Disease
abnormalities NN O I-Disease
with NN O O
specific NN O O
genetic NN O B-Disease
lesions NN O I-Disease
, NN O O
the NN O O
mutations NN O O
identified NN O O
in NN O O
patients NN O O
with NN O O
cardiomyopathy NN O B-Disease
fell NN O O
in NN O O
the NN O O
GLB1 NN O O
cDNA NN O O
region NN O O
common NN O O
to NN O O
the NN O O
lysosomal NN O O
enzyme NN O O
and NN O O
the NN O O
Hbeta NN O O
- NN O O
Gal NN O O
- NN O O
related NN O O
protein NN O O
, NN O O
also NN O O
known NN O O
as NN O O
the NN O O
elastin NN O O
binding NN O O
protein NN O O
( NN O O
EBP NN O O
) NN O O
. NN O O

Consequently NN O O
, NN O O
both NN O O
molecules NN O O
are NN O O
affected NN O O
by NN O O
the NN O O
mutations NN O O
, NN O O
and NN O O
they NN O O
may NN O O
contribute NN O O
differently NN O O
to NN O O
the NN O O
occurrence NN O O
of NN O O
specific NN O O
clinical NN O O
manifestations NN O O
. NN O O
. NN O O

In NN O O
vivo NN O O
modulation NN O O
of NN O O
Hmgic NN O O
reduces NN O O
obesity NN O B-Disease
. NN O O

The NN O O
HMGI NN O O
family NN O O
of NN O O
proteins NN O O
consists NN O O
of NN O O
three NN O O
members NN O O
, NN O O
HMGIC NN O O
, NN O O
HMGI NN O O
and NN O O
HMGI NN O O
( NN O O
Y NN O O
) NN O O
, NN O O
that NN O O
function NN O O
as NN O O
architectural NN O O
factors NN O O
and NN O O
are NN O O
essential NN O O
components NN O O
of NN O O
the NN O O
enhancesome NN O O
. NN O O

HMGIC NN O O
is NN O O
predominantly NN O O
expressed NN O O
in NN O O
proliferating NN O O
, NN O O
undifferentiated NN O O
mesenchymal NN O O
cells NN O O
and NN O O
is NN O O
not NN O O
detected NN O O
in NN O O
adult NN O O
tissues NN O O
. NN O O

It NN O O
is NN O O
disrupted NN O O
and NN O O
misexpressed NN O O
in NN O O
a NN O O
number NN O O
of NN O O
mesenchymal NN O B-Disease
tumour NN O I-Disease
cell NN O O
types NN O O
, NN O O
including NN O O
fat NN O B-Disease
- NN O I-Disease
cell NN O I-Disease
tumours NN O I-Disease
( NN O O
lipomas NN O B-Disease
) NN O O
. NN O O

In NN O O
addition NN O O
Hmgic NN O O
- NN O O
/ NN O O
- NN O O
mice NN O O
have NN O O
a NN O O
deficiency NN O O
in NN O O
fat NN O O
tissue NN O O
. NN O O

To NN O O
study NN O O
its NN O O
role NN O O
in NN O O
adipogenesis NN O O
and NN O O
obesity NN O B-Disease
, NN O O
we NN O O
examined NN O O
Hmgic NN O O
expression NN O O
in NN O O
the NN O O
adipose NN O O
tissue NN O O
of NN O O
adult NN O O
, NN O O
obese NN O B-Disease
mice NN O O
. NN O O

Mice NN O O
with NN O O
a NN O O
partial NN O B-Disease
or NN O I-Disease
complete NN O I-Disease
deficiency NN O I-Disease
of NN O I-Disease
Hmgic NN O I-Disease
resisted NN O O
diet NN O O
- NN O O
induced NN O O
obesity NN O B-Disease
. NN O O

Disruption NN O O
of NN O O
Hmgic NN O O
caused NN O O
a NN O O
reduction NN O O
in NN O O
the NN O O
obesity NN O B-Disease
induced NN O O
by NN O O
leptin NN O B-Disease
deficiency NN O I-Disease
( NN O O
Lepob NN O O
/ NN O O
Lepob NN O O
) NN O O
in NN O O
a NN O O
gene NN O O
- NN O O
dose NN O O
- NN O O
dependent NN O O
manner NN O O
. NN O O

Our NN O O
studies NN O O
implicate NN O O
a NN O O
role NN O O
for NN O O
HMGIC NN O O
in NN O O
fat NN O O
- NN O O
cell NN O O
proliferation NN O O
, NN O O
indicating NN O O
that NN O O
it NN O O
may NN O O
be NN O O
an NN O O
adipose NN O O
- NN O O
specific NN O O
target NN O O
for NN O O
the NN O O
treatment NN O O
of NN O O
obesity NN O B-Disease
. NN O O
. NN O O

Molecular NN O O
analysis NN O O
of NN O O
the NN O O
genotype NN O O
- NN O O
phenotype NN O O
relationship NN O O
in NN O O
factor NN O B-Disease
X NN O I-Disease
deficiency NN O I-Disease
. NN O O

Factor NN O B-Disease
X NN O I-Disease
deficiency NN O I-Disease
is NN O O
a NN O O
rare NN O O
haemorrhagic NN O B-Disease
condition NN O I-Disease
, NN O O
normally NN O O
inherited NN O O
as NN O O
an NN O O
autosomal NN O O
recessive NN O O
trait NN O O
, NN O O
in NN O O
which NN O O
a NN O O
variable NN O O
clinical NN O O
presentation NN O O
correlates NN O O
poorly NN O O
with NN O O
laboratory NN O O
phenotype NN O O
. NN O O

The NN O O
factor NN O O
X NN O O
( NN O O
F10 NN O O
) NN O O
genes NN O O
of NN O O
14 NN O O
unrelated NN O O
individuals NN O O
with NN O O
factor NN O B-Disease
X NN O I-Disease
deficiency NN O I-Disease
( NN O O
12 NN O O
familial NN O O
and NN O O
two NN O O
sporadic NN O O
cases NN O O
) NN O O
were NN O O
sequenced NN O O
yielding NN O O
a NN O O
total NN O O
of NN O O
13 NN O O
novel NN O O
mutations NN O O
. NN O O

Family NN O O
studies NN O O
were NN O O
performed NN O O
in NN O O
order NN O O
to NN O O
distinguish NN O O
the NN O O
contributions NN O O
of NN O O
individual NN O O
mutant NN O O
F10 NN O O
alleles NN O O
to NN O O
the NN O O
clinical NN O O
and NN O O
laboratory NN O O
phenotypes NN O O
. NN O O

Missense NN O O
mutations NN O O
were NN O O
studied NN O O
by NN O O
means NN O O
of NN O O
molecular NN O O
modelling NN O O
, NN O O
whereas NN O O
single NN O O
basepair NN O O
substitutions NN O O
in NN O O
splice NN O O
sites NN O O
and NN O O
the NN O O
5 NN O O
flanking NN O O
region NN O O
were NN O O
examined NN O O
by NN O O
in NN O O
vitro NN O O
splicing NN O O
assay NN O O
and NN O O
luciferase NN O O
reporter NN O O
gene NN O O
assay NN O O
respectively NN O O
. NN O O

The NN O O
deletion NN O O
allele NN O O
of NN O O
a NN O O
novel NN O O
hexanucleotide NN O O
insertion NN O O
/ NN O O
deletion NN O O
polymorphism NN O O
in NN O O
the NN O O
F10 NN O O
gene NN O O
promoter NN O O
region NN O O
was NN O O
shown NN O O
by NN O O
reporter NN O O
gene NN O O
assay NN O O
, NN O O
to NN O O
reduce NN O O
promoter NN O O
activity NN O O
by NN O O
approximately NN O O
20 NN O O
% NN O O
. NN O O

One NN O O
family NN O O
manifesting NN O O
an NN O O
autosomal NN O O
dominant NN O O
pattern NN O O
of NN O O
inheritance NN O O
possessed NN O O
three NN O O
clinically NN O O
affected NN O O
members NN O O
who NN O O
were NN O O
heterozygous NN O O
for NN O O
a NN O O
splice NN O O
- NN O O
site NN O O
mutation NN O O
that NN O O
was NN O O
predicted NN O O
to NN O O
lead NN O O
to NN O O
the NN O O
production NN O O
of NN O O
a NN O O
truncated NN O O
protein NN O O
product NN O O
. NN O O

A NN O O
model NN O O
which NN O O
accounts NN O O
for NN O O
the NN O O
dominant NN O O
negative NN O O
effect NN O O
of NN O O
this NN O O
lesion NN O O
is NN O O
presented NN O O
. NN O O

Variation NN O O
in NN O O
the NN O O
antigen NN O O
level NN O O
of NN O O
heterozygous NN O O
relatives NN O O
of NN O O
probands NN O O
was NN O O
found NN O O
to NN O O
be NN O O
significantly NN O O
higher NN O O
between NN O O
families NN O O
than NN O O
within NN O O
families NN O O
, NN O O
consistent NN O O
with NN O O
the NN O O
view NN O O
that NN O O
the NN O O
nature NN O O
of NN O O
the NN O O
F10 NN O O
lesion NN O O
( NN O O
s NN O O
) NN O O
segregating NN O O
in NN O O
a NN O O
given NN O O
family NN O O
is NN O O
a NN O O
prime NN O O
determinant NN O O
of NN O O
the NN O O
laboratory NN O O
phenotype NN O O
. NN O O

By NN O O
contrast NN O O
, NN O O
no NN O O
such NN O O
relationship NN O O
could NN O O
be NN O O
discerned NN O O
between NN O O
laboratory NN O O
phenotype NN O O
and NN O O
polymorphism NN O O
genotype NN O O
. NN O O
. NN O O

Transgenic NN O O
mice NN O O
expressing NN O O
a NN O O
truncated NN O O
form NN O O
of NN O O
the NN O O
high NN O O
mobility NN O O
group NN O O
I NN O O
- NN O O
C NN O O
protein NN O O
develop NN O O
adiposity NN O O
and NN O O
an NN O O
abnormally NN O O
high NN O O
prevalence NN O O
of NN O O
lipomas NN O B-Disease
. NN O O

Chromosomal NN O O
translocations NN O O
in NN O O
human NN O O
lipomas NN O B-Disease
frequently NN O O
create NN O O
fusion NN O O
transcripts NN O O
encoding NN O O
high NN O O
mobility NN O O
group NN O O
( NN O O
HMG NN O O
) NN O O
I NN O O
- NN O O
C NN O O
DNA NN O O
- NN O O
binding NN O O
domains NN O O
and NN O O
C NN O O
- NN O O
terminal NN O O
sequences NN O O
from NN O O
different NN O O
presumed NN O O
transcription NN O O
factors NN O O
, NN O O
suggesting NN O O
a NN O O
potential NN O O
role NN O O
for NN O O
HMG NN O O
I NN O O
- NN O O
C NN O O
in NN O O
the NN O O
development NN O O
of NN O O
lipomas NN O B-Disease
. NN O O

To NN O O
evaluate NN O O
the NN O O
role NN O O
of NN O O
the NN O O
HMG NN O O
I NN O O
- NN O O
C NN O O
component NN O O
, NN O O
the NN O O
three NN O O
DNA NN O O
- NN O O
binding NN O O
domains NN O O
of NN O O
HMG NN O O
I NN O O
- NN O O
C NN O O
have NN O O
now NN O O
been NN O O
expressed NN O O
in NN O O
transgenic NN O O
mice NN O O
. NN O O

Despite NN O O
the NN O O
ubiquitous NN O O
expression NN O O
of NN O O
the NN O O
truncated NN O O
HMG NN O O
I NN O O
- NN O O
C NN O O
protein NN O O
, NN O O
the NN O O
transgenic NN O O
mice NN O O
develop NN O O
a NN O O
selective NN O O
abundance NN O O
of NN O O
fat NN O O
tissue NN O O
early NN O O
in NN O O
life NN O O
, NN O O
show NN O O
marked NN O O
adipose NN O B-Disease
tissue NN O I-Disease
inflammation NN O I-Disease
, NN O O
and NN O O
have NN O O
an NN O O
abnormally NN O O
high NN O O
incidence NN O O
of NN O O
lipomas NN O B-Disease
. NN O O

These NN O O
findings NN O O
demonstrate NN O O
that NN O O
the NN O O
DNA NN O O
- NN O O
binding NN O O
domains NN O O
of NN O O
HMG NN O O
I NN O O
- NN O O
C NN O O
, NN O O
in NN O O
the NN O O
absence NN O O
of NN O O
a NN O O
C NN O O
- NN O O
terminal NN O O
fusion NN O O
partner NN O O
, NN O O
are NN O O
sufficient NN O O
to NN O O
perturb NN O O
adipogenesis NN O O
and NN O O
predispose NN O O
to NN O O
lipomas NN O B-Disease
. NN O O

We NN O O
provide NN O O
data NN O O
supporting NN O O
the NN O O
central NN O O
utility NN O O
of NN O O
this NN O O
animal NN O O
model NN O O
as NN O O
a NN O O
tool NN O O
to NN O O
understand NN O O
the NN O O
molecular NN O O
mechanisms NN O O
underlying NN O O
the NN O O
development NN O O
of NN O O
one NN O O
of NN O O
the NN O O
most NN O O
common NN O O
kind NN O O
of NN O O
human NN O O
benign NN O B-Disease
tumors NN O I-Disease
. NN O O
. NN O O

ATM NN O O
phosphorylates NN O O
p95 NN O O
/ NN O O
nbs1 NN O O
in NN O O
an NN O O
S NN O O
- NN O O
phase NN O O
checkpoint NN O O
pathway NN O O
. NN O O

The NN O O
rare NN O B-Disease
diseases NN O I-Disease
ataxia NN O B-Disease
- NN O I-Disease
telangiectasia NN O I-Disease
( NN O O
AT NN O B-Disease
) NN O O
, NN O O
caused NN O O
by NN O O
mutations NN O O
in NN O O
the NN O O
ATM NN O O
gene NN O O
, NN O O
and NN O O
Nijmegen NN O B-Disease
breakage NN O I-Disease
syndrome NN O I-Disease
( NN O O
NBS NN O B-Disease
) NN O O
, NN O O
with NN O O
mutations NN O O
in NN O O
the NN O O
p95 NN O O
/ NN O O
nbs1 NN O O
gene NN O O
, NN O O
share NN O O
a NN O O
variety NN O O
of NN O O
phenotypic NN O B-Disease
abnormalities NN O I-Disease
such NN O O
as NN O O
chromosomal NN O B-Disease
instability NN O I-Disease
, NN O O
radiation NN O O
sensitivity NN O O
and NN O O
defects NN O O
in NN O O
cell NN O O
- NN O O
cycle NN O O
checkpoints NN O O
in NN O O
response NN O O
to NN O O
ionizing NN O O
radiation NN O O
. NN O O

The NN O O
ATM NN O O
gene NN O O
encodes NN O O
a NN O O
protein NN O O
kinase NN O O
that NN O O
is NN O O
activated NN O O
by NN O O
ionizing NN O O
radiation NN O O
or NN O O
radiomimetic NN O O
drugs NN O O
, NN O O
whereas NN O O
p95 NN O O
/ NN O O
nbs1 NN O O
is NN O O
part NN O O
of NN O O
a NN O O
protein NN O O
complex NN O O
that NN O O
is NN O O
involved NN O O
in NN O O
responses NN O O
to NN O O
DNA NN O O
double NN O O
- NN O O
strand NN O O
breaks NN O O
. NN O O

Here NN O O
, NN O O
because NN O O
of NN O O
the NN O O
similarities NN O O
between NN O O
AT NN O B-Disease
and NN O O
NBS NN O B-Disease
, NN O O
we NN O O
evaluated NN O O
the NN O O
functional NN O O
interactions NN O O
between NN O O
ATM NN O O
and NN O O
p95 NN O O
/ NN O O
nbs1 NN O O
. NN O O

Activation NN O O
of NN O O
the NN O O
ATM NN O O
kinase NN O O
by NN O O
ionizing NN O O
radiation NN O O
and NN O O
induction NN O O
of NN O O
ATM NN O O
- NN O O
dependent NN O O
responses NN O O
in NN O O
NBS NN O B-Disease
cells NN O O
indicated NN O O
that NN O O
p95 NN O O
/ NN O O
nbs1 NN O O
may NN O O
not NN O O
be NN O O
required NN O O
for NN O O
signalling NN O O
to NN O O
ATM NN O O
after NN O O
ionizing NN O O
radiation NN O O
. NN O O

However NN O O
, NN O O
p95 NN O O
/ NN O O
nbs1 NN O O
was NN O O
phosphorylated NN O O
on NN O O
serine NN O O
343 NN O O
in NN O O
an NN O O
ATM NN O O
- NN O O
dependent NN O O
manner NN O O
in NN O O
vitro NN O O
and NN O O
in NN O O
vivo NN O O
after NN O O
ionizing NN O O
radiation NN O O
. NN O O

A NN O O
p95 NN O O
/ NN O O
nbs1 NN O O
construct NN O O
mutated NN O O
at NN O O
the NN O O
ATM NN O O
phosphorylation NN O O
site NN O O
abrogated NN O O
an NN O O
S NN O O
- NN O O
phase NN O O
checkpoint NN O O
induced NN O O
by NN O O
ionizing NN O O
radiation NN O O
in NN O O
normal NN O O
cells NN O O
and NN O O
failed NN O O
to NN O O
compensate NN O O
for NN O O
this NN O O
functional NN O O
deficiency NN O O
in NN O O
NBS NN O B-Disease
cells NN O O
. NN O O

These NN O O
observations NN O O
link NN O O
ATM NN O O
and NN O O
p95 NN O O
/ NN O O
nbs1 NN O O
in NN O O
a NN O O
common NN O O
signalling NN O O
pathway NN O O
and NN O O
provide NN O O
an NN O O
explanation NN O O
for NN O O
phenotypic NN O O
similarities NN O O
in NN O O
these NN O O
two NN O O
diseases NN O O
. NN O O
. NN O O

Understanding NN O O
the NN O O
molecular NN O O
basis NN O O
of NN O O
fragile NN O B-Disease
X NN O I-Disease
syndrome NN O I-Disease
. NN O O

Fragile NN O B-Disease
X NN O I-Disease
syndrome NN O I-Disease
, NN O O
a NN O O
common NN O O
form NN O O
of NN O O
inherited NN O B-Disease
mental NN O I-Disease
retardation NN O I-Disease
, NN O O
is NN O O
mainly NN O O
caused NN O O
by NN O O
massive NN O O
expansion NN O O
of NN O O
CGG NN O O
triplet NN O O
repeats NN O O
located NN O O
in NN O O
the NN O O
5 NN O O
- NN O O
untranslated NN O O
region NN O O
of NN O O
the NN O O
fragile NN O B-Disease
X NN O I-Disease
mental NN O I-Disease
retardation NN O I-Disease
- NN O O
1 NN O O
( NN O O
FMR1 NN O O
) NN O O
gene NN O O
. NN O O

In NN O O
patients NN O O
with NN O O
fragile NN O B-Disease
X NN O I-Disease
syndrome NN O I-Disease
, NN O O
the NN O O
expanded NN O O
CGG NN O O
triplet NN O O
repeats NN O O
are NN O O
hypermethylated NN O O
and NN O O
the NN O O
expression NN O O
of NN O O
the NN O O
FMR1 NN O O
gene NN O O
is NN O O
repressed NN O O
, NN O O
which NN O O
leads NN O O
to NN O O
the NN O O
absence NN O O
of NN O O
FMR1 NN O O
protein NN O O
( NN O O
FMRP NN O O
) NN O O
and NN O O
subsequent NN O O
mental NN O B-Disease
retardation NN O I-Disease
. NN O O

FMRP NN O O
is NN O O
an NN O O
RNA NN O O
- NN O O
binding NN O O
protein NN O O
that NN O O
shuttles NN O O
between NN O O
the NN O O
nucleus NN O O
and NN O O
cytoplasm NN O O
. NN O O

This NN O O
protein NN O O
has NN O O
been NN O O
implicated NN O O
in NN O O
protein NN O O
translation NN O O
as NN O O
it NN O O
is NN O O
found NN O O
associated NN O O
with NN O O
polyribosomes NN O O
and NN O O
the NN O O
rough NN O O
endoplasmic NN O O
reticulum NN O O
. NN O O

We NN O O
discuss NN O O
here NN O O
the NN O O
recent NN O O
progress NN O O
made NN O O
towards NN O O
understanding NN O O
the NN O O
molecular NN O O
mechanism NN O O
of NN O O
CGG NN O O
repeat NN O O
expansion NN O O
and NN O O
physiological NN O O
function NN O O
( NN O O
s NN O O
) NN O O
of NN O O
FMRP NN O O
. NN O O

These NN O O
studies NN O O
will NN O O
not NN O O
only NN O O
help NN O O
to NN O O
illuminate NN O O
the NN O O
molecular NN O O
basis NN O O
of NN O O
the NN O O
general NN O O
class NN O O
of NN O O
human NN O O
diseases NN O O
with NN O O
trinucleotide NN O O
repeat NN O O
expansion NN O O
but NN O O
also NN O O
provide NN O O
an NN O O
avenue NN O O
to NN O O
understand NN O O
aspects NN O O
of NN O O
human NN O O
cognition NN O O
and NN O O
intelligence NN O O
. NN O O
. NN O O

Haploinsufficiency NN O B-Disease
of NN O I-Disease
the NN O I-Disease
transcription NN O I-Disease
factors NN O I-Disease
FOXC1 NN O I-Disease
and NN O I-Disease
FOXC2 NN O I-Disease
results NN O O
in NN O O
aberrant NN O O
ocular NN O O
development NN O O
. NN O O

Anterior NN O B-Disease
segment NN O I-Disease
developmental NN O I-Disease
disorders NN O I-Disease
, NN O O
including NN O O
Axenfeld NN O B-Disease
- NN O I-Disease
Rieger NN O I-Disease
anomaly NN O I-Disease
( NN O O
ARA NN O B-Disease
) NN O O
, NN O O
variably NN O O
associate NN O O
with NN O O
harmfully NN O O
elevated NN O O
intraocular NN O O
pressure NN O O
( NN O O
IOP NN O O
) NN O O
, NN O O
which NN O O
causes NN O O
glaucoma NN O B-Disease
. NN O O

Clinically NN O O
observed NN O O
dysgenesis NN O O
does NN O O
not NN O O
correlate NN O O
with NN O O
IOP NN O O
, NN O O
however NN O O
, NN O O
and NN O O
the NN O O
etiology NN O O
of NN O O
glaucoma NN O B-Disease
development NN O O
is NN O O
not NN O O
understood NN O O
. NN O O

The NN O O
forkhead NN O O
transcription NN O O
factor NN O O
genes NN O O
Foxc1 NN O O
( NN O O
formerly NN O O
Mf1 NN O O
) NN O O
and NN O O
Foxc2 NN O O
( NN O O
formerly NN O O
Mfh1 NN O O
) NN O O
are NN O O
expressed NN O O
in NN O O
the NN O O
mesenchyme NN O O
from NN O O
which NN O O
the NN O O
ocular NN O O
drainage NN O O
structures NN O O
derive NN O O
. NN O O

Mutations NN O O
in NN O O
the NN O O
human NN O O
homolog NN O O
of NN O O
Foxc1 NN O O
, NN O O
FKHL7 NN O O
, NN O O
cause NN O O
dominant NN O O
anterior NN O B-Disease
segment NN O I-Disease
defects NN O I-Disease
and NN O O
glaucoma NN O B-Disease
in NN O O
various NN O O
families NN O O
. NN O O

We NN O O
show NN O O
that NN O O
Foxc1 NN O O
( NN O O
+ NN O O
/ NN O O
- NN O O
) NN O O
mice NN O O
have NN O O
anterior NN O B-Disease
segment NN O I-Disease
abnormalities NN O I-Disease
similar NN O O
to NN O O
those NN O O
reported NN O O
in NN O O
human NN O O
patients NN O O
. NN O O

These NN O O
abnormalities NN O O
include NN O O
small NN O O
or NN O O
absent NN O O
Schlemms NN O O
canal NN O O
, NN O O
aberrantly NN O O
developed NN O O
trabecular NN O O
meshwork NN O O
, NN O O
iris NN O B-Disease
hypoplasia NN O I-Disease
, NN O O
severely NN O O
eccentric NN O O
pupils NN O O
and NN O O
displaced NN O O
Schwalbes NN O O
line NN O O
. NN O O

The NN O O
penetrance NN O O
of NN O O
clinically NN O O
obvious NN O O
abnormalities NN O O
varies NN O O
with NN O O
genetic NN O O
background NN O O
. NN O O

In NN O O
some NN O O
affected NN O O
eyes NN O O
, NN O O
collagen NN O O
bundles NN O O
were NN O O
half NN O O
normal NN O O
diameter NN O O
, NN O O
or NN O O
collagen NN O O
and NN O O
elastic NN O O
tissue NN O O
were NN O O
very NN O O
sparse NN O O
. NN O O

Thus NN O O
, NN O O
abnormalities NN O O
in NN O O
extracellular NN O O
matrix NN O O
synthesis NN O O
or NN O O
organization NN O O
may NN O O
contribute NN O O
to NN O O
development NN O O
of NN O O
the NN O O
ocular NN O O
phenotypes NN O O
. NN O O

Despite NN O O
the NN O O
abnormalities NN O O
in NN O O
ocular NN O O
drainage NN O O
structures NN O O
in NN O O
Foxc1 NN O O
( NN O O
+ NN O O
/ NN O O
- NN O O
) NN O O
mice NN O O
, NN O O
IOP NN O O
was NN O O
normal NN O O
in NN O O
almost NN O O
all NN O O
mice NN O O
analyzed NN O O
, NN O O
on NN O O
all NN O O
genetic NN O O
backgrounds NN O O
and NN O O
at NN O O
all NN O O
ages NN O O
. NN O O

Similar NN O O
abnormalities NN O O
were NN O O
found NN O O
in NN O O
Foxc2 NN O O
( NN O O
+ NN O O
/ NN O O
- NN O O
) NN O O
mice NN O O
, NN O O
but NN O O
no NN O O
disease NN O O
- NN O O
associated NN O O
mutations NN O O
were NN O O
identified NN O O
in NN O O
the NN O O
human NN O O
homolog NN O O
FKHL14 NN O O
in NN O O
32 NN O O
ARA NN O B-Disease
patients NN O O
. NN O O

Foxc1 NN O O
( NN O O
+ NN O O
/ NN O O
- NN O O
) NN O O
and NN O O
Foxc2 NN O O
( NN O O
+ NN O O
/ NN O O
- NN O O
) NN O O
mice NN O O
are NN O O
useful NN O O
models NN O O
for NN O O
studying NN O O
anterior NN O O
segment NN O O
development NN O O
and NN O O
its NN O O
anomalies NN O O
, NN O O
and NN O O
may NN O O
allow NN O O
identification NN O O
of NN O O
genes NN O O
that NN O O
interact NN O O
with NN O O
Foxc1 NN O O
and NN O O
Foxc2 NN O O
( NN O O
or NN O O
FKHL7 NN O O
and NN O O
FKHL14 NN O O
) NN O O
to NN O O
produce NN O O
a NN O O
phenotype NN O O
with NN O O
elevated NN O O
IOP NN O O
and NN O O
glaucoma NN O B-Disease
. NN O O
. NN O O

( NN O O
Over NN O O
) NN O O
correction NN O O
of NN O O
FMR1 NN O B-Disease
deficiency NN O I-Disease
with NN O O
YAC NN O O
transgenics NN O O
: NN O O
behavioral NN O O
and NN O O
physical NN O O
features NN O O
. NN O O

Fragile NN O B-Disease
X NN O I-Disease
syndrome NN O I-Disease
is NN O O
a NN O O
common NN O O
cause NN O O
of NN O O
mental NN O B-Disease
retardation NN O I-Disease
involving NN O O
loss NN O O
of NN O O
expression NN O O
of NN O O
the NN O O
FMR1 NN O O
gene NN O O
. NN O O

The NN O O
role NN O O
of NN O O
FMR1 NN O O
remains NN O O
undetermined NN O O
but NN O O
the NN O O
protein NN O O
appears NN O O
to NN O O
be NN O O
involved NN O O
in NN O O
RNA NN O O
metabolism NN O O
. NN O O

Fmr1 NN O O
knockout NN O O
mice NN O O
exhibit NN O O
a NN O O
phenotype NN O O
with NN O O
some NN O O
similarities NN O O
to NN O O
humans NN O O
, NN O O
such NN O O
as NN O O
macroorchidism NN O B-Disease
and NN O O
behavioral NN O O
abnormalities NN O O
. NN O O

As NN O O
a NN O O
step NN O O
toward NN O O
understanding NN O O
the NN O O
function NN O O
of NN O O
FMR1 NN O O
and NN O O
the NN O O
determination NN O O
of NN O O
the NN O O
potential NN O O
for NN O O
therapeutic NN O O
approaches NN O O
to NN O O
fragile NN O B-Disease
X NN O I-Disease
syndrome NN O I-Disease
, NN O O
yeast NN O O
artificial NN O O
chromosome NN O O
( NN O O
YAC NN O O
) NN O O
transgenic NN O O
mice NN O O
were NN O O
generated NN O O
in NN O O
order NN O O
to NN O O
determine NN O O
whether NN O O
the NN O O
Fmr1 NN O O
knockout NN O O
mouse NN O O
phenotype NN O O
could NN O O
be NN O O
rescued NN O O
. NN O O

Several NN O O
transgenic NN O O
lines NN O O
were NN O O
generated NN O O
that NN O O
carried NN O O
the NN O O
entire NN O O
FMR1 NN O O
locus NN O O
with NN O O
extensive NN O O
amounts NN O O
of NN O O
flanking NN O O
sequence NN O O
. NN O O

We NN O O
observed NN O O
that NN O O
the NN O O
YAC NN O O
transgene NN O O
supported NN O O
production NN O O
of NN O O
the NN O O
human NN O O
protein NN O O
( NN O O
FMRP NN O O
) NN O O
which NN O O
was NN O O
present NN O O
at NN O O
levels NN O O
10 NN O O
to NN O O
15 NN O O
times NN O O
that NN O O
of NN O O
endogenous NN O O
protein NN O O
and NN O O
was NN O O
expressed NN O O
in NN O O
a NN O O
cell NN O O
- NN O O
and NN O O
tissue NN O O
- NN O O
specific NN O O
manner NN O O
. NN O O

Macro NN O O
- NN O O
orchidism NN O O
was NN O O
absent NN O O
in NN O O
knockout NN O O
mice NN O O
carrying NN O O
the NN O O
YAC NN O O
transgene NN O O
indicating NN O O
functional NN O O
rescue NN O O
by NN O O
the NN O O
human NN O O
protein NN O O
. NN O O

Given NN O O
the NN O O
complex NN O O
behavioral NN O O
phenotype NN O O
in NN O O
fragile NN O B-Disease
X NN O I-Disease
patients NN O O
and NN O O
the NN O O
mild NN O O
phenotype NN O O
previously NN O O
reported NN O O
for NN O O
the NN O O
Fmr1 NN O O
knockout NN O O
mouse NN O O
, NN O O
we NN O O
performed NN O O
a NN O O
more NN O O
thorough NN O O
evaluation NN O O
of NN O O
the NN O O
Fmr1 NN O O
knockout NN O O
phenotype NN O O
using NN O O
additional NN O O
behavioral NN O O
assays NN O O
that NN O O
had NN O O
not NN O O
previously NN O O
been NN O O
reported NN O O
for NN O O
this NN O O
animal NN O O
model NN O O
. NN O O

The NN O O
mouse NN O O
displayed NN O O
reduced NN O O
anxiety NN O B-Disease
- NN O O
related NN O O
responses NN O O
with NN O O
increased NN O O
exploratory NN O O
behavior NN O O
. NN O O

FMR1 NN O O
YAC NN O O
transgenic NN O O
mice NN O O
overexpressing NN O O
the NN O O
human NN O O
protein NN O O
did NN O O
produce NN O O
opposing NN O O
behavioral NN O O
responses NN O O
and NN O O
additional NN O O
abnormal NN O O
behaviors NN O O
were NN O O
also NN O O
observed NN O O
. NN O O

These NN O O
findings NN O O
have NN O O
significant NN O O
implications NN O O
for NN O O
gene NN O O
therapy NN O O
for NN O O
fragile NN O B-Disease
X NN O I-Disease
syndrome NN O I-Disease
since NN O O
overexpression NN O O
of NN O O
the NN O O
gene NN O O
may NN O O
harbor NN O O
its NN O O
own NN O O
phenotype NN O O
. NN O O
. NN O O

Transgenic NN O O
mice NN O O
carrying NN O O
large NN O O
human NN O O
genomic NN O O
sequences NN O O
with NN O O
expanded NN O O
CTG NN O O
repeat NN O O
mimic NN O O
closely NN O O
the NN O O
DM NN O B-Disease
CTG NN O O
repeat NN O O
intergenerational NN O O
and NN O O
somatic NN O O
instability NN O O
. NN O O

Myotonic NN O B-Disease
dystrophy NN O I-Disease
( NN O O
DM NN O B-Disease
) NN O O
is NN O O
caused NN O O
by NN O O
a NN O O
CTG NN O O
repeat NN O O
expansion NN O O
in NN O O
the NN O O
3UTR NN O O
of NN O O
the NN O O
DM NN O B-Disease
protein NN O O
kinase NN O O
( NN O O
DMPK NN O O
) NN O O
gene NN O O
. NN O O

A NN O O
very NN O O
high NN O O
level NN O O
of NN O O
instability NN O O
is NN O O
observed NN O O
through NN O O
successive NN O O
generations NN O O
and NN O O
the NN O O
size NN O O
of NN O O
the NN O O
repeat NN O O
is NN O O
generally NN O O
correlated NN O O
with NN O O
the NN O O
severity NN O O
of NN O O
the NN O O
disease NN O O
and NN O O
with NN O O
age NN O O
at NN O O
onset NN O O
. NN O O

Furthermore NN O O
, NN O O
tissues NN O O
from NN O O
DM NN O B-Disease
patients NN O O
exhibit NN O O
somatic NN O O
mosaicism NN O O
that NN O O
increases NN O O
with NN O O
age NN O O
. NN O O

We NN O O
generated NN O O
transgenic NN O O
mice NN O O
carrying NN O O
large NN O O
human NN O O
genomic NN O O
sequences NN O O
with NN O O
20 NN O O
, NN O O
55 NN O O
or NN O O
> NN O O
300 NN O O
CTG NN O O
, NN O O
cloned NN O O
from NN O O
patients NN O O
from NN O O
the NN O O
same NN O O
affected NN O O
DM NN O B-Disease
family NN O O
. NN O O

Using NN O O
large NN O O
human NN O O
flanking NN O O
sequences NN O O
and NN O O
a NN O O
large NN O O
amplification NN O O
, NN O O
we NN O O
demonstrate NN O O
that NN O O
the NN O O
intergenerational NN O O
CTG NN O O
repeat NN O O
instability NN O O
is NN O O
reproduced NN O O
in NN O O
mice NN O O
, NN O O
with NN O O
a NN O O
strong NN O O
bias NN O O
towards NN O O
expansions NN O O
and NN O O
with NN O O
the NN O O
same NN O O
sex NN O O
- NN O O
and NN O O
size NN O O
- NN O O
dependent NN O O
characteristics NN O O
as NN O O
in NN O O
humans NN O O
. NN O O

Moreover NN O O
, NN O O
a NN O O
high NN O O
level NN O O
of NN O O
instability NN O O
, NN O O
increasing NN O O
with NN O O
age NN O O
, NN O O
can NN O O
be NN O O
observed NN O O
in NN O O
tissues NN O O
and NN O O
in NN O O
sperm NN O O
. NN O O

Although NN O O
we NN O O
did NN O O
not NN O O
observe NN O O
dramatic NN O O
expansions NN O O
( NN O O
or NN O O
big NN O O
jumps NN O O
over NN O O
several NN O O
hundred NN O O
CTG NN O O
repeats NN O O
) NN O O
as NN O O
in NN O O
congenital NN O O
forms NN O O
of NN O O
DM NN O B-Disease
, NN O O
our NN O O
model NN O O
carrying NN O O
> NN O O
300 NN O O
CTG NN O O
is NN O O
the NN O O
first NN O O
to NN O O
show NN O O
instability NN O O
so NN O O
close NN O O
to NN O O
the NN O O
human NN O O
DM NN O B-Disease
situation NN O O
. NN O O

Our NN O O
three NN O O
models NN O O
carrying NN O O
different NN O O
sizes NN O O
of NN O O
CTG NN O O
repeat NN O O
provide NN O O
insight NN O O
on NN O O
the NN O O
different NN O O
factors NN O O
modulating NN O O
the NN O O
CTG NN O O
repeat NN O O
instability NN O O
. NN O O
. NN O O

Inactivation NN O O
of NN O O
the NN O O
Friedreich NN O B-Disease
ataxia NN O I-Disease
mouse NN O O
gene NN O O
leads NN O O
to NN O O
early NN O O
embryonic NN O B-Disease
lethality NN O I-Disease
without NN O O
iron NN O O
accumulation NN O O
. NN O O

Friedreich NN O B-Disease
ataxia NN O I-Disease
( NN O O
FRDA NN O B-Disease
) NN O O
, NN O O
the NN O O
most NN O O
common NN O O
autosomal NN O B-Disease
recessive NN O I-Disease
ataxia NN O I-Disease
, NN O O
is NN O O
caused NN O O
in NN O O
almost NN O O
all NN O O
cases NN O O
by NN O O
homozygous NN O O
intronic NN O O
expansions NN O O
resulting NN O O
in NN O O
the NN O O
loss NN O O
of NN O O
frataxin NN O O
, NN O O
a NN O O
mitochondrial NN O O
protein NN O O
conserved NN O O
through NN O O
evolution NN O O
, NN O O
and NN O O
involved NN O O
in NN O O
mitochondrial NN O O
iron NN O O
homeostasis NN O O
. NN O O

Yeast NN O O
knockout NN O O
models NN O O
, NN O O
and NN O O
histological NN O O
and NN O O
biochemical NN O O
data NN O O
from NN O O
patient NN O O
heart NN O O
biopsies NN O O
or NN O O
autopsies NN O O
indicate NN O O
that NN O O
the NN O O
frataxin NN O O
defect NN O O
causes NN O O
a NN O O
specific NN O O
iron NN O B-Disease
- NN O I-Disease
sulfur NN O I-Disease
protein NN O I-Disease
deficiency NN O I-Disease
and NN O O
mitochondrial NN O O
iron NN O O
accumulation NN O O
leading NN O O
to NN O O
the NN O O
pathological NN O O
changes NN O O
. NN O O

Affected NN O O
human NN O O
tissues NN O O
are NN O O
rarely NN O O
available NN O O
to NN O O
further NN O O
examine NN O O
this NN O O
hypothesis NN O O
. NN O O

To NN O O
study NN O O
the NN O O
mechanism NN O O
of NN O O
the NN O O
disease NN O O
, NN O O
we NN O O
generated NN O O
a NN O O
mouse NN O O
model NN O O
by NN O O
deletion NN O O
of NN O O
exon NN O O
4 NN O O
leading NN O O
to NN O O
inactivation NN O O
of NN O O
the NN O O
Frda NN O B-Disease
gene NN O O
product NN O O
. NN O O

We NN O O
show NN O O
that NN O O
homozygous NN O O
deletions NN O O
cause NN O O
embryonic NN O B-Disease
lethality NN O I-Disease
a NN O O
few NN O O
days NN O O
after NN O O
implantation NN O O
, NN O O
demonstrating NN O O
an NN O O
important NN O O
role NN O O
for NN O O
frataxin NN O O
during NN O O
early NN O O
development NN O O
. NN O O

These NN O O
results NN O O
suggest NN O O
that NN O O
the NN O O
milder NN O O
phenotype NN O O
in NN O O
humans NN O O
is NN O O
due NN O O
to NN O O
residual NN O O
frataxin NN O O
expression NN O O
associated NN O O
with NN O O
the NN O O
expansion NN O O
mutations NN O O
. NN O O

Surprisingly NN O O
, NN O O
in NN O O
the NN O O
frataxin NN O O
knockout NN O O
mouse NN O O
, NN O O
no NN O O
iron NN O O
accumulation NN O O
was NN O O
observed NN O O
during NN O O
embryonic NN O O
resorption NN O O
, NN O O
suggesting NN O O
that NN O O
cell NN O O
death NN O O
could NN O O
be NN O O
due NN O O
to NN O O
a NN O O
mechanism NN O O
independent NN O O
of NN O O
iron NN O O
accumulation NN O O
. NN O O
. NN O O

Gaucher NN O B-Disease
disease NN O I-Disease
: NN O O
the NN O O
origins NN O O
of NN O O
the NN O O
Ashkenazi NN O O
Jewish NN O O
N370S NN O O
and NN O O
84GG NN O O
acid NN O O
beta NN O O
- NN O O
glucosidase NN O O
mutations NN O O
. NN O O

Type NN O O
1 NN O O
Gaucher NN O B-Disease
disease NN O I-Disease
( NN O O
GD NN O B-Disease
) NN O O
, NN O O
a NN O O
non NN O O
- NN O O
neuronopathic NN O O
lysosomal NN O B-Disease
storage NN O I-Disease
disorder NN O I-Disease
, NN O O
results NN O O
from NN O O
the NN O O
deficient NN O O
activity NN O O
of NN O O
acid NN O O
beta NN O O
- NN O O
glucosidase NN O O
( NN O O
GBA NN O O
) NN O O
. NN O O

Type NN O O
1 NN O O
disease NN O O
is NN O O
panethnic NN O O
but NN O O
is NN O O
more NN O O
prevalent NN O O
in NN O O
individuals NN O O
of NN O O
Ashkenazi NN O O
Jewish NN O O
( NN O O
AJ NN O O
) NN O O
descent NN O O
. NN O O

Of NN O O
the NN O O
causative NN O O
GBA NN O O
mutations NN O O
, NN O O
N370S NN O O
is NN O O
particularly NN O O
frequent NN O O
in NN O O
the NN O O
AJ NN O O
population NN O O
, NN O O
( NN O O
q NN O O
approximately NN O O
. NN O O
03 NN O O
) NN O O
, NN O O
whereas NN O O
the NN O O
84GG NN O O
insertion NN O O
( NN O O
q NN O O
approximately NN O O
. NN O O
003 NN O O
) NN O O
occurs NN O O
exclusively NN O O
in NN O O
the NN O O
Ashkenazim NN O O
. NN O O

To NN O O
investigate NN O O
the NN O O
genetic NN O O
history NN O O
of NN O O
these NN O O
mutations NN O O
in NN O O
the NN O O
AJ NN O O
population NN O O
, NN O O
short NN O O
tandem NN O O
repeat NN O O
( NN O O
STR NN O O
) NN O O
markers NN O O
were NN O O
used NN O O
to NN O O
map NN O O
a NN O O
9 NN O O
. NN O O

3 NN O O
- NN O O
cM NN O O
region NN O O
containing NN O O
the NN O O
GBA NN O O
locus NN O O
and NN O O
to NN O O
genotype NN O O
261 NN O O
AJ NN O O
N370S NN O O
chromosomes NN O O
, NN O O
60 NN O O
European NN O O
non NN O O
- NN O O
Jewish NN O O
N370S NN O O
chromosomes NN O O
, NN O O
and NN O O
62 NN O O
AJ NN O O
84GG NN O O
chromosomes NN O O
. NN O O

A NN O O
highly NN O O
conserved NN O O
haplotype NN O O
at NN O O
four NN O O
markers NN O O
flanking NN O O
GBA NN O O
( NN O O
PKLR NN O O
, NN O O
D1S1595 NN O O
, NN O O
D1S2721 NN O O
, NN O O
and NN O O
D1S2777 NN O O
) NN O O
was NN O O
observed NN O O
on NN O O
both NN O O
the NN O O
AJ NN O O
chromosomes NN O O
and NN O O
the NN O O
non NN O O
- NN O O
Jewish NN O O
N370S NN O O
chromosomes NN O O
, NN O O
suggesting NN O O
the NN O O
occurrence NN O O
of NN O O
a NN O O
founder NN O O
common NN O O
to NN O O
both NN O O
populations NN O O
. NN O O

Of NN O O
note NN O O
, NN O O
the NN O O
presence NN O O
of NN O O
different NN O O
divergent NN O O
haplotypes NN O O
suggested NN O O
the NN O O
occurrence NN O O
of NN O O
de NN O O
novo NN O O
, NN O O
recurrent NN O O
N370S NN O O
mutations NN O O
. NN O O

In NN O O
contrast NN O O
, NN O O
a NN O O
different NN O O
conserved NN O O
haplotype NN O O
at NN O O
these NN O O
markers NN O O
was NN O O
identified NN O O
on NN O O
the NN O O
84GG NN O O
chromosomes NN O O
, NN O O
which NN O O
was NN O O
unique NN O O
to NN O O
the NN O O
AJ NN O O
population NN O O
. NN O O

On NN O O
the NN O O
basis NN O O
of NN O O
the NN O O
linkage NN O O
disequilibrium NN O O
( NN O O
LD NN O O
) NN O O
delta NN O O
values NN O O
, NN O O
the NN O O
non NN O O
- NN O O
Jewish NN O O
European NN O O
N370S NN O O
chromosomes NN O O
had NN O O
greater NN O O
haplotype NN O O
diversity NN O O
and NN O O
less NN O O
LD NN O O
at NN O O
the NN O O
markers NN O O
flanking NN O O
the NN O O
conserved NN O O
haplotype NN O O
than NN O O
did NN O O
the NN O O
AJ NN O O
N370S NN O O
chromosomes NN O O
. NN O O

This NN O O
finding NN O O
is NN O O
consistent NN O O
with NN O O
the NN O O
presence NN O O
of NN O O
the NN O O
N370S NN O O
mutation NN O O
in NN O O
the NN O O
non NN O O
- NN O O
Jewish NN O O
European NN O O
population NN O O
prior NN O O
to NN O O
the NN O O
founding NN O O
of NN O O
the NN O O
AJ NN O O
population NN O O
. NN O O

Coalescence NN O O
analyses NN O O
for NN O O
the NN O O
N370S NN O O
and NN O O
84GG NN O O
mutations NN O O
estimated NN O O
similar NN O O
coalescence NN O O
times NN O O
, NN O O
of NN O O
48 NN O O
and NN O O
55 NN O O
. NN O O
5 NN O O
generations NN O O
ago NN O O
, NN O O
respectively NN O O
. NN O O

The NN O O
results NN O O
of NN O O
these NN O O
studies NN O O
are NN O O
consistent NN O O
with NN O O
a NN O O
significant NN O O
bottleneck NN O O
occurring NN O O
in NN O O
the NN O O
AJ NN O O
population NN O O
during NN O O
the NN O O
first NN O O
millennium NN O O
, NN O O
when NN O O
the NN O O
population NN O O
became NN O O
established NN O O
in NN O O
Europe NN O O
. NN O O

HLA NN O O
B27 NN O O
and NN O O
the NN O O
genetics NN O O
of NN O O
ankylosing NN O B-Disease
spondylitis NN O I-Disease
. NN O O

One NN O O
hundred NN O O
and NN O O
twenty NN O O
- NN O O
eight NN O O
of NN O O
145 NN O O
patients NN O O
with NN O O
ankylosing NN O B-Disease
spondylitis NN O I-Disease
( NN O O
AS NN O B-Disease
) NN O O
were NN O O
found NN O O
to NN O O
be NN O O
HLA NN O O
B27 NN O O
positive NN O O
. NN O O

Five NN O O
patients NN O O
had NN O O
evidence NN O O
of NN O O
a NN O O
sero NN O O
- NN O O
negative NN O O
peripheral NN O B-Disease
arthritis NN O I-Disease
resembling NN O O
peripheral NN O B-Disease
psoriatic NN O I-Disease
arthritis NN O I-Disease
and NN O O
3 NN O O
of NN O O
these NN O O
were NN O O
B27 NN O O
negative NN O O
. NN O O

One NN O O
further NN O O
B27 NN O O
negative NN O O
patients NN O O
had NN O O
a NN O O
sister NN O O
with NN O O
ankylosing NN O B-Disease
spondylitis NN O I-Disease
and NN O O
ulcerative NN O B-Disease
colitis NN O I-Disease
and NN O O
a NN O O
mother NN O O
with NN O O
ulcerative NN O B-Disease
colitis NN O I-Disease
. NN O O

There NN O O
was NN O O
evidence NN O O
of NN O O
a NN O O
somewhat NN O O
later NN O O
age NN O O
of NN O O
onset NN O O
of NN O O
symptoms NN O O
in NN O O
B27 NN O O
negative NN O O
patients NN O O
. NN O O

These NN O O
findings NN O O
are NN O O
interpreted NN O O
as NN O O
suggesting NN O O
some NN O O
degree NN O O
of NN O O
clinical NN O O
and NN O O
genetic NN O O
heterogeneity NN O O
in NN O O
ankylosing NN O B-Disease
spondylitis NN O I-Disease
with NN O O
genes NN O O
for NN O O
psoriasis NN O B-Disease
and NN O O
inflammatory NN O B-Disease
bowel NN O I-Disease
disease NN O I-Disease
being NN O O
important NN O O
in NN O O
some NN O O
individuals NN O O
, NN O O
particularly NN O O
those NN O O
who NN O O
are NN O O
B27 NN O O
negative NN O O
. NN O O

Twenty NN O O
- NN O O
five NN O O
first NN O O
- NN O O
degree NN O O
relatives NN O O
with NN O O
ankylosing NN O B-Disease
spondylitis NN O I-Disease
were NN O O
all NN O O
B27 NN O O
positive NN O O
. NN O O

The NN O O
only NN O O
instance NN O O
of NN O O
disassociation NN O O
of NN O O
B27 NN O O
and NN O O
spondylitis NN O B-Disease
in NN O O
a NN O O
family NN O O
was NN O O
where NN O O
the NN O O
proband NN O O
had NN O O
ulcerative NN O B-Disease
colitis NN O I-Disease
as NN O O
well NN O O
as NN O O
spondylitis NN O B-Disease
. NN O O

Of NN O O
13 NN O O
B27 NN O O
positive NN O O
fathers NN O O
3 NN O O
could NN O O
be NN O O
diagnosed NN O O
as NN O O
having NN O O
definite NN O O
ankylosing NN O B-Disease
spondylitis NN O I-Disease
( NN O O
23 NN O O
% NN O O
) NN O O
. NN O O

These NN O O
findings NN O O
are NN O O
thought NN O O
to NN O O
provide NN O O
evidence NN O O
against NN O O
the NN O O
concept NN O O
that NN O O
the NN O O
gene NN O O
for NN O O
ankylosing NN O B-Disease
spondylitis NN O I-Disease
is NN O O
not NN O O
B27 NN O O
but NN O O
a NN O O
closely NN O O
linked NN O O
gene NN O O
and NN O O
favour NN O O
the NN O O
occurrence NN O O
of NN O O
an NN O O
environmental NN O O
event NN O O
affecting NN O O
approximately NN O O
one NN O O
- NN O O
fifth NN O O
of NN O O
B27 NN O O
positive NN O O
males NN O O
to NN O O
result NN O O
in NN O O
disease NN O O
. NN O O
. NN O O

Founder NN O O
mutations NN O O
in NN O O
the NN O O
BRCA1 NN O O
gene NN O O
in NN O O
Polish NN O O
families NN O O
with NN O O
breast NN O B-Disease
- NN O I-Disease
ovarian NN O I-Disease
cancer NN O I-Disease
. NN O O

We NN O O
have NN O O
undertaken NN O O
a NN O O
hospital NN O O
- NN O O
based NN O O
study NN O O
, NN O O
to NN O O
identify NN O O
possible NN O O
BRCA1 NN O O
and NN O O
BRCA2 NN O O
founder NN O O
mutations NN O O
in NN O O
the NN O O
Polish NN O O
population NN O O
. NN O O

The NN O O
study NN O O
group NN O O
consisted NN O O
of NN O O
66 NN O O
Polish NN O O
families NN O O
with NN O O
cancer NN O B-Disease
who NN O O
have NN O O
at NN O O
least NN O O
three NN O O
related NN O O
females NN O O
affected NN O O
with NN O O
breast NN O B-Disease
or NN O I-Disease
ovarian NN O I-Disease
cancer NN O I-Disease
and NN O O
who NN O O
had NN O O
cancer NN O B-Disease
diagnosed NN O O
, NN O O
in NN O O
at NN O O
least NN O O
one NN O O
of NN O O
the NN O O
three NN O O
affected NN O O
females NN O O
, NN O O
at NN O O
age NN O O
< NN O O
50 NN O O
years NN O O
. NN O O

A NN O O
total NN O O
of NN O O
26 NN O O
families NN O O
had NN O O
both NN O O
breast NN O B-Disease
and NN O I-Disease
ovarian NN O I-Disease
cancers NN O I-Disease
, NN O O
4 NN O O
families NN O O
had NN O O
ovarian NN O B-Disease
cancers NN O I-Disease
only NN O O
, NN O O
and NN O O
36 NN O O
families NN O O
had NN O O
breast NN O B-Disease
cancers NN O I-Disease
only NN O O
. NN O O

Genomic NN O O
DNA NN O O
was NN O O
prepared NN O O
from NN O O
the NN O O
peripheral NN O O
blood NN O O
leukocytes NN O O
of NN O O
at NN O O
least NN O O
one NN O O
affected NN O O
woman NN O O
from NN O O
each NN O O
family NN O O
. NN O O

The NN O O
entire NN O O
coding NN O O
region NN O O
of NN O O
BRCA1 NN O O
and NN O O
BRCA2 NN O O
was NN O O
screened NN O O
for NN O O
the NN O O
presence NN O O
of NN O O
germline NN O O
mutations NN O O
, NN O O
by NN O O
use NN O O
of NN O O
SSCP NN O O
followed NN O O
by NN O O
direct NN O O
sequencing NN O O
of NN O O
observed NN O O
variants NN O O
. NN O O

Mutations NN O O
were NN O O
found NN O O
in NN O O
35 NN O O
( NN O O
53 NN O O
% NN O O
) NN O O
of NN O O
the NN O O
66 NN O O
families NN O O
studied NN O O
. NN O O

All NN O O
but NN O O
one NN O O
of NN O O
the NN O O
mutations NN O O
were NN O O
detected NN O O
within NN O O
the NN O O
BRCA1 NN O O
gene NN O O
. NN O O

BRCA1 NN O B-Disease
abnormalities NN O I-Disease
were NN O O
identified NN O O
in NN O O
all NN O O
four NN O O
families NN O O
with NN O O
ovarian NN O B-Disease
cancer NN O I-Disease
only NN O O
, NN O O
in NN O O
67 NN O O
% NN O O
of NN O O
27 NN O O
families NN O O
with NN O O
both NN O O
breast NN O B-Disease
and NN O I-Disease
ovarian NN O I-Disease
cancer NN O I-Disease
, NN O O
and NN O O
in NN O O
34 NN O O
% NN O O
of NN O O
35 NN O O
families NN O O
with NN O O
breast NN O B-Disease
cancer NN O I-Disease
only NN O O
. NN O O

The NN O O
single NN O O
family NN O O
with NN O O
a NN O O
BRCA2 NN O O
mutation NN O O
had NN O O
the NN O O
breast NN O B-Disease
- NN O I-Disease
ovarian NN O I-Disease
cancer NN O I-Disease
syndrome NN O I-Disease
. NN O O

Seven NN O O
distinct NN O O
mutations NN O O
were NN O O
identified NN O O
; NN O O
five NN O O
of NN O O
these NN O O
occurred NN O O
in NN O O
two NN O O
or NN O O
more NN O O
families NN O O
. NN O O

In NN O O
total NN O O
, NN O O
recurrent NN O O
mutations NN O O
were NN O O
found NN O O
in NN O O
33 NN O O
( NN O O
94 NN O O
% NN O O
) NN O O
of NN O O
the NN O O
35 NN O O
families NN O O
with NN O O
detected NN O O
mutations NN O O
. NN O O

Three NN O O
BRCA1 NN O B-Disease
abnormalities NN O I-Disease
- NN O O
5382insC NN O O
, NN O O
C61G NN O O
, NN O O
and NN O O
4153delA NN O O
- NN O O
accounted NN O O
for NN O O
51 NN O O
% NN O O
, NN O O
20 NN O O
% NN O O
, NN O O
and NN O O
11 NN O O
% NN O O
of NN O O
the NN O O
identified NN O O
mutations NN O O
, NN O O
respectively NN O O
. NN O O
. NN O O

Molecular NN O O
basis NN O O
of NN O O
very NN O B-Disease
long NN O I-Disease
chain NN O I-Disease
acyl NN O I-Disease
- NN O I-Disease
CoA NN O I-Disease
dehydrogenase NN O I-Disease
deficiency NN O I-Disease
in NN O O
three NN O O
Israeli NN O O
patients NN O O
: NN O O
identification NN O O
of NN O O
a NN O O
complex NN O O
mutant NN O O
allele NN O O
with NN O O
P65L NN O O
and NN O O
K247Q NN O O
mutations NN O O
, NN O O
the NN O O
former NN O O
being NN O O
an NN O O
exonic NN O O
mutation NN O O
causing NN O O
exon NN O O
3 NN O O
skipping NN O O
. NN O O

Very NN O B-Disease
long NN O I-Disease
chain NN O I-Disease
acyl NN O I-Disease
- NN O I-Disease
CoA NN O I-Disease
dehydrogenase NN O I-Disease
( NN O I-Disease
VLCAD NN O I-Disease
) NN O I-Disease
deficiency NN O I-Disease
is NN O O
a NN O O
life NN O O
- NN O O
threatening NN O O
disorder NN O O
of NN O O
mitochondrial NN O O
fatty NN O O
acid NN O O
beta NN O O
- NN O O
oxidation NN O O
. NN O O

We NN O O
identified NN O O
four NN O O
novel NN O O
mutations NN O O
in NN O O
three NN O O
unrelated NN O O
patients NN O O
. NN O O

All NN O O
patients NN O O
had NN O O
the NN O O
severe NN O O
childhood NN O O
form NN O O
of NN O O
VLCAD NN O B-Disease
deficiency NN O I-Disease
with NN O O
early NN O O
onset NN O O
and NN O O
high NN O O
mortality NN O O
. NN O O

Immunoblot NN O O
analysis NN O O
revealed NN O O
that NN O O
VLCAD NN O O
protein NN O O
was NN O O
undetectable NN O O
in NN O O
patients NN O O
2 NN O O
and NN O O
3 NN O O
, NN O O
whereas NN O O
normal NN O O
- NN O O
size NN O O
VLCAD NN O O
protein NN O O
and NN O O
an NN O O
aberrant NN O O
form NN O O
of NN O O
VLCAD NN O O
( NN O O
4kDa NN O O
smaller NN O O
) NN O O
were NN O O
detected NN O O
in NN O O
patient NN O O
1 NN O O
. NN O O

As NN O O
expected NN O O
, NN O O
null NN O O
mutations NN O O
were NN O O
found NN O O
in NN O O
patients NN O O
2 NN O O
and NN O O
3 NN O O
patient NN O O
2 NN O O
is NN O O
homozygous NN O O
for NN O O
a NN O O
frameshift NN O O
mutation NN O O
, NN O O
del NN O O
4 NN O O
bp NN O O
at NN O O
798 NN O O
- NN O O
801 NN O O
, NN O O
and NN O O
patient NN O O
3 NN O O
is NN O O
homozygous NN O O
for NN O O
a NN O O
nonsense NN O O
mutation NN O O
65C NN O O
> NN O O
A NN O O
( NN O O
S22X NN O O
) NN O O
. NN O O

Patient NN O O
1 NN O O
was NN O O
homozygous NN O O
for NN O O
a NN O O
complex NN O O
mutant NN O O
allele NN O O
containing NN O O
two NN O O
alterations NN O O
, NN O O
including NN O O
a NN O O
194C NN O O
> NN O O
T NN O O
transition NN O O
( NN O O
P65L NN O O
) NN O O
and NN O O
739A NN O O
> NN O O
C NN O O
transversion NN O O
( NN O O
K247Q NN O O
) NN O O
; NN O O
in NN O O
the NN O O
case NN O O
of NN O O
P65L NN O O
, NN O O
the NN O O
amino NN O O
acid NN O O
change NN O O
does NN O O
not NN O O
reduce NN O O
enzyme NN O O
activity NN O O
. NN O O

However NN O O
, NN O O
the NN O O
nucleotide NN O O
change NN O O
resulted NN O O
in NN O O
exon NN O O
3 NN O O
skipping NN O O
, NN O O
whereas NN O O
the NN O O
latter NN O O
K247Q NN O O
mutation NN O O
had NN O O
a NN O O
drastic NN O O
effect NN O O
on NN O O
enzyme NN O O
activity NN O O
. NN O O

We NN O O
verified NN O O
these NN O O
events NN O O
by NN O O
in NN O O
vivo NN O O
splicing NN O O
experiments NN O O
and NN O O
transient NN O O
expression NN O O
analysis NN O O
of NN O O
mutant NN O O
cDNAs NN O O
. NN O O

The NN O O
P65L NN O O
mutation NN O O
locates NN O O
11 NN O O
bases NN O O
upstream NN O O
of NN O O
a NN O O
splice NN O O
donor NN O O
site NN O O
of NN O O
intron NN O O
3 NN O O
. NN O O

This NN O O
is NN O O
an NN O O
example NN O O
of NN O O
an NN O O
exonic NN O O
mutation NN O O
which NN O O
affects NN O O
exon NN O O
- NN O O
splicing NN O O
. NN O O
. NN O O

Submicroscopic NN O O
deletion NN O O
in NN O O
cousins NN O O
with NN O O
Prader NN O B-Disease
- NN O I-Disease
Willi NN O I-Disease
syndrome NN O I-Disease
causes NN O O
a NN O O
grandmatrilineal NN O O
inheritance NN O O
pattern NN O O
: NN O O
effects NN O O
of NN O O
imprinting NN O O
. NN O O

The NN O O
Prader NN O B-Disease
- NN O I-Disease
Willi NN O I-Disease
syndrome NN O I-Disease
( NN O O
PWS NN O B-Disease
) NN O O
critical NN O O
region NN O O
on NN O O
15q11 NN O O
- NN O O
q13 NN O O
is NN O O
subject NN O O
to NN O O
imprinting NN O O
. NN O O

PWS NN O B-Disease
becomes NN O O
apparent NN O O
when NN O O
genes NN O O
on NN O O
the NN O O
paternally NN O O
inherited NN O O
chromosome NN O O
are NN O O
not NN O O
expressed NN O O
. NN O O

Familial NN O B-Disease
PWS NN O I-Disease
is NN O O
rare NN O O
. NN O O

We NN O O
report NN O O
on NN O O
a NN O O
family NN O O
in NN O O
which NN O O
a NN O O
male NN O O
and NN O O
a NN O O
female NN O O
paternal NN O O
first NN O O
cousin NN O O
both NN O O
have NN O O
PWS NN O B-Disease
with NN O O
cytogenetically NN O O
normal NN O O
karyotypes NN O O
. NN O O

Fluorescence NN O O
in NN O O
situ NN O O
hybridization NN O O
( NN O O
FISH NN O O
) NN O O
analysis NN O O
shows NN O O
a NN O O
submicroscopic NN O O
deletion NN O O
of NN O O
SNRPN NN O O
, NN O O
but NN O O
not NN O O
the NN O O
closely NN O O
associated NN O O
loci NN O O
D15S10 NN O O
, NN O O
D15S11 NN O O
, NN O O
D15S63 NN O O
, NN O O
and NN O O
GABRB3 NN O O
. NN O O

The NN O O
cousins NN O O
fathers NN O O
and NN O O
two NN O O
paternal NN O O
aunts NN O O
have NN O O
the NN O O
same NN O O
deletion NN O O
and NN O O
are NN O O
clinically NN O O
normal NN O O
. NN O O

The NN O O
grandmother NN O O
of NN O O
the NN O O
cousins NN O O
is NN O O
deceased NN O O
and NN O O
not NN O O
available NN O O
for NN O O
study NN O O
, NN O O
and NN O O
their NN O O
grandfather NN O O
is NN O O
not NN O O
deleted NN O O
for NN O O
SNRPN NN O O
. NN O O

DNA NN O O
methylation NN O O
analysis NN O O
of NN O O
D15S63 NN O O
is NN O O
consistent NN O O
with NN O O
an NN O O
abnormality NN O O
of NN O O
the NN O O
imprinting NN O O
center NN O O
associated NN O O
with NN O O
PWS NN O B-Disease
. NN O O

" NN O O
Grandmatrilineal NN O O
" NN O O
inheritance NN O O
occurs NN O O
when NN O O
a NN O O
woman NN O O
with NN O O
deletion NN O O
of NN O O
an NN O O
imprinted NN O O
, NN O O
paternally NN O O
expressed NN O O
gene NN O O
is NN O O
at NN O O
risk NN O O
of NN O O
having NN O O
affected NN O O
grandchildren NN O O
through NN O O
her NN O O
sons NN O O
. NN O O

In NN O O
this NN O O
case NN O O
, NN O O
PWS NN O B-Disease
does NN O O
not NN O O
become NN O O
evident NN O O
as NN O O
long NN O O
as NN O O
the NN O O
deletion NN O O
is NN O O
passed NN O O
through NN O O
the NN O O
matrilineal NN O O
line NN O O
. NN O O

This NN O O
represents NN O O
a NN O O
unique NN O O
inheritance NN O O
pattern NN O O
due NN O O
to NN O O
imprinting NN O O
. NN O O
. NN O O

Human NN O O
glycine NN O O
decarboxylase NN O O
gene NN O O
( NN O O
GLDC NN O O
) NN O O
and NN O O
its NN O O
highly NN O O
conserved NN O O
processed NN O O
pseudogene NN O O
( NN O O
psiGLDC NN O O
) NN O O
: NN O O
their NN O O
structure NN O O
and NN O O
expression NN O O
, NN O O
and NN O O
the NN O O
identification NN O O
of NN O O
a NN O O
large NN O O
deletion NN O O
in NN O O
a NN O O
family NN O O
with NN O O
nonketotic NN O B-Disease
hyperglycinemia NN O I-Disease
. NN O O

Mutations NN O O
in NN O O
the NN O O
glycine NN O O
decarboxylase NN O O
gene NN O O
( NN O O
GLDC NN O O
) NN O O
cause NN O O
nonketotic NN O B-Disease
hyperglycinemia NN O I-Disease
( NN O O
NKH NN O B-Disease
) NN O O
, NN O O
an NN O O
in NN O B-Disease
- NN O I-Disease
born NN O I-Disease
error NN O I-Disease
of NN O I-Disease
metabolism NN O I-Disease
characterized NN O O
by NN O O
severe NN O O
neurological NN O B-Disease
disturbance NN O I-Disease
. NN O O

We NN O O
have NN O O
determined NN O O
the NN O O
structure NN O O
of NN O O
GLDC NN O O
and NN O O
of NN O O
its NN O O
pseudogene NN O O
( NN O O
psiGLDC NN O O
) NN O O
and NN O O
studied NN O O
their NN O O
expression NN O O
for NN O O
a NN O O
molecular NN O O
analysis NN O O
of NN O O
NKH NN O B-Disease
. NN O O

The NN O O
GLDC NN O O
gene NN O O
spans NN O O
at NN O O
least NN O O
135 NN O O
kb NN O O
and NN O O
consists NN O O
of NN O O
25 NN O O
exons NN O O
. NN O O

All NN O O
donor NN O O
and NN O O
acceptor NN O O
sites NN O O
adhere NN O O
to NN O O
the NN O O
canonical NN O O
GT NN O O
- NN O O
AG NN O O
rule NN O O
, NN O O
except NN O O
for NN O O
the NN O O
donor NN O O
site NN O O
of NN O O
intron NN O O
21 NN O O
, NN O O
where NN O O
a NN O O
variant NN O O
form NN O O
GC NN O O
is NN O O
used NN O O
instead NN O O
of NN O O
GT NN O O
. NN O O

The NN O O
transcription NN O O
initiation NN O O
site NN O O
has NN O O
been NN O O
assigned NN O O
to NN O O
a NN O O
residue NN O O
163 NN O O
bp NN O O
upstream NN O O
from NN O O
the NN O O
translation NN O O
initiation NN O O
triplet NN O O
by NN O O
primer NN O O
extension NN O O
analysis NN O O
. NN O O

The NN O O
psiGLDC NN O O
gene NN O O
has NN O O
no NN O O
intron NN O O
and NN O O
shares NN O O
97 NN O O
. NN O O

5 NN O O
% NN O O
homology NN O O
with NN O O
the NN O O
coding NN O O
region NN O O
of NN O O
functional NN O O
GLDC NN O O
, NN O O
suggesting NN O O
that NN O O
psiGLDC NN O O
is NN O O
a NN O O
processed NN O O
pseudogene NN O O
that NN O O
arose NN O O
from NN O O
the NN O O
GLDC NN O O
transcript NN O O
about NN O O
4 NN O O
- NN O O
8 NN O O
million NN O O
years NN O O
ago NN O O
. NN O O

RNA NN O O
blotting NN O O
analysis NN O O
has NN O O
revealed NN O O
that NN O O
GLDC NN O O
is NN O O
expressed NN O O
in NN O O
human NN O O
liver NN O O
, NN O O
kidney NN O O
, NN O O
brain NN O O
, NN O O
and NN O O
placenta NN O O
. NN O O

We NN O O
have NN O O
also NN O O
examined NN O O
a NN O O
patient NN O O
with NN O O
NKH NN O B-Disease
with NN O O
no NN O O
detectable NN O O
GLDC NN O O
mRNA NN O O
in NN O O
his NN O O
lymphoblasts NN O O
. NN O O

Exons NN O O
1 NN O O
- NN O O
3 NN O O
of NN O O
the NN O O
functional NN O O
GLDC NN O O
gene NN O O
from NN O O
this NN O O
patient NN O O
are NN O O
not NN O O
amplified NN O O
by NN O O
polymerase NN O O
chain NN O O
reaction NN O O
( NN O O
PCR NN O O
) NN O O
, NN O O
whereas NN O O
those NN O O
from NN O O
control NN O O
subjects NN O O
are NN O O
. NN O O

These NN O O
results NN O O
suggest NN O O
a NN O O
large NN O O
homozygous NN O O
deletion NN O O
( NN O O
at NN O O
least NN O O
30 NN O O
kb NN O O
) NN O O
in NN O O
the NN O O
patient NN O O
. NN O O

Furthermore NN O O
, NN O O
we NN O O
have NN O O
devised NN O O
a NN O O
semi NN O O
- NN O O
quantitative NN O O
PCR NN O O
to NN O O
estimate NN O O
the NN O O
number NN O O
of NN O O
GLDC NN O O
alleles NN O O
by NN O O
using NN O O
psiGLDC NN O O
as NN O O
an NN O O
internal NN O O
control NN O O
and NN O O
have NN O O
confirmed NN O O
the NN O O
homozygosity NN O O
and NN O O
heterozygosity NN O O
of NN O O
the NN O O
deletion NN O O
in NN O O
the NN O O
patient NN O O
and NN O O
his NN O O
parents NN O O
, NN O O
respectively NN O O
. NN O O

Structural NN O O
information NN O O
of NN O O
GLDC NN O O
and NN O O
psiGLDC NN O O
should NN O O
facilitate NN O O
the NN O O
molecular NN O O
analysis NN O O
of NN O O
NKH NN O B-Disease
. NN O O

De NN O O
novo NN O O
deletions NN O O
of NN O O
SNRPN NN O O
exon NN O O
1 NN O O
in NN O O
early NN O O
human NN O O
and NN O O
mouse NN O O
embryos NN O O
result NN O O
in NN O O
a NN O O
paternal NN O O
to NN O O
maternal NN O O
imprint NN O O
switch NN O O
. NN O O

Prader NN O B-Disease
- NN O I-Disease
Willi NN O I-Disease
syndrome NN O I-Disease
( NN O O
PWS NN O B-Disease
) NN O O
is NN O O
a NN O O
neurogenetic NN O B-Disease
disease NN O I-Disease
characterized NN O O
by NN O O
infantile NN O B-Disease
hypotonia NN O I-Disease
, NN O O
gonadal NN O B-Disease
hypoplasia NN O I-Disease
, NN O O
obsessive NN O O
behaviour NN O O
and NN O O
neonatal NN O O
feeding NN O O
difficulties NN O O
followed NN O O
by NN O O
hyperphagia NN O B-Disease
, NN O O
leading NN O O
to NN O O
profound NN O O
obesity NN O B-Disease
. NN O O

PWS NN O B-Disease
is NN O O
due NN O O
to NN O O
a NN O O
lack NN O O
of NN O O
paternal NN O O
genetic NN O O
information NN O O
at NN O O
15q11 NN O O
- NN O O
q13 NN O O
( NN O O
ref NN O O
. NN O O
2 NN O O
) NN O O
. NN O O

Five NN O O
imprinted NN O O
, NN O O
paternally NN O O
expressed NN O O
genes NN O O
map NN O O
to NN O O
the NN O O
PWS NN O B-Disease
region NN O O
, NN O O
MKRN3 NN O O
( NN O O
ref NN O O
. NN O O
3 NN O O
) NN O O
, NN O O
NDN NN O O
( NN O O
ref NN O O
. NN O O
4 NN O O
) NN O O
, NN O O
NDNL1 NN O O
( NN O O
ref NN O O
. NN O O
5 NN O O
) NN O O
, NN O O
SNRPN NN O O
( NN O O
refs NN O O
6 NN O O
- NN O O
8 NN O O
) NN O O
and NN O O
IPW NN O O
( NN O O
ref NN O O
. NN O O
9 NN O O
) NN O O
, NN O O
as NN O O
well NN O O
as NN O O
two NN O O
poorly NN O O
characterized NN O O
framents NN O O
designated NN O O
PAR NN O O
- NN O O
1 NN O O
and NN O O
PAR NN O O
- NN O O
5 NN O O
( NN O O
ref NN O O
. NN O O
10 NN O O
) NN O O
. NN O O

Imprinting NN O O
of NN O O
this NN O O
region NN O O
involves NN O O
a NN O O
bipartite NN O O
imprinting NN O O
centre NN O O
( NN O O
IC NN O O
) NN O O
, NN O O
which NN O O
overlaps NN O O
SNRPN NN O O
( NN O O
refs NN O O
10 NN O O
, NN O O
11 NN O O
) NN O O
. NN O O

Deletion NN O O
of NN O O
the NN O O
SNRPN NN O O
promoter NN O O
/ NN O O
exon NN O O
1 NN O O
region NN O O
( NN O O
the NN O O
PWS NN O B-Disease
IC NN O O
element NN O O
) NN O O
appears NN O O
to NN O O
impair NN O O
the NN O O
establishment NN O O
of NN O O
the NN O O
paternal NN O O
imprint NN O O
in NN O O
the NN O O
male NN O O
germ NN O O
line NN O O
and NN O O
leads NN O O
to NN O O
PWS NN O B-Disease
. NN O O

Here NN O O
we NN O O
report NN O O
a NN O O
PWS NN O B-Disease
family NN O O
in NN O O
which NN O O
the NN O O
father NN O O
is NN O O
mosaic NN O O
for NN O O
an NN O O
IC NN O O
deletion NN O O
on NN O O
his NN O O
paternal NN O O
chromosome NN O O
. NN O O

The NN O O
deletion NN O O
chromosome NN O O
has NN O O
acquired NN O O
a NN O O
maternal NN O O
methylation NN O O
imprint NN O O
in NN O O
his NN O O
somatic NN O O
cells NN O O
. NN O O

We NN O O
have NN O O
made NN O O
identical NN O O
findings NN O O
in NN O O
chimaeric NN O O
mice NN O O
generated NN O O
from NN O O
two NN O O
independent NN O O
embryonic NN O O
stem NN O O
( NN O O
ES NN O O
) NN O O
cell NN O O
lines NN O O
harbouring NN O O
a NN O O
similar NN O O
deletion NN O O
. NN O O

Our NN O O
studies NN O O
demonstrate NN O O
that NN O O
the NN O O
PWS NN O B-Disease
IC NN O O
element NN O O
is NN O O
not NN O O
only NN O O
required NN O O
for NN O O
the NN O O
establishment NN O O
of NN O O
the NN O O
paternal NN O O
imprint NN O O
, NN O O
but NN O O
also NN O O
for NN O O
its NN O O
postzygotic NN O O
maintenance NN O O
. NN O O
. NN O O

Mice NN O O
deficient NN O B-Disease
in NN O I-Disease
Six5 NN O I-Disease
develop NN O O
cataracts NN O B-Disease
: NN O O
implications NN O O
for NN O O
myotonic NN O B-Disease
dystrophy NN O I-Disease
. NN O O

Expansion NN O O
of NN O O
a NN O O
CTG NN O O
trinucleotide NN O O
repeat NN O O
in NN O O
the NN O O
3 NN O O
UTR NN O O
of NN O O
the NN O O
gene NN O O
DMPK NN O O
at NN O O
the NN O O
DM1 NN O O
locus NN O O
on NN O O
chromosome NN O O
19 NN O O
causes NN O O
myotonic NN O B-Disease
dystrophy NN O I-Disease
, NN O O
a NN O O
dominantly NN O B-Disease
inherited NN O I-Disease
disease NN O I-Disease
characterized NN O O
by NN O O
skeletal NN O O
muscle NN O B-Disease
dystrophy NN O I-Disease
and NN O O
myotonia NN O B-Disease
, NN O O
cataracts NN O B-Disease
and NN O O
cardiac NN O B-Disease
conduction NN O I-Disease
defects NN O I-Disease
. NN O O

Targeted NN O O
deletion NN O O
of NN O O
Dm15 NN O O
, NN O O
the NN O O
mouse NN O O
orthologue NN O O
of NN O O
human NN O O
DMPK NN O O
, NN O O
produced NN O O
mice NN O O
with NN O O
a NN O O
mild NN O O
myopathy NN O B-Disease
and NN O O
cardiac NN O B-Disease
conduction NN O I-Disease
abnormalities NN O I-Disease
, NN O O
but NN O O
without NN O O
other NN O O
features NN O O
of NN O O
myotonic NN O B-Disease
dystrophy NN O I-Disease
, NN O O
such NN O O
as NN O O
myotonia NN O B-Disease
and NN O O
cataracts NN O B-Disease
. NN O O

We NN O O
, NN O O
and NN O O
others NN O O
, NN O O
have NN O O
demonstrated NN O O
that NN O O
repeat NN O O
expansion NN O O
decreases NN O O
expression NN O O
of NN O O
the NN O O
adjacent NN O O
gene NN O O
SIX5 NN O O
( NN O O
refs NN O O
7 NN O O
, NN O O
8 NN O O
) NN O O
, NN O O
which NN O O
encodes NN O O
a NN O O
homeodomain NN O O
transcription NN O O
factor NN O O
. NN O O

To NN O O
determine NN O O
whether NN O O
SIX5 NN O B-Disease
deficiency NN O I-Disease
contributes NN O O
to NN O O
the NN O O
myotonic NN O B-Disease
dystrophy NN O I-Disease
phenotype NN O O
, NN O O
we NN O O
disrupted NN O O
mouse NN O O
Six5 NN O O
by NN O O
replacing NN O O
the NN O O
first NN O O
exon NN O O
with NN O O
a NN O O
beta NN O O
- NN O O
galactosidase NN O O
reporter NN O O
. NN O O

Six5 NN O O
- NN O O
mutant NN O O
mice NN O O
showed NN O O
reporter NN O O
expression NN O O
in NN O O
multiple NN O O
tissues NN O O
, NN O O
including NN O O
the NN O O
developing NN O O
lens NN O O
. NN O O

Homozygous NN O O
mutant NN O O
mice NN O O
had NN O O
no NN O O
apparent NN O O
abnormalities NN O B-Disease
of NN O I-Disease
skeletal NN O I-Disease
muscle NN O I-Disease
function NN O I-Disease
, NN O O
but NN O O
developed NN O O
lenticular NN O B-Disease
opacities NN O I-Disease
at NN O O
a NN O O
higher NN O O
rate NN O O
than NN O O
controls NN O O
. NN O O

Our NN O O
results NN O O
suggest NN O O
that NN O O
SIX5 NN O B-Disease
deficiency NN O I-Disease
contributes NN O O
to NN O O
the NN O O
cataract NN O B-Disease
phenotype NN O O
in NN O O
myotonic NN O B-Disease
dystrophy NN O I-Disease
, NN O O
and NN O O
that NN O O
myotonic NN O B-Disease
dystrophy NN O I-Disease
represents NN O O
a NN O O
multigenic NN O B-Disease
disorder NN O I-Disease
. NN O O
. NN O O

Heterozygous NN O O
loss NN O O
of NN O O
Six5 NN O O
in NN O O
mice NN O O
is NN O O
sufficient NN O O
to NN O O
cause NN O O
ocular NN O O
cataracts NN O B-Disease
. NN O O

Myotonic NN O B-Disease
dystrophy NN O I-Disease
( NN O O
DM NN O B-Disease
) NN O O
is NN O O
an NN O O
autosomal NN O B-Disease
dominant NN O I-Disease
disorder NN O I-Disease
characterized NN O O
by NN O O
skeletal NN O O
muscle NN O B-Disease
wasting NN O I-Disease
, NN O O
myotonia NN O B-Disease
, NN O O
cardiac NN O B-Disease
arrhythmia NN O I-Disease
, NN O O
hyperinsulinaemia NN O B-Disease
, NN O O
mental NN O B-Disease
retardation NN O I-Disease
and NN O O
ocular NN O O
cataracts NN O B-Disease
. NN O O

The NN O O
genetic NN O B-Disease
defect NN O I-Disease
in NN O O
DM NN O B-Disease
is NN O O
a NN O O
CTG NN O O
repeat NN O O
expansion NN O O
located NN O O
in NN O O
the NN O O
3 NN O O
untranslated NN O O
region NN O O
of NN O O
DMPK NN O O
and NN O O
5 NN O O
of NN O O
a NN O O
homeodomain NN O O
- NN O O
encoding NN O O
gene NN O O
, NN O O
SIX5 NN O O
( NN O O
formerly NN O O
DMAHP NN O O
; NN O O
refs NN O O
2 NN O O
- NN O O
5 NN O O
) NN O O
. NN O O

There NN O O
are NN O O
three NN O O
mechanisms NN O O
by NN O O
which NN O O
CTG NN O O
expansion NN O O
can NN O O
result NN O O
in NN O O
DM NN O B-Disease
. NN O O

First NN O O
, NN O O
repeat NN O O
expansion NN O O
may NN O O
alter NN O O
the NN O O
processing NN O O
or NN O O
transport NN O O
of NN O O
the NN O O
mutant NN O O
DMPK NN O O
mRNA NN O O
and NN O O
consequently NN O O
reduce NN O O
DMPK NN O O
levels NN O O
. NN O O

Second NN O O
, NN O O
CTG NN O O
expansion NN O O
may NN O O
establish NN O O
a NN O O
region NN O O
of NN O O
heterochromatin NN O O
3 NN O O
of NN O O
the NN O O
repeat NN O O
sequence NN O O
and NN O O
decrease NN O O
SIX5 NN O O
transcription NN O O
. NN O O

Third NN O O
, NN O O
toxic NN O O
effects NN O O
of NN O O
the NN O O
repeat NN O O
expansion NN O O
may NN O O
be NN O O
intrinsic NN O O
to NN O O
the NN O O
repeated NN O O
elements NN O O
at NN O O
the NN O O
level NN O O
of NN O O
DNA NN O O
or NN O O
RNA NN O O
( NN O O
refs NN O O
10 NN O O
, NN O O
11 NN O O
) NN O O
. NN O O

Previous NN O O
studies NN O O
have NN O O
demonstrated NN O O
that NN O O
a NN O O
dose NN O O
- NN O O
dependent NN O O
loss NN O O
of NN O O
Dm15 NN O O
( NN O O
the NN O O
mouse NN O O
DMPK NN O O
homologue NN O O
) NN O O
in NN O O
mice NN O O
produces NN O O
a NN O O
partial NN O O
DM NN O B-Disease
phenotype NN O O
characterized NN O O
by NN O O
decreased NN O O
development NN O O
of NN O O
skeletal NN O O
muscle NN O O
force NN O O
and NN O O
cardiac NN O B-Disease
conduction NN O I-Disease
disorders NN O I-Disease
. NN O O

To NN O O
test NN O O
the NN O O
role NN O O
of NN O O
Six5 NN O O
loss NN O O
in NN O O
DM NN O B-Disease
, NN O O
we NN O O
have NN O O
analysed NN O O
a NN O O
strain NN O O
of NN O O
mice NN O O
in NN O O
which NN O O
Six5 NN O O
was NN O O
deleted NN O O
. NN O O

Our NN O O
results NN O O
demonstrate NN O O
that NN O O
the NN O O
rate NN O O
and NN O O
severity NN O O
of NN O O
cataract NN O B-Disease
formation NN O O
is NN O O
inversely NN O O
related NN O O
to NN O O
Six5 NN O O
dosage NN O O
and NN O O
is NN O O
temporally NN O O
progressive NN O O
. NN O O

Six5 NN O O
+ NN O O
/ NN O O
- NN O O
and NN O O
Six5 NN O O
- NN O O
/ NN O O
- NN O O
mice NN O O
show NN O O
increased NN O O
steady NN O O
- NN O O
state NN O O
levels NN O O
of NN O O
the NN O O
Na NN O O
+ NN O O
/ NN O O
K NN O O
+ NN O O
- NN O O
ATPase NN O O
alpha NN O O
- NN O O
1 NN O O
subunit NN O O
and NN O O
decreased NN O O
Dm15 NN O O
mRNA NN O O
levels NN O O
. NN O O

Thus NN O O
, NN O O
altered NN O O
ion NN O O
homeostasis NN O O
within NN O O
the NN O O
lens NN O O
may NN O O
contribute NN O O
to NN O O
cataract NN O B-Disease
formation NN O O
. NN O O

As NN O O
ocular NN O O
cataracts NN O B-Disease
are NN O O
a NN O O
characteristic NN O O
feature NN O O
of NN O O
DM NN O B-Disease
, NN O O
these NN O O
results NN O O
demonstrate NN O O
that NN O O
decreased NN O O
SIX5 NN O O
transcription NN O O
is NN O O
important NN O O
in NN O O
the NN O O
aetiology NN O O
of NN O O
DM NN O B-Disease
. NN O O

Our NN O O
data NN O O
support NN O O
the NN O O
hypothesis NN O O
that NN O O
DM NN O B-Disease
is NN O O
a NN O O
contiguous NN O O
gene NN O O
syndrome NN O O
associated NN O O
with NN O O
the NN O O
partial NN O O
loss NN O O
of NN O O
both NN O O
DMPK NN O O
and NN O O
SIX5 NN O O
. NN O O
. NN O O

ATM NN O O
- NN O O
dependent NN O O
phosphorylation NN O O
of NN O O
nibrin NN O O
in NN O O
response NN O O
to NN O O
radiation NN O O
exposure NN O O
. NN O O

Mutations NN O O
in NN O O
the NN O O
gene NN O O
ATM NN O O
are NN O O
responsible NN O O
for NN O O
the NN O O
genetic NN O B-Disease
disorder NN O I-Disease
ataxia NN O B-Disease
- NN O I-Disease
telangiectasia NN O I-Disease
( NN O O
A NN O B-Disease
- NN O I-Disease
T NN O I-Disease
) NN O O
, NN O O
which NN O O
is NN O O
characterized NN O O
by NN O O
cerebellar NN O B-Disease
dysfunction NN O I-Disease
, NN O O
radiosensitivity NN O O
, NN O O
chromosomal NN O O
instability NN O O
and NN O O
cancer NN O B-Disease
predisposition NN O O
. NN O O

Both NN O O
the NN O O
A NN O B-Disease
- NN O I-Disease
T NN O I-Disease
phenotype NN O O
and NN O O
the NN O O
similarity NN O O
of NN O O
the NN O O
ATM NN O O
protein NN O O
to NN O O
other NN O O
DNA NN O O
- NN O O
damage NN O O
sensors NN O O
suggests NN O O
a NN O O
role NN O O
for NN O O
ATM NN O O
in NN O O
biochemical NN O O
pathways NN O O
involved NN O O
in NN O O
the NN O O
recognition NN O O
, NN O O
signalling NN O O
and NN O O
repair NN O O
of NN O O
DNA NN O O
double NN O O
- NN O O
strand NN O O
breaks NN O O
( NN O O
DSBs NN O O
) NN O O
. NN O O

There NN O O
are NN O O
strong NN O O
parallels NN O O
between NN O O
the NN O O
pattern NN O O
of NN O O
radiosensitivity NN O O
, NN O O
chromosomal NN O O
instability NN O O
and NN O O
cancer NN O B-Disease
predisposition NN O O
in NN O O
A NN O B-Disease
- NN O I-Disease
T NN O I-Disease
patients NN O O
and NN O O
that NN O O
in NN O O
patients NN O O
with NN O O
Nijmegen NN O B-Disease
breakage NN O I-Disease
syndrome NN O I-Disease
( NN O O
NBS NN O B-Disease
) NN O O
. NN O O

The NN O O
protein NN O O
defective NN O O
in NN O O
NBS NN O B-Disease
, NN O O
nibrin NN O O
( NN O O
encoded NN O O
by NN O O
NBS1 NN O O
) NN O O
, NN O O
forms NN O O
a NN O O
complex NN O O
with NN O O
MRE11 NN O O
and NN O O
RAD50 NN O O
( NN O O
refs NN O O
1 NN O O
, NN O O
2 NN O O
) NN O O
. NN O O

This NN O O
complex NN O O
localizes NN O O
to NN O O
DSBs NN O O
within NN O O
30 NN O O
minutes NN O O
after NN O O
cellular NN O O
exposure NN O O
to NN O O
ionizing NN O O
radiation NN O O
( NN O O
IR NN O O
) NN O O
and NN O O
is NN O O
observed NN O O
in NN O O
brightly NN O O
staining NN O O
nuclear NN O O
foci NN O O
after NN O O
a NN O O
longer NN O O
period NN O O
of NN O O
time NN O O
. NN O O

The NN O O
overlap NN O O
between NN O O
clinical NN O O
and NN O O
cellular NN O O
phenotypes NN O O
in NN O O
A NN O B-Disease
- NN O I-Disease
T NN O I-Disease
and NN O O
NBS NN O B-Disease
suggests NN O O
that NN O O
ATM NN O O
and NN O O
nibrin NN O O
may NN O O
function NN O O
in NN O O
the NN O O
same NN O O
biochemical NN O O
pathway NN O O
. NN O O

Here NN O O
we NN O O
demonstrate NN O O
that NN O O
nibrin NN O O
is NN O O
phosphorylated NN O O
within NN O O
one NN O O
hour NN O O
of NN O O
treatment NN O O
of NN O O
cells NN O O
with NN O O
IR NN O O
. NN O O

This NN O O
response NN O O
is NN O O
abrogated NN O O
in NN O O
A NN O B-Disease
- NN O I-Disease
T NN O I-Disease
cells NN O O
that NN O O
either NN O O
do NN O O
not NN O O
express NN O O
ATM NN O O
protein NN O O
or NN O O
express NN O O
near NN O O
full NN O O
- NN O O
length NN O O
mutant NN O O
protein NN O O
. NN O O

We NN O O
also NN O O
show NN O O
that NN O O
ATM NN O O
physically NN O O
interacts NN O O
with NN O O
and NN O O
phosphorylates NN O O
nibrin NN O O
on NN O O
serine NN O O
343 NN O O
both NN O O
in NN O O
vivo NN O O
and NN O O
in NN O O
vitro NN O O
. NN O O

Phosphorylation NN O O
of NN O O
this NN O O
site NN O O
appears NN O O
to NN O O
be NN O O
functionally NN O O
important NN O O
because NN O O
mutated NN O O
nibrin NN O O
( NN O O
S343A NN O O
) NN O O
does NN O O
not NN O O
completely NN O O
complement NN O O
radiosensitivity NN O O
in NN O O
NBS NN O B-Disease
cells NN O O
. NN O O

ATM NN O O
phosphorylation NN O O
of NN O O
nibrin NN O O
does NN O O
not NN O O
affect NN O O
nibrin NN O O
- NN O O
MRE11 NN O O
- NN O O
RAD50 NN O O
association NN O O
as NN O O
revealed NN O O
by NN O O
radiation NN O O
- NN O O
induced NN O O
foci NN O O
formation NN O O
. NN O O

Our NN O O
data NN O O
provide NN O O
a NN O O
biochemical NN O O
explanation NN O O
for NN O O
the NN O O
similarity NN O O
in NN O O
phenotype NN O O
between NN O O
A NN O B-Disease
- NN O I-Disease
T NN O I-Disease
and NN O O
NBS NN O B-Disease
. NN O O
. NN O O

Clinicopathologic NN O O
features NN O O
of NN O O
BRCA NN O B-Disease
- NN O I-Disease
linked NN O I-Disease
and NN O I-Disease
sporadic NN O I-Disease
ovarian NN O I-Disease
cancer NN O I-Disease
. NN O O

CONTEXT NN O O
Most NN O O
hereditary NN O B-Disease
ovarian NN O I-Disease
cancers NN O I-Disease
are NN O O
associated NN O O
with NN O O
germline NN O O
mutations NN O O
in NN O O
BRCA1 NN O O
or NN O O
BRCA2 NN O O
. NN O O

Attempts NN O O
to NN O O
define NN O O
the NN O O
clinical NN O O
significance NN O O
of NN O O
BRCA NN O O
mutation NN O O
status NN O O
in NN O O
ovarian NN O B-Disease
cancer NN O I-Disease
have NN O O
produced NN O O
conflicting NN O O
results NN O O
, NN O O
especially NN O O
regarding NN O O
survival NN O O
. NN O O

OBJECTIVE NN O O
To NN O O
determine NN O O
whether NN O O
hereditary NN O B-Disease
ovarian NN O I-Disease
cancers NN O I-Disease
have NN O O
distinct NN O O
clinical NN O O
and NN O O
pathological NN O O
features NN O O
compared NN O O
with NN O O
sporadic NN O B-Disease
( NN O I-Disease
nonhereditary NN O I-Disease
) NN O I-Disease
ovarian NN O I-Disease
cancers NN O I-Disease
. NN O O

DESIGN NN O O
AND NN O O
SETTING NN O O
Retrospective NN O O
cohort NN O O
study NN O O
of NN O O
a NN O O
consecutive NN O O
series NN O O
of NN O O
933 NN O O
ovarian NN O B-Disease
cancers NN O I-Disease
diagnosed NN O O
and NN O O
treated NN O O
at NN O O
our NN O O
institution NN O O
, NN O O
which NN O O
is NN O O
a NN O O
comprehensive NN O O
cancer NN O B-Disease
center NN O O
as NN O O
designated NN O O
by NN O O
the NN O O
National NN O O
Cancer NN O B-Disease
Institute NN O O
, NN O O
over NN O O
a NN O O
12 NN O O
- NN O O
year NN O O
period NN O O
( NN O O
December NN O O
1986 NN O O
to NN O O
August NN O O
1998 NN O O
) NN O O
. NN O O

PATIENTS NN O O
The NN O O
study NN O O
was NN O O
restricted NN O O
to NN O O
patients NN O O
of NN O O
Jewish NN O O
origin NN O O
because NN O O
of NN O O
the NN O O
ease NN O O
of NN O O
BRCA1 NN O O
and NN O O
BRCA2 NN O O
genotyping NN O O
in NN O O
this NN O O
ethnic NN O O
group NN O O
. NN O O

From NN O O
the NN O O
189 NN O O
patients NN O O
who NN O O
identified NN O O
themselves NN O O
as NN O O
Jewish NN O O
, NN O O
88 NN O O
hereditary NN O O
cases NN O O
were NN O O
identified NN O O
with NN O O
the NN O O
presence NN O O
of NN O O
a NN O O
germline NN O O
founder NN O O
mutation NN O O
in NN O O
BRCA1 NN O O
or NN O O
BRCA2 NN O O
. NN O O

The NN O O
remaining NN O O
101 NN O O
cases NN O O
from NN O O
the NN O O
same NN O O
series NN O O
not NN O O
associated NN O O
with NN O O
a NN O O
BRCA NN O O
mutation NN O O
and NN O O
2 NN O O
additional NN O O
groups NN O O
( NN O O
Gynecologic NN O O
Oncology NN O O
Group NN O O
protocols NN O O
52 NN O O
and NN O O
111 NN O O
) NN O O
with NN O O
ovarian NN O B-Disease
cancer NN O I-Disease
from NN O O
clinical NN O O
trials NN O O
( NN O O
for NN O O
the NN O O
survival NN O O
analysis NN O O
) NN O O
were NN O O
included NN O O
for NN O O
comparison NN O O
. NN O O

MAIN NN O O
OUTCOME NN O O
MEASURES NN O O
Age NN O O
at NN O O
diagnosis NN O O
, NN O O
surgical NN O O
stage NN O O
, NN O O
histologic NN O O
cell NN O O
type NN O O
and NN O O
grade NN O O
, NN O O
and NN O O
surgical NN O O
outcome NN O O
; NN O O
and NN O O
response NN O O
to NN O O
chemotherapy NN O O
and NN O O
survival NN O O
for NN O O
advanced NN O O
- NN O O
stage NN O O
( NN O O
II NN O O
and NN O O
IV NN O O
) NN O O
cases NN O O
. NN O O

RESULTS NN O O
Hereditary NN O B-Disease
cancers NN O I-Disease
were NN O O
rarely NN O O
diagnosed NN O O
before NN O O
age NN O O
40 NN O O
years NN O O
and NN O O
were NN O O
common NN O O
after NN O O
age NN O O
60 NN O O
years NN O O
, NN O O
with NN O O
mean NN O O
age NN O O
at NN O O
diagnosis NN O O
being NN O O
significantly NN O O
younger NN O O
for NN O O
BRCA1 NN O O
- NN O O
vs NN O O
BRCA2 NN O O
- NN O O
linked NN O O
patients NN O O
( NN O O
54 NN O O
vs NN O O
62 NN O O
years NN O O
; NN O O
P NN O O
= NN O O
. NN O O
04 NN O O
) NN O O
. NN O O

Histology NN O O
, NN O O
grade NN O O
, NN O O
stage NN O O
, NN O O
and NN O O
success NN O O
of NN O O
cytoreductive NN O O
surgery NN O O
were NN O O
similar NN O O
for NN O O
hereditary NN O O
and NN O O
sporadic NN O O
cases NN O O
. NN O O

The NN O O
hereditary NN O O
group NN O O
had NN O O
a NN O O
longer NN O O
disease NN O O
- NN O O
free NN O O
interval NN O O
following NN O O
primary NN O O
chemotherapy NN O O
in NN O O
comparison NN O O
with NN O O
the NN O O
nonhereditary NN O O
group NN O O
, NN O O
with NN O O
a NN O O
median NN O O
time NN O O
to NN O O
recurrence NN O O
of NN O O
14 NN O O
months NN O O
and NN O O
7 NN O O
months NN O O
, NN O O
respectively NN O O
( NN O O
P NN O O
< NN O O
. NN O O
001 NN O O
) NN O O
. NN O O

Those NN O O
with NN O O
hereditary NN O B-Disease
cancers NN O I-Disease
had NN O O
improved NN O O
survival NN O O
compared NN O O
with NN O O
the NN O O
nonhereditary NN O O
group NN O O
( NN O O
P NN O O
= NN O O
. NN O O
004 NN O O
) NN O O
. NN O O

For NN O O
stage NN O B-Disease
III NN O I-Disease
cancers NN O I-Disease
, NN O O
BRCA NN O O
mutation NN O O
status NN O O
was NN O O
an NN O O
independent NN O O
prognostic NN O O
variable NN O O
( NN O O
P NN O O
= NN O O
. NN O O
03 NN O O
) NN O O
. NN O O

CONCLUSIONS NN O O
Although NN O O
BRCA NN O B-Disease
- NN O I-Disease
associated NN O I-Disease
hereditary NN O I-Disease
ovarian NN O I-Disease
cancers NN O I-Disease
in NN O O
this NN O O
population NN O O
have NN O O
surgical NN O O
and NN O O
pathological NN O O
characteristics NN O O
similar NN O O
to NN O O
those NN O O
of NN O O
sporadic NN O B-Disease
cancers NN O I-Disease
, NN O O
advanced NN O B-Disease
- NN O I-Disease
stage NN O I-Disease
hereditary NN O I-Disease
cancer NN O I-Disease
patients NN O O
survive NN O O
longer NN O O
than NN O O
nonhereditary NN O B-Disease
cancer NN O I-Disease
patients NN O O
. NN O O

Age NN O O
penetrance NN O O
is NN O O
greater NN O O
for NN O O
BRCA1 NN O B-Disease
- NN O I-Disease
linked NN O I-Disease
than NN O I-Disease
for NN O I-Disease
BRCA2 NN O I-Disease
- NN O I-Disease
linked NN O I-Disease
cancers NN O I-Disease
in NN O O
this NN O O
population NN O O
. NN O O

The NN O O
gene NN O O
for NN O O
familial NN O B-Disease
Mediterranean NN O I-Disease
fever NN O I-Disease
, NN O O
MEFV NN O O
, NN O O
is NN O O
expressed NN O O
in NN O O
early NN O O
leukocyte NN O O
development NN O O
and NN O O
is NN O O
regulated NN O O
in NN O O
response NN O O
to NN O O
inflammatory NN O O
mediators NN O O
. NN O O

Familial NN O B-Disease
Mediterranean NN O I-Disease
fever NN O I-Disease
( NN O O
FMF NN O B-Disease
) NN O O
is NN O O
a NN O O
recessive NN O B-Disease
disorder NN O I-Disease
characterized NN O O
by NN O O
episodes NN O O
of NN O O
fever NN O B-Disease
and NN O O
neutrophil NN O B-Disease
- NN O I-Disease
mediated NN O I-Disease
serosal NN O I-Disease
inflammation NN O I-Disease
. NN O O

We NN O O
recently NN O O
identified NN O O
the NN O O
gene NN O O
causing NN O O
FMF NN O B-Disease
, NN O O
designated NN O O
MEFV NN O O
, NN O O
and NN O O
found NN O O
it NN O O
to NN O O
be NN O O
expressed NN O O
in NN O O
mature NN O O
neutrophils NN O O
, NN O O
suggesting NN O O
that NN O O
it NN O O
functions NN O O
as NN O O
an NN O O
inflammatory NN O O
regulator NN O O
. NN O O

To NN O O
facilitate NN O O
our NN O O
understanding NN O O
of NN O O
the NN O O
normal NN O O
function NN O O
of NN O O
MEFV NN O O
, NN O O
we NN O O
extended NN O O
our NN O O
previous NN O O
studies NN O O
. NN O O

MEFV NN O O
messenger NN O O
RNA NN O O
was NN O O
detected NN O O
by NN O O
reverse NN O O
transcriptase NN O O
- NN O O
polymerase NN O O
chain NN O O
reaction NN O O
in NN O O
bone NN O O
marrow NN O O
leukocytes NN O O
, NN O O
with NN O O
differential NN O O
expression NN O O
observed NN O O
among NN O O
cells NN O O
by NN O O
in NN O O
situ NN O O
hybridization NN O O
. NN O O

CD34 NN O O
hematopoietic NN O O
stem NN O O
- NN O O
cell NN O O
cultures NN O O
induced NN O O
toward NN O O
the NN O O
granulocytic NN O O
lineage NN O O
expressed NN O O
MEFV NN O O
at NN O O
the NN O O
myelocyte NN O O
stage NN O O
, NN O O
concurrently NN O O
with NN O O
lineage NN O O
commitment NN O O
. NN O O

The NN O O
prepromyelocytic NN O O
cell NN O O
line NN O O
HL60 NN O O
expressed NN O O
MEFV NN O O
only NN O O
at NN O O
granulocytic NN O O
and NN O O
monocytic NN O O
differentiation NN O O
. NN O O

MEFV NN O O
was NN O O
also NN O O
expressed NN O O
in NN O O
the NN O O
monocytic NN O O
cell NN O O
lines NN O O
U937 NN O O
and NN O O
THP NN O O
- NN O O
1 NN O O
. NN O O

Among NN O O
peripheral NN O O
blood NN O O
leukocytes NN O O
, NN O O
MEFV NN O O
expression NN O O
was NN O O
detected NN O O
in NN O O
neutrophils NN O O
, NN O O
eosinophils NN O O
, NN O O
and NN O O
to NN O O
varying NN O O
degrees NN O O
, NN O O
monocytes NN O O
. NN O O

Consistent NN O O
with NN O O
the NN O O
tissue NN O O
specificity NN O O
of NN O O
expression NN O O
, NN O O
complete NN O O
sequencing NN O O
and NN O O
analysis NN O O
of NN O O
upstream NN O O
regulatory NN O O
regions NN O O
of NN O O
MEFV NN O O
revealed NN O O
homology NN O O
to NN O O
myeloid NN O O
- NN O O
specific NN O O
promoters NN O O
and NN O O
to NN O O
more NN O O
broadly NN O O
expressed NN O O
inflammatory NN O O
promoter NN O O
elements NN O O
. NN O O

In NN O O
vitro NN O O
stimulation NN O O
of NN O O
monocytes NN O O
with NN O O
the NN O O
proinflammatory NN O O
agents NN O O
interferon NN O O
( NN O O
IFN NN O O
) NN O O
gamma NN O O
, NN O O
tumor NN O B-Disease
necrosis NN O O
factor NN O O
, NN O O
and NN O O
lipopolysaccharide NN O O
induced NN O O
MEFV NN O O
expression NN O O
, NN O O
whereas NN O O
the NN O O
antiinflammatory NN O O
cytokines NN O O
interleukin NN O O
( NN O O
IL NN O O
) NN O O
4 NN O O
, NN O O
IL NN O O
- NN O O
10 NN O O
, NN O O
and NN O O
transforming NN O O
growth NN O O
factor NN O O
beta NN O O
inhibited NN O O
such NN O O
expression NN O O
. NN O O

Induction NN O O
by NN O O
IFN NN O O
- NN O O
gamma NN O O
occurred NN O O
rapidly NN O O
and NN O O
was NN O O
resistant NN O O
to NN O O
cycloheximide NN O O
. NN O O

IFN NN O O
- NN O O
alpha NN O O
also NN O O
induced NN O O
MEFV NN O O
expression NN O O
. NN O O

In NN O O
granulocytes NN O O
, NN O O
MEFV NN O O
was NN O O
up NN O O
- NN O O
regulated NN O O
by NN O O
IFN NN O O
- NN O O
gamma NN O O
and NN O O
the NN O O
combination NN O O
of NN O O
IFN NN O O
- NN O O
alpha NN O O
and NN O O
colchicine NN O O
. NN O O

These NN O O
results NN O O
refine NN O O
understanding NN O O
of NN O O
MEFV NN O O
by NN O O
placing NN O O
the NN O O
gene NN O O
in NN O O
the NN O O
myelomonocytic NN O O
- NN O O
specific NN O O
proinflammatory NN O O
pathway NN O O
and NN O O
identifying NN O O
it NN O O
as NN O O
an NN O O
IFN NN O O
- NN O O
gamma NN O O
immediate NN O O
early NN O O
gene NN O O
. NN O O
. NN O O

Biochemical NN O O
and NN O O
structural NN O O
analysis NN O O
of NN O O
missense NN O O
mutations NN O O
in NN O O
N NN O O
- NN O O
acetylgalactosamine NN O O
- NN O O
6 NN O O
- NN O O
sulfate NN O O
sulfatase NN O O
causing NN O O
mucopolysaccharidosis NN O B-Disease
IVA NN O I-Disease
phenotypes NN O O
. NN O O

Mucopolysaccharidosis NN O B-Disease
IVA NN O I-Disease
( NN O O
MPS NN O B-Disease
IVA NN O I-Disease
; NN O O
OMIM NN O O
# NN O O
253000 NN O O
) NN O O
, NN O O
a NN O O
lysosomal NN O B-Disease
storage NN O I-Disease
disorder NN O I-Disease
caused NN O O
by NN O O
a NN O O
deficiency NN O B-Disease
of NN O I-Disease
N NN O I-Disease
- NN O I-Disease
acetylgalactosamine NN O I-Disease
- NN O I-Disease
6 NN O I-Disease
- NN O I-Disease
sulfate NN O I-Disease
sulfatase NN O I-Disease
( NN O O
GALNS NN O O
) NN O O
, NN O O
has NN O O
variable NN O O
clinical NN O O
phenotypes NN O O
. NN O O

To NN O O
date NN O O
we NN O O
have NN O O
identified NN O O
65 NN O O
missense NN O O
mutations NN O O
in NN O O
the NN O O
GALNS NN O O
gene NN O O
from NN O O
MPS NN O B-Disease
IVA NN O I-Disease
patients NN O O
, NN O O
but NN O O
the NN O O
correlation NN O O
between NN O O
genotype NN O O
and NN O O
phenotype NN O O
has NN O O
remained NN O O
unclear NN O O
. NN O O

We NN O O
studied NN O O
17 NN O O
missense NN O O
mutations NN O O
using NN O O
biochemical NN O O
approaches NN O O
and NN O O
32 NN O O
missense NN O O
mutations NN O O
, NN O O
using NN O O
structural NN O O
analyses NN O O
. NN O O

Fifteen NN O O
missense NN O O
mutations NN O O
and NN O O
two NN O O
newly NN O O
engineered NN O O
active NN O O
site NN O O
mutations NN O O
( NN O O
C79S NN O O
, NN O O
C79T NN O O
) NN O O
were NN O O
characterized NN O O
by NN O O
transient NN O O
expression NN O O
analysis NN O O
. NN O O

Mutant NN O O
proteins NN O O
, NN O O
except NN O O
for NN O O
C79S NN O O
and NN O O
C79T NN O O
, NN O O
were NN O O
destabilized NN O O
and NN O O
detected NN O O
as NN O O
insoluble NN O O
precursor NN O O
forms NN O O
while NN O O
the NN O O
C79S NN O O
and NN O O
C79T NN O O
mutants NN O O
were NN O O
of NN O O
a NN O O
soluble NN O O
mature NN O O
size NN O O
. NN O O

Mutants NN O O
found NN O O
in NN O O
the NN O O
severe NN O O
phenotype NN O O
had NN O O
no NN O O
activity NN O O
. NN O O

Mutants NN O O
found NN O O
in NN O O
the NN O O
mild NN O O
phenotype NN O O
had NN O O
a NN O O
considerable NN O O
residual NN O O
activity NN O O
( NN O O
1 NN O O
. NN O O
3 NN O O
- NN O O
13 NN O O
. NN O O
3 NN O O
% NN O O
of NN O O
wild NN O O
- NN O O
type NN O O
GALNS NN O O
activity NN O O
) NN O O
. NN O O

Sulfatases NN O O
, NN O O
including NN O O
GALNS NN O O
, NN O O
are NN O O
members NN O O
of NN O O
a NN O O
highly NN O O
conserved NN O O
gene NN O O
family NN O O
sharing NN O O
an NN O O
extensive NN O O
sequence NN O O
homology NN O O
. NN O O

Thus NN O O
, NN O O
a NN O O
tertiary NN O O
structural NN O O
model NN O O
of NN O O
human NN O O
GALNS NN O O
was NN O O
constructed NN O O
from NN O O
the NN O O
X NN O O
- NN O O
ray NN O O
crystal NN O O
structure NN O O
of NN O O
N NN O O
- NN O O
acetylgalacto NN O O
- NN O O
samine NN O O
- NN O O
4 NN O O
- NN O O
sulfatase NN O O
and NN O O
arylsulfatase NN O O
A NN O O
, NN O O
using NN O O
homology NN O O
modeling NN O O
, NN O O
and NN O O
32 NN O O
missense NN O O
mutations NN O O
were NN O O
investigated NN O O
. NN O O

Consequently NN O O
, NN O O
we NN O O
propose NN O O
that NN O O
there NN O O
are NN O O
at NN O O
least NN O O
three NN O O
different NN O O
reasons NN O O
for NN O O
the NN O O
severe NN O O
phenotype NN O O
( NN O O
i NN O O
) NN O O
destruction NN O O
of NN O O
the NN O O
hydrophobic NN O O
core NN O O
or NN O O
modification NN O O
of NN O O
the NN O O
packing NN O O
; NN O O
( NN O O
ii NN O O
) NN O O
removal NN O O
of NN O O
a NN O O
salt NN O O
bridge NN O O
to NN O O
destabilize NN O O
the NN O O
entire NN O O
conformation NN O O
; NN O O
( NN O O
iii NN O O
) NN O O
modification NN O O
of NN O O
the NN O O
active NN O O
site NN O O
. NN O O

In NN O O
contrast NN O O
, NN O O
mild NN O O
mutations NN O O
were NN O O
mostly NN O O
located NN O O
on NN O O
the NN O O
surface NN O O
of NN O O
the NN O O
GALNS NN O O
protein NN O O
. NN O O

These NN O O
studies NN O O
shed NN O O
further NN O O
light NN O O
on NN O O
the NN O O
genotype NN O O
- NN O O
phenotype NN O O
correlation NN O O
of NN O O
MPS NN O B-Disease
IVA NN O I-Disease
and NN O O
structure NN O O
- NN O O
function NN O O
relationship NN O O
in NN O O
the NN O O
sulfatase NN O O
family NN O O
. NN O O

Mutations NN O O
at NN O O
the NN O O
ataxia NN O B-Disease
- NN O I-Disease
telangiectasia NN O I-Disease
locus NN O O
and NN O O
clinical NN O O
phenotypes NN O O
of NN O O
A NN O B-Disease
- NN O I-Disease
T NN O I-Disease
patients NN O O
. NN O O

Mutations NN O O
at NN O O
the NN O O
ataxia NN O B-Disease
- NN O I-Disease
telangiectasia NN O I-Disease
( NN O O
A NN O B-Disease
- NN O I-Disease
T NN O I-Disease
) NN O O
locus NN O O
on NN O O
chromosome NN O O
band NN O O
11q22 NN O O
cause NN O O
a NN O O
distinctive NN O O
autosomal NN O B-Disease
recessive NN O I-Disease
syndrome NN O I-Disease
in NN O O
homozygotes NN O O
and NN O O
predispose NN O O
heterozygotes NN O O
to NN O O
cancer NN O B-Disease
, NN O O
ischemic NN O B-Disease
heart NN O I-Disease
disease NN O I-Disease
, NN O O
and NN O O
early NN O O
mortality NN O O
. NN O O

PCR NN O O
amplification NN O O
from NN O O
genomic NN O O
DNA NN O O
and NN O O
automated NN O O
sequencing NN O O
of NN O O
the NN O O
entire NN O O
coding NN O O
region NN O O
( NN O O
66 NN O O
exons NN O O
) NN O O
and NN O O
splice NN O O
junctions NN O O
detected NN O O
77 NN O O
mutations NN O O
( NN O O
85 NN O O
% NN O O
) NN O O
in NN O O
90 NN O O
A NN O B-Disease
- NN O I-Disease
T NN O I-Disease
chromosomes NN O O
. NN O O

Heteroduplex NN O O
analysis NN O O
detected NN O O
another NN O O
42 NN O O
mutations NN O O
at NN O O
the NN O O
A NN O B-Disease
- NN O I-Disease
T NN O I-Disease
locus NN O O
. NN O O

Out NN O O
of NN O O
a NN O O
total NN O O
of NN O O
71 NN O O
unique NN O O
mutations NN O O
, NN O O
50 NN O O
were NN O O
found NN O O
only NN O O
in NN O O
a NN O O
single NN O O
family NN O O
, NN O O
and NN O O
51 NN O O
had NN O O
not NN O O
been NN O O
reported NN O O
previously NN O O
. NN O O

Most NN O O
( NN O O
58 NN O O
/ NN O O
71 NN O O
, NN O O
82 NN O O
% NN O O
) NN O O
mutations NN O O
were NN O O
frameshift NN O O
and NN O O
nonsense NN O O
mutations NN O O
that NN O O
are NN O O
predicted NN O O
to NN O O
cause NN O O
truncation NN O O
of NN O O
the NN O O
A NN O B-Disease
- NN O I-Disease
T NN O I-Disease
protein NN O O
; NN O O
the NN O O
less NN O O
common NN O O
mutation NN O O
types NN O O
were NN O O
missense NN O O
( NN O O
9 NN O O
/ NN O O
71 NN O O
, NN O O
13 NN O O
% NN O O
) NN O O
, NN O O
splicing NN O O
( NN O O
3 NN O O
/ NN O O
71 NN O O
, NN O O
4 NN O O
% NN O O
) NN O O
and NN O O
one NN O O
in NN O O
- NN O O
frame NN O O
deletion NN O O
, NN O O
2546 NN O O
3 NN O O
( NN O O
1 NN O O
/ NN O O
71 NN O O
, NN O O
1 NN O O
% NN O O
) NN O O
. NN O O

The NN O O
mean NN O O
survival NN O O
and NN O O
height NN O O
distribution NN O O
of NN O O
134 NN O O
A NN O B-Disease
- NN O I-Disease
T NN O I-Disease
patients NN O O
correlated NN O O
significantly NN O O
with NN O O
the NN O O
specific NN O O
mutations NN O O
present NN O O
in NN O O
the NN O O
patients NN O O
. NN O O

Patients NN O O
homozygous NN O O
for NN O O
a NN O O
single NN O O
truncating NN O O
mutation NN O O
, NN O O
typically NN O O
near NN O O
the NN O O
N NN O O
- NN O O
terminal NN O O
end NN O O
of NN O O
the NN O O
gene NN O O
, NN O O
or NN O O
heterozygous NN O O
for NN O O
the NN O O
in NN O O
- NN O O
frame NN O O
deletion NN O O
2546 NN O O
3 NN O O
, NN O O
were NN O O
shorter NN O O
and NN O O
had NN O O
significantly NN O O
shorter NN O O
survival NN O O
than NN O O
those NN O O
heterozygous NN O O
for NN O O
a NN O O
splice NN O O
site NN O O
or NN O O
missense NN O O
mutation NN O O
, NN O O
or NN O O
heterozygous NN O O
for NN O O
two NN O O
truncating NN O O
mutations NN O O
. NN O O

Alterations NN O O
of NN O O
the NN O O
length NN O O
or NN O O
amino NN O O
acid NN O O
composition NN O O
of NN O O
the NN O O
A NN O B-Disease
- NN O I-Disease
T NN O I-Disease
gene NN O O
product NN O O
affect NN O O
the NN O O
A NN O B-Disease
- NN O I-Disease
T NN O I-Disease
clinical NN O O
phenotype NN O O
in NN O O
different NN O O
ways NN O O
. NN O O

Mutation NN O O
analysis NN O O
at NN O O
the NN O O
A NN O B-Disease
- NN O I-Disease
T NN O I-Disease
locus NN O O
may NN O O
help NN O O
estimate NN O O
the NN O O
prognosis NN O O
of NN O O
A NN O B-Disease
- NN O I-Disease
T NN O I-Disease
patients NN O O
. NN O O
. NN O O

Isolation NN O O
, NN O O
genomic NN O O
organization NN O O
, NN O O
and NN O O
expression NN O O
analysis NN O O
of NN O O
the NN O O
mouse NN O O
and NN O O
rat NN O O
homologs NN O O
of NN O O
MEFV NN O O
, NN O O
the NN O O
gene NN O O
for NN O O
familial NN O B-Disease
mediterranean NN O I-Disease
fever NN O I-Disease
. NN O O

Familial NN O B-Disease
Mediterranean NN O I-Disease
fever NN O I-Disease
( NN O O
FMF NN O B-Disease
) NN O O
is NN O O
a NN O O
recessive NN O B-Disease
disorder NN O I-Disease
characterized NN O O
by NN O O
episodes NN O O
of NN O O
fever NN O B-Disease
with NN O O
serositis NN O B-Disease
or NN O O
synovitis NN O B-Disease
. NN O O

Recently NN O O
the NN O O
FMF NN O B-Disease
gene NN O O
( NN O O
MEFV NN O O
) NN O O
was NN O O
cloned NN O O
; NN O O
the NN O O
protein NN O O
product NN O O
, NN O O
pyrin NN O O
/ NN O O
marenostrin NN O O
, NN O O
is NN O O
thought NN O O
to NN O O
regulate NN O O
inflammation NN O O
in NN O O
myeloid NN O O
cells NN O O
. NN O O

In NN O O
this NN O O
manuscript NN O O
we NN O O
report NN O O
the NN O O
mouse NN O O
and NN O O
rat NN O O
homologs NN O O
of NN O O
MEFV NN O O
. NN O O

The NN O O
murine NN O O
gene NN O O
contains NN O O
ten NN O O
exons NN O O
with NN O O
a NN O O
coding NN O O
sequence NN O O
of NN O O
2304 NN O O
bp NN O O
, NN O O
while NN O O
the NN O O
rat NN O O
homolog NN O O
has NN O O
nine NN O O
exons NN O O
with NN O O
a NN O O
coding NN O O
sequence NN O O
of NN O O
2253 NN O O
bp NN O O
. NN O O

A NN O O
considerable NN O O
amino NN O O
acid NN O O
sequence NN O O
homology NN O O
was NN O O
observed NN O O
between NN O O
the NN O O
mouse NN O O
and NN O O
human NN O O
( NN O O
47 NN O O
. NN O O
6 NN O O
% NN O O
identity NN O O
and NN O O
65 NN O O
. NN O O
5 NN O O
% NN O O
similarity NN O O
) NN O O
and NN O O
between NN O O
the NN O O
mouse NN O O
and NN O O
rat NN O O
genes NN O O
( NN O O
73 NN O O
. NN O O
5 NN O O
% NN O O
identity NN O O
and NN O O
82 NN O O
. NN O O
1 NN O O
% NN O O
similarity NN O O
) NN O O
. NN O O

The NN O O
predicted NN O O
rodent NN O O
proteins NN O O
have NN O O
several NN O O
important NN O O
domains NN O O
and NN O O
signals NN O O
found NN O O
in NN O O
human NN O O
pyrin NN O O
, NN O O
including NN O O
a NN O O
B NN O O
- NN O O
box NN O O
zinc NN O O
finger NN O O
domain NN O O
, NN O O
Robbins NN O O
- NN O O
Dingwall NN O O
nuclear NN O O
localization NN O O
signal NN O O
, NN O O
and NN O O
coiled NN O O
- NN O O
coil NN O O
domain NN O O
. NN O O

However NN O O
, NN O O
perhaps NN O O
because NN O O
of NN O O
an NN O O
ancient NN O O
frame NN O O
- NN O O
shift NN O O
mutation NN O O
, NN O O
neither NN O O
the NN O O
mouse NN O O
nor NN O O
the NN O O
rat NN O O
protein NN O O
has NN O O
an NN O O
intact NN O O
C NN O O
- NN O O
terminal NN O O
B30 NN O O
. NN O O

2 NN O O
domain NN O O
, NN O O
in NN O O
which NN O O
most NN O O
FMF NN O B-Disease
- NN O O
associated NN O O
mutations NN O O
have NN O O
been NN O O
found NN O O
in NN O O
human NN O O
MEFV NN O O
. NN O O

Nevertheless NN O O
, NN O O
like NN O O
the NN O O
human NN O O
gene NN O O
, NN O O
mouse NN O O
Mefv NN O O
is NN O O
expressed NN O O
in NN O O
peripheral NN O O
blood NN O O
granulocytes NN O O
but NN O O
not NN O O
lymphocytes NN O O
. NN O O

Consistent NN O O
with NN O O
its NN O O
expression NN O O
in NN O O
granulocytes NN O O
, NN O O
Mefv NN O O
was NN O O
detected NN O O
at NN O O
high NN O O
levels NN O O
in NN O O
the NN O O
primary NN O O
follicles NN O O
and NN O O
marginal NN O O
zones NN O O
of NN O O
the NN O O
splenic NN O O
white NN O O
pulp NN O O
. NN O O

Mefv NN O O
is NN O O
localized NN O O
on NN O O
mouse NN O O
Chromosome NN O O
( NN O O
Chr NN O O
) NN O O
16 NN O O
, NN O O
region NN O O
A3 NN O O
- NN O O
B1 NN O O
, NN O O
extending NN O O
a NN O O
region NN O O
of NN O O
synteny NN O O
with NN O O
human NN O O
Chr NN O O
16p13 NN O O
. NN O O

3 NN O O
. NN O O

Development NN O O
of NN O O
knockout NN O O
and NN O O
knockin NN O O
mouse NN O O
models NN O O
may NN O O
provide NN O O
further NN O O
insights NN O O
into NN O O
the NN O O
functional NN O O
evolution NN O O
of NN O O
this NN O O
gene NN O O
. NN O O

Additional NN O O
copies NN O O
of NN O O
the NN O O
proteolipid NN O O
protein NN O O
gene NN O O
causing NN O O
Pelizaeus NN O B-Disease
- NN O I-Disease
Merzbacher NN O I-Disease
disease NN O I-Disease
arise NN O O
by NN O O
separate NN O O
integration NN O O
into NN O O
the NN O O
X NN O O
chromosome NN O O
. NN O O

The NN O O
proteolipid NN O O
protein NN O O
gene NN O O
( NN O O
PLP NN O O
) NN O O
is NN O O
normally NN O O
present NN O O
at NN O O
chromosome NN O O
Xq22 NN O O
. NN O O

Mutations NN O O
and NN O O
duplications NN O O
of NN O O
this NN O O
gene NN O O
are NN O O
associated NN O O
with NN O O
Pelizaeus NN O B-Disease
- NN O I-Disease
Merzbacher NN O I-Disease
disease NN O I-Disease
( NN O O
PMD NN O B-Disease
) NN O O
. NN O O

Here NN O O
we NN O O
describe NN O O
two NN O O
new NN O O
families NN O O
in NN O O
which NN O O
males NN O O
affected NN O O
with NN O O
PMD NN O B-Disease
were NN O O
found NN O O
to NN O O
have NN O O
a NN O O
copy NN O O
of NN O O
PLP NN O O
on NN O O
the NN O O
short NN O O
arm NN O O
of NN O O
the NN O O
X NN O O
chromosome NN O O
, NN O O
in NN O O
addition NN O O
to NN O O
a NN O O
normal NN O O
copy NN O O
on NN O O
Xq22 NN O O
. NN O O

In NN O O
the NN O O
first NN O O
family NN O O
, NN O O
the NN O O
extra NN O O
copy NN O O
was NN O O
first NN O O
detected NN O O
by NN O O
the NN O O
presence NN O O
of NN O O
heterozygosity NN O O
of NN O O
the NN O O
AhaII NN O O
dimorphism NN O O
within NN O O
the NN O O
PLP NN O O
gene NN O O
. NN O O

The NN O O
results NN O O
of NN O O
FISH NN O O
analysis NN O O
showed NN O O
an NN O O
additional NN O O
copy NN O O
of NN O O
PLP NN O O
in NN O O
Xp22 NN O O
. NN O O

1 NN O O
, NN O O
although NN O O
no NN O O
chromosomal NN O O
rearrangements NN O O
could NN O O
be NN O O
detected NN O O
by NN O O
standard NN O O
karyotype NN O O
analysis NN O O
. NN O O

Another NN O O
three NN O O
affected NN O O
males NN O O
from NN O O
the NN O O
family NN O O
had NN O O
similar NN O O
findings NN O O
. NN O O

In NN O O
a NN O O
second NN O O
unrelated NN O O
family NN O O
with NN O O
signs NN O O
of NN O O
PMD NN O B-Disease
, NN O O
cytogenetic NN O O
analysis NN O O
showed NN O O
a NN O O
pericentric NN O O
inversion NN O O
of NN O O
the NN O O
X NN O O
chromosome NN O O
. NN O O

In NN O O
the NN O O
inv NN O O
( NN O O
X NN O O
) NN O O
carried NN O O
by NN O O
several NN O O
affected NN O O
family NN O O
members NN O O
, NN O O
FISH NN O O
showed NN O O
PLP NN O O
signals NN O O
at NN O O
Xp11 NN O O
. NN O O

4 NN O O
and NN O O
Xq22 NN O O
. NN O O

A NN O O
third NN O O
family NN O O
has NN O O
previously NN O O
been NN O O
reported NN O O
, NN O O
in NN O O
which NN O O
affected NN O O
members NN O O
had NN O O
an NN O O
extra NN O O
copy NN O O
of NN O O
the NN O O
PLP NN O O
gene NN O O
detected NN O O
at NN O O
Xq26 NN O O
in NN O O
a NN O O
chromosome NN O O
with NN O O
an NN O O
otherwise NN O O
normal NN O O
banding NN O O
pattern NN O O
. NN O O

The NN O O
identification NN O O
of NN O O
three NN O O
separate NN O O
families NN O O
in NN O O
which NN O O
PLP NN O O
is NN O O
duplicated NN O O
at NN O O
a NN O O
noncontiguous NN O O
site NN O O
suggests NN O O
that NN O O
such NN O O
duplications NN O O
could NN O O
be NN O O
a NN O O
relatively NN O O
common NN O O
but NN O O
previously NN O O
undetected NN O O
cause NN O O
of NN O O
genetic NN O B-Disease
disorders NN O I-Disease
. NN O O

The NN O O
exon NN O O
13 NN O O
duplication NN O O
in NN O O
the NN O O
BRCA1 NN O O
gene NN O O
is NN O O
a NN O O
founder NN O O
mutation NN O O
present NN O O
in NN O O
geographically NN O O
diverse NN O O
populations NN O O
. NN O O

The NN O O
BRCA1 NN O O
Exon NN O O
13 NN O O
Duplication NN O O
Screening NN O O
Group NN O O
. NN O O

Recently NN O O
, NN O O
a NN O O
6 NN O O
- NN O O
kb NN O O
duplication NN O O
of NN O O
exon NN O O
13 NN O O
, NN O O
which NN O O
creates NN O O
a NN O O
frameshift NN O O
in NN O O
the NN O O
coding NN O O
sequence NN O O
of NN O O
the NN O O
BRCA1 NN O O
gene NN O O
, NN O O
has NN O O
been NN O O
described NN O O
in NN O O
three NN O O
unrelated NN O O
U NN O O
. NN O O

S NN O O
S NN O O
. NN O O
families NN O O
of NN O O
European NN O O
ancestry NN O O
and NN O O
in NN O O
one NN O O
Portuguese NN O O
family NN O O
. NN O O

Here NN O O
, NN O O
our NN O O
goal NN O O
was NN O O
to NN O O
estimate NN O O
the NN O O
frequency NN O O
and NN O O
geographic NN O O
diversity NN O O
of NN O O
carriers NN O O
of NN O O
this NN O O
duplication NN O O
. NN O O

To NN O O
do NN O O
this NN O O
, NN O O
a NN O O
collaborative NN O O
screening NN O O
study NN O O
was NN O O
set NN O O
up NN O O
that NN O O
involved NN O O
39 NN O O
institutions NN O O
from NN O O
19 NN O O
countries NN O O
and NN O O
included NN O O
3 NN O O
, NN O O
580 NN O O
unrelated NN O O
individuals NN O O
with NN O O
a NN O O
family NN O O
history NN O O
of NN O O
the NN O O
disease NN O O
and NN O O
934 NN O O
early NN O O
- NN O O
onset NN O O
breast NN O B-Disease
and NN O I-Disease
/ NN O I-Disease
or NN O I-Disease
ovarian NN O I-Disease
cancer NN O I-Disease
cases NN O O
. NN O O

A NN O O
total NN O O
of NN O O
11 NN O O
additional NN O O
families NN O O
carrying NN O O
this NN O O
mutation NN O O
were NN O O
identified NN O O
in NN O O
Australia NN O O
( NN O O
1 NN O O
) NN O O
, NN O O
Belgium NN O O
( NN O O
1 NN O O
) NN O O
, NN O O
Canada NN O O
( NN O O
1 NN O O
) NN O O
, NN O O
Great NN O O
Britain NN O O
( NN O O
6 NN O O
) NN O O
, NN O O
and NN O O
the NN O O
United NN O O
States NN O O
( NN O O
2 NN O O
) NN O O
. NN O O

Haplotyping NN O O
showed NN O O
that NN O O
they NN O O
are NN O O
likely NN O O
to NN O O
derive NN O O
from NN O O
a NN O O
common NN O O
ancestor NN O O
, NN O O
possibly NN O O
of NN O O
northern NN O O
British NN O O
origin NN O O
. NN O O

Our NN O O
results NN O O
demonstrate NN O O
that NN O O
it NN O O
is NN O O
strongly NN O O
advisable NN O O
, NN O O
for NN O O
laboratories NN O O
carrying NN O O
out NN O O
screening NN O O
either NN O O
in NN O O
English NN O O
- NN O O
speaking NN O O
countries NN O O
or NN O O
in NN O O
countries NN O O
with NN O O
historical NN O O
links NN O O
with NN O O
Britain NN O O
, NN O O
to NN O O
include NN O O
within NN O O
their NN O O
BRCA1 NN O O
screening NN O O
protocols NN O O
the NN O O
polymerase NN O O
chain NN O O
reaction NN O O
- NN O O
based NN O O
assay NN O O
described NN O O
in NN O O
this NN O O
report NN O O
. NN O O

Genotype NN O O
- NN O O
phenotype NN O O
correlations NN O O
in NN O O
families NN O O
with NN O O
deletions NN O O
in NN O O
the NN O O
von NN O B-Disease
Hippel NN O I-Disease
- NN O I-Disease
Lindau NN O I-Disease
( NN O O
VHL NN O B-Disease
) NN O O
gene NN O O
. NN O O

Von NN O B-Disease
Hippel NN O I-Disease
- NN O I-Disease
Lindau NN O I-Disease
( NN O I-Disease
VHL NN O I-Disease
) NN O I-Disease
disease NN O I-Disease
is NN O O
a NN O O
hereditary NN O B-Disease
tumor NN O I-Disease
syndrome NN O I-Disease
characterized NN O O
by NN O O
predisposition NN O O
for NN O O
bilateral NN O B-Disease
and NN O I-Disease
multi NN O I-Disease
- NN O I-Disease
centric NN O I-Disease
hemangioblastoma NN O I-Disease
in NN O O
the NN O O
retina NN O O
and NN O O
central NN O O
nervous NN O O
system NN O O
, NN O O
pheochromocytoma NN O B-Disease
, NN O O
renal NN O B-Disease
cell NN O I-Disease
carcinoma NN O I-Disease
, NN O O
and NN O O
cysts NN O B-Disease
in NN O I-Disease
the NN O I-Disease
kidney NN O I-Disease
, NN O I-Disease
pancreas NN O I-Disease
, NN O I-Disease
and NN O I-Disease
epididymis NN O I-Disease
. NN O O

We NN O O
describe NN O O
five NN O O
families NN O O
for NN O O
which NN O O
direct NN O O
sequencing NN O O
of NN O O
the NN O O
coding NN O O
region NN O O
of NN O O
the NN O O
VHL NN O B-Disease
gene NN O O
had NN O O
failed NN O O
to NN O O
identify NN O O
the NN O O
family NN O O
- NN O O
specific NN O O
mutation NN O O
. NN O O

Further NN O O
molecular NN O O
analysis NN O O
revealed NN O O
deletions NN O O
involving NN O O
the NN O O
VHL NN O B-Disease
gene NN O O
in NN O O
each NN O O
of NN O O
these NN O O
families NN O O
. NN O O

In NN O O
four NN O O
families NN O O
, NN O O
partial NN O O
deletions NN O O
of NN O O
one NN O O
or NN O O
more NN O O
exons NN O O
were NN O O
detected NN O O
by NN O O
Southern NN O O
blot NN O O
analysis NN O O
. NN O O

In NN O O
the NN O O
fifth NN O O
family NN O O
, NN O O
FISH NN O O
analysis NN O O
demonstrated NN O O
the NN O O
deletion NN O O
of NN O O
the NN O O
entire NN O O
VHL NN O B-Disease
gene NN O O
. NN O O

Our NN O O
results NN O O
show NN O O
that NN O O
( NN O O
quantitative NN O O
) NN O O
Southern NN O O
blot NN O O
analysis NN O O
is NN O O
a NN O O
sensitive NN O O
method NN O O
for NN O O
detecting NN O O
germline NN O O
deletions NN O O
of NN O O
the NN O O
VHL NN O B-Disease
gene NN O O
and NN O O
should NN O O
be NN O O
implemented NN O O
in NN O O
routine NN O O
DNA NN O O
diagnosis NN O O
for NN O O
VHL NN O B-Disease
disease NN O I-Disease
. NN O O

Our NN O O
data NN O O
support NN O O
the NN O O
previously NN O O
established NN O O
observation NN O O
that NN O O
families NN O O
with NN O O
a NN O O
germline NN O O
deletion NN O O
have NN O O
a NN O O
low NN O O
risk NN O O
for NN O O
pheochromocytoma NN O B-Disease
. NN O O

Further NN O O
unraveling NN O O
of NN O O
genotype NN O O
- NN O O
phenotype NN O O
correlations NN O O
in NN O O
VHL NN O B-Disease
disease NN O I-Disease
has NN O O
revealed NN O O
that NN O O
families NN O O
with NN O O
a NN O O
full NN O O
or NN O O
partial NN O O
deletion NN O O
of NN O O
the NN O O
VHL NN O B-Disease
gene NN O O
exhibit NN O O
a NN O O
phenotype NN O O
with NN O O
a NN O O
preponderance NN O O
of NN O O
central NN O B-Disease
nervous NN O I-Disease
system NN O I-Disease
hemangioblastoma NN O I-Disease
. NN O O
. NN O O

Age NN O O
of NN O O
the NN O O
intronic NN O O
GAA NN O O
triplet NN O O
repeat NN O O
expansion NN O O
mutation NN O O
in NN O O
Friedreich NN O B-Disease
ataxia NN O I-Disease
. NN O O

Friedreich NN O B-Disease
ataxia NN O I-Disease
( NN O O
FRDA NN O B-Disease
) NN O O
, NN O O
the NN O O
most NN O O
frequently NN O O
inherited NN O B-Disease
ataxia NN O I-Disease
, NN O O
is NN O O
due NN O O
in NN O O
the NN O O
vast NN O O
majority NN O O
of NN O O
cases NN O O
to NN O O
a NN O O
large NN O O
expansion NN O O
of NN O O
an NN O O
intronic NN O O
GAA NN O O
repeat NN O O
. NN O O

Using NN O O
linkage NN O O
disequilibrium NN O O
analysis NN O O
based NN O O
on NN O O
haplotype NN O O
data NN O O
of NN O O
seven NN O O
polymorphic NN O O
markers NN O O
close NN O O
to NN O O
the NN O O
frataxin NN O O
gene NN O O
, NN O O
the NN O O
age NN O O
of NN O O
FRDA NN O B-Disease
founding NN O O
mutational NN O O
event NN O O
( NN O O
s NN O O
) NN O O
is NN O O
estimated NN O O
to NN O O
be NN O O
at NN O O
least NN O O
682 NN O O
+ NN O O
/ NN O O
- NN O O
203 NN O O
generations NN O O
( NN O O
95 NN O O
% NN O O
confidence NN O O
interval NN O O
564 NN O O
- NN O O
801 NN O O
g NN O O
) NN O O
, NN O O
a NN O O
dating NN O O
which NN O O
is NN O O
consistent NN O O
with NN O O
little NN O O
or NN O O
no NN O O
negative NN O O
selection NN O O
and NN O O
provides NN O O
further NN O O
evidence NN O O
for NN O O
an NN O O
ancient NN O O
spread NN O O
of NN O O
a NN O O
pre NN O O
- NN O O
mutation NN O O
( NN O O
at NN O O
- NN O O
risk NN O O
alleles NN O O
) NN O O
in NN O O
western NN O O
Europe NN O O
. NN O O
. NN O O

Functional NN O O
link NN O O
between NN O O
ataxia NN O B-Disease
- NN O I-Disease
telangiectasia NN O I-Disease
and NN O O
Nijmegen NN O B-Disease
breakage NN O I-Disease
syndrome NN O I-Disease
gene NN O O
products NN O O
. NN O O

Ataxia NN O B-Disease
- NN O I-Disease
telangiectasia NN O I-Disease
( NN O O
A NN O B-Disease
- NN O I-Disease
T NN O I-Disease
) NN O O
and NN O O
Nijmegen NN O B-Disease
breakage NN O I-Disease
syndrome NN O I-Disease
( NN O O
NBS NN O B-Disease
) NN O O
are NN O O
recessive NN O B-Disease
genetic NN O I-Disease
disorders NN O I-Disease
with NN O O
susceptibility NN O O
to NN O O
cancer NN O B-Disease
and NN O O
similar NN O O
cellular NN O O
phenotypes NN O O
. NN O O

The NN O O
protein NN O O
product NN O O
of NN O O
the NN O O
gene NN O O
responsible NN O O
for NN O O
A NN O B-Disease
- NN O I-Disease
T NN O I-Disease
, NN O O
designated NN O O
ATM NN O O
, NN O O
is NN O O
a NN O O
member NN O O
of NN O O
a NN O O
family NN O O
of NN O O
kinases NN O O
characterized NN O O
by NN O O
a NN O O
carboxy NN O O
- NN O O
terminal NN O O
phosphatidylinositol NN O O
3 NN O O
- NN O O
kinase NN O O
- NN O O
like NN O O
domain NN O O
. NN O O

The NN O O
NBS1 NN O O
protein NN O O
is NN O O
specifically NN O O
mutated NN O O
in NN O O
patients NN O O
with NN O O
Nijmegen NN O B-Disease
breakage NN O I-Disease
syndrome NN O I-Disease
and NN O O
forms NN O O
a NN O O
complex NN O O
with NN O O
the NN O O
DNA NN O O
repair NN O O
proteins NN O O
Rad50 NN O O
and NN O O
Mrel1 NN O O
. NN O O

Here NN O O
we NN O O
show NN O O
that NN O O
phosphorylation NN O O
of NN O O
NBS1 NN O O
, NN O O
induced NN O O
by NN O O
ionizing NN O O
radiation NN O O
, NN O O
requires NN O O
catalytically NN O O
active NN O O
ATM NN O O
. NN O O

Complexes NN O O
containing NN O O
ATM NN O O
and NN O O
NBS1 NN O O
exist NN O O
in NN O O
vivo NN O O
in NN O O
both NN O O
untreated NN O O
cells NN O O
and NN O O
cells NN O O
treated NN O O
with NN O O
ionizing NN O O
radiation NN O O
. NN O O

We NN O O
have NN O O
identified NN O O
two NN O O
residues NN O O
of NN O O
NBS1 NN O O
, NN O O
Ser NN O O
278 NN O O
and NN O O
Ser NN O O
343 NN O O
that NN O O
are NN O O
phosphorylated NN O O
in NN O O
vitro NN O O
by NN O O
ATM NN O O
and NN O O
whose NN O O
modification NN O O
in NN O O
vivo NN O O
is NN O O
essential NN O O
for NN O O
the NN O O
cellular NN O O
response NN O O
to NN O O
DNA NN O O
damage NN O O
. NN O O

This NN O O
response NN O O
includes NN O O
S NN O O
- NN O O
phase NN O O
checkpoint NN O O
activation NN O O
, NN O O
formation NN O O
of NN O O
the NN O O
NBS1 NN O O
/ NN O O
Mrel1 NN O O
/ NN O O
Rad50 NN O O
nuclear NN O O
foci NN O O
and NN O O
rescue NN O O
of NN O O
hypersensitivity NN O B-Disease
to NN O I-Disease
ionizing NN O I-Disease
radiation NN O I-Disease
. NN O O

Together NN O O
, NN O O
these NN O O
results NN O O
demonstrate NN O O
a NN O O
biochemical NN O O
link NN O O
between NN O O
cell NN O O
- NN O O
cycle NN O O
checkpoints NN O O
activated NN O O
by NN O O
DNA NN O O
damage NN O O
and NN O O
DNA NN O O
repair NN O O
in NN O O
two NN O O
genetic NN O B-Disease
diseases NN O I-Disease
with NN O O
overlapping NN O O
phenotypes NN O O
. NN O O
. NN O O

Homozygosity NN O O
mapping NN O O
in NN O O
a NN O O
family NN O O
with NN O O
microcephaly NN O B-Disease
, NN O O
mental NN O B-Disease
retardation NN O I-Disease
, NN O O
and NN O O
short NN O B-Disease
stature NN O I-Disease
to NN O O
a NN O O
Cohen NN O B-Disease
syndrome NN O I-Disease
region NN O O
on NN O O
8q21 NN O O
. NN O O
3 NN O O
- NN O O
8q22 NN O O
. NN O O
1 NN O O
: NN O O
redefining NN O O
a NN O O
clinical NN O O
entity NN O O
. NN O O

A NN O O
syndrome NN O O
of NN O O
microcephaly NN O B-Disease
, NN O O
progressive NN O O
postnatal NN O B-Disease
growth NN O I-Disease
deficiency NN O I-Disease
, NN O O
and NN O O
mental NN O B-Disease
retardation NN O I-Disease
was NN O O
observed NN O O
in NN O O
two NN O O
brothers NN O O
and NN O O
their NN O O
cousin NN O O
from NN O O
a NN O O
multiply NN O O
consanguineous NN O O
kindred NN O O
of NN O O
Lebanese NN O O
descent NN O O
. NN O O

Hypotonia NN O B-Disease
, NN O O
chorioretinal NN O B-Disease
dystrophy NN O I-Disease
, NN O O
and NN O O
myopia NN O B-Disease
were NN O O
also NN O O
identified NN O O
. NN O O

The NN O O
severity NN O O
of NN O O
the NN O O
condition NN O O
varied NN O O
among NN O O
the NN O O
closely NN O O
related NN O O
patients NN O O
. NN O O

Because NN O O
of NN O O
absence NN O O
of NN O O
a NN O O
distinctive NN O O
facial NN O O
appearance NN O O
, NN O O
the NN O O
degree NN O O
of NN O O
mental NN O B-Disease
retardation NN O I-Disease
, NN O O
and NN O O
short NN O B-Disease
stature NN O I-Disease
, NN O O
the NN O O
initially NN O O
considered NN O O
clinical NN O O
diagnosis NN O O
of NN O O
Cohen NN O B-Disease
syndrome NN O I-Disease
was NN O O
withdrawn NN O O
and NN O O
a NN O O
novel NN O O
genetic NN O O
entity NN O O
was NN O O
assumed NN O O
. NN O O

Homozygosity NN O O
mapping NN O O
in NN O O
this NN O O
family NN O O
assigned NN O O
the NN O O
gene NN O O
to NN O O
a NN O O
26 NN O O
. NN O O

8 NN O O
- NN O O
cM NN O O
region NN O O
on NN O O
the NN O O
chromosome NN O O
band NN O O
8q21 NN O O
. NN O O

3 NN O O
- NN O O
22 NN O O
. NN O O

1 NN O O
, NN O O
between NN O O
the NN O O
microsatellites NN O O
at NN O O
D8S270 NN O O
and NN O O
D8S514 NN O O
. NN O O

The NN O O
maximum NN O O
two NN O O
- NN O O
point NN O O
LOD NN O O
score NN O O
was NN O O
found NN O O
for NN O O
marker NN O O
at NN O O
D8S267 NN O O
( NN O O
Zmax NN O O
= NN O O
3 NN O O
. NN O O
. NN O O
237 NN O O
at NN O O
Omax NN O O
= NN O O
0 NN O O
. NN O O
00 NN O O
) NN O O
. NN O O

Intriguingly NN O O
enough NN O O
, NN O O
the NN O O
identified NN O O
gene NN O O
region NN O O
overlaps NN O O
the NN O O
refined NN O O
gene NN O O
region NN O O
for NN O O
Cohen NN O B-Disease
syndrome NN O I-Disease
( NN O O
COH1 NN O O
) NN O O
[ NN O O
Kolehmainen NN O O
et NN O O
al NN O O
. NN O O
, NN O O
1997 NN O O
Euro NN O O
J NN O O
Hum NN O O
Genet NN O O
5 NN O O
206 NN O O
- NN O O
213 NN O O
] NN O O
. NN O O

This NN O O
fact NN O O
encourages NN O O
the NN O O
hypothesis NN O O
that NN O O
the NN O O
described NN O O
kindred NN O O
segregates NN O O
for NN O O
a NN O O
variant NN O O
of NN O O
Cohen NN O B-Disease
syndrome NN O I-Disease
and NN O O
suggests NN O O
a NN O O
redefinition NN O O
of NN O O
its NN O O
phenotype NN O O

Polymorphisms NN O O
of NN O O
the NN O O
CYP2D6 NN O O
gene NN O O
increase NN O O
susceptibility NN O O
to NN O O
ankylosing NN O B-Disease
spondylitis NN O I-Disease
. NN O O

Ankylosing NN O B-Disease
spondylitis NN O I-Disease
( NN O O
AS NN O B-Disease
) NN O O
is NN O O
a NN O O
common NN O O
and NN O O
highly NN O O
familial NN O O
rheumatic NN O B-Disease
disorder NN O I-Disease
. NN O O

The NN O O
sibling NN O O
recurrence NN O O
risk NN O O
ratio NN O O
for NN O O
the NN O O
disease NN O O
is NN O O
63 NN O O
and NN O O
heritability NN O O
assessed NN O O
in NN O O
twins NN O O
> NN O O
90 NN O O
% NN O O
. NN O O

Although NN O O
MHC NN O O
genes NN O O
, NN O O
including NN O O
HLA NN O O
- NN O O
B27 NN O O
, NN O O
contribute NN O O
only NN O O
20 NN O O
- NN O O
50 NN O O
% NN O O
of NN O O
the NN O O
genetic NN O O
risk NN O O
for NN O O
the NN O O
disease NN O O
, NN O O
no NN O O
non NN O O
- NN O O
MHC NN O O
gene NN O O
has NN O O
yet NN O O
been NN O O
convincingly NN O O
demonstrated NN O O
to NN O O
influence NN O O
either NN O O
susceptibility NN O O
to NN O O
the NN O O
disease NN O O
or NN O O
its NN O O
phenotypic NN O O
expression NN O O
. NN O O

Previous NN O O
linkage NN O O
and NN O O
association NN O O
studies NN O O
have NN O O
suggested NN O O
the NN O O
presence NN O O
of NN O O
a NN O O
susceptibility NN O O
gene NN O O
for NN O O
AS NN O B-Disease
close NN O O
to NN O O
, NN O O
or NN O O
within NN O O
, NN O O
the NN O O
cytochrome NN O O
P450 NN O O
2D6 NN O O
gene NN O O
( NN O O
CYP2D6 NN O O
, NN O O
debrisoquine NN O O
hydroxylase NN O O
) NN O O
located NN O O
at NN O O
chromosome NN O O
22q13 NN O O
. NN O O
1 NN O O
. NN O O

We NN O O
performed NN O O
a NN O O
linkage NN O O
study NN O O
of NN O O
chromosome NN O O
22 NN O O
in NN O O
200 NN O O
families NN O O
with NN O O
AS NN O B-Disease
affected NN O O
sibling NN O O
- NN O O
pairs NN O O
. NN O O

Association NN O O
of NN O O
alleles NN O O
of NN O O
the NN O O
CYP2D6 NN O O
gene NN O O
was NN O O
examined NN O O
by NN O O
both NN O O
case NN O O
- NN O O
control NN O O
and NN O O
within NN O O
- NN O O
family NN O O
means NN O O
. NN O O

For NN O O
case NN O O
- NN O O
control NN O O
studies NN O O
, NN O O
617 NN O O
unrelated NN O O
individuals NN O O
with NN O O
AS NN O B-Disease
( NN O O
361 NN O O
probands NN O O
from NN O O
sibling NN O O
- NN O O
pair NN O O
and NN O O
parent NN O O
- NN O O
case NN O O
trio NN O O
families NN O O
and NN O O
256 NN O O
unrelated NN O O
non NN O O
- NN O O
familial NN O O
sporadic NN O O
cases NN O O
) NN O O
and NN O O
402 NN O O
healthy NN O O
ethnically NN O O
matched NN O O
controls NN O O
were NN O O
employed NN O O
. NN O O

For NN O O
within NN O O
- NN O O
family NN O O
association NN O O
studies NN O O
, NN O O
361 NN O O
families NN O O
including NN O O
161 NN O O
parent NN O O
- NN O O
case NN O O
trios NN O O
and NN O O
200 NN O O
affected NN O O
sibling NN O O
- NN O O
pair NN O O
families NN O O
were NN O O
employed NN O O
. NN O O

Homozygosity NN O O
for NN O O
poor NN O O
metabolizer NN O O
alleles NN O O
was NN O O
found NN O O
to NN O O
be NN O O
associated NN O O
with NN O O
AS NN O B-Disease
. NN O O

Heterozygosity NN O O
for NN O O
the NN O O
most NN O O
frequent NN O O
poor NN O O
metabolizer NN O O
allele NN O O
( NN O O
CYP2D6 NN O O
* NN O O
4 NN O O
) NN O O
was NN O O
not NN O O
associated NN O O
with NN O O
increased NN O O
susceptibility NN O O
to NN O O
AS NN O B-Disease
. NN O O

Significant NN O O
within NN O O
- NN O O
family NN O O
association NN O O
of NN O O
CYP2D6 NN O O
* NN O O
4 NN O O
alleles NN O O
and NN O O
AS NN O B-Disease
was NN O O
demonstrated NN O O
. NN O O

Weak NN O O
linkage NN O O
was NN O O
also NN O O
demonstrated NN O O
between NN O O
CYP2D6 NN O O
and NN O O
AS NN O B-Disease
. NN O O

We NN O O
postulate NN O O
that NN O O
altered NN O O
metabolism NN O O
of NN O O
a NN O O
natural NN O O
toxin NN O O
or NN O O
antigen NN O O
by NN O O
the NN O O
CYP2D6 NN O O
gene NN O O
may NN O O
increase NN O O
susceptibility NN O O
to NN O O
AS NN O B-Disease
. NN O O

Functional NN O O
differences NN O O
of NN O O
the NN O O
PDS NN O B-Disease
gene NN O O
product NN O O
are NN O O
associated NN O O
with NN O O
phenotypic NN O O
variation NN O O
in NN O O
patients NN O O
with NN O O
Pendred NN O B-Disease
syndrome NN O I-Disease
and NN O O
non NN O B-Disease
- NN O I-Disease
syndromic NN O I-Disease
hearing NN O I-Disease
loss NN O I-Disease
( NN O O
DFNB4 NN O B-Disease
) NN O O
. NN O O

The NN O O
PDS NN O B-Disease
gene NN O O
encodes NN O O
a NN O O
transmembrane NN O O
protein NN O O
, NN O O
known NN O O
as NN O O
pendrin NN O O
, NN O O
which NN O O
functions NN O O
as NN O O
a NN O O
transporter NN O O
of NN O O
iodide NN O O
and NN O O
chloride NN O O
. NN O O

Mutations NN O O
in NN O O
this NN O O
gene NN O O
are NN O O
responsible NN O O
for NN O O
Pendred NN O B-Disease
syndrome NN O I-Disease
and NN O O
autosomal NN O B-Disease
recessive NN O I-Disease
non NN O I-Disease
- NN O I-Disease
syndromic NN O I-Disease
hearing NN O I-Disease
loss NN O I-Disease
at NN O O
the NN O O
DFNB4 NN O B-Disease
locus NN O O
on NN O O
chromosome NN O O
7q31 NN O O
. NN O O

A NN O O
screen NN O O
of NN O O
20 NN O O
individuals NN O O
from NN O O
the NN O O
midwestern NN O O
USA NN O O
with NN O O
non NN O B-Disease
- NN O I-Disease
syndromic NN O I-Disease
hearing NN O I-Disease
loss NN O I-Disease
and NN O O
dilated NN O O
vestibular NN O O
aqueducts NN O O
identified NN O O
three NN O O
people NN O O
( NN O O
15 NN O O
% NN O O
) NN O O
with NN O O
PDS NN O B-Disease
mutations NN O O
. NN O O

To NN O O
determine NN O O
whether NN O O
PDS NN O B-Disease
mutations NN O O
in NN O O
individuals NN O O
with NN O O
Pendred NN O B-Disease
syndrome NN O I-Disease
differ NN O O
functionally NN O O
from NN O O
PDS NN O B-Disease
mutations NN O O
in NN O O
individuals NN O O
with NN O O
non NN O B-Disease
- NN O I-Disease
syndromic NN O I-Disease
hearing NN O I-Disease
loss NN O I-Disease
, NN O O
we NN O O
compared NN O O
three NN O O
common NN O O
Pendred NN O B-Disease
syndrome NN O I-Disease
allele NN O O
variants NN O O
( NN O O
L236P NN O O
, NN O O
T416P NN O O
and NN O O
E384G NN O O
) NN O O
, NN O O
with NN O O
three NN O O
PDS NN O B-Disease
mutations NN O O
reported NN O O
only NN O O
in NN O O
individuals NN O O
with NN O O
non NN O B-Disease
- NN O I-Disease
syndromic NN O I-Disease
hearing NN O I-Disease
loss NN O I-Disease
( NN O O
V480D NN O O
, NN O O
V653A NN O O
and NN O O
I490L NN O O
/ NN O O
G497S NN O O
) NN O O
. NN O O

The NN O O
mutations NN O O
associated NN O O
with NN O O
Pendred NN O B-Disease
syndrome NN O I-Disease
have NN O O
complete NN O O
loss NN O O
of NN O O
pendrin NN O O
- NN O O
induced NN O O
chloride NN O O
and NN O O
iodide NN O O
transport NN O O
, NN O O
while NN O O
alleles NN O O
unique NN O O
to NN O O
people NN O O
with NN O O
DFNB4 NN O B-Disease
are NN O O
able NN O O
to NN O O
transport NN O O
both NN O O
iodide NN O O
and NN O O
chloride NN O O
, NN O O
albeit NN O O
at NN O O
a NN O O
much NN O O
lower NN O O
level NN O O
than NN O O
wild NN O O
- NN O O
type NN O O
pendrin NN O O
. NN O O

We NN O O
hypothesize NN O O
that NN O O
this NN O O
residual NN O O
level NN O O
of NN O O
anion NN O O
transport NN O O
is NN O O
sufficient NN O O
to NN O O
eliminate NN O O
or NN O O
postpone NN O O
the NN O O
onset NN O O
of NN O O
goiter NN O B-Disease
in NN O O
individuals NN O O
with NN O O
DFNB4 NN O B-Disease
. NN O O

We NN O O
propose NN O O
a NN O O
model NN O O
for NN O O
pendrin NN O O
function NN O O
in NN O O
the NN O O
thyroid NN O O
in NN O O
which NN O O
pendrin NN O O
transports NN O O
iodide NN O O
across NN O O
the NN O O
apical NN O O
membrane NN O O
of NN O O
the NN O O
thyrocyte NN O O
into NN O O
the NN O O
colloid NN O O
space NN O O
. NN O O
. NN O O

The NN O O
human NN O O
factor NN O O
IX NN O O
gene NN O O
as NN O O
germline NN O O
mutagen NN O O
test NN O O
: NN O O
samples NN O O
from NN O O
Mainland NN O O
China NN O O
have NN O O
the NN O O
putatively NN O O
endogenous NN O O
pattern NN O O
of NN O O
mutation NN O O
. NN O O

Germline NN O O
mutations NN O O
are NN O O
the NN O O
major NN O O
source NN O O
of NN O O
genetic NN O O
variation NN O O
that NN O O
allows NN O O
a NN O O
species NN O O
to NN O O
evolve NN O O
over NN O O
time NN O O
but NN O O
at NN O O
the NN O O
cost NN O O
of NN O O
Mendelian NN O B-Disease
disease NN O I-Disease
and NN O O
genetic NN O O
predisposition NN O O
to NN O O
multifactorial NN O B-Disease
diseases NN O I-Disease
. NN O O

Previous NN O O
analyses NN O O
have NN O O
revealed NN O O
that NN O O
the NN O O
pattern NN O O
of NN O O
germline NN O O
mutations NN O O
in NN O O
the NN O O
factor NN O O
IX NN O O
gene NN O O
( NN O O
F9 NN O O
) NN O O
is NN O O
similar NN O O
among NN O O
a NN O O
variety NN O O
of NN O O
ethnically NN O O
and NN O O
geographically NN O O
diverse NN O O
populations NN O O
and NN O O
compatible NN O O
with NN O O
the NN O O
ancient NN O O
pattern NN O O
that NN O O
has NN O O
shaped NN O O
the NN O O
mammalian NN O O
genome NN O O
. NN O O

Here NN O O
, NN O O
we NN O O
compare NN O O
the NN O O
pattern NN O O
of NN O O
germline NN O O
mutation NN O O
in NN O O
a NN O O
population NN O O
of NN O O
hemophilia NN O B-Disease
B NN O I-Disease
patients NN O O
from NN O O
Mainland NN O O
China NN O O
( NN O O
n NN O O
= NN O O
66 NN O O
) NN O O
to NN O O
that NN O O
in NN O O
U NN O O
. NN O O

S NN O O
. NN O O

Caucasians NN O O
, NN O O
Blacks NN O O
, NN O O
and NN O O
Mexican NN O O
Hispanics NN O O
and NN O O
stratify NN O O
by NN O O
disease NN O O
severity NN O O
and NN O O
ethnicity NN O O
. NN O O

The NN O O
similar NN O O
pattern NN O O
of NN O O
germline NN O O
mutation NN O O
in NN O O
all NN O O
ethnic NN O O
groups NN O O
studied NN O O
to NN O O
date NN O O
provides NN O O
additional NN O O
data NN O O
compatible NN O O
with NN O O
the NN O O
inference NN O O
that NN O O
endogenous NN O O
processes NN O O
predominate NN O O
in NN O O
germline NN O O
mutations NN O O
. NN O O

Fas NN O O
preassociation NN O O
required NN O O
for NN O O
apoptosis NN O O
signaling NN O O
and NN O O
dominant NN O O
inhibition NN O O
by NN O O
pathogenic NN O O
mutations NN O O
. NN O O

Heterozygous NN O O
mutations NN O O
encoding NN O O
abnormal NN O O
forms NN O O
of NN O O
the NN O O
death NN O O
receptor NN O O
Fas NN O O
dominantly NN O O
interfere NN O O
with NN O O
Fas NN O O
- NN O O
induced NN O O
lymphocyte NN O O
apoptosis NN O O
in NN O O
human NN O O
autoimmune NN O B-Disease
lymphoproliferative NN O I-Disease
syndrome NN O I-Disease
. NN O O

This NN O O
effect NN O O
, NN O O
rather NN O O
than NN O O
depending NN O O
on NN O O
ligand NN O O
- NN O O
induced NN O O
receptor NN O O
oligomerization NN O O
, NN O O
was NN O O
found NN O O
to NN O O
stem NN O O
from NN O O
ligand NN O O
- NN O O
independent NN O O
interaction NN O O
of NN O O
wild NN O O
- NN O O
type NN O O
and NN O O
mutant NN O O
Fas NN O O
receptors NN O O
through NN O O
a NN O O
specific NN O O
region NN O O
in NN O O
the NN O O
extracellular NN O O
domain NN O O
. NN O O

Preassociated NN O O
Fas NN O O
complexes NN O O
were NN O O
found NN O O
in NN O O
living NN O O
cells NN O O
by NN O O
means NN O O
of NN O O
fluorescence NN O O
resonance NN O O
energy NN O O
transfer NN O O
between NN O O
variants NN O O
of NN O O
green NN O O
fluorescent NN O O
protein NN O O
. NN O O

These NN O O
results NN O O
show NN O O
that NN O O
formation NN O O
of NN O O
preassociated NN O O
receptor NN O O
complexes NN O O
is NN O O
necessary NN O O
for NN O O
Fas NN O O
signaling NN O O
and NN O O
dominant NN O O
interference NN O O
in NN O O
human NN O O
disease NN O O
. NN O O
. NN O O

Determination NN O O
of NN O O
carrier NN O O
status NN O O
for NN O O
the NN O O
Wiskott NN O B-Disease
- NN O I-Disease
Aldrich NN O I-Disease
syndrome NN O I-Disease
by NN O O
flow NN O O
cytometric NN O O
analysis NN O O
of NN O O
Wiskott NN O B-Disease
- NN O I-Disease
Aldrich NN O I-Disease
syndrome NN O I-Disease
protein NN O O
expression NN O O
in NN O O
peripheral NN O O
blood NN O O
mononuclear NN O O
cells NN O O
. NN O O

The NN O O
Wiskott NN O B-Disease
- NN O I-Disease
Aldrich NN O I-Disease
syndrome NN O I-Disease
( NN O O
WAS NN O B-Disease
) NN O O
is NN O O
caused NN O O
by NN O O
defects NN O O
in NN O O
the NN O O
WAS NN O B-Disease
protein NN O O
( NN O O
WASP NN O O
) NN O O
gene NN O O
on NN O O
the NN O O
X NN O O
chromosome NN O O
. NN O O

Previous NN O O
study NN O O
disclosed NN O O
that NN O O
flow NN O O
cytometric NN O O
analysis NN O O
of NN O O
intracellular NN O O
WASP NN O O
expression NN O O
( NN O O
FCM NN O O
- NN O O
WASP NN O O
analysis NN O O
) NN O O
in NN O O
lymphocytes NN O O
was NN O O
useful NN O O
for NN O O
the NN O O
diagnosis NN O O
of NN O O
WAS NN O B-Disease
patients NN O O
. NN O O

Lymphocytes NN O O
from NN O O
all NN O O
WAS NN O B-Disease
patients NN O O
showed NN O O
WASPdim NN O O
instead NN O O
of NN O O
WASPbright NN O O
. NN O O

Here NN O O
we NN O O
report NN O O
that NN O O
FCM NN O O
- NN O O
WASP NN O O
analysis NN O O
in NN O O
monocytes NN O O
could NN O O
be NN O O
a NN O O
useful NN O O
tool NN O O
for NN O O
the NN O O
WAS NN O B-Disease
carrier NN O O
diagnosis NN O O
. NN O O

Monocytes NN O O
from NN O O
all NN O O
nine NN O O
WAS NN O B-Disease
carriers NN O O
showed NN O O
varied NN O O
population NN O O
of NN O O
WASPdim NN O O
together NN O O
with NN O O
WASPbright NN O O
. NN O O

None NN O O
of NN O O
control NN O O
individuals NN O O
possessed NN O O
the NN O O
WASPdim NN O O
population NN O O
. NN O O

In NN O O
contrast NN O O
, NN O O
lymphocytes NN O O
from NN O O
all NN O O
the NN O O
carriers NN O O
except NN O O
two NN O O
lacked NN O O
the NN O O
WASPdim NN O O
population NN O O
. NN O O

The NN O O
difference NN O O
of NN O O
the NN O O
WASPdim NN O O
population NN O O
in NN O O
monocytes NN O O
and NN O O
lymphocytes NN O O
observed NN O O
in NN O O
WAS NN O B-Disease
carriers NN O O
suggests NN O O
that NN O O
WASP NN O O
plays NN O O
a NN O O
more NN O O
critical NN O O
role NN O O
in NN O O
the NN O O
development NN O O
of NN O O
lymphocytes NN O O
than NN O O
in NN O O
that NN O O
of NN O O
monocytes NN O O
. NN O O

The NN O O
present NN O O
studies NN O O
suggest NN O O
that NN O O
a NN O O
skewed NN O O
X NN O O
- NN O O
chromosomal NN O O
inactivation NN O O
pattern NN O O
observed NN O O
in NN O O
WAS NN O B-Disease
carrier NN O O
peripheral NN O O
blood NN O O
cells NN O O
is NN O O
not NN O O
fixed NN O O
at NN O O
the NN O O
hemopoietic NN O O
stem NN O O
cell NN O O
level NN O O
but NN O O
progresses NN O O
after NN O O
the NN O O
lineage NN O O
commitment NN O O
. NN O O
. NN O O

Restoration NN O O
of NN O O
photoreceptor NN O O
ultrastructure NN O O
and NN O O
function NN O O
in NN O O
retinal NN O B-Disease
degeneration NN O I-Disease
slow NN O O
mice NN O O
by NN O O
gene NN O O
therapy NN O O
. NN O O

The NN O O
gene NN O O
Prph2 NN O O
encodes NN O O
a NN O O
photoreceptor NN O O
- NN O O
specific NN O O
membrane NN O O
glycoprotein NN O O
, NN O O
peripherin NN O O
- NN O O
2 NN O O
( NN O O
also NN O O
known NN O O
as NN O O
peripherin NN O O
/ NN O O
rds NN O O
) NN O O
, NN O O
which NN O O
is NN O O
inserted NN O O
into NN O O
the NN O O
rims NN O O
of NN O O
photoreceptor NN O O
outer NN O O
segment NN O O
discs NN O O
in NN O O
a NN O O
complex NN O O
with NN O O
rom NN O O
- NN O O
1 NN O O
( NN O O
ref NN O O
. NN O O
2 NN O O
) NN O O
. NN O O

The NN O O
complex NN O O
is NN O O
necessary NN O O
for NN O O
the NN O O
stabilization NN O O
of NN O O
the NN O O
discs NN O O
, NN O O
which NN O O
are NN O O
renewed NN O O
constantly NN O O
throughout NN O O
life NN O O
, NN O O
and NN O O
which NN O O
contain NN O O
the NN O O
visual NN O O
pigments NN O O
necessary NN O O
for NN O O
photon NN O O
capture NN O O
. NN O O

Mutations NN O O
in NN O O
Prph2 NN O O
have NN O O
been NN O O
shown NN O O
to NN O O
result NN O O
in NN O O
a NN O O
variety NN O O
of NN O O
photoreceptor NN O B-Disease
dystrophies NN O I-Disease
, NN O O
including NN O O
autosomal NN O B-Disease
dominant NN O I-Disease
retinitis NN O I-Disease
pigmentosa NN O I-Disease
and NN O O
macular NN O B-Disease
dystrophy NN O I-Disease
. NN O O

A NN O O
common NN O O
feature NN O O
of NN O O
these NN O O
diseases NN O O
is NN O O
the NN O O
loss NN O O
of NN O O
photoreceptor NN O O
function NN O O
, NN O O
also NN O O
seen NN O O
in NN O O
the NN O O
retinal NN O B-Disease
degeneration NN O I-Disease
slow NN O O
( NN O O
rds NN O O
or NN O O
Prph2 NN O O
Rd2 NN O O
/ NN O O
Rd2 NN O O
) NN O O
mouse NN O O
, NN O O
which NN O O
is NN O O
homozygous NN O O
for NN O O
a NN O O
null NN O O
mutation NN O O
in NN O O
Prph2 NN O O
. NN O O

It NN O O
is NN O O
characterized NN O O
by NN O O
a NN O O
complete NN O O
failure NN O O
to NN O O
develop NN O O
photoreceptor NN O O
discs NN O O
and NN O O
outer NN O O
segments NN O O
, NN O O
downregulation NN O O
of NN O O
rhodopsin NN O O
and NN O O
apoptotic NN O O
loss NN O O
of NN O O
photoreceptor NN O O
cells NN O O
. NN O O

The NN O O
electroretinograms NN O O
( NN O O
ERGs NN O O
) NN O O
of NN O O
Prph2Rd2 NN O O
/ NN O O
Rd2 NN O O
mice NN O O
have NN O O
greatly NN O O
diminished NN O O
a NN O O
- NN O O
wave NN O O
and NN O O
b NN O O
- NN O O
wave NN O O
amplitudes NN O O
, NN O O
which NN O O
decline NN O O
to NN O O
virtually NN O O
undetectable NN O O
concentrations NN O O
by NN O O
two NN O O
months NN O O
. NN O O

Subretinal NN O O
injection NN O O
of NN O O
recombinant NN O O
adeno NN O O
- NN O O
associated NN O O
virus NN O O
( NN O O
AAV NN O O
) NN O O
encoding NN O O
a NN O O
Prph2 NN O O
transgene NN O O
results NN O O
in NN O O
stable NN O O
generation NN O O
of NN O O
outer NN O O
segment NN O O
structures NN O O
and NN O O
formation NN O O
of NN O O
new NN O O
stacks NN O O
of NN O O
discs NN O O
containing NN O O
both NN O O
perpherin NN O O
- NN O O
2 NN O O
and NN O O
rhodopsin NN O O
, NN O O
which NN O O
in NN O O
many NN O O
cases NN O O
are NN O O
morphologically NN O O
similar NN O O
to NN O O
normal NN O O
outer NN O O
segments NN O O
. NN O O

Moreover NN O O
, NN O O
the NN O O
re NN O O
- NN O O
establishment NN O O
of NN O O
the NN O O
structural NN O O
integrity NN O O
of NN O O
the NN O O
photoreceptor NN O O
layer NN O O
also NN O O
results NN O O
in NN O O
electrophysiological NN O O
correction NN O O
. NN O O

These NN O O
studies NN O O
demonstrate NN O O
for NN O O
the NN O O
first NN O O
time NN O O
that NN O O
a NN O O
complex NN O O
ultrastructural NN O O
cell NN O O
defect NN O O
can NN O O
be NN O O
corrected NN O O
both NN O O
morphologically NN O O
and NN O O
functionally NN O O
by NN O O
in NN O O
vivo NN O O
gene NN O O
transfer NN O O
. NN O O
. NN O O

Mutations NN O O
in NN O O
the NN O O
fibrinogen NN O O
aalpha NN O O
gene NN O O
account NN O O
for NN O O
the NN O O
majority NN O O
of NN O O
cases NN O O
of NN O O
congenital NN O B-Disease
afibrinogenemia NN O I-Disease
. NN O O

Congenital NN O B-Disease
afibrinogenemia NN O I-Disease
is NN O O
a NN O O
rare NN O O
, NN O O
autosomal NN O B-Disease
, NN O I-Disease
recessive NN O I-Disease
disorder NN O I-Disease
characterized NN O O
by NN O O
the NN O O
complete NN O O
absence NN O O
of NN O O
detectable NN O O
fibrinogen NN O O
. NN O O

We NN O O
previously NN O O
identified NN O O
the NN O O
first NN O O
causative NN O O
mutations NN O O
in NN O O
a NN O O
nonconsanguineous NN O O
Swiss NN O O
family NN O O
; NN O O
the NN O O
4 NN O O
affected NN O O
persons NN O O
have NN O O
homozygous NN O O
deletions NN O O
of NN O O
approximately NN O O
11 NN O O
kb NN O O
of NN O O
the NN O O
fibrinogen NN O O
alpha NN O O
( NN O O
FGA NN O O
) NN O O
gene NN O O
. NN O O

Haplotype NN O O
data NN O O
implied NN O O
that NN O O
these NN O O
deletions NN O O
occurred NN O O
on NN O O
distinct NN O O
ancestral NN O O
chromosomes NN O O
, NN O O
suggesting NN O O
that NN O O
this NN O O
region NN O O
may NN O O
be NN O O
susceptible NN O O
to NN O O
deletion NN O O
by NN O O
a NN O O
common NN O O
mechanism NN O O
. NN O O

We NN O O
subsequently NN O O
showed NN O O
that NN O O
all NN O O
the NN O O
deletions NN O O
were NN O O
identical NN O O
to NN O O
the NN O O
base NN O O
pair NN O O
and NN O O
probably NN O O
resulted NN O O
from NN O O
a NN O O
nonhomologous NN O O
recombination NN O O
mediated NN O O
by NN O O
7 NN O O
- NN O O
bp NN O O
direct NN O O
repeats NN O O
. NN O O

In NN O O
this NN O O
study NN O O
, NN O O
we NN O O
have NN O O
collected NN O O
data NN O O
on NN O O
13 NN O O
additional NN O O
unrelated NN O O
patients NN O O
to NN O O
identify NN O O
the NN O O
causative NN O O
mutations NN O O
and NN O O
to NN O O
determine NN O O
the NN O O
prevalence NN O O
of NN O O
the NN O O
11 NN O O
- NN O O
kb NN O O
deletion NN O O
. NN O O

A NN O O
common NN O O
recurrent NN O O
mutation NN O O
, NN O O
at NN O O
the NN O O
donor NN O O
splice NN O O
site NN O O
of NN O O
FGA NN O O
intron NN O O
4 NN O O
( NN O O
IVS4 NN O O
+ NN O O
1 NN O O
G NN O O
> NN O O
T NN O O
) NN O O
, NN O O
accounted NN O O
for NN O O
14 NN O O
of NN O O
the NN O O
26 NN O O
( NN O O
54 NN O O
% NN O O
) NN O O
alleles NN O O
. NN O O

One NN O O
patient NN O O
was NN O O
heterozygous NN O O
for NN O O
the NN O O
previously NN O O
identified NN O O
deletion NN O O
. NN O O

Three NN O O
more NN O O
frameshift NN O O
mutations NN O O
, NN O O
2 NN O O
nonsense NN O O
mutations NN O O
, NN O O
and NN O O
a NN O O
second NN O O
splice NN O O
site NN O O
mutation NN O O
were NN O O
also NN O O
identified NN O O
. NN O O

Consequently NN O O
, NN O O
86 NN O O
% NN O O
of NN O O
afibrinogenemia NN O B-Disease
alleles NN O O
analyzed NN O O
to NN O O
date NN O O
have NN O O
truncating NN O O
mutations NN O O
of NN O O
FGA NN O O
, NN O O
though NN O O
mutations NN O O
in NN O O
all NN O O
3 NN O O
fibrinogen NN O O
genes NN O O
, NN O O
FGG NN O O
, NN O O
FGA NN O O
, NN O O
and NN O O
FGB NN O O
, NN O O
might NN O O
be NN O O
predicted NN O O
to NN O O
cause NN O O
congenital NN O B-Disease
afibrinogenemia NN O I-Disease
. NN O O
. NN O O

Myotonic NN O B-Disease
dystrophy NN O I-Disease
: NN O O
the NN O O
role NN O O
of NN O O
the NN O O
CUG NN O O
triplet NN O O
repeats NN O O
in NN O O
splicing NN O O
of NN O O
a NN O O
novel NN O O
DMPK NN O O
exon NN O O
and NN O O
altered NN O O
cytoplasmic NN O O
DMPK NN O O
mRNA NN O O
isoform NN O O
ratios NN O O
. NN O O

The NN O O
mechanism NN O O
by NN O O
which NN O O
( NN O O
CTG NN O O
) NN O O
n NN O O
expansion NN O O
in NN O O
the NN O O
3 NN O O
UTR NN O O
of NN O O
the NN O O
DMPK NN O O
gene NN O O
causes NN O O
myotonic NN O B-Disease
dystrophy NN O I-Disease
( NN O O
DM NN O B-Disease
) NN O O
is NN O O
unknown NN O O
. NN O O

We NN O O
identified NN O O
four NN O O
RNA NN O O
splicing NN O O
factors NN O O
- NN O O
- NN O O
hnRNP NN O O
C NN O O
, NN O O
U2AF NN O O
( NN O O
U2 NN O O
auxiliary NN O O
factor NN O O
) NN O O
, NN O O
PTB NN O O
( NN O O
polypyrimidine NN O O
tract NN O O
binding NN O O
protein NN O O
) NN O O
, NN O O
and NN O O
PSF NN O O
( NN O O
PTB NN O O
associated NN O O
splicing NN O O
factor NN O O
) NN O O
- NN O O
- NN O O
that NN O O
bind NN O O
to NN O O
two NN O O
short NN O O
regions NN O O
3 NN O O
of NN O O
the NN O O
( NN O O
CUG NN O O
) NN O O
n NN O O
, NN O O
and NN O O
found NN O O
a NN O O
novel NN O O
3 NN O O
DMPK NN O O
exon NN O O
resulting NN O O
in NN O O
an NN O O
mRNA NN O O
lacking NN O O
the NN O O
repeats NN O O
. NN O O

We NN O O
propose NN O O
that NN O O
the NN O O
( NN O O
CUG NN O O
) NN O O
n NN O O
is NN O O
an NN O O
essential NN O O
cis NN O O
acting NN O O
element NN O O
for NN O O
this NN O O
splicing NN O O
event NN O O
. NN O O

In NN O O
contrast NN O O
to NN O O
( NN O O
CUG NN O O
) NN O O
n NN O O
containing NN O O
mRNAs NN O O
, NN O O
the NN O O
novel NN O O
isoform NN O O
is NN O O
not NN O O
retained NN O O
in NN O O
the NN O O
nucleus NN O O
in NN O O
DM NN O B-Disease
cells NN O O
, NN O O
resulting NN O O
in NN O O
imbalances NN O O
in NN O O
relative NN O O
levels NN O O
of NN O O
cytoplasmic NN O O
DMPK NN O O
mRNA NN O O
isoforms NN O O
and NN O O
a NN O O
new NN O O
dominant NN O O
effect NN O O
of NN O O
the NN O O
mutation NN O O
on NN O O
DMPK NN O O
. NN O O
. NN O O

Expression NN O O
and NN O O
imprinting NN O O
of NN O O
MAGEL2 NN O O
suggest NN O O
a NN O O
role NN O O
in NN O O
Prader NN O B-Disease
- NN O I-Disease
willi NN O I-Disease
syndrome NN O I-Disease
and NN O O
the NN O O
homologous NN O O
murine NN O O
imprinting NN O O
phenotype NN O O
. NN O O

Prader NN O B-Disease
- NN O I-Disease
Willi NN O I-Disease
syndrome NN O I-Disease
( NN O O
PWS NN O B-Disease
) NN O O
is NN O O
caused NN O O
by NN O O
the NN O O
loss NN O O
of NN O O
expression NN O O
of NN O O
imprinted NN O O
genes NN O O
in NN O O
chromosome NN O O
15q11 NN O O
- NN O O
q13 NN O O
. NN O O

Affected NN O O
individuals NN O O
exhibit NN O O
neonatal NN O B-Disease
hypotonia NN O I-Disease
, NN O O
developmental NN O B-Disease
delay NN O I-Disease
and NN O O
childhood NN O B-Disease
- NN O I-Disease
onset NN O I-Disease
obesity NN O I-Disease
. NN O O

Necdin NN O O
, NN O O
a NN O O
protein NN O O
implicated NN O O
in NN O O
the NN O O
terminal NN O O
differentiation NN O O
of NN O O
neurons NN O O
, NN O O
is NN O O
the NN O O
only NN O O
PWS NN O B-Disease
candidate NN O O
gene NN O O
to NN O O
reduce NN O O
viability NN O O
when NN O O
disrupted NN O O
in NN O O
a NN O O
mouse NN O O
model NN O O
. NN O O

In NN O O
this NN O O
study NN O O
, NN O O
we NN O O
have NN O O
characterized NN O O
MAGEL2 NN O O
( NN O O
also NN O O
known NN O O
as NN O O
NDNL1 NN O O
) NN O O
, NN O O
a NN O O
gene NN O O
with NN O O
51 NN O O
% NN O O
amino NN O O
acid NN O O
sequence NN O O
similarity NN O O
to NN O O
necdin NN O O
and NN O O
located NN O O
41 NN O O
kb NN O O
distal NN O O
to NN O O
NDN NN O O
in NN O O
the NN O O
PWS NN O B-Disease
deletion NN O O
region NN O O
. NN O O

MAGEL2 NN O O
is NN O O
expressed NN O O
predominantly NN O O
in NN O O
brain NN O O
, NN O O
the NN O O
primary NN O O
tissue NN O O
affected NN O O
in NN O O
PWS NN O B-Disease
and NN O O
in NN O O
several NN O O
fetal NN O O
tissues NN O O
as NN O O
shown NN O O
by NN O O
northern NN O O
blot NN O O
analysis NN O O
. NN O O

MAGEL2 NN O O
is NN O O
imprinted NN O O
with NN O O
monoallelic NN O O
expression NN O O
in NN O O
control NN O O
brain NN O O
, NN O O
and NN O O
paternal NN O O
- NN O O
only NN O O
expression NN O O
in NN O O
the NN O O
central NN O O
nervous NN O O
system NN O O
as NN O O
demonstrated NN O O
by NN O O
its NN O O
lack NN O O
of NN O O
expression NN O O
in NN O O
brain NN O O
from NN O O
a NN O O
PWS NN O B-Disease
- NN O O
affected NN O O
individual NN O O
. NN O O

The NN O O
orthologous NN O O
mouse NN O O
gene NN O O
( NN O O
Magel2 NN O O
) NN O O
is NN O O
located NN O O
within NN O O
150 NN O O
kb NN O O
of NN O O
NDN NN O O
, NN O O
is NN O O
imprinted NN O O
with NN O O
paternal NN O O
- NN O O
only NN O O
expression NN O O
and NN O O
is NN O O
expressed NN O O
predominantly NN O O
in NN O O
late NN O O
developmental NN O O
stages NN O O
and NN O O
adult NN O O
brain NN O O
as NN O O
shown NN O O
by NN O O
northern NN O O
blotting NN O O
, NN O O
RT NN O O
- NN O O
PCR NN O O
and NN O O
whole NN O O
- NN O O
mount NN O O
RNA NN O O
in NN O O
situ NN O O
hybridization NN O O
. NN O O

Magel2 NN O O
distribution NN O O
partially NN O O
overlaps NN O O
that NN O O
of NN O O
NDN NN O O
, NN O O
with NN O O
strong NN O O
expression NN O O
being NN O O
detected NN O O
in NN O O
the NN O O
central NN O O
nervous NN O O
system NN O O
in NN O O
mid NN O O
- NN O O
gestation NN O O
mouse NN O O
embryos NN O O
by NN O O
in NN O O
situ NN O O
hybridization NN O O
. NN O O

We NN O O
hypothesize NN O O
that NN O O
, NN O O
although NN O O
loss NN O O
of NN O O
necdin NN O O
expression NN O O
may NN O O
be NN O O
important NN O O
in NN O O
the NN O O
neonatal NN O O
presentation NN O O
of NN O O
PWS NN O B-Disease
, NN O O
loss NN O O
of NN O O
MAGEL2 NN O O
may NN O O
be NN O O
critical NN O O
to NN O O
abnormalities NN O B-Disease
in NN O I-Disease
brain NN O I-Disease
development NN O I-Disease
and NN O O
dysmorphic NN O B-Disease
features NN O I-Disease
in NN O O
individuals NN O O
with NN O O
PWS NN O B-Disease
. NN O O
. NN O O

Retinoschisin NN O O
, NN O O
the NN O O
X NN O B-Disease
- NN O I-Disease
linked NN O I-Disease
retinoschisis NN O I-Disease
protein NN O O
, NN O O
is NN O O
a NN O O
secreted NN O O
photoreceptor NN O O
protein NN O O
, NN O O
and NN O O
is NN O O
expressed NN O O
and NN O O
released NN O O
by NN O O
Weri NN O O
- NN O O
Rb1 NN O O
cells NN O O
. NN O O

X NN O B-Disease
- NN O I-Disease
linked NN O I-Disease
retinoschisis NN O I-Disease
is NN O O
characterized NN O O
by NN O O
microcystic NN O O
- NN O O
like NN O O
changes NN O O
of NN O O
the NN O O
macular NN O O
region NN O O
and NN O O
schisis NN O O
within NN O O
the NN O O
inner NN O O
retinal NN O O
layers NN O O
, NN O O
leading NN O O
to NN O O
visual NN O B-Disease
deterioration NN O I-Disease
in NN O O
males NN O O
. NN O O

Many NN O O
missense NN O O
and NN O O
protein NN O O
- NN O O
truncating NN O O
mutations NN O O
of NN O O
the NN O O
causative NN O O
gene NN O O
RS1 NN O O
have NN O O
now NN O O
been NN O O
identified NN O O
and NN O O
are NN O O
thought NN O O
to NN O O
be NN O O
inactivating NN O O
. NN O O

RS1 NN O O
encodes NN O O
a NN O O
224 NN O O
amino NN O O
acid NN O O
protein NN O O
, NN O O
retinoschisin NN O O
, NN O O
which NN O O
contains NN O O
a NN O O
discoidin NN O O
domain NN O O
but NN O O
is NN O O
of NN O O
unknown NN O O
function NN O O
. NN O O

We NN O O
have NN O O
generated NN O O
a NN O O
polyclonal NN O O
antibody NN O O
against NN O O
a NN O O
peptide NN O O
from NN O O
a NN O O
unique NN O O
region NN O O
within NN O O
retinoschisin NN O O
, NN O O
which NN O O
detects NN O O
a NN O O
protein NN O O
of NN O O
approximately NN O O
28 NN O O
kDa NN O O
in NN O O
retinal NN O O
samples NN O O
reduced NN O O
with NN O O
dithiothreitol NN O O
, NN O O
but NN O O
multimers NN O O
sized NN O O
> NN O O
40 NN O O
kDa NN O O
under NN O O
non NN O O
- NN O O
reducing NN O O
conditions NN O O
. NN O O

A NN O O
screen NN O O
of NN O O
human NN O O
tissues NN O O
with NN O O
this NN O O
antibody NN O O
reveals NN O O
retinoschisin NN O O
to NN O O
be NN O O
retina NN O O
specific NN O O
and NN O O
the NN O O
antibody NN O O
detects NN O O
a NN O O
protein NN O O
of NN O O
similar NN O O
size NN O O
in NN O O
bovine NN O O
and NN O O
murine NN O O
retinae NN O O
. NN O O

We NN O O
investigated NN O O
the NN O O
expression NN O O
pattern NN O O
in NN O O
the NN O O
retina NN O O
of NN O O
both NN O O
RS1 NN O O
mRNA NN O O
( NN O O
using NN O O
in NN O O
situ NN O O
hybridization NN O O
with NN O O
riboprobes NN O O
) NN O O
and NN O O
retinoschisin NN O O
( NN O O
using NN O O
immunohistochemistry NN O O
) NN O O
. NN O O

The NN O O
antisense NN O O
riboprobe NN O O
detected NN O O
RS1 NN O O
mRNA NN O O
only NN O O
in NN O O
the NN O O
photoreceptor NN O O
layer NN O O
but NN O O
the NN O O
protein NN O O
product NN O O
of NN O O
the NN O O
gene NN O O
was NN O O
present NN O O
both NN O O
in NN O O
the NN O O
photoreceptors NN O O
and NN O O
within NN O O
the NN O O
inner NN O O
portions NN O O
of NN O O
the NN O O
retina NN O O
. NN O O

Furthermore NN O O
, NN O O
differentiated NN O O
retinoblastoma NN O B-Disease
cells NN O O
( NN O O
Weri NN O O
- NN O O
Rb1 NN O O
cells NN O O
) NN O O
were NN O O
found NN O O
to NN O O
express NN O O
RS1 NN O O
mRNA NN O O
and NN O O
to NN O O
release NN O O
retinoschisin NN O O
. NN O O

These NN O O
results NN O O
suggest NN O O
that NN O O
retinoschisin NN O O
is NN O O
released NN O O
by NN O O
photo NN O O
- NN O O
receptors NN O O
and NN O O
has NN O O
functions NN O O
within NN O O
the NN O O
inner NN O O
retinal NN O O
layers NN O O
. NN O O

Thus NN O O
, NN O O
X NN O B-Disease
- NN O I-Disease
linked NN O I-Disease
retinoschisis NN O I-Disease
is NN O O
caused NN O O
by NN O O
abnormalities NN O O
in NN O O
a NN O O
putative NN O O
secreted NN O O
photoreceptor NN O O
protein NN O O
and NN O O
is NN O O
the NN O O
first NN O O
example NN O O
of NN O O
a NN O O
secreted NN O O
photo NN O O
- NN O O
receptor NN O O
protein NN O O
associated NN O O
with NN O O
a NN O O
retinal NN O B-Disease
dystrophy NN O I-Disease
. NN O O
. NN O O

Study NN O O
of NN O O
the NN O O
voltage NN O O
- NN O O
gated NN O O
sodium NN O O
channel NN O O
beta NN O O
1 NN O O
subunit NN O O
gene NN O O
( NN O O
SCN1B NN O O
) NN O O
in NN O O
the NN O O
benign NN O B-Disease
familial NN O I-Disease
infantile NN O I-Disease
convulsions NN O I-Disease
syndrome NN O I-Disease
( NN O O
BFIC NN O B-Disease
) NN O O
. NN O O

Benign NN O B-Disease
familial NN O I-Disease
infantile NN O I-Disease
convulsions NN O I-Disease
( NN O O
BFIC NN O B-Disease
) NN O O
is NN O O
a NN O O
rare NN O O
autosomal NN O B-Disease
dominant NN O I-Disease
epilepsy NN O I-Disease
syndrome NN O I-Disease
. NN O O

This NN O O
syndrome NN O O
has NN O O
been NN O O
recently NN O O
described NN O O
in NN O O
Italian NN O O
and NN O O
French NN O O
pedigrees NN O O
. NN O O

Patients NN O O
present NN O O
with NN O O
partial NN O O
, NN O O
then NN O O
generalized NN O O
seizures NN O O
, NN O O
with NN O O
onset NN O O
at NN O O
age NN O O
three NN O O
months NN O O
. NN O O

The NN O O
seizures NN O O
usually NN O O
spontaneously NN O O
cease NN O O
after NN O O
one NN O O
year NN O O
without NN O O
treatment NN O O
, NN O O
leaving NN O O
no NN O O
neurological NN O B-Disease
abnormalities NN O I-Disease
. NN O O

We NN O O
have NN O O
mapped NN O O
BFIC NN O B-Disease
to NN O O
chromosome NN O O
19q NN O O
in NN O O
five NN O O
Italian NN O O
pedigrees NN O O
. NN O O

The NN O O
sodium NN O O
channel NN O O
beta1 NN O O
subunit NN O O
gene NN O O
( NN O O
SCN1B NN O O
) NN O O
maps NN O O
to NN O O
this NN O O
candidate NN O O
region NN O O
and NN O O
has NN O O
been NN O O
shown NN O O
to NN O O
be NN O O
involved NN O O
in NN O O
one NN O O
Australian NN O O
pedigree NN O O
with NN O O
generalized NN O B-Disease
epilepsy NN O I-Disease
and NN O I-Disease
febrile NN O I-Disease
seizures NN O I-Disease
" NN O I-Disease
plus NN O I-Disease
" NN O I-Disease
( NN O O
GEFS NN O O
+ NN O O
) NN O O
. NN O O

In NN O O
this NN O O
family NN O O
, NN O O
a NN O O
missense NN O O
mutation NN O O
in NN O O
SCN1B NN O O
cosegregates NN O O
with NN O O
the NN O O
GEFS NN O O
+ NN O O
phenotype NN O O
. NN O O

BFIC NN O B-Disease
and NN O O
GEFS NN O O
+ NN O O
have NN O O
clinical NN O O
features NN O O
in NN O O
common NN O O
, NN O O
therefore NN O O
SCN1B NN O O
is NN O O
a NN O O
candidate NN O O
gene NN O O
for NN O O
BFIC NN O B-Disease
. NN O O

We NN O O
studied NN O O
SCN1B NN O O
exons NN O O
1 NN O O
, NN O O
2 NN O O
, NN O O
3 NN O O
, NN O O
4 NN O O
, NN O O
and NN O O
5 NN O O
, NN O O
using NN O O
four NN O O
SSCP NN O O
methods NN O O
in NN O O
10 NN O O
Caucasian NN O O
BFIC NN O B-Disease
probands NN O O
of NN O O
Western NN O O
Europe NN O O
. NN O O

We NN O O
found NN O O
no NN O O
exon NN O O
variants NN O O
. NN O O

One NN O O
variant NN O O
was NN O O
identified NN O O
in NN O O
intron NN O O
5 NN O O
( NN O O
IVS5 NN O O
- NN O O
10C NN O O
> NN O O
G NN O O
) NN O O
, NN O O
which NN O O
did NN O O
not NN O O
segregate NN O O
with NN O O
BFIC NN O B-Disease
and NN O O
was NN O O
observed NN O O
in NN O O
9 NN O O
. NN O O

2 NN O O
% NN O O
controls NN O O
. NN O O

A NN O O
second NN O O
variant NN O O
in NN O O
intron NN O O
5 NN O O
was NN O O
identified NN O O
( NN O O
IVS5 NN O O
+ NN O O
30G NN O O
> NN O O
A NN O O
) NN O O
. NN O O

It NN O O
was NN O O
rare NN O O
, NN O O
as NN O O
not NN O O
observed NN O O
in NN O O
controls NN O O
, NN O O
but NN O O
not NN O O
segregating NN O O
with NN O O
the NN O O
BFIC NN O B-Disease
phenotype NN O O
. NN O O

Inactivation NN O O
of NN O O
germline NN O O
mutant NN O O
APC NN O B-Disease
alleles NN O O
by NN O O
attenuated NN O O
somatic NN O O
mutations NN O O
: NN O O
a NN O O
molecular NN O O
genetic NN O O
mechanism NN O O
for NN O O
attenuated NN O B-Disease
familial NN O I-Disease
adenomatous NN O I-Disease
polyposis NN O I-Disease
. NN O O

Germline NN O O
mutations NN O O
of NN O O
the NN O O
adenomatous NN O B-Disease
polyposis NN O I-Disease
coli NN O I-Disease
( NN O I-Disease
APC NN O I-Disease
) NN O I-Disease
tumor NN O I-Disease
- NN O O
suppressor NN O O
gene NN O O
result NN O O
in NN O O
familial NN O B-Disease
adenomatous NN O I-Disease
polyposis NN O I-Disease
( NN O O
FAP NN O B-Disease
) NN O O
. NN O O

Patients NN O O
with NN O O
FAP NN O B-Disease
typically NN O O
develop NN O O
hundreds NN O O
to NN O O
thousands NN O O
of NN O O
benign NN O B-Disease
colorectal NN O I-Disease
tumors NN O I-Disease
and NN O O
early NN O O
- NN O O
onset NN O O
colorectal NN O B-Disease
cancer NN O I-Disease
. NN O O

A NN O O
subset NN O O
of NN O O
germline NN O O
APC NN O B-Disease
mutations NN O O
results NN O O
in NN O O
an NN O O
attenuated NN O B-Disease
FAP NN O I-Disease
( NN O O
AFAP NN O B-Disease
) NN O O
phenotype NN O O
, NN O O
in NN O O
which NN O O
patients NN O O
develop NN O O
fewer NN O O
tumors NN O B-Disease
and NN O O
develop NN O O
them NN O O
at NN O O
an NN O O
older NN O O
age NN O O
. NN O O

Although NN O O
a NN O O
genotype NN O O
- NN O O
phenotype NN O O
correlation NN O O
between NN O O
the NN O O
locations NN O O
of NN O O
APC NN O B-Disease
germline NN O O
mutations NN O O
and NN O O
the NN O O
development NN O O
of NN O O
AFAP NN O B-Disease
has NN O O
been NN O O
well NN O O
documented NN O O
, NN O O
the NN O O
mechanism NN O O
for NN O O
AFAP NN O B-Disease
has NN O O
not NN O O
been NN O O
well NN O O
defined NN O O
. NN O O

We NN O O
investigated NN O O
the NN O O
mechanism NN O O
for NN O O
AFAP NN O B-Disease
in NN O O
patients NN O O
carrying NN O O
a NN O O
mutant NN O O
APC NN O B-Disease
allele NN O O
( NN O O
APC NN O O
( NN O O
AS9 NN O O
) NN O O
) NN O O
that NN O O
has NN O O
a NN O O
mutation NN O O
in NN O O
the NN O O
alternatively NN O O
spliced NN O O
region NN O O
of NN O O
exon NN O O
9 NN O O
. NN O O

APC NN O O
( NN O O
AS9 NN O O
) NN O O
was NN O O
found NN O O
to NN O O
down NN O O
- NN O O
regulate NN O O
beta NN O O
- NN O O
catenin NN O O
- NN O O
regulated NN O O
transcription NN O O
, NN O O
the NN O O
major NN O O
tumor NN O B-Disease
- NN O O
suppressor NN O O
function NN O O
of NN O O
APC NN O O
, NN O O
as NN O O
did NN O O
the NN O O
wild NN O O
- NN O O
type NN O O
APC NN O O
. NN O O

Mutation NN O O
analysis NN O O
showed NN O O
that NN O O
both NN O O
APC NN O O
( NN O O
AS9 NN O O
) NN O O
and NN O O
the NN O O
wild NN O O
- NN O O
type NN O O
APC NN O B-Disease
alleles NN O O
were NN O O
somatically NN O O
mutated NN O O
in NN O O
most NN O O
colorectal NN O B-Disease
tumors NN O I-Disease
from NN O O
these NN O O
patients NN O O
. NN O O

Functional NN O O
analysis NN O O
showed NN O O
that NN O O
4666insA NN O O
, NN O O
a NN O O
common NN O O
somatic NN O O
mutation NN O O
in NN O O
APC NN O O
( NN O O
AS9 NN O O
) NN O O
in NN O O
these NN O O
tumors NN O B-Disease
, NN O O
did NN O O
not NN O O
inactivate NN O O
the NN O O
wild NN O O
- NN O O
type NN O O
APC NN O O
. NN O O

Our NN O O
results NN O O
indicate NN O O
that NN O O
carriers NN O O
of NN O O
APC NN O O
( NN O O
AS9 NN O O
) NN O O
develop NN O O
fewer NN O O
colorectal NN O B-Disease
tumors NN O I-Disease
than NN O O
do NN O O
typical NN O O
patients NN O O
with NN O O
FAP NN O B-Disease
because NN O O
somatic NN O O
inactivation NN O O
of NN O O
both NN O O
APC NN O B-Disease
alleles NN O O
is NN O O
necessary NN O O
for NN O O
colorectal NN O O
tumorigenesis NN O O
. NN O O

However NN O O
, NN O O
these NN O O
patients NN O O
develop NN O O
colorectal NN O B-Disease
tumors NN O I-Disease
more NN O O
frequently NN O O
than NN O O
does NN O O
the NN O O
general NN O O
population NN O O
because NN O O
APC NN O O
( NN O O
AS9 NN O O
) NN O O
is NN O O
inactivated NN O O
by NN O O
mutations NN O O
that NN O O
do NN O O
not NN O O
inactivate NN O O
the NN O O
wild NN O O
- NN O O
type NN O O
APC NN O O
. NN O O
. NN O O

Iron NN O O
- NN O O
dependent NN O O
self NN O O
- NN O O
assembly NN O O
of NN O O
recombinant NN O O
yeast NN O O
frataxin NN O O
: NN O O
implications NN O O
for NN O O
Friedreich NN O B-Disease
ataxia NN O I-Disease
. NN O O

Frataxin NN O B-Disease
deficiency NN O I-Disease
is NN O O
the NN O O
primary NN O O
cause NN O O
of NN O O
Friedreich NN O B-Disease
ataxia NN O I-Disease
( NN O O
FRDA NN O B-Disease
) NN O O
, NN O O
an NN O O
autosomal NN O B-Disease
recessive NN O I-Disease
cardiodegenerative NN O I-Disease
and NN O I-Disease
neurodegenerative NN O I-Disease
disease NN O I-Disease
. NN O O

Frataxin NN O O
is NN O O
a NN O O
nuclear NN O O
- NN O O
encoded NN O O
mitochondrial NN O O
protein NN O O
that NN O O
is NN O O
widely NN O O
conserved NN O O
among NN O O
eukaryotes NN O O
. NN O O

Genetic NN O O
inactivation NN O O
of NN O O
the NN O O
yeast NN O O
frataxin NN O O
homologue NN O O
( NN O O
Yfh1p NN O O
) NN O O
results NN O O
in NN O O
mitochondrial NN O B-Disease
iron NN O I-Disease
accumulation NN O I-Disease
and NN O O
hypersensitivity NN O B-Disease
to NN O I-Disease
oxidative NN O I-Disease
stress NN O I-Disease
. NN O O

Increased NN O O
iron NN O O
deposition NN O O
and NN O O
evidence NN O O
of NN O O
oxidative NN O O
damage NN O O
have NN O O
also NN O O
been NN O O
observed NN O O
in NN O O
cardiac NN O O
tissue NN O O
and NN O O
cultured NN O O
fibroblasts NN O O
from NN O O
patients NN O O
with NN O O
FRDA NN O B-Disease
. NN O O

These NN O O
findings NN O O
indicate NN O O
that NN O O
frataxin NN O O
is NN O O
essential NN O O
for NN O O
mitochondrial NN O O
iron NN O O
homeostasis NN O O
and NN O O
protection NN O O
from NN O O
iron NN O O
- NN O O
induced NN O O
formation NN O O
of NN O O
free NN O O
radicals NN O O
. NN O O

The NN O O
functional NN O O
mechanism NN O O
of NN O O
frataxin NN O O
, NN O O
however NN O O
, NN O O
is NN O O
still NN O O
unknown NN O O
. NN O O

We NN O O
have NN O O
expressed NN O O
the NN O O
mature NN O O
form NN O O
of NN O O
Yfh1p NN O O
( NN O O
mYfh1p NN O O
) NN O O
in NN O O
Escherichia NN O O
coli NN O O
and NN O O
have NN O O
analyzed NN O O
its NN O O
function NN O O
in NN O O
vitro NN O O
. NN O O

Isolated NN O O
mYfh1p NN O O
is NN O O
a NN O O
soluble NN O O
monomer NN O O
( NN O O
13 NN O O
, NN O O
783 NN O O
Da NN O O
) NN O O
that NN O O
contains NN O O
no NN O O
iron NN O O
and NN O O
shows NN O O
no NN O O
significant NN O O
tendency NN O O
to NN O O
self NN O O
- NN O O
associate NN O O
. NN O O

Aerobic NN O O
addition NN O O
of NN O O
ferrous NN O O
iron NN O O
to NN O O
mYfh1p NN O O
results NN O O
in NN O O
assembly NN O O
of NN O O
regular NN O O
spherical NN O O
multimers NN O O
with NN O O
a NN O O
molecular NN O O
mass NN O O
of NN O O
approximately NN O O
1 NN O O
. NN O O

1 NN O O
MDa NN O O
( NN O O
megadaltons NN O O
) NN O O
and NN O O
a NN O O
diameter NN O O
of NN O O
13 NN O O
+ NN O O
/ NN O O
- NN O O
2 NN O O
nm NN O O
. NN O O

Each NN O O
multimer NN O O
consists NN O O
of NN O O
approximately NN O O
60 NN O O
subunits NN O O
and NN O O
can NN O O
sequester NN O O
> NN O O
3 NN O O
, NN O O
000 NN O O
atoms NN O O
of NN O O
iron NN O O
. NN O O

Titration NN O O
of NN O O
mYfh1p NN O O
with NN O O
increasing NN O O
iron NN O O
concentrations NN O O
supports NN O O
a NN O O
stepwise NN O O
mechanism NN O O
of NN O O
multimer NN O O
assembly NN O O
. NN O O

Sequential NN O O
addition NN O O
of NN O O
an NN O O
iron NN O O
chelator NN O O
and NN O O
a NN O O
reducing NN O O
agent NN O O
results NN O O
in NN O O
quantitative NN O O
iron NN O O
release NN O O
with NN O O
concomitant NN O O
disassembly NN O O
of NN O O
the NN O O
multimer NN O O
, NN O O
indicating NN O O
that NN O O
mYfh1p NN O O
sequesters NN O O
iron NN O O
in NN O O
an NN O O
available NN O O
form NN O O
. NN O O

In NN O O
yeast NN O O
mitochondria NN O O
, NN O O
native NN O O
mYfh1p NN O O
exists NN O O
as NN O O
monomer NN O O
and NN O O
a NN O O
higher NN O O
- NN O O
order NN O O
species NN O O
with NN O O
a NN O O
molecular NN O O
weight NN O O
> NN O O
600 NN O O
, NN O O
000 NN O O
. NN O O

After NN O O
addition NN O O
of NN O O
( NN O O
55 NN O O
) NN O O
Fe NN O O
to NN O O
the NN O O
medium NN O O
, NN O O
immunoprecipitates NN O O
of NN O O
this NN O O
species NN O O
contain NN O O
> NN O O
16 NN O O
atoms NN O O
of NN O O
( NN O O
55 NN O O
) NN O O
Fe NN O O
per NN O O
molecule NN O O
of NN O O
mYfh1p NN O O
. NN O O

We NN O O
propose NN O O
that NN O O
iron NN O O
- NN O O
dependent NN O O
self NN O O
- NN O O
assembly NN O O
of NN O O
recombinant NN O O
mYfh1p NN O O
reflects NN O O
a NN O O
physiological NN O O
role NN O O
for NN O O
frataxin NN O O
in NN O O
mitochondrial NN O O
iron NN O O
sequestration NN O O
and NN O O
bioavailability NN O O
. NN O O
. NN O O

A NN O O
mutation NN O O
in NN O O
the NN O O
pleckstrin NN O O
homology NN O O
( NN O O
PH NN O O
) NN O O
domain NN O O
of NN O O
the NN O O
FGD1 NN O O
gene NN O O
in NN O O
an NN O O
Italian NN O O
family NN O O
with NN O O
faciogenital NN O B-Disease
dysplasia NN O I-Disease
( NN O O
Aarskog NN O B-Disease
- NN O I-Disease
Scott NN O I-Disease
syndrome NN O I-Disease
) NN O O
. NN O O

Aarskog NN O B-Disease
- NN O I-Disease
Scott NN O I-Disease
Syndrome NN O I-Disease
( NN O O
AAS NN O B-Disease
) NN O O
is NN O O
an NN O O
X NN O B-Disease
- NN O I-Disease
linked NN O I-Disease
disorder NN O I-Disease
characterised NN O O
by NN O O
short NN O B-Disease
stature NN O I-Disease
and NN O O
multiple NN O O
facial NN O B-Disease
, NN O I-Disease
limb NN O I-Disease
and NN O I-Disease
genital NN O I-Disease
abnormalities NN O I-Disease
. NN O O

A NN O O
gene NN O O
, NN O O
FGD1 NN O O
, NN O O
altered NN O O
in NN O O
a NN O O
patient NN O O
with NN O O
AAS NN O B-Disease
phenotype NN O O
, NN O O
has NN O O
been NN O O
identified NN O O
and NN O O
found NN O O
to NN O O
encode NN O O
a NN O O
protein NN O O
with NN O O
homology NN O O
to NN O O
Rho NN O O
/ NN O O
Rac NN O O
guanine NN O O
nucleotide NN O O
exchange NN O O
factors NN O O
( NN O O
Rho NN O O
/ NN O O
Rac NN O O
GEF NN O O
) NN O O
. NN O O

However NN O O
, NN O O
since NN O O
this NN O O
original NN O O
report NN O O
on NN O O
identification NN O O
of NN O O
a NN O O
mutated NN O O
FGD1 NN O O
gene NN O O
in NN O O
an NN O O
AAS NN O B-Disease
patient NN O O
, NN O O
no NN O O
additional NN O O
mutations NN O O
in NN O O
the NN O O
FGD1 NN O O
gene NN O O
have NN O O
been NN O O
described NN O O
. NN O O

We NN O O
analysed NN O O
13 NN O O
independent NN O O
patients NN O O
with NN O O
clinical NN O O
diagnosis NN O O
of NN O O
AAS NN O B-Disease
. NN O O

One NN O O
patient NN O O
presented NN O O
a NN O O
mutation NN O O
that NN O O
results NN O O
in NN O O
a NN O O
nucleotide NN O O
change NN O O
in NN O O
exon NN O O
10 NN O O
of NN O O
the NN O O
FGD1 NN O O
gene NN O O
( NN O O
G2559 NN O O
> NN O O
A NN O O
) NN O O
substituting NN O O
a NN O O
Gln NN O O
for NN O O
Arg NN O O
in NN O O
position NN O O
610 NN O O
. NN O O

The NN O O
mutation NN O O
was NN O O
found NN O O
to NN O O
segregate NN O O
with NN O O
the NN O O
AAS NN O B-Disease
phenotype NN O O
in NN O O
affected NN O O
males NN O O
and NN O O
carrier NN O O
females NN O O
in NN O O
the NN O O
family NN O O
of NN O O
this NN O O
patient NN O O
. NN O O

Interestingly NN O O
, NN O O
Arg NN O O
- NN O O
610 NN O O
is NN O O
located NN O O
within NN O O
one NN O O
of NN O O
the NN O O
two NN O O
pleckstrin NN O O
homology NN O O
( NN O O
PH NN O O
) NN O O
domains NN O O
of NN O O
the NN O O
FGD1 NN O O
gene NN O O
and NN O O
it NN O O
corresponds NN O O
to NN O O
a NN O O
highly NN O O
conserved NN O O
residue NN O O
which NN O O
has NN O O
been NN O O
involved NN O O
in NN O O
InsP NN O O
binding NN O O
in NN O O
PH NN O O
domains NN O O
of NN O O
other NN O O
proteins NN O O
. NN O O

The NN O O
same NN O O
residue NN O O
is NN O O
often NN O O
mutated NN O O
in NN O O
the NN O O
Brutons NN O O
tyrosine NN O O
kinase NN O O
( NN O O
Btk NN O O
) NN O O
gene NN O O
in NN O O
patients NN O O
with NN O O
an NN O O
X NN O B-Disease
- NN O I-Disease
linked NN O I-Disease
agammaglobulinemia NN O I-Disease
. NN O O

The NN O O
Arg610Gln NN O O
mutation NN O O
represents NN O O
the NN O O
first NN O O
case NN O O
of NN O O
a NN O O
mutation NN O O
in NN O O
the NN O O
PH NN O O
domain NN O O
of NN O O
the NN O O
FGD1 NN O O
gene NN O O
and NN O O
additional NN O O
evidence NN O O
that NN O O
mutations NN O O
in NN O O
PH NN O O
domains NN O O
can NN O O
be NN O O
associated NN O O
to NN O O
human NN O O
diseases NN O O
. NN O O
. NN O O

Amino NN O O
- NN O O
terminal NN O O
fragments NN O O
of NN O O
mutant NN O O
huntingtin NN O O
show NN O O
selective NN O O
accumulation NN O O
in NN O O
striatal NN O O
neurons NN O O
and NN O O
synaptic NN O O
toxicity NN O O
. NN O O

Huntington NN O B-Disease
disease NN O I-Disease
( NN O O
HD NN O B-Disease
) NN O O
is NN O O
caused NN O O
by NN O O
expansion NN O O
of NN O O
a NN O O
glutamine NN O O
repeat NN O O
in NN O O
the NN O O
amino NN O O
- NN O O
terminal NN O O
region NN O O
of NN O O
huntingtin NN O O
. NN O O

Despite NN O O
its NN O O
widespread NN O O
expression NN O O
, NN O O
mutant NN O O
huntingtin NN O O
induces NN O O
selective NN O O
neuronal NN O O
loss NN O O
in NN O O
striatal NN O O
neurons NN O O
. NN O O

Here NN O O
we NN O O
report NN O O
that NN O O
, NN O O
in NN O O
mutant NN O O
mice NN O O
expressing NN O O
HD NN O B-Disease
repeats NN O O
, NN O O
the NN O O
production NN O O
and NN O O
aggregation NN O O
of NN O O
N NN O O
- NN O O
terminal NN O O
huntingtin NN O O
fragments NN O O
preferentially NN O O
occur NN O O
in NN O O
HD NN O B-Disease
- NN O O
affected NN O O
neurons NN O O
and NN O O
their NN O O
processes NN O O
and NN O O
axonal NN O O
terminals NN O O
. NN O O

N NN O O
- NN O O
terminal NN O O
fragments NN O O
of NN O O
mutant NN O O
huntingtin NN O O
form NN O O
aggregates NN O O
and NN O O
induce NN O O
neuritic NN O B-Disease
degeneration NN O I-Disease
in NN O O
cultured NN O O
striatal NN O O
neurons NN O O
. NN O O

N NN O O
- NN O O
terminal NN O O
mutant NN O O
huntingtin NN O O
also NN O O
binds NN O O
to NN O O
synaptic NN O O
vesicles NN O O
and NN O O
inhibits NN O O
their NN O O
glutamate NN O O
uptake NN O O
in NN O O
vitro NN O O
. NN O O

The NN O O
specific NN O O
processing NN O O
and NN O O
accumulation NN O O
of NN O O
toxic NN O O
fragments NN O O
of NN O O
N NN O O
- NN O O
terminal NN O O
huntingtin NN O O
in NN O O
HD NN O B-Disease
- NN O O
affected NN O O
striatal NN O O
neurons NN O O
, NN O O
especially NN O O
in NN O O
their NN O O
neuronal NN O O
processes NN O O
and NN O O
axonal NN O O
terminals NN O O
, NN O O
may NN O O
contribute NN O O
to NN O O
the NN O O
selective NN O O
neuropathology NN O O
of NN O O
HD NN O B-Disease
. NN O O
. NN O O

BRCA1 NN O O
is NN O O
associated NN O O
with NN O O
a NN O O
human NN O O
SWI NN O O
/ NN O O
SNF NN O O
- NN O O
related NN O O
complex NN O O
: NN O O
linking NN O O
chromatin NN O O
remodeling NN O O
to NN O O
breast NN O B-Disease
cancer NN O I-Disease
. NN O O

Germline NN O O
mutations NN O O
in NN O O
the NN O O
tumor NN O B-Disease
suppressor NN O O
gene NN O O
, NN O O
BRCA1 NN O O
, NN O O
predispose NN O O
individuals NN O O
to NN O O
breast NN O B-Disease
and NN O I-Disease
ovarian NN O I-Disease
cancers NN O I-Disease
. NN O O

Using NN O O
a NN O O
combination NN O O
of NN O O
affinity NN O O
- NN O O
and NN O O
conventional NN O O
chromatographic NN O O
techniques NN O O
, NN O O
we NN O O
have NN O O
isolated NN O O
a NN O O
predominant NN O O
form NN O O
of NN O O
a NN O O
multiprotein NN O O
BRCA1 NN O O
- NN O O
containing NN O O
complex NN O O
from NN O O
human NN O O
cells NN O O
displaying NN O O
chromatin NN O O
- NN O O
remodeling NN O O
activity NN O O
. NN O O

Mass NN O O
spectrometric NN O O
sequencing NN O O
of NN O O
components NN O O
of NN O O
this NN O O
complex NN O O
indicated NN O O
that NN O O
BRCA1 NN O O
is NN O O
associated NN O O
with NN O O
a NN O O
SWI NN O O
/ NN O O
SNF NN O O
- NN O O
related NN O O
complex NN O O
. NN O O

We NN O O
show NN O O
that NN O O
BRCA1 NN O O
can NN O O
directly NN O O
interact NN O O
with NN O O
the NN O O
BRG1 NN O O
subunit NN O O
of NN O O
the NN O O
SWI NN O O
/ NN O O
SNF NN O O
complex NN O O
. NN O O

Moreover NN O O
, NN O O
p53 NN O O
- NN O O
mediated NN O O
stimulation NN O O
of NN O O
transcription NN O O
by NN O O
BRCA1 NN O O
was NN O O
completely NN O O
abrogated NN O O
by NN O O
either NN O O
a NN O O
dominant NN O O
- NN O O
negative NN O O
mutant NN O O
of NN O O
BRG1 NN O O
or NN O O
the NN O O
cancer NN O B-Disease
- NN O O
causing NN O O
deletion NN O O
in NN O O
exon NN O O
11 NN O O
of NN O O
BRCA1 NN O O
. NN O O

These NN O O
findings NN O O
reveal NN O O
a NN O O
direct NN O O
function NN O O
for NN O O
BRCA1 NN O O
in NN O O
transcriptional NN O O
control NN O O
through NN O O
modulation NN O O
of NN O O
chromatin NN O O
structure NN O O
. NN O O
. NN O O

Asef NN O O
, NN O O
a NN O O
link NN O O
between NN O O
the NN O O
tumor NN O B-Disease
suppressor NN O O
APC NN O O
and NN O O
G NN O O
- NN O O
protein NN O O
signaling NN O O
. NN O O

The NN O O
adenomatous NN O B-Disease
polyposis NN O I-Disease
coli NN O I-Disease
gene NN O O
( NN O O
APC NN O O
) NN O O
is NN O O
mutated NN O O
in NN O O
familial NN O B-Disease
adenomatous NN O I-Disease
polyposis NN O I-Disease
and NN O O
in NN O O
sporadic NN O O
colorectal NN O B-Disease
tumors NN O I-Disease
. NN O O

Here NN O O
the NN O O
APC NN O B-Disease
gene NN O O
product NN O O
is NN O O
shown NN O O
to NN O O
bind NN O O
through NN O O
its NN O O
armadillo NN O O
repeat NN O O
domain NN O O
to NN O O
a NN O O
Rac NN O O
- NN O O
specific NN O O
guanine NN O O
nucleotide NN O O
exchange NN O O
factor NN O O
( NN O O
GEF NN O O
) NN O O
, NN O O
termed NN O O
Asef NN O O
. NN O O

Endogenous NN O O
APC NN O O
colocalized NN O O
with NN O O
Asef NN O O
in NN O O
mouse NN O O
colon NN O O
epithelial NN O O
cells NN O O
and NN O O
neuronal NN O O
cells NN O O
. NN O O

Furthermore NN O O
, NN O O
APC NN O O
enhanced NN O O
the NN O O
GEF NN O O
activity NN O O
of NN O O
Asef NN O O
and NN O O
stimulated NN O O
Asef NN O O
- NN O O
mediated NN O O
cell NN O O
flattening NN O O
, NN O O
membrane NN O O
ruffling NN O O
, NN O O
and NN O O
lamellipodia NN O O
formation NN O O
in NN O O
MDCK NN O O
cells NN O O
. NN O O

These NN O O
results NN O O
suggest NN O O
that NN O O
the NN O O
APC NN O O
- NN O O
Asef NN O O
complex NN O O
may NN O O
regulate NN O O
the NN O O
actin NN O O
cytoskeletal NN O O
network NN O O
, NN O O
cell NN O O
morphology NN O O
and NN O O
migration NN O O
, NN O O
and NN O O
neuronal NN O O
function NN O O
. NN O O
. NN O O

Function NN O O
of NN O O
an NN O O
axonal NN O O
chemoattractant NN O O
modulated NN O O
by NN O O
metalloprotease NN O O
activity NN O O
. NN O O

The NN O O
axonal NN O O
chemoattractant NN O O
netrin NN O O
- NN O O
1 NN O O
guides NN O O
spinal NN O O
commissural NN O O
axons NN O O
by NN O O
activating NN O O
its NN O O
receptor NN O O
DCC NN O O
( NN O O
Deleted NN O O
in NN O O
Colorectal NN O B-Disease
Cancer NN O I-Disease
) NN O O
. NN O O

We NN O O
have NN O O
found NN O O
that NN O O
chemical NN O O
inhibitors NN O O
of NN O O
metalloproteases NN O O
potentiate NN O O
netrin NN O O
- NN O O
mediated NN O O
axon NN O O
outgrowth NN O O
in NN O O
vitro NN O O
. NN O O

We NN O O
have NN O O
also NN O O
found NN O O
that NN O O
DCC NN O O
is NN O O
a NN O O
substrate NN O O
for NN O O
metalloprotease NN O O
- NN O O
dependent NN O O
ectodomain NN O O
shedding NN O O
, NN O O
and NN O O
that NN O O
the NN O O
inhibitors NN O O
block NN O O
proteolytic NN O O
processing NN O O
of NN O O
DCC NN O O
and NN O O
cause NN O O
an NN O O
increase NN O O
in NN O O
DCC NN O O
protein NN O O
levels NN O O
on NN O O
axons NN O O
within NN O O
spinal NN O O
cord NN O O
explants NN O O
. NN O O

Thus NN O O
, NN O O
potentiation NN O O
of NN O O
netrin NN O O
activity NN O O
by NN O O
inhibitors NN O O
may NN O O
result NN O O
from NN O O
stabilization NN O O
of NN O O
DCC NN O O
on NN O O
the NN O O
axons NN O O
, NN O O
and NN O O
proteolytic NN O O
activity NN O O
may NN O O
regulate NN O O
axon NN O O
migration NN O O
by NN O O
controlling NN O O
the NN O O
number NN O O
of NN O O
functional NN O O
extracellular NN O O
axon NN O O
guidance NN O O
receptors NN O O
. NN O O
. NN O O

Myotonic NN O B-Disease
dystrophy NN O I-Disease
in NN O O
transgenic NN O O
mice NN O O
expressing NN O O
an NN O O
expanded NN O O
CUG NN O O
repeat NN O O
. NN O O

Myotonic NN O B-Disease
dystrophy NN O I-Disease
( NN O O
DM NN O B-Disease
) NN O O
, NN O O
the NN O O
most NN O O
common NN O O
form NN O O
of NN O O
muscular NN O B-Disease
dystrophy NN O I-Disease
in NN O O
adult NN O O
humans NN O O
, NN O O
results NN O O
from NN O O
expansion NN O O
of NN O O
a NN O O
CTG NN O O
repeat NN O O
in NN O O
the NN O O
3 NN O O
untranslated NN O O
region NN O O
of NN O O
the NN O O
DMPK NN O O
gene NN O O
. NN O O

The NN O O
mutant NN O O
DMPK NN O O
messenger NN O O
RNA NN O O
( NN O O
mRNA NN O O
) NN O O
contains NN O O
an NN O O
expanded NN O O
CUG NN O O
repeat NN O O
and NN O O
is NN O O
retained NN O O
in NN O O
the NN O O
nucleus NN O O
. NN O O

We NN O O
have NN O O
expressed NN O O
an NN O O
untranslated NN O O
CUG NN O O
repeat NN O O
in NN O O
an NN O O
unrelated NN O O
mRNA NN O O
in NN O O
transgenic NN O O
mice NN O O
. NN O O

Mice NN O O
that NN O O
expressed NN O O
expanded NN O O
CUG NN O O
repeats NN O O
developed NN O O
myotonia NN O B-Disease
and NN O O
myopathy NN O B-Disease
, NN O O
whereas NN O O
mice NN O O
expressing NN O O
a NN O O
nonexpanded NN O O
repeat NN O O
did NN O O
not NN O O
. NN O O

Thus NN O O
, NN O O
transcripts NN O O
with NN O O
expanded NN O O
CUG NN O O
repeats NN O O
are NN O O
sufficient NN O O
to NN O O
generate NN O O
a NN O O
DM NN O B-Disease
phenotype NN O O
. NN O O

This NN O O
result NN O O
supports NN O O
a NN O O
role NN O O
for NN O O
RNA NN O O
gain NN O O
of NN O O
function NN O O
in NN O O
disease NN O O
pathogenesis NN O O
. NN O O
. NN O O

Genomic NN O O
rearrangements NN O O
of NN O O
the NN O O
APC NN O B-Disease
tumor NN O I-Disease
- NN O O
suppressor NN O O
gene NN O O
in NN O O
familial NN O B-Disease
adenomatous NN O I-Disease
polyposis NN O I-Disease
. NN O O

Germline NN O O
mutations NN O O
of NN O O
the NN O O
adenomatous NN O B-Disease
polyposis NN O I-Disease
coli NN O I-Disease
( NN O I-Disease
APC NN O I-Disease
) NN O I-Disease
tumor NN O I-Disease
- NN O O
suppressor NN O O
gene NN O O
result NN O O
in NN O O
the NN O O
hereditary NN O B-Disease
colorectal NN O I-Disease
cancer NN O I-Disease
syndrome NN O I-Disease
familial NN O B-Disease
adenomatous NN O I-Disease
polyposis NN O I-Disease
( NN O O
FAP NN O B-Disease
) NN O O
. NN O O

Almost NN O O
all NN O O
APC NN O B-Disease
mutations NN O O
that NN O O
have NN O O
been NN O O
identified NN O O
are NN O O
single NN O O
- NN O O
nucleotide NN O O
alterations NN O O
, NN O O
small NN O O
insertions NN O O
, NN O O
or NN O O
small NN O O
deletions NN O O
that NN O O
would NN O O
truncate NN O O
the NN O O
protein NN O O
product NN O O
of NN O O
the NN O O
gene NN O O
. NN O O

No NN O O
well NN O O
- NN O O
characterized NN O O
intragenic NN O O
rearrangement NN O O
of NN O O
APC NN O O
has NN O O
been NN O O
described NN O O
, NN O O
and NN O O
the NN O O
prevalence NN O O
of NN O O
this NN O O
type NN O O
of NN O O
mutation NN O O
in NN O O
FAP NN O B-Disease
patients NN O O
is NN O O
not NN O O
clear NN O O
. NN O O

We NN O O
screened NN O O
49 NN O O
potential NN O O
FAP NN O B-Disease
families NN O O
and NN O O
identified NN O O
26 NN O O
different NN O O
germline NN O O
APC NN O B-Disease
mutations NN O O
in NN O O
30 NN O O
families NN O O
. NN O O

Four NN O O
of NN O O
these NN O O
mutations NN O O
were NN O O
genomic NN O O
rearrangements NN O O
resulting NN O O
from NN O O
homologous NN O O
and NN O O
nonhomologous NN O O
recombinations NN O O
mediated NN O O
by NN O O
Alu NN O O
elements NN O O
. NN O O

Two NN O O
of NN O O
these NN O O
four NN O O
rearrangements NN O O
were NN O O
complex NN O O
, NN O O
involving NN O O
deletion NN O O
and NN O O
insertion NN O O
of NN O O
nucleotides NN O O
. NN O O

Of NN O O
these NN O O
four NN O O
rearrangements NN O O
, NN O O
one NN O O
resulted NN O O
in NN O O
the NN O O
deletion NN O O
of NN O O
exons NN O O
11 NN O O
and NN O O
12 NN O O
and NN O O
two NN O O
others NN O O
resulted NN O O
in NN O O
either NN O O
complete NN O O
or NN O O
partial NN O O
deletion NN O O
of NN O O
exon NN O O
14 NN O O
. NN O O

The NN O O
fourth NN O O
rearrangement NN O O
grossly NN O O
altered NN O O
the NN O O
sequence NN O O
within NN O O
intron NN O O
14 NN O O
. NN O O

Although NN O O
this NN O O
rearrangement NN O O
did NN O O
not NN O O
affect NN O O
any NN O O
coding NN O O
sequence NN O O
of NN O O
APC NN O O
at NN O O
the NN O O
genomic NN O O
DNA NN O O
level NN O O
, NN O O
it NN O O
caused NN O O
inappropriate NN O O
splicing NN O O
of NN O O
exon NN O O
14 NN O O
. NN O O

These NN O O
rearrangements NN O O
were NN O O
initially NN O O
revealed NN O O
by NN O O
analyzing NN O O
cDNAs NN O O
and NN O O
could NN O O
not NN O O
have NN O O
been NN O O
identified NN O O
by NN O O
using NN O O
mutation NN O O
detection NN O O
methods NN O O
that NN O O
screened NN O O
each NN O O
exon NN O O
individually NN O O
. NN O O

The NN O O
identification NN O O
of NN O O
a NN O O
rearrangement NN O O
that NN O O
did NN O O
not NN O O
alter NN O O
any NN O O
coding NN O O
exons NN O O
yet NN O O
affected NN O O
the NN O O
splicing NN O O
further NN O O
underscores NN O O
the NN O O
importance NN O O
of NN O O
using NN O O
cDNA NN O O
for NN O O
mutation NN O O
analysis NN O O
. NN O O

The NN O O
identification NN O O
of NN O O
four NN O O
genomic NN O O
rearrangements NN O O
among NN O O
30 NN O O
mutations NN O O
suggests NN O O
that NN O O
genomic NN O O
rearrangements NN O O
are NN O O
frequent NN O O
germline NN O O
APC NN O B-Disease
mutations NN O O
. NN O O
. NN O O

Detection NN O O
of NN O O
a NN O O
novel NN O O
missense NN O O
mutation NN O O
and NN O O
second NN O O
recurrent NN O O
mutation NN O O
in NN O O
the NN O O
CACNA1A NN O O
gene NN O O
in NN O O
individuals NN O O
with NN O O
EA NN O B-Disease
- NN O I-Disease
2 NN O I-Disease
and NN O O
FHM NN O B-Disease
. NN O O

Mutations NN O O
in NN O O
the NN O O
brain NN O O
specific NN O O
P NN O O
/ NN O O
Q NN O O
type NN O O
Ca2 NN O O
+ NN O O
channel NN O O
alpha1 NN O O
subunit NN O O
gene NN O O
, NN O O
CACNA1A NN O O
, NN O O
have NN O O
been NN O O
identified NN O O
in NN O O
three NN O O
clinically NN O O
distinct NN O O
disorders NN O O
, NN O O
viz NN O O
. NN O O
episodic NN O B-Disease
ataxia NN O I-Disease
type NN O I-Disease
2 NN O I-Disease
( NN O O
EA NN O B-Disease
- NN O I-Disease
2 NN O I-Disease
) NN O O
, NN O O
familial NN O B-Disease
hemiplegic NN O I-Disease
migraine NN O I-Disease
( NN O O
FHM NN O B-Disease
) NN O O
and NN O O
spinocerebellar NN O B-Disease
ataxia NN O I-Disease
6 NN O I-Disease
( NN O O
SCA6 NN O B-Disease
) NN O O
. NN O O

For NN O O
individuals NN O O
with NN O O
EA NN O B-Disease
- NN O I-Disease
2 NN O I-Disease
, NN O O
the NN O O
mutations NN O O
described NN O O
thus NN O O
far NN O O
are NN O O
presumed NN O O
to NN O O
result NN O O
in NN O O
a NN O O
truncated NN O O
protein NN O O
product NN O O
. NN O O

Several NN O O
different NN O O
missense NN O O
mutations NN O O
have NN O O
been NN O O
identified NN O O
in NN O O
patients NN O O
with NN O O
FHM NN O B-Disease
. NN O O

At NN O O
least NN O O
two NN O O
of NN O O
these NN O O
mutations NN O O
have NN O O
been NN O O
identified NN O O
on NN O O
two NN O O
different NN O O
chromosome NN O O
19p13 NN O O
haplotypes NN O O
and NN O O
thus NN O O
represent NN O O
recurrent NN O O
mutations NN O O
. NN O O

In NN O O
the NN O O
present NN O O
study NN O O
, NN O O
we NN O O
have NN O O
screened NN O O
several NN O O
individuals NN O O
for NN O O
mutations NN O O
in NN O O
all NN O O
47 NN O O
exons NN O O
in NN O O
the NN O O
CACNA1A NN O O
gene NN O O
by NN O O
single NN O O
- NN O O
strand NN O O
conformation NN O O
analysis NN O O
. NN O O

We NN O O
have NN O O
characterised NN O O
a NN O O
novel NN O O
missense NN O O
mutation NN O O
, NN O O
G5260A NN O O
, NN O O
in NN O O
exon NN O O
32 NN O O
in NN O O
a NN O O
family NN O O
segregating NN O O
for NN O O
EA NN O B-Disease
- NN O I-Disease
2 NN O I-Disease
. NN O O

The NN O O
consequence NN O O
of NN O O
this NN O O
mutation NN O O
is NN O O
an NN O O
amino NN O O
acid NN O O
substitution NN O O
at NN O O
a NN O O
highly NN O O
conserved NN O O
position NN O O
within NN O O
the NN O O
CACNA1A NN O O
gene NN O O
. NN O O

This NN O O
represents NN O O
the NN O O
first NN O O
point NN O O
mutation NN O O
not NN O O
resulting NN O O
in NN O O
a NN O O
proposed NN O O
truncated NN O O
protein NN O O
. NN O O

Furthermore NN O O
, NN O O
this NN O O
mutation NN O O
has NN O O
been NN O O
detected NN O O
in NN O O
a NN O O
family NN O O
member NN O O
with NN O O
mild NN O O
clinical NN O O
signs NN O O
including NN O O
only NN O O
migraine NN O B-Disease
. NN O O

Additionally NN O O
, NN O O
a NN O O
second NN O O
previously NN O O
identified NN O O
recurrent NN O O
muta NN O O
tion NN O O
, NN O O
C2272T NN O O
, NN O O
in NN O O
exon NN O O
16 NN O O
has NN O O
been NN O O
discovered NN O O
in NN O O
a NN O O
patient NN O O
with NN O O
FHM NN O B-Disease
. NN O O
. NN O O

Analbuminemia NN O B-Disease
in NN O O
a NN O O
neonate NN O O
. NN O O

A NN O O
small NN O O
- NN O O
for NN O O
- NN O O
gestational NN O O
- NN O O
age NN O O
infant NN O O
, NN O O
found NN O O
to NN O O
have NN O O
analbuminemia NN O B-Disease
in NN O O
the NN O O
neonatal NN O O
period NN O O
, NN O O
is NN O O
reported NN O O
and NN O O
the NN O O
twelve NN O O
cases NN O O
recorded NN O O
in NN O O
the NN O O
world NN O O
literature NN O O
are NN O O
reviewed NN O O
. NN O O

Patients NN O O
lacking NN O O
this NN O O
serum NN O O
protein NN O O
are NN O O
essentially NN O O
asymptomatic NN O O
, NN O O
apart NN O O
from NN O O
minimal NN O O
ankle NN O B-Disease
edema NN O I-Disease
and NN O O
ease NN O B-Disease
of NN O I-Disease
fatigue NN O I-Disease
. NN O O

Apparent NN O O
compensatory NN O O
mechanisms NN O O
which NN O O
come NN O O
into NN O O
play NN O O
when NN O O
serum NN O O
albumin NN O O
is NN O O
low NN O O
include NN O O
prolonged NN O O
half NN O O
- NN O O
life NN O O
of NN O O
albumin NN O O
and NN O O
transferrin NN O O
, NN O O
an NN O O
increase NN O O
in NN O O
serum NN O O
globulins NN O O
, NN O O
beta NN O O
lipoprotein NN O O
, NN O O
and NN O O
glycoproteins NN O O
, NN O O
arterial NN O B-Disease
hypotension NN O I-Disease
with NN O O
reduced NN O O
capillary NN O O
hydrostatic NN O O
pressure NN O O
, NN O O
and NN O O
the NN O O
ability NN O O
to NN O O
respond NN O O
with NN O O
rapid NN O O
sodium NN O O
and NN O O
chloride NN O O
diuresis NN O O
in NN O O
response NN O O
to NN O O
small NN O O
volume NN O O
changes NN O O
. NN O O

Examination NN O O
of NN O O
plasma NN O O
amino NN O O
acids NN O O
, NN O O
an NN O O
investigation NN O O
not NN O O
previously NN O O
reported NN O O
, NN O O
revealed NN O O
an NN O O
extremely NN O O
low NN O O
plasma NN O O
tryptophan NN O O
level NN O O
, NN O O
a NN O O
finding NN O O
which NN O O
may NN O O
be NN O O
important NN O O
in NN O O
view NN O O
of NN O O
the NN O O
role NN O O
of NN O O
tryptophan NN O O
in NN O O
albumin NN O O
synthesis NN O O
. NN O O
. NN O O

Histidinemia NN O B-Disease
. NN O O

Classical NN O O
and NN O O
atypical NN O O
form NN O O
in NN O O
siblings NN O O
. NN O O

Two NN O O
brothers NN O O
, NN O O
6 NN O O
and NN O O
13 NN O O
years NN O O
old NN O O
, NN O O
had NN O O
histidinemia NN O B-Disease
. NN O O

On NN O O
the NN O O
basis NN O O
of NN O O
clinical NN O O
and NN O O
biochemical NN O O
observations NN O O
, NN O O
the NN O O
younger NN O O
boy NN O O
was NN O O
considered NN O O
to NN O O
have NN O O
a NN O O
classical NN O O
type NN O O
of NN O O
the NN O O
disease NN O O
, NN O O
while NN O O
the NN O O
older NN O O
boy NN O O
had NN O O
an NN O O
atypical NN O O
form NN O O
characterized NN O O
by NN O O
partial NN O O
impairment NN O O
of NN O O
the NN O O
skin NN O O
histidase NN O O
activity NN O O
and NN O O
a NN O O
moderately NN O O
prolonged NN O O
half NN O O
- NN O O
life NN O O
of NN O O
blood NN O O
histidine NN O O
. NN O O

The NN O O
mother NN O O
is NN O O
a NN O O
heterozygous NN O O
carrier NN O O
, NN O O
while NN O O
the NN O O
father NN O O
and NN O O
sister NN O O
seem NN O O
to NN O O
be NN O O
normal NN O O
. NN O O
. NN O O

Carrier NN O O
detection NN O O
of NN O O
pyruvate NN O B-Disease
carboxylase NN O I-Disease
deficiency NN O I-Disease
in NN O O
fibroblasts NN O O
and NN O O
lymphocytes NN O O
. NN O O

Pyruvate NN O O
carboxylase NN O O
( NN O O
E NN O O
. NN O O
C NN O O
. NN O O
6 NN O O
. NN O O
4 NN O O
. NN O O
1 NN O O
. NN O O
1 NN O O
) NN O O
activity NN O O
was NN O O
determined NN O O
in NN O O
the NN O O
circulating NN O O
peripheral NN O O
lymphocytes NN O O
and NN O O
cultured NN O O
skin NN O O
fibroblasts NN O O
from NN O O
the NN O O
family NN O O
of NN O O
a NN O O
patient NN O O
with NN O O
hepatic NN O O
, NN O O
cerebral NN O O
, NN O O
renal NN O O
cortical NN O O
, NN O O
leukocyte NN O O
, NN O O
and NN O O
fibroblast NN O O
pyruvate NN O B-Disease
carboxylase NN O I-Disease
deficiency NN O I-Disease
( NN O O
PC NN O B-Disease
Portland NN O I-Disease
deficiency NN O I-Disease
) NN O O
. NN O O

Lymphocyte NN O O
activities NN O O
were NN O O
mother NN O O
, NN O O
33 NN O O
- NN O O
- NN O O
39 NN O O
% NN O O
; NN O O
father NN O O
, NN O O
11 NN O O
- NN O O
- NN O O
29 NN O O
% NN O O
; NN O O
brother NN O O
, NN O O
82 NN O O
- NN O O
- NN O O
103 NN O O
% NN O O
; NN O O
and NN O O
sister NN O O
, NN O O
38 NN O O
- NN O O
- NN O O
48 NN O O
% NN O O
of NN O O
the NN O O
lowest NN O O
normal NN O O
. NN O O

Fibroblasts NN O O
from NN O O
the NN O O
patients NN O O
mother NN O O
and NN O O
father NN O O
had NN O O
42 NN O O
and NN O O
34 NN O O
% NN O O
, NN O O
respectively NN O O
, NN O O
of NN O O
the NN O O
activity NN O O
of NN O O
the NN O O
lowest NN O O
normal NN O O
. NN O O

These NN O O
data NN O O
demonstrate NN O O
that NN O O
the NN O O
disease NN O O
is NN O O
inherited NN O O
in NN O O
an NN O O
autosomal NN O O
recessive NN O O
manner NN O O
and NN O O
that NN O O
lymphocytes NN O O
and NN O O
fibroblasts NN O O
can NN O O
be NN O O
used NN O O
to NN O O
detect NN O O
carriers NN O O
. NN O O

Neither NN O O
pyruvate NN O O
carboxylase NN O O
nor NN O O
mitochondrial NN O O
PEPCK NN O O
activity NN O O
in NN O O
lymphocytes NN O O
was NN O O
increased NN O O
by NN O O
a NN O O
21 NN O O
- NN O O
hr NN O O
fast NN O O
. NN O O

Glucose NN O O
- NN O O
6 NN O O
- NN O O
phosphate NN O O
dehydrogenase NN O O
variants NN O O
from NN O O
Italian NN O O
subjects NN O O
associated NN O O
with NN O O
severe NN O B-Disease
neonatal NN O I-Disease
jaundice NN O I-Disease
. NN O O

Screening NN O O
for NN O O
the NN O O
G6PD NN O B-Disease
deficiency NN O I-Disease
was NN O O
carried NN O O
out NN O O
at NN O O
the NN O O
Maternity NN O O
Division NN O O
of NN O O
the NN O O
Galliera NN O O
Hospital NN O O
in NN O O
Genoa NN O O
, NN O O
Italy NN O O
. NN O O

Two NN O O
groups NN O O
of NN O O
subjects NN O O
with NN O O
hyperbilirubinaemia NN O B-Disease
of NN O O
non NN O O
- NN O O
immunological NN O O
origin NN O O
were NN O O
examined NN O O
( NN O O
a NN O O
) NN O O
302 NN O O
newborn NN O O
babies NN O O
of NN O O
Sardinian NN O O
extraction NN O O
( NN O O
on NN O O
cord NN O O
blood NN O O
) NN O O
and NN O O
( NN O O
b NN O O
) NN O O
201 NN O O
newborn NN O O
babies NN O O
of NN O O
south NN O O
Italian NN O O
ancestry NN O O
( NN O O
on NN O O
peripheral NN O O
blood NN O O
) NN O O
. NN O O

Among NN O O
503 NN O O
subjects NN O O
, NN O O
43 NN O O
showed NN O O
an NN O O
enzyme NN O O
deficiency NN O O
; NN O O
in NN O O
39 NN O O
the NN O O
defect NN O O
was NN O O
of NN O O
the NN O O
Mediterranean NN O O
type NN O O
. NN O O

In NN O O
one NN O O
case NN O O
, NN O O
previously NN O O
described NN O O
, NN O O
the NN O O
enzyme NN O O
was NN O O
of NN O O
the NN O O
A NN O O
- NN O O
type NN O O
. NN O O

In NN O O
the NN O O
remaining NN O O
cases NN O O
three NN O O
different NN O O
variants NN O O
were NN O O
identified NN O O
. NN O O

In NN O O
the NN O O
present NN O O
work NN O O
these NN O O
three NN O O
cases NN O O
, NN O O
each NN O O
with NN O O
severe NN O B-Disease
neonatal NN O I-Disease
jaundice NN O I-Disease
, NN O O
are NN O O
reported NN O O
. NN O O

Their NN O O
parents NN O O
originated NN O O
from NN O O
Calabria NN O O
, NN O O
from NN O O
Sardinia NN O O
and NN O O
from NN O O
Sicily NN O O
. NN O O

The NN O O
abnormal NN O O
enzymes NN O O
are NN O O
respectively NN O O
designated NN O O
as NN O O
GdDcbrousse NN O O
- NN O O
like NN O O
, NN O O
GdGallura NN O O
and NN O O
GdAgrigento NN O O
. NN O O
. NN O O

Cytogenetic NN O O
investigations NN O O
in NN O O
families NN O O
with NN O O
ataxia NN O B-Disease
- NN O I-Disease
telangiectasia NN O I-Disease
. NN O O

Chromosomal NN O O
studies NN O O
were NN O O
performed NN O O
on NN O O
peripheral NN O O
blood NN O O
lymphocytes NN O O
and NN O O
cultured NN O O
skin NN O O
fibroblasts NN O O
from NN O O
five NN O O
Israeli NN O O
- NN O O
Moroccan NN O O
families NN O O
with NN O O
ataxia NN O B-Disease
- NN O I-Disease
telangiectasia NN O I-Disease
. NN O O

A NN O O
total NN O O
of NN O O
24 NN O O
individuals NN O O
, NN O O
including NN O O
seven NN O O
propositi NN O O
, NN O O
was NN O O
investigated NN O O
. NN O O

Among NN O O
the NN O O
probands NN O O
, NN O O
significantly NN O O
elevated NN O O
rates NN O O
of NN O O
chromosome NN O O
damage NN O O
were NN O O
observed NN O O
in NN O O
both NN O O
blood NN O O
and NN O O
skin NN O O
. NN O O

Skin NN O O
fibroblasts NN O O
of NN O O
affected NN O O
individuals NN O O
showed NN O O
several NN O O
orders NN O O
of NN O O
magnitude NN O O
more NN O O
chromosome NN O O
breakage NN O O
than NN O O
lymphocytes NN O O
. NN O O

Increased NN O O
rates NN O O
of NN O O
chromosome NN O O
damage NN O O
were NN O O
also NN O O
observed NN O O
in NN O O
the NN O O
fibroblasts NN O O
of NN O O
some NN O O
phenotypically NN O O
normal NN O O
family NN O O
members NN O O
( NN O O
obligate NN O O
heterozygotes NN O O
and NN O O
sibs NN O O
) NN O O
when NN O O
compared NN O O
to NN O O
normal NN O O
controls NN O O
. NN O O

An NN O O
apparent NN O O
abnormal NN O O
clone NN O O
of NN O O
cells NN O O
, NN O O
possessing NN O O
a NN O O
large NN O O
acrocentric NN O O
marker NN O O
chromosome NN O O
( NN O O
14q NN O O
+ NN O O
) NN O O
, NN O O
was NN O O
observed NN O O
in NN O O
varying NN O O
proportions NN O O
among NN O O
cells NN O O
of NN O O
all NN O O
the NN O O
propositi NN O O
( NN O O
2 NN O O
- NN O O
5 NN O O
% NN O O
of NN O O
lymphocytes NN O O
; NN O O
1 NN O O
- NN O O
9 NN O O
% NN O O
of NN O O
fibroblasts NN O O
) NN O O
. NN O O
. NN O O

Prenatal NN O O
diagnosis NN O O
of NN O O
Wolman NN O B-Disease
disease NN O I-Disease
. NN O O

Two NN O O
pregnancies NN O O
at NN O O
risk NN O O
for NN O O
Wolman NN O B-Disease
disease NN O I-Disease
were NN O O
monitored NN O O
by NN O O
assay NN O O
and NN O O
electrophoresis NN O O
of NN O O
acid NN O O
lipase NN O O
in NN O O
cultured NN O O
amniotic NN O O
- NN O O
fluid NN O O
cells NN O O
. NN O O

Cells NN O O
from NN O O
patient NN O O
1 NN O O
had NN O O
5 NN O O
% NN O O
of NN O O
control NN O O
levels NN O O
of NN O O
acid NN O O
lipase NN O O
, NN O O
using NN O O
14C NN O O
- NN O O
triolein NN O O
as NN O O
substrate NN O O
; NN O O
however NN O O
, NN O O
when NN O O
artificial NN O O
substrates NN O O
( NN O O
esters NN O O
of NN O O
4 NN O O
- NN O O
methylumbelliferone NN O O
and NN O O
p NN O O
- NN O O
nitrophenol NN O O
) NN O O
were NN O O
used NN O O
to NN O O
measure NN O O
acid NN O O
lipase NN O O
, NN O O
these NN O O
cells NN O O
had NN O O
30 NN O O
% NN O O
of NN O O
control NN O O
levels NN O O
. NN O O

Electrophoresis NN O O
of NN O O
cell NN O O
extracts NN O O
revealed NN O O
the NN O O
absence NN O O
of NN O O
the NN O O
A NN O O
form NN O O
of NN O O
acid NN O O
lipase NN O O
, NN O O
consistent NN O O
with NN O O
the NN O O
diagnosis NN O O
of NN O O
Wolman NN O B-Disease
disease NN O I-Disease
. NN O O

Analysis NN O O
of NN O O
fetal NN O O
tissues NN O O
following NN O O
prostaglandin NN O O
termination NN O O
of NN O O
this NN O O
pregnancy NN O O
confirmed NN O O
the NN O O
diagnosis NN O O
. NN O O

Assay NN O O
of NN O O
fetal NN O O
- NN O O
skin NN O O
fibroblasts NN O O
with NN O O
14C NN O O
- NN O O
triolein NN O O
, NN O O
as NN O O
well NN O O
as NN O O
with NN O O
artificial NN O O
substrates NN O O
, NN O O
showed NN O O
marked NN O O
deficiency NN O O
of NN O O
acid NN O O
lipase NN O O
activity NN O O
. NN O O

Electrophoresis NN O O
of NN O O
fetal NN O O
- NN O O
tissue NN O O
extracts NN O O
also NN O O
demonstrated NN O O
the NN O O
absence NN O O
of NN O O
the NN O O
A NN O O
form NN O O
of NN O O
acid NN O O
lipase NN O O
. NN O O

Amniotic NN O O
- NN O O
fluid NN O O
cells NN O O
from NN O O
patient NN O O
2 NN O O
showed NN O O
normal NN O O
levels NN O O
of NN O O
acid NN O O
lipase NN O O
with NN O O
all NN O O
substrates NN O O
tested NN O O
; NN O O
the NN O O
electrophoretic NN O O
pattern NN O O
of NN O O
acid NN O O
lipase NN O O
was NN O O
normal NN O O
. NN O O

The NN O O
results NN O O
suggest NN O O
that NN O O
the NN O O
prenatal NN O O
diagnosis NN O O
of NN O O
Wolman NN O B-Disease
disease NN O I-Disease
be NN O O
made NN O O
using NN O O
the NN O O
radioassay NN O O
of NN O O
acid NN O O
lipase NN O O
and NN O O
/ NN O O
or NN O O
electrophoresis NN O O
. NN O O
. NN O O

Malignant NN O B-Disease
neoplasms NN O I-Disease
in NN O O
the NN O O
families NN O O
of NN O O
patients NN O O
with NN O O
ataxia NN O B-Disease
- NN O I-Disease
telangiectasia NN O I-Disease
. NN O O

Ataxia NN O B-Disease
- NN O I-Disease
telangiectasia NN O I-Disease
( NN O O
A NN O B-Disease
- NN O I-Disease
T NN O I-Disease
) NN O O
is NN O O
an NN O O
autosomal NN O B-Disease
recessive NN O I-Disease
syndrome NN O I-Disease
associated NN O O
with NN O O
a NN O O
greatly NN O O
increased NN O O
incidence NN O O
of NN O O
malignant NN O B-Disease
neoplasms NN O I-Disease
in NN O O
homozygous NN O O
affected NN O O
individuals NN O O
. NN O O

Heterozygotes NN O O
for NN O O
the NN O O
gene NN O O
for NN O O
A NN O B-Disease
- NN O I-Disease
T NN O I-Disease
are NN O O
thought NN O O
to NN O O
comprise NN O O
about NN O O
1 NN O O
% NN O O
of NN O O
the NN O O
general NN O O
population NN O O
and NN O O
, NN O O
therefore NN O O
, NN O O
it NN O O
is NN O O
important NN O O
to NN O O
know NN O O
whether NN O O
this NN O O
gene NN O O
also NN O O
predisposes NN O O
the NN O O
heterozygous NN O O
carrier NN O O
to NN O O
cancers NN O B-Disease
. NN O O

Heterozygous NN O O
carriers NN O O
of NN O O
this NN O O
gene NN O O
are NN O O
common NN O O
among NN O O
the NN O O
close NN O O
relatives NN O O
of NN O O
patients NN O O
with NN O O
A NN O B-Disease
- NN O I-Disease
T NN O I-Disease
, NN O O
although NN O O
individual NN O O
carriers NN O O
cannot NN O O
be NN O O
identified NN O O
by NN O O
any NN O O
clinical NN O O
criterion NN O O
or NN O O
laboratory NN O O
test NN O O
. NN O O

For NN O O
this NN O O
reason NN O O
, NN O O
we NN O O
compared NN O O
the NN O O
incidence NN O O
of NN O O
death NN O O
from NN O O
malignant NN O B-Disease
neoplasms NN O I-Disease
in NN O O
2 NN O O
families NN O O
of NN O O
patients NN O O
with NN O O
A NN O B-Disease
- NN O I-Disease
T NN O I-Disease
to NN O O
that NN O O
expected NN O O
in NN O O
a NN O O
random NN O O
sample NN O O
of NN O O
the NN O O
general NN O O
population NN O O
. NN O O

There NN O O
were NN O O
59 NN O O
deaths NN O O
from NN O O
malignant NN O B-Disease
neoplasms NN O I-Disease
in NN O O
relatives NN O O
dying NN O O
before NN O O
age NN O O
75 NN O O
, NN O O
compared NN O O
to NN O O
42 NN O O
. NN O O

6 NN O O
expected NN O O
( NN O O
p NN O O
less NN O O
than NN O O
0 NN O O
. NN O O
02 NN O O
) NN O O
. NN O O

For NN O O
A NN O B-Disease
- NN O I-Disease
T NN O I-Disease
heterozygotes NN O O
younger NN O O
than NN O O
age NN O O
45 NN O O
, NN O O
the NN O O
risk NN O O
of NN O O
dying NN O O
from NN O O
a NN O O
malignant NN O B-Disease
neoplasm NN O I-Disease
was NN O O
estimated NN O O
to NN O O
be NN O O
greater NN O O
than NN O O
5 NN O O
times NN O O
the NN O O
risk NN O O
for NN O O
the NN O O
general NN O O
population NN O O
. NN O O

A NN O B-Disease
- NN O I-Disease
T NN O I-Disease
heterozygotes NN O O
may NN O O
comprise NN O O
more NN O O
than NN O O
5 NN O O
% NN O O
of NN O O
all NN O O
persons NN O O
dying NN O O
from NN O O
a NN O O
cancer NN O B-Disease
before NN O O
age NN O O
45 NN O O
. NN O O

The NN O O
incidence NN O O
of NN O O
ovarian NN O B-Disease
, NN O I-Disease
gastric NN O I-Disease
, NN O I-Disease
and NN O I-Disease
biliary NN O I-Disease
system NN O I-Disease
carcinomas NN O I-Disease
and NN O O
of NN O O
leukemia NN O B-Disease
and NN O O
lymphoma NN O B-Disease
was NN O O
increased NN O O
in NN O O
these NN O O
A NN O B-Disease
- NN O I-Disease
T NN O I-Disease
families NN O O
. NN O O

Other NN O O
neoplasms NN O B-Disease
that NN O O
may NN O O
be NN O O
associated NN O O
with NN O O
this NN O O
gene NN O O
in NN O O
heterozygotes NN O O
include NN O O
pancreatic NN O B-Disease
, NN O I-Disease
basal NN O I-Disease
cell NN O I-Disease
, NN O I-Disease
colonic NN O I-Disease
, NN O I-Disease
breast NN O I-Disease
, NN O I-Disease
and NN O I-Disease
cervical NN O I-Disease
carcinomas NN O I-Disease
. NN O O

Striking NN O O
prevalence NN O O
of NN O O
ankylosing NN O B-Disease
spondylitis NN O I-Disease
in NN O O
" NN O O
healthy NN O O
" NN O O
w27 NN O O
positive NN O O
males NN O O
and NN O O
females NN O O
. NN O O

Ankylosing NN O B-Disease
spondylitis NN O I-Disease
is NN O O
diagnosed NN O O
once NN O O
or NN O O
twice NN O O
in NN O O
each NN O O
1000 NN O O
males NN O O
and NN O O
one NN O O
tenth NN O O
as NN O O
frequently NN O O
in NN O O
females NN O O
, NN O O
but NN O O
the NN O O
true NN O O
prevalence NN O O
is NN O O
unknown NN O O
. NN O O

Indentification NN O O
of NN O O
genetic NN O O
marker NN O O
, NN O O
HL NN O O
- NN O O
A NN O O
W27 NN O O
, NN O O
for NN O O
susceptible NN O O
persons NN O O
has NN O O
provided NN O O
a NN O O
tool NN O O
facilitating NN O O
epidemiologic NN O O
studies NN O O
and NN O O
allowing NN O O
identification NN O O
of NN O O
" NN O O
control NN O O
" NN O O
populations NN O O
without NN O O
the NN O O
marker NN O O
. NN O O

Evaluation NN O O
by NN O O
postal NN O O
questionnaires NN O O
, NN O O
and NN O O
pelvic NN O O
radiography NN O O
of NN O O
78 NN O O
HL NN O O
- NN O O
A NN O O
27W NN O O
- NN O O
positive NN O O
blood NN O O
donors NN O O
selected NN O O
from NN O O
a NN O O
group NN O O
of NN O O
apparently NN O O
healthy NN O O
subjects NN O O
revealed NN O O
14 NN O O
who NN O O
satisfied NN O O
the NN O O
criteria NN O O
for NN O O
definite NN O O
ankylosing NN O B-Disease
spondylitis NN O I-Disease
. NN O O

The NN O O
prevalence NN O O
was NN O O
similar NN O O
in NN O O
both NN O O
sexes NN O O
. NN O O

One NN O O
hundred NN O O
and NN O O
twenty NN O O
- NN O O
six NN O O
W27 NN O O
- NN O O
negative NN O O
controls NN O O
matched NN O O
for NN O O
race NN O O
, NN O O
sex NN O O
, NN O O
and NN O O
age NN O O
failed NN O O
to NN O O
yield NN O O
a NN O O
single NN O O
case NN O O
. NN O O

For NN O O
a NN O O
person NN O O
of NN O O
either NN O O
sex NN O O
with NN O O
HL NN O O
- NN O O
A NN O O
W27 NN O O
, NN O O
there NN O O
appears NN O O
to NN O O
be NN O O
about NN O O
a NN O O
20 NN O O
per NN O O
cent NN O O
chance NN O O
that NN O O
ankylosing NN O B-Disease
spondylitis NN O I-Disease
will NN O O
develop NN O O
, NN O O
suggesting NN O O
a NN O O
prevalence NN O O
of NN O O
10 NN O O
to NN O O
15 NN O O
per NN O O
thousand NN O O
. NN O O

Hitherto NN O O
accepted NN O O
figures NN O O
may NN O O
underestimate NN O O
the NN O O
frequency NN O O
by NN O O
a NN O O
factor NN O O
of NN O O
10 NN O O
to NN O O
20 NN O O
. NN O O
. NN O O

Analbuminemia NN O B-Disease
in NN O O
an NN O O
American NN O O
Indian NN O O
girl NN O O
. NN O O

Analbuminemia NN O B-Disease
was NN O O
fortuitously NN O O
detected NN O O
in NN O O
a NN O O
nonedematous NN O O
12 NN O O
- NN O O
year NN O O
- NN O O
old NN O O
American NN O O
Indian NN O O
girl NN O O
with NN O O
atopic NN O B-Disease
dermatitis NN O I-Disease
, NN O O
mild NN O O
bronchial NN O B-Disease
asthma NN O I-Disease
, NN O O
a NN O O
mild NN O O
seizure NN O B-Disease
disorder NN O I-Disease
, NN O O
and NN O O
hyperlipoproteinemia NN O B-Disease
with NN O O
a NN O O
corneal NN O B-Disease
arcus NN O I-Disease
. NN O O

Immunologic NN O O
methods NN O O
revealed NN O O
trace NN O O
amounts NN O O
( NN O O
17 NN O O
mg NN O O
/ NN O O
100 NN O O
ml NN O O
) NN O O
of NN O O
apparently NN O O
normal NN O O
serum NN O O
albumin NN O O
. NN O O

The NN O O
patients NN O O
parents NN O O
were NN O O
remotely NN O O
related NN O O
. NN O O

The NN O O
pedigree NN O O
and NN O O
clinical NN O O
findings NN O O
were NN O O
compatible NN O O
with NN O O
autosomal NN O O
recessive NN O O
transmission NN O O
of NN O O
analbuminemia NN O B-Disease
. NN O O

Heterozygotes NN O O
had NN O O
subnormal NN O O
levels NN O O
of NN O O
serum NN O O
albumin NN O O
. NN O O

The NN O O
Gc NN O O
- NN O O
locus NN O O
is NN O O
closely NN O O
linked NN O O
to NN O O
the NN O O
structural NN O O
albumin NN O O
locus NN O O
. NN O O

Gc NN O O
- NN O O
protein NN O O
levels NN O O
were NN O O
normal NN O O
in NN O O
the NN O O
patient NN O O
and NN O O
together NN O O
with NN O O
normal NN O O
chromosomal NN O O
banding NN O O
studies NN O O
make NN O O
it NN O O
unlikely NN O O
that NN O O
a NN O O
chromosomal NN O O
deletion NN O O
caused NN O O
analbuminemia NN O B-Disease
. NN O O

Gc NN O O
- NN O O
types NN O O
in NN O O
the NN O O
family NN O O
were NN O O
compatible NN O O
with NN O O
, NN O O
but NN O O
did NN O O
not NN O O
prove NN O O
, NN O O
linkage NN O O
of NN O O
analbuminemia NN O B-Disease
to NN O O
the NN O O
Gc NN O O
- NN O O
locus NN O O
. NN O O

These NN O O
findings NN O O
suggest NN O O
a NN O O
" NN O O
thalassemia NN O B-Disease
" NN O O
- NN O O
like NN O O
mutation NN O O
for NN O O
this NN O O
disorder NN O O
. NN O O
. NN O O

Deletion NN O O
of NN O O
the NN O O
KIT NN O O
and NN O O
PDGFRA NN O O
genes NN O O
in NN O O
a NN O O
patient NN O O
with NN O O
piebaldism NN O B-Disease
. NN O O

We NN O O
have NN O O
previously NN O O
shown NN O O
that NN O O
human NN O O
piebaldism NN O B-Disease
results NN O O
from NN O O
mutations NN O O
of NN O O
the NN O O
KIT NN O O
gene NN O O
, NN O O
which NN O O
encodes NN O O
the NN O O
receptor NN O O
for NN O O
the NN O O
mast NN O O
/ NN O O
stem NN O O
cell NN O O
growth NN O O
factor NN O O
and NN O O
is NN O O
located NN O O
in NN O O
chromosome NN O O
segment NN O O
4q12 NN O O
. NN O O

Using NN O O
DNA NN O O
of NN O O
a NN O O
patient NN O O
with NN O O
piebaldism NN O B-Disease
, NN O O
mental NN O B-Disease
retardation NN O I-Disease
, NN O O
and NN O O
multiple NN O B-Disease
congenital NN O I-Disease
anomalies NN O I-Disease
associated NN O O
with NN O O
a NN O O
46 NN O O
, NN O O
XY NN O O
, NN O O
del NN O O
( NN O O
4 NN O O
) NN O O
( NN O O
q12q21 NN O O
. NN O O
1 NN O O
) NN O O
karyotype NN O O
, NN O O
we NN O O
carried NN O O
out NN O O
quantitative NN O O
Southern NN O O
blot NN O O
hybridization NN O O
analyses NN O O
of NN O O
the NN O O
KIT NN O O
gene NN O O
and NN O O
the NN O O
adjacent NN O O
PDGFRA NN O O
( NN O O
platelet NN O O
- NN O O
derived NN O O
growth NN O O
factor NN O O
receptor NN O O
alpha NN O O
subunit NN O O
) NN O O
genes NN O O
. NN O O

The NN O O
patient NN O O
was NN O O
hemizygous NN O O
for NN O O
both NN O O
the NN O O
KIT NN O O
and NN O O
PDGFRA NN O O
genes NN O O
, NN O O
indicating NN O O
that NN O O
both NN O O
of NN O O
these NN O O
genes NN O O
are NN O O
included NN O O
within NN O O
the NN O O
deleted NN O O
region NN O O
. NN O O

Therefore NN O O
, NN O O
deletion NN O O
of NN O O
the NN O O
KIT NN O O
and NN O O
PDGFRA NN O O
genes NN O O
may NN O O
account NN O O
for NN O O
the NN O O
piebald NN O B-Disease
phenotype NN O O
in NN O O
this NN O O
patient NN O O
. NN O O

A NN O O
germ NN O O
line NN O O
mutation NN O O
within NN O O
the NN O O
coding NN O O
sequence NN O O
for NN O O
the NN O O
putative NN O O
5 NN O O
- NN O O
phosphoribosyl NN O O
- NN O O
1 NN O O
- NN O O
pyrophosphate NN O O
binding NN O O
site NN O O
of NN O O
hypoxanthine NN O O
- NN O O
guanine NN O O
phosphoribosyltransferase NN O O
( NN O O
HPRT NN O O
) NN O O
in NN O O
a NN O O
Lesch NN O B-Disease
- NN O I-Disease
Nyhan NN O I-Disease
patient NN O O
: NN O O
missense NN O O
mutations NN O O
within NN O O
a NN O O
functionally NN O O
important NN O O
region NN O O
probably NN O O
cause NN O O
disease NN O O
. NN O O

Lesch NN O B-Disease
- NN O I-Disease
Nyhan NN O I-Disease
syndrome NN O I-Disease
caused NN O O
by NN O O
a NN O O
complete NN O B-Disease
deficiency NN O I-Disease
of NN O I-Disease
hypoxanthine NN O I-Disease
guanine NN O I-Disease
phosphoribosyltransferase NN O I-Disease
( NN O O
HPRT NN O O
) NN O O
is NN O O
the NN O O
result NN O O
of NN O O
a NN O O
heterogeneous NN O O
group NN O O
of NN O O
germ NN O O
line NN O O
mutations NN O O
. NN O O

Identification NN O O
of NN O O
each NN O O
mutant NN O O
gene NN O O
provides NN O O
valuable NN O O
information NN O O
as NN O O
to NN O O
the NN O O
type NN O O
of NN O O
mutation NN O O
that NN O O
occurs NN O O
spontaneously NN O O
. NN O O

We NN O O
report NN O O
here NN O O
a NN O O
newly NN O O
identified NN O O
HPRT NN O O
mutation NN O O
in NN O O
a NN O O
Japanese NN O O
patient NN O O
with NN O O
Lesch NN O B-Disease
- NN O I-Disease
Nyhan NN O I-Disease
syndrome NN O I-Disease
. NN O O

This NN O O
gene NN O O
, NN O O
designated NN O O
HPRT NN O O
Tokyo NN O O
, NN O O
had NN O O
a NN O O
single NN O O
nucleotide NN O O
change NN O O
from NN O O
G NN O O
to NN O O
A NN O O
, NN O O
as NN O O
identified NN O O
by NN O O
sequencing NN O O
cDNA NN O O
amplified NN O O
by NN O O
the NN O O
polymerase NN O O
chain NN O O
reaction NN O O
. NN O O

Allele NN O O
specific NN O O
oligonucleotide NN O O
hybridization NN O O
analysis NN O O
using NN O O
amplified NN O O
genomic NN O O
DNA NN O O
showed NN O O
that NN O O
the NN O O
mutant NN O O
gene NN O O
was NN O O
transmitted NN O O
from NN O O
the NN O O
maternal NN O O
germ NN O O
line NN O O
. NN O O

This NN O O
mutation NN O O
would NN O O
lead NN O O
to NN O O
an NN O O
amino NN O O
acid NN O O
substitution NN O O
of NN O O
Asp NN O O
for NN O O
Gly NN O O
at NN O O
the NN O O
amino NN O O
acid NN O O
position NN O O
140 NN O O
located NN O O
within NN O O
the NN O O
putative NN O O
5 NN O O
- NN O O
phosphoribosyl NN O O
- NN O O
1 NN O O
- NN O O
pyrophosphate NN O O
( NN O O
PRPP NN O O
) NN O O
binding NN O O
region NN O O
. NN O O

Missense NN O O
mutations NN O O
in NN O O
human NN O O
HPRT NN O B-Disease
deficient NN O I-Disease
patients NN O O
thus NN O O
far NN O O
reported NN O O
tend NN O O
to NN O O
accumulate NN O O
in NN O O
this NN O O
functionally NN O O
active NN O O
region NN O O
. NN O O

However NN O O
, NN O O
a NN O O
comparison NN O O
of NN O O
the NN O O
data NN O O
suggested NN O O
that NN O O
both NN O O
missense NN O O
and NN O O
synonymous NN O O
mutations NN O O
can NN O O
occur NN O O
at NN O O
any NN O O
coding NN O O
sequence NN O O
of NN O O
the NN O O
human NN O O
germ NN O O
line NN O O
HPRT NN O O
gene NN O O
, NN O O
but NN O O
that NN O O
a NN O O
limited NN O O
percentage NN O O
of NN O O
all NN O O
the NN O O
missense NN O O
mutations NN O O
cause NN O O
disease NN O O
. NN O O

The NN O O
probability NN O O
that NN O O
a NN O O
mutation NN O O
will NN O O
cause NN O O
disease NN O O
tends NN O O
to NN O O
be NN O O
higher NN O O
when NN O O
the NN O O
missense NN O O
mutation NN O O
is NN O O
within NN O O
a NN O O
functionally NN O O
important NN O O
sequence NN O O
. NN O O
. NN O O

Characterisation NN O O
of NN O O
a NN O O
new NN O O
rare NN O O
fragile NN O O
site NN O O
easily NN O O
confused NN O O
with NN O O
the NN O O
fragile NN O B-Disease
X NN O I-Disease
. NN O O

A NN O O
new NN O O
fragile NN O O
site NN O O
( NN O O
FRAXE NN O O
) NN O O
in NN O O
Xq28 NN O O
is NN O O
described NN O O
. NN O O

It NN O O
appears NN O O
to NN O O
be NN O O
a NN O O
typical NN O O
folate NN O O
sensitive NN O O
fragile NN O O
site NN O O
. NN O O

The NN O O
fragile NN O O
site NN O O
is NN O O
not NN O O
associated NN O O
with NN O O
mental NN O B-Disease
retardation NN O I-Disease
, NN O O
it NN O O
does NN O O
not NN O O
give NN O O
abnormal NN O O
results NN O O
when NN O O
subjected NN O O
to NN O O
Southern NN O O
analysis NN O O
with NN O O
probe NN O O
pfxa3 NN O O
which NN O O
detects NN O O
the NN O O
unstable NN O O
DNA NN O O
sequence NN O O
characteristic NN O O
of NN O O
fragile NN O B-Disease
X NN O I-Disease
syndrome NN O I-Disease
. NN O O

In NN O O
situ NN O O
hybridization NN O O
mapping NN O O
locates NN O O
the NN O O
fragile NN O O
site NN O O
between NN O O
150 NN O O
kb NN O O
and NN O O
600 NN O O
kb NN O O
distal NN O O
to NN O O
FRAXA NN O O
. NN O O

The NN O O
distinction NN O O
between NN O O
the NN O O
two NN O O
fragile NN O O
sites NN O O
is NN O O
important NN O O
clinically NN O O
since NN O O
cytogenetic NN O O
detection NN O O
of NN O O
FRAXE NN O O
, NN O O
without NN O O
molecular NN O O
analysis NN O O
, NN O O
could NN O O
result NN O O
in NN O O
misdiagnosis NN O O
of NN O O
fragile NN O B-Disease
X NN O I-Disease
syndrome NN O I-Disease
. NN O O
. NN O O

The NN O O
Norrie NN O B-Disease
disease NN O I-Disease
gene NN O O
maps NN O O
to NN O O
a NN O O
150 NN O O
kb NN O O
region NN O O
on NN O O
chromosome NN O O
Xp11 NN O O
. NN O O
3 NN O O
. NN O O

Norrie NN O B-Disease
disease NN O I-Disease
is NN O O
a NN O O
human NN O O
X NN O B-Disease
- NN O I-Disease
linked NN O I-Disease
recessive NN O I-Disease
disorder NN O I-Disease
of NN O O
unknown NN O O
etiology NN O O
characterized NN O O
by NN O O
congenital NN O B-Disease
blindness NN O I-Disease
, NN O O
sensory NN O B-Disease
neural NN O I-Disease
deafness NN O I-Disease
and NN O O
mental NN O B-Disease
retardation NN O I-Disease
. NN O O

This NN O O
disease NN O O
gene NN O O
was NN O O
previously NN O O
linked NN O O
to NN O O
the NN O O
DXS7 NN O O
( NN O O
L1 NN O O
. NN O O
28 NN O O
) NN O O
locus NN O O
and NN O O
the NN O O
MAO NN O O
genes NN O O
in NN O O
band NN O O
Xp11 NN O O
. NN O O

3 NN O O
3 NN O O
. NN O O

We NN O O
report NN O O
here NN O O
fine NN O O
physical NN O O
mapping NN O O
of NN O O
the NN O O
obligate NN O O
region NN O O
containing NN O O
the NN O O
Norrie NN O B-Disease
disease NN O I-Disease
gene NN O O
( NN O O
NDP NN O O
) NN O O
defined NN O O
by NN O O
a NN O O
recombination NN O O
and NN O O
by NN O O
the NN O O
smallest NN O O
submicroscopic NN O O
chromosomal NN O O
deletion NN O O
associated NN O O
with NN O O
Norrie NN O B-Disease
disease NN O I-Disease
identified NN O O
to NN O O
date NN O O
. NN O O

Analysis NN O O
, NN O O
using NN O O
in NN O O
addition NN O O
two NN O O
overlapping NN O O
YAC NN O O
clones NN O O
from NN O O
this NN O O
region NN O O
, NN O O
allowed NN O O
orientation NN O O
of NN O O
the NN O O
MAOA NN O O
and NN O O
MAOB NN O O
genes NN O O
in NN O O
a NN O O
5 NN O O
- NN O O
3 NN O O
- NN O O
3 NN O O
- NN O O
5 NN O O
configuration NN O O
. NN O O

A NN O O
recombination NN O O
event NN O O
between NN O O
a NN O O
( NN O O
GT NN O O
) NN O O
n NN O O
polymorphism NN O O
in NN O O
intron NN O O
2 NN O O
of NN O O
the NN O O
MAOB NN O O
gene NN O O
and NN O O
the NN O O
NDP NN O O
locus NN O O
, NN O O
in NN O O
a NN O O
family NN O O
previously NN O O
reported NN O O
to NN O O
have NN O O
a NN O O
recombination NN O O
between NN O O
DXS7 NN O O
and NN O O
NDP NN O O
, NN O O
delineates NN O O
a NN O O
flanking NN O O
marker NN O O
telomeric NN O O
to NN O O
this NN O O
disease NN O O
gene NN O O
. NN O O

An NN O O
anonymous NN O O
DNA NN O O
probe NN O O
, NN O O
dc12 NN O O
, NN O O
present NN O O
in NN O O
one NN O O
of NN O O
the NN O O
YACs NN O O
and NN O O
in NN O O
a NN O O
patient NN O O
with NN O O
a NN O O
submicroscopic NN O O
deletion NN O O
which NN O O
includes NN O O
MAOA NN O O
and NN O O
MAOB NN O O
but NN O O
not NN O O
L1 NN O O
. NN O O

28 NN O O
, NN O O
serves NN O O
as NN O O
a NN O O
flanking NN O O
marker NN O O
centromeric NN O O
to NN O O
the NN O O
disease NN O O
gene NN O O
. NN O O

An NN O O
Alu NN O O
- NN O O
PCR NN O O
fragment NN O O
from NN O O
the NN O O
right NN O O
arm NN O O
of NN O O
the NN O O
MAO NN O O
YAC NN O O
( NN O O
YMAO NN O O
. NN O O
AluR NN O O
) NN O O
is NN O O
not NN O O
deleted NN O O
in NN O O
this NN O O
patient NN O O
and NN O O
also NN O O
delineates NN O O
the NN O O
centromeric NN O O
extent NN O O
of NN O O
the NN O O
obligate NN O O
disease NN O O
region NN O O
. NN O O

The NN O O
apparent NN O O
order NN O O
of NN O O
these NN O O
loci NN O O
is NN O O
telomere NN O O
. NN O O

DXS7 NN O O
- NN O O
MAOA NN O O
- NN O O
MAOB NN O O
- NN O O
NDP NN O O
- NN O O
dc12 NN O O
- NN O O
YMAO NN O O
DXS7 NN O O
- NN O O
MAOA NN O O
- NN O O
MAOB NN O O
- NN O O
NDP NN O O
- NN O O
dc12 NN O O
- NN O O
YMAO NN O O
. NN O O

AluR NN O O
. NN O O
centromere NN O O
. NN O O

Together NN O O
these NN O O
data NN O O
define NN O O
the NN O O
obligate NN O O
region NN O O
containing NN O O
the NN O O
NDP NN O O
gene NN O O
to NN O O
a NN O O
chromosomal NN O O
segment NN O O
less NN O O
than NN O O
150 NN O O
kb NN O O
. NN O O

Molecular NN O O
basis NN O O
of NN O O
phenylketonuria NN O B-Disease
and NN O O
related NN O O
hyperphenylalaninemias NN O B-Disease
: NN O O
mutations NN O O
and NN O O
polymorphisms NN O O
in NN O O
the NN O O
human NN O O
phenylalanine NN O O
hydroxylase NN O O
gene NN O O
. NN O O

Mutations NN O O
in NN O O
the NN O O
human NN O O
phenylalanine NN O O
hydroxylase NN O O
gene NN O O
producing NN O O
phenylketonuria NN O B-Disease
or NN O O
hyperphenylalaninemia NN O B-Disease
have NN O O
now NN O O
been NN O O
identified NN O O
in NN O O
many NN O O
patients NN O O
from NN O O
various NN O O
ethnic NN O O
groups NN O O
. NN O O

These NN O O
mutations NN O O
all NN O O
exhibit NN O O
a NN O O
high NN O O
degree NN O O
of NN O O
association NN O O
with NN O O
specific NN O O
restriction NN O O
fragment NN O O
- NN O O
length NN O O
polymorphism NN O O
haplotypes NN O O
at NN O O
the NN O O
PAH NN O O
locus NN O O
. NN O O

About NN O O
50 NN O O
of NN O O
these NN O O
mutations NN O O
are NN O O
single NN O O
- NN O O
base NN O O
substitutions NN O O
, NN O O
including NN O O
six NN O O
nonsense NN O O
mutations NN O O
and NN O O
eight NN O O
splicing NN O O
mutations NN O O
, NN O O
with NN O O
the NN O O
remainder NN O O
being NN O O
missense NN O O
mutations NN O O
. NN O O

One NN O O
splicing NN O O
mutation NN O O
results NN O O
in NN O O
a NN O O
3 NN O O
amino NN O O
acid NN O O
in NN O O
- NN O O
frame NN O O
insertion NN O O
. NN O O

Two NN O O
or NN O O
3 NN O O
large NN O O
deletions NN O O
, NN O O
2 NN O O
single NN O O
codon NN O O
deletions NN O O
, NN O O
and NN O O
2 NN O O
single NN O O
base NN O O
deletions NN O O
have NN O O
been NN O O
found NN O O
. NN O O

Twelve NN O O
of NN O O
the NN O O
missense NN O O
mutations NN O O
apparently NN O O
result NN O O
from NN O O
the NN O O
methylation NN O O
and NN O O
subsequent NN O O
deamination NN O O
of NN O O
highly NN O O
mutagenic NN O O
CpG NN O O
dinucleotides NN O O
. NN O O

Recurrent NN O O
mutation NN O O
has NN O O
been NN O O
observed NN O O
at NN O O
several NN O O
of NN O O
these NN O O
sites NN O O
, NN O O
producing NN O O
associations NN O O
with NN O O
different NN O O
haplotypes NN O O
in NN O O
different NN O O
populations NN O O
. NN O O

About NN O O
half NN O O
of NN O O
all NN O O
missense NN O O
mutations NN O O
have NN O O
been NN O O
examined NN O O
by NN O O
in NN O O
vitro NN O O
expression NN O O
analysis NN O O
, NN O O
and NN O O
a NN O O
significant NN O O
correlation NN O O
has NN O O
been NN O O
observed NN O O
between NN O O
residual NN O O
PAH NN O O
activity NN O O
and NN O O
disease NN O O
phenotype NN O O
. NN O O

Since NN O O
continuing NN O O
advances NN O O
in NN O O
molecular NN O O
methodologies NN O O
have NN O O
dramatically NN O O
accelerated NN O O
the NN O O
rate NN O O
in NN O O
which NN O O
new NN O O
mutations NN O O
are NN O O
being NN O O
identified NN O O
and NN O O
characterized NN O O
, NN O O
this NN O O
register NN O O
of NN O O
mutations NN O O
will NN O O
be NN O O
updated NN O O
periodically NN O O
. NN O O
. NN O O

A NN O O
glycine250 NN O O
- NN O O
- NN O O
> NN O O
aspartate NN O O
substitution NN O O
in NN O O
the NN O O
alpha NN O O
- NN O O
subunit NN O O
of NN O O
hexosaminidase NN O O
A NN O O
causes NN O O
juvenile NN O O
- NN O O
onset NN O O
Tay NN O B-Disease
- NN O I-Disease
Sachs NN O I-Disease
disease NN O I-Disease
in NN O O
a NN O O
Lebanese NN O O
- NN O O
Canadian NN O O
family NN O O
. NN O O

The NN O O
mutation NN O O
causing NN O O
juvenile NN O O
Tay NN O B-Disease
- NN O I-Disease
Sachs NN O I-Disease
disease NN O I-Disease
( NN O O
TSD NN O B-Disease
) NN O O
in NN O O
two NN O O
sibs NN O O
of NN O O
Lebanese NN O O
- NN O O
Maronite NN O O
origin NN O O
is NN O O
described NN O O
. NN O O

An NN O O
mRNA NN O O
- NN O O
containing NN O O
extract NN O O
of NN O O
cultured NN O O
fibroblasts NN O O
obtained NN O O
from NN O O
one NN O O
of NN O O
the NN O O
probands NN O O
was NN O O
used NN O O
as NN O O
a NN O O
template NN O O
to NN O O
amplify NN O O
the NN O O
coding NN O O
sequence NN O O
of NN O O
the NN O O
hexosaminidase NN O O
A NN O O
( NN O O
Hex NN O O
A NN O O
) NN O O
alpha NN O O
- NN O O
subunit NN O O
. NN O O

Sequencing NN O O
of NN O O
amplified NN O O
cDNA NN O O
fragments NN O O
revealed NN O O
a NN O O
single NN O O
alteration NN O O
, NN O O
guanine NN O O
to NN O O
adenine NN O O
at NN O O
nt NN O O
749 NN O O
creating NN O O
a NN O O
G250D NN O O
mutation NN O O
. NN O O

The NN O O
mutation NN O O
introduces NN O O
a NN O O
new NN O O
recognition NN O O
site NN O O
for NN O O
the NN O O
restriction NN O O
enzyme NN O O
Eco NN O O
RV NN O O
, NN O O
permitting NN O O
identification NN O O
of NN O O
heterozygotes NN O O
for NN O O
this NN O O
allele NN O O
following NN O O
PCR NN O O
amplification NN O O
and NN O O
Eco NN O O
RV NN O O
digestion NN O O
of NN O O
exon NN O O
7 NN O O
sequences NN O O
from NN O O
genomic NN O O
DNA NN O O
templates NN O O
. NN O O

In NN O O
order NN O O
to NN O O
test NN O O
the NN O O
effect NN O O
of NN O O
this NN O O
substitution NN O O
, NN O O
an NN O O
in NN O O
vitro NN O O
mutagenized NN O O
cDNA NN O O
construct NN O O
was NN O O
introduced NN O O
into NN O O
a NN O O
mammalian NN O O
expression NN O O
vector NN O O
and NN O O
transfected NN O O
into NN O O
monkey NN O O
Cos NN O O
- NN O O
1 NN O O
cells NN O O
separately NN O O
or NN O O
along NN O O
with NN O O
a NN O O
beta NN O O
- NN O O
cDNA NN O O
expression NN O O
vector NN O O
. NN O O

When NN O O
the NN O O
mutant NN O O
alpha NN O O
- NN O O
cDNA NN O O
was NN O O
the NN O O
only NN O O
gene NN O O
introduced NN O O
into NN O O
COS NN O O
cells NN O O
no NN O O
enzymatic NN O O
activity NN O O
above NN O O
endogenous NN O O
COS NN O O
cell NN O O
activity NN O O
was NN O O
detected NN O O
. NN O O

Cotransfection NN O O
of NN O O
normal NN O O
alpha NN O O
- NN O O
cDNA NN O O
and NN O O
beta NN O O
- NN O O
cDNA NN O O
followed NN O O
by NN O O
immunoprecipitation NN O O
of NN O O
human NN O O
Hex NN O O
A NN O O
resulted NN O O
in NN O O
20 NN O O
- NN O O
fold NN O O
increase NN O O
in NN O O
the NN O O
ratio NN O O
between NN O O
positive NN O O
and NN O O
negative NN O O
( NN O O
mock NN O O
transfection NN O O
) NN O O
control NN O O
values NN O O
. NN O O

This NN O O
allowed NN O O
the NN O O
detection NN O O
of NN O O
some NN O O
residual NN O O
activity NN O O
( NN O O
12 NN O O
% NN O O
of NN O O
the NN O O
positive NN O O
control NN O O
) NN O O
when NN O O
the NN O O
mutant NN O O
alpha NN O O
- NN O O
cDNA NN O O
replaced NN O O
its NN O O
wild NN O O
- NN O O
type NN O O
counterpart NN O O
. NN O O

The NN O O
predicted NN O O
protein NN O O
environment NN O O
in NN O O
which NN O O
the NN O O
mutation NN O O
occurs NN O O
is NN O O
compared NN O O
to NN O O
that NN O O
of NN O O
the NN O O
adult NN O O
- NN O O
onset NN O O
Tay NN O B-Disease
- NN O I-Disease
Sachs NN O I-Disease
disease NN O I-Disease
mutation NN O O
caused NN O O
by NN O O
a NN O O
Gly269 NN O O
- NN O O
- NN O O
> NN O O
Ser NN O O
substitution NN O O
in NN O O
exon NN O O
7 NN O O
. NN O O

( NN O O
ABSTRACT NN O O
TRUNCATED NN O O
AT NN O O
250 NN O O
WORDS NN O O
) NN O O
. NN O O

Novel NN O O
Tay NN O B-Disease
- NN O I-Disease
Sachs NN O I-Disease
disease NN O I-Disease
mutations NN O O
from NN O O
China NN O O
. NN O O

We NN O O
describe NN O O
three NN O O
HEXA NN O O
mutations NN O O
associated NN O O
with NN O O
infantile NN O O
Tay NN O B-Disease
- NN O I-Disease
Sachs NN O I-Disease
disease NN O I-Disease
( NN O O
TSD NN O B-Disease
) NN O O
in NN O O
three NN O O
unrelated NN O O
nonconsanguineous NN O O
Chinese NN O O
families NN O O
. NN O O

Novel NN O O
mutations NN O O
were NN O O
found NN O O
in NN O O
two NN O O
of NN O O
these NN O O
families NN O O
. NN O O

The NN O O
third NN O O
is NN O O
a NN O O
previously NN O O
reported NN O O
mutation NN O O
( NN O O
G NN O O
- NN O O
- NN O O
> NN O O
A NN O O
transition NN O O
at NN O O
nt NN O O
1444 NN O O
) NN O O
( NN O O
Nakano NN O O
et NN O O
al NN O O
. NN O O
, NN O O
1988 NN O O
) NN O O
. NN O O

Direct NN O O
sequencing NN O O
of NN O O
PCR NN O O
products NN O O
identified NN O O
a NN O O
novel NN O O
insertion NN O O
of NN O O
an NN O O
A NN O O
after NN O O
nt NN O O
547 NN O O
in NN O O
family NN O O
1 NN O O
. NN O O

This NN O O
change NN O O
generates NN O O
an NN O O
early NN O O
termination NN O O
codon NN O O
6 NN O O
bp NN O O
downstream NN O O
from NN O O
the NN O O
insertion NN O O
site NN O O
. NN O O

Allele NN O O
- NN O O
specific NN O O
oligonucleotide NN O O
hybridization NN O O
confirmed NN O O
homozygosity NN O O
in NN O O
the NN O O
proband NN O O
. NN O O

Single NN O O
strand NN O O
conformational NN O O
polymorphism NN O O
analysis NN O O
and NN O O
direct NN O O
sequencing NN O O
of NN O O
amplified NN O O
exon NN O O
13 NN O O
revealed NN O O
a NN O O
T NN O O
- NN O O
- NN O O
> NN O O
C NN O O
transition NN O O
at NN O O
nt NN O O
1453 NN O O
with NN O O
the NN O O
corresponding NN O O
amino NN O O
acid NN O O
substitution NN O O
W485R NN O O
in NN O O
the NN O O
second NN O O
family NN O O
. NN O O

This NN O O
mutation NN O O
creates NN O O
an NN O O
Fnu4HI NN O O
restriction NN O O
site NN O O
. NN O O

The NN O O
proband NN O O
is NN O O
homozygous NN O O
for NN O O
this NN O O
allele NN O O
. NN O O

When NN O O
the NN O O
site NN O O
- NN O O
specific NN O O
mutagenized NN O O
alpha NN O O
cDNA NN O O
carrying NN O O
the NN O O
T NN O O
- NN O O
- NN O O
> NN O O
C NN O O
transition NN O O
at NN O O
nt NN O O
1453 NN O O
was NN O O
expressed NN O O
in NN O O
COS NN O O
1 NN O O
cells NN O O
hexosaminidase NN O O
S NN O O
activity NN O O
was NN O O
not NN O O
detectable NN O O
above NN O O
background NN O O
. NN O O

A NN O O
G NN O O
- NN O O
- NN O O
> NN O O
A NN O O
transition NN O O
at NN O O
nt NN O O
1444 NN O O
( NN O O
exon NN O O
13 NN O O
) NN O O
corresponding NN O O
to NN O O
the NN O O
E482K NN O O
substitution NN O O
was NN O O
found NN O O
in NN O O
the NN O O
third NN O O
family NN O O
. NN O O

This NN O O
mutation NN O O
occurs NN O O
at NN O O
a NN O O
CpG NN O O
dinucleotide NN O O
. NN O O

It NN O O
has NN O O
been NN O O
reported NN O O
in NN O O
an NN O O
Italian NN O O
TSD NN O B-Disease
proband NN O O
and NN O O
causes NN O O
defective NN O O
intracellular NN O O
transport NN O O
of NN O O
the NN O O
alpha NN O O
- NN O O
subunit NN O O
from NN O O
the NN O O
rough NN O O
endoplasmic NN O O
reticulum NN O O
to NN O O
the NN O O
Golgi NN O O
apparatus NN O O
. NN O O

Two NN O O
missense NN O O
mutations NN O O
causing NN O O
mild NN O O
hyperphenylalaninemia NN O B-Disease
associated NN O O
with NN O O
DNA NN O O
haplotype NN O O
12 NN O O
. NN O O

The NN O O
genetic NN O B-Disease
defects NN O I-Disease
responsible NN O O
for NN O O
most NN O O
phenylketonuria NN O B-Disease
( NN O O
PKU NN O B-Disease
) NN O O
and NN O O
hyperphenylalaninemia NN O B-Disease
( NN O O
HPA NN O B-Disease
) NN O O
cases NN O O
are NN O O
located NN O O
in NN O O
the NN O O
phenylalanine NN O O
hydroxylase NN O O
( NN O O
PAH NN O O
) NN O O
gene NN O O
. NN O O

Approximately NN O O
50 NN O O
- NN O O
60 NN O O
mutations NN O O
have NN O O
been NN O O
reported NN O O
in NN O O
Caucasians NN O O
and NN O O
are NN O O
reflected NN O O
in NN O O
a NN O O
wide NN O O
range NN O O
of NN O O
clinical NN O O
severities NN O O
. NN O O

Most NN O O
mutations NN O O
are NN O O
linked NN O O
to NN O O
specific NN O O
haplotypes NN O O
, NN O O
as NN O O
defined NN O O
by NN O O
eight NN O O
polymorphic NN O O
restriction NN O O
sites NN O O
in NN O O
the NN O O
PAH NN O O
gene NN O O
. NN O O

We NN O O
hypothesized NN O O
that NN O O
there NN O O
is NN O O
at NN O O
least NN O O
one NN O O
mild NN O O
mutation NN O O
linked NN O O
to NN O O
haplotype NN O O
12 NN O O
in NN O O
the NN O O
Swedish NN O O
PKU NN O B-Disease
/ NN O O
HPA NN O B-Disease
population NN O O
, NN O O
since NN O O
7 NN O O
of NN O O
8 NN O O
patients NN O O
carrying NN O O
haplotype NN O O
12 NN O O
had NN O O
mild NN O O
HPA NN O B-Disease
. NN O O

Sequence NN O O
analysis NN O O
revealed NN O O
a NN O O
C NN O O
- NN O O
to NN O O
- NN O O
G NN O O
transversion NN O O
at NN O O
the NN O O
second NN O O
base NN O O
of NN O O
codon NN O O
322 NN O O
, NN O O
resulting NN O O
in NN O O
a NN O O
substitution NN O O
of NN O O
glycine NN O O
for NN O O
alanine NN O O
, NN O O
in NN O O
four NN O O
mutant NN O O
haplotype NN O O
12 NN O O
genes NN O O
, NN O O
and NN O O
a NN O O
G NN O O
- NN O O
to NN O O
- NN O O
A NN O O
transition NN O O
at NN O O
the NN O O
second NN O O
base NN O O
of NN O O
codon NN O O
408 NN O O
, NN O O
resulting NN O O
in NN O O
a NN O O
substitution NN O O
of NN O O
glutamine NN O O
for NN O O
arginine NN O O
, NN O O
in NN O O
another NN O O
three NN O O
mutant NN O O
haplotype NN O O
12 NN O O
genes NN O O
. NN O O

These NN O O
mutations NN O O
segregated NN O O
with NN O O
mutant NN O O
haplotype NN O O
12 NN O O
alleles NN O O
in NN O O
nuclear NN O O
families NN O O
but NN O O
were NN O O
not NN O O
present NN O O
on NN O O
normal NN O O
or NN O O
other NN O O
mutant NN O O
alleles NN O O
. NN O O

Both NN O O
mutations NN O O
were NN O O
tested NN O O
in NN O O
a NN O O
eukaryotic NN O O
expression NN O O
system NN O O
in NN O O
which NN O O
enzyme NN O O
activities NN O O
of NN O O
different NN O O
mutant NN O O
PAH NN O O
enzymes NN O O
reflect NN O O
the NN O O
relative NN O O
severities NN O O
of NN O O
the NN O O
mutations NN O O
, NN O O
although NN O O
these NN O O
in NN O O
vitro NN O O
activities NN O O
cannot NN O O
be NN O O
translated NN O O
directly NN O O
into NN O O
in NN O O
vivo NN O O
hepatic NN O O
activities NN O O
. NN O O

The NN O O
A322G NN O O
mutant NN O O
PAH NN O O
had NN O O
about NN O O
75 NN O O
% NN O O
and NN O O
the NN O O
R408Q NN O O
mutant NN O O
PAH NN O O
about NN O O
55 NN O O
% NN O O
of NN O O
the NN O O
wild NN O O
- NN O O
type NN O O
PAH NN O O
enzyme NN O O
activity NN O O
. NN O O

These NN O O
in NN O O
vitro NN O O
activities NN O O
are NN O O
the NN O O
highest NN O O
reported NN O O
for NN O O
mutant NN O O
PAH NN O O
enzymes NN O O
produced NN O O
in NN O O
the NN O O
same NN O O
expression NN O O
system NN O O
. NN O O

( NN O O
ABSTRACT NN O O
TRUNCATED NN O O
AT NN O O
250 NN O O
WORDS NN O O
) NN O O
. NN O O

In NN O O
vitro NN O O
and NN O O
in NN O O
vivo NN O O
correlations NN O O
for NN O O
I65T NN O O
and NN O O
M1V NN O O
mutations NN O O
at NN O O
the NN O O
phenylalanine NN O O
hydroxylase NN O O
locus NN O O
. NN O O

Mutations NN O O
at NN O O
the NN O O
phenylalanine NN O O
hydroxylase NN O O
( NN O O
PAH NN O O
) NN O O
locus NN O O
are NN O O
the NN O O
major NN O O
cause NN O O
of NN O O
hyperphenylalaninemia NN O B-Disease
. NN O O

We NN O O
have NN O O
previously NN O O
described NN O O
four NN O O
mutations NN O O
( NN O O
M1V NN O O
, NN O O
IVS12nt1 NN O O
, NN O O
R408W NN O O
, NN O O
and NN O O
S349P NN O O
) NN O O
at NN O O
the NN O O
PAH NN O O
locus NN O O
in NN O O
French NN O O
Canadians NN O O
with NN O O
ancestry NN O O
in NN O O
eastern NN O O
Quebec NN O O
. NN O O

Here NN O O
we NN O O
report NN O O
( NN O O
1 NN O O
) NN O O
identification NN O O
of NN O O
another NN O O
mutation NN O O
, NN O O
on NN O O
a NN O O
haplotype NN O O
9 NN O O
chromosome NN O O
, NN O O
which NN O O
converts NN O O
codon NN O O
65 NN O O
from NN O O
isoleucine NN O O
( NN O O
ATT NN O O
) NN O O
to NN O O
threonine NN O O
( NN O O
ACT NN O O
) NN O O
, NN O O
( NN O O
2 NN O O
) NN O O
expression NN O O
analysis NN O O
of NN O O
the NN O O
I65T NN O O
mutation NN O O
in NN O O
COS NN O O
cells NN O O
demonstrating NN O O
75 NN O O
% NN O O
loss NN O O
of NN O O
both NN O O
immunoreactive NN O O
protein NN O O
and NN O O
enzyme NN O O
activity NN O O
, NN O O
and NN O O
( NN O O
3 NN O O
) NN O O
expression NN O O
analysis NN O O
of NN O O
the NN O O
most NN O O
prevalent NN O O
PKU NN O B-Disease
allele NN O O
( NN O O
M1V NN O O
) NN O O
in NN O O
eastern NN O O
Quebec NN O O
, NN O O
showing NN O O
nondetectable NN O O
levels NN O O
of NN O O
PAH NN O O
protein NN O O
and NN O O
activity NN O O
, NN O O
a NN O O
finding NN O O
compatible NN O O
with NN O O
a NN O O
mutation NN O O
in NN O O
the NN O O
translation NN O O
initiation NN O O
codon NN O O
. NN O O

Homozygosity NN O O
for NN O O
M1V NN O O
and NN O O
codominant NN O O
inheritance NN O O
of NN O O
I65T NN O O
/ NN O O
R408W NN O O
were NN O O
both NN O O
associated NN O O
with NN O O
classical NN O B-Disease
phenylketonuria NN O I-Disease
. NN O O
. NN O O

Molecular NN O O
basis NN O O
of NN O O
hexosaminidase NN O B-Disease
A NN O I-Disease
deficiency NN O I-Disease
and NN O O
pseudodeficiency NN O O
in NN O O
the NN O O
Berks NN O O
County NN O O
Pennsylvania NN O O
Dutch NN O O
. NN O O

Following NN O O
the NN O O
birth NN O O
of NN O O
two NN O O
infants NN O O
with NN O O
Tay NN O B-Disease
- NN O I-Disease
Sachs NN O I-Disease
disease NN O I-Disease
( NN O O
TSD NN O B-Disease
) NN O O
, NN O O
a NN O O
non NN O O
- NN O O
Jewish NN O O
, NN O O
Pennsylvania NN O O
Dutch NN O O
kindred NN O O
was NN O O
screened NN O O
for NN O O
TSD NN O B-Disease
carriers NN O O
using NN O O
the NN O O
biochemical NN O O
assay NN O O
. NN O O

A NN O O
high NN O O
frequency NN O O
of NN O O
individuals NN O O
who NN O O
appeared NN O O
to NN O O
be NN O O
TSD NN O B-Disease
heterozygotes NN O O
was NN O O
detected NN O O
( NN O O
Kelly NN O O
et NN O O
al NN O O
. NN O O
, NN O O
1975 NN O O
) NN O O
. NN O O

Clinical NN O O
and NN O O
biochemical NN O O
evidence NN O O
suggested NN O O
that NN O O
the NN O O
increased NN O O
carrier NN O O
frequency NN O O
was NN O O
due NN O O
to NN O O
at NN O O
least NN O O
two NN O O
altered NN O O
alleles NN O O
for NN O O
the NN O O
hexosaminidase NN O O
A NN O O
alpha NN O O
- NN O O
subunit NN O O
. NN O O

We NN O O
now NN O O
report NN O O
two NN O O
mutant NN O O
alleles NN O O
in NN O O
this NN O O
Pennsylvania NN O O
Dutch NN O O
kindred NN O O
, NN O O
and NN O O
one NN O O
polymorphism NN O O
. NN O O

One NN O O
allele NN O O
, NN O O
reported NN O O
originally NN O O
in NN O O
a NN O O
French NN O O
TSD NN O B-Disease
patient NN O O
( NN O O
Akli NN O O
et NN O O
al NN O O
. NN O O
, NN O O
1991 NN O O
) NN O O
, NN O O
is NN O O
a NN O O
GT NN O O
- NN O O
- NN O O
> NN O O
AT NN O O
transition NN O O
at NN O O
the NN O O
donor NN O O
splice NN O O
- NN O O
site NN O O
of NN O O
intron NN O O
9 NN O O
. NN O O

The NN O O
second NN O O
, NN O O
a NN O O
C NN O O
- NN O O
- NN O O
> NN O O
T NN O O
transition NN O O
at NN O O
nucleotide NN O O
739 NN O O
( NN O O
Arg247Trp NN O O
) NN O O
, NN O O
has NN O O
been NN O O
shown NN O O
by NN O O
Triggs NN O O
- NN O O
Raine NN O O
et NN O O
al NN O O
. NN O O

( NN O O
1992 NN O O
) NN O O
to NN O O
be NN O O
a NN O O
clinically NN O O
benign NN O O
" NN O O
pseudodeficient NN O O
" NN O O
allele NN O O
associated NN O O
with NN O O
reduced NN O O
enzyme NN O O
activity NN O O
against NN O O
artificial NN O O
substrate NN O O
. NN O O

Finally NN O O
, NN O O
a NN O O
polymorphism NN O O
[ NN O O
G NN O O
- NN O O
- NN O O
> NN O O
A NN O O
( NN O O
759 NN O O
) NN O O
] NN O O
, NN O O
which NN O O
leaves NN O O
valine NN O O
at NN O O
codon NN O O
253 NN O O
unchanged NN O O
, NN O O
is NN O O
described NN O O
. NN O O

A NN O O
mutation NN O O
common NN O O
in NN O O
non NN O O
- NN O O
Jewish NN O O
Tay NN O B-Disease
- NN O I-Disease
Sachs NN O I-Disease
disease NN O I-Disease
: NN O O
frequency NN O O
and NN O O
RNA NN O O
studies NN O O
. NN O O

Tay NN O B-Disease
- NN O I-Disease
Sachs NN O I-Disease
disease NN O I-Disease
( NN O O
TSD NN O B-Disease
) NN O O
is NN O O
an NN O O
autosomal NN O B-Disease
recessive NN O I-Disease
genetic NN O I-Disease
disorder NN O I-Disease
resulting NN O O
from NN O O
mutation NN O O
of NN O O
the NN O O
HEXA NN O O
gene NN O O
encoding NN O O
the NN O O
alpha NN O O
- NN O O
subunit NN O O
of NN O O
the NN O O
lysosomal NN O O
enzyme NN O O
, NN O O
beta NN O O
- NN O O
N NN O O
- NN O O
acetylhexosaminidase NN O O
A NN O O
( NN O O
Hex NN O O
A NN O O
) NN O O
. NN O O

We NN O O
have NN O O
discovered NN O O
that NN O O
a NN O O
Tay NN O B-Disease
- NN O I-Disease
Sachs NN O I-Disease
mutation NN O O
, NN O O
IVS NN O O
- NN O O
9 NN O O
+ NN O O
1 NN O O
G NN O O
- NN O O
- NN O O
> NN O O
A NN O O
, NN O O
first NN O O
detected NN O O
by NN O O
Akli NN O O
et NN O O
al NN O O
. NN O O

( NN O O
Genomics NN O O
11 NN O O
124 NN O O
- NN O O
134 NN O O
, NN O O
1991 NN O O
) NN O O
, NN O O
is NN O O
a NN O O
common NN O O
disease NN O O
allele NN O O
in NN O O
non NN O O
- NN O O
Jewish NN O O
Caucasians NN O O
( NN O O
10 NN O O
/ NN O O
58 NN O O
alleles NN O O
examined NN O O
) NN O O
. NN O O

A NN O O
PCR NN O O
- NN O O
based NN O O
diagnostic NN O O
test NN O O
, NN O O
which NN O O
detects NN O O
an NN O O
NlaIII NN O O
site NN O O
generated NN O O
by NN O O
the NN O O
mutation NN O O
, NN O O
revealed NN O O
a NN O O
frequency NN O O
among NN O O
enzyme NN O O
- NN O O
defined NN O O
carriers NN O O
of NN O O
9 NN O O
/ NN O O
64 NN O O
( NN O O
14 NN O O
% NN O O
) NN O O
. NN O O

Most NN O O
of NN O O
those NN O O
carrying NN O O
the NN O O
allele NN O O
trace NN O O
their NN O O
origins NN O O
to NN O O
the NN O O
United NN O O
Kingdom NN O O
, NN O O
Ireland NN O O
, NN O O
or NN O O
Western NN O O
Europe NN O O
. NN O O

It NN O O
was NN O O
not NN O O
identified NN O O
among NN O O
12 NN O O
Black NN O O
American NN O O
TSD NN O B-Disease
alleles NN O O
or NN O O
in NN O O
any NN O O
of NN O O
18 NN O O
Ashkenazi NN O O
Jewish NN O O
, NN O O
enzyme NN O O
- NN O O
defined NN O O
carriers NN O O
who NN O O
did NN O O
not NN O O
carry NN O O
any NN O O
of NN O O
the NN O O
mutations NN O O
common NN O O
to NN O O
this NN O O
population NN O O
. NN O O

No NN O O
normally NN O O
spliced NN O O
RNA NN O O
was NN O O
detected NN O O
in NN O O
PCR NN O O
products NN O O
generated NN O O
from NN O O
reverse NN O O
transcription NN O O
of NN O O
RNA NN O O
carrying NN O O
the NN O O
IVS NN O O
- NN O O
9 NN O O
mutation NN O O
. NN O O

Instead NN O O
, NN O O
the NN O O
low NN O O
levels NN O O
of NN O O
mRNA NN O O
from NN O O
this NN O O
allele NN O O
were NN O O
comprised NN O O
of NN O O
aberrant NN O O
species NN O O
resulting NN O O
from NN O O
the NN O O
use NN O O
of NN O O
either NN O O
of NN O O
two NN O O
cryptic NN O O
donor NN O O
sites NN O O
, NN O O
one NN O O
truncating NN O O
exon NN O O
9 NN O O
and NN O O
the NN O O
other NN O O
within NN O O
IVS NN O O
- NN O O
9 NN O O
, NN O O
spliced NN O O
to NN O O
exon NN O O
10 NN O O
. NN O O

Numerous NN O O
additional NN O O
splice NN O O
products NN O O
were NN O O
detected NN O O
, NN O O
most NN O O
involving NN O O
skipping NN O O
of NN O O
one NN O O
or NN O O
more NN O O
surrounding NN O O
exons NN O O
. NN O O

Together NN O O
with NN O O
a NN O O
recently NN O O
identified NN O O
allele NN O O
responsible NN O O
for NN O O
Hex NN O O
A NN O O
pseudodeficiency NN O O
( NN O O
Triggs NN O O
- NN O O
Raine NN O O
et NN O O
al NN O O
. NN O O
Am NN O O
J NN O O
Hum NN O O
Genet NN O O
, NN O O
1992 NN O O
) NN O O
, NN O O
these NN O O
two NN O O
alleles NN O O
accounted NN O O
for NN O O
almost NN O O
50 NN O O
% NN O O
( NN O O
29 NN O O
/ NN O O
64 NN O O
) NN O O
of NN O O
TSD NN O B-Disease
or NN O O
carrier NN O O
alleles NN O O
ascertained NN O O
by NN O O
enzyme NN O O
screening NN O O
tests NN O O
in NN O O
non NN O O
- NN O O
Jewish NN O O
Caucasians NN O O
. NN O O
. NN O O

Aberrant NN O O
splicing NN O O
of NN O O
the NN O O
CHM NN O B-Disease
gene NN O O
is NN O O
a NN O O
significant NN O O
cause NN O O
of NN O O
choroideremia NN O B-Disease
. NN O O

Choroideremia NN O B-Disease
( NN O O
CHM NN O B-Disease
) NN O O
is NN O O
an NN O O
X NN O B-Disease
- NN O I-Disease
linked NN O I-Disease
progressive NN O I-Disease
degeneration NN O I-Disease
of NN O I-Disease
the NN O I-Disease
choroid NN O I-Disease
and NN O I-Disease
retina NN O I-Disease
. NN O O

12 NN O O
% NN O O
of NN O O
unrelated NN O O
male NN O O
patients NN O O
carry NN O O
deletions NN O O
of NN O O
the NN O O
partially NN O O
cloned NN O O
CHM NN O B-Disease
gene NN O O
. NN O O

In NN O O
Finland NN O O
, NN O O
there NN O O
are NN O O
more NN O O
than NN O O
120 NN O O
living NN O O
CHM NN O B-Disease
patients NN O O
belonging NN O O
to NN O O
eight NN O O
apparently NN O O
unrelated NN O O
pedigrees NN O O
. NN O O

Molecular NN O O
deletions NN O O
involving NN O O
the NN O O
CHM NN O B-Disease
gene NN O O
have NN O O
been NN O O
detected NN O O
in NN O O
three NN O O
families NN O O
. NN O O

We NN O O
have NN O O
screened NN O O
the NN O O
remaining NN O O
five NN O O
families NN O O
for NN O O
point NN O O
mutations NN O O
. NN O O

In NN O O
one NN O O
large NN O O
family NN O O
a NN O O
single NN O O
nucleotide NN O O
( NN O O
T NN O O
) NN O O
insertion NN O O
into NN O O
the NN O O
donor NN O O
splice NN O O
site NN O O
of NN O O
exon NN O O
C NN O O
leads NN O O
to NN O O
two NN O O
aberrantly NN O O
spliced NN O O
mRNAs NN O O
both NN O O
producing NN O O
a NN O O
premature NN O O
stop NN O O
codon NN O O
. NN O O

The NN O O
mutation NN O O
can NN O O
be NN O O
assayed NN O O
easily NN O O
by NN O O
amplification NN O O
and NN O O
digestion NN O O
with NN O O
Msel NN O O
. NN O O

Our NN O O
findings NN O O
provide NN O O
additional NN O O
evidence NN O O
for NN O O
the NN O O
pathogenetic NN O O
role NN O O
of NN O O
CHM NN O B-Disease
mutations NN O O
and NN O O
provide NN O O
a NN O O
diagnostic NN O O
tool NN O O
for NN O O
one NN O O
fifth NN O O
of NN O O
the NN O O
worlds NN O O
known NN O O
CHM NN O B-Disease
patients NN O O
. NN O O
. NN O O

Germline NN O O
intronic NN O O
and NN O O
exonic NN O O
mutations NN O O
in NN O O
the NN O O
Wilms NN O B-Disease
' NN O I-Disease
tumour NN O I-Disease
gene NN O O
( NN O O
WT1 NN O O
) NN O O
affecting NN O O
urogenital NN O O
development NN O O
. NN O O

Denys NN O B-Disease
- NN O I-Disease
Drash NN O I-Disease
syndrome NN O I-Disease
is NN O O
a NN O O
rare NN O O
human NN O O
developmental NN O B-Disease
disorder NN O I-Disease
affecting NN O O
the NN O O
urogenital NN O O
system NN O O
and NN O O
leading NN O O
to NN O O
renal NN O B-Disease
failure NN O I-Disease
, NN O O
intersex NN O B-Disease
disorders NN O I-Disease
and NN O O
Wilms NN O B-Disease
tumour NN O I-Disease
. NN O O

In NN O O
this NN O O
report NN O O
, NN O O
four NN O O
individuals NN O O
with NN O O
this NN O O
syndrome NN O O
are NN O O
described NN O O
carrying NN O O
germline NN O O
point NN O O
mutations NN O O
in NN O O
the NN O O
Wilms NN O B-Disease
tumour NN O I-Disease
suppressor NN O O
gene NN O O
, NN O O
WT1 NN O O
. NN O O

Three NN O O
of NN O O
these NN O O
mutations NN O O
were NN O O
in NN O O
the NN O O
zinc NN O O
finger NN O O
domains NN O O
of NN O O
WT1 NN O O
. NN O O

The NN O O
fourth NN O O
occurred NN O O
within NN O O
intron NN O O
9 NN O O
, NN O O
preventing NN O O
splicing NN O O
at NN O O
one NN O O
of NN O O
the NN O O
alternatively NN O O
chosen NN O O
splice NN O O
donor NN O O
sites NN O O
of NN O O
exon NN O O
9 NN O O
when NN O O
assayed NN O O
in NN O O
vitro NN O O
. NN O O

These NN O O
results NN O O
provide NN O O
genetic NN O O
evidence NN O O
for NN O O
distinct NN O O
functional NN O O
roles NN O O
of NN O O
the NN O O
WT1 NN O O
isoforms NN O O
in NN O O
urogenital NN O O
development NN O O
. NN O O
. NN O O

Characterization NN O O
of NN O O
the NN O O
myotonic NN O B-Disease
dystrophy NN O I-Disease
region NN O O
predicts NN O O
multiple NN O O
protein NN O O
isoform NN O O
- NN O O
encoding NN O O
mRNAs NN O O
. NN O O

The NN O O
mutation NN O O
underlying NN O O
myotonic NN O B-Disease
dystrophy NN O I-Disease
( NN O O
DM NN O B-Disease
) NN O O
has NN O O
been NN O O
identified NN O O
as NN O O
an NN O O
expansion NN O O
of NN O O
a NN O O
polymorphic NN O O
CTG NN O O
- NN O O
repeat NN O O
in NN O O
a NN O O
gene NN O O
encoding NN O O
protein NN O O
kinase NN O O
activity NN O O
. NN O O

Brain NN O O
and NN O O
heart NN O O
transcripts NN O O
of NN O O
the NN O O
DM NN O O
- NN O O
kinase NN O O
( NN O O
DMR NN O O
- NN O O
B15 NN O O
) NN O O
gene NN O O
are NN O O
subject NN O O
to NN O O
alternative NN O O
RNA NN O O
splicing NN O O
in NN O O
both NN O O
human NN O O
and NN O O
mouse NN O O
. NN O O

The NN O O
unstable NN O O
[ NN O O
CTG NN O O
] NN O O
5 NN O O
- NN O O
30 NN O O
motif NN O O
is NN O O
found NN O O
uniquely NN O O
in NN O O
humans NN O O
, NN O O
although NN O O
the NN O O
flanking NN O O
nucleotides NN O O
are NN O O
also NN O O
present NN O O
in NN O O
mouse NN O O
. NN O O

Characterization NN O O
of NN O O
the NN O O
DM NN O B-Disease
region NN O O
of NN O O
both NN O O
species NN O O
reveals NN O O
another NN O O
active NN O O
gene NN O O
( NN O O
DMR NN O O
- NN O O
N9 NN O O
) NN O O
in NN O O
close NN O O
proximity NN O O
to NN O O
the NN O O
kinase NN O O
gene NN O O
. NN O O

DMR NN O O
- NN O O
N9 NN O O
transcripts NN O O
, NN O O
mainly NN O O
expressed NN O O
in NN O O
brain NN O O
and NN O O
testis NN O O
, NN O O
possess NN O O
a NN O O
single NN O O
, NN O O
large NN O O
open NN O O
reading NN O O
frame NN O O
, NN O O
but NN O O
the NN O O
function NN O O
of NN O O
its NN O O
protein NN O O
product NN O O
is NN O O
unknown NN O O
. NN O O

Clinical NN O O
manifestation NN O O
of NN O O
DM NN O B-Disease
may NN O O
be NN O O
caused NN O O
by NN O O
the NN O O
expanded NN O O
CTG NN O O
- NN O O
repeat NN O O
compromising NN O O
the NN O O
( NN O O
alternative NN O O
) NN O O
expression NN O O
of NN O O
DM NN O O
- NN O O
kinase NN O O
or NN O O
DMR NN O O
- NN O O
N9 NN O O
proteins NN O O
. NN O O
. NN O O

Fragile NN O B-Disease
X NN O I-Disease
syndrome NN O I-Disease
without NN O O
CCG NN O O
amplification NN O O
has NN O O
an NN O O
FMR1 NN O O
deletion NN O O
. NN O O

We NN O O
describe NN O O
a NN O O
patient NN O O
with NN O O
typical NN O O
clinical NN O O
features NN O O
of NN O O
the NN O O
fragile NN O B-Disease
X NN O I-Disease
syndrome NN O I-Disease
, NN O O
but NN O O
without NN O O
cytogenetic NN O O
expression NN O O
of NN O O
the NN O O
fragile NN O B-Disease
X NN O I-Disease
or NN O O
an NN O O
amplified NN O O
CCG NN O O
trinucleotide NN O O
repeat NN O O
fragment NN O O
. NN O O

The NN O O
patient NN O O
has NN O O
a NN O O
previously NN O O
uncharacterized NN O O
submicroscopic NN O O
deletion NN O O
encompassing NN O O
the NN O O
CCG NN O O
repeat NN O O
, NN O O
the NN O O
entire NN O O
FMR1 NN O O
gene NN O O
and NN O O
about NN O O
2 NN O O
. NN O O

5 NN O O
megabases NN O O
of NN O O
flanking NN O O
sequences NN O O
. NN O O

This NN O O
finding NN O O
confirms NN O O
that NN O O
the NN O O
fragile NN O B-Disease
X NN O I-Disease
phenotype NN O O
can NN O O
exist NN O O
, NN O O
without NN O O
amplification NN O O
of NN O O
the NN O O
CCG NN O O
repeat NN O O
or NN O O
cytogenetic NN O O
expression NN O O
of NN O O
the NN O O
fragile NN O B-Disease
X NN O I-Disease
, NN O O
and NN O O
that NN O O
fragile NN O B-Disease
X NN O I-Disease
syndrome NN O I-Disease
is NN O O
a NN O O
genetically NN O O
homogeneous NN O O
disorder NN O O
involving NN O O
FMR1 NN O O
. NN O O

We NN O O
also NN O O
found NN O O
random NN O O
X NN O O
- NN O O
inactivation NN O O
in NN O O
the NN O O
mother NN O O
of NN O O
the NN O O
patient NN O O
who NN O O
was NN O O
shown NN O O
to NN O O
be NN O O
a NN O O
carrier NN O O
of NN O O
this NN O O
deletion NN O O
. NN O O

Cloning NN O O
of NN O O
the NN O O
Huntington NN O B-Disease
disease NN O I-Disease
region NN O O
in NN O O
yeast NN O O
artificial NN O O
chromosomes NN O O
. NN O O

The NN O O
gene NN O O
responsible NN O O
for NN O O
Huntington NN O B-Disease
disease NN O I-Disease
has NN O O
been NN O O
localized NN O O
to NN O O
a NN O O
2 NN O O
. NN O O

5 NN O O
million NN O O
base NN O O
pair NN O O
( NN O O
Mb NN O O
) NN O O
region NN O O
between NN O O
the NN O O
loci NN O O
D4S10 NN O O
and NN O O
D4S168 NN O O
on NN O O
the NN O O
short NN O O
arm NN O O
of NN O O
chromosome NN O O
4 NN O O
. NN O O

As NN O O
part NN O O
of NN O O
a NN O O
strategy NN O O
to NN O O
clone NN O O
the NN O O
HD NN O B-Disease
gene NN O O
on NN O O
the NN O O
basis NN O O
of NN O O
its NN O O
chromosomal NN O O
location NN O O
, NN O O
we NN O O
isolated NN O O
genomic NN O O
DNA NN O O
from NN O O
the NN O O
HD NN O B-Disease
region NN O O
as NN O O
a NN O O
set NN O O
of NN O O
overlapping NN O O
yeast NN O O
artificial NN O O
chromosome NN O O
( NN O O
YAC NN O O
) NN O O
clones NN O O
. NN O O

Twenty NN O O
- NN O O
eight NN O O
YAC NN O O
clones NN O O
were NN O O
identified NN O O
by NN O O
screening NN O O
human NN O O
YAC NN O O
libraries NN O O
with NN O O
twelve NN O O
PCR NN O O
- NN O O
based NN O O
sequence NN O O
- NN O O
tagged NN O O
sites NN O O
( NN O O
STSs NN O O
) NN O O
from NN O O
the NN O O
region NN O O
. NN O O

We NN O O
assembled NN O O
the NN O O
YAC NN O O
clones NN O O
into NN O O
overlapping NN O O
sets NN O O
by NN O O
hybridizing NN O O
them NN O O
to NN O O
a NN O O
large NN O O
number NN O O
of NN O O
DNA NN O O
probes NN O O
from NN O O
the NN O O
HD NN O B-Disease
region NN O O
, NN O O
including NN O O
the NN O O
STSs NN O O
. NN O O

In NN O O
addition NN O O
, NN O O
we NN O O
isolated NN O O
the NN O O
ends NN O O
of NN O O
the NN O O
human NN O O
DNA NN O O
inserts NN O O
of NN O O
most NN O O
of NN O O
the NN O O
YAC NN O O
clones NN O O
to NN O O
assist NN O O
in NN O O
the NN O O
construction NN O O
of NN O O
the NN O O
contig NN O O
. NN O O

Although NN O O
almost NN O O
half NN O O
of NN O O
the NN O O
YACs NN O O
appear NN O O
to NN O O
contain NN O O
chimeric NN O O
inserts NN O O
and NN O O
several NN O O
contain NN O O
internal NN O O
deletions NN O O
or NN O O
other NN O O
rearrangements NN O O
, NN O O
we NN O O
were NN O O
able NN O O
to NN O O
obtain NN O O
over NN O O
2 NN O O
. NN O O

2 NN O O
Mb NN O O
of NN O O
the NN O O
HD NN O B-Disease
region NN O O
in NN O O
YACs NN O O
, NN O O
including NN O O
one NN O O
continuous NN O O
segment NN O O
of NN O O
2 NN O O
. NN O O

0 NN O O
Mb NN O O
covering NN O O
the NN O O
region NN O O
that NN O O
most NN O O
likely NN O O
contains NN O O
the NN O O
HD NN O B-Disease
gene NN O O
. NN O O

Ten NN O O
of NN O O
the NN O O
twenty NN O O
eight NN O O
YAC NN O O
clones NN O O
comprise NN O O
a NN O O
minimal NN O O
set NN O O
spanning NN O O
the NN O O
2 NN O O
. NN O O

2 NN O O
Mb NN O O
. NN O O

These NN O O
clones NN O O
provide NN O O
reagents NN O O
for NN O O
the NN O O
complete NN O O
characterization NN O O
of NN O O
this NN O O
region NN O O
of NN O O
the NN O O
genome NN O O
and NN O O
for NN O O
the NN O O
eventual NN O O
isolation NN O O
of NN O O
the NN O O
HD NN O B-Disease
gene NN O O
. NN O O

Characterization NN O O
of NN O O
a NN O O
YAC NN O O
containing NN O O
part NN O O
or NN O O
all NN O O
of NN O O
the NN O O
Norrie NN O B-Disease
disease NN O I-Disease
locus NN O O
. NN O O

It NN O O
has NN O O
been NN O O
shown NN O O
from NN O O
pulsed NN O O
- NN O O
field NN O O
gel NN O O
electrophoresis NN O O
( NN O O
PFGE NN O O
) NN O O
that NN O O
the NN O O
monoamine NN O O
oxidase NN O O
genes NN O O
A NN O O
and NN O O
B NN O O
( NN O O
MAOA NN O O
& NN O O
MAOB NN O O
) NN O O
and NN O O
DXS7 NN O O
loci NN O O
are NN O O
physically NN O O
very NN O O
close NN O O
. NN O O

We NN O O
have NN O O
therefore NN O O
extended NN O O
studies NN O O
on NN O O
their NN O O
relationship NN O O
through NN O O
the NN O O
characterisation NN O O
of NN O O
a NN O O
650 NN O O
kb NN O O
YAC NN O O
isolated NN O O
using NN O O
L1 NN O O
. NN O O

28 NN O O
( NN O O
recognising NN O O
the NN O O
DXS7 NN O O
locus NN O O
) NN O O
as NN O O
a NN O O
probe NN O O
. NN O O

Restriction NN O O
mapping NN O O
of NN O O
the NN O O
YAC NN O O
indicates NN O O
that NN O O
it NN O O
contains NN O O
both NN O O
MAOA NN O O
and NN O O
MAOB NN O O
genes NN O O
in NN O O
addition NN O O
to NN O O
the NN O O
DXS7 NN O O
locus NN O O
. NN O O

The NN O O
map NN O O
derived NN O O
from NN O O
the NN O O
YL1 NN O O
. NN O O

28 NN O O
- NN O O
YAC NN O O
is NN O O
compatible NN O O
both NN O O
with NN O O
the NN O O
map NN O O
from NN O O
an NN O O
independently NN O O
derived NN O O
YAC NN O O
carrying NN O O
MAOA NN O O
and NN O O
B NN O O
genes NN O O
and NN O O
with NN O O
the NN O O
long NN O O
range NN O O
genomic NN O O
map NN O O
for NN O O
the NN O O
region NN O O
. NN O O

A NN O O
series NN O O
of NN O O
subclones NN O O
prepared NN O O
from NN O O
a NN O O
phage NN O O
library NN O O
( NN O O
lambda NN O O
DASH NN O O
II NN O O
) NN O O
of NN O O
the NN O O
YAC NN O O
have NN O O
been NN O O
characterised NN O O
and NN O O
have NN O O
been NN O O
employed NN O O
to NN O O
determine NN O O
the NN O O
end NN O O
point NN O O
of NN O O
the NN O O
deletion NN O O
of NN O O
a NN O O
Norrie NN O B-Disease
disease NN O I-Disease
( NN O O
NDP NN O B-Disease
) NN O O
patient NN O O
who NN O O
has NN O O
been NN O O
shown NN O O
to NN O O
lack NN O O
both NN O O
DXS7 NN O O
and NN O O
MAO NN O O
coding NN O O
sequences NN O O
. NN O O

The NN O O
pattern NN O O
of NN O O
retention NN O O
of NN O O
subclones NN O O
in NN O O
the NN O O
deletion NN O O
patient NN O O
place NN O O
the NN O O
end NN O O
point NN O O
of NN O O
the NN O O
deletion NN O O
within NN O O
30 NN O O
- NN O O
130 NN O O
kb NN O O
of NN O O
the NN O O
proximal NN O O
end NN O O
of NN O O
the NN O O
YAC NN O O
. NN O O

By NN O O
combining NN O O
the NN O O
data NN O O
with NN O O
established NN O O
recombination NN O O
analysis NN O O
, NN O O
we NN O O
provide NN O O
evidence NN O O
that NN O O
all NN O O
or NN O O
part NN O O
of NN O O
the NN O O
NDP NN O O
lies NN O O
in NN O O
the NN O O
interval NN O O
of NN O O
approximately NN O O
250kb NN O O
within NN O O
the NN O O
YAC NN O O
. NN O O

Both NN O O
mutations NN O O
in NN O O
G6PD NN O O
A NN O O
- NN O O
are NN O O
necessary NN O O
to NN O O
produce NN O O
the NN O O
G6PD NN O B-Disease
deficient NN O I-Disease
phenotype NN O O
. NN O O

The NN O O
high NN O O
prevalence NN O O
of NN O O
glucose NN O B-Disease
6 NN O I-Disease
- NN O I-Disease
phosphate NN O I-Disease
dehydrogenase NN O I-Disease
( NN O I-Disease
G6PD NN O I-Disease
) NN O I-Disease
deficiency NN O I-Disease
in NN O O
African NN O O
populations NN O O
is NN O O
due NN O O
almost NN O O
entirely NN O O
to NN O O
the NN O O
enzyme NN O O
variant NN O O
A NN O O
- NN O O
, NN O O
which NN O O
differs NN O O
from NN O O
the NN O O
wild NN O O
- NN O O
type NN O O
G6PD NN O O
B NN O O
by NN O O
two NN O O
amino NN O O
acid NN O O
replacements NN O O
, NN O O
68 NN O O
Val NN O O
- NN O O
- NN O O
> NN O O
Met NN O O
and NN O O
126 NN O O
Asn NN O O
- NN O O
- NN O O
> NN O O
Asp NN O O
. NN O O

The NN O O
non NN O O
- NN O O
deficient NN O O
polymorphic NN O O
variant NN O O
G6PD NN O O
A NN O O
contains NN O O
only NN O O
the NN O O
mutation NN O O
126 NN O O
Asn NN O O
- NN O O
- NN O O
> NN O O
Asp NN O O
. NN O O

The NN O O
frequencies NN O O
of NN O O
the NN O O
G6PD NN O O
A NN O O
and NN O O
of NN O O
the NN O O
G6PD NN O O
A NN O O
- NN O O
genes NN O O
in NN O O
parts NN O O
of NN O O
Africa NN O O
are NN O O
both NN O O
about NN O O
0 NN O O
. NN O O

2 NN O O
. NN O O

The NN O O
68 NN O O
Val NN O O
- NN O O
- NN O O
> NN O O
Met NN O O
mutation NN O O
has NN O O
not NN O O
been NN O O
found NN O O
in NN O O
a NN O O
B NN O O
background NN O O
. NN O O

This NN O O
could NN O O
be NN O O
because NN O O
the NN O O
68 NN O O
Val NN O O
- NN O O
- NN O O
> NN O O
Met NN O O
mutation NN O O
happened NN O O
to NN O O
arise NN O O
in NN O O
an NN O O
A NN O O
gene NN O O
in NN O O
the NN O O
first NN O O
instance NN O O
, NN O O
or NN O O
because NN O O
the NN O O
68 NN O O
Val NN O O
- NN O O
- NN O O
> NN O O
Met NN O O
mutation NN O O
alone NN O O
is NN O O
not NN O O
sufficient NN O O
to NN O O
cause NN O O
G6PD NN O B-Disease
deficiency NN O I-Disease
. NN O O

We NN O O
have NN O O
approached NN O O
this NN O O
question NN O O
by NN O O
producing NN O O
G6PD NN O O
B NN O O
, NN O O
A NN O O
, NN O O
A NN O O
- NN O O
, NN O O
and NN O O
G6PD NN O O
68 NN O O
Val NN O O
- NN O O
- NN O O
> NN O O
Met NN O O
in NN O O
a NN O O
bacterial NN O O
expression NN O O
system NN O O
and NN O O
analysing NN O O
their NN O O
biochemical NN O O
properties NN O O
. NN O O

With NN O O
each NN O O
single NN O O
mutation NN O O
we NN O O
found NN O O
a NN O O
slight NN O O
decrease NN O O
in NN O O
both NN O O
the NN O O
specific NN O O
activity NN O O
and NN O O
the NN O O
yield NN O O
of NN O O
enzyme NN O O
when NN O O
compared NN O O
to NN O O
G6PD NN O O
B NN O O
. NN O O

When NN O O
both NN O O
mutations NN O O
were NN O O
introduced NN O O
together NN O O
, NN O O
there NN O O
was NN O O
a NN O O
roughly NN O O
additive NN O O
effect NN O O
on NN O O
specific NN O O
activity NN O O
, NN O O
but NN O O
a NN O O
much NN O O
more NN O O
drastic NN O O
effect NN O O
on NN O O
enzyme NN O O
yield NN O O
( NN O O
4 NN O O
% NN O O
of NN O O
normal NN O O
) NN O O
. NN O O

This NN O O
synergistic NN O O
effect NN O O
was NN O O
also NN O O
demonstrated NN O O
on NN O O
thermal NN O O
stability NN O O
, NN O O
especially NN O O
at NN O O
low NN O O
NADP NN O O
concentrations NN O O
. NN O O

Comparable NN O O
results NN O O
were NN O O
produced NN O O
when NN O O
the NN O O
replacement NN O O
119 NN O O
Gln NN O O
- NN O O
- NN O O
> NN O O
Glu NN O O
was NN O O
studied NN O O
instead NN O O
of NN O O
126 NN O O
Asn NN O O
- NN O O
- NN O O
> NN O O
Asp NN O O
. NN O O

We NN O O
infer NN O O
that NN O O
the NN O O
coexistence NN O O
of NN O O
the NN O O
two NN O O
mutations NN O O
is NN O O
responsible NN O O
for NN O O
enzyme NN O B-Disease
deficiency NN O I-Disease
in NN O I-Disease
G6PD NN O I-Disease
A NN O O
- NN O O
because NN O O
they NN O O
act NN O O
synergistically NN O O
in NN O O
causing NN O O
instability NN O O
of NN O O
the NN O O
enzyme NN O O
. NN O O

Small NN O O
nuclear NN O O
ribonucleoprotein NN O O
polypeptide NN O O
N NN O O
( NN O O
SNRPN NN O O
) NN O O
, NN O O
an NN O O
expressed NN O O
gene NN O O
in NN O O
the NN O O
Prader NN O B-Disease
- NN O I-Disease
Willi NN O I-Disease
syndrome NN O I-Disease
critical NN O O
region NN O O
. NN O O

Prader NN O B-Disease
- NN O I-Disease
Willi NN O I-Disease
syndrome NN O I-Disease
( NN O O
PWS NN O B-Disease
) NN O O
is NN O O
associated NN O O
with NN O O
paternally NN O O
derived NN O O
chromosomal NN O O
deletions NN O O
in NN O O
region NN O O
15q11 NN O O
- NN O O
13 NN O O
or NN O O
with NN O O
maternal NN O B-Disease
disomy NN O I-Disease
for NN O I-Disease
chromosome NN O I-Disease
15 NN O I-Disease
. NN O O

Therefore NN O O
, NN O O
loss NN O O
of NN O O
the NN O O
expressed NN O O
paternal NN O O
alleles NN O O
of NN O O
maternally NN O O
imprinted NN O O
genes NN O O
must NN O O
be NN O O
responsible NN O O
for NN O O
the NN O O
PWS NN O B-Disease
phenotype NN O O
. NN O O

We NN O O
have NN O O
mapped NN O O
the NN O O
gene NN O O
encoding NN O O
the NN O O
small NN O O
nuclear NN O O
RNA NN O O
associated NN O O
polypeptide NN O O
SmN NN O O
( NN O O
SNRPN NN O O
) NN O O
to NN O O
human NN O O
chromosome NN O O
15q12 NN O O
and NN O O
a NN O O
processed NN O O
pseudogene NN O O
SNRPNP1 NN O O
to NN O O
chromosome NN O O
region NN O O
6pter NN O O
- NN O O
p21 NN O O
. NN O O

Furthermore NN O O
, NN O O
SNRPN NN O O
was NN O O
mapped NN O O
to NN O O
the NN O O
minimal NN O O
deletion NN O O
interval NN O O
that NN O O
is NN O O
critical NN O O
for NN O O
PWS NN O B-Disease
. NN O O

The NN O O
fact NN O O
that NN O O
the NN O O
mouse NN O O
Snrpn NN O O
gene NN O O
is NN O O
maternally NN O O
imprinted NN O O
in NN O O
brain NN O O
suggests NN O O
that NN O O
loss NN O O
of NN O O
the NN O O
paternally NN O O
derived NN O O
SNRPN NN O O
allele NN O O
may NN O O
be NN O O
involved NN O O
in NN O O
the NN O O
PWS NN O B-Disease
phenotype NN O O
. NN O O
. NN O O

The NN O O
presence NN O O
of NN O O
two NN O O
different NN O O
infantile NN O O
Tay NN O B-Disease
- NN O I-Disease
Sachs NN O I-Disease
disease NN O I-Disease
mutations NN O O
in NN O O
a NN O O
Cajun NN O O
population NN O O
. NN O O

A NN O O
study NN O O
was NN O O
undertaken NN O O
to NN O O
characterize NN O O
the NN O O
mutation NN O O
( NN O O
s NN O O
) NN O O
responsible NN O O
for NN O O
Tay NN O B-Disease
- NN O I-Disease
Sachs NN O I-Disease
disease NN O I-Disease
( NN O O
TSD NN O B-Disease
) NN O O
in NN O O
a NN O O
Cajun NN O O
population NN O O
in NN O O
southwest NN O O
Louisiana NN O O
and NN O O
to NN O O
identify NN O O
the NN O O
origins NN O O
of NN O O
these NN O O
mutations NN O O
. NN O O

Eleven NN O O
of NN O O
12 NN O O
infantile NN O O
TSD NN O B-Disease
alleles NN O O
examined NN O O
in NN O O
six NN O O
families NN O O
had NN O O
the NN O O
beta NN O O
- NN O O
hexosaminidase NN O O
A NN O O
( NN O O
Hex NN O O
A NN O O
) NN O O
alpha NN O O
- NN O O
subunit NN O O
exon NN O O
11 NN O O
insertion NN O O
mutation NN O O
that NN O O
is NN O O
present NN O O
in NN O O
approximately NN O O
70 NN O O
% NN O O
of NN O O
Ashkenazi NN O O
Jewish NN O O
TSD NN O B-Disease
heterozygotes NN O O
. NN O O

The NN O O
mutation NN O O
in NN O O
the NN O O
remaining NN O O
allele NN O O
was NN O O
a NN O O
single NN O O
- NN O O
base NN O O
transition NN O O
in NN O O
the NN O O
donor NN O O
splice NN O O
site NN O O
of NN O O
the NN O O
alpha NN O O
- NN O O
subunit NN O O
intron NN O O
9 NN O O
. NN O O

To NN O O
determine NN O O
the NN O O
origins NN O O
of NN O O
these NN O O
two NN O O
mutations NN O O
in NN O O
the NN O O
Cajun NN O O
population NN O O
, NN O O
the NN O O
TSD NN O B-Disease
carrier NN O O
status NN O O
was NN O O
enzymatically NN O O
determined NN O O
for NN O O
90 NN O O
members NN O O
of NN O O
four NN O O
of NN O O
the NN O O
six NN O O
families NN O O
, NN O O
and NN O O
extensive NN O O
pedigrees NN O O
were NN O O
constructed NN O O
for NN O O
all NN O O
carriers NN O O
. NN O O

A NN O O
single NN O O
ancestral NN O O
couple NN O O
from NN O O
France NN O O
was NN O O
found NN O O
to NN O O
be NN O O
common NN O O
to NN O O
most NN O O
of NN O O
the NN O O
carriers NN O O
of NN O O
the NN O O
exon NN O O
11 NN O O
insertion NN O O
. NN O O

Pedigree NN O O
data NN O O
suggest NN O O
that NN O O
this NN O O
mutation NN O O
has NN O O
been NN O O
in NN O O
the NN O O
Cajun NN O O
population NN O O
since NN O O
its NN O O
founding NN O O
over NN O O
2 NN O O
centuries NN O O
ago NN O O
and NN O O
that NN O O
it NN O O
may NN O O
be NN O O
widely NN O O
distributed NN O O
within NN O O
the NN O O
population NN O O
. NN O O

In NN O O
contrast NN O O
, NN O O
the NN O O
intron NN O O
9 NN O O
mutation NN O O
apparently NN O O
was NN O O
introduced NN O O
within NN O O
the NN O O
last NN O O
century NN O O
and NN O O
probably NN O O
is NN O O
limited NN O O
to NN O O
a NN O O
few NN O O
Louisiana NN O O
families NN O O
. NN O O
. NN O O

Mutations NN O O
in NN O O
the NN O O
candidate NN O O
gene NN O O
for NN O O
Norrie NN O B-Disease
disease NN O I-Disease
. NN O O

Recently NN O O
, NN O O
we NN O O
and NN O O
others NN O O
have NN O O
isolated NN O O
a NN O O
candidate NN O O
gene NN O O
for NN O O
X NN O B-Disease
linked NN O I-Disease
Norrie NN O I-Disease
disease NN O I-Disease
( NN O O
ND NN O B-Disease
) NN O O
which NN O O
was NN O O
found NN O O
to NN O O
be NN O O
deleted NN O O
or NN O O
disrupted NN O O
in NN O O
several NN O O
patients NN O O
. NN O O

As NN O O
a NN O O
prerequisite NN O O
for NN O O
the NN O O
identification NN O O
of NN O O
point NN O O
mutations NN O O
in NN O O
the NN O O
ND NN O B-Disease
gene NN O O
we NN O O
have NN O O
established NN O O
the NN O O
exon NN O O
- NN O O
intron NN O O
structure NN O O
of NN O O
this NN O O
gene NN O O
. NN O O

In NN O O
17 NN O O
unrelated NN O O
patients NN O O
and NN O O
15 NN O O
controls NN O O
, NN O O
PCR NN O O
products NN O O
derived NN O O
from NN O O
the NN O O
promoter NN O O
region NN O O
, NN O O
exons NN O O
1 NN O O
and NN O O
2 NN O O
as NN O O
well NN O O
as NN O O
the NN O O
coding NN O O
part NN O O
of NN O O
exon NN O O
3 NN O O
were NN O O
analysed NN O O
with NN O O
the NN O O
single NN O O
strand NN O O
conformation NN O O
polymorphism NN O O
( NN O O
SSCP NN O O
) NN O O
technique NN O O
. NN O O

In NN O O
12 NN O O
patients NN O O
altered NN O O
PCR NN O O
fragments NN O O
were NN O O
detected NN O O
which NN O O
were NN O O
studied NN O O
in NN O O
detail NN O O
by NN O O
direct NN O O
sequencing NN O O
. NN O O

Eleven NN O O
different NN O O
mutations NN O O
were NN O O
found NN O O
, NN O O
and NN O O
all NN O O
but NN O O
one NN O O
are NN O O
likely NN O O
to NN O O
give NN O O
rise NN O O
to NN O O
significant NN O O
structural NN O O
changes NN O O
in NN O O
the NN O O
predicted NN O O
protein NN O O
. NN O O

These NN O O
findings NN O O
, NN O O
and NN O O
the NN O O
absence NN O O
of NN O O
functionally NN O O
relevant NN O O
base NN O O
changes NN O O
in NN O O
healthy NN O O
controls NN O O
, NN O O
emphasize NN O O
the NN O O
causal NN O O
role NN O O
of NN O O
this NN O O
candidate NN O O
gene NN O O
in NN O O
Norrie NN O B-Disease
disease NN O I-Disease
and NN O O
pave NN O O
the NN O O
way NN O O
for NN O O
reliable NN O O
diagnosis NN O O
and NN O O
carrier NN O O
detection NN O O
. NN O O
. NN O O

Detection NN O O
of NN O O
a NN O O
nonsense NN O O
mutation NN O O
in NN O O
the NN O O
dystrophin NN O O
gene NN O O
by NN O O
multiple NN O O
SSCP NN O O
. NN O O

A NN O O
combination NN O O
of NN O O
multiplex NN O O
PCR NN O O
with NN O O
the NN O O
single NN O O
strand NN O O
conformation NN O O
polymorphism NN O O
( NN O O
SSCP NN O O
) NN O O
technique NN O O
was NN O O
employed NN O O
to NN O O
screen NN O O
for NN O O
point NN O O
mutations NN O O
in NN O O
the NN O O
human NN O O
dystrophin NN O O
gene NN O O
. NN O O

Co NN O O
- NN O O
amplification NN O O
of NN O O
11 NN O O
exons NN O O
from NN O O
genomic NN O O
DNA NN O O
of NN O O
Duchenne NN O B-Disease
and NN O I-Disease
Becker NN O I-Disease
muscular NN O I-Disease
dystrophy NN O I-Disease
( NN O O
DMD NN O B-Disease
/ NN O O
BMD NN O B-Disease
) NN O O
patients NN O O
with NN O O
no NN O O
deletion NN O O
or NN O O
duplication NN O O
was NN O O
performed NN O O
and NN O O
the NN O O
samples NN O O
subjected NN O O
to NN O O
multiple NN O O
SSCP NN O O
analysis NN O O
. NN O O

We NN O O
report NN O O
the NN O O
case NN O O
of NN O O
a NN O O
nonsense NN O O
mutation NN O O
in NN O O
a NN O O
Duchenne NN O B-Disease
patient NN O O
identified NN O O
by NN O O
this NN O O
approach NN O O
. NN O O

The NN O O
mutation NN O O
introduces NN O O
a NN O O
termination NN O O
codon NN O O
within NN O O
exon NN O O
8 NN O O
of NN O O
the NN O O
dystrophin NN O O
gene NN O O
. NN O O

It NN O O
is NN O O
predicted NN O O
to NN O O
cause NN O O
a NN O O
very NN O O
premature NN O O
translational NN O O
termination NN O O
accounting NN O O
for NN O O
the NN O O
severe NN O O
phenotype NN O O
observed NN O O
. NN O O

The NN O O
patient NN O O
inherited NN O O
this NN O O
mutation NN O O
from NN O O
his NN O O
mother NN O O
. NN O O

In NN O O
addition NN O O
the NN O O
analysis NN O O
revealed NN O O
5 NN O O
polymorphisms NN O O
useful NN O O
for NN O O
internal NN O O
control NN O O
. NN O O
. NN O O

Proliferation NN O O
- NN O O
related NN O O
expression NN O O
of NN O O
p19 NN O O
/ NN O O
nm23 NN O O
nucleoside NN O O
diphosphate NN O O
kinase NN O O
. NN O O

High NN O O
level NN O O
expression NN O O
of NN O O
the NN O O
nm23 NN O O
- NN O O
H1 NN O O
gene NN O O
, NN O O
which NN O O
encodes NN O O
for NN O O
a NN O O
nucleoside NN O O
diphosphate NN O O
kinase NN O O
, NN O O
has NN O O
been NN O O
found NN O O
to NN O O
correlate NN O O
with NN O O
diminished NN O O
metastasis NN O O
in NN O O
some NN O O
tumors NN O B-Disease
but NN O O
not NN O O
in NN O O
others NN O O
. NN O O

We NN O O
have NN O O
previously NN O O
identified NN O O
the NN O O
protein NN O O
product NN O O
of NN O O
the NN O O
nm23 NN O O
- NN O O
H1 NN O O
gene NN O O
in NN O O
two NN O O
- NN O O
dimensional NN O O
electrophoretic NN O O
gels NN O O
and NN O O
have NN O O
designated NN O O
it NN O O
p19 NN O O
/ NN O O
nm23 NN O O
. NN O O

In NN O O
neuroblastoma NN O B-Disease
, NN O O
higher NN O O
levels NN O O
of NN O O
p19 NN O O
/ NN O O
nm23 NN O O
, NN O O
which NN O O
are NN O O
associated NN O O
with NN O O
amplification NN O O
of NN O O
the NN O O
N NN O O
- NN O O
myc NN O O
oncogene NN O O
, NN O O
large NN O O
tumor NN O B-Disease
mass NN O O
, NN O O
and NN O O
metastasis NN O O
, NN O O
were NN O O
observed NN O O
in NN O O
advanced NN O O
stage NN O O
tumors NN O B-Disease
compared NN O O
with NN O O
limited NN O O
stage NN O O
disease NN O O
. NN O O

Because NN O O
of NN O O
the NN O O
variable NN O O
expression NN O O
of NN O O
nm23 NN O O
- NN O O
H1 NN O O
in NN O O
different NN O O
tumors NN O B-Disease
, NN O O
we NN O O
have NN O O
investigated NN O O
the NN O O
relationship NN O O
between NN O O
amounts NN O O
of NN O O
the NN O O
protein NN O O
and NN O O
cell NN O O
proliferation NN O O
. NN O O

The NN O O
levels NN O O
of NN O O
p19 NN O O
/ NN O O
nm23 NN O O
were NN O O
compared NN O O
between NN O O
resting NN O O
and NN O O
mitotically NN O O
stimulated NN O O
normal NN O O
human NN O O
PBLs NN O O
and NN O O
in NN O O
leukemia NN O B-Disease
cells NN O O
. NN O O

The NN O O
amount NN O O
of NN O O
p19 NN O O
/ NN O O
nm23 NN O O
increased NN O O
in NN O O
normal NN O O
lymphocytes NN O O
in NN O O
response NN O O
to NN O O
mitotic NN O O
stimulation NN O O
and NN O O
paralleled NN O O
the NN O O
increase NN O O
in NN O O
DNA NN O O
synthesis NN O O
. NN O O

In NN O O
leukemia NN O B-Disease
cells NN O O
obtained NN O O
from NN O O
patients NN O O
with NN O O
different NN O O
subtypes NN O O
of NN O O
acute NN O B-Disease
leukemia NN O I-Disease
, NN O O
p19 NN O O
/ NN O O
nm23 NN O O
levels NN O O
were NN O O
also NN O O
increased NN O O
relative NN O O
to NN O O
resting NN O O
normal NN O O
lymphocytes NN O O
. NN O O

Treatment NN O O
of NN O O
mitotically NN O O
stimulated NN O O
lymphocytes NN O O
with NN O O
cyclosporin NN O O
, NN O O
which NN O O
inhibits NN O O
proliferation NN O O
, NN O O
blocked NN O O
the NN O O
increase NN O O
in NN O O
p19 NN O O
/ NN O O
nm23 NN O O
; NN O O
treatment NN O O
of NN O O
the NN O O
leukemia NN O B-Disease
cell NN O O
line NN O O
HL NN O O
- NN O O
60 NN O O
with NN O O
dimethylsulfoxide NN O O
, NN O O
which NN O O
induces NN O O
terminal NN O O
differentiation NN O O
, NN O O
resulted NN O O
in NN O O
diminished NN O O
levels NN O O
of NN O O
p19 NN O O
/ NN O O
nm23 NN O O
. NN O O

Our NN O O
data NN O O
therefore NN O O
provide NN O O
evidence NN O O
that NN O O
nm23 NN O O
- NN O O
H1 NN O O
expression NN O O
is NN O O
related NN O O
to NN O O
cell NN O O
proliferative NN O O
activity NN O O
. NN O O
. NN O O

An NN O O
intrachromosomal NN O O
insertion NN O O
causing NN O O
5q22 NN O O
deletion NN O O
and NN O O
familial NN O B-Disease
adenomatous NN O I-Disease
polyposis NN O I-Disease
coli NN O I-Disease
in NN O O
two NN O O
generations NN O O
. NN O O

We NN O O
report NN O O
familial NN O B-Disease
adenomatous NN O I-Disease
polyposis NN O I-Disease
coli NN O I-Disease
( NN O O
FAPC NN O B-Disease
) NN O O
with NN O O
epidermoid NN O B-Disease
cysts NN O I-Disease
, NN O O
osteomata NN O B-Disease
, NN O O
and NN O O
areas NN O O
of NN O O
congenital NN O B-Disease
hypertrophy NN O I-Disease
of NN O I-Disease
the NN O I-Disease
retinal NN O I-Disease
pigment NN O I-Disease
epithelium NN O I-Disease
( NN O O
CHRPEs NN O B-Disease
) NN O O
in NN O O
a NN O O
male NN O O
patient NN O O
and NN O O
his NN O O
maternal NN O O
aunt NN O O
, NN O O
both NN O O
of NN O O
whom NN O O
suffered NN O O
a NN O O
mild NN O O
to NN O O
moderate NN O O
degree NN O O
of NN O O
mental NN O B-Disease
handicap NN O I-Disease
. NN O O

Both NN O O
had NN O O
an NN O O
interstitial NN O O
deletion NN O O
of NN O O
the NN O O
long NN O O
arm NN O O
of NN O O
chromosome NN O O
5 NN O O
( NN O O
del NN O O
( NN O O
5 NN O O
) NN O O
( NN O O
q22q23 NN O O
. NN O O
2 NN O O
) NN O O
) NN O O
. NN O O

Two NN O O
other NN O O
normal NN O O
family NN O O
members NN O O
had NN O O
the NN O O
underlying NN O O
direct NN O O
insertion NN O O
of NN O O
chromosome NN O O
5 NN O O
( NN O O
dir NN O O
ins NN O O
( NN O O
5 NN O O
) NN O O
( NN O O
q31 NN O O
. NN O O
3q22q23 NN O O
3q22q23 NN O O
. NN O O
2 NN O O
) NN O O
) NN O O
. NN O O

Molecular NN O O
genetic NN O O
and NN O O
fluorescent NN O O
hybridisation NN O O
studies NN O O
have NN O O
shown NN O O
that NN O O
loci NN O O
D5S37 NN O O
and NN O O
D5S98 NN O O
are NN O O
outside NN O O
the NN O O
deletion NN O O
whereas NN O O
loci NN O O
detected NN O O
by NN O O
probes NN O O
EF5 NN O O
. NN O O

44 NN O O
and NN O O
YN5 NN O O
. NN O O

48 NN O O
are NN O O
lost NN O O
. NN O O

As NN O O
expected NN O O
, NN O O
the NN O O
molecular NN O O
analyses NN O O
indicate NN O O
loss NN O O
of NN O O
one NN O O
allele NN O O
at NN O O
the NN O O
MCC NN O O
and NN O O
APC NN O B-Disease
loci NN O O
. NN O O

The NN O O
APC NN O B-Disease
gene NN O O
is NN O O
located NN O O
within NN O O
band NN O O
5q22 NN O O
. NN O O

Familial NN O O
direct NN O O
insertions NN O O
should NN O O
be NN O O
considered NN O O
as NN O O
a NN O O
cause NN O O
of NN O O
recurrent NN O O
microdeletion NN O O
syndromes NN O O
. NN O O

Chromosome NN O O
mapping NN O O
of NN O O
the NN O O
rod NN O O
photoreceptor NN O O
cGMP NN O O
phosphodiesterase NN O O
beta NN O O
- NN O O
subunit NN O O
gene NN O O
in NN O O
mouse NN O O
and NN O O
human NN O O
: NN O O
tight NN O O
linkage NN O O
to NN O O
the NN O O
Huntington NN O B-Disease
disease NN O I-Disease
region NN O O
( NN O O
4p16 NN O O
. NN O O
3 NN O O
) NN O O
. NN O O

The NN O O
retinal NN O B-Disease
degeneration NN O I-Disease
mouse NN O O
( NN O O
gene NN O O
symbol NN O O
, NN O O
rd NN O O
) NN O O
is NN O O
an NN O O
animal NN O O
model NN O O
for NN O O
certain NN O O
forms NN O O
of NN O O
human NN O O
hereditary NN O B-Disease
retinopathies NN O I-Disease
. NN O O

Recent NN O O
findings NN O O
of NN O O
a NN O O
nonsense NN O O
mutation NN O O
in NN O O
the NN O O
rd NN O O
mouse NN O O
PDE NN O O
beta NN O O
- NN O O
subunit NN O O
gene NN O O
( NN O O
Pdeb NN O O
) NN O O
prompted NN O O
us NN O O
to NN O O
investigate NN O O
the NN O O
chromosome NN O O
locations NN O O
of NN O O
the NN O O
mouse NN O O
and NN O O
human NN O O
genes NN O O
. NN O O

We NN O O
have NN O O
utilized NN O O
backcross NN O O
analysis NN O O
in NN O O
mice NN O O
to NN O O
verify NN O O
and NN O O
define NN O O
more NN O O
precisely NN O O
the NN O O
location NN O O
of NN O O
the NN O O
Pdeb NN O O
locus NN O O
6 NN O O
. NN O O

1 NN O O
+ NN O O
/ NN O O
- NN O O
2 NN O O
. NN O O

3 NN O O
cM NN O O
distal NN O O
of NN O O
Mgsa NN O O
on NN O O
mouse NN O O
chromosome NN O O
5 NN O O
. NN O O

We NN O O
have NN O O
determined NN O O
that NN O O
the NN O O
human NN O O
gene NN O O
( NN O O
PDEB NN O O
) NN O O
maps NN O O
to NN O O
4p16 NN O O
. NN O O

3 NN O O
, NN O O
very NN O O
close NN O O
to NN O O
the NN O O
Huntington NN O B-Disease
disease NN O I-Disease
( NN O O
HD NN O B-Disease
) NN O O
region NN O O
. NN O O

Analysis NN O O
of NN O O
the NN O O
comparative NN O O
map NN O O
for NN O O
mice NN O O
and NN O O
humans NN O O
shows NN O O
that NN O O
the NN O O
mouse NN O O
homologue NN O O
of NN O O
the NN O O
HD NN O B-Disease
gene NN O O
will NN O O
reside NN O O
on NN O O
chromosome NN O O
5 NN O O
. NN O O

Linkage NN O O
of NN O O
the NN O O
mouse NN O O
Pdeb NN O O
locus NN O O
with NN O O
other NN O O
homologues NN O O
in NN O O
the NN O O
human NN O O
4p16 NN O O
. NN O O

3 NN O O
region NN O O
is NN O O
maintained NN O O
but NN O O
gene NN O O
order NN O O
is NN O O
not NN O O
, NN O O
suggesting NN O O
at NN O O
least NN O O
three NN O O
possible NN O O
sites NN O O
for NN O O
the NN O O
corresponding NN O O
mouse NN O O
HD NN O B-Disease
gene NN O O
. NN O O

Coincident NN O O
Kaposi NN O B-Disease
sarcoma NN O I-Disease
and NN O O
T NN O B-Disease
- NN O I-Disease
cell NN O I-Disease
lymphoma NN O I-Disease
in NN O O
a NN O O
patient NN O O
with NN O O
the NN O O
Wiskott NN O B-Disease
- NN O I-Disease
Aldrich NN O I-Disease
syndrome NN O I-Disease
. NN O O

A NN O O
24 NN O O
year NN O O
old NN O O
male NN O O
with NN O O
a NN O O
history NN O O
of NN O O
eczema NN O B-Disease
, NN O O
recurrent NN O O
mild NN O O
infections NN O O
, NN O O
and NN O O
thrombocytopenia NN O B-Disease
consistent NN O O
with NN O O
the NN O O
Wiskott NN O B-Disease
- NN O I-Disease
Aldrich NN O I-Disease
syndrome NN O I-Disease
( NN O O
WAS NN O B-Disease
) NN O O
presented NN O O
with NN O O
a NN O O
mediastinal NN O O
mass NN O O
, NN O O
generalized NN O O
lymphadenopathy NN O B-Disease
, NN O O
splenomegaly NN O B-Disease
, NN O O
and NN O O
severe NN O O
thrombocytopenia NN O B-Disease
. NN O O

Studies NN O O
of NN O O
immune NN O O
function NN O O
including NN O O
immunoglobulin NN O O
levels NN O O
and NN O O
T NN O O
- NN O O
cell NN O O
subsets NN O O
were NN O O
normal NN O O
. NN O O

Furthermore NN O O
, NN O O
his NN O O
T NN O O
lymphocytes NN O O
proliferated NN O O
normally NN O O
in NN O O
response NN O O
to NN O O
phytohemagglutinin NN O O
, NN O O
concanavalin NN O O
A NN O O
, NN O O
and NN O O
the NN O O
combination NN O O
of NN O O
neuraminidase NN O O
/ NN O O
galactose NN O O
oxidase NN O O
. NN O O

However NN O O
, NN O O
their NN O O
proliferative NN O O
responses NN O O
to NN O O
anti NN O O
- NN O O
CD43 NN O O
antibody NN O O
and NN O O
periodate NN O O
were NN O O
diminished NN O O
, NN O O
consistent NN O O
with NN O O
the NN O O
clinical NN O O
diagnosis NN O O
of NN O O
WAS NN O B-Disease
. NN O O

An NN O O
initial NN O O
inguinal NN O O
lymph NN O O
node NN O O
biopsy NN O O
surprisingly NN O O
revealed NN O O
Kaposi NN O B-Disease
sarcoma NN O I-Disease
. NN O O

However NN O O
, NN O O
following NN O O
splenectomy NN O O
to NN O O
increase NN O O
the NN O O
platelet NN O O
count NN O O
, NN O O
biopsy NN O O
of NN O O
the NN O O
mediastinal NN O O
mass NN O O
revealed NN O O
T NN O B-Disease
- NN O I-Disease
cell NN O I-Disease
large NN O I-Disease
cell NN O I-Disease
lymphoma NN O I-Disease
. NN O O

Studies NN O O
of NN O O
biopsied NN O O
tissue NN O O
for NN O O
the NN O O
presence NN O O
of NN O O
Epstein NN O B-Disease
- NN O I-Disease
Barr NN O I-Disease
virus NN O I-Disease
and NN O O
cytomegalovirus NN O B-Disease
were NN O O
negative NN O O
, NN O O
as NN O O
were NN O O
studies NN O O
of NN O O
blood NN O O
, NN O O
including NN O O
the NN O O
polymerase NN O O
chain NN O O
reaction NN O O
, NN O O
for NN O O
the NN O O
presence NN O O
of NN O O
the NN O O
human NN O B-Disease
immunodeficiency NN O I-Disease
virus NN O I-Disease
( NN O O
HIV NN O B-Disease
) NN O O
. NN O O

This NN O O
is NN O O
the NN O O
first NN O O
report NN O O
of NN O O
Kaposi NN O B-Disease
sarcoma NN O I-Disease
arising NN O O
in NN O O
a NN O O
patient NN O O
with NN O O
a NN O O
congenital NN O B-Disease
immunodeficiency NN O I-Disease
syndrome NN O I-Disease
. NN O O

Although NN O O
Kaposi NN O B-Disease
sarcoma NN O I-Disease
can NN O O
arise NN O O
in NN O O
the NN O O
face NN O O
of NN O O
the NN O O
severe NN O O
immunosuppression NN O O
that NN O O
follows NN O O
allograft NN O O
transplantation NN O O
and NN O O
in NN O O
patients NN O O
infected NN O O
with NN O O
HIV NN O B-Disease
, NN O O
we NN O O
postulate NN O O
that NN O O
longevity NN O O
in NN O O
the NN O O
face NN O O
of NN O O
mild NN O O
immunosuppression NN O O
was NN O O
the NN O O
major NN O O
factor NN O O
in NN O O
the NN O O
development NN O O
of NN O O
Kaposi NN O B-Disease
sarcoma NN O I-Disease
in NN O O
this NN O O
patient NN O O
. NN O O
. NN O O

The NN O O
APC NN O B-Disease
gene NN O O
, NN O O
responsible NN O O
for NN O O
familial NN O B-Disease
adenomatous NN O I-Disease
polyposis NN O I-Disease
, NN O O
is NN O O
mutated NN O O
in NN O O
human NN O O
gastric NN O B-Disease
cancer NN O I-Disease
. NN O O

Although NN O O
gastric NN O B-Disease
cancer NN O I-Disease
is NN O O
the NN O O
most NN O O
common NN O O
cancer NN O B-Disease
in NN O O
the NN O O
world NN O O
, NN O O
genetic NN O O
changes NN O O
during NN O O
its NN O O
carcinogenesis NN O O
are NN O O
not NN O O
well NN O O
understood NN O O
. NN O O

Since NN O O
some NN O O
gastric NN O B-Disease
cancers NN O I-Disease
are NN O O
considered NN O O
to NN O O
originate NN O O
from NN O O
the NN O O
intestinal NN O O
metaplasia NN O O
, NN O O
it NN O O
is NN O O
likely NN O O
that NN O O
the NN O O
adenomatous NN O B-Disease
polyposis NN O I-Disease
coli NN O I-Disease
( NN O O
APC NN O B-Disease
) NN O O
gene NN O O
, NN O O
the NN O O
mutation NN O O
of NN O O
which NN O O
causes NN O O
adenomatous NN O B-Disease
polyps NN O I-Disease
in NN O I-Disease
the NN O I-Disease
colon NN O I-Disease
, NN O O
is NN O O
associated NN O O
with NN O O
carcinogenesis NN O O
of NN O O
gastric NN O B-Disease
cancer NN O I-Disease
. NN O O

Based NN O O
on NN O O
this NN O O
idea NN O O
, NN O O
DNAs NN O O
isolated NN O O
from NN O O
gastric NN O B-Disease
cancers NN O I-Disease
were NN O O
examined NN O O
by NN O O
means NN O O
of NN O O
a NN O O
RNase NN O O
protection NN O O
analysis NN O O
coupled NN O O
with NN O O
polymerase NN O O
chain NN O O
reaction NN O O
followed NN O O
by NN O O
sequencing NN O O
of NN O O
the NN O O
polymerase NN O O
chain NN O O
reaction NN O O
products NN O O
. NN O O

By NN O O
screening NN O O
nearly NN O O
one NN O O
- NN O O
half NN O O
of NN O O
the NN O O
coding NN O O
region NN O O
of NN O O
the NN O O
APC NN O B-Disease
gene NN O O
in NN O O
44 NN O O
tumors NN O B-Disease
, NN O O
somatic NN O O
mutations NN O O
were NN O O
detected NN O O
in NN O O
three NN O O
tumors NN O B-Disease
a NN O O
missense NN O O
mutation NN O O
, NN O O
a NN O O
nonsense NN O O
mutation NN O O
, NN O O
and NN O O
a NN O O
5 NN O O
- NN O O
base NN O O
pair NN O O
deletion NN O O
resulting NN O O
in NN O O
a NN O O
frame NN O O
shift NN O O
which NN O O
causes NN O O
truncation NN O O
of NN O O
the NN O O
gene NN O O
product NN O O
. NN O O

These NN O O
results NN O O
suggest NN O O
that NN O O
the NN O O
mutation NN O O
of NN O O
the NN O O
APC NN O B-Disease
gene NN O O
also NN O O
plays NN O O
an NN O O
important NN O O
role NN O O
during NN O O
the NN O O
carcinogenesis NN O O
of NN O O
at NN O O
least NN O O
some NN O O
gastric NN O B-Disease
cancers NN O I-Disease
. NN O O
. NN O O

A NN O O
71 NN O O
- NN O O
kilodalton NN O O
protein NN O O
is NN O O
a NN O O
major NN O O
product NN O O
of NN O O
the NN O O
Duchenne NN O B-Disease
muscular NN O I-Disease
dystrophy NN O I-Disease
gene NN O O
in NN O O
brain NN O O
and NN O O
other NN O O
nonmuscle NN O O
tissues NN O O
. NN O O

The NN O O
known NN O O
Duchenne NN O B-Disease
muscular NN O I-Disease
dystrophy NN O I-Disease
( NN O O
DMD NN O B-Disease
) NN O O
gene NN O O
products NN O O
, NN O O
the NN O O
muscle NN O O
- NN O O
and NN O O
brain NN O O
- NN O O
type NN O O
dystrophin NN O O
isoforms NN O O
, NN O O
are NN O O
427 NN O O
- NN O O
kDa NN O O
proteins NN O O
translated NN O O
from NN O O
14 NN O O
- NN O O
kilobase NN O O
( NN O O
kb NN O O
) NN O O
mRNAs NN O O
. NN O O

Recently NN O O
we NN O O
described NN O O
a NN O O
6 NN O O
. NN O O

5 NN O O
- NN O O
kb NN O O
mRNA NN O O
that NN O O
also NN O O
is NN O O
transcribed NN O O
from NN O O
the NN O O
DMD NN O B-Disease
gene NN O O
. NN O O

Cloning NN O O
and NN O O
in NN O O
vitro NN O O
transcription NN O O
and NN O O
translation NN O O
of NN O O
the NN O O
entire NN O O
coding NN O O
region NN O O
show NN O O
that NN O O
the NN O O
6 NN O O
. NN O O

5 NN O O
- NN O O
kb NN O O
mRNA NN O O
encodes NN O O
a NN O O
70 NN O O
. NN O O

8 NN O O
- NN O O
kDa NN O O
protein NN O O
that NN O O
is NN O O
a NN O O
major NN O O
product NN O O
of NN O O
the NN O O
DMD NN O B-Disease
gene NN O O
. NN O O

It NN O O
contains NN O O
the NN O O
C NN O O
- NN O O
terminal NN O O
and NN O O
the NN O O
cysteine NN O O
- NN O O
rich NN O O
domains NN O O
of NN O O
dystrophin NN O O
, NN O O
seven NN O O
additional NN O O
amino NN O O
acids NN O O
at NN O O
the NN O O
N NN O O
terminus NN O O
, NN O O
and NN O O
some NN O O
modifications NN O O
formed NN O O
by NN O O
alternative NN O O
splicing NN O O
in NN O O
the NN O O
C NN O O
- NN O O
terminal NN O O
domain NN O O
. NN O O

It NN O O
lacks NN O O
the NN O O
entire NN O O
large NN O O
domain NN O O
of NN O O
spectrin NN O O
- NN O O
like NN O O
repeats NN O O
and NN O O
the NN O O
actin NN O O
- NN O O
binding NN O O
N NN O O
- NN O O
terminal NN O O
domain NN O O
of NN O O
dystrophin NN O O
. NN O O

This NN O O
protein NN O O
is NN O O
the NN O O
major NN O O
DMD NN O B-Disease
gene NN O O
product NN O O
in NN O O
brain NN O O
and NN O O
other NN O O
nonmuscle NN O O
tissues NN O O
but NN O O
is NN O O
undetectable NN O O
in NN O O
skeletal NN O O
muscle NN O O
extracts NN O O
. NN O O

Correlation NN O O
between NN O O
the NN O O
location NN O O
of NN O O
germ NN O O
- NN O O
line NN O O
mutations NN O O
in NN O O
the NN O O
APC NN O B-Disease
gene NN O O
and NN O O
the NN O O
number NN O O
of NN O O
colorectal NN O B-Disease
polyps NN O I-Disease
in NN O O
familial NN O B-Disease
adenomatous NN O I-Disease
polyposis NN O I-Disease
patients NN O O
. NN O O

Recently NN O O
we NN O O
have NN O O
isolated NN O O
the NN O O
adenomatous NN O B-Disease
polyposis NN O I-Disease
coli NN O I-Disease
( NN O O
APC NN O B-Disease
) NN O O
gene NN O O
which NN O O
causes NN O O
familial NN O B-Disease
adenomatous NN O I-Disease
polyposis NN O I-Disease
( NN O O
FAP NN O B-Disease
) NN O O
, NN O O
and NN O O
its NN O O
germ NN O O
- NN O O
line NN O O
mutations NN O O
in NN O O
a NN O O
substantial NN O O
number NN O O
of NN O O
FAP NN O B-Disease
patients NN O O
have NN O O
been NN O O
identified NN O O
. NN O O

On NN O O
the NN O O
basis NN O O
of NN O O
this NN O O
information NN O O
, NN O O
we NN O O
compared NN O O
the NN O O
location NN O O
of NN O O
germ NN O O
- NN O O
line NN O O
mutations NN O O
in NN O O
the NN O O
APC NN O B-Disease
gene NN O O
in NN O O
22 NN O O
unrelated NN O O
patients NN O O
( NN O O
12 NN O O
of NN O O
whom NN O O
have NN O O
been NN O O
reported NN O O
previously NN O O
) NN O O
with NN O O
the NN O O
number NN O O
of NN O O
colorectal NN O B-Disease
polyps NN O I-Disease
developed NN O O
in NN O O
FAP NN O B-Disease
patients NN O O
; NN O O
17 NN O O
were NN O O
sparse NN O O
types NN O O
and NN O O
five NN O O
were NN O O
profuse NN O O
types NN O O
. NN O O

All NN O O
but NN O O
one NN O O
of NN O O
the NN O O
mutations NN O O
were NN O O
considered NN O O
to NN O O
cause NN O O
truncation NN O O
of NN O O
the NN O O
gene NN O O
product NN O O
by NN O O
frame NN O O
- NN O O
shift NN O O
due NN O O
to NN O O
deletion NN O O
( NN O O
14 NN O O
cases NN O O
) NN O O
or NN O O
nonsense NN O O
mutation NN O O
( NN O O
seven NN O O
cases NN O O
) NN O O
. NN O O

The NN O O
location NN O O
of NN O O
the NN O O
germ NN O O
- NN O O
line NN O O
mutations NN O O
seems NN O O
to NN O O
correlate NN O O
with NN O O
the NN O O
two NN O O
clinical NN O O
types NN O O
; NN O O
germ NN O O
- NN O O
line NN O O
mutations NN O O
in NN O O
five NN O O
FAP NN O B-Disease
patients NN O O
with NN O O
profuse NN O O
polyps NN O B-Disease
were NN O O
observed NN O O
between NN O O
codon NN O O
1250 NN O O
and NN O O
codon NN O O
1464 NN O O
, NN O O
whereas NN O O
mutations NN O O
in NN O O
17 NN O O
FAP NN O B-Disease
patients NN O O
with NN O O
fewer NN O O
polyps NN O B-Disease
were NN O O
observed NN O O
in NN O O
the NN O O
other NN O O
regions NN O O
of NN O O
the NN O O
APC NN O B-Disease
gene NN O O
. NN O O

The NN O O
result NN O O
suggests NN O O
that NN O O
the NN O O
number NN O O
of NN O O
colorectal NN O B-Disease
polyps NN O I-Disease
in NN O O
FAP NN O B-Disease
patients NN O O
may NN O O
be NN O O
associated NN O O
with NN O O
a NN O O
difference NN O O
in NN O O
the NN O O
stability NN O O
or NN O O
biological NN O O
function NN O O
of NN O O
the NN O O
truncated NN O O
APC NN O B-Disease
protein NN O O
. NN O O
. NN O O

Identification NN O O
and NN O O
rapid NN O O
detection NN O O
of NN O O
three NN O O
Tay NN O B-Disease
- NN O I-Disease
Sachs NN O I-Disease
mutations NN O O
in NN O O
the NN O O
Moroccan NN O O
Jewish NN O O
population NN O O
. NN O O

Infantile NN O O
Tay NN O B-Disease
- NN O I-Disease
Sachs NN O I-Disease
disease NN O I-Disease
( NN O O
TSD NN O B-Disease
) NN O O
is NN O O
caused NN O O
by NN O O
mutations NN O O
in NN O O
the NN O O
HEXA NN O O
gene NN O O
that NN O O
result NN O O
in NN O O
the NN O O
complete NN O O
absence NN O O
of NN O O
beta NN O O
- NN O O
hexosaminidase NN O O
A NN O O
activity NN O O
. NN O O

It NN O O
is NN O O
well NN O O
known NN O O
that NN O O
an NN O O
elevated NN O O
frequency NN O O
of NN O O
TSD NN O B-Disease
mutations NN O O
exists NN O O
among NN O O
Ashkenazi NN O O
Jews NN O O
. NN O O

More NN O O
recently NN O O
it NN O O
has NN O O
become NN O O
apparent NN O O
that NN O O
elevated NN O O
carrier NN O O
frequencies NN O O
for NN O O
TSD NN O B-Disease
also NN O O
occur NN O O
in NN O O
several NN O O
other NN O O
ethnic NN O O
groups NN O O
, NN O O
including NN O O
Moroccan NN O O
Jews NN O O
, NN O O
a NN O O
subgroup NN O O
of NN O O
Sephardic NN O O
Jews NN O O
. NN O O

Elsewhere NN O O
we NN O O
reported NN O O
an NN O O
in NN O O
- NN O O
frame NN O O
deletion NN O O
of NN O O
one NN O O
of NN O O
the NN O O
two NN O O
adjacent NN O O
phenylalanine NN O O
codons NN O O
at NN O O
position NN O O
304 NN O O
or NN O O
305 NN O O
( NN O O
delta NN O O
F304 NN O O
/ NN O O
305 NN O O
) NN O O
in NN O O
one NN O O
HEXA NN O O
allele NN O O
of NN O O
a NN O O
Moroccan NN O O
Jewish NN O O
TSD NN O B-Disease
patient NN O O
and NN O O
in NN O O
three NN O O
obligate NN O O
carriers NN O O
from NN O O
six NN O O
unrelated NN O O
Moroccan NN O O
Jewish NN O O
families NN O O
. NN O O

We NN O O
have NN O O
now NN O O
identified NN O O
two NN O O
additional NN O O
mutations NN O O
within NN O O
exon NN O O
5 NN O O
of NN O O
the NN O O
HEXA NN O O
gene NN O O
that NN O O
account NN O O
for NN O O
the NN O O
remaining NN O O
TSD NN O B-Disease
alleles NN O O
in NN O O
the NN O O
patient NN O O
and NN O O
carriers NN O O
. NN O O

One NN O O
of NN O O
the NN O O
mutations NN O O
is NN O O
a NN O O
novel NN O O
C NN O O
- NN O O
to NN O O
- NN O O
G NN O O
transversion NN O O
, NN O O
resulting NN O O
in NN O O
a NN O O
replacement NN O O
of NN O O
Tyr180 NN O O
by NN O O
a NN O O
stop NN O O
codon NN O O
. NN O O

The NN O O
other NN O O
mutation NN O O
is NN O O
a NN O O
G NN O O
- NN O O
to NN O O
- NN O O
A NN O O
transition NN O O
resulting NN O O
in NN O O
an NN O O
Arg170 NN O O
- NN O O
to NN O O
- NN O O
Gln NN O O
substitution NN O O
. NN O O

This NN O O
mutation NN O O
is NN O O
at NN O O
a NN O O
CpG NN O O
site NN O O
in NN O O
a NN O O
Japanese NN O O
infant NN O O
with NN O O
Tay NN O B-Disease
- NN O I-Disease
Sachs NN O I-Disease
disease NN O I-Disease
and NN O O
was NN O O
described NN O O
elsewhere NN O O
. NN O O

Analysis NN O O
of NN O O
nine NN O O
obligate NN O O
carriers NN O O
from NN O O
seven NN O O
unrelated NN O O
families NN O O
showed NN O O
that NN O O
four NN O O
harbor NN O O
the NN O O
delta NN O O
F304 NN O O
/ NN O O
305 NN O O
mutation NN O O
, NN O O
two NN O O
the NN O O
Arg170 NN O O
- NN O O
- NN O O
- NN O O
- NN O O
Gln NN O O
mutation NN O O
, NN O O
and NN O O
one NN O O
the NN O O
Tyr180 NN O O
- NN O O
- NN O O
- NN O O
- NN O O
Stop NN O O
mutation NN O O
. NN O O

We NN O O
also NN O O
have NN O O
developed NN O O
rapid NN O O
, NN O O
nonradioactive NN O O
assays NN O O
for NN O O
the NN O O
detection NN O O
of NN O O
each NN O O
mutation NN O O
, NN O O
which NN O O
should NN O O
be NN O O
helpful NN O O
for NN O O
carrier NN O O
screening NN O O
. NN O O
. NN O O

Molecular NN O O
characterization NN O O
of NN O O
glucose NN O B-Disease
- NN O I-Disease
6 NN O I-Disease
- NN O I-Disease
phosphate NN O I-Disease
dehydrogenase NN O I-Disease
( NN O I-Disease
G6PD NN O I-Disease
) NN O I-Disease
deficiency NN O I-Disease
by NN O O
natural NN O O
and NN O O
amplification NN O O
created NN O O
restriction NN O O
sites NN O O
: NN O O
five NN O O
mutations NN O O
account NN O O
for NN O O
most NN O O
G6PD NN O B-Disease
deficiency NN O I-Disease
cases NN O O
in NN O O
Taiwan NN O O
. NN O O

We NN O O
have NN O O
developed NN O O
a NN O O
rapid NN O O
and NN O O
simple NN O O
method NN O O
to NN O O
diagnose NN O O
the NN O O
molecular NN O O
defects NN O O
of NN O O
glucose NN O B-Disease
- NN O I-Disease
6 NN O I-Disease
- NN O I-Disease
phosphate NN O I-Disease
dehydrogenase NN O I-Disease
( NN O I-Disease
G6PD NN O I-Disease
) NN O I-Disease
deficiency NN O I-Disease
in NN O O
Chinese NN O O
in NN O O
Taiwan NN O O
. NN O O

This NN O O
method NN O O
involves NN O O
the NN O O
selective NN O O
amplification NN O O
of NN O O
a NN O O
DNA NN O O
fragment NN O O
from NN O O
human NN O O
G6PD NN O O
gene NN O O
with NN O O
specific NN O O
oligonucleotide NN O O
primers NN O O
followed NN O O
by NN O O
digestion NN O O
with NN O O
restriction NN O O
enzymes NN O O
that NN O O
recognize NN O O
artificially NN O O
created NN O O
or NN O O
naturally NN O O
occurring NN O O
restriction NN O O
sites NN O O
. NN O O

Ninety NN O O
- NN O O
four NN O O
Chinese NN O O
males NN O O
with NN O O
G6PD NN O B-Disease
deficiency NN O I-Disease
were NN O O
studied NN O O
. NN O O

The NN O O
results NN O O
show NN O O
that NN O O
50 NN O O
% NN O O
( NN O O
47 NN O O
of NN O O
94 NN O O
) NN O O
were NN O O
G NN O O
to NN O O
T NN O O
mutation NN O O
at NN O O
nucleotide NN O O
( NN O O
nt NN O O
) NN O O
1376 NN O O
, NN O O
21 NN O O
. NN O O

3 NN O O
% NN O O
( NN O O
20 NN O O
of NN O O
94 NN O O
) NN O O
were NN O O
G NN O O
to NN O O
A NN O O
mutation NN O O
at NN O O
nt NN O O
1388 NN O O
, NN O O
7 NN O O
. NN O O

4 NN O O
% NN O O
( NN O O
7 NN O O
of NN O O
94 NN O O
) NN O O
were NN O O
A NN O O
to NN O O
G NN O O
mutation NN O O
at NN O O
nt NN O O
493 NN O O
, NN O O
7 NN O O
. NN O O

4 NN O O
% NN O O
( NN O O
7 NN O O
of NN O O
94 NN O O
) NN O O
were NN O O
A NN O O
to NN O O
G NN O O
mutation NN O O
at NN O O
nt NN O O
95 NN O O
, NN O O
4 NN O O
. NN O O

2 NN O O
% NN O O
( NN O O
4 NN O O
of NN O O
94 NN O O
) NN O O
were NN O O
C NN O O
to NN O O
T NN O O
mutation NN O O
at NN O O
nt NN O O
1024 NN O O
, NN O O
1 NN O O
. NN O O

1 NN O O
% NN O O
( NN O O
1 NN O O
of NN O O
94 NN O O
) NN O O
was NN O O
G NN O O
to NN O O
T NN O O
mutation NN O O
at NN O O
nt NN O O
392 NN O O
, NN O O
and NN O O
1 NN O O
. NN O O

1 NN O O
% NN O O
( NN O O
1 NN O O
of NN O O
94 NN O O
) NN O O
was NN O O
G NN O O
to NN O O
A NN O O
mutation NN O O
at NN O O
nt NN O O
487 NN O O
. NN O O

These NN O O
results NN O O
show NN O O
that NN O O
the NN O O
former NN O O
five NN O O
mutations NN O O
account NN O O
for NN O O
more NN O O
than NN O O
90 NN O O
% NN O O
of NN O O
G6PD NN O B-Disease
deficiency NN O I-Disease
cases NN O O
in NN O O
Taiwan NN O O
. NN O O

Aside NN O O
from NN O O
showing NN O O
that NN O O
G NN O O
to NN O O
T NN O O
change NN O O
at NN O O
nt NN O O
1376 NN O O
is NN O O
the NN O O
most NN O O
common NN O O
mutation NN O O
, NN O O
our NN O O
research NN O O
indicates NN O O
that NN O O
nt NN O O
493 NN O O
mutation NN O O
is NN O O
a NN O O
frequent NN O O
mutation NN O O
among NN O O
Chinese NN O O
in NN O O
Taiwan NN O O
. NN O O

We NN O O
compared NN O O
G6PD NN O O
activity NN O O
among NN O O
different NN O O
mutations NN O O
, NN O O
without NN O O
discovering NN O O
significant NN O O
differences NN O O
between NN O O
them NN O O
. NN O O

Eight NN O O
novel NN O O
inactivating NN O O
germ NN O O
line NN O O
mutations NN O O
at NN O O
the NN O O
APC NN O B-Disease
gene NN O O
identified NN O O
by NN O O
denaturing NN O O
gradient NN O O
gel NN O O
electrophoresis NN O O
. NN O O

Familial NN O B-Disease
adenomatous NN O I-Disease
polyposis NN O I-Disease
( NN O O
FAP NN O B-Disease
) NN O O
is NN O O
a NN O O
dominantly NN O O
inherited NN O O
condition NN O O
predisposing NN O O
to NN O O
colorectal NN O B-Disease
cancer NN O I-Disease
. NN O O

The NN O O
recent NN O O
isolation NN O O
of NN O O
the NN O O
responsible NN O O
gene NN O O
( NN O O
adenomatous NN O B-Disease
polyposis NN O I-Disease
coli NN O I-Disease
or NN O O
APC NN O B-Disease
) NN O O
has NN O O
facilitated NN O O
the NN O O
search NN O O
for NN O O
germ NN O O
line NN O O
mutations NN O O
in NN O O
affected NN O O
individuals NN O O
. NN O O

Previous NN O O
authors NN O O
have NN O O
used NN O O
the NN O O
RNase NN O O
protection NN O O
assay NN O O
and NN O O
the NN O O
single NN O O
- NN O O
strand NN O O
conformation NN O O
polymorphisms NN O O
procedure NN O O
to NN O O
screen NN O O
for NN O O
mutations NN O O
. NN O O

In NN O O
this NN O O
study NN O O
we NN O O
used NN O O
denaturing NN O O
gradient NN O O
gel NN O O
electrophoresis NN O O
( NN O O
DGGE NN O O
) NN O O
. NN O O

DGGE NN O O
analysis NN O O
of NN O O
10 NN O O
APC NN O B-Disease
exons NN O O
( NN O O
4 NN O O
, NN O O
5 NN O O
, NN O O
7 NN O O
, NN O O
8 NN O O
, NN O O
9 NN O O
, NN O O
10 NN O O
, NN O O
12 NN O O
, NN O O
13 NN O O
, NN O O
14 NN O O
, NN O O
and NN O O
part NN O O
of NN O O
15 NN O O
) NN O O
in NN O O
33 NN O O
unrelated NN O O
Dutch NN O O
FAP NN O B-Disease
patients NN O O
has NN O O
led NN O O
to NN O O
the NN O O
identification NN O O
of NN O O
eight NN O O
novel NN O O
germ NN O O
line NN O O
mutations NN O O
resulting NN O O
in NN O O
stop NN O O
codons NN O O
or NN O O
frameshifts NN O O
. NN O O

The NN O O
results NN O O
reported NN O O
here NN O O
indicate NN O O
that NN O O
( NN O O
1 NN O O
) NN O O
familial NN O B-Disease
adenomatous NN O I-Disease
polyposis NN O I-Disease
is NN O O
caused NN O O
by NN O O
an NN O O
extremely NN O O
heterogeneous NN O O
spectrum NN O O
of NN O O
point NN O O
mutations NN O O
; NN O O
( NN O O
2 NN O O
) NN O O
all NN O O
the NN O O
mutations NN O O
found NN O O
in NN O O
this NN O O
study NN O O
are NN O O
chain NN O O
terminating NN O O
; NN O O
and NN O O
( NN O O
3 NN O O
) NN O O
DGGE NN O O
represents NN O O
a NN O O
rapid NN O O
and NN O O
sensitive NN O O
technique NN O O
for NN O O
the NN O O
detection NN O O
of NN O O
mutations NN O O
in NN O O
the NN O O
unusually NN O O
large NN O O
APC NN O B-Disease
gene NN O O
. NN O O

An NN O O
extension NN O O
of NN O O
the NN O O
DGGE NN O O
analysis NN O O
to NN O O
the NN O O
entire NN O O
coding NN O O
region NN O O
in NN O O
a NN O O
sufficient NN O O
number NN O O
of NN O O
clinically NN O O
well NN O O
- NN O O
characterized NN O O
, NN O O
unrelated NN O O
patients NN O O
will NN O O
facilitate NN O O
the NN O O
establishment NN O O
of NN O O
genotype NN O O
- NN O O
phenotype NN O O
correlations NN O O
. NN O O

On NN O O
the NN O O
other NN O O
hand NN O O
, NN O O
the NN O O
occurrence NN O O
of NN O O
an NN O O
extremely NN O O
heterogeneous NN O O
spectrum NN O O
of NN O O
mutations NN O O
spread NN O O
throughout NN O O
the NN O O
entire NN O O
length NN O O
of NN O O
the NN O O
large NN O O
APC NN O B-Disease
gene NN O O
among NN O O
the NN O O
FAP NN O B-Disease
patients NN O O
indicates NN O O
that NN O O
this NN O O
approach NN O O
may NN O O
not NN O O
be NN O O
useful NN O O
as NN O O
a NN O O
rapid NN O O
presymptomatic NN O O
diagnostic NN O O
procedure NN O O
in NN O O
a NN O O
routine NN O O
laboratory NN O O
. NN O O

Nevertheless NN O O
, NN O O
the NN O O
above NN O O
DGGE NN O O
approach NN O O
has NN O O
incidentally NN O O
led NN O O
to NN O O
the NN O O
identification NN O O
of NN O O
a NN O O
common NN O O
polymorphism NN O O
in NN O O
exon NN O O
13 NN O O
. NN O O

Such NN O O
intragenic NN O O
polymorphisms NN O O
offer NN O O
a NN O O
practical NN O O
approach NN O O
to NN O O
a NN O O
more NN O O
rapid NN O O
procedure NN O O
for NN O O
presymptomatic NN O O
diagnosis NN O O
of NN O O
FAP NN O B-Disease
by NN O O
linkage NN O O
analysis NN O O
in NN O O
informative NN O O
families NN O O
. NN O O
. NN O O

Yeast NN O O
artificial NN O O
chromosomes NN O O
for NN O O
the NN O O
molecular NN O O
analysis NN O O
of NN O O
the NN O O
familial NN O B-Disease
polyposis NN O I-Disease
APC NN O I-Disease
gene NN O O
region NN O O
. NN O O

Two NN O O
yeast NN O O
artificial NN O O
chromosomes NN O O
( NN O O
YACs NN O O
) NN O O
spanning NN O O
a NN O O
total NN O O
distance NN O O
of NN O O
1 NN O O
. NN O O

1 NN O O
megabase NN O O
pairs NN O O
of NN O O
DNA NN O O
around NN O O
the NN O O
MCC NN O O
( NN O O
for NN O O
mutated NN O O
in NN O O
colorectal NN O B-Disease
carcinoma NN O I-Disease
) NN O O
and NN O O
APC NN O B-Disease
( NN O O
for NN O O
adenomatous NN O B-Disease
polyposis NN O I-Disease
coli NN O I-Disease
) NN O O
genes NN O O
at NN O O
5q21 NN O O
have NN O O
been NN O O
isolated NN O O
and NN O O
characterized NN O O
. NN O O

Starting NN O O
from NN O O
the NN O O
MCC NN O O
gene NN O O
, NN O O
a NN O O
strategy NN O O
was NN O O
undertaken NN O O
to NN O O
identify NN O O
constitutional NN O O
submicroscopic NN O O
deletions NN O O
in NN O O
familial NN O B-Disease
adenomatous NN O I-Disease
polyposis NN O I-Disease
patients NN O O
that NN O O
might NN O O
considerably NN O O
narrow NN O O
down NN O O
the NN O O
position NN O O
of NN O O
the NN O O
APC NN O B-Disease
gene NN O O
. NN O O

To NN O O
this NN O O
end NN O O
, NN O O
YACs NN O O
identified NN O O
by NN O O
the NN O O
MCC NN O O
gene NN O O
were NN O O
screened NN O O
across NN O O
a NN O O
chromosome NN O O
5 NN O O
- NN O O
specific NN O O
cosmid NN O O
library NN O O
to NN O O
provide NN O O
a NN O O
source NN O O
of NN O O
DNA NN O O
probes NN O O
for NN O O
genomic NN O O
scanning NN O O
. NN O O

The NN O O
cosmids NN O O
isolated NN O O
from NN O O
these NN O O
experiments NN O O
were NN O O
used NN O O
to NN O O
screen NN O O
a NN O O
panel NN O O
of NN O O
somatic NN O O
cell NN O O
hybrids NN O O
containing NN O O
chromosome NN O O
5 NN O O
segregated NN O O
from NN O O
patients NN O O
suspected NN O O
to NN O O
carry NN O O
putative NN O O
interstitial NN O O
deletions NN O O
. NN O O

This NN O O
screening NN O O
approach NN O O
led NN O O
to NN O O
the NN O O
confirmation NN O O
of NN O O
a NN O O
small NN O O
heterozygous NN O O
deletion NN O O
in NN O O
a NN O O
polyposis NN O B-Disease
patient NN O O
that NN O O
overlaps NN O O
one NN O O
of NN O O
the NN O O
two NN O O
isolated NN O O
YACs NN O O
. NN O O

This NN O O
YAC NN O O
has NN O O
been NN O O
shown NN O O
to NN O O
contain NN O O
the NN O O
entire NN O O
APC NN O B-Disease
gene NN O O
, NN O O
in NN O O
addition NN O O
to NN O O
a NN O O
significant NN O O
portion NN O O
of NN O O
DNA NN O O
flanking NN O O
the NN O O
5 NN O O
end NN O O
of NN O O
the NN O O
gene NN O O
, NN O O
and NN O O
should NN O O
therefore NN O O
prove NN O O
a NN O O
valuable NN O O
resource NN O O
for NN O O
functional NN O O
studies NN O O
by NN O O
transfer NN O O
to NN O O
colorectal NN O B-Disease
tumor NN O I-Disease
- NN O O
derived NN O O
cell NN O O
lines NN O O
. NN O O

Inherited NN O O
WT1 NN O O
mutation NN O O
in NN O O
Denys NN O B-Disease
- NN O I-Disease
Drash NN O I-Disease
syndrome NN O I-Disease
. NN O O

Patients NN O O
with NN O O
the NN O O
Denys NN O B-Disease
- NN O I-Disease
Drash NN O I-Disease
syndrome NN O I-Disease
( NN O O
Wilms NN O B-Disease
tumor NN O I-Disease
, NN O O
genital NN O B-Disease
anomalies NN O I-Disease
, NN O O
and NN O O
nephropathy NN O B-Disease
) NN O O
have NN O O
been NN O O
demonstrated NN O O
to NN O O
carry NN O O
de NN O O
novo NN O O
constitutional NN O O
mutations NN O O
in NN O O
WT1 NN O O
, NN O O
the NN O O
Wilms NN O B-Disease
tumor NN O I-Disease
gene NN O O
at NN O O
chromosome NN O O
11p13 NN O O
. NN O O

We NN O O
report NN O O
three NN O O
new NN O O
cases NN O O
, NN O O
two NN O O
carrying NN O O
a NN O O
previously NN O O
described NN O O
WT1 NN O O
exon NN O O
9 NN O O
mutation NN O O
and NN O O
one NN O O
with NN O O
a NN O O
novel NN O O
WT1 NN O O
exon NN O O
8 NN O O
mutation NN O O
. NN O O

However NN O O
, NN O O
unlike NN O O
patients NN O O
in NN O O
previous NN O O
reports NN O O
, NN O O
one NN O O
of NN O O
our NN O O
three NN O O
patients NN O O
inherited NN O O
the NN O O
affected NN O O
allele NN O O
from NN O O
his NN O O
phenotypically NN O O
unaffected NN O O
father NN O O
. NN O O

This NN O O
observation NN O O
indicates NN O O
that NN O O
the NN O O
WT1 NN O O
exon NN O O
9 NN O O
mutation NN O O
affecting NN O O
394Arg NN O O
demonstrated NN O O
in NN O O
over NN O O
one NN O O
- NN O O
half NN O O
of NN O O
the NN O O
patients NN O O
with NN O O
the NN O O
Denys NN O B-Disease
- NN O I-Disease
Drash NN O I-Disease
syndrome NN O I-Disease
may NN O O
exhibit NN O O
incomplete NN O O
penetrance NN O O
. NN O O

Consequently NN O O
, NN O O
familial NN O O
studies NN O O
in NN O O
patients NN O O
affected NN O O
by NN O O
this NN O O
syndrome NN O O
are NN O O
recommended NN O O
. NN O O
. NN O O

Submicroscopic NN O O
deletions NN O O
at NN O O
the NN O O
WAGR NN O B-Disease
locus NN O O
, NN O O
revealed NN O O
by NN O O
nonradioactive NN O O
in NN O O
situ NN O O
hybridization NN O O
. NN O O

Fluorescence NN O O
in NN O O
situ NN O O
hybridization NN O O
( NN O O
FISH NN O O
) NN O O
with NN O O
biotin NN O O
- NN O O
labeled NN O O
probes NN O O
mapping NN O O
to NN O O
11p13 NN O O
has NN O O
been NN O O
used NN O O
for NN O O
the NN O O
molecular NN O O
analysis NN O O
of NN O O
deletions NN O O
of NN O O
the NN O O
WAGR NN O B-Disease
( NN O O
Wilms NN O B-Disease
tumor NN O I-Disease
, NN O O
aniridia NN O B-Disease
, NN O O
genitourinary NN O B-Disease
abnormalities NN O I-Disease
, NN O O
and NN O O
mental NN O B-Disease
retardation NN O I-Disease
) NN O O
locus NN O O
. NN O O

We NN O O
have NN O O
detected NN O O
a NN O O
submicroscopic NN O O
11p13 NN O O
deletion NN O O
in NN O O
a NN O O
child NN O O
with NN O O
inherited NN O O
aniridia NN O B-Disease
who NN O O
subsequently NN O O
presented NN O O
with NN O O
Wilms NN O B-Disease
tumor NN O I-Disease
in NN O O
a NN O O
horseshoe NN O O
kidney NN O O
, NN O O
only NN O O
revealed NN O O
at NN O O
surgery NN O O
. NN O O

The NN O O
mother NN O O
, NN O O
who NN O O
has NN O O
aniridia NN O B-Disease
, NN O O
was NN O O
also NN O O
found NN O O
to NN O O
carry NN O O
a NN O O
deletion NN O O
including NN O O
both NN O O
the NN O O
aniridia NN O B-Disease
candidate NN O O
gene NN O O
( NN O O
AN2 NN O O
) NN O O
and NN O O
the NN O O
Wilms NN O B-Disease
tumor NN O I-Disease
predisposition NN O O
gene NN O O
( NN O O
WT1 NN O O
) NN O O
. NN O O

This NN O O
is NN O O
therefore NN O O
a NN O O
rare NN O O
case NN O O
of NN O O
an NN O O
inherited NN O O
WAGR NN O B-Disease
deletion NN O O
. NN O O

Wilms NN O B-Disease
tumor NN O I-Disease
has NN O O
so NN O O
far NN O O
only NN O O
been NN O O
associated NN O O
with NN O O
sporadic NN O O
de NN O O
novo NN O O
aniridia NN O B-Disease
cases NN O O
. NN O O

We NN O O
have NN O O
shown NN O O
that NN O O
a NN O O
cosmid NN O O
probe NN O O
for NN O O
a NN O O
candidate NN O O
aniridia NN O B-Disease
gene NN O O
, NN O O
homologous NN O O
to NN O O
the NN O O
mouse NN O O
Pax NN O O
- NN O O
6 NN O O
gene NN O O
, NN O O
is NN O O
deleted NN O O
in NN O O
cell NN O O
lines NN O O
from NN O O
aniridia NN O B-Disease
patients NN O O
with NN O O
previously NN O O
characterized NN O O
deletions NN O O
at NN O O
11p13 NN O O
, NN O O
while NN O O
another NN O O
cosmid NN O O
marker NN O O
mapping NN O O
between NN O O
two NN O O
aniridia NN O B-Disease
- NN O O
associated NN O O
translocation NN O O
breakpoints NN O O
( NN O O
and NN O O
hence NN O O
a NN O O
second NN O O
candidate NN O O
marker NN O O
) NN O O
is NN O O
present NN O O
on NN O O
both NN O O
chromosomes NN O O
. NN O O

These NN O O
results NN O O
support NN O O
the NN O O
Pax NN O O
- NN O O
6 NN O O
homologue NN O O
as NN O O
a NN O O
strong NN O O
candidate NN O O
for NN O O
the NN O O
AN2 NN O O
gene NN O O
. NN O O

FISH NN O O
with NN O O
cosmid NN O O
probes NN O O
has NN O O
proved NN O O
to NN O O
be NN O O
a NN O O
fast NN O O
and NN O O
reliable NN O O
technique NN O O
for NN O O
the NN O O
molecular NN O O
analysis NN O O
of NN O O
deletions NN O O
. NN O O

It NN O O
can NN O O
be NN O O
used NN O O
with NN O O
limited NN O O
amounts NN O O
of NN O O
material NN O O
and NN O O
has NN O O
strong NN O O
potential NN O O
for NN O O
clinical NN O O
applications NN O O
. NN O O
. NN O O

Linkage NN O O
of NN O O
gene NN O O
for NN O O
C2 NN O B-Disease
deficiency NN O I-Disease
and NN O O
the NN O O
major NN O O
histocompatibility NN O O
complex NN O O
MHC NN O O
in NN O O
man NN O O
. NN O O

Family NN O O
study NN O O
of NN O O
a NN O O
further NN O O
case NN O O
. NN O O

Close NN O O
linkage NN O O
between NN O O
HL NN O O
- NN O O
A NN O O
and NN O O
C2 NN O B-Disease
deficiency NN O I-Disease
was NN O O
first NN O O
reported NN O O
by NN O O
FU NN O O
and NN O O
co NN O O
- NN O O
workers NN O O
in NN O O
1974 NN O O
. NN O O

We NN O O
present NN O O
here NN O O
a NN O O
pedigree NN O O
of NN O O
a NN O O
31 NN O O
- NN O O
year NN O O
- NN O O
old NN O O
C2 NN O B-Disease
- NN O I-Disease
deficient NN O I-Disease
individual NN O O
with NN O O
clinical NN O O
manifestations NN O O
of NN O O
Hodgkins NN O B-Disease
disease NN O I-Disease
. NN O O

The NN O O
following NN O O
markers NN O O
were NN O O
tested NN O O
C2 NN O O
levels NN O O
, NN O O
factor NN O O
B NN O O
polymorphism NN O O
, NN O O
blood NN O O
groups NN O O
, NN O O
and NN O O
enzyme NN O O
typing NN O O
. NN O O

In NN O O
addition NN O O
to NN O O
close NN O O
linkage NN O O
between NN O O
HL NN O O
- NN O O
A NN O O
and NN O O
C2 NN O B-Disease
deficiency NN O I-Disease
, NN O O
both NN O O
parents NN O O
were NN O O
heterozygous NN O O
for NN O O
Bf NN O O
( NN O O
HL NN O O
- NN O O
A NN O O
linked NN O O
, NN O O
electrophoretic NN O O
variation NN O O
of NN O O
B NN O O
) NN O O
. NN O O

The NN O O
two NN O O
HL NN O O
- NN O O
A NN O O
haplotypes NN O O
closely NN O O
linked NN O O
to NN O O
C2 NN O B-Disease
deficiency NN O I-Disease
are NN O O
different NN O O
2 NN O O
, NN O O
W18 NN O O
and NN O O
W24 NN O O
, NN O O
W18 NN O O
. NN O O

They NN O O
share NN O O
, NN O O
however NN O O
, NN O O
the NN O O
SD2 NN O O
antigen NN O O
W18 NN O O
and NN O O
the NN O O
LD NN O O
type NN O O
7a NN O O
. NN O O
. NN O O

Screening NN O O
for NN O O
germ NN O O
- NN O O
line NN O O
mutations NN O O
in NN O O
familial NN O B-Disease
adenomatous NN O I-Disease
polyposis NN O I-Disease
patients NN O O
: NN O O
61 NN O O
new NN O O
patients NN O O
and NN O O
a NN O O
summary NN O O
of NN O O
150 NN O O
unrelated NN O O
patients NN O O
. NN O O

We NN O O
report NN O O
here NN O O
the NN O O
result NN O O
of NN O O
a NN O O
screening NN O O
for NN O O
germ NN O O
- NN O O
line NN O O
mutations NN O O
in NN O O
the NN O O
adenomatous NN O B-Disease
polyposis NN O I-Disease
coli NN O I-Disease
( NN O O
APC NN O B-Disease
) NN O O
gene NN O O
in NN O O
61 NN O O
new NN O O
familial NN O B-Disease
adenomatous NN O I-Disease
polyposis NN O I-Disease
( NN O O
FAP NN O B-Disease
) NN O O
patients NN O O
as NN O O
well NN O O
as NN O O
a NN O O
summary NN O O
of NN O O
the NN O O
results NN O O
of NN O O
150 NN O O
patients NN O O
. NN O O

Examination NN O O
of NN O O
the NN O O
entire NN O O
coding NN O O
region NN O O
of NN O O
the NN O O
APC NN O B-Disease
gene NN O O
, NN O O
based NN O O
on NN O O
a NN O O
ribonuclease NN O O
protection NN O O
assay NN O O
coupled NN O O
with NN O O
the NN O O
polymerase NN O O
chain NN O O
reaction NN O O
( NN O O
PCR NN O O
) NN O O
, NN O O
disclosed NN O O
mutations NN O O
that NN O O
were NN O O
considered NN O O
to NN O O
cause NN O O
significant NN O O
defects NN O O
in NN O O
the NN O O
APC NN O B-Disease
product NN O O
in NN O O
97 NN O O
of NN O O
150 NN O O
unrelated NN O O
FAP NN O B-Disease
patients NN O O
. NN O O

Our NN O O
findings NN O O
revealed NN O O
the NN O O
following NN O O
characteristics NN O O
of NN O O
the NN O O
germ NN O O
- NN O O
line NN O O
mutations NN O O
of NN O O
APC NN O O
1 NN O O
) NN O O
the NN O O
great NN O O
majority NN O O
of NN O O
the NN O O
mutations NN O O
were NN O O
found NN O O
to NN O O
truncate NN O O
the NN O O
APC NN O B-Disease
product NN O O
; NN O O
2 NN O O
) NN O O
almost NN O O
all NN O O
of NN O O
the NN O O
mutations NN O O
were NN O O
located NN O O
within NN O O
the NN O O
first NN O O
half NN O O
of NN O O
the NN O O
coding NN O O
region NN O O
; NN O O
3 NN O O
) NN O O
no NN O O
correlation NN O O
was NN O O
observed NN O O
between NN O O
the NN O O
locations NN O O
of NN O O
germ NN O O
- NN O O
line NN O O
mutations NN O O
and NN O O
extracolonic NN O O
manifestations NN O O
in NN O O
FAP NN O B-Disease
patients NN O O
; NN O O
4 NN O O
) NN O O
more NN O O
than NN O O
80 NN O O
% NN O O
of NN O O
base NN O O
substitutions NN O O
in NN O O
the NN O O
APC NN O B-Disease
gene NN O O
were NN O O
from NN O O
cytosine NN O O
to NN O O
other NN O O
nucleotides NN O O
, NN O O
nearly NN O O
one NN O O
- NN O O
third NN O O
of NN O O
which NN O O
occurred NN O O
at NN O O
the NN O O
GpG NN O O
site NN O O
. NN O O

Our NN O O
results NN O O
provide NN O O
information NN O O
helpful NN O O
to NN O O
an NN O O
understanding NN O O
of NN O O
the NN O O
APC NN O B-Disease
gene NN O O
and NN O O
will NN O O
also NN O O
contribute NN O O
to NN O O
presymptomatic NN O O
diagnosis NN O O
of NN O O
members NN O O
in NN O O
FAP NN O B-Disease
families NN O O
. NN O O
. NN O O

Somatic NN O O
mutations NN O O
of NN O O
the NN O O
APC NN O B-Disease
gene NN O O
in NN O O
colorectal NN O B-Disease
tumors NN O I-Disease
: NN O O
mutation NN O O
cluster NN O O
region NN O O
in NN O O
the NN O O
APC NN O B-Disease
gene NN O O
. NN O O

We NN O O
examined NN O O
somatic NN O O
mutations NN O O
of NN O O
the NN O O
adenomatous NN O B-Disease
polyposis NN O I-Disease
coli NN O I-Disease
( NN O O
APC NN O B-Disease
) NN O O
gene NN O O
in NN O O
63 NN O O
colorectal NN O B-Disease
tumors NN O I-Disease
( NN O O
16 NN O O
adenomas NN O B-Disease
and NN O O
47 NN O O
carcinomas NN O B-Disease
) NN O O
developed NN O O
in NN O O
familial NN O B-Disease
adenomatous NN O I-Disease
polyposis NN O I-Disease
( NN O O
FAP NN O B-Disease
) NN O O
and NN O O
non NN O O
- NN O O
FAP NN O O
patients NN O O
. NN O O

In NN O O
addition NN O O
to NN O O
loss NN O O
of NN O O
heterozygosity NN O O
( NN O O
LOH NN O O
) NN O O
at NN O O
the NN O O
APC NN O B-Disease
locus NN O O
in NN O O
30 NN O O
tumors NN O B-Disease
, NN O O
43 NN O O
other NN O O
somatic NN O O
mutations NN O O
were NN O O
detected NN O O
. NN O O

Twenty NN O O
- NN O O
one NN O O
of NN O O
them NN O O
were NN O O
point NN O O
mutations NN O O
; NN O O
16 NN O O
nonsense NN O O
and NN O O
two NN O O
missense NN O O
mutations NN O O
, NN O O
and NN O O
three NN O O
occurred NN O O
in NN O O
introns NN O O
at NN O O
the NN O O
splicing NN O O
site NN O O
. NN O O

Twenty NN O O
- NN O O
two NN O O
tumors NN O B-Disease
had NN O O
frameshift NN O O
mutations NN O O
due NN O O
to NN O O
deletion NN O O
or NN O O
insertion NN O O
; NN O O
nineteen NN O O
of NN O O
them NN O O
were NN O O
deletions NN O O
of NN O O
one NN O O
to NN O O
31 NN O O
bp NN O O
and NN O O
three NN O O
were NN O O
a NN O O
1 NN O O
- NN O O
bp NN O O
insertion NN O O
. NN O O

One NN O O
tumor NN O B-Disease
had NN O O
a NN O O
1 NN O O
- NN O O
bp NN O O
deletion NN O O
in NN O O
an NN O O
intron NN O O
near NN O O
the NN O O
splicing NN O O
site NN O O
. NN O O

Hence NN O O
, NN O O
41 NN O O
( NN O O
95 NN O O
% NN O O
) NN O O
of NN O O
43 NN O O
mutations NN O O
resulted NN O O
in NN O O
truncation NN O O
of NN O O
the NN O O
APC NN O B-Disease
protein NN O O
. NN O O

Over NN O O
60 NN O O
% NN O O
of NN O O
the NN O O
somatic NN O O
mutations NN O O
in NN O O
the NN O O
APC NN O B-Disease
gene NN O O
were NN O O
clustered NN O O
within NN O O
a NN O O
small NN O O
region NN O O
of NN O O
exon NN O O
15 NN O O
, NN O O
designated NN O O
as NN O O
MCR NN O O
( NN O O
mutation NN O O
cluster NN O O
region NN O O
) NN O O
, NN O O
which NN O O
accounted NN O O
for NN O O
less NN O O
than NN O O
10 NN O O
% NN O O
of NN O O
the NN O O
coding NN O O
region NN O O
. NN O O

Combining NN O O
these NN O O
data NN O O
and NN O O
the NN O O
results NN O O
of NN O O
LOH NN O O
, NN O O
more NN O O
than NN O O
80 NN O O
% NN O O
of NN O O
tumors NN O B-Disease
( NN O O
14 NN O O
adenomas NN O B-Disease
and NN O O
39 NN O O
carcinomas NN O B-Disease
) NN O O
had NN O O
at NN O O
least NN O O
one NN O O
mutation NN O O
in NN O O
the NN O O
APC NN O B-Disease
gene NN O O
, NN O O
of NN O O
which NN O O
more NN O O
than NN O O
60 NN O O
% NN O O
( NN O O
9 NN O O
adenomas NN O B-Disease
and NN O O
23 NN O O
carcinomas NN O B-Disease
) NN O O
had NN O O
two NN O O
mutations NN O O
. NN O O

These NN O O
results NN O O
strongly NN O O
suggest NN O O
that NN O O
somatic NN O O
mutations NN O O
of NN O O
the NN O O
APC NN O B-Disease
gene NN O O
are NN O O
associated NN O O
with NN O O
development NN O O
of NN O O
a NN O O
great NN O O
majority NN O O
of NN O O
colorectal NN O B-Disease
tumors NN O I-Disease
. NN O O
. NN O O

Constitutional NN O O
mutations NN O O
in NN O O
the NN O O
WT1 NN O O
gene NN O O
in NN O O
patients NN O O
with NN O O
Denys NN O B-Disease
- NN O I-Disease
Drash NN O I-Disease
syndrome NN O I-Disease
. NN O O

The NN O O
Denys NN O B-Disease
- NN O I-Disease
Drash NN O I-Disease
syndrome NN O I-Disease
is NN O O
characterised NN O O
by NN O O
a NN O O
typical NN O O
nephropathy NN O B-Disease
, NN O O
genital NN O B-Disease
abnormalities NN O I-Disease
and NN O O
also NN O O
predisposes NN O O
to NN O O
the NN O O
development NN O O
of NN O O
Wilms NN O B-Disease
tumor NN O I-Disease
. NN O O

These NN O O
patients NN O O
eventually NN O O
go NN O O
into NN O O
end NN O O
stage NN O O
renal NN O B-Disease
failure NN O I-Disease
. NN O O

A NN O O
candidate NN O O
Wilms NN O B-Disease
tumor NN O I-Disease
gene NN O O
, NN O O
WT1 NN O O
, NN O O
from NN O O
the NN O O
11p13 NN O O
chromosome NN O O
region NN O O
has NN O O
recently NN O O
been NN O O
cloned NN O O
. NN O O

We NN O O
have NN O O
analysed NN O O
the NN O O
DNA NN O O
sequence NN O O
in NN O O
constitutional NN O O
cells NN O O
from NN O O
eight NN O O
patients NN O O
and NN O O
have NN O O
shown NN O O
heterozygous NN O O
mutations NN O O
in NN O O
six NN O O
of NN O O
them NN O O
. NN O O

Four NN O O
of NN O O
the NN O O
mutations NN O O
were NN O O
in NN O O
exon NN O O
9 NN O O
, NN O O
all NN O O
resulting NN O O
in NN O O
missense NN O O
mutations NN O O
. NN O O

Three NN O O
were NN O O
at NN O O
nucleotide NN O O
position NN O O
1180 NN O O
resulting NN O O
in NN O O
an NN O O
arg NN O O
> NN O O
trp NN O O
amino NN O O
acid NN O O
change NN O O
. NN O O

The NN O O
other NN O O
was NN O O
at NN O O
position NN O O
1186 NN O O
converting NN O O
an NN O O
asp NN O O
> NN O O
asn NN O O
in NN O O
the NN O O
predicted NN O O
resultant NN O O
protein NN O O
. NN O O

One NN O O
patient NN O O
had NN O O
a NN O O
missense NN O O
mutation NN O O
in NN O O
exon NN O O
8 NN O O
, NN O O
converting NN O O
an NN O O
arg NN O O
> NN O O
his NN O O
. NN O O

A NN O O
single NN O O
base NN O O
pair NN O O
insertion NN O O
at NN O O
nucleotide NN O O
position NN O O
821 NN O O
in NN O O
exon NN O O
6 NN O O
resulted NN O O
in NN O O
the NN O O
generation NN O O
of NN O O
a NN O O
premature NN O O
stop NN O O
codon NN O O
in NN O O
the NN O O
last NN O O
patient NN O O
. NN O O

We NN O O
were NN O O
unable NN O O
to NN O O
find NN O O
a NN O O
mutation NN O O
in NN O O
one NN O O
patient NN O O
despite NN O O
complete NN O O
sequencing NN O O
of NN O O
the NN O O
genomic NN O O
sequence NN O O
of NN O O
the NN O O
gene NN O O
. NN O O

The NN O O
last NN O O
patient NN O O
carried NN O O
a NN O O
constitutional NN O O
deletion NN O O
of NN O O
the NN O O
11p13 NN O O
region NN O O
and NN O O
no NN O O
additional NN O O
mutation NN O O
was NN O O
found NN O O
. NN O O

There NN O O
was NN O O
no NN O O
obvious NN O O
correlation NN O O
between NN O O
the NN O O
type NN O O
of NN O O
mutation NN O O
and NN O O
phenotypic NN O O
expression NN O O
. NN O O

These NN O O
results NN O O
further NN O O
demonstrate NN O O
that NN O O
the NN O O
WT1 NN O O
gene NN O O
is NN O O
important NN O O
in NN O O
both NN O O
the NN O O
development NN O O
of NN O O
the NN O O
kidney NN O O
and NN O O
the NN O O
genito NN O O
- NN O O
urinary NN O O
system NN O O
. NN O O
. NN O O

Linkage NN O O
disequilibrium NN O O
mapping NN O O
in NN O O
isolated NN O O
founder NN O O
populations NN O O
: NN O O
diastrophic NN O B-Disease
dysplasia NN O I-Disease
in NN O O
Finland NN O O
. NN O O

Linkage NN O O
disequilibrium NN O O
mapping NN O O
in NN O O
isolated NN O O
populations NN O O
provides NN O O
a NN O O
powerful NN O O
tool NN O O
for NN O O
fine NN O O
structure NN O O
localization NN O O
of NN O O
disease NN O O
genes NN O O
. NN O O

Here NN O O
, NN O O
Luria NN O O
and NN O O
Delbrucks NN O O
classical NN O O
methods NN O O
for NN O O
analysing NN O O
bacterial NN O O
cultures NN O O
are NN O O
adapted NN O O
to NN O O
the NN O O
study NN O O
of NN O O
human NN O O
isolated NN O O
founder NN O O
populations NN O O
in NN O O
order NN O O
to NN O O
estimate NN O O
( NN O O
i NN O O
) NN O O
the NN O O
recombination NN O O
fraction NN O O
between NN O O
a NN O O
disease NN O O
locus NN O O
and NN O O
a NN O O
marker NN O O
; NN O O
( NN O O
ii NN O O
) NN O O
the NN O O
expected NN O O
degree NN O O
of NN O O
allelic NN O O
homogeneity NN O O
in NN O O
a NN O O
population NN O O
; NN O O
and NN O O
( NN O O
iii NN O O
) NN O O
the NN O O
mutation NN O O
rate NN O O
of NN O O
marker NN O O
loci NN O O
. NN O O

Using NN O O
these NN O O
methods NN O O
, NN O O
we NN O O
report NN O O
striking NN O O
linkage NN O O
disequilibrium NN O O
for NN O O
diastrophic NN O B-Disease
dysplasia NN O I-Disease
( NN O O
DTD NN O B-Disease
) NN O O
in NN O O
Finland NN O O
indicating NN O O
that NN O O
the NN O O
DTD NN O B-Disease
gene NN O O
should NN O O
lie NN O O
within NN O O
0 NN O O
. NN O O

06 NN O O
centimorgans NN O O
( NN O O
or NN O O
about NN O O
60 NN O O
kilobases NN O O
) NN O O
of NN O O
the NN O O
CSF1R NN O O
gene NN O O
. NN O O

Predictions NN O O
about NN O O
allelic NN O O
homogeneity NN O O
in NN O O
Finland NN O O
and NN O O
mutation NN O O
rates NN O O
in NN O O
simple NN O O
sequence NN O O
repeats NN O O
are NN O O
confirmed NN O O
by NN O O
independent NN O O
observations NN O O
. NN O O

The NN O O
Wiskott NN O B-Disease
- NN O I-Disease
Aldrich NN O I-Disease
syndrome NN O I-Disease
: NN O O
refinement NN O O
of NN O O
the NN O O
localization NN O O
on NN O O
Xp NN O O
and NN O O
identification NN O O
of NN O O
another NN O O
closely NN O O
linked NN O O
marker NN O O
locus NN O O
, NN O O
OATL1 NN O O
. NN O O

The NN O O
Wiskott NN O B-Disease
- NN O I-Disease
Aldrich NN O I-Disease
syndrome NN O I-Disease
( NN O O
WAS NN O B-Disease
) NN O O
has NN O O
previously NN O O
been NN O O
mapped NN O O
to NN O O
the NN O O
proximal NN O O
short NN O O
arm NN O O
of NN O O
the NN O O
X NN O O
chromosome NN O O
between NN O O
the NN O O
DXS14 NN O O
and NN O O
DXS7 NN O O
loci NN O O
. NN O O

In NN O O
this NN O O
study NN O O
, NN O O
further NN O O
segregation NN O O
analysis NN O O
has NN O O
been NN O O
performed NN O O
using NN O O
a NN O O
newly NN O O
identified NN O O
WAS NN O B-Disease
family NN O O
as NN O O
well NN O O
as NN O O
an NN O O
additional NN O O
marker NN O O
probe NN O O
, NN O O
HOATL1 NN O O
. NN O O

The NN O O
results NN O O
indicate NN O O
close NN O O
linkage NN O O
between NN O O
the NN O O
WAS NN O B-Disease
and NN O O
OATL1 NN O O
loci NN O O
( NN O O
Z NN O O
= NN O O
6 NN O O
. NN O O
08 NN O O
at NN O O
theta NN O O
= NN O O
0 NN O O
. NN O O
00 NN O O
) NN O O
and NN O O
localize NN O O
the NN O O
TIMP NN O O
, NN O O
OATL1 NN O O
, NN O O
DXS255 NN O O
, NN O O
and NN O O
WAS NN O B-Disease
loci NN O O
distal NN O O
to NN O O
DXS146 NN O O
and NN O O
the NN O O
OATL1 NN O O
and NN O O
WAS NN O B-Disease
loci NN O O
proximal NN O O
to NN O O
TIMP NN O O
. NN O O

These NN O O
linkage NN O O
data NN O O
narrow NN O O
the NN O O
boundaries NN O O
within NN O O
which NN O O
the NN O O
WAS NN O B-Disease
locus NN O O
maps NN O O
to NN O O
the NN O O
chromosomal NN O O
region NN O O
bracketed NN O O
by NN O O
TIMP NN O O
and NN O O
DXS146 NN O O
and NN O O
support NN O O
the NN O O
loci NN O O
order NN O O
Xpter NN O O
- NN O O
DXS7 NN O O
- NN O O
TIMP NN O O
- NN O O
( NN O O
OATL1 NN O O
, NN O O
WAS NN O O
, NN O O
DXS255 NN O O
) NN O O
- NN O O
DXS146 NN O O
. NN O O

Detection NN O O
of NN O O
an NN O O
unstable NN O O
fragment NN O O
of NN O O
DNA NN O O
specific NN O O
to NN O O
individuals NN O O
with NN O O
myotonic NN O B-Disease
dystrophy NN O I-Disease
. NN O O

Myotonic NN O B-Disease
dystrophy NN O I-Disease
( NN O O
DM NN O B-Disease
) NN O O
is NN O O
the NN O O
most NN O O
common NN O O
form NN O O
of NN O O
adult NN O O
muscular NN O B-Disease
dystrophy NN O I-Disease
, NN O O
with NN O O
a NN O O
prevalence NN O O
of NN O O
2 NN O O
- NN O O
14 NN O O
per NN O O
100 NN O O
, NN O O
000 NN O O
individuals NN O O
. NN O O

The NN O O
disease NN O O
is NN O O
characterized NN O O
by NN O O
progressive NN O O
muscle NN O B-Disease
weakness NN O I-Disease
and NN O O
sustained NN O B-Disease
muscle NN O I-Disease
contraction NN O I-Disease
, NN O O
often NN O O
with NN O O
a NN O O
wide NN O O
range NN O O
of NN O O
accompanying NN O O
symptoms NN O O
. NN O O

The NN O O
age NN O O
at NN O O
onset NN O O
and NN O O
severity NN O O
of NN O O
the NN O O
disease NN O O
show NN O O
extreme NN O O
variation NN O O
, NN O O
both NN O O
within NN O O
and NN O O
between NN O O
families NN O O
. NN O O

Despite NN O O
its NN O O
clinical NN O O
variability NN O O
, NN O O
this NN O O
dominant NN O O
condition NN O O
segregates NN O O
as NN O O
a NN O O
single NN O O
locus NN O O
at NN O O
chromosome NN O O
19q13 NN O O
. NN O O

3 NN O O
in NN O O
every NN O O
population NN O O
studied NN O O
. NN O O

It NN O O
is NN O O
flanked NN O O
by NN O O
the NN O O
tightly NN O O
linked NN O O
genetic NN O O
markers NN O O
ERCC1 NN O O
proximally NN O O
and NN O O
D19S51 NN O O
distally NN O O
; NN O O
these NN O O
define NN O O
the NN O O
DM NN O B-Disease
critical NN O O
region NN O O
. NN O O

We NN O O
report NN O O
the NN O O
isolation NN O O
of NN O O
an NN O O
expressed NN O O
sequence NN O O
from NN O O
this NN O O
region NN O O
which NN O O
detects NN O O
a NN O O
DNA NN O O
fragment NN O O
that NN O O
is NN O O
larger NN O O
in NN O O
affected NN O O
individuals NN O O
than NN O O
in NN O O
normal NN O O
siblings NN O O
or NN O O
unaffected NN O O
controls NN O O
. NN O O

The NN O O
size NN O O
of NN O O
this NN O O
fragment NN O O
varies NN O O
between NN O O
affected NN O O
siblings NN O O
, NN O O
and NN O O
increases NN O O
in NN O O
size NN O O
through NN O O
generations NN O O
in NN O O
parallel NN O O
with NN O O
increasing NN O O
severity NN O O
of NN O O
the NN O O
disease NN O O
. NN O O

We NN O O
postulate NN O O
that NN O O
this NN O O
unstable NN O O
DNA NN O O
sequence NN O O
is NN O O
the NN O O
molecular NN O O
feature NN O O
that NN O O
underlies NN O O
DM NN O B-Disease
. NN O O

Common NN O O
sequence NN O O
motifs NN O O
at NN O O
the NN O O
rearrangement NN O O
sites NN O O
of NN O O
a NN O O
constitutional NN O O
X NN O O
/ NN O O
autosome NN O O
translocation NN O O
and NN O O
associated NN O O
deletion NN O O
. NN O O

Reciprocal NN O O
chromosome NN O O
translocations NN O O
are NN O O
common NN O O
de NN O O
novo NN O O
rearrangements NN O O
that NN O O
occur NN O O
randomly NN O O
throughout NN O O
the NN O O
human NN O O
genome NN O O
. NN O O

To NN O O
learn NN O O
about NN O O
causative NN O O
mechanisms NN O O
, NN O O
we NN O O
have NN O O
cloned NN O O
and NN O O
sequenced NN O O
the NN O O
breakpoints NN O O
of NN O O
a NN O O
cytologically NN O O
balanced NN O O
constitutional NN O O
reciprocal NN O O
translocation NN O O
, NN O O
t NN O O
( NN O O
X NN O O
; NN O O
4 NN O O
) NN O O
( NN O O
p21 NN O O
. NN O O
2 NN O O
; NN O O
q31 NN O O
. NN O O
22 NN O O
) NN O O
, NN O O
present NN O O
in NN O O
a NN O O
girl NN O O
with NN O O
Duchenne NN O B-Disease
muscular NN O I-Disease
dystrophy NN O I-Disease
( NN O O
DMD NN O B-Disease
) NN O O
. NN O O

Physical NN O O
mapping NN O O
of NN O O
the NN O O
derivative NN O O
chromosomes NN O O
, NN O O
after NN O O
their NN O O
separation NN O O
in NN O O
somatic NN O O
cell NN O O
hybrids NN O O
, NN O O
reveals NN O O
that NN O O
the NN O O
translocation NN O O
disrupts NN O O
the NN O O
DMD NN O B-Disease
gene NN O O
in NN O O
Xp21 NN O O
within NN O O
the NN O O
18 NN O O
- NN O O
kb NN O O
intron NN O O
16 NN O O
. NN O O

Restriction NN O O
mapping NN O O
and NN O O
sequencing NN O O
of NN O O
clones NN O O
that NN O O
span NN O O
both NN O O
translocation NN O O
breakpoints NN O O
as NN O O
well NN O O
as NN O O
the NN O O
corresponding NN O O
normal NN O O
regions NN O O
indicate NN O O
the NN O O
loss NN O O
of NN O O
approximately NN O O
5 NN O O
kb NN O O
in NN O O
the NN O O
formation NN O O
of NN O O
the NN O O
derivative NN O O
X NN O O
chromosome NN O O
, NN O O
with NN O O
4 NN O O
- NN O O
6 NN O O
bp NN O O
deleted NN O O
from NN O O
chromosome NN O O
4 NN O O
. NN O O

RFLP NN O O
and NN O O
Southern NN O O
analyses NN O O
indicate NN O O
that NN O O
the NN O O
de NN O O
novo NN O O
translocation NN O O
is NN O O
a NN O O
paternal NN O O
origin NN O O
and NN O O
that NN O O
the NN O O
fathers NN O O
X NN O O
chromosome NN O O
contains NN O O
the NN O O
DNA NN O O
that NN O O
is NN O O
deleted NN O O
in NN O O
the NN O O
derivative NN O O
X NN O O
. NN O O

Most NN O O
likely NN O O
, NN O O
deletion NN O O
and NN O O
translation NN O O
arose NN O O
simultaneously NN O O
from NN O O
a NN O O
complex NN O O
rearrangement NN O O
event NN O O
that NN O O
involves NN O O
three NN O O
chromosomal NN O O
breakpoints NN O O
. NN O O

Short NN O O
regions NN O O
of NN O O
sequence NN O O
homology NN O O
were NN O O
present NN O O
at NN O O
the NN O O
three NN O O
sites NN O O
. NN O O

A NN O O
5 NN O O
- NN O O
bp NN O O
sequence NN O O
, NN O O
GGAAT NN O O
, NN O O
found NN O O
exactly NN O O
at NN O O
the NN O O
translocation NN O O
breakpoints NN O O
on NN O O
both NN O O
normal NN O O
chromosomes NN O O
X NN O O
and NN O O
4 NN O O
, NN O O
has NN O O
been NN O O
preserved NN O O
only NN O O
on NN O O
the NN O O
der NN O O
( NN O O
4 NN O O
) NN O O
chromosome NN O O
. NN O O

It NN O O
is NN O O
likely NN O O
that NN O O
the NN O O
X NN O O
- NN O O
derived NN O O
sequence NN O O
GGAATCA NN O O
has NN O O
been NN O O
lost NN O O
in NN O O
the NN O O
formation NN O O
of NN O O
the NN O O
der NN O O
( NN O O
X NN O O
) NN O O
chromosome NN O O
, NN O O
as NN O O
it NN O O
matches NN O O
an NN O O
inverted NN O O
GAATCA NN O O
sequence NN O O
present NN O O
on NN O O
the NN O O
opposite NN O O
strand NN O O
exactly NN O O
at NN O O
the NN O O
other NN O O
end NN O O
of NN O O
the NN O O
deleted NN O O
5 NN O O
- NN O O
kb NN O O
fragment NN O O
. NN O O

A NN O O
genetic NN O O
etiology NN O O
for NN O O
DiGeorge NN O B-Disease
syndrome NN O I-Disease
: NN O O
consistent NN O O
deletions NN O O
and NN O O
microdeletions NN O O
of NN O O
22q11 NN O O
. NN O O

DiGeorge NN O B-Disease
syndrome NN O I-Disease
( NN O O
DGS NN O B-Disease
) NN O O
, NN O O
a NN O O
developmental NN O O
field NN O O
defect NN O O
of NN O O
the NN O O
third NN O O
and NN O O
fourth NN O O
pharyngeal NN O O
pouches NN O O
, NN O O
is NN O O
characterized NN O O
by NN O O
aplasia NN O B-Disease
or NN O I-Disease
hypoplasia NN O I-Disease
of NN O I-Disease
the NN O I-Disease
thymus NN O I-Disease
and NN O I-Disease
parathyroid NN O I-Disease
glands NN O I-Disease
and NN O O
by NN O O
conotruncal NN O B-Disease
cardiac NN O I-Disease
malformations NN O I-Disease
. NN O O

Cytogenetic NN O O
studies NN O O
support NN O O
the NN O O
presence NN O O
of NN O O
a NN O O
DGS NN O B-Disease
critical NN O O
region NN O O
in NN O O
band NN O O
22q11 NN O O
. NN O O

In NN O O
the NN O O
present NN O O
study NN O O
, NN O O
we NN O O
report NN O O
the NN O O
results NN O O
of NN O O
clinical NN O O
, NN O O
cytogenetic NN O O
, NN O O
and NN O O
molecular NN O O
studies NN O O
of NN O O
14 NN O O
patients NN O O
with NN O O
DGS NN O B-Disease
. NN O O

Chromosome NN O O
analysis NN O O
, NN O O
utilizing NN O O
high NN O O
- NN O O
resolution NN O O
banding NN O O
techniques NN O O
, NN O O
detected NN O O
interstitial NN O O
deletions NN O O
in NN O O
five NN O O
probands NN O O
and NN O O
was NN O O
inconclusive NN O O
for NN O O
a NN O O
deletion NN O O
in NN O O
three NN O O
probands NN O O
. NN O O

The NN O O
remaining NN O O
six NN O O
patients NN O O
had NN O O
normal NN O O
karyotypes NN O O
. NN O O

In NN O O
contrast NN O O
, NN O O
molecular NN O O
analysis NN O O
detected NN O O
DNA NN O O
deletions NN O O
in NN O O
all NN O O
14 NN O O
probands NN O O
. NN O O

Two NN O O
of NN O O
10 NN O O
loci NN O O
tested NN O O
, NN O O
D22S75 NN O O
and NN O O
D22S259 NN O O
, NN O O
are NN O O
deleted NN O O
in NN O O
all NN O O
14 NN O O
patients NN O O
. NN O O

A NN O O
third NN O O
locus NN O O
, NN O O
D22S66 NN O O
, NN O O
is NN O O
deleted NN O O
in NN O O
the NN O O
eight NN O O
DGS NN O B-Disease
probands NN O O
tested NN O O
. NN O O

Physical NN O O
mapping NN O O
using NN O O
somatic NN O O
cell NN O O
hybrids NN O O
places NN O O
D22S66 NN O O
between NN O O
D22S75 NN O O
and NN O O
D22S259 NN O O
, NN O O
suggesting NN O O
that NN O O
it NN O O
should NN O O
be NN O O
deleted NN O O
in NN O O
the NN O O
remaining NN O O
six NN O O
cases NN O O
. NN O O

Parent NN O O
- NN O O
of NN O O
- NN O O
origin NN O O
studies NN O O
were NN O O
performed NN O O
in NN O O
five NN O O
families NN O O
. NN O O

Four NN O O
probands NN O O
failed NN O O
to NN O O
inherit NN O O
a NN O O
maternal NN O O
allele NN O O
, NN O O
and NN O O
one NN O O
failed NN O O
to NN O O
inherit NN O O
a NN O O
paternal NN O O
allele NN O O
. NN O O

On NN O O
the NN O O
basis NN O O
of NN O O
these NN O O
families NN O O
, NN O O
and NN O O
of NN O O
six NN O O
maternally NN O O
and NN O O
five NN O O
paternally NN O O
derived NN O O
unbalanced NN O O
- NN O O
translocation NN O O
DGS NN O B-Disease
probands NN O O
in NN O O
the NN O O
literature NN O O
, NN O O
parent NN O O
of NN O O
origin NN O O
or NN O O
imprinting NN O O
does NN O O
not NN O O
appear NN O O
to NN O O
play NN O O
an NN O O
important NN O O
role NN O O
in NN O O
the NN O O
pathogenesis NN O O
of NN O O
DGS NN O B-Disease
. NN O O

Deletion NN O O
of NN O O
the NN O O
same NN O O
three NN O O
loci NN O O
in NN O O
all NN O O
14 NN O O
DGS NN O B-Disease
probands NN O O
begins NN O O
to NN O O
delineate NN O O
the NN O O
region NN O O
of NN O O
chromosome NN O O
22 NN O O
critical NN O O
for NN O O
DGS NN O B-Disease
and NN O O
confirms NN O O
the NN O O
hypothesis NN O O
that NN O O
submicroscopic NN O O
deletions NN O O
of NN O O
22q11 NN O O
are NN O O
etiologic NN O O
in NN O O
the NN O O
vast NN O O
majority NN O O
of NN O O
cases NN O O
. NN O O
. NN O O

Loss NN O O
of NN O O
normal NN O O
allele NN O O
of NN O O
the NN O O
APC NN O B-Disease
gene NN O O
in NN O O
an NN O O
adrenocortical NN O B-Disease
carcinoma NN O I-Disease
from NN O O
a NN O O
patient NN O O
with NN O O
familial NN O B-Disease
adenomatous NN O I-Disease
polyposis NN O I-Disease
. NN O O

Endocrine NN O B-Disease
neoplasms NN O I-Disease
have NN O O
been NN O O
reported NN O O
occasionally NN O O
in NN O O
patients NN O O
with NN O O
familial NN O B-Disease
adenomatous NN O I-Disease
polyposis NN O I-Disease
( NN O O
FAP NN O B-Disease
) NN O O
. NN O O

An NN O O
adrenocorotical NN O B-Disease
carcinoma NN O I-Disease
was NN O O
studied NN O O
in NN O O
a NN O O
patient NN O O
with NN O O
a NN O O
family NN O O
history NN O O
of NN O O
FAP NN O B-Disease
. NN O O

Loss NN O O
of NN O O
heterozygosity NN O O
( NN O O
LOH NN O O
) NN O O
in NN O O
the NN O O
region NN O O
close NN O O
to NN O O
the NN O O
adenomatous NN O B-Disease
polyposis NN O I-Disease
coli NN O I-Disease
( NN O O
APC NN O B-Disease
) NN O O
gene NN O O
was NN O O
detected NN O O
in NN O O
this NN O O
carcinoma NN O B-Disease
, NN O O
and NN O O
evidence NN O O
was NN O O
obtained NN O O
that NN O O
there NN O O
was NN O O
a NN O O
loss NN O O
of NN O O
the NN O O
normal NN O O
allele NN O O
of NN O O
the NN O O
APC NN O B-Disease
gene NN O O
. NN O O

This NN O O
is NN O O
the NN O O
first NN O O
demonstration NN O O
of NN O O
LOH NN O O
at NN O O
the NN O O
APC NN O B-Disease
locus NN O O
in NN O O
adrenocortical NN O B-Disease
tumors NN O I-Disease
. NN O O

The NN O O
present NN O O
results NN O O
and NN O O
our NN O O
previous NN O O
data NN O O
on NN O O
LOH NN O O
in NN O O
a NN O O
recurring NN O O
desmoid NN O B-Disease
tumor NN O I-Disease
suggest NN O O
that NN O O
the NN O O
heterozygous NN O O
mutant NN O O
/ NN O O
wild NN O O
- NN O O
type NN O O
condition NN O O
of NN O O
the NN O O
APC NN O B-Disease
gene NN O O
may NN O O
give NN O O
rise NN O O
to NN O O
benign NN O B-Disease
tumors NN O I-Disease
, NN O O
and NN O O
that NN O O
functional NN O O
loss NN O O
of NN O O
this NN O O
gene NN O O
leads NN O O
to NN O O
development NN O O
of NN O O
tumors NN O B-Disease
not NN O O
only NN O O
in NN O O
the NN O O
colon NN O O
but NN O O
also NN O O
in NN O O
other NN O O
various NN O O
parts NN O O
of NN O O
the NN O O
body NN O O
in NN O O
FAP NN O B-Disease
patients NN O O
. NN O O
. NN O O

Oncogenic NN O O
point NN O O
mutations NN O O
in NN O O
exon NN O O
20 NN O O
of NN O O
the NN O O
RB1 NN O O
gene NN O O
in NN O O
families NN O O
showing NN O O
incomplete NN O O
penetrance NN O O
and NN O O
mild NN O O
expression NN O O
of NN O O
the NN O O
retinoblastoma NN O B-Disease
phenotype NN O O
. NN O O

The NN O O
retinoblastoma NN O B-Disease
- NN O O
predisposition NN O O
gene NN O O
, NN O O
RB1 NN O O
, NN O O
segregates NN O O
as NN O O
an NN O O
autosomal NN O O
dominant NN O O
trait NN O O
with NN O O
high NN O O
( NN O O
90 NN O O
% NN O O
) NN O O
penetrance NN O O
. NN O O

Certain NN O O
families NN O O
, NN O O
however NN O O
, NN O O
show NN O O
an NN O O
unusual NN O O
low NN O O
- NN O O
penetrance NN O O
phenotype NN O O
with NN O O
many NN O O
individuals NN O O
being NN O O
unaffected NN O O
, NN O O
unilaterally NN O O
affected NN O O
, NN O O
or NN O O
with NN O O
evidence NN O O
of NN O O
spontaneously NN O O
regressed NN O O
tumors NN O B-Disease
. NN O O

We NN O O
have NN O O
used NN O O
single NN O O
- NN O O
strand NN O O
conformation NN O O
polymorphism NN O O
analysis NN O O
and NN O O
PCR NN O O
sequencing NN O O
to NN O O
study NN O O
two NN O O
such NN O O
families NN O O
. NN O O

Mutations NN O O
were NN O O
found NN O O
in NN O O
exon NN O O
20 NN O O
of NN O O
RB1 NN O O
in NN O O
both NN O O
cases NN O O
. NN O O

In NN O O
one NN O O
family NN O O
a NN O O
C NN O O
- NN O O
- NN O O
- NN O O
- NN O O
T NN O O
transition NN O O
in NN O O
codon NN O O
661 NN O O
converts NN O O
an NN O O
arginine NN O O
( NN O O
CGG NN O O
) NN O O
to NN O O
a NN O O
tryptophan NN O O
( NN O O
TGG NN O O
) NN O O
codon NN O O
. NN O O

In NN O O
this NN O O
family NN O O
, NN O O
incomplete NN O O
penetrance NN O O
and NN O O
mild NN O O
phenotypic NN O O
expression NN O O
were NN O O
observed NN O O
in NN O O
virtually NN O O
all NN O O
patients NN O O
, NN O O
possibly NN O O
indicating NN O O
that NN O O
single NN O O
amino NN O O
acid NN O O
changes NN O O
may NN O O
modify NN O O
protein NN O O
structure NN O O
/ NN O O
function NN O O
such NN O O
that NN O O
tumorigenesis NN O O
is NN O O
not NN O O
inevitable NN O O
. NN O O

In NN O O
the NN O O
second NN O O
family NN O O
the NN O O
mutation NN O O
in NN O O
codon NN O O
675 NN O O
is NN O O
a NN O O
G NN O O
- NN O O
- NN O O
- NN O O
- NN O O
T NN O O
transversion NN O O
that NN O O
converts NN O O
a NN O O
glutamine NN O O
( NN O O
GAA NN O O
) NN O O
to NN O O
a NN O O
stop NN O O
( NN O O
TAA NN O O
) NN O O
codon NN O O
. NN O O

However NN O O
, NN O O
this NN O O
mutation NN O O
also NN O O
occurs NN O O
near NN O O
a NN O O
potential NN O O
cryptic NN O O
splice NN O O
acceptor NN O O
site NN O O
, NN O O
raising NN O O
the NN O O
possibility NN O O
of NN O O
alternative NN O O
splicing NN O O
resulting NN O O
in NN O O
a NN O O
less NN O O
severely NN O O
disrupted NN O O
protein NN O O
. NN O O
. NN O O

Late NN O O
- NN O O
onset NN O O
metachromatic NN O B-Disease
leukodystrophy NN O I-Disease
: NN O O
molecular NN O O
pathology NN O O
in NN O O
two NN O O
siblings NN O O
. NN O O

We NN O O
report NN O O
on NN O O
a NN O O
new NN O O
allele NN O O
at NN O O
the NN O O
arylsulfatase NN O O
A NN O O
( NN O O
ARSA NN O O
) NN O O
locus NN O O
causing NN O O
late NN O O
- NN O O
onset NN O O
metachromatic NN O B-Disease
leukodystrophy NN O I-Disease
( NN O O
MLD NN O B-Disease
) NN O O
. NN O O

In NN O O
that NN O O
allele NN O O
arginine84 NN O O
, NN O O
a NN O O
residue NN O O
that NN O O
is NN O O
highly NN O O
conserved NN O O
in NN O O
the NN O O
arylsulfatase NN O O
gene NN O O
family NN O O
, NN O O
is NN O O
replaced NN O O
by NN O O
glutamine NN O O
. NN O O

In NN O O
contrast NN O O
to NN O O
alleles NN O O
that NN O O
cause NN O O
early NN O O
- NN O O
onset NN O O
MLD NN O B-Disease
, NN O O
the NN O O
arginine84 NN O O
to NN O O
glutamine NN O O
substitution NN O O
is NN O O
associated NN O O
with NN O O
some NN O O
residual NN O O
ARSA NN O O
activity NN O O
. NN O O

A NN O O
comparison NN O O
of NN O O
genotypes NN O O
, NN O O
ARSA NN O O
activities NN O O
, NN O O
and NN O O
clinical NN O O
data NN O O
on NN O O
4 NN O O
individuals NN O O
carrying NN O O
the NN O O
allele NN O O
of NN O O
81 NN O O
patients NN O O
with NN O O
MLD NN O B-Disease
examined NN O O
, NN O O
further NN O O
validates NN O O
the NN O O
concept NN O O
that NN O O
different NN O O
degrees NN O O
of NN O O
residual NN O O
ARSA NN O O
activity NN O O
are NN O O
the NN O O
basis NN O O
of NN O O
phenotypical NN O O
variation NN O O
in NN O O
MLD NN O B-Disease
. NN O O
. NN O O

Trisomy NN O B-Disease
15 NN O I-Disease
with NN O O
loss NN O O
of NN O O
the NN O O
paternal NN O O
15 NN O O
as NN O O
a NN O O
cause NN O O
of NN O O
Prader NN O B-Disease
- NN O I-Disease
Willi NN O I-Disease
syndrome NN O I-Disease
due NN O O
to NN O O
maternal NN O B-Disease
disomy NN O I-Disease
. NN O O

Uniparental NN O B-Disease
disomy NN O I-Disease
has NN O O
recently NN O O
been NN O O
recognized NN O O
to NN O O
cause NN O O
human NN O O
disorders NN O O
, NN O O
including NN O O
Prader NN O B-Disease
- NN O I-Disease
Willi NN O I-Disease
syndrome NN O I-Disease
( NN O O
PWS NN O B-Disease
) NN O O
. NN O O

We NN O O
describe NN O O
a NN O O
particularly NN O O
instructive NN O O
case NN O O
which NN O O
raises NN O O
important NN O O
issues NN O O
concerning NN O O
the NN O O
mechanisms NN O O
producing NN O O
uniparental NN O B-Disease
disomy NN O I-Disease
and NN O O
whose NN O O
evaluation NN O O
provides NN O O
evidence NN O O
that NN O O
trisomy NN O O
may NN O O
precede NN O O
uniparental NN O B-Disease
disomy NN O I-Disease
in NN O O
a NN O O
fetus NN O O
. NN O O

Chorionic NN O O
villus NN O O
sampling NN O O
performed NN O O
for NN O O
advanced NN O O
maternal NN O O
age NN O O
revealed NN O O
trisomy NN O B-Disease
15 NN O I-Disease
in NN O O
all NN O O
direct NN O O
and NN O O
cultured NN O O
cells NN O O
, NN O O
though NN O O
the NN O O
fetus NN O O
appeared NN O O
normal NN O O
. NN O O

Chromosome NN O O
analysis NN O O
of NN O O
amniocytes NN O O
obtained NN O O
at NN O O
15 NN O O
wk NN O O
was NN O O
normal NN O O
in NN O O
over NN O O
100 NN O O
cells NN O O
studied NN O O
. NN O O

The NN O O
child NN O O
was NN O O
hypotonic NN O B-Disease
at NN O O
birth NN O O
, NN O O
and NN O O
high NN O O
- NN O O
resolution NN O O
banding NN O O
failed NN O O
to NN O O
reveal NN O O
the NN O O
deletion NN O O
of NN O O
15q11 NN O O
- NN O O
13 NN O O
, NN O O
a NN O O
deletion NN O O
which NN O O
is NN O O
found NN O O
in NN O O
50 NN O O
% NN O O
- NN O O
70 NN O O
% NN O O
of NN O O
patients NN O O
with NN O O
PWS NN O B-Disease
. NN O O

Over NN O O
time NN O O
, NN O O
typical NN O O
features NN O O
of NN O O
PWS NN O B-Disease
developed NN O O
. NN O O

Molecular NN O O
genetic NN O O
analysis NN O O
using NN O O
probes NN O O
for NN O O
chromosome NN O O
15 NN O O
revealed NN O O
maternal NN O O
disomy NN O O
. NN O O

Maternal NN O O
nondisjunction NN O O
with NN O O
fertilization NN O O
of NN O O
a NN O O
disomic NN O O
egg NN O O
by NN O O
a NN O O
normal NN O O
sperm NN O O
, NN O O
followed NN O O
by NN O O
loss NN O O
of NN O O
the NN O O
paternal NN O O
15 NN O O
, NN O O
is NN O O
a NN O O
likely NN O O
cause NN O O
of NN O O
confined NN O O
placental NN O O
mosaicism NN O O
and NN O O
uniparental NN O B-Disease
disomy NN O I-Disease
in NN O O
this NN O O
case NN O O
of NN O O
PWS NN O B-Disease
, NN O O
and NN O O
advanced NN O O
maternal NN O O
age NN O O
may NN O O
be NN O O
a NN O O
predisposing NN O O
factor NN O O
. NN O O
. NN O O

Genetic NN O O
heterogeneity NN O O
in NN O O
X NN O B-Disease
- NN O I-Disease
linked NN O I-Disease
amelogenesis NN O I-Disease
imperfecta NN O I-Disease
. NN O O

The NN O O
AMELX NN O O
gene NN O O
located NN O O
at NN O O
Xp22 NN O O
. NN O O

1 NN O O
- NN O O
p22 NN O O
. NN O O

3 NN O O
encodes NN O O
for NN O O
the NN O O
enamel NN O O
protein NN O O
amelogenin NN O O
and NN O O
has NN O O
been NN O O
implicated NN O O
as NN O O
the NN O O
gene NN O O
responsible NN O O
for NN O O
the NN O O
inherited NN O B-Disease
dental NN O I-Disease
abnormality NN O I-Disease
X NN O B-Disease
- NN O I-Disease
linked NN O I-Disease
amelogenesis NN O I-Disease
imperfecta NN O I-Disease
( NN O O
XAI NN O B-Disease
) NN O O
. NN O O

Three NN O O
families NN O O
with NN O O
XAI NN O B-Disease
have NN O O
been NN O O
investigated NN O O
using NN O O
polymorphic NN O O
DNA NN O O
markers NN O O
flanking NN O O
the NN O O
position NN O O
of NN O O
AMELX NN O O
. NN O O

Using NN O O
two NN O O
- NN O O
point NN O O
linkage NN O O
analysis NN O O
, NN O O
linkage NN O O
was NN O O
established NN O O
between NN O O
XAI NN O B-Disease
and NN O O
several NN O O
of NN O O
these NN O O
markers NN O O
in NN O O
two NN O O
families NN O O
, NN O O
with NN O O
a NN O O
combined NN O O
lod NN O O
score NN O O
of NN O O
6 NN O O
. NN O O

05 NN O O
for NN O O
DXS16 NN O O
at NN O O
theta NN O O
= NN O O
0 NN O O
. NN O O

04 NN O O
04 NN O O
. NN O O

This NN O O
supports NN O O
the NN O O
involvement NN O O
of NN O O
AMELX NN O O
, NN O O
located NN O O
close NN O O
to NN O O
DXS16 NN O O
, NN O O
in NN O O
the NN O O
XAI NN O B-Disease
disease NN O I-Disease
process NN O O
( NN O O
AIH1 NN O O
) NN O O
in NN O O
those NN O O
families NN O O
. NN O O

Using NN O O
multipoint NN O O
linkage NN O O
analysis NN O O
, NN O O
the NN O O
combined NN O O
maximum NN O O
lod NN O O
score NN O O
for NN O O
these NN O O
two NN O O
families NN O O
was NN O O
7 NN O O
. NN O O

30 NN O O
for NN O O
a NN O O
location NN O O
of NN O O
AIH1 NN O O
at NN O O
2 NN O O
cM NN O O
distal NN O O
to NN O O
DXS16 NN O O
. NN O O

The NN O O
support NN O O
interval NN O O
around NN O O
this NN O O
location NN O O
extended NN O O
about NN O O
8 NN O O
cM NN O O
proximal NN O O
to NN O O
DXS92 NN O O
, NN O O
and NN O O
the NN O O
AIH1 NN O O
location NN O O
could NN O O
not NN O O
be NN O O
precisely NN O O
defined NN O O
by NN O O
multipoint NN O O
mapping NN O O
. NN O O

Study NN O O
of NN O O
recombination NN O O
events NN O O
indicated NN O O
that NN O O
AIH1 NN O O
lies NN O O
in NN O O
the NN O O
interval NN O O
between NN O O
DXS143 NN O O
and NN O O
DXS85 NN O O
. NN O O

There NN O O
was NN O O
significant NN O O
evidence NN O O
against NN O O
linkage NN O O
to NN O O
this NN O O
region NN O O
in NN O O
the NN O O
third NN O O
family NN O O
, NN O O
indicating NN O O
locus NN O O
heterogeneity NN O O
in NN O O
XAI NN O B-Disease
. NN O O

Further NN O O
analysis NN O O
with NN O O
markers NN O O
on NN O O
the NN O O
long NN O O
arm NN O O
of NN O O
the NN O O
X NN O O
chromosome NN O O
showed NN O O
evidence NN O O
of NN O O
linkage NN O O
to NN O O
DXS144E NN O O
and NN O O
F9 NN O O
with NN O O
no NN O O
recombination NN O O
with NN O O
either NN O O
of NN O O
these NN O O
markers NN O O
. NN O O

Two NN O O
- NN O O
point NN O O
analysis NN O O
gave NN O O
a NN O O
peak NN O O
lod NN O O
score NN O O
at NN O O
DXS144E NN O O
with NN O O
a NN O O
maximum NN O O
lod NN O O
score NN O O
of NN O O
2 NN O O
. NN O O

83 NN O O
at NN O O
theta NN O O
= NN O O
0 NN O O
, NN O O
with NN O O
a NN O O
peak NN O O
lod NN O O
score NN O O
in NN O O
multipoint NN O O
linkage NN O O
analysis NN O O
of NN O O
2 NN O O
. NN O O

84 NN O O
at NN O O
theta NN O O
= NN O O
0 NN O O
. NN O O

The NN O O
support NN O O
interval NN O O
extended NN O O
9 NN O O
cM NN O O
proximal NN O O
to NN O O
DXS144E NN O O
and NN O O
14 NN O O
cM NN O O
distal NN O O
to NN O O
F9 NN O O
. NN O O

( NN O O
ABSTRACT NN O O
TRUNCATED NN O O
AT NN O O
250 NN O O
WORDS NN O O
) NN O O
. NN O O

Multiple NN O O
origins NN O O
for NN O O
phenylketonuria NN O B-Disease
in NN O O
Europe NN O O
. NN O O

Phenylketonuria NN O B-Disease
( NN O O
PKU NN O B-Disease
) NN O O
, NN O O
a NN O O
disorder NN O B-Disease
of NN O I-Disease
amino NN O I-Disease
acid NN O I-Disease
metabolism NN O I-Disease
prevalent NN O O
among NN O O
Caucasians NN O O
and NN O O
other NN O O
ethnic NN O O
groups NN O O
, NN O O
is NN O O
caused NN O O
primarily NN O O
by NN O O
a NN O O
deficiency NN O B-Disease
of NN O I-Disease
the NN O I-Disease
hepatic NN O I-Disease
enzyme NN O I-Disease
phenylalanine NN O I-Disease
hydroxylase NN O I-Disease
( NN O O
PAH NN O O
) NN O O
. NN O O

PKU NN O B-Disease
is NN O O
a NN O O
highly NN O O
heterogeneous NN O O
disorder NN O O
, NN O O
with NN O O
more NN O O
than NN O O
60 NN O O
molecular NN O O
lesions NN O O
identified NN O O
in NN O O
the NN O O
PAH NN O O
gene NN O O
. NN O O

The NN O O
haplotype NN O O
associations NN O O
, NN O O
relative NN O O
frequencies NN O O
, NN O O
and NN O O
distributions NN O O
of NN O O
five NN O O
prevalent NN O O
PAH NN O O
mutations NN O O
( NN O O
R158Q NN O O
, NN O O
R261Q NN O O
, NN O O
IVS10nt546 NN O O
, NN O O
R408W NN O O
, NN O O
and NN O O
IVS12n1 NN O O
) NN O O
were NN O O
established NN O O
in NN O O
a NN O O
comprehensive NN O O
European NN O O
sample NN O O
population NN O O
and NN O O
subsequently NN O O
were NN O O
examined NN O O
to NN O O
determine NN O O
the NN O O
potential NN O O
roles NN O O
of NN O O
several NN O O
genetic NN O O
mechanisms NN O O
in NN O O
explaining NN O O
the NN O O
present NN O O
distribution NN O O
of NN O O
the NN O O
major NN O O
PKU NN O B-Disease
alleles NN O O
. NN O O

Each NN O O
of NN O O
these NN O O
five NN O O
mutations NN O O
was NN O O
strongly NN O O
associated NN O O
with NN O O
only NN O O
one NN O O
of NN O O
the NN O O
more NN O O
than NN O O
70 NN O O
chromosomal NN O O
haplotypes NN O O
defined NN O O
by NN O O
eight NN O O
RFLPs NN O O
in NN O O
or NN O O
near NN O O
the NN O O
PAH NN O O
gene NN O O
. NN O O

These NN O O
findings NN O O
suggest NN O O
that NN O O
each NN O O
of NN O O
these NN O O
mutations NN O O
arose NN O O
through NN O O
a NN O O
single NN O O
founding NN O O
event NN O O
that NN O O
occurred NN O O
within NN O O
time NN O O
periods NN O O
ranging NN O O
from NN O O
several NN O O
hundred NN O O
to NN O O
several NN O O
thousand NN O O
years NN O O
ago NN O O
. NN O O

From NN O O
the NN O O
significant NN O O
differences NN O O
observed NN O O
in NN O O
the NN O O
relative NN O O
frequencies NN O O
and NN O O
distributions NN O O
of NN O O
these NN O O
five NN O O
alleles NN O O
throughout NN O O
Europe NN O O
, NN O O
four NN O O
of NN O O
these NN O O
putative NN O O
founding NN O O
events NN O O
could NN O O
be NN O O
localized NN O O
to NN O O
specific NN O O
ethnic NN O O
subgroups NN O O
. NN O O

Together NN O O
, NN O O
these NN O O
data NN O O
suggest NN O O
that NN O O
there NN O O
were NN O O
multiple NN O O
, NN O O
geographically NN O O
and NN O O
ethnically NN O O
distinct NN O O
origins NN O O
for NN O O
PKU NN O B-Disease
within NN O O
the NN O O
European NN O O
population NN O O
. NN O O
. NN O O

Complement NN O B-Disease
factor NN O I-Disease
2 NN O I-Disease
deficiency NN O I-Disease
: NN O O
a NN O O
clinical NN O O
and NN O O
serological NN O O
family NN O O
study NN O O
. NN O O

Inherited NN O B-Disease
complement NN O I-Disease
deficiencies NN O I-Disease
are NN O O
associated NN O O
with NN O O
a NN O O
variety NN O O
of NN O O
connective NN O O
tissue NN O O
diseases NN O O
. NN O O

A NN O O
family NN O O
with NN O O
inherited NN O B-Disease
deficiency NN O I-Disease
of NN O I-Disease
complement NN O I-Disease
factor NN O I-Disease
2 NN O I-Disease
( NN O O
C2 NN O O
) NN O O
is NN O O
described NN O O
in NN O O
which NN O O
two NN O O
family NN O O
members NN O O
with NN O O
homozygous NN O O
C2 NN O B-Disease
deficiency NN O I-Disease
developed NN O O
cutaneous NN O B-Disease
vasculitis NN O I-Disease
and NN O O
sicca NN O B-Disease
syndrome NN O I-Disease
. NN O O

The NN O O
other NN O O
family NN O O
members NN O O
had NN O O
heterozygous NN O O
C2 NN O B-Disease
deficiency NN O I-Disease
and NN O O
each NN O O
member NN O O
had NN O O
the NN O O
HLA NN O O
- NN O O
A25 NN O O
, NN O O
B18 NN O O
, NN O O
DR2 NN O O
( NN O O
w15 NN O O
) NN O O
haplotype NN O O
. NN O O

The NN O O
mother NN O O
had NN O O
seropositive NN O B-Disease
rheumatoid NN O I-Disease
arthritis NN O I-Disease
. NN O O

Further NN O O
studies NN O O
showed NN O O
the NN O O
presence NN O O
of NN O O
cryoglobulins NN O O
, NN O O
antibodies NN O O
against NN O O
endothelial NN O O
cells NN O O
, NN O O
and NN O O
anticardiolipin NN O O
antibodies NN O O
. NN O O
. NN O O

New NN O O
variant NN O O
in NN O O
exon NN O O
3 NN O O
of NN O O
the NN O O
proteolipid NN O O
protein NN O O
( NN O O
PLP NN O O
) NN O O
gene NN O O
in NN O O
a NN O O
family NN O O
with NN O O
Pelizaeus NN O B-Disease
- NN O I-Disease
Merzbacher NN O I-Disease
disease NN O I-Disease
. NN O O

A NN O O
C NN O O
- NN O O
- NN O O
greater NN O O
than NN O O
G NN O O
transversion NN O O
has NN O O
been NN O O
found NN O O
in NN O O
exon NN O O
3 NN O O
of NN O O
the NN O O
PLP NN O O
gene NN O O
of NN O O
affected NN O O
males NN O O
and NN O O
their NN O O
mother NN O O
in NN O O
a NN O O
single NN O O
sibship NN O O
with NN O O
Pelizaeus NN O B-Disease
- NN O I-Disease
merzbacher NN O I-Disease
disease NN O I-Disease
( NN O O
PMD NN O B-Disease
) NN O O
. NN O O

The NN O O
transversion NN O O
should NN O O
not NN O O
result NN O O
in NN O O
an NN O O
amino NN O O
acid NN O O
change NN O O
in NN O O
the NN O O
protein NN O O
but NN O O
it NN O O
does NN O O
result NN O O
in NN O O
the NN O O
loss NN O O
of NN O O
a NN O O
HaeIII NN O O
restriction NN O O
endonuclease NN O O
cleavage NN O O
site NN O O
. NN O O

It NN O O
is NN O O
concordant NN O O
with NN O O
the NN O O
disease NN O O
in NN O O
this NN O O
family NN O O
. NN O O

One NN O O
- NN O O
hundred NN O O
- NN O O
ten NN O O
unrelated NN O O
X NN O O
chromosomes NN O O
are NN O O
negative NN O O
for NN O O
this NN O O
mutation NN O O
. NN O O

No NN O O
other NN O O
sequence NN O O
defect NN O O
was NN O O
found NN O O
in NN O O
the NN O O
PLP NN O O
exons NN O O
of NN O O
the NN O O
affected NN O O
males NN O O
. NN O O

The NN O O
cause NN O O
of NN O O
disease NN O O
in NN O O
this NN O O
family NN O O
remains NN O O
unknown NN O O
, NN O O
but NN O O
the NN O O
association NN O O
between NN O O
this NN O O
rare NN O O
mutation NN O O
and NN O O
PMD NN O B-Disease
is NN O O
intriguing NN O O
. NN O O

The NN O O
mutation NN O O
can NN O O
serve NN O O
as NN O O
a NN O O
marker NN O O
for NN O O
following NN O O
segregation NN O O
of NN O O
the NN O O
PLP NN O O
gene NN O O
. NN O O
. NN O O

Uncoupling NN O O
of NN O O
hypomyelination NN O B-Disease
and NN O O
glial NN O B-Disease
cell NN O I-Disease
death NN O I-Disease
by NN O O
a NN O O
mutation NN O O
in NN O O
the NN O O
proteolipid NN O O
protein NN O O
gene NN O O
. NN O O

Proteolipid NN O O
protein NN O O
( NN O O
PLP NN O O
; NN O O
M NN O O
( NN O O
r NN O O
) NN O O
30 NN O O
, NN O O
000 NN O O
) NN O O
is NN O O
a NN O O
highly NN O O
conserved NN O O
major NN O O
polytopic NN O O
membrane NN O O
protein NN O O
in NN O O
myelin NN O O
but NN O O
its NN O O
cellular NN O O
function NN O O
remains NN O O
obscure NN O O
. NN O O

Neurological NN O O
mutant NN O O
mice NN O O
can NN O O
often NN O O
provide NN O O
model NN O O
systems NN O O
for NN O O
human NN O O
genetic NN O B-Disease
disorders NN O I-Disease
. NN O O

Mutations NN O O
of NN O O
the NN O O
X NN O O
- NN O O
chromosome NN O O
- NN O O
linked NN O O
PLP NN O O
gene NN O O
are NN O O
lethal NN O O
, NN O O
identified NN O O
first NN O O
in NN O O
the NN O O
jimpy NN O O
mouse NN O O
and NN O O
subsequently NN O O
in NN O O
patients NN O O
with NN O O
Pelizaeus NN O B-Disease
- NN O I-Disease
Merzbacher NN O I-Disease
disease NN O I-Disease
. NN O O

The NN O O
unexplained NN O O
phenotype NN O O
of NN O O
these NN O O
mutations NN O O
includes NN O O
degeneration NN O B-Disease
and NN O I-Disease
premature NN O I-Disease
cell NN O I-Disease
death NN O I-Disease
of NN O I-Disease
oligodendrocytes NN O I-Disease
with NN O O
associated NN O O
hypomyelination NN O B-Disease
. NN O O

Here NN O O
we NN O O
show NN O O
that NN O O
a NN O O
new NN O O
mouse NN O O
mutant NN O O
rumpshaker NN O O
is NN O O
defined NN O O
by NN O O
the NN O O
amino NN O O
- NN O O
acid NN O O
substitution NN O O
Ile NN O O
- NN O O
to NN O O
- NN O O
Thr NN O O
at NN O O
residue NN O O
186 NN O O
in NN O O
a NN O O
membrane NN O O
- NN O O
embedded NN O O
domain NN O O
of NN O O
PLP NN O O
. NN O O

Surprisingly NN O O
, NN O O
rumpshaker NN O O
mice NN O O
, NN O O
although NN O O
myelin NN O B-Disease
- NN O I-Disease
deficient NN O I-Disease
, NN O O
have NN O O
normal NN O O
longevity NN O O
and NN O O
a NN O O
full NN O O
complement NN O O
of NN O O
morphologically NN O O
normal NN O O
oligodendrocytes NN O O
. NN O O

Hypomyelination NN O B-Disease
can NN O O
thus NN O O
be NN O O
genetically NN O O
separated NN O O
from NN O O
the NN O O
PLP NN O O
- NN O O
dependent NN O O
oligodendrocyte NN O B-Disease
degeneration NN O I-Disease
. NN O O

We NN O O
suggest NN O O
that NN O O
PLP NN O O
has NN O O
a NN O O
vital NN O O
function NN O O
in NN O O
glial NN O O
cell NN O O
development NN O O
, NN O O
distinct NN O O
from NN O O
its NN O O
later NN O O
role NN O O
in NN O O
myelin NN O O
assembly NN O O
, NN O O
and NN O O
that NN O O
this NN O O
dichotomy NN O O
of NN O O
action NN O O
may NN O O
explain NN O O
the NN O O
clinical NN O O
spectrum NN O O
of NN O O
Pelizaeus NN O B-Disease
- NN O I-Disease
Merzbacher NN O I-Disease
disease NN O I-Disease
. NN O O
. NN O O

A NN O O
pseudodeficiency NN O O
allele NN O O
common NN O O
in NN O O
non NN O O
- NN O O
Jewish NN O O
Tay NN O B-Disease
- NN O I-Disease
Sachs NN O I-Disease
carriers NN O O
: NN O O
implications NN O O
for NN O O
carrier NN O O
screening NN O O
. NN O O

Deficiency NN O B-Disease
of NN O I-Disease
beta NN O I-Disease
- NN O I-Disease
hexosaminidase NN O I-Disease
A NN O I-Disease
( NN O O
Hex NN O O
A NN O O
) NN O O
activity NN O O
typically NN O O
results NN O O
in NN O O
Tay NN O B-Disease
- NN O I-Disease
Sachs NN O I-Disease
disease NN O I-Disease
. NN O O

However NN O O
, NN O O
healthy NN O O
subjects NN O O
found NN O O
to NN O O
be NN O O
deficient NN O B-Disease
in NN O I-Disease
Hex NN O I-Disease
A NN O I-Disease
activity NN O O
( NN O O
i NN O O
. NN O O
e NN O O
. NN O O
, NN O O
pseudodeficient NN O O
) NN O O
by NN O O
means NN O O
of NN O O
in NN O O
vitro NN O O
biochemical NN O O
tests NN O O
have NN O O
been NN O O
described NN O O
. NN O O

We NN O O
analyzed NN O O
the NN O O
HEXA NN O O
gene NN O O
of NN O O
one NN O O
pseudodeficient NN O O
subject NN O O
and NN O O
identified NN O O
both NN O O
a NN O O
C739 NN O O
- NN O O
to NN O O
- NN O O
T NN O O
substitution NN O O
that NN O O
changes NN O O
Arg247 NN O O
- NN O O
- NN O O
- NN O O
- NN O O
Trp NN O O
on NN O O
one NN O O
allele NN O O
and NN O O
a NN O O
previously NN O O
identified NN O O
Tay NN O B-Disease
- NN O I-Disease
Sachs NN O I-Disease
disease NN O I-Disease
mutation NN O O
on NN O O
the NN O O
second NN O O
allele NN O O
. NN O O

Six NN O O
additional NN O O
pseudodeficient NN O O
subjects NN O O
were NN O O
found NN O O
to NN O O
have NN O O
the NN O O
C739 NN O O
- NN O O
to NN O O
- NN O O
T NN O O
mutation NN O O
. NN O O

This NN O O
allele NN O O
accounted NN O O
for NN O O
32 NN O O
% NN O O
( NN O O
20 NN O O
/ NN O O
62 NN O O
) NN O O
of NN O O
non NN O O
- NN O O
Jewish NN O O
enzyme NN O O
- NN O O
defined NN O O
Tay NN O B-Disease
- NN O I-Disease
Sachs NN O I-Disease
disease NN O I-Disease
carriers NN O O
but NN O O
for NN O O
none NN O O
of NN O O
36 NN O O
Jewish NN O O
enzyme NN O O
- NN O O
defined NN O O
carriers NN O O
who NN O O
did NN O O
not NN O O
have NN O O
one NN O O
of NN O O
three NN O O
known NN O O
mutations NN O O
common NN O O
to NN O O
this NN O O
group NN O O
. NN O O

The NN O O
C739 NN O O
- NN O O
to NN O O
- NN O O
T NN O O
allele NN O O
, NN O O
together NN O O
with NN O O
a NN O O
" NN O O
true NN O O
" NN O O
Tay NN O B-Disease
- NN O I-Disease
Sachs NN O I-Disease
disease NN O I-Disease
allele NN O O
, NN O O
causes NN O O
Hex NN O O
A NN O O
pseudodeficiency NN O O
. NN O O

Given NN O O
both NN O O
the NN O O
large NN O O
proportion NN O O
of NN O O
non NN O O
- NN O O
Jewish NN O O
carriers NN O O
with NN O O
this NN O O
allele NN O O
and NN O O
that NN O O
standard NN O O
biochemical NN O O
screening NN O O
cannot NN O O
differentiate NN O O
between NN O O
heterozygotes NN O O
for NN O O
the NN O O
C739 NN O O
- NN O O
to NN O O
- NN O O
T NN O O
mutations NN O O
and NN O O
Tay NN O B-Disease
- NN O I-Disease
Sachs NN O I-Disease
disease NN O I-Disease
carriers NN O O
, NN O O
DNA NN O O
testing NN O O
for NN O O
this NN O O
mutation NN O O
in NN O O
at NN O O
- NN O O
risk NN O O
couples NN O O
is NN O O
essential NN O O
. NN O O

Pelizaeus NN O B-Disease
- NN O I-Disease
Merzbacher NN O I-Disease
disease NN O I-Disease
: NN O O
detection NN O O
of NN O O
mutations NN O O
Thr181 NN O O
- NN O O
- NN O O
- NN O O
- NN O O
Pro NN O O
and NN O O
Leu223 NN O O
- NN O O
- NN O O
- NN O O
- NN O O
Pro NN O O
in NN O O
the NN O O
proteolipid NN O O
protein NN O O
gene NN O O
, NN O O
and NN O O
prenatal NN O O
diagnosis NN O O
. NN O O

A NN O O
family NN O O
with NN O O
an NN O O
apparent NN O O
history NN O O
of NN O O
X NN O O
- NN O O
linked NN O O
Pelizaeus NN O B-Disease
- NN O I-Disease
Merzbacher NN O I-Disease
disease NN O I-Disease
presented NN O O
for NN O O
genetic NN O O
counseling NN O O
, NN O O
requesting NN O O
carrier NN O O
detection NN O O
and NN O O
prenatal NN O O
diagnosis NN O O
. NN O O

RFLP NN O O
analysis NN O O
using NN O O
the NN O O
proteolipid NN O O
protein NN O O
( NN O O
PLP NN O O
) NN O O
gene NN O O
probe NN O O
was NN O O
uninformative NN O O
in NN O O
this NN O O
family NN O O
. NN O O

A NN O O
prenatal NN O O
diagnosis NN O O
on NN O O
a NN O O
chorionic NN O O
villus NN O O
sample NN O O
( NN O O
CVS NN O O
) NN O O
was NN O O
carried NN O O
out NN O O
using NN O O
single NN O O
- NN O O
strand NN O O
conformation NN O O
polymorphism NN O O
( NN O O
SSCP NN O O
) NN O O
analysis NN O O
of NN O O
a NN O O
variant NN O O
in NN O O
exon NN O O
4 NN O O
of NN O O
the NN O O
PLP NN O O
gene NN O O
. NN O O

The NN O O
fetus NN O O
was NN O O
predicted NN O O
to NN O O
be NN O O
unaffected NN O O
. NN O O

Sequencing NN O O
of NN O O
the NN O O
exon NN O O
from NN O O
the NN O O
CVS NN O O
, NN O O
the NN O O
predicted NN O O
- NN O O
carrier NN O O
mother NN O O
, NN O O
and NN O O
the NN O O
obligate NN O O
- NN O O
carrier NN O O
grandmother NN O O
revealed NN O O
an NN O O
A NN O O
- NN O O
to NN O O
- NN O O
C NN O O
change NN O O
at NN O O
nucleotide NN O O
541 NN O O
in NN O O
the NN O O
two NN O O
women NN O O
but NN O O
not NN O O
in NN O O
the NN O O
fetus NN O O
. NN O O

As NN O O
this NN O O
change NN O O
results NN O O
in NN O O
a NN O O
Thr NN O O
- NN O O
to NN O O
- NN O O
Pro NN O O
change NN O O
at NN O O
amino NN O O
acid NN O O
181 NN O O
in NN O O
a NN O O
region NN O O
of NN O O
the NN O O
gene NN O O
predicted NN O O
to NN O O
be NN O O
part NN O O
of NN O O
a NN O O
transmembrane NN O O
segment NN O O
, NN O O
it NN O O
was NN O O
concluded NN O O
that NN O O
this NN O O
was NN O O
the NN O O
mutation NN O O
causing NN O O
the NN O O
disease NN O O
in NN O O
this NN O O
family NN O O
. NN O O

In NN O O
addition NN O O
, NN O O
in NN O O
a NN O O
second NN O O
family NN O O
, NN O O
an NN O O
exon NN O O
5 NN O O
variant NN O O
band NN O O
pattern NN O O
on NN O O
SSCP NN O O
analysis NN O O
was NN O O
shown NN O O
by NN O O
sequencing NN O O
to NN O O
be NN O O
due NN O O
to NN O O
a NN O O
T NN O O
- NN O O
to NN O O
- NN O O
C NN O O
change NN O O
at NN O O
nucleotide NN O O
668 NN O O
. NN O O

This NN O O
results NN O O
in NN O O
a NN O O
Leu NN O O
- NN O O
to NN O O
- NN O O
Pro NN O O
change NN O O
in NN O O
a NN O O
carrier NN O O
mother NN O O
and NN O O
in NN O O
her NN O O
two NN O O
affected NN O O
sons NN O O
. NN O O

These NN O O
results NN O O
provide NN O O
further NN O O
examples NN O O
of NN O O
mutations NN O O
in NN O O
PLP NN O O
that NN O O
cause NN O O
Pelizaeus NN O B-Disease
- NN O I-Disease
Merzbacher NN O I-Disease
disease NN O I-Disease
and NN O O
illustrate NN O O
the NN O O
value NN O O
of NN O O
SSCP NN O O
in NN O O
genetic NN O O
analysis NN O O
. NN O O
. NN O O

von NN O B-Disease
Willebrand NN O I-Disease
disease NN O I-Disease
type NN O I-Disease
B NN O I-Disease
: NN O O
a NN O O
missense NN O O
mutation NN O O
selectively NN O O
abolishes NN O O
ristocetin NN O O
- NN O O
induced NN O O
von NN O B-Disease
Willebrand NN O I-Disease
factor NN O O
binding NN O O
to NN O O
platelet NN O O
glycoprotein NN O O
Ib NN O O
. NN O O

von NN O B-Disease
Willebrand NN O I-Disease
factor NN O O
( NN O O
vWF NN O O
) NN O O
is NN O O
a NN O O
multimeric NN O O
glycoprotein NN O O
that NN O O
mediates NN O O
the NN O O
adhesion NN O O
of NN O O
platelets NN O O
to NN O O
the NN O O
subendothelium NN O O
by NN O O
binding NN O O
to NN O O
platelet NN O O
glycoprotein NN O O
Ib NN O O
. NN O O

For NN O O
human NN O O
vWF NN O O
, NN O O
this NN O O
interaction NN O O
can NN O O
be NN O O
induced NN O O
in NN O O
vitro NN O O
by NN O O
the NN O O
antibiotic NN O O
ristocetin NN O O
or NN O O
the NN O O
snake NN O O
venom NN O O
protein NN O O
botrocetin NN O O
. NN O O

A NN O O
missense NN O O
mutation NN O O
, NN O O
Gly NN O O
- NN O O
561 NN O O
- NN O O
- NN O O
> NN O O
Ser NN O O
, NN O O
was NN O O
identified NN O O
within NN O O
the NN O O
proposed NN O O
glycoprotein NN O O
Ib NN O O
binding NN O O
domain NN O O
of NN O O
vWF NN O O
in NN O O
the NN O O
proband NN O O
with NN O O
von NN O B-Disease
Willebrand NN O I-Disease
disease NN O I-Disease
type NN O I-Disease
B NN O I-Disease
, NN O O
a NN O O
unique NN O O
variant NN O O
characterized NN O O
by NN O O
no NN O O
ristocetin NN O O
- NN O O
induced NN O O
, NN O O
but NN O O
normal NN O O
botrocetin NN O O
- NN O O
induced NN O O
, NN O O
binding NN O O
to NN O O
glycoprotein NN O O
Ib NN O O
. NN O O

The NN O O
corresponding NN O O
mutant NN O O
recombinant NN O O
protein NN O O
, NN O O
rvWF NN O O
( NN O O
G561S NN O O
) NN O O
, NN O O
formed NN O O
normal NN O O
multimers NN O O
and NN O O
exhibited NN O O
the NN O O
same NN O O
functional NN O O
defect NN O O
as NN O O
the NN O O
patients NN O O
plasma NN O O
vWF NN O O
, NN O O
confirming NN O O
that NN O O
this NN O O
mutation NN O O
causes NN O O
von NN O B-Disease
Willebrand NN O I-Disease
disease NN O I-Disease
type NN O I-Disease
B NN O I-Disease
. NN O O

These NN O O
data NN O O
show NN O O
that NN O O
botrocetin NN O O
and NN O O
ristocetin NN O O
cofactor NN O O
activities NN O O
of NN O O
vWF NN O O
can NN O O
be NN O O
dissociated NN O O
by NN O O
a NN O O
point NN O O
mutation NN O O
and NN O O
confirm NN O O
that NN O O
these NN O O
mediators NN O O
promote NN O O
vWF NN O O
binding NN O O
to NN O O
platelets NN O O
by NN O O
different NN O O
mechanisms NN O O
. NN O O

The NN O O
normal NN O O
botrocetin NN O O
- NN O O
induced NN O O
binding NN O O
and NN O O
the NN O O
defective NN O O
ristocetin NN O O
- NN O O
induced NN O O
binding NN O O
of NN O O
rvWF NN O O
( NN O O
G561S NN O O
) NN O O
suggest NN O O
that NN O O
the NN O O
primary NN O O
defect NN O O
in NN O O
von NN O B-Disease
Willebrand NN O I-Disease
disease NN O I-Disease
type NN O I-Disease
B NN O I-Disease
may NN O O
be NN O O
a NN O O
failure NN O O
of NN O O
normal NN O O
allosteric NN O O
regulation NN O O
of NN O O
the NN O O
glycoprotein NN O O
Ib NN O O
binding NN O O
function NN O O
of NN O O
vWF NN O O
. NN O O
. NN O O

Typical NN O O
and NN O O
partial NN O O
cat NN O B-Disease
eye NN O I-Disease
syndrome NN O I-Disease
: NN O O
identification NN O O
of NN O O
the NN O O
marker NN O O
chromosome NN O O
by NN O O
FISH NN O O
. NN O O

Three NN O O
children NN O O
are NN O O
reported NN O O
with NN O O
typical NN O O
cat NN O B-Disease
eye NN O I-Disease
syndrome NN O I-Disease
( NN O O
CES NN O B-Disease
) NN O O
and NN O O
three NN O O
more NN O O
children NN O O
with NN O O
partial NN O O
CES NN O B-Disease
because NN O O
of NN O O
absence NN O O
of NN O O
coloboma NN O O
, NN O O
in NN O O
which NN O O
the NN O O
supernumerary NN O O
marker NN O O
chromosome NN O O
was NN O O
studied NN O O
by NN O O
FISH NN O O
. NN O O

Using NN O O
a NN O O
genomic NN O O
library NN O O
, NN O O
and NN O O
also NN O O
a NN O O
centromeric NN O O
and NN O O
particularly NN O O
a NN O O
cosmid NN O O
probe NN O O
of NN O O
22q11 NN O O
, NN O O
partial NN O O
tetrasomy NN O B-Disease
was NN O O
shown NN O O
in NN O O
all NN O O
cases NN O O
. NN O O
. NN O O

[ NN O O
Genetic NN O O
heterogeneity NN O O
of NN O O
G6PD NN O B-Disease
deficiency NN O I-Disease
: NN O O
mutant NN O O
alleles NN O O
of NN O O
G6PD NN O O
in NN O O
the NN O O
Shekii NN O O
district NN O O
of NN O O
Azerbaijan NN O O
] NN O O

Examination NN O O
on NN O O
G6PD NN O B-Disease
deficiency NN O I-Disease
in NN O O
349 NN O O
patients NN O O
of NN O O
Shekii NN O O
district NN O O
hospital NN O O
( NN O O
Azerbaijan NN O O
) NN O O
revealed NN O O
16 NN O O
hemi NN O O
- NN O O
, NN O O
4 NN O O
homo NN O O
- NN O O
and NN O O
9 NN O O
heterozygotic NN O O
carriers NN O O
of NN O O
the NN O O
defect NN O O
. NN O O

Gd NN O O
- NN O O
frequency NN O O
, NN O O
calculated NN O O
from NN O O
the NN O O
data NN O O
obtained NN O O
( NN O O
7 NN O O
. NN O O
7 NN O O
% NN O O
) NN O O
, NN O O
may NN O O
be NN O O
compared NN O O
to NN O O
neighbouring NN O O
regions NN O O
frequencies NN O O
( NN O O
6 NN O O
- NN O O
30 NN O O
% NN O O
) NN O O
. NN O O

Carriers NN O O
of NN O O
G6PD NN O B-Disease
deficiency NN O I-Disease
are NN O O
residents NN O O
of NN O O
11 NN O O
villages NN O O
located NN O O
in NN O O
Alasani NN O O
- NN O O
Aphtalan NN O O
valley NN O O
, NN O O
highly NN O O
endemic NN O O
with NN O O
malaria NN O B-Disease
in NN O O
the NN O O
past NN O O
; NN O O
nearly NN O O
all NN O O
marriages NN O O
are NN O O
endogamic NN O O
. NN O O

Physico NN O O
- NN O O
chemical NN O O
and NN O O
kinetic NN O O
study NN O O
of NN O O
10 NN O O
mutant NN O O
forms NN O O
of NN O O
G6PD NN O O
, NN O O
according NN O O
to NN O O
WHO NN O O
program NN O O
, NN O O
led NN O O
to NN O O
identification NN O O
of NN O O
5 NN O O
variants NN O O
of NN O O
the NN O O
II NN O O
class NN O O
( NN O O
Shekii NN O O
, NN O O
Bideiz NN O O
, NN O O
Shirin NN O O
- NN O O
Bulakh NN O O
, NN O O
Okhut NN O O
I NN O O
and NN O O
Zakataly NN O O
) NN O O
and NN O O
2 NN O O
variants NN O O
of NN O O
the NN O O
III NN O O
class NN O O
( NN O O
Okhut NN O O
II NN O O
and NN O O
Martinique NN O O
- NN O O
like NN O O
) NN O O
. NN O O

Resemblance NN O O
of NN O O
the NN O O
majority NN O O
of NN O O
variants NN O O
in NN O O
electrophoretic NN O O
mobility NN O O
and NN O O
the NN O O
level NN O O
of NN O O
erythrocyte NN O O
enzyme NN O O
activity NN O O
permit NN O O
to NN O O
suggest NN O O
the NN O O
existence NN O O
of NN O O
a NN O O
common NN O O
parental NN O O
mutant NN O O
G6PD NN O O
allele NN O O
distributed NN O O
in NN O O
this NN O O
area NN O O
. NN O O

Craniofrontonasal NN O B-Disease
dysplasia NN O I-Disease
. NN O O

We NN O O
report NN O O
on NN O O
nine NN O O
patients NN O O
with NN O O
craniofrontonasal NN O B-Disease
dysplasia NN O I-Disease
( NN O O
CFND NN O B-Disease
) NN O O
. NN O O

Seven NN O O
classical NN O O
cases NN O O
had NN O O
facial NN O O
features NN O O
suggestive NN O O
of NN O O
frontonasal NN O B-Disease
dysplasia NN O I-Disease
and NN O O
coronal NN O B-Disease
craniosynostosis NN O I-Disease
. NN O O

Extracranial NN O B-Disease
abnormalities NN O I-Disease
such NN O O
as NN O O
brittle NN O B-Disease
nails NN O I-Disease
with NN O I-Disease
prominent NN O I-Disease
longitudinal NN O I-Disease
grooves NN O I-Disease
or NN O O
syndactyly NN O B-Disease
of NN O I-Disease
fingers NN O I-Disease
and NN O I-Disease
toes NN O I-Disease
were NN O O
observed NN O O
in NN O O
individual NN O O
patients NN O O
. NN O O

In NN O O
two NN O O
families NN O O
the NN O O
father NN O O
of NN O O
classical NN O O
cases NN O O
showed NN O O
a NN O O
milder NN O O
pattern NN O O
of NN O O
abnormalities NN O O
, NN O O
consistent NN O O
with NN O O
the NN O O
diagnosis NN O O
. NN O O

We NN O O
present NN O O
a NN O O
2 NN O O
- NN O O
to NN O O
13 NN O O
- NN O O
year NN O O
follow NN O O
- NN O O
up NN O O
on NN O O
our NN O O
patients NN O O
. NN O O

Hypotonia NN O B-Disease
and NN O O
laxity NN O B-Disease
of NN O I-Disease
joints NN O I-Disease
are NN O O
common NN O O
and NN O O
may NN O O
necessitate NN O O
supportive NN O O
measures NN O O
. NN O O

Mild NN O O
developmental NN O B-Disease
delay NN O I-Disease
was NN O O
noted NN O O
in NN O O
three NN O O
out NN O O
of NN O O
six NN O O
classical NN O O
cases NN O O
studied NN O O
in NN O O
detail NN O O
. NN O O

Unlike NN O O
almost NN O O
all NN O O
other NN O O
X NN O B-Disease
- NN O I-Disease
linked NN O I-Disease
disorders NN O I-Disease
, NN O O
clinical NN O O
expression NN O O
in NN O O
CFND NN O B-Disease
is NN O O
generally NN O O
much NN O O
more NN O O
severe NN O O
in NN O O
females NN O O
than NN O O
in NN O O
males NN O O
. NN O O

In NN O O
contrast NN O O
to NN O O
previous NN O O
reports NN O O
of NN O O
this NN O O
condition NN O O
, NN O O
one NN O O
of NN O O
our NN O O
severely NN O O
affected NN O O
cases NN O O
is NN O O
a NN O O
male NN O O
. NN O O
. NN O O

The NN O O
intron NN O O
7 NN O O
donor NN O O
splice NN O O
site NN O O
transition NN O O
: NN O O
a NN O O
second NN O O
Tay NN O B-Disease
- NN O I-Disease
Sachs NN O I-Disease
disease NN O I-Disease
mutation NN O O
in NN O O
French NN O O
Canada NN O O
. NN O O

Mutations NN O O
at NN O O
the NN O O
hexosaminidase NN O O
A NN O O
( NN O O
HEXA NN O O
) NN O O
gene NN O O
which NN O O
cause NN O O
Tay NN O B-Disease
- NN O I-Disease
Sachs NN O I-Disease
disease NN O I-Disease
( NN O O
TSD NN O B-Disease
) NN O O
have NN O O
elevated NN O O
frequency NN O O
in NN O O
the NN O O
Ashkenazi NN O O
Jewish NN O O
and NN O O
French NN O O
- NN O O
Canadian NN O O
populations NN O O
. NN O O

We NN O O
report NN O O
a NN O O
novel NN O O
TSD NN O B-Disease
allele NN O O
in NN O O
the NN O O
French NN O O
- NN O O
Canadian NN O O
population NN O O
associated NN O O
with NN O O
the NN O O
infantile NN O O
form NN O O
of NN O O
the NN O O
disease NN O O
. NN O O

The NN O O
mutation NN O O
, NN O O
a NN O O
G NN O O
- NN O O
- NN O O
> NN O O
A NN O O
transition NN O O
at NN O O
the NN O O
+ NN O O
1 NN O O
position NN O O
of NN O O
intron NN O O
7 NN O O
, NN O O
abolishes NN O O
the NN O O
donor NN O O
splice NN O O
site NN O O
. NN O O

Cultured NN O O
human NN O O
fibroblasts NN O O
from NN O O
a NN O O
compound NN O O
heterozygote NN O O
for NN O O
this NN O O
transition NN O O
( NN O O
and NN O O
for NN O O
a NN O O
deletion NN O O
mutation NN O O
) NN O O
produce NN O O
no NN O O
detectable NN O O
HEXA NN O O
mRNA NN O O
. NN O O

The NN O O
intron NN O O
7 NN O O
+ NN O O
1 NN O O
mutation NN O O
occurs NN O O
in NN O O
the NN O O
base NN O O
adjacent NN O O
to NN O O
the NN O O
site NN O O
of NN O O
the NN O O
adult NN O O
- NN O O
onset NN O O
TSD NN O B-Disease
mutation NN O O
( NN O O
G805A NN O O
) NN O O
. NN O O

In NN O O
both NN O O
mutations NN O O
a NN O O
restriction NN O O
site NN O O
for NN O O
the NN O O
endonuclease NN O O
EcoRII NN O O
is NN O O
abolished NN O O
. NN O O

Unambiguous NN O O
diagnosis NN O O
, NN O O
therefore NN O O
, NN O O
requires NN O O
allele NN O O
- NN O O
specific NN O O
oligonucleotide NN O O
hybridization NN O O
to NN O O
distinguish NN O O
between NN O O
these NN O O
two NN O O
mutant NN O O
alleles NN O O
. NN O O

The NN O O
intron NN O O
7 NN O O
+ NN O O
1 NN O O
mutation NN O O
has NN O O
been NN O O
detected NN O O
in NN O O
three NN O O
unrelated NN O O
families NN O O
. NN O O

Obligate NN O O
heterozygotes NN O O
for NN O O
the NN O O
intron NN O O
7 NN O O
+ NN O O
1 NN O O
mutation NN O O
were NN O O
born NN O O
in NN O O
the NN O O
Saguenay NN O O
- NN O O
Lac NN O O
- NN O O
St NN O O
- NN O O
Jean NN O O
region NN O O
of NN O O
Quebec NN O O
. NN O O

The NN O O
most NN O O
recent NN O O
ancestors NN O O
common NN O O
to NN O O
obligate NN O O
carriers NN O O
of NN O O
this NN O O
mutation NN O O
were NN O O
from NN O O
the NN O O
Charlevoix NN O O
region NN O O
of NN O O
the NN O O
province NN O O
of NN O O
Quebec NN O O
. NN O O

This NN O O
mutation NN O O
thus NN O O
has NN O O
a NN O O
different NN O O
geographic NN O O
centre NN O O
of NN O O
diffusion NN O O
and NN O O
is NN O O
probably NN O O
less NN O O
common NN O O
than NN O O
the NN O O
exon NN O O
1 NN O O
deletion NN O O
TSD NN O B-Disease
mutation NN O O
in NN O O
French NN O O
Canadians NN O O
. NN O O

Neither NN O O
mutation NN O O
has NN O O
been NN O O
detected NN O O
in NN O O
France NN O O
, NN O O
the NN O O
ancestral NN O O
homeland NN O O
of NN O O
French NN O O
Canada NN O O
. NN O O
. NN O O

Assignment NN O O
of NN O O
the NN O O
aspartylglucosaminidase NN O O
gene NN O O
( NN O O
AGA NN O O
) NN O O
to NN O O
4q33 NN O O
- NN O O
- NN O O
- NN O O
- NN O O
q35 NN O O
based NN O O
on NN O O
decreased NN O O
activity NN O O
in NN O O
a NN O O
girl NN O O
with NN O O
a NN O O
46 NN O O
, NN O O
XX NN O O
, NN O O
del NN O O
( NN O O
4 NN O O
) NN O O
( NN O O
q33 NN O O
) NN O O
karyotype NN O O
. NN O O

Aspartylglucosaminuria NN O B-Disease
( NN O O
AGU NN O B-Disease
) NN O O
is NN O O
a NN O O
recessive NN O O
autosomally NN O O
inherited NN O O
lysosomal NN O B-Disease
storage NN O I-Disease
disorder NN O I-Disease
due NN O O
to NN O O
deficiency NN O B-Disease
of NN O I-Disease
the NN O I-Disease
enzyme NN O I-Disease
aspartylglucosaminidase NN O I-Disease
( NN O O
AGA NN O O
) NN O O
. NN O O

The NN O O
structural NN O O
gene NN O O
for NN O O
this NN O O
human NN O O
enzyme NN O O
( NN O O
AGA NN O O
) NN O O
has NN O O
been NN O O
assigned NN O O
to NN O O
the NN O O
region NN O O
4q21 NN O O
- NN O O
- NN O O
- NN O O
- NN O O
qter NN O O
. NN O O

We NN O O
determined NN O O
the NN O O
AGA NN O O
activity NN O O
in NN O O
cultured NN O O
fibroblasts NN O O
of NN O O
a NN O O
girl NN O O
with NN O O
a NN O O
46 NN O O
, NN O O
XX NN O O
, NN O O
del NN O O
( NN O O
4 NN O O
) NN O O
( NN O O
q33 NN O O
) NN O O
karyotype NN O O
. NN O O

The NN O O
results NN O O
indicate NN O O
that NN O O
the NN O O
girl NN O O
is NN O O
a NN O O
hemizygote NN O O
for NN O O
AGA NN O O
, NN O O
permitting NN O O
the NN O O
assignment NN O O
of NN O O
human NN O O
AGA NN O O
to NN O O
the NN O O
region NN O O
4q33 NN O O
- NN O O
- NN O O
- NN O O
- NN O O
qter NN O O
. NN O O
. NN O O

Resolution NN O O
of NN O O
the NN O O
two NN O O
loci NN O O
for NN O O
autosomal NN O O
dominant NN O O
aniridia NN O B-Disease
, NN O O
AN1 NN O O
and NN O O
AN2 NN O O
, NN O O
to NN O O
a NN O O
single NN O O
locus NN O O
on NN O O
chromosome NN O O
11p13 NN O O
. NN O O

Two NN O O
distinct NN O O
loci NN O O
have NN O O
been NN O O
proposed NN O O
for NN O O
aniridia NN O B-Disease
; NN O O
AN1 NN O O
for NN O O
autosomal NN O O
dominant NN O O
aniridia NN O B-Disease
on NN O O
chromosome NN O O
2p NN O O
and NN O O
AN2 NN O O
for NN O O
the NN O O
aniridia NN O B-Disease
in NN O O
the NN O O
WAGR NN O B-Disease
contiguous NN O I-Disease
gene NN O I-Disease
syndrome NN O I-Disease
on NN O O
chromosome NN O O
11p13 NN O O
. NN O O

In NN O O
this NN O O
report NN O O
, NN O O
the NN O O
kindred NN O O
segregating NN O O
for NN O O
autosomal NN O O
dominant NN O O
aniridia NN O B-Disease
, NN O O
which NN O O
suggested NN O O
linkage NN O O
to NN O O
acid NN O O
phosphatase NN O O
- NN O O
1 NN O O
( NN O O
ACP1 NN O O
) NN O O
and NN O O
led NN O O
to NN O O
the NN O O
assignment NN O O
of NN O O
the NN O O
AN1 NN O O
locus NN O O
on NN O O
chromosome NN O O
2p NN O O
, NN O O
has NN O O
been NN O O
updated NN O O
and NN O O
expanded NN O O
. NN O O

Linkage NN O O
analysis NN O O
between NN O O
the NN O O
aniridia NN O B-Disease
phenotype NN O O
and NN O O
ACP1 NN O O
does NN O O
not NN O O
support NN O O
the NN O O
original NN O O
linkage NN O O
results NN O O
, NN O O
excluding NN O O
linkage NN O O
up NN O O
to NN O O
theta NN O O
= NN O O
0 NN O O
. NN O O

17 NN O O
with NN O O
Z NN O O
= NN O O
- NN O O
2 NN O O
. NN O O

Tests NN O O
for NN O O
linkage NN O O
to NN O O
other NN O O
chromosome NN O O
2p NN O O
markers NN O O
. NN O O

APOB NN O O
, NN O O
D2S71 NN O O
, NN O O
D2S5 NN O O
, NN O O
and NN O O
D2S1 NN O O
, NN O O
also NN O O
excluded NN O O
linkage NN O O
to NN O O
aniridia NN O B-Disease
. NN O O

Markers NN O O
that NN O O
have NN O O
been NN O O
isolated NN O O
from NN O O
the NN O O
chromosome NN O O
11p13 NN O O
region NN O O
were NN O O
then NN O O
analyzed NN O O
in NN O O
this NN O O
aniridia NN O B-Disease
family NN O O
. NN O O

Two NN O O
RFLPs NN O O
at NN O O
the NN O O
D11S323 NN O O
locus NN O O
give NN O O
significant NN O O
evidence NN O O
for NN O O
linkage NN O O
. NN O O

The NN O O
PvuII NN O O
polymorphism NN O O
detected NN O O
by NN O O
probe NN O O
p5S1 NN O O
. NN O O

6 NN O O
detects NN O O
no NN O O
recombinants NN O O
, NN O O
with NN O O
a NN O O
maximum NN O O
lod NN O O
score NN O O
of NN O O
Z NN O O
= NN O O
6 NN O O
. NN O O

97 NN O O
at NN O O
theta NN O O
= NN O O
0 NN O O
. NN O O

00 NN O O
00 NN O O
. NN O O

The NN O O
HaeIII NN O O
polymorphism NN O O
detected NN O O
by NN O O
the NN O O
probe NN O O
p5BE1 NN O O
. NN O O

2 NN O O
gives NN O O
a NN O O
maximum NN O O
lod NN O O
score NN O O
of NN O O
Z NN O O
= NN O O
2 NN O O
. NN O O

57 NN O O
at NN O O
theta NN O O
= NN O O
0 NN O O
. NN O O

00 NN O O
00 NN O O
. NN O O

Locus NN O O
D11S325 NN O O
gives NN O O
a NN O O
lod NN O O
score NN O O
of NN O O
Z NN O O
= NN O O
1 NN O O
. NN O O

53 NN O O
at NN O O
theta NN O O
= NN O O
0 NN O O
. NN O O

00 NN O O
00 NN O O
. NN O O

These NN O O
data NN O O
suggest NN O O
that NN O O
a NN O O
locus NN O O
for NN O O
aniridia NN O B-Disease
( NN O O
AN1 NN O O
) NN O O
on NN O O
chromosome NN O O
2p NN O O
has NN O O
been NN O O
misassigned NN O O
and NN O O
that NN O O
this NN O O
autosomal NN O O
dominant NN O O
aniridia NN O B-Disease
family NN O O
is NN O O
segregating NN O O
for NN O O
an NN O O
aniridia NN O B-Disease
mutation NN O O
linked NN O O
to NN O O
markers NN O O
in NN O O
the NN O O
11p13 NN O O
region NN O O
. NN O O

Fatal NN O O
pyoderma NN O B-Disease
gangrenosum NN O I-Disease
in NN O O
association NN O O
with NN O O
C7 NN O B-Disease
deficiency NN O I-Disease
. NN O O

Although NN O O
pyoderma NN O B-Disease
gangrenosum NN O I-Disease
( NN O O
PG NN O B-Disease
) NN O O
is NN O O
often NN O O
associated NN O O
with NN O O
systemic NN O B-Disease
diseases NN O I-Disease
, NN O O
it NN O O
has NN O O
not NN O O
been NN O O
reported NN O O
in NN O O
association NN O O
with NN O O
congenital NN O B-Disease
complement NN O I-Disease
deficiencies NN O I-Disease
. NN O O

We NN O O
describe NN O O
an NN O O
aggressive NN O O
and NN O O
ultimately NN O O
fatal NN O O
case NN O O
of NN O O
PG NN O B-Disease
in NN O O
a NN O O
patient NN O O
with NN O O
a NN O O
congenital NN O O
C7 NN O B-Disease
deficiency NN O I-Disease
. NN O O

Deficiencies NN O B-Disease
of NN O I-Disease
C7 NN O I-Disease
can NN O O
be NN O O
associated NN O O
with NN O O
decreased NN O O
neutrophil NN O O
chemotaxis NN O O
, NN O O
phagocytosis NN O O
, NN O O
and NN O O
opsonization NN O O
, NN O O
similar NN O O
to NN O O
the NN O O
immunologic NN O B-Disease
abnormalities NN O I-Disease
described NN O O
in NN O O
patients NN O O
with NN O O
PG NN O B-Disease
. NN O O

Our NN O O
patients NN O O
decreased NN O O
complement NN O O
level NN O O
, NN O O
if NN O O
not NN O O
directly NN O O
related NN O O
to NN O O
the NN O O
development NN O O
of NN O O
PG NN O B-Disease
, NN O O
may NN O O
have NN O O
contributed NN O O
to NN O O
the NN O O
aggressive NN O O
nature NN O O
of NN O O
her NN O O
disease NN O O
. NN O O
. NN O O

Diverse NN O O
point NN O O
mutations NN O O
result NN O O
in NN O O
glucose NN O O
- NN O O
6 NN O O
- NN O O
phosphate NN O O
dehydrogenase NN O O
( NN O O
G6PD NN O O
) NN O O
polymorphism NN O O
in NN O O
Taiwan NN O O
. NN O O

Glucose NN O B-Disease
- NN O I-Disease
6 NN O I-Disease
- NN O I-Disease
PHOSPHATE NN O I-Disease
dehydrogenase NN O I-Disease
( NN O I-Disease
G6PD NN O I-Disease
; NN O I-Disease
EC NN O I-Disease
1 NN O I-Disease
. NN O I-Disease
1 NN O I-Disease
. NN O I-Disease
1 NN O I-Disease
. NN O I-Disease
49 NN O I-Disease
) NN O I-Disease
deficiency NN O I-Disease
is NN O O
the NN O O
most NN O O
common NN O O
human NN O O
enzymopathy NN O B-Disease
, NN O O
affecting NN O O
more NN O O
than NN O O
200 NN O O
million NN O O
people NN O O
worldwide NN O O
. NN O O

Although NN O O
greater NN O O
than NN O O
400 NN O O
variants NN O O
have NN O O
been NN O O
described NN O O
based NN O O
on NN O O
clinical NN O O
and NN O O
biochemical NN O O
criteria NN O O
, NN O O
little NN O O
is NN O O
known NN O O
about NN O O
the NN O O
molecular NN O O
basis NN O O
of NN O O
these NN O O
G6PD NN O B-Disease
deficiencies NN O I-Disease
. NN O O

Recently NN O O
, NN O O
the NN O O
gene NN O O
that NN O O
encodes NN O O
human NN O O
G6PD NN O O
has NN O O
been NN O O
cloned NN O O
and NN O O
sequenced NN O O
, NN O O
which NN O O
enables NN O O
us NN O O
to NN O O
examine NN O O
directly NN O O
the NN O O
heterogeneity NN O O
of NN O O
G6PD NN O O
at NN O O
the NN O O
DNA NN O O
level NN O O
. NN O O

During NN O O
the NN O O
past NN O O
10 NN O O
years NN O O
, NN O O
we NN O O
examined NN O O
the NN O O
G6PD NN O O
activity NN O O
in NN O O
21 NN O O
, NN O O
271 NN O O
newborn NN O O
Chinese NN O O
infants NN O O
( NN O O
11 NN O O
, NN O O
400 NN O O
males NN O O
and NN O O
9 NN O O
, NN O O
871 NN O O
females NN O O
) NN O O
and NN O O
identified NN O O
314 NN O O
( NN O O
2 NN O O
. NN O O
8 NN O O
% NN O O
) NN O O
males NN O O
and NN O O
246 NN O O
( NN O O
2 NN O O
. NN O O
5 NN O O
% NN O O
) NN O O
females NN O O
having NN O O
low NN O O
G6PD NN O O
activity NN O O
. NN O O

The NN O O
G6PD NN O O
gene NN O O
from NN O O
10 NN O O
randomly NN O O
selected NN O O
affected NN O O
individuals NN O O
and NN O O
their NN O O
relatives NN O O
was NN O O
polymerase NN O O
chain NN O O
reaction NN O O
( NN O O
PCR NN O O
) NN O O
amplified NN O O
, NN O O
subcloned NN O O
, NN O O
and NN O O
sequenced NN O O
. NN O O

Our NN O O
results NN O O
indicate NN O O
that NN O O
at NN O O
least NN O O
four NN O O
types NN O O
of NN O O
mutation NN O O
are NN O O
responsible NN O O
for NN O O
the NN O O
G6PD NN O O
polymorphism NN O O
in NN O O
Taiwan NN O O
. NN O O

The NN O O
first NN O O
type NN O O
of NN O O
mutation NN O O
( NN O O
487 NN O O
G NN O O
- NN O O
- NN O O
- NN O O
- NN O O
A NN O O
) NN O O
was NN O O
found NN O O
in NN O O
an NN O O
affected NN O O
Chinese NN O O
with NN O O
a NN O O
G NN O O
to NN O O
A NN O O
change NN O O
at NN O O
nucleotide NN O O
487 NN O O
, NN O O
which NN O O
results NN O O
in NN O O
a NN O O
( NN O O
163 NN O O
) NN O O
Gly NN O O
to NN O O
Ser NN O O
substitution NN O O
. NN O O

The NN O O
second NN O O
type NN O O
of NN O O
mutation NN O O
( NN O O
493 NN O O
A NN O O
- NN O O
- NN O O
- NN O O
- NN O O
G NN O O
) NN O O
is NN O O
a NN O O
novel NN O O
mutation NN O O
that NN O O
has NN O O
not NN O O
been NN O O
reported NN O O
in NN O O
any NN O O
other NN O O
ethnic NN O O
group NN O O
and NN O O
was NN O O
identified NN O O
in NN O O
two NN O O
affected NN O O
Chinese NN O O
. NN O O

This NN O O
mutation NN O O
causes NN O O
an NN O O
A NN O O
to NN O O
G NN O O
change NN O O
at NN O O
nucleotide NN O O
position NN O O
493 NN O O
, NN O O
producing NN O O
an NN O O
( NN O O
165 NN O O
) NN O O
Asn NN O O
to NN O O
Asp NN O O
substitution NN O O
. NN O O

Interestingly NN O O
, NN O O
the NN O O
487 NN O O
G NN O O
- NN O O
- NN O O
- NN O O
- NN O O
A NN O O
and NN O O
493 NN O O
A NN O O
- NN O O
- NN O O
- NN O O
- NN O O
G NN O O
mutations NN O O
create NN O O
Alu NN O O
I NN O O
and NN O O
Ava NN O O
II NN O O
recognition NN O O
sites NN O O
, NN O O
respectively NN O O
, NN O O
which NN O O
enabled NN O O
us NN O O
to NN O O
rapidly NN O O
detect NN O O
these NN O O
two NN O O
mutations NN O O
by NN O O
PCR NN O O
/ NN O O
restriction NN O O
enzyme NN O O
( NN O O
RE NN O O
) NN O O
digestion NN O O
method NN O O
. NN O O

The NN O O
third NN O O
mutation NN O O
( NN O O
1376 NN O O
G NN O O
- NN O O
- NN O O
- NN O O
- NN O O
T NN O O
) NN O O
was NN O O
found NN O O
in NN O O
four NN O O
affected NN O O
Chinese NN O O
. NN O O

This NN O O
mutation NN O O
causes NN O O
a NN O O
G NN O O
to NN O O
T NN O O
change NN O O
at NN O O
nucleotide NN O O
position NN O O
1376 NN O O
that NN O O
results NN O O
in NN O O
an NN O O
( NN O O
459 NN O O
) NN O O
Arg NN O O
to NN O O
Leu NN O O
substitution NN O O
. NN O O

The NN O O
1376 NN O O
G NN O O
- NN O O
- NN O O
- NN O O
- NN O O
T NN O O
mutation NN O O
seems NN O O
to NN O O
be NN O O
the NN O O
dominant NN O O
allele NN O O
that NN O O
causes NN O O
G6PD NN O B-Disease
deficiency NN O I-Disease
in NN O O
Taiwan NN O O
. NN O O

Finally NN O O
, NN O O
two NN O O
affected NN O O
Chinese NN O O
were NN O O
identified NN O O
as NN O O
having NN O O
the NN O O
fourth NN O O
mutation NN O O
( NN O O
1388 NN O O
G NN O O
- NN O O
- NN O O
- NN O O
- NN O O
A NN O O
) NN O O
. NN O O

This NN O O
mutation NN O O
causes NN O O
a NN O O
G NN O O
to NN O O
A NN O O
change NN O O
at NN O O
nucleotide NN O O
1388 NN O O
that NN O O
produces NN O O
an NN O O
( NN O O
463 NN O O
) NN O O
Arg NN O O
to NN O O
His NN O O
substitution NN O O
. NN O O

Our NN O O
studies NN O O
provide NN O O
the NN O O
direct NN O O
proof NN O O
of NN O O
the NN O O
genetic NN O O
heterogeneity NN O O
of NN O O
G6PD NN O B-Disease
deficiency NN O I-Disease
in NN O O
the NN O O
Chinese NN O O
populations NN O O
of NN O O
Taiwan NN O O
and NN O O
the NN O O
PCR NN O O
/ NN O O
RE NN O O
digestion NN O O
method NN O O
is NN O O
suitable NN O O
for NN O O
simultaneous NN O O
detection NN O O
of NN O O
the NN O O
487 NN O O
G NN O O
- NN O O
- NN O O
- NN O O
- NN O O
A NN O O
and NN O O
493 NN O O
A NN O O
- NN O O
- NN O O
- NN O O
- NN O O
G NN O O
mutations NN O O
. NN O O

An NN O O
error NN O O
in NN O O
dystrophin NN O O
mRNA NN O O
processing NN O O
in NN O O
golden NN O B-Disease
retriever NN O I-Disease
muscular NN O I-Disease
dystrophy NN O I-Disease
, NN O O
an NN O O
animal NN O O
homologue NN O O
of NN O O
Duchenne NN O B-Disease
muscular NN O I-Disease
dystrophy NN O I-Disease
. NN O O

Golden NN O B-Disease
retriever NN O I-Disease
muscular NN O I-Disease
dystrophy NN O I-Disease
( NN O O
GRMD NN O B-Disease
) NN O O
is NN O O
a NN O O
spontaneous NN O O
, NN O O
X NN O O
- NN O O
linked NN O O
, NN O O
progressively NN O O
fatal NN O O
disease NN O O
of NN O O
dogs NN O O
and NN O O
is NN O O
also NN O O
a NN O O
homologue NN O O
of NN O O
Duchenne NN O B-Disease
muscular NN O I-Disease
dystrophy NN O I-Disease
( NN O O
DMD NN O B-Disease
) NN O O
. NN O O

Two NN O O
- NN O O
thirds NN O O
of NN O O
DMD NN O B-Disease
patients NN O O
carry NN O O
detectable NN O O
deletions NN O O
in NN O O
their NN O O
dystrophin NN O O
gene NN O O
. NN O O

The NN O O
defect NN O O
underlying NN O O
the NN O O
remaining NN O O
one NN O O
- NN O O
third NN O O
of NN O O
DMD NN O B-Disease
patients NN O O
is NN O O
undetermined NN O O
. NN O O

Analysis NN O O
of NN O O
the NN O O
canine NN O O
dystrophin NN O O
gene NN O O
in NN O O
normal NN O O
and NN O O
GRMD NN O B-Disease
dogs NN O O
has NN O O
failed NN O O
to NN O O
demonstrate NN O O
any NN O O
detectable NN O O
loss NN O O
of NN O O
exons NN O O
. NN O O

Here NN O O
, NN O O
we NN O O
have NN O O
demonstrated NN O O
a NN O O
RNA NN O O
processing NN O O
error NN O O
in NN O O
GRMD NN O B-Disease
that NN O O
results NN O O
from NN O O
a NN O O
single NN O O
base NN O O
change NN O O
in NN O O
the NN O O
3 NN O O
consensus NN O O
splice NN O O
site NN O O
of NN O O
intron NN O O
6 NN O O
. NN O O

The NN O O
seventh NN O O
exon NN O O
is NN O O
then NN O O
skipped NN O O
, NN O O
which NN O O
predicts NN O O
a NN O O
termination NN O O
of NN O O
the NN O O
dystrophin NN O O
reading NN O O
frame NN O O
within NN O O
its NN O O
N NN O O
- NN O O
terminal NN O O
domain NN O O
in NN O O
exon NN O O
8 NN O O
. NN O O

This NN O O
is NN O O
the NN O O
first NN O O
example NN O O
of NN O O
dystrophin NN O B-Disease
deficiency NN O I-Disease
caused NN O O
by NN O O
a NN O O
splice NN O O
- NN O O
site NN O O
mutation NN O O
. NN O O
. NN O O

Type NN O B-Disease
I NN O I-Disease
human NN O I-Disease
complement NN O I-Disease
C2 NN O I-Disease
deficiency NN O I-Disease
. NN O O

A NN O O
28 NN O O
- NN O O
base NN O O
pair NN O O
gene NN O O
deletion NN O O
causes NN O O
skipping NN O O
of NN O O
exon NN O O
6 NN O O
during NN O O
RNA NN O O
splicing NN O O
. NN O O

Two NN O O
variants NN O O
of NN O O
a NN O O
genetic NN O O
deficiency NN O B-Disease
of NN O I-Disease
complement NN O I-Disease
protein NN O I-Disease
C2 NN O I-Disease
( NN O O
C2D NN O O
) NN O O
have NN O O
been NN O O
previously NN O O
identified NN O O
. NN O O

No NN O O
C2 NN O O
protein NN O O
translation NN O O
is NN O O
detected NN O O
in NN O O
type NN O O
I NN O O
deficiency NN O O
, NN O O
while NN O O
type NN O O
II NN O O
deficiency NN O O
is NN O O
characterized NN O O
by NN O O
a NN O O
selective NN O O
block NN O O
in NN O O
C2 NN O O
secretion NN O O
. NN O O

Type NN O B-Disease
I NN O I-Disease
C2 NN O I-Disease
deficiency NN O I-Disease
was NN O O
described NN O O
in NN O O
a NN O O
family NN O O
in NN O O
which NN O O
the NN O O
C2 NN O O
null NN O O
allele NN O O
( NN O O
C2Q0 NN O O
) NN O O
is NN O O
associated NN O O
with NN O O
the NN O O
major NN O O
histocompatibility NN O O
haplotype NN O O
/ NN O O
complotype NN O O
HLA NN O O
- NN O O
A25 NN O O
, NN O O
B18 NN O O
, NN O O
C2Q0 NN O O
, NN O O
BfS NN O O
, NN O O
C4A4 NN O O
, NN O O
C4B2 NN O O
, NN O O
Drw2 NN O O
; NN O O
this NN O O
extended NN O O
haplotype NN O O
occurs NN O O
in NN O O
over NN O O
90 NN O O
% NN O O
of NN O O
C2 NN O B-Disease
- NN O I-Disease
deficient NN O I-Disease
individuals NN O O
( NN O O
common NN O O
complotype NN O O
/ NN O O
haplotype NN O O
) NN O O
. NN O O

To NN O O
determine NN O O
the NN O O
molecular NN O O
basis NN O O
of NN O O
type NN O B-Disease
I NN O I-Disease
C2 NN O I-Disease
deficiency NN O I-Disease
, NN O O
the NN O O
C2 NN O O
gene NN O O
and NN O O
cDNA NN O O
were NN O O
characterized NN O O
from NN O O
a NN O O
homozygous NN O O
type NN O B-Disease
I NN O I-Disease
C2 NN O I-Disease
- NN O I-Disease
deficient NN O I-Disease
individual NN O O
with NN O O
the NN O O
common NN O O
associated NN O O
haplotype NN O O
/ NN O O
complotype NN O O
. NN O O

We NN O O
found NN O O
a NN O O
28 NN O O
- NN O O
base NN O O
pair NN O O
deletion NN O O
in NN O O
the NN O O
type NN O O
I NN O O
C2Q0 NN O O
gene NN O O
, NN O O
beginning NN O O
9 NN O O
base NN O O
pairs NN O O
upstream NN O O
of NN O O
the NN O O
3 NN O O
- NN O O
end NN O O
of NN O O
exon NN O O
6 NN O O
, NN O O
that NN O O
generates NN O O
a NN O O
C2 NN O O
transcript NN O O
with NN O O
a NN O O
complete NN O O
deletion NN O O
of NN O O
exon NN O O
6 NN O O
( NN O O
134 NN O O
base NN O O
pair NN O O
) NN O O
and NN O O
a NN O O
premature NN O O
termination NN O O
codon NN O O
. NN O O

In NN O O
studies NN O O
of NN O O
eight NN O O
kindred NN O O
, NN O O
the NN O O
28 NN O O
- NN O O
base NN O O
pair NN O O
deletion NN O O
was NN O O
observed NN O O
in NN O O
all NN O O
C2Q0 NN O O
alleles NN O O
associated NN O O
with NN O O
the NN O O
common NN O O
type NN O O
I NN O O
deficient NN O O
complotype NN O O
/ NN O O
haplotype NN O O
; NN O O
this NN O O
deletion NN O O
was NN O O
not NN O O
present NN O O
in NN O O
normal NN O O
C2 NN O O
nor NN O O
in NN O O
type NN O B-Disease
II NN O I-Disease
C2 NN O I-Disease
- NN O I-Disease
deficient NN O I-Disease
genes NN O O
. NN O O

These NN O O
data NN O O
demonstrate NN O O
that NN O O
1 NN O O
) NN O O
type NN O B-Disease
I NN O I-Disease
human NN O I-Disease
complement NN O I-Disease
C2 NN O I-Disease
deficiency NN O I-Disease
is NN O O
caused NN O O
by NN O O
a NN O O
28 NN O O
- NN O O
base NN O O
pair NN O O
genomic NN O O
deletion NN O O
that NN O O
causes NN O O
skipping NN O O
of NN O O
exon NN O O
6 NN O O
during NN O O
RNA NN O O
splicing NN O O
, NN O O
resulting NN O O
in NN O O
generation NN O O
of NN O O
a NN O O
premature NN O O
termination NN O O
codon NN O O
, NN O O
2 NN O O
) NN O O
the NN O O
28 NN O O
- NN O O
base NN O O
pair NN O O
deletion NN O O
in NN O O
the NN O O
type NN O O
I NN O O
C2Q0 NN O O
gene NN O O
is NN O O
strongly NN O O
associated NN O O
with NN O O
the NN O O
HLA NN O O
haplotype NN O O
/ NN O O
complotype NN O O
A25 NN O O
, NN O O
B18 NN O O
, NN O O
C2Q0 NN O O
, NN O O
BfS NN O O
, NN O O
C4A4 NN O O
, NN O O
C4B2 NN O O
, NN O O
Drw2 NN O O
, NN O O
suggesting NN O O
that NN O O
all NN O O
C2 NN O B-Disease
- NN O I-Disease
deficient NN O I-Disease
individuals NN O O
with NN O O
this NN O O
haplotype NN O O
/ NN O O
complotype NN O O
will NN O O
harbor NN O O
the NN O O
28 NN O O
- NN O O
base NN O O
pair NN O O
C2 NN O O
gene NN O O
deletion NN O O
, NN O O
and NN O O
3 NN O O
) NN O O
type NN O B-Disease
II NN O I-Disease
C2 NN O I-Disease
deficiency NN O I-Disease
is NN O O
caused NN O O
by NN O O
a NN O O
different NN O O
, NN O O
as NN O O
yet NN O O
uncharacterized NN O O
, NN O O
molecular NN O O
genetic NN O B-Disease
defect NN O I-Disease
. NN O O
. NN O O

Molecular NN O O
characterization NN O O
of NN O O
two NN O O
galactosemia NN O B-Disease
mutations NN O O
and NN O O
one NN O O
polymorphism NN O O
: NN O O
implications NN O O
for NN O O
structure NN O O
- NN O O
function NN O O
analysis NN O O
of NN O O
human NN O O
galactose NN O O
- NN O O
1 NN O O
- NN O O
phosphate NN O O
uridyltransferase NN O O
. NN O O

We NN O O
report NN O O
here NN O O
the NN O O
molecular NN O O
characterization NN O O
of NN O O
two NN O O
galactosemia NN O B-Disease
mutations NN O O
, NN O O
L74P NN O O
and NN O O
F171S NN O O
, NN O O
and NN O O
one NN O O
polymorphism NN O O
, NN O O
S135L NN O O
, NN O O
in NN O O
human NN O O
galactose NN O O
- NN O O
1 NN O O
- NN O O
phosphate NN O O
uridyltransferase NN O O
( NN O O
GALT NN O O
) NN O O
. NN O O

Both NN O O
galactosemia NN O B-Disease
mutations NN O O
result NN O O
in NN O O
reduced NN O O
enzymatic NN O O
activity NN O O
when NN O O
reconstructed NN O O
in NN O O
the NN O O
cDNA NN O O
and NN O O
overexpressed NN O O
. NN O O

The NN O O
polymorphism NN O O
, NN O O
in NN O O
contrast NN O O
, NN O O
has NN O O
near NN O O
normal NN O O
activity NN O O
. NN O O

Both NN O O
mutations NN O O
affect NN O O
evolutionarily NN O O
conserved NN O O
residues NN O O
, NN O O
suggesting NN O O
that NN O O
they NN O O
are NN O O
functionally NN O O
important NN O O
, NN O O
while NN O O
the NN O O
polymorphism NN O O
occurs NN O O
in NN O O
a NN O O
nonconserved NN O O
domain NN O O
which NN O O
is NN O O
presumably NN O O
not NN O O
critical NN O O
for NN O O
enzymatic NN O O
function NN O O
. NN O O

The NN O O
F171S NN O O
mutation NN O O
is NN O O
close NN O O
to NN O O
the NN O O
putative NN O O
active NN O O
- NN O O
site NN O O
nucleophile NN O O
. NN O O

Our NN O O
data NN O O
further NN O O
support NN O O
the NN O O
notion NN O O
of NN O O
molecular NN O O
heterogeneity NN O O
of NN O O
galactosemia NN O B-Disease
and NN O O
suggest NN O O
that NN O O
galactosemia NN O B-Disease
mutations NN O O
and NN O O
GALT NN O O
polymorphisms NN O O
may NN O O
be NN O O
useful NN O O
tools NN O O
in NN O O
highlighting NN O O
different NN O O
functional NN O O
domains NN O O
in NN O O
human NN O O
GALT NN O O
. NN O O
. NN O O

Linkage NN O O
relationship NN O O
of NN O O
C2 NN O B-Disease
deficiency NN O I-Disease
, NN O O
HLA NN O O
and NN O O
glyoxalase NN O O
I NN O O
loci NN O O
. NN O O

Immunogenetic NN O O
analysis NN O O
of NN O O
a NN O O
homozygous NN O O
C2 NN O B-Disease
- NN O I-Disease
deficient NN O I-Disease
individual NN O O
and NN O O
family NN O O
members NN O O
demonstrated NN O O
linkage NN O O
of NN O O
HLA NN O O
- NN O O
A25 NN O O
, NN O O
B18 NN O O
and NN O O
C2o NN O O
. NN O O

HLA NN O O
- NN O O
D NN O O
typing NN O O
showed NN O O
that NN O O
5 NN O O
members NN O O
typed NN O O
with NN O O
homozygous NN O O
Dw2 NN O O
typing NN O O
cells NN O O
from NN O O
an NN O O
individual NN O O
with NN O O
C2 NN O B-Disease
deficiency NN O I-Disease
but NN O O
not NN O O
with NN O O
Dw2 NN O O
typing NN O O
cells NN O O
from NN O O
2 NN O O
individuals NN O O
with NN O O
normal NN O O
C2 NN O O
. NN O O

The NN O O
homozygous NN O O
C2 NN O B-Disease
- NN O I-Disease
deficient NN O I-Disease
propositus NN O O
and NN O O
brother NN O O
were NN O O
HLA NN O O
- NN O O
A NN O O
and NN O O
B NN O O
homozygous NN O O
but NN O O
heterozygous NN O O
at NN O O
the NN O O
HLA NN O O
- NN O O
D NN O O
and NN O O
glyoxalase NN O O
I NN O O
loci NN O O
. NN O O

Therefore NN O O
, NN O O
in NN O O
this NN O O
family NN O O
, NN O O
the NN O O
C2o NN O O
gene NN O O
is NN O O
linked NN O O
with NN O O
two NN O O
distinct NN O O
haplotypes NN O O
HLA NN O O
- NN O O
A25 NN O O
, NN O O
B18 NN O O
, NN O O
Dw2 NN O O
, NN O O
GLO1 NN O O
and NN O O
HLA NN O O
- NN O O
A25 NN O O
, NN O O
B18 NN O O
, NN O O
D NN O O
unknown NN O O
, NN O O
GL02 NN O O
. NN O O

These NN O O
results NN O O
could NN O O
be NN O O
explained NN O O
by NN O O
an NN O O
ancestral NN O O
recombinant NN O O
event NN O O
, NN O O
which NN O O
occurred NN O O
between NN O O
the NN O O
C2o NN O O
locus NN O O
and NN O O
HLA NN O O
- NN O O
D NN O O
locus NN O O
in NN O O
which NN O O
C2o NN O O
segregated NN O O
with NN O O
HLA NN O O
- NN O O
B NN O O
. NN O O

This NN O O
would NN O O
suggest NN O O
that NN O O
the NN O O
locus NN O O
for NN O O
the NN O O
C2o NN O O
gene NN O O
maps NN O O
between NN O O
HLA NN O O
- NN O O
B NN O O
and NN O O
HLA NN O O
- NN O O
D NN O O
on NN O O
the NN O O
sixth NN O O
chromosome NN O O
. NN O O
. NN O O

Germline NN O O
mutations NN O O
in NN O O
the NN O O
Wilms NN O B-Disease
' NN O I-Disease
tumor NN O I-Disease
suppressor NN O O
gene NN O O
are NN O O
associated NN O O
with NN O O
abnormal NN O O
urogenital NN O O
development NN O O
in NN O O
Denys NN O B-Disease
- NN O I-Disease
Drash NN O I-Disease
syndrome NN O I-Disease
. NN O O

Denys NN O B-Disease
- NN O I-Disease
Drash NN O I-Disease
syndrome NN O I-Disease
is NN O O
a NN O O
rare NN O O
human NN O O
condition NN O O
in NN O O
which NN O O
severe NN O O
urogenital NN O B-Disease
aberrations NN O I-Disease
result NN O O
in NN O O
renal NN O B-Disease
failure NN O I-Disease
, NN O O
pseudohermaphroditism NN O B-Disease
, NN O O
and NN O O
Wilms NN O B-Disease
tumor NN O I-Disease
( NN O O
nephroblastoma NN O B-Disease
) NN O O
. NN O O

To NN O O
investigate NN O O
its NN O O
possible NN O O
role NN O O
, NN O O
we NN O O
have NN O O
analyzed NN O O
the NN O O
coding NN O O
exons NN O O
of NN O O
the NN O O
Wilms NN O B-Disease
tumor NN O I-Disease
suppressor NN O O
gene NN O O
( NN O O
WT1 NN O O
) NN O O
for NN O O
germline NN O O
mutations NN O O
. NN O O

In NN O O
ten NN O O
independent NN O O
cases NN O O
of NN O O
Denys NN O B-Disease
- NN O I-Disease
Drash NN O I-Disease
syndrome NN O I-Disease
, NN O O
point NN O O
mutations NN O O
in NN O O
the NN O O
zinc NN O O
finger NN O O
domains NN O O
of NN O O
one NN O O
WT1 NN O O
gene NN O O
copy NN O O
were NN O O
found NN O O
. NN O O

Nine NN O O
of NN O O
these NN O O
mutations NN O O
are NN O O
found NN O O
within NN O O
exon NN O O
9 NN O O
( NN O O
zinc NN O O
finger NN O O
III NN O O
) NN O O
; NN O O
the NN O O
remaining NN O O
mutation NN O O
is NN O O
in NN O O
exon NN O O
8 NN O O
( NN O O
zinc NN O O
finger NN O O
II NN O O
) NN O O
. NN O O

These NN O O
mutations NN O O
directly NN O O
affect NN O O
DNA NN O O
sequence NN O O
recognition NN O O
. NN O O

In NN O O
two NN O O
families NN O O
analyzed NN O O
, NN O O
the NN O O
mutations NN O O
were NN O O
shown NN O O
to NN O O
arise NN O O
de NN O O
novo NN O O
. NN O O

Wilms NN O B-Disease
tumors NN O I-Disease
from NN O O
three NN O O
individuals NN O O
and NN O O
one NN O O
juvenile NN O O
granulosa NN O O
cell NN O O
tumor NN O B-Disease
demonstrate NN O O
reduction NN O O
to NN O O
homozygosity NN O O
for NN O O
the NN O O
mutated NN O O
WT1 NN O O
allele NN O O
. NN O O

Our NN O O
results NN O O
provide NN O O
evidence NN O O
of NN O O
a NN O O
direct NN O O
role NN O O
for NN O O
WT1 NN O O
in NN O O
Denys NN O B-Disease
- NN O I-Disease
Drash NN O I-Disease
syndrome NN O I-Disease
and NN O O
thus NN O O
urogenital NN O O
system NN O O
development NN O O
. NN O O
. NN O O

Linkage NN O O
analysis NN O O
in NN O O
X NN O B-Disease
- NN O I-Disease
linked NN O I-Disease
adrenoleukodystrophy NN O I-Disease
and NN O O
application NN O O
in NN O O
post NN O O
- NN O O
and NN O O
prenatal NN O O
diagnosis NN O O
. NN O O

We NN O O
have NN O O
performed NN O O
linkage NN O O
analysis NN O O
with NN O O
the NN O O
DNA NN O O
markers NN O O
DXS52 NN O O
and NN O O
the NN O O
clotting NN O O
factor NN O O
VIII NN O O
gene NN O O
( NN O O
F8C NN O O
) NN O O
, NN O O
in NN O O
several NN O O
large NN O O
families NN O O
with NN O O
X NN O B-Disease
- NN O I-Disease
linked NN O I-Disease
adrenoleukodystrophy NN O I-Disease
( NN O O
ALD NN O B-Disease
) NN O O
. NN O O

The NN O O
tight NN O O
linkage NN O O
to NN O O
DXS52 NN O O
could NN O O
be NN O O
extended NN O O
giving NN O O
a NN O O
maximal NN O O
LOD NN O O
score NN O O
of NN O O
22 NN O O
. NN O O

5 NN O O
at NN O O
1 NN O O
cM NN O O
. NN O O

F8C NN O O
was NN O O
also NN O O
tightly NN O O
linked NN O O
to NN O O
ALD NN O B-Disease
with NN O O
a NN O O
maximal NN O O
LOD NN O O
score NN O O
of NN O O
7 NN O O
. NN O O

8 NN O O
without NN O O
recombination NN O O
. NN O O

Multipoint NN O O
linkage NN O O
analysis NN O O
with NN O O
the NN O O
markers NN O O
DXS304 NN O O
, NN O O
DXS52 NN O O
, NN O O
and NN O O
F8C NN O O
indicated NN O O
that NN O O
both NN O O
the NN O O
gene NN O O
for NN O O
ALD NN O B-Disease
and NN O O
for NN O O
F8C NN O O
are NN O O
distal NN O O
to NN O O
DXS52 NN O O
. NN O O

In NN O O
four NN O O
patients NN O O
with NN O O
ALD NN O B-Disease
, NN O O
no NN O O
major NN O O
structural NN O O
rearrangement NN O O
in NN O O
the NN O O
Xqter NN O O
region NN O O
was NN O O
observed NN O O
; NN O O
in NN O O
particular NN O O
, NN O O
there NN O O
were NN O O
no NN O O
abnormalities NN O B-Disease
in NN O I-Disease
the NN O I-Disease
vision NN O I-Disease
blindness NN O I-Disease
genes NN O I-Disease
. NN O O

DNA NN O O
analysis NN O O
appeared NN O O
to NN O O
be NN O O
of NN O O
use NN O O
in NN O O
determination NN O O
of NN O O
the NN O O
carrier NN O O
status NN O O
of NN O O
females NN O O
at NN O O
risk NN O O
, NN O O
for NN O O
the NN O O
determination NN O O
of NN O O
the NN O O
origin NN O O
of NN O O
the NN O O
mutation NN O O
in NN O O
a NN O O
particular NN O O
family NN O O
, NN O O
and NN O O
for NN O O
prenatal NN O O
diagnosis NN O O
. NN O O

Two NN O O
distinct NN O O
mutations NN O O
at NN O O
a NN O O
single NN O O
BamHI NN O O
site NN O O
in NN O O
phenylketonuria NN O B-Disease
. NN O O

Classical NN O B-Disease
phenylketonuria NN O I-Disease
is NN O O
an NN O O
autosomal NN O B-Disease
recessive NN O I-Disease
disease NN O I-Disease
caused NN O O
by NN O O
a NN O O
deficiency NN O B-Disease
of NN O I-Disease
hepatic NN O I-Disease
phenylalanine NN O I-Disease
hydroxylase NN O I-Disease
( NN O O
PAH NN O O
) NN O O
. NN O O

The NN O O
abolition NN O O
of NN O O
an NN O O
invariant NN O O
BamHI NN O O
site NN O O
located NN O O
in NN O O
the NN O O
coding NN O O
sequence NN O O
of NN O O
the NN O O
PAH NN O O
gene NN O O
( NN O O
exon NN O O
7 NN O O
) NN O O
led NN O O
to NN O O
the NN O O
recognition NN O O
of NN O O
two NN O O
new NN O O
point NN O O
mutations NN O O
at NN O O
codon NN O O
272 NN O O
and NN O O
273 NN O O
( NN O O
272gly NN O O
- NN O O
- NN O O
- NN O O
- NN O O
stop NN O O
and NN O O
273ser NN O O
- NN O O
- NN O O
- NN O O
- NN O O
phe NN O O
, NN O O
respectively NN O O
) NN O O
. NN O O

Both NN O O
mutations NN O O
were NN O O
detected NN O O
in NN O O
north NN O O
eastern NN O O
France NN O O
or NN O O
Belgium NN O O
and NN O O
occurred NN O O
on NN O O
the NN O O
background NN O O
of NN O O
RFLP NN O O
haplotype NN O O
7 NN O O
alleles NN O O
. NN O O

The NN O O
present NN O O
study NN O O
supports NN O O
the NN O O
view NN O O
that NN O O
the NN O O
clinical NN O O
heterogeneity NN O O
in NN O O
PKU NN O B-Disease
is NN O O
accounted NN O O
for NN O O
by NN O O
the NN O O
large NN O O
variety NN O O
of NN O O
mutant NN O O
genotypes NN O O
associated NN O O
with NN O O
PAH NN O B-Disease
deficiencies NN O I-Disease
. NN O O
. NN O O

A NN O O
detailed NN O O
multipoint NN O O
map NN O O
of NN O O
human NN O O
chromosome NN O O
4 NN O O
provides NN O O
evidence NN O O
for NN O O
linkage NN O O
heterogeneity NN O O
and NN O O
position NN O O
- NN O O
specific NN O O
recombination NN O O
rates NN O O
. NN O O

Utilizing NN O O
the NN O O
CEPH NN O O
reference NN O O
panel NN O O
and NN O O
genotypic NN O O
data NN O O
for NN O O
53 NN O O
markers NN O O
, NN O O
we NN O O
have NN O O
constructed NN O O
a NN O O
20 NN O O
- NN O O
locus NN O O
multipoint NN O O
genetic NN O O
map NN O O
of NN O O
human NN O O
chromosome NN O O
4 NN O O
. NN O O

New NN O O
RFLPs NN O O
are NN O O
reported NN O O
for NN O O
four NN O O
loci NN O O
. NN O O

The NN O O
map NN O O
integrates NN O O
a NN O O
high NN O O
- NN O O
resolution NN O O
genetic NN O O
map NN O O
of NN O O
4p16 NN O O
into NN O O
a NN O O
continuous NN O O
map NN O O
extending NN O O
to NN O O
4q31 NN O O
and NN O O
an NN O O
unlinked NN O O
cluster NN O O
of NN O O
three NN O O
loci NN O O
at NN O O
4q35 NN O O
. NN O O

The NN O O
20 NN O O
linked NN O O
markers NN O O
form NN O O
a NN O O
continuous NN O O
linkage NN O O
group NN O O
of NN O O
152 NN O O
cM NN O O
in NN O O
males NN O O
and NN O O
202 NN O O
cM NN O O
in NN O O
females NN O O
. NN O O

Likely NN O O
genetic NN O O
locations NN O O
are NN O O
provided NN O O
for NN O O
25 NN O O
polymorphic NN O O
anonymous NN O O
sequences NN O O
and NN O O
28 NN O O
gene NN O O
- NN O O
specific NN O O
RFLPs NN O O
. NN O O

The NN O O
map NN O O
was NN O O
constructed NN O O
employing NN O O
the NN O O
LINKAGE NN O O
and NN O O
CRIMAP NN O O
computational NN O O
methodologies NN O O
to NN O O
build NN O O
the NN O O
multipoint NN O O
map NN O O
via NN O O
a NN O O
stepwise NN O O
algorithm NN O O
. NN O O

A NN O O
detailed NN O O
10 NN O O
- NN O O
point NN O O
map NN O O
of NN O O
the NN O O
4p16 NN O O
region NN O O
constructed NN O O
from NN O O
the NN O O
CEPH NN O O
panel NN O O
provides NN O O
evidence NN O O
for NN O O
heterogeneity NN O O
in NN O O
the NN O O
linkage NN O O
maps NN O O
constructed NN O O
from NN O O
families NN O O
segregating NN O O
for NN O O
Huntington NN O B-Disease
disease NN O I-Disease
( NN O O
HD NN O B-Disease
) NN O O
. NN O O

It NN O O
additionally NN O O
provides NN O O
evidence NN O O
for NN O O
position NN O O
- NN O O
specific NN O O
recombination NN O O
frequencies NN O O
in NN O O
the NN O O
telomeric NN O O
region NN O O
of NN O O
4p NN O O
. NN O O
. NN O O

Carrier NN O O
detection NN O O
and NN O O
prenatal NN O O
diagnosis NN O O
of NN O O
Pelizaeus NN O B-Disease
- NN O I-Disease
Merzbacher NN O I-Disease
disease NN O I-Disease
using NN O O
a NN O O
combination NN O O
of NN O O
anonymous NN O O
DNA NN O O
polymorphisms NN O O
and NN O O
the NN O O
proteolipid NN O O
protein NN O O
( NN O O
PLP NN O O
) NN O O
gene NN O O
cDNA NN O O
. NN O O

We NN O O
report NN O O
carrier NN O O
identification NN O O
and NN O O
a NN O O
prenatal NN O O
diagnosis NN O O
using NN O O
DNA NN O O
polymorphisms NN O O
in NN O O
2 NN O O
families NN O O
with NN O O
X NN O B-Disease
- NN O I-Disease
linked NN O I-Disease
Pelizaeus NN O I-Disease
- NN O I-Disease
Merzbacher NN O I-Disease
disease NN O I-Disease
( NN O O
PMD NN O B-Disease
) NN O O
. NN O O

In NN O O
both NN O O
families NN O O
, NN O O
the NN O O
proteolipid NN O O
protein NN O O
( NN O O
PLP NN O O
) NN O O
gene NN O O
in NN O O
the NN O O
single NN O O
affected NN O O
male NN O O
could NN O O
be NN O O
traced NN O O
back NN O O
to NN O O
his NN O O
unaffected NN O O
maternal NN O O
grandfather NN O O
. NN O O

Therefore NN O O
, NN O O
each NN O O
family NN O O
contains NN O O
a NN O O
new NN O O
mutation NN O O
. NN O O

In NN O O
the NN O O
case NN O O
of NN O O
the NN O O
prenatal NN O O
diagnosis NN O O
, NN O O
the NN O O
fetus NN O O
was NN O O
shown NN O O
by NN O O
cytogenetic NN O O
analysis NN O O
to NN O O
be NN O O
a NN O O
female NN O O
, NN O O
who NN O O
we NN O O
predict NN O O
will NN O O
be NN O O
a NN O O
noncarrier NN O O
of NN O O
PMD NN O B-Disease
based NN O O
on NN O O
her NN O O
genotype NN O O
with NN O O
the NN O O
PLP NN O O
intragenic NN O O
polymorphism NN O O
. NN O O
. NN O O

Identification NN O O
of NN O O
deletion NN O O
mutations NN O O
and NN O O
three NN O O
new NN O O
genes NN O O
at NN O O
the NN O O
familial NN O B-Disease
polyposis NN O I-Disease
locus NN O O
. NN O O

Small NN O O
( NN O O
100 NN O O
- NN O O
260 NN O O
kb NN O O
) NN O O
, NN O O
nested NN O O
deletions NN O O
were NN O O
characterized NN O O
in NN O O
DNA NN O O
from NN O O
two NN O O
unrelated NN O O
patients NN O O
with NN O O
familial NN O B-Disease
adenomatous NN O I-Disease
polyposis NN O I-Disease
coli NN O I-Disease
( NN O O
APC NN O B-Disease
) NN O O
. NN O O

Three NN O O
candidate NN O O
genes NN O O
located NN O O
within NN O O
the NN O O
deleted NN O O
region NN O O
were NN O O
ascertained NN O O
and NN O O
a NN O O
previous NN O O
candidate NN O O
gene NN O O
, NN O O
MCC NN O O
, NN O O
was NN O O
shown NN O O
to NN O O
be NN O O
located NN O O
outside NN O O
the NN O O
deleted NN O O
region NN O O
. NN O O

One NN O O
of NN O O
the NN O O
new NN O O
genes NN O O
contained NN O O
sequence NN O O
identical NN O O
to NN O O
SRP19 NN O O
, NN O O
the NN O O
gene NN O O
coding NN O O
for NN O O
the NN O O
19 NN O O
kd NN O O
component NN O O
of NN O O
the NN O O
ribosomal NN O O
signal NN O O
recognition NN O O
particle NN O O
. NN O O

The NN O O
second NN O O
, NN O O
provisionally NN O O
designated NN O O
DP1 NN O O
( NN O O
deleted NN O O
in NN O O
polyposis NN O O
1 NN O O
) NN O O
, NN O O
was NN O O
found NN O O
to NN O O
be NN O O
transcribed NN O O
in NN O O
the NN O O
same NN O O
orientation NN O O
as NN O O
MCC NN O O
. NN O O

Two NN O O
other NN O O
cDNAs NN O O
, NN O O
DP2 NN O O
and NN O O
DP3 NN O O
, NN O O
were NN O O
found NN O O
to NN O O
overlap NN O O
, NN O O
forming NN O O
a NN O O
single NN O O
gene NN O O
, NN O O
DP2 NN O O
. NN O O

5 NN O O
, NN O O
that NN O O
is NN O O
transcribed NN O O
in NN O O
the NN O O
same NN O O
orientation NN O O
as NN O O
SRP19 NN O O
. NN O O

Exclusion NN O O
of NN O O
linkage NN O O
between NN O O
familial NN O B-Disease
Mediterranean NN O I-Disease
fever NN O I-Disease
and NN O O
the NN O O
human NN O O
serum NN O O
amyloid NN O O
A NN O O
( NN O O
SAA NN O O
) NN O O
gene NN O O
cluster NN O O
. NN O O

We NN O O
studied NN O O
the NN O O
relationship NN O O
between NN O O
the NN O O
autosomal NN O O
recessive NN O O
trait NN O O
familial NN O B-Disease
Mediterranean NN O I-Disease
fever NN O I-Disease
( NN O O
FMF NN O B-Disease
) NN O O
and NN O O
the NN O O
serum NN O O
amyloid NN O O
A NN O O
( NN O O
SAA NN O O
) NN O O
genes NN O O
by NN O O
comparing NN O O
alleles NN O O
of NN O O
a NN O O
highly NN O O
polymorphic NN O O
dinucleotide NN O O
repeat NN O O
and NN O O
a NN O O
conventional NN O O
restriction NN O O
fragment NN O O
length NN O O
polymorphism NN O O
( NN O O
RFLP NN O O
) NN O O
in NN O O
the NN O O
SAA NN O O
gene NN O O
cluster NN O O
in NN O O
Israeli NN O O
FMF NN O B-Disease
kindreds NN O O
. NN O O

By NN O O
haplotype NN O O
analysis NN O O
, NN O O
our NN O O
data NN O O
indicate NN O O
a NN O O
minimum NN O O
crossover NN O O
frequency NN O O
of NN O O
22 NN O O
% NN O O
between NN O O
the NN O O
SAA NN O O
gene NN O O
marker NN O O
and NN O O
FMF NN O B-Disease
. NN O O

By NN O O
conventional NN O O
linkage NN O O
analysis NN O O
this NN O O
eliminates NN O O
a NN O O
minimum NN O O
of NN O O
10 NN O O
. NN O O

4 NN O O
cM NN O O
including NN O O
and NN O O
surrounding NN O O
the NN O O
SAA NN O O
gene NN O O
cluster NN O O
as NN O O
the NN O O
site NN O O
of NN O O
the NN O O
FMF NN O B-Disease
mutation NN O O
although NN O O
SAA NN O O
proteins NN O O
are NN O O
prominent NN O O
physiologic NN O O
markers NN O O
of NN O O
the NN O O
acute NN O O
attacks NN O O
. NN O O

PRAD1 NN O O
, NN O O
a NN O O
candidate NN O O
BCL1 NN O O
oncogene NN O O
: NN O O
mapping NN O O
and NN O O
expression NN O O
in NN O O
centrocytic NN O B-Disease
lymphoma NN O I-Disease
. NN O O

Rearrangement NN O O
of NN O O
the NN O O
BCL1 NN O O
( NN O O
B NN O O
- NN O O
cell NN O O
lymphoma NN O O
1 NN O O
) NN O O
region NN O O
on NN O O
chromosome NN O O
11q13 NN O O
appears NN O O
to NN O O
be NN O O
highly NN O O
characteristic NN O O
of NN O O
centrocytic NN O B-Disease
lymphoma NN O I-Disease
and NN O O
also NN O O
is NN O O
found NN O O
infrequently NN O O
in NN O O
other NN O O
B NN O B-Disease
- NN O I-Disease
cell NN O I-Disease
neoplasms NN O I-Disease
. NN O O

Rearrangement NN O O
is NN O O
thought NN O O
to NN O O
deregulate NN O O
a NN O O
nearby NN O O
protooncogene NN O O
, NN O O
but NN O O
transcribed NN O O
sequences NN O O
in NN O O
the NN O O
immediate NN O O
vicinity NN O O
of NN O O
BCL1 NN O O
breakpoints NN O O
had NN O O
not NN O O
been NN O O
identified NN O O
. NN O O

PRAD1 NN O O
, NN O O
previously NN O O
designated NN O O
D11S287E NN O O
, NN O O
was NN O O
identified NN O O
on NN O O
11q13 NN O O
as NN O O
a NN O O
chromosomal NN O O
breakpoint NN O O
region NN O O
rearranged NN O O
with NN O O
the NN O O
parathyroid NN O O
hormone NN O O
gene NN O O
in NN O O
a NN O O
subset NN O O
of NN O O
parathyroid NN O B-Disease
adenomas NN O I-Disease
; NN O O
this NN O O
highly NN O O
conserved NN O O
putative NN O O
oncogene NN O O
, NN O O
which NN O O
encodes NN O O
a NN O O
novel NN O O
cyclin NN O O
, NN O O
has NN O O
been NN O O
linked NN O O
to NN O O
BCL1 NN O O
and NN O O
implicated NN O O
also NN O O
in NN O O
subsets NN O O
of NN O O
breast NN O B-Disease
and NN O I-Disease
squamous NN O I-Disease
cell NN O I-Disease
neoplasms NN O I-Disease
with NN O O
11q13 NN O O
amplification NN O O
. NN O O

We NN O O
report NN O O
pulsed NN O O
- NN O O
field NN O O
gel NN O O
electrophoresis NN O O
data NN O O
showing NN O O
BCL1 NN O O
and NN O O
PRAD1 NN O O
to NN O O
be NN O O
no NN O O
more NN O O
than NN O O
130 NN O O
kilobases NN O O
apart NN O O
. NN O O

PRAD1 NN O O
mRNA NN O O
is NN O O
abundantly NN O O
expressed NN O O
in NN O O
seven NN O O
of NN O O
seven NN O O
centrocytic NN O B-Disease
lymphomas NN O I-Disease
( NN O O
Kiel NN O O
classification NN O O
) NN O O
, NN O O
in NN O O
contrast NN O O
to NN O O
13 NN O O
closely NN O O
related NN O O
but NN O O
noncentrocytic NN O B-Disease
lymphomas NN O I-Disease
. NN O O

Three NN O O
of NN O O
the NN O O
seven NN O O
centrocytic NN O B-Disease
lymphomas NN O I-Disease
had NN O O
detectable NN O O
BCL1 NN O O
DNA NN O O
rearrangement NN O O
. NN O O

Also NN O O
, NN O O
two NN O O
unusual NN O O
cases NN O O
of NN O O
CLL NN O O
with NN O O
BCL1 NN O O
rearrangement NN O O
overexpressed NN O O
PRAD1 NN O O
, NN O O
in NN O O
contrast NN O O
to NN O O
five NN O O
CLL NN O O
controls NN O O
. NN O O

Thus NN O O
, NN O O
PRAD1 NN O O
is NN O O
an NN O O
excellent NN O O
candidate NN O O
" NN O O
BCL1 NN O O
oncogene NN O O
. NN O O

" NN O O
Its NN O O
overexpression NN O O
may NN O O
be NN O O
a NN O O
key NN O O
consequence NN O O
of NN O O
rearrangement NN O O
of NN O O
the NN O O
BCL1 NN O O
vicinity NN O O
in NN O O
B NN O B-Disease
- NN O I-Disease
cell NN O I-Disease
neoplasms NN O I-Disease
and NN O O
a NN O O
unifying NN O O
pathogenetic NN O O
feature NN O O
in NN O O
centrocytic NN O B-Disease
lymphoma NN O I-Disease
. NN O O

Two NN O O
new NN O O
arylsulfatase NN O O
A NN O O
( NN O O
ARSA NN O O
) NN O O
mutations NN O O
in NN O O
a NN O O
juvenile NN O O
metachromatic NN O B-Disease
leukodystrophy NN O I-Disease
( NN O O
MLD NN O B-Disease
) NN O O
patient NN O O
. NN O O

Fragments NN O O
of NN O O
the NN O O
arylsulfatase NN O O
A NN O O
( NN O O
ARSA NN O O
) NN O O
gene NN O O
from NN O O
a NN O O
patient NN O O
with NN O O
juvenile NN O O
- NN O O
onset NN O O
metachromatic NN O B-Disease
leukodystrophy NN O I-Disease
( NN O O
MLD NN O B-Disease
) NN O O
were NN O O
amplified NN O O
by NN O O
PCR NN O O
and NN O O
ligated NN O O
into NN O O
MP13 NN O O
cloning NN O O
vectors NN O O
. NN O O

Clones NN O O
hybridizing NN O O
with NN O O
cDNA NN O O
for NN O O
human NN O O
ARSA NN O O
were NN O O
selected NN O O
, NN O O
examined NN O O
for NN O O
appropriate NN O O
size NN O O
inserts NN O O
, NN O O
and NN O O
used NN O O
to NN O O
prepare NN O O
single NN O O
- NN O O
stranded NN O O
phage NN O O
DNA NN O O
. NN O O

Examination NN O O
of NN O O
the NN O O
entire NN O O
coding NN O O
and NN O O
most NN O O
of NN O O
the NN O O
intronic NN O O
sequence NN O O
revealed NN O O
two NN O O
putative NN O O
disease NN O O
- NN O O
related NN O O
mutations NN O O
. NN O O

One NN O O
, NN O O
a NN O O
point NN O O
mutation NN O O
in NN O O
exon NN O O
3 NN O O
, NN O O
resulted NN O O
in NN O O
the NN O O
substitution NN O O
of NN O O
isoleucine NN O O
by NN O O
serine NN O O
. NN O O

Introduction NN O O
of NN O O
this NN O O
alteration NN O O
into NN O O
the NN O O
normal NN O O
ARSA NN O O
cDNA NN O O
sequence NN O O
resulted NN O O
in NN O O
a NN O O
substantial NN O O
decrease NN O O
in NN O O
ARSA NN O O
activity NN O O
on NN O O
transient NN O O
expression NN O O
in NN O O
cultured NN O O
baby NN O O
hamster NN O O
kidney NN O O
cells NN O O
. NN O O

About NN O O
5 NN O O
% NN O O
of NN O O
the NN O O
control NN O O
expression NN O O
was NN O O
observed NN O O
, NN O O
suggesting NN O O
a NN O O
small NN O O
residual NN O O
activity NN O O
in NN O O
the NN O O
mutated NN O O
ARSA NN O O
. NN O O

The NN O O
second NN O O
mutation NN O O
, NN O O
a NN O O
G NN O O
- NN O O
to NN O O
- NN O O
A NN O O
transition NN O O
, NN O O
occurred NN O O
in NN O O
the NN O O
other NN O O
allele NN O O
and NN O O
resulted NN O O
in NN O O
an NN O O
altered NN O O
splice NN O O
- NN O O
recognition NN O O
sequence NN O O
between NN O O
exon NN O O
7 NN O O
and NN O O
the NN O O
following NN O O
intron NN O O
. NN O O

The NN O O
mutation NN O O
also NN O O
resulted NN O O
in NN O O
the NN O O
loss NN O O
of NN O O
a NN O O
restriction NN O O
site NN O O
. NN O O

Apparently NN O O
normal NN O O
levels NN O O
of NN O O
mRNA NN O O
were NN O O
generated NN O O
from NN O O
this NN O O
allele NN O O
, NN O O
but NN O O
no NN O O
ARSA NN O O
activity NN O O
or NN O O
immuno NN O O
- NN O O
cross NN O O
- NN O O
reactive NN O O
material NN O O
could NN O O
be NN O O
detected NN O O
. NN O O

A NN O O
collection NN O O
of NN O O
DNA NN O O
samples NN O O
from NN O O
known NN O O
or NN O O
suspected NN O O
MLD NN O B-Disease
patients NN O O
, NN O O
members NN O O
of NN O O
their NN O O
families NN O O
, NN O O
and NN O O
normal NN O O
controls NN O O
was NN O O
screened NN O O
for NN O O
these NN O O
mutations NN O O
. NN O O

Four NN O O
additional NN O O
individuals NN O O
carrying NN O O
each NN O O
of NN O O
the NN O O
mutations NN O O
were NN O O
found NN O O
among NN O O
the NN O O
nearly NN O O
100 NN O O
MLD NN O B-Disease
patients NN O O
in NN O O
the NN O O
sample NN O O
. NN O O

Gene NN O O
segregation NN O O
in NN O O
the NN O O
original NN O O
patients NN O O
family NN O O
was NN O O
consistent NN O O
with NN O O
available NN O O
clinical NN O O
and NN O O
biochemical NN O O
data NN O O
. NN O O

No NN O O
individuals NN O O
homozygous NN O O
for NN O O
either NN O O
of NN O O
these NN O O
two NN O O
mutations NN O O
were NN O O
identified NN O O
. NN O O

However NN O O
, NN O O
combinations NN O O
with NN O O
other NN O O
MLD NN O B-Disease
mutations NN O O
suggest NN O O
that NN O O
the NN O O
point NN O O
mutation NN O O
in NN O O
exon NN O O
3 NN O O
does NN O O
result NN O O
in NN O O
some NN O O
residual NN O O
enzyme NN O O
activity NN O O
and NN O O
is NN O O
associated NN O O
with NN O O
late NN O O
- NN O O
onset NN O O
forms NN O O
of NN O O
the NN O O
disease NN O O
. NN O O

The NN O O
splice NN O O
- NN O O
site NN O O
mutation NN O O
following NN O O
exon NN O O
7 NN O O
produces NN O O
late NN O O
- NN O O
infantile NN O O
MLD NN O B-Disease
when NN O O
combined NN O O
with NN O O
other NN O O
enzyme NN O O
- NN O O
null NN O O
mutations NN O O
, NN O O
implying NN O O
that NN O O
it NN O O
is NN O O
completely NN O O
silent NN O O
enzymatically NN O O
. NN O O
. NN O O

Analysis NN O O
of NN O O
X NN O O
- NN O O
chromosome NN O O
inactivation NN O O
and NN O O
presumptive NN O O
expression NN O O
of NN O O
the NN O O
Wiskott NN O B-Disease
- NN O I-Disease
Aldrich NN O I-Disease
syndrome NN O I-Disease
( NN O O
WAS NN O B-Disease
) NN O O
gene NN O O
in NN O O
hematopoietic NN O O
cell NN O O
lineages NN O O
of NN O O
a NN O O
thrombocytopenic NN O O
carrier NN O O
female NN O O
of NN O O
WAS NN O B-Disease
. NN O O

We NN O O
report NN O O
on NN O O
a NN O O
thrombocytopenic NN O B-Disease
female NN O O
belonging NN O O
to NN O O
a NN O O
pedigree NN O O
with NN O O
the NN O O
Wiskott NN O B-Disease
- NN O I-Disease
Aldrich NN O I-Disease
syndrome NN O I-Disease
( NN O O
WAS NN O B-Disease
) NN O O
. NN O O

Restriction NN O O
fragment NN O O
length NN O O
polymorphism NN O O
( NN O O
RFLP NN O O
) NN O O
analysis NN O O
with NN O O
probe NN O O
M27 NN O O
beta NN O O
, NN O O
closely NN O O
linked NN O O
to NN O O
the NN O O
WAS NN O B-Disease
gene NN O O
, NN O O
demonstrated NN O O
that NN O O
she NN O O
is NN O O
a NN O O
carrier NN O O
of NN O O
WAS NN O B-Disease
. NN O O

Both NN O O
small NN O O
- NN O O
sized NN O O
and NN O O
normal NN O O
- NN O O
sized NN O O
platelets NN O O
were NN O O
present NN O O
, NN O O
suggesting NN O O
that NN O O
, NN O O
unlike NN O O
the NN O O
vast NN O O
majority NN O O
of NN O O
WAS NN O B-Disease
carriers NN O O
, NN O O
she NN O O
does NN O O
not NN O O
manifest NN O O
nonrandom NN O O
X NN O O
- NN O O
chromosome NN O O
inactivation NN O O
in NN O O
the NN O O
thrombopoietic NN O O
cell NN O O
lineage NN O O
. NN O O

Study NN O O
of NN O O
X NN O O
- NN O O
chromosome NN O O
inactivation NN O O
by NN O O
means NN O O
of NN O O
RFLP NN O O
and NN O O
methylation NN O O
analysis NN O O
demonstrated NN O O
that NN O O
the NN O O
pattern NN O O
of NN O O
X NN O O
- NN O O
chromosome NN O O
inactivation NN O O
was NN O O
nonrandom NN O O
in NN O O
T NN O O
lymphocytes NN O O
, NN O O
but NN O O
random NN O O
in NN O O
granulocytes NN O O
. NN O O

While NN O O
this NN O O
is NN O O
the NN O O
first NN O O
complete NN O O
report NN O O
on NN O O
the NN O O
occurrence NN O O
of NN O O
thrombocytopenia NN O B-Disease
in NN O O
a NN O O
carrier NN O O
female NN O O
of NN O O
WAS NN O B-Disease
as NN O O
the NN O O
result NN O O
of NN O O
atypical NN O O
lyonization NN O O
, NN O O
it NN O O
also NN O O
suggests NN O O
that NN O O
expression NN O O
of NN O O
the NN O O
WAS NN O B-Disease
gene NN O O
occurs NN O O
at NN O O
( NN O O
or NN O O
extends NN O O
up NN O O
to NN O O
) NN O O
a NN O O
later NN O O
stage NN O O
than NN O O
the NN O O
multipotent NN O O
stem NN O O
cell NN O O
along NN O O
the NN O O
hematopoietic NN O O
differentiation NN O O
pathway NN O O
. NN O O
. NN O O

A NN O O
new NN O O
mutation NN O O
in NN O O
the NN O O
proteolipid NN O O
protein NN O O
( NN O O
PLP NN O O
) NN O O
gene NN O O
in NN O O
a NN O O
German NN O O
family NN O O
with NN O O
Pelizaeus NN O B-Disease
- NN O I-Disease
Merzbacher NN O I-Disease
disease NN O I-Disease
. NN O O

A NN O O
C NN O O
- NN O O
to NN O O
- NN O O
T NN O O
transition NN O O
in NN O O
exon NN O O
4 NN O O
of NN O O
the NN O O
PLP NN O O
gene NN O O
was NN O O
found NN O O
in NN O O
2 NN O O
affected NN O O
males NN O O
and NN O O
two NN O O
obligate NN O O
carriers NN O O
in NN O O
a NN O O
German NN O O
family NN O O
with NN O O
Pelizaeus NN O B-Disease
- NN O I-Disease
Merzbacher NN O I-Disease
disease NN O I-Disease
. NN O O

The NN O O
mutation NN O O
, NN O O
which NN O O
causes NN O O
loss NN O O
of NN O O
an NN O O
HphI NN O O
site NN O O
and NN O O
changes NN O O
amino NN O O
acid NN O O
155 NN O O
from NN O O
threonine NN O O
to NN O O
isoleucine NN O O
, NN O O
was NN O O
absent NN O O
from NN O O
108 NN O O
normal NN O O
chromosomes NN O O
. NN O O

There NN O O
are NN O O
5 NN O O
concordances NN O O
and NN O O
1 NN O O
discrepancy NN O O
between NN O O
these NN O O
results NN O O
and NN O O
those NN O O
obtained NN O O
by NN O O
magnetic NN O O
resonance NN O O
imaging NN O O
in NN O O
this NN O O
family NN O O
. NN O O
. NN O O

A NN O O
3 NN O O
- NN O O
base NN O O
pair NN O O
in NN O O
- NN O O
frame NN O O
deletion NN O O
of NN O O
the NN O O
phenylalanine NN O O
hydroxylase NN O O
gene NN O O
results NN O O
in NN O O
a NN O O
kinetic NN O O
variant NN O O
of NN O O
phenylketonuria NN O B-Disease
. NN O O

Phenylketonuria NN O B-Disease
( NN O O
PKU NN O B-Disease
) NN O O
is NN O O
an NN O O
autosomal NN O B-Disease
recessive NN O I-Disease
disease NN O I-Disease
due NN O O
to NN O O
deficiency NN O B-Disease
of NN O I-Disease
a NN O I-Disease
hepatic NN O I-Disease
enzyme NN O I-Disease
, NN O I-Disease
phenylalanine NN O I-Disease
hydroxylase NN O I-Disease
( NN O O
PAH NN O O
) NN O O
. NN O O

The NN O O
absence NN O O
of NN O O
PAH NN O O
activity NN O O
results NN O O
in NN O O
typical NN O O
PKU NN O B-Disease
while NN O O
persistence NN O O
of NN O O
a NN O O
residual NN O O
enzyme NN O O
activity NN O O
gives NN O O
rise NN O O
to NN O O
variant NN O O
forms NN O O
of NN O O
the NN O O
disease NN O O
. NN O O

We NN O O
report NN O O
here NN O O
a NN O O
3 NN O O
- NN O O
base NN O O
pair NN O O
in NN O O
- NN O O
frame NN O O
deletion NN O O
of NN O O
the NN O O
PAH NN O O
gene NN O O
( NN O O
delta NN O O
194 NN O O
) NN O O
in NN O O
a NN O O
mild NN O O
variant NN O O
, NN O O
with NN O O
markedly NN O O
reduced NN O O
affinity NN O O
of NN O O
the NN O O
enzyme NN O O
for NN O O
phenylalanine NN O O
( NN O O
Km NN O O
= NN O O
160 NN O O
nM NN O O
) NN O O
, NN O O
and NN O O
we NN O O
provide NN O O
functional NN O O
evidence NN O O
for NN O O
responsibility NN O O
of NN O O
the NN O O
deletion NN O O
in NN O O
the NN O O
mutant NN O O
phenotype NN O O
. NN O O

Since NN O O
the NN O O
deletion NN O O
was NN O O
located NN O O
in NN O O
the NN O O
third NN O O
exon NN O O
of NN O O
the NN O O
gene NN O O
, NN O O
which NN O O
presents NN O O
no NN O O
homology NN O O
with NN O O
other NN O O
hydroxylases NN O O
, NN O O
we NN O O
suggest NN O O
that NN O O
exon NN O O
3 NN O O
is NN O O
involved NN O O
in NN O O
the NN O O
specificity NN O O
of NN O O
the NN O O
enzyme NN O O
for NN O O
phenylalanine NN O O
. NN O O

Finally NN O O
, NN O O
since NN O O
none NN O O
of NN O O
the NN O O
98 NN O O
PKU NN O B-Disease
patients NN O O
tested NN O O
were NN O O
found NN O O
to NN O O
carry NN O O
this NN O O
particular NN O O
deletion NN O O
, NN O O
our NN O O
study NN O O
suggests NN O O
that NN O O
this NN O O
molecular NN O O
event NN O O
probably NN O O
occurred NN O O
recently NN O O
on NN O O
the NN O O
background NN O O
of NN O O
a NN O O
haplotype NN O O
2 NN O O
gene NN O O
in NN O O
Portugal NN O O
. NN O O
. NN O O

Mutation NN O O
of NN O O
the NN O O
KIT NN O O
( NN O O
mast NN O O
/ NN O O
stem NN O O
cell NN O O
growth NN O O
factor NN O O
receptor NN O O
) NN O O
protooncogene NN O O
in NN O O
human NN O O
piebaldism NN O B-Disease
. NN O O

Piebaldism NN O B-Disease
is NN O O
an NN O O
autosomal NN O B-Disease
dominant NN O I-Disease
genetic NN O I-Disease
disorder NN O I-Disease
characterized NN O O
by NN O O
cogenital NN O O
patches NN O O
of NN O O
skin NN O O
and NN O O
hair NN O O
from NN O O
which NN O O
melanocytes NN O O
are NN O O
completely NN O O
absent NN O O
. NN O O

A NN O O
similar NN O O
disorder NN O O
of NN O O
mouse NN O O
, NN O O
dominant NN O O
white NN O O
spotting NN O O
( NN O O
W NN O O
) NN O O
, NN O O
results NN O O
from NN O O
mutations NN O O
of NN O O
the NN O O
c NN O O
- NN O O
Kit NN O O
protooncogene NN O O
, NN O O
which NN O O
encodes NN O O
and NN O O
receptor NN O O
for NN O O
mast NN O O
/ NN O O
stem NN O O
cell NN O O
growth NN O O
factor NN O O
. NN O O

We NN O O
identified NN O O
a NN O O
KIT NN O O
gene NN O O
mutation NN O O
in NN O O
a NN O O
proband NN O O
with NN O O
classic NN O O
autosomal NN O O
dominant NN O O
piebaldism NN O B-Disease
. NN O O

This NN O O
mutation NN O O
results NN O O
in NN O O
a NN O O
Gly NN O O
- NN O O
- NN O O
- NN O O
- NN O O
Arg NN O O
substitution NN O O
at NN O O
codon NN O O
664 NN O O
, NN O O
within NN O O
the NN O O
tyrosine NN O O
kinase NN O O
domain NN O O
. NN O O

This NN O O
substitution NN O O
was NN O O
not NN O O
seen NN O O
in NN O O
any NN O O
normal NN O O
individuals NN O O
and NN O O
was NN O O
completely NN O O
linked NN O O
to NN O O
the NN O O
piebald NN O B-Disease
phenotype NN O O
in NN O O
the NN O O
probands NN O O
family NN O O
. NN O O

Piebaldism NN O B-Disease
in NN O O
this NN O O
family NN O O
thus NN O O
appears NN O O
to NN O O
be NN O O
the NN O O
human NN O O
homologue NN O O
to NN O O
dominant NN O O
white NN O O
spotting NN O O
( NN O O
W NN O O
) NN O O
of NN O O
the NN O O
mouse NN O O
. NN O O
. NN O O

Genetic NN O O
analysis NN O O
of NN O O
a NN O O
Japanese NN O O
family NN O O
with NN O O
normotriglyceridemic NN O B-Disease
abetalipoproteinemia NN O I-Disease
indicates NN O O
a NN O O
lack NN O O
of NN O O
linkage NN O O
to NN O O
the NN O O
apolipoprotein NN O O
B NN O O
gene NN O O
. NN O O

Normotriglyceridemic NN O B-Disease
abetalipoproteinemia NN O I-Disease
is NN O O
a NN O O
rare NN O O
familial NN O B-Disease
disorder NN O I-Disease
characterized NN O O
by NN O O
an NN O O
isolated NN O O
deficiency NN O B-Disease
of NN O I-Disease
apoB NN O I-Disease
- NN O I-Disease
100 NN O I-Disease
. NN O O

We NN O O
have NN O O
previously NN O O
reported NN O O
a NN O O
patient NN O O
with NN O O
this NN O O
disease NN O O
, NN O O
who NN O O
had NN O O
normal NN O O
apoB NN O O
- NN O O
48 NN O O
but NN O O
no NN O O
apoB NN O O
- NN O O
100 NN O O
. NN O O

To NN O O
elucidate NN O O
the NN O O
genetic NN O B-Disease
abnormalities NN O I-Disease
in NN O O
this NN O O
family NN O O
, NN O O
we NN O O
studied NN O O
the NN O O
linkage NN O O
of NN O O
apoB NN O O
gene NN O O
using NN O O
three NN O O
genetic NN O O
markers NN O O
. NN O O

The NN O O
proband NN O O
and NN O O
her NN O O
affected NN O O
brother NN O O
showed NN O O
completely NN O O
different NN O O
apoB NN O O
gene NN O O
alleles NN O O
, NN O O
suggesting NN O O
that NN O O
the NN O O
apoB NN O O
gene NN O O
itself NN O O
is NN O O
not NN O O
related NN O O
to NN O O
this NN O O
disorder NN O O
in NN O O
this NN O O
family NN O O
. NN O O

By NN O O
contrast NN O O
, NN O O
an NN O O
American NN O O
case NN O O
had NN O O
a NN O O
point NN O O
substitution NN O O
in NN O O
the NN O O
apoB NN O O
gene NN O O
generating NN O O
an NN O O
in NN O O
- NN O O
frame NN O O
stop NN O O
codon NN O O
. NN O O

These NN O O
results NN O O
indicate NN O O
that NN O O
this NN O O
disorder NN O O
can NN O O
be NN O O
caused NN O O
by NN O O
defect NN O O
( NN O O
s NN O O
) NN O O
of NN O O
either NN O O
an NN O O
apoB NN O O
gene NN O O
or NN O O
other NN O O
genes NN O O
. NN O O
. NN O O

Localisation NN O O
of NN O O
the NN O O
gene NN O O
for NN O O
Norrie NN O B-Disease
disease NN O I-Disease
to NN O O
between NN O O
DXS7 NN O O
and NN O O
DXS426 NN O O
on NN O O
Xp NN O O
. NN O O

A NN O O
highly NN O O
informative NN O O
microsatellite NN O O
marker NN O O
, NN O O
DXS426 NN O O
, NN O O
which NN O O
maps NN O O
proximal NN O O
to NN O O
DXS7 NN O O
in NN O O
the NN O O
interval NN O O
Xp11 NN O O
. NN O O

4 NN O O
- NN O O
Xp11 NN O O
4 NN O O
- NN O O
Xp11 NN O O
. NN O O

23 NN O O
, NN O O
has NN O O
been NN O O
used NN O O
to NN O O
refine NN O O
further NN O O
the NN O O
localisation NN O O
of NN O O
the NN O O
gene NN O O
for NN O O
Norrie NN O B-Disease
disease NN O I-Disease
( NN O O
NDP NN O B-Disease
) NN O O
. NN O O

The NN O O
results NN O O
from NN O O
a NN O O
multiply NN O O
informative NN O O
crossover NN O O
localize NN O O
the NN O O
NDP NN O B-Disease
gene NN O O
proximal NN O O
to NN O O
DXS7 NN O O
. NN O O

In NN O O
conjunction NN O O
with NN O O
information NN O O
from NN O O
2 NN O O
NDP NN O B-Disease
patients NN O O
who NN O O
have NN O O
a NN O O
deletion NN O O
for NN O O
DXS7 NN O O
but NN O O
not NN O O
for NN O O
DSX426 NN O O
, NN O O
our NN O O
data NN O O
indicate NN O O
that NN O O
the NN O O
NDP NN O B-Disease
gene NN O O
lies NN O O
between NN O O
DXS7 NN O O
and NN O O
DXS426 NN O O
on NN O O
proximal NN O O
Xp NN O O
. NN O O

Aberrant NN O O
splicing NN O O
of NN O O
phenylalanine NN O O
hydroxylase NN O O
mRNA NN O O
: NN O O
the NN O O
major NN O O
cause NN O O
for NN O O
phenylketonuria NN O B-Disease
in NN O O
parts NN O O
of NN O O
southern NN O O
Europe NN O O
. NN O O

We NN O O
report NN O O
a NN O O
mutation NN O O
within NN O O
the NN O O
phenylalanine NN O O
hydroxylase NN O O
( NN O O
PAH NN O O
) NN O O
gene NN O O
that NN O O
causes NN O O
aberrant NN O O
splicing NN O O
of NN O O
the NN O O
mRNA NN O O
and NN O O
that NN O O
is NN O O
in NN O O
tight NN O O
association NN O O
with NN O O
chromosomal NN O O
haplotypes NN O O
6 NN O O
, NN O O
10 NN O O
, NN O O
and NN O O
36 NN O O
. NN O O

Because NN O O
of NN O O
the NN O O
high NN O O
frequency NN O O
of NN O O
these NN O O
particular NN O O
haplotypes NN O O
in NN O O
Bulgaria NN O O
, NN O O
Italy NN O O
, NN O O
and NN O O
Turkey NN O O
, NN O O
it NN O O
appears NN O O
to NN O O
be NN O O
one NN O O
of NN O O
the NN O O
more NN O O
frequent NN O O
defects NN O O
in NN O O
the NN O O
PAH NN O O
gene NN O O
causing NN O O
classical NN O O
phenylketonuria NN O B-Disease
in NN O O
this NN O O
part NN O O
of NN O O
Europe NN O O
. NN O O

The NN O O
mutation NN O O
is NN O O
a NN O O
G NN O O
to NN O O
A NN O O
transition NN O O
at NN O O
position NN O O
546 NN O O
in NN O O
intron NN O O
10 NN O O
of NN O O
the NN O O
PAH NN O O
gene NN O O
, NN O O
11 NN O O
bp NN O O
upstream NN O O
from NN O O
the NN O O
intron NN O O
10 NN O O
/ NN O O
exon NN O O
11 NN O O
boundary NN O O
. NN O O

It NN O O
activates NN O O
a NN O O
cryptic NN O O
splice NN O O
site NN O O
and NN O O
results NN O O
in NN O O
an NN O O
in NN O O
- NN O O
frame NN O O
insertion NN O O
of NN O O
9 NN O O
nucleotides NN O O
between NN O O
exon NN O O
10 NN O O
and NN O O
exon NN O O
11 NN O O
of NN O O
the NN O O
processed NN O O
mRNA NN O O
. NN O O

Normal NN O O
amounts NN O O
of NN O O
liver NN O O
PAH NN O O
protein NN O O
are NN O O
present NN O O
in NN O O
homozygous NN O O
patients NN O O
, NN O O
but NN O O
no NN O O
catalytic NN O O
activity NN O O
can NN O O
be NN O O
detected NN O O
. NN O O

This NN O O
loss NN O O
of NN O O
enzyme NN O O
activity NN O O
is NN O O
probably NN O O
caused NN O O
by NN O O
conformational NN O O
changes NN O O
resulting NN O O
from NN O O
the NN O O
insertion NN O O
of NN O O
three NN O O
additional NN O O
amino NN O O
acids NN O O
( NN O O
Gly NN O O
- NN O O
Leu NN O O
- NN O O
Gln NN O O
) NN O O
between NN O O
the NN O O
normal NN O O
sequences NN O O
encoded NN O O
by NN O O
exon NN O O
10 NN O O
and NN O O
exon NN O O
11 NN O O
. NN O O
. NN O O

Gardner NN O B-Disease
syndrome NN O I-Disease
in NN O O
a NN O O
boy NN O O
with NN O O
interstitial NN O O
deletion NN O O
of NN O O
the NN O O
long NN O O
arm NN O O
of NN O O
chromosome NN O O
5 NN O O
. NN O O

We NN O O
described NN O O
a NN O O
15 NN O O
- NN O O
year NN O O
- NN O O
old NN O O
boy NN O O
with NN O O
Gardner NN O B-Disease
syndrome NN O I-Disease
( NN O O
GS NN O B-Disease
) NN O O
, NN O O
mental NN O B-Disease
retardation NN O I-Disease
, NN O O
and NN O O
craniofacial NN O B-Disease
abnormalities NN O I-Disease
. NN O O

High NN O O
- NN O O
resolution NN O O
banding NN O O
analysis NN O O
showed NN O O
an NN O O
interstitial NN O O
deletion NN O O
of NN O O
the NN O O
long NN O O
arm NN O O
of NN O O
chromosome NN O O
5 NN O O
( NN O O
q22 NN O O
. NN O O
1 NN O O
- NN O O
- NN O O
- NN O O
- NN O O
q31 NN O O
1 NN O O
- NN O O
- NN O O
- NN O O
- NN O O
q31 NN O O
. NN O O
1 NN O O
) NN O O
. NN O O

The NN O O
breakpoints NN O O
in NN O O
the NN O O
present NN O O
case NN O O
and NN O O
in NN O O
3 NN O O
previously NN O O
reported NN O O
5q NN O O
- NN O O
patients NN O O
with NN O O
adenomatous NN O B-Disease
polyposis NN O I-Disease
coli NN O I-Disease
suggest NN O O
that NN O O
the NN O O
gene NN O O
responsible NN O O
for NN O O
GS NN O B-Disease
/ NN O O
or NN O O
familial NN O B-Disease
polyposis NN O I-Disease
coli NN O I-Disease
( NN O O
FPC NN O B-Disease
) NN O O
is NN O O
in NN O O
the NN O O
5q22 NN O O
region NN O O
, NN O O
a NN O O
result NN O O
consistent NN O O
with NN O O
the NN O O
findings NN O O
of NN O O
linkage NN O O
studies NN O O

Huntington NN O B-Disease
disease NN O I-Disease
and NN O O
childhood NN O O
- NN O O
onset NN O O
Tourette NN O B-Disease
syndrome NN O I-Disease
. NN O O

A NN O O
40 NN O O
- NN O O
year NN O O
- NN O O
old NN O O
man NN O O
with NN O O
childhood NN O O
- NN O O
onset NN O O
Tourette NN O B-Disease
syndrome NN O I-Disease
( NN O O
TS NN O B-Disease
) NN O O
developed NN O O
Huntington NN O B-Disease
disease NN O I-Disease
( NN O O
HD NN O B-Disease
) NN O O
. NN O O

We NN O O
believe NN O O
this NN O O
to NN O O
be NN O O
the NN O O
first NN O O
reported NN O O
case NN O O
of NN O O
childhood NN O O
- NN O O
onset NN O O
TS NN O B-Disease
with NN O O
adult NN O O
onset NN O O
HD NN O B-Disease
. NN O O

Discovery NN O O
of NN O O
other NN O O
cases NN O O
with NN O O
both NN O O
disorders NN O O
may NN O O
provide NN O O
clues NN O O
to NN O O
the NN O O
pathophysiology NN O O
of NN O O
both NN O O
conditions NN O O
. NN O O
. NN O O

Sequence NN O O
of NN O O
DNA NN O O
flanking NN O O
the NN O O
exons NN O O
of NN O O
the NN O O
HEXA NN O O
gene NN O O
, NN O O
and NN O O
identification NN O O
of NN O O
mutations NN O O
in NN O O
Tay NN O B-Disease
- NN O I-Disease
Sachs NN O I-Disease
disease NN O I-Disease
. NN O O

The NN O O
rapid NN O O
identification NN O O
of NN O O
mutations NN O O
causing NN O O
Tay NN O B-Disease
- NN O I-Disease
Sachs NN O I-Disease
disease NN O I-Disease
requires NN O O
the NN O O
capacity NN O O
to NN O O
readily NN O O
screen NN O O
the NN O O
regions NN O O
of NN O O
the NN O O
HEXA NN O O
gene NN O O
most NN O O
likely NN O O
to NN O O
be NN O O
affected NN O O
by NN O O
mutation NN O O
. NN O O

We NN O O
have NN O O
sequenced NN O O
the NN O O
portions NN O O
of NN O O
the NN O O
introns NN O O
flanking NN O O
each NN O O
of NN O O
the NN O O
14 NN O O
HEXA NN O O
exons NN O O
in NN O O
order NN O O
to NN O O
specify NN O O
oligonucleotide NN O O
primers NN O O
for NN O O
the NN O O
PCR NN O O
- NN O O
dependent NN O O
amplification NN O O
of NN O O
each NN O O
exon NN O O
and NN O O
splice NN O O
- NN O O
junction NN O O
sequence NN O O
. NN O O

The NN O O
amplified NN O O
products NN O O
were NN O O
analyzed NN O O
, NN O O
by NN O O
electrophoresis NN O O
in NN O O
nondenaturing NN O O
polyacrylamide NN O O
gels NN O O
, NN O O
for NN O O
the NN O O
presence NN O O
of NN O O
either NN O O
heteroduplexes NN O O
, NN O O
derived NN O O
from NN O O
the NN O O
annealing NN O O
of NN O O
normal NN O O
and NN O O
mutant NN O O
DNA NN O O
strands NN O O
, NN O O
or NN O O
single NN O O
- NN O O
strand NN O O
conformational NN O O
polymorphisms NN O O
( NN O O
SSCP NN O O
) NN O O
, NN O O
derived NN O O
from NN O O
the NN O O
renaturation NN O O
of NN O O
single NN O O
- NN O O
stranded NN O O
DNA NN O O
. NN O O

Five NN O O
novel NN O O
mutations NN O O
from NN O O
Tay NN O B-Disease
- NN O I-Disease
Sachs NN O I-Disease
disease NN O I-Disease
patients NN O O
were NN O O
detected NN O O
a NN O O
5 NN O O
- NN O O
bp NN O O
deletion NN O O
of NN O O
TCTCC NN O O
in NN O O
IVS NN O O
- NN O O
9 NN O O
; NN O O
a NN O O
2 NN O O
- NN O O
bp NN O O
deletion NN O O
of NN O O
TG NN O O
in NN O O
exon NN O O
5 NN O O
; NN O O
G78 NN O O
to NN O O
A NN O O
, NN O O
giving NN O O
a NN O O
stop NN O O
codon NN O O
in NN O O
exon NN O O
1 NN O O
; NN O O
G533 NN O O
to NN O O
T NN O O
in NN O O
exon NN O O
5 NN O O
, NN O O
producing NN O O
the NN O O
third NN O O
amino NN O O
acid NN O O
substitution NN O O
detected NN O O
at NN O O
this NN O O
site NN O O
; NN O O
and NN O O
G NN O O
to NN O O
C NN O O
at NN O O
position NN O O
1 NN O O
of NN O O
IVS NN O O
- NN O O
2 NN O O
, NN O O
expected NN O O
to NN O O
produce NN O O
abnormal NN O O
splicing NN O O
. NN O O

In NN O O
addition NN O O
, NN O O
two NN O O
mutations NN O O
, NN O O
( NN O O
G1496 NN O O
to NN O O
A NN O O
in NN O O
exon NN O O
13 NN O O
and NN O O
a NN O O
4 NN O O
- NN O O
bp NN O O
insertion NN O O
in NN O O
exon NN O O
11 NN O O
) NN O O
that NN O O
have NN O O
previously NN O O
been NN O O
reported NN O O
were NN O O
identified NN O O
. NN O O
. NN O O

Molecular NN O O
characterization NN O O
of NN O O
two NN O O
galactosemia NN O B-Disease
mutations NN O O
: NN O O
correlation NN O O
of NN O O
mutations NN O O
with NN O O
highly NN O O
conserved NN O O
domains NN O O
in NN O O
galactose NN O O
- NN O O
1 NN O O
- NN O O
phosphate NN O O
uridyl NN O O
transferase NN O O
. NN O O

Galactosemia NN O B-Disease
is NN O O
an NN O O
autosomal NN O B-Disease
recessive NN O I-Disease
disorder NN O I-Disease
of NN O I-Disease
human NN O I-Disease
galactose NN O I-Disease
metabolism NN O I-Disease
caused NN O O
by NN O O
deficiency NN O B-Disease
of NN O I-Disease
the NN O I-Disease
enzyme NN O I-Disease
galactose NN O I-Disease
- NN O I-Disease
1 NN O I-Disease
- NN O I-Disease
phosphate NN O I-Disease
uridyl NN O I-Disease
transferase NN O I-Disease
( NN O O
GALT NN O O
) NN O O
. NN O O

The NN O O
molecular NN O O
basis NN O O
of NN O O
this NN O O
disorder NN O O
is NN O O
at NN O O
present NN O O
not NN O O
well NN O O
understood NN O O
. NN O O

We NN O O
report NN O O
here NN O O
two NN O O
missense NN O O
mutations NN O O
which NN O O
result NN O O
in NN O O
low NN O O
or NN O O
undetectable NN O O
enzymatic NN O O
activity NN O O
. NN O O

First NN O O
, NN O O
we NN O O
identified NN O O
at NN O O
nucleotide NN O O
591 NN O O
a NN O O
transition NN O O
which NN O O
substitutes NN O O
glutamine NN O O
188 NN O O
by NN O O
arginine NN O O
. NN O O

The NN O O
mutated NN O O
glutamine NN O O
is NN O O
not NN O O
only NN O O
highly NN O O
conserved NN O O
in NN O O
evolution NN O O
( NN O O
conserved NN O O
also NN O O
in NN O O
Escherichia NN O O
coli NN O O
and NN O O
Saccharomyces NN O O
cerevisiae NN O O
) NN O O
, NN O O
but NN O O
is NN O O
also NN O O
two NN O O
amino NN O O
acid NN O O
residues NN O O
downstream NN O O
from NN O O
the NN O O
active NN O O
site NN O O
histidine NN O O
- NN O O
proline NN O O
- NN O O
histidine NN O O
triad NN O O
and NN O O
results NN O O
in NN O O
about NN O O
10 NN O O
% NN O O
of NN O O
normal NN O O
enzymatic NN O O
activity NN O O
. NN O O

The NN O O
arginine NN O O
188 NN O O
mutation NN O O
is NN O O
the NN O O
most NN O O
common NN O O
galactosemia NN O B-Disease
mutation NN O O
characterized NN O O
to NN O O
date NN O O
. NN O O

It NN O O
accounts NN O O
for NN O O
one NN O O
- NN O O
fourth NN O O
of NN O O
the NN O O
galactosemia NN O B-Disease
alleles NN O O
studied NN O O
. NN O O

Second NN O O
, NN O O
we NN O O
report NN O O
the NN O O
substitution NN O O
of NN O O
arginine NN O O
333 NN O O
by NN O O
tryptophan NN O O
, NN O O
caused NN O O
by NN O O
a NN O O
transition NN O O
at NN O O
nucleotide NN O O
1025 NN O O
. NN O O

The NN O O
area NN O O
surrounding NN O O
this NN O O
missense NN O O
mutation NN O O
is NN O O
the NN O O
most NN O O
highly NN O O
conserved NN O O
domain NN O O
in NN O O
the NN O O
homologous NN O O
enzymes NN O O
from NN O O
E NN O O
. NN O O
coli NN O O
, NN O O
yeast NN O O
, NN O O
and NN O O
humans NN O O
, NN O O
and NN O O
this NN O O
mutation NN O O
results NN O O
in NN O O
undetectable NN O O
enzymatic NN O O
activity NN O O
, NN O O
suggesting NN O O
that NN O O
this NN O O
is NN O O
a NN O O
severe NN O O
mutation NN O O
. NN O O

This NN O O
second NN O O
mutation NN O O
appears NN O O
to NN O O
be NN O O
rare NN O O
, NN O O
since NN O O
it NN O O
was NN O O
found NN O O
only NN O O
in NN O O
the NN O O
patient NN O O
we NN O O
sequenced NN O O
. NN O O

Our NN O O
data NN O O
provide NN O O
further NN O O
evidence NN O O
for NN O O
the NN O O
heterogeneity NN O O
of NN O O
galactosemia NN O B-Disease
at NN O O
the NN O O
molecular NN O O
level NN O O
, NN O O
heterogeneity NN O O
which NN O O
might NN O O
be NN O O
related NN O O
to NN O O
the NN O O
variable NN O O
clinical NN O O
outcome NN O O
observed NN O O
in NN O O
this NN O O
disorder NN O O
. NN O O
. NN O O

Hypoxanthine NN O B-Disease
- NN O I-Disease
guanine NN O I-Disease
phosphoribosyltransferase NN O I-Disease
deficiency NN O I-Disease
: NN O O
analysis NN O O
of NN O O
HPRT NN O O
mutations NN O O
by NN O O
direct NN O O
sequencing NN O O
and NN O O
allele NN O O
- NN O O
specific NN O O
amplification NN O O
. NN O O

The NN O O
Lesch NN O B-Disease
- NN O I-Disease
Nyhan NN O I-Disease
syndrome NN O I-Disease
is NN O O
a NN O O
severe NN O O
X NN O B-Disease
chromosome NN O I-Disease
- NN O I-Disease
linked NN O I-Disease
human NN O I-Disease
disease NN O I-Disease
caused NN O O
by NN O O
a NN O O
virtual NN O O
absence NN O B-Disease
of NN O I-Disease
hypoxanthine NN O I-Disease
- NN O I-Disease
guanine NN O I-Disease
phosphoribosyltransferase NN O I-Disease
( NN O I-Disease
HPRT NN O I-Disease
) NN O I-Disease
activity NN O I-Disease
. NN O O

A NN O O
partial NN O O
deficiency NN O O
in NN O O
the NN O O
activity NN O O
of NN O O
this NN O O
enzyme NN O O
can NN O O
result NN O O
in NN O O
gouty NN O B-Disease
arthritis NN O I-Disease
. NN O O

To NN O O
determine NN O O
the NN O O
genetic NN O O
basis NN O O
for NN O O
reduction NN O O
or NN O O
loss NN O O
of NN O O
enzyme NN O O
activity NN O O
, NN O O
we NN O O
have NN O O
amplified NN O O
and NN O O
sequenced NN O O
the NN O O
coding NN O O
region NN O O
of NN O O
HPRT NN O O
cDNA NN O O
from NN O O
four NN O O
patients NN O O
one NN O O
with NN O O
Lesch NN O B-Disease
- NN O I-Disease
Nyhan NN O I-Disease
syndrome NN O I-Disease
( NN O O
HPRTPerth NN O O
) NN O O
and NN O O
three NN O O
with NN O O
partial NN O B-Disease
deficiencies NN O I-Disease
of NN O I-Disease
HPRT NN O I-Disease
activity NN O I-Disease
, NN O O
which NN O O
have NN O O
been NN O O
designated NN O O
HPRTUrangan NN O O
, NN O O
HPRTSwan NN O O
and NN O O
HPRTToowong NN O O
. NN O O

In NN O O
all NN O O
four NN O O
patients NN O O
, NN O O
the NN O O
only NN O O
mutation NN O O
identified NN O O
was NN O O
a NN O O
single NN O O
base NN O O
substitution NN O O
in NN O O
exons NN O O
2 NN O O
or NN O O
3 NN O O
of NN O O
the NN O O
coding NN O O
region NN O O
, NN O O
which NN O O
in NN O O
each NN O O
case NN O O
predicts NN O O
a NN O O
single NN O O
amino NN O O
acid NN O O
substitution NN O O
in NN O O
the NN O O
translated NN O O
protein NN O O
. NN O O

Each NN O O
base NN O O
change NN O O
was NN O O
confirmed NN O O
by NN O O
allele NN O O
- NN O O
specific NN O O
amplification NN O O
of NN O O
the NN O O
patients NN O O
genomic NN O O
DNA NN O O
. NN O O

It NN O O
is NN O O
interesting NN O O
to NN O O
note NN O O
that NN O O
the NN O O
mutation NN O O
found NN O O
for NN O O
HPRTPerth NN O O
is NN O O
identical NN O O
to NN O O
that NN O O
reported NN O O
for NN O O
HPRTFlint NN O O
. NN O O

It NN O O
appears NN O O
that NN O O
the NN O O
two NN O O
mutations NN O O
are NN O O
de NN O O
novo NN O O
events NN O O
. NN O O
. NN O O

Molecular NN O O
and NN O O
metabolic NN O O
basis NN O O
for NN O O
the NN O O
metabolic NN O B-Disease
disorder NN O I-Disease
normotriglyceridemic NN O B-Disease
abetalipoproteinemia NN O I-Disease
. NN O O

We NN O O
have NN O O
previously NN O O
described NN O O
a NN O O
disorder NN O O
, NN O O
normotriglyceridemic NN O B-Disease
abetalipoproteinemia NN O I-Disease
, NN O O
that NN O O
is NN O O
characterized NN O O
by NN O O
the NN O O
virtual NN O O
absence NN O O
of NN O O
plasma NN O O
low NN O O
density NN O O
lipoproteins NN O O
and NN O O
complete NN O O
absence NN O O
of NN O O
apoB NN O O
- NN O O
100 NN O O
, NN O O
but NN O O
with NN O O
apparently NN O O
normal NN O O
secretion NN O O
of NN O O
triglyceride NN O O
- NN O O
rich NN O O
lipoproteins NN O O
containing NN O O
apoB NN O O
- NN O O
48 NN O O
. NN O O

The NN O O
patients NN O O
plasma NN O O
lipoproteins NN O O
were NN O O
shown NN O O
on NN O O
polyacrylamide NN O O
gels NN O O
and NN O O
by NN O O
antibody NN O O
mapping NN O O
to NN O O
have NN O O
a NN O O
new NN O O
truncated NN O O
apoB NN O O
variant NN O O
, NN O O
apoB NN O O
- NN O O
50 NN O O
, NN O O
circulating NN O O
along NN O O
with NN O O
her NN O O
apoB NN O O
- NN O O
48 NN O O
. NN O O

We NN O O
have NN O O
found NN O O
this NN O O
individual NN O O
to NN O O
be NN O O
homozygous NN O O
for NN O O
a NN O O
single NN O O
C NN O O
- NN O O
to NN O O
- NN O O
T NN O O
nucleotide NN O O
substitution NN O O
at NN O O
apoB NN O O
codon NN O O
2252 NN O O
, NN O O
which NN O O
produces NN O O
a NN O O
premature NN O O
in NN O O
- NN O O
frame NN O O
stop NN O O
codon NN O O
. NN O O

Thus NN O O
, NN O O
this NN O O
is NN O O
a NN O O
rare NN O O
example NN O O
of NN O O
homozygous NN O B-Disease
hypobetalipoproteinemia NN O I-Disease
. NN O O

Electron NN O O
photomicrographs NN O O
revealed NN O O
that NN O O
the NN O O
diameters NN O O
of NN O O
particles NN O O
in NN O O
the NN O O
d NN O O
less NN O O
than NN O O
1 NN O O
. NN O O

006 NN O O
g NN O O
/ NN O O
ml NN O O
lipoprotein NN O O
fraction NN O O
, NN O O
in NN O O
both NN O O
the NN O O
postprandial NN O O
and NN O O
postabsorptive NN O O
state NN O O
, NN O O
are NN O O
bimodally NN O O
distributed NN O O
. NN O O

The NN O O
molar NN O O
ratio NN O O
of NN O O
apoE NN O O
to NN O O
apoB NN O O
in NN O O
these NN O O
particles NN O O
is NN O O
3 NN O O
. NN O O

5 NN O O
1 NN O O
, NN O O
similar NN O O
to NN O O
normal NN O O
VLDL NN O O
. NN O O

The NN O O
plasma NN O O
LDL NN O O
interval NN O O
contains NN O O
both NN O O
spherical NN O O
and NN O O
cuboidal NN O O
particles NN O O
. NN O O

Autologous NN O O
reinfusion NN O O
of NN O O
labeled NN O O
d NN O O
less NN O O
than NN O O
1 NN O O
. NN O O

006 NN O O
g NN O O
/ NN O O
ml NN O O
lipoproteins NN O O
showed NN O O
exponential NN O O
disappearance NN O O
from NN O O
plasma NN O O
, NN O O
with NN O O
an NN O O
apparent NN O O
half NN O O
- NN O O
removal NN O O
time NN O O
of NN O O
50 NN O O
min NN O O
, NN O O
somewhat NN O O
slower NN O O
than NN O O
for NN O O
normal NN O O
chylomicrons NN O O
but NN O O
within NN O O
the NN O O
normal NN O O
range NN O O
for NN O O
VLDL NN O O
. NN O O

The NN O O
calculated NN O O
production NN O O
rate NN O O
for NN O O
apoB NN O O
was NN O O
within NN O O
the NN O O
normal NN O O
range NN O O
in NN O O
this NN O O
subject NN O O
. NN O O

A NN O O
single NN O O
origin NN O O
of NN O O
phenylketonuria NN O B-Disease
in NN O O
Yemenite NN O O
Jews NN O O
. NN O O

Phenylketonuria NN O B-Disease
( NN O O
PKU NN O B-Disease
) NN O O
is NN O O
a NN O O
metabolic NN O B-Disease
disease NN O I-Disease
caused NN O O
by NN O O
recessive NN O O
mutations NN O O
of NN O O
the NN O O
gene NN O O
encoding NN O O
the NN O O
hepatic NN O O
enzyme NN O O
phenylalanine NN O O
hydroxylase NN O O
( NN O O
PAH NN O O
) NN O O
. NN O O

The NN O O
incidence NN O O
of NN O O
PKU NN O B-Disease
varies NN O O
widely NN O O
across NN O O
different NN O O
geographic NN O O
areas NN O O
, NN O O
and NN O O
is NN O O
highest NN O O
( NN O O
about NN O O
1 NN O O
in NN O O
5 NN O O
, NN O O
000 NN O O
live NN O O
births NN O O
) NN O O
in NN O O
Ireland NN O O
and NN O O
western NN O O
Scotland NN O O
, NN O O
and NN O O
among NN O O
Yemenite NN O O
Jews NN O O
. NN O O

A NN O O
limited NN O O
number NN O O
of NN O O
point NN O O
mutations NN O O
account NN O O
for NN O O
most NN O O
of NN O O
the NN O O
PKU NN O B-Disease
cases NN O O
in NN O O
the NN O O
European NN O O
population NN O O
. NN O O

Here NN O O
we NN O O
report NN O O
that NN O O
a NN O O
single NN O O
molecular NN O O
defect NN O O
- NN O O
- NN O O
a NN O O
deletion NN O O
spanning NN O O
the NN O O
third NN O O
exon NN O O
of NN O O
the NN O O
PAH NN O O
gene NN O O
- NN O O
- NN O O
is NN O O
responsible NN O O
for NN O O
all NN O O
the NN O O
PKU NN O B-Disease
cases NN O O
among NN O O
the NN O O
Yemenite NN O O
Jews NN O O
. NN O O

Examination NN O O
of NN O O
a NN O O
random NN O O
sample NN O O
of NN O O
Yemenite NN O O
Jews NN O O
using NN O O
a NN O O
molecular NN O O
probe NN O O
that NN O O
detects NN O O
the NN O O
carriers NN O O
of NN O O
this NN O O
deletion NN O O
indicated NN O O
a NN O O
high NN O O
frequency NN O O
of NN O O
the NN O O
defective NN O O
gene NN O O
in NN O O
this NN O O
community NN O O
. NN O O

Although NN O O
the NN O O
deleted NN O O
PAH NN O O
gene NN O O
was NN O O
traced NN O O
to NN O O
25 NN O O
different NN O O
locations NN O O
throughout NN O O
Yemen NN O O
, NN O O
family NN O O
histories NN O O
and NN O O
official NN O O
documents NN O O
of NN O O
the NN O O
Yemenite NN O O
Jewish NN O O
community NN O O
showed NN O O
that NN O O
the NN O O
common NN O O
ancestor NN O O
of NN O O
all NN O O
the NN O O
carriers NN O O
of NN O O
this NN O O
genetic NN O B-Disease
defect NN O I-Disease
lived NN O O
in NN O O
Sana NN O O
, NN O O
the NN O O
capital NN O O
of NN O O
Yemen NN O O
, NN O O
before NN O O
the NN O O
eighteenth NN O O
century NN O O
. NN O O
. NN O O

Linkage NN O O
of NN O O
aspartylglucosaminuria NN O B-Disease
( NN O O
AGU NN O B-Disease
) NN O O
to NN O O
marker NN O O
loci NN O O
on NN O O
the NN O O
long NN O O
arm NN O O
of NN O O
chromosome NN O O
4 NN O O
. NN O O

Aspartylglucosaminuria NN O B-Disease
( NN O O
AGU NN O B-Disease
) NN O O
is NN O O
caused NN O O
by NN O O
deficient NN O O
activity NN O O
of NN O O
the NN O O
enzyme NN O O
aspartylglucosaminidase NN O O
( NN O O
AGA NN O O
) NN O O
. NN O O

The NN O O
structural NN O O
gene NN O O
for NN O O
AGA NN O O
has NN O O
been NN O O
assigned NN O O
to NN O O
the NN O O
region NN O O
4q21 NN O O
- NN O O
qter NN O O
of NN O O
chromosome NN O O
4 NN O O
. NN O O

We NN O O
have NN O O
studied NN O O
the NN O O
map NN O O
position NN O O
of NN O O
the NN O O
AGU NN O O
locus NN O O
in NN O O
relation NN O O
to NN O O
other NN O O
marker NN O O
loci NN O O
on NN O O
the NN O O
long NN O O
arm NN O O
of NN O O
chromosome NN O O
4 NN O O
using NN O O
linkage NN O O
analyses NN O O
. NN O O

Restriction NN O O
fragment NN O O
length NN O O
polymorphism NN O O
alleles NN O O
for NN O O
the NN O O
ADH2 NN O O
, NN O O
ADH3 NN O O
, NN O O
EGF NN O O
, NN O O
FG NN O O
alpha NN O O
and NN O O
FG NN O O
beta NN O O
loci NN O O
and NN O O
blood NN O O
group NN O O
antigens NN O O
for NN O O
the NN O O
MNS NN O O
locus NN O O
were NN O O
determined NN O O
in NN O O
a NN O O
panel NN O O
of NN O O
12 NN O O
Finnish NN O O
AGU NN O B-Disease
families NN O O
. NN O O

The NN O O
heterozygous NN O O
family NN O O
members NN O O
were NN O O
identified NN O O
by NN O O
reduced NN O O
activity NN O O
of NN O O
AGA NN O O
in NN O O
lymphocytes NN O O
. NN O O

Linkage NN O O
studies NN O O
were NN O O
performed NN O O
using NN O O
both NN O O
pairwise NN O O
and NN O O
multipoint NN O O
analyses NN O O
. NN O O

Loose NN O O
linkage NN O O
of NN O O
the NN O O
AGU NN O B-Disease
locus NN O O
to NN O O
the NN O O
FG NN O O
and NN O O
MNS NN O O
loci NN O O
was NN O O
observed NN O O
( NN O O
z NN O O
= NN O O
1 NN O O
. NN O O
16 NN O O
, NN O O
z NN O O
= NN O O
1 NN O O
. NN O O
39 NN O O
, NN O O
respectively NN O O
) NN O O
. NN O O

Multipoint NN O O
analysis NN O O
to NN O O
the NN O O
fixed NN O O
map NN O O
[ NN O O
ADH NN O O
- NN O O
( NN O O
0 NN O O
. NN O O
03 NN O O
) NN O O
- NN O O
EGF NN O O
- NN O O
( NN O O
0 NN O O
. NN O O
35 NN O O
) NN O O
- NN O O
FG NN O O
- NN O O
( NN O O
0 NN O O
. NN O O
11 NN O O
) NN O O
- NN O O
MNS NN O O
] NN O O
suggests NN O O
that NN O O
the NN O O
location NN O O
of NN O O
the NN O O
AGU NN O O
locus NN O O
is NN O O
0 NN O O
. NN O O

05 NN O O
- NN O O
0 NN O O
. NN O O

30 NN O O
recombination NN O O
units NN O O
distal NN O O
to NN O O
MNS NN O O
( NN O O
z NN O O
= NN O O
3 NN O O
. NN O O
03 NN O O
) NN O O
. NN O O

The NN O O
order NN O O
cen NN O O
- NN O O
ADH NN O O
- NN O O
EGF NN O O
- NN O O
FG NN O O
- NN O O
MNS NN O O
- NN O O
AGU NN O O
is NN O O
35 NN O O
times NN O O
more NN O O
likely NN O O
than NN O O
the NN O O
next NN O O
best NN O O
order NN O O
cen NN O O
- NN O O
ADH NN O O
- NN O O
EGF NN O O
- NN O O
AGU NN O O
- NN O O
FG NN O O
- NN O O
MNS NN O O
. NN O O

Linkage NN O O
relationships NN O O
of NN O O
the NN O O
apolipoprotein NN O O
C1 NN O O
gene NN O O
and NN O O
a NN O O
cytochrome NN O O
P450 NN O O
gene NN O O
( NN O O
CYP2A NN O O
) NN O O
to NN O O
myotonic NN O B-Disease
dystrophy NN O I-Disease
. NN O O

We NN O O
have NN O O
studied NN O O
the NN O O
genetic NN O O
linkage NN O O
of NN O O
two NN O O
markers NN O O
, NN O O
the NN O O
apolipoprotein NN O O
C1 NN O O
( NN O O
APOC1 NN O O
) NN O O
gene NN O O
and NN O O
a NN O O
cytochrome NN O O
P450 NN O O
( NN O O
CYP2A NN O O
) NN O O
gene NN O O
, NN O O
in NN O O
relation NN O O
to NN O O
the NN O O
gene NN O O
for NN O O
myotonic NN O B-Disease
dystrophy NN O I-Disease
( NN O O
DM NN O B-Disease
) NN O O
. NN O O

A NN O O
peak NN O O
lod NN O O
score NN O O
of NN O O
9 NN O O
. NN O O

29 NN O O
at NN O O
2 NN O O
cM NN O O
was NN O O
observed NN O O
for NN O O
APOC1 NN O O
- NN O O
DM NN O O
, NN O O
with NN O O
a NN O O
lod NN O O
score NN O O
of NN O O
8 NN O O
. NN O O

55 NN O O
at NN O O
4 NN O O
cM NN O O
for NN O O
CYP2A NN O O
- NN O O
DM NN O O
. NN O O

These NN O O
two NN O O
markers NN O O
also NN O O
show NN O O
close NN O O
linkage NN O O
to NN O O
each NN O O
other NN O O
( NN O O
theta NN O O
max NN O O
= NN O O
0 NN O O
. NN O O
05 NN O O
, NN O O
Zmax NN O O
= NN O O
9 NN O O
. NN O O
09 NN O O
) NN O O
. NN O O

From NN O O
examination NN O O
of NN O O
the NN O O
genotypes NN O O
of NN O O
the NN O O
recombinant NN O O
individuals NN O O
, NN O O
CYP2A NN O O
appears NN O O
to NN O O
map NN O O
proximal NN O O
to NN O O
DM NN O O
because NN O O
in NN O O
one NN O O
recombinant NN O O
individual NN O O
CYP2A NN O O
, NN O O
APOC2 NN O O
and NN O O
CKMM NN O O
had NN O O
all NN O O
recombined NN O O
with NN O O
DM NN O O
. NN O O

Evidence NN O O
from NN O O
another NN O O
CYP2A NN O O
- NN O O
DM NN O O
recombinant NN O O
individual NN O O
places NN O O
CYP2A NN O O
proximal NN O O
to NN O O
APOC2 NN O O
and NN O O
CKMM NN O O
. NN O O

Localisation NN O O
of NN O O
CYP2A NN O O
on NN O O
a NN O O
panel NN O O
of NN O O
somatic NN O O
cell NN O O
hybrids NN O O
also NN O O
suggests NN O O
that NN O O
it NN O O
is NN O O
proximal NN O O
to NN O O
DM NN O O
and NN O O
APOC2 NN O O
/ NN O O
C1 NN O O
/ NN O O
E NN O O
gene NN O O
cluster NN O O
. NN O O

Genetic NN O O
linkage NN O O
map NN O O
of NN O O
six NN O O
polymorphic NN O O
DNA NN O O
markers NN O O
around NN O O
the NN O O
gene NN O O
for NN O O
familial NN O B-Disease
adenomatous NN O I-Disease
polyposis NN O I-Disease
on NN O O
chromosome NN O O
5 NN O O
. NN O O

A NN O O
genetic NN O O
linkage NN O O
map NN O O
of NN O O
six NN O O
polymorphic NN O O
DNA NN O O
markers NN O O
close NN O O
to NN O O
the NN O O
gene NN O O
( NN O O
APC NN O O
) NN O O
for NN O O
familial NN O B-Disease
adenomatous NN O I-Disease
polyposis NN O I-Disease
( NN O O
FAP NN O B-Disease
) NN O O
on NN O O
chromosome NN O O
5q NN O O
is NN O O
reported NN O O
. NN O O

One NN O O
hundred NN O O
fifty NN O O
- NN O O
five NN O O
typed NN O O
members NN O O
of NN O O
nine NN O O
FAP NN O B-Disease
kindred NN O O
provided NN O O
more NN O O
than NN O O
90 NN O O
meioses NN O O
for NN O O
linkage NN O O
analysis NN O O
. NN O O

A NN O O
number NN O O
of NN O O
crucial NN O O
recombination NN O O
events NN O O
have NN O O
been NN O O
identified NN O O
which NN O O
are NN O O
informative NN O O
at NN O O
three NN O O
or NN O O
more NN O O
loci NN O O
, NN O O
allowing NN O O
confident NN O O
ordering NN O O
of NN O O
parts NN O O
of NN O O
the NN O O
map NN O O
. NN O O

There NN O O
was NN O O
no NN O O
evidence NN O O
of NN O O
genetic NN O O
heterogeneity NN O O
, NN O O
with NN O O
all NN O O
families NN O O
showing NN O O
linkage NN O O
of NN O O
at NN O O
least NN O O
one NN O O
chromosome NN O O
5 NN O O
marker NN O O
to NN O O
the NN O O
gene NN O O
. NN O O

Recombination NN O O
data NN O O
and NN O O
two NN O O
- NN O O
point NN O O
linkage NN O O
analysis NN O O
support NN O O
a NN O O
locus NN O O
order NN O O
of NN O O
centromere NN O O
- NN O O
pi NN O O
227 NN O O
- NN O O
C11P11 NN O O
- NN O O
ECB27 NN O O
- NN O O
L5 NN O O
. NN O O

62 NN O O
- NN O O
APC NN O O
- NN O O
EF5 NN O O
62 NN O O
- NN O O
APC NN O O
- NN O O
EF5 NN O O
. NN O O

44 NN O O
- NN O O
YN5 NN O O
44 NN O O
- NN O O
YN5 NN O O
. NN O O

48 NN O O
- NN O O
telomer NN O O
e NN O O
, NN O O
although NN O O
EF5 NN O O
. NN O O

44 NN O O
could NN O O
lie NN O O
in NN O O
the NN O O
interval NN O O
L5 NN O O
. NN O O

62 NN O O
- NN O O
APC NN O O
or NN O O
ECB27 NN O O
- NN O O
L5 NN O O
. NN O O

62 NN O O
. NN O O

No NN O O
recombinants NN O O
were NN O O
identified NN O O
between NN O O
APC NN O O
and NN O O
either NN O O
EF5 NN O O
. NN O O

44 NN O O
or NN O O
YN5 NN O O
. NN O O

48 NN O O
, NN O O
but NN O O
published NN O O
deletion NN O O
mapping NN O O
in NN O O
colorectal NN O B-Disease
carcinomas NN O I-Disease
and NN O O
linkage NN O O
analysis NN O O
in NN O O
FAP NN O B-Disease
suggest NN O O
that NN O O
YN5 NN O O
. NN O O

48 NN O O
is NN O O
1 NN O O
- NN O O
3 NN O O
cM NN O O
from NN O O
APC NN O O
. NN O O

The NN O O
present NN O O
study NN O O
suggests NN O O
that NN O O
YN5 NN O O
. NN O O

48 NN O O
and NN O O
L5 NN O O
. NN O O

62 NN O O
delineate NN O O
a NN O O
small NN O O
region NN O O
of NN O O
chromosome NN O O
5 NN O O
within NN O O
which NN O O
the NN O O
EF5 NN O O
. NN O O

44 NN O O
locus NN O O
lies NN O O
very NN O O
close NN O O
to NN O O
the NN O O
APC NN O B-Disease
gene NN O O
. NN O O

These NN O O
data NN O O
not NN O O
only NN O O
allow NN O O
use NN O O
of NN O O
flanking NN O O
markers NN O O
for NN O O
presymptomatic NN O O
diagnosis NN O O
of NN O O
FAP NN O B-Disease
but NN O O
also NN O O
provide NN O O
a NN O O
high NN O O
- NN O O
density NN O O
map NN O O
of NN O O
the NN O O
region NN O O
for NN O O
isolation NN O O
of NN O O
the NN O O
APC NN O B-Disease
gene NN O O
itself NN O O
and NN O O
for NN O O
further NN O O
assessment NN O O
of NN O O
the NN O O
role NN O O
of NN O O
chromosome NN O O
5 NN O O
deletions NN O O
in NN O O
the NN O O
biology NN O O
of NN O O
sporadic NN O O
colorectal NN O B-Disease
cancer NN O I-Disease
. NN O O

Serum NN O O
amyloid NN O O
A NN O O
and NN O O
P NN O O
protein NN O O
genes NN O O
in NN O O
familial NN O B-Disease
Mediterranean NN O I-Disease
fever NN O I-Disease
. NN O O

Two NN O O
recent NN O O
studies NN O O
have NN O O
suggested NN O O
the NN O O
involvement NN O O
of NN O O
serum NN O O
amyloid NN O O
A NN O O
( NN O O
SAA NN O O
) NN O O
and NN O O
P NN O O
( NN O O
APCS NN O O
) NN O O
genes NN O O
in NN O O
familial NN O B-Disease
Mediterranean NN O I-Disease
fever NN O I-Disease
( NN O O
MEF NN O B-Disease
) NN O O
. NN O O

To NN O O
test NN O O
the NN O O
role NN O O
of NN O O
SAA NN O O
and NN O O
APCS NN O O
in NN O O
MEF NN O B-Disease
and NN O O
MEF NN O B-Disease
- NN O I-Disease
amyloidosis NN O I-Disease
, NN O O
we NN O O
studied NN O O
17 NN O O
informative NN O O
families NN O O
( NN O O
15 NN O O
Armenians NN O O
, NN O O
2 NN O O
non NN O O
- NN O O
Ashkenazi NN O O
Jews NN O O
) NN O O
and NN O O
8 NN O O
MEF NN O B-Disease
patients NN O O
with NN O O
amyloidosis NN O B-Disease
using NN O O
a NN O O
candidate NN O O
gene NN O O
approach NN O O
. NN O O

No NN O O
evidence NN O O
for NN O O
any NN O O
MEF NN O B-Disease
- NN O O
associated NN O O
polymorphism NN O O
was NN O O
found NN O O
in NN O O
any NN O O
of NN O O
the NN O O
41 NN O O
Armenian NN O O
and NN O O
Jewish NN O O
MEF NN O B-Disease
patients NN O O
tested NN O O
. NN O O

Our NN O O
family NN O O
studies NN O O
allowed NN O O
us NN O O
to NN O O
rule NN O O
out NN O O
tight NN O O
linkage NN O O
between NN O O
SAA NN O O
and NN O O
MEF NN O B-Disease
( NN O O
lod NN O O
score NN O O
= NN O O
- NN O O
2 NN O O
. NN O O
16 NN O O
, NN O O
theta NN O O
less NN O O
than NN O O
or NN O O
equal NN O O
to NN O O
0 NN O O
. NN O O
06 NN O O
) NN O O
. NN O O

For NN O O
APCS NN O O
we NN O O
found NN O O
that NN O O
the NN O O
allele NN O O
frequency NN O O
in NN O O
the NN O O
MEF NN O B-Disease
- NN O I-Disease
amyloidosis NN O I-Disease
patients NN O O
was NN O O
similar NN O O
to NN O O
that NN O O
in NN O O
18 NN O O
unrelated NN O O
MEF NN O B-Disease
patients NN O O
without NN O O
amyloidosis NN O B-Disease
and NN O O
their NN O O
33 NN O O
healthy NN O O
parents NN O O
. NN O O

Some NN O O
Mexican NN O O
glucose NN O O
- NN O O
6 NN O O
- NN O O
phosphate NN O O
dehydrogenase NN O O
variants NN O O
revisited NN O O
. NN O O

Glucose NN O B-Disease
- NN O I-Disease
6 NN O I-Disease
- NN O I-Disease
phosphate NN O I-Disease
dehydrogenase NN O I-Disease
( NN O I-Disease
G6PD NN O I-Disease
) NN O I-Disease
deficiency NN O I-Disease
appears NN O O
to NN O O
be NN O O
fairly NN O O
common NN O O
in NN O O
Mexico NN O O
. NN O O

We NN O O
have NN O O
now NN O O
examined NN O O
the NN O O
DNA NN O O
of NN O O
three NN O O
previously NN O O
reported NN O O
electrophoretically NN O O
fast NN O O
Mexican NN O O
G6PD NN O O
variants NN O O
, NN O O
- NN O O
G6PD NN O O
Distrito NN O O
Federal NN O O
, NN O O
G6PD NN O O
Tepic NN O O
, NN O O
and NN O O
G6PD NN O O
Castilla NN O O
. NN O O

All NN O O
three NN O O
of NN O O
these NN O O
variants NN O O
, NN O O
believed NN O O
on NN O O
the NN O O
basis NN O O
of NN O O
biochemical NN O O
characterization NN O O
and NN O O
population NN O O
origin NN O O
to NN O O
be NN O O
unique NN O O
, NN O O
have NN O O
the NN O O
G NN O O
- NN O O
- NN O O
- NN O O
- NN O O
A NN O O
transition NN O O
at NN O O
nucleotide NN O O
202 NN O O
and NN O O
the NN O O
A NN O O
- NN O O
- NN O O
- NN O O
- NN O O
G NN O O
transition NN O O
at NN O O
nucleotide NN O O
376 NN O O
, NN O O
mutations NN O O
that NN O O
we NN O O
now NN O O
recognize NN O O
to NN O O
be NN O O
characteristic NN O O
of NN O O
G6PD NN O O
A NN O O
- NN O O
. NN O O

Two NN O O
other NN O O
Mexican NN O O
males NN O O
with NN O O
G6PD NN O B-Disease
deficiency NN O I-Disease
were NN O O
found NN O O
to NN O O
have NN O O
the NN O O
same NN O O
mutation NN O O
. NN O O

All NN O O
five NN O O
have NN O O
the NN O O
( NN O O
NlaIII NN O O
/ NN O O
FokI NN O O
/ NN O O
PvuII NN O O
/ NN O O
PstI NN O O
) NN O O
haplotype NN O O
characteristic NN O O
of NN O O
G6PD NN O O
A NN O O
- NN O O
in NN O O
Africa NN O O
. NN O O

Since NN O O
the NN O O
PvuII NN O O
+ NN O O
genotype NN O O
seems NN O O
to NN O O
be NN O O
rare NN O O
in NN O O
Europe NN O O
, NN O O
we NN O O
conclude NN O O
that NN O O
all NN O O
of NN O O
these NN O O
G6PD NN O O
A NN O O
- NN O O
genes NN O O
had NN O O
their NN O O
ancient NN O O
origin NN O O
in NN O O
Africa NN O O
, NN O O
although NN O O
in NN O O
many NN O O
of NN O O
the NN O O
Mexican NN O O
patients NN O O
with NN O O
G6PD NN O O
A NN O O
- NN O O
202A NN O O
/ NN O O
376G NN O O
the NN O O
gene NN O O
may NN O O
have NN O O
been NN O O
imported NN O O
more NN O O
recently NN O O
from NN O O
Spain NN O O
, NN O O
where NN O O
this NN O O
variant NN O O
, NN O O
formerly NN O O
known NN O O
as NN O O
G6PD NN O O
Betica NN O O
, NN O O
is NN O O
also NN O O
prevalent NN O O
. NN O O
. NN O O

Hereditary NN O O
deficiency NN O B-Disease
of NN O I-Disease
C5 NN O I-Disease
in NN O O
association NN O O
with NN O O
discoid NN O B-Disease
lupus NN O I-Disease
erythematosus NN O I-Disease
. NN O O

A NN O O
29 NN O O
- NN O O
year NN O O
- NN O O
old NN O O
woman NN O O
with NN O O
discoid NN O B-Disease
lupus NN O I-Disease
erythematosus NN O I-Disease
had NN O O
undetectable NN O O
classic NN O O
pathway NN O O
complement NN O O
activity NN O O
. NN O O

Hypocomplementemia NN O B-Disease
was NN O O
due NN O O
to NN O O
selective NN O O
deficiency NN O B-Disease
of NN O I-Disease
C5 NN O I-Disease
. NN O O

One NN O O
of NN O O
her NN O O
children NN O O
was NN O O
also NN O O
deficient NN O O
. NN O O

To NN O O
our NN O O
knowledge NN O O
this NN O O
is NN O O
the NN O O
first NN O O
documented NN O O
case NN O O
of NN O O
an NN O O
association NN O O
between NN O O
discoid NN O B-Disease
lupus NN O I-Disease
erythematosus NN O I-Disease
and NN O O
C5 NN O B-Disease
deficiency NN O I-Disease
. NN O O
. NN O O

Founder NN O O
effect NN O O
of NN O O
a NN O O
prevalent NN O O
phenylketonuria NN O B-Disease
mutation NN O O
in NN O O
the NN O O
Oriental NN O O
population NN O O
. NN O O

A NN O O
missense NN O O
mutation NN O O
has NN O O
been NN O O
identified NN O O
in NN O O
the NN O O
human NN O O
phenylalanine NN O O
hydroxylase NN O O
[ NN O O
PAH NN O O
; NN O O
phenylalanine NN O O
4 NN O O
- NN O O
monooxygenase NN O O
; NN O O
L NN O O
- NN O O
phenylalanine NN O O
, NN O O
tetrahydrobiopterin NN O O
oxygen NN O O
oxidoreductase NN O O
( NN O O
4 NN O O
- NN O O
hydroxylating NN O O
) NN O O
, NN O O
EC NN O O
1 NN O O
. NN O O
14 NN O O
. NN O O
16 NN O O
. NN O O
1 NN O O
] NN O O
gene NN O O
in NN O O
a NN O O
Chinese NN O O
patient NN O O
with NN O O
classic NN O O
phenylketonuria NN O B-Disease
( NN O O
PKU NN O B-Disease
) NN O O
. NN O O

A NN O O
G NN O O
- NN O O
to NN O O
- NN O O
C NN O O
transition NN O O
at NN O O
the NN O O
second NN O O
base NN O O
of NN O O
codon NN O O
413 NN O O
in NN O O
exon NN O O
12 NN O O
of NN O O
the NN O O
gene NN O O
results NN O O
in NN O O
the NN O O
substitution NN O O
of NN O O
Pro413 NN O O
for NN O O
Arg413 NN O O
in NN O O
the NN O O
mutant NN O O
protein NN O O
. NN O O

This NN O O
mutation NN O O
( NN O O
R413P NN O O
) NN O O
results NN O O
in NN O O
negligible NN O O
enzymatic NN O O
activity NN O O
when NN O O
expressed NN O O
in NN O O
heterologous NN O O
mammalian NN O O
cells NN O O
and NN O O
is NN O O
compatible NN O O
with NN O O
a NN O O
classic NN O O
PKU NN O B-Disease
phenotype NN O O
in NN O O
the NN O O
patient NN O O
. NN O O

Population NN O O
genetic NN O O
studies NN O O
reveal NN O O
that NN O O
this NN O O
mutation NN O O
is NN O O
tightly NN O O
linked NN O O
to NN O O
restriction NN O O
fragment NN O O
length NN O O
polymorphism NN O O
haplotype NN O O
4 NN O O
, NN O O
which NN O O
is NN O O
the NN O O
predominant NN O O
haplotype NN O O
of NN O O
the NN O O
PAH NN O O
locus NN O O
in NN O O
the NN O O
Oriental NN O O
population NN O O
. NN O O

It NN O O
accounts NN O O
for NN O O
13 NN O O
. NN O O

8 NN O O
% NN O O
of NN O O
northern NN O O
Chinese NN O O
and NN O O
27 NN O O
% NN O O
of NN O O
Japanese NN O O
PKU NN O B-Disease
alleles NN O O
, NN O O
but NN O O
it NN O O
is NN O O
rare NN O O
in NN O O
southern NN O O
Chinese NN O O
( NN O O
2 NN O O
. NN O O
2 NN O O
% NN O O
) NN O O
and NN O O
is NN O O
absent NN O O
in NN O O
the NN O O
Caucasian NN O O
population NN O O
. NN O O

The NN O O
data NN O O
demonstrate NN O O
unambiguously NN O O
that NN O O
the NN O O
mutation NN O O
occurred NN O O
after NN O O
racial NN O O
divergence NN O O
of NN O O
Orientals NN O O
and NN O O
Caucasians NN O O
and NN O O
suggest NN O O
that NN O O
the NN O O
allele NN O O
has NN O O
spread NN O O
throughout NN O O
the NN O O
Orient NN O O
by NN O O
a NN O O
founder NN O O
effect NN O O
. NN O O

Previous NN O O
protein NN O O
polymorphism NN O O
studies NN O O
in NN O O
eastern NN O O
Asia NN O O
have NN O O
led NN O O
to NN O O
the NN O O
hypothesis NN O O
that NN O O
" NN O O
northern NN O O
Mongoloids NN O O
" NN O O
represented NN O O
a NN O O
founding NN O O
population NN O O
in NN O O
Asia NN O O
. NN O O

Our NN O O
results NN O O
are NN O O
compatible NN O O
with NN O O
this NN O O
hypothesis NN O O
in NN O O
that NN O O
the NN O O
PKU NN O B-Disease
mutation NN O O
might NN O O
have NN O O
occurred NN O O
in NN O O
northern NN O O
Mongoloids NN O O
and NN O O
subsequently NN O O
spread NN O O
to NN O O
the NN O O
Chinese NN O O
and NN O O
Japanese NN O O
populations NN O O
. NN O O

Glucose NN O B-Disease
/ NN O I-Disease
galactose NN O I-Disease
malabsorption NN O I-Disease
caused NN O O
by NN O O
a NN O O
defect NN O O
in NN O O
the NN O O
Na NN O O
+ NN O O
/ NN O O
glucose NN O O
cotransporter NN O O
. NN O O

Glucose NN O B-Disease
/ NN O I-Disease
galactose NN O I-Disease
malabsorption NN O I-Disease
( NN O O
GGM NN O B-Disease
) NN O O
is NN O O
an NN O O
autosomal NN O B-Disease
recessive NN O I-Disease
disease NN O I-Disease
manifesting NN O O
within NN O O
the NN O O
first NN O O
weeks NN O O
of NN O O
life NN O O
and NN O O
characterized NN O O
by NN O O
a NN O O
selective NN O O
failure NN O O
to NN O O
absorb NN O O
dietary NN O O
glucose NN O O
and NN O O
galactose NN O O
from NN O O
the NN O O
intestine NN O O
. NN O O

The NN O O
consequent NN O O
severe NN O O
diarrhoea NN O B-Disease
and NN O O
dehydration NN O B-Disease
are NN O O
usually NN O O
fatal NN O O
unless NN O O
these NN O O
sugars NN O O
are NN O O
eliminated NN O O
from NN O O
the NN O O
diet NN O O
. NN O O

Intestinal NN O O
biopsies NN O O
of NN O O
GGM NN O B-Disease
patients NN O O
have NN O O
revealed NN O O
a NN O O
specific NN O O
defect NN O O
in NN O O
Na NN O O
( NN O O
+ NN O O
) NN O O
- NN O O
dependent NN O O
absorption NN O O
of NN O O
glucose NN O O
in NN O O
the NN O O
brush NN O O
border NN O O
. NN O O

Normal NN O O
glucose NN O O
absorption NN O O
is NN O O
mediated NN O O
by NN O O
the NN O O
Na NN O O
+ NN O O
/ NN O O
glucose NN O O
cotransporter NN O O
in NN O O
the NN O O
brush NN O O
border NN O O
membrane NN O O
of NN O O
the NN O O
intestinal NN O O
epithelium NN O O
. NN O O

Cellular NN O O
influx NN O O
is NN O O
driven NN O O
by NN O O
the NN O O
transmembrane NN O O
Na NN O O
+ NN O O
electrochemical NN O O
potential NN O O
gradient NN O O
; NN O O
thereafter NN O O
the NN O O
sugar NN O O
moves NN O O
to NN O O
the NN O O
blood NN O O
across NN O O
the NN O O
basolateral NN O O
membrane NN O O
via NN O O
the NN O O
facilitated NN O O
glucose NN O O
carrier NN O O
. NN O O

We NN O O
have NN O O
previously NN O O
cloned NN O O
and NN O O
sequenced NN O O
a NN O O
Na NN O O
+ NN O O
/ NN O O
glucose NN O O
cotransporter NN O O
from NN O O
normal NN O O
human NN O O
ileum NN O O
and NN O O
shown NN O O
that NN O O
this NN O O
gene NN O O
, NN O O
SGLT1 NN O O
, NN O O
resides NN O O
on NN O O
the NN O O
distal NN O O
q NN O O
arm NN O O
of NN O O
chromosome NN O O
22 NN O O
. NN O O

We NN O O
have NN O O
now NN O O
amplified NN O O
SGLT1 NN O O
complementary NN O O
DNA NN O O
and NN O O
genomic NN O O
DNA NN O O
from NN O O
members NN O O
of NN O O
a NN O O
family NN O O
affected NN O O
with NN O O
GGM NN O B-Disease
by NN O O
the NN O O
polymerase NN O O
chain NN O O
reaction NN O O
. NN O O

Sequence NN O O
analysis NN O O
of NN O O
the NN O O
amplified NN O O
products NN O O
has NN O O
revealed NN O O
a NN O O
single NN O O
missense NN O O
mutation NN O O
in NN O O
SGLT1 NN O O
which NN O O
cosegregates NN O O
with NN O O
the NN O O
GGM NN O B-Disease
phenotype NN O O
and NN O O
results NN O O
in NN O O
a NN O O
complete NN O O
loss NN O O
of NN O O
Na NN O O
( NN O O
+ NN O O
) NN O O
- NN O O
dependent NN O O
glucose NN O O
transport NN O O
in NN O O
Xenopus NN O O
oocytes NN O O
injected NN O O
with NN O O
this NN O O
complementary NN O O
RNA NN O O
. NN O O
. NN O O

A NN O O
de NN O O
novo NN O O
unbalanced NN O O
reciprocal NN O O
translocation NN O O
identified NN O O
as NN O O
paternal NN O O
in NN O O
origin NN O O
in NN O O
the NN O O
Prader NN O B-Disease
- NN O I-Disease
Willi NN O I-Disease
syndrome NN O I-Disease
. NN O O

Interstitial NN O O
cytogenetic NN O O
deletions NN O O
involving NN O O
the NN O O
paternally NN O O
derived NN O O
chromosome NN O O
15q11 NN O O
- NN O O
13 NN O O
have NN O O
been NN O O
described NN O O
in NN O O
patients NN O O
with NN O O
the NN O O
Prader NN O B-Disease
- NN O I-Disease
Willi NN O I-Disease
syndrome NN O I-Disease
( NN O O
PWS NN O B-Disease
) NN O O
. NN O O

We NN O O
report NN O O
a NN O O
child NN O O
with NN O O
PWS NN O B-Disease
and NN O O
a NN O O
de NN O O
novo NN O O
unbalanced NN O O
karyotype NN O O
- NN O O
45 NN O O
, NN O O
XY NN O O
, NN O O
- NN O O
9 NN O O
, NN O O
- NN O O
15 NN O O
, NN O O
+ NN O O
der NN O O
( NN O O
9 NN O O
) NN O O
t NN O O
( NN O O
9 NN O O
; NN O O
15 NN O O
) NN O O
( NN O O
q34 NN O O
; NN O O
q13 NN O O
) NN O O
. NN O O

Molecular NN O O
studies NN O O
with NN O O
the NN O O
DNA NN O O
probe NN O O
pML34 NN O O
confirmed NN O O
that NN O O
only NN O O
a NN O O
single NN O O
Prader NN O B-Disease
Willi NN O I-Disease
critical NN O O
region NN O O
( NN O O
PWCR NN O O
15q11 NN O O
. NN O O
2 NN O O
- NN O O
q12 NN O O
) NN O O
copy NN O O
was NN O O
present NN O O
. NN O O

Hybridisation NN O O
of NN O O
patient NN O O
and NN O O
parental NN O O
DNA NN O O
with NN O O
the NN O O
multi NN O O
- NN O O
allelic NN O O
probe NN O O
CMW1 NN O O
, NN O O
which NN O O
maps NN O O
to NN O O
pter NN O O
- NN O O
15q13 NN O O
, NN O O
showed NN O O
that NN O O
the NN O O
chromosome NN O O
involved NN O O
in NN O O
the NN O O
translocation NN O O
was NN O O
paternal NN O O
in NN O O
origin NN O O
. NN O O

This NN O O
is NN O O
the NN O O
first NN O O
example NN O O
of NN O O
a NN O O
paternally NN O O
- NN O O
derived NN O O
PWCR NN O O
allele NN O O
loss NN O O
caused NN O O
by NN O O
an NN O O
unbalanced NN O O
translocation NN O O
that NN O O
has NN O O
arisen NN O O
de NN O O
novo NN O O
. NN O O

Localisation NN O O
of NN O O
the NN O O
myotonic NN O B-Disease
dystrophy NN O I-Disease
locus NN O O
to NN O O
19q13 NN O O
. NN O O
2 NN O O
- NN O O
19q13 NN O O
. NN O O
3 NN O O
and NN O O
its NN O O
relationship NN O O
to NN O O
twelve NN O O
polymorphic NN O O
loci NN O O
on NN O O
19q NN O O
. NN O O

The NN O O
order NN O O
of NN O O
fourteen NN O O
polymorphic NN O O
markers NN O O
localised NN O O
to NN O O
the NN O O
long NN O O
arm NN O O
of NN O O
human NN O O
chromosome NN O O
19 NN O O
has NN O O
been NN O O
established NN O O
by NN O O
multipoint NN O O
mapping NN O O
in NN O O
a NN O O
set NN O O
of NN O O
40 NN O O
CEPH NN O O
( NN O O
Centre NN O O
dEtude NN O O
de NN O O
Polymorphisme NN O O
Humain NN O O
, NN O O
Paris NN O O
) NN O O
reference NN O O
families NN O O
. NN O O

We NN O O
report NN O O
here NN O O
the NN O O
linkage NN O O
relationship NN O O
of NN O O
the NN O O
myotonic NN O B-Disease
dystrophy NN O I-Disease
( NN O O
DM NN O B-Disease
) NN O O
locus NN O O
to NN O O
twelve NN O O
of NN O O
these NN O O
markers NN O O
as NN O O
studied NN O O
in NN O O
45 NN O O
families NN O O
with NN O O
DM NN O B-Disease
. NN O O

The NN O O
resulting NN O O
genetic NN O O
map NN O O
is NN O O
supported NN O O
by NN O O
the NN O O
localisation NN O O
of NN O O
the NN O O
DNA NN O O
markers NN O O
in NN O O
a NN O O
panel NN O O
of NN O O
somatic NN O O
cell NN O O
hybrids NN O O
. NN O O

Ten NN O O
of NN O O
the NN O O
twelve NN O O
markers NN O O
have NN O O
been NN O O
shown NN O O
to NN O O
be NN O O
proximal NN O O
to NN O O
the NN O O
DM NN O B-Disease
gene NN O O
and NN O O
two NN O O
, NN O O
PRKCG NN O O
and NN O O
D19S22 NN O O
, NN O O
distal NN O O
but NN O O
at NN O O
distances NN O O
of NN O O
approximately NN O O
25 NN O O
cM NN O O
and NN O O
15 NN O O
cM NN O O
, NN O O
respectively NN O O
. NN O O

The NN O O
closest NN O O
proximal NN O O
markers NN O O
are NN O O
APOC2 NN O O
( NN O O
apolipoprotein NN O O
C NN O O
- NN O O
II NN O O
) NN O O
and NN O O
CKM NN O O
( NN O O
creatine NN O O
kinase NN O O
, NN O O
muscle NN O O
) NN O O
approximately NN O O
3 NN O O
cM NN O O
and NN O O
2 NN O O
cM NN O O
from NN O O
the NN O O
DM NN O B-Disease
gene NN O O
respectively NN O O
, NN O O
in NN O O
the NN O O
order NN O O
APOC2 NN O O
- NN O O
CKM NN O O
- NN O O
DM NN O O
. NN O O

The NN O O
distance NN O O
between NN O O
APOC2 NN O O
, NN O O
CKM NN O O
and NN O O
DM NN O B-Disease
( NN O O
of NN O O
the NN O O
order NN O O
of NN O O
2 NN O O
million NN O O
base NN O O
pairs NN O O
) NN O O
and NN O O
their NN O O
known NN O O
orientation NN O O
should NN O O
permit NN O O
directional NN O O
chromosome NN O O
walking NN O O
and NN O O
jumping NN O O
. NN O O

The NN O O
data NN O O
presented NN O O
here NN O O
should NN O O
enable NN O O
us NN O O
to NN O O
determine NN O O
whether NN O O
or NN O O
not NN O O
new NN O O
markers NN O O
are NN O O
distal NN O O
to NN O O
APOC2 NN O O
/ NN O O
CKM NN O O
and NN O O
thus NN O O
potentially NN O O
flank NN O O
the NN O O
DM NN O B-Disease
gene NN O O
. NN O O
. NN O O

Localization NN O O
of NN O O
histidase NN O O
to NN O O
human NN O O
chromosome NN O O
region NN O O
12q22 NN O O
- NN O O
- NN O O
- NN O O
- NN O O
q24 NN O O
. NN O O
1 NN O O
and NN O O
mouse NN O O
chromosome NN O O
region NN O O
10C2 NN O O
- NN O O
- NN O O
- NN O O
- NN O O
D1 NN O O
. NN O O

The NN O O
human NN O O
gene NN O O
for NN O O
histidase NN O O
( NN O O
histidine NN O O
ammonia NN O O
- NN O O
lyase NN O O
; NN O O
HAL NN O O
) NN O O
, NN O O
the NN O O
enzyme NN O O
deficient NN O O
in NN O O
histidinemia NN O B-Disease
, NN O O
was NN O O
assigned NN O O
to NN O O
human NN O O
chromosome NN O O
12 NN O O
by NN O O
Southern NN O O
blot NN O O
analysis NN O O
of NN O O
human NN O O
X NN O O
mouse NN O O
somatic NN O O
cell NN O O
hybrid NN O O
DNA NN O O
. NN O O

The NN O O
gene NN O O
was NN O O
sublocalized NN O O
to NN O O
region NN O O
12q22 NN O O
- NN O O
- NN O O
- NN O O
- NN O O
q24 NN O O
. NN O O

1 NN O O
by NN O O
in NN O O
situ NN O O
hybridization NN O O
, NN O O
using NN O O
a NN O O
human NN O O
histidase NN O O
cDNA NN O O
. NN O O

The NN O O
homologous NN O O
locus NN O O
in NN O O
the NN O O
mouse NN O O
( NN O O
Hal NN O O
) NN O O
was NN O O
mapped NN O O
to NN O O
region NN O O
10C2 NN O O
- NN O O
- NN O O
- NN O O
- NN O O
D1 NN O O
by NN O O
in NN O O
situ NN O O
hybridization NN O O
, NN O O
using NN O O
a NN O O
cell NN O O
line NN O O
from NN O O
a NN O O
mouse NN O O
homozygous NN O O
for NN O O
a NN O O
1 NN O O
. NN O O

10 NN O O
Robertsonian NN O O
translocation NN O O
. NN O O

These NN O O
assignments NN O O
extend NN O O
the NN O O
conserved NN O O
syntenic NN O O
region NN O O
between NN O O
human NN O O
chromosome NN O O
12 NN O O
and NN O O
mouse NN O O
chromosome NN O O
10 NN O O
that NN O O
includes NN O O
the NN O O
genes NN O O
for NN O O
phenylalanine NN O O
hydroxylase NN O O
, NN O O
gamma NN O O
interferon NN O O
, NN O O
peptidase NN O O
, NN O O
and NN O O
citrate NN O O
synthase NN O O
. NN O O

The NN O O
localization NN O O
of NN O O
histidase NN O O
to NN O O
mouse NN O O
chromosome NN O O
10 NN O O
suggests NN O O
that NN O O
the NN O O
histidase NN O O
regulatory NN O O
locus NN O O
( NN O O
Hsd NN O O
) NN O O
and NN O O
the NN O O
histidinemia NN O O
mutation NN O O
( NN O O
his NN O O
) NN O O
, NN O O
which NN O O
are NN O O
both NN O O
known NN O O
to NN O O
be NN O O
on NN O O
chromosome NN O O
10 NN O O
, NN O O
may NN O O
be NN O O
alleles NN O O
of NN O O
the NN O O
histidase NN O O
structural NN O O
gene NN O O
locus NN O O
. NN O O

Determination NN O O
of NN O O
the NN O O
mutations NN O O
responsible NN O O
for NN O O
the NN O O
Lesch NN O B-Disease
- NN O I-Disease
Nyhan NN O I-Disease
syndrome NN O I-Disease
in NN O O
17 NN O O
subjects NN O O
. NN O O

Hypoxanthine NN O O
- NN O O
- NN O O
guanine NN O O
phosphoribosyltransferase NN O O
( NN O O
HPRT NN O O
) NN O O
is NN O O
a NN O O
purine NN O O
salvage NN O O
enzyme NN O O
that NN O O
catalyzes NN O O
the NN O O
conversion NN O O
of NN O O
hypoxanthine NN O O
to NN O O
inosine NN O O
monophosphate NN O O
and NN O O
guanine NN O O
to NN O O
guanosine NN O O
monophosphate NN O O
. NN O O

Previous NN O O
studies NN O O
of NN O O
mutant NN O O
HPRT NN O O
proteins NN O O
analyzed NN O O
at NN O O
the NN O O
molecular NN O O
level NN O O
have NN O O
shown NN O O
a NN O O
significant NN O O
heterogeneity NN O O
. NN O O

This NN O O
investigation NN O O
further NN O O
verifies NN O O
this NN O O
heterogeneity NN O O
and NN O O
identifies NN O O
insertions NN O O
, NN O O
deletions NN O O
, NN O O
and NN O O
point NN O O
mutations NN O O
. NN O O

The NN O O
direct NN O O
sequencing NN O O
of NN O O
the NN O O
polymerase NN O O
chain NN O O
reaction NN O O
- NN O O
amplified NN O O
product NN O O
of NN O O
reverse NN O O
- NN O O
transcribed NN O O
HPRT NN O O
mRNA NN O O
enabled NN O O
the NN O O
rapid NN O O
identification NN O O
of NN O O
the NN O O
mutations NN O O
found NN O O
in NN O O
17 NN O O
previously NN O O
uncharacterized NN O O
cell NN O O
lines NN O O
derived NN O O
from NN O O
patients NN O O
with NN O O
the NN O O
Lesch NN O B-Disease
- NN O I-Disease
Nyhan NN O I-Disease
syndrome NN O I-Disease
. NN O O
. NN O O

Linkage NN O O
of NN O O
DNA NN O O
markers NN O O
at NN O O
Xq28 NN O O
to NN O O
adrenoleukodystrophy NN O B-Disease
and NN O O
adrenomyeloneuropathy NN O B-Disease
present NN O O
within NN O O
the NN O O
same NN O O
family NN O O
. NN O O

We NN O O
present NN O O
a NN O O
large NN O O
kindred NN O O
that NN O O
contained NN O O
patients NN O O
with NN O O
either NN O O
adrenoleukodystrophy NN O B-Disease
( NN O O
ALD NN O B-Disease
) NN O O
or NN O O
adrenomyeloneuropathy NN O B-Disease
( NN O O
AMN NN O B-Disease
) NN O O
. NN O O

The NN O O
pedigree NN O O
clearly NN O O
supported NN O O
the NN O O
X NN O O
- NN O O
linked NN O O
mode NN O O
of NN O O
inheritance NN O O
of NN O O
the NN O O
nonneonatal NN O O
form NN O O
of NN O O
ALD NN O B-Disease
/ NN O O
AMN NN O B-Disease
. NN O O

Analysis NN O O
with NN O O
DNA NN O O
markers NN O O
at NN O O
Xq28 NN O O
suggested NN O O
segregation NN O O
of NN O O
both NN O O
ALD NN O B-Disease
and NN O O
AMN NN O B-Disease
with NN O O
an NN O O
identical NN O O
haplotype NN O O
. NN O O

This NN O O
indicated NN O O
that NN O O
nonneonatal NN O O
ALD NN O B-Disease
and NN O O
AMN NN O B-Disease
are NN O O
caused NN O O
by NN O O
a NN O O
mutation NN O O
in NN O O
the NN O O
same NN O O
gene NN O O
at NN O O
Xq28 NN O O
. NN O O

It NN O O
showed NN O O
, NN O O
furthermore NN O O
, NN O O
that NN O O
phenotypic NN O O
differences NN O O
between NN O O
ALD NN O B-Disease
and NN O O
AMN NN O B-Disease
are NN O O
not NN O O
necessarily NN O O
the NN O O
consequence NN O O
of NN O O
allelic NN O O
heterogeneity NN O O
due NN O O
to NN O O
different NN O O
mutations NN O O
within NN O O
the NN O O
same NN O O
gene NN O O
. NN O O

The NN O O
maximal NN O O
lod NN O O
score NN O O
for NN O O
linkage NN O O
of NN O O
the NN O O
ALD NN O B-Disease
/ NN O O
AMN NN O B-Disease
gene NN O O
and NN O O
the NN O O
multiallelic NN O O
anonymous NN O O
DNA NN O O
marker NN O O
at NN O O
DXS52 NN O O
was NN O O
3 NN O O
. NN O O

0 NN O O
at NN O O
a NN O O
recombination NN O O
fraction NN O O
of NN O O
0 NN O O
. NN O O

00 NN O O
. NN O O

This NN O O
made NN O O
a NN O O
prenatal NN O O
or NN O O
presymptomatic NN O O
diagnosis NN O O
and NN O O
heterozygote NN O O
detection NN O O
by NN O O
DNA NN O O
analysis NN O O
with NN O O
this NN O O
marker NN O O
reliable NN O O
. NN O O

Skewed NN O O
X NN O O
inactivation NN O O
in NN O O
a NN O O
female NN O O
MZ NN O O
twin NN O O
results NN O O
in NN O O
Duchenne NN O B-Disease
muscular NN O I-Disease
dystrophy NN O I-Disease
. NN O O

One NN O O
of NN O O
female NN O O
MZ NN O O
twins NN O O
presented NN O O
with NN O O
muscular NN O B-Disease
dystrophy NN O I-Disease
. NN O O

Physical NN O O
examination NN O O
, NN O O
creatine NN O O
phosphokinase NN O O
levels NN O O
, NN O O
and NN O O
muscle NN O O
biopsy NN O O
were NN O O
consistent NN O O
with NN O O
Duchenne NN O B-Disease
muscular NN O I-Disease
dystrophy NN O I-Disease
( NN O O
DMD NN O B-Disease
) NN O O
. NN O O

However NN O O
, NN O O
because NN O O
of NN O O
her NN O O
sex NN O O
she NN O O
was NN O O
diagnosed NN O O
as NN O O
having NN O O
limb NN O B-Disease
- NN O I-Disease
girdle NN O I-Disease
muscular NN O I-Disease
dystrophy NN O I-Disease
. NN O O

With NN O O
cDNA NN O O
probes NN O O
to NN O O
the NN O O
DMD NN O B-Disease
gene NN O O
, NN O O
a NN O O
gene NN O O
deletion NN O O
was NN O O
detected NN O O
in NN O O
the NN O O
twins NN O O
and NN O O
their NN O O
mother NN O O
. NN O O

The NN O O
de NN O O
novo NN O O
mutation NN O O
which NN O O
arose NN O O
in NN O O
the NN O O
mother NN O O
was NN O O
shown NN O O
by NN O O
novel NN O O
junction NN O O
fragments NN O O
generated NN O O
by NN O O
HindIII NN O O
, NN O O
PstI NN O O
, NN O O
or NN O O
TaqI NN O O
when NN O O
probed NN O O
with NN O O
cDNA8 NN O O
. NN O O

Additional NN O O
evidence NN O O
of NN O O
a NN O O
large NN O O
gene NN O O
deletion NN O O
was NN O O
given NN O O
by NN O O
novel NN O O
SfiI NN O O
junction NN O O
fragments NN O O
detected NN O O
by NN O O
probes NN O O
p20 NN O O
, NN O O
J NN O O
- NN O O
Bir NN O O
, NN O O
and NN O O
J NN O O
- NN O O
66 NN O O
on NN O O
pulsed NN O O
- NN O O
field NN O O
gel NN O O
electrophoresis NN O O
( NN O O
PFGE NN O O
) NN O O
. NN O O

Immunoblot NN O O
analysis NN O O
of NN O O
muscle NN O O
from NN O O
the NN O O
affected NN O O
twin NN O O
showed NN O O
dystrophin NN O O
of NN O O
normal NN O O
size NN O O
but NN O O
of NN O O
reduced NN O O
amount NN O O
. NN O O

Immunofluorescent NN O O
visualization NN O O
of NN O O
dystrophin NN O O
revealed NN O O
foci NN O O
of NN O O
dystrophin NN O O
- NN O O
positive NN O O
fibers NN O O
adjacent NN O O
to NN O O
foci NN O O
of NN O O
dystrophin NN O O
- NN O O
negative NN O O
fibers NN O O
. NN O O

These NN O O
data NN O O
indicate NN O O
that NN O O
the NN O O
affected NN O O
twin NN O O
is NN O O
a NN O O
manifesting NN O O
carrier NN O O
of NN O O
an NN O O
abnormal NN O O
DMD NN O B-Disease
gene NN O O
, NN O O
her NN O O
myopathy NN O B-Disease
being NN O O
a NN O O
direct NN O O
result NN O O
of NN O O
underexpression NN O O
of NN O O
dystrophin NN O O
. NN O O

Cytogenetic NN O O
analysis NN O O
revealed NN O O
normal NN O O
karyotypes NN O O
, NN O O
eliminating NN O O
the NN O O
possibility NN O O
of NN O O
a NN O O
translocation NN O O
affecting NN O O
DMD NN O B-Disease
gene NN O O
function NN O O
. NN O O

Both NN O O
linkage NN O O
analysis NN O O
and NN O O
DNA NN O O
fingerprint NN O O
analysis NN O O
revealed NN O O
that NN O O
each NN O O
twin NN O O
has NN O O
two NN O O
different NN O O
X NN O O
chromosomes NN O O
, NN O O
eliminating NN O O
the NN O O
possibility NN O O
of NN O O
uniparental NN O B-Disease
disomy NN O I-Disease
as NN O O
a NN O O
mechanism NN O O
for NN O O
DMD NN O B-Disease
expression NN O O
. NN O O

On NN O O
the NN O O
basis NN O O
of NN O O
methylation NN O O
differences NN O O
of NN O O
the NN O O
paternal NN O O
and NN O O
maternal NN O O
X NN O O
chromosomes NN O O
in NN O O
these NN O O
MZ NN O O
twins NN O O
, NN O O
we NN O O
propose NN O O
uneven NN O O
lyonization NN O O
( NN O O
X NN O O
chromosome NN O O
inactivation NN O O
) NN O O
as NN O O
the NN O O
underlying NN O O
mechanism NN O O
for NN O O
disease NN O O
expression NN O O
in NN O O
the NN O O
affected NN O O
female NN O O
. NN O O
. NN O O

Adrenoleukodystrophy NN O B-Disease
and NN O O
adrenomyeloneuropathy NN O B-Disease
associated NN O O
with NN O O
partial NN O O
adrenal NN O B-Disease
insufficiency NN O I-Disease
in NN O O
three NN O O
generations NN O O
of NN O O
a NN O O
kindred NN O O
. NN O O

Four NN O O
cases NN O O
of NN O O
adrenoleukodystrophy NN O B-Disease
( NN O O
ALD NN O B-Disease
) NN O O
and NN O O
one NN O O
case NN O O
of NN O O
adrenomyeloneuropathy NN O B-Disease
( NN O O
AMN NN O B-Disease
) NN O O
have NN O O
developed NN O O
in NN O O
a NN O O
kindred NN O O
over NN O O
three NN O O
generations NN O O
demonstrating NN O O
that NN O O
AMN NN O B-Disease
is NN O O
a NN O O
clinical NN O O
variant NN O O
of NN O O
ALD NN O B-Disease
. NN O O

Pituitary NN O O
- NN O O
adrenal NN O O
function NN O O
studies NN O O
were NN O O
performed NN O O
in NN O O
10 NN O O
family NN O O
members NN O O
, NN O O
including NN O O
two NN O O
affected NN O O
males NN O O
and NN O O
four NN O O
females NN O O
identified NN O O
as NN O O
carriers NN O O
of NN O O
ALD NN O B-Disease
/ NN O O
AMN NN O B-Disease
. NN O O

No NN O O
pituitary NN O B-Disease
- NN O I-Disease
adrenal NN O I-Disease
abnormality NN O I-Disease
was NN O O
found NN O O
in NN O O
the NN O O
carriers NN O O
. NN O O

However NN O O
, NN O O
basal NN O O
morning NN O O
plasma NN O O
adrenocorticotropic NN O O
hormone NN O O
( NN O O
ACTH NN O O
) NN O O
levels NN O O
were NN O O
markedly NN O O
elevated NN O O
in NN O O
the NN O O
two NN O O
males NN O O
with NN O O
ALD NN O B-Disease
and NN O O
AMN NN O B-Disease
, NN O O
despite NN O O
the NN O O
fact NN O O
that NN O O
they NN O O
had NN O O
no NN O O
clinical NN O O
signs NN O O
of NN O O
adrenal NN O B-Disease
insufficiency NN O I-Disease
and NN O O
that NN O O
morning NN O O
plasma NN O O
cortisol NN O O
levels NN O O
and NN O O
their NN O O
response NN O O
to NN O O
maximal NN O O
exogenous NN O O
ACTH NN O O
stimulation NN O O
appeared NN O O
to NN O O
be NN O O
normal NN O O
. NN O O

In NN O O
addition NN O O
, NN O O
the NN O O
integrated NN O O
24 NN O O
- NN O O
hour NN O O
response NN O O
to NN O O
the NN O O
administration NN O O
were NN O O
also NN O O
subnormal NN O O
in NN O O
these NN O O
two NN O O
cases NN O O
. NN O O

Thus NN O O
, NN O O
people NN O O
with NN O O
ALD NN O B-Disease
and NN O O
AMN NN O B-Disease
may NN O O
have NN O O
subclinical NN O O
partial NN O O
adrenocrotical NN O B-Disease
insufficiency NN O I-Disease
. NN O O

No NN O O
other NN O O
endocrinologic NN O B-Disease
dysfunction NN O I-Disease
was NN O O
identified NN O O
. NN O O
. NN O O

Regional NN O O
localisation NN O O
of NN O O
the NN O O
Friedreich NN O B-Disease
ataxia NN O I-Disease
locus NN O O
to NN O O
human NN O O
chromosome NN O O
9q13 NN O O
- NN O O
- NN O O
- NN O O
- NN O O
q21 NN O O
. NN O O
1 NN O O
. NN O O

We NN O O
have NN O O
previously NN O O
assigned NN O O
the NN O O
Friedreich NN O B-Disease
ataxia NN O I-Disease
locus NN O O
( NN O O
FRDA NN O O
) NN O O
to NN O O
chromosome NN O O
9 NN O O
; NN O O
the NN O O
current NN O O
maximal NN O O
lod NN O O
score NN O O
between NN O O
FRDA NN O O
and NN O O
MCT112 NN O O
( NN O O
D9S15 NN O O
) NN O O
is NN O O
greater NN O O
than NN O O
50 NN O O
at NN O O
a NN O O
recombination NN O O
fraction NN O O
of NN O O
theta NN O O
= NN O O
0 NN O O
. NN O O

The NN O O
physical NN O O
assignment NN O O
of NN O O
the NN O O
locus NN O O
defined NN O O
by NN O O
MCT112 NN O O
, NN O O
and NN O O
hence NN O O
FRDA NN O O
, NN O O
has NN O O
not NN O O
been NN O O
determined NN O O
, NN O O
although NN O O
linkage NN O O
analysis NN O O
of NN O O
MCT112 NN O O
with NN O O
other NN O O
chromosome NN O O
9 NN O O
markers NN O O
inferred NN O O
a NN O O
location NN O O
close NN O O
to NN O O
the NN O O
centromere NN O O
. NN O O

We NN O O
have NN O O
used NN O O
in NN O O
situ NN O O
hybridisation NN O O
with NN O O
MCT112 NN O O
, NN O O
a NN O O
corresponding NN O O
cosmid NN O O
MJ1 NN O O
, NN O O
and NN O O
DR47 NN O O
( NN O O
D9S5 NN O O
) NN O O
, NN O O
coupled NN O O
with NN O O
mapping NN O O
studies NN O O
on NN O O
hybrid NN O O
cell NN O O
panels NN O O
, NN O O
to NN O O
define NN O O
more NN O O
precisely NN O O
the NN O O
location NN O O
of NN O O
the NN O O
disease NN O O
locus NN O O
. NN O O

The NN O O
in NN O O
situ NN O O
location NN O O
of NN O O
all NN O O
three NN O O
probes NN O O
is NN O O
9q13 NN O O
- NN O O
- NN O O
- NN O O
- NN O O
q21 NN O O
. NN O O

1 NN O O
, NN O O
distal NN O O
to NN O O
the NN O O
variable NN O O
heterochromatin NN O O
region NN O O
. NN O O

Physical NN O O
assignment NN O O
of NN O O
FRDA NN O O
will NN O O
allow NN O O
us NN O O
to NN O O
identify NN O O
hybrid NN O O
cell NN O O
lines NN O O
containing NN O O
the NN O O
mutated NN O O
gene NN O O
. NN O O

Increased NN O O
high NN O O
- NN O O
density NN O O
lipoprotein NN O O
levels NN O O
caused NN O O
by NN O O
a NN O O
common NN O O
cholesteryl NN O O
- NN O O
ester NN O O
transfer NN O O
protein NN O O
gene NN O O
mutation NN O O
. NN O O

BACKGROUND NN O O
AND NN O O
METHODS NN O O
. NN O O

The NN O O
plasma NN O O
cholesteryl NN O O
- NN O O
ester NN O O
transfer NN O O
protein NN O O
( NN O O
CETP NN O O
) NN O O
catalyzes NN O O
the NN O O
transfer NN O O
of NN O O
cholesteryl NN O O
esters NN O O
from NN O O
high NN O O
- NN O O
density NN O O
lipoprotein NN O O
( NN O O
HDL NN O O
) NN O O
to NN O O
other NN O O
lipoproteins NN O O
. NN O O

We NN O O
recently NN O O
described NN O O
a NN O O
Japanese NN O O
family NN O O
with NN O O
increased NN O O
HDL NN O O
levels NN O O
and NN O O
CETP NN O B-Disease
deficiency NN O I-Disease
due NN O O
to NN O O
a NN O O
splicing NN O O
defect NN O O
of NN O O
the NN O O
CETP NN O O
gene NN O O
. NN O O

To NN O O
assess NN O O
the NN O O
frequency NN O O
and NN O O
phenotype NN O O
of NN O O
this NN O O
condition NN O O
, NN O O
we NN O O
screened NN O O
11 NN O O
additional NN O O
families NN O O
with NN O O
high NN O O
HDL NN O O
levels NN O O
by NN O O
means NN O O
of NN O O
a NN O O
radioimmunoassay NN O O
for NN O O
CETP NN O O
and NN O O
DNA NN O O
analysis NN O O
. NN O O

RESULTS NN O O
. NN O O

We NN O O
found NN O O
the NN O O
same NN O O
CETP NN O O
gene NN O O
mutation NN O O
in NN O O
four NN O O
families NN O O
from NN O O
three NN O O
different NN O O
regions NN O O
of NN O O
Japan NN O O
. NN O O

Analysis NN O O
of NN O O
restriction NN O O
- NN O O
fragment NN O O
- NN O O
length NN O O
polymorphisms NN O O
of NN O O
the NN O O
mutant NN O O
CETP NN O O
allele NN O O
showed NN O O
that NN O O
all NN O O
probands NN O O
were NN O O
homozygous NN O O
for NN O O
the NN O O
identical NN O O
haplotype NN O O
. NN O O

Family NN O O
members NN O O
homozygous NN O O
for NN O O
CETP NN O B-Disease
deficiency NN O I-Disease
( NN O O
n NN O O
= NN O O
10 NN O O
) NN O O
had NN O O
moderate NN O O
hypercholesterolemia NN O B-Disease
( NN O O
mean NN O O
total NN O O
cholesterol NN O O
level NN O O
[ NN O O
+ NN O O
/ NN O O
- NN O O
SD NN O O
] NN O O
, NN O O
7 NN O O
. NN O O
01 NN O O
+ NN O O
/ NN O O
- NN O O
0 NN O O
. NN O O
83 NN O O
mmol NN O O
per NN O O
liter NN O O
) NN O O
, NN O O
markedly NN O O
increased NN O O
levels NN O O
of NN O O
HDL NN O O
cholesterol NN O O
( NN O O
4 NN O O
. NN O O
24 NN O O
+ NN O O
/ NN O O
- NN O O
1 NN O O
. NN O O
01 NN O O
mmol NN O O
per NN O O
liter NN O O
) NN O O
and NN O O
apolipoprotein NN O O
A NN O O
- NN O O
I NN O O
, NN O O
and NN O O
decreased NN O O
levels NN O O
of NN O O
low NN O O
- NN O O
density NN O O
lipoprotein NN O O
cholesterol NN O O
( NN O O
1 NN O O
. NN O O
99 NN O O
+ NN O O
/ NN O O
- NN O O
0 NN O O
. NN O O
80 NN O O
mmol NN O O
per NN O O
liter NN O O
) NN O O
and NN O O
apolipoprotein NN O O
B NN O O
. NN O O

Members NN O O
heterozygous NN O O
for NN O O
the NN O O
deficiency NN O O
( NN O O
n NN O O
= NN O O
20 NN O O
) NN O O
, NN O O
whose NN O O
CETP NN O O
levels NN O O
were NN O O
in NN O O
the NN O O
lower NN O O
part NN O O
of NN O O
the NN O O
normal NN O O
range NN O O
, NN O O
had NN O O
moderately NN O O
increased NN O O
levels NN O O
of NN O O
HDL NN O O
cholesterol NN O O
and NN O O
apolipoprotein NN O O
A NN O O
- NN O O
I NN O O
and NN O O
an NN O O
increased NN O O
ratio NN O O
of NN O O
HDL NN O O
subclass NN O O
2 NN O O
to NN O O
HDL NN O O
subclass NN O O
3 NN O O
, NN O O
as NN O O
compared NN O O
with NN O O
unaffected NN O O
family NN O O
members NN O O
( NN O O
1 NN O O
. NN O O
5 NN O O
+ NN O O
/ NN O O
- NN O O
0 NN O O
. NN O O
8 NN O O
vs NN O O
. NN O O
0 NN O O
. NN O O
7 NN O O
+ NN O O
/ NN O O
- NN O O
0 NN O O
. NN O O
4 NN O O
) NN O O
. NN O O

CETP NN O B-Disease
deficiency NN O I-Disease
was NN O O
not NN O O
found NN O O
in NN O O
six NN O O
unrelated NN O O
subjects NN O O
with NN O O
elevated NN O O
HDL NN O O
cholesterol NN O O
levels NN O O
who NN O O
were NN O O
from NN O O
different NN O O
parts NN O O
of NN O O
the NN O O
United NN O O
States NN O O
. NN O O

CONCLUSIONS NN O O
. NN O O

CETP NN O B-Disease
deficiency NN O I-Disease
appears NN O O
to NN O O
be NN O O
a NN O O
frequent NN O O
cause NN O O
of NN O O
increased NN O O
HDL NN O O
levels NN O O
in NN O O
the NN O O
population NN O O
of NN O O
Japan NN O O
, NN O O
possibly NN O O
because NN O O
of NN O O
a NN O O
founder NN O O
effect NN O O
. NN O O

The NN O O
results NN O O
that NN O O
we NN O O
observed NN O O
in NN O O
heterozygotes NN O O
suggest NN O O
that NN O O
CETP NN O O
normally NN O O
plays NN O O
a NN O O
part NN O O
in NN O O
the NN O O
regulation NN O O
of NN O O
levels NN O O
of NN O O
HDL NN O O
subclass NN O O
2 NN O O
. NN O O

There NN O O
was NN O O
no NN O O
evidence NN O O
of NN O O
premature NN O B-Disease
atherosclerosis NN O I-Disease
in NN O O
the NN O O
families NN O O
with NN O O
CETP NN O B-Disease
deficiency NN O I-Disease
. NN O O

In NN O O
fact NN O O
, NN O O
the NN O O
lipoprotein NN O O
profile NN O O
of NN O O
persons NN O O
with NN O O
CETP NN O B-Disease
deficiency NN O I-Disease
is NN O O
potentially NN O O
antiatherogenic NN O O
and NN O O
may NN O O
be NN O O
associated NN O O
with NN O O
an NN O O
increased NN O O
life NN O O
span NN O O
. NN O O

Further NN O O
mapping NN O O
of NN O O
an NN O O
ataxia NN O B-Disease
- NN O I-Disease
telangiectasia NN O I-Disease
locus NN O O
to NN O O
the NN O O
chromosome NN O O
11q23 NN O O
region NN O O
. NN O O

We NN O O
recently NN O O
mapped NN O O
the NN O O
gene NN O O
for NN O O
ataxia NN O B-Disease
- NN O I-Disease
telangiectasia NN O I-Disease
group NN O O
A NN O O
( NN O O
ATA NN O O
) NN O O
to NN O O
chromosome NN O O
11q22 NN O O
- NN O O
23 NN O O
by NN O O
linkage NN O O
analysis NN O O
, NN O O
using NN O O
the NN O O
genetic NN O O
markers NN O O
THY1 NN O O
and NN O O
pYNB3 NN O O
. NN O O

12 NN O O
( NN O O
D11S144 NN O O
) NN O O
. NN O O

The NN O O
most NN O O
likely NN O O
order NN O O
was NN O O
cent NN O O
- NN O O
AT NN O O
- NN O O
S144 NN O O
- NN O O
THY1 NN O O
. NN O O

The NN O O
present NN O O
paper NN O O
describes NN O O
further NN O O
mapping NN O O
of NN O O
the NN O O
AT NN O B-Disease
locus NN O O
by NN O O
means NN O O
of NN O O
a NN O O
panel NN O O
of NN O O
10 NN O O
markers NN O O
that NN O O
span NN O O
approximately NN O O
60 NN O O
cM NN O O
in NN O O
the NN O O
11q22 NN O O
- NN O O
23 NN O O
region NN O O
centered NN O O
around NN O O
S144 NN O O
and NN O O
THY1 NN O O
. NN O O

Location NN O O
scores NN O O
indicate NN O O
that NN O O
three NN O O
contiguous NN O O
subsegments NN O O
within NN O O
the NN O O
[ NN O O
S144 NN O O
- NN O O
THY1 NN O O
] NN O O
segment NN O O
, NN O O
as NN O O
well NN O O
as NN O O
three NN O O
contiguous NN O O
segments NN O O
telomeric NN O O
to NN O O
THY1 NN O O
, NN O O
are NN O O
each NN O O
unlikely NN O O
to NN O O
contain NN O O
the NN O O
AT NN O B-Disease
locus NN O O
, NN O O
while NN O O
the NN O O
more NN O O
centromeric NN O O
[ NN O O
STMY NN O O
- NN O O
S144 NN O O
] NN O O
segment NN O O
is NN O O
most NN O O
likely NN O O
to NN O O
contain NN O O
the NN O O
AT NN O B-Disease
locus NN O O
. NN O O

These NN O O
data NN O O
, NN O O
together NN O O
with NN O O
recent NN O O
refinements NN O O
in NN O O
the NN O O
linkage NN O O
and NN O O
physical NN O O
maps NN O O
of NN O O
11q22 NN O O
- NN O O
23 NN O O
, NN O O
place NN O O
the NN O O
AT NN O B-Disease
locus NN O O
at NN O O
11q23 NN O O
. NN O O

Recurrent NN O O
meningitis NN O B-Disease
in NN O O
a NN O O
patient NN O O
with NN O O
congenital NN O B-Disease
deficiency NN O I-Disease
of NN O I-Disease
the NN O I-Disease
C9 NN O I-Disease
component NN O I-Disease
of NN O I-Disease
complement NN O I-Disease
. NN O O

First NN O O
case NN O O
of NN O O
C9 NN O B-Disease
deficiency NN O I-Disease
in NN O O
Europe NN O O
. NN O O

We NN O O
describe NN O O
the NN O O
first NN O O
cases NN O O
, NN O O
to NN O O
our NN O O
knowledge NN O O
, NN O O
of NN O O
C9 NN O B-Disease
deficiency NN O I-Disease
in NN O O
Europe NN O O
that NN O O
were NN O O
detected NN O O
in NN O O
a NN O O
Swiss NN O O
family NN O O
, NN O O
of NN O O
which NN O O
two NN O O
members NN O O
- NN O O
- NN O O
one NN O O
with NN O O
a NN O O
complete NN O O
deficiency NN O O
and NN O O
the NN O O
other NN O O
with NN O O
approximately NN O O
half NN O O
- NN O O
normal NN O O
C9 NN O O
levels NN O O
- NN O O
- NN O O
experienced NN O O
bacterial NN O B-Disease
meningitis NN O I-Disease
. NN O O

The NN O O
index NN O O
patient NN O O
, NN O O
a NN O O
56 NN O O
- NN O O
year NN O O
- NN O O
old NN O O
white NN O O
man NN O O
with NN O O
a NN O O
history NN O O
of NN O O
purulent NN O B-Disease
meningitis NN O I-Disease
at NN O O
the NN O O
age NN O O
of NN O O
23 NN O O
years NN O O
, NN O O
presented NN O O
with NN O O
an NN O O
acute NN O B-Disease
meningococcal NN O I-Disease
meningitis NN O I-Disease
. NN O O

No NN O O
impairment NN O B-Disease
of NN O I-Disease
cellular NN O I-Disease
immunity NN O I-Disease
or NN O O
immunoglobulin NN O B-Disease
deficiency NN O I-Disease
could NN O O
be NN O O
found NN O O
. NN O O

Complement NN O O
assays NN O O
showed NN O O
a NN O O
complete NN O B-Disease
deficiency NN O I-Disease
of NN O I-Disease
the NN O I-Disease
C9 NN O I-Disease
component NN O I-Disease
, NN O O
while NN O O
the NN O O
other NN O O
individual NN O O
component NN O O
levels NN O O
were NN O O
normal NN O O
and NN O O
the NN O O
hemolytic NN O O
activity NN O O
( NN O O
measured NN O O
using NN O O
the NN O O
CH50 NN O O
assay NN O O
) NN O O
was NN O O
only NN O O
slightly NN O O
reduced NN O O
. NN O O

A NN O O
family NN O O
study NN O O
revealed NN O O
complete NN O B-Disease
C9 NN O I-Disease
deficiency NN O I-Disease
in NN O O
the NN O O
patients NN O O
healthy NN O O
brother NN O O
and NN O O
half NN O O
- NN O O
normal NN O O
C9 NN O O
concentrations NN O O
in NN O O
his NN O O
sister NN O O
, NN O O
his NN O O
son NN O O
( NN O O
who NN O O
also NN O O
had NN O O
experienced NN O O
an NN O O
episode NN O O
of NN O O
bacterial NN O B-Disease
meningitis NN O I-Disease
) NN O O
, NN O O
and NN O O
his NN O O
niece NN O O
, NN O O
consistent NN O O
with NN O O
an NN O O
inherited NN O O
C9 NN O B-Disease
deficiency NN O I-Disease
. NN O O

This NN O O
first NN O O
case NN O O
of NN O O
recurrent NN O B-Disease
meningitis NN O I-Disease
in NN O O
a NN O O
white NN O O
patient NN O O
with NN O O
complete NN O B-Disease
C9 NN O I-Disease
deficiency NN O I-Disease
suggests NN O O
that NN O O
this NN O O
complement NN O B-Disease
defect NN O I-Disease
may NN O O
also NN O O
be NN O O
a NN O O
risk NN O O
factor NN O O
for NN O O
bacterial NN O B-Disease
, NN O I-Disease
especially NN O I-Disease
neisserial NN O I-Disease
, NN O I-Disease
infections NN O I-Disease
. NN O O
. NN O O

Detection NN O O
of NN O O
98 NN O O
% NN O O
of NN O O
DMD NN O B-Disease
/ NN O O
BMD NN O B-Disease
gene NN O O
deletions NN O O
by NN O O
polymerase NN O O
chain NN O O
reaction NN O O
. NN O O

We NN O O
describe NN O O
oligonucleotide NN O O
primer NN O O
sequences NN O O
that NN O O
can NN O O
be NN O O
used NN O O
to NN O O
amplify NN O O
eight NN O O
exons NN O O
plus NN O O
the NN O O
muscle NN O O
promoter NN O O
of NN O O
the NN O O
dystrophin NN O O
gene NN O O
in NN O O
a NN O O
single NN O O
multiplex NN O O
polymerase NN O O
chain NN O O
reaction NN O O
( NN O O
PCR NN O O
) NN O O
. NN O O

When NN O O
used NN O O
in NN O O
conjunction NN O O
with NN O O
an NN O O
existing NN O O
primer NN O O
set NN O O
, NN O O
these NN O O
two NN O O
multiplex NN O O
reactions NN O O
detect NN O O
about NN O O
98 NN O O
% NN O O
of NN O O
deletions NN O O
in NN O O
patients NN O O
with NN O O
Duchenne NN O B-Disease
or NN O I-Disease
Becker NN O I-Disease
muscular NN O I-Disease
dystrophy NN O I-Disease
( NN O O
DMD NN O B-Disease
, NN O O
BMD NN O B-Disease
) NN O O
. NN O O

Furthermore NN O O
, NN O O
these NN O O
primers NN O O
amplify NN O O
most NN O O
of NN O O
the NN O O
exons NN O O
in NN O O
the NN O O
deletion NN O O
prone NN O O
" NN O O
hot NN O O
spot NN O O
" NN O O
region NN O O
around NN O O
exons NN O O
44 NN O O
to NN O O
53 NN O O
, NN O O
allowing NN O O
determination NN O O
of NN O O
deletion NN O O
endpoints NN O O
and NN O O
prediction NN O O
of NN O O
mutational NN O O
effects NN O O
on NN O O
the NN O O
translational NN O O
reading NN O O
frame NN O O
. NN O O

Thus NN O O
, NN O O
use NN O O
of NN O O
these NN O O
PCR NN O O
- NN O O
based NN O O
assays NN O O
will NN O O
allow NN O O
deletion NN O O
detection NN O O
and NN O O
prenatal NN O O
diagnosis NN O O
for NN O O
most NN O O
DMD NN O B-Disease
/ NN O O
BMD NN O B-Disease
patients NN O O
in NN O O
a NN O O
fraction NN O O
of NN O O
the NN O O
time NN O O
required NN O O
for NN O O
Southern NN O O
blot NN O O
analysis NN O O
. NN O O
. NN O O

Genetic NN O O
heterogeneity NN O O
at NN O O
the NN O O
glucose NN O O
- NN O O
6 NN O O
- NN O O
phosphate NN O O
dehydrogenase NN O O
locus NN O O
in NN O O
southern NN O O
Italy NN O O
: NN O O
a NN O O
study NN O O
on NN O O
a NN O O
population NN O O
from NN O O
the NN O O
Matera NN O O
district NN O O
. NN O O

Glucose NN O O
- NN O O
6 NN O O
- NN O O
phosphate NN O O
dehydrogenase NN O O
( NN O O
G6PD NN O O
) NN O O
has NN O O
been NN O O
analyzed NN O O
by NN O O
gel NN O O
electrophoresis NN O O
and NN O O
by NN O O
quantitative NN O O
assay NN O O
in NN O O
an NN O O
unselected NN O O
sample NN O O
of NN O O
1524 NN O O
schoolboys NN O O
from NN O O
the NN O O
province NN O O
of NN O O
Matera NN O O
( NN O O
Lucania NN O O
) NN O O
in NN O O
southern NN O O
Italy NN O O
. NN O O

We NN O O
have NN O O
identified NN O O
43 NN O O
subjects NN O O
with NN O O
a NN O O
G6PD NN O O
variant NN O O
. NN O O

Of NN O O
these NN O O
, NN O O
31 NN O O
had NN O O
severe NN O O
G6PD NN O B-Disease
deficiency NN O I-Disease
, NN O O
nine NN O O
had NN O O
mild NN O O
to NN O O
moderate NN O O
deficiency NN O O
, NN O O
and NN O O
three NN O O
had NN O O
a NN O O
non NN O O
- NN O O
deficient NN O O
electrophoretic NN O O
variant NN O O
. NN O O

The NN O O
overall NN O O
rate NN O O
of NN O O
G6PD NN O B-Disease
deficiency NN O I-Disease
was NN O O
2 NN O O
. NN O O

6 NN O O
% NN O O
. NN O O

The NN O O
frequency NN O O
of NN O O
G6PD NN O B-Disease
deficiency NN O I-Disease
, NN O O
ranging NN O O
from NN O O
7 NN O O
. NN O O

2 NN O O
% NN O O
on NN O O
the NN O O
Ionian NN O O
Coast NN O O
to NN O O
zero NN O O
on NN O O
the NN O O
eastern NN O O
side NN O O
of NN O O
the NN O O
Lucanian NN O O
Apennines NN O O
, NN O O
appears NN O O
to NN O O
be NN O O
inversely NN O O
related NN O O
to NN O O
the NN O O
distance NN O O
of NN O O
each NN O O
town NN O O
examined NN O O
from NN O O
the NN O O
Ionian NN O O
Coast NN O O
, NN O O
suggesting NN O O
that NN O O
this NN O O
geographic NN O O
distribution NN O O
may NN O O
reflect NN O O
, NN O O
at NN O O
least NN O O
in NN O O
part NN O O
, NN O O
gene NN O O
flow NN O O
from NN O O
Greek NN O O
settlers NN O O
. NN O O

Biochemical NN O O
characterization NN O O
has NN O O
shown NN O O
that NN O O
most NN O O
of NN O O
the NN O O
G6PD NN O B-Disease
deficiency NN O I-Disease
in NN O O
this NN O O
population NN O O
is NN O O
accounted NN O O
for NN O O
by NN O O
G6PD NN O O
Mediterranean NN O O
. NN O O

In NN O O
addition NN O O
, NN O O
we NN O O
have NN O O
found NN O O
several NN O O
examples NN O O
of NN O O
two NN O O
other NN O O
known NN O O
polymorphic NN O O
variants NN O O
( NN O O
G6PD NN O O
Cagliari NN O O
and NN O O
G6PD NN O O
A NN O O
- NN O O
) NN O O
; NN O O
three NN O O
new NN O O
polymorphic NN O O
variants NN O O
, NN O O
G6PD NN O O
Metaponto NN O O
( NN O O
class NN O O
III NN O O
) NN O O
, NN O O
G6PD NN O O
Montalbano NN O O
( NN O O
class NN O O
III NN O O
) NN O O
, NN O O
and NN O O
G6PD NN O O
Pisticci NN O O
( NN O O
class NN O O
IV NN O O
) NN O O
; NN O O
and NN O O
two NN O O
sporadic NN O O
variants NN O O
, NN O O
G6PD NN O O
Tursi NN O O
( NN O O
class NN O O
III NN O O
) NN O O
and NN O O
G6PD NN O O
Ferrandina NN O O
( NN O O
class NN O O
II NN O O
) NN O O
. NN O O

These NN O O
data NN O O
provide NN O O
further NN O O
evidence NN O O
for NN O O
the NN O O
marked NN O O
genetic NN O O
heterogeneity NN O O
of NN O O
G6PD NN O B-Disease
deficiency NN O I-Disease
within NN O O
a NN O O
relatively NN O O
narrow NN O O
geographic NN O O
area NN O O
and NN O O
they NN O O
prove NN O O
the NN O O
presence NN O O
in NN O O
the NN O O
Italian NN O O
peninsula NN O O
of NN O O
a NN O O
gene NN O O
( NN O O
GdA NN O O
- NN O O
) NN O O
regarded NN O O
as NN O O
characteristically NN O O
African NN O O
. NN O O

Deficiency NN O B-Disease
of NN O I-Disease
the NN O I-Disease
murine NN O I-Disease
fifth NN O I-Disease
complement NN O I-Disease
component NN O I-Disease
( NN O I-Disease
C5 NN O I-Disease
) NN O I-Disease
. NN O O

A NN O O
2 NN O O
- NN O O
base NN O O
pair NN O O
gene NN O O
deletion NN O O
in NN O O
a NN O O
5 NN O O
' NN O O
- NN O O
exon NN O O
. NN O O

To NN O O
ascertain NN O O
the NN O O
molecular NN O O
mechanism NN O O
that NN O O
causes NN O O
murine NN O O
C5 NN O B-Disease
deficiency NN O I-Disease
, NN O O
genomic NN O O
and NN O O
cDNA NN O O
libraries NN O O
were NN O O
constructed NN O O
from NN O O
mouse NN O O
liver NN O O
DNA NN O O
and NN O O
mRNA NN O O
employing NN O O
the NN O O
congenic NN O O
strains NN O O
B10 NN O O
. NN O O

D2 NN O O
/ NN O O
nSnJ NN O O
and NN O O
B10 NN O O
. NN O O

D2 NN O O
/ NN O O
oSnJ NN O O
that NN O O
are NN O O
sufficient NN O O
and NN O O
deficient NN O B-Disease
for NN O I-Disease
C5 NN O I-Disease
, NN O O
respectively NN O O
. NN O O

Genomic NN O O
fragments NN O O
were NN O O
isolated NN O O
which NN O O
correspond NN O O
to NN O O
PvuII NN O O
and NN O O
HindIII NN O O
restriction NN O O
fragment NN O O
length NN O O
polymorphisms NN O O
associated NN O O
with NN O O
C5 NN O B-Disease
deficiency NN O I-Disease
. NN O O

Sequence NN O O
analyses NN O O
demonstrated NN O O
that NN O O
each NN O O
of NN O O
these NN O O
polymorphisms NN O O
resulted NN O O
from NN O O
single NN O O
base NN O O
pair NN O O
substitutions NN O O
and NN O O
that NN O O
neither NN O O
substitution NN O O
would NN O O
probably NN O O
cause NN O O
or NN O O
contribute NN O O
to NN O O
the NN O O
C5 NN O B-Disease
deficiency NN O I-Disease
. NN O O

Sequence NN O O
analyses NN O O
of NN O O
C5 NN O O
sufficient NN O O
and NN O O
deficient NN O O
cDNAs NN O O
revealed NN O O
a NN O O
2 NN O O
base NN O O
- NN O O
pair NN O O
deletion NN O O
in NN O O
the NN O O
deficient NN O O
cDNAs NN O O
. NN O O

The NN O O
" NN O O
TA NN O O
" NN O O
deletion NN O O
was NN O O
located NN O O
near NN O O
the NN O O
5 NN O O
end NN O O
of NN O O
the NN O O
cDNA NN O O
. NN O O

This NN O O
deletion NN O O
shifts NN O O
the NN O O
reading NN O O
frame NN O O
of NN O O
the NN O O
C5 NN O O
mRNA NN O O
so NN O O
that NN O O
the NN O O
termination NN O O
codon NN O O
UGA NN O O
is NN O O
present NN O O
4 NN O O
base NN O O
pairs NN O O
downstream NN O O
from NN O O
the NN O O
deletion NN O O
. NN O O

Genomic NN O O
DNA NN O O
was NN O O
amplified NN O O
and NN O O
sequenced NN O O
corresponding NN O O
to NN O O
the NN O O
area NN O O
surrounding NN O O
the NN O O
2 NN O O
- NN O O
base NN O O
pair NN O O
deletion NN O O
. NN O O

Six NN O O
C5 NN O B-Disease
- NN O I-Disease
deficient NN O I-Disease
strains NN O O
, NN O O
A NN O O
/ NN O O
HeJ NN O O
, NN O O
AKR NN O O
/ NN O O
J NN O O
, NN O O
DBA NN O O
/ NN O O
2J NN O O
, NN O O
NZB NN O O
/ NN O O
B1NJ NN O O
, NN O O
SWR NN O O
/ NN O O
J NN O O
, NN O O
and NN O O
B10 NN O O
. NN O O

D2 NN O O
/ NN O O
oSnJ NN O O
, NN O O
and NN O O
four NN O O
C5 NN O O
- NN O O
sufficient NN O O
strains NN O O
, NN O O
Balb NN O O
/ NN O O
CJ NN O O
, NN O O
C57Bl NN O O
/ NN O O
6J NN O O
, NN O O
DBA NN O O
/ NN O O
1J NN O O
, NN O O
and NN O O
B10 NN O O
. NN O O

D2 NN O O
/ NN O O
nSnJ NN O O
, NN O O
were NN O O
analyzed NN O O
. NN O O

The NN O O
sequencing NN O O
data NN O O
revealed NN O O
that NN O O
the NN O O
2 NN O O
base NN O O
pairs NN O O
were NN O O
deleted NN O O
from NN O O
the NN O O
C5 NN O O
gene NN O O
of NN O O
each NN O O
deficient NN O O
mouse NN O O
tested NN O O
but NN O O
not NN O O
from NN O O
the NN O O
C5 NN O O
gene NN O O
of NN O O
any NN O O
sufficient NN O O
mouse NN O O
. NN O O

These NN O O
data NN O O
demonstrate NN O O
that NN O O
1 NN O O
) NN O O
there NN O O
is NN O O
an NN O O
identical NN O O
2 NN O O
- NN O O
base NN O O
pair NN O O
deletion NN O O
in NN O O
an NN O O
exon NN O O
of NN O O
the NN O O
C5 NN O O
gene NN O O
in NN O O
several NN O O
different NN O O
C5 NN O B-Disease
- NN O I-Disease
deficient NN O I-Disease
mouse NN O O
strains NN O O
; NN O O
2 NN O O
) NN O O
the NN O O
mRNA NN O O
transcribed NN O O
from NN O O
the NN O O
C5D NN O O
gene NN O O
retains NN O O
this NN O O
deletion NN O O
; NN O O
and NN O O
3 NN O O
) NN O O
this NN O O
mutation NN O O
should NN O O
result NN O O
in NN O O
C5 NN O B-Disease
protein NN O I-Disease
deficiency NN O I-Disease
. NN O O

Molecular NN O O
genetics NN O O
of NN O O
PKU NN O B-Disease
in NN O O
eastern NN O O
Europe NN O O
: NN O O
a NN O O
nonsense NN O O
mutation NN O O
associated NN O O
with NN O O
haplotype NN O O
4 NN O O
of NN O O
the NN O O
phenylalanine NN O O
hydroxylase NN O O
gene NN O O
. NN O O

Phenylketonuria NN O B-Disease
( NN O O
PKU NN O B-Disease
) NN O O
is NN O O
a NN O O
genetic NN O B-Disease
disorder NN O I-Disease
secondary NN O O
to NN O O
a NN O O
deficiency NN O B-Disease
of NN O I-Disease
hepatic NN O I-Disease
phenylalanine NN O I-Disease
hydroxylase NN O I-Disease
( NN O O
PAH NN O O
) NN O O
. NN O O

Several NN O O
mutations NN O O
in NN O O
the NN O O
PAH NN O O
gene NN O O
have NN O O
recently NN O O
been NN O O
reported NN O O
, NN O O
and NN O O
linkage NN O O
disequilibrium NN O O
was NN O O
observed NN O O
between NN O O
RFLP NN O O
haplotypes NN O O
and NN O O
specific NN O O
mutations NN O O
. NN O O

A NN O O
new NN O O
molecular NN O B-Disease
lesion NN O I-Disease
has NN O O
been NN O O
identified NN O O
in NN O O
exon NN O O
7 NN O O
of NN O O
the NN O O
PAH NN O O
gene NN O O
in NN O O
a NN O O
Hungarian NN O O
PKU NN O B-Disease
patient NN O O
by NN O O
direct NN O O
sequencing NN O O
of NN O O
PCR NN O O
- NN O O
amplified NN O O
DNA NN O O
. NN O O

The NN O O
C NN O O
- NN O O
to NN O O
- NN O O
T NN O O
transition NN O O
causes NN O O
the NN O O
substitution NN O O
of NN O O
Arg243 NN O O
to NN O O
a NN O O
termination NN O O
codon NN O O
, NN O O
and NN O O
the NN O O
mutant NN O O
allele NN O O
is NN O O
associated NN O O
with NN O O
haplotype NN O O
4 NN O O
of NN O O
the NN O O
PAH NN O O
gene NN O O
. NN O O

The NN O O
mutation NN O O
is NN O O
present NN O O
in NN O O
two NN O O
of NN O O
nine NN O O
mutant NN O O
haplotype NN O O
4 NN O O
alleles NN O O
among NN O O
Eastern NN O O
Europeans NN O O
and NN O O
is NN O O
not NN O O
present NN O O
among NN O O
Western NN O O
Europeans NN O O
and NN O O
Asians NN O O
. NN O O

The NN O O
rarity NN O O
of NN O O
this NN O O
mutant NN O O
allele NN O O
and NN O O
its NN O O
restricted NN O O
geographic NN O O
distribution NN O O
suggest NN O O
that NN O O
the NN O O
mutational NN O O
event NN O O
occurred NN O O
recently NN O O
on NN O O
a NN O O
normal NN O O
haplotype NN O O
4 NN O O
background NN O O
in NN O O
Eastern NN O O
Europe NN O O
. NN O O
. NN O O

The NN O O
red NN O O
- NN O O
green NN O O
visual NN O O
pigment NN O O
gene NN O O
region NN O O
in NN O O
adrenoleukodystrophy NN O B-Disease
. NN O O

Although NN O O
recent NN O O
data NN O O
established NN O O
that NN O O
a NN O O
specific NN O O
very NN O O
- NN O O
long NN O O
- NN O O
chain NN O O
fatty NN O O
acyl NN O O
- NN O O
CoA NN O O
synthetase NN O O
is NN O O
defective NN O O
in NN O O
X NN O B-Disease
- NN O I-Disease
linked NN O I-Disease
adrenoleukodystrophy NN O I-Disease
( NN O O
ALD NN O B-Disease
) NN O O
, NN O O
the NN O O
ALD NN O B-Disease
gene NN O O
is NN O O
still NN O O
unidentified NN O O
. NN O O

The NN O O
ALD NN O B-Disease
locus NN O O
has NN O O
been NN O O
mapped NN O O
to NN O O
Xq28 NN O O
, NN O O
like NN O O
the NN O O
red NN O O
and NN O O
green NN O O
color NN O O
pigment NN O O
genes NN O O
. NN O O

Abnormal NN O B-Disease
color NN O I-Disease
vision NN O I-Disease
has NN O O
been NN O O
observed NN O O
in NN O O
12 NN O O
of NN O O
27 NN O O
patients NN O O
with NN O O
adrenomyeloneuropathy NN O B-Disease
( NN O O
AMN NN O B-Disease
) NN O O
, NN O O
a NN O O
milder NN O O
form NN O O
of NN O O
ALD NN O B-Disease
. NN O O

Furthermore NN O O
, NN O O
rearrangements NN O O
of NN O O
the NN O O
color NN O O
vision NN O O
gene NN O O
cluster NN O O
were NN O O
found NN O O
in NN O O
four NN O O
of NN O O
eight NN O O
ALD NN O B-Disease
kindreds NN O O
. NN O O

This NN O O
led NN O O
us NN O O
to NN O O
propose NN O O
that NN O O
a NN O O
single NN O O
DNA NN O O
rearrangement NN O O
could NN O O
underlie NN O O
both NN O O
ALD NN O B-Disease
and NN O O
abnormal NN O B-Disease
color NN O I-Disease
vision NN O I-Disease
in NN O O
these NN O O
patients NN O O
. NN O O

Study NN O O
of NN O O
34 NN O O
French NN O O
ALD NN O B-Disease
patients NN O O
failed NN O O
to NN O O
reveal NN O O
a NN O O
higher NN O O
than NN O O
expected NN O O
frequency NN O O
of NN O O
green NN O O
/ NN O O
red NN O O
visual NN O O
pigment NN O O
rearrangements NN O O
3 NN O O
to NN O O
the NN O O
red NN O O
/ NN O O
green NN O O
color NN O O
vision NN O O
gene NN O O
complex NN O O
. NN O O

The NN O O
previous NN O O
report NN O O
of NN O O
such NN O O
rearrangements NN O O
was NN O O
based NN O O
on NN O O
small NN O O
numbers NN O O
and NN O O
lack NN O O
of NN O O
knowledge NN O O
that NN O O
the NN O O
frequency NN O O
of NN O O
" NN O O
abnormal NN O O
" NN O O
color NN O O
vision NN O O
arrays NN O O
on NN O O
molecular NN O O
analysis NN O O
was NN O O
twice NN O O
as NN O O
high NN O O
as NN O O
expected NN O O
on NN O O
the NN O O
basis NN O O
of NN O O
the NN O O
frequency NN O O
of NN O O
phenotypic NN O B-Disease
color NN O I-Disease
vision NN O I-Disease
defects NN O I-Disease
. NN O O

The NN O O
red NN O O
/ NN O O
green NN O O
color NN O O
pigment NN O O
( NN O O
R NN O O
/ NN O O
GCP NN O O
) NN O O
region NN O O
was NN O O
studied NN O O
by NN O O
pulsed NN O O
- NN O O
field NN O O
gel NN O O
electrophoresis NN O O
in NN O O
14 NN O O
of NN O O
these NN O O
patients NN O O
, NN O O
and NN O O
we NN O O
did NN O O
not NN O O
find NN O O
any NN O O
fragment NN O O
size NN O O
difference NN O O
between NN O O
the NN O O
patients NN O O
and NN O O
normal NN O O
individuals NN O O
who NN O O
have NN O O
the NN O O
same NN O O
number NN O O
of NN O O
pigment NN O O
genes NN O O
. NN O O

The NN O O
R NN O O
/ NN O O
GCP NN O O
region NN O O
was NN O O
also NN O O
analyzed NN O O
in NN O O
29 NN O O
French NN O O
and NN O O
seven NN O O
North NN O O
American NN O O
ALD NN O B-Disease
patients NN O O
by NN O O
using NN O O
six NN O O
genomic NN O O
DNA NN O O
probes NN O O
, NN O O
isolated NN O O
from NN O O
a NN O O
cosmid NN O O
walk NN O O
, NN O O
that NN O O
flank NN O O
the NN O O
color NN O O
vision NN O O
genes NN O O
. NN O O

No NN O O
deletions NN O O
were NN O O
found NN O O
with NN O O
probes NN O O
that NN O O
lie NN O O
3 NN O O
of NN O O
the NN O O
green NN O O
pigment NN O O
genes NN O O
. NN O O

One NN O O
of NN O O
the NN O O
eight NN O O
previously NN O O
reported NN O O
ALD NN O B-Disease
individuals NN O O
has NN O O
a NN O O
long NN O O
deletion NN O O
5 NN O O
of NN O O
the NN O O
red NN O O
pigment NN O O
gene NN O O
, NN O O
a NN O O
deletion NN O O
causing NN O O
blue NN O O
cone NN O O
monochromacy NN O O
. NN O O

This NN O O
finding NN O O
and NN O O
the NN O O
previous NN O O
findings NN O O
of NN O O
a NN O O
45 NN O O
% NN O O
frequency NN O O
of NN O O
phenotypic NN O O
color NN O O
vision NN O O
defects NN O O
in NN O O
patients NN O O
with NN O O
AMN NN O B-Disease
may NN O O
suggest NN O O
that NN O O
the NN O O
ALD NN O B-Disease
/ NN O O
AMN NN O B-Disease
gene NN O O
lies NN O O
5 NN O O
to NN O O
the NN O O
red NN O O
pigment NN O O
gene NN O O
and NN O O
that NN O O
the NN O O
frequent NN O O
phenotypic NN O O
color NN O B-Disease
vision NN O I-Disease
anomalies NN O I-Disease
owe NN O O
their NN O O
origin NN O O
to NN O O
deleted NN O O
DNA NN O O
that NN O O
includes NN O O
regulatory NN O O
genes NN O O
for NN O O
color NN O O
vision NN O O
. NN O O

It NN O O
is NN O O
possible NN O O
, NN O O
however NN O O
, NN O O
that NN O O
phenotypic NN O O
color NN O B-Disease
vision NN O I-Disease
anomalies NN O I-Disease
in NN O O
AMN NN O B-Disease
may NN O O
be NN O O
phenocopies NN O O
secondary NN O O
to NN O O
retinal NN O O
or NN O O
neural NN O O
involvement NN O O
by NN O O
the NN O O
disease NN O O
. NN O O

The NN O O
single NN O O
case NN O O
of NN O O
blue NN O O
cone NN O O
monochromacy NN O O
may NN O O
therefore NN O O
be NN O O
a NN O O
fortuitous NN O O
coincidence NN O O
of NN O O
two NN O O
diseases NN O O
. NN O O
. NN O O

Paroxysmal NN O B-Disease
nocturnal NN O I-Disease
haemoglobinuria NN O I-Disease
with NN O O
coexisting NN O O
deficiency NN O B-Disease
of NN O I-Disease
the NN O I-Disease
ninth NN O I-Disease
component NN O I-Disease
of NN O I-Disease
complement NN O I-Disease
: NN O O
lack NN O O
of NN O O
massive NN O O
haemolytic NN O B-Disease
attack NN O I-Disease
. NN O O

A NN O O
47 NN O O
- NN O O
year NN O O
- NN O O
old NN O O
woman NN O O
with NN O O
paroxysmal NN O B-Disease
nocturnal NN O I-Disease
haemoglobinuria NN O I-Disease
( NN O O
PNH NN O B-Disease
) NN O O
was NN O O
found NN O O
to NN O O
have NN O O
an NN O O
inherited NN O B-Disease
deficiency NN O I-Disease
in NN O I-Disease
the NN O I-Disease
ninth NN O I-Disease
complement NN O I-Disease
component NN O I-Disease
( NN O O
C9 NN O O
) NN O O
. NN O O

In NN O O
complement NN O O
- NN O O
sensitivity NN O O
lysis NN O O
tests NN O O
, NN O O
80 NN O O
% NN O O
of NN O O
her NN O O
erythrocytes NN O O
were NN O O
markedly NN O O
complement NN O O
- NN O O
sensitive NN O O
( NN O O
PNH NN O O
- NN O O
III NN O O
) NN O O
. NN O O

Laser NN O O
cytofluorimetry NN O O
with NN O O
a NN O O
monoclonal NN O O
antibody NN O O
against NN O O
decay NN O O
- NN O O
accelerating NN O O
factor NN O O
( NN O O
DAF NN O O
) NN O O
revealed NN O O
that NN O O
95 NN O O
% NN O O
of NN O O
her NN O O
erythrocytes NN O O
were NN O O
DAF NN O O
- NN O O
negative NN O O
. NN O O

Surprisingly NN O O
, NN O O
she NN O O
has NN O O
suffered NN O O
only NN O O
mild NN O O
haemolysis NN O B-Disease
and NN O O
has NN O O
never NN O O
experienced NN O O
massive NN O O
spontaneous NN O O
haemolysis NN O B-Disease
. NN O O

Gross NN O O
haemoglobinuria NN O B-Disease
and NN O O
jaundice NN O B-Disease
occurred NN O O
only NN O O
after NN O O
receiving NN O O
postoperative NN O O
transfusion NN O O
of NN O O
whole NN O O
blood NN O O
. NN O O

In NN O O
her NN O O
serum NN O O
, NN O O
C9 NN O O
was NN O O
not NN O O
detectable NN O O
either NN O O
by NN O O
immunological NN O O
or NN O O
by NN O O
functional NN O O
assays NN O O
. NN O O

Both NN O O
the NN O O
Ham NN O O
test NN O O
and NN O O
the NN O O
sugar NN O O
water NN O O
test NN O O
using NN O O
normal NN O O
human NN O O
serum NN O O
or NN O O
plasma NN O O
yielded NN O O
marked NN O O
haemolysis NN O O
of NN O O
the NN O O
patients NN O O
erythrocytes NN O O
. NN O O

When NN O O
the NN O O
patients NN O O
serum NN O O
or NN O O
plasma NN O O
was NN O O
used NN O O
, NN O O
only NN O O
a NN O O
trace NN O O
of NN O O
lysis NN O O
was NN O O
detected NN O O
. NN O O

Addition NN O O
of NN O O
purified NN O O
human NN O O
C9 NN O O
to NN O O
her NN O O
plasma NN O O
fully NN O O
restored NN O O
haemolysis NN O O
. NN O O

These NN O O
observations NN O O
indicated NN O O
that NN O O
C9 NN O O
may NN O O
play NN O O
a NN O O
critical NN O O
role NN O O
in NN O O
haemolytic NN O B-Disease
attacks NN O I-Disease
in NN O O
patients NN O O
with NN O O
PNH NN O B-Disease
and NN O O
that NN O O
characteristic NN O O
haemolysis NN O B-Disease
in NN O O
PNH NN O B-Disease
may NN O O
be NN O O
tempered NN O O
by NN O O
coexisting NN O O
C9 NN O B-Disease
deficiency NN O I-Disease
. NN O O
. NN O O

Duplicational NN O O
mutation NN O O
at NN O O
the NN O O
Duchenne NN O B-Disease
muscular NN O I-Disease
dystrophy NN O I-Disease
locus NN O O
: NN O O
its NN O O
frequency NN O O
, NN O O
distribution NN O O
, NN O O
origin NN O O
, NN O O
and NN O O
phenotypegenotype NN O O
correlation NN O O
. NN O O

Partial NN O O
gene NN O O
deletion NN O O
is NN O O
the NN O O
major NN O O
cause NN O O
of NN O O
mutation NN O O
leading NN O O
to NN O O
Duchenne NN O B-Disease
muscular NN O I-Disease
dystrophy NN O I-Disease
( NN O O
DMD NN O B-Disease
) NN O O
and NN O O
Becker NN O B-Disease
muscular NN O I-Disease
dystrophy NN O I-Disease
( NN O O
BMD NN O B-Disease
) NN O O
. NN O O

Partial NN O O
gene NN O O
duplication NN O O
has NN O O
also NN O O
been NN O O
recognized NN O O
in NN O O
a NN O O
few NN O O
cases NN O O
. NN O O

We NN O O
have NN O O
conducted NN O O
a NN O O
survey NN O O
for NN O O
duplication NN O O
in NN O O
72 NN O O
unrelated NN O O
nondeletion NN O O
patients NN O O
, NN O O
analyzed NN O O
by NN O O
Southern NN O O
blot NN O O
hybridization NN O O
with NN O O
clones NN O O
representing NN O O
the NN O O
entire NN O O
DMD NN O B-Disease
cDNA NN O O
. NN O O

With NN O O
careful NN O O
quantitative NN O O
analysis NN O O
of NN O O
hybridization NN O O
band NN O O
intensity NN O O
, NN O O
10 NN O O
cases NN O O
were NN O O
found NN O O
to NN O O
carry NN O O
a NN O O
duplication NN O O
of NN O O
part NN O O
of NN O O
the NN O O
gene NN O O
, NN O O
a NN O O
frequency NN O O
of NN O O
14 NN O O
% NN O O
for NN O O
nondeletion NN O O
cases NN O O
( NN O O
10 NN O O
/ NN O O
72 NN O O
) NN O O
, NN O O
or NN O O
6 NN O O
% NN O O
for NN O O
all NN O O
cases NN O O
( NN O O
10 NN O O
/ NN O O
181 NN O O
) NN O O
. NN O O

The NN O O
extent NN O O
of NN O O
these NN O O
duplications NN O O
has NN O O
been NN O O
characterized NN O O
according NN O O
to NN O O
the NN O O
published NN O O
exon NN O O
- NN O O
containing NN O O
HindIII NN O O
fragment NN O O
map NN O O
, NN O O
and NN O O
in NN O O
six NN O O
of NN O O
the NN O O
10 NN O O
duplications NN O O
a NN O O
novel NN O O
restriction NN O O
fragment NN O O
that NN O O
spanned NN O O
the NN O O
duplication NN O O
junction NN O O
was NN O O
detected NN O O
. NN O O

The NN O O
resulting NN O O
translational NN O O
reading NN O O
frame NN O O
of NN O O
mRNA NN O O
has NN O O
been NN O O
predicted NN O O
for NN O O
nine NN O O
duplications NN O O
. NN O O

A NN O O
shift NN O O
of NN O O
the NN O O
reading NN O O
frame NN O O
was NN O O
predicted NN O O
in NN O O
four NN O O
of NN O O
the NN O O
six NN O O
DMD NN O B-Disease
cases NN O O
and NN O O
in NN O O
one NN O O
of NN O O
the NN O O
two NN O O
intermediate NN O O
cases NN O O
, NN O O
while NN O O
the NN O O
reading NN O O
frame NN O O
remained NN O O
uninterrupted NN O O
in NN O O
both NN O O
BMD NN O B-Disease
cases NN O O
. NN O O

RFLP NN O O
and NN O O
quantitative NN O O
Southern NN O O
blot NN O O
analyses NN O O
revealed NN O O
a NN O O
grandpaternal NN O O
origin NN O O
of NN O O
duplication NN O O
in NN O O
four NN O O
families NN O O
and NN O O
grandmaternal NN O O
origin NN O O
in NN O O
one NN O O
family NN O O
. NN O O

In NN O O
all NN O O
five NN O O
families NN O O
, NN O O
the NN O O
duplication NN O O
was NN O O
found NN O O
to NN O O
originate NN O O
from NN O O
a NN O O
single NN O O
X NN O O
chromosome NN O O
. NN O O

Unequal NN O O
sister NN O O
- NN O O
chromatid NN O O
exchange NN O O
is NN O O
proposed NN O O
to NN O O
be NN O O
the NN O O
mechanism NN O O
for NN O O
the NN O O
formation NN O O
of NN O O
these NN O O
duplications NN O O
. NN O O
. NN O O

Glucose NN O O
6 NN O O
- NN O O
phosphate NN O O
dehydrogenase NN O O
variants NN O O
: NN O O
Gd NN O O
( NN O O
+ NN O O
) NN O O
Alexandra NN O O
associated NN O O
with NN O O
neonatal NN O B-Disease
jaundice NN O I-Disease
and NN O O
Gd NN O O
( NN O O
- NN O O
) NN O O
Camperdown NN O O
in NN O O
a NN O O
young NN O O
man NN O O
with NN O O
lamellar NN O B-Disease
cataracts NN O I-Disease
. NN O O

Two NN O O
male NN O O
subjects NN O O
are NN O O
described NN O O
, NN O O
with NN O O
unusual NN O O
clinical NN O O
presentations NN O O
and NN O O
with NN O O
hitherto NN O O
undescribed NN O O
G6PD NN O O
variants NN O O
. NN O O

The NN O O
first NN O O
, NN O O
of NN O O
Italian NN O O
extraction NN O O
, NN O O
suffered NN O O
from NN O O
severe NN O O
neonatal NN O B-Disease
jaundice NN O I-Disease
following NN O O
maternal NN O O
ingestion NN O O
of NN O O
fresh NN O O
broad NN O O
beans NN O O
( NN O O
Vicia NN O O
fava NN O O
) NN O O
both NN O O
prenatally NN O O
and NN O O
postnatally NN O O
the NN O O
expression NN O O
of NN O O
the NN O O
enzymatic NN O O
defect NN O O
was NN O O
much NN O O
more NN O O
severe NN O O
in NN O O
the NN O O
neonatal NN O O
period NN O O
than NN O O
on NN O O
retesting NN O O
in NN O O
adolescence NN O O
, NN O O
when NN O O
biochemical NN O O
characterization NN O O
showed NN O O
unique NN O O
features NN O O
which NN O O
justify NN O O
designation NN O O
as NN O O
a NN O O
new NN O O
variant NN O O
Gd NN O O
( NN O O
+ NN O O
) NN O O
Alexandra NN O O
. NN O O

The NN O O
second NN O O
patient NN O O
, NN O O
a NN O O
boy NN O O
of NN O O
Maltese NN O O
extraction NN O O
who NN O O
was NN O O
found NN O O
to NN O O
have NN O O
bilateral NN O B-Disease
lamellar NN O I-Disease
cataracts NN O I-Disease
at NN O O
the NN O O
age NN O O
of NN O O
4 NN O O
years NN O O
, NN O O
was NN O O
identified NN O O
as NN O O
G6PD NN O B-Disease
deficient NN O I-Disease
only NN O O
as NN O O
a NN O O
result NN O O
of NN O O
a NN O O
survey NN O O
of NN O O
children NN O O
of NN O O
Mediterranean NN O O
origin NN O O
with NN O O
unexplained NN O O
cataract NN O B-Disease
formation NN O O
; NN O O
he NN O O
has NN O O
approximately NN O O
15 NN O O
% NN O O
of NN O O
normal NN O O
enzyme NN O O
activity NN O O
, NN O O
with NN O O
another NN O O
unique NN O O
combination NN O O
of NN O O
biochemical NN O O
characteristics NN O O
which NN O O
has NN O O
led NN O O
to NN O O
its NN O O
designation NN O O
as NN O O
Gd NN O O
( NN O O
- NN O O
) NN O O
Camperdown NN O O
. NN O O

Although NN O O
this NN O O
association NN O O
may NN O O
be NN O O
coincidental NN O O
, NN O O
it NN O O
prompts NN O O
further NN O O
attention NN O O
to NN O O
the NN O O
possibility NN O O
that NN O O
under NN O O
certain NN O O
circumstances NN O O
G6PD NN O B-Disease
deficiency NN O I-Disease
may NN O O
favor NN O O
cataract NN O B-Disease
formation NN O O
. NN O O

The NN O O
two NN O O
cases NN O O
illustrate NN O O
the NN O O
value NN O O
of NN O O
characterization NN O O
of NN O O
the NN O O
mutant NN O O
enzyme NN O O
whenever NN O O
unexpected NN O O
clinical NN O O
or NN O O
laboratory NN O O
results NN O O
are NN O O
obtained NN O O
. NN O O
. NN O O

Statistical NN O O
analysis NN O O
of NN O O
the NN O O
two NN O O
stage NN O O
mutation NN O O
model NN O O
in NN O O
von NN O B-Disease
Hippel NN O I-Disease
- NN O I-Disease
Lindau NN O I-Disease
disease NN O I-Disease
, NN O O
and NN O O
in NN O O
sporadic NN O B-Disease
cerebellar NN O I-Disease
haemangioblastoma NN O I-Disease
and NN O O
renal NN O B-Disease
cell NN O I-Disease
carcinoma NN O I-Disease
. NN O O

Analysis NN O O
of NN O O
the NN O O
age NN O O
incidence NN O O
curves NN O O
for NN O O
unilateral NN O B-Disease
and NN O I-Disease
bilateral NN O I-Disease
retinoblastoma NN O I-Disease
led NN O O
Knudson NN O O
to NN O O
propose NN O O
that NN O O
hereditary NN O B-Disease
tumours NN O I-Disease
may NN O O
arise NN O O
by NN O O
a NN O O
single NN O O
event NN O O
and NN O O
sporadic NN O B-Disease
tumours NN O I-Disease
by NN O O
a NN O O
two NN O O
stage NN O O
mutation NN O O
process NN O O
. NN O O

It NN O O
has NN O O
been NN O O
suggested NN O O
recently NN O O
that NN O O
sporadic NN O B-Disease
renal NN O I-Disease
cell NN O I-Disease
carcinoma NN O I-Disease
may NN O O
arise NN O O
from NN O O
a NN O O
two NN O O
stage NN O O
mutation NN O O
process NN O O
. NN O O

We NN O O
analysed NN O O
the NN O O
age NN O O
incidence NN O O
curves NN O O
for NN O O
symptomatic NN O O
renal NN O B-Disease
cell NN O I-Disease
carcinoma NN O I-Disease
( NN O O
n NN O O
= NN O O
26 NN O O
) NN O O
and NN O O
cerebellar NN O B-Disease
haemangioblastoma NN O I-Disease
( NN O O
n NN O O
= NN O O
68 NN O O
) NN O O
in NN O O
109 NN O O
patients NN O O
with NN O O
von NN O B-Disease
Hippel NN O I-Disease
- NN O I-Disease
Lindau NN O I-Disease
( NN O I-Disease
VHL NN O I-Disease
) NN O I-Disease
disease NN O I-Disease
, NN O O
and NN O O
compared NN O O
them NN O O
to NN O O
104 NN O O
patients NN O O
with NN O O
sporadic NN O B-Disease
renal NN O I-Disease
cell NN O I-Disease
carcinoma NN O I-Disease
and NN O O
43 NN O O
patients NN O O
with NN O O
sporadic NN O B-Disease
cerebellar NN O I-Disease
haemangioblastoma NN O I-Disease
. NN O O

The NN O O
age NN O O
incidence NN O O
curves NN O O
for NN O O
renal NN O B-Disease
cell NN O I-Disease
carcinoma NN O I-Disease
and NN O O
cerebellar NN O B-Disease
haemangioblastoma NN O I-Disease
in NN O O
VHL NN O B-Disease
disease NN O I-Disease
were NN O O
compatible NN O O
with NN O O
a NN O O
single NN O O
mutation NN O O
model NN O O
, NN O O
whereas NN O O
the NN O O
age NN O O
incidence NN O O
curves NN O O
for NN O O
sporadic NN O B-Disease
renal NN O I-Disease
cell NN O I-Disease
carcinoma NN O I-Disease
and NN O O
cerebellar NN O B-Disease
haemangioblastoma NN O I-Disease
suggested NN O O
a NN O O
two NN O O
stage NN O O
mutation NN O O
process NN O O
. NN O O

These NN O O
data NN O O
are NN O O
compatible NN O O
with NN O O
the NN O O
VHL NN O B-Disease
gene NN O O
functioning NN O O
as NN O O
a NN O O
recessive NN O O
tumour NN O B-Disease
suppressor NN O O
gene NN O O
. NN O O

Sporadic NN O B-Disease
cerebellar NN O I-Disease
haemangioblastoma NN O I-Disease
and NN O O
some NN O O
renal NN O B-Disease
cell NN O I-Disease
carcinoma NN O I-Disease
may NN O O
arise NN O O
from NN O O
somatic NN O O
mutations NN O O
inactivating NN O O
both NN O O
alleles NN O O
at NN O O
the NN O O
VHL NN O B-Disease
locus NN O O
. NN O O
. NN O O

Screening NN O O
for NN O O
carriers NN O O
of NN O O
Tay NN O B-Disease
- NN O I-Disease
Sachs NN O I-Disease
disease NN O I-Disease
among NN O O
Ashkenazi NN O O
Jews NN O O
. NN O O

A NN O O
comparison NN O O
of NN O O
DNA NN O O
- NN O O
based NN O O
and NN O O
enzyme NN O O
- NN O O
based NN O O
tests NN O O
. NN O O

BACKGROUND NN O O
AND NN O O
METHODS NN O O
. NN O O

The NN O O
prevention NN O O
of NN O O
Tay NN O B-Disease
- NN O I-Disease
Sachs NN O I-Disease
disease NN O I-Disease
( NN O O
GM2 NN O B-Disease
gangliosidosis NN O I-Disease
, NN O I-Disease
type NN O I-Disease
1 NN O I-Disease
) NN O O
depends NN O O
on NN O O
the NN O O
identification NN O O
of NN O O
carriers NN O O
of NN O O
the NN O O
gene NN O O
for NN O O
this NN O O
autosomal NN O B-Disease
recessive NN O I-Disease
disorder NN O I-Disease
. NN O O

We NN O O
compared NN O O
the NN O O
enzyme NN O O
- NN O O
based NN O O
test NN O O
widely NN O O
used NN O O
in NN O O
screening NN O O
for NN O O
Tay NN O B-Disease
- NN O I-Disease
Sachs NN O I-Disease
disease NN O I-Disease
with NN O O
a NN O O
test NN O O
based NN O O
on NN O O
analysis NN O O
of NN O O
DNA NN O O
. NN O O

We NN O O
developed NN O O
methods NN O O
to NN O O
detect NN O O
the NN O O
three NN O O
mutations NN O O
in NN O O
the NN O O
HEXA NN O O
gene NN O O
that NN O O
occur NN O O
with NN O O
high NN O O
frequency NN O O
among NN O O
Ashkenazi NN O O
Jews NN O O
two NN O O
mutations NN O O
cause NN O O
infantile NN O O
Tay NN O B-Disease
- NN O I-Disease
Sachs NN O I-Disease
disease NN O I-Disease
, NN O O
and NN O O
the NN O O
third NN O O
causes NN O O
the NN O O
adult NN O O
- NN O O
onset NN O O
form NN O O
of NN O O
the NN O O
disease NN O O
. NN O O

DNA NN O O
segments NN O O
containing NN O O
these NN O O
mutation NN O O
sites NN O O
were NN O O
amplified NN O O
with NN O O
the NN O O
polymerase NN O O
chain NN O O
reaction NN O O
and NN O O
analyzed NN O O
for NN O O
the NN O O
presence NN O O
of NN O O
the NN O O
mutations NN O O
. NN O O

RESULTS NN O O
. NN O O

Among NN O O
62 NN O O
Ashkenazi NN O O
obligate NN O O
carriers NN O O
of NN O O
Tay NN O B-Disease
- NN O I-Disease
Sachs NN O I-Disease
disease NN O I-Disease
, NN O O
the NN O O
three NN O O
specific NN O O
mutations NN O O
accounted NN O O
for NN O O
all NN O O
but NN O O
one NN O O
of NN O O
the NN O O
mutant NN O O
alleles NN O O
( NN O O
98 NN O O
percent NN O O
) NN O O
. NN O O

In NN O O
216 NN O O
Ashkenazi NN O O
carriers NN O O
identified NN O O
by NN O O
the NN O O
enzyme NN O O
test NN O O
, NN O O
DNA NN O O
analysis NN O O
showed NN O O
that NN O O
177 NN O O
( NN O O
82 NN O O
percent NN O O
) NN O O
had NN O O
one NN O O
of NN O O
the NN O O
identified NN O O
mutations NN O O
. NN O O

Of NN O O
the NN O O
177 NN O O
, NN O O
79 NN O O
percent NN O O
had NN O O
the NN O O
exon NN O O
11 NN O O
insertion NN O O
mutation NN O O
, NN O O
18 NN O O
percent NN O O
had NN O O
the NN O O
intron NN O O
12 NN O O
splice NN O O
- NN O O
junction NN O O
mutation NN O O
, NN O O
and NN O O
3 NN O O
percent NN O O
had NN O O
the NN O O
less NN O O
severe NN O O
exon NN O O
7 NN O O
mutation NN O O
associated NN O O
with NN O O
adult NN O O
- NN O O
onset NN O O
disease NN O O
. NN O O

The NN O O
results NN O O
of NN O O
the NN O O
enzyme NN O O
tests NN O O
in NN O O
the NN O O
39 NN O O
subjects NN O O
( NN O O
18 NN O O
percent NN O O
) NN O O
who NN O O
were NN O O
defined NN O O
as NN O O
carriers NN O O
but NN O O
in NN O O
whom NN O O
DNA NN O O
analysis NN O O
did NN O O
not NN O O
identify NN O O
a NN O O
mutant NN O O
allele NN O O
were NN O O
probably NN O O
false NN O O
positive NN O O
( NN O O
although NN O O
there NN O O
remains NN O O
some NN O O
possibility NN O O
of NN O O
unidentified NN O O
mutations NN O O
) NN O O
. NN O O

In NN O O
addition NN O O
, NN O O
of NN O O
152 NN O O
persons NN O O
defined NN O O
as NN O O
noncarriers NN O O
by NN O O
the NN O O
enzyme NN O O
- NN O O
based NN O O
test NN O O
, NN O O
1 NN O O
was NN O O
identified NN O O
as NN O O
a NN O O
carrier NN O O
by NN O O
DNA NN O O
analysis NN O O
( NN O O
i NN O O
. NN O O
e NN O O
e NN O O
. NN O O
, NN O O
a NN O O
false NN O O
negative NN O O
enzyme NN O O
- NN O O
test NN O O
result NN O O
) NN O O
. NN O O

CONCLUSIONS NN O O
. NN O O

The NN O O
increased NN O O
specificity NN O O
and NN O O
predictive NN O O
value NN O O
of NN O O
the NN O O
DNA NN O O
- NN O O
based NN O O
test NN O O
make NN O O
it NN O O
a NN O O
useful NN O O
adjunct NN O O
to NN O O
the NN O O
diagnostic NN O O
tests NN O O
currently NN O O
used NN O O
to NN O O
screen NN O O
for NN O O
carriers NN O O
of NN O O
Tay NN O B-Disease
- NN O I-Disease
Sachs NN O I-Disease
disease NN O I-Disease
. NN O O

Total NN O B-Disease
deficiency NN O I-Disease
of NN O I-Disease
plasma NN O I-Disease
cholesteryl NN O I-Disease
ester NN O I-Disease
transfer NN O I-Disease
protein NN O I-Disease
in NN O O
subjects NN O O
homozygous NN O O
and NN O O
heterozygous NN O O
for NN O O
the NN O O
intron NN O O
14 NN O O
splicing NN O O
defect NN O O
. NN O O

The NN O O
molecular NN O O
basis NN O O
of NN O O
cholesteryl NN O B-Disease
ester NN O I-Disease
transfer NN O I-Disease
protein NN O I-Disease
( NN O I-Disease
CETP NN O I-Disease
) NN O I-Disease
deficiency NN O I-Disease
was NN O O
investigated NN O O
in NN O O
4 NN O O
unrelated NN O O
CETP NN O B-Disease
- NN O I-Disease
deficient NN O I-Disease
families NN O O
. NN O O

The NN O O
high NN O O
density NN O O
lipoprotein NN O O
- NN O O
cholesterol NN O O
levels NN O O
of NN O O
the NN O O
probands NN O O
exceeded NN O O
150 NN O O
mg NN O O
/ NN O O
dl NN O O
. NN O O

The NN O O
plasma NN O O
of NN O O
the NN O O
probands NN O O
was NN O O
totally NN O O
deficient NN O O
in NN O O
CETP NN O O
activity NN O O
and NN O O
mass NN O O
. NN O O

The NN O O
genomic NN O O
DNA NN O O
of NN O O
the NN O O
patients NN O O
was NN O O
amplified NN O O
by NN O O
polymerase NN O O
chain NN O O
reaction NN O O
, NN O O
using NN O O
two NN O O
oligonucleotide NN O O
primers NN O O
located NN O O
in NN O O
the NN O O
intron NN O O
12 NN O O
and NN O O
14 NN O O
of NN O O
the NN O O
CETP NN O O
gene NN O O
, NN O O
and NN O O
the NN O O
amplified NN O O
products NN O O
were NN O O
directly NN O O
sequenced NN O O
. NN O O

Two NN O O
patients NN O O
were NN O O
homozygous NN O O
for NN O O
a NN O O
G NN O O
- NN O O
to NN O O
- NN O O
A NN O O
change NN O O
at NN O O
the NN O O
5 NN O O
- NN O O
splice NN O O
donor NN O O
site NN O O
of NN O O
the NN O O
intron NN O O
14 NN O O
. NN O O

The NN O O
G NN O O
- NN O O
to NN O O
- NN O O
A NN O O
change NN O O
would NN O O
cause NN O O
impaired NN O O
splicing NN O O
of NN O O
pre NN O O
- NN O O
messenger NN O O
RNA NN O O
. NN O O

The NN O O
other NN O O
two NN O O
probands NN O O
were NN O O
heterozygous NN O O
for NN O O
the NN O O
mutation NN O O
, NN O O
but NN O O
totally NN O O
lacked NN O O
CETP NN O O
. NN O O

Their NN O O
lipoprotein NN O O
patterns NN O O
were NN O O
also NN O O
similar NN O O
to NN O O
those NN O O
of NN O O
the NN O O
two NN O O
homozygotes NN O O
. NN O O

Thus NN O O
, NN O O
other NN O O
genetic NN O B-Disease
defects NN O I-Disease
or NN O O
metabolic NN O O
factors NN O O
influencing NN O O
CETP NN O O
expression NN O O
are NN O O
implicated NN O O
. NN O O

The NN O O
data NN O O
suggest NN O O
that NN O O
the NN O O
G NN O O
- NN O O
to NN O O
- NN O O
A NN O O
mutation NN O O
may NN O O
be NN O O
common NN O O
in NN O O
human NN O O
plasma NN O O
CETP NN O B-Disease
deficiency NN O I-Disease
. NN O O

Furthermore NN O O
, NN O O
there NN O O
could NN O O
be NN O O
compound NN O O
heterozygotes NN O O
who NN O O
totally NN O O
lack NN O O
plasma NN O O
CETP NN O O
and NN O O
have NN O O
lipoprotein NN O O
profiles NN O O
similar NN O O
to NN O O
those NN O O
of NN O O
homozygotes NN O O
. NN O O
. NN O O

Molecular NN O O
genetics NN O O
of NN O O
the NN O O
glucose NN O O
- NN O O
6 NN O O
- NN O O
phosphate NN O O
dehydrogenase NN O O
( NN O O
G6PD NN O O
) NN O O
Mediterranean NN O O
variant NN O O
and NN O O
description NN O O
of NN O O
a NN O O
new NN O O
G6PD NN O O
mutant NN O O
, NN O O
G6PD NN O O
Andalus1361A NN O O
. NN O O

Glucose NN O B-Disease
- NN O I-Disease
6 NN O I-Disease
- NN O I-Disease
phosphate NN O I-Disease
dehydrogenase NN O I-Disease
( NN O I-Disease
G6PD NN O I-Disease
; NN O I-Disease
E NN O I-Disease
. NN O I-Disease
C NN O I-Disease
. NN O I-Disease
1 NN O I-Disease
. NN O I-Disease
1 NN O I-Disease
. NN O I-Disease
1 NN O I-Disease
. NN O I-Disease
49 NN O I-Disease
) NN O I-Disease
deficiency NN O I-Disease
is NN O O
the NN O O
most NN O O
common NN O O
human NN O O
enzymopathy NN O B-Disease
; NN O O
more NN O O
than NN O O
300 NN O O
different NN O O
biochemical NN O O
variants NN O O
of NN O O
the NN O O
enzyme NN O O
have NN O O
been NN O O
described NN O O
. NN O O

In NN O O
many NN O O
parts NN O O
of NN O O
the NN O O
world NN O O
the NN O O
Mediterranean NN O O
type NN O O
of NN O O
G6PD NN O B-Disease
deficiency NN O I-Disease
is NN O O
prevalent NN O O
. NN O O

However NN O O
, NN O O
G6PD NN O O
Mediterranean NN O O
has NN O O
come NN O O
to NN O O
be NN O O
regarded NN O O
as NN O O
a NN O O
generic NN O O
term NN O O
applied NN O O
to NN O O
similar NN O O
G6PD NN O O
mutations NN O O
thought NN O O
, NN O O
however NN O O
, NN O O
to NN O O
represent NN O O
a NN O O
somewhat NN O O
heterogeneous NN O O
group NN O O
. NN O O

A NN O O
C NN O O
- NN O O
- NN O O
- NN O O
- NN O O
T NN O O
mutation NN O O
at NN O O
nucleotide NN O O
563 NN O O
of NN O O
G6PD NN O O
Mediterranean NN O O
has NN O O
been NN O O
identified NN O O
by NN O O
Vulliamy NN O O
et NN O O
al NN O O
. NN O O
, NN O O
and NN O O
the NN O O
same NN O O
mutation NN O O
has NN O O
been NN O O
found NN O O
by NN O O
De NN O O
Vita NN O O
et NN O O
al NN O O
. NN O O
in NN O O
G6PD NN O O
Mediterranean NN O O
, NN O O
G6PD NN O O
Sassari NN O O
, NN O O
and NN O O
G6PD NN O O
Cagliari NN O O
. NN O O

The NN O O
latter NN O O
subjects NN O O
had NN O O
an NN O O
additional NN O O
mutation NN O O
, NN O O
at NN O O
nucleotide NN O O
1311 NN O O
, NN O O
that NN O O
did NN O O
not NN O O
produce NN O O
a NN O O
coding NN O O
change NN O O
. NN O O

We NN O O
have NN O O
examined NN O O
genomic NN O O
DNA NN O O
of NN O O
five NN O O
patients NN O O
- NN O O
- NN O O
four NN O O
of NN O O
Spanish NN O O
origin NN O O
and NN O O
one NN O O
of NN O O
Jewish NN O O
origin NN O O
- NN O O
- NN O O
having NN O O
enzymatically NN O O
documented NN O O
G6PD NN O O
Mediterranean NN O O
. NN O O

All NN O O
had NN O O
both NN O O
the NN O O
mutation NN O O
at NN O O
nucleotide NN O O
563 NN O O
and NN O O
that NN O O
at NN O O
nucleotide NN O O
1311 NN O O
. NN O O

A NN O O
sixth NN O O
sample NN O O
, NN O O
resembling NN O O
G6PD NN O O
Mediterranean NN O O
kinetically NN O O
but NN O O
with NN O O
a NN O O
slightly NN O O
rapid NN O O
electrophoretic NN O O
mobility NN O O
, NN O O
was NN O O
designated NN O O
G6PD NN O O
Andalus NN O O
and NN O O
was NN O O
found NN O O
to NN O O
have NN O O
a NN O O
different NN O O
mutation NN O O
, NN O O
a NN O O
G NN O O
- NN O O
- NN O O
- NN O O
- NN O O
A NN O O
transition NN O O
at NN O O
nucleotide NN O O
1361 NN O O
, NN O O
producing NN O O
an NN O O
arginine NN O O
- NN O O
to NN O O
- NN O O
histidine NN O O
substitution NN O O
. NN O O

These NN O O
studies NN O O
suggest NN O O
that NN O O
G6PD NN O O
Mediterranean NN O O
is NN O O
, NN O O
after NN O O
all NN O O
, NN O O
relatively NN O O
homogeneous NN O O
. NN O O

A NN O O
normal NN O O
male NN O O
with NN O O
an NN O O
inherited NN O O
deletion NN O O
of NN O O
one NN O O
exon NN O O
within NN O O
the NN O O
DMD NN O B-Disease
gene NN O O
. NN O O

We NN O O
describe NN O O
two NN O O
brothers NN O O
with NN O O
identical NN O O
inherited NN O O
deletions NN O O
of NN O O
one NN O O
single NN O O
exon NN O O
within NN O O
the NN O O
middle NN O O
of NN O O
the NN O O
DMD NN O B-Disease
gene NN O O
; NN O O
one NN O O
brother NN O O
has NN O O
Becker NN O B-Disease
muscular NN O I-Disease
dystrophy NN O I-Disease
diagnosed NN O O
at NN O O
11 NN O O
years NN O O
of NN O O
age NN O O
, NN O O
whereas NN O O
the NN O O
older NN O O
brother NN O O
is NN O O
normal NN O O
at NN O O
18 NN O O
. NN O O

These NN O O
results NN O O
have NN O O
implications NN O O
for NN O O
genetic NN O O
counselling NN O O
and NN O O
prenatal NN O O
diagnosis NN O O
in NN O O
families NN O O
with NN O O
Becker NN O B-Disease
muscular NN O I-Disease
dystrophy NN O I-Disease
. NN O O
. NN O O

Duchenne NN O B-Disease
muscular NN O I-Disease
dystrophy NN O I-Disease
gene NN O O
expression NN O O
in NN O O
normal NN O O
and NN O O
diseased NN O O
human NN O O
muscle NN O O
. NN O O

A NN O O
probe NN O O
for NN O O
the NN O O
5 NN O O
end NN O O
of NN O O
the NN O O
Duchenne NN O B-Disease
muscular NN O I-Disease
dystrophy NN O I-Disease
( NN O O
DMD NN O B-Disease
) NN O O
gene NN O O
was NN O O
used NN O O
to NN O O
study NN O O
expression NN O O
of NN O O
the NN O O
gene NN O O
in NN O O
normal NN O O
human NN O O
muscle NN O O
, NN O O
myogenic NN O O
cell NN O O
cultures NN O O
, NN O O
and NN O O
muscle NN O O
from NN O O
patients NN O O
with NN O O
DMD NN O B-Disease
. NN O O

Expression NN O O
was NN O O
found NN O O
in NN O O
RNA NN O O
from NN O O
normal NN O O
fetal NN O O
muscle NN O O
, NN O O
adult NN O O
cardiac NN O O
and NN O O
skeletal NN O O
muscle NN O O
, NN O O
and NN O O
cultured NN O O
muscle NN O O
after NN O O
myoblast NN O O
fusion NN O O
. NN O O

In NN O O
DMD NN O B-Disease
muscle NN O O
, NN O O
expression NN O O
of NN O O
this NN O O
portion NN O O
of NN O O
the NN O O
gene NN O O
was NN O O
also NN O O
revealed NN O O
by NN O O
in NN O O
situ NN O O
RNA NN O O
hybridization NN O O
, NN O O
particularly NN O O
in NN O O
regenerating NN O O
muscle NN O O
fibers NN O O
. NN O O
. NN O O

Molecular NN O O
and NN O O
phenotypic NN O O
analysis NN O O
of NN O O
patients NN O O
with NN O O
deletions NN O O
within NN O O
the NN O O
deletion NN O O
- NN O O
rich NN O O
region NN O O
of NN O O
the NN O O
Duchenne NN O B-Disease
muscular NN O I-Disease
dystrophy NN O I-Disease
( NN O O
DMD NN O B-Disease
) NN O O
gene NN O O
. NN O O

Eighty NN O O
unrelated NN O O
individuals NN O O
with NN O O
Duchenne NN O B-Disease
muscular NN O I-Disease
dystrophy NN O I-Disease
( NN O O
DMD NN O B-Disease
) NN O O
or NN O O
Becker NN O B-Disease
muscular NN O I-Disease
dystrophy NN O I-Disease
( NN O O
BMD NN O B-Disease
) NN O O
were NN O O
found NN O O
to NN O O
have NN O O
deletions NN O O
in NN O O
the NN O O
major NN O O
deletion NN O O
- NN O O
rich NN O O
region NN O O
of NN O O
the NN O O
DMD NN O B-Disease
locus NN O O
. NN O O

This NN O O
region NN O O
includes NN O O
the NN O O
last NN O O
five NN O O
exons NN O O
detected NN O O
by NN O O
cDNA5b NN O O
- NN O O
7 NN O O
, NN O O
all NN O O
exons NN O O
detected NN O O
by NN O O
cDNA8 NN O O
, NN O O
and NN O O
the NN O O
first NN O O
two NN O O
exons NN O O
detected NN O O
by NN O O
cDNA9 NN O O
. NN O O

These NN O O
80 NN O O
individuals NN O O
account NN O O
for NN O O
approximately NN O O
75 NN O O
% NN O O
of NN O O
109 NN O O
deletions NN O O
of NN O O
the NN O O
gene NN O O
, NN O O
detected NN O O
among NN O O
181 NN O O
patients NN O O
analyzed NN O O
with NN O O
the NN O O
entire NN O O
dystrophin NN O O
cDNA NN O O
. NN O O

Endpoints NN O O
for NN O O
many NN O O
of NN O O
these NN O O
deletions NN O O
were NN O O
further NN O O
characterized NN O O
using NN O O
two NN O O
genomic NN O O
probes NN O O
, NN O O
p20 NN O O
( NN O O
DXS269 NN O O
; NN O O
Wapenaar NN O O
et NN O O
al NN O O
. NN O O
) NN O O
and NN O O
GMGX11 NN O O
( NN O O
DXS239 NN O O
; NN O O
present NN O O
paper NN O O
) NN O O
. NN O O

Clinical NN O O
findings NN O O
are NN O O
presented NN O O
for NN O O
all NN O O
80 NN O O
patients NN O O
allowing NN O O
a NN O O
correlation NN O O
of NN O O
phenotypic NN O O
severity NN O O
with NN O O
the NN O O
genotype NN O O
. NN O O

Thirty NN O O
- NN O O
eight NN O O
independent NN O O
patients NN O O
were NN O O
old NN O O
enough NN O O
to NN O O
be NN O O
classified NN O O
as NN O O
DMD NN O B-Disease
, NN O O
BMD NN O B-Disease
, NN O O
or NN O O
intermediate NN O O
phenotype NN O O
and NN O O
had NN O O
deletions NN O O
of NN O O
exons NN O O
with NN O O
sequenced NN O O
intron NN O O
/ NN O O
exon NN O O
boundaries NN O O
. NN O O

Of NN O O
these NN O O
, NN O O
eight NN O O
BMD NN O B-Disease
patients NN O O
and NN O O
one NN O O
intermediate NN O O
patient NN O O
had NN O O
gene NN O O
deletions NN O O
predicted NN O O
to NN O O
leave NN O O
the NN O O
reading NN O O
frame NN O O
intact NN O O
, NN O O
while NN O O
21 NN O O
DMD NN O B-Disease
patients NN O O
, NN O O
7 NN O O
intermediate NN O O
patients NN O O
, NN O O
and NN O O
1 NN O O
BMD NN O B-Disease
patient NN O O
had NN O O
gene NN O O
deletions NN O O
predicted NN O O
to NN O O
disrupt NN O O
the NN O O
reading NN O O
frame NN O O
. NN O O

Thus NN O O
, NN O O
with NN O O
two NN O O
exceptions NN O O
, NN O O
frameshift NN O O
deletions NN O O
of NN O O
the NN O O
gene NN O O
resulted NN O O
in NN O O
more NN O O
severe NN O O
phenotype NN O O
than NN O O
did NN O O
in NN O O
- NN O O
frame NN O O
deletions NN O O
. NN O O

This NN O O
is NN O O
in NN O O
agreement NN O O
with NN O O
recent NN O O
findings NN O O
by NN O O
Baumbach NN O O
et NN O O
al NN O O
. NN O O
and NN O O
Koenig NN O O
et NN O O
al NN O O
. NN O O
but NN O O
is NN O O
in NN O O
contrast NN O O
to NN O O
findings NN O O
, NN O O
by NN O O
Malhotra NN O O
et NN O O
al NN O O
. NN O O
at NN O O
the NN O O
5 NN O O
' NN O O
end NN O O
of NN O O
the NN O O
gene NN O O
. NN O O

Cloning NN O O
of NN O O
breakpoints NN O O
of NN O O
a NN O O
chromosome NN O O
translocation NN O O
identifies NN O O
the NN O O
AN2 NN O O
locus NN O O
. NN O O

Chromosome NN O O
translocations NN O O
involving NN O O
11p13 NN O O
have NN O O
been NN O O
associated NN O O
with NN O O
familial NN O B-Disease
aniridia NN O I-Disease
in NN O O
two NN O O
kindreds NN O O
highlighting NN O O
the NN O O
chromosomal NN O O
localization NN O O
of NN O O
the NN O O
AN2 NN O O
locus NN O O
. NN O O

This NN O O
locus NN O O
is NN O O
also NN O O
part NN O O
of NN O O
the NN O O
WAGR NN O B-Disease
complex NN O O
( NN O O
Wilms NN O B-Disease
tumor NN O I-Disease
, NN O O
aniridia NN O B-Disease
, NN O O
genitourinary NN O B-Disease
abnormalities NN O I-Disease
, NN O O
and NN O O
mental NN O B-Disease
retardation NN O I-Disease
) NN O O
. NN O O

In NN O O
one NN O O
kindred NN O O
, NN O O
the NN O O
translocation NN O O
is NN O O
associated NN O O
with NN O O
a NN O O
deletion NN O O
, NN O O
and NN O O
probes NN O O
for NN O O
this NN O O
region NN O O
were NN O O
used NN O O
to NN O O
identify NN O O
and NN O O
clone NN O O
the NN O O
breakpoints NN O O
of NN O O
the NN O O
translocation NN O O
in NN O O
the NN O O
second NN O O
kindred NN O O
. NN O O

Comparison NN O O
of NN O O
phage NN O O
restriction NN O O
maps NN O O
exclude NN O O
the NN O O
presence NN O O
of NN O O
any NN O O
sizable NN O O
deletion NN O O
in NN O O
this NN O O
case NN O O
. NN O O

Sequences NN O O
at NN O O
the NN O O
chromosome NN O O
11 NN O O
breakpoint NN O O
are NN O O
conserved NN O O
in NN O O
multiple NN O O
species NN O O
, NN O O
suggesting NN O O
that NN O O
the NN O O
translocation NN O O
falls NN O O
within NN O O
the NN O O
AN2 NN O O
gene NN O O
. NN O O
. NN O O

Linkage NN O O
analysis NN O O
of NN O O
the NN O O
apolipoprotein NN O O
C2 NN O O
gene NN O O
and NN O O
myotonic NN O B-Disease
dystrophy NN O I-Disease
on NN O O
human NN O O
chromosome NN O O
19 NN O O
reveals NN O O
linkage NN O O
disequilibrium NN O O
in NN O O
a NN O O
French NN O O
- NN O O
Canadian NN O O
population NN O O
. NN O O

The NN O O
gene NN O O
for NN O O
human NN O O
apolipoprotein NN O O
C2 NN O O
( NN O O
APOC2 NN O O
) NN O O
, NN O O
situated NN O O
on NN O O
the NN O O
proximal NN O O
long NN O O
arm NN O O
of NN O O
chromosome NN O O
19 NN O O
, NN O O
is NN O O
closely NN O O
linked NN O O
to NN O O
the NN O O
gene NN O O
for NN O O
the NN O O
most NN O O
common NN O O
form NN O O
of NN O O
adult NN O O
muscular NN O B-Disease
dystrophy NN O I-Disease
, NN O O
myotonic NN O B-Disease
dystrophy NN O I-Disease
( NN O O
DM NN O B-Disease
) NN O O
. NN O O

Six NN O O
APOC2 NN O O
RFLPs NN O O
( NN O O
TaqI NN O O
, NN O O
BglI NN O O
, NN O O
BanI NN O O
, NN O O
BamHI NN O O
, NN O O
NcoI NN O O
, NN O O
and NN O O
AvaII NN O O
) NN O O
have NN O O
been NN O O
identified NN O O
to NN O O
date NN O O
. NN O O

We NN O O
have NN O O
conducted NN O O
a NN O O
comprehensive NN O O
DM NN O B-Disease
linkage NN O O
study NN O O
utilizing NN O O
all NN O O
six NN O O
RFLPs NN O O
and NN O O
involving NN O O
50 NN O O
families NN O O
and NN O O
372 NN O O
individuals NN O O
. NN O O

The NN O O
most NN O O
informative NN O O
RFLPs NN O O
are NN O O
, NN O O
in NN O O
descending NN O O
order NN O O
, NN O O
NcoI NN O O
( NN O O
lod NN O O
= NN O O
6 NN O O
. NN O O
64 NN O O
, NN O O
theta NN O O
= NN O O
0 NN O O
. NN O O
05 NN O O
) NN O O
, NN O O
BglI NN O O
( NN O O
lod NN O O
= NN O O
6 NN O O
. NN O O
12 NN O O
, NN O O
theta NN O O
= NN O O
0 NN O O
. NN O O
05 NN O O
) NN O O
, NN O O
AvaII NN O O
( NN O O
lod NN O O
= NN O O
6 NN O O
. NN O O
02 NN O O
, NN O O
theta NN O O
= NN O O
0 NN O O
. NN O O
03 NN O O
) NN O O
, NN O O
BanI NN O O
( NN O O
lod NN O O
= NN O O
5 NN O O
. NN O O
76 NN O O
, NN O O
theta NN O O
= NN O O
0 NN O O
. NN O O
04 NN O O
) NN O O
, NN O O
TaqI NN O O
( NN O O
lod NN O O
= NN O O
4 NN O O
. NN O O
29 NN O O
, NN O O
theta NN O O
= NN O O
0 NN O O
. NN O O
06 NN O O
) NN O O
, NN O O
and NN O O
BamHI NN O O
( NN O O
lod NN O O
= NN O O
1 NN O O
. NN O O
75 NN O O
, NN O O
theta NN O O
= NN O O
0 NN O O
. NN O O
01 NN O O
) NN O O
. NN O O

A NN O O
substantial NN O O
increase NN O O
in NN O O
the NN O O
lod NN O O
scores NN O O
over NN O O
those NN O O
seen NN O O
with NN O O
the NN O O
individual NN O O
RFLPs NN O O
was NN O O
obtained NN O O
when NN O O
the NN O O
linkage NN O O
of NN O O
the NN O O
entire NN O O
APOC2 NN O O
haplotype NN O O
( NN O O
composed NN O O
of NN O O
the NN O O
six NN O O
RFLPs NN O O
) NN O O
was NN O O
studied NN O O
( NN O O
lod NN O O
= NN O O
17 NN O O
. NN O O
87 NN O O
, NN O O
theta NN O O
= NN O O
0 NN O O
. NN O O
04 NN O O
) NN O O
. NN O O

We NN O O
have NN O O
observed NN O O
significant NN O O
inter NN O O
- NN O O
APOC2 NN O O
RFLP NN O O
linkage NN O O
disequilibrium NN O O
. NN O O

Consequently NN O O
, NN O O
the NN O O
three NN O O
most NN O O
informative NN O O
RFLPs NN O O
have NN O O
been NN O O
found NN O O
to NN O O
be NN O O
BanI NN O O
, NN O O
TaqI NN O O
, NN O O
and NN O O
either NN O O
BglI NN O O
, NN O O
AvaII NN O O
, NN O O
or NN O O
NcoI NN O O
polymorphisms NN O O
. NN O O

We NN O O
also NN O O
demonstrate NN O O
linkage NN O O
disequilibrium NN O O
between NN O O
DM NN O O
and NN O O
APOC2 NN O O
in NN O O
our NN O O
French NN O O
- NN O O
Canadian NN O O
population NN O O
( NN O O
standardized NN O O
disequilibrium NN O O
constant NN O O
phi NN O O
= NN O O
. NN O O
22 NN O O
, NN O O
chi NN O O
2 NN O O
= NN O O
5 NN O O
. NN O O
12 NN O O
, NN O O
df NN O O
= NN O O
1 NN O O
, NN O O
P NN O O
less NN O O
than NN O O
0 NN O O
. NN O O
04 NN O O
) NN O O
. NN O O

This NN O O
represents NN O O
the NN O O
first NN O O
evidence NN O O
of NN O O
linkage NN O O
disequilibrium NN O O
between NN O O
APOC2 NN O O
and NN O O
the NN O O
DM NN O B-Disease
locus NN O O
. NN O O

Phenylalanine NN O O
hydroxylase NN O O
gene NN O O
haplotypes NN O O
in NN O O
Polynesians NN O O
: NN O O
evolutionary NN O O
origins NN O O
and NN O O
absence NN O O
of NN O O
alleles NN O O
associated NN O O
with NN O O
severe NN O O
phenylketonuria NN O B-Disease
. NN O O

A NN O O
total NN O O
of NN O O
630 NN O O
haplotypes NN O O
for NN O O
the NN O O
phenylalanine NN O O
hydroxylase NN O O
( NN O O
PAH NN O O
) NN O O
gene NN O O
locus NN O O
were NN O O
established NN O O
in NN O O
five NN O O
groups NN O O
of NN O O
Polynesians NN O O
comprising NN O O
Samoans NN O O
, NN O O
Tongans NN O O
, NN O O
Cook NN O O
Islanders NN O O
, NN O O
Maori NN O O
, NN O O
and NN O O
Niueans NN O O
. NN O O

Considerable NN O O
genetic NN O O
continuity NN O O
was NN O O
demonstrated NN O O
between NN O O
these NN O O
widely NN O O
dispersed NN O O
populations NN O O
, NN O O
since NN O O
three NN O O
common NN O O
haplotypes NN O O
( NN O O
4 NN O O
, NN O O
1 NN O O
, NN O O
and NN O O
7 NN O O
) NN O O
constituted NN O O
over NN O O
95 NN O O
% NN O O
of NN O O
alleles NN O O
. NN O O

A NN O O
control NN O O
group NN O O
of NN O O
individuals NN O O
from NN O O
Southeast NN O O
Asia NN O O
shared NN O O
the NN O O
same NN O O
major NN O O
haplotypes NN O O
, NN O O
4 NN O O
, NN O O
1 NN O O
, NN O O
and NN O O
7 NN O O
, NN O O
with NN O O
Polynesians NN O O
. NN O O

These NN O O
data NN O O
provide NN O O
further NN O O
support NN O O
for NN O O
the NN O O
theories NN O O
of NN O O
genetic NN O O
homogeneity NN O O
and NN O O
of NN O O
Asian NN O O
affinities NN O O
of NN O O
the NN O O
Polynesian NN O O
precursor NN O O
populations NN O O
. NN O O

The NN O O
absence NN O O
of NN O O
severe NN O O
phenylketonuria NN O B-Disease
( NN O O
PKU NN O B-Disease
) NN O O
in NN O O
both NN O O
Polynesians NN O O
and NN O O
Southeast NN O O
Asians NN O O
is NN O O
consistent NN O O
with NN O O
the NN O O
lack NN O O
of NN O O
PAH NN O O
haplotypes NN O O
2 NN O O
and NN O O
3 NN O O
, NN O O
on NN O O
which NN O O
the NN O O
severe NN O O
PKU NN O B-Disease
mutants NN O O
have NN O O
arisen NN O O
among NN O O
Caucasians NN O O
. NN O O
. NN O O

Preferential NN O O
germline NN O O
mutation NN O O
of NN O O
the NN O O
paternal NN O O
allele NN O O
in NN O O
retinoblastoma NN O B-Disease
. NN O O

The NN O O
event NN O O
triggering NN O O
malignant NN O O
proliferation NN O O
in NN O O
70 NN O O
% NN O O
of NN O O
retinoblastoma NN O B-Disease
tumours NN O I-Disease
is NN O O
loss NN O O
of NN O O
heterozygosity NN O O
for NN O O
chromosome NN O O
13q14 NN O O
, NN O O
whereby NN O O
the NN O O
normal NN O O
retinoblastoma NN O B-Disease
gene NN O O
( NN O O
RB1 NN O O
) NN O O
allele NN O O
is NN O O
lost NN O O
and NN O O
an NN O O
already NN O O
mutated NN O O
RB1 NN O O
allele NN O O
remains NN O O
in NN O O
the NN O O
tumour NN O B-Disease
. NN O O

The NN O O
first NN O O
allele NN O O
suffers NN O O
a NN O O
mutational NN O O
event NN O O
- NN O O
- NN O O
deletion NN O O
, NN O O
duplication NN O O
or NN O O
point NN O O
mutation NN O O
( NN O O
manuscript NN O O
in NN O O
preparation NN O O
) NN O O
- NN O O
- NN O O
either NN O O
in NN O O
the NN O O
germ NN O O
line NN O O
( NN O O
all NN O O
bilateral NN O O
patients NN O O
) NN O O
or NN O O
in NN O O
a NN O O
somatic NN O O
retinal NN O O
cell NN O O
( NN O O
most NN O O
unilateral NN O O
patients NN O O
) NN O O
. NN O O

Most NN O O
bilateral NN O O
patients NN O O
have NN O O
no NN O O
family NN O O
history NN O O
of NN O O
retinoblastoma NN O B-Disease
and NN O O
are NN O O
presumed NN O O
to NN O O
have NN O O
new NN O O
germline NN O O
mutations NN O O
which NN O O
arose NN O O
in NN O O
the NN O O
egg NN O O
, NN O O
sperm NN O O
or NN O O
early NN O O
embryo NN O O
. NN O O

We NN O O
have NN O O
determined NN O O
the NN O O
parental NN O O
origin NN O O
of NN O O
the NN O O
retained NN O O
allele NN O O
in NN O O
nine NN O O
retinoblastoma NN O B-Disease
tumours NN O I-Disease
from NN O O
eight NN O O
unrelated NN O O
non NN O O
- NN O O
familial NN O O
cases NN O O
by NN O O
using NN O O
RB1 NN O O
- NN O O
linked NN O O
genetic NN O O
markers NN O O
. NN O O

Six NN O O
tumours NN O B-Disease
retained NN O O
the NN O O
paternal NN O O
allele NN O O
and NN O O
three NN O O
retained NN O O
the NN O O
maternal NN O O
allele NN O O
. NN O O

Of NN O O
the NN O O
three NN O O
unilateral NN O B-Disease
tumours NN O I-Disease
, NN O O
only NN O O
one NN O O
retained NN O O
the NN O O
paternal NN O O
RB1 NN O O
allele NN O O
. NN O O

Thus NN O O
, NN O O
there NN O O
is NN O O
no NN O O
evidence NN O O
that NN O O
the NN O O
paternal NN O O
RB1 NN O O
allele NN O O
is NN O O
preferentially NN O O
retained NN O O
in NN O O
retinoblastoma NN O B-Disease
, NN O O
as NN O O
has NN O O
been NN O O
suggested NN O O
to NN O O
be NN O O
the NN O O
case NN O O
in NN O O
osteosarcoma NN O B-Disease
. NN O O

By NN O O
contrast NN O O
, NN O O
tumours NN O B-Disease
from NN O O
four NN O O
of NN O O
the NN O O
five NN O O
bilateral NN O O
patients NN O O
retained NN O O
the NN O O
paternal NN O O
RB1 NN O O
allele NN O O
. NN O O

This NN O O
suggests NN O O
either NN O O
that NN O O
new NN O O
germline NN O O
RB1 NN O O
mutations NN O O
arise NN O O
more NN O O
frequently NN O O
during NN O O
spermatogenesis NN O O
than NN O O
during NN O O
oogenesis NN O O
, NN O O
or NN O O
that NN O O
imprinting NN O O
in NN O O
the NN O O
early NN O O
embryo NN O O
affects NN O O
chromosomal NN O O
susceptibility NN O O
to NN O O
mutation NN O O
. NN O O
. NN O O

Haplotype NN O O
analysis NN O O
of NN O O
the NN O O
phenylalanine NN O O
hydroxylase NN O O
gene NN O O
in NN O O
Turkish NN O O
phenylketonuria NN O B-Disease
families NN O O
. NN O O

We NN O O
have NN O O
estimated NN O O
the NN O O
haplotype NN O O
distribution NN O O
of NN O O
mutant NN O O
and NN O O
normal NN O O
phenylalanine NN O O
hydroxylase NN O O
( NN O O
PAH NN O O
) NN O O
alleles NN O O
for NN O O
17 NN O O
Turkish NN O O
phenylketonuria NN O B-Disease
( NN O O
PKU NN O B-Disease
) NN O O
families NN O O
20 NN O O
normal NN O O
and NN O O
27 NN O O
mutated NN O O
PAH NN O O
alleles NN O O
could NN O O
be NN O O
identified NN O O
. NN O O

Of NN O O
the NN O O
latter NN O O
, NN O O
the NN O O
most NN O O
prevalent NN O O
were NN O O
associated NN O O
with NN O O
haplotype NN O O
6 NN O O
( NN O O
29 NN O O
. NN O O
6 NN O O
% NN O O
) NN O O
, NN O O
1 NN O O
( NN O O
18 NN O O
. NN O O
5 NN O O
% NN O O
) NN O O
and NN O O
36 NN O O
( NN O O
11 NN O O
. NN O O
1 NN O O
% NN O O
) NN O O
, NN O O
while NN O O
the NN O O
normal NN O O
alleles NN O O
were NN O O
preferentially NN O O
associated NN O O
with NN O O
haplotype NN O O
1 NN O O
( NN O O
20 NN O O
% NN O O
) NN O O
. NN O O

Of NN O O
the NN O O
19 NN O O
different NN O O
haplotypes NN O O
observed NN O O
, NN O O
5 NN O O
have NN O O
not NN O O
been NN O O
described NN O O
previously NN O O
. NN O O

The NN O O
haplotype NN O O
distribution NN O O
differed NN O O
significantly NN O O
from NN O O
that NN O O
of NN O O
the NN O O
Northern NN O O
European NN O O
population NN O O
. NN O O

Two NN O O
of NN O O
the NN O O
eight NN O O
polymorphic NN O O
sites NN O O
were NN O O
in NN O O
association NN O O
with NN O O
PKU NN O B-Disease
. NN O O

No NN O O
deletions NN O O
of NN O O
exon NN O O
sequences NN O O
were NN O O
found NN O O
in NN O O
the NN O O
families NN O O
analysed NN O O
. NN O O

Huntington NN O B-Disease
disease NN O I-Disease
: NN O O
no NN O O
evidence NN O O
for NN O O
locus NN O O
heterogeneity NN O O
. NN O O

A NN O O
total NN O O
of NN O O
63 NN O O
families NN O O
with NN O O
Huntington NN O B-Disease
disease NN O I-Disease
( NN O O
HD NN O B-Disease
) NN O O
were NN O O
examined NN O O
for NN O O
linkage NN O O
between NN O O
HD NN O B-Disease
and NN O O
G8 NN O O
( NN O O
D4S10 NN O O
) NN O O
. NN O O

The NN O O
families NN O O
included NN O O
57 NN O O
Caucasian NN O O
, NN O O
four NN O O
Black NN O O
American NN O O
, NN O O
and NN O O
two NN O O
Japanese NN O O
. NN O O

The NN O O
combined NN O O
maximum NN O O
lod NN O O
score NN O O
was NN O O
87 NN O O
. NN O O

69 NN O O
at NN O O
theta NN O O
= NN O O
0 NN O O
. NN O O

04 NN O O
( NN O O
99 NN O O
% NN O O
confidence NN O O
interval NN O O
0 NN O O
. NN O O
018 NN O O
- NN O O
0 NN O O
. NN O O
071 NN O O
) NN O O
. NN O O

The NN O O
maximum NN O O
frequency NN O O
of NN O O
recombination NN O O
was NN O O
0 NN O O
. NN O O

03 NN O O
in NN O O
males NN O O
and NN O O
0 NN O O
. NN O O

05 NN O O
in NN O O
females NN O O
. NN O O

Fifty NN O O
- NN O O
seven NN O O
families NN O O
gave NN O O
positive NN O O
lod NN O O
scores NN O O
; NN O O
five NN O O
small NN O O
families NN O O
gave NN O O
mildly NN O O
negative NN O O
lod NN O O
scores NN O O
. NN O O

The NN O O
maximum NN O O
likelihood NN O O
estimate NN O O
of NN O O
alpha NN O O
, NN O O
the NN O O
proportion NN O O
of NN O O
linked NN O O
loci NN O O
, NN O O
was NN O O
1 NN O O
. NN O O

0 NN O O
with NN O O
a NN O O
lower NN O O
99 NN O O
% NN O O
confidence NN O O
interval NN O O
of NN O O
0 NN O O
. NN O O

88 NN O O
. NN O O

These NN O O
data NN O O
suggest NN O O
that NN O O
there NN O O
is NN O O
only NN O O
one NN O O
HD NN O B-Disease
locus NN O O
, NN O O
although NN O O
a NN O O
second NN O O
rare NN O O
locus NN O O
cannot NN O O
be NN O O
ruled NN O O
out NN O O
. NN O O

Haplotype NN O O
and NN O O
multipoint NN O O
linkage NN O O
analysis NN O O
in NN O O
Finnish NN O O
choroideremia NN O B-Disease
families NN O O
. NN O O

Multipoint NN O O
linkage NN O O
analysis NN O O
of NN O O
choroideremia NN O B-Disease
( NN O O
TCD NN O B-Disease
) NN O O
and NN O O
seven NN O O
X NN O O
chromosomal NN O O
restriction NN O O
fragment NN O O
length NN O O
polymorphisms NN O O
( NN O O
RFLPs NN O O
) NN O O
was NN O O
carried NN O O
out NN O O
in NN O O
18 NN O O
Finnish NN O O
TCD NN O B-Disease
families NN O O
. NN O O

The NN O O
data NN O O
place NN O O
TCD NN O B-Disease
distal NN O O
to NN O O
PGK NN O O
and NN O O
DXS72 NN O O
, NN O O
very NN O O
close NN O O
to NN O O
DXYS1 NN O O
and NN O O
DXYS5 NN O O
( NN O O
Zmax NN O O
= NN O O
24 NN O O
at NN O O
theta NN O O
= NN O O
0 NN O O
) NN O O
and NN O O
proximal NN O O
to NN O O
DXYS4 NN O O
and NN O O
DXYS12 NN O O
. NN O O

This NN O O
agrees NN O O
with NN O O
the NN O O
data NN O O
obtained NN O O
from NN O O
other NN O O
linkage NN O O
studies NN O O
and NN O O
from NN O O
physical NN O O
mapping NN O O
. NN O O

All NN O O
the NN O O
TCD NN O B-Disease
males NN O O
and NN O O
carrier NN O O
females NN O O
studied NN O O
have NN O O
the NN O O
same NN O O
DXYS1 NN O O
allele NN O O
in NN O O
coupling NN O O
with NN O O
TCD NN O B-Disease
. NN O O

In NN O O
Northeastern NN O O
Finland NN O O
, NN O O
66 NN O O
/ NN O O
69 NN O O
chromosomes NN O O
carrying NN O O
TCD NN O B-Disease
had NN O O
the NN O O
same NN O O
haplotype NN O O
at NN O O
loci NN O O
DXS72 NN O O
, NN O O
DXYS1 NN O O
, NN O O
DXYS4 NN O O
, NN O O
and NN O O
DXYS12 NN O O
. NN O O

The NN O O
same NN O O
haplotype NN O O
is NN O O
seen NN O O
in NN O O
only NN O O
15 NN O O
/ NN O O
99 NN O O
chromosomes NN O O
not NN O O
carrying NN O O
TCD NN O B-Disease
. NN O O

Moreover NN O O
, NN O O
in NN O O
71 NN O O
/ NN O O
104 NN O O
non NN O O
- NN O O
TCD NN O O
chromosomes NN O O
, NN O O
the NN O O
haplotype NN O O
at NN O O
six NN O O
marker NN O O
loci NN O O
is NN O O
different NN O O
from NN O O
those NN O O
seen NN O O
in NN O O
any NN O O
of NN O O
the NN O O
76 NN O O
TCD NN O B-Disease
chromosomes NN O O
. NN O O

This NN O O
supports NN O O
the NN O O
previously NN O O
described NN O O
hypothesis NN O O
that NN O O
the NN O O
large NN O O
Northern NN O O
Finnish NN O O
choroideremia NN O B-Disease
pedigrees NN O O
, NN O O
comprising NN O O
a NN O O
total NN O O
of NN O O
over NN O O
80 NN O O
living NN O O
patients NN O O
representing NN O O
more NN O O
than NN O O
a NN O O
fifth NN O O
of NN O O
all NN O O
TCD NN O B-Disease
patients NN O O
described NN O O
worldwide NN O O
, NN O O
carry NN O O
the NN O O
same NN O O
mutation NN O O
. NN O O

These NN O O
linkage NN O O
and NN O O
haplotype NN O O
data NN O O
provide NN O O
improved NN O O
opportunities NN O O
for NN O O
prenatal NN O O
diagnosis NN O O
based NN O O
on NN O O
RFLP NN O O
studies NN O O
. NN O O
. NN O O

Autosomal NN O O
dominant NN O O
aniridia NN O B-Disease
linked NN O O
to NN O O
the NN O O
chromosome NN O O
11p13 NN O O
markers NN O O
catalase NN O O
and NN O O
D11S151 NN O O
in NN O O
a NN O O
large NN O O
Dutch NN O O
family NN O O
. NN O O

In NN O O
a NN O O
large NN O O
pedigree NN O O
with NN O O
autosomal NN O O
dominant NN O O
aniridia NN O B-Disease
, NN O O
we NN O O
found NN O O
close NN O O
linkage NN O O
between NN O O
the NN O O
aniridia NN O B-Disease
locus NN O O
AN2 NN O O
and NN O O
the NN O O
markers NN O O
catalase NN O O
( NN O O
CAT NN O O
) NN O O
( NN O O
zeta NN O O
= NN O O
7 NN O O
. NN O O
27 NN O O
at NN O O
theta NN O O
= NN O O
0 NN O O
. NN O O
00 NN O O
) NN O O
and NN O O
D11S151 NN O O
( NN O O
zeta NN O O
= NN O O
3 NN O O
. NN O O
86 NN O O
at NN O O
theta NN O O
= NN O O
0 NN O O
. NN O O
10 NN O O
) NN O O
flanking NN O O
the NN O O
AN2 NN O O
locus NN O O
on NN O O
11p13 NN O O
. NN O O

Positive NN O O
lod NN O O
scores NN O O
were NN O O
also NN O O
obtained NN O O
for NN O O
the NN O O
11p13 NN O O
- NN O O
- NN O O
- NN O O
- NN O O
11p14 NN O O
markers NN O O
D11S16 NN O O
and NN O O
FSHB NN O O
with NN O O
the NN O O
linkage NN O O
group NN O O
CAT NN O O
/ NN O O
AN2 NN O O
/ NN O O
D11S151 NN O O
. NN O O

We NN O O
conclude NN O O
that NN O O
the NN O O
autosomal NN O O
dominant NN O O
aniridia NN O B-Disease
in NN O O
this NN O O
family NN O O
is NN O O
due NN O O
to NN O O
a NN O O
mutation NN O O
at NN O O
the NN O O
AN2 NN O O
locus NN O O
on NN O O
11p13 NN O O
. NN O O

We NN O O
have NN O O
excluded NN O O
linkage NN O O
( NN O O
zeta NN O O
less NN O O
than NN O O
- NN O O
2 NN O O
at NN O O
theta NN O O
less NN O O
than NN O O
0 NN O O
. NN O O
18 NN O O
) NN O O
between NN O O
the NN O O
aniridia NN O B-Disease
and NN O O
the NN O O
chromosome NN O O
2p25 NN O O
marker NN O O
D2S1 NN O O
( NN O O
linked NN O O
to NN O O
ACP1 NN O O
) NN O O
. NN O O

Recombination NN O O
events NN O O
that NN O O
locate NN O O
myotonic NN O B-Disease
dystrophy NN O I-Disease
distal NN O O
to NN O O
APOC2 NN O O
on NN O O
19q NN O O
. NN O O

We NN O O
previously NN O O
reported NN O O
a NN O O
recombination NN O O
in NN O O
an NN O O
individual NN O O
with NN O O
myotonic NN O B-Disease
dystrophy NN O I-Disease
( NN O O
DM NN O B-Disease
) NN O O
which NN O O
placed NN O O
the NN O O
markers NN O O
D19S19 NN O O
and NN O O
APOC2 NN O O
on NN O O
the NN O O
same NN O O
side NN O O
of NN O O
the NN O O
DM NN O B-Disease
locus NN O O
. NN O O

Haplotyping NN O O
of NN O O
this NN O O
family NN O O
with NN O O
more NN O O
recently NN O O
characterized NN O O
probes NN O O
which NN O O
are NN O O
either NN O O
tightly NN O O
linked NN O O
to NN O O
DM NN O B-Disease
or NN O O
distal NN O O
to NN O O
the NN O O
linkage NN O O
group NN O O
at NN O O
q13 NN O O
. NN O O

2 NN O O
shows NN O O
that NN O O
the NN O O
DM NN O B-Disease
locus NN O O
is NN O O
distal NN O O
to NN O O
APOC2 NN O O
. NN O O

This NN O O
is NN O O
confirmed NN O O
by NN O O
other NN O O
recombinants NN O O
where NN O O
DM NN O B-Disease
segregates NN O O
with NN O O
distal NN O O
probes NN O O
. NN O O

Additional NN O O
marker NN O O
to NN O O
marker NN O O
recombinations NN O O
in NN O O
unaffected NN O O
individuals NN O O
are NN O O
reported NN O O
and NN O O
support NN O O
the NN O O
order NN O O
and NN O O
orientation NN O O
of NN O O
the NN O O
DM NN O B-Disease
linkage NN O O
group NN O O
as NN O O
pter NN O O
- NN O O
( NN O O
INSR NN O O
, NN O O
LDLR NN O O
, NN O O
S9 NN O O
) NN O O
- NN O O
( NN O O
S19 NN O O
, NN O O
BCL3 NN O O
, NN O O
APOC2 NN O O
) NN O O
- NN O O
( NN O O
CKMM NN O O
, NN O O
DM NN O O
) NN O O
- NN O O
( NN O O
S22 NN O O
, NN O O
+ NN O O
+ NN O O
+ NN O O
PRKCG NN O O
) NN O O
- NN O O
qter NN O O
. NN O O

The NN O O
data NN O O
presented NN O O
here NN O O
cannot NN O O
determine NN O O
whether NN O O
DM NN O B-Disease
is NN O O
proximal NN O O
or NN O O
distal NN O O
to NN O O
CKMM NN O O
. NN O O

The NN O O
consequences NN O O
of NN O O
this NN O O
probe NN O O
order NN O O
for NN O O
antenatal NN O O
diagnosis NN O O
and NN O O
future NN O O
research NN O O
aiming NN O O
to NN O O
isolate NN O O
the NN O O
gene NN O O
which NN O O
is NN O O
affected NN O O
in NN O O
DM NN O B-Disease
are NN O O
discussed NN O O
. NN O O

Mutations NN O O
in NN O O
the NN O O
RB1 NN O O
gene NN O O
and NN O O
their NN O O
effects NN O O
on NN O O
transcription NN O O
. NN O O

Inactivation NN O O
of NN O O
both NN O O
alleles NN O O
of NN O O
the NN O O
RB1 NN O O
gene NN O O
during NN O O
normal NN O O
retinal NN O O
development NN O O
initiates NN O O
the NN O O
formation NN O O
of NN O O
a NN O O
retinoblastoma NN O B-Disease
( NN O I-Disease
RB NN O I-Disease
) NN O I-Disease
tumor NN O I-Disease
. NN O O

To NN O O
identify NN O O
the NN O O
mutations NN O O
which NN O O
inactivate NN O O
RB1 NN O O
, NN O O
21 NN O O
RB NN O B-Disease
tumors NN O I-Disease
isolated NN O O
from NN O O
19 NN O O
patients NN O O
were NN O O
analyzed NN O O
with NN O O
the NN O O
polymerase NN O O
chain NN O O
reaction NN O O
or NN O O
an NN O O
RNase NN O O
protection NN O O
assay NN O O
or NN O O
both NN O O
. NN O O

Mutations NN O O
were NN O O
identified NN O O
in NN O O
13 NN O O
of NN O O
21 NN O O
RB NN O B-Disease
tumors NN O I-Disease
; NN O O
in NN O O
8 NN O O
tumors NN O B-Disease
, NN O O
the NN O O
precise NN O O
errors NN O O
in NN O O
nucleotide NN O O
sequence NN O O
were NN O O
characterized NN O O
. NN O O

Each NN O O
of NN O O
four NN O O
germ NN O O
line NN O O
mutations NN O O
involved NN O O
a NN O O
small NN O O
deletion NN O O
or NN O O
duplication NN O O
, NN O O
while NN O O
three NN O O
somatic NN O O
mutations NN O O
were NN O O
point NN O O
mutations NN O O
leading NN O O
to NN O O
splice NN O O
alterations NN O O
and NN O O
loss NN O O
of NN O O
an NN O O
exon NN O O
from NN O O
the NN O O
mature NN O O
RB1 NN O O
mRNA NN O O
. NN O O

We NN O O
were NN O O
unable NN O O
to NN O O
detect NN O O
expression NN O O
of NN O O
the NN O O
mutant NN O O
allele NN O O
in NN O O
lymphoblasts NN O O
of NN O O
three NN O O
bilaterally NN O O
affected NN O O
patients NN O O
, NN O O
although NN O O
the NN O O
mutation NN O O
was NN O O
present NN O O
in NN O O
the NN O O
genomic NN O O
DNA NN O O
and NN O O
transcripts NN O O
containing NN O O
the NN O O
mutations NN O O
were NN O O
obvious NN O O
in NN O O
the NN O O
RB NN O B-Disease
tumors NN O I-Disease
in NN O O
the NN O O
absence NN O O
of NN O O
a NN O O
normal NN O O
RB1 NN O O
allele NN O O
. NN O O

The NN O O
variations NN O O
in NN O O
the NN O O
level NN O O
of NN O O
expression NN O O
of NN O O
mutant NN O O
transcripts NN O O
suggest NN O O
deregulation NN O O
of NN O O
RB1 NN O O
transcription NN O O
in NN O O
the NN O O
absence NN O O
of NN O O
a NN O O
functional NN O O
RB1 NN O O
gene NN O O
product NN O O
. NN O O
. NN O O

Partial NN O O
deletion NN O O
8q NN O O
without NN O O
Langer NN O B-Disease
- NN O I-Disease
Giedion NN O I-Disease
syndrome NN O I-Disease
: NN O O
a NN O O
recognisable NN O O
syndrome NN O O
. NN O O

We NN O O
report NN O O
two NN O O
de NN O O
novo NN O O
cases NN O O
of NN O O
del NN O O
( NN O O
8 NN O O
) NN O O
( NN O O
pter NN O O
- NN O O
- NN O O
- NN O O
- NN O O
q24 NN O O
. NN O O
1 NN O O
) NN O O
with NN O O
breakpoints NN O O
involving NN O O
the NN O O
distal NN O O
part NN O O
of NN O O
band NN O O
8q24 NN O O
. NN O O

1 NN O O
1 NN O O
. NN O O

The NN O O
clinical NN O O
features NN O O
were NN O O
similar NN O O
and NN O O
there NN O O
were NN O O
no NN O O
obvious NN O O
stigmata NN O O
of NN O O
Langer NN O B-Disease
- NN O I-Disease
Giedion NN O I-Disease
syndrome NN O I-Disease
( NN O O
LGS NN O B-Disease
) NN O O
. NN O O

There NN O O
are NN O O
three NN O O
other NN O O
cases NN O O
reported NN O O
with NN O O
a NN O O
deletion NN O O
of NN O O
chromosome NN O O
8 NN O O
at NN O O
approximately NN O O
the NN O O
same NN O O
breakpoint NN O O
, NN O O
one NN O O
without NN O O
LGS NN O B-Disease
and NN O O
some NN O O
similarities NN O O
to NN O O
our NN O O
cases NN O O
, NN O O
the NN O O
other NN O O
two NN O O
with NN O O
LGS NN O B-Disease
. NN O O

Our NN O O
findings NN O O
would NN O O
support NN O O
the NN O O
observation NN O O
that NN O O
the NN O O
critical NN O O
segment NN O O
for NN O O
the NN O O
assignment NN O O
of NN O O
LGS NN O B-Disease
is NN O O
proximal NN O O
to NN O O
or NN O O
involves NN O O
the NN O O
proximal NN O O
part NN O O
of NN O O
8q24 NN O O
. NN O O

1 NN O O
, NN O O
but NN O O
a NN O O
review NN O O
of NN O O
published NN O O
reports NN O O
suggests NN O O
that NN O O
the NN O O
aetiology NN O O
of NN O O
LGS NN O B-Disease
may NN O O
be NN O O
a NN O O
more NN O O
complex NN O O
issue NN O O

Myotonic NN O B-Disease
dystrophy NN O I-Disease
is NN O O
closely NN O O
linked NN O O
to NN O O
the NN O O
gene NN O O
for NN O O
muscle NN O O
- NN O O
type NN O O
creatine NN O O
kinase NN O O
( NN O O
CKMM NN O O
) NN O O
. NN O O

We NN O O
have NN O O
studied NN O O
genetic NN O O
linkage NN O O
between NN O O
the NN O O
gene NN O O
for NN O O
creatine NN O O
kinase NN O O
muscle NN O O
type NN O O
( NN O O
CKMM NN O O
) NN O O
and NN O O
the NN O O
gene NN O O
for NN O O
myotonic NN O B-Disease
dystrophy NN O I-Disease
( NN O O
DM NN O B-Disease
) NN O O
. NN O O

In NN O O
a NN O O
panel NN O O
of NN O O
65 NN O O
myotonic NN O B-Disease
dystrophy NN O I-Disease
families NN O O
from NN O O
Canada NN O O
and NN O O
the NN O O
Netherlands NN O O
, NN O O
a NN O O
maximum NN O O
lod NN O O
score NN O O
( NN O O
Zmax NN O O
) NN O O
of NN O O
22 NN O O
. NN O O

8 NN O O
at NN O O
a NN O O
recombination NN O O
frequency NN O O
( NN O O
theta NN O O
) NN O O
of NN O O
0 NN O O
. NN O O

03 NN O O
was NN O O
obtained NN O O
. NN O O

Tight NN O O
linkage NN O O
was NN O O
also NN O O
demonstrated NN O O
for NN O O
CKMM NN O O
and NN O O
the NN O O
gene NN O O
for NN O O
apolipoprotein NN O O
C2 NN O O
( NN O O
ApoC2 NN O O
) NN O O
. NN O O

This NN O O
establishes NN O O
CKMM NN O O
as NN O O
a NN O O
useful NN O O
marker NN O O
for NN O O
myotonic NN O B-Disease
dystrophy NN O I-Disease

Color NN O B-Disease
vision NN O I-Disease
defects NN O I-Disease
in NN O O
adrenomyeloneuropathy NN O B-Disease
. NN O O

The NN O O
relationship NN O O
between NN O O
abnormal NN O B-Disease
color NN O I-Disease
vision NN O I-Disease
and NN O O
adrenomyeloneuropathy NN O B-Disease
( NN O O
AMN NN O B-Disease
) NN O O
was NN O O
investigated NN O O
in NN O O
27 NN O O
AMN NN O B-Disease
patients NN O O
and NN O O
31 NN O O
age NN O O
- NN O O
matched NN O O
controls NN O O
by NN O O
using NN O O
the NN O O
Farnsworth NN O O
- NN O O
Munsell NN O O
100 NN O O
Hue NN O O
test NN O O
. NN O O

Twelve NN O O
( NN O O
44 NN O O
% NN O O
) NN O O
of NN O O
27 NN O O
patients NN O O
showed NN O O
test NN O O
scores NN O O
significantly NN O O
above NN O O
normal NN O O
. NN O O

The NN O O
axes NN O O
of NN O O
bipolarity NN O O
determined NN O O
by NN O O
the NN O O
testing NN O O
differed NN O O
widely NN O O
between NN O O
the NN O O
patients NN O O
with NN O O
abnormal NN O O
scores NN O O
, NN O O
compatible NN O O
with NN O O
the NN O O
notion NN O O
that NN O O
different NN O O
alterations NN O O
in NN O O
visual NN O O
pigment NN O O
genes NN O O
occur NN O O
in NN O O
different NN O O
AMN NN O B-Disease
kindreds NN O O
. NN O O

These NN O O
observations NN O O
confirm NN O O
our NN O O
earlier NN O O
impression NN O O
that NN O O
the NN O O
frequency NN O O
of NN O O
abnormal NN O B-Disease
color NN O I-Disease
vision NN O I-Disease
is NN O O
increased NN O O
in NN O O
these NN O O
kindreds NN O O
, NN O O
and NN O O
it NN O O
supports NN O O
our NN O O
contentions NN O O
that NN O O
( NN O O
1 NN O O
) NN O O
AMN NN O B-Disease
( NN O O
and NN O O
its NN O O
companion NN O O
, NN O O
adrenoleukodystrophy NN O B-Disease
) NN O O
are NN O O
very NN O O
closely NN O O
linked NN O O
to NN O O
the NN O O
visual NN O O
pigment NN O O
loci NN O O
at NN O O
Xq28 NN O O
and NN O O
( NN O O
2 NN O O
) NN O O
this NN O O
proximity NN O O
might NN O O
provide NN O O
the NN O O
opportunity NN O O
to NN O O
observe NN O O
contiguous NN O B-Disease
gene NN O I-Disease
defects NN O I-Disease
. NN O O
. NN O O

Molecular NN O O
analysis NN O O
of NN O O
a NN O O
female NN O O
Lesch NN O B-Disease
- NN O I-Disease
Nyhan NN O I-Disease
patient NN O O
. NN O O

We NN O O
report NN O O
the NN O O
identification NN O O
of NN O O
a NN O O
female NN O O
patient NN O O
with NN O O
the NN O O
X NN O O
- NN O O
linked NN O O
recessive NN O O
Lesch NN O B-Disease
- NN O I-Disease
Nyhan NN O I-Disease
syndrome NN O I-Disease
( NN O O
hypoxanthine NN O B-Disease
phosphoribosyltransferase NN O I-Disease
[ NN O I-Disease
HPRT NN O I-Disease
] NN O I-Disease
deficiency NN O I-Disease
) NN O O
. NN O O

Cytogenetic NN O O
and NN O O
carrier NN O O
studies NN O O
revealed NN O O
structurally NN O O
normal NN O O
chromosomes NN O O
for NN O O
this NN O O
patient NN O O
and NN O O
her NN O O
parents NN O O
and NN O O
demonstrated NN O O
that NN O O
this NN O O
mutation NN O O
arose NN O O
through NN O O
a NN O O
de NN O O
novo NN O O
gametic NN O O
event NN O O
. NN O O

Comparison NN O O
of NN O O
this NN O O
patients NN O O
DNA NN O O
with NN O O
the NN O O
DNA NN O O
of NN O O
her NN O O
parents NN O O
revealed NN O O
that NN O O
a NN O O
microdeletion NN O O
, NN O O
which NN O O
occurred NN O O
within NN O O
a NN O O
maternal NN O O
gamete NN O O
and NN O O
involved NN O O
the NN O O
entire NN O O
HPRT NN O O
gene NN O O
, NN O O
was NN O O
partially NN O O
responsible NN O O
for NN O O
the NN O O
disease NN O O
in NN O O
this NN O O
patient NN O O
. NN O O

Somatic NN O O
cell NN O O
hybrids NN O O
, NN O O
generated NN O O
to NN O O
separate NN O O
maternal NN O O
and NN O O
paternal NN O O
X NN O O
chromosomes NN O O
, NN O O
showed NN O O
that NN O O
expression NN O O
of NN O O
two NN O O
additional NN O O
X NN O O
- NN O O
linked NN O O
enzymes NN O O
, NN O O
phosphoglycerate NN O O
kinase NN O O
and NN O O
glucose NN O O
- NN O O
6 NN O O
- NN O O
phosphate NN O O
dehydrogenase NN O O
, NN O O
were NN O O
expressed NN O O
only NN O O
in NN O O
cells NN O O
that NN O O
contained NN O O
the NN O O
maternal NN O O
X NN O O
chromosome NN O O
, NN O O
suggesting NN O O
the NN O O
presence NN O O
of NN O O
a NN O O
functionally NN O O
inactive NN O O
paternal NN O O
X NN O O
chromosome NN O O
. NN O O

Furthermore NN O O
, NN O O
comparison NN O O
of NN O O
methylation NN O O
patterns NN O O
within NN O O
a NN O O
region NN O O
of NN O O
the NN O O
HPRT NN O O
gene NN O O
known NN O O
to NN O O
be NN O O
important NN O O
in NN O O
gene NN O O
regulation NN O O
revealed NN O O
differences NN O O
between NN O O
DNA NN O O
from NN O O
the NN O O
father NN O O
and NN O O
the NN O O
patient NN O O
, NN O O
in NN O O
keeping NN O O
with NN O O
an NN O O
active NN O O
HPRT NN O O
locus NN O O
in NN O O
the NN O O
father NN O O
and NN O O
an NN O O
inactive NN O O
HPRT NN O O
locus NN O O
in NN O O
the NN O O
patient NN O O
. NN O O

Together NN O O
these NN O O
data NN O O
indicate NN O O
that NN O O
nonrandom NN O O
inactivation NN O O
of NN O O
the NN O O
cytogenetically NN O O
normal NN O O
paternal NN O O
X NN O O
chromosome NN O O
and NN O O
a NN O O
microdeletion NN O O
of NN O O
the NN O O
HPRT NN O O
gene NN O O
on NN O O
an NN O O
active NN O O
maternal NN O O
X NN O O
chromosome NN O O
were NN O O
responsible NN O O
for NN O O
the NN O O
absence NN O O
of NN O O
HPRT NN O O
in NN O O
this NN O O
patient NN O O
. NN O O
. NN O O

Pelizaeus NN O B-Disease
- NN O I-Disease
Merzbacher NN O I-Disease
disease NN O I-Disease
: NN O O
an NN O O
X NN O B-Disease
- NN O I-Disease
linked NN O I-Disease
neurologic NN O I-Disease
disorder NN O I-Disease
of NN O I-Disease
myelin NN O I-Disease
metabolism NN O I-Disease
with NN O O
a NN O O
novel NN O O
mutation NN O O
in NN O O
the NN O O
gene NN O O
encoding NN O O
proteolipid NN O O
protein NN O O
. NN O O

The NN O O
nosology NN O O
of NN O O
the NN O O
inborn NN O B-Disease
errors NN O I-Disease
of NN O I-Disease
myelin NN O I-Disease
metabolism NN O I-Disease
has NN O O
been NN O O
stymied NN O O
by NN O O
the NN O O
lack NN O O
of NN O O
molecular NN O O
genetic NN O O
analysis NN O O
. NN O O

Historically NN O O
, NN O O
Pelizaeus NN O B-Disease
- NN O I-Disease
Merzbacher NN O I-Disease
disease NN O I-Disease
has NN O O
encompassed NN O O
a NN O O
host NN O O
of NN O O
neurologic NN O B-Disease
disorders NN O I-Disease
that NN O O
present NN O O
with NN O O
a NN O O
deficit NN O B-Disease
of NN O I-Disease
myelin NN O I-Disease
, NN O O
the NN O O
membrane NN O O
elaborated NN O O
by NN O O
glial NN O O
cells NN O O
that NN O O
encircles NN O O
and NN O O
successively NN O O
enwraps NN O O
axons NN O O
. NN O O

We NN O O
describe NN O O
here NN O O
a NN O O
Pelizaeus NN O B-Disease
- NN O I-Disease
Merzbacher NN O I-Disease
pedigree NN O O
of NN O O
the NN O O
classical NN O O
type NN O O
, NN O O
with NN O O
X NN O O
- NN O O
linked NN O O
inheritance NN O O
, NN O O
a NN O O
typical NN O O
clinical NN O O
progression NN O O
, NN O O
and NN O O
a NN O O
pathologic NN O O
loss NN O O
of NN O O
myelinating NN O O
cells NN O O
and NN O O
myelin NN O O
in NN O O
the NN O O
central NN O O
nervous NN O O
system NN O O
. NN O O

To NN O O
discriminate NN O O
variants NN O O
of NN O O
Pelizaeus NN O B-Disease
- NN O I-Disease
Merzbacher NN O I-Disease
disease NN O I-Disease
, NN O O
a NN O O
set NN O O
of NN O O
oligonucleotide NN O O
primers NN O O
was NN O O
constructed NN O O
to NN O O
polymerase NN O O
- NN O O
chain NN O O
- NN O O
reaction NN O O
( NN O O
PCR NN O O
) NN O O
amplify NN O O
and NN O O
sequence NN O O
the NN O O
gene NN O O
encoding NN O O
proteolipid NN O O
protein NN O O
( NN O O
PLP NN O O
) NN O O
, NN O O
a NN O O
structural NN O O
protein NN O O
that NN O O
comprises NN O O
half NN O O
of NN O O
the NN O O
protein NN O O
of NN O O
the NN O O
myelin NN O O
sheath NN O O
. NN O O

The NN O O
PLP NN O O
gene NN O O
in NN O O
one NN O O
of NN O O
two NN O O
affected NN O O
males NN O O
and NN O O
the NN O O
carrier NN O O
mother NN O O
of NN O O
this NN O O
family NN O O
exhibited NN O O
a NN O O
single NN O O
base NN O O
difference NN O O
in NN O O
the NN O O
more NN O O
than NN O O
2 NN O O
kb NN O O
of NN O O
the NN O O
PLP NN O O
gene NN O O
sequenced NN O O
, NN O O
a NN O O
C NN O O
- NN O O
- NN O O
- NN O O
- NN O O
T NN O O
transition NN O O
that NN O O
would NN O O
create NN O O
a NN O O
serine NN O O
substitution NN O O
for NN O O
proline NN O O
at NN O O
the NN O O
carboxy NN O O
end NN O O
of NN O O
the NN O O
protein NN O O
. NN O O

Our NN O O
results NN O O
delineate NN O O
the NN O O
clinical NN O O
features NN O O
of NN O O
Pelizaeus NN O B-Disease
- NN O I-Disease
Merzbacher NN O I-Disease
disease NN O I-Disease
, NN O O
define NN O O
the NN O O
possible NN O O
molecular NN O O
pathology NN O O
of NN O O
this NN O O
dysmyelinating NN O B-Disease
disorder NN O I-Disease
, NN O O
and NN O O
address NN O O
the NN O O
molecular NN O O
classification NN O O
of NN O O
inborn NN O B-Disease
errors NN O I-Disease
of NN O I-Disease
myelin NN O I-Disease
metabolism NN O I-Disease
. NN O O

Patients NN O O
with NN O O
the NN O O
classical NN O O
form NN O O
( NN O O
type NN O O
I NN O O
) NN O O
and NN O O
the NN O O
more NN O O
severely NN O O
affected NN O O
, NN O O
connatal NN O O
variant NN O O
of NN O O
Pelizaeus NN O B-Disease
- NN O I-Disease
Merzbacher NN O I-Disease
disease NN O I-Disease
( NN O I-Disease
type NN O I-Disease
II NN O I-Disease
) NN O I-Disease
would NN O O
be NN O O
predicted NN O O
to NN O O
display NN O O
mutation NN O O
at NN O O
the NN O O
PLP NN O O
locus NN O O
. NN O O

The NN O O
other NN O O
variants NN O O
( NN O O
types NN O O
III NN O O
- NN O O
VI NN O O
) NN O O
, NN O O
which NN O O
have NN O O
sometimes NN O O
been NN O O
categorized NN O O
as NN O O
Pelizaeus NN O B-Disease
- NN O I-Disease
Merzbacher NN O I-Disease
disease NN O I-Disease
, NN O O
may NN O O
represent NN O O
mutations NN O O
in NN O O
genes NN O O
encoding NN O O
other NN O O
structural NN O O
myelin NN O O
proteins NN O O
or NN O O
proteins NN O O
critical NN O O
to NN O O
myelination NN O O
. NN O O
. NN O O

Molecular NN O O
basis NN O O
of NN O O
human NN O O
von NN O B-Disease
Willebrand NN O I-Disease
disease NN O I-Disease
: NN O O
analysis NN O O
of NN O O
platelet NN O O
von NN O B-Disease
Willebrand NN O I-Disease
factor NN O O
mRNA NN O O
. NN O O

von NN O B-Disease
Willebrand NN O I-Disease
disease NN O I-Disease
( NN O O
vWD NN O B-Disease
) NN O O
, NN O O
the NN O O
most NN O O
common NN O O
inherited NN O B-Disease
bleeding NN O I-Disease
disorder NN O I-Disease
in NN O O
humans NN O O
, NN O O
can NN O O
result NN O O
from NN O O
either NN O O
a NN O O
quantitative NN O O
or NN O O
a NN O O
qualitative NN O O
defect NN O O
in NN O O
the NN O O
adhesive NN O O
glycoprotein NN O O
, NN O O
von NN O B-Disease
Willebrand NN O I-Disease
factor NN O O
( NN O O
vWF NN O O
) NN O O
. NN O O

Molecular NN O O
studies NN O O
of NN O O
vWD NN O B-Disease
have NN O O
been NN O O
limited NN O O
by NN O O
the NN O O
large NN O O
size NN O O
of NN O O
the NN O O
vWF NN O O
gene NN O O
and NN O O
difficulty NN O O
in NN O O
obtaining NN O O
the NN O O
vWF NN O O
mRNA NN O O
from NN O O
patients NN O O
. NN O O

By NN O O
use NN O O
of NN O O
an NN O O
adaptation NN O O
of NN O O
the NN O O
polymerase NN O O
chain NN O O
reaction NN O O
, NN O O
vWF NN O O
mRNA NN O O
was NN O O
amplified NN O O
and NN O O
sequenced NN O O
from NN O O
peripheral NN O O
blood NN O O
platelets NN O O
. NN O O

A NN O O
silent NN O O
vWF NN O O
allele NN O O
was NN O O
identified NN O O
, NN O O
resulting NN O O
from NN O O
a NN O O
cis NN O O
defect NN O O
in NN O O
vWF NN O O
mRNA NN O O
transcription NN O O
or NN O O
processing NN O O
. NN O O

In NN O O
two NN O O
type NN O B-Disease
IIA NN O I-Disease
vWD NN O I-Disease
patients NN O O
, NN O O
two NN O O
different NN O O
but NN O O
adjacent NN O O
missense NN O O
mutations NN O O
were NN O O
identified NN O O
, NN O O
the NN O O
locations NN O O
of NN O O
which NN O O
may NN O O
identify NN O O
an NN O O
important NN O O
vWF NN O O
functional NN O O
domain NN O O
. NN O O

Expression NN O O
in NN O O
heterologous NN O O
cells NN O O
of NN O O
recombinant NN O O
vWF NN O O
containing NN O O
one NN O O
of NN O O
these NN O O
latter NN O O
mutations NN O O
reproduced NN O O
the NN O O
characteristic NN O O
structural NN O O
abnormality NN O O
seen NN O O
in NN O O
type NN O B-Disease
IIA NN O I-Disease
vWD NN O I-Disease
plasma NN O O
. NN O O
. NN O O

Familial NN O B-Disease
deficiency NN O I-Disease
of NN O I-Disease
the NN O I-Disease
seventh NN O I-Disease
component NN O I-Disease
of NN O I-Disease
complement NN O I-Disease
associated NN O O
with NN O O
recurrent NN O O
meningococcal NN O B-Disease
infections NN O I-Disease
. NN O O

We NN O O
describe NN O O
an NN O O
11 NN O O
- NN O O
year NN O O
- NN O O
old NN O O
girl NN O O
suffering NN O O
from NN O O
recurrent NN O B-Disease
meningitis NN O I-Disease
with NN O O
a NN O O
complete NN O O
absence NN O B-Disease
of NN O I-Disease
the NN O I-Disease
seventh NN O I-Disease
component NN O I-Disease
of NN O I-Disease
complement NN O I-Disease
( NN O O
C7 NN O O
) NN O O
. NN O O

Diagnosis NN O O
was NN O O
established NN O O
by NN O O
haemolytic NN O O
titration NN O O
and NN O O
western NN O O
blotting NN O O
. NN O O

The NN O O
patients NN O O
serum NN O O
lacked NN O O
the NN O O
85 NN O O
kDa NN O O
C7 NN O O
chain NN O O
. NN O O

Haemolytic NN O O
activity NN O O
of NN O O
serum NN O O
was NN O O
reconstituted NN O O
with NN O O
either NN O O
pooled NN O O
normal NN O O
human NN O O
serum NN O O
or NN O O
with NN O O
purified NN O O
C7 NN O O
. NN O O

The NN O O
relatives NN O O
( NN O O
parents NN O O
and NN O O
one NN O O
sister NN O O
) NN O O
had NN O O
half NN O O
- NN O O
normal NN O O
levels NN O O
of NN O O
both NN O O
immunochemically NN O O
and NN O O
functionally NN O O
determined NN O O
C7 NN O O
, NN O O
indicating NN O O
a NN O O
heterozygous NN O O
state NN O O
for NN O O
C7 NN O B-Disease
deficiency NN O I-Disease
. NN O O
. NN O O

Translocation NN O O
t NN O O
( NN O O
5 NN O O
; NN O O
11 NN O O
) NN O O
( NN O O
q13 NN O O
. NN O O
1 NN O O
; NN O O
p13 NN O O
) NN O O
associated NN O O
with NN O O
familial NN O O
isolated NN O B-Disease
aniridia NN O I-Disease
. NN O O

A NN O O
father NN O O
and NN O O
daughter NN O O
with NN O O
isolated NN O B-Disease
aniridia NN O I-Disease
were NN O O
observed NN O O
to NN O O
have NN O O
an NN O O
apparently NN O O
balanced NN O O
, NN O O
reciprocal NN O O
translocation NN O O
involving NN O O
chromosomes NN O O
5 NN O O
and NN O O
11 NN O O
[ NN O O
t NN O O
( NN O O
5 NN O O
; NN O O
11 NN O O
) NN O O
( NN O O
q13 NN O O
. NN O O
1 NN O O
; NN O O
p13 NN O O
) NN O O
] NN O O
. NN O O

No NN O O
other NN O O
clinical NN O O
characteristics NN O O
often NN O O
associated NN O O
with NN O O
the NN O O
deletion NN O O
of NN O O
11p13 NN O O
were NN O O
observed NN O O
in NN O O
this NN O O
family NN O O
. NN O O

This NN O O
finding NN O O
, NN O O
in NN O O
association NN O O
with NN O O
3 NN O O
other NN O O
instances NN O O
of NN O O
single NN O O
breaks NN O O
at NN O O
11p13 NN O O
and NN O O
aniridia NN O B-Disease
, NN O O
supports NN O O
the NN O O
assignment NN O O
of NN O O
AN2 NN O O
to NN O O
11p13 NN O O
. NN O O

Homozygous NN O B-Disease
hypobetalipoproteinemia NN O I-Disease
: NN O O
a NN O O
disease NN O O
distinct NN O O
from NN O O
abetalipoproproteinemia NN O B-Disease
at NN O O
the NN O O
molecular NN O O
level NN O O
. NN O O

apoB NN O O
DNA NN O O
, NN O O
RNA NN O O
, NN O O
and NN O O
protein NN O O
from NN O O
two NN O O
patients NN O O
with NN O O
homozygous NN O B-Disease
hypobetalipoproteinemia NN O I-Disease
( NN O O
HBL NN O B-Disease
) NN O O
were NN O O
evaluated NN O O
and NN O O
compared NN O O
with NN O O
normal NN O O
individuals NN O O
. NN O O

Southern NN O O
blot NN O O
analysis NN O O
with NN O O
10 NN O O
different NN O O
cDNA NN O O
probes NN O O
revealed NN O O
a NN O O
normal NN O O
gene NN O O
without NN O O
major NN O O
insertions NN O O
, NN O O
deletions NN O O
, NN O O
or NN O O
rearrangements NN O O
. NN O O

Northern NN O O
and NN O O
slot NN O O
blot NN O O
analyses NN O O
of NN O O
total NN O O
liver NN O O
mRNA NN O O
from NN O O
HBL NN O B-Disease
patients NN O O
documented NN O O
a NN O O
normal NN O O
size NN O O
apoB NN O O
mRNA NN O O
that NN O O
was NN O O
present NN O O
in NN O O
greatly NN O O
reduced NN O O
quantities NN O O
. NN O O

ApoB NN O O
protein NN O O
was NN O O
detected NN O O
within NN O O
HBL NN O B-Disease
hepatocytes NN O O
utilizing NN O O
immunohistochemical NN O O
techniques NN O O
; NN O O
however NN O O
, NN O O
it NN O O
was NN O O
markedly NN O O
reduced NN O O
in NN O O
quantity NN O O
when NN O O
compared NN O O
with NN O O
control NN O O
samples NN O O
. NN O O

No NN O O
apoB NN O O
was NN O O
detectable NN O O
in NN O O
the NN O O
plasma NN O O
of NN O O
HBL NN O B-Disease
individuals NN O O
with NN O O
an NN O O
ELISA NN O O
assay NN O O
. NN O O

These NN O O
data NN O O
are NN O O
most NN O O
consistent NN O O
with NN O O
a NN O O
mutation NN O O
in NN O O
the NN O O
coding NN O O
portion NN O O
of NN O O
the NN O O
apoB NN O O
gene NN O O
in NN O O
HBL NN O B-Disease
patients NN O O
, NN O O
leading NN O O
to NN O O
an NN O O
abnormal NN O O
apoB NN O O
protein NN O O
and NN O O
apoB NN O O
mRNA NN O O
instability NN O O
. NN O O

These NN O O
results NN O O
are NN O O
distinct NN O O
from NN O O
those NN O O
previously NN O O
noted NN O O
in NN O O
abetalipoproteinemia NN O B-Disease
, NN O O
which NN O O
was NN O O
characterized NN O O
by NN O O
an NN O O
elevated NN O O
level NN O O
of NN O O
hepatic NN O O
apoB NN O O
mRNA NN O O
and NN O O
accumulation NN O O
of NN O O
intracellular NN O O
hepatic NN O O
apoB NN O O
protein NN O O
. NN O O
. NN O O

Spontaneous NN O O
reversion NN O O
of NN O O
novel NN O O
Lesch NN O B-Disease
- NN O I-Disease
Nyhan NN O I-Disease
mutation NN O O
by NN O O
HPRT NN O O
gene NN O O
rearrangement NN O O
. NN O O

Molecular NN O O
analysis NN O O
of NN O O
an NN O O
unusual NN O O
patient NN O O
with NN O O
the NN O O
Lesch NN O B-Disease
- NN O I-Disease
Nyhan NN O I-Disease
syndrome NN O I-Disease
has NN O O
suggested NN O O
that NN O O
the NN O O
mutation NN O O
is NN O O
due NN O O
to NN O O
a NN O O
partial NN O O
HPRT NN O O
gene NN O O
duplication NN O O
. NN O O

We NN O O
now NN O O
report NN O O
the NN O O
cloning NN O O
and NN O O
sequencing NN O O
of NN O O
the NN O O
mutant NN O O
HPRT NN O O
cDNA NN O O
which NN O O
shows NN O O
the NN O O
precise NN O O
duplication NN O O
of NN O O
exons NN O O
2 NN O O
and NN O O
3 NN O O
. NN O O

This NN O O
mutation NN O O
is NN O O
the NN O O
result NN O O
of NN O O
an NN O O
internal NN O O
duplication NN O O
of NN O O
16 NN O O
- NN O O
20 NN O O
kilobases NN O O
of NN O O
the NN O O
gene NN O O
. NN O O

The NN O O
structure NN O O
of NN O O
the NN O O
mutant NN O O
gene NN O O
suggests NN O O
that NN O O
the NN O O
duplication NN O O
was NN O O
not NN O O
generated NN O O
by NN O O
a NN O O
single NN O O
unequal NN O O
crossing NN O O
- NN O O
over NN O O
event NN O O
between NN O O
two NN O O
normal NN O O
HPRT NN O O
alleles NN O O
. NN O O

Growth NN O O
of NN O O
Epstein NN O B-Disease
- NN O I-Disease
Barr NN O I-Disease
virus NN O O
- NN O O
transformed NN O O
lymphoblasts NN O O
from NN O O
this NN O O
patient NN O O
in NN O O
selective NN O O
medium NN O O
has NN O O
permitted NN O O
isolation NN O O
of NN O O
spontaneous NN O O
HPRT NN O O
+ NN O O
revertants NN O O
of NN O O
this NN O O
mutation NN O O
. NN O O

The NN O O
reversion NN O O
event NN O O
involves NN O O
a NN O O
second NN O O
major NN O O
HPRT NN O O
gene NN O O
rearrangement NN O O
where NN O O
most NN O O
or NN O O
all NN O O
of NN O O
the NN O O
duplicated NN O O
portion NN O O
of NN O O
the NN O O
mutant NN O O
gene NN O O
is NN O O
deleted NN O O
. NN O O

The NN O O
original NN O O
mutation NN O O
therefore NN O O
has NN O O
the NN O O
potential NN O O
for NN O O
spontaneous NN O O
somatic NN O O
reversion NN O O
. NN O O

This NN O O
may NN O O
explain NN O O
the NN O O
relatively NN O O
mild NN O O
symptoms NN O O
of NN O O
the NN O O
Lesch NN O B-Disease
- NN O I-Disease
Nyhan NN O I-Disease
syndrome NN O I-Disease
exhibited NN O O
by NN O O
this NN O O
patient NN O O
. NN O O
. NN O O

Complex NN O B-Disease
glycerol NN O I-Disease
kinase NN O I-Disease
deficiency NN O I-Disease
: NN O O
molecular NN O O
- NN O O
genetic NN O O
, NN O O
cytogenetic NN O O
, NN O O
and NN O O
clinical NN O O
studies NN O O
of NN O O
five NN O O
Japanese NN O O
patients NN O O
. NN O O

Five NN O O
male NN O O
Japanese NN O O
patients NN O O
with NN O O
complex NN O B-Disease
glycerol NN O I-Disease
kinase NN O I-Disease
deficiency NN O I-Disease
( NN O O
CGKD NN O B-Disease
) NN O O
and NN O O
their NN O O
relatives NN O O
were NN O O
studied NN O O
clinically NN O O
, NN O O
cytogenetically NN O O
, NN O O
and NN O O
molecular NN O O
- NN O O
genetically NN O O
. NN O O

All NN O O
patients NN O O
had NN O O
muscular NN O B-Disease
dystrophy NN O I-Disease
or NN O O
muscle NN O B-Disease
weakness NN O I-Disease
, NN O O
mental NN O B-Disease
retardation NN O I-Disease
, NN O O
congenital NN O B-Disease
adrenal NN O I-Disease
hypoplasia NN O I-Disease
, NN O O
and NN O O
glycerol NN O B-Disease
kinase NN O I-Disease
deficiency NN O I-Disease
. NN O O

High NN O O
- NN O O
resolution NN O O
GTG NN O O
- NN O O
banded NN O O
chromosomes NN O O
showed NN O O
a NN O O
microdeletion NN O O
in NN O O
the NN O O
Xp21 NN O O
region NN O O
in NN O O
all NN O O
four NN O O
patients NN O O
examined NN O O
and NN O O
in NN O O
all NN O O
five NN O O
mothers NN O O
. NN O O

Southern NN O O
hybridizations NN O O
, NN O O
after NN O O
digestions NN O O
by NN O O
restriction NN O O
endonucleases NN O O
, NN O O
with NN O O
various NN O O
cloned NN O O
DNAs NN O O
( NN O O
D2 NN O O
, NN O O
99 NN O O
- NN O O
6 NN O O
, NN O O
B24 NN O O
, NN O O
C7 NN O O
, NN O O
L1 NN O O
- NN O O
4 NN O O
, NN O O
cDMD13 NN O O
- NN O O
14 NN O O
, NN O O
J66 NN O O
- NN O O
HI NN O O
, NN O O
P20 NN O O
, NN O O
J NN O O
- NN O O
Bir NN O O
, NN O O
ERT87 NN O O
- NN O O
30 NN O O
, NN O O
ERT87 NN O O
- NN O O
15 NN O O
, NN O O
ERT87 NN O O
- NN O O
8 NN O O
, NN O O
ERT87 NN O O
- NN O O
1 NN O O
, NN O O
XJ NN O O
- NN O O
1 NN O O
. NN O O
1 NN O O
, NN O O
754 NN O O
, NN O O
cx5 NN O O
. NN O O
7 NN O O
, NN O O
and NN O O
OTC NN O O
- NN O O
1 NN O O
) NN O O
that NN O O
are NN O O
located NN O O
around NN O O
Xp21 NN O O
also NN O O
showed NN O O
a NN O O
deletion NN O O
in NN O O
the NN O O
genome NN O O
of NN O O
all NN O O
patients NN O O
and NN O O
mothers NN O O
. NN O O

Although NN O O
the NN O O
deletion NN O O
differed NN O O
in NN O O
size NN O O
among NN O O
patients NN O O
, NN O O
a NN O O
segment NN O O
commonly NN O O
absent NN O O
was NN O O
located NN O O
between NN O O
the NN O O
genomic NN O O
sequences NN O O
corresponding NN O O
to NN O O
L1 NN O O
- NN O O
4 NN O O
and NN O O
cDMD13 NN O O
- NN O O
14 NN O O
. NN O O

This NN O O
finding NN O O
indicated NN O O
that NN O O
the NN O O
gene NN O O
coding NN O O
for NN O O
glycerol NN O O
kinase NN O O
( NN O O
GK NN O O
) NN O O
is NN O O
located NN O O
within NN O O
this NN O O
segment NN O O
. NN O O

A NN O O
comparison NN O O
of NN O O
the NN O O
clinical NN O O
manifestations NN O O
of NN O O
the NN O O
present NN O O
five NN O O
patients NN O O
and NN O O
reported NN O O
CGKD NN O B-Disease
or NN O O
Duchenne NN O B-Disease
muscular NN O I-Disease
dystrophy NN O I-Disease
( NN O O
DMD NN O B-Disease
) NN O O
patients NN O O
with NN O O
DNA NN O O
deletion NN O O
suggests NN O O
the NN O O
existence NN O O
of NN O O
a NN O O
certain NN O O
gene NN O O
responsible NN O O
for NN O O
gonadotropin NN O B-Disease
deficiency NN O I-Disease
( NN O O
GTD NN O B-Disease
) NN O O
. NN O O

The NN O O
result NN O O
of NN O O
the NN O O
present NN O O
study NN O O
and NN O O
results NN O O
of NN O O
previous NN O O
studies NN O O
suggest NN O O
that NN O O
genes NN O O
for NN O O
ornithine NN O O
transcarbamylase NN O O
( NN O O
OTC NN O O
) NN O O
, NN O O
DMD NN O B-Disease
, NN O O
and NN O O
GK NN O O
and NN O O
putative NN O O
genes NN O O
responsible NN O O
for NN O O
congenital NN O B-Disease
adrenal NN O I-Disease
hypoplasia NN O I-Disease
( NN O O
AHC NN O B-Disease
) NN O O
and NN O O
GTD NN O B-Disease
are NN O O
arranged NN O O
from NN O O
telomere NN O O
to NN O O
centromere NN O O
as NN O O
pter NN O O
- NN O O
- NN O O
GTD NN O O
- NN O O
- NN O O
AHC NN O O
- NN O O
- NN O O
GK NN O O
- NN O O
- NN O O
DMD NN O O
- NN O O
- NN O O
OTC NN O O
- NN O O
- NN O O
cen NN O O

Genetically NN O O
determined NN O O
low NN O O
C4 NN O O
: NN O O
a NN O O
predisposing NN O O
factor NN O O
to NN O O
autoimmune NN O B-Disease
chronic NN O I-Disease
active NN O I-Disease
hepatitis NN O I-Disease
. NN O O

Of NN O O
26 NN O O
patients NN O O
with NN O O
autoimmune NN O B-Disease
chronic NN O I-Disease
active NN O I-Disease
hepatitis NN O I-Disease
( NN O O
CAH NN O B-Disease
) NN O O
starting NN O O
in NN O O
childhood NN O O
18 NN O O
( NN O O
69 NN O O
% NN O O
) NN O O
had NN O O
low NN O O
C4 NN O O
and NN O O
5 NN O O
( NN O O
19 NN O O
% NN O O
) NN O O
had NN O O
low NN O O
C3 NN O O
serum NN O O
levels NN O O
. NN O O

Impaired NN O O
hepatic NN O O
synthesis NN O O
and NN O O
immune NN O O
- NN O O
consumption NN O O
were NN O O
unlikely NN O O
since NN O O
transferrin NN O O
levels NN O O
were NN O O
normal NN O O
in NN O O
all NN O O
patients NN O O
, NN O O
albumin NN O O
levels NN O O
were NN O O
persistently NN O O
low NN O O
in NN O O
only NN O O
3 NN O O
, NN O O
and NN O O
only NN O O
3 NN O O
had NN O O
raised NN O O
levels NN O O
of NN O O
activation NN O O
fragment NN O O
C3d NN O O
. NN O O

C4d NN O O
was NN O O
normal NN O O
in NN O O
all NN O O
patients NN O O
studied NN O O
. NN O O

In NN O O
the NN O O
families NN O O
of NN O O
12 NN O O
probands NN O O
with NN O O
low NN O O
C4 NN O O
, NN O O
7 NN O O
parents NN O O
had NN O O
low NN O O
C4 NN O O
and NN O O
2 NN O O
had NN O O
levels NN O O
which NN O O
were NN O O
at NN O O
the NN O O
lower NN O O
limit NN O O
of NN O O
normal NN O O
. NN O O

5 NN O O
of NN O O
10 NN O O
siblings NN O O
from NN O O
5 NN O O
families NN O O
had NN O O
low NN O O
C4 NN O O
. NN O O

These NN O O
results NN O O
suggest NN O O
that NN O O
low NN O O
C4 NN O O
levels NN O O
in NN O O
CAH NN O B-Disease
are NN O O
genetically NN O O
determined NN O O
. NN O O

C4 NN O O
phenotyping NN O O
in NN O O
20 NN O O
patients NN O O
and NN O O
in NN O O
26 NN O O
parents NN O O
showed NN O O
that NN O O
90 NN O O
% NN O O
and NN O O
81 NN O O
% NN O O
, NN O O
respectively NN O O
, NN O O
had NN O O
null NN O O
allotypes NN O O
at NN O O
either NN O O
the NN O O
C4A NN O O
or NN O O
C4B NN O O
locus NN O O
compared NN O O
with NN O O
59 NN O O
% NN O O
in NN O O
controls NN O O
, NN O O
indicating NN O O
that NN O O
defective NN O O
expression NN O O
of NN O O
structural NN O O
genes NN O O
may NN O O
contribute NN O O
to NN O O
the NN O O
observed NN O O
C4 NN O B-Disease
deficiency NN O I-Disease
. NN O O
. NN O O

An NN O O
amino NN O O
- NN O O
acid NN O O
substitution NN O O
involved NN O O
in NN O O
phenylketonuria NN O B-Disease
is NN O O
in NN O O
linkage NN O O
disequilibrium NN O O
with NN O O
DNA NN O O
haplotype NN O O
2 NN O O
. NN O O

Phenylketonuria NN O B-Disease
( NN O O
PKU NN O B-Disease
) NN O O
is NN O O
an NN O O
autosomal NN O B-Disease
recessive NN O I-Disease
human NN O I-Disease
genetic NN O I-Disease
disorder NN O I-Disease
caused NN O O
by NN O O
a NN O O
deficiency NN O B-Disease
of NN O I-Disease
hepatic NN O I-Disease
phenylalanine NN O I-Disease
hydroxylase NN O I-Disease
( NN O O
PAH NN O O
, NN O O
phenylalanine NN O O
4 NN O O
- NN O O
monooxygenase NN O O
, NN O O
EC NN O O
1 NN O O
. NN O O
14 NN O O
. NN O O
16 NN O O
. NN O O
1 NN O O
) NN O O
. NN O O

PKU NN O B-Disease
is NN O O
a NN O O
common NN O O
inborn NN O B-Disease
error NN O I-Disease
of NN O I-Disease
amino NN O I-Disease
- NN O I-Disease
acid NN O I-Disease
metabolism NN O I-Disease
in NN O O
caucasian NN O O
populations NN O O
and NN O O
approximately NN O O
1 NN O O
in NN O O
50 NN O O
individuals NN O O
are NN O O
carriers NN O O
of NN O O
a NN O O
PKU NN O B-Disease
allele NN O O
. NN O O

To NN O O
define NN O O
the NN O O
molecular NN O O
basis NN O O
of NN O O
PKU NN O B-Disease
, NN O O
we NN O O
characterized NN O O
twelve NN O O
restriction NN O O
fragment NN O O
- NN O O
length NN O O
polymorphism NN O O
( NN O O
RFLP NN O O
) NN O O
haplotypes NN O O
of NN O O
the NN O O
PAH NN O O
locus NN O O
in NN O O
the NN O O
northern NN O O
European NN O O
population NN O O
and NN O O
observed NN O O
that NN O O
90 NN O O
% NN O O
of NN O O
the NN O O
PKU NN O B-Disease
alleles NN O O
in NN O O
this NN O O
population NN O O
are NN O O
confined NN O O
to NN O O
four NN O O
common NN O O
RFLP NN O O
haplotypes NN O O
. NN O O

We NN O O
have NN O O
recently NN O O
reported NN O O
a NN O O
splicing NN O O
mutation NN O O
in NN O O
the NN O O
PAH NN O O
gene NN O O
that NN O O
is NN O O
associated NN O O
with NN O O
RFLP NN O O
haplotype NN O O
3 NN O O
which NN O O
is NN O O
present NN O O
at NN O O
about NN O O
40 NN O O
% NN O O
of NN O O
mutant NN O O
alleles NN O O
. NN O O

We NN O O
now NN O O
report NN O O
the NN O O
molecular NN O B-Disease
lesion NN O I-Disease
associated NN O O
with NN O O
the NN O O
RFLP NN O O
haplotype NN O O
2 NN O O
mutant NN O O
allele NN O O
. NN O O

This NN O O
defect NN O O
is NN O O
caused NN O O
by NN O O
a NN O O
C NN O O
- NN O O
to NN O O
- NN O O
T NN O O
transition NN O O
in NN O O
exon NN O O
12 NN O O
resulting NN O O
in NN O O
an NN O O
amino NN O O
- NN O O
acid NN O O
substitution NN O O
( NN O O
Arg NN O O
to NN O O
Trp NN O O
) NN O O
at NN O O
residue NN O O
408 NN O O
of NN O O
PAH NN O O
. NN O O

Direct NN O O
hybridization NN O O
analysis NN O O
of NN O O
the NN O O
point NN O O
mutation NN O O
using NN O O
a NN O O
specific NN O O
oligonucleotide NN O O
probe NN O O
demonstrated NN O O
that NN O O
this NN O O
mutation NN O O
is NN O O
also NN O O
in NN O O
linkage NN O O
disequilibrium NN O O
with NN O O
RFLP NN O O
haplotype NN O O
2 NN O O
alleles NN O O
that NN O O
make NN O O
up NN O O
about NN O O
20 NN O O
% NN O O
of NN O O
mutant NN O O
PAH NN O O
genes NN O O

Choroideremia NN O B-Disease
: NN O O
close NN O O
linkage NN O O
to NN O O
DXYS1 NN O O
and NN O O
DXYS12 NN O O
demonstrated NN O O
by NN O O
segregation NN O O
analysis NN O O
and NN O O
historical NN O O
- NN O O
genealogical NN O O
evidence NN O O
. NN O O

Linkage NN O O
studies NN O O
using NN O O
restriction NN O O
fragment NN O O
length NN O O
polymorphisms NN O O
were NN O O
conducted NN O O
in NN O O
the NN O O
X NN O B-Disease
- NN O I-Disease
linked NN O I-Disease
disorder NN O I-Disease
, NN O O
choroideremia NN O B-Disease
, NN O O
designated NN O O
TCD NN O B-Disease
for NN O O
Progressive NN O B-Disease
Tapeto NN O I-Disease
- NN O I-Disease
Choroidal NN O I-Disease
Dystrophy NN O I-Disease
. NN O O

Previously NN O O
demonstrated NN O O
close NN O O
linkage NN O O
with NN O O
locus NN O O
DXYS1 NN O O
was NN O O
confirmed NN O O
( NN O O
lod NN O O
11 NN O O
. NN O O
44 NN O O
at NN O O
0 NN O O
recombination NN O O
distance NN O O
) NN O O
. NN O O

In NN O O
addition NN O O
, NN O O
locus NN O O
DXYS12 NN O O
was NN O O
found NN O O
to NN O O
be NN O O
closely NN O O
linked NN O O
with NN O O
TCD NN O B-Disease
( NN O O
lod NN O O
3 NN O O
. NN O O
31 NN O O
at NN O O
0 NN O O
recombination NN O O
distance NN O O
) NN O O
. NN O O

The NN O O
disease NN O O
mainly NN O O
occurs NN O O
in NN O O
three NN O O
large NN O O
kindreds NN O O
in NN O O
remote NN O O
Northern NN O O
Finland NN O O
. NN O O

While NN O O
formal NN O O
genealogical NN O O
proof NN O O
is NN O O
lacking NN O O
, NN O O
all NN O O
presently NN O O
living NN O O
( NN O O
more NN O O
than NN O O
80 NN O O
affected NN O O
males NN O O
and NN O O
120 NN O O
carrier NN O O
females NN O O
) NN O O
probably NN O O
originate NN O O
from NN O O
a NN O O
common NN O O
founder NN O O
couple NN O O
born NN O O
in NN O O
1644 NN O O
and NN O O
1646 NN O O
, NN O O
twelve NN O O
generations NN O O
ago NN O O
. NN O O

All NN O O
36 NN O O
patients NN O O
and NN O O
48 NN O O
carriers NN O O
tested NN O O
from NN O O
the NN O O
three NN O O
kindreds NN O O
had NN O O
the NN O O
same NN O O
haplotype NN O O
( NN O O
TCD NN O B-Disease
/ NN O O
DXYS1 NN O O
, NN O O
11kb NN O O
/ NN O O
DXYS12 NN O O
, NN O O
1 NN O O
. NN O O
6kb NN O O
) NN O O
. NN O O

Given NN O O
that NN O O
at NN O O
least NN O O
105 NN O O
female NN O O
meioses NN O O
transmitting NN O O
TCD NN O B-Disease
have NN O O
occurred NN O O
since NN O O
1650 NN O O
in NN O O
these NN O O
kindreds NN O O
, NN O O
extremely NN O O
close NN O O
linkage NN O O
between NN O O
TCD NN O B-Disease
, NN O O
DXYS1 NN O O
and NN O O
DXYS12 NN O O
is NN O O
suggested NN O O
. NN O O

The NN O O
above NN O O
haplotype NN O O
is NN O O
a NN O O
very NN O O
useful NN O O
diagnostic NN O O
tool NN O O
in NN O O
these NN O O
TCD NN O B-Disease
families NN O O
. NN O O

We NN O O
suggest NN O O
that NN O O
our NN O O
historical NN O O
- NN O O
genealogical NN O O
approach NN O O
to NN O O
linkage NN O O
analysis NN O O
may NN O O
be NN O O
possible NN O O
elsewhere NN O O
in NN O O
similar NN O O
isolated NN O O
populations NN O O

Von NN O B-Disease
Hippel NN O I-Disease
- NN O I-Disease
Lindau NN O I-Disease
disease NN O I-Disease
maps NN O O
to NN O O
the NN O O
region NN O O
of NN O O
chromosome NN O O
3 NN O O
associated NN O O
with NN O O
renal NN O B-Disease
cell NN O I-Disease
carcinoma NN O I-Disease
. NN O O

Von NN O B-Disease
Hippel NN O I-Disease
- NN O I-Disease
Lindau NN O I-Disease
disease NN O I-Disease
( NN O O
VHL NN O B-Disease
) NN O O
is NN O O
an NN O O
autosomal NN O B-Disease
dominant NN O I-Disease
disorder NN O I-Disease
with NN O O
inherited NN O O
susceptibility NN O O
to NN O O
various NN O O
forms NN O O
of NN O O
cancer NN O B-Disease
, NN O O
including NN O O
hemangioblastomas NN O B-Disease
of NN O O
the NN O O
central NN O O
nervous NN O O
system NN O O
, NN O O
phaeochromocytomas NN O B-Disease
, NN O O
pancreatic NN O B-Disease
malignancies NN O I-Disease
, NN O O
and NN O O
renal NN O B-Disease
cell NN O I-Disease
carcinomas NN O I-Disease
. NN O O

Renal NN O B-Disease
cell NN O I-Disease
carcinomas NN O I-Disease
constitute NN O O
a NN O O
particularly NN O O
frequent NN O O
cause NN O O
of NN O O
death NN O O
in NN O O
this NN O O
disorder NN O O
, NN O O
occurring NN O O
as NN O O
bilateral NN O B-Disease
and NN O I-Disease
multifocal NN O I-Disease
tumours NN O I-Disease
, NN O O
and NN O O
presenting NN O O
at NN O O
an NN O O
earlier NN O O
age NN O O
than NN O O
in NN O O
sporadic NN O O
, NN O O
non NN O O
- NN O O
familial NN O O
cases NN O O
of NN O O
this NN O O
tumour NN O B-Disease
type NN O O
. NN O O

We NN O O
report NN O O
here NN O O
that NN O O
the NN O O
VHL NN O B-Disease
gene NN O O
is NN O O
linked NN O O
to NN O O
the NN O O
locus NN O O
encoding NN O O
the NN O O
human NN O O
homologoue NN O O
of NN O O
the NN O O
RAF1 NN O O
oncogene NN O O
, NN O O
which NN O O
maps NN O O
to NN O O
chromosome NN O O
3p25 NN O O
( NN O O
ref NN O O
. NN O O
4 NN O O
) NN O O
. NN O O

Crossovers NN O O
with NN O O
the NN O O
VHL NN O B-Disease
locus NN O O
suggest NN O O
that NN O O
the NN O O
defect NN O O
responsible NN O O
for NN O O
the NN O O
VHL NN O B-Disease
phenotype NN O O
is NN O O
not NN O O
a NN O O
mutation NN O O
in NN O O
the NN O O
RAF1 NN O O
gene NN O O
itself NN O O
. NN O O

An NN O O
alternative NN O O
or NN O O
prior NN O O
event NN O O
to NN O O
oncogene NN O O
activation NN O O
in NN O O
tumour NN O B-Disease
formation NN O O
may NN O O
be NN O O
the NN O O
inactivation NN O O
of NN O O
a NN O O
putative NN O O
tumour NN O B-Disease
suppressor NN O O
which NN O O
can NN O O
be NN O O
associated NN O O
with NN O O
both NN O O
the NN O O
inherited NN O B-Disease
and NN O I-Disease
sporadic NN O I-Disease
forms NN O I-Disease
of NN O I-Disease
the NN O I-Disease
cancer NN O I-Disease
. NN O O

Sporadic NN O B-Disease
renal NN O I-Disease
cell NN O I-Disease
carcinomas NN O I-Disease
have NN O O
previously NN O O
been NN O O
associated NN O O
with NN O O
the NN O O
loss NN O O
of NN O O
regions NN O O
on NN O O
chromosome NN O O
3p NN O O
( NN O O
refs NN O O
5 NN O O
, NN O O
6 NN O O
) NN O O
. NN O O

Consequently NN O O
, NN O O
sporadic NN O O
and NN O O
VHL NN O O
- NN O O
associated NN O O
forms NN O O
of NN O O
renal NN O B-Disease
cell NN O I-Disease
carcinoma NN O I-Disease
might NN O O
both NN O O
result NN O O
from NN O O
alterations NN O O
causing NN O O
loss NN O O
of NN O O
function NN O O
of NN O O
the NN O O
same NN O O
tumour NN O B-Disease
suppressor NN O O
gene NN O O
on NN O O
this NN O O
chromosome NN O O
. NN O O
. NN O O

Tightly NN O O
linked NN O O
flanking NN O O
markers NN O O
for NN O O
the NN O O
Lowe NN O B-Disease
oculocerebrorenal NN O I-Disease
syndrome NN O I-Disease
, NN O O
with NN O O
application NN O O
to NN O O
carrier NN O O
assessment NN O O
. NN O O

The NN O O
Lowe NN O B-Disease
oculocerebrorenal NN O I-Disease
syndrome NN O I-Disease
( NN O O
OCRL NN O B-Disease
) NN O O
is NN O O
characterized NN O O
by NN O O
congenital NN O O
cataract NN O B-Disease
, NN O O
mental NN O B-Disease
retardation NN O I-Disease
, NN O O
and NN O O
defective NN O B-Disease
renal NN O I-Disease
tubular NN O I-Disease
function NN O I-Disease
. NN O O

A NN O O
map NN O O
assignment NN O O
of NN O O
OCRL NN O B-Disease
to NN O O
Xq24 NN O O
- NN O O
q26 NN O O
has NN O O
been NN O O
made NN O O
previously NN O O
by NN O O
linkage NN O O
analysis NN O O
with NN O O
DXS42 NN O O
at NN O O
Xq24 NN O O
- NN O O
q26 NN O O
( NN O O
theta NN O O
= NN O O
0 NN O O
, NN O O
z NN O O
= NN O O
5 NN O O
. NN O O
09 NN O O
) NN O O
and NN O O
with NN O O
DXS10 NN O O
at NN O O
Xq26 NN O O
( NN O O
theta NN O O
= NN O O
0 NN O O
, NN O O
z NN O O
= NN O O
6 NN O O
. NN O O
45 NN O O
) NN O O
. NN O O

Two NN O O
additional NN O O
families NN O O
were NN O O
studied NN O O
and NN O O
three NN O O
additional NN O O
polymorphisms NN O O
were NN O O
identified NN O O
at NN O O
DXS42 NN O O
by NN O O
using NN O O
a NN O O
35 NN O O
- NN O O
kb NN O O
sequence NN O O
isolated NN O O
with NN O O
the NN O O
probe NN O O
detecting NN O O
the NN O O
original NN O O
polymorphism NN O O
at NN O O
DXS42 NN O O
. NN O O

With NN O O
additional NN O O
OCRL NN O B-Disease
families NN O O
made NN O O
informative NN O O
for NN O O
DXS42 NN O O
, NN O O
theta NN O O
remained NN O O
0 NN O O
with NN O O
z NN O O
= NN O O
6 NN O O
. NN O O

63 NN O O
; NN O O
and NN O O
for NN O O
DXS10 NN O O
theta NN O O
= NN O O
0 NN O O
. NN O O

03 NN O O
and NN O O
z NN O O
= NN O O
7 NN O O
. NN O O

07 NN O O
. NN O O

Evidence NN O O
for NN O O
placing NN O O
OCRL NN O O
at NN O O
Xq25 NN O O
also NN O O
comes NN O O
from NN O O
a NN O O
female NN O O
with NN O O
Lowe NN O B-Disease
syndrome NN O I-Disease
and NN O O
an NN O O
X NN O O
; NN O O
3 NN O O
translocation NN O O
. NN O O

We NN O O
have NN O O
used NN O O
the NN O O
Xq25 NN O O
breakpoint NN O O
in NN O O
this NN O O
patient NN O O
to NN O O
determine NN O O
the NN O O
position NN O O
of NN O O
OCRL NN O O
relative NN O O
to NN O O
the NN O O
two NN O O
linked NN O O
markers NN O O
. NN O O

Each NN O O
derivative NN O O
chromosome NN O O
was NN O O
isolated NN O O
away NN O O
from NN O O
its NN O O
normal NN O O
counterpart NN O O
in NN O O
somatic NN O O
cell NN O O
hybrids NN O O
. NN O O

DXS42 NN O O
was NN O O
mapped NN O O
to NN O O
the NN O O
derivative NN O O
chromosome NN O O
X NN O O
containing NN O O
Xpterq25 NN O O
, NN O O
and NN O O
DXS10 NN O O
was NN O O
mapped NN O O
to NN O O
the NN O O
derivative NN O O
chromosome NN O O
3 NN O O
containing NN O O
Xq25 NN O O
- NN O O
qter NN O O
. NN O O

The NN O O
markers NN O O
DXS10 NN O O
and NN O O
DXS42 NN O O
therefore NN O O
show NN O O
tight NN O O
linkage NN O O
with NN O O
OCRL NN O B-Disease
in NN O O
six NN O O
families NN O O
and NN O O
flank NN O O
the NN O O
Xq25 NN O O
breakpoint NN O O
in NN O O
a NN O O
female NN O O
patient NN O O
with NN O O
an NN O O
X NN O O
; NN O O
3 NN O O
translocation NN O O
. NN O O

Linkage NN O O
analysis NN O O
with NN O O
flanking NN O O
markers NN O O
was NN O O
used NN O O
to NN O O
assess NN O O
OCRL NN O B-Disease
carrier NN O O
status NN O O
in NN O O
women NN O O
at NN O O
risk NN O O
. NN O O

Results NN O O
, NN O O
when NN O O
compared NN O O
with NN O O
carrier NN O O
determination NN O O
by NN O O
ophthalmologic NN O O
examination NN O O
, NN O O
indicated NN O O
that NN O O
the NN O O
slit NN O O
- NN O O
lamp NN O O
exam NN O O
can NN O O
be NN O O
a NN O O
sensitive NN O O
and NN O O
specific NN O O
method NN O O
of NN O O
carrier NN O O
determination NN O O
in NN O O
many NN O O
cases NN O O

Identification NN O O
of NN O O
a NN O O
single NN O O
nucleotide NN O O
change NN O O
in NN O O
the NN O O
hypoxanthine NN O O
- NN O O
guanine NN O O
phosphoribosyltransferase NN O O
gene NN O O
( NN O O
HPRTYale NN O O
) NN O O
responsible NN O O
for NN O O
Lesch NN O B-Disease
- NN O I-Disease
Nyhan NN O I-Disease
syndrome NN O I-Disease
. NN O O

Complete NN O O
deficiency NN O B-Disease
of NN O I-Disease
hypoxanthine NN O I-Disease
- NN O I-Disease
guanine NN O I-Disease
phosphoribosyltransferase NN O I-Disease
( NN O O
HPRT NN O O
) NN O O
causes NN O O
the NN O O
Lesch NN O B-Disease
- NN O I-Disease
Nyhan NN O I-Disease
syndrome NN O I-Disease
. NN O O

Previous NN O O
characterization NN O O
of NN O O
a NN O O
mutant NN O O
form NN O O
of NN O O
HPRT NN O O
, NN O O
HPRTYale NN O O
, NN O O
from NN O O
a NN O O
subject NN O O
with NN O O
the NN O O
Lesch NN O B-Disease
- NN O I-Disease
Nyhan NN O I-Disease
syndrome NN O I-Disease
revealed NN O O
normal NN O O
mRNA NN O O
and NN O O
protein NN O O
concentrations NN O O
, NN O O
no NN O O
residual NN O O
catalytic NN O O
activity NN O O
, NN O O
and NN O O
cathodal NN O O
migration NN O O
upon NN O O
PAGE NN O O
. NN O O

We NN O O
have NN O O
cloned NN O O
and NN O O
sequenced NN O O
HPRTYale NN O O
cDNA NN O O
. NN O O

The NN O O
nucleotide NN O O
sequence NN O O
of NN O O
full NN O O
- NN O O
length NN O O
HPRTYale NN O O
cDNA NN O O
revealed NN O O
a NN O O
single NN O O
nucleotide NN O O
substitution NN O O
compared NN O O
with NN O O
normal NN O O
HPRT NN O O
cDNA NN O O
G NN O O
- NN O O
- NN O O
- NN O O
- NN O O
C NN O O
at NN O O
nucleotide NN O O
position NN O O
211 NN O O
. NN O O

This NN O O
transversion NN O O
predicts NN O O
substitution NN O O
of NN O O
arginine NN O O
for NN O O
glycine NN O O
at NN O O
amino NN O O
acid NN O O
position NN O O
71 NN O O
, NN O O
explaining NN O O
the NN O O
cathodal NN O O
migration NN O O
of NN O O
HPRTYale NN O O
. NN O O

Chou NN O O
- NN O O
Fasman NN O O
secondary NN O O
structure NN O O
analysis NN O O
predicts NN O O
a NN O O
change NN O O
in NN O O
the NN O O
probability NN O O
of NN O O
beta NN O O
- NN O O
turn NN O O
formation NN O O
in NN O O
the NN O O
region NN O O
containing NN O O
the NN O O
mutation NN O O
. NN O O

Inclusion NN O O
of NN O O
the NN O O
bulky NN O O
arginine NN O O
side NN O O
chain NN O O
in NN O O
place NN O O
of NN O O
glycine NN O O
probably NN O O
disrupts NN O O
protein NN O O
folding NN O O
as NN O O
well NN O O
. NN O O

Cloning NN O O
mutant NN O O
forms NN O O
of NN O O
cDNA NN O O
allows NN O O
identification NN O O
of NN O O
specific NN O O
mutations NN O O
, NN O O
provides NN O O
insight NN O O
into NN O O
mutational NN O O
mechanisms NN O O
, NN O O
and NN O O
facilitates NN O O
structure NN O O
- NN O O
function NN O O
analysis NN O O
of NN O O
mutant NN O O
proteins NN O O
. NN O O
. NN O O

Two NN O O
point NN O O
mutations NN O O
are NN O O
responsible NN O O
for NN O O
G6PD NN O O
polymorphism NN O O
in NN O O
Sardinia NN O O
. NN O O

The NN O O
human NN O O
X NN O O
- NN O O
linked NN O O
gene NN O O
encoding NN O O
glucose NN O O
6 NN O O
- NN O O
phosphate NN O O
dehydrogenase NN O O
( NN O O
G6PD NN O O
) NN O O
is NN O O
highly NN O O
polymorphic NN O O
; NN O O
more NN O O
than NN O O
300 NN O O
G6PD NN O O
variants NN O O
have NN O O
been NN O O
identified NN O O
. NN O O

G6PD NN O B-Disease
deficiency NN O I-Disease
in NN O O
different NN O O
geographical NN O O
areas NN O O
appears NN O O
to NN O O
have NN O O
arisen NN O O
through NN O O
independent NN O O
mutational NN O O
events NN O O
, NN O O
but NN O O
within NN O O
the NN O O
same NN O O
population NN O O
it NN O O
may NN O O
also NN O O
be NN O O
heterogeneous NN O O
. NN O O

One NN O O
example NN O O
is NN O O
the NN O O
island NN O O
of NN O O
Sardinia NN O O
, NN O O
where NN O O
careful NN O O
clinical NN O O
and NN O O
biochemical NN O O
studies NN O O
have NN O O
identified NN O O
four NN O O
different NN O O
G6PD NN O O
variants NN O O
. NN O O

We NN O O
cloned NN O O
and NN O O
sequenced NN O O
the NN O O
four NN O O
G6PD NN O O
variants NN O O
from NN O O
Sardinia NN O O
and NN O O
found NN O O
that NN O O
only NN O O
two NN O O
mutations NN O O
are NN O O
responsible NN O O
for NN O O
G6PD NN O B-Disease
deficiency NN O I-Disease
in NN O O
this NN O O
area NN O O
one NN O O
mutation NN O O
is NN O O
the NN O O
cause NN O O
of NN O O
the NN O O
G6PD NN O B-Disease
Seattle NN O I-Disease
- NN O I-Disease
like NN O I-Disease
phenotype NN O I-Disease
, NN O O
a NN O O
milder NN O O
form NN O O
of NN O O
G6PD NN O B-Disease
deficiency NN O I-Disease
; NN O O
the NN O O
other NN O O
mutation NN O O
is NN O O
responsible NN O O
for NN O O
all NN O O
forms NN O O
of NN O O
very NN O O
severe NN O O
G6PD NN O B-Disease
deficiency NN O I-Disease
in NN O O
Sardinia NN O O
and NN O O
, NN O O
possibly NN O O
, NN O O
in NN O O
the NN O O
Mediterranean NN O O
. NN O O
. NN O O

Chronic NN O B-Disease
nonspherocytic NN O I-Disease
hemolytic NN O I-Disease
anemia NN O I-Disease
( NN O O
CNSHA NN O B-Disease
) NN O O
and NN O O
glucose NN O B-Disease
6 NN O I-Disease
phosphate NN O I-Disease
dehydrogenase NN O I-Disease
( NN O I-Disease
G6PD NN O I-Disease
) NN O I-Disease
deficiency NN O I-Disease
in NN O O
a NN O O
patient NN O O
with NN O O
familial NN O B-Disease
amyloidotic NN O I-Disease
polyneuropathy NN O I-Disease
( NN O O
FAP NN O B-Disease
) NN O O
. NN O O

Molecular NN O O
study NN O O
of NN O O
a NN O O
new NN O O
variant NN O O
( NN O O
G6PD NN O O
Clinic NN O O
) NN O O
with NN O O
markedly NN O O
acidic NN O O
pH NN O O
optimum NN O O
. NN O O

A NN O O
new NN O O
glucose NN O O
- NN O O
6 NN O O
- NN O O
phosphate NN O O
dehydrogenase NN O O
( NN O O
G6PD NN O O
) NN O O
variant NN O O
with NN O O
severe NN O O
erythrocytic NN O B-Disease
G6PD NN O I-Disease
deficiency NN O I-Disease
and NN O O
a NN O O
unique NN O O
pH NN O O
optimum NN O O
is NN O O
described NN O O
in NN O O
a NN O O
young NN O O
patient NN O O
with NN O O
chronic NN O B-Disease
nonspherocytic NN O I-Disease
hemolytic NN O I-Disease
anemia NN O I-Disease
( NN O O
CNSHA NN O B-Disease
) NN O O
and NN O O
familial NN O B-Disease
amyloidotic NN O I-Disease
polyneuropathy NN O I-Disease
( NN O O
FAP NN O B-Disease
) NN O O
. NN O O

Chronic NN O B-Disease
hemolysis NN O I-Disease
was NN O O
present NN O O
in NN O O
the NN O O
absence NN O O
of NN O O
infections NN O O
, NN O O
oxidant NN O O
drugs NN O O
or NN O O
ingestion NN O O
of NN O O
faba NN O O
beans NN O O
. NN O O

Residual NN O O
enzyme NN O O
activity NN O O
was NN O O
about NN O O
2 NN O O
. NN O O

6 NN O O
% NN O O
and NN O O
63 NN O O
% NN O O
of NN O O
normal NN O O
activity NN O O
in NN O O
erythrocytes NN O O
and NN O O
leucocytes NN O O
, NN O O
respectively NN O O
. NN O O

A NN O O
molecular NN O O
study NN O O
using NN O O
standard NN O O
methods NN O O
showed NN O O
G6PD NN O O
in NN O O
the NN O O
patient NN O O
to NN O O
have NN O O
normal NN O O
electrophoretic NN O O
mobility NN O O
( NN O O
at NN O O
pH NN O O
7 NN O O
. NN O O
0 NN O O
, NN O O
8 NN O O
. NN O O
0 NN O O
and NN O O
8 NN O O
. NN O O
8 NN O O
) NN O O
, NN O O
normal NN O O
apparent NN O O
affinity NN O O
for NN O O
substrates NN O O
( NN O O
Km NN O O
, NN O O
G6P NN O O
and NN O O
NADP NN O O
) NN O O
and NN O O
a NN O O
slightly NN O O
abnormal NN O O
utilization NN O O
of NN O O
substrate NN O O
analogues NN O O
( NN O O
decreased NN O O
deamino NN O O
- NN O O
NADP NN O O
and NN O O
increased NN O O
2 NN O O
- NN O O
deoxyglucose NN O O
- NN O O
6 NN O O
- NN O O
phosphate NN O O
utilization NN O O
) NN O O
. NN O O

Heat NN O O
stability NN O O
was NN O O
found NN O O
to NN O O
be NN O O
markedly NN O O
decreased NN O O
( NN O O
8 NN O O
% NN O O
of NN O O
residual NN O O
activity NN O O
after NN O O
20 NN O O
min NN O O
of NN O O
incubation NN O O
at NN O O
46 NN O O
degrees NN O O
C NN O O
) NN O O
and NN O O
a NN O O
particular NN O O
characteristic NN O O
of NN O O
this NN O O
enzyme NN O O
was NN O O
a NN O O
biphasic NN O O
pH NN O O
curve NN O O
with NN O O
a NN O O
greatly NN O O
increased NN O O
activity NN O O
at NN O O
low NN O O
pH NN O O
. NN O O

Although NN O O
molecular NN O O
characteristics NN O O
of NN O O
this NN O O
variant NN O O
closely NN O O
resemble NN O O
those NN O O
of NN O O
G6PD NN O O
Bangkok NN O O
and NN O O
G6PD NN O O
Duarte NN O O
, NN O O
it NN O O
can NN O O
be NN O O
distinguished NN O O
from NN O O
these NN O O
and NN O O
all NN O O
other NN O O
previously NN O O
reported NN O O
variants NN O O
by NN O O
virtue NN O O
of NN O O
its NN O O
unusual NN O O
pH NN O O
curve NN O O
. NN O O

Therefore NN O O
the NN O O
present NN O O
variant NN O O
has NN O O
been NN O O
designated NN O O
G6PD NN O O
Clinic NN O O
to NN O O
distinguish NN O O
it NN O O
from NN O O
other NN O O
G6PD NN O O
variants NN O O
previously NN O O
described NN O O

Molecular NN O O
detection NN O O
of NN O O
chromosomal NN O O
translocations NN O O
that NN O O
disrupt NN O O
the NN O O
putative NN O O
retinoblastoma NN O B-Disease
susceptibility NN O O
locus NN O O
. NN O O

A NN O O
candidate NN O O
DNA NN O O
sequence NN O O
with NN O O
many NN O O
of NN O O
the NN O O
properties NN O O
predicted NN O O
for NN O O
the NN O O
retinoblastoma NN O B-Disease
susceptibility NN O O
( NN O O
RB1 NN O O
) NN O O
locus NN O O
has NN O O
been NN O O
cloned NN O O
( NN O O
S NN O O
. NN O O
H NN O O
. NN O O
Friend NN O O
, NN O O
R NN O O
. NN O O
Bernards NN O O
, NN O O
S NN O O
. NN O O
Rogelj NN O O
, NN O O
R NN O O
. NN O O
A NN O O
. NN O O
Weinberg NN O O
, NN O O
J NN O O
. NN O O
M NN O O
. NN O O
Rapaport NN O O
, NN O O
D NN O O
. NN O O
M NN O O
. NN O O
Albert NN O O
, NN O O
and NN O O
T NN O O
. NN O O
P NN O O
. NN O O
Dryja NN O O
, NN O O
Nature NN O O
[ NN O O
London NN O O
] NN O O
323 NN O O
643 NN O O
- NN O O
645 NN O O
, NN O O
1986 NN O O
) NN O O
. NN O O

The NN O O
large NN O O
size NN O O
of NN O O
this NN O O
gene NN O O
( NN O O
ca NN O O
. NN O O
200 NN O O
kilobases NN O O
[ NN O O
kb NN O O
] NN O O
) NN O O
and NN O O
its NN O O
multiple NN O O
dispersed NN O O
exons NN O O
( NN O O
Wiggs NN O O
et NN O O
al NN O O
. NN O O
, NN O O
N NN O O
. NN O O
Engl NN O O
. NN O O
J NN O O
. NN O O
Med NN O O
. NN O O
318 NN O O
151 NN O O
- NN O O
157 NN O O
, NN O O
1988 NN O O
) NN O O
complicate NN O O
molecular NN O O
screening NN O O
strategies NN O O
important NN O O
in NN O O
prenatal NN O O
and NN O O
presymptomatic NN O O
diagnosis NN O O
and NN O O
in NN O O
carrier NN O O
detection NN O O
. NN O O

Here NN O O
we NN O O
used NN O O
field NN O O
inversion NN O O
gel NN O O
electrophoresis NN O O
( NN O O
FIGE NN O O
) NN O O
to NN O O
construct NN O O
a NN O O
restriction NN O O
map NN O O
of NN O O
approximately NN O O
1 NN O O
, NN O O
000 NN O O
kb NN O O
of NN O O
DNA NN O O
surrounding NN O O
the NN O O
RB1 NN O O
locus NN O O
and NN O O
to NN O O
detect NN O O
the NN O O
translocation NN O O
breakpoints NN O O
in NN O O
three NN O O
retinoblastoma NN O B-Disease
patients NN O O
. NN O O

DNA NN O O
probes NN O O
from NN O O
either NN O O
the NN O O
5 NN O O
or NN O O
3 NN O O
end NN O O
of NN O O
the NN O O
gene NN O O
were NN O O
used NN O O
to NN O O
detect NN O O
a NN O O
250 NN O O
- NN O O
kb NN O O
EagI NN O O
restriction NN O O
fragment NN O O
in NN O O
DNA NN O O
from NN O O
unaffected NN O O
individuals NN O O
. NN O O

Both NN O O
probes NN O O
identified NN O O
an NN O O
additional NN O O
hybridizing NN O O
fragment NN O O
in NN O O
the NN O O
DNA NN O O
from NN O O
each NN O O
patient NN O O
, NN O O
permitting NN O O
the NN O O
breakpoints NN O O
in NN O O
all NN O O
three NN O O
to NN O O
be NN O O
mapped NN O O
within NN O O
the NN O O
cloned NN O O
RB1 NN O O
gene NN O O
. NN O O

Analysis NN O O
of NN O O
the NN O O
breakpoint NN O O
in NN O O
one NN O O
translocation NN O O
cell NN O O
line NN O O
allowed NN O O
the NN O O
RB1 NN O O
gene NN O O
to NN O O
be NN O O
oriented NN O O
with NN O O
its NN O O
5 NN O O
end NN O O
toward NN O O
the NN O O
centromere NN O O
. NN O O

The NN O O
5 NN O O
end NN O O
of NN O O
the NN O O
gene NN O O
also NN O O
appeared NN O O
to NN O O
be NN O O
associated NN O O
with NN O O
a NN O O
clustering NN O O
of NN O O
sites NN O O
for NN O O
several NN O O
infrequently NN O O
cleaving NN O O
restriction NN O O
enzymes NN O O
, NN O O
indicating NN O O
the NN O O
presence NN O O
of NN O O
an NN O O
HpaII NN O O
tiny NN O O
fragment NN O O
island NN O O
. NN O O

The NN O O
detection NN O O
and NN O O
mapping NN O O
of NN O O
the NN O O
translocation NN O O
breakpoints NN O O
of NN O O
all NN O O
three NN O O
retinoblastoma NN O B-Disease
patients NN O O
to NN O O
within NN O O
the NN O O
putative NN O O
RB1 NN O O
gene NN O O
substantiated NN O O
the NN O O
authenticity NN O O
of NN O O
this NN O O
candidate NN O O
sequence NN O O
and NN O O
demonstrated NN O O
the NN O O
utility NN O O
of NN O O
FIGE NN O O
in NN O O
detecting NN O O
chromosomal NN O O
rearrangements NN O O
affecting NN O O
this NN O O
locus NN O O
. NN O O

Inherited NN O O
C3 NN O B-Disease
deficiency NN O I-Disease
with NN O O
recurrent NN O O
infections NN O O
and NN O O
glomerulonephritis NN O B-Disease
. NN O O

A NN O O
10 NN O O
- NN O O
year NN O O
- NN O O
old NN O O
Laotian NN O O
boy NN O O
had NN O O
homozygous NN O O
deficiency NN O B-Disease
of NN O I-Disease
the NN O I-Disease
third NN O I-Disease
component NN O I-Disease
of NN O I-Disease
complement NN O I-Disease
and NN O O
recurrent NN O O
bacterial NN O B-Disease
infections NN O I-Disease
beginning NN O O
at NN O O
age NN O O
5 NN O O
months NN O O
. NN O O

Cellular NN O O
and NN O O
humoral NN O O
immunity NN O O
were NN O O
normal NN O O
, NN O O
as NN O O
were NN O O
polymorphonuclear NN O O
leukocyte NN O O
chemotaxis NN O O
and NN O O
bactericidal NN O O
activities NN O O
. NN O O

Serum NN O O
complement NN O O
- NN O O
mediated NN O O
hemolytic NN O O
, NN O O
chemotactic NN O O
, NN O O
and NN O O
opsonic NN O O
activities NN O O
were NN O O
deficient NN O O
. NN O O

In NN O O
vitro NN O O
addition NN O O
of NN O O
purified NN O O
C3 NN O O
to NN O O
patient NN O O
serum NN O O
restored NN O O
hemolytic NN O O
complement NN O O
to NN O O
normal NN O O
levels NN O O
, NN O O
and NN O O
plasma NN O O
infusion NN O O
during NN O O
each NN O O
of NN O O
four NN O O
episodes NN O O
of NN O O
pneumonia NN O B-Disease
significantly NN O O
enhanced NN O O
serum NN O O
opsonic NN O O
activity NN O O
for NN O O
as NN O O
long NN O O
as NN O O
36 NN O O
hours NN O O
. NN O O

A NN O O
renal NN O O
biopsy NN O O
specimen NN O O
revealed NN O O
mesangiopathic NN O B-Disease
glomerulonephritis NN O I-Disease
, NN O O
although NN O O
significant NN O O
levels NN O O
of NN O O
circulating NN O O
IgG NN O O
immune NN O O
complexes NN O O
were NN O O
not NN O O
detected NN O O
. NN O O

These NN O O
findings NN O O
further NN O O
support NN O O
the NN O O
association NN O O
of NN O O
C3 NN O B-Disease
deficiency NN O I-Disease
with NN O O
immune NN O B-Disease
- NN O I-Disease
complex NN O I-Disease
disease NN O I-Disease
and NN O O
suggest NN O O
that NN O O
plasma NN O O
infusion NN O O
may NN O O
be NN O O
an NN O O
adjunct NN O O
to NN O O
antibiotic NN O O
therapy NN O O
in NN O O
the NN O O
management NN O O
of NN O O
severe NN O O
pyogenic NN O B-Disease
infections NN O I-Disease
in NN O O
patients NN O O
with NN O O
C3 NN O B-Disease
deficiency NN O I-Disease
. NN O O
. NN O O

DNA NN O O
restriction NN O O
fragments NN O O
associated NN O O
with NN O O
alpha NN O O
1 NN O O
- NN O O
antitrypsin NN O O
indicate NN O O
a NN O O
single NN O O
origin NN O O
for NN O O
deficiency NN O O
allele NN O O
PI NN O O
Z NN O O
. NN O O

The NN O O
alpha NN O O
1 NN O O
- NN O O
protease NN O O
inhibitor NN O O
, NN O O
or NN O O
alpha NN O O
- NN O O
antitrypsin NN O O
( NN O O
AAT NN O O
) NN O O
, NN O O
a NN O O
major NN O O
plasma NN O O
inhibitor NN O O
of NN O O
leukocyte NN O O
elastase NN O O
and NN O O
bacterial NN O O
proteases NN O O
, NN O O
is NN O O
encoded NN O O
at NN O O
the NN O O
PI NN O O
locus NN O O
on NN O O
chromosome NN O O
14 NN O O
( NN O O
14q24 NN O O
. NN O O
3 NN O O
- NN O O
q32 NN O O
. NN O O
1 NN O O
) NN O O
. NN O O

A NN O O
deficiency NN O B-Disease
of NN O I-Disease
AAT NN O I-Disease
in NN O O
individuals NN O O
homozygous NN O O
for NN O O
the NN O O
PI NN O O
Z NN O O
allele NN O O
occurs NN O O
in NN O O
about NN O O
1 NN O O
in NN O O
2 NN O O
, NN O O
000 NN O O
- NN O O
8 NN O O
, NN O O
000 NN O O
caucasians NN O O
and NN O O
is NN O O
associated NN O O
with NN O O
an NN O O
increased NN O O
risk NN O O
of NN O O
early NN O O
adult NN O O
onset NN O O
emphysema NN O B-Disease
and NN O O
liver NN O B-Disease
disease NN O I-Disease
in NN O O
childhood NN O O
. NN O O

We NN O O
have NN O O
now NN O O
used NN O O
DNA NN O O
polymorphisms NN O O
associated NN O O
with NN O O
the NN O O
AAT NN O O
gene NN O O
to NN O O
investigate NN O O
the NN O O
origin NN O O
of NN O O
the NN O O
PI NN O O
Z NN O O
allele NN O O
. NN O O

Using NN O O
two NN O O
genomic NN O O
probes NN O O
extending NN O O
into NN O O
the NN O O
5 NN O O
and NN O O
3 NN O O
flanking NN O O
regions NN O O
, NN O O
respectively NN O O
, NN O O
we NN O O
have NN O O
identified NN O O
eight NN O O
polymorphic NN O O
restriction NN O O
sites NN O O
. NN O O

Extensive NN O O
linkage NN O O
disequilibrium NN O O
occurs NN O O
throughout NN O O
the NN O O
probed NN O O
region NN O O
with NN O O
the NN O O
PI NN O O
Z NN O O
allele NN O O
, NN O O
but NN O O
not NN O O
with NN O O
normal NN O O
PI NN O O
M NN O O
alleles NN O O
. NN O O

The NN O O
Z NN O O
allele NN O O
occurs NN O O
mainly NN O O
with NN O O
one NN O O
haplotype NN O O
, NN O O
indicating NN O O
a NN O O
single NN O O
, NN O O
relatively NN O O
recent NN O O
, NN O O
origin NN O O
in NN O O
caucasians NN O O

Segregation NN O O
analysis NN O O
of NN O O
a NN O O
marker NN O O
localised NN O O
Xp21 NN O O
. NN O O
2 NN O O
- NN O O
Xp21 NN O O
. NN O O
3 NN O O
in NN O O
Duchenne NN O B-Disease
and NN O I-Disease
Becker NN O I-Disease
muscular NN O I-Disease
dystrophy NN O I-Disease
families NN O O
. NN O O

A NN O O
DNA NN O O
marker NN O O
C7 NN O O
, NN O O
localised NN O O
Xp21 NN O O
. NN O O

1 NN O O
- NN O O
Xp21 NN O O
. NN O O

3 NN O O
, NN O O
has NN O O
been NN O O
studied NN O O
in NN O O
kindreds NN O O
segregating NN O O
for NN O O
Duchenne NN O B-Disease
muscular NN O I-Disease
dystrophy NN O I-Disease
( NN O O
DMD NN O B-Disease
) NN O O
and NN O O
Becker NN O B-Disease
muscular NN O I-Disease
dystrophy NN O I-Disease
( NN O O
BMD NN O B-Disease
) NN O O
. NN O O

In NN O O
DMD NN O B-Disease
families NN O O
four NN O O
crossovers NN O O
were NN O O
observed NN O O
in NN O O
38 NN O O
informative NN O O
meioses NN O O
between NN O O
C7 NN O O
and NN O O
the NN O O
DMD NN O B-Disease
locus NN O O
( NN O O
theta NN O O
= NN O O
0 NN O O
. NN O O
12 NN O O
, NN O O
z NN O O
max NN O O
= NN O O
+ NN O O
2 NN O O
. NN O O
72 NN O O
) NN O O
. NN O O

In NN O O
BMD NN O B-Disease
families NN O O
no NN O O
recombinants NN O O
were NN O O
observed NN O O
in NN O O
the NN O O
16 NN O O
informative NN O O
meioses NN O O
studied NN O O
. NN O O

These NN O O
data NN O O
are NN O O
consistent NN O O
with NN O O
the NN O O
localisation NN O O
of NN O O
the NN O O
mutations NN O O
in NN O O
these NN O O
disorders NN O O
being NN O O
in NN O O
the NN O O
same NN O O
region NN O O
of NN O O
Xp21 NN O O
. NN O O

Studies NN O O
in NN O O
families NN O O
also NN O O
segregating NN O O
for NN O O
the NN O O
DNA NN O O
marker NN O O
754 NN O O
support NN O O
the NN O O
previously NN O O
reported NN O O
physical NN O O
order NN O O
of NN O O
these NN O O
loci NN O O
as NN O O
X NN O O
centromere NN O O
- NN O O
754 NN O O
- NN O O
DMD NN O O
- NN O O
BMD NN O O
- NN O O
C7 NN O O
- NN O O
X NN O O
telomere NN O O
. NN O O

A NN O O
recombination NN O O
fraction NN O O
of NN O O
0 NN O O
. NN O O

11 NN O O
( NN O O
z NN O O
max NN O O
= NN O O
+ NN O O
5 NN O O
. NN O O
58 NN O O
) NN O O
was NN O O
found NN O O
between NN O O
DMD NN O O
- NN O O
754 NN O O
by NN O O
combining NN O O
our NN O O
previously NN O O
published NN O O
data NN O O
with NN O O
the NN O O
data NN O O
presented NN O O
here NN O O
. NN O O

C7 NN O O
and NN O O
754 NN O O
thus NN O O
provide NN O O
good NN O O
bridging NN O O
markers NN O O
for NN O O
the NN O O
diagnosis NN O O
of NN O O
DMD NN O B-Disease
and NN O O
BMD NN O B-Disease

Isolation NN O O
of NN O O
molecular NN O O
probes NN O O
associated NN O O
with NN O O
the NN O O
chromosome NN O O
15 NN O O
instability NN O O
in NN O O
the NN O O
Prader NN O B-Disease
- NN O I-Disease
Willi NN O I-Disease
syndrome NN O I-Disease
. NN O O

Flow NN O O
cytometry NN O O
and NN O O
recombinant NN O O
DNA NN O O
techniques NN O O
have NN O O
been NN O O
used NN O O
to NN O O
obtain NN O O
reagents NN O O
for NN O O
a NN O O
molecular NN O O
analysis NN O O
of NN O O
the NN O O
Prader NN O B-Disease
- NN O I-Disease
Willi NN O I-Disease
syndrome NN O I-Disease
( NN O O
PWS NN O B-Disease
) NN O O
. NN O O

HindIII NN O O
total NN O O
- NN O O
digest NN O O
libraries NN O O
were NN O O
prepared NN O O
in NN O O
lambda NN O O
phage NN O O
Charon NN O O
21A NN O O
from NN O O
flow NN O O
- NN O O
sorted NN O O
inverted NN O O
duplicated NN O O
no NN O O
. NN O O
15 NN O O
human NN O O
chromosomes NN O O
and NN O O
propagated NN O O
on NN O O
recombination NN O O
- NN O O
proficient NN O O
( NN O O
LE392 NN O O
) NN O O
and NN O O
recBC NN O O
- NN O O
, NN O O
sbcB NN O O
- NN O O
( NN O O
DB1257 NN O O
) NN O O
bacteria NN O O
. NN O O

Twelve NN O O
distinct NN O O
chromosome NN O O
15 NN O O
- NN O O
specific NN O O
probes NN O O
have NN O O
been NN O O
isolated NN O O
. NN O O

Eight NN O O
localized NN O O
to NN O O
the NN O O
region NN O O
15q11 NN O O
- NN O O
- NN O O
- NN O O
- NN O O
13 NN O O
. NN O O

Four NN O O
of NN O O
these NN O O
eight NN O O
sublocalized NN O O
to NN O O
band NN O O
15q11 NN O O
. NN O O

2 NN O O
and NN O O
are NN O O
shown NN O O
to NN O O
be NN O O
deleted NN O O
in NN O O
DNA NN O O
of NN O O
one NN O O
of NN O O
two NN O O
patients NN O O
examined NN O O
with NN O O
the NN O O
PWS NN O B-Disease
. NN O O

Heteroduplex NN O O
analysis NN O O
of NN O O
two NN O O
of NN O O
these NN O O
clones NN O O
, NN O O
which NN O O
grew NN O O
on NN O O
DB1257 NN O O
but NN O O
not NN O O
on NN O O
LE392 NN O O
, NN O O
revealed NN O O
stem NN O O
- NN O O
loop NN O O
structures NN O O
in NN O O
the NN O O
inserts NN O O
, NN O O
indicative NN O O
of NN O O
inverted NN O O
, NN O O
repeated NN O O
DNA NN O O
elements NN O O
. NN O O

Such NN O O
DNA NN O O
repeats NN O O
might NN O O
account NN O O
for NN O O
some NN O O
of NN O O
the NN O O
cloning NN O O
instability NN O O
of NN O O
DNA NN O O
segments NN O O
from NN O O
proximal NN O O
15q NN O O
. NN O O

Analysis NN O O
of NN O O
the NN O O
genetic NN O O
and NN O O
physical NN O O
instability NN O O
associated NN O O
with NN O O
the NN O O
repeated NN O O
sequences NN O O
we NN O O
have NN O O
isolated NN O O
from NN O O
band NN O O
15q11 NN O O
. NN O O

2 NN O O
may NN O O
elucidate NN O O
the NN O O
molecular NN O O
basis NN O O
for NN O O
the NN O O
instability NN O O
of NN O O
this NN O O
chromosomal NN O O
region NN O O
in NN O O
patients NN O O
with NN O O
the NN O O
PWS NN O B-Disease
or NN O O
other NN O O
diseases NN O O
associated NN O O
with NN O O
chromosomal NN O B-Disease
abnormalities NN O I-Disease
in NN O O
the NN O O
proximal NN O O
long NN O O
arm NN O O
of NN O O
human NN O O
chromosome NN O O
15 NN O O

Analysis NN O O
of NN O O
deletions NN O O
in NN O O
DNA NN O O
from NN O O
patients NN O O
with NN O O
Becker NN O B-Disease
and NN O I-Disease
Duchenne NN O I-Disease
muscular NN O I-Disease
dystrophy NN O I-Disease
. NN O O

Duchenne NN O B-Disease
muscular NN O I-Disease
dystrophy NN O I-Disease
( NN O O
DMD NN O B-Disease
) NN O O
is NN O O
an NN O O
X NN O B-Disease
- NN O I-Disease
linked NN O I-Disease
recessive NN O I-Disease
genetic NN O I-Disease
disorder NN O I-Disease
for NN O O
which NN O O
the NN O O
biochemical NN O O
defect NN O O
is NN O O
as NN O O
yet NN O O
unknown NN O O
. NN O O

Recently NN O O
, NN O O
two NN O O
cloned NN O O
segments NN O O
of NN O O
human NN O O
X NN O O
- NN O O
chromosome NN O O
DNA NN O O
have NN O O
been NN O O
described NN O O
which NN O O
detect NN O O
structural NN O O
alterations NN O O
within NN O O
or NN O O
near NN O O
the NN O O
genetic NN O O
locus NN O O
responsible NN O O
for NN O O
the NN O O
disorder NN O O
. NN O O

Both NN O O
of NN O O
these NN O O
cloned NN O O
segments NN O O
were NN O O
described NN O O
as NN O O
tightly NN O O
linked NN O O
to NN O O
the NN O O
locus NN O O
and NN O O
were NN O O
capable NN O O
of NN O O
detecting NN O O
deletions NN O O
in NN O O
the NN O O
DNA NN O O
of NN O O
boys NN O O
affected NN O O
with NN O O
DMD NN O B-Disease
. NN O O

In NN O O
an NN O O
attempt NN O O
to NN O O
determine NN O O
more NN O O
precisely NN O O
the NN O O
occurrence NN O O
of NN O O
these NN O O
deletions NN O O
within NN O O
a NN O O
large NN O O
population NN O O
of NN O O
DMD NN O B-Disease
patients NN O O
and NN O O
the NN O O
accuracy NN O O
of NN O O
one NN O O
of NN O O
the NN O O
segments NN O O
, NN O O
DXS164 NN O O
( NN O O
pERT87 NN O O
) NN O O
, NN O O
in NN O O
determining NN O O
the NN O O
inheritance NN O O
of NN O O
the NN O O
DMD NN O B-Disease
X NN O O
chromosome NN O O
, NN O O
the NN O O
subclones NN O O
1 NN O O
, NN O O
8 NN O O
and NN O O
15 NN O O
were NN O O
made NN O O
available NN O O
to NN O O
many NN O O
investigators NN O O
throughout NN O O
the NN O O
world NN O O
. NN O O

Here NN O O
we NN O O
describe NN O O
the NN O O
combined NN O O
results NN O O
of NN O O
more NN O O
than NN O O
20 NN O O
research NN O O
laboratories NN O O
with NN O O
respect NN O O
to NN O O
the NN O O
occurrence NN O O
of NN O O
deletions NN O O
at NN O O
the NN O O
DXS164 NN O O
locus NN O O
in NN O O
DNA NN O O
samples NN O O
isolated NN O O
from NN O O
patients NN O O
with NN O O
DMD NN O B-Disease
and NN O O
Becker NN O B-Disease
muscular NN O I-Disease
dystrophy NN O I-Disease
( NN O O
BMD NN O B-Disease
) NN O O
. NN O O

The NN O O
results NN O O
indicate NN O O
that NN O O
the NN O O
DXS164 NN O O
locus NN O O
apparently NN O O
recombines NN O O
with NN O O
DMD NN O B-Disease
5 NN O O
% NN O O
of NN O O
the NN O O
time NN O O
, NN O O
but NN O O
is NN O O
probably NN O O
located NN O O
between NN O O
independent NN O O
sites NN O O
of NN O O
mutation NN O O
which NN O O
yield NN O O
DMD NN O B-Disease
. NN O O

The NN O O
breakpoints NN O O
of NN O O
some NN O O
deletions NN O O
are NN O O
delineated NN O O
within NN O O
the NN O O
DXS164 NN O O
locus NN O O
, NN O O
and NN O O
it NN O O
is NN O O
evident NN O O
that NN O O
the NN O O
deletions NN O O
at NN O O
the NN O O
DMD NN O B-Disease
locus NN O O
are NN O O
frequent NN O O
and NN O O
extremely NN O O
large NN O O
. NN O O
. NN O O

A NN O O
potential NN O O
animal NN O O
model NN O O
for NN O O
Lesch NN O B-Disease
- NN O I-Disease
Nyhan NN O I-Disease
syndrome NN O I-Disease
through NN O O
introduction NN O O
of NN O O
HPRT NN O O
mutations NN O O
into NN O O
mice NN O O
. NN O O

The NN O O
human NN O O
Lesch NN O B-Disease
- NN O I-Disease
Nyhan NN O I-Disease
syndrome NN O I-Disease
is NN O O
a NN O O
rare NN O O
neurological NN O B-Disease
and NN O I-Disease
behavioural NN O I-Disease
disorder NN O I-Disease
, NN O O
affecting NN O O
only NN O O
males NN O O
, NN O O
which NN O O
is NN O O
caused NN O O
by NN O O
an NN O O
inherited NN O B-Disease
deficiency NN O I-Disease
in NN O O
the NN O O
level NN O O
of NN O O
activity NN O O
of NN O O
the NN O O
purine NN O O
salvage NN O O
enzyme NN O O
hypoxanthine NN O O
- NN O O
guanosine NN O O
phosphoribosyl NN O O
transferase NN O O
( NN O O
HPRT NN O O
) NN O O
. NN O O

How NN O O
the NN O O
resulting NN O O
alterations NN O O
in NN O O
purine NN O O
metabolism NN O O
lead NN O O
to NN O O
the NN O O
severe NN O O
symptoms NN O O
characteristic NN O O
of NN O O
Lesch NN O B-Disease
- NN O I-Disease
Nyhan NN O I-Disease
patients NN O O
is NN O O
still NN O O
not NN O O
understood NN O O
. NN O O

No NN O O
mutations NN O O
at NN O O
the NN O O
Hprt NN O O
locus NN O O
leading NN O O
to NN O O
loss NN O O
of NN O O
activity NN O O
have NN O O
been NN O O
described NN O O
in NN O O
laboratory NN O O
animals NN O O
. NN O O

To NN O O
derive NN O O
an NN O O
animal NN O O
model NN O O
for NN O O
the NN O O
Lesch NN O B-Disease
- NN O I-Disease
Nyhan NN O I-Disease
syndrome NN O I-Disease
, NN O O
we NN O O
have NN O O
used NN O O
cultured NN O O
mouse NN O O
embryonic NN O O
stem NN O O
cells NN O O
, NN O O
mutagenized NN O O
by NN O O
retroviral NN O O
insertion NN O O
and NN O O
selected NN O O
for NN O O
loss NN O O
of NN O O
HPRT NN O O
activity NN O O
, NN O O
to NN O O
construct NN O O
chimaeric NN O O
mice NN O O
. NN O O

Two NN O O
clonal NN O O
lines NN O O
carrying NN O O
different NN O O
mutant NN O O
Hprt NN O O
alleles NN O O
have NN O O
given NN O O
rise NN O O
to NN O O
germ NN O O
cells NN O O
in NN O O
chimaeras NN O O
, NN O O
allowing NN O O
the NN O O
derivation NN O O
of NN O O
strains NN O O
of NN O O
mutant NN O O
mice NN O O
having NN O O
the NN O O
same NN O O
biochemical NN O O
defect NN O O
as NN O O
Lesch NN O B-Disease
- NN O I-Disease
Nyhan NN O I-Disease
patients NN O O
. NN O O

Male NN O O
mice NN O O
carrying NN O O
the NN O O
mutant NN O O
alleles NN O O
are NN O O
viable NN O O
and NN O O
analysis NN O O
of NN O O
their NN O O
cells NN O O
shows NN O O
a NN O O
total NN O O
lack NN O O
of NN O O
HPRT NN O O
activity NN O O
. NN O O
. NN O O

Re NN O O
- NN O O
evaluation NN O O
of NN O O
the NN O O
sublocalization NN O O
of NN O O
esterase NN O O
D NN O O
and NN O O
its NN O O
relation NN O O
to NN O O
the NN O O
retinoblastoma NN O B-Disease
locus NN O O
by NN O O
in NN O O
situ NN O O
hybridization NN O O
. NN O O

In NN O O
situ NN O O
hybridization NN O O
of NN O O
a NN O O
cDNA NN O O
probe NN O O
for NN O O
the NN O O
esterase NN O O
D NN O O
gene NN O O
( NN O O
ESD NN O O
) NN O O
was NN O O
carried NN O O
out NN O O
on NN O O
human NN O O
chromosomes NN O O
. NN O O

The NN O O
probe NN O O
hybridized NN O O
most NN O O
strongly NN O O
to NN O O
13q14 NN O O
. NN O O

2 NN O O
and NN O O
13q14 NN O O
. NN O O

3 NN O O
. NN O O

This NN O O
observation NN O O
raises NN O O
doubts NN O O
concerning NN O O
the NN O O
most NN O O
recently NN O O
published NN O O
assignment NN O O
of NN O O
ESD NN O O
to NN O O
13q14 NN O O
. NN O O

1 NN O O
. NN O O

A NN O O
deletion NN O O
in NN O O
an NN O O
individual NN O O
with NN O O
retinoblastoma NN O B-Disease
was NN O O
reported NN O O
to NN O O
separate NN O O
the NN O O
closely NN O O
linked NN O O
ESD NN O O
and NN O O
retinoblastoma NN O B-Disease
( NN O O
RB1 NN O O
) NN O O
loci NN O O
, NN O O
placing NN O O
ESD NN O O
proximal NN O O
to NN O O
RB1 NN O O
. NN O O

Quantitative NN O O
in NN O O
situ NN O O
hybridization NN O O
studies NN O O
of NN O O
this NN O O
deletion NN O O
do NN O O
not NN O O
confirm NN O O
this NN O O
interpretation NN O O
. NN O O

Rather NN O O
, NN O O
they NN O O
suggest NN O O
that NN O O
ESD NN O O
is NN O O
missing NN O O
from NN O O
the NN O O
deleted NN O O
chromosome NN O O
13 NN O O
and NN O O
duplicated NN O O
on NN O O
the NN O O
normal NN O O
homolog NN O O
. NN O O

From NN O O
these NN O O
findings NN O O
, NN O O
we NN O O
conclude NN O O
that NN O O
the NN O O
deletion NN O O
in NN O O
this NN O O
individual NN O O
cannot NN O O
be NN O O
used NN O O
to NN O O
determine NN O O
the NN O O
orientation NN O O
nor NN O O
the NN O O
sublocalization NN O O
of NN O O
ESD NN O O
and NN O O
RB1 NN O O
within NN O O
the NN O O
13q14 NN O O
region NN O O
. NN O O

Hereditary NN O B-Disease
C2 NN O I-Disease
deficiency NN O I-Disease
associated NN O O
with NN O O
common NN O O
variable NN O O
immunodeficiency NN O B-Disease
. NN O O

Homozygous NN O O
C2 NN O B-Disease
deficiency NN O I-Disease
in NN O O
a NN O O
19 NN O O
- NN O O
year NN O O
- NN O O
old NN O O
boy NN O O
was NN O O
associated NN O O
with NN O O
variable NN O O
immunodeficiency NN O B-Disease
manifested NN O O
by NN O O
marked NN O O
hypoimmunoglobulinemia NN O B-Disease
and NN O O
impaired NN O O
antibody NN O O
responses NN O O
, NN O O
normal NN O O
circulating NN O O
B NN O O
lymphocytes NN O O
, NN O O
and NN O O
subnormal NN O O
T NN O O
- NN O O
cell NN O O
functions NN O O
. NN O O

Neither NN O O
antilymphocytic NN O O
autoantibodies NN O O
nor NN O O
chromosomal NN O B-Disease
abnormalities NN O I-Disease
were NN O O
found NN O O
. NN O O

Serum NN O O
immunoglobulin NN O O
levels NN O O
were NN O O
within NN O O
normal NN O O
limits NN O O
in NN O O
his NN O O
parents NN O O
and NN O O
brother NN O O
who NN O O
were NN O O
heterozygous NN O O
for NN O O
C2 NN O B-Disease
deficiency NN O I-Disease
. NN O O

The NN O O
patients NN O O
lymphocytes NN O O
were NN O O
homozygous NN O O
at NN O O
the NN O O
HLA NN O O
- NN O O
D NN O O
locus NN O O
but NN O O
expressed NN O O
an NN O O
antigen NN O O
different NN O O
from NN O O
DW2 NN O O
. NN O O
. NN O O

Mild NN O O
and NN O O
severe NN O O
muscular NN O B-Disease
dystrophy NN O I-Disease
associated NN O O
with NN O O
deletions NN O O
in NN O O
Xp21 NN O O
of NN O O
the NN O O
human NN O O
X NN O O
chromosome NN O O
. NN O O

We NN O O
have NN O O
analysed NN O O
over NN O O
300 NN O O
patients NN O O
suffering NN O O
from NN O O
Duchenne NN O B-Disease
or NN O I-Disease
Becker NN O I-Disease
muscular NN O I-Disease
dystrophy NN O I-Disease
( NN O O
DMD NN O B-Disease
or NN O O
BMD NN O B-Disease
) NN O O
. NN O O

Deletions NN O O
have NN O O
been NN O O
characterised NN O O
which NN O O
encompass NN O O
either NN O O
the NN O O
pERT87 NN O O
( NN O O
DXS164 NN O O
) NN O O
locus NN O O
only NN O O
, NN O O
the NN O O
XJ1 NN O O
. NN O O

1 NN O O
( NN O O
DXS206 NN O O
) NN O O
and NN O O
HIP25 NN O O
loci NN O O
only NN O O
, NN O O
or NN O O
all NN O O
three NN O O
loci NN O O
. NN O O

These NN O O
loci NN O O
have NN O O
been NN O O
shown NN O O
to NN O O
lie NN O O
within NN O O
the NN O O
DMD NN O B-Disease
region NN O O
covering NN O O
several NN O O
hundred NN O O
kilobases NN O O
( NN O O
kb NN O O
) NN O O
of NN O O
DNA NN O O
. NN O O

One NN O O
mildly NN O O
affected NN O O
BMD NN O B-Disease
patient NN O O
possesses NN O O
a NN O O
deletion NN O O
of NN O O
at NN O O
least NN O O
110 NN O O
kb NN O O
including NN O O
exons NN O O
of NN O O
the NN O O
DMD NN O B-Disease
gene NN O O
. NN O O

Other NN O O
patients NN O O
with NN O O
similar NN O O
exon NN O O
deletions NN O O
, NN O O
or NN O O
smaller NN O O
deletions NN O O
, NN O O
show NN O O
the NN O O
more NN O O
severe NN O O
phenotype NN O O
typical NN O O
of NN O O
DMD NN O B-Disease
. NN O O

We NN O O
conclude NN O O
from NN O O
these NN O O
studies NN O O
that NN O O
the NN O O
severity NN O O
of NN O O
the NN O O
clinical NN O O
phenotype NN O O
cannot NN O O
be NN O O
explained NN O O
on NN O O
the NN O O
basis NN O O
of NN O O
the NN O O
size NN O O
of NN O O
the NN O O
deletion NN O O
. NN O O

We NN O O
discuss NN O O
this NN O O
in NN O O
the NN O O
context NN O O
of NN O O
candidate NN O O
gene NN O O
sequences NN O O
. NN O O

Patterns NN O O
of NN O O
exon NN O O
deletions NN O O
in NN O O
Duchenne NN O B-Disease
and NN O I-Disease
Becker NN O I-Disease
muscular NN O I-Disease
dystrophy NN O I-Disease
. NN O O

A NN O O
panel NN O O
of NN O O
patients NN O O
with NN O O
Duchenne NN O B-Disease
and NN O I-Disease
Becker NN O I-Disease
muscular NN O I-Disease
dystrophy NN O I-Disease
( NN O O
DMD NN O B-Disease
and NN O O
BMD NN O B-Disease
) NN O O
has NN O O
been NN O O
screened NN O O
with NN O O
the NN O O
cDNA NN O O
probes NN O O
Cf56a NN O O
and NN O O
Cf23a NN O O
, NN O O
which NN O O
detect NN O O
exons NN O O
in NN O O
the NN O O
central NN O O
part NN O O
of NN O O
the NN O O
DMD NN O B-Disease
gene NN O O
. NN O O

One NN O O
or NN O O
more NN O O
exons NN O O
were NN O O
deleted NN O O
in NN O O
60 NN O O
% NN O O
of NN O O
patients NN O O
. NN O O

The NN O O
deletions NN O O
were NN O O
mapped NN O O
and NN O O
prove NN O O
to NN O O
be NN O O
heterogeneous NN O O
in NN O O
size NN O O
and NN O O
extent NN O O
, NN O O
particularly NN O O
in NN O O
DMD NN O B-Disease
. NN O O

Deletions NN O O
specific NN O O
to NN O O
DMD NN O B-Disease
and NN O O
to NN O O
BMD NN O B-Disease
are NN O O
described NN O O
. NN O O

Half NN O O
of NN O O
all NN O O
BMD NN O B-Disease
patients NN O O
have NN O O
a NN O O
deletion NN O O
of NN O O
one NN O O
particular NN O O
small NN O O
group NN O O
of NN O O
exons NN O O
; NN O O
smaller NN O O
deletions NN O O
within NN O O
this NN O O
same NN O O
group NN O O
produce NN O O
the NN O O
more NN O O
severe NN O O
DMD NN O B-Disease
. NN O O
. NN O O

Hereditary NN O B-Disease
deficiency NN O I-Disease
of NN O I-Disease
the NN O I-Disease
third NN O I-Disease
component NN O I-Disease
of NN O I-Disease
complement NN O I-Disease
in NN O O
a NN O O
child NN O O
with NN O O
fever NN O B-Disease
, NN O O
skin NN O B-Disease
rash NN O I-Disease
, NN O O
and NN O O
arthralgias NN O B-Disease
: NN O O
response NN O O
to NN O O
transfusion NN O O
of NN O O
whole NN O O
blood NN O O
. NN O O

A NN O O
previously NN O O
well NN O O
34 NN O O
- NN O O
month NN O O
- NN O O
old NN O O
male NN O O
presenting NN O O
with NN O O
fever NN O B-Disease
, NN O O
skin NN O B-Disease
rash NN O I-Disease
, NN O O
and NN O O
arthralgias NN O B-Disease
was NN O O
found NN O O
to NN O O
lack NN O O
C3 NN O O
by NN O O
immunochemical NN O O
( NN O O
undetectable NN O O
) NN O O
and NN O O
hemolytic NN O O
( NN O O
1 NN O O
% NN O O
normal NN O O
) NN O O
assays NN O O
. NN O O

No NN O O
infectious NN O O
agent NN O O
could NN O O
be NN O O
demonstrated NN O O
. NN O O

Protein NN O O
levels NN O O
of NN O O
Clq NN O O
. NN O O

C4 NN O O
, NN O O
C5 NN O O
, NN O O
properdin NN O O
, NN O O
and NN O O
C3b NN O O
- NN O O
INA NN O O
and NN O O
hemolytic NN O O
activities NN O O
of NN O O
complement NN O O
components NN O O
C1 NN O O
to NN O O
C9 NN O O
except NN O O
C3 NN O O
were NN O O
normal NN O O
or NN O O
elevated NN O O
; NN O O
total NN O O
hemolytic NN O O
complement NN O O
activity NN O O
was NN O O
13 NN O O
% NN O O
of NN O O
normal NN O O
and NN O O
was NN O O
reconstituted NN O O
by NN O O
purified NN O O
C3 NN O O
. NN O O

Properdin NN O O
factor NN O O
B NN O O
was NN O O
702 NN O O
( NN O O
normal NN O O
175 NN O O
to NN O O
275 NN O O
) NN O O
mug NN O O
/ NN O O
ml NN O O
, NN O O
and NN O O
was NN O O
not NN O O
cleaver NN O O
upon NN O O
addition NN O O
of NN O O
zymosan NN O O
or NN O O
cobra NN O O
venom NN O O
factor NN O O
. NN O O

The NN O O
serum NN O O
had NN O O
normal NN O O
immune NN O O
adherence NN O O
activity NN O O
, NN O O
but NN O O
was NN O O
deficient NN O O
in NN O O
ability NN O O
to NN O O
opsonize NN O O
Candida NN O O
albicans NN O O
for NN O O
uptake NN O O
and NN O O
Escherichia NN O O
coli NN O O
for NN O O
killing NN O O
by NN O O
neurophils NN O O
, NN O O
generate NN O O
neutrophil NN O O
chemotactic NN O O
factors NN O O
and NN O O
inhibit NN O O
the NN O O
growth NN O O
of NN O O
E NN O O
. NN O O
coli NN O O
; NN O O
these NN O O
activities NN O O
were NN O O
restored NN O O
by NN O O
purified NN O O
C3 NN O O
. NN O O

A NN O O
transfusion NN O O
of NN O O
320 NN O O
ml NN O O
1 NN O O
- NN O O
hour NN O O
- NN O O
old NN O O
normal NN O O
whole NN O O
blood NN O O
on NN O O
the NN O O
fifty NN O O
- NN O O
second NN O O
day NN O O
resulted NN O O
in NN O O
transitory NN O O
elevation NN O O
of NN O O
the NN O O
C3 NN O O
level NN O O
to NN O O
25 NN O O
mg NN O O
/ NN O O
dl NN O O
with NN O O
a NN O O
fall NN O O
- NN O O
off NN O O
( NN O O
approximately NN O O
2 NN O O
1 NN O O
/ NN O O
2 NN O O
% NN O O
per NN O O
hour NN O O
) NN O O
to NN O O
undetectable NN O O
levels NN O O
by NN O O
69 NN O O
hours NN O O
; NN O O
it NN O O
was NN O O
followed NN O O
by NN O O
disappearance NN O O
of NN O O
the NN O O
skin NN O B-Disease
rash NN O I-Disease
and NN O O
arthralgias NN O B-Disease
and NN O O
return NN O O
to NN O O
normal NN O O
of NN O O
the NN O O
previously NN O O
elevated NN O O
temperature NN O O
and NN O O
CRP NN O O
levels NN O O
. NN O O

C3 NN O O
levels NN O O
in NN O O
family NN O O
members NN O O
( NN O O
seven NN O O
of NN O O
24 NN O O
half NN O O
- NN O O
normal NN O O
) NN O O
, NN O O
lack NN O O
of NN O O
anti NN O O
- NN O O
C3 NN O O
activity NN O O
, NN O O
normal NN O O
C3b NN O O
- NN O O
INA NN O O
levels NN O O
and NN O O
a NN O O
normal NN O O
rate NN O O
of NN O O
catabolism NN O O
of NN O O
transfused NN O O
C3 NN O O
indicated NN O O
that NN O O
the NN O O
deficiency NN O O
was NN O O
inherited NN O O
with NN O O
autosomal NN O O
codominance NN O O
and NN O O
involved NN O O
decreased NN O B-Disease
synthesis NN O I-Disease
of NN O I-Disease
C3 NN O I-Disease
. NN O O

Thus NN O O
, NN O O
this NN O O
child NN O O
is NN O O
a NN O O
unique NN O O
individual NN O O
with NN O O
inherited NN O B-Disease
C3 NN O I-Disease
deficiency NN O I-Disease
presenting NN O O
with NN O O
absence NN O O
of NN O O
repeated NN O O
infections NN O O
, NN O O
whose NN O O
symptoms NN O O
of NN O O
fever NN O B-Disease
, NN O O
skin NN O B-Disease
rash NN O I-Disease
, NN O O
and NN O O
arthralgia NN O B-Disease
were NN O O
abated NN O O
by NN O O
whole NN O O
blood NN O O
transfusion NN O O
. NN O O
. NN O O

Glucose NN O O
- NN O O
6 NN O O
- NN O O
phosphate NN O O
dehydrogenase NN O O
variants NN O O
and NN O O
their NN O O
frequency NN O O
in NN O O
Guangdong NN O O
, NN O O
China NN O O
. NN O O

Erythrocyte NN O O
glucose NN O O
- NN O O
6 NN O O
- NN O O
phosphate NN O O
dehydrogenase NN O O
( NN O O
G6PD NN O O
) NN O O
was NN O O
characterized NN O O
in NN O O
blood NN O O
samples NN O O
obtained NN O O
from NN O O
97 NN O O
randomly NN O O
selected NN O O
males NN O O
with NN O O
enzyme NN O B-Disease
deficiency NN O I-Disease
from NN O O
various NN O O
regions NN O O
of NN O O
Guangdong NN O O
Province NN O O
, NN O O
China NN O O
. NN O O

Nine NN O O
new NN O O
variants NN O O
( NN O O
Gd NN O O
Kaiping NN O O
, NN O O
Gd NN O O
Boluo NN O O
, NN O O
Gd NN O O
Huiyang NN O O
, NN O O
Gd NN O O
Gaomin NN O O
, NN O O
Gd NN O O
Qing NN O O
- NN O O
Baijiang NN O O
, NN O O
Gd NN O O
Gaozhou NN O O
, NN O O
Gd NN O O
Huazhou NN O O
, NN O O
Gd NN O O
Nanhai NN O O
, NN O O
and NN O O
Gd NN O O
Guangzhou NN O O
) NN O O
were NN O O
identified NN O O
. NN O O

Of NN O O
the NN O O
31 NN O O
variants NN O O
found NN O O
in NN O O
this NN O O
province NN O O
, NN O O
Gd NN O O
Kaiping NN O O
, NN O O
Gd NN O O
Taiwan NN O O
- NN O O
Hakka NN O O
, NN O O
Gd NN O O
Haad NN O O
Yai NN O O
, NN O O
Gd NN O O
Haad NN O O
Yai NN O O
- NN O O
like NN O O
and NN O O
Gd NN O O
Huiyang NN O O
occurred NN O O
most NN O O
frequently NN O O
. NN O O

The NN O O
frequency NN O O
of NN O O
each NN O O
variant NN O O
was NN O O
calculated NN O O
. NN O O

The NN O O
results NN O O
demonstrated NN O O
that NN O O
the NN O O
genetic NN O O
heterogeneity NN O O
of NN O O
G6PD NN O B-Disease
deficiency NN O I-Disease
was NN O O
high NN O O
in NN O O
this NN O O
area NN O O
. NN O O
. NN O O

Homozygous NN O O
and NN O O
heterozygous NN O O
deletions NN O O
of NN O O
the NN O O
von NN O B-Disease
Willebrand NN O I-Disease
factor NN O O
gene NN O O
in NN O O
patients NN O O
and NN O O
carriers NN O O
of NN O O
severe NN O B-Disease
von NN O I-Disease
Willebrand NN O I-Disease
disease NN O I-Disease
. NN O O

Severe NN O B-Disease
von NN O I-Disease
Willebrand NN O I-Disease
disease NN O I-Disease
is NN O O
characterized NN O O
by NN O O
undetectable NN O O
or NN O O
trace NN O O
quantities NN O O
of NN O O
von NN O B-Disease
Willebrand NN O I-Disease
factor NN O O
in NN O O
plasma NN O O
and NN O O
tissue NN O O
stores NN O O
. NN O O

We NN O O
have NN O O
studied NN O O
the NN O O
genomic NN O O
DNA NN O O
of NN O O
10 NN O O
affected NN O O
individuals NN O O
from NN O O
six NN O O
families NN O O
with NN O O
this NN O O
disorder NN O O
using NN O O
probes NN O O
from NN O O
the NN O O
5 NN O O
and NN O O
3 NN O O
ends NN O O
of NN O O
the NN O O
vWF NN O O
cDNA NN O O
and NN O O
with NN O O
a NN O O
probe NN O O
extending NN O O
from NN O O
the NN O O
5 NN O O
end NN O O
into NN O O
the NN O O
central NN O O
region NN O O
. NN O O

Southern NN O O
blots NN O O
of NN O O
restriction NN O O
endonuclease NN O O
digests NN O O
and NN O O
gene NN O O
dosage NN O O
analysis NN O O
measurements NN O O
carried NN O O
out NN O O
with NN O O
quantitative NN O O
slot NN O O
blots NN O O
of NN O O
undigested NN O O
genomic NN O O
DNA NN O O
separated NN O O
these NN O O
patients NN O O
into NN O O
three NN O O
groups NN O O
. NN O O

The NN O O
first NN O O
group NN O O
consisted NN O O
of NN O O
a NN O O
family NN O O
with NN O O
complete NN O O
homozygous NN O O
deletions NN O O
of NN O O
the NN O O
vWF NN O O
gene NN O O
in NN O O
the NN O O
four NN O O
probands NN O O
. NN O O

Gene NN O O
dosage NN O O
analysis NN O O
was NN O O
consistent NN O O
with NN O O
heterozygous NN O O
deletions NN O O
in NN O O
both NN O O
of NN O O
the NN O O
asymptomatic NN O O
parents NN O O
and NN O O
four NN O O
asymptomatic NN O O
siblings NN O O
of NN O O
this NN O O
kindred NN O O
( NN O O
P NN O O
less NN O O
than NN O O
0 NN O O
. NN O O
01 NN O O
) NN O O
. NN O O

The NN O O
second NN O O
group NN O O
was NN O O
comprised NN O O
of NN O O
a NN O O
family NN O O
in NN O O
which NN O O
there NN O O
was NN O O
a NN O O
complete NN O O
heterozygous NN O O
deletion NN O O
of NN O O
the NN O O
vWF NN O O
gene NN O O
in NN O O
the NN O O
proband NN O O
and NN O O
one NN O O
asymptomatic NN O O
parent NN O O
, NN O O
suggesting NN O O
that NN O O
a NN O O
different NN O O
type NN O O
of NN O O
genetic NN O B-Disease
abnormality NN O I-Disease
was NN O O
inherited NN O O
from NN O O
the NN O O
other NN O O
parent NN O O
. NN O O

Thus NN O O
, NN O O
the NN O O
patient NN O O
appeared NN O O
to NN O O
be NN O O
doubly NN O O
heterozygous NN O O
for NN O O
interacting NN O O
genetic NN O B-Disease
abnormalities NN O I-Disease
affecting NN O O
vWF NN O O
expression NN O O
. NN O O

In NN O O
the NN O O
third NN O O
group NN O O
, NN O O
no NN O O
gene NN O O
deletions NN O O
could NN O O
be NN O O
detected NN O O
. NN O O

Alloantibodies NN O O
developed NN O O
only NN O O
in NN O O
the NN O O
kindred NN O O
with NN O O
homozygous NN O O
deletions NN O O
. NN O O

These NN O O
techniques NN O O
should NN O O
prove NN O O
useful NN O O
in NN O O
identifying NN O O
carriers NN O O
of NN O O
severe NN O B-Disease
von NN O I-Disease
Willebrand NN O I-Disease
disease NN O I-Disease
and NN O O
also NN O O
in NN O O
defining NN O O
patients NN O O
predictably NN O O
at NN O O
risk NN O O
of NN O O
developing NN O O
alloantibodies NN O O
to NN O O
vWF NN O O
. NN O O

Sjogren NN O B-Disease
- NN O I-Disease
Larsson NN O I-Disease
syndrome NN O I-Disease
. NN O O

Impaired NN O O
fatty NN O O
alcohol NN O O
oxidation NN O O
in NN O O
cultured NN O O
fibroblasts NN O O
due NN O O
to NN O O
deficient NN O O
fatty NN O O
alcohol NN O O
: NN O O
nicotinamide NN O O
adenine NN O O
dinucleotide NN O O
oxidoreductase NN O O
activity NN O O
. NN O O

Lipid NN O O
metabolism NN O O
was NN O O
studied NN O O
in NN O O
cultured NN O O
skin NN O O
fibroblasts NN O O
from NN O O
patients NN O O
with NN O O
the NN O O
inherited NN O B-Disease
disorder NN O I-Disease
, NN O O
Sjogren NN O B-Disease
- NN O I-Disease
Larsson NN O I-Disease
syndrome NN O I-Disease
( NN O O
SLS NN O B-Disease
) NN O O
. NN O O

Intact NN O O
SLS NN O B-Disease
fibroblasts NN O O
incubated NN O O
in NN O O
the NN O O
presence NN O O
of NN O O
[ NN O O
1 NN O O
- NN O O
14C NN O O
] NN O O
palmitate NN O O
accumulated NN O O
more NN O O
radioactive NN O O
hexadecanol NN O O
than NN O O
did NN O O
normal NN O O
cells NN O O
, NN O O
whereas NN O O
incorporation NN O O
of NN O O
radioactivity NN O O
into NN O O
other NN O O
cellular NN O O
lipids NN O O
was NN O O
unaltered NN O O
. NN O O

The NN O O
hexadecanol NN O O
content NN O O
of NN O O
SLS NN O B-Disease
fibroblasts NN O O
was NN O O
abnormally NN O O
elevated NN O O
. NN O O

Hexadecanol NN O O
accumulation NN O O
was NN O O
not NN O O
due NN O O
to NN O O
increased NN O O
fatty NN O O
alcohol NN O O
synthesis NN O O
nor NN O O
its NN O O
deficient NN O O
utilization NN O O
for NN O O
glycerol NN O O
ether NN O O
synthesis NN O O
. NN O O

The NN O O
half NN O O
- NN O O
life NN O O
of NN O O
intracellular NN O O
hexadecanol NN O O
loaded NN O O
into NN O O
SLS NN O B-Disease
fibroblasts NN O O
was NN O O
increased NN O O
( NN O O
70 NN O O
min NN O O
) NN O O
compared NN O O
with NN O O
normal NN O O
( NN O O
15 NN O O
min NN O O
) NN O O
, NN O O
and NN O O
intact NN O O
SLS NN O B-Disease
fibroblasts NN O O
showed NN O O
impaired NN O O
oxidation NN O O
of NN O O
[ NN O O
14C NN O O
] NN O O
- NN O O
hexadecanol NN O O
to NN O O
fatty NN O O
acid NN O O
. NN O O

Fatty NN O O
alcohol NN O O
NAD NN O O
+ NN O O
oxidoreductase NN O O
, NN O O
the NN O O
enzyme NN O O
catalyzing NN O O
this NN O O
reaction NN O O
, NN O O
was NN O O
deficient NN O O
in NN O O
SLS NN O B-Disease
fibroblasts NN O O
. NN O O

Mean NN O O
total NN O O
activity NN O O
in NN O O
SLS NN O B-Disease
fibroblasts NN O O
( NN O O
n NN O O
= NN O O
5 NN O O
) NN O O
was NN O O
13 NN O O
% NN O O
of NN O O
that NN O O
in NN O O
normal NN O O
fibroblasts NN O O
, NN O O
and NN O O
palmitoyl NN O O
CoA NN O O
- NN O O
inhibitable NN O O
activity NN O O
was NN O O
1 NN O O
% NN O O
of NN O O
normal NN O O
. NN O O

Fibroblasts NN O O
from NN O O
two NN O O
obligate NN O O
SLS NN O B-Disease
heterozygotes NN O O
had NN O O
enzyme NN O O
activities NN O O
intermediate NN O O
between NN O O
that NN O O
in NN O O
normal NN O O
fibroblasts NN O O
and NN O O
individuals NN O O
with NN O O
SLS NN O B-Disease
. NN O O

These NN O O
results NN O O
suggest NN O O
that NN O O
the NN O O
primary NN O O
defect NN O O
in NN O O
SLS NN O B-Disease
is NN O O
deficiency NN O B-Disease
of NN O I-Disease
fatty NN O I-Disease
alcohol NN O I-Disease
NAD NN O I-Disease
+ NN O I-Disease
oxidoreductase NN O I-Disease
. NN O O

SLS NN O B-Disease
represents NN O O
the NN O O
first NN O O
inherited NN O B-Disease
disorder NN O I-Disease
in NN O O
man NN O O
associated NN O O
with NN O O
an NN O O
isolated NN O O
abnormality NN O B-Disease
in NN O I-Disease
fatty NN O I-Disease
alcohol NN O I-Disease
metabolism NN O I-Disease
. NN O O
. NN O O

Germinal NN O O
mosaicism NN O O
in NN O O
Duchenne NN O B-Disease
muscular NN O I-Disease
dystrophy NN O I-Disease
. NN O O

We NN O O
have NN O O
identified NN O O
a NN O O
Duchenne NN O B-Disease
muscular NN O I-Disease
dystrophy NN O I-Disease
( NN O O
DMD NN O B-Disease
) NN O O
pedigree NN O O
where NN O O
the NN O O
disease NN O O
is NN O O
associated NN O O
with NN O O
a NN O O
molecular NN O O
deletion NN O O
within NN O O
the NN O O
DMD NN O B-Disease
locus NN O O
. NN O O

We NN O O
have NN O O
examined NN O O
the NN O O
meiotic NN O O
segregation NN O O
products NN O O
of NN O O
the NN O O
common NN O O
female NN O O
ancestor NN O O
using NN O O
marker NN O O
restriction NN O O
fragment NN O O
length NN O O
polymorphisms NN O O
( NN O O
RFLPs NN O O
) NN O O
detected NN O O
by NN O O
probes NN O O
that NN O O
lie NN O O
within NN O O
this NN O O
deletion NN O O
. NN O O

These NN O O
studies NN O O
show NN O O
that NN O O
this NN O O
female NN O O
has NN O O
transmitted NN O O
three NN O O
distinct NN O O
types NN O O
of NN O O
X NN O O
chromosome NN O O
to NN O O
her NN O O
offspring NN O O
. NN O O

This NN O O
observation NN O O
may NN O O
be NN O O
explained NN O O
by NN O O
postulating NN O O
that NN O O
the NN O O
mutation NN O O
arose NN O O
as NN O O
a NN O O
postzygotic NN O O
deletion NN O O
within NN O O
this NN O O
common NN O O
ancestor NN O O
, NN O O
who NN O O
was NN O O
consequently NN O O
germinally NN O O
mosaic NN O O
. NN O O
. NN O O

Nebulin NN O O
seen NN O O
in NN O O
DMD NN O B-Disease
males NN O O
including NN O O
one NN O O
patient NN O O
with NN O O
a NN O O
large NN O O
DNA NN O O
deletion NN O O
encompassing NN O O
the NN O O
DMD NN O B-Disease
gene NN O O
. NN O O

The NN O O
presence NN O O
of NN O O
nebulin NN O O
in NN O O
a NN O O
muscle NN O O
specimen NN O O
from NN O O
a NN O O
patient NN O O
with NN O O
Duchenne NN O B-Disease
muscular NN O I-Disease
dystrophy NN O I-Disease
( NN O O
DMD NN O B-Disease
) NN O O
due NN O O
to NN O O
a NN O O
large NN O O
deletion NN O O
precludes NN O O
the NN O O
possibility NN O O
that NN O O
this NN O O
protein NN O O
is NN O O
the NN O O
DMD NN O B-Disease
gene NN O O
product NN O O
. NN O O
. NN O O

Expression NN O O
of NN O O
the NN O O
murine NN O O
Duchenne NN O B-Disease
muscular NN O I-Disease
dystrophy NN O I-Disease
gene NN O O
in NN O O
muscle NN O O
and NN O O
brain NN O O
. NN O O

Complementary NN O O
DNA NN O O
clones NN O O
were NN O O
isolated NN O O
that NN O O
represent NN O O
the NN O O
5 NN O O
terminal NN O O
2 NN O O
. NN O O

5 NN O O
kilobases NN O O
of NN O O
the NN O O
murine NN O O
Duchenne NN O B-Disease
muscular NN O I-Disease
dystrophy NN O I-Disease
( NN O O
Dmd NN O O
) NN O O
messenger NN O O
RNA NN O O
( NN O O
mRNA NN O O
) NN O O
. NN O O

Mouse NN O O
Dmd NN O O
mRNA NN O O
was NN O O
detectable NN O O
in NN O O
skeletal NN O O
and NN O O
cardiac NN O O
muscle NN O O
and NN O O
at NN O O
a NN O O
level NN O O
approximately NN O O
90 NN O O
percent NN O O
lower NN O O
in NN O O
brain NN O O
. NN O O

Dmd NN O O
mRNA NN O O
is NN O O
also NN O O
present NN O O
, NN O O
but NN O O
at NN O O
much NN O O
lower NN O O
than NN O O
normal NN O O
levels NN O O
, NN O O
in NN O O
both NN O O
the NN O O
muscle NN O O
and NN O O
brain NN O O
of NN O O
three NN O O
different NN O O
strains NN O O
of NN O O
dystrophic NN O B-Disease
mdx NN O O
mice NN O O
. NN O O

The NN O O
identification NN O O
of NN O O
Dmd NN O O
mRNA NN O O
in NN O O
brain NN O O
raises NN O O
the NN O O
possibility NN O O
of NN O O
a NN O O
relation NN O O
between NN O O
human NN O O
Duchenne NN O B-Disease
muscular NN O I-Disease
dystrophy NN O I-Disease
( NN O O
DMD NN O B-Disease
) NN O O
gene NN O O
expression NN O O
and NN O O
the NN O O
mental NN O B-Disease
retardation NN O I-Disease
found NN O O
in NN O O
some NN O O
DMD NN O B-Disease
males NN O O
. NN O O

These NN O O
results NN O O
also NN O O
provide NN O O
evidence NN O O
that NN O O
the NN O O
mdx NN O O
mutations NN O O
are NN O O
allelic NN O O
variants NN O O
of NN O O
mouse NN O O
Dmd NN O O
gene NN O O
mutations NN O O
. NN O O

Glucose NN O B-Disease
6 NN O I-Disease
- NN O I-Disease
phosphate NN O I-Disease
dehydrogenase NN O I-Disease
deficiency NN O I-Disease
and NN O O
incidence NN O O
of NN O O
hematologic NN O B-Disease
malignancy NN O I-Disease
. NN O O

We NN O O
have NN O O
evaluated NN O O
the NN O O
hypothesis NN O O
of NN O O
a NN O O
negative NN O O
association NN O O
between NN O O
glucose NN O B-Disease
6 NN O I-Disease
- NN O I-Disease
phosphate NN O I-Disease
dehydrogenase NN O I-Disease
( NN O I-Disease
G6PD NN O I-Disease
) NN O I-Disease
deficiency NN O I-Disease
and NN O O
cancer NN O B-Disease
in NN O O
a NN O O
cohort NN O O
of NN O O
481 NN O O
Sardinian NN O O
males NN O O
with NN O O
hematological NN O B-Disease
malignancies NN O I-Disease
. NN O O

The NN O O
frequency NN O O
of NN O O
G6PD NN O B-Disease
deficiency NN O I-Disease
in NN O O
the NN O O
patients NN O O
was NN O O
not NN O O
different NN O O
from NN O O
the NN O O
incidence NN O O
in NN O O
a NN O O
group NN O O
of NN O O
16 NN O O
, NN O O
219 NN O O
controls NN O O
. NN O O

The NN O O
same NN O O
conclusion NN O O
resulted NN O O
from NN O O
the NN O O
comparison NN O O
of NN O O
the NN O O
frequency NN O O
of NN O O
expression NN O O
of NN O O
the NN O O
GdB NN O O
gene NN O O
in NN O O
23 NN O O
heterozygous NN O O
women NN O O
having NN O O
a NN O O
clonal NN O O
hematologic NN O B-Disease
disease NN O I-Disease
and NN O O
a NN O O
control NN O O
group NN O O
of NN O O
37 NN O O
healthy NN O O
heterozygotes NN O O
. NN O O

Therefore NN O O
at NN O O
present NN O O
there NN O O
is NN O O
no NN O O
evidence NN O O
that NN O O
G6PD NN O B-Disease
deficiency NN O I-Disease
has NN O O
a NN O O
protective NN O O
effect NN O O
against NN O O
development NN O O
of NN O O
hematologic NN O B-Disease
neoplasms NN O I-Disease
. NN O O
. NN O O

Hepatoblastoma NN O B-Disease
, NN O O
pigmented NN O B-Disease
ocular NN O I-Disease
fundus NN O I-Disease
lesions NN O I-Disease
and NN O O
jaw NN O B-Disease
lesions NN O I-Disease
in NN O O
Gardner NN O B-Disease
syndrome NN O I-Disease
. NN O O

Hepatoblastoma NN O B-Disease
is NN O O
a NN O O
rare NN O O
neoplasm NN O B-Disease
of NN O O
infants NN O O
and NN O O
children NN O O
only NN O O
recently NN O O
documented NN O O
in NN O O
association NN O O
with NN O O
hereditary NN O B-Disease
adenomatous NN O I-Disease
polyposis NN O I-Disease
of NN O I-Disease
the NN O I-Disease
colon NN O I-Disease
[ NN O O
Kingston NN O O
et NN O O
al NN O O
. NN O O
, NN O O
1983 NN O O
] NN O O
. NN O O

We NN O O
report NN O O
four NN O O
children NN O O
with NN O O
hepatoblastoma NN O B-Disease
from NN O O
four NN O O
unrelated NN O O
families NN O O
with NN O O
Gardner NN O B-Disease
syndrome NN O I-Disease
( NN O O
GS NN O B-Disease
) NN O O
. NN O O

One NN O O
child NN O O
, NN O O
now NN O O
19 NN O O
years NN O O
old NN O O
, NN O O
survived NN O O
after NN O O
a NN O O
resection NN O O
of NN O O
a NN O O
hepatoblastoma NN O B-Disease
in NN O O
infancy NN O O
and NN O O
recently NN O O
was NN O O
found NN O O
to NN O O
have NN O O
GS NN O B-Disease
. NN O O

He NN O O
has NN O O
an NN O O
associated NN O O
odontoma NN O B-Disease
and NN O O
pigmented NN O B-Disease
ocular NN O I-Disease
fundus NN O I-Disease
lesions NN O I-Disease
, NN O O
both NN O O
of NN O O
which NN O O
have NN O O
been NN O O
shown NN O O
to NN O O
be NN O O
clinical NN O O
markers NN O O
of NN O O
GS NN O B-Disease
. NN O O

Many NN O O
individuals NN O O
in NN O O
these NN O O
four NN O O
GS NN O B-Disease
families NN O O
, NN O O
both NN O O
affected NN O O
and NN O O
at NN O O
risk NN O O
, NN O O
have NN O O
osteomatous NN O B-Disease
jaw NN O I-Disease
lesions NN O I-Disease
and NN O O
pigmented NN O B-Disease
ocular NN O I-Disease
fundus NN O I-Disease
lesions NN O I-Disease
. NN O O

A NN O O
search NN O O
for NN O O
colonic NN O B-Disease
polyps NN O I-Disease
should NN O O
be NN O O
made NN O O
in NN O O
families NN O O
of NN O O
infants NN O O
and NN O O
children NN O O
with NN O O
hepatoblastoma NN O B-Disease
. NN O O

If NN O O
the NN O O
child NN O O
survives NN O O
, NN O O
he NN O O
or NN O O
she NN O O
should NN O O
be NN O O
monitored NN O O
for NN O O
the NN O O
later NN O O
appearance NN O O
of NN O O
colonic NN O B-Disease
polyps NN O I-Disease
. NN O O

The NN O O
finding NN O O
of NN O O
jaw NN O B-Disease
lesions NN O I-Disease
and NN O O
/ NN O O
or NN O O
pigmented NN O B-Disease
ocular NN O I-Disease
fundus NN O I-Disease
lesions NN O I-Disease
in NN O O
relatives NN O O
at NN O O
risk NN O O
are NN O O
indications NN O O
of NN O O
the NN O O
possible NN O O
presence NN O O
of NN O O
the NN O O
GS NN O B-Disease
gene NN O O
. NN O O

Identification NN O O
of NN O O
an NN O O
altered NN O O
splice NN O O
site NN O O
in NN O O
Ashkenazi NN O O
Tay NN O B-Disease
- NN O I-Disease
Sachs NN O I-Disease
disease NN O I-Disease
. NN O O

Tay NN O B-Disease
- NN O I-Disease
Sachs NN O I-Disease
disease NN O I-Disease
is NN O O
an NN O O
autosomal NN O B-Disease
recessive NN O I-Disease
genetic NN O I-Disease
disorder NN O I-Disease
resulting NN O O
from NN O O
mutation NN O O
of NN O O
the NN O O
HEXA NN O O
gene NN O O
encoding NN O O
the NN O O
alpha NN O O
- NN O O
subunit NN O O
of NN O O
the NN O O
lysosomal NN O O
enzyme NN O O
, NN O O
beta NN O O
- NN O O
N NN O O
- NN O O
acetylhexosaminidase NN O O
A NN O O
( NN O O
ref NN O O
. NN O O
1 NN O O
) NN O O
. NN O O

A NN O O
relatively NN O O
high NN O O
frequency NN O O
of NN O O
carriers NN O O
( NN O O
1 NN O O
/ NN O O
27 NN O O
) NN O O
of NN O O
a NN O O
lethal NN O O
, NN O O
infantile NN O O
form NN O O
of NN O O
the NN O O
disease NN O O
is NN O O
found NN O O
in NN O O
the NN O O
Ashkenazi NN O O
Jewish NN O O
population NN O O
, NN O O
but NN O O
it NN O O
is NN O O
not NN O O
yet NN O O
evident NN O O
whether NN O O
this NN O O
has NN O O
resulted NN O O
from NN O O
a NN O O
founder NN O O
effect NN O O
and NN O O
random NN O O
genetic NN O O
drift NN O O
or NN O O
from NN O O
a NN O O
selective NN O O
advantage NN O O
of NN O O
heterozygotes NN O O
. NN O O

We NN O O
have NN O O
identified NN O O
a NN O O
single NN O O
- NN O O
base NN O O
mutation NN O O
in NN O O
a NN O O
cloned NN O O
fragment NN O O
of NN O O
the NN O O
HEXA NN O O
gene NN O O
from NN O O
an NN O O
Ashkenazi NN O O
Jewish NN O O
patient NN O O
. NN O O

This NN O O
change NN O O
, NN O O
the NN O O
substitution NN O O
of NN O O
a NN O O
C NN O O
for NN O O
G NN O O
in NN O O
the NN O O
first NN O O
nucleotide NN O O
of NN O O
intron NN O O
12 NN O O
is NN O O
expected NN O O
to NN O O
result NN O O
in NN O O
defective NN O O
splicing NN O O
of NN O O
the NN O O
messenger NN O O
RNA NN O O
. NN O O

A NN O O
test NN O O
for NN O O
the NN O O
mutant NN O O
allele NN O O
based NN O O
on NN O O
amplification NN O O
of NN O O
DNA NN O O
by NN O O
the NN O O
polymerase NN O O
chain NN O O
rection NN O O
and NN O O
cleavage NN O O
of NN O O
a NN O O
DdeI NN O O
restriction NN O O
site NN O O
generated NN O O
by NN O O
the NN O O
mutation NN O O
revealed NN O O
that NN O O
this NN O O
case NN O O
and NN O O
two NN O O
other NN O O
cases NN O O
of NN O O
the NN O O
Ashkenazi NN O O
, NN O O
infantile NN O O
form NN O O
of NN O O
Tay NN O B-Disease
- NN O I-Disease
Sachs NN O I-Disease
disease NN O I-Disease
are NN O O
heterozygous NN O O
for NN O O
two NN O O
different NN O O
mutations NN O O
. NN O O

The NN O O
occurrence NN O O
of NN O O
multiple NN O O
mutant NN O O
alleles NN O O
warrants NN O O
further NN O O
examination NN O O
of NN O O
the NN O O
selective NN O O
advantage NN O O
hypothesis NN O O
. NN O O
. NN O O

X NN O B-Disease
- NN O I-Disease
linked NN O I-Disease
glucose NN O I-Disease
- NN O I-Disease
6 NN O I-Disease
- NN O I-Disease
phosphate NN O I-Disease
dehydrogenase NN O I-Disease
deficiency NN O I-Disease
in NN O O
Mus NN O O
musculus NN O O
. NN O O

A NN O O
mouse NN O O
with NN O O
X NN O B-Disease
- NN O I-Disease
linked NN O I-Disease
glucose NN O I-Disease
- NN O I-Disease
6 NN O I-Disease
- NN O I-Disease
phosphate NN O I-Disease
dehydrogenase NN O I-Disease
( NN O I-Disease
G6PD NN O I-Disease
) NN O I-Disease
deficiency NN O I-Disease
has NN O O
been NN O O
recovered NN O O
in NN O O
offspring NN O O
of NN O O
1 NN O O
- NN O O
ethyl NN O O
- NN O O
1 NN O O
- NN O O
nitrosourea NN O O
- NN O O
treated NN O O
male NN O O
mice NN O O
. NN O O

The NN O O
activity NN O O
alteration NN O O
was NN O O
detected NN O O
in NN O O
blood NN O O
but NN O O
can NN O O
also NN O O
be NN O O
observed NN O O
in NN O O
other NN O O
tissue NN O O
extracts NN O O
. NN O O

Hemizygous NN O O
, NN O O
heterozygous NN O O
, NN O O
and NN O O
homozygous NN O O
mutants NN O O
have NN O O
, NN O O
respectively NN O O
, NN O O
about NN O O
15 NN O O
, NN O O
60 NN O O
, NN O O
and NN O O
15 NN O O
% NN O O
G6PD NN O O
remaining NN O O
activity NN O O
in NN O O
the NN O O
blood NN O O
as NN O O
compared NN O O
to NN O O
the NN O O
wild NN O O
type NN O O
. NN O O

Erythrocyte NN O O
indices NN O O
did NN O O
not NN O O
show NN O O
differences NN O O
between NN O O
mutants NN O O
and NN O O
wild NN O O
types NN O O
. NN O O

The NN O O
mutation NN O O
does NN O O
not NN O O
affect NN O O
the NN O O
electrophoretic NN O O
migration NN O O
, NN O O
the NN O O
isoelectric NN O O
point NN O O
, NN O O
or NN O O
the NN O O
thermal NN O O
stability NN O O
. NN O O

Kinetic NN O O
properties NN O O
, NN O O
such NN O O
as NN O O
the NN O O
Km NN O O
for NN O O
glucose NN O O
- NN O O
6 NN O O
- NN O O
phosphate NN O O
or NN O O
for NN O O
NADP NN O O
and NN O O
the NN O O
relative NN O O
utilization NN O O
of NN O O
substrate NN O O
analogues NN O O
, NN O O
showed NN O O
no NN O O
differences NN O O
between NN O O
wild NN O O
types NN O O
and NN O O
mutants NN O O
with NN O O
the NN O O
exception NN O O
of NN O O
the NN O O
relative NN O O
utilization NN O O
of NN O O
deamino NN O O
- NN O O
NADP NN O O
which NN O O
was NN O O
significantly NN O O
lower NN O O
in NN O O
mutants NN O O
. NN O O

This NN O O
is NN O O
presently NN O O
the NN O O
only NN O O
animal NN O O
model NN O O
for NN O O
X NN O B-Disease
- NN O I-Disease
linked NN O I-Disease
G6PD NN O I-Disease
deficiency NN O I-Disease
in NN O O
humans NN O O
. NN O O
. NN O O

Diverse NN O O
point NN O O
mutations NN O O
in NN O O
the NN O O
human NN O O
glucose NN O O
- NN O O
6 NN O O
- NN O O
phosphate NN O O
dehydrogenase NN O O
gene NN O O
cause NN O O
enzyme NN O B-Disease
deficiency NN O I-Disease
and NN O O
mild NN O O
or NN O O
severe NN O O
hemolytic NN O B-Disease
anemia NN O I-Disease
. NN O O

Glucose NN O B-Disease
- NN O I-Disease
6 NN O I-Disease
- NN O I-Disease
phosphate NN O I-Disease
dehydrogenase NN O I-Disease
( NN O I-Disease
G6PD NN O I-Disease
; NN O I-Disease
EC NN O I-Disease
1 NN O I-Disease
. NN O I-Disease
1 NN O I-Disease
. NN O I-Disease
1 NN O I-Disease
. NN O I-Disease
49 NN O I-Disease
) NN O I-Disease
deficiency NN O I-Disease
is NN O O
a NN O O
common NN O O
genetic NN O B-Disease
abnormality NN O I-Disease
affecting NN O O
an NN O O
estimated NN O O
400 NN O O
million NN O O
people NN O O
worldwide NN O O
. NN O O

Clinical NN O O
and NN O O
biochemical NN O O
analyses NN O O
have NN O O
identified NN O O
many NN O O
variants NN O O
exhibiting NN O O
a NN O O
range NN O O
of NN O O
phenotypes NN O O
, NN O O
which NN O O
have NN O O
been NN O O
well NN O O
characterized NN O O
from NN O O
the NN O O
hematological NN O O
point NN O O
of NN O O
view NN O O
. NN O O

However NN O O
, NN O O
until NN O O
now NN O O
, NN O O
their NN O O
precise NN O O
molecular NN O O
basis NN O O
has NN O O
remained NN O O
unknown NN O O
. NN O O

We NN O O
have NN O O
cloned NN O O
and NN O O
sequenced NN O O
seven NN O O
mutant NN O O
G6PD NN O O
alleles NN O O
. NN O O

In NN O O
the NN O O
nondeficient NN O O
polymorphic NN O O
African NN O O
variant NN O O
G6PD NN O O
A NN O O
we NN O O
have NN O O
found NN O O
a NN O O
single NN O O
point NN O O
mutation NN O O
. NN O O

The NN O O
other NN O O
six NN O O
mutants NN O O
investigated NN O O
were NN O O
all NN O O
associated NN O O
with NN O O
enzyme NN O B-Disease
deficiency NN O I-Disease
. NN O O

In NN O O
one NN O O
of NN O O
the NN O O
commonest NN O O
, NN O O
G6PD NN O O
Mediterranean NN O O
, NN O O
which NN O O
is NN O O
associated NN O O
with NN O O
favism NN O B-Disease
among NN O O
other NN O O
clinical NN O O
manifestations NN O O
, NN O O
a NN O O
single NN O O
amino NN O O
acid NN O O
replacement NN O O
was NN O O
found NN O O
( NN O O
serine NN O O
- NN O O
- NN O O
- NN O O
- NN O O
phenylalanine NN O O
) NN O O
it NN O O
must NN O O
be NN O O
responsible NN O O
for NN O O
the NN O O
decreased NN O O
stability NN O O
and NN O O
the NN O O
reduced NN O O
catalytic NN O O
efficiency NN O O
of NN O O
this NN O O
enzyme NN O O
. NN O O

Single NN O O
point NN O O
mutations NN O O
were NN O O
also NN O O
found NN O O
in NN O O
G6PD NN O O
Metaponto NN O O
( NN O O
Southern NN O O
Italy NN O O
) NN O O
and NN O O
in NN O O
G6PD NN O O
Ilesha NN O O
( NN O O
Nigeria NN O O
) NN O O
, NN O O
which NN O O
are NN O O
asymptomatic NN O O
, NN O O
and NN O O
in NN O O
G6PD NN O O
Chatham NN O O
, NN O O
which NN O O
was NN O O
observed NN O O
in NN O O
an NN O O
Indian NN O O
boy NN O O
with NN O O
neonatal NN O B-Disease
jaundice NN O I-Disease
. NN O O

In NN O O
G6PD NN O O
" NN O O
Matera NN O O
, NN O O
" NN O O
which NN O O
is NN O O
now NN O O
known NN O O
to NN O O
be NN O O
the NN O O
same NN O O
as NN O O
G6PD NN O O
A NN O O
- NN O O
, NN O O
two NN O O
separate NN O O
point NN O O
mutations NN O O
were NN O O
found NN O O
, NN O O
one NN O O
of NN O O
which NN O O
is NN O O
the NN O O
same NN O O
as NN O O
in NN O O
G6PD NN O O
A NN O O
. NN O O

In NN O O
G6PD NN O O
Santiago NN O O
, NN O O
a NN O O
de NN O O
novo NN O O
mutation NN O O
( NN O O
glycine NN O O
- NN O O
- NN O O
- NN O O
- NN O O
arginine NN O O
) NN O O
is NN O O
associated NN O O
with NN O O
severe NN O O
chronic NN O O
hemolytic NN O B-Disease
anemia NN O I-Disease
. NN O O

The NN O O
mutations NN O O
observed NN O O
show NN O O
a NN O O
striking NN O O
predominance NN O O
of NN O O
C NN O O
- NN O O
- NN O O
- NN O O
- NN O O
T NN O O
transitions NN O O
, NN O O
with NN O O
CG NN O O
doublets NN O O
involved NN O O
in NN O O
four NN O O
of NN O O
seven NN O O
cases NN O O
. NN O O

Thus NN O O
, NN O O
diverse NN O O
point NN O O
mutations NN O O
may NN O O
account NN O O
largely NN O O
for NN O O
the NN O O
phenotypic NN O O
heterogeneity NN O O
of NN O O
G6PD NN O B-Disease
deficiency NN O I-Disease
. NN O O

Tight NN O O
linkage NN O O
between NN O O
myotonic NN O B-Disease
dystrophy NN O I-Disease
and NN O O
apolipoprotein NN O O
E NN O O
genes NN O O
revealed NN O O
with NN O O
allele NN O O
- NN O O
specific NN O O
oligonucleotides NN O O
. NN O O

In NN O O
16 NN O O
families NN O O
with NN O O
myotonic NN O B-Disease
dystrophy NN O I-Disease
( NN O O
DM NN O B-Disease
) NN O O
a NN O O
novel NN O O
approach NN O O
based NN O O
on NN O O
use NN O O
of NN O O
allele NN O O
- NN O O
specific NN O O
oligonucleotides NN O O
has NN O O
been NN O O
employed NN O O
to NN O O
study NN O O
the NN O O
linkage NN O O
relationship NN O O
between NN O O
the NN O O
apolipoprotein NN O O
E NN O O
( NN O O
APOE NN O O
) NN O O
gene NN O O
and NN O O
DM NN O B-Disease
. NN O O

Synthetic NN O O
oligonucleotides NN O O
, NN O O
designed NN O O
to NN O O
discriminate NN O O
between NN O O
APOE NN O O
alleles NN O O
epsilon NN O O
3 NN O O
and NN O O
epsilon NN O O
4 NN O O
, NN O O
enabled NN O O
us NN O O
to NN O O
distinguish NN O O
heterozygous NN O O
carriers NN O O
in NN O O
a NN O O
hybridization NN O O
assay NN O O
. NN O O

In NN O O
a NN O O
subset NN O O
of NN O O
families NN O O
, NN O O
the NN O O
relevant NN O O
segment NN O O
of NN O O
the NN O O
APOE NN O O
gene NN O O
was NN O O
enzymatically NN O O
amplified NN O O
to NN O O
increase NN O O
the NN O O
sensitivity NN O O
of NN O O
the NN O O
method NN O O
. NN O O

For NN O O
DM NN O O
and NN O O
APOE NN O O
, NN O O
a NN O O
maximum NN O O
lod NN O O
score NN O O
( NN O O
zmax NN O O
of NN O O
7 NN O O
. NN O O

47 NN O O
was NN O O
obtained NN O O
at NN O O
a NN O O
recombination NN O O
frequency NN O O
( NN O O
theta NN O O
) NN O O
of NN O O
0 NN O O
. NN O O

047 NN O O
( NN O O
male NN O O
theta NN O O
= NN O O
female NN O O
theta NN O O
) NN O O
. NN O O

No NN O O
recombination NN O O
( NN O O
maximum NN O O
lod NN O O
score NN O O
of NN O O
5 NN O O
. NN O O
61 NN O O
at NN O O
theta NN O O
= NN O O
0 NN O O
. NN O O
0 NN O O
) NN O O
was NN O O
found NN O O
between NN O O
APOE NN O O
and NN O O
the NN O O
apolipoprotein NN O O
CII NN O O
( NN O O
APOC2 NN O O
) NN O O
gene NN O O
. NN O O

These NN O O
results NN O O
suggest NN O O
that NN O O
, NN O O
in NN O O
addition NN O O
to NN O O
APOC2 NN O O
, NN O O
APOE NN O O
is NN O O
a NN O O
useful NN O O
marker NN O O
for NN O O
presymptomatic NN O O
DM NN O B-Disease
diagnosis NN O O
. NN O O

Regional NN O O
localization NN O O
of NN O O
polymorphic NN O O
DNA NN O O
loci NN O O
on NN O O
the NN O O
proximal NN O O
long NN O O
arm NN O O
of NN O O
the NN O O
X NN O O
chromosome NN O O
using NN O O
deletions NN O O
associated NN O O
with NN O O
choroideremia NN O B-Disease
. NN O O

In NN O O
two NN O O
unrelated NN O O
families NN O O
, NN O O
males NN O O
have NN O O
been NN O O
identified NN O O
who NN O O
suffer NN O O
from NN O O
choroideremia NN O B-Disease
and NN O O
at NN O O
the NN O O
same NN O O
time NN O O
have NN O O
an NN O O
interstitial NN O O
deletion NN O O
on NN O O
the NN O O
proximal NN O O
long NN O O
arm NN O O
of NN O O
the NN O O
X NN O O
chromosome NN O O
. NN O O

By NN O O
high NN O O
- NN O O
resolution NN O O
banding NN O O
we NN O O
have NN O O
characterized NN O O
the NN O O
deletion NN O O
chromosomes NN O O
as NN O O
del NN O O
( NN O O
X NN O O
) NN O O
( NN O O
q21 NN O O
. NN O O
1 NN O O
- NN O O
q21 NN O O
1 NN O O
- NN O O
q21 NN O O
. NN O O
33 NN O O
) NN O O
and NN O O
del NN O O
( NN O O
X NN O O
) NN O O
( NN O O
q21 NN O O
. NN O O
2 NN O O
- NN O O
q21 NN O O
2 NN O O
- NN O O
q21 NN O O
. NN O O
31 NN O O
) NN O O
respectively NN O O
. NN O O

By NN O O
Southern NN O O
blot NN O O
analysis NN O O
we NN O O
have NN O O
mapped NN O O
ten NN O O
different NN O O
polymorphic NN O O
DNA NN O O
loci NN O O
relative NN O O
to NN O O
the NN O O
position NN O O
of NN O O
the NN O O
deletion NN O O
and NN O O
the NN O O
choroideremia NN O B-Disease
locus NN O O
TCD NN O O
. NN O O

One NN O O
probe NN O O
, NN O O
p31 NN O O
, NN O O
was NN O O
shown NN O O
to NN O O
cover NN O O
one NN O O
of NN O O
the NN O O
breakpoints NN O O
of NN O O
the NN O O
smallest NN O O
deletion NN O O
. NN O O

The NN O O
following NN O O
order NN O O
of NN O O
the NN O O
loci NN O O
was NN O O
suggested NN O O
by NN O O
deletion NN O O
mapping NN O O
cen NN O O
- NN O O
DXS106 NN O O
- NN O O
DXS72 NN O O
- NN O O
TCD NN O O
- NN O O
( NN O O
DXYS1 NN O O
/ NN O O
DXYS23 NN O O
/ NN O O
DXYS5 NN O O
) NN O O
- NN O O
DXYS2 NN O O
- NN O O
( NN O O
DXYS12 NN O O
/ NN O O
DXS3 NN O O
) NN O O
- NN O O
( NN O O
DXS17 NN O O
/ NN O O
DXS101 NN O O
) NN O O
- NN O O
Xqter NN O O
. NN O O

Retroviral NN O O
- NN O O
mediated NN O O
gene NN O O
transfer NN O O
of NN O O
human NN O O
phenylalanine NN O O
hydroxylase NN O O
into NN O O
NIH NN O O
3T3 NN O O
and NN O O
hepatoma NN O B-Disease
cells NN O O
. NN O O

Phenylketonuria NN O B-Disease
( NN O O
PKU NN O B-Disease
) NN O O
is NN O O
caused NN O O
by NN O O
deficiency NN O B-Disease
of NN O I-Disease
the NN O I-Disease
hepatic NN O I-Disease
enzyme NN O I-Disease
phenylalanine NN O I-Disease
hydroxylase NN O I-Disease
( NN O O
PAH NN O O
) NN O O
. NN O O

A NN O O
full NN O O
- NN O O
length NN O O
human NN O O
PAH NN O O
cDNA NN O O
sequence NN O O
has NN O O
been NN O O
inserted NN O O
into NN O O
pzip NN O O
- NN O O
neoSV NN O O
( NN O O
X NN O O
) NN O O
, NN O O
which NN O O
is NN O O
a NN O O
retroviral NN O O
vector NN O O
containing NN O O
the NN O O
bacterial NN O O
neo NN O O
gene NN O O
. NN O O

The NN O O
recombinant NN O O
has NN O O
been NN O O
transfected NN O O
into NN O O
psi NN O O
2 NN O O
cells NN O O
, NN O O
which NN O O
provide NN O O
synthesis NN O O
of NN O O
the NN O O
retroviral NN O O
capsid NN O O
. NN O O

Recombinant NN O O
virus NN O O
was NN O O
detected NN O O
in NN O O
the NN O O
culture NN O O
medium NN O O
of NN O O
the NN O O
transfected NN O O
psi NN O O
2 NN O O
cells NN O O
, NN O O
which NN O O
is NN O O
capable NN O O
of NN O O
transmitting NN O O
the NN O O
human NN O O
PAH NN O O
gene NN O O
into NN O O
mouse NN O O
NIH NN O O
3T3 NN O O
cells NN O O
by NN O O
infection NN O O
leading NN O O
to NN O O
stable NN O O
incorporation NN O O
of NN O O
the NN O O
recombinant NN O O
provirus NN O O
. NN O O

Infected NN O O
cells NN O O
express NN O O
PAH NN O O
mRNA NN O O
, NN O O
immunoreactive NN O O
PAH NN O O
protein NN O O
, NN O O
and NN O O
exhibit NN O O
pterin NN O O
- NN O O
dependent NN O O
phenylalanine NN O O
hydroxylase NN O O
activity NN O O
. NN O O

The NN O O
recombinant NN O O
virus NN O O
is NN O O
also NN O O
capable NN O O
of NN O O
infecting NN O O
a NN O O
mouse NN O O
hepatoma NN O B-Disease
cell NN O O
line NN O O
that NN O O
does NN O O
not NN O O
normally NN O O
synthesize NN O O
PAH NN O O
. NN O O

PAH NN O O
activity NN O O
is NN O O
present NN O O
in NN O O
the NN O O
cellular NN O O
extracts NN O O
and NN O O
the NN O O
entire NN O O
hydroxylation NN O O
system NN O O
is NN O O
reconstituted NN O O
in NN O O
the NN O O
hepatoma NN O B-Disease
cells NN O O
infected NN O O
with NN O O
the NN O O
recombinant NN O O
viruses NN O O
. NN O O

Thus NN O O
, NN O O
recombinant NN O O
viruses NN O O
containing NN O O
human NN O O
PAH NN O O
cDNA NN O O
provide NN O O
a NN O O
means NN O O
for NN O O
introducing NN O O
functional NN O O
PAH NN O O
into NN O O
mammalian NN O O
cells NN O O
of NN O O
hepatic NN O O
origin NN O O
and NN O O
can NN O O
potentially NN O O
be NN O O
introduced NN O O
into NN O O
whole NN O O
animals NN O O
as NN O O
a NN O O
model NN O O
for NN O O
somatic NN O O
gene NN O O
therapy NN O O
for NN O O
PKU NN O B-Disease
. NN O O
. NN O O

Estimation NN O O
of NN O O
the NN O O
male NN O O
to NN O O
female NN O O
ratio NN O O
of NN O O
mutation NN O O
rates NN O O
from NN O O
the NN O O
segregation NN O O
of NN O O
X NN O O
- NN O O
chromosomal NN O O
DNA NN O O
haplotypes NN O O
in NN O O
Duchenne NN O B-Disease
muscular NN O I-Disease
dystrophy NN O I-Disease
families NN O O
. NN O O

A NN O O
novel NN O O
procedure NN O O
is NN O O
presented NN O O
to NN O O
estimate NN O O
the NN O O
ratio NN O O
of NN O O
male NN O O
to NN O O
female NN O O
mutation NN O O
rates NN O O
for NN O O
Duchenne NN O B-Disease
muscular NN O I-Disease
dystrophy NN O I-Disease
( NN O O
DMD NN O B-Disease
) NN O O
. NN O O

X NN O O
- NN O O
specific NN O O
restriction NN O O
fragment NN O O
length NN O O
polymorphisms NN O O
are NN O O
used NN O O
to NN O O
establish NN O O
DNA NN O O
haplotypes NN O O
in NN O O
three NN O O
- NN O O
generation NN O O
DMD NN O B-Disease
families NN O O
. NN O O

From NN O O
the NN O O
proportion NN O O
of NN O O
DMD NN O B-Disease
patients NN O O
who NN O O
have NN O O
inherited NN O O
their NN O O
maternal NN O O
grandfathers NN O O
X NN O O
chromosome NN O O
, NN O O
the NN O O
ratio NN O O
of NN O O
mutation NN O O
rates NN O O
can NN O O
be NN O O
calculated NN O O
. NN O O

In NN O O
contrast NN O O
to NN O O
classical NN O O
methods NN O O
, NN O O
the NN O O
proposed NN O O
procedure NN O O
is NN O O
not NN O O
restricted NN O O
to NN O O
sporadic NN O O
or NN O O
familiar NN O O
cases NN O O
nor NN O O
is NN O O
any NN O O
information NN O O
on NN O O
the NN O O
carrier NN O O
status NN O O
of NN O O
female NN O O
relatives NN O O
required NN O O
. NN O O
. NN O O

Deletions NN O O
of NN O O
a NN O O
DNA NN O O
sequence NN O O
in NN O O
retinoblastomas NN O B-Disease
and NN O O
mesenchymal NN O B-Disease
tumors NN O I-Disease
: NN O O
organization NN O O
of NN O O
the NN O O
sequence NN O O
and NN O O
its NN O O
encoded NN O O
protein NN O O
. NN O O

Retinoblastoma NN O B-Disease
is NN O O
a NN O O
childhood NN O B-Disease
tumor NN O I-Disease
that NN O O
can NN O O
arise NN O O
because NN O O
of NN O O
mutant NN O O
alleles NN O O
acquired NN O O
as NN O O
somatic NN O O
or NN O O
germinal NN O O
mutations NN O O
. NN O O

The NN O O
mutant NN O O
allele NN O O
can NN O O
be NN O O
carried NN O O
in NN O O
the NN O O
germ NN O O
line NN O O
. NN O O

The NN O O
mutations NN O O
creating NN O O
these NN O O
alleles NN O O
act NN O O
by NN O O
inactivating NN O O
copies NN O O
of NN O O
a NN O O
recessive NN O O
oncogene NN O O
located NN O O
within NN O O
band NN O O
q14 NN O O
of NN O O
chromosome NN O O
13 NN O O
and NN O O
termed NN O O
the NN O O
RB1 NN O O
locus NN O O
. NN O O

We NN O O
have NN O O
reported NN O O
isolation NN O O
of NN O O
a NN O O
cDNA NN O O
fragment NN O O
that NN O O
recognizes NN O O
chromosomal NN O O
sequences NN O O
possessing NN O O
many NN O O
of NN O O
the NN O O
attributes NN O O
of NN O O
the NN O O
retinoblastoma NN O B-Disease
gene NN O O
associated NN O O
with NN O O
the NN O O
RB1 NN O O
locus NN O O
. NN O O

We NN O O
now NN O O
report NN O O
that NN O O
this NN O O
segment NN O O
is NN O O
additionally NN O O
the NN O O
target NN O O
of NN O O
somatic NN O O
mutations NN O O
in NN O O
mesenchymal NN O B-Disease
tumors NN O I-Disease
among NN O O
patients NN O O
having NN O O
no NN O O
apparent NN O O
predisposition NN O O
to NN O O
retinoblastoma NN O B-Disease
and NN O O
no NN O O
previous NN O O
evidence NN O O
of NN O O
retinoblastoma NN O B-Disease
. NN O O

These NN O O
tumors NN O B-Disease
provide NN O O
additional NN O O
evidence NN O O
that NN O O
the NN O O
cloned NN O O
sequences NN O O
are NN O O
representative NN O O
of NN O O
a NN O O
gene NN O O
that NN O O
is NN O O
a NN O O
frequent NN O O
target NN O O
of NN O O
inactivation NN O O
during NN O O
tumorigenesis NN O O
. NN O O

Sequence NN O O
analysis NN O O
of NN O O
this NN O O
cDNA NN O O
provides NN O O
little NN O O
insight NN O O
into NN O O
its NN O O
normal NN O O
functional NN O O
role NN O O
. NN O O
. NN O O

Treatment NN O O
of NN O O
Duchenne NN O B-Disease
muscular NN O I-Disease
dystrophy NN O I-Disease
with NN O O
growth NN O O
hormone NN O O
inhibitors NN O O
. NN O O

A NN O O
controlled NN O O
, NN O O
double NN O O
- NN O O
blind NN O O
therapeutic NN O O
trial NN O O
with NN O O
the NN O O
drug NN O O
mazindol NN O O
, NN O O
a NN O O
growth NN O O
hormone NN O O
inhibitor NN O O
, NN O O
was NN O O
performed NN O O
in NN O O
a NN O O
pair NN O O
of NN O O
7 NN O O
1 NN O O
/ NN O O
2 NN O O
year NN O O
- NN O O
old NN O O
monozygotic NN O O
twins NN O O
, NN O O
with NN O O
Duchenne NN O B-Disease
muscular NN O I-Disease
dystrophy NN O I-Disease
( NN O O
DMD NN O B-Disease
) NN O O
. NN O O

The NN O O
rationale NN O O
for NN O O
this NN O O
trial NN O O
was NN O O
based NN O O
on NN O O
a NN O O
patient NN O O
( NN O O
reported NN O O
previously NN O O
) NN O O
affected NN O O
simultaneously NN O O
with NN O O
DMD NN O B-Disease
and NN O O
growth NN O B-Disease
hormone NN O I-Disease
( NN O I-Disease
GH NN O I-Disease
) NN O I-Disease
deficiency NN O I-Disease
, NN O O
who NN O O
is NN O O
showing NN O O
a NN O O
benign NN O O
course NN O O
of NN O O
the NN O O
dystrophic NN O B-Disease
process NN O I-Disease
and NN O O
is NN O O
still NN O O
walking NN O O
at NN O O
18 NN O O
years NN O O
. NN O O

One NN O O
of NN O O
the NN O O
twins NN O O
received NN O O
2 NN O O
mg NN O O
of NN O O
mazindol NN O O
daily NN O O
, NN O O
while NN O O
the NN O O
other NN O O
received NN O O
a NN O O
placebo NN O O
. NN O O

The NN O O
assessment NN O O
, NN O O
repeated NN O O
every NN O O
2 NN O O
months NN O O
, NN O O
included NN O O
weight NN O O
and NN O O
height NN O O
measurements NN O O
, NN O O
functional NN O O
and NN O O
motor NN O O
ability NN O O
tests NN O O
, NN O O
ergometry NN O O
and NN O O
determinations NN O O
of NN O O
serum NN O O
enzymes NN O O
and NN O O
GH NN O O
levels NN O O
. NN O O

After NN O O
one NN O O
year NN O O
of NN O O
trial NN O O
the NN O O
code NN O O
was NN O O
broken NN O O
and NN O O
it NN O O
was NN O O
seen NN O O
that NN O O
the NN O O
twin NN O O
under NN O O
placebo NN O O
treatment NN O O
was NN O O
strikingly NN O O
worse NN O O
than NN O O
his NN O O
brother NN O O
, NN O O
the NN O O
progression NN O O
of NN O O
whose NN O O
condition NN O O
was NN O O
practically NN O O
arrested NN O O
. NN O O

These NN O O
results NN O O
strongly NN O O
suggest NN O O
that NN O O
treatment NN O O
with NN O O
a NN O O
GH NN O O
inhibitor NN O O
is NN O O
beneficial NN O O
for NN O O
DMD NN O B-Disease
patients NN O O
. NN O O
. NN O O

Identification NN O O
and NN O O
localization NN O O
of NN O O
mutations NN O O
at NN O O
the NN O O
Lesch NN O B-Disease
- NN O I-Disease
Nyhan NN O I-Disease
locus NN O O
by NN O O
ribonuclease NN O O
A NN O O
cleavage NN O O
. NN O O

Many NN O O
mutations NN O O
leading NN O O
to NN O O
human NN O O
disease NN O O
are NN O O
the NN O O
result NN O O
of NN O O
single NN O O
DNA NN O O
base NN O O
pair NN O O
changes NN O O
that NN O O
cannot NN O O
be NN O O
identified NN O O
by NN O O
Southern NN O O
analysis NN O O
. NN O O

This NN O O
has NN O O
prompted NN O O
the NN O O
development NN O O
of NN O O
alternative NN O O
assays NN O O
for NN O O
point NN O O
mutation NN O O
detection NN O O
. NN O O

The NN O O
recently NN O O
described NN O O
ribonuclease NN O O
A NN O O
cleavage NN O O
procedure NN O O
, NN O O
with NN O O
a NN O O
polyuridylic NN O O
acid NN O O
- NN O O
paper NN O O
affinity NN O O
chromatography NN O O
step NN O O
, NN O O
has NN O O
been NN O O
used NN O O
to NN O O
identify NN O O
the NN O O
mutational NN O O
lesions NN O O
in NN O O
the NN O O
hypoxanthine NN O O
phosphoribosyltransferase NN O O
( NN O O
HPRT NN O O
) NN O O
messenger NN O O
RNAs NN O O
of NN O O
patients NN O O
with NN O O
Lesch NN O B-Disease
- NN O I-Disease
Nyhan NN O I-Disease
syndrome NN O I-Disease
. NN O O

Distinctive NN O O
ribonuclease NN O O
A NN O O
cleavage NN O O
patterns NN O O
were NN O O
identified NN O O
in NN O O
messenger NN O O
RNA NN O O
from NN O O
5 NN O O
of NN O O
14 NN O O
Lesch NN O B-Disease
- NN O I-Disease
Nyhan NN O I-Disease
patients NN O O
who NN O O
were NN O O
chosen NN O O
because NN O O
no NN O O
HPRT NN O O
Southern NN O O
or NN O O
Northern NN O O
blotting NN O O
pattern NN O O
changes NN O O
had NN O O
been NN O O
found NN O O
. NN O O

This NN O O
approach NN O O
now NN O O
allows NN O O
HPRT NN O O
mutation NN O O
detection NN O O
in NN O O
50 NN O O
percent NN O O
of NN O O
the NN O O
cases NN O O
of NN O O
Lesch NN O B-Disease
- NN O I-Disease
Nyhan NN O I-Disease
syndrome NN O I-Disease
. NN O O

The NN O O
polyuridylic NN O O
acid NN O O
- NN O O
paper NN O O
affinity NN O O
procedure NN O O
provides NN O O
a NN O O
general NN O O
method NN O O
for NN O O
analysis NN O O
of NN O O
low NN O O
abundance NN O O
messenger NN O O
RNAs NN O O
. NN O O
. NN O O

Two NN O O
new NN O O
variants NN O O
of NN O O
glucose NN O O
- NN O O
6 NN O O
- NN O O
phosphate NN O O
dehydrogenase NN O O
associated NN O O
with NN O O
hereditary NN O B-Disease
non NN O I-Disease
- NN O I-Disease
spherocytic NN O I-Disease
hemolytic NN O I-Disease
anemia NN O I-Disease
: NN O O
G6PD NN O O
Wayne NN O O
and NN O O
G6PD NN O O
Huron NN O O
. NN O O

Two NN O O
new NN O O
deficient NN O O
variants NN O O
of NN O O
glucose NN O O
- NN O O
6 NN O O
- NN O O
phosphate NN O O
dehydrogenase NN O O
( NN O O
G6PD NN O O
) NN O O
causing NN O O
hereditary NN O B-Disease
nonspherocytic NN O I-Disease
hemolytic NN O I-Disease
anemia NN O I-Disease
( NN O O
HNSHA NN O B-Disease
) NN O O
are NN O O
described NN O O
. NN O O

Both NN O O
of NN O O
these NN O O
are NN O O
unique NN O O
and NN O O
they NN O O
have NN O O
been NN O O
named NN O O
G6PD NN O O
Wayne NN O O
and NN O O
G6PD NN O O
Huron NN O O
. NN O O

Patients NN O O
with NN O O
G6PD NN O O
Wayne NN O O
underwent NN O O
splenectomy NN O O
and NN O O
no NN O O
objective NN O O
improvement NN O O
was NN O O
noted NN O O
. NN O O

The NN O O
patients NN O O
with NN O O
G6PD NN O O
Huron NN O O
were NN O O
under NN O O
medical NN O O
observation NN O O
for NN O O
a NN O O
considerable NN O O
period NN O O
of NN O O
time NN O O
without NN O O
the NN O O
diagnosis NN O O
of NN O O
G6PD NN O B-Disease
deficiency NN O I-Disease
being NN O O
entertained NN O O
because NN O O
the NN O O
family NN O O
was NN O O
of NN O O
Northern NN O O
European NN O O
origin NN O O
. NN O O

Since NN O O
sporadic NN O O
variants NN O O
of NN O O
G6PD NN O O
causing NN O O
HNSHA NN O B-Disease
show NN O O
no NN O O
special NN O O
racial NN O O
predilection NN O O
, NN O O
the NN O O
diagnosis NN O O
of NN O O
G6PD NN O B-Disease
deficiency NN O I-Disease
should NN O O
always NN O O
be NN O O
considered NN O O
in NN O O
patients NN O O
with NN O O
this NN O O
syndrome NN O O
. NN O O
. NN O O

Sialophorin NN O O
, NN O O
a NN O O
surface NN O O
sialoglycoprotein NN O O
defective NN O O
in NN O O
the NN O O
Wiskott NN O B-Disease
- NN O I-Disease
Aldrich NN O I-Disease
syndrome NN O I-Disease
, NN O O
is NN O O
involved NN O O
in NN O O
human NN O O
T NN O O
lymphocyte NN O O
proliferation NN O O
. NN O O

The NN O O
mAb NN O O
L10 NN O O
was NN O O
used NN O O
to NN O O
determine NN O O
the NN O O
distribution NN O O
and NN O O
the NN O O
function NN O O
of NN O O
sialophorin NN O O
, NN O O
the NN O O
heavily NN O O
glycosylated NN O O
surface NN O O
molecule NN O O
that NN O O
is NN O O
deficient NN O O
/ NN O O
defective NN O O
in NN O O
lymphocytes NN O O
of NN O O
patients NN O O
with NN O O
the NN O O
X NN O B-Disease
- NN O I-Disease
linked NN O I-Disease
immunodeficiency NN O I-Disease
Wiskott NN O I-Disease
- NN O I-Disease
Aldrich NN O I-Disease
syndrome NN O I-Disease
. NN O O

Dual NN O O
- NN O O
parameter NN O O
FACS NN O O
analysis NN O O
indicated NN O O
that NN O O
sialophorin NN O O
is NN O O
expressed NN O O
on NN O O
CD4 NN O O
+ NN O O
and NN O O
CD8 NN O O
+ NN O O
lymphocytes NN O O
, NN O O
on NN O O
a NN O O
subpopulation NN O O
of NN O O
peripheral NN O O
blood NN O O
B NN O O
lymphocytes NN O O
, NN O O
on NN O O
all NN O O
thymocytes NN O O
, NN O O
and NN O O
on NN O O
a NN O O
subpopulation NN O O
of NN O O
bone NN O O
marrow NN O O
cells NN O O
. NN O O

Functional NN O O
studies NN O O
demonstrated NN O O
that NN O O
L10 NN O O
mAb NN O O
stimulates NN O O
the NN O O
proliferation NN O O
of NN O O
peripheral NN O O
blood NN O O
T NN O O
lymphocytes NN O O
as NN O O
measured NN O O
by NN O O
stimulation NN O O
of NN O O
[ NN O O
3H NN O O
] NN O O
thymidine NN O O
incorporation NN O O
. NN O O

The NN O O
time NN O O
course NN O O
and NN O O
magnitude NN O O
of NN O O
increased NN O O
[ NN O O
3H NN O O
] NN O O
thymidine NN O O
incorporation NN O O
by NN O O
T NN O O
lymphocytes NN O O
in NN O O
response NN O O
to NN O O
L10 NN O O
mAb NN O O
paralleled NN O O
that NN O O
induced NN O O
by NN O O
anti NN O O
- NN O O
CD3 NN O O
mAb NN O O
. NN O O

Effective NN O O
stimulation NN O O
was NN O O
dependent NN O O
on NN O O
the NN O O
presence NN O O
of NN O O
monocytes NN O O
and NN O O
the NN O O
Fc NN O O
portion NN O O
of NN O O
L10 NN O O
mAb NN O O
. NN O O

Stimulation NN O O
of NN O O
lymphocytes NN O O
by NN O O
L10 NN O O
, NN O O
like NN O O
stimulation NN O O
by NN O O
anti NN O O
- NN O O
CD3 NN O O
mAb NN O O
, NN O O
involves NN O O
increased NN O O
expression NN O O
of NN O O
4F2 NN O O
, NN O O
HLA NN O O
- NN O O
DR NN O O
, NN O O
and NN O O
IL NN O O
- NN O O
2 NN O O
- NN O O
R NN O O
. NN O O

These NN O O
observations NN O O
suggest NN O O
that NN O O
sialophorin NN O O
functions NN O O
in NN O O
T NN O O
cell NN O O
activation NN O O
. NN O O
. NN O O

Hypopigmentation NN O B-Disease
in NN O O
the NN O O
Prader NN O B-Disease
- NN O I-Disease
Willi NN O I-Disease
syndrome NN O I-Disease
. NN O O

Cutaneous NN O B-Disease
and NN O I-Disease
ocular NN O I-Disease
pigmentation NN O I-Disease
were NN O O
evaluated NN O O
in NN O O
29 NN O O
individuals NN O O
with NN O O
the NN O O
Prader NN O B-Disease
- NN O I-Disease
Willi NN O I-Disease
syndrome NN O I-Disease
( NN O O
PWS NN O B-Disease
) NN O O
. NN O O

Criteria NN O O
for NN O O
hypopigmentation NN O B-Disease
included NN O O
the NN O O
presence NN O O
of NN O O
type NN O O
I NN O O
or NN O O
II NN O O
skin NN O O
, NN O O
the NN O O
lightest NN O O
skin NN O O
type NN O O
in NN O O
the NN O O
family NN O O
by NN O O
history NN O O
, NN O O
and NN O O
iris NN O O
translucency NN O O
on NN O O
globe NN O O
transillumination NN O O
. NN O O

On NN O O
the NN O O
basis NN O O
of NN O O
these NN O O
criteria NN O O
, NN O O
48 NN O O
% NN O O
of NN O O
the NN O O
PWS NN O B-Disease
individuals NN O O
were NN O O
hypopigmented NN O B-Disease
. NN O O

The NN O O
presence NN O O
of NN O O
hypopigmentation NN O B-Disease
correlated NN O O
with NN O O
a NN O O
small NN O O
interstitial NN O O
deletion NN O O
on NN O O
the NN O O
proximal NN O O
long NN O O
arm NN O O
of NN O O
chromosome NN O O
15 NN O O
; NN O O
however NN O O
, NN O O
this NN O O
deletion NN O O
was NN O O
also NN O O
found NN O O
in NN O O
individuals NN O O
who NN O O
did NN O O
not NN O O
meet NN O O
the NN O O
full NN O O
criteria NN O O
for NN O O
hypopigmentation NN O B-Disease
. NN O O

Hairbulb NN O O
tyrosinase NN O O
activity NN O O
and NN O O
glutathione NN O O
content NN O O
, NN O O
as NN O O
well NN O O
as NN O O
urine NN O O
cysteinyldopa NN O O
excretion NN O O
, NN O O
were NN O O
low NN O O
in NN O O
PWS NN O B-Disease
individuals NN O O
with NN O O
and NN O O
without NN O O
hypopigmentation NN O B-Disease
and NN O O
did NN O O
not NN O O
separate NN O O
these NN O O
two NN O O
groups NN O O
. NN O O

We NN O O
conclude NN O O
that NN O O
hypopigmentation NN O B-Disease
is NN O O
found NN O O
in NN O O
a NN O O
significant NN O O
proportion NN O O
of NN O O
individuals NN O O
with NN O O
PWS NN O B-Disease
and NN O O
that NN O O
the NN O O
hypopigmentation NN O B-Disease
may NN O O
be NN O O
associated NN O O
with NN O O
a NN O O
deletion NN O O
of NN O O
the NN O O
long NN O O
arm NN O O
of NN O O
chromosome NN O O
15 NN O O
. NN O O

The NN O O
mechanism NN O O
for NN O O
the NN O O
hypopigmentation NN O B-Disease
is NN O O
unknown NN O O
. NN O O
. NN O O

Phenotype NN O O
heterogeneity NN O O
among NN O O
hemizygotes NN O O
in NN O O
a NN O O
family NN O O
biochemically NN O O
screened NN O O
for NN O O
adrenoleukodystrophy NN O B-Disease
. NN O O

We NN O O
report NN O O
on NN O O
two NN O O
clinically NN O O
, NN O O
neurologically NN O O
normal NN O O
relatives NN O O
of NN O O
a NN O O
boy NN O O
affected NN O O
by NN O O
adrenoleukodystrophy NN O B-Disease
( NN O O
ALD NN O B-Disease
) NN O O
; NN O O
they NN O O
were NN O O
found NN O O
repeatedly NN O O
to NN O O
have NN O O
the NN O O
biochemical NN O O
defect NN O O
of NN O O
an NN O O
ALD NN O B-Disease
hemizygote NN O O
. NN O O

The NN O O
assay NN O O
consisted NN O O
in NN O O
the NN O O
determination NN O O
of NN O O
very NN O O
- NN O O
long NN O O
- NN O O
chain NN O O
fatty NN O O
acids NN O O
in NN O O
lyophilized NN O O
and NN O O
reconstituted NN O O
plasma NN O O
. NN O O

While NN O O
no NN O O
evidence NN O O
of NN O O
neurologic NN O B-Disease
disease NN O I-Disease
( NN O O
leukodystrophy NN O B-Disease
or NN O O
myeloneuropathy NN O B-Disease
) NN O O
was NN O O
present NN O O
in NN O O
these NN O O
hemizygotes NN O O
, NN O O
adrenocortical NN O B-Disease
insufficiency NN O I-Disease
provoking NN O O
compensatory NN O O
high NN O O
ACTH NN O O
release NN O O
was NN O O
found NN O O
in NN O O
both NN O O
. NN O O

These NN O O
findings NN O O
should NN O O
be NN O O
taken NN O O
into NN O O
consideration NN O O
when NN O O
counseling NN O O
families NN O O
in NN O O
which NN O O
cases NN O O
with NN O O
clinically NN O O
expressed NN O O
ALD NN O B-Disease
are NN O O
represented NN O O
in NN O O
several NN O O
generations NN O O
. NN O O
. NN O O

The NN O O
mapping NN O O
of NN O O
a NN O O
cDNA NN O O
from NN O O
the NN O O
human NN O O
X NN O B-Disease
- NN O I-Disease
linked NN O I-Disease
Duchenne NN O I-Disease
muscular NN O I-Disease
dystrophy NN O I-Disease
gene NN O O
to NN O O
the NN O O
mouse NN O O
X NN O O
chromosome NN O O
. NN O O

The NN O O
recent NN O O
discovery NN O O
of NN O O
sequences NN O O
at NN O O
the NN O O
site NN O O
of NN O O
the NN O O
Duchenne NN O B-Disease
muscular NN O I-Disease
dystrophy NN O I-Disease
( NN O O
DMD NN O B-Disease
) NN O O
gene NN O O
in NN O O
humans NN O O
has NN O O
opened NN O O
up NN O O
the NN O O
possibility NN O O
of NN O O
a NN O O
detailed NN O O
molecular NN O O
analysis NN O O
of NN O O
the NN O O
genes NN O O
in NN O O
humans NN O O
and NN O O
in NN O O
related NN O O
mammalian NN O O
species NN O O
. NN O O

Until NN O O
relatively NN O O
recently NN O O
, NN O O
there NN O O
was NN O O
no NN O O
obvious NN O O
mouse NN O O
model NN O O
of NN O O
this NN O O
genetic NN O B-Disease
disease NN O I-Disease
for NN O O
the NN O O
development NN O O
of NN O O
therapeutic NN O O
strategies NN O O
. NN O O

The NN O O
identification NN O O
of NN O O
a NN O O
mouse NN O O
X NN O O
- NN O O
linked NN O O
mutant NN O O
showing NN O O
muscular NN O B-Disease
dystrophy NN O I-Disease
, NN O O
mdx NN O O
, NN O O
has NN O O
provided NN O O
a NN O O
candidate NN O O
mouse NN O O
genetic NN O O
homologue NN O O
to NN O O
the NN O O
DMD NN O B-Disease
locus NN O O
; NN O O
the NN O O
relatively NN O O
mild NN O O
pathological NN O O
features NN O O
of NN O O
mdx NN O O
suggest NN O O
it NN O O
may NN O O
have NN O O
more NN O O
in NN O O
common NN O O
with NN O O
mutations NN O O
of NN O O
the NN O O
Becker NN O B-Disease
muscular NN O I-Disease
dystrophy NN O I-Disease
type NN O O
at NN O O
the NN O O
same NN O O
human NN O O
locus NN O O
, NN O O
however NN O O
. NN O O

But NN O O
the NN O O
close NN O O
genetic NN O O
linkage NN O O
of NN O O
mdx NN O O
to NN O O
G6PD NN O O
and NN O O
Hprt NN O O
on NN O O
the NN O O
mouse NN O O
X NN O O
chromosome NN O O
, NN O O
coupled NN O O
with NN O O
its NN O O
comparatively NN O O
mild NN O O
pathology NN O O
, NN O O
have NN O O
suggested NN O O
that NN O O
the NN O O
mdx NN O O
mutation NN O O
may NN O O
instead NN O O
correspond NN O O
to NN O O
Emery NN O B-Disease
Dreifuss NN O I-Disease
muscular NN O I-Disease
dystrophy NN O I-Disease
which NN O O
itself NN O O
is NN O O
closely NN O O
linked NN O O
to NN O O
DNA NN O O
markers NN O O
at NN O O
Xq28 NN O O
- NN O O
qter NN O O
in NN O O
the NN O O
region NN O O
of NN O O
G6PD NN O O
on NN O O
the NN O O
human NN O O
X NN O O
chromosome NN O O
. NN O O

Using NN O O
an NN O O
interspecific NN O O
mouse NN O O
domesticus NN O O
/ NN O O
spretus NN O O
cross NN O O
, NN O O
segregating NN O O
for NN O O
a NN O O
variety NN O O
of NN O O
markers NN O O
on NN O O
the NN O O
mouse NN O O
X NN O O
chromosome NN O O
, NN O O
we NN O O
have NN O O
positioned NN O O
on NN O O
the NN O O
mouse NN O O
X NN O O
chromosome NN O O
sequences NN O O
homologous NN O O
to NN O O
a NN O O
DMD NN O B-Disease
cDNA NN O O
clone NN O O
. NN O O

These NN O O
sequences NN O O
map NN O O
provocatively NN O O
close NN O O
to NN O O
the NN O O
mdx NN O O
mutation NN O O
and NN O O
unexpectedly NN O O
distant NN O O
from NN O O
sparse NN O O
fur NN O O
, NN O O
spf NN O O
, NN O O
the NN O O
mouse NN O O
homologue NN O O
of NN O O
OTC NN O O
( NN O O
ornithine NN O O
transcarbamylase NN O O
) NN O O
which NN O O
is NN O O
closely NN O O
linked NN O O
to NN O O
DMD NN O B-Disease
on NN O O
the NN O O
human NN O O
X NN O O
chromosome NN O O
. NN O O
. NN O O

Localization NN O O
of NN O O
the NN O O
region NN O O
homologous NN O O
to NN O O
the NN O O
Duchenne NN O B-Disease
muscular NN O I-Disease
dystrophy NN O I-Disease
locus NN O O
on NN O O
the NN O O
mouse NN O O
X NN O O
chromosome NN O O
. NN O O

Recent NN O O
progress NN O O
has NN O O
resulted NN O O
in NN O O
part NN O O
of NN O O
the NN O O
gene NN O O
mutated NN O O
in NN O O
Duchenne NN O B-Disease
and NN O I-Disease
the NN O I-Disease
milder NN O I-Disease
Becker NN O I-Disease
muscular NN O I-Disease
dystrophies NN O I-Disease
being NN O O
cloned NN O O
and NN O O
has NN O O
suggested NN O O
that NN O O
the NN O O
gene NN O O
itself NN O O
extends NN O O
over NN O O
1 NN O O
, NN O O
000 NN O O
to NN O O
2 NN O O
, NN O O
000 NN O O
kilobases NN O O
( NN O O
kb NN O O
) NN O O
. NN O O

To NN O O
study NN O O
how NN O O
mutations NN O O
in NN O O
this NN O O
gene NN O O
affect NN O O
muscle NN O O
development NN O O
and NN O O
integrity NN O O
, NN O O
it NN O O
would NN O O
be NN O O
of NN O O
interest NN O O
to NN O O
have NN O O
available NN O O
a NN O O
mouse NN O O
model NN O O
of NN O O
the NN O O
human NN O O
disease NN O O
. NN O O

The NN O O
mouse NN O O
mdx NN O O
mutation NN O O
affects NN O O
muscle NN O O
and NN O O
confers NN O O
a NN O O
mild NN O O
dystrophic NN O B-Disease
syndrome NN O I-Disease
, NN O O
but NN O O
it NN O O
is NN O O
not NN O O
clear NN O O
whether NN O O
this NN O O
mutation NN O O
is NN O O
equivalent NN O O
to NN O O
Duchenne NN O B-Disease
/ NN O I-Disease
Becker NN O I-Disease
muscular NN O I-Disease
dystrophy NN O I-Disease
in NN O O
man NN O O
. NN O O

Here NN O O
we NN O O
describe NN O O
the NN O O
use NN O O
of NN O O
two NN O O
sequences NN O O
from NN O O
the NN O O
human NN O O
Duchenne NN O B-Disease
muscular NN O I-Disease
dystrophy NN O I-Disease
( NN O O
DMD NN O B-Disease
) NN O O
gene NN O O
that NN O O
cross NN O O
- NN O O
hybridize NN O O
to NN O O
mouse NN O O
X NN O O
- NN O O
linked NN O O
sequences NN O O
to NN O O
localize NN O O
the NN O O
gene NN O O
homologous NN O O
to NN O O
DMD NN O B-Disease
in NN O O
the NN O O
mouse NN O O
. NN O O

Both NN O O
sequences NN O O
map NN O O
to NN O O
the NN O O
region NN O O
of NN O O
10 NN O O
centimorgan NN O O
lying NN O O
between NN O O
the NN O O
Tabby NN O O
( NN O O
Ta NN O O
) NN O O
and NN O O
St14 NN O O
- NN O O
1 NN O O
( NN O O
DxPas8 NN O O
) NN O O
loci NN O O
, NN O O
close NN O O
to NN O O
the NN O O
phosphorylase NN O O
b NN O O
kinase NN O O
locus NN O O
( NN O O
Phk NN O O
) NN O O
. NN O O

By NN O O
analogy NN O O
with NN O O
the NN O O
human NN O O
X NN O O
- NN O O
chromosome NN O O
, NN O O
we NN O O
conclude NN O O
that NN O O
the NN O O
region NN O O
in NN O O
the NN O O
mouse NN O O
around NN O O
the NN O O
G6pd NN O O
and NN O O
St14 NN O O
- NN O O
1 NN O O
loci NN O O
may NN O O
contain NN O O
two NN O O
genes NN O O
corresponding NN O O
to NN O O
distinct NN O O
human NN O O
myopathies NN O B-Disease
Emery NN O B-Disease
Dreifuss NN O I-Disease
muscular NN O I-Disease
dystrophy NN O I-Disease
which NN O O
is NN O O
known NN O O
to NN O O
be NN O O
closely NN O O
linked NN O O
to NN O O
St14 NN O O
- NN O O
1 NN O O
in NN O O
man NN O O
and NN O O
the NN O O
DMD NN O B-Disease
homologue NN O O
described NN O O
here NN O O
. NN O O
. NN O O

GT NN O O
to NN O O
AT NN O O
transition NN O O
at NN O O
a NN O O
splice NN O O
donor NN O O
site NN O O
causes NN O O
skipping NN O O
of NN O O
the NN O O
preceding NN O O
exon NN O O
in NN O O
phenylketonuria NN O B-Disease
. NN O O

Classical NN O B-Disease
Phenylketonuria NN O I-Disease
( NN O O
PKU NN O B-Disease
) NN O O
is NN O O
an NN O O
autosomal NN O B-Disease
recessive NN O I-Disease
human NN O I-Disease
genetic NN O I-Disease
disorder NN O I-Disease
caused NN O O
by NN O O
a NN O O
deficiency NN O B-Disease
of NN O I-Disease
hepatic NN O I-Disease
phenylalanine NN O I-Disease
hydroxylase NN O I-Disease
( NN O O
PAH NN O O
) NN O O
. NN O O

We NN O O
isolated NN O O
several NN O O
mutant NN O O
PAH NN O O
cDNA NN O O
clones NN O O
from NN O O
a NN O O
PKU NN O B-Disease
carrier NN O O
individual NN O O
and NN O O
showed NN O O
that NN O O
they NN O O
contained NN O O
an NN O O
internal NN O O
116 NN O O
base NN O O
pair NN O O
deletion NN O O
, NN O O
corresponding NN O O
precisely NN O O
to NN O O
exon NN O O
12 NN O O
of NN O O
the NN O O
human NN O O
chromosomal NN O O
PAH NN O O
gene NN O O
. NN O O

The NN O O
deletion NN O O
causes NN O O
the NN O O
synthesis NN O O
of NN O O
a NN O O
truncated NN O O
protein NN O O
lacking NN O O
the NN O O
C NN O O
- NN O O
terminal NN O O
52 NN O O
amino NN O O
acids NN O O
. NN O O

Gene NN O O
transfer NN O O
and NN O O
expression NN O O
studies NN O O
using NN O O
the NN O O
mutant NN O O
PAH NN O O
cDNA NN O O
indicated NN O O
that NN O O
the NN O O
deletion NN O O
abolishes NN O O
PAH NN O O
activity NN O O
in NN O O
the NN O O
cell NN O O
as NN O O
a NN O O
result NN O O
of NN O O
protein NN O O
instability NN O O
. NN O O

To NN O O
determine NN O O
the NN O O
molecular NN O O
basis NN O O
of NN O O
the NN O O
deletion NN O O
, NN O O
the NN O O
mutant NN O O
chromosomal NN O O
PAH NN O O
gene NN O O
was NN O O
isolated NN O O
from NN O O
this NN O O
individual NN O O
and NN O O
shown NN O O
to NN O O
contain NN O O
a NN O O
GT NN O O
- NN O O
- NN O O
greater NN O O
than NN O O
AT NN O O
substitution NN O O
at NN O O
the NN O O
5 NN O O
splice NN O O
donor NN O O
site NN O O
of NN O O
intron NN O O
12 NN O O
. NN O O

Thus NN O O
, NN O O
the NN O O
consequence NN O O
of NN O O
the NN O O
splice NN O O
donor NN O O
site NN O O
mutation NN O O
in NN O O
the NN O O
human NN O O
liver NN O O
is NN O O
the NN O O
skipping NN O O
of NN O O
the NN O O
preceding NN O O
exon NN O O
during NN O O
RNA NN O O
splicing NN O O
. NN O O
. NN O O

Conservation NN O O
of NN O O
the NN O O
Duchenne NN O B-Disease
muscular NN O I-Disease
dystrophy NN O I-Disease
gene NN O O
in NN O O
mice NN O O
and NN O O
humans NN O O
. NN O O

A NN O O
portion NN O O
of NN O O
the NN O O
Duchenne NN O B-Disease
muscular NN O I-Disease
dystrophy NN O I-Disease
( NN O O
DMD NN O B-Disease
) NN O O
gene NN O O
transcript NN O O
from NN O O
human NN O O
fetal NN O O
skeletal NN O O
muscle NN O O
and NN O O
mouse NN O O
adult NN O O
heart NN O O
was NN O O
sequenced NN O O
, NN O O
representing NN O O
approximately NN O O
25 NN O O
percent NN O O
of NN O O
the NN O O
total NN O O
, NN O O
14 NN O O
- NN O O
kb NN O O
DMD NN O B-Disease
transcript NN O O
. NN O O

The NN O O
nucleic NN O O
acid NN O O
and NN O O
predicted NN O O
amino NN O O
acid NN O O
sequences NN O O
from NN O O
the NN O O
two NN O O
species NN O O
are NN O O
nearly NN O O
90 NN O O
percent NN O O
homologous NN O O
. NN O O

The NN O O
amino NN O O
acid NN O O
sequence NN O O
that NN O O
is NN O O
predicted NN O O
from NN O O
this NN O O
portion NN O O
of NN O O
the NN O O
DMD NN O B-Disease
gene NN O O
indicates NN O O
that NN O O
the NN O O
protein NN O O
product NN O O
might NN O O
serve NN O O
a NN O O
structural NN O O
role NN O O
in NN O O
muscle NN O O
, NN O O
but NN O O
the NN O O
abundance NN O O
and NN O O
tissue NN O O
distribution NN O O
of NN O O
the NN O O
messenger NN O O
RNA NN O O
suggests NN O O
that NN O O
the NN O O
DMD NN O B-Disease
protein NN O O
is NN O O
not NN O O
nebulin NN O O
. NN O O
. NN O O

Familial NN O O
Prader NN O B-Disease
- NN O I-Disease
Willi NN O I-Disease
syndrome NN O I-Disease
with NN O O
apparently NN O O
normal NN O O
chromosomes NN O O
. NN O O

We NN O O
report NN O O
on NN O O
4 NN O O
sibs NN O O
( NN O O
2F NN O O
, NN O O
2M NN O O
) NN O O
with NN O O
Prader NN O B-Disease
- NN O I-Disease
Willi NN O I-Disease
syndrome NN O I-Disease
( NN O O
PWS NN O B-Disease
) NN O O
. NN O O

Diagnosis NN O O
was NN O O
made NN O O
clinically NN O O
on NN O O
the NN O O
basis NN O O
of NN O O
history NN O O
, NN O O
behavior NN O O
, NN O O
and NN O O
physical NN O O
findings NN O O
in NN O O
3 NN O O
of NN O O
the NN O O
sibs NN O O
. NN O O

The NN O O
other NN O O
child NN O O
had NN O O
died NN O O
at NN O O
age NN O O
10 NN O O
months NN O O
with NN O O
a NN O O
history NN O O
and NN O O
clinical NN O O
findings NN O O
typical NN O O
of NN O O
first NN O O
phase NN O O
of NN O O
PWS NN O B-Disease
. NN O O

Results NN O O
of NN O O
chromosome NN O O
studies NN O O
on NN O O
the NN O O
parents NN O O
and NN O O
surviving NN O O
sibs NN O O
were NN O O
normal NN O O
. NN O O

The NN O O
implications NN O O
of NN O O
this NN O O
unusual NN O O
familial NN O O
occurrence NN O O
for NN O O
our NN O O
understanding NN O O
of NN O O
PWS NN O B-Disease
are NN O O
discussed NN O O
. NN O O
. NN O O

Nebulin NN O O
and NN O O
titin NN O O
expression NN O O
in NN O O
Duchenne NN O B-Disease
muscular NN O I-Disease
dystrophy NN O I-Disease
appears NN O O
normal NN O O
. NN O O

Monoclonal NN O O
antibodies NN O O
which NN O O
recognize NN O O
different NN O O
epitopes NN O O
on NN O O
either NN O O
titin NN O O
or NN O O
nebulin NN O O
show NN O O
normal NN O O
staining NN O O
patterns NN O O
on NN O O
frozen NN O O
sections NN O O
of NN O O
three NN O O
muscle NN O O
biopsies NN O O
of NN O O
Duchenne NN O B-Disease
muscular NN O I-Disease
dystrophy NN O I-Disease
( NN O O
DMD NN O B-Disease
) NN O O
. NN O O

Gel NN O O
electrophoresis NN O O
and NN O O
immunoblotting NN O O
performed NN O O
on NN O O
two NN O O
of NN O O
these NN O O
muscle NN O O
biopsies NN O O
show NN O O
the NN O O
normal NN O O
pattern NN O O
of NN O O
titin NN O O
and NN O O
nebulin NN O O
polypeptides NN O O
. NN O O

Since NN O O
the NN O O
donor NN O O
of NN O O
one NN O O
of NN O O
these NN O O
biopsies NN O O
has NN O O
a NN O O
large NN O O
deletion NN O O
of NN O O
the NN O O
5 NN O O
- NN O O
region NN O O
of NN O O
the NN O O
DMD NN O B-Disease
gene NN O O
, NN O O
our NN O O
results NN O O
argue NN O O
against NN O O
the NN O O
recent NN O O
proposal NN O O
that NN O O
nebulin NN O O
is NN O O
the NN O O
gene NN O O
mutated NN O O
in NN O O
DMD NN O B-Disease
. NN O O
. NN O O

Heterozygous NN O B-Disease
C2 NN O I-Disease
deficiency NN O I-Disease
associated NN O O
with NN O O
angioedema NN O B-Disease
, NN O O
myasthenia NN O B-Disease
gravis NN O I-Disease
, NN O O
and NN O O
systemic NN O B-Disease
lupus NN O I-Disease
erythematosus NN O I-Disease
. NN O O

We NN O O
describe NN O O
a NN O O
patient NN O O
with NN O O
myasthenia NN O B-Disease
gravis NN O I-Disease
, NN O O
systemic NN O B-Disease
lupus NN O I-Disease
erythematosus NN O I-Disease
, NN O O
and NN O O
angioedema NN O B-Disease
associated NN O O
with NN O O
heterozygous NN O O
complement NN O B-Disease
factor NN O I-Disease
2 NN O I-Disease
( NN O I-Disease
C2 NN O I-Disease
) NN O I-Disease
deficiency NN O I-Disease
. NN O O

The NN O O
significance NN O O
of NN O O
this NN O O
association NN O O
is NN O O
controversial NN O O
, NN O O
though NN O O
the NN O O
association NN O O
of NN O O
C2 NN O B-Disease
deficiency NN O I-Disease
with NN O O
certain NN O O
histocompatibility NN O O
antigens NN O O
suggests NN O O
possible NN O O
linkage NN O O
to NN O O
immune NN O O
response NN O O
genes NN O O
. NN O O

To NN O O
our NN O O
knowledge NN O O
this NN O O
is NN O O
the NN O O
first NN O O
report NN O O
of NN O O
heterozygous NN O O
C2 NN O B-Disease
deficiency NN O I-Disease
in NN O O
association NN O O
with NN O O
this NN O O
combination NN O O
of NN O O
autoimmune NN O B-Disease
disorders NN O I-Disease
, NN O O
and NN O O
we NN O O
discuss NN O O
the NN O O
aetiological NN O O
implications NN O O
. NN O O
. NN O O

Genetic NN O O
analysis NN O O
of NN O O
an NN O O
inherited NN O O
deficiency NN O B-Disease
of NN O I-Disease
the NN O I-Disease
third NN O I-Disease
component NN O I-Disease
of NN O I-Disease
complement NN O I-Disease
in NN O O
Brittany NN O O
spaniel NN O O
dogs NN O O
. NN O O

Genetically NN O O
determined NN O O
C3 NN O B-Disease
deficiency NN O I-Disease
in NN O O
Brittany NN O O
spaniel NN O O
dogs NN O O
shares NN O O
a NN O O
number NN O O
of NN O O
biochemical NN O O
and NN O O
clinical NN O O
characteristics NN O O
with NN O O
the NN O O
human NN O O
disorder NN O O
. NN O O

In NN O O
humans NN O O
, NN O O
the NN O O
gene NN O O
for NN O O
C3 NN O B-Disease
deficiency NN O I-Disease
is NN O O
a NN O O
null NN O O
gene NN O O
that NN O O
is NN O O
allelic NN O O
to NN O O
the NN O O
structural NN O O
gene NN O O
for NN O O
C3 NN O O
and NN O O
is NN O O
not NN O O
linked NN O O
to NN O O
the NN O O
major NN O O
histocompatibility NN O O
locus NN O O
. NN O O

The NN O O
current NN O O
study NN O O
used NN O O
allotype NN O O
analysis NN O O
of NN O O
canine NN O O
C3 NN O O
in NN O O
order NN O O
to NN O O
demonstrate NN O O
that NN O O
the NN O O
gene NN O O
for NN O O
C3 NN O B-Disease
deficiency NN O I-Disease
in NN O O
these NN O O
dogs NN O O
is NN O O
also NN O O
a NN O O
null NN O O
gene NN O O
allelic NN O O
to NN O O
the NN O O
structural NN O O
gene NN O O
for NN O O
C3 NN O O
. NN O O

In NN O O
addition NN O O
, NN O O
preliminary NN O O
pedigree NN O O
analysis NN O O
suggests NN O O
that NN O O
the NN O O
gene NN O O
for NN O O
canine NN O O
C3 NN O B-Disease
deficiency NN O I-Disease
is NN O O
apparently NN O O
not NN O O
closely NN O O
linked NN O O
to NN O O
the NN O O
major NN O O
histocompatibility NN O O
complex NN O O
of NN O O
the NN O O
dog NN O O
. NN O O

Thus NN O O
, NN O O
it NN O O
appears NN O O
that NN O O
C3 NN O B-Disease
deficiency NN O I-Disease
in NN O O
Brittany NN O O
spaniel NN O O
dogs NN O O
not NN O O
only NN O O
shares NN O O
biochemical NN O O
and NN O O
clinical NN O O
features NN O O
with NN O O
C3 NN O B-Disease
deficiency NN O I-Disease
in NN O O
humans NN O O
, NN O O
but NN O O
also NN O O
shares NN O O
some NN O O
genetic NN O O
characteristics NN O O
with NN O O
the NN O O
human NN O O
disorder NN O O
. NN O O
. NN O O

Gene NN O O
transfer NN O O
and NN O O
expression NN O O
of NN O O
human NN O O
phenylalanine NN O O
hydroxylase NN O O
. NN O O

Phenylketonuria NN O B-Disease
( NN O O
PKU NN O B-Disease
) NN O O
is NN O O
caused NN O O
by NN O O
a NN O O
genetic NN O O
deficiency NN O B-Disease
of NN O I-Disease
the NN O I-Disease
enzyme NN O I-Disease
phenylalanine NN O I-Disease
hydroxylase NN O I-Disease
( NN O O
PAH NN O O
) NN O O
. NN O O

A NN O O
full NN O O
- NN O O
length NN O O
complementary NN O O
DNA NN O O
clone NN O O
of NN O O
human NN O O
PAH NN O O
was NN O O
inserted NN O O
into NN O O
a NN O O
eukaryotic NN O O
expression NN O O
vector NN O O
and NN O O
transferred NN O O
into NN O O
mouse NN O O
NIH3T3 NN O O
cells NN O O
which NN O O
do NN O O
not NN O O
normally NN O O
express NN O O
PAH NN O O
. NN O O

The NN O O
transformed NN O O
mouse NN O O
cells NN O O
expressed NN O O
PAH NN O O
messenger NN O O
RNA NN O O
, NN O O
immunoreactive NN O O
protein NN O O
, NN O O
and NN O O
enzymatic NN O O
activity NN O O
that NN O O
are NN O O
characteristic NN O O
of NN O O
the NN O O
normal NN O O
human NN O O
liver NN O O
products NN O O
, NN O O
demonstrating NN O O
that NN O O
a NN O O
single NN O O
gene NN O O
contains NN O O
all NN O O
of NN O O
the NN O O
necessary NN O O
genetic NN O O
information NN O O
to NN O O
code NN O O
for NN O O
functional NN O O
PAH NN O O
. NN O O

These NN O O
results NN O O
support NN O O
the NN O O
use NN O O
of NN O O
the NN O O
human NN O O
PAH NN O O
probe NN O O
in NN O O
prenatal NN O O
diagnosis NN O O
and NN O O
detection NN O O
of NN O O
carriers NN O O
, NN O O
to NN O O
provide NN O O
new NN O O
opportunities NN O O
for NN O O
the NN O O
biochemical NN O O
characterization NN O O
of NN O O
normal NN O O
and NN O O
mutant NN O O
enzymes NN O O
, NN O O
and NN O O
in NN O O
the NN O O
investigation NN O O
of NN O O
alternative NN O O
genetic NN O O
therapies NN O O
for NN O O
PKU NN O B-Disease
. NN O O
. NN O O

Regional NN O O
mapping NN O O
of NN O O
the NN O O
phenylalanine NN O O
hydroxylase NN O O
gene NN O O
and NN O O
the NN O O
phenylketonuria NN O B-Disease
locus NN O O
in NN O O
the NN O O
human NN O O
genome NN O O
. NN O O

Phenylketonuria NN O B-Disease
( NN O O
PKU NN O B-Disease
) NN O O
is NN O O
an NN O O
autosomal NN O B-Disease
recessive NN O I-Disease
disorder NN O I-Disease
of NN O O
amino NN O O
acid NN O O
metabolism NN O O
caused NN O O
by NN O O
a NN O O
deficiency NN O B-Disease
of NN O I-Disease
the NN O I-Disease
hepatic NN O I-Disease
enzyme NN O I-Disease
phenylalanine NN O I-Disease
hydroxylase NN O I-Disease
( NN O O
PAH NN O O
; NN O O
phenylalanine NN O O
4 NN O O
- NN O O
monooxygenase NN O O
, NN O O
EC NN O O
1 NN O O
. NN O O
14 NN O O
. NN O O
16 NN O O
. NN O O
1 NN O O
) NN O O
. NN O O

A NN O O
cDNA NN O O
clone NN O O
for NN O O
human NN O O
PAH NN O O
has NN O O
previously NN O O
been NN O O
used NN O O
to NN O O
assign NN O O
the NN O O
corresponding NN O O
gene NN O O
to NN O O
human NN O O
chromosome NN O O
12 NN O O
. NN O O

To NN O O
define NN O O
the NN O O
regional NN O O
map NN O O
position NN O O
of NN O O
the NN O O
disease NN O O
locus NN O O
and NN O O
the NN O O
PAH NN O O
gene NN O O
on NN O O
human NN O O
chromosome NN O O
12 NN O O
, NN O O
DNA NN O O
was NN O O
isolated NN O O
from NN O O
human NN O O
- NN O O
hamster NN O O
somatic NN O O
cell NN O O
hybrids NN O O
with NN O O
various NN O O
deletions NN O O
of NN O O
human NN O O
chromosome NN O O
12 NN O O
and NN O O
was NN O O
analyzed NN O O
by NN O O
Southern NN O O
blot NN O O
analysis NN O O
using NN O O
the NN O O
human NN O O
cDNA NN O O
PAH NN O O
clone NN O O
as NN O O
a NN O O
hybridization NN O O
probe NN O O
. NN O O

From NN O O
these NN O O
results NN O O
, NN O O
together NN O O
with NN O O
detailed NN O O
biochemical NN O O
and NN O O
cytogenetic NN O O
characterization NN O O
of NN O O
the NN O O
hybrid NN O O
cells NN O O
, NN O O
the NN O O
region NN O O
on NN O O
chromosome NN O O
12 NN O O
containing NN O O
the NN O O
human NN O O
PAH NN O O
gene NN O O
has NN O O
been NN O O
defined NN O O
as NN O O
12q14 NN O O
. NN O O

3 NN O O
- NN O O
- NN O O
- NN O O
- NN O O
qter NN O O
3 NN O O
- NN O O
- NN O O
- NN O O
- NN O O
qter NN O O
. NN O O

The NN O O
PAH NN O O
map NN O O
position NN O O
on NN O O
chromosome NN O O
12 NN O O
was NN O O
further NN O O
localized NN O O
by NN O O
in NN O O
situ NN O O
hybridization NN O O
of NN O O
125I NN O O
- NN O O
labeled NN O O
human NN O O
PAH NN O O
cDNA NN O O
to NN O O
chromosomes NN O O
prepared NN O O
from NN O O
a NN O O
human NN O O
lymphoblastoid NN O O
cell NN O O
line NN O O
. NN O O

Results NN O O
of NN O O
these NN O O
experiments NN O O
demonstrated NN O O
that NN O O
the NN O O
region NN O O
on NN O O
chromosome NN O O
12 NN O O
containing NN O O
the NN O O
PAH NN O O
gene NN O O
and NN O O
the NN O O
PKU NN O B-Disease
locus NN O O
in NN O O
man NN O O
is NN O O
12q22 NN O O
- NN O O
- NN O O
- NN O O
- NN O O
12q24 NN O O
. NN O O

1 NN O O
. NN O O

These NN O O
results NN O O
not NN O O
only NN O O
provide NN O O
a NN O O
regionalized NN O O
map NN O O
position NN O O
for NN O O
a NN O O
major NN O O
human NN O O
disease NN O O
locus NN O O
but NN O O
also NN O O
can NN O O
serve NN O O
as NN O O
a NN O O
reference NN O O
point NN O O
for NN O O
linkage NN O O
analysis NN O O
with NN O O
other NN O O
DNA NN O O
markers NN O O
on NN O O
human NN O O
chromosome NN O O
12 NN O O

Heterogeneity NN O O
of NN O O
type NN O B-Disease
I NN O I-Disease
von NN O I-Disease
Willebrand NN O I-Disease
disease NN O I-Disease
: NN O O
evidence NN O O
for NN O O
a NN O O
subgroup NN O O
with NN O O
an NN O O
abnormal NN O O
von NN O B-Disease
Willebrand NN O I-Disease
factor NN O O
. NN O O

Type NN O B-Disease
I NN O I-Disease
von NN O I-Disease
Willebrand NN O I-Disease
disease NN O I-Disease
( NN O O
vWD NN O B-Disease
) NN O O
is NN O O
characterized NN O O
by NN O O
equally NN O O
low NN O O
plasma NN O O
concentrations NN O O
of NN O O
von NN O B-Disease
Willebrand NN O I-Disease
factor NN O O
antigen NN O O
( NN O O
vWF NN O O
Ag NN O O
) NN O O
and NN O O
ristocetin NN O O
cofactor NN O O
( NN O O
RiCof NN O O
) NN O O
and NN O O
by NN O O
the NN O O
presence NN O O
of NN O O
all NN O O
vWF NN O O
multimers NN O O
in NN O O
sodium NN O O
dodecyl NN O O
sulfate NN O O
( NN O O
SDS NN O O
) NN O O
- NN O O
agarose NN O O
gel NN O O
electrophoresis NN O O
. NN O O

For NN O O
17 NN O O
patients NN O O
( NN O O
13 NN O O
kindreds NN O O
) NN O O
diagnosed NN O O
with NN O O
these NN O O
criteria NN O O
, NN O O
we NN O O
have NN O O
studied NN O O
the NN O O
platelet NN O O
contents NN O O
of NN O O
vWF NN O O
Ag NN O O
and NN O O
RiCof NN O O
and NN O O
the NN O O
changes NN O O
of NN O O
these NN O O
in NN O O
plasma NN O O
after NN O O
DDAVP NN O O
infusion NN O O
. NN O O

Platelet NN O O
vWF NN O O
Ag NN O O
and NN O O
RiCof NN O O
were NN O O
normal NN O O
in NN O O
four NN O O
kindreds NN O O
( NN O O
called NN O O
" NN O O
platelet NN O O
normal NN O O
" NN O O
subgroup NN O O
) NN O O
; NN O O
following NN O O
1 NN O O
- NN O O
deamino NN O O
- NN O O
8 NN O O
- NN O O
D NN O O
- NN O O
arginine NN O O
vasopressin NN O O
; NN O O
plasma NN O O
vWF NN O O
Ag NN O O
, NN O O
RiCof NN O O
and NN O O
the NN O O
bleeding NN O O
time NN O O
( NN O O
BT NN O O
) NN O O
became NN O O
normal NN O O
. NN O O

In NN O O
six NN O O
kindreds NN O O
, NN O O
platelet NN O O
vWF NN O O
Ag NN O O
and NN O O
RiCof NN O O
were NN O O
equally NN O O
low NN O O
( NN O O
platelet NN O O
low NN O O
) NN O O
; NN O O
after NN O O
DDAVP NN O O
, NN O O
plasma NN O O
vWF NN O O
Ag NN O O
and NN O O
RiCof NN O O
remained NN O O
low NN O O
, NN O O
and NN O O
the NN O O
BT NN O O
was NN O O
prolonged NN O O
. NN O O

In NN O O
three NN O O
additional NN O O
kindreds NN O O
, NN O O
platelets NN O O
contained NN O O
normal NN O O
concentrations NN O O
of NN O O
vWF NN O O
Ag NN O O
, NN O O
but NN O O
RiCof NN O O
was NN O O
very NN O O
low NN O O
( NN O O
platelet NN O O
discordant NN O O
) NN O O
; NN O O
even NN O O
though NN O O
a NN O O
complete NN O O
set NN O O
of NN O O
multimers NN O O
was NN O O
found NN O O
in NN O O
plasma NN O O
and NN O O
platelets NN O O
, NN O O
there NN O O
was NN O O
a NN O O
relatively NN O O
small NN O O
amount NN O O
of NN O O
large NN O O
multimers NN O O
. NN O O

After NN O O
DDAVP NN O O
, NN O O
plasma NN O O
vWF NN O O
Ag NN O O
became NN O O
normal NN O O
, NN O O
but NN O O
RiCof NN O O
remained NN O O
low NN O O
and NN O O
the NN O O
BT NN O O
was NN O O
very NN O O
prolonged NN O O
. NN O O

These NN O O
findings NN O O
demonstrated NN O O
that NN O O
there NN O O
can NN O O
be NN O O
an NN O O
abnormal NN O O
vWF NN O O
( NN O O
RiCof NN O O
less NN O O
than NN O O
vWF NN O O
Ag NN O O
) NN O O
even NN O O
in NN O O
type NN O B-Disease
I NN O I-Disease
vWD NN O I-Disease
, NN O O
coexisting NN O O
with NN O O
a NN O O
complete NN O O
set NN O O
of NN O O
vWF NN O O
multimers NN O O
( NN O O
platelet NN O O
discordant NN O O
) NN O O
; NN O O
that NN O O
the NN O O
abnormal NN O O
vWF NN O O
can NN O O
be NN O O
shown NN O O
more NN O O
clearly NN O O
in NN O O
platelets NN O O
than NN O O
in NN O O
plasma NN O O
or NN O O
else NN O O
in NN O O
plasma NN O O
after NN O O
DDAVP NN O O
infusion NN O O
; NN O O
and NN O O
that NN O O
DDAVP NN O O
normalizes NN O O
the NN O O
BT NN O O
only NN O O
in NN O O
those NN O O
patients NN O O
with NN O O
normal NN O O
platelet NN O O
levels NN O O
of NN O O
both NN O O
vWF NN O O
Ag NN O O
and NN O O
RiCof NN O O
( NN O O
platelet NN O O
normal NN O O
) NN O O
. NN O O
. NN O O

Genetic NN O O
analysis NN O O
in NN O O
families NN O O
with NN O O
van NN O B-Disease
der NN O I-Disease
Woude NN O I-Disease
syndrome NN O I-Disease
. NN O O

We NN O O
have NN O O
brought NN O O
together NN O O
information NN O O
on NN O O
864 NN O O
affected NN O O
individuals NN O O
in NN O O
164 NN O O
families NN O O
( NN O O
including NN O O
three NN O O
new NN O O
pedigrees NN O O
) NN O O
reported NN O O
in NN O O
the NN O O
137 NN O O
year NN O O
period NN O O
since NN O O
1845 NN O O
when NN O O
Demarquay NN O O
first NN O O
described NN O O
a NN O O
family NN O O
with NN O O
what NN O O
was NN O O
later NN O O
called NN O O
van NN O B-Disease
der NN O I-Disease
Woude NN O I-Disease
syndrome NN O I-Disease
( NN O O
VWS NN O B-Disease
) NN O O
. NN O O

Both NN O O
types NN O O
of NN O O
oral NN O B-Disease
cleft NN O I-Disease
, NN O O
cleft NN O B-Disease
palate NN O I-Disease
( NN O O
CP NN O B-Disease
) NN O O
and NN O O
cleft NN O B-Disease
lip NN O I-Disease
with NN O O
or NN O O
without NN O O
CP NN O B-Disease
( NN O O
CLP NN O B-Disease
) NN O O
, NN O O
segregate NN O O
in NN O O
these NN O O
families NN O O
together NN O O
with NN O O
lower NN O O
lip NN O B-Disease
pits NN O I-Disease
or NN O O
fistulae NN O B-Disease
in NN O O
an NN O O
autosomal NN O O
dominant NN O O
mode NN O O
with NN O O
high NN O O
penetrance NN O O
estimated NN O O
to NN O O
be NN O O
K NN O O
= NN O O
. NN O O

89 NN O O
and NN O O
. NN O O

99 NN O O
by NN O O
different NN O O
methods NN O O
. NN O O

Cleft NN O O
types NN O O
( NN O O
CLP NN O B-Disease
and NN O O
CP NN O B-Disease
) NN O O
occur NN O O
in NN O O
VWS NN O B-Disease
in NN O O
the NN O O
same NN O O
proportions NN O O
as NN O O
in NN O O
the NN O O
general NN O O
non NN O O
- NN O O
VWS NN O O
population NN O O
, NN O O
ie NN O O
, NN O O
about NN O O
twice NN O O
as NN O O
many NN O O
cleft NN O O
- NN O O
bearing NN O O
individuals NN O O
have NN O O
CLP NN O B-Disease
as NN O O
have NN O O
CP NN O B-Disease
. NN O O

On NN O O
the NN O O
other NN O O
hand NN O O
, NN O O
we NN O O
do NN O O
not NN O O
find NN O O
the NN O O
usually NN O O
observed NN O O
excess NN O O
of NN O O
females NN O O
with NN O O
CP NN O B-Disease
and NN O O
excess NN O O
of NN O O
males NN O O
with NN O O
CLP NN O B-Disease
; NN O O
in NN O O
VWS NN O B-Disease
the NN O O
sex NN O O
ratios NN O O
are NN O O
more NN O O
nearly NN O O
equal NN O O
. NN O O

Lip NN O B-Disease
pits NN O I-Disease
also NN O O
are NN O O
equally NN O O
distributed NN O O
between NN O O
the NN O O
sexes NN O O
. NN O O

Affected NN O O
males NN O O
and NN O O
females NN O O
are NN O O
equally NN O O
likely NN O O
to NN O O
transmit NN O O
VWS NN O B-Disease
. NN O O

However NN O O
, NN O O
there NN O O
is NN O O
an NN O O
excess NN O O
of NN O O
less NN O O
severely NN O O
affected NN O O
individuals NN O O
among NN O O
transmitters NN O O
and NN O O
a NN O O
deficiency NN O O
of NN O O
more NN O O
severely NN O O
affected NN O O
, NN O O
brought NN O O
about NN O O
by NN O O
a NN O O
proband NN O O
bias NN O O
and NN O O
differential NN O O
fecundity NN O O
. NN O O

The NN O O
expression NN O O
of NN O O
VWS NN O B-Disease
is NN O O
significantly NN O O
modified NN O O
by NN O O
the NN O O
genetic NN O O
background NN O O
More NN O O
extreme NN O O
phenotypes NN O O
in NN O O
parents NN O O
tend NN O O
to NN O O
produce NN O O
more NN O O
extreme NN O O
expression NN O O
in NN O O
their NN O O
children NN O O
. NN O O

For NN O O
a NN O O
VWS NN O B-Disease
gene NN O O
carrier NN O O
the NN O O
relative NN O O
risk NN O O
of NN O O
transmitting NN O O
a NN O O
cleft NN O O
is NN O O
26 NN O O
. NN O O

45 NN O O
% NN O O
; NN O O
that NN O O
of NN O O
transmitting NN O O
lower NN O O
lip NN O B-Disease
pits NN O I-Disease
is NN O O
23 NN O O
. NN O O

55 NN O O
% NN O O
. NN O O

Three NN O O
pedigrees NN O O
of NN O O
lip NN O B-Disease
pits NN O I-Disease
in NN O O
the NN O O
literature NN O O
show NN O O
no NN O O
clefts NN O O
among NN O O
a NN O O
significant NN O O
number NN O O
of NN O O
affected NN O O
individuals NN O O
. NN O O

Control NN O O
of NN O O
gene NN O O
expression NN O O
in NN O O
VWS NN O B-Disease
in NN O O
the NN O O
three NN O O
target NN O O
tissues NN O O
appears NN O O
to NN O O
be NN O O
independent NN O O
and NN O O
separately NN O O
designated NN O O
. NN O O

Mutation NN O O
rate NN O O
of NN O O
the NN O O
VWS NN O B-Disease
gene NN O O
is NN O O
calculated NN O O
to NN O O
be NN O O
1 NN O O
. NN O O

8 NN O O
X NN O O
10 NN O O
( NN O O
- NN O O
5 NN O O
) NN O O

Hereditary NN O B-Disease
C7 NN O I-Disease
deficiency NN O I-Disease
. NN O O

Diagnosis NN O O
and NN O O
HLA NN O O
studies NN O O
in NN O O
a NN O O
French NN O O
- NN O O
Canadian NN O O
family NN O O
. NN O O

The NN O O
serum NN O O
of NN O O
a NN O O
44 NN O O
- NN O O
yr NN O O
- NN O O
old NN O O
woman NN O O
of NN O O
French NN O O
- NN O O
Canadian NN O O
descent NN O O
having NN O O
a NN O O
B NN O O
- NN O O
27 NN O O
positive NN O O
ankylosing NN O B-Disease
spondylitis NN O I-Disease
was NN O O
deficient NN O B-Disease
in NN O I-Disease
the NN O I-Disease
seventh NN O I-Disease
component NN O I-Disease
of NN O I-Disease
complement NN O I-Disease
( NN O O
C7 NN O O
) NN O O
as NN O O
determined NN O O
by NN O O
hemolytic NN O O
and NN O O
immunochemical NN O O
methods NN O O
. NN O O

No NN O O
inhibitor NN O O
against NN O O
C7 NN O O
was NN O O
detected NN O O
, NN O O
and NN O O
the NN O O
levels NN O O
of NN O O
all NN O O
other NN O O
complement NN O O
components NN O O
were NN O O
normal NN O O
. NN O O

No NN O O
deficiency NN O O
in NN O O
the NN O O
opsonic NN O O
activity NN O O
of NN O O
the NN O O
serum NN O O
was NN O O
found NN O O
, NN O O
and NN O O
the NN O O
results NN O O
of NN O O
basic NN O O
coagulation NN O O
studies NN O O
of NN O O
the NN O O
plasma NN O O
were NN O O
normal NN O O
. NN O O

On NN O O
investigation NN O O
of NN O O
the NN O O
patients NN O O
family NN O O
, NN O O
two NN O O
sisters NN O O
were NN O O
found NN O O
to NN O O
have NN O O
the NN O O
same NN O O
deficiency NN O O
but NN O O
were NN O O
otherwise NN O O
in NN O O
good NN O O
health NN O O
. NN O O

The NN O O
seven NN O O
other NN O O
siblings NN O O
were NN O O
heterozygous NN O O
for NN O O
C7 NN O B-Disease
deficiency NN O I-Disease
, NN O O
while NN O O
the NN O O
paternal NN O O
aunt NN O O
had NN O O
a NN O O
normal NN O O
C7 NN O O
level NN O O
. NN O O

In NN O O
the NN O O
third NN O O
generation NN O O
, NN O O
six NN O O
children NN O O
of NN O O
the NN O O
three NN O O
homozygous NN O O
sisters NN O O
and NN O O
five NN O O
children NN O O
of NN O O
heterozygotes NN O O
were NN O O
available NN O O
for NN O O
testing NN O O
. NN O O

Studies NN O O
of NN O O
the NN O O
HLA NN O O
antigens NN O O
in NN O O
all NN O O
the NN O O
22 NN O O
subjects NN O O
and NN O O
in NN O O
three NN O O
spouses NN O O
indicated NN O O
no NN O O
close NN O O
linkage NN O O
between NN O O
the NN O O
CM NN O B-Disease
deficienty NN O I-Disease
and NN O O
the NN O O
HLA NN O O
system NN O O
. NN O O

In NN O O
addition NN O O
, NN O O
the NN O O
simultaneous NN O O
occurrence NN O O
of NN O O
two NN O O
hereditary NN O O
complement NN O B-Disease
deficiencies NN O I-Disease
( NN O I-Disease
C2 NN O I-Disease
and NN O I-Disease
C7 NN O I-Disease
) NN O I-Disease
was NN O O
discovered NN O O
in NN O O
one NN O O
family NN O O
of NN O O
this NN O O
remarkable NN O O
kindred NN O O
. NN O O
. NN O O

Genetic NN O O
defect NN O B-Disease
in NN O I-Disease
secretion NN O I-Disease
of NN O I-Disease
complement NN O I-Disease
C5 NN O I-Disease
in NN O O
mice NN O O
. NN O O

A NN O O
genetic NN O O
deficiency NN O B-Disease
of NN O I-Disease
the NN O I-Disease
fifth NN O I-Disease
( NN O I-Disease
C5 NN O I-Disease
) NN O I-Disease
component NN O I-Disease
of NN O I-Disease
complement1 NN O I-Disease
- NN O I-Disease
3 NN O I-Disease
, NN O O
a NN O O
serum NN O O
glycoprotein NN O O
of NN O O
molecular NN O O
weight NN O O
( NN O O
MW NN O O
) NN O O
220 NN O O
, NN O O
000 NN O O
( NN O O
ref NN O O
. NN O O
4 NN O O
) NN O O
, NN O O
has NN O O
been NN O O
found NN O O
in NN O O
39 NN O O
% NN O O
of NN O O
inbred NN O O
strains NN O O
of NN O O
mice3 NN O O
. NN O O

Sera NN O O
of NN O O
deficient NN O O
mice NN O O
lack NN O O
detectable NN O O
C5 NN O O
activity NN O O
and NN O O
protein2 NN O O
, NN O O
3 NN O O
. NN O O

In NN O O
addition NN O O
deficient NN O O
mice NN O O
produce NN O O
antibody NN O O
to NN O O
mouse NN O O
C5 NN O O
when NN O O
injected NN O O
with NN O O
sera NN O O
from NN O O
C5 NN O O
sufficient NN O O
( NN O O
normal NN O O
) NN O O
strains NN O O
. NN O O

Levy NN O O
et NN O O
al NN O O
. NN O O

5 NN O O
showed NN O O
that NN O O
somatic NN O O
cell NN O O
hybrids NN O O
between NN O O
C5 NN O O
deficient NN O O
( NN O O
B10 NN O O
. NN O O
D2 NN O O
/ NN O O
old NN O O
line NN O O
) NN O O
macrophages NN O O
and NN O O
either NN O O
C5 NN O O
sufficient NN O O
( NN O O
B10 NN O O
. NN O O
D2 NN O O
/ NN O O
new NN O O
line NN O O
) NN O O
mouse NN O O
kidney NN O O
or NN O O
chicken NN O O
erythroblasts NN O O
secreted NN O O
haemolytically NN O O
active NN O O
mouse NN O O
C5 NN O O
in NN O O
vitro NN O O
. NN O O

Several NN O O
possible NN O O
molecular NN O O
mechanisms NN O O
to NN O O
account NN O O
for NN O O
the NN O O
findings NN O O
were NN O O
considered NN O O
, NN O O
but NN O O
insufficient NN O O
direct NN O O
data NN O O
were NN O O
available NN O O
to NN O O
choose NN O O
among NN O O
them NN O O
. NN O O

We NN O O
recently NN O O
reported NN O O
that NN O O
mouse NN O O
( NN O O
CD NN O O
. NN O O
1 NN O O
strain NN O O
) NN O O
peritoneal NN O O
cells NN O O
in NN O O
culture NN O O
synthesise NN O O
and NN O O
secrete NN O O
a NN O O
single NN O O
chain NN O O
precursor NN O O
, NN O O
pro NN O O
- NN O O
C5 NN O O
( NN O O
MW NN O O
approximately NN O O
210 NN O O
, NN O O
000 NN O O
) NN O O
, NN O O
of NN O O
the NN O O
two NN O O
- NN O O
chain NN O O
( NN O O
alpha NN O O
chain NN O O
, NN O O
125 NN O O
, NN O O
000 NN O O
and NN O O
beta NN O O
chain NN O O
83 NN O O
, NN O O
000 NN O O
MW NN O O
) NN O O
C5 NN O O
protein6 NN O O
. NN O O

Radiolabelled NN O O
precursor NN O O
C5 NN O O
was NN O O
contained NN O O
within NN O O
the NN O O
cells NN O O
and NN O O
was NN O O
secreted NN O O
into NN O O
the NN O O
tissue NN O O
culture NN O O
media NN O O
. NN O O

Using NN O O
similar NN O O
methods NN O O
, NN O O
we NN O O
now NN O O
find NN O O
that NN O O
C5 NN O B-Disease
deficiency NN O I-Disease
in NN O O
each NN O O
of NN O O
five NN O O
different NN O O
mouse NN O O
strains NN O O
( NN O O
AKR NN O O
, NN O O
SWR NN O O
, NN O O
DBA NN O O
/ NN O O
2J8 NN O O
A NN O O
/ NN O O
HeJ NN O O
and NN O O
B10 NN O O
. NN O O
D2 NN O O
/ NN O O
old NN O O
line NN O O
) NN O O
is NN O O
due NN O O
to NN O O
a NN O O
failure NN O O
in NN O O
secretion NN O O
of NN O O
C5 NN O O
protein NN O O
and NN O O
not NN O O
to NN O O
a NN O O
failure NN O O
in NN O O
biosynthesis NN O O
of NN O O
pro NN O O
- NN O O
C5 NN O O

Recurrent NN O O
meningococcal NN O B-Disease
meningitis NN O I-Disease
with NN O O
absence NN O B-Disease
of NN O I-Disease
the NN O I-Disease
sixth NN O I-Disease
component NN O I-Disease
of NN O I-Disease
complement NN O I-Disease
: NN O O
an NN O O
evaluation NN O O
of NN O O
underlying NN O O
immunologic NN O O
mechanisms NN O O
. NN O O

A NN O O
51 NN O O
/ NN O O
2 NN O O
- NN O O
year NN O O
- NN O O
old NN O O
black NN O O
girl NN O O
with NN O O
recurrent NN O O
meningococcal NN O B-Disease
meningitis NN O I-Disease
and NN O O
absence NN O B-Disease
of NN O I-Disease
the NN O I-Disease
sixth NN O I-Disease
component NN O I-Disease
of NN O I-Disease
complement NN O I-Disease
( NN O O
C6 NN O O
) NN O O
is NN O O
reported NN O O
. NN O O

To NN O O
explore NN O O
the NN O O
pathogenesis NN O O
of NN O O
recurrent NN O O
neisserial NN O B-Disease
infections NN O I-Disease
in NN O O
C6 NN O B-Disease
deficiency NN O I-Disease
, NN O O
a NN O O
detailed NN O O
analysis NN O O
of NN O O
her NN O O
immune NN O O
competence NN O O
was NN O O
conducted NN O O
. NN O O

Her NN O O
serum NN O O
had NN O O
normal NN O O
chemotactic NN O O
, NN O O
opsonic NN O O
, NN O O
alternative NN O O
complement NN O O
pathway NN O O
, NN O O
and NN O O
specific NN O O
antibody NN O O
activity NN O O
, NN O O
but NN O O
lacked NN O O
complement NN O O
- NN O O
mediated NN O O
bacteriolytic NN O O
activity NN O O
. NN O O

In NN O O
addition NN O O
, NN O O
her NN O O
C6 NN O B-Disease
- NN O I-Disease
deficient NN O I-Disease
serum NN O O
was NN O O
indistinguishable NN O O
from NN O O
normal NN O O
serum NN O O
in NN O O
a NN O O
complement NN O O
- NN O O
dependent NN O O
assay NN O O
of NN O O
phagocyte NN O O
bactericidal NN O O
activity NN O O
. NN O O

Absent NN O O
bacteriolysis NN O O
remains NN O O
the NN O O
only NN O O
consistent NN O O
defect NN O O
associated NN O O
with NN O O
recurrent NN O O
neisserial NN O B-Disease
infections NN O I-Disease
and NN O O
absence NN O O
of NN O O
one NN O O
of NN O O
the NN O O
late NN O O
- NN O O
acting NN O O
complement NN O O
components NN O O
. NN O O
. NN O O

Deficiency NN O B-Disease
of NN O I-Disease
the NN O I-Disease
fifth NN O I-Disease
component NN O I-Disease
of NN O I-Disease
complement NN O I-Disease
in NN O O
human NN O O
subjects NN O O
. NN O O

Clinical NN O O
, NN O O
genetic NN O O
and NN O O
immunologic NN O O
studies NN O O
in NN O O
a NN O O
large NN O O
kindred NN O O
. NN O O

The NN O O
discovery NN O O
of NN O O
a NN O O
large NN O O
kindred NN O O
with NN O O
a NN O O
heritable NN O O
deficiency NN O B-Disease
of NN O I-Disease
the NN O I-Disease
fifth NN O I-Disease
component NN O I-Disease
of NN O I-Disease
complement NN O I-Disease
( NN O O
C5 NN O O
) NN O O
has NN O O
permitted NN O O
the NN O O
accumulation NN O O
of NN O O
new NN O O
clinical NN O O
, NN O O
genetic NN O O
and NN O O
immunologic NN O O
data NN O O
concerning NN O O
the NN O O
role NN O O
of NN O O
C5 NN O O
in NN O O
human NN O O
subjects NN O O
. NN O O

The NN O O
proband NN O O
, NN O O
who NN O O
has NN O O
had NN O O
nine NN O O
episodes NN O O
of NN O O
disseminated NN O O
gonococcal NN O B-Disease
infection NN O I-Disease
, NN O O
has NN O O
a NN O O
hemolytic NN O O
C5 NN O O
level NN O O
of NN O O
approximately NN O O
0 NN O O
. NN O O

5 NN O O
per NN O O
cent NN O O
of NN O O
normal NN O O
. NN O O

No NN O O
C5 NN O O
protein NN O O
was NN O O
detectable NN O O
, NN O O
but NN O O
low NN O O
levels NN O O
of NN O O
functional NN O O
C5 NN O O
activity NN O O
could NN O O
be NN O O
found NN O O
using NN O O
a NN O O
sensitive NN O O
bactericidal NN O O
assay NN O O
. NN O O

The NN O O
probands NN O O
twin NN O O
as NN O O
well NN O O
as NN O O
another NN O O
sister NN O O
also NN O O
had NN O O
extremely NN O O
low NN O O
levels NN O O
of NN O O
hemolytic NN O O
C5 NN O O
( NN O O
approximately NN O O
0 NN O O
. NN O O
5 NN O O
per NN O O
cent NN O O
normal NN O O
) NN O O
, NN O O
but NN O O
both NN O O
these NN O O
subjects NN O O
have NN O O
been NN O O
healthy NN O O
. NN O O

Hemolytic NN O O
complement NN O O
and NN O O
bacteriolytic NN O O
activity NN O O
could NN O O
be NN O O
restored NN O O
by NN O O
the NN O O
addition NN O O
of NN O O
purified NN O O
C5 NN O O
. NN O O

No NN O O
chemotactic NN O O
activity NN O O
for NN O O
polymorphonuclear NN O O
leukocytes NN O O
could NN O O
be NN O O
generated NN O O
in NN O O
the NN O O
C5 NN O B-Disease
- NN O I-Disease
deficient NN O I-Disease
serums NN O O
upon NN O O
activation NN O O
of NN O O
either NN O O
the NN O O
classic NN O O
or NN O O
alternative NN O O
pathways NN O O
, NN O O
again NN O O
demonstrating NN O O
the NN O O
importance NN O O
of NN O O
C5 NN O O
in NN O O
human NN O O
subjects NN O O
for NN O O
the NN O O
production NN O O
of NN O O
chemotactic NN O O
factors NN O O
. NN O O

The NN O O
chemotactic NN O O
responsiveness NN O O
of NN O O
the NN O O
patients NN O O
polymorphonuclear NN O O
leukocytes NN O O
and NN O O
monocytes NN O O
to NN O O
preformed NN O O
chemotactic NN O O
factors NN O O
was NN O O
not NN O O
depressed NN O O
. NN O O

Twenty NN O O
- NN O O
two NN O O
of NN O O
32 NN O O
other NN O O
family NN O O
members NN O O
from NN O O
three NN O O
generations NN O O
had NN O O
depressed NN O O
whole NN O O
hemolytic NN O O
complement NN O O
levels NN O O
. NN O O

In NN O O
19 NN O O
of NN O O
30 NN O O
family NN O O
members NN O O
, NN O O
levels NN O O
of NN O O
hemolytic NN O O
C5 NN O O
ranged NN O O
from NN O O
13 NN O O
to NN O O
64 NN O O
per NN O O
cent NN O O
of NN O O
normal NN O O
. NN O O

No NN O O
linkage NN O O
for NN O O
C5 NN O B-Disease
deficiency NN O I-Disease
and NN O O
the NN O O
A NN O O
or NN O O
B NN O O
loci NN O O
of NN O O
the NN O O
major NN O O
histocompatibility NN O O
complex NN O O
could NN O O
be NN O O
found NN O O
. NN O O

These NN O O
data NN O O
suggest NN O O
an NN O O
autosomal NN O O
codominant NN O O
mode NN O O
of NN O O
inheritance NN O O
of NN O O
C5 NN O B-Disease
deficiency NN O I-Disease
. NN O O

Deficiency NN O B-Disease
of NN O I-Disease
C5 NN O I-Disease
is NN O O
compatible NN O O
with NN O O
good NN O O
health NN O O
, NN O O
but NN O O
it NN O O
can NN O O
be NN O O
associated NN O O
with NN O O
repeated NN O O
disseminated NN O O
gonococcal NN O B-Disease
infection NN O I-Disease

Incidence NN O O
and NN O O
characteristics NN O O
of NN O O
glucose NN O O
- NN O O
6 NN O O
- NN O O
phosphate NN O O
dehydrogenase NN O O
variants NN O O
in NN O O
Japan NN O O
. NN O O

A NN O O
total NN O O
of NN O O
3000 NN O O
men NN O O
living NN O O
in NN O O
Yamaguchi NN O O
were NN O O
screened NN O O
for NN O O
glucose NN O B-Disease
- NN O I-Disease
6 NN O I-Disease
- NN O I-Disease
phosphate NN O I-Disease
dehydrogenase NN O I-Disease
( NN O I-Disease
G6PD NN O I-Disease
) NN O I-Disease
deficiency NN O I-Disease
using NN O O
Beutlers NN O O
spot NN O O
test NN O O
and NN O O
three NN O O
types NN O O
of NN O O
starch NN O O
gel NN O O
electrophoresis NN O O
. NN O O

These NN O O
electrophoresis NN O O
used NN O O
a NN O O
phosphate NN O O
buffer NN O O
system NN O O
at NN O O
pH NN O O
7 NN O O
. NN O O

0 NN O O
, NN O O
a NN O O
TRIS NN O O
- NN O O
EDTA NN O O
- NN O O
borate NN O O
buffer NN O O
system NN O O
at NN O O
pH NN O O
8 NN O O
. NN O O

6 NN O O
, NN O O
and NN O O
a NN O O
TRIS NN O O
- NN O O
hydrochloride NN O O
buffer NN O O
system NN O O
at NN O O
pH NN O O
8 NN O O
. NN O O
. NN O O

Fifteen NN O O
G6PD NN O B-Disease
- NN O I-Disease
deficient NN O I-Disease
variants NN O O
were NN O O
found NN O O
at NN O O
the NN O O
rate NN O O
of NN O O
0 NN O O
. NN O O

5 NN O O
% NN O O
and NN O O
classified NN O O
into NN O O
four NN O O
groups NN O O
. NN O O

As NN O O
new NN O O
variants NN O O
, NN O O
G6PD NN O O
Konan NN O O
, NN O O
Kamiube NN O O
, NN O O
and NN O O
Kiwa NN O O
were NN O O
identified NN O O
. NN O O

These NN O O
three NN O O
variants NN O O
had NN O O
a NN O O
mild NN O O
to NN O O
moderate NN O O
G6PD NN O B-Disease
deficiency NN O I-Disease
and NN O O
were NN O O
not NN O O
associated NN O O
with NN O O
any NN O O
clinical NN O O
signs NN O O
. NN O O

G6PD NN O O
Konan NN O O
had NN O O
fast NN O O
electrophoretic NN O O
mobility NN O O
as NN O O
compared NN O O
with NN O O
normal NN O O
levels NN O O
, NN O O
G6PD NN O O
Kiwa NN O O
had NN O O
slightly NN O O
elevated NN O O
electrophoretic NN O O
mobility NN O O
, NN O O
and NN O O
G6PD NN O O
Kamiube NN O O
had NN O O
normal NN O O
electrophoretic NN O O
mobility NN O O
. NN O O

These NN O O
three NN O O
variants NN O O
had NN O O
normal NN O O
levels NN O O
of NN O O
Km NN O O
G6P NN O O
, NN O O
Km NN O O
NADP NN O O
, NN O O
and NN O O
Ki NN O O
NADPH NN O O
, NN O O
normal NN O O
utilizations NN O O
of NN O O
both NN O O
2 NN O O
- NN O O
deoxy NN O O
- NN O O
G6P NN O O
and NN O O
deamino NN O O
- NN O O
NAPD NN O O
, NN O O
normal NN O O
heat NN O O
stability NN O O
, NN O O
and NN O O
a NN O O
normal NN O O
pH NN O O
curve NN O O
. NN O O

The NN O O
other NN O O
variant NN O O
was NN O O
G6PD NN O O
Ube NN O O
, NN O O
which NN O O
we NN O O
had NN O O
previously NN O O
found NN O O
in NN O O
Yamaguchi NN O O
( NN O O
Nakashima NN O O
et NN O O
al NN O O
. NN O O
, NN O O
1977 NN O O
) NN O O
. NN O O

One NN O O
boy NN O O
with NN O O
G6PD NN O O
Ube NN O O
was NN O O
Korean NN O O

Utilization NN O O
of NN O O
purines NN O O
by NN O O
an NN O O
HPRT NN O O
variant NN O O
in NN O O
an NN O O
intelligent NN O O
, NN O O
nonmutilative NN O O
patient NN O O
with NN O O
features NN O O
of NN O O
the NN O O
Lesch NN O B-Disease
- NN O I-Disease
Nyhan NN O I-Disease
syndrome NN O I-Disease
. NN O O

The NN O O
patient NN O O
, NN O O
H NN O O
. NN O O

Chr NN O O
. NN O O

B NN O O
. NN O O
, NN O O
was NN O O
among NN O O
the NN O O
first NN O O
reported NN O O
with NN O O
hyperuricemia NN O B-Disease
and NN O O
central NN O B-Disease
nervous NN O I-Disease
system NN O I-Disease
symptoms NN O I-Disease
. NN O O

He NN O O
has NN O O
been NN O O
found NN O O
to NN O O
have NN O O
a NN O O
variant NN O O
of NN O O
hypoxanthine NN O O
guanine NN O O
phosphoribosyl NN O O
transferase NN O O
( NN O O
HPRT NN O O
; NN O O
E NN O O
. NN O O
C NN O O
. NN O O
2 NN O O
. NN O O
4 NN O O
. NN O O
2 NN O O
. NN O O
8 NN O O
) NN O O
distinct NN O O
from NN O O
the NN O O
enzyme NN O O
present NN O O
in NN O O
patients NN O O
with NN O O
the NN O O
Lesch NN O B-Disease
- NN O I-Disease
Nyhan NN O I-Disease
syndrome NN O I-Disease
. NN O O

The NN O O
patient NN O O
had NN O O
chroeoathetosis NN O B-Disease
, NN O O
spasticity NN O B-Disease
, NN O O
dysarthric NN O B-Disease
speech NN O I-Disease
, NN O O
and NN O O
hyperuricemia NN O B-Disease
. NN O O

However NN O O
, NN O O
his NN O O
intelligence NN O O
was NN O O
normal NN O O
and NN O O
he NN O O
had NN O O
no NN O O
evidence NN O O
of NN O O
self NN O O
- NN O O
mutilation NN O O
. NN O O

There NN O O
was NN O O
no NN O O
activity NN O O
of NN O O
HPRT NN O O
in NN O O
the NN O O
lysates NN O O
of NN O O
erythrocytes NN O O
and NN O O
cultured NN O O
fibroblasts NN O O
when NN O O
analyzed NN O O
in NN O O
the NN O O
usual NN O O
manner NN O O
. NN O O

Using NN O O
a NN O O
newly NN O O
developed NN O O
method NN O O
for NN O O
the NN O O
study NN O O
of NN O O
purine NN O O
metabolism NN O O
in NN O O
intact NN O O
cultured NN O O
cells NN O O
, NN O O
this NN O O
patient NN O O
was NN O O
found NN O O
to NN O O
metabolize NN O O
some NN O O
9 NN O O
% NN O O
of NN O O
8 NN O O
- NN O O
14C NN O O
- NN O O
hypoxanthine NN O O
, NN O O
and NN O O
90 NN O O
% NN O O
of NN O O
the NN O O
isotope NN O O
utilized NN O O
was NN O O
converted NN O O
to NN O O
adenine NN O O
and NN O O
guanine NN O O
nucleotides NN O O
. NN O O

In NN O O
contrast NN O O
, NN O O
cells NN O O
from NN O O
patients NN O O
with NN O O
the NN O O
Lesch NN O B-Disease
- NN O I-Disease
Nyhan NN O I-Disease
syndrome NN O I-Disease
were NN O O
virtually NN O O
completely NN O O
unable NN O O
to NN O O
convert NN O O
hypoxanthine NN O O
to NN O O
nucleotides NN O O
. NN O O

The NN O O
patients NN O O
fibroblasts NN O O
were NN O O
even NN O O
more NN O O
efficient NN O O
in NN O O
the NN O O
metabolism NN O O
of NN O O
8 NN O O
- NN O O
14C NN O O
- NN O O
guanine NN O O
, NN O O
which NN O O
was NN O O
utilized NN O O
to NN O O
the NN O O
extent NN O O
of NN O O
27 NN O O
% NN O O
, NN O O
over NN O O
80 NN O O
% NN O O
of NN O O
which NN O O
was NN O O
converted NN O O
to NN O O
guanine NN O O
and NN O O
adenine NN O O
nucleotides NN O O
. NN O O

The NN O O
growth NN O O
of NN O O
the NN O O
cultured NN O O
fibroblasts NN O O
of NN O O
this NN O O
patient NN O O
was NN O O
intermediate NN O O
in NN O O
media NN O O
containing NN O O
hypoxanthine NN O O
aminopterin NN O O
thymidine NN O O
( NN O O
HAT NN O O
) NN O O
, NN O O
whereas NN O O
the NN O O
growth NN O O
of NN O O
Lesch NN O B-Disease
- NN O I-Disease
Nyhan NN O I-Disease
cells NN O O
was NN O O
inhibited NN O O
and NN O O
normal NN O O
cells NN O O
grew NN O O
normally NN O O
. NN O O

Similarly NN O O
in NN O O
8 NN O O
- NN O O
azaguanine NN O O
, NN O O
6 NN O O
- NN O O
thioguanine NN O O
, NN O O
and NN O O
8 NN O O
- NN O O
azahypoxanthine NN O O
, NN O O
the NN O O
growth NN O O
of NN O O
the NN O O
patients NN O O
cells NN O O
was NN O O
intermediate NN O O
between NN O O
normal NN O O
and NN O O
Lesch NN O B-Disease
- NN O I-Disease
Nyhan NN O I-Disease
cells NN O O
. NN O O

These NN O O
observations NN O O
provide NN O O
further NN O O
evidence NN O O
for NN O O
genetic NN O O
heterogeneity NN O O
among NN O O
patients NN O O
with NN O O
disorders NN O O
in NN O O
purine NN O O
metabolism NN O O
involving NN O O
the NN O O
HPRT NN O O
gene NN O O
. NN O O

They NN O O
document NN O O
that NN O O
this NN O O
famous NN O O
patient NN O O
did NN O O
not NN O O
have NN O O
the NN O O
Lesch NN O B-Disease
- NN O I-Disease
Nyhan NN O I-Disease
syndrome NN O I-Disease

Localisation NN O O
of NN O O
the NN O O
Becker NN O B-Disease
muscular NN O I-Disease
dystrophy NN O I-Disease
gene NN O O
on NN O O
the NN O O
short NN O O
arm NN O O
of NN O O
the NN O O
X NN O O
chromosome NN O O
by NN O O
linkage NN O O
to NN O O
cloned NN O O
DNA NN O O
sequences NN O O
. NN O O

A NN O O
linkage NN O O
study NN O O
in NN O O
30 NN O O
Becker NN O B-Disease
muscular NN O I-Disease
dystrophy NN O I-Disease
( NN O O
BMD NN O B-Disease
) NN O O
kindreds NN O O
using NN O O
three NN O O
cloned NN O O
DNA NN O O
sequences NN O O
from NN O O
the NN O O
X NN O O
chromosome NN O O
which NN O O
demonstrate NN O O
restriction NN O O
fragment NN O O
length NN O O
polymorphisms NN O O
( NN O O
RFLPs NN O O
) NN O O
, NN O O
suggests NN O O
that NN O O
the NN O O
BMD NN O B-Disease
gene NN O O
is NN O O
located NN O O
on NN O O
the NN O O
short NN O O
arm NN O O
of NN O O
the NN O O
X NN O O
chromosome NN O O
, NN O O
in NN O O
the NN O O
p21 NN O O
region NN O O
. NN O O

The NN O O
genes NN O O
for NN O O
Becker NN O B-Disease
and NN O I-Disease
Duchenne NN O I-Disease
dystrophies NN O I-Disease
must NN O O
therefore NN O O
be NN O O
closely NN O O
linked NN O O
, NN O O
if NN O O
not NN O O
allelic NN O O
, NN O O
and NN O O
any NN O O
future NN O O
DNA NN O O
probes NN O O
found NN O O
to NN O O
be NN O O
of NN O O
practical NN O O
use NN O O
in NN O O
one NN O O
disorder NN O O
should NN O O
be NN O O
equally NN O O
applicable NN O O
to NN O O
the NN O O
other NN O O
. NN O O

The NN O O
linkage NN O O
analysis NN O O
also NN O O
provides NN O O
data NN O O
on NN O O
the NN O O
frequency NN O O
of NN O O
recombination NN O O
along NN O O
the NN O O
short NN O O
arm NN O O
of NN O O
the NN O O
X NN O O
chromosome NN O O
, NN O O
and NN O O
across NN O O
the NN O O
centromeric NN O O
region NN O O
. NN O O
. NN O O

Molecular NN O O
evidence NN O O
for NN O O
new NN O O
mutation NN O O
at NN O O
the NN O O
hprt NN O O
locus NN O O
in NN O O
Lesch NN O B-Disease
- NN O I-Disease
Nyhan NN O I-Disease
patients NN O O
. NN O O

Hypoxanthine NN O O
- NN O O
guanine NN O O
phosphoribosyltransferase NN O O
( NN O O
HPRT NN O O
; NN O O
EC2 NN O O
. NN O O
4 NN O O
. NN O O
2 NN O O
. NN O O
8 NN O O
) NN O O
, NN O O
which NN O O
functions NN O O
in NN O O
the NN O O
metabolic NN O O
salvage NN O O
of NN O O
purines NN O O
, NN O O
is NN O O
encoded NN O O
by NN O O
an NN O O
X NN O O
- NN O O
linked NN O O
gene NN O O
in NN O O
man NN O O
. NN O O

Partial NN O O
HPRT NN O B-Disease
deficiencies NN O I-Disease
are NN O O
associated NN O O
with NN O O
gouty NN O B-Disease
arthritis NN O I-Disease
, NN O O
while NN O O
absence NN O O
of NN O O
activity NN O O
results NN O O
in NN O O
Lesch NN O B-Disease
- NN O I-Disease
Nyhan NN O I-Disease
syndrome NN O I-Disease
( NN O O
L NN O B-Disease
- NN O I-Disease
N NN O I-Disease
) NN O O
. NN O O

L NN O B-Disease
- NN O I-Disease
N NN O I-Disease
patients NN O O
fail NN O O
to NN O O
reproduce NN O O
and NN O O
the NN O O
heterozygous NN O O
state NN O O
appears NN O O
to NN O O
confer NN O O
no NN O O
selective NN O O
advantage NN O O
. NN O O

Thus NN O O
, NN O O
Haldanes NN O O
principle NN O O
predicts NN O O
that NN O O
new NN O O
mutations NN O O
at NN O O
the NN O O
hprt NN O O
locus NN O O
must NN O O
occur NN O O
frequently NN O O
in NN O O
order NN O O
for NN O O
L NN O B-Disease
- NN O I-Disease
N NN O I-Disease
syndrome NN O I-Disease
to NN O O
be NN O O
maintained NN O O
in NN O O
the NN O O
population NN O O
. NN O O

This NN O O
constant NN O O
introduction NN O O
of NN O O
new NN O O
mutations NN O O
would NN O O
be NN O O
expected NN O O
to NN O O
result NN O O
in NN O O
a NN O O
heterogeneous NN O O
collection NN O O
of NN O O
genetic NN O B-Disease
lesions NN O I-Disease
, NN O O
some NN O O
of NN O O
which NN O O
may NN O O
be NN O O
novel NN O O
. NN O O

As NN O O
we NN O O
report NN O O
here NN O O
, NN O O
the NN O O
mutations NN O O
in NN O O
the NN O O
hprt NN O O
gene NN O O
of NN O O
seven NN O O
L NN O B-Disease
- NN O I-Disease
N NN O I-Disease
patients NN O O
, NN O O
selected NN O O
from NN O O
an NN O O
initial NN O O
survey NN O O
of NN O O
28 NN O O
patients NN O O
, NN O O
have NN O O
been NN O O
characterized NN O O
and NN O O
all NN O O
were NN O O
found NN O O
to NN O O
be NN O O
distinctly NN O O
different NN O O
, NN O O
as NN O O
predicted NN O O
. NN O O

The NN O O
origin NN O O
of NN O O
one NN O O
unusual NN O O
mutation NN O O
has NN O O
been NN O O
identified NN O O
by NN O O
analysis NN O O
of NN O O
DNA NN O O
from NN O O
four NN O O
generations NN O O
of NN O O
family NN O O
members NN O O
. NN O O

Further NN O O
molecular NN O O
analysis NN O O
of NN O O
the NN O O
origin NN O O
of NN O O
new NN O O
mutations NN O O
at NN O O
the NN O O
hprt NN O O
locus NN O O
should NN O O
aid NN O O
in NN O O
resolving NN O O
the NN O O
issue NN O O
of NN O O
an NN O O
apparent NN O O
difference NN O O
in NN O O
the NN O O
frequency NN O O
of NN O O
hprt NN O O
mutations NN O O
in NN O O
males NN O O
and NN O O
females NN O O

Allelic NN O O
exclusion NN O O
of NN O O
glucose NN O O
- NN O O
6 NN O O
- NN O O
phosphate NN O O
dehydrogenase NN O O
in NN O O
platelets NN O O
and NN O O
T NN O O
lymphocytes NN O O
from NN O O
a NN O O
Wiskott NN O B-Disease
- NN O I-Disease
Aldrich NN O I-Disease
syndrome NN O I-Disease
carrier NN O O
. NN O O

An NN O O
obligate NN O O
carrier NN O O
of NN O O
the NN O O
Wiskott NN O B-Disease
- NN O I-Disease
Aldrich NN O I-Disease
syndrome NN O I-Disease
( NN O O
WAS NN O B-Disease
) NN O O
who NN O O
was NN O O
also NN O O
heterozygous NN O O
for NN O O
the NN O O
A NN O O
and NN O O
B NN O O
types NN O O
of NN O O
X NN O O
- NN O O
linked NN O O
glucose NN O O
- NN O O
6 NN O O
- NN O O
phosphate NN O O
dehydrogenase NN O O
was NN O O
found NN O O
. NN O O

With NN O O
her NN O O
it NN O O
became NN O O
possible NN O O
to NN O O
determine NN O O
whether NN O O
allelic NN O O
exclusion NN O O
occurs NN O O
in NN O O
particular NN O O
cell NN O O
- NN O O
types NN O O
of NN O O
the NN O O
WAS NN O B-Disease
carrier NN O O
. NN O O

If NN O O
so NN O O
, NN O O
the NN O O
remaining NN O O
cells NN O O
of NN O O
a NN O O
particular NN O O
cell NN O O
- NN O O
type NN O O
would NN O O
express NN O O
only NN O O
the NN O O
normal NN O O
X NN O O
chromosome NN O O
and NN O O
only NN O O
one NN O O
glucose NN O O
- NN O O
6 NN O O
- NN O O
phosphate NN O O
dehydrogenase NN O O
isoenzyme NN O O
would NN O O
be NN O O
demonstrable NN O O
. NN O O

This NN O O
carrier NN O O
had NN O O
only NN O O
the NN O O
B NN O O
isoenzyme NN O O
of NN O O
glucose NN O O
- NN O O
6 NN O O
- NN O O
phosphate NN O O
dehydrogenase NN O O
in NN O O
platelets NN O O
and NN O O
thymus NN O O
- NN O O
derived NN O O
T NN O O
lymphocytes NN O O
, NN O O
although NN O O
both NN O O
isoenzymes NN O O
A NN O O
and NN O O
B NN O O
were NN O O
present NN O O
in NN O O
erythrocytes NN O O
and NN O O
neutrophils NN O O
. NN O O

These NN O O
findings NN O O
suggest NN O O
that NN O O
selection NN O O
against NN O O
the NN O O
WAS NN O B-Disease
gene NN O O
occurs NN O O
in NN O O
platelets NN O O
and NN O O
thymus NN O O
- NN O O
derived NN O O
T NN O O
lymphocytes NN O O
and NN O O
that NN O O
the NN O O
defects NN O O
associated NN O O
with NN O O
WAS NN O B-Disease
expressed NN O O
in NN O O
these NN O O
cell NN O O
- NN O O
types NN O O
may NN O O
be NN O O
implicated NN O O
in NN O O
the NN O O
genesis NN O O
of NN O O
the NN O O
Wiskott NN O B-Disease
- NN O I-Disease
Aldrich NN O I-Disease
syndrome NN O I-Disease
. NN O O
. NN O O

Complement NN O B-Disease
deficiency NN O I-Disease
and NN O O
nephritis NN O B-Disease
. NN O O

A NN O O
report NN O O
of NN O O
a NN O O
family NN O O
. NN O O

A NN O O
family NN O O
is NN O O
described NN O O
in NN O O
which NN O O
three NN O O
children NN O O
had NN O O
homozygous NN O O
deficiency NN O B-Disease
of NN O I-Disease
C3 NN O I-Disease
and NN O O
in NN O O
which NN O O
both NN O O
parents NN O O
and NN O O
two NN O O
other NN O O
children NN O O
were NN O O
heterozygous NN O O
for NN O O
the NN O O
C3 NN O O
null NN O O
gene NN O O
. NN O O

One NN O O
child NN O O
with NN O O
heterozygous NN O O
C3 NN O B-Disease
deficiency NN O I-Disease
was NN O O
found NN O O
to NN O O
have NN O O
membranoproliferative NN O O
glomerulonephritis NN O B-Disease
; NN O O
proteinuria NN O B-Disease
and NN O O
/ NN O O
or NN O O
microscopical NN O O
haematuria NN O B-Disease
was NN O O
present NN O O
in NN O O
all NN O O
three NN O O
homozygous NN O O
C3 NN O B-Disease
- NN O I-Disease
deficient NN O I-Disease
children NN O O
. NN O O

All NN O O
children NN O O
with NN O O
homozygous NN O O
or NN O O
heterozygous NN O O
C3 NN O B-Disease
deficiency NN O I-Disease
were NN O O
, NN O O
to NN O O
a NN O O
varying NN O O
degree NN O O
, NN O O
susceptible NN O O
to NN O O
infection NN O O
. NN O O

The NN O O
only NN O O
child NN O O
of NN O O
the NN O O
family NN O O
with NN O O
normal NN O O
complement NN O O
had NN O O
no NN O O
increased NN O O
risk NN O O
of NN O O
infection NN O O
and NN O O
no NN O O
renal NN O B-Disease
disease NN O I-Disease
. NN O O

This NN O O
family NN O O
study NN O O
provides NN O O
further NN O O
support NN O O
for NN O O
the NN O O
proposal NN O O
that NN O O
C3 NN O B-Disease
deficiency NN O I-Disease
predisposes NN O O
to NN O O
nephritis NN O B-Disease
. NN O O
. NN O O

Heterogeneity NN O O
of NN O O
glucose NN O B-Disease
- NN O I-Disease
6 NN O I-Disease
- NN O I-Disease
phosphate NN O I-Disease
dehydrogenase NN O I-Disease
deficiency NN O I-Disease
in NN O O
Algeria NN O O
. NN O O

Study NN O O
in NN O O
Northern NN O O
Algeria NN O O
with NN O O
description NN O O
of NN O O
five NN O O
new NN O O
variants NN O O
. NN O O

Glucose NN O B-Disease
- NN O I-Disease
6 NN O I-Disease
- NN O I-Disease
phosphate NN O I-Disease
dehydrogenase NN O I-Disease
( NN O I-Disease
G6PD NN O I-Disease
) NN O I-Disease
deficiency NN O I-Disease
was NN O O
found NN O O
in NN O O
3 NN O O
. NN O O

2 NN O O
% NN O O
of NN O O
the NN O O
male NN O O
population NN O O
living NN O O
in NN O O
the NN O O
urban NN O O
area NN O O
of NN O O
Algiers NN O O
. NN O O

The NN O O
deficient NN O O
subjects NN O O
originated NN O O
from NN O O
multiple NN O O
geographic NN O O
regions NN O O
of NN O O
Northern NN O O
Algeria NN O O
, NN O O
with NN O O
prevalence NN O O
of NN O O
individuals NN O O
of NN O O
Berber NN O O
- NN O O
Kabyle NN O O
origin NN O O
. NN O O

Red NN O O
blood NN O O
cell NN O O
G6PD NN O O
was NN O O
partially NN O O
purified NN O O
and NN O O
characterized NN O O
in NN O O
deficient NN O O
males NN O O
from NN O O
17 NN O O
families NN O O
, NN O O
and NN O O
six NN O O
different NN O O
variants NN O O
were NN O O
found NN O O
. NN O O

Among NN O O
them NN O O
, NN O O
only NN O O
one NN O O
, NN O O
the NN O O
Gd NN O O
( NN O O
- NN O O
) NN O O
Kabyle NN O O
variant NN O O
, NN O O
had NN O O
been NN O O
previously NN O O
described NN O O
. NN O O

It NN O O
was NN O O
detected NN O O
in NN O O
nine NN O O
families NN O O
. NN O O

The NN O O
other NN O O
five NN O O
variants NN O O
were NN O O
new NN O O
Gd NN O O
( NN O O
- NN O O
) NN O O
Laghouat NN O O
( NN O O
four NN O O
cases NN O O
) NN O O
, NN O O
Gd NN O O
( NN O O
- NN O O
) NN O O
Blida NN O O
( NN O O
one NN O O
case NN O O
) NN O O
, NN O O
Gd NN O O
( NN O O
- NN O O
) NN O O
Thenia NN O O
( NN O O
one NN O O
case NN O O
) NN O O
, NN O O
Gd NN O O
( NN O O
- NN O O
) NN O O
Titteri NN O O
( NN O O
one NN O O
case NN O O
) NN O O
, NN O O
and NN O O
Gd NN O O
( NN O O
- NN O O
) NN O O
Alger NN O O
( NN O O
two NN O O
brothers NN O O
) NN O O
. NN O O

Strikingly NN O O
, NN O O
the NN O O
common NN O O
Mediterranean NN O O
variant NN O O
was NN O O
not NN O O
found NN O O
. NN O O

G6PD NN O B-Disease
deficiency NN O I-Disease
is NN O O
heterogeneous NN O O
in NN O O
northern NN O O
Algeria NN O O
where NN O O
autochtonous NN O O
variants NN O O
seem NN O O
to NN O O
prevail NN O O
. NN O O

The NN O O
Kabyle NN O O
variant NN O O
may NN O O
be NN O O
common NN O O
in NN O O
this NN O O
country NN O O
. NN O O

Glucose NN O B-Disease
- NN O I-Disease
6 NN O I-Disease
- NN O I-Disease
phosphate NN O I-Disease
dehydrogenase NN O I-Disease
deficiency NN O I-Disease
inhibits NN O O
in NN O O
vitro NN O O
growth NN O O
of NN O O
Plasmodium NN O O
falciparum NN O O
. NN O O

Glucose NN O B-Disease
- NN O I-Disease
6 NN O I-Disease
- NN O I-Disease
phosphate NN O I-Disease
dehydrogenase NN O I-Disease
( NN O I-Disease
G6PD NN O I-Disease
; NN O I-Disease
EC NN O I-Disease
1 NN O I-Disease
. NN O I-Disease
1 NN O I-Disease
. NN O I-Disease
1 NN O I-Disease
. NN O I-Disease
49 NN O I-Disease
) NN O I-Disease
- NN O I-Disease
deficient NN O I-Disease
red NN O O
blood NN O O
cells NN O O
from NN O O
male NN O O
hemizygotes NN O O
and NN O O
female NN O O
heterozygotes NN O O
from NN O O
the NN O O
island NN O O
of NN O O
Sardinia NN O O
were NN O O
studied NN O O
for NN O O
their NN O O
ability NN O O
to NN O O
support NN O O
growth NN O O
in NN O O
vitro NN O O
of NN O O
the NN O O
malaria NN O B-Disease
- NN O O
causing NN O O
organism NN O O
Plasmodium NN O O
falciparum NN O O
. NN O O

Parasite NN O O
growth NN O O
was NN O O
approximately NN O O
one NN O O
- NN O O
third NN O O
of NN O O
normal NN O O
in NN O O
both NN O O
hemi NN O O
- NN O O
and NN O O
heterozygotes NN O O
for NN O O
G6PD NN O B-Disease
deficiency NN O I-Disease
. NN O O

In NN O O
Sardinians NN O O
with NN O O
the NN O O
beta NN O O
0 NN O O
- NN O O
thalassemia NN O O
trait NN O O
, NN O O
parasite NN O O
growth NN O O
was NN O O
normal NN O O
except NN O O
when NN O O
G6PD NN O B-Disease
deficiency NN O I-Disease
occurred NN O O
together NN O O
with NN O O
the NN O O
thalassemia NN O B-Disease
trait NN O O
. NN O O

The NN O O
data NN O O
support NN O O
the NN O O
hypothesis NN O O
that NN O O
G6PD NN O B-Disease
deficiency NN O I-Disease
may NN O O
confer NN O O
a NN O O
selective NN O O
advantage NN O O
in NN O O
a NN O O
malarious NN O B-Disease
area NN O O
; NN O O
the NN O O
female NN O O
heterozygote NN O O
may NN O O
be NN O O
at NN O O
a NN O O
particular NN O O
advantage NN O O
because NN O O
resistance NN O O
to NN O O
malaria NN O B-Disease
equals NN O O
that NN O O
of NN O O
male NN O O
hemizygotes NN O O
, NN O O
but NN O O
the NN O O
risk NN O O
of NN O O
fatal NN O B-Disease
hemolysis NN O I-Disease
may NN O O
be NN O O
less NN O O
. NN O O

However NN O O
, NN O O
more NN O O
female NN O O
heterozygotes NN O O
must NN O O
be NN O O
studied NN O O
to NN O O
confirm NN O O
this NN O O
hypothesis NN O O
. NN O O

No NN O O
protective NN O O
effect NN O O
of NN O O
beta NN O O
0 NN O O
- NN O O
thalassemia NN O O
trait NN O O
could NN O O
be NN O O
demonstrated NN O O
in NN O O
vitro NN O O
. NN O O

Bone NN O O
marrow NN O O
transplant NN O O
in NN O O
adrenoleukodystrophy NN O B-Disease
. NN O O

An NN O O
allogeneic NN O O
bone NN O O
marrow NN O O
transplant NN O O
( NN O O
BMT NN O O
) NN O O
from NN O O
a NN O O
normal NN O O
HLA NN O O
identical NN O O
sibling NN O O
donor NN O O
was NN O O
performed NN O O
in NN O O
a NN O O
13 NN O O
- NN O O
year NN O O
- NN O O
old NN O O
boy NN O O
with NN O O
rapidly NN O O
progressive NN O O
adrenoleukodystrophy NN O B-Disease
( NN O O
ALD NN O B-Disease
) NN O O
. NN O O

Engraftment NN O O
and NN O O
complete NN O O
hematologic NN O O
recovery NN O O
occurred NN O O
within NN O O
4 NN O O
weeks NN O O
, NN O O
but NN O O
neurologic NN O B-Disease
deterioration NN O I-Disease
continued NN O O
. NN O O

The NN O O
patient NN O O
died NN O O
of NN O O
an NN O O
adenovirus NN O B-Disease
infection NN O I-Disease
141 NN O O
days NN O O
after NN O O
BMT NN O O
. NN O O

ALD NN O B-Disease
is NN O O
characterized NN O O
by NN O O
abnormally NN O O
high NN O O
plasma NN O O
levels NN O O
of NN O O
very NN O O
long NN O O
chain NN O O
fatty NN O O
acids NN O O
( NN O O
VLCFA NN O O
) NN O O
as NN O O
a NN O O
result NN O O
of NN O O
impaired NN O O
capacity NN O O
to NN O O
degrade NN O O
them NN O O
. NN O O

Ten NN O O
days NN O O
after NN O O
BMT NN O O
, NN O O
the NN O O
white NN O O
blood NN O O
cell NN O O
VLCFA NN O O
levels NN O O
and NN O O
enzyme NN O O
activity NN O O
became NN O O
normal NN O O
; NN O O
after NN O O
3 NN O O
months NN O O
, NN O O
there NN O O
was NN O O
progressive NN O O
reduction NN O O
of NN O O
plasma NN O O
VLCFA NN O O
to NN O O
levels NN O O
only NN O O
slightly NN O O
above NN O O
normal NN O O
. NN O O
. NN O O

[ NN O O
Gd NN O O
- NN O O
allele NN O O
distribution NN O O
patterns NN O O
in NN O O
Azerbaijan NN O O
. NN O O
III NN O O
. NN O O
The NN O O
identification NN O O
of NN O O
mutant NN O O
forms NN O O
of NN O O
glucose NN O O
- NN O O
6 NN O O
- NN O O
phosphate NN O O
dehydrogenase NN O O
] NN O O

In NN O O
28 NN O O
families NN O O
with NN O O
G6PD NN O B-Disease
deficiency NN O I-Disease
living NN O O
in NN O O
3 NN O O
settlements NN O O
of NN O O
Shekii NN O O
district NN O O
of NN O O
Azerbaijan NN O O
11 NN O O
G6PD NN O O
variants NN O O
of NN O O
II NN O O
and NN O O
III NN O O
classes NN O O
differing NN O O
by NN O O
kinetic NN O O
properties NN O O
were NN O O
identified NN O O
according NN O O
WHO NN O O
program NN O O
. NN O O

9 NN O O
of NN O O
them NN O O
are NN O O
characterized NN O O
with NN O O
the NN O O
same NN O O
electrophoretic NN O O
mobility NN O O
. NN O O

Comparison NN O O
of NN O O
G6PD NN O O
spectra NN O O
in NN O O
two NN O O
subpopulations NN O O
and NN O O
in NN O O
a NN O O
mixed NN O O
group NN O O
permits NN O O
to NN O O
make NN O O
a NN O O
conclusion NN O O
about NN O O
existence NN O O
of NN O O
common NN O O
and NN O O
rare NN O O
G6PD NN O O
alleles NN O O
in NN O O
examined NN O O
population NN O O
. NN O O

They NN O O
distribute NN O O
by NN O O
gene NN O O
drift NN O O
supported NN O O
by NN O O
natural NN O O
selection NN O O
. NN O O

Among NN O O
7 NN O O
samples NN O O
of NN O O
G6PD NN O O
with NN O O
normal NN O O
and NN O O
increased NN O O
activity NN O O
two NN O O
new NN O O
variants NN O O
of NN O O
IV NN O O
class NN O O
- NN O O
- NN O O
Nukha NN O O
and NN O O
Bash NN O O
- NN O O
Kungut NN O O
- NN O O
- NN O O
were NN O O
found NN O O
. NN O O
. NN O O

Adrenoleukodystrophy NN O B-Disease
: NN O O
survey NN O O
of NN O O
303 NN O O
cases NN O O
: NN O O
biochemistry NN O O
, NN O O
diagnosis NN O O
, NN O O
and NN O O
therapy NN O O
. NN O O

Adrenoleukodystrophy NN O B-Disease
( NN O O
ALD NN O B-Disease
) NN O O
is NN O O
a NN O O
genetically NN O O
determined NN O O
disorder NN O O
associated NN O O
with NN O O
progressive NN O B-Disease
central NN O I-Disease
demyelination NN O I-Disease
and NN O O
adrenal NN O B-Disease
cortical NN O I-Disease
insufficiency NN O I-Disease
. NN O O

All NN O O
affected NN O O
persons NN O O
show NN O O
increased NN O O
levels NN O O
of NN O O
saturated NN O O
unbranched NN O O
very NN O O
- NN O O
long NN O O
- NN O O
chain NN O O
fatty NN O O
acids NN O O
, NN O O
particularly NN O O
hexacosanoate NN O O
( NN O O
C26 NN O O
0 NN O O
) NN O O
, NN O O
because NN O O
of NN O O
impaired NN O O
capacity NN O O
to NN O O
degrade NN O O
these NN O O
acids NN O O
. NN O O

This NN O O
degradation NN O O
normally NN O O
takes NN O O
place NN O O
in NN O O
a NN O O
subcellular NN O O
organelle NN O O
called NN O O
the NN O O
peroxisome NN O O
, NN O O
and NN O O
ALD NN O B-Disease
, NN O O
together NN O O
with NN O O
Zellwegers NN O B-Disease
cerebrohepatorenal NN O I-Disease
syndrome NN O I-Disease
, NN O O
is NN O O
now NN O O
considered NN O O
to NN O O
belong NN O O
to NN O O
the NN O O
newly NN O O
formed NN O O
category NN O O
of NN O O
peroxisomal NN O B-Disease
disorders NN O I-Disease
. NN O O

Biochemical NN O O
assays NN O O
permit NN O O
prenatal NN O O
diagnosis NN O O
, NN O O
as NN O O
well NN O O
as NN O O
identification NN O O
of NN O O
most NN O O
heterozygotes NN O O
. NN O O

We NN O O
have NN O O
identified NN O O
303 NN O O
patients NN O O
with NN O O
ALD NN O B-Disease
in NN O O
217 NN O O
kindreds NN O O
. NN O O

These NN O O
patients NN O O
show NN O O
a NN O O
wide NN O O
phenotypic NN O O
variation NN O O
. NN O O

Sixty NN O O
percent NN O O
of NN O O
patients NN O O
had NN O O
childhood NN O O
ALD NN O B-Disease
and NN O O
17 NN O O
% NN O O
adrenomyeloneuropathy NN O B-Disease
, NN O O
both NN O O
of NN O O
which NN O O
are NN O O
X NN O O
- NN O O
linked NN O O
, NN O O
with NN O O
the NN O O
gene NN O O
mapped NN O O
to NN O O
Xq28 NN O O
. NN O O

Neonatal NN O B-Disease
ALD NN O I-Disease
, NN O O
a NN O O
distinct NN O O
entity NN O O
with NN O O
autosomal NN O O
recessive NN O O
inheritance NN O O
and NN O O
points NN O O
of NN O O
resemblance NN O O
to NN O O
Zellwegers NN O B-Disease
syndrome NN O I-Disease
, NN O O
accounted NN O O
for NN O O
7 NN O O
% NN O O
of NN O O
the NN O O
cases NN O O
. NN O O

Although NN O O
excess NN O O
C26 NN O O
0 NN O O
in NN O O
the NN O O
brain NN O O
of NN O O
patients NN O O
with NN O O
ALD NN O B-Disease
is NN O O
partially NN O O
of NN O O
dietary NN O O
origin NN O O
, NN O O
dietary NN O O
C26 NN O O
0 NN O O
restriction NN O O
did NN O O
not NN O O
produce NN O O
clear NN O O
benefit NN O O
. NN O O

Bone NN O O
marrow NN O O
transplant NN O O
lowered NN O O
the NN O O
plasma NN O O
C26 NN O O
0 NN O O
level NN O O
but NN O O
failed NN O O
to NN O O
arrest NN O O
neurological NN O O
progression NN O O
. NN O O
. NN O O

Genetic NN O O
polymorphism NN O O
of NN O O
G6PD NN O O
in NN O O
a NN O O
Bulgarian NN O O
population NN O O
. NN O O

Considerable NN O O
genetic NN O O
heterogeneity NN O O
in NN O O
G6PD NN O O
was NN O O
found NN O O
in NN O O
the NN O O
Bulgarian NN O O
population NN O O
- NN O O
14 NN O O
G6PD NN O O
variants NN O O
isolated NN O O
from NN O O
117 NN O O
hemizygous NN O O
carriers NN O O
of NN O O
G6PD NN O B-Disease
deficiency NN O I-Disease
. NN O O

Of NN O O
these NN O O
, NN O O
G6PD NN O O
Mediterranean NN O O
type NN O O
was NN O O
a NN O O
polymorphic NN O O
variant NN O O
and NN O O
G6PD NN O O
Corinth NN O O
occurred NN O O
with NN O O
high NN O O
frequency NN O O
. NN O O

Two NN O O
new NN O O
variants NN O O
were NN O O
identified NN O O
- NN O O
G6PD NN O O
Rudosem NN O O
and NN O O
G6PD NN O O
Nedelino NN O O
. NN O O

In NN O O
a NN O O
selected NN O O
group NN O O
of NN O O
78 NN O O
subjects NN O O
with NN O O
clinical NN O O
manifestations NN O O
, NN O O
four NN O O
variants NN O O
were NN O O
established NN O O
G6PD NN O O
Mediterranian NN O O
, NN O O
G6PD NN O O
Corinth NN O O
, NN O O
G6PD NN O O
Seattle NN O O
and NN O O
G6PD NN O O
Ohut NN O O
II NN O O
. NN O O
. NN O O

Clinical NN O O
use NN O O
of NN O O
DNA NN O O
markers NN O O
linked NN O O
to NN O O
the NN O O
gene NN O O
for NN O O
Duchenne NN O B-Disease
muscular NN O I-Disease
dystrophy NN O I-Disease
. NN O O

Seventy NN O O
families NN O O
with NN O O
Duchenne NN O B-Disease
muscular NN O I-Disease
dystrophy NN O I-Disease
( NN O O
DMD NN O B-Disease
) NN O O
known NN O O
to NN O O
the NN O O
Institute NN O O
of NN O O
Child NN O O
Health NN O O
fall NN O O
into NN O O
three NN O O
categories NN O O
with NN O O
respect NN O O
to NN O O
potential NN O O
linkage NN O O
analysis NN O O
with NN O O
the NN O O
X NN O O
chromosome NN O O
DNA NN O O
markers NN O O
RC8 NN O O
and NN O O
L1 NN O O
. NN O O

28 NN O O
that NN O O
bridge NN O O
the NN O O
DMD NN O B-Disease
gene NN O O
. NN O O

Families NN O O
in NN O O
which NN O O
there NN O O
is NN O O
at NN O O
least NN O O
one NN O O
obligatory NN O O
female NN O O
heterozygote NN O O
( NN O O
n NN O O
= NN O O
13 NN O O
) NN O O
. NN O O

Here NN O O
prediction NN O O
and NN O O
exclusion NN O O
of NN O O
DMD NN O B-Disease
gene NN O O
transmission NN O O
may NN O O
be NN O O
possible NN O O
, NN O O
the NN O O
accuracy NN O O
being NN O O
dependent NN O O
on NN O O
the NN O O
closeness NN O O
of NN O O
the NN O O
linkage NN O O
of NN O O
the NN O O
DNA NN O O
marker NN O O
( NN O O
s NN O O
) NN O O
to NN O O
the NN O O
DMD NN O B-Disease
gene NN O O
; NN O O
an NN O O
illustrative NN O O
case NN O O
is NN O O
reported NN O O
. NN O O

Families NN O O
in NN O O
which NN O O
there NN O O
is NN O O
a NN O O
single NN O O
affected NN O O
boy NN O O
, NN O O
who NN O O
also NN O O
has NN O O
one NN O O
or NN O O
more NN O O
healthy NN O O
brothers NN O O
( NN O O
n NN O O
= NN O O
26 NN O O
) NN O O
. NN O O

Given NN O O
an NN O O
informative NN O O
restriction NN O O
fragment NN O O
length NN O O
polymorphism NN O O
( NN O O
RFLP NN O O
) NN O O
, NN O O
the NN O O
probability NN O O
that NN O O
the NN O O
boy NN O O
represents NN O O
a NN O O
new NN O O
mutation NN O O
can NN O O
be NN O O
reassessed NN O O
; NN O O
it NN O O
is NN O O
also NN O O
possible NN O O
to NN O O
exclude NN O O
the NN O O
DMD NN O B-Disease
gene NN O O
in NN O O
a NN O O
sister NN O O
. NN O O

Families NN O O
with NN O O
a NN O O
single NN O O
affected NN O O
boy NN O O
with NN O O
no NN O O
brother NN O O
( NN O O
n NN O O
= NN O O
30 NN O O
) NN O O
. NN O O

Here NN O O
exclusion NN O O
of NN O O
the NN O O
DMD NN O B-Disease
gene NN O O
in NN O O
a NN O O
sister NN O O
may NN O O
be NN O O
possible NN O O
. NN O O

Only NN O O
in NN O O
one NN O O
family NN O O
was NN O O
there NN O O
no NN O O
possibility NN O O
of NN O O
useful NN O O
linkage NN O O
analysis NN O O
. NN O O

The NN O O
linkage NN O O
analysis NN O O
required NN O O
is NN O O
described NN O O
, NN O O
and NN O O
the NN O O
need NN O O
to NN O O
check NN O O
DMD NN O B-Disease
families NN O O
for NN O O
informative NN O O
RFLPs NN O O
is NN O O
stressed NN O O
. NN O O

Family NN O O
studies NN O O
in NN O O
Bechterew NN O B-Disease
' NN O I-Disease
s NN O I-Disease
syndrome NN O I-Disease
( NN O O
ankylosing NN O B-Disease
spondylitis NN O I-Disease
) NN O O
III NN O O
. NN O O

Genetics NN O O
. NN O O

The NN O O
results NN O O
of NN O O
segregation NN O O
analyses NN O O
in NN O O
75 NN O O
families NN O O
where NN O O
the NN O O
proband NN O O
had NN O O
ankylosing NN O B-Disease
spondylitis NN O I-Disease
, NN O O
are NN O O
presented NN O O
. NN O O

Of NN O O
the NN O O
278 NN O O
adult NN O O
, NN O O
living NN O O
first NN O O
degree NN O O
relatives NN O O
, NN O O
approximately NN O O
85 NN O O
% NN O O
cooperated NN O O
in NN O O
the NN O O
study NN O O
. NN O O

Clinical NN O O
and NN O O
radiographical NN O O
examinations NN O O
were NN O O
performed NN O O
and NN O O
HLA NN O O
typing NN O O
was NN O O
conducted NN O O
. NN O O

The NN O O
results NN O O
were NN O O
in NN O O
agreement NN O O
with NN O O
our NN O O
hypothesis NN O O
that NN O O
ankylosing NN O B-Disease
spondylitis NN O I-Disease
is NN O O
part NN O O
of NN O O
a NN O O
syndrome NN O O
where NN O O
different NN O O
genetic NN O O
factors NN O O
interact NN O O
. NN O O

Such NN O O
known NN O O
factors NN O O
are NN O O
HLA NN O O
B27 NN O O
associated NN O O
disease NN O O
susceptibility NN O O
, NN O O
susceptibility NN O O
to NN O O
psoriatic NN O B-Disease
arthropathy NN O I-Disease
and NN O O
susceptibility NN O O
to NN O O
entero NN O B-Disease
- NN O I-Disease
arthropathy NN O I-Disease
. NN O O

Radiographical NN O O
sacro NN O B-Disease
- NN O I-Disease
iliitis NN O I-Disease
was NN O O
restricted NN O O
to NN O O
HLA NN O O
B27 NN O O
positive NN O O
relatives NN O O
, NN O O
and NN O O
was NN O O
more NN O O
frequently NN O O
found NN O O
in NN O O
relatives NN O O
to NN O O
probands NN O O
with NN O O
psoriasis NN O B-Disease
than NN O O
in NN O O
relatives NN O O
to NN O O
probands NN O O
without NN O O
psoriasis NN O B-Disease
. NN O O

Environmental NN O O
factors NN O O
( NN O O
intestinal NN O O
bacteria NN O O
) NN O O
are NN O O
known NN O O
to NN O O
trigger NN O O
the NN O O
disease NN O O
at NN O O
least NN O O
in NN O O
some NN O O
persons NN O O
, NN O O
and NN O O
we NN O O
have NN O O
postulated NN O O
that NN O O
all NN O O
or NN O O
most NN O O
of NN O O
them NN O O
have NN O O
the NN O O
predisposition NN O O
to NN O O
develop NN O O
disease NN O O
. NN O O

Thus NN O O
, NN O O
the NN O O
syndrome NN O O
has NN O O
a NN O O
multifactorial NN O O
etiology NN O O
. NN O O

The NN O O
phenotypic NN O O
expressions NN O O
of NN O O
the NN O O
different NN O O
genetic NN O O
predispositions NN O O
involved NN O O
, NN O O
include NN O O
sacro NN O B-Disease
- NN O I-Disease
iliitis NN O I-Disease
, NN O O
psoriasis NN O B-Disease
, NN O O
acute NN O B-Disease
anterior NN O I-Disease
uveitis NN O I-Disease
, NN O O
peripheral NN O O
arthropathy NN O B-Disease
and NN O O
inflammatory NN O B-Disease
bowel NN O I-Disease
disease NN O I-Disease
. NN O O

We NN O O
suggest NN O O
the NN O O
descriptive NN O O
name NN O O
HEREDITARY NN O B-Disease
MULTIFOCAL NN O I-Disease
RELAPSING NN O I-Disease
INFLAMMATION NN O I-Disease
( NN O O
HEMRI NN O B-Disease
) NN O O
for NN O O
this NN O O
syndrome NN O O
. NN O O

Ankylosing NN O B-Disease
spondylitis NN O I-Disease
, NN O O
psoriatic NN O B-Disease
arthropathy NN O I-Disease
and NN O O
entero NN O B-Disease
- NN O I-Disease
arthropathy NN O I-Disease
may NN O O
be NN O O
regarded NN O O
as NN O O
clinical NN O O
sub NN O O
- NN O O
types NN O O
of NN O O
the NN O O
syndrome NN O O
. NN O O
. NN O O

Prader NN O B-Disease
- NN O I-Disease
Willi NN O I-Disease
syndrome NN O I-Disease
and NN O O
chromosome NN O O
15 NN O O
. NN O O

A NN O O
clinical NN O O
discussion NN O O
of NN O O
20 NN O O
cases NN O O
. NN O O

A NN O O
chromosome NN O B-Disease
15 NN O I-Disease
anomaly NN O I-Disease
was NN O O
observed NN O O
in NN O O
12 NN O O
of NN O O
20 NN O O
patients NN O O
, NN O O
17 NN O O
of NN O O
whom NN O O
were NN O O
clinically NN O O
suspected NN O O
of NN O O
having NN O O
Prader NN O B-Disease
- NN O I-Disease
Willi NN O I-Disease
syndrome NN O I-Disease
( NN O O
PWS NN O B-Disease
) NN O O
. NN O O

The NN O O
clinical NN O O
features NN O O
of NN O O
eight NN O O
cases NN O O
with NN O O
15q11 NN O O
- NN O O
12 NN O O
deletion NN O O
were NN O O
very NN O O
similar NN O O
to NN O O
those NN O O
originally NN O O
described NN O O
in NN O O
PWS NN O B-Disease
. NN O O

On NN O O
the NN O O
other NN O O
hand NN O O
, NN O O
the NN O O
group NN O O
of NN O O
normal NN O O
karyotype NN O O
patients NN O O
is NN O O
heterogeneous NN O O
, NN O O
and NN O O
their NN O O
features NN O O
do NN O O
not NN O O
strictly NN O O
correspond NN O O
to NN O O
the NN O O
clinical NN O O
definition NN O O
of NN O O
PWS NN O B-Disease
. NN O O

However NN O O
, NN O O
the NN O O
hypothesis NN O O
that NN O O
PWS NN O B-Disease
is NN O O
associated NN O O
with NN O O
deletion NN O O
of NN O O
15q11 NN O O
- NN O O
12 NN O O
can NN O O
neither NN O O
explain NN O O
the NN O O
apparently NN O O
balanced NN O O
translocations NN O O
of NN O O
chromosome NN O O
15 NN O O
nor NN O O
account NN O O
for NN O O
the NN O O
small NN O O
supernumerary NN O O
metacentric NN O O
chromosomes NN O O
corresponding NN O O
to NN O O
an NN O O
isochromosome NN O O
15 NN O O
for NN O O
band NN O O
15q11 NN O O
observed NN O O
in NN O O
some NN O O
cases NN O O
. NN O O
. NN O O

The NN O O
Tay NN O B-Disease
- NN O I-Disease
Sachs NN O I-Disease
disease NN O I-Disease
gene NN O O
in NN O O
North NN O O
American NN O O
Jewish NN O O
populations NN O O
: NN O O
geographic NN O O
variations NN O O
and NN O O
origin NN O O
. NN O O

From NN O O
data NN O O
collected NN O O
in NN O O
a NN O O
North NN O O
American NN O O
Tay NN O B-Disease
- NN O I-Disease
Sachs NN O I-Disease
disease NN O I-Disease
( NN O O
TSD NN O B-Disease
) NN O O
heterozygote NN O O
screening NN O O
program NN O O
, NN O O
the NN O O
TSD NN O B-Disease
carrier NN O O
frequency NN O O
among NN O O
46 NN O O
, NN O O
304 NN O O
Jewish NN O O
individuals NN O O
was NN O O
found NN O O
to NN O O
be NN O O
. NN O O

0324 NN O O
( NN O O
1 NN O O
in NN O O
31 NN O O
individuals NN O O
) NN O O
. NN O O

This NN O O
frequency NN O O
is NN O O
consistent NN O O
with NN O O
earlier NN O O
estimates NN O O
based NN O O
on NN O O
TSD NN O B-Disease
incidence NN O O
data NN O O
. NN O O

TSD NN O B-Disease
carrier NN O O
frequencies NN O O
were NN O O
then NN O O
examined NN O O
by NN O O
single NN O O
country NN O O
and NN O O
single NN O O
region NN O O
of NN O O
origin NN O O
in NN O O
28 NN O O
, NN O O
029 NN O O
Jews NN O O
within NN O O
this NN O O
sample NN O O
for NN O O
whom NN O O
such NN O O
data NN O O
were NN O O
available NN O O
for NN O O
analysis NN O O
. NN O O

Jews NN O O
with NN O O
Polish NN O O
and NN O O
/ NN O O
or NN O O
Russian NN O O
ancestry NN O O
constituted NN O O
88 NN O O
% NN O O
of NN O O
this NN O O
sample NN O O
and NN O O
had NN O O
a NN O O
TSD NN O B-Disease
carrier NN O O
frequency NN O O
of NN O O
. NN O O

0327 NN O O
. NN O O

No NN O O
TSD NN O B-Disease
carriers NN O O
were NN O O
observed NN O O
among NN O O
the NN O O
166 NN O O
Jews NN O O
of NN O O
Near NN O O
Eastern NN O O
origins NN O O
. NN O O

Relative NN O O
to NN O O
Jews NN O O
of NN O O
Polish NN O O
and NN O O
Russian NN O O
origins NN O O
, NN O O
there NN O O
was NN O O
at NN O O
least NN O O
a NN O O
twofold NN O O
increase NN O O
in NN O O
the NN O O
TSD NN O B-Disease
carrier NN O O
frequency NN O O
in NN O O
Jews NN O O
of NN O O
Austrian NN O O
, NN O O
Hungarian NN O O
, NN O O
and NN O O
Czechoslovakian NN O O
origins NN O O
( NN O O
P NN O O
less NN O O
than NN O O
. NN O O
005 NN O O
) NN O O
. NN O O

These NN O O
findings NN O O
suggest NN O O
that NN O O
the NN O O
TSD NN O B-Disease
gene NN O O
proliferated NN O O
among NN O O
the NN O O
antecedents NN O O
of NN O O
modern NN O O
Ashkenazi NN O O
Jewry NN O O
after NN O O
the NN O O
Second NN O O
Diaspora NN O O
( NN O O
70 NN O O
A NN O O
. NN O O
D NN O O
. NN O O
) NN O O
and NN O O
before NN O O
their NN O O
major NN O O
migrations NN O O
to NN O O
regions NN O O
of NN O O
Poland NN O O
and NN O O
Russia NN O O
( NN O O
before NN O O
1100 NN O O
A NN O O
. NN O O
D NN O O
. NN O O
) NN O O
. NN O O

Human NN O O
deficiency NN O B-Disease
of NN O I-Disease
the NN O I-Disease
sixth NN O I-Disease
component NN O I-Disease
of NN O I-Disease
complement NN O I-Disease
in NN O O
a NN O O
patient NN O O
with NN O O
meningococcal NN O B-Disease
meningitis NN O I-Disease
and NN O O
no NN O O
haemostasis NN O B-Disease
abnormality NN O I-Disease
. NN O O

A NN O O
case NN O O
of NN O O
human NN O O
complete NN O O
C6 NN O B-Disease
deficiency NN O I-Disease
is NN O O
reported NN O O
. NN O O

The NN O O
patient NN O O
, NN O O
a NN O O
31 NN O O
year NN O O
old NN O O
white NN O O
male NN O O
, NN O O
was NN O O
seen NN O O
on NN O O
the NN O O
occasion NN O O
of NN O O
an NN O O
isolated NN O O
episode NN O O
of NN O O
meningococcal NN O B-Disease
meningitis NN O I-Disease
. NN O O

Serum NN O O
complement NN O O
hemolytic NN O O
and NN O O
bactericidal NN O O
activities NN O O
were NN O O
lacking NN O O
and NN O O
could NN O O
be NN O O
restored NN O O
to NN O O
normal NN O O
by NN O O
addition NN O O
of NN O O
appropriate NN O O
amounts NN O O
of NN O O
purified NN O O
C6 NN O O
. NN O O

No NN O O
hemostatic NN O B-Disease
abnormalities NN O I-Disease
were NN O O
observed NN O O
. NN O O
. NN O O

Absence NN O B-Disease
of NN O I-Disease
the NN O I-Disease
seventh NN O I-Disease
component NN O I-Disease
of NN O I-Disease
complement NN O I-Disease
in NN O O
a NN O O
patient NN O O
with NN O O
chronic NN O B-Disease
meningococcemia NN O I-Disease
presenting NN O O
as NN O O
vasculitis NN O B-Disease
. NN O O

A NN O O
previously NN O O
healthy NN O O
40 NN O O
- NN O O
year NN O O
- NN O O
old NN O O
man NN O O
presenting NN O O
with NN O O
fever NN O B-Disease
, NN O O
arthritis NN O B-Disease
, NN O O
and NN O O
cutaneous NN O B-Disease
vasculitis NN O I-Disease
was NN O O
found NN O O
to NN O O
have NN O O
chronic NN O B-Disease
meningococcemia NN O I-Disease
. NN O O

Evaluation NN O O
of NN O O
his NN O O
complement NN O O
system NN O O
showed NN O O
an NN O O
absence NN O O
of NN O O
functional NN O O
and NN O O
antigenic NN O O
C7 NN O O
, NN O O
compatible NN O O
with NN O O
a NN O O
complete NN O O
deficiency NN O B-Disease
of NN O I-Disease
the NN O I-Disease
seventh NN O I-Disease
component NN O I-Disease
of NN O I-Disease
complement NN O I-Disease
. NN O O

Study NN O O
of NN O O
the NN O O
patients NN O O
family NN O O
spanning NN O O
four NN O O
generations NN O O
showed NN O O
heterozygous NN O O
deficiency NN O B-Disease
of NN O I-Disease
C7 NN O I-Disease
in NN O O
five NN O O
members NN O O
. NN O O

Chronic NN O B-Disease
neisserial NN O I-Disease
infection NN O I-Disease
can NN O O
be NN O O
associated NN O O
with NN O O
C7 NN O B-Disease
deficiency NN O I-Disease
and NN O O
must NN O O
be NN O O
distinguished NN O O
from NN O O
other NN O O
causes NN O O
of NN O O
cutaneous NN O B-Disease
vasculitis NN O I-Disease
. NN O O
. NN O O

Familial NN O B-Disease
discoid NN O I-Disease
lupus NN O I-Disease
erythematosus NN O I-Disease
associated NN O O
with NN O O
heterozygote NN O O
C2 NN O B-Disease
deficiency NN O I-Disease
. NN O O

Two NN O O
siblings NN O O
with NN O O
chronic NN O B-Disease
discoid NN O I-Disease
lupus NN O I-Disease
erythematosus NN O I-Disease
and NN O O
several NN O O
family NN O O
members NN O O
were NN O O
found NN O O
with NN O O
heterozygous NN O O
C2 NN O B-Disease
deficiency NN O I-Disease
. NN O O

An NN O O
association NN O O
with NN O O
histocompatibility NN O O
markers NN O O
HLA NN O O
- NN O O
B18 NN O O
and NN O O
HLA NN O O
- NN O O
Dw2 NN O O
was NN O O
demonstrated NN O O
, NN O O
and NN O O
the NN O O
slow NN O O
allotype NN O O
of NN O O
factor NN O O
B NN O O
was NN O O
present NN O O
. NN O O

Linkage NN O O
studies NN O O
in NN O O
this NN O O
family NN O O
suggested NN O O
a NN O O
close NN O O
linkage NN O O
between NN O O
the NN O O
C2 NN O B-Disease
deficiency NN O I-Disease
gene NN O O
and NN O O
genes NN O O
coding NN O O
for NN O O
B18 NN O O
, NN O O
Dw2 NN O O
, NN O O
and NN O O
BfS NN O O
antigens NN O O
. NN O O

One NN O O
HLA NN O O
- NN O O
ACB NN O O
/ NN O O
DBf NN O O
recombinant NN O O
was NN O O
observed NN O O
showing NN O O
closer NN O O
linkage NN O O
between NN O O
HLA NN O O
- NN O O
D NN O O
and NN O O
Bf NN O O
than NN O O
between NN O O
HLA NN O O
- NN O O
B NN O O
and NN O O
Bf NN O O
. NN O O
. NN O O

Severe NN O B-Disease
- NN O I-Disease
glucose NN O I-Disease
- NN O I-Disease
6 NN O I-Disease
- NN O I-Disease
phosphate NN O I-Disease
dehydrogenase NN O I-Disease
( NN O I-Disease
G6PD NN O I-Disease
) NN O I-Disease
deficiency NN O I-Disease
associated NN O O
with NN O O
chronic NN O O
hemolytic NN O B-Disease
anemia NN O I-Disease
, NN O O
granulocyte NN O B-Disease
dysfunction NN O I-Disease
, NN O O
and NN O O
increased NN O O
susceptibility NN O O
to NN O O
infections NN O O
: NN O O
description NN O O
of NN O O
a NN O O
new NN O O
molecular NN O O
variant NN O O
( NN O O
G6PD NN O O
Barcelona NN O O
) NN O O
. NN O O

Molecular NN O O
, NN O O
kinetic NN O O
, NN O O
and NN O O
functional NN O O
studies NN O O
were NN O O
carried NN O O
out NN O O
on NN O O
erythrocytes NN O O
and NN O O
leukocytes NN O O
in NN O O
a NN O O
Spanish NN O O
male NN O O
with NN O O
G6PD NN O B-Disease
deficiency NN O I-Disease
, NN O O
congenital NN O B-Disease
nonspherocytic NN O I-Disease
hemolytic NN O I-Disease
anemia NN O I-Disease
( NN O O
CNSHA NN O B-Disease
) NN O O
, NN O O
and NN O O
increased NN O O
susceptibility NN O O
to NN O O
infections NN O O
. NN O O

G6PD NN O O
activity NN O O
was NN O O
absent NN O O
in NN O O
patients NN O O
red NN O O
cells NN O O
and NN O O
was NN O O
about NN O O
2 NN O O
% NN O O
of NN O O
normal NN O O
in NN O O
leukocytes NN O O
. NN O O

Molecular NN O O
studies NN O O
using NN O O
standard NN O O
methods NN O O
( NN O O
WHO NN O O
, NN O O
1967 NN O O
) NN O O
showed NN O O
G6PD NN O O
in NN O O
the NN O O
patient NN O O
to NN O O
have NN O O
a NN O O
slightly NN O O
fast NN O O
electrophoretic NN O O
mobility NN O O
at NN O O
pH NN O O
8 NN O O
. NN O O

0 NN O O
with NN O O
otherwise NN O O
normal NN O O
properties NN O O
( NN O O
heat NN O O
stability NN O O
at NN O O
46 NN O O
degrees NN O O
C NN O O
, NN O O
apparent NN O O
affinity NN O O
for NN O O
substrates NN O O
, NN O O
optimum NN O O
pH NN O O
, NN O O
and NN O O
utilization NN O O
of NN O O
substrate NN O O
analogues NN O O
) NN O O
. NN O O

Other NN O O
tests NN O O
showed NN O O
the NN O O
patients NN O O
granulocytes NN O O
to NN O O
engulf NN O O
latex NN O O
particles NN O O
normally NN O O
, NN O O
but NN O O
to NN O O
have NN O O
impaired NN O O
reduction NN O O
of NN O O
nitroblue NN O O
tetrazolium NN O O
and NN O O
ferricytochrome NN O O
- NN O O
c NN O O
as NN O O
well NN O O
as NN O O
reduced NN O O
iodination NN O O
. NN O O

Chemotaxis NN O O
and NN O O
random NN O O
migration NN O O
of NN O O
the NN O O
patients NN O O
granulocytes NN O O
were NN O O
normal NN O O
as NN O O
were NN O O
myeloperoxidase NN O O
, NN O O
leukocyte NN O O
alkaline NN O O
phosphatase NN O O
( NN O O
LAP NN O O
) NN O O
, NN O O
and NN O O
ultrastructural NN O O
features NN O O
. NN O O

The NN O O
molecular NN O O
characteristics NN O O
of NN O O
G6PD NN O O
in NN O O
the NN O O
patient NN O O
differed NN O O
from NN O O
those NN O O
of NN O O
all NN O O
previously NN O O
reported NN O O
variants NN O O
associated NN O O
with NN O O
CNSHA NN O B-Disease
, NN O O
so NN O O
the NN O O
present NN O O
variant NN O O
was NN O O
provisionally NN O O
called NN O O
G6PD NN O O
Barcelona NN O O
to NN O O
distinguish NN O O
it NN O O
from NN O O
other NN O O
G6PD NN O O
variants NN O O
previously NN O O
described NN O O
. NN O O

Possible NN O O
mechanisms NN O O
for NN O O
the NN O O
severe NN O O
deficiency NN O B-Disease
of NN O I-Disease
G6PD NN O I-Disease
in NN O O
erythrocytes NN O O
and NN O O
granulocytes NN O O
was NN O O
investigated NN O O
by NN O O
studies NN O O
on NN O O
the NN O O
immunologic NN O O
specific NN O O
activity NN O O
of NN O O
the NN O O
mutant NN O O
enzyme NN O O
. NN O O

Glucose NN O B-Disease
- NN O I-Disease
6 NN O I-Disease
- NN O I-Disease
phosphate NN O I-Disease
dehydrogenase NN O I-Disease
deficiency NN O I-Disease
in NN O O
Papua NN O O
New NN O O
Guinea NN O O
. NN O O

The NN O O
description NN O O
of NN O O
13 NN O O
new NN O O
variants NN O O
. NN O O

A NN O O
total NN O O
of NN O O
362 NN O O
males NN O O
from NN O O
various NN O O
regions NN O O
of NN O O
Papua NN O O
New NN O O
Guinea NN O O
were NN O O
screened NN O O
for NN O O
red NN O O
cell NN O O
glucose NN O O
- NN O O
6 NN O O
- NN O O
phosphate NN O O
dehydrogenase NN O O
( NN O O
G6PD NN O O
) NN O O
activity NN O O
. NN O O

Twenty NN O O
- NN O O
six NN O O
G6PD NN O B-Disease
deficient NN O I-Disease
individuals NN O O
were NN O O
identified NN O O
. NN O O

Biochemical NN O O
characterization NN O O
of NN O O
G6PD NN O O
purified NN O O
from NN O O
these NN O O
subjects NN O O
has NN O O
revealed NN O O
13 NN O O
new NN O O
variants NN O O
and NN O O
several NN O O
copies NN O O
of NN O O
previously NN O O
described NN O O
forms NN O O
of NN O O
G6PD NN O O
. NN O O

This NN O O
study NN O O
illustrates NN O O
the NN O O
extreme NN O O
heterogeneity NN O O
of NN O O
G6PD NN O B-Disease
deficiency NN O I-Disease
among NN O O
the NN O O
people NN O O
of NN O O
Papua NN O O
New NN O O
Guinea NN O O
. NN O O
. NN O O

Heterogeneity NN O O
of NN O O
" NN O O
Mediterranean NN O O
type NN O O
" NN O O
glucose NN O B-Disease
- NN O I-Disease
6 NN O I-Disease
- NN O I-Disease
phosphate NN O I-Disease
dehydrogenase NN O I-Disease
( NN O I-Disease
G6PD NN O I-Disease
) NN O I-Disease
deficiency NN O I-Disease
in NN O O
Spain NN O O
and NN O O
description NN O O
of NN O O
two NN O O
new NN O O
variants NN O O
associated NN O O
with NN O O
favism NN O B-Disease
. NN O O

Glucose NN O O
- NN O O
6 NN O O
- NN O O
phosphate NN O O
dehydrogenase NN O O
( NN O O
G6PD NN O O
) NN O O
; NN O O
EC NN O O
1 NN O O
. NN O O

1 NN O O
. NN O O

1 NN O O
. NN O O

49 NN O O
from NN O O
thirty NN O O
- NN O O
six NN O O
unrelated NN O O
Spanish NN O O
males NN O O
was NN O O
partially NN O O
purified NN O O
from NN O O
blood NN O O
, NN O O
and NN O O
the NN O O
variants NN O O
were NN O O
characterized NN O O
biochemically NN O O
and NN O O
electrophoretically NN O O
according NN O O
to NN O O
the NN O O
methods NN O O
recommended NN O O
by NN O O
the NN O O
world NN O O
Health NN O O
Organization NN O O
. NN O O

Subjects NN O O
were NN O O
from NN O O
multiple NN O O
geographic NN O O
regions NN O O
within NN O O
Spain NN O O
, NN O O
and NN O O
all NN O O
suffered NN O O
from NN O O
hemolytic NN O B-Disease
anemia NN O I-Disease
, NN O O
either NN O O
acute NN O O
( NN O O
34 NN O O
cases NN O O
) NN O O
or NN O O
chronic NN O O
nonspherocytic NN O O
( NN O O
2 NN O O
cases NN O O
) NN O O
. NN O O

Almost NN O O
all NN O O
the NN O O
variants NN O O
studied NN O O
presented NN O O
residual NN O O
erythrocyte NN O O
G6PD NN O O
activity NN O O
ranging NN O O
from NN O O
0 NN O O
to NN O O
10 NN O O
% NN O O
of NN O O
normal NN O O
, NN O O
and NN O O
five NN O O
different NN O O
mutants NN O O
were NN O O
responsible NN O O
for NN O O
the NN O O
deficient NN O O
phenotype NN O O
. NN O O

Three NN O O
variants NN O O
were NN O O
similar NN O O
to NN O O
others NN O O
previously NN O O
described NN O O
G6PD NN O O
Mediterranean NN O O
( NN O O
11 NN O O
cases NN O O
) NN O O
, NN O O
G6PD NN O O
Athens NN O O
- NN O O
like NN O O
( NN O O
3 NN O O
cases NN O O
) NN O O
, NN O O
and NN O O
G6PD NN O O
Union NN O O
( NN O O
2 NN O O
cases NN O O
) NN O O
. NN O O

The NN O O
remaining NN O O
variants NN O O
were NN O O
different NN O O
from NN O O
the NN O O
numerous NN O O
variants NN O O
already NN O O
reported NN O O
and NN O O
have NN O O
been NN O O
considered NN O O
as NN O O
new NN O O
mutants NN O O
. NN O O

Provisionally NN O O
they NN O O
are NN O O
called NN O O
G6PD NN O O
Betica NN O O
( NN O O
19 NN O O
cases NN O O
) NN O O
and NN O O
G6PD NN O O
Menorca NN O O
( NN O O
1 NN O O
case NN O O
) NN O O
. NN O O

The NN O O
present NN O O
study NN O O
constitutes NN O O
the NN O O
first NN O O
attempt NN O O
to NN O O
characterize NN O O
the NN O O
deficient NN O B-Disease
G6PD NN O I-Disease
variants NN O O
found NN O O
in NN O O
Spain NN O O
and NN O O
supplies NN O O
new NN O O
data NN O O
on NN O O
the NN O O
relationship NN O O
between NN O O
molecular NN O O
characteristics NN O O
of NN O O
deficient NN O O
variants NN O O
and NN O O
their NN O O
clinical NN O O
manifestations NN O O
. NN O O

The NN O O
most NN O O
important NN O O
findings NN O O
can NN O O
be NN O O
summarized NN O O
as NN O O
follows NN O O
( NN O O
1 NN O O
) NN O O
The NN O O
Spanish NN O O
population NN O O
is NN O O
characterized NN O O
by NN O O
an NN O O
important NN O O
heterogeneity NN O O
in NN O O
G6PD NN O B-Disease
deficiency NN O I-Disease
. NN O O

( NN O O
2 NN O O
) NN O O
Although NN O O
G6PD NN O O
Mediterranean NN O O
is NN O O
very NN O O
frequent NN O O
, NN O O
it NN O O
presents NN O O
a NN O O
relatively NN O O
high NN O O
degree NN O O
of NN O O
polymorphism NN O O
. NN O O

( NN O O
3 NN O O
) NN O O
Favism NN O B-Disease
has NN O O
been NN O O
observed NN O O
associated NN O O
with NN O O
all NN O O
kinds NN O O
of NN O O
variants NN O O
described NN O O
here NN O O
. NN O O

( NN O O
4 NN O O
) NN O O
G6PD NN O O
Betica NN O O
, NN O O
which NN O O
is NN O O
the NN O O
most NN O O
frequent NN O O
variant NN O O
found NN O O
in NN O O
subjects NN O O
of NN O O
Southern NN O O
Spanish NN O O
origin NN O O
, NN O O
has NN O O
been NN O O
observed NN O O
associated NN O O
with NN O O
favism NN O B-Disease
in NN O O
all NN O O
cases NN O O
except NN O O
one NN O O
. NN O O

A NN O O
new NN O O
glucose NN O O
- NN O O
6 NN O O
- NN O O
phosphate NN O O
dehydrogenase NN O O
variant NN O O
( NN O O
G6PD NN O O
Nagano NN O O
) NN O O
associated NN O O
with NN O O
congenital NN O B-Disease
hemolytic NN O I-Disease
anemia NN O I-Disease
. NN O O

A NN O O
new NN O O
glucose NN O O
- NN O O
6 NN O O
- NN O O
phosphate NN O O
dehydrogenase NN O O
( NN O O
G6PD NN O O
) NN O O
variant NN O O
associated NN O O
with NN O O
chronic NN O B-Disease
nonspherocytic NN O I-Disease
hemolytic NN O I-Disease
anemia NN O I-Disease
was NN O O
reported NN O O
. NN O O

The NN O O
patient NN O O
, NN O O
a NN O O
6 NN O O
- NN O O
year NN O O
- NN O O
old NN O O
Japanese NN O O
male NN O O
, NN O O
was NN O O
noticed NN O O
to NN O O
have NN O O
hemolytic NN O B-Disease
anemia NN O I-Disease
soon NN O O
after NN O O
birth NN O O
, NN O O
and NN O O
a NN O O
diagnosis NN O O
of NN O O
G6PD NN O B-Disease
deficiency NN O I-Disease
was NN O O
made NN O O
at NN O O
the NN O O
age NN O O
of NN O O
2 NN O O
. NN O O

He NN O O
had NN O O
episodes NN O O
of NN O O
hemolytic NN O B-Disease
crisis NN O I-Disease
several NN O O
times NN O O
after NN O O
upper NN O B-Disease
respiratory NN O I-Disease
infection NN O I-Disease
. NN O O

G6PD NN O O
activity NN O O
of NN O O
the NN O O
patient NN O O
was NN O O
5 NN O O
. NN O O

5 NN O O
% NN O O
of NN O O
normal NN O O
. NN O O

The NN O O
enzymatic NN O O
characteristics NN O O
were NN O O
examined NN O O
when NN O O
he NN O O
was NN O O
5 NN O O
years NN O O
old NN O O
, NN O O
and NN O O
his NN O O
G6PD NN O O
showed NN O O
faster NN O O
- NN O O
than NN O O
- NN O O
normal NN O O
electrophoretic NN O O
mobility NN O O
, NN O O
low NN O O
Km NN O O
G6P NN O O
, NN O O
high NN O O
Km NN O O
NADP NN O O
, NN O O
low NN O O
Ki NN O O
NADPH NN O O
, NN O O
normal NN O O
utilization NN O O
of NN O O
substrate NN O O
analogues NN O O
, NN O O
heat NN O O
instability NN O O
, NN O O
and NN O O
a NN O O
normal NN O O
pH NN O O
optimum NN O O
curve NN O O
. NN O O

From NN O O
these NN O O
results NN O O
, NN O O
this NN O O
was NN O O
considered NN O O
to NN O O
be NN O O
a NN O O
new NN O O
variant NN O O
and NN O O
was NN O O
designated NN O O
G6PD NN O O
Nagano NN O O
. NN O O

Infection NN O O
- NN O O
induced NN O O
hemolysis NN O B-Disease
and NN O O
chronic NN O B-Disease
hemolytic NN O I-Disease
anemia NN O I-Disease
seem NN O O
to NN O O
be NN O O
due NN O O
to NN O O
markedly NN O O
impaired NN O O
enzyme NN O O
activity NN O O
and NN O O
thermal NN O O
instability NN O O
. NN O O

Heterozygous NN O O
C2 NN O B-Disease
- NN O I-Disease
deficiency NN O I-Disease
and NN O O
myasthenia NN O B-Disease
gravis NN O I-Disease
. NN O O

Complement NN O B-Disease
deficiency NN O I-Disease
states NN O O
in NN O O
myasthenia NN O B-Disease
gravis NN O I-Disease
( NN O O
MG NN O B-Disease
) NN O O
have NN O O
not NN O O
been NN O O
reported NN O O
previously NN O O
. NN O O

We NN O O
describe NN O O
a NN O O
19 NN O O
- NN O O
year NN O O
- NN O O
old NN O O
woman NN O O
with NN O O
typical NN O O
MG NN O B-Disease
and NN O O
heterozygous NN O O
C2 NN O B-Disease
deficiency NN O I-Disease
, NN O O
along NN O O
with NN O O
HLA NN O O
typing NN O O
of NN O O
the NN O O
patient NN O O
and NN O O
her NN O O
immediate NN O O
family NN O O
. NN O O
. NN O O

Adrenoleukodystrophy NN O B-Disease
: NN O O
increased NN O O
plasma NN O O
content NN O O
of NN O O
saturated NN O O
very NN O O
long NN O O
chain NN O O
fatty NN O O
acids NN O O
. NN O O

With NN O O
a NN O O
new NN O O
method NN O O
we NN O O
measured NN O O
the NN O O
saturated NN O O
very NN O O
long NN O O
chain NN O O
fatty NN O O
acids NN O O
in NN O O
the NN O O
plasma NN O O
of NN O O
adrenoleukodystrophy NN O B-Disease
( NN O O
ALD NN O B-Disease
) NN O O
hemizygotes NN O O
, NN O O
ALD NN O B-Disease
heterozygotes NN O O
, NN O O
and NN O O
controls NN O O
. NN O O

ALD NN O B-Disease
hemizygotes NN O O
showed NN O O
increased NN O O
levels NN O O
of NN O O
hexacosanoate NN O O
( NN O O
C26 NN O O
fatty NN O O
acid NN O O
) NN O O
which NN O O
represented NN O O
0 NN O O
. NN O O

081 NN O O
+ NN O O
/ NN O O
- NN O O
0 NN O O
. NN O O

0066 NN O O
% NN O O
( NN O O
SEM NN O O
) NN O O
of NN O O
total NN O O
fatty NN O O
acids NN O O
, NN O O
compared NN O O
to NN O O
0 NN O O
. NN O O

015 NN O O
+ NN O O
/ NN O O
- NN O O
0 NN O O
. NN O O

0032 NN O O
% NN O O
in NN O O
the NN O O
controls NN O O
. NN O O

C25 NN O O
, NN O O
C24 NN O O
, NN O O
and NN O O
C23 NN O O
fatty NN O O
acids NN O O
were NN O O
also NN O O
increased NN O O
, NN O O
but NN O O
the NN O O
C22 NN O O
and NN O O
C20 NN O O
fatty NN O O
acids NN O O
were NN O O
normal NN O O
. NN O O

C26 NN O O
levels NN O O
were NN O O
also NN O O
increased NN O O
in NN O O
most NN O O
ALD NN O B-Disease
heterozygotes NN O O
, NN O O
with NN O O
a NN O O
mean NN O O
level NN O O
0 NN O O
. NN O O

057 NN O O
+ NN O O
/ NN O O
- NN O O
0 NN O O
. NN O O

0063 NN O O
% NN O O
of NN O O
total NN O O
fatty NN O O
acids NN O O
. NN O O

The NN O O
technique NN O O
can NN O O
be NN O O
used NN O O
for NN O O
diagnosis NN O O
and NN O O
carrier NN O O
identification NN O O
, NN O O
and NN O O
in NN O O
the NN O O
evaluation NN O O
of NN O O
therapy NN O O
. NN O O

Abnormal NN O O
high NN O O
density NN O O
lipoproteins NN O O
in NN O O
cerebrotendinous NN O B-Disease
xanthomatosis NN O I-Disease
. NN O O

The NN O O
plasma NN O O
lipoprotein NN O O
profiles NN O O
and NN O O
high NN O O
density NN O O
lipoproteins NN O O
( NN O O
HDL NN O O
) NN O O
were NN O O
characterized NN O O
in NN O O
patients NN O O
with NN O O
the NN O O
genetic NN O B-Disease
disease NN O I-Disease
cerebrotendinous NN O B-Disease
xanthomatosis NN O I-Disease
( NN O O
CTX NN O B-Disease
) NN O O
. NN O O

Abnormalities NN O B-Disease
in NN O I-Disease
the NN O I-Disease
HDL NN O I-Disease
may NN O O
contribute NN O O
to NN O O
their NN O O
increased NN O O
atherogenesis NN O O
and NN O O
excessive NN O O
deposits NN O O
of NN O O
tissue NN O O
sterols NN O O
in NN O O
the NN O O
presence NN O O
of NN O O
low NN O O
or NN O O
low NN O O
- NN O O
normal NN O O
concentrations NN O O
of NN O O
plasma NN O O
cholesterol NN O O
( NN O O
165 NN O O
+ NN O O
/ NN O O
- NN O O
25 NN O O
mg NN O O
/ NN O O
dl NN O O
) NN O O
and NN O O
low NN O O
density NN O O
lipoproteins NN O O
( NN O O
LDL NN O O
) NN O O
. NN O O

The NN O O
mean NN O O
HDL NN O O
- NN O O
cholesterol NN O O
concentration NN O O
in NN O O
the NN O O
CTX NN O B-Disease
plasmas NN O O
was NN O O
14 NN O O
. NN O O

5 NN O O
+ NN O O
/ NN O O
- NN O O
3 NN O O
. NN O O

2 NN O O
mg NN O O
/ NN O O
dl NN O O
, NN O O
about NN O O
one NN O O
- NN O O
third NN O O
the NN O O
normal NN O O
value NN O O
. NN O O

The NN O O
low NN O O
HDL NN O O
- NN O O
cholesterol NN O O
reflects NN O O
a NN O O
low NN O O
concentration NN O O
and NN O O
an NN O O
abnormal NN O O
lipid NN O O
composition NN O O
of NN O O
the NN O O
plasma NN O O
HDL NN O O
. NN O O

Relative NN O O
to NN O O
normal NN O O
HDL NN O O
, NN O O
the NN O O
cholesteryl NN O O
esters NN O O
are NN O O
low NN O O
, NN O O
free NN O O
cholesterol NN O O
and NN O O
phospholipids NN O O
essentially NN O O
normal NN O O
, NN O O
and NN O O
triglycerides NN O O
increased NN O O
. NN O O

The NN O O
ratio NN O O
of NN O O
apoprotein NN O O
( NN O O
apo NN O O
) NN O O
to NN O O
total NN O O
cholesterol NN O O
in NN O O
the NN O O
HDL NN O O
of NN O O
CTX NN O B-Disease
was NN O O
two NN O O
to NN O O
three NN O O
times NN O O
greater NN O O
than NN O O
normal NN O O
. NN O O

In NN O O
the NN O O
CTX NN O B-Disease
HDL NN O O
, NN O O
the NN O O
ratio NN O O
of NN O O
apoAI NN O O
to NN O O
apoAII NN O O
was NN O O
high NN O O
, NN O O
the NN O O
proportion NN O O
of NN O O
apoC NN O O
low NN O O
, NN O O
and NN O O
a NN O O
normally NN O O
minor NN O O
form NN O O
of NN O O
apoAI NN O O
increased NN O O
relative NN O O
to NN O O
other NN O O
forms NN O O
. NN O O

The NN O O
HDL NN O O
in NN O O
electron NN O O
micrographs NN O O
appeared NN O O
normal NN O O
morphologically NN O O
and NN O O
in NN O O
particle NN O O
size NN O O
. NN O O

The NN O O
abnormalities NN O O
in NN O O
lipoprotein NN O O
distribution NN O O
profile NN O O
and NN O O
composition NN O O
of NN O O
the NN O O
plasma NN O O
HDL NN O O
result NN O O
from NN O O
metabolic NN O O
defects NN O O
that NN O O
are NN O O
not NN O O
understood NN O O
but NN O O
may NN O O
be NN O O
linked NN O O
to NN O O
the NN O O
genetic NN O B-Disease
defect NN O I-Disease
in NN O O
bile NN O O
acid NN O O
synthesis NN O O
in NN O O
CTX NN O B-Disease
. NN O O

As NN O O
a NN O O
consequence NN O O
, NN O O
it NN O O
is NN O O
probable NN O O
that NN O O
the NN O O
normal NN O O
functions NN O O
of NN O O
the NN O O
HDL NN O O
, NN O O
possibly NN O O
including NN O O
modulation NN O O
of NN O O
LDL NN O O
- NN O O
cholesterol NN O O
uptake NN O O
and NN O O
the NN O O
removal NN O O
of NN O O
excess NN O O
cholesterol NN O O
from NN O O
peripheral NN O O
tissues NN O O
, NN O O
are NN O O
perturbed NN O O
significantly NN O O
in NN O O
this NN O O
disease NN O O
. NN O O

Genetics NN O O
of NN O O
cerebrotendinous NN O B-Disease
xanthomatosis NN O I-Disease
( NN O O
CTX NN O B-Disease
) NN O O
: NN O O
an NN O O
autosomal NN O O
recessive NN O O
trait NN O O
with NN O O
high NN O O
gene NN O O
frequency NN O O
in NN O O
Sephardim NN O O
of NN O O
Moroccan NN O O
origin NN O O
. NN O O

We NN O O
described NN O O
6 NN O O
patients NN O O
( NN O O
from NN O O
3 NN O O
families NN O O
) NN O O
affected NN O O
with NN O O
cerebrotendinous NN O B-Disease
xanthomatosis NN O I-Disease
( NN O O
CTX NN O B-Disease
) NN O O
. NN O O

All NN O O
are NN O O
Sephardic NN O O
Jews NN O O
of NN O O
Moroccan NN O O
extraction NN O O
. NN O O

In NN O O
view NN O O
of NN O O
the NN O O
small NN O O
number NN O O
of NN O O
CTX NN O B-Disease
patients NN O O
diagnosed NN O O
in NN O O
the NN O O
world NN O O
( NN O O
a NN O O
total NN O O
of NN O O
50 NN O O
including NN O O
our NN O O
6 NN O O
patients NN O O
) NN O O
, NN O O
we NN O O
are NN O O
probably NN O O
dealing NN O O
with NN O O
an NN O O
ethnic NN O O
subgroup NN O O
with NN O O
a NN O O
high NN O O
CTX NN O O
gene NN O O
frequency NN O O
, NN O O
which NN O O
we NN O O
have NN O O
estimated NN O O
to NN O O
be NN O O
1 NN O O
/ NN O O
108 NN O O
. NN O O

Since NN O O
there NN O O
are NN O O
differences NN O O
in NN O O
expression NN O O
in NN O O
this NN O O
disease NN O O
, NN O O
we NN O O
recommend NN O O
cholestanol NN O O
study NN O O
in NN O O
cases NN O O
of NN O O
undiagnosed NN O O
cataract NN O B-Disease
or NN O O
tendinous NN O B-Disease
xanthomas NN O I-Disease
in NN O O
childhood NN O O
or NN O O
early NN O O
adolescence NN O O
. NN O O

The NN O O
diagnosis NN O O
in NN O O
CTX NN O B-Disease
is NN O O
important NN O O
not NN O O
only NN O O
for NN O O
genetic NN O O
counseling NN O O
, NN O O
but NN O O
also NN O O
in NN O O
veiw NN O O
of NN O O
possible NN O O
treatment NN O O
. NN O O
. NN O O

New NN O O
genetic NN O O
variants NN O O
of NN O O
glucose NN O O
6 NN O O
- NN O O
phosphate NN O O
dehydrogenase NN O O
( NN O O
G6PD NN O O
) NN O O
in NN O O
Italy NN O O
. NN O O

Six NN O O
new NN O O
variants NN O O
of NN O O
human NN O O
erythrocyte NN O O
G6PD NN O O
have NN O O
been NN O O
characterized NN O O
. NN O O

All NN O O
of NN O O
them NN O O
were NN O O
found NN O O
in NN O O
Italian NN O O
males NN O O
and NN O O
all NN O O
were NN O O
associated NN O O
with NN O O
enzyme NN O B-Disease
deficiency NN O I-Disease
, NN O O
but NN O O
only NN O O
two NN O O
with NN O O
signs NN O O
of NN O O
haemolysis NN O B-Disease
. NN O O

These NN O O
and NN O O
other NN O O
variants NN O O
reported NN O O
in NN O O
the NN O O
literature NN O O
, NN O O
which NN O O
must NN O O
thus NN O O
far NN O O
be NN O O
regarded NN O O
as NN O O
sporadic NN O O
, NN O O
are NN O O
found NN O O
to NN O O
map NN O O
in NN O O
parts NN O O
of NN O O
Italy NN O O
where NN O O
common NN O O
types NN O O
of NN O O
G6PD NN O B-Disease
deficiency NN O I-Disease
are NN O O
also NN O O
prevalent NN O O
. NN O O
. NN O O

Variants NN O O
of NN O O
erythrocyte NN O O
glucose NN O O
- NN O O
6 NN O O
- NN O O
phosphate NN O O
dehydrogenase NN O O
( NN O O
G6PD NN O O
) NN O O
in NN O O
Bulgarian NN O O
populations NN O O
. NN O O

Ten NN O O
variants NN O O
of NN O O
erythrocyte NN O O
glucose NN O O
- NN O O
6 NN O O
- NN O O
phosphate NN O O
dehydrogenase NN O O
were NN O O
identified NN O O
in NN O O
22 NN O O
patients NN O O
with NN O O
G6PD NN O B-Disease
deficiency NN O I-Disease
from NN O O
three NN O O
districts NN O O
of NN O O
Bulgaria NN O O
. NN O O

Corinth NN O O
- NN O O
like NN O O
and NN O O
Fayoum NN O O
- NN O O
like NN O O
variants NN O O
were NN O O
the NN O O
most NN O O
frequent NN O O
; NN O O
Mediterranean NN O O
, NN O O
Ohut NN O O
II NN O O
, NN O O
Kilgore NN O O
, NN O O
Boston NN O O
, NN O O
Poznan NN O O
, NN O O
and NN O O
Panay NN O O
variants NN O O
and NN O O
two NN O O
new NN O O
variants NN O O
, NN O O
Petrich NN O O
and NN O O
Gotze NN O O
Delchev NN O O
, NN O O
were NN O O
each NN O O
found NN O O
in NN O O
one NN O O
or NN O O
two NN O O
carriers NN O O
. NN O O

No NN O O
correlation NN O O
was NN O O
revealed NN O O
between NN O O
clinical NN O O
and NN O O
biochemical NN O O
polymorphism NN O O
. NN O O
. NN O O

Nephropathy NN O B-Disease
in NN O O
the NN O O
Wiskott NN O B-Disease
- NN O I-Disease
Aldrich NN O I-Disease
syndrome NN O I-Disease
. NN O O

Nephropathy NN O B-Disease
was NN O O
detected NN O O
in NN O O
five NN O O
of NN O O
32 NN O O
patients NN O O
with NN O O
the NN O O
Wiskott NN O B-Disease
- NN O I-Disease
Aldrich NN O I-Disease
syndrome NN O I-Disease
who NN O O
were NN O O
participating NN O O
in NN O O
a NN O O
study NN O O
of NN O O
transfer NN O O
factor NN O O
( NN O O
TF NN O O
) NN O O
therapy NN O O
. NN O O

In NN O O
two NN O O
patients NN O O
, NN O O
nephropathy NN O B-Disease
was NN O O
present NN O O
before NN O O
TF NN O O
and NN O O
did NN O O
not NN O O
appear NN O O
changed NN O O
by NN O O
TF NN O O
therapy NN O O
. NN O O

One NN O O
of NN O O
these NN O O
patients NN O O
subsequently NN O O
developed NN O O
progressive NN O O
renal NN O B-Disease
failure NN O I-Disease
requiring NN O O
dialysis NN O O
beginning NN O O
5 NN O O
1 NN O O
/ NN O O
2 NN O O
years NN O O
after NN O O
TF NN O O
therapy NN O O
. NN O O

In NN O O
two NN O O
patients NN O O
, NN O O
decreased NN O O
renal NN O O
function NN O O
appeared NN O O
very NN O O
soon NN O O
after NN O O
the NN O O
administration NN O O
of NN O O
TF NN O O
. NN O O

One NN O O
patient NN O O
showed NN O O
gradually NN O O
decreasing NN O O
renal NN O O
function NN O O
beginning NN O O
after NN O O
two NN O O
years NN O O
of NN O O
TF NN O O
therapy NN O O
. NN O O

An NN O O
additional NN O O
patient NN O O
was NN O O
identified NN O O
who NN O O
died NN O O
with NN O O
renal NN O B-Disease
failure NN O I-Disease
without NN O O
having NN O O
received NN O O
TF NN O O
. NN O O

The NN O O
results NN O O
suggest NN O O
that NN O O
renal NN O B-Disease
failure NN O I-Disease
occurs NN O O
in NN O O
the NN O O
Wiskott NN O B-Disease
- NN O I-Disease
Aldrich NN O I-Disease
syndrome NN O I-Disease
more NN O O
frequently NN O O
than NN O O
generally NN O O
recognized NN O O
and NN O O
that NN O O
administration NN O O
of NN O O
TF NN O O
may NN O O
precipitate NN O O
or NN O O
accelerate NN O O
the NN O O
renal NN O B-Disease
disease NN O I-Disease
in NN O O
patients NN O O
with NN O O
this NN O O
syndrome NN O O
. NN O O
. NN O O

Wiskott NN O B-Disease
- NN O I-Disease
Aldrich NN O I-Disease
syndrome NN O I-Disease
: NN O O
cellular NN O O
impairments NN O O
and NN O O
their NN O O
implication NN O O
for NN O O
carrier NN O O
detection NN O O
. NN O O

A NN O O
family NN O O
in NN O O
which NN O O
two NN O O
male NN O O
siblings NN O O
were NN O O
affected NN O O
with NN O O
Wiskott NN O B-Disease
- NN O I-Disease
Aldrich NN O I-Disease
syndrome NN O I-Disease
( NN O O
WAS NN O B-Disease
) NN O O
was NN O O
studied NN O O
using NN O O
G NN O O
- NN O O
6 NN O O
- NN O O
PD NN O O
isoenzymes NN O O
as NN O O
an NN O O
X NN O O
- NN O O
linked NN O O
marker NN O O
in NN O O
order NN O O
to NN O O
investigate NN O O
the NN O O
nature NN O O
of NN O O
cellular NN O O
abnormalities NN O O
. NN O O

Isolated NN O O
peripheral NN O O
blood NN O O
cell NN O O
types NN O O
from NN O O
the NN O O
doubly NN O O
heterozygous NN O O
mother NN O O
of NN O O
the NN O O
affected NN O O
males NN O O
seemingly NN O O
failed NN O O
to NN O O
express NN O O
the NN O O
G NN O O
- NN O O
6 NN O O
- NN O O
PD NN O O
allele NN O O
in NN O O
cis NN O O
position NN O O
with NN O O
the NN O O
WAS NN O B-Disease
allele NN O O
while NN O O
her NN O O
cultured NN O O
skin NN O O
fibroblasts NN O O
expressed NN O O
both NN O O
G NN O O
- NN O O
6 NN O O
- NN O O
PD NN O O
alleles NN O O
. NN O O

Additionally NN O O
, NN O O
a NN O O
histogram NN O O
analysis NN O O
of NN O O
platelet NN O O
size NN O O
revealed NN O O
a NN O O
single NN O O
population NN O O
of NN O O
abnormally NN O O
small NN O O
platelets NN O O
in NN O O
the NN O O
affected NN O O
propositus NN O O
, NN O O
whereas NN O O
the NN O O
heterozygous NN O O
mother NN O O
had NN O O
no NN O O
appreciable NN O O
small NN O O
platelet NN O O
subpopulation NN O O
. NN O O

In NN O O
vitro NN O O
culture NN O O
of NN O O
hemopoietic NN O O
progenitor NN O O
cells NN O O
of NN O O
the NN O O
heterozygous NN O O
mother NN O O
showed NN O O
that NN O O
the NN O O
majority NN O O
of NN O O
progenitor NN O O
cells NN O O
did NN O O
not NN O O
express NN O O
the NN O O
WAS NN O B-Disease
allele NN O O
. NN O O

However NN O O
, NN O O
a NN O O
small NN O O
number NN O O
of NN O O
cells NN O O
expressing NN O O
the NN O O
G NN O O
- NN O O
6 NN O O
- NN O O
PD NN O O
type NN O O
linked NN O O
with NN O O
the NN O O
WAS NN O B-Disease
allele NN O O
were NN O O
detected NN O O
. NN O O

The NN O O
proportion NN O O
of NN O O
the NN O O
latter NN O O
progenitors NN O O
was NN O O
significantly NN O O
higher NN O O
among NN O O
more NN O O
primitive NN O O
progenitors NN O O
( NN O O
those NN O O
giving NN O O
rise NN O O
to NN O O
later NN O O
appearing NN O O
colonies NN O O
) NN O O
. NN O O

This NN O O
observation NN O O
suggests NN O O
that NN O O
selection NN O O
against NN O O
cells NN O O
expressing NN O O
the NN O O
Wiskott NN O B-Disease
- NN O I-Disease
Aldrich NN O I-Disease
defect NN O I-Disease
takes NN O O
place NN O O
in NN O O
the NN O O
hemopoietic NN O O
system NN O O
of NN O O
the NN O O
heterozygous NN O O
female NN O O
and NN O O
offers NN O O
a NN O O
possible NN O O
means NN O O
of NN O O
carrier NN O O
detection NN O O
in NN O O
some NN O O
women NN O O
. NN O O

Linkage NN O O
studies NN O O
in NN O O
this NN O O
family NN O O
revealed NN O O
one NN O O
example NN O O
of NN O O
probable NN O O
recombination NN O O
between NN O O
the NN O O
loci NN O O
for NN O O
WAS NN O B-Disease
and NN O O
G NN O O
- NN O O
6 NN O O
- NN O O
PD NN O O
among NN O O
three NN O O
informative NN O O
subjects NN O O
, NN O O
suggesting NN O O
that NN O O
these NN O O
two NN O O
loci NN O O
may NN O O
not NN O O
be NN O O
closely NN O O
linked NN O O
on NN O O
the NN O O
X NN O O
- NN O O
chromosome NN O O
. NN O O
. NN O O

A NN O O
new NN O O
CT NN O O
pattern NN O O
in NN O O
adrenoleukodystrophy NN O B-Disease
. NN O O

A NN O O
new NN O O
CT NN O O
pattern NN O O
was NN O O
observed NN O O
in NN O O
2 NN O O
patients NN O O
with NN O O
adrenoleukodystrophy NN O B-Disease
( NN O O
ALD NN O B-Disease
) NN O O
. NN O O

This NN O O
pattern NN O O
, NN O O
which NN O O
the NN O O
authors NN O O
call NN O O
Type NN O O
II NN O O
, NN O O
is NN O O
characterized NN O O
by NN O O
the NN O O
absence NN O O
of NN O O
posterior NN O O
periventricular NN O O
areas NN O O
of NN O O
decreased NN O O
attenuation NN O O
around NN O O
the NN O O
trigone NN O O
on NN O O
non NN O O
- NN O O
contrast NN O O
scans NN O O
after NN O O
contrast NN O O
infusion NN O O
, NN O O
however NN O O
, NN O O
there NN O O
is NN O O
striking NN O O
enhancement NN O O
of NN O O
various NN O O
white NN O O
- NN O O
matter NN O O
structures NN O O
( NN O O
tracts NN O O
or NN O O
fiber NN O O
systems NN O O
) NN O O
such NN O O
as NN O O
the NN O O
internal NN O O
capsules NN O O
, NN O O
corpus NN O O
callosum NN O O
, NN O O
corona NN O O
radiata NN O O
, NN O O
forceps NN O O
major NN O O
, NN O O
and NN O O
cerebral NN O O
peduncles NN O O
. NN O O

This NN O O
is NN O O
different NN O O
from NN O O
numerous NN O O
previous NN O O
descriptions NN O O
of NN O O
the NN O O
CT NN O O
pattern NN O O
in NN O O
ALD NN O B-Disease
. NN O O

Type NN O B-Disease
II NN O I-Disease
ALD NN O I-Disease
does NN O O
not NN O O
appear NN O O
to NN O O
have NN O O
been NN O O
seen NN O O
in NN O O
any NN O O
other NN O O
leukoencephalopathy NN O B-Disease
and NN O O
is NN O O
probably NN O O
specific NN O O
for NN O O
a NN O O
phenotypic NN O O
variant NN O O
or NN O O
an NN O O
evolving NN O O
stage NN O O
of NN O O
ALD NN O B-Disease
. NN O O
. NN O O

Further NN O O
evidence NN O O
for NN O O
heterogeneity NN O O
of NN O O
glucose NN O B-Disease
- NN O I-Disease
6 NN O I-Disease
- NN O I-Disease
phosphate NN O I-Disease
dehydrogenase NN O I-Disease
deficiency NN O I-Disease
in NN O O
Papua NN O O
New NN O O
Guinea NN O O
. NN O O

Four NN O O
new NN O O
G6PD NN O O
variants NN O O
have NN O O
been NN O O
characterized NN O O
in NN O O
individuals NN O O
from NN O O
Papua NN O O
New NN O O
Guinea NN O O
. NN O O

This NN O O
study NN O O
demonstrates NN O O
that NN O O
the NN O O
previously NN O O
reported NN O O
Markham NN O O
variant NN O O
and NN O O
the NN O O
newly NN O O
characterized NN O O
Salata NN O O
variant NN O O
may NN O O
be NN O O
widely NN O O
distributed NN O O
in NN O O
Papua NN O O
New NN O O
Guinea NN O O
. NN O O

Th NN O O
data NN O O
presented NN O O
here NN O O
together NN O O
with NN O O
those NN O O
of NN O O
previously NN O O
published NN O O
studies NN O O
demonstrate NN O O
a NN O O
degree NN O O
of NN O O
heterogeneity NN O O
of NN O O
G6PD NN O B-Disease
deficiency NN O I-Disease
that NN O O
is NN O O
much NN O O
higher NN O O
than NN O O
that NN O O
in NN O O
other NN O O
regions NN O O
of NN O O
the NN O O
world NN O O
where NN O O
G6PD NN O B-Disease
deficiency NN O I-Disease
is NN O O
common NN O O
. NN O O
. NN O O

Increased NN O O
incidence NN O O
of NN O O
cataracts NN O B-Disease
in NN O O
male NN O O
subjects NN O O
deficient NN O B-Disease
in NN O I-Disease
glucose NN O I-Disease
- NN O I-Disease
6 NN O I-Disease
- NN O I-Disease
phosphate NN O I-Disease
dehydrogenase NN O I-Disease
. NN O O

Glucose NN O B-Disease
- NN O I-Disease
6 NN O I-Disease
- NN O I-Disease
phosphate NN O I-Disease
dehydrogenase NN O I-Disease
( NN O I-Disease
G6PD NN O I-Disease
) NN O I-Disease
deficiency NN O I-Disease
in NN O O
RBCs NN O O
was NN O O
found NN O O
significantly NN O O
more NN O O
frequently NN O O
in NN O O
210 NN O O
male NN O O
cataractous NN O B-Disease
patients NN O O
than NN O O
in NN O O
672 NN O O
control NN O O
subjects NN O O
of NN O O
Sardinian NN O O
origin NN O O
. NN O O

The NN O O
frequency NN O O
of NN O O
the NN O O
deficiency NN O O
was NN O O
increasingly NN O O
higher NN O O
in NN O O
presenile NN O O
cataracts NN O B-Disease
. NN O O

In NN O O
the NN O O
G6PD NN O B-Disease
- NN O I-Disease
deficient NN O I-Disease
group NN O O
, NN O O
the NN O O
incidence NN O O
of NN O O
cortical NN O B-Disease
and NN O I-Disease
total NN O I-Disease
cataracts NN O I-Disease
was NN O O
also NN O O
increased NN O O
. NN O O

It NN O O
is NN O O
suggested NN O O
that NN O O
decrease NN O O
of NN O O
the NN O O
G6PD NN O O
activity NN O O
in NN O O
the NN O O
lens NN O O
, NN O O
which NN O O
accompanies NN O O
its NN O O
deficiency NN O O
in NN O O
the NN O O
erythrocyte NN O O
, NN O O
might NN O O
play NN O O
a NN O O
role NN O O
in NN O O
the NN O O
cataracto NN O O
- NN O O
genesis NN O O
of NN O O
these NN O O
patients NN O O
. NN O O

Moreover NN O O
, NN O O
G6PD NN O B-Disease
deficiency NN O I-Disease
should NN O O
be NN O O
added NN O O
to NN O O
other NN O O
conditions NN O O
, NN O O
such NN O O
as NN O O
the NN O O
galactosemic NN O B-Disease
states NN O O
and NN O O
riboflavin NN O B-Disease
deficiency NN O I-Disease
, NN O O
where NN O O
cataracts NN O B-Disease
represent NN O O
a NN O O
sensitive NN O O
indicator NN O O
of NN O O
metabolic NN O B-Disease
abnormalities NN O I-Disease
of NN O O
the NN O O
RBC NN O O
. NN O O
. NN O O

Molecular NN O O
basis NN O O
of NN O O
human NN O O
mitochondrial NN O O
very NN O B-Disease
- NN O I-Disease
long NN O I-Disease
- NN O I-Disease
chain NN O I-Disease
acyl NN O I-Disease
- NN O I-Disease
CoA NN O I-Disease
dehydrogenase NN O I-Disease
deficiency NN O I-Disease
causing NN O O
cardiomyopathy NN O B-Disease
and NN O O
sudden NN O B-Disease
death NN O I-Disease
in NN O O
childhood NN O O
. NN O O

beta NN O O
- NN O O
Oxidation NN O O
of NN O O
long NN O O
- NN O O
chain NN O O
fatty NN O O
acids NN O O
provides NN O O
the NN O O
major NN O O
source NN O O
of NN O O
energy NN O O
in NN O O
the NN O O
heart NN O O
. NN O O

Defects NN O O
in NN O O
enzymes NN O O
of NN O O
the NN O O
beta NN O O
- NN O O
oxidation NN O O
pathway NN O O
cause NN O O
sudden NN O B-Disease
, NN O I-Disease
unexplained NN O I-Disease
death NN O I-Disease
in NN O O
childhood NN O O
, NN O O
acute NN O O
hepatic NN O B-Disease
encephalopathy NN O I-Disease
or NN O O
liver NN O B-Disease
failure NN O I-Disease
, NN O O
skeletal NN O B-Disease
myopathy NN O I-Disease
, NN O O
and NN O O
cardiomyopathy NN O B-Disease
. NN O O

Very NN O O
- NN O O
long NN O O
- NN O O
chain NN O O
acyl NN O O
- NN O O
CoA NN O O
dehydrogenase NN O O
[ NN O O
VLCAD NN O O
; NN O O
very NN O O
- NN O O
long NN O O
- NN O O
chain NN O O
- NN O O
acyl NN O O
- NN O O
CoA NN O O
( NN O O
acceptor NN O O
) NN O O
2 NN O O
, NN O O
3 NN O O
- NN O O
oxidoreductase NN O O
, NN O O
EC NN O O
1 NN O O
. NN O O
3 NN O O
3 NN O O
. NN O O
99 NN O O
99 NN O O
. NN O O
13 NN O O
] NN O O
catalyzes NN O O
the NN O O
first NN O O
step NN O O
in NN O O
beta NN O O
- NN O O
oxidation NN O O
. NN O O

We NN O O
have NN O O
isolated NN O O
the NN O O
human NN O O
VLCAD NN O O
cDNA NN O O
and NN O O
gene NN O O
and NN O O
determined NN O O
the NN O O
complete NN O O
nucleotide NN O O
sequences NN O O
. NN O O

Polymerase NN O O
chain NN O O
reaction NN O O
amplification NN O O
of NN O O
VLCAD NN O O
mRNA NN O O
and NN O O
genomic NN O O
exons NN O O
defined NN O O
the NN O O
molecular NN O O
defects NN O O
in NN O O
two NN O O
patients NN O O
with NN O O
VLCAD NN O B-Disease
deficiency NN O I-Disease
who NN O O
presented NN O O
with NN O O
unexplained NN O O
cardiac NN O B-Disease
arrest NN O I-Disease
and NN O O
cardiomyopathy NN O B-Disease
. NN O O

In NN O O
one NN O O
, NN O O
a NN O O
homozygous NN O O
mutation NN O O
in NN O O
the NN O O
consensus NN O O
dinucleotide NN O O
of NN O O
the NN O O
donor NN O O
splice NN O O
site NN O O
( NN O O
g NN O O
+ NN O O
1 NN O O
- NN O O
- NN O O
> NN O O
a NN O O
) NN O O
was NN O O
associated NN O O
with NN O O
universal NN O O
skipping NN O O
of NN O O
the NN O O
prior NN O O
exon NN O O
( NN O O
exon NN O O
11 NN O O
) NN O O
. NN O O

The NN O O
second NN O O
patient NN O O
was NN O O
a NN O O
compound NN O O
heterozygote NN O O
, NN O O
with NN O O
a NN O O
missense NN O O
mutation NN O O
, NN O O
C1837 NN O O
- NN O O
- NN O O
> NN O O
T NN O O
, NN O O
changing NN O O
the NN O O
arginine NN O O
at NN O O
residue NN O O
613 NN O O
to NN O O
tryptophan NN O O
on NN O O
one NN O O
allele NN O O
and NN O O
a NN O O
single NN O O
base NN O O
deletion NN O O
at NN O O
the NN O O
intron NN O O
- NN O O
exon NN O O
6 NN O O
boundary NN O O
as NN O O
the NN O O
second NN O O
mutation NN O O
. NN O O

This NN O O
initial NN O O
delineation NN O O
of NN O O
human NN O O
mutations NN O O
in NN O O
VLCAD NN O O
suggests NN O O
that NN O O
VLCAD NN O B-Disease
deficiency NN O I-Disease
reduces NN O O
myocardial NN O O
fatty NN O O
acid NN O O
beta NN O O
- NN O O
oxidation NN O O
and NN O O
energy NN O O
production NN O O
and NN O O
is NN O O
associated NN O O
with NN O O
cardiomyopathy NN O B-Disease
and NN O O
sudden NN O B-Disease
death NN O I-Disease
in NN O O
childhood NN O O
. NN O O

Aberrant NN O O
subcellular NN O O
localization NN O O
of NN O O
BRCA1 NN O O
in NN O O
breast NN O B-Disease
cancer NN O I-Disease
. NN O O

The NN O O
BRCA1 NN O O
gene NN O O
product NN O O
was NN O O
identified NN O O
as NN O O
a NN O O
220 NN O O
- NN O O
kilodalton NN O O
nuclear NN O O
phosphoprotein NN O O
in NN O O
normal NN O O
cells NN O O
, NN O O
including NN O O
breast NN O O
ductal NN O O
epithelial NN O O
cells NN O O
, NN O O
and NN O O
in NN O O
18 NN O O
of NN O O
20 NN O O
tumor NN O B-Disease
cell NN O O
lines NN O O
derived NN O O
from NN O O
tissues NN O O
other NN O O
than NN O O
breast NN O O
and NN O O
ovary NN O O
. NN O O

In NN O O
16 NN O O
of NN O O
17 NN O O
breast NN O B-Disease
and NN O I-Disease
ovarian NN O I-Disease
cancer NN O I-Disease
lines NN O O
and NN O O
17 NN O O
of NN O O
17 NN O O
samples NN O O
of NN O O
cells NN O O
obtained NN O O
from NN O O
malignant NN O O
effusions NN O O
, NN O O
however NN O O
, NN O O
BRCA1 NN O O
localized NN O O
mainly NN O O
in NN O O
cytoplasm NN O O
. NN O O

Absence NN O O
of NN O O
BRCA1 NN O O
or NN O O
aberrant NN O O
subcellular NN O O
location NN O O
was NN O O
also NN O O
observed NN O O
to NN O O
a NN O O
variable NN O O
extent NN O O
in NN O O
histological NN O O
sections NN O O
of NN O O
many NN O O
breast NN O B-Disease
cancer NN O I-Disease
biopsies NN O O
. NN O O

These NN O O
findings NN O O
suggest NN O O
that NN O O
BRCA1 NN O B-Disease
abnormalities NN O I-Disease
may NN O O
be NN O O
involved NN O O
in NN O O
the NN O O
pathogenesis NN O O
of NN O O
many NN O O
breast NN O B-Disease
cancers NN O I-Disease
, NN O O
sporadic NN O O
as NN O O
well NN O O
as NN O O
familial NN O O
. NN O O
. NN O O

Mapping NN O O
of NN O O
the NN O O
mouse NN O O
homologue NN O O
of NN O O
the NN O O
Wilson NN O B-Disease
disease NN O I-Disease
gene NN O O
to NN O O
mouse NN O O
chromosome NN O O
8 NN O O
. NN O O

ATP7B NN O O
, NN O O
the NN O O
gene NN O O
altered NN O O
in NN O O
Wilson NN O B-Disease
disease NN O I-Disease
( NN O O
WD NN O B-Disease
) NN O O
patients NN O O
, NN O O
lies NN O O
in NN O O
a NN O O
block NN O O
of NN O O
homology NN O O
shared NN O O
between NN O O
human NN O O
chromosome NN O O
13q14 NN O O
and NN O O
the NN O O
central NN O O
region NN O O
of NN O O
mouse NN O O
chromosome NN O O
14 NN O O
. NN O O

However NN O O
, NN O O
we NN O O
have NN O O
mapped NN O O
the NN O O
murine NN O O
homologue NN O O
of NN O O
ATP7B NN O O
( NN O O
Atp7b NN O O
) NN O O
to NN O O
mouse NN O O
chromosome NN O O
8 NN O O
by NN O O
somatic NN O O
cell NN O O
hybrid NN O O
analysis NN O O
. NN O O

Analysis NN O O
of NN O O
80 NN O O
interspecific NN O O
backcross NN O O
offspring NN O O
was NN O O
used NN O O
to NN O O
position NN O O
Atp7b NN O O
close NN O O
to NN O O
D8Mit3 NN O O
and NN O O
another NN O O
ATPase NN O O
locus NN O O
, NN O O
Atp4b NN O O
, NN O O
on NN O O
mouse NN O O
chromosome NN O O
8 NN O O
. NN O O

ATP4B NN O O
lies NN O O
in NN O O
13q34 NN O O
and NN O O
is NN O O
separated NN O O
from NN O O
ATP7B NN O O
by NN O O
several NN O O
loci NN O O
whose NN O O
mouse NN O O
homologues NN O O
map NN O O
to NN O O
mouse NN O O
chromosome NN O O
14 NN O O
. NN O O

The NN O O
assignment NN O O
of NN O O
Atp7b NN O O
to NN O O
mouse NN O O
chromosome NN O O
8 NN O O
identifies NN O O
a NN O O
previously NN O O
unrecognized NN O O
region NN O O
of NN O O
homology NN O O
between NN O O
this NN O O
chromosome NN O O
and NN O O
human NN O O
chromosome NN O O
13 NN O O
. NN O O

This NN O O
assignment NN O O
suggests NN O O
a NN O O
possible NN O O
location NN O O
for NN O O
the NN O O
toxic NN O O
milk NN O O
mutation NN O O
in NN O O
the NN O O
mouse NN O O
, NN O O
which NN O O
has NN O O
been NN O O
proposed NN O O
as NN O O
a NN O O
homologue NN O O
of NN O O
WD NN O B-Disease
. NN O O
. NN O O

Germline NN O O
mutations NN O O
of NN O O
the NN O O
BRCA1 NN O O
gene NN O O
in NN O O
breast NN O B-Disease
and NN O I-Disease
ovarian NN O I-Disease
cancer NN O I-Disease
families NN O O
provide NN O O
evidence NN O O
for NN O O
a NN O O
genotype NN O O
- NN O O
phenotype NN O O
correlation NN O O
. NN O O

Mutations NN O O
in NN O O
the NN O O
BRCA1 NN O O
gene NN O O
, NN O O
discovered NN O O
in NN O O
1994 NN O O
, NN O O
are NN O O
associated NN O O
with NN O O
an NN O O
80 NN O O
- NN O O
90 NN O O
% NN O O
lifetime NN O O
risk NN O O
of NN O O
breast NN O B-Disease
cancer NN O I-Disease
. NN O O

We NN O O
have NN O O
analysed NN O O
60 NN O O
families NN O O
with NN O O
a NN O O
history NN O O
of NN O O
breast NN O B-Disease
and NN O I-Disease
/ NN O I-Disease
or NN O I-Disease
ovarian NN O I-Disease
cancer NN O I-Disease
for NN O O
germline NN O O
mutations NN O O
in NN O O
BRCA1 NN O O
. NN O O

Twenty NN O O
- NN O O
two NN O O
different NN O O
mutations NN O O
were NN O O
detected NN O O
in NN O O
32 NN O O
families NN O O
( NN O O
53 NN O O
% NN O O
) NN O O
, NN O O
of NN O O
which NN O O
14 NN O O
are NN O O
previously NN O O
unreported NN O O
. NN O O

We NN O O
observed NN O O
a NN O O
significant NN O O
correlation NN O O
between NN O O
the NN O O
location NN O O
of NN O O
the NN O O
mutation NN O O
in NN O O
the NN O O
gene NN O O
and NN O O
the NN O O
ratio NN O O
of NN O O
breast NN O B-Disease
to NN O I-Disease
ovarian NN O I-Disease
cancer NN O I-Disease
incidence NN O O
within NN O O
each NN O O
family NN O O
. NN O O

Our NN O O
data NN O O
suggest NN O O
a NN O O
transition NN O O
in NN O O
risk NN O O
such NN O O
that NN O O
mutations NN O O
in NN O O
the NN O O
3 NN O O
third NN O O
of NN O O
the NN O O
gene NN O O
are NN O O
associated NN O O
with NN O O
a NN O O
lower NN O O
proportion NN O O
of NN O O
ovarian NN O B-Disease
cancer NN O I-Disease
. NN O O

Haplotype NN O O
analysis NN O O
supports NN O O
previous NN O O
data NN O O
which NN O O
suggest NN O O
some NN O O
BRCA1 NN O O
mutation NN O O
carriers NN O O
have NN O O
common NN O O
ancestors NN O O
; NN O O
however NN O O
, NN O O
we NN O O
have NN O O
found NN O O
at NN O O
least NN O O
two NN O O
examples NN O O
where NN O O
recurrent NN O O
mutations NN O O
appear NN O O
to NN O O
have NN O O
arisen NN O O
independently NN O O
. NN O O
. NN O O

Hereditary NN O O
deficiency NN O B-Disease
of NN O I-Disease
the NN O I-Disease
seventh NN O I-Disease
component NN O I-Disease
of NN O I-Disease
complement NN O I-Disease
and NN O O
recurrent NN O O
meningococcal NN O B-Disease
infection NN O I-Disease
: NN O O
investigations NN O O
of NN O O
an NN O O
Irish NN O O
family NN O O
using NN O O
a NN O O
novel NN O O
haemolytic NN O O
screening NN O O
assay NN O O
for NN O O
complement NN O O
activity NN O O
and NN O O
C7 NN O O
M NN O O
/ NN O O
N NN O O
allotyping NN O O
. NN O O

Terminal NN O B-Disease
complement NN O I-Disease
component NN O I-Disease
deficiency NN O I-Disease
predisposes NN O O
to NN O O
meningococcal NN O B-Disease
infection NN O I-Disease
and NN O O
is NN O O
inherited NN O O
in NN O O
an NN O O
autosomal NN O O
co NN O O
- NN O O
dominant NN O O
manner NN O O
. NN O O

An NN O O
Irish NN O O
family NN O O
is NN O O
described NN O O
, NN O O
in NN O O
which NN O O
2 NN O O
of NN O O
3 NN O O
brothers NN O O
had NN O O
recurrent NN O O
meningococcal NN O B-Disease
infection NN O I-Disease
. NN O O

A NN O O
novel NN O O
screening NN O O
assay NN O O
was NN O O
used NN O O
to NN O O
investigate NN O O
for NN O O
terminal NN O B-Disease
complement NN O I-Disease
deficiency NN O I-Disease
and NN O O
the NN O O
2 NN O O
affected NN O O
brothers NN O O
were NN O O
found NN O O
to NN O O
be NN O O
completely NN O B-Disease
deficient NN O I-Disease
in NN O I-Disease
the NN O I-Disease
seventh NN O I-Disease
component NN O I-Disease
of NN O I-Disease
complement NN O I-Disease
( NN O O
C7 NN O O
) NN O O
. NN O O

Enzyme NN O O
- NN O O
linked NN O O
immunosorbent NN O O
assay NN O O
for NN O O
C7 NN O O
revealed NN O O
lower NN O O
than NN O O
normal NN O O
levels NN O O
in NN O O
the NN O O
remaining NN O O
brother NN O O
and NN O O
parents NN O O
. NN O O

C7 NN O O
M NN O O
/ NN O O
N NN O O
protein NN O O
polymorphism NN O O
allotyping NN O O
, NN O O
used NN O O
to NN O O
investigate NN O O
the NN O O
segregation NN O O
of NN O O
the NN O O
C7 NN O B-Disease
deficiency NN O I-Disease
genes NN O O
, NN O O
showed NN O O
that NN O O
the NN O O
apparently NN O O
complement NN O O
sufficient NN O O
brother NN O O
was NN O O
heterozygous NN O O
C7 NN O B-Disease
deficient NN O I-Disease
and NN O O
a NN O O
carrier NN O O
of NN O O
one NN O O
of NN O O
the NN O O
deficiency NN O O
genes NN O O
. NN O O

Complement NN O O
screening NN O O
should NN O O
be NN O O
carried NN O O
out NN O O
in NN O O
any NN O O
individual NN O O
suffering NN O O
recurrent NN O O
meningococcal NN O B-Disease
infection NN O I-Disease
or NN O O
infection NN O O
with NN O O
an NN O O
uncommon NN O O
meningococcal NN O B-Disease
serogroup NN O O
. NN O O

Identification NN O O
of NN O O
complement NN O B-Disease
deficient NN O I-Disease
patients NN O O
allows NN O O
the NN O O
implementation NN O O
of NN O O
strategies NN O O
to NN O O
prevent NN O O
recurrent NN O O
infection NN O O
. NN O O
. NN O O

Molecular NN O O
basis NN O O
of NN O O
subtotal NN O B-Disease
complement NN O I-Disease
C6 NN O I-Disease
deficiency NN O I-Disease
. NN O O

A NN O O
carboxy NN O O
- NN O O
terminally NN O O
truncated NN O O
but NN O O
functionally NN O O
active NN O O
C6 NN O O
. NN O O

Individuals NN O O
with NN O O
subtotal NN O B-Disease
complement NN O I-Disease
C6 NN O I-Disease
deficiency NN O I-Disease
possess NN O O
a NN O O
C6 NN O O
molecule NN O O
that NN O O
is NN O O
14 NN O O
% NN O O
shorter NN O O
than NN O O
normal NN O O
C6 NN O O
and NN O O
present NN O O
in NN O O
low NN O O
but NN O O
detectable NN O O
concentrations NN O O
( NN O O
1 NN O O
- NN O O
2 NN O O
% NN O O
of NN O O
the NN O O
normal NN O O
mean NN O O
) NN O O
. NN O O

We NN O O
now NN O O
show NN O O
that NN O O
this NN O O
dysmorphic NN O O
C6 NN O O
is NN O O
bactericidally NN O O
active NN O O
and NN O O
lacks NN O O
an NN O O
epitope NN O O
that NN O O
was NN O O
mapped NN O O
to NN O O
the NN O O
most NN O O
carboxy NN O O
- NN O O
terminal NN O O
part NN O O
of NN O O
C6 NN O O
using NN O O
C6 NN O O
cDNA NN O O
fragments NN O O
expressed NN O O
as NN O O
fusion NN O O
proteins NN O O
in NN O O
the NN O O
pUEX NN O O
expression NN O O
system NN O O
. NN O O

We NN O O
thus NN O O
predicted NN O O
that NN O O
the NN O O
abnormal NN O O
C6 NN O O
molecule NN O O
might NN O O
be NN O O
carboxy NN O O
- NN O O
terminally NN O O
truncated NN O O
and NN O O
sought NN O O
a NN O O
mutation NN O O
in NN O O
an NN O O
area NN O O
approximately NN O O
14 NN O O
% NN O O
from NN O O
the NN O O
carboxy NN O O
- NN O O
terminal NN O O
end NN O O
of NN O O
the NN O O
coding NN O O
sequence NN O O
. NN O O

By NN O O
sequencing NN O O
PCR NN O O
- NN O O
amplified NN O O
products NN O O
from NN O O
this NN O O
region NN O O
, NN O O
we NN O O
found NN O O
, NN O O
in NN O O
three NN O O
individuals NN O O
from NN O O
two NN O O
families NN O O
, NN O O
a NN O O
mutation NN O O
that NN O O
might NN O O
plausibly NN O O
be NN O O
responsible NN O O
for NN O O
the NN O O
defect NN O O
. NN O O

All NN O O
three NN O O
have NN O O
an NN O O
abnormal NN O O
5 NN O O
splice NN O O
donor NN O O
site NN O O
of NN O O
intron NN O O
15 NN O O
, NN O O
which NN O O
would NN O O
probably NN O O
prevent NN O O
splicing NN O O
. NN O O

An NN O O
in NN O O
- NN O O
frame NN O O
stop NN O O
codon NN O O
is NN O O
found NN O O
17 NN O O
codons NN O O
downstream NN O O
from NN O O
the NN O O
intron NN O O
boundary NN O O
, NN O O
which NN O O
would NN O O
lead NN O O
to NN O O
a NN O O
truncated NN O O
polypeptide NN O O
13 NN O O
. NN O O

5 NN O O
% NN O O
smaller NN O O
than NN O O
normal NN O O
C6 NN O O
. NN O O

This NN O O
result NN O O
was NN O O
unexpected NN O O
, NN O O
as NN O O
earlier NN O O
studies NN O O
mapped NN O O
the NN O O
C5b NN O O
binding NN O O
site NN O O
, NN O O
or NN O O
a NN O O
putative NN O O
enzymatic NN O O
region NN O O
, NN O O
to NN O O
this NN O O
part NN O O
of NN O O
C6 NN O O
. NN O O

Interestingly NN O O
, NN O O
all NN O O
three NN O O
subjects NN O O
were NN O O
probably NN O O
heterozygous NN O O
for NN O O
both NN O O
subtotal NN O B-Disease
C6 NN O I-Disease
and NN O I-Disease
complete NN O I-Disease
C6 NN O I-Disease
deficiency NN O I-Disease
. NN O O

Myotonic NN O B-Disease
dystrophy NN O I-Disease
: NN O O
evidence NN O O
for NN O O
a NN O O
possible NN O O
dominant NN O O
- NN O O
negative NN O O
RNA NN O O
mutation NN O O
. NN O O

The NN O O
trinucleotide NN O O
expansion NN O O
mutation NN O O
causing NN O O
myotonic NN O B-Disease
dystrophy NN O I-Disease
is NN O O
in NN O O
the NN O O
3 NN O O
untranslated NN O O
region NN O O
of NN O O
a NN O O
protein NN O O
kinase NN O O
gene NN O O
. NN O O

The NN O O
molecular NN O O
mechanisms NN O O
by NN O O
which NN O O
the NN O O
expanded NN O O
repeat NN O O
causes NN O O
the NN O O
clinically NN O O
variable NN O O
and NN O O
multisystemic NN O B-Disease
disease NN O I-Disease
, NN O O
myotonic NN O B-Disease
dystrophy NN O I-Disease
, NN O O
are NN O O
not NN O O
understood NN O O
. NN O O

It NN O O
has NN O O
been NN O O
particularly NN O O
difficult NN O O
to NN O O
rationalize NN O O
the NN O O
dominant NN O O
inheritance NN O O
with NN O O
the NN O O
fact NN O O
that NN O O
the NN O O
expansion NN O O
mutation NN O O
lies NN O O
outside NN O O
of NN O O
the NN O O
protein NN O O
- NN O O
encoding NN O O
gene NN O O
elements NN O O
, NN O O
and NN O O
should NN O O
not NN O O
be NN O O
translated NN O O
into NN O O
protein NN O O
. NN O O

Here NN O O
we NN O O
use NN O O
muscle NN O O
biopsies NN O O
from NN O O
classical NN O O
adult NN O O
- NN O O
onset NN O O
myotonic NN O B-Disease
dystrophy NN O I-Disease
patients NN O O
to NN O O
study NN O O
the NN O O
accumulation NN O O
of NN O O
transcripts NN O O
from NN O O
both NN O O
the NN O O
normal NN O O
and NN O O
expanded NN O O
DM NN O B-Disease
kinase NN O O
genes NN O O
in NN O O
patient NN O O
muscle NN O O
, NN O O
and NN O O
compare NN O O
the NN O O
results NN O O
to NN O O
normal NN O O
and NN O O
myopathic NN O B-Disease
controls NN O O
. NN O O

We NN O O
found NN O O
relatively NN O O
small NN O O
decreases NN O O
of NN O O
DM NN O B-Disease
kinase NN O O
RNA NN O O
in NN O O
the NN O O
total NN O O
RNA NN O O
pool NN O O
from NN O O
muscle NN O O
; NN O O
however NN O O
, NN O O
these NN O O
reductions NN O O
were NN O O
not NN O O
disease NN O O
specific NN O O
. NN O O

Analysis NN O O
of NN O O
poly NN O O
( NN O O
A NN O O
) NN O O
+ NN O O
RNA NN O O
showed NN O O
dramatic NN O O
decreases NN O O
of NN O O
both NN O O
the NN O O
mutant NN O O
and NN O O
normal NN O O
DM NN O B-Disease
kinase NN O O
RNAs NN O O
, NN O O
and NN O O
these NN O O
changes NN O O
were NN O O
disease NN O O
- NN O O
specific NN O O
. NN O O

Our NN O O
findings NN O O
are NN O O
consistent NN O O
with NN O O
a NN O O
novel NN O O
molecular NN O O
pathogenetic NN O O
mechanism NN O O
for NN O O
myotonic NN O B-Disease
dystrophy NN O I-Disease
both NN O O
the NN O O
normal NN O O
and NN O O
expanded NN O O
DM NN O B-Disease
kinase NN O O
genes NN O O
are NN O O
transcribed NN O O
in NN O O
patient NN O O
muscle NN O O
, NN O O
but NN O O
the NN O O
abnormal NN O O
expansion NN O O
- NN O O
containing NN O O
RNA NN O O
has NN O O
a NN O O
dominant NN O O
effect NN O O
on NN O O
RNA NN O O
metabolism NN O O
by NN O O
preventing NN O O
the NN O O
accumulation NN O O
of NN O O
poly NN O O
( NN O O
A NN O O
) NN O O
+ NN O O
RNA NN O O
. NN O O

The NN O O
ability NN O O
of NN O O
the NN O O
expansion NN O O
mutation NN O O
to NN O O
alter NN O O
accumulation NN O O
of NN O O
poly NN O O
( NN O O
A NN O O
) NN O O
+ NN O O
RNA NN O O
in NN O O
trans NN O O
suggests NN O O
that NN O O
myotonic NN O B-Disease
dystrophy NN O I-Disease
may NN O O
be NN O O
the NN O O
first NN O O
example NN O O
of NN O O
a NN O O
dominant NN O O
- NN O O
negative NN O O
mutation NN O O
manifested NN O O
at NN O O
the NN O O
RNA NN O O
level NN O O
. NN O O
. NN O O

A NN O O
strong NN O O
candidate NN O O
for NN O O
the NN O O
breast NN O B-Disease
and NN O I-Disease
ovarian NN O I-Disease
cancer NN O I-Disease
susceptibility NN O O
gene NN O O
BRCA1 NN O O
. NN O O

A NN O O
strong NN O O
candidate NN O O
for NN O O
the NN O O
17q NN O O
- NN O O
linked NN O O
BRCA1 NN O O
gene NN O O
, NN O O
which NN O O
influences NN O O
susceptibility NN O O
to NN O O
breast NN O B-Disease
and NN O I-Disease
ovarian NN O I-Disease
cancer NN O I-Disease
, NN O O
has NN O O
been NN O O
identified NN O O
by NN O O
positional NN O O
cloning NN O O
methods NN O O
. NN O O

Probable NN O O
predisposing NN O O
mutations NN O O
have NN O O
been NN O O
detected NN O O
in NN O O
five NN O O
of NN O O
eight NN O O
kindreds NN O O
presumed NN O O
to NN O O
segregate NN O O
BRCA1 NN O O
susceptibility NN O O
alleles NN O O
. NN O O

The NN O O
mutations NN O O
include NN O O
an NN O O
11 NN O O
- NN O O
base NN O O
pair NN O O
deletion NN O O
, NN O O
a NN O O
1 NN O O
- NN O O
base NN O O
pair NN O O
insertion NN O O
, NN O O
a NN O O
stop NN O O
codon NN O O
, NN O O
a NN O O
missense NN O O
substitution NN O O
, NN O O
and NN O O
an NN O O
inferred NN O O
regulatory NN O O
mutation NN O O
. NN O O

The NN O O
BRCA1 NN O O
gene NN O O
is NN O O
expressed NN O O
in NN O O
numerous NN O O
tissues NN O O
, NN O O
including NN O O
breast NN O O
and NN O O
ovary NN O O
, NN O O
and NN O O
encodes NN O O
a NN O O
predicted NN O O
protein NN O O
of NN O O
1863 NN O O
amino NN O O
acids NN O O
. NN O O

This NN O O
protein NN O O
contains NN O O
a NN O O
zinc NN O O
finger NN O O
domain NN O O
in NN O O
its NN O O
amino NN O O
- NN O O
terminal NN O O
region NN O O
, NN O O
but NN O O
is NN O O
otherwise NN O O
unrelated NN O O
to NN O O
previously NN O O
described NN O O
proteins NN O O
. NN O O

Identification NN O O
of NN O O
BRCA1 NN O O
should NN O O
facilitate NN O O
early NN O O
diagnosis NN O O
of NN O O
breast NN O B-Disease
and NN O I-Disease
ovarian NN O I-Disease
cancer NN O I-Disease
susceptibility NN O O
in NN O O
some NN O O
individuals NN O O
as NN O O
well NN O O
as NN O O
a NN O O
better NN O O
understanding NN O O
of NN O O
breast NN O B-Disease
cancer NN O I-Disease
biology NN O O
. NN O O
. NN O O

Molecular NN O O
characterization NN O O
of NN O O
galactosemia NN O B-Disease
( NN O O
type NN O O
1 NN O O
) NN O O
mutations NN O O
in NN O O
Japanese NN O O
. NN O O

We NN O O
characterized NN O O
two NN O O
novel NN O O
mutations NN O O
of NN O O
the NN O O
galactose NN O O
- NN O O
1 NN O O
- NN O O
phosphate NN O O
uridyltransferase NN O O
( NN O O
GALT NN O O
) NN O O
gene NN O O
in NN O O
two NN O O
Japanese NN O O
patients NN O O
with NN O O
GALT NN O B-Disease
deficiency NN O I-Disease
and NN O O
identified NN O O
N314D NN O O
and NN O O
R333W NN O O
mutations NN O O
, NN O O
previously NN O O
found NN O O
in NN O O
Caucasians NN O O
. NN O O

One NN O O
novel NN O O
missense NN O O
mutation NN O O
was NN O O
an NN O O
G NN O O
- NN O O
to NN O O
- NN O O
A NN O O
transition NN O O
in NN O O
exon NN O O
8 NN O O
, NN O O
resulting NN O O
in NN O O
the NN O O
substitution NN O O
of NN O O
arginine NN O O
by NN O O
histidine NN O O
at NN O O
the NN O O
codon NN O O
231 NN O O
( NN O O
R231H NN O O
) NN O O
. NN O O

GALT NN O O
activity NN O O
of NN O O
the NN O O
R231H NN O O
mutant NN O O
construct NN O O
was NN O O
reduced NN O O
to NN O O
15 NN O O
% NN O O
of NN O O
normal NN O O
controls NN O O
in NN O O
a NN O O
COS NN O O
cell NN O O
expression NN O O
system NN O O
. NN O O

The NN O O
other NN O O
was NN O O
a NN O O
splicing NN O O
mutation NN O O
, NN O O
an NN O O
A NN O O
- NN O O
to NN O O
- NN O O
G NN O O
transition NN O O
at NN O O
the NN O O
38th NN O O
nucleotide NN O O
in NN O O
exon NN O O
3 NN O O
( NN O O
318A NN O O
- NN O O
- NN O O
> NN O O
G NN O O
) NN O O
, NN O O
resulting NN O O
in NN O O
a NN O O
38 NN O O
- NN O O
bp NN O O
deletion NN O O
in NN O O
the NN O O
GALT NN O O
cDNA NN O O
by NN O O
activating NN O O
a NN O O
cryptic NN O O
splice NN O O
acceptor NN O O
site NN O O
. NN O O

In NN O O
seven NN O O
Japanese NN O O
families NN O O
( NN O O
14 NN O O
alleles NN O O
for NN O O
classic NN O O
form NN O O
and NN O O
one NN O O
allele NN O O
for NN O O
Duarte NN O O
variant NN O O
) NN O O
with NN O O
GALT NN O B-Disease
deficiency NN O I-Disease
, NN O O
the NN O O
R231H NN O O
and NN O O
318A NN O O
- NN O O
- NN O O
> NN O O
G NN O O
mutations NN O O
were NN O O
found NN O O
only NN O O
on NN O O
both NN O O
alleles NN O O
of NN O O
the NN O O
proband NN O O
. NN O O

The NN O O
N314D NN O O
and NN O O
R333W NN O O
mutations NN O O
were NN O O
found NN O O
on NN O O
one NN O O
allele NN O O
each NN O O
. NN O O

The NN O O
Q188R NN O O
was NN O O
prevalent NN O O
in NN O O
the NN O O
United NN O O
States NN O O
but NN O O
not NN O O
in NN O O
Japanese NN O O
patients NN O O
. NN O O

The NN O O
N314D NN O O
mutation NN O O
was NN O O
associated NN O O
with NN O O
the NN O O
Duarte NN O O
variant NN O O
in NN O O
Japanese NN O O
persons NN O O
, NN O O
as NN O O
well NN O O
as NN O O
in NN O O
the NN O O
United NN O O
States NN O O
. NN O O

We NN O O
speculate NN O O
that NN O O
classic NN O B-Disease
galactosemia NN O I-Disease
mutations NN O O
appear NN O O
to NN O O
differ NN O O
between NN O O
Japanese NN O O
and NN O O
Caucasian NN O O
patients NN O O
. NN O O

Our NN O O
limited NN O O
data NN O O
set NN O O
on NN O O
galactosemia NN O B-Disease
mutations NN O O
in NN O O
Japanese NN O O
suggests NN O O
that NN O O
the NN O O
N314D NN O O
GALT NN O O
mutation NN O O
encoding NN O O
the NN O O
Duarte NN O O
variant NN O O
arose NN O O
before NN O O
Asian NN O O
and NN O O
Caucasian NN O O
people NN O O
diverged NN O O
and NN O O
that NN O O
classic NN O B-Disease
galactosemia NN O I-Disease
mutations NN O O
arose NN O O
and NN O O
/ NN O O
or NN O O
accumulated NN O O
after NN O O
the NN O O
divergence NN O O
of NN O O
Asian NN O O
and NN O O
Caucasian NN O O
populations NN O O
. NN O O
. NN O O

Three NN O O
novel NN O O
aniridia NN O B-Disease
mutations NN O O
in NN O O
the NN O O
human NN O O
PAX6 NN O O
gene NN O O
. NN O O

Aniridia NN O B-Disease
( NN O O
iris NN O B-Disease
hypoplasia NN O I-Disease
) NN O O
is NN O O
an NN O O
autosomal NN O B-Disease
dominant NN O I-Disease
congenital NN O I-Disease
disorder NN O I-Disease
of NN O I-Disease
the NN O I-Disease
eye NN O I-Disease
. NN O O

Mutations NN O O
in NN O O
the NN O O
human NN O O
aniridia NN O B-Disease
( NN O O
PAX6 NN O O
) NN O O
gene NN O O
have NN O O
now NN O O
been NN O O
identified NN O O
in NN O O
many NN O O
patients NN O O
from NN O O
various NN O O
ethnic NN O O
groups NN O O
. NN O O

In NN O O
the NN O O
study NN O O
reported NN O O
here NN O O
we NN O O
describe NN O O
PAX6 NN O O
mutations NN O O
in NN O O
one NN O O
sporadic NN O O
and NN O O
five NN O O
familial NN O O
cases NN O O
with NN O O
aniridia NN O B-Disease
. NN O O

Of NN O O
the NN O O
four NN O O
different NN O O
mutations NN O O
identified NN O O
, NN O O
one NN O O
was NN O O
identical NN O O
to NN O O
a NN O O
previously NN O O
reported NN O O
mutation NN O O
( NN O O
C NN O O
- NN O O
- NN O O
> NN O O
T NN O O
transition NN O O
at NN O O
codon NN O O
240 NN O O
) NN O O
, NN O O
and NN O O
three NN O O
were NN O O
novel NN O O
two NN O O
in NN O O
the NN O O
glycine NN O O
- NN O O
rich NN O O
region NN O O
and NN O O
one NN O O
in NN O O
the NN O O
proline NN O O
/ NN O O
serine NN O O
/ NN O O
threonine NN O O
- NN O O
rich NN O O
( NN O O
PST NN O O
) NN O O
region NN O O
. NN O O

One NN O O
PAX6 NN O O
mutation NN O O
found NN O O
in NN O O
the NN O O
PST NN O O
region NN O O
was NN O O
associated NN O O
with NN O O
cataracts NN O B-Disease
in NN O O
an NN O O
aniridia NN O B-Disease
family NN O O
. NN O O

Another NN O O
splice NN O O
mutation NN O O
in NN O O
the NN O O
PST NN O O
domain NN O O
occurred NN O O
in NN O O
an NN O O
aniridia NN O B-Disease
patient NN O O
with NN O O
anosmia NN O B-Disease
( NN O O
inability NN O O
to NN O O
smell NN O O
) NN O O
. NN O O

The NN O O
six NN O O
new NN O O
aniridia NN O B-Disease
cases NN O O
reported NN O O
here NN O O
have NN O O
mutations NN O O
predicted NN O O
to NN O O
generate NN O O
incomplete NN O O
PAX6 NN O O
proteins NN O O
. NN O O

These NN O O
results NN O O
support NN O O
the NN O O
theory NN O O
that NN O O
human NN O O
aniridia NN O B-Disease
is NN O O
caused NN O O
by NN O O
haploinsufficiency NN O B-Disease
of NN O I-Disease
PAX6 NN O I-Disease
. NN O O
. NN O O

The NN O O
carrier NN O O
frequency NN O O
of NN O O
the NN O O
BRCA1 NN O O
185delAG NN O O
mutation NN O O
is NN O O
approximately NN O O
1 NN O O
percent NN O O
in NN O O
Ashkenazi NN O O
Jewish NN O O
individuals NN O O
. NN O O

Since NN O O
BRCA1 NN O O
, NN O O
the NN O O
first NN O O
major NN O O
gene NN O O
responsible NN O O
for NN O O
inherited NN O B-Disease
breast NN O I-Disease
cancer NN O I-Disease
, NN O O
was NN O O
cloned NN O O
, NN O O
more NN O O
than NN O O
50 NN O O
unique NN O O
mutations NN O O
have NN O O
been NN O O
detected NN O O
in NN O O
the NN O O
germline NN O O
of NN O O
individuals NN O O
with NN O O
breast NN O B-Disease
and NN O I-Disease
ovarian NN O I-Disease
cancer NN O I-Disease
. NN O O

In NN O O
high NN O O
- NN O O
risk NN O O
pedigrees NN O O
, NN O O
female NN O O
carriers NN O O
of NN O O
BRCA1 NN O O
mutations NN O O
have NN O O
an NN O O
80 NN O O
- NN O O
90 NN O O
% NN O O
lifetime NN O O
risk NN O O
of NN O O
breast NN O B-Disease
cancer NN O I-Disease
, NN O O
and NN O O
a NN O O
40 NN O O
- NN O O
50 NN O O
% NN O O
risk NN O O
of NN O O
ovarian NN O B-Disease
cancer NN O I-Disease
. NN O O

However NN O O
, NN O O
the NN O O
mutation NN O O
stats NN O O
of NN O O
individuals NN O O
unselected NN O O
for NN O O
breast NN O B-Disease
or NN O I-Disease
ovarian NN O I-Disease
cancer NN O I-Disease
has NN O O
not NN O O
been NN O O
determined NN O O
, NN O O
and NN O O
it NN O O
is NN O O
not NN O O
known NN O O
whether NN O O
mutations NN O O
in NN O O
such NN O O
individuals NN O O
confer NN O O
the NN O O
same NN O O
risk NN O O
of NN O O
cancer NN O B-Disease
as NN O O
in NN O O
individuals NN O O
from NN O O
the NN O O
high NN O O
- NN O O
risk NN O O
families NN O O
studied NN O O
so NN O O
far NN O O
. NN O O

Following NN O O
the NN O O
finding NN O O
of NN O O
a NN O O
185delAG NN O O
frameshift NN O O
mutation NN O O
in NN O O
several NN O O
Ashkenazi NN O O
Jewish NN O O
breast NN O O
/ NN O O
ovarian NN O O
families NN O O
, NN O O
we NN O O
have NN O O
determined NN O O
the NN O O
frequency NN O O
of NN O O
this NN O O
mutation NN O O
in NN O O
858 NN O O
Ashkenazim NN O O
seeking NN O O
genetic NN O O
testing NN O O
for NN O O
conditions NN O O
unrelated NN O O
to NN O O
cancer NN O B-Disease
, NN O O
and NN O O
in NN O O
815 NN O O
reference NN O O
individuals NN O O
not NN O O
selected NN O O
for NN O O
ethnic NN O O
origin NN O O
. NN O O

We NN O O
observed NN O O
the NN O O
185delAG NN O O
mutation NN O O
in NN O O
0 NN O O
. NN O O

9 NN O O
% NN O O
of NN O O
Ashkenazim NN O O
( NN O O
95 NN O O
% NN O O
confidence NN O O
limit NN O O
, NN O O
0 NN O O
. NN O O
4 NN O O
- NN O O
1 NN O O
. NN O O
8 NN O O
% NN O O
) NN O O
and NN O O
in NN O O
none NN O O
of NN O O
the NN O O
reference NN O O
samples NN O O
. NN O O

Our NN O O
results NN O O
suggest NN O O
that NN O O
one NN O O
in NN O O
a NN O O
hundred NN O O
women NN O O
of NN O O
Ashkenazi NN O O
descent NN O O
may NN O O
be NN O O
at NN O O
especially NN O O
high NN O O
risk NN O O
of NN O O
developing NN O O
breast NN O B-Disease
and NN O I-Disease
/ NN O I-Disease
or NN O I-Disease
ovarian NN O I-Disease
cancer NN O I-Disease
. NN O O

Identification NN O O
and NN O O
localization NN O O
of NN O O
huntingtin NN O O
in NN O O
brain NN O O
and NN O O
human NN O O
lymphoblastoid NN O O
cell NN O O
lines NN O O
with NN O O
anti NN O O
- NN O O
fusion NN O O
protein NN O O
antibodies NN O O
. NN O O

The NN O O
Huntington NN O B-Disease
disease NN O I-Disease
( NN O O
HD NN O B-Disease
) NN O O
phenotype NN O O
is NN O O
associated NN O O
with NN O O
expansion NN O O
of NN O O
a NN O O
trinucleotide NN O O
repeat NN O O
in NN O O
the NN O O
IT15 NN O O
gene NN O O
, NN O O
which NN O O
is NN O O
predicted NN O O
to NN O O
encode NN O O
a NN O O
348 NN O O
- NN O O
kDa NN O O
protein NN O O
named NN O O
huntington NN O O
. NN O O

We NN O O
used NN O O
polyclonal NN O O
and NN O O
monoclonal NN O O
anti NN O O
- NN O O
fusion NN O O
protein NN O O
antibodies NN O O
to NN O O
identify NN O O
native NN O O
huntingtin NN O O
in NN O O
rat NN O O
, NN O O
monkey NN O O
, NN O O
and NN O O
human NN O O
. NN O O

Western NN O O
blots NN O O
revealed NN O O
a NN O O
protein NN O O
with NN O O
the NN O O
expected NN O O
molecular NN O O
weight NN O O
which NN O O
is NN O O
present NN O O
in NN O O
the NN O O
soluble NN O O
fraction NN O O
of NN O O
rat NN O O
and NN O O
monkey NN O O
brain NN O O
tissues NN O O
and NN O O
lymphoblastoid NN O O
cells NN O O
from NN O O
control NN O O
cases NN O O
. NN O O

In NN O O
lymphoblastoid NN O O
cell NN O O
lines NN O O
from NN O O
juvenile NN O O
- NN O O
onset NN O O
heterozygote NN O O
HD NN O B-Disease
cases NN O O
, NN O O
both NN O O
normal NN O O
and NN O O
mutant NN O O
huntingtin NN O O
are NN O O
expressed NN O O
, NN O O
and NN O O
increasing NN O O
repeat NN O O
expansion NN O O
leads NN O O
to NN O O
lower NN O O
levels NN O O
of NN O O
the NN O O
mutant NN O O
protein NN O O
. NN O O

Immunocytochemistry NN O O
indicates NN O O
that NN O O
huntingtin NN O O
is NN O O
located NN O O
in NN O O
neurons NN O O
throughout NN O O
the NN O O
brain NN O O
, NN O O
with NN O O
the NN O O
highest NN O O
levels NN O O
evident NN O O
in NN O O
larger NN O O
neurons NN O O
. NN O O

In NN O O
the NN O O
human NN O O
striatum NN O O
, NN O O
huntingtin NN O O
is NN O O
enriched NN O O
in NN O O
a NN O O
patch NN O O
- NN O O
like NN O O
distribution NN O O
, NN O O
potentially NN O O
corresponding NN O O
to NN O O
the NN O O
first NN O O
areas NN O O
affected NN O O
in NN O O
HD NN O B-Disease
. NN O O

Subcellular NN O O
localization NN O O
of NN O O
huntingtin NN O O
is NN O O
consistent NN O O
with NN O O
a NN O O
cytosolic NN O O
protein NN O O
primarily NN O O
found NN O O
in NN O O
somatodendritic NN O O
regions NN O O
. NN O O

Huntingtin NN O O
appears NN O O
to NN O O
particularly NN O O
associate NN O O
with NN O O
microtubules NN O O
, NN O O
although NN O O
some NN O O
is NN O O
also NN O O
associated NN O O
with NN O O
synaptic NN O O
vesicles NN O O
. NN O O

On NN O O
the NN O O
basis NN O O
of NN O O
the NN O O
localization NN O O
of NN O O
huntingtin NN O O
in NN O O
association NN O O
with NN O O
microtubules NN O O
, NN O O
we NN O O
speculate NN O O
that NN O O
the NN O O
mutation NN O O
impairs NN O O
the NN O O
cytoskeletal NN O O
anchoring NN O O
or NN O O
transport NN O O
of NN O O
mitochondria NN O O
, NN O O
vesicles NN O O
, NN O O
or NN O O
other NN O O
organelles NN O O
or NN O O
molecules NN O O
. NN O O
. NN O O

Marked NN O O
phenotypic NN O O
heterogeneity NN O O
associated NN O O
with NN O O
expansion NN O O
of NN O O
a NN O O
CAG NN O O
repeat NN O O
sequence NN O O
at NN O O
the NN O O
spinocerebellar NN O B-Disease
ataxia NN O I-Disease
3 NN O I-Disease
/ NN O I-Disease
Machado NN O I-Disease
- NN O I-Disease
Joseph NN O I-Disease
disease NN O I-Disease
locus NN O O
. NN O O

The NN O O
spinocerebellar NN O B-Disease
ataxia NN O I-Disease
3 NN O I-Disease
locus NN O O
( NN O O
SCA3 NN O B-Disease
) NN O O
for NN O O
type NN O B-Disease
I NN O I-Disease
autosomal NN O I-Disease
dominant NN O I-Disease
cerebellar NN O I-Disease
ataxia NN O I-Disease
( NN O O
ADCA NN O B-Disease
type NN O I-Disease
I NN O I-Disease
) NN O O
, NN O O
a NN O O
clinically NN O O
and NN O O
genetically NN O O
heterogeneous NN O O
group NN O O
of NN O O
neurodegenerative NN O B-Disease
disorders NN O I-Disease
, NN O O
has NN O O
been NN O O
mapped NN O O
to NN O O
chromosome NN O O
14q32 NN O O
. NN O O

1 NN O O
1 NN O O
. NN O O

ADCA NN O B-Disease
type NN O I-Disease
I NN O I-Disease
patients NN O O
from NN O O
families NN O O
segregating NN O O
SCA3 NN O B-Disease
share NN O O
clinical NN O O
features NN O O
in NN O O
common NN O O
with NN O O
those NN O O
with NN O O
Machado NN O B-Disease
- NN O I-Disease
Joseph NN O I-Disease
disease NN O I-Disease
( NN O O
MJD NN O B-Disease
) NN O O
, NN O O
the NN O O
gene NN O O
of NN O O
which NN O O
maps NN O O
to NN O O
the NN O O
same NN O O
region NN O O
. NN O O

We NN O O
show NN O O
here NN O O
that NN O O
the NN O O
disease NN O O
gene NN O O
segregating NN O O
in NN O O
each NN O O
of NN O O
three NN O O
French NN O O
ADCA NN O B-Disease
type NN O I-Disease
I NN O I-Disease
kindreds NN O O
and NN O O
in NN O O
a NN O O
French NN O O
family NN O O
with NN O O
neuropathological NN O O
findings NN O O
suggesting NN O O
the NN O O
ataxochoreic NN O O
form NN O O
of NN O O
dentatorubropallidoluysian NN O B-Disease
atrophy NN O I-Disease
carries NN O O
an NN O O
expanded NN O O
CAG NN O O
repeat NN O O
sequence NN O O
located NN O O
at NN O O
the NN O O
same NN O O
locus NN O O
as NN O O
that NN O O
for NN O O
MJD NN O B-Disease
. NN O O

Analysis NN O O
of NN O O
the NN O O
mutation NN O O
in NN O O
these NN O O
families NN O O
shows NN O O
a NN O O
strong NN O O
negative NN O O
correlation NN O O
between NN O O
size NN O O
of NN O O
the NN O O
expanded NN O O
CAG NN O O
repeat NN O O
and NN O O
age NN O O
at NN O O
onset NN O O
of NN O O
clinical NN O O
disease NN O O
. NN O O

Instability NN O O
of NN O O
the NN O O
expanded NN O O
triplet NN O O
repeat NN O O
was NN O O
not NN O O
found NN O O
to NN O O
be NN O O
affected NN O O
by NN O O
sex NN O O
of NN O O
the NN O O
parent NN O O
transmitting NN O O
the NN O O
mutation NN O O
. NN O O

Evidence NN O O
was NN O O
found NN O O
for NN O O
somatic NN O O
and NN O O
gonadal NN O O
mosaicism NN O O
for NN O O
alleles NN O O
carrying NN O O
expanded NN O O
trinucleotide NN O O
repeats NN O O
. NN O O

Overexpression NN O O
of NN O O
DM20 NN O O
messenger NN O O
RNA NN O O
in NN O O
two NN O O
brothers NN O O
with NN O O
Pelizaeus NN O B-Disease
- NN O I-Disease
Merzbacher NN O I-Disease
disease NN O I-Disease
. NN O O

Pelizaeus NN O B-Disease
- NN O I-Disease
Merzbacher NN O I-Disease
disease NN O I-Disease
is NN O O
a NN O O
rare NN O B-Disease
, NN O I-Disease
sex NN O I-Disease
- NN O I-Disease
linked NN O I-Disease
recessive NN O I-Disease
, NN O I-Disease
dysmyelinating NN O I-Disease
disease NN O I-Disease
of NN O I-Disease
the NN O I-Disease
central NN O I-Disease
nervous NN O I-Disease
system NN O I-Disease
that NN O O
has NN O O
been NN O O
associated NN O O
with NN O O
mutations NN O O
in NN O O
the NN O O
myelin NN O O
proteolipid NN O O
protein NN O O
( NN O O
PLP NN O O
) NN O O
gene NN O O
. NN O O

Only NN O O
25 NN O O
% NN O O
of NN O O
patients NN O O
studied NN O O
with NN O O
Pelizaeus NN O B-Disease
- NN O I-Disease
Merzbacher NN O I-Disease
disease NN O I-Disease
have NN O O
exonic NN O O
mutations NN O O
in NN O O
this NN O O
gene NN O O
, NN O O
the NN O O
underlying NN O O
cause NN O O
of NN O O
the NN O O
disease NN O O
in NN O O
the NN O O
remaining NN O O
patients NN O O
is NN O O
unknown NN O O
. NN O O

The NN O O
PLP NN O O
gene NN O O
encodes NN O O
two NN O O
major NN O O
alternatively NN O O
spliced NN O O
transcripts NN O O
called NN O O
PLP NN O O
and NN O O
DM20 NN O O
. NN O O

PLP NN O O
messenger NN O O
RNA NN O O
is NN O O
specifically NN O O
expressed NN O O
in NN O O
central NN O O
nervous NN O O
system NN O O
tissue NN O O
, NN O O
whereas NN O O
DM20 NN O O
messenger NN O O
RNA NN O O
is NN O O
found NN O O
in NN O O
central NN O O
nervous NN O O
system NN O O
, NN O O
cardiac NN O O
, NN O O
and NN O O
other NN O O
tissues NN O O
. NN O O

We NN O O
studied NN O O
cultured NN O O
skin NN O O
fibroblasts NN O O
from NN O O
2 NN O O
brothers NN O O
with NN O O
Pelizaeus NN O B-Disease
- NN O I-Disease
Merzbacher NN O I-Disease
disease NN O I-Disease
who NN O O
exhibited NN O O
no NN O O
detectable NN O O
exonic NN O O
mutation NN O O
of NN O O
the NN O O
PLP NN O O
gene NN O O
. NN O O

Examination NN O O
of NN O O
RNA NN O O
from NN O O
these NN O O
cells NN O O
showed NN O O
that NN O O
the NN O O
level NN O O
of NN O O
DM20 NN O O
messenger NN O O
RNA NN O O
is NN O O
elevated NN O O
sixfold NN O O
relative NN O O
to NN O O
male NN O O
control NN O O
skin NN O O
fibroblasts NN O O
. NN O O

An NN O O
unrelated NN O O
female NN O O
carrier NN O O
, NN O O
also NN O O
with NN O O
no NN O O
detectable NN O O
exonic NN O O
mutation NN O O
, NN O O
showed NN O O
a NN O O
threefold NN O O
increase NN O O
in NN O O
DM20 NN O O
messenger NN O O
RNA NN O O
in NN O O
cultured NN O O
skin NN O O
fibroblasts NN O O
. NN O O

Our NN O O
findings NN O O
suggest NN O O
that NN O O
in NN O O
some NN O O
patients NN O O
, NN O O
Pelizaeus NN O B-Disease
- NN O I-Disease
Merzbacher NN O I-Disease
disease NN O I-Disease
is NN O O
caused NN O O
by NN O O
overexpression NN O O
of NN O O
PLP NN O O
gene NN O O
transcripts NN O O
, NN O O
and NN O O
that NN O O
in NN O O
these NN O O
families NN O O
a NN O O
50 NN O O
% NN O O
increase NN O O
of NN O O
DM20 NN O O
messenger NN O O
RNA NN O O
in NN O O
females NN O O
, NN O O
relative NN O O
to NN O O
the NN O O
increase NN O O
in NN O O
affected NN O O
males NN O O
, NN O O
can NN O O
identify NN O O
a NN O O
female NN O O
carrier NN O O
. NN O O
. NN O O

The NN O O
Wiskott NN O B-Disease
- NN O I-Disease
Aldrich NN O I-Disease
syndrome NN O I-Disease
and NN O O
X NN O B-Disease
- NN O I-Disease
linked NN O I-Disease
congenital NN O I-Disease
thrombocytopenia NN O I-Disease
are NN O O
caused NN O O
by NN O O
mutations NN O O
of NN O O
the NN O O
same NN O O
gene NN O O
. NN O O

The NN O O
Wiskott NN O B-Disease
- NN O I-Disease
Aldrich NN O I-Disease
syndrome NN O I-Disease
( NN O O
WAS NN O B-Disease
) NN O O
is NN O O
an NN O O
X NN O B-Disease
- NN O I-Disease
linked NN O I-Disease
recessive NN O I-Disease
disorder NN O I-Disease
characterized NN O O
by NN O O
thrombocytopenia NN O B-Disease
, NN O O
small NN O O
platelets NN O O
, NN O O
eczema NN O B-Disease
, NN O O
recurrent NN O O
infections NN O O
, NN O O
and NN O O
immunodeficiency NN O B-Disease
. NN O O

Besides NN O O
the NN O O
classic NN O O
WAS NN O B-Disease
phenotype NN O O
, NN O O
there NN O O
is NN O O
a NN O O
group NN O O
of NN O O
patients NN O O
with NN O O
congenital NN O B-Disease
X NN O I-Disease
- NN O I-Disease
linked NN O I-Disease
thrombocytopenia NN O I-Disease
( NN O O
XLT NN O B-Disease
) NN O O
who NN O O
have NN O O
small NN O O
platelets NN O O
but NN O O
only NN O O
transient NN O O
eczema NN O B-Disease
, NN O O
if NN O O
any NN O O
, NN O O
and NN O O
minimal NN O O
immune NN O B-Disease
deficiency NN O I-Disease
. NN O O

Because NN O O
the NN O O
gene NN O O
responsible NN O O
for NN O O
WAS NN O B-Disease
has NN O O
been NN O O
sequenced NN O O
, NN O O
it NN O O
was NN O O
possible NN O O
to NN O O
correlate NN O O
the NN O O
WAS NN O B-Disease
phenotypes NN O O
with NN O O
WAS NN O B-Disease
gene NN O O
mutations NN O O
. NN O O

Using NN O O
a NN O O
fingerprinting NN O O
screening NN O O
technique NN O O
, NN O O
we NN O O
determined NN O O
the NN O O
approximate NN O O
location NN O O
of NN O O
the NN O O
mutation NN O O
in NN O O
13 NN O O
unrelated NN O O
WAS NN O B-Disease
patients NN O O
with NN O O
mild NN O O
to NN O O
severe NN O O
clinical NN O O
symptoms NN O O
. NN O O

Direct NN O O
sequence NN O O
analysis NN O O
of NN O O
cDNA NN O O
and NN O O
genomic NN O O
DNA NN O O
obtained NN O O
from NN O O
patient NN O O
- NN O O
derived NN O O
cell NN O O
lines NN O O
showed NN O O
12 NN O O
unique NN O O
mutations NN O O
distributed NN O O
throughout NN O O
the NN O O
WAS NN O B-Disease
gene NN O O
, NN O O
including NN O O
insertions NN O O
, NN O O
deletions NN O O
, NN O O
and NN O O
point NN O O
mutations NN O O
resulting NN O O
in NN O O
amino NN O O
acid NN O O
substitutions NN O O
, NN O O
termination NN O O
, NN O O
exon NN O O
skipping NN O O
, NN O O
or NN O O
splicing NN O O
defects NN O O
. NN O O

Of NN O O
4 NN O O
unrelated NN O O
patients NN O O
with NN O O
the NN O O
XLT NN O B-Disease
phenotype NN O O
, NN O O
3 NN O O
had NN O O
missense NN O O
mutations NN O O
affecting NN O O
exon NN O O
2 NN O O
and NN O O
1 NN O O
had NN O O
a NN O O
splice NN O O
- NN O O
site NN O O
mutation NN O O
affecting NN O O
exon NN O O
9 NN O O
. NN O O

Patients NN O O
with NN O O
classic NN O O
WAS NN O B-Disease
had NN O O
more NN O O
complex NN O O
mutations NN O O
, NN O O
resulting NN O O
in NN O O
termination NN O O
codons NN O O
, NN O O
frameshift NN O O
, NN O O
and NN O O
early NN O O
termination NN O O
. NN O O

These NN O O
findings NN O O
provide NN O O
direct NN O O
evidence NN O O
that NN O O
XLT NN O B-Disease
and NN O O
WAS NN O B-Disease
are NN O O
caused NN O O
by NN O O
mutations NN O O
of NN O O
the NN O O
same NN O O
gene NN O O
and NN O O
suggest NN O O
that NN O O
severe NN O O
clinical NN O O
phenotypes NN O O
are NN O O
associated NN O O
with NN O O
complex NN O O
mutations NN O O
. NN O O
. NN O O

Myotonia NN O B-Disease
levior NN O I-Disease
is NN O O
a NN O O
chloride NN O B-Disease
channel NN O I-Disease
disorder NN O I-Disease
. NN O O

The NN O O
group NN O O
of NN O O
dominant NN O B-Disease
non NN O I-Disease
- NN O I-Disease
dystrophic NN O I-Disease
myotonias NN O I-Disease
, NN O O
comprising NN O O
disorders NN O O
characterized NN O O
by NN O O
clinically NN O O
similar NN O O
forms NN O O
of NN O O
myogenic NN O O
muscle NN O O
stiffness NN O O
, NN O O
is NN O O
genetically NN O O
inhomogeneous NN O O
. NN O O

Dominant NN O B-Disease
myotonia NN O I-Disease
congenita NN O I-Disease
( NN O O
Thomsens NN O B-Disease
disease NN O I-Disease
) NN O O
is NN O O
linked NN O O
to NN O O
CLCN1 NN O O
, NN O O
the NN O O
gene NN O O
encoding NN O O
the NN O O
major NN O O
muscle NN O O
chloride NN O O
channel NN O O
, NN O O
localized NN O O
on NN O O
chromosome NN O O
7q35 NN O O
. NN O O

In NN O O
contrast NN O O
, NN O O
dominant NN O B-Disease
myotonias NN O I-Disease
sensitive NN O O
to NN O O
potassium NN O O
are NN O O
caused NN O O
by NN O O
point NN O O
mutations NN O O
in NN O O
SCN4A NN O O
on NN O O
chromosome NN O O
17q NN O O
, NN O O
the NN O O
gene NN O O
for NN O O
the NN O O
alpha NN O O
subunit NN O O
of NN O O
the NN O O
adult NN O O
skeletal NN O O
muscle NN O O
sodium NN O O
channel NN O O
. NN O O

No NN O O
linkage NN O O
or NN O O
molecular NN O O
genetic NN O O
data NN O O
are NN O O
as NN O O
yet NN O O
available NN O O
on NN O O
myotonia NN O B-Disease
levior NN O I-Disease
characterized NN O O
by NN O O
milder NN O O
symptoms NN O O
and NN O O
later NN O O
onset NN O O
of NN O O
myotonia NN O B-Disease
than NN O O
in NN O O
Thomsens NN O B-Disease
disease NN O I-Disease
, NN O O
and NN O O
absence NN O O
of NN O O
muscle NN O B-Disease
hypertrophy NN O I-Disease
. NN O O

We NN O O
report NN O O
a NN O O
CLCN1 NN O O
Gln NN O O
- NN O O
552 NN O O
- NN O O
Arg NN O O
substitution NN O O
for NN O O
a NN O O
family NN O O
with NN O O
dominant NN O O
inheritance NN O O
previously NN O O
diagnosed NN O O
to NN O O
have NN O O
myotonia NN O B-Disease
levior NN O I-Disease
. NN O O

Thus NN O O
, NN O O
this NN O O
disorder NN O O
appears NN O O
as NN O O
a NN O O
variant NN O O
of NN O O
Thomsens NN O B-Disease
disease NN O I-Disease
due NN O O
to NN O O
mutations NN O O
leading NN O O
to NN O O
low NN O O
clinical NN O O
expressivity NN O O
. NN O O

In NN O O
addition NN O O
, NN O O
we NN O O
report NN O O
a NN O O
novel NN O O
Ile NN O O
- NN O O
290 NN O O
- NN O O
Met NN O O
CLCN1 NN O O
mutation NN O O
for NN O O
a NN O O
typical NN O O
Thomsen NN O O
pedigree NN O O
. NN O O

In NN O O
another NN O O
family NN O O
previously NN O O
diagnosed NN O O
as NN O O
having NN O O
Thomsens NN O B-Disease
disease NN O I-Disease
, NN O O
we NN O O
unexpectedly NN O O
found NN O O
a NN O O
CLCN1 NN O O
14 NN O O
bp NN O O
deletion NN O O
known NN O O
to NN O O
cause NN O O
recessive NN O B-Disease
myotonia NN O I-Disease
, NN O O
and NN O O
a NN O O
rare NN O O
Trp NN O O
- NN O O
118 NN O O
- NN O O
Gly NN O O
polymorphism NN O O
. NN O O
. NN O O

Southern NN O O
analysis NN O O
reveals NN O O
a NN O O
large NN O O
deletion NN O O
at NN O O
the NN O O
hypoxanthine NN O O
phosphoribosyltransferase NN O O
locus NN O O
in NN O O
a NN O O
patient NN O O
with NN O O
Lesch NN O B-Disease
- NN O I-Disease
Nyhan NN O I-Disease
syndrome NN O I-Disease
. NN O O

Whole NN O O
genomic NN O O
hprt NN O O
clones NN O O
were NN O O
used NN O O
in NN O O
Southern NN O O
analysis NN O O
to NN O O
screen NN O O
the NN O O
integrity NN O O
of NN O O
the NN O O
hprt NN O O
gene NN O O
in NN O O
a NN O O
family NN O O
that NN O O
includes NN O O
a NN O O
patient NN O O
with NN O O
HPRT NN O B-Disease
enzyme NN O I-Disease
deficiency NN O I-Disease
causal NN O O
to NN O O
Lesch NN O B-Disease
- NN O I-Disease
Nyhan NN O I-Disease
syndrome NN O I-Disease
. NN O O

A NN O O
5 NN O O
kb NN O O
DNA NN O O
sequence NN O O
deletion NN O O
was NN O O
found NN O O
to NN O O
have NN O O
its NN O O
endpoints NN O O
in NN O O
the NN O O
first NN O O
and NN O O
third NN O O
introns NN O O
. NN O O

The NN O O
probes NN O O
identified NN O O
the NN O O
carrier NN O O
status NN O O
of NN O O
female NN O O
family NN O O
members NN O O
, NN O O
aided NN O O
by NN O O
an NN O O
RFLP NN O O
carried NN O O
by NN O O
the NN O O
mothers NN O O
normal NN O O
X NN O O
- NN O O
chromosome NN O O
. NN O O
. NN O O

Characterisation NN O O
of NN O O
molecular NN O O
defects NN O O
in NN O O
X NN O B-Disease
- NN O I-Disease
linked NN O I-Disease
amelogenesis NN O I-Disease
imperfecta NN O I-Disease
( NN O O
AIH1 NN O O
) NN O O
. NN O O

Amelogenins NN O O
are NN O O
an NN O O
heterogenous NN O O
family NN O O
of NN O O
proteins NN O O
produced NN O O
by NN O O
ameloblasts NN O O
of NN O O
the NN O O
enamel NN O O
organ NN O O
during NN O O
tooth NN O O
development NN O O
. NN O O

Disturbances NN O O
of NN O O
enamel NN O O
formation NN O O
occur NN O O
in NN O O
amelogenesis NN O B-Disease
imperfecta NN O I-Disease
, NN O O
a NN O O
clinically NN O O
heterogenous NN O O
group NN O O
of NN O O
inherited NN O B-Disease
disorders NN O I-Disease
characterised NN O O
by NN O O
defective NN O O
enamel NN O O
biomineralisation NN O O
. NN O O

An NN O O
amelogenin NN O O
gene NN O O
, NN O O
AMGX NN O O
, NN O O
has NN O O
been NN O O
mapped NN O O
to NN O O
the NN O O
short NN O O
of NN O O
the NN O O
X NN O O
chromosome NN O O
( NN O O
Xp22 NN O O
. NN O O
1 NN O O
- NN O O
p22 NN O O
. NN O O
3 NN O O
) NN O O
and NN O O
has NN O O
been NN O O
implicated NN O O
in NN O O
the NN O O
molecular NN O O
pathology NN O O
of NN O O
X NN O B-Disease
- NN O I-Disease
linked NN O I-Disease
amelogenesis NN O I-Disease
imperfecta NN O I-Disease
( NN O O
AIH1 NN O B-Disease
) NN O O
. NN O O

We NN O O
have NN O O
identified NN O O
three NN O O
families NN O O
exhibiting NN O O
AIH1 NN O B-Disease
and NN O O
screened NN O O
the NN O O
AMGX NN O O
gene NN O O
for NN O O
mutations NN O O
using NN O O
single NN O O
- NN O O
strand NN O O
conformational NN O O
polymorphism NN O O
analysis NN O O
and NN O O
DNA NN O O
sequencing NN O O
. NN O O

Three NN O O
novel NN O O
mutations NN O O
were NN O O
identified NN O O
a NN O O
C NN O O
- NN O O
T NN O O
substitution NN O O
in NN O O
exon NN O O
5 NN O O
, NN O O
and NN O O
a NN O O
G NN O O
- NN O O
T NN O O
substitution NN O O
and NN O O
single NN O O
cytosine NN O O
deletion NN O O
in NN O O
exon NN O O
6 NN O O
, NN O O
confirming NN O O
the NN O O
existence NN O O
of NN O O
extensive NN O O
allelic NN O O
heterogeneity NN O O
in NN O O
this NN O O
condition NN O O
. NN O O

The NN O O
identification NN O O
of NN O O
family NN O O
- NN O O
specific NN O O
mutations NN O O
will NN O O
enable NN O O
early NN O O
identification NN O O
of NN O O
affected NN O O
individuals NN O O
and NN O O
correlation NN O O
of NN O O
clinical NN O O
phenotype NN O O
with NN O O
genotype NN O O
will NN O O
facilitate NN O O
an NN O O
objective NN O O
system NN O O
of NN O O
disease NN O O
classification NN O O
. NN O O

Frequency NN O O
of NN O O
exon NN O O
15 NN O O
missense NN O O
mutation NN O O
( NN O O
442D NN O O
: NN O O
G NN O O
) NN O O
in NN O O
cholesteryl NN O O
ester NN O O
transfer NN O O
protein NN O O
gene NN O O
in NN O O
hyperalphalipoproteinemic NN O B-Disease
Japanese NN O O
subjects NN O O
. NN O O

Cholesteryl NN O O
ester NN O O
transfer NN O O
protein NN O O
( NN O O
CETP NN O O
) NN O O
transfers NN O O
cholesteryl NN O O
ester NN O O
from NN O O
high NN O O
density NN O O
lipoprotein NN O O
( NN O O
HDL NN O O
) NN O O
to NN O O
apo NN O O
B NN O O
- NN O O
containing NN O O
lipoproteins NN O O
. NN O O

The NN O O
hyperalphalipoproteinemia NN O B-Disease
caused NN O O
by NN O O
CETP NN O B-Disease
deficiency NN O I-Disease
is NN O O
fairly NN O O
common NN O O
in NN O O
Japan NN O O
and NN O O
one NN O O
of NN O O
the NN O O
most NN O O
common NN O O
mutations NN O O
in NN O O
the NN O O
CETP NN O O
gene NN O O
is NN O O
the NN O O
splicing NN O O
defect NN O O
of NN O O
the NN O O
intron NN O O
14 NN O O
, NN O O
the NN O O
allelic NN O O
frequency NN O O
of NN O O
which NN O O
has NN O O
been NN O O
shown NN O O
to NN O O
be NN O O
0 NN O O
. NN O O

0049 NN O O
in NN O O
the NN O O
Japanese NN O O
general NN O O
population NN O O
. NN O O

Recently NN O O
, NN O O
we NN O O
have NN O O
reported NN O O
a NN O O
missense NN O O
mutation NN O O
in NN O O
exon NN O O
15 NN O O
of NN O O
the NN O O
CETP NN O O
gene NN O O
( NN O O
442D NN O O
G NN O O
) NN O O
, NN O O
showing NN O O
a NN O O
dominant NN O O
effect NN O O
on NN O O
the NN O O
CETP NN O O
activity NN O O
and NN O O
HDL NN O O
- NN O O
cholesterol NN O O
level NN O O
. NN O O

In NN O O
the NN O O
current NN O O
study NN O O
, NN O O
we NN O O
determined NN O O
the NN O O
frequency NN O O
of NN O O
this NN O O
new NN O O
mutation NN O O
in NN O O
Japanese NN O O
hyperalphalipoproteinemic NN O B-Disease
( NN O O
HDL NN O O
- NN O O
cholesterol NN O O
> NN O O
or NN O O
= NN O O
100 NN O O
mg NN O O
/ NN O O
dl NN O O
) NN O O
subjects NN O O
. NN O O

A NN O O
rapid NN O O
and NN O O
easy NN O O
screening NN O O
method NN O O
for NN O O
this NN O O
new NN O O
mutation NN O O
was NN O O
developed NN O O
using NN O O
a NN O O
polymerase NN O O
chain NN O O
reaction NN O O
( NN O O
PCR NN O O
) NN O O
- NN O O
mediated NN O O
site NN O O
- NN O O
directed NN O O
mutagenesis NN O O
. NN O O

Among NN O O
117 NN O O
Japanese NN O O
hyperalphalipoproteinemic NN O B-Disease
subjects NN O O
( NN O O
HDL NN O O
- NN O O
cholesterol NN O O
; NN O O
116 NN O O
. NN O O
7 NN O O
+ NN O O
/ NN O O
- NN O O
16 NN O O
. NN O O
5 NN O O
mg NN O O
/ NN O O
dl NN O O
, NN O O
mean NN O O
+ NN O O
/ NN O O
- NN O O
S NN O O
. NN O O
D NN O O
. NN O O
) NN O O
without NN O O
the NN O O
intron NN O O
14 NN O O
splice NN O O
defect NN O O
, NN O O
three NN O O
homozygotes NN O O
( NN O O
2 NN O O
. NN O O
5 NN O O
% NN O O
) NN O O
and NN O O
34 NN O O
heterozygotes NN O O
( NN O O
29 NN O O
. NN O O
1 NN O O
% NN O O
) NN O O
were NN O O
found NN O O
to NN O O
have NN O O
the NN O O
442D NN O O
G NN O O
mutation NN O O
. NN O O

The NN O O
relative NN O O
allelic NN O O
frequency NN O O
of NN O O
this NN O O
mutation NN O O
was NN O O
calculated NN O O
to NN O O
be NN O O
0 NN O O
. NN O O

17 NN O O
. NN O O

One NN O O
of NN O O
the NN O O
homozygotes NN O O
for NN O O
the NN O O
442D NN O O
G NN O O
mutation NN O O
was NN O O
the NN O O
patient NN O O
previously NN O O
described NN O O
by NN O O
us NN O O
as NN O O
having NN O O
hyperalphalipoproteinemia NN O B-Disease
with NN O O
corneal NN O B-Disease
opacity NN O I-Disease
and NN O O
coronary NN O B-Disease
heart NN O I-Disease
disease NN O I-Disease
. NN O O

This NN O O
was NN O O
the NN O O
first NN O O
reported NN O O
subject NN O O
homozygous NN O O
for NN O O
the NN O O
CETP NN O B-Disease
deficiency NN O I-Disease
who NN O O
also NN O O
demonstrated NN O O
atherosclerotic NN O B-Disease
symptoms NN O I-Disease
. NN O O

In NN O O
homozygous NN O O
subjects NN O O
, NN O O
CETP NN O O
activity NN O O
ranged NN O O
from NN O O
37 NN O O
% NN O O
to NN O O
62 NN O O
% NN O O
of NN O O
the NN O O
normal NN O O
value NN O O
, NN O O
which NN O O
was NN O O
consistent NN O O
with NN O O
the NN O O
results NN O O
obtained NN O O
from NN O O
the NN O O
transient NN O O
expression NN O O
experiment NN O O
previously NN O O
reported NN O O
; NN O O
however NN O O
, NN O O
the NN O O
specific NN O O
activity NN O O
of NN O O
CETP NN O O
was NN O O
not NN O O
as NN O O
low NN O O
as NN O O
expected NN O O
. NN O O

( NN O O
ABSTRACT NN O O
TRUNCATED NN O O
AT NN O O
250 NN O O
WORDS NN O O
) NN O O

Mucopolysaccharidosis NN O B-Disease
type NN O I-Disease
IVA NN O I-Disease
: NN O O
common NN O O
double NN O O
deletion NN O O
in NN O O
the NN O O
N NN O O
- NN O O
acetylgalactosamine NN O O
- NN O O
6 NN O O
- NN O O
sulfatase NN O O
gene NN O O
( NN O O
GALNS NN O O
) NN O O
. NN O O

Mucopolysaccharidosis NN O B-Disease
IVA NN O I-Disease
( NN O O
MPS NN O B-Disease
IVA NN O I-Disease
) NN O O
is NN O O
an NN O O
autosomal NN O B-Disease
recessive NN O I-Disease
disorder NN O I-Disease
caused NN O O
by NN O O
a NN O O
deficiency NN O B-Disease
in NN O I-Disease
N NN O I-Disease
- NN O I-Disease
acetylgalactosamine NN O I-Disease
- NN O I-Disease
6 NN O I-Disease
- NN O I-Disease
sulfatase NN O I-Disease
( NN O O
GALNS NN O O
) NN O O
. NN O O

We NN O O
found NN O O
two NN O O
separate NN O O
deletions NN O O
of NN O O
nearly NN O O
8 NN O O
. NN O O

0 NN O O
and NN O O
6 NN O O
. NN O O

0 NN O O
kb NN O O
in NN O O
the NN O O
GALNS NN O O
gene NN O O
, NN O O
including NN O O
some NN O O
exons NN O O
. NN O O

There NN O O
are NN O O
Alu NN O O
repetitive NN O O
elements NN O O
near NN O O
the NN O O
breakpoints NN O O
of NN O O
the NN O O
8 NN O O
. NN O O

0 NN O O
- NN O O
kb NN O O
deletion NN O O
, NN O O
and NN O O
this NN O O
deletion NN O O
resulted NN O O
from NN O O
an NN O O
Alu NN O O
- NN O O
Alu NN O O
recombination NN O O
. NN O O

The NN O O
other NN O O
6 NN O O
. NN O O

0 NN O O
- NN O O
kb NN O O
deletion NN O O
involved NN O O
illegitimate NN O O
recombinational NN O O
events NN O O
between NN O O
incomplete NN O O
short NN O O
direct NN O O
repeats NN O O
of NN O O
8 NN O O
bp NN O O
at NN O O
deletion NN O O
breakpoints NN O O
. NN O O

The NN O O
same NN O O
rearrangement NN O O
has NN O O
been NN O O
observed NN O O
in NN O O
a NN O O
heteroallelic NN O O
state NN O O
in NN O O
four NN O O
unrelated NN O O
patients NN O O
. NN O O

This NN O O
is NN O O
the NN O O
first NN O O
documentation NN O O
of NN O O
a NN O O
common NN O O
double NN O O
deletion NN O O
a NN O O
gene NN O O
that NN O O
is NN O O
not NN O O
a NN O O
member NN O O
of NN O O
a NN O O
gene NN O O
cluster NN O O
. NN O O

Detection NN O O
of NN O O
eight NN O O
BRCA1 NN O O
mutations NN O O
in NN O O
10 NN O O
breast NN O B-Disease
/ NN O I-Disease
ovarian NN O I-Disease
cancer NN O I-Disease
families NN O O
, NN O O
including NN O O
1 NN O O
family NN O O
with NN O O
male NN O B-Disease
breast NN O I-Disease
cancer NN O I-Disease
. NN O O

Genetic NN O O
epidemiological NN O O
evidence NN O O
suggests NN O O
that NN O O
mutations NN O O
in NN O O
BRCA1 NN O O
may NN O O
be NN O O
responsible NN O O
for NN O O
approximately NN O O
one NN O O
half NN O O
of NN O O
early NN O O
onset NN O O
familial NN O B-Disease
breast NN O I-Disease
cancer NN O I-Disease
and NN O O
the NN O O
majority NN O O
of NN O O
familial NN O B-Disease
breast NN O I-Disease
/ NN O I-Disease
ovarian NN O I-Disease
cancer NN O I-Disease
. NN O O

The NN O O
recent NN O O
cloning NN O O
of NN O O
BRCA1 NN O O
allows NN O O
for NN O O
the NN O O
direct NN O O
detection NN O O
of NN O O
mutations NN O O
, NN O O
but NN O O
the NN O O
feasibility NN O O
of NN O O
presymptomatic NN O O
screening NN O O
for NN O O
cancer NN O B-Disease
susceptibility NN O O
is NN O O
unknown NN O O
. NN O O

We NN O O
analyzed NN O O
genomic NN O O
DNA NN O O
from NN O O
one NN O O
affected NN O O
individual NN O O
from NN O O
each NN O O
of NN O O
24 NN O O
families NN O O
with NN O O
at NN O O
least NN O O
three NN O O
cases NN O O
of NN O O
ovarian NN O B-Disease
or NN O I-Disease
breast NN O I-Disease
cancer NN O I-Disease
, NN O O
using NN O O
SSCP NN O O
assays NN O O
. NN O O

Variant NN O O
SSCP NN O O
bands NN O O
were NN O O
subcloned NN O O
and NN O O
sequenced NN O O
. NN O O

Allele NN O O
- NN O O
specific NN O O
oligonucleotide NN O O
hybridization NN O O
was NN O O
used NN O O
to NN O O
verify NN O O
sequence NN O O
changes NN O O
and NN O O
to NN O O
screen NN O O
DNA NN O O
from NN O O
control NN O O
individuals NN O O
. NN O O

Six NN O O
frameshift NN O O
and NN O O
two NN O O
missense NN O O
mutations NN O O
were NN O O
detected NN O O
in NN O O
10 NN O O
different NN O O
families NN O O
. NN O O

A NN O O
frameshift NN O O
mutation NN O O
was NN O O
detected NN O O
in NN O O
a NN O O
male NN O O
proband NN O O
affected NN O O
with NN O O
both NN O O
breast NN O B-Disease
and NN O I-Disease
prostate NN O I-Disease
cancer NN O I-Disease
. NN O O

A NN O O
40 NN O O
- NN O O
bp NN O O
deletion NN O O
was NN O O
detected NN O O
in NN O O
a NN O O
patient NN O O
who NN O O
developed NN O O
intra NN O B-Disease
- NN O I-Disease
abdominal NN O I-Disease
carcinomatosis NN O I-Disease
1 NN O O
year NN O O
after NN O O
prophylactic NN O O
oophorectomy NN O O
. NN O O

Mutations NN O O
were NN O O
detected NN O O
throughout NN O O
the NN O O
gene NN O O
, NN O O
and NN O O
only NN O O
one NN O O
was NN O O
detected NN O O
in NN O O
more NN O O
than NN O O
a NN O O
single NN O O
family NN O O
. NN O O

These NN O O
results NN O O
provide NN O O
further NN O O
evidence NN O O
that NN O O
inherited NN O B-Disease
breast NN O I-Disease
and NN O I-Disease
ovarian NN O I-Disease
cancer NN O I-Disease
can NN O O
occur NN O O
as NN O O
a NN O O
consequence NN O O
of NN O O
a NN O O
wide NN O O
array NN O O
of NN O O
BRCA1 NN O O
mutations NN O O
. NN O O

These NN O O
results NN O O
suggests NN O O
that NN O O
development NN O O
of NN O O
a NN O O
screening NN O O
test NN O O
for NN O O
BRCA1 NN O O
mutations NN O O
will NN O O
be NN O O
technically NN O O
challenging NN O O
. NN O O

The NN O O
finding NN O O
of NN O O
a NN O O
mutation NN O O
in NN O O
a NN O O
family NN O O
with NN O O
male NN O B-Disease
breast NN O I-Disease
cancer NN O I-Disease
, NN O O
not NN O O
previously NN O O
thought NN O O
to NN O O
be NN O O
related NN O O
to NN O O
BRCA1 NN O O
, NN O O
also NN O O
illustrates NN O O
the NN O O
potential NN O O
difficulties NN O O
of NN O O
genetic NN O O
counseling NN O O
for NN O O
individuals NN O O
known NN O O
to NN O O
carry NN O O
mutations NN O O
. NN O O
. NN O O

Natural NN O O
selection NN O O
of NN O O
hemi NN O O
- NN O O
and NN O O
heterozygotes NN O O
for NN O O
G6PD NN O B-Disease
deficiency NN O I-Disease
in NN O O
Africa NN O O
by NN O O
resistance NN O O
to NN O O
severe NN O O
malaria NN O B-Disease
. NN O O

Glucose NN O B-Disease
- NN O I-Disease
6 NN O I-Disease
- NN O I-Disease
phosphate NN O I-Disease
dehydrogenase NN O I-Disease
( NN O I-Disease
G6PD NN O I-Disease
) NN O I-Disease
deficiency NN O I-Disease
, NN O O
the NN O O
most NN O O
common NN O O
enzymopathy NN O B-Disease
of NN O O
humans NN O O
, NN O O
affects NN O O
over NN O O
400 NN O O
million NN O O
people NN O O
. NN O O

The NN O O
geographical NN O O
correlation NN O O
of NN O O
its NN O O
distribution NN O O
with NN O O
the NN O O
historical NN O O
endemicity NN O O
of NN O O
malaria NN O B-Disease
suggests NN O O
that NN O O
this NN O O
disorder NN O O
has NN O O
risen NN O O
in NN O O
frequency NN O O
through NN O O
natural NN O O
selection NN O O
by NN O O
malaria NN O B-Disease
. NN O O

However NN O O
, NN O O
attempts NN O O
to NN O O
confirm NN O O
that NN O O
G6PD NN O B-Disease
deficiency NN O I-Disease
is NN O O
protective NN O O
in NN O O
case NN O O
- NN O O
control NN O O
studies NN O O
of NN O O
malaria NN O B-Disease
have NN O O
yielded NN O O
conflicting NN O O
results NN O O
. NN O O

Hence NN O O
, NN O O
for NN O O
this NN O O
X NN O B-Disease
- NN O I-Disease
linked NN O I-Disease
disorder NN O I-Disease
, NN O O
it NN O O
is NN O O
unclear NN O O
whether NN O O
both NN O O
male NN O O
hemizygotes NN O O
and NN O O
female NN O O
heterozygotes NN O O
are NN O O
protected NN O O
or NN O O
, NN O O
as NN O O
frequently NN O O
suggested NN O O
, NN O O
only NN O O
females NN O O
. NN O O

Furthermore NN O O
, NN O O
how NN O O
much NN O O
protection NN O O
may NN O O
be NN O O
afforded NN O O
is NN O O
unknown NN O O
. NN O O

Here NN O O
we NN O O
report NN O O
that NN O O
, NN O O
in NN O O
two NN O O
large NN O O
case NN O O
- NN O O
control NN O O
studies NN O O
of NN O O
over NN O O
2 NN O O
, NN O O
000 NN O O
African NN O O
children NN O O
, NN O O
the NN O O
common NN O O
African NN O O
form NN O O
of NN O O
G6PD NN O B-Disease
deficiency NN O I-Disease
( NN O O
G6PD NN O B-Disease
A NN O I-Disease
- NN O I-Disease
) NN O O
is NN O O
associated NN O O
with NN O O
a NN O O
46 NN O O
- NN O O
58 NN O O
% NN O O
reduction NN O O
in NN O O
risk NN O O
of NN O O
severe NN O O
malaria NN O B-Disease
for NN O O
both NN O O
female NN O O
heterozygotes NN O O
and NN O O
male NN O O
hemizygotes NN O O
. NN O O

A NN O O
mathematical NN O O
model NN O O
incorporating NN O O
the NN O O
measured NN O O
selective NN O O
advantage NN O O
against NN O O
malaria NN O B-Disease
suggests NN O O
that NN O O
a NN O O
counterbalancing NN O O
selective NN O O
disadvantage NN O O
, NN O O
associated NN O O
with NN O O
this NN O O
enzyme NN O B-Disease
deficiency NN O I-Disease
, NN O O
has NN O O
retarded NN O O
its NN O O
rise NN O O
in NN O O
frequency NN O O
in NN O O
malaria NN O B-Disease
- NN O O
endemic NN O O
regions NN O O
. NN O O

Although NN O O
G6PD NN O B-Disease
deficiency NN O I-Disease
is NN O O
now NN O O
regarded NN O O
as NN O O
a NN O O
generally NN O O
benign NN O O
disorder NN O O
, NN O O
in NN O O
earlier NN O O
environmental NN O O
conditions NN O O
it NN O O
could NN O O
have NN O O
been NN O O
significantly NN O O
disadvantageous NN O O
. NN O O
. NN O O

The NN O O
alveolar NN O B-Disease
rhabdomyosarcoma NN O I-Disease
PAX3 NN O O
/ NN O O
FKHR NN O O
fusion NN O O
protein NN O O
is NN O O
a NN O O
transcriptional NN O O
activator NN O O
. NN O O

Chimeric NN O O
transcription NN O O
factors NN O O
, NN O O
created NN O O
by NN O O
gene NN O O
fusions NN O O
as NN O O
the NN O O
result NN O O
of NN O O
chromosomal NN O O
translocations NN O O
, NN O O
have NN O O
been NN O O
implicated NN O O
in NN O O
the NN O O
pathogenesis NN O O
of NN O O
several NN O O
pathologically NN O O
disparate NN O O
solid NN O B-Disease
tumors NN O I-Disease
. NN O O

The NN O O
PAX3 NN O O
/ NN O O
FKHR NN O O
fusion NN O O
gene NN O O
, NN O O
formed NN O O
by NN O O
a NN O O
t NN O O
( NN O O
2 NN O O
; NN O O
13 NN O O
) NN O O
( NN O O
q35 NN O O
; NN O O
q14 NN O O
) NN O O
in NN O O
alveolar NN O B-Disease
rhabdomyosarcoma NN O I-Disease
, NN O O
encodes NN O O
a NN O O
hybrid NN O O
protein NN O O
that NN O O
contains NN O O
both NN O O
PAX3 NN O O
DNA NN O O
binding NN O O
domains NN O O
, NN O O
the NN O O
paired NN O O
box NN O O
and NN O O
homeodomain NN O O
, NN O O
linked NN O O
to NN O O
the NN O O
bisected NN O O
DNA NN O O
binding NN O O
domain NN O O
of NN O O
FKHR NN O O
, NN O O
a NN O O
member NN O O
of NN O O
the NN O O
forkhead NN O O
family NN O O
of NN O O
transcription NN O O
factors NN O O
. NN O O

Here NN O O
we NN O O
report NN O O
that NN O O
PAX3 NN O O
and NN O O
PAX3 NN O O
/ NN O O
FKHR NN O O
display NN O O
similar NN O O
, NN O O
but NN O O
not NN O O
identical NN O O
transactivation NN O O
activities NN O O
when NN O O
tested NN O O
with NN O O
model NN O O
Pax NN O O
recognition NN O O
sequences NN O O
. NN O O

No NN O O
functional NN O O
role NN O O
could NN O O
be NN O O
ascribed NN O O
solely NN O O
to NN O O
the NN O O
residual NN O O
FKHR NN O O
binding NN O O
domain NN O O
present NN O O
in NN O O
the NN O O
fusion NN O O
protein NN O O
, NN O O
but NN O O
FKHR NN O O
was NN O O
found NN O O
to NN O O
contribute NN O O
a NN O O
strong NN O O
carboxyl NN O O
terminal NN O O
activation NN O O
domain NN O O
replacing NN O O
the NN O O
one NN O O
located NN O O
in NN O O
the NN O O
unrearranged NN O O
PAX3 NN O O
gene NN O O
. NN O O

We NN O O
show NN O O
that NN O O
the NN O O
native NN O O
PAX3 NN O O
/ NN O O
FKHR NN O O
protein NN O O
present NN O O
in NN O O
tumor NN O B-Disease
cells NN O O
with NN O O
this NN O O
translocation NN O O
has NN O O
transcriptional NN O O
characteristics NN O O
similar NN O O
to NN O O
the NN O O
in NN O O
vitro NN O O
expressed NN O O
protein NN O O
. NN O O

The NN O O
ability NN O O
of NN O O
the NN O O
PAX3 NN O O
/ NN O O
FKHR NN O O
hybrid NN O O
protein NN O O
to NN O O
bind NN O O
DNA NN O O
in NN O O
a NN O O
sequence NN O O
specific NN O O
manner NN O O
and NN O O
to NN O O
transactivate NN O O
the NN O O
expression NN O O
of NN O O
artificial NN O O
reporter NN O O
genes NN O O
suggests NN O O
that NN O O
its NN O O
aberrant NN O O
expression NN O O
could NN O O
subvert NN O O
the NN O O
transcriptional NN O O
programs NN O O
that NN O O
normally NN O O
control NN O O
the NN O O
growth NN O O
, NN O O
differentiation NN O O
, NN O O
and NN O O
survival NN O O
of NN O O
primitive NN O O
myogenic NN O O
precursors NN O O
in NN O O
vivo NN O O
. NN O O
. NN O O

A NN O O
p16INK4a NN O O
- NN O O
insensitive NN O O
CDK4 NN O O
mutant NN O O
targeted NN O O
by NN O O
cytolytic NN O O
T NN O O
lymphocytes NN O O
in NN O O
a NN O O
human NN O O
melanoma NN O B-Disease
. NN O O

A NN O O
mutated NN O O
cyclin NN O O
- NN O O
dependent NN O O
kinase NN O O
4 NN O O
( NN O O
CDK4 NN O O
) NN O O
was NN O O
identified NN O O
as NN O O
a NN O O
tumor NN O B-Disease
- NN O O
specific NN O O
antigen NN O O
recognized NN O O
by NN O O
HLA NN O O
- NN O O
A2 NN O O
. NN O O

1 NN O O
- NN O O
restricted NN O O
autologous NN O O
cytolytic NN O O
T NN O O
lymphocytes NN O O
( NN O O
CTLs NN O O
) NN O O
in NN O O
a NN O O
human NN O O
melanoma NN O B-Disease
. NN O O

The NN O O
mutated NN O O
CDK4 NN O O
allele NN O O
was NN O O
present NN O O
in NN O O
autologous NN O O
cultured NN O O
melanoma NN O B-Disease
cells NN O O
and NN O O
metastasis NN O O
tissue NN O O
, NN O O
but NN O O
not NN O O
in NN O O
the NN O O
patients NN O O
lymphocytes NN O O
. NN O O

The NN O O
mutation NN O O
, NN O O
an NN O O
arginine NN O O
- NN O O
to NN O O
- NN O O
cysteine NN O O
exchange NN O O
at NN O O
residue NN O O
24 NN O O
, NN O O
was NN O O
part NN O O
of NN O O
the NN O O
CDK4 NN O O
peptide NN O O
recognized NN O O
by NN O O
CTLs NN O O
and NN O O
prevented NN O O
binding NN O O
of NN O O
the NN O O
CDK4 NN O O
inhibitor NN O O
p16INK4a NN O O
, NN O O
but NN O O
not NN O O
of NN O O
p21 NN O O
or NN O O
of NN O O
p27KIP1 NN O O
. NN O O

The NN O O
same NN O O
mutation NN O O
was NN O O
found NN O O
in NN O O
one NN O O
additional NN O O
melanoma NN O B-Disease
among NN O O
28 NN O O
melanomas NN O B-Disease
analyzed NN O O
. NN O O

These NN O O
results NN O O
suggest NN O O
that NN O O
mutation NN O O
of NN O O
CDK4 NN O O
can NN O O
create NN O O
a NN O O
tumor NN O B-Disease
- NN O O
specific NN O O
antigen NN O O
and NN O O
can NN O O
disrupt NN O O
the NN O O
cell NN O O
- NN O O
cycle NN O O
regulation NN O O
exerted NN O O
by NN O O
the NN O O
tumor NN O B-Disease
suppressor NN O O
p16INK4a NN O O
. NN O O
. NN O O

Rapid NN O O
detection NN O O
of NN O O
BRCA1 NN O O
mutations NN O O
by NN O O
the NN O O
protein NN O O
truncation NN O O
test NN O O
. NN O O

More NN O O
than NN O O
75 NN O O
% NN O O
of NN O O
the NN O O
reported NN O O
mutations NN O O
in NN O O
the NN O O
hereditary NN O B-Disease
breast NN O I-Disease
and NN O I-Disease
ovarian NN O I-Disease
cancer NN O I-Disease
gene NN O O
, NN O O
BRCA1 NN O O
, NN O O
result NN O O
in NN O O
truncated NN O O
proteins NN O O
. NN O O

We NN O O
have NN O O
used NN O O
the NN O O
protein NN O O
truncation NN O O
test NN O O
( NN O O
PTT NN O O
) NN O O
to NN O O
screen NN O O
for NN O O
mutations NN O O
in NN O O
exon NN O O
11 NN O O
, NN O O
which NN O O
encodes NN O O
61 NN O O
% NN O O
of NN O O
BRCA1 NN O O
. NN O O

In NN O O
45 NN O O
patients NN O O
from NN O O
breast NN O B-Disease
and NN O I-Disease
/ NN O I-Disease
or NN O I-Disease
ovarian NN O I-Disease
cancer NN O I-Disease
families NN O O
we NN O O
found NN O O
six NN O O
novel NN O O
mutations NN O O
two NN O O
single NN O O
nucleotide NN O O
insertions NN O O
, NN O O
three NN O O
small NN O O
deletions NN O O
( NN O O
1 NN O O
- NN O O
5 NN O O
bp NN O O
) NN O O
and NN O O
a NN O O
nonsense NN O O
mutation NN O O
identified NN O O
two NN O O
unrelated NN O O
families NN O O
. NN O O

Furthermore NN O O
, NN O O
we NN O O
were NN O O
able NN O O
to NN O O
amplify NN O O
the NN O O
remaining NN O O
coding NN O O
region NN O O
by NN O O
RT NN O O
- NN O O
PCR NN O O
using NN O O
lymphocyte NN O O
RNA NN O O
. NN O O

Combined NN O O
with NN O O
PTT NN O O
, NN O O
we NN O O
detected NN O O
aberrantly NN O O
spliced NN O O
products NN O O
affecting NN O O
exons NN O O
5 NN O O
and NN O O
6 NN O O
in NN O O
one NN O O
of NN O O
two NN O O
BRCA1 NN O O
- NN O O
linked NN O O
families NN O O
examined NN O O
. NN O O

The NN O O
protein NN O O
truncation NN O O
test NN O O
promises NN O O
to NN O O
become NN O O
a NN O O
valuable NN O O
technique NN O O
in NN O O
detecting NN O O
BRCA1 NN O O
mutations NN O O
. NN O O
. NN O O

Cloning NN O O
of NN O O
human NN O O
very NN O O
- NN O O
long NN O O
- NN O O
chain NN O O
acyl NN O O
- NN O O
coenzyme NN O O
A NN O O
dehydrogenase NN O O
and NN O O
molecular NN O O
characterization NN O O
of NN O O
its NN O O
deficiency NN O O
in NN O O
two NN O O
patients NN O O
. NN O O

Two NN O O
overlapping NN O O
cDNA NN O O
clones NN O O
( NN O O
1 NN O O
, NN O O
991 NN O O
bp NN O O
and NN O O
736 NN O O
bp NN O O
, NN O O
respectively NN O O
) NN O O
encoding NN O O
the NN O O
precursor NN O O
of NN O O
human NN O O
mitochondrial NN O O
very NN O O
- NN O O
long NN O O
- NN O O
chain NN O O
acyl NN O O
- NN O O
coenzyme NN O O
A NN O O
dehydrogenase NN O O
( NN O O
VLCAD NN O O
) NN O O
were NN O O
cloned NN O O
and NN O O
sequenced NN O O
. NN O O

The NN O O
cDNA NN O O
inserts NN O O
of NN O O
these NN O O
clones NN O O
together NN O O
encompass NN O O
a NN O O
region NN O O
of NN O O
2 NN O O
, NN O O
177 NN O O
bases NN O O
, NN O O
encoding NN O O
the NN O O
entire NN O O
protein NN O O
of NN O O
655 NN O O
amino NN O O
acids NN O O
, NN O O
including NN O O
a NN O O
40 NN O O
- NN O O
amino NN O O
acid NN O O
leader NN O O
peptide NN O O
and NN O O
a NN O O
615 NN O O
- NN O O
amino NN O O
acid NN O O
mature NN O O
polypeptide NN O O
. NN O O

PCR NN O O
- NN O O
amplified NN O O
VLCAD NN O O
cDNAs NN O O
were NN O O
sequenced NN O O
in NN O O
cultured NN O O
fibroblasts NN O O
from NN O O
two NN O O
VLCAD NN O B-Disease
- NN O I-Disease
deficient NN O I-Disease
patients NN O O
. NN O O

In NN O O
both NN O O
patients NN O O
, NN O O
a NN O O
105 NN O O
- NN O O
bp NN O O
deletion NN O O
encompassing NN O O
bases NN O O
1078 NN O O
- NN O O
1182 NN O O
in NN O O
VLCAD NN O O
cDNA NN O O
was NN O O
identified NN O O
. NN O O

The NN O O
deletion NN O O
seems NN O O
to NN O O
occur NN O O
due NN O O
to NN O O
exon NN O O
skipping NN O O
during NN O O
processing NN O O
of NN O O
VLCAD NN O O
pre NN O O
- NN O O
mRNA NN O O
. NN O O

This NN O O
is NN O O
the NN O O
first NN O O
demonstration NN O O
of NN O O
a NN O O
mutation NN O O
causing NN O O
VLCAD NN O B-Disease
deficiency NN O I-Disease
. NN O O

Quantitative NN O O
cDNA NN O O
expression NN O O
of NN O O
normal NN O O
human NN O O
VLCAD NN O O
was NN O O
performed NN O O
in NN O O
the NN O O
patients NN O O
fibroblasts NN O O
, NN O O
using NN O O
vaccinia NN O O
viral NN O O
system NN O O
, NN O O
which NN O O
demonstrated NN O O
that NN O O
the NN O O
deficiency NN O B-Disease
of NN O I-Disease
the NN O I-Disease
normal NN O I-Disease
VLCAD NN O I-Disease
protein NN O I-Disease
causes NN O O
impaired NN O O
long NN O O
- NN O O
chain NN O O
fatty NN O O
acid NN O O
beta NN O O
- NN O O
oxidation NN O O
activity NN O O
in NN O O
the NN O O
patients NN O O
fibroblasts NN O O
. NN O O

In NN O O
patient NN O O
fibroblasts NN O O
, NN O O
raising NN O O
VLCAD NN O O
activity NN O O
to NN O O
approximately NN O O
20 NN O O
% NN O O
of NN O O
normal NN O O
control NN O O
fibroblast NN O O
activity NN O O
raised NN O O
palmitic NN O O
acid NN O O
beta NN O O
- NN O O
oxidation NN O O
flux NN O O
to NN O O
the NN O O
level NN O O
found NN O O
in NN O O
control NN O O
fibroblasts NN O O
, NN O O
which NN O O
may NN O O
offer NN O O
important NN O O
information NN O O
for NN O O
the NN O O
rational NN O O
design NN O O
of NN O O
future NN O O
somatic NN O O
gene NN O O
therapy NN O O
for NN O O
VLCAD NN O B-Disease
deficiency NN O I-Disease
. NN O O
. NN O O

Brain NN O B-Disease
disease NN O I-Disease
and NN O O
molecular NN O O
analysis NN O O
in NN O O
myotonic NN O B-Disease
dystrophy NN O I-Disease
. NN O O

Abnormal NN O O
amplification NN O O
of NN O O
a NN O O
CTG NN O O
repeat NN O O
on NN O O
chromosome NN O O
19 NN O O
is NN O O
the NN O O
molecular NN O O
basis NN O O
of NN O O
myotonic NN O B-Disease
dystrophy NN O I-Disease
( NN O O
DM NN O B-Disease
) NN O O
. NN O O

Expansion NN O O
of NN O O
the NN O O
repeat NN O O
has NN O O
been NN O O
correlated NN O O
with NN O O
severity NN O O
of NN O O
several NN O O
clinical NN O O
features NN O O
of NN O O
the NN O O
disease NN O O
. NN O O

We NN O O
performed NN O O
extensive NN O O
cognitive NN O O
testing NN O O
, NN O O
cerebral NN O O
magnetic NN O O
resonance NN O O
imaging NN O O
( NN O O
MRI NN O O
) NN O O
and NN O O
a NN O O
molecular NN O O
analysis NN O O
in NN O O
28 NN O O
cases NN O O
of NN O O
DM NN O B-Disease
to NN O O
determine NN O O
the NN O O
relationship NN O O
between NN O O
the NN O O
molecular NN O O
defect NN O O
and NN O O
brain NN O B-Disease
disease NN O I-Disease
. NN O O

Performance NN O O
in NN O O
two NN O O
or NN O O
more NN O O
cognitive NN O O
tests NN O O
was NN O O
pathological NN O O
in NN O O
10 NN O O
cases NN O O
. NN O O

Fourteen NN O O
patients NN O O
had NN O O
subcortical NN O O
white NN O B-Disease
matter NN O I-Disease
lesions NN O I-Disease
on NN O O
MRI NN O O
, NN O O
14 NN O O
had NN O O
cerebral NN O B-Disease
atrophy NN O I-Disease
. NN O O

Amplification NN O O
of NN O O
the NN O O
CTG NN O O
repeat NN O O
showed NN O O
a NN O O
strong NN O O
correlation NN O O
with NN O O
cognitive NN O O
test NN O O
deficits NN O O
when NN O O
exceeding NN O O
a NN O O
length NN O O
of NN O O
over NN O O
1000 NN O O
trinucleotides NN O O
. NN O O

MRI NN O O
lesions NN O O
were NN O O
associated NN O O
with NN O O
impaired NN O O
psychometric NN O O
performance NN O O
, NN O O
but NN O O
MRI NN O O
and NN O O
molecular NN O O
findings NN O O
were NN O O
only NN O O
weakly NN O O
related NN O O
. NN O O

Disease NN O O
duration NN O O
influenced NN O O
the NN O O
appearance NN O O
and NN O O
amount NN O O
of NN O O
white NN O B-Disease
matter NN O I-Disease
lesions NN O I-Disease
on NN O O
MRI NN O O
. NN O O

Quantification NN O O
of NN O O
CTG NN O O
repeat NN O O
size NN O O
may NN O O
allow NN O O
an NN O O
early NN O O
estimate NN O O
on NN O O
the NN O O
probability NN O O
of NN O O
brain NN O O
involvement NN O O
in NN O O
DM NN O B-Disease
; NN O O
cognitive NN O B-Disease
dysfunction NN O I-Disease
is NN O O
associated NN O O
with NN O O
white NN O B-Disease
matter NN O I-Disease
lesions NN O I-Disease
and NN O O
cerebral NN O B-Disease
atrophy NN O I-Disease
later NN O O
on NN O O
in NN O O
the NN O O
course NN O O
. NN O O
. NN O O

Mutations NN O O
in NN O O
the NN O O
gene NN O O
for NN O O
X NN O B-Disease
- NN O I-Disease
linked NN O I-Disease
adrenoleukodystrophy NN O I-Disease
in NN O O
patients NN O O
with NN O O
different NN O O
clinical NN O O
phenotypes NN O O
. NN O O

Recently NN O O
, NN O O
the NN O O
gene NN O O
for NN O O
the NN O O
most NN O O
common NN O O
peroxisomal NN O B-Disease
disorder NN O I-Disease
, NN O O
X NN O B-Disease
- NN O I-Disease
linked NN O I-Disease
adrenoleukodystrophy NN O I-Disease
( NN O O
X NN O B-Disease
- NN O I-Disease
ALD NN O I-Disease
) NN O O
, NN O O
has NN O O
been NN O O
described NN O O
encoding NN O O
a NN O O
peroxisomal NN O O
membrane NN O O
transporter NN O O
protein NN O O
. NN O O

We NN O O
analyzed NN O O
the NN O O
entire NN O O
protein NN O O
- NN O O
coding NN O O
sequence NN O O
of NN O O
this NN O O
gene NN O O
by NN O O
reverse NN O O
- NN O O
transcription NN O O
PCR NN O O
, NN O O
SSCP NN O O
, NN O O
and NN O O
DNA NN O O
sequencing NN O O
in NN O O
five NN O O
patients NN O O
with NN O O
different NN O O
clinical NN O O
expression NN O O
of NN O O
X NN O B-Disease
- NN O I-Disease
ALD NN O I-Disease
and NN O O
in NN O O
their NN O O
female NN O O
relatives NN O O
; NN O O
these NN O O
clinical NN O O
expressions NN O O
were NN O O
cerebral NN O O
childhood NN O O
ALD NN O B-Disease
, NN O O
adrenomyeloneuropathy NN O B-Disease
( NN O O
AMN NN O B-Disease
) NN O O
, NN O O
and NN O O
" NN O O
Addison NN O B-Disease
disease NN O I-Disease
only NN O I-Disease
" NN O O
( NN O O
ADO NN O B-Disease
) NN O O
phenotype NN O O
. NN O O

In NN O O
the NN O O
three NN O O
patients NN O O
exhibiting NN O O
the NN O O
classical NN O O
picture NN O O
of NN O O
severe NN O O
childhood NN O O
ALD NN O B-Disease
we NN O O
identified NN O O
in NN O O
the NN O O
5 NN O O
portion NN O O
of NN O O
the NN O O
X NN O B-Disease
- NN O I-Disease
ALD NN O I-Disease
gene NN O O
a NN O O
38 NN O O
- NN O O
bp NN O O
deletion NN O O
that NN O O
causes NN O O
a NN O O
frameshift NN O O
mutation NN O O
, NN O O
a NN O O
3 NN O O
- NN O O
bp NN O O
deletion NN O O
leading NN O O
to NN O O
a NN O O
deletion NN O O
of NN O O
an NN O O
amino NN O O
acid NN O O
in NN O O
the NN O O
ATP NN O O
- NN O O
binding NN O O
domain NN O O
of NN O O
the NN O O
ALD NN O B-Disease
protein NN O O
, NN O O
and NN O O
a NN O O
missense NN O O
mutation NN O O
. NN O O

In NN O O
the NN O O
patient NN O O
with NN O O
the NN O O
clinical NN O O
phenotype NN O O
of NN O O
AMN NN O B-Disease
, NN O O
a NN O O
nonsense NN O O
mutation NN O O
in NN O O
codon NN O O
212 NN O O
, NN O O
along NN O O
with NN O O
a NN O O
second NN O O
site NN O O
mutation NN O O
at NN O O
codon NN O O
178 NN O O
, NN O O
was NN O O
observed NN O O
. NN O O

Analysis NN O O
of NN O O
the NN O O
patient NN O O
with NN O O
the NN O O
ADO NN O B-Disease
phenotype NN O O
revealed NN O O
a NN O O
further NN O O
missense NN O O
mutation NN O O
at NN O O
a NN O O
highly NN O O
conserved NN O O
position NN O O
in NN O O
the NN O O
ALDP NN O O
/ NN O O
PMP70 NN O O
comparison NN O O
. NN O O

The NN O O
disruptive NN O O
nature NN O O
of NN O O
two NN O O
mutations NN O O
( NN O O
i NN O O
. NN O O
e NN O O
. NN O O
, NN O O
the NN O O
frameshift NN O O
and NN O O
the NN O O
nonsense NN O O
mutation NN O O
) NN O O
in NN O O
patients NN O O
with NN O O
biochemically NN O O
proved NN O O
childhood NN O O
ALD NN O B-Disease
and NN O O
AMN NN O B-Disease
further NN O O
strongly NN O O
supports NN O O
the NN O O
hypothesis NN O O
that NN O O
alterations NN O O
in NN O O
this NN O O
gene NN O O
play NN O O
a NN O O
crucial NN O O
role NN O O
in NN O O
the NN O O
pathogenesis NN O O
of NN O O
X NN O B-Disease
- NN O I-Disease
ALD NN O I-Disease
. NN O O

Since NN O O
the NN O O
current NN O O
biochemical NN O O
techniques NN O O
for NN O O
X NN O B-Disease
- NN O I-Disease
ALD NN O I-Disease
carrier NN O O
detection NN O O
in NN O O
affected NN O O
families NN O O
lack NN O O
sufficient NN O O
reliability NN O O
, NN O O
our NN O O
procedure NN O O
described NN O O
for NN O O
systematic NN O O
mutation NN O O
scanning NN O O
is NN O O
also NN O O
capable NN O O
of NN O O
improving NN O O
genetic NN O O
counseling NN O O
and NN O O
prenatal NN O O
diagnosis NN O O

Duchenne NN O B-Disease
muscular NN O I-Disease
dystrophy NN O I-Disease
and NN O O
myotonic NN O B-Disease
dystrophy NN O I-Disease
in NN O O
the NN O O
same NN O O
patient NN O O
. NN O O

We NN O O
report NN O O
on NN O O
the NN O O
first NN O O
patient NN O O
identified NN O O
with NN O O
myotonic NN O B-Disease
dystrophy NN O I-Disease
and NN O O
Duchenne NN O B-Disease
muscular NN O I-Disease
dystrophy NN O I-Disease
( NN O O
DMD NN O B-Disease
) NN O O
. NN O O

The NN O O
family NN O O
of NN O O
the NN O O
propositus NN O O
had NN O O
a NN O O
strong NN O O
history NN O O
of NN O O
myotonic NN O B-Disease
dystrophy NN O I-Disease
, NN O O
and NN O O
there NN O O
was NN O O
an NN O O
intrafamilial NN O O
pathological NN O O
expansion NN O O
of NN O O
the NN O O
responsible NN O O
CTG NN O O
repeat NN O O
between NN O O
the NN O O
mildly NN O O
affected NN O O
mother NN O O
( NN O O
160 NN O O
repeats NN O O
; NN O O
normal NN O O
27 NN O O
repeats NN O O
) NN O O
and NN O O
her NN O O
more NN O O
severely NN O O
affected NN O O
son NN O O
( NN O O
650 NN O O
repeats NN O O
) NN O O
, NN O O
and NN O O
his NN O O
sister NN O O
( NN O O
650 NN O O
repeats NN O O
) NN O O
. NN O O

The NN O O
propositus NN O O
was NN O O
an NN O O
isolated NN O O
case NN O O
of NN O O
Duchenne NN O B-Disease
muscular NN O I-Disease
dystrophy NN O I-Disease
with NN O O
marked NN O O
dystrophin NN O B-Disease
deficiency NN O I-Disease
in NN O O
muscle NN O O
biopsy NN O O
. NN O O

The NN O O
patient NN O O
was NN O O
still NN O O
ambulatory NN O O
post NN O O
age NN O O
16 NN O O
. NN O O

Myotonic NN O B-Disease
dystrophy NN O I-Disease
could NN O O
interfere NN O O
to NN O O
some NN O O
extent NN O O
with NN O O
the NN O O
progression NN O O
of NN O O
Duchenne NN O B-Disease
dystrophy NN O I-Disease
. NN O O

However NN O O
, NN O O
other NN O O
interpretations NN O O
are NN O O
possible NN O O
. NN O O

Twelve NN O O
percent NN O O
of NN O O
dystrophin NN O O
revertant NN O O
fibers NN O O
as NN O O
observed NN O O
by NN O O
immunohistochemistry NN O O
could NN O O
be NN O O
sufficient NN O O
to NN O O
ameliorate NN O O
typical NN O O
DMD NN O B-Disease
clinical NN O O
severity NN O O
, NN O O
or NN O O
the NN O O
patient NN O O
may NN O O
present NN O O
a NN O O
somatic NN O O
mosaic NN O O
. NN O O

The NN O O
pathophysiological NN O O
interactions NN O O
of NN O O
these NN O O
two NN O O
unlinked NN O O
disorders NN O O
are NN O O
discussed NN O O
at NN O O
the NN O O
clinical NN O O
and NN O O
histopathological NN O O
levels NN O O
. NN O O
. NN O O

Age NN O O
at NN O O
diagnosis NN O O
as NN O O
an NN O O
indicator NN O O
of NN O O
eligibility NN O O
for NN O O
BRCA1 NN O O
DNA NN O O
testing NN O O
in NN O O
familial NN O B-Disease
breast NN O I-Disease
cancer NN O I-Disease
. NN O O

We NN O O
searched NN O O
for NN O O
criteria NN O O
that NN O O
could NN O O
indicate NN O O
breast NN O B-Disease
cancer NN O I-Disease
families NN O O
with NN O O
a NN O O
high NN O O
prior NN O O
probability NN O O
of NN O O
being NN O O
caused NN O O
by NN O O
the NN O O
breast NN O B-Disease
/ NN O I-Disease
ovarian NN O I-Disease
cancer NN O I-Disease
susceptibility NN O O
locus NN O O
BRCA1 NN O O
on NN O O
chromosome NN O O
17 NN O O
. NN O O

To NN O O
this NN O O
end NN O O
, NN O O
we NN O O
performed NN O O
a NN O O
linkage NN O O
study NN O O
with NN O O
59 NN O O
consecutively NN O O
collected NN O O
Dutch NN O O
breast NN O B-Disease
cancer NN O I-Disease
families NN O O
, NN O O
including NN O O
16 NN O O
with NN O O
at NN O O
least NN O O
one NN O O
case NN O O
of NN O O
ovarian NN O B-Disease
cancer NN O I-Disease
. NN O O

We NN O O
used NN O O
an NN O O
intake NN O O
cut NN O O
- NN O O
off NN O O
of NN O O
at NN O O
least NN O O
three NN O O
first NN O O
- NN O O
degree NN O O
relatives NN O O
with NN O O
breast NN O B-Disease
and NN O I-Disease
/ NN O I-Disease
or NN O I-Disease
ovarian NN O I-Disease
cancer NN O I-Disease
at NN O O
any NN O O
age NN O O
. NN O O

Significant NN O O
evidence NN O O
for NN O O
linkage NN O O
was NN O O
found NN O O
only NN O O
among NN O O
the NN O O
13 NN O O
breast NN O B-Disease
cancer NN O I-Disease
families NN O O
with NN O O
a NN O O
mean NN O O
age NN O O
at NN O O
diagnosis NN O O
of NN O O
less NN O O
than NN O O
45 NN O O
years NN O O
. NN O O

An NN O O
unexpectedly NN O O
low NN O O
proportion NN O O
of NN O O
the NN O O
breast NN O B-Disease
- NN O I-Disease
ovarian NN O I-Disease
cancer NN O I-Disease
families NN O O
were NN O O
estimated NN O O
to NN O O
be NN O O
linked NN O O
to NN O O
BRCA1 NN O O
, NN O O
which NN O O
could NN O O
be NN O O
due NN O O
to NN O O
a NN O O
founder NN O O
effect NN O O
in NN O O
the NN O O
Dutch NN O O
population NN O O
. NN O O

Given NN O O
the NN O O
expected NN O O
logistical NN O O
problems NN O O
in NN O O
clinical NN O O
management NN O O
now NN O O
that NN O O
BRCA1 NN O O
has NN O O
been NN O O
identified NN O O
, NN O O
we NN O O
propose NN O O
an NN O O
interim NN O O
period NN O O
in NN O O
which NN O O
only NN O O
families NN O O
with NN O O
a NN O O
strong NN O O
positive NN O O
family NN O O
history NN O O
for NN O O
early NN O O
onset NN O O
breast NN O B-Disease
and NN O I-Disease
/ NN O I-Disease
or NN O I-Disease
ovarian NN O I-Disease
cancer NN O I-Disease
will NN O O
be NN O O
offered NN O O
BRCA1 NN O O
mutation NN O O
testing NN O O
. NN O O
. NN O O

Linkage NN O O
analysis NN O O
of NN O O
26 NN O O
Canadian NN O O
breast NN O B-Disease
and NN O I-Disease
breast NN O I-Disease
- NN O I-Disease
ovarian NN O I-Disease
cancer NN O I-Disease
families NN O O
. NN O O

We NN O O
have NN O O
examined NN O O
26 NN O O
Canadian NN O O
families NN O O
with NN O O
hereditary NN O B-Disease
breast NN O I-Disease
or NN O I-Disease
ovarian NN O I-Disease
cancer NN O I-Disease
for NN O O
linkage NN O O
to NN O O
markers NN O O
flanking NN O O
the NN O O
BRCA1 NN O O
gene NN O O
on NN O O
chromosome NN O O
17q12 NN O O
- NN O O
q21 NN O O
. NN O O

Of NN O O
the NN O O
15 NN O O
families NN O O
that NN O O
contain NN O O
cases NN O O
of NN O O
ovarian NN O B-Disease
cancer NN O I-Disease
, NN O O
94 NN O O
% NN O O
were NN O O
estimated NN O O
to NN O O
be NN O O
linked NN O O
to NN O O
BRCA1 NN O O
. NN O O

In NN O O
contrast NN O O
, NN O O
there NN O O
was NN O O
no NN O O
overall NN O O
evidence NN O O
of NN O O
linkage NN O O
in NN O O
the NN O O
group NN O O
of NN O O
10 NN O O
families NN O O
with NN O O
breast NN O B-Disease
cancer NN O I-Disease
without NN O O
ovarian NN O B-Disease
cancer NN O I-Disease
. NN O O

A NN O O
genetic NN O O
recombinant NN O O
in NN O O
a NN O O
breast NN O B-Disease
- NN O I-Disease
ovarian NN O I-Disease
cancer NN O I-Disease
family NN O O
indicates NN O O
a NN O O
placement NN O O
of NN O O
BRCA1 NN O O
telomeric NN O O
to NN O O
D17S776 NN O O
, NN O O
and NN O O
helps NN O O
to NN O O
define NN O O
the NN O O
region NN O O
of NN O O
assignment NN O O
of NN O O
the NN O O
cancer NN O B-Disease
susceptibility NN O O
gene NN O O
. NN O O

Other NN O O
cancers NN O B-Disease
of NN O O
interest NN O O
that NN O O
appeared NN O O
in NN O O
the NN O O
BRCA1 NN O O
- NN O O
linked NN O O
families NN O O
included NN O O
primary NN O B-Disease
peritoneal NN O I-Disease
cancer NN O I-Disease
, NN O O
cancer NN O B-Disease
of NN O I-Disease
the NN O I-Disease
fallopian NN O I-Disease
tube NN O I-Disease
, NN O O
and NN O O
malignant NN O B-Disease
melanoma NN O I-Disease
. NN O O
. NN O O

Structural NN O O
analysis NN O O
of NN O O
the NN O O
5 NN O O
' NN O O
region NN O O
of NN O O
mouse NN O O
and NN O O
human NN O O
Huntington NN O B-Disease
disease NN O I-Disease
genes NN O O
reveals NN O O
conservation NN O O
of NN O O
putative NN O O
promoter NN O O
region NN O O
and NN O O
di NN O O
- NN O O
and NN O O
trinucleotide NN O O
polymorphisms NN O O
. NN O O

We NN O O
have NN O O
previously NN O O
cloned NN O O
and NN O O
characterized NN O O
the NN O O
murine NN O O
homologue NN O O
of NN O O
the NN O O
Huntington NN O B-Disease
disease NN O I-Disease
( NN O O
HD NN O B-Disease
) NN O O
gene NN O O
and NN O O
shown NN O O
that NN O O
it NN O O
maps NN O O
to NN O O
mouse NN O O
chromosome NN O O
5 NN O O
within NN O O
a NN O O
region NN O O
of NN O O
conserved NN O O
synteny NN O O
with NN O O
human NN O O
chromosome NN O O
4p16 NN O O
. NN O O

3 NN O O
3 NN O O
. NN O O

Here NN O O
we NN O O
present NN O O
a NN O O
detailed NN O O
comparison NN O O
of NN O O
the NN O O
sequence NN O O
of NN O O
the NN O O
putative NN O O
promoter NN O O
and NN O O
the NN O O
organization NN O O
of NN O O
the NN O O
5 NN O O
genomic NN O O
region NN O O
of NN O O
the NN O O
murine NN O O
( NN O O
Hdh NN O O
) NN O O
and NN O O
human NN O O
HD NN O B-Disease
genes NN O O
encompassing NN O O
the NN O O
first NN O O
five NN O O
exons NN O O
. NN O O

We NN O O
show NN O O
that NN O O
in NN O O
this NN O O
region NN O O
these NN O O
two NN O O
genes NN O O
share NN O O
identical NN O O
exon NN O O
boundaries NN O O
, NN O O
but NN O O
have NN O O
different NN O O
- NN O O
size NN O O
introns NN O O
. NN O O

Two NN O O
dinucleotide NN O O
( NN O O
CT NN O O
) NN O O
and NN O O
one NN O O
trinucleotide NN O O
intronic NN O O
polymorphism NN O O
in NN O O
Hdh NN O O
and NN O O
an NN O O
intronic NN O O
CA NN O O
polymorphism NN O O
in NN O O
the NN O O
HD NN O B-Disease
gene NN O O
were NN O O
identified NN O O
. NN O O

Comparison NN O O
of NN O O
940 NN O O
- NN O O
bp NN O O
sequence NN O O
5 NN O O
to NN O O
the NN O O
putative NN O O
translation NN O O
start NN O O
site NN O O
reveals NN O O
a NN O O
highly NN O O
conserved NN O O
region NN O O
( NN O O
78 NN O O
. NN O O
8 NN O O
% NN O O
nucleotide NN O O
identity NN O O
) NN O O
between NN O O
Hdh NN O O
and NN O O
the NN O O
HD NN O B-Disease
gene NN O O
from NN O O
nucleotide NN O O
- NN O O
56 NN O O
to NN O O
- NN O O
206 NN O O
( NN O O
of NN O O
Hdh NN O O
) NN O O
. NN O O

Neither NN O O
Hdh NN O O
nor NN O O
the NN O O
HD NN O B-Disease
gene NN O O
have NN O O
typical NN O O
TATA NN O O
or NN O O
CCAAT NN O O
elements NN O O
, NN O O
but NN O O
both NN O O
show NN O O
one NN O O
putative NN O O
AP2 NN O O
binding NN O O
site NN O O
and NN O O
numerous NN O O
potential NN O O
Sp1 NN O O
binding NN O O
sites NN O O
. NN O O

The NN O O
high NN O O
sequence NN O O
identity NN O O
between NN O O
Hdh NN O O
and NN O O
the NN O O
HD NN O B-Disease
gene NN O O
for NN O O
approximately NN O O
200 NN O O
bp NN O O
5 NN O O
to NN O O
the NN O O
putative NN O O
translation NN O O
start NN O O
site NN O O
indicates NN O O
that NN O O
these NN O O
sequences NN O O
may NN O O
play NN O O
a NN O O
role NN O O
in NN O O
regulating NN O O
expression NN O O
of NN O O
the NN O O
Huntington NN O B-Disease
disease NN O I-Disease
gene NN O O

The NN O O
protein NN O O
deficient NN O O
in NN O O
Lowe NN O B-Disease
syndrome NN O I-Disease
is NN O O
a NN O O
phosphatidylinositol NN O O
- NN O O
4 NN O O
, NN O O
5 NN O O
- NN O O
bisphosphate NN O O
5 NN O O
- NN O O
phosphatase NN O O
. NN O O

Lowe NN O B-Disease
syndrome NN O I-Disease
, NN O O
also NN O O
known NN O O
as NN O O
oculocerebrorenal NN O B-Disease
syndrome NN O I-Disease
, NN O O
is NN O O
caused NN O O
by NN O O
mutations NN O O
in NN O O
the NN O O
X NN O O
chromosome NN O O
- NN O O
encoded NN O O
OCRL NN O O
gene NN O O
. NN O O

The NN O O
OCRL NN O O
protein NN O O
is NN O O
51 NN O O
% NN O O
identical NN O O
to NN O O
inositol NN O O
polyphosphate NN O O
5 NN O O
- NN O O
phosphatase NN O O
II NN O O
( NN O O
5 NN O O
- NN O O
phosphatase NN O O
II NN O O
) NN O O
from NN O O
human NN O O
platelets NN O O
over NN O O
a NN O O
span NN O O
of NN O O
744 NN O O
aa NN O O
, NN O O
suggesting NN O O
that NN O O
OCRL NN O O
may NN O O
be NN O O
a NN O O
similar NN O O
enzyme NN O O
. NN O O

We NN O O
engineered NN O O
a NN O O
construct NN O O
of NN O O
the NN O O
OCRL NN O O
cDNA NN O O
that NN O O
encodes NN O O
amino NN O O
acids NN O O
homologous NN O O
to NN O O
the NN O O
platelet NN O O
5 NN O O
- NN O O
phosphatase NN O O
for NN O O
expression NN O O
in NN O O
baculovirus NN O O
- NN O O
infected NN O O
Sf9 NN O O
insect NN O O
cells NN O O
. NN O O

This NN O O
cDNA NN O O
encodes NN O O
aa NN O O
264 NN O O
- NN O O
968 NN O O
of NN O O
the NN O O
OCRL NN O O
protein NN O O
. NN O O

The NN O O
recombinant NN O O
protein NN O O
was NN O O
found NN O O
to NN O O
catalyze NN O O
the NN O O
reactions NN O O
also NN O O
carried NN O O
out NN O O
by NN O O
platelet NN O O
5 NN O O
- NN O O
phosphatase NN O O
II NN O O
. NN O O

Thus NN O O
OCRL NN O O
converts NN O O
inositol NN O O
1 NN O O
, NN O O
4 NN O O
, NN O O
5 NN O O
- NN O O
trisphosphate NN O O
to NN O O
inositol NN O O
1 NN O O
, NN O O
4 NN O O
- NN O O
bisphosphate NN O O
, NN O O
and NN O O
it NN O O
converts NN O O
inositol NN O O
1 NN O O
, NN O O
3 NN O O
, NN O O
4 NN O O
, NN O O
5 NN O O
- NN O O
tetrakisphosphate NN O O
to NN O O
inositol NN O O
1 NN O O
, NN O O
3 NN O O
, NN O O
4 NN O O
- NN O O
trisphosphate NN O O
. NN O O

Most NN O O
important NN O O
, NN O O
the NN O O
enzyme NN O O
converts NN O O
phosphatidylinositol NN O O
4 NN O O
, NN O O
5 NN O O
- NN O O
bisphosphate NN O O
to NN O O
phosphatidylinositol NN O O
4 NN O O
- NN O O
phosphate NN O O
. NN O O

The NN O O
relative NN O O
ability NN O O
of NN O O
OCRL NN O O
to NN O O
catalyze NN O O
the NN O O
three NN O O
reactions NN O O
is NN O O
different NN O O
from NN O O
that NN O O
of NN O O
5 NN O O
- NN O O
phosphatase NN O O
II NN O O
and NN O O
from NN O O
that NN O O
of NN O O
another NN O O
5 NN O O
- NN O O
phosphatase NN O O
isoenzyme NN O O
from NN O O
platelets NN O O
, NN O O
5 NN O O
- NN O O
phosphatase NN O O
I NN O O
. NN O O

The NN O O
recombinant NN O O
OCRL NN O O
protein NN O O
hydrolyzes NN O O
the NN O O
phospholipid NN O O
substrate NN O O
10 NN O O
- NN O O
to NN O O
30 NN O O
- NN O O
fold NN O O
better NN O O
than NN O O
5 NN O O
- NN O O
phosphatase NN O O
II NN O O
, NN O O
and NN O O
5 NN O O
- NN O O
phosphatase NN O O
I NN O O
does NN O O
not NN O O
cleave NN O O
the NN O O
lipid NN O O
at NN O O
all NN O O
. NN O O

We NN O O
also NN O O
show NN O O
that NN O O
OCRL NN O O
functions NN O O
as NN O O
a NN O O
phosphatidylinositol NN O O
4 NN O O
, NN O O
5 NN O O
- NN O O
bisphosphate NN O O
5 NN O O
- NN O O
phosphatase NN O O
in NN O O
OCRL NN O O
- NN O O
expressing NN O O
Sf9 NN O O
cells NN O O
. NN O O

These NN O O
results NN O O
suggest NN O O
that NN O O
OCRL NN O O
is NN O O
mainly NN O O
a NN O O
lipid NN O O
phosphatase NN O O
that NN O O
may NN O O
control NN O O
cellular NN O O
levels NN O O
of NN O O
a NN O O
critical NN O O
metabolite NN O O
, NN O O
phosphatidylinositol NN O O
4 NN O O
, NN O O
5 NN O O
- NN O O
bisphosphate NN O O
. NN O O

Deficiency NN O O
of NN O O
this NN O O
enzyme NN O O
apparently NN O O
causes NN O O
the NN O O
protean NN O O
manifestations NN O O
of NN O O
Lowe NN O B-Disease
syndrome NN O I-Disease
. NN O O
. NN O O

New NN O O
founder NN O O
haplotypes NN O O
at NN O O
the NN O O
myotonic NN O B-Disease
dystrophy NN O I-Disease
locus NN O O
in NN O O
southern NN O O
Africa NN O O
. NN O O

The NN O O
association NN O O
between NN O O
normal NN O O
alleles NN O O
at NN O O
the NN O O
CTG NN O O
repeat NN O O
and NN O O
two NN O O
nearby NN O O
polymorphisms NN O O
in NN O O
the NN O O
myotonin NN O O
protein NN O O
kinase NN O O
gene NN O O
, NN O O
the NN O O
Alu NN O O
insertion NN O O
/ NN O O
deletion NN O O
polymorphism NN O O
and NN O O
the NN O O
myotonic NN O B-Disease
dystrophy NN O I-Disease
kinase NN O O
( NN O O
DMK NN O O
) NN O O
( NN O O
G NN O O
/ NN O O
T NN O O
) NN O O
intron NN O O
9 NN O O
/ NN O O
HinfI NN O O
polymorphism NN O O
, NN O O
has NN O O
been NN O O
analyzed NN O O
in NN O O
South NN O O
African NN O O
Negroids NN O O
, NN O O
a NN O O
population NN O O
in NN O O
which NN O O
myotonic NN O B-Disease
dystrophy NN O I-Disease
( NN O O
DM NN O B-Disease
) NN O O
has NN O O
not NN O O
been NN O O
described NN O O
. NN O O

South NN O O
African NN O O
Negroids NN O O
have NN O O
a NN O O
CTG NN O O
allelic NN O O
distribution NN O O
that NN O O
is NN O O
significantly NN O O
different NN O O
from NN O O
that NN O O
in NN O O
Caucasoids NN O O
and NN O O
Japanese NN O O
the NN O O
CTG NN O O
repeat NN O O
lengths NN O O
of NN O O
> NN O O
or NN O O
= NN O O
19 NN O O
are NN O O
very NN O O
rare NN O O
. NN O O

The NN O O
striking NN O O
linkage NN O O
disequilibrium NN O O
between NN O O
specific NN O O
alleles NN O O
at NN O O
the NN O O
Alu NN O O
polymorphism NN O O
( NN O O
Alu NN O O
( NN O O
ins NN O O
) NN O O
and NN O O
Alu NN O O
( NN O O
del NN O O
) NN O O
) NN O O
, NN O O
the NN O O
HinfI NN O O
polymorphism NN O O
( NN O O
HinfI NN O O
- NN O O
1 NN O O
and NN O O
HinfI NN O O
- NN O O
2 NN O O
) NN O O
, NN O O
and NN O O
the NN O O
CTG NN O O
repeat NN O O
polymorphism NN O O
seen NN O O
in NN O O
Caucasoid NN O O
( NN O O
Europeans NN O O
and NN O O
Canadians NN O O
) NN O O
populations NN O O
was NN O O
also NN O O
found NN O O
in NN O O
the NN O O
South NN O O
African NN O O
Negroid NN O O
population NN O O
. NN O O

Numerous NN O O
haplotypes NN O O
, NN O O
not NN O O
previously NN O O
described NN O O
in NN O O
Europeans NN O O
, NN O O
were NN O O
, NN O O
however NN O O
, NN O O
found NN O O
. NN O O

It NN O O
thus NN O O
seems NN O O
likely NN O O
that NN O O
only NN O O
a NN O O
small NN O O
number NN O O
of NN O O
these NN O O
" NN O O
African NN O O
" NN O O
chromosomes NN O O
were NN O O
present NN O O
in NN O O
the NN O O
progenitors NN O O
of NN O O
all NN O O
non NN O O
- NN O O
African NN O O
peoples NN O O
. NN O O

These NN O O
data NN O O
provide NN O O
support NN O O
for NN O O
the NN O O
" NN O O
out NN O O
of NN O O
Africa NN O O
" NN O O
model NN O O
for NN O O
the NN O O
origin NN O O
of NN O O
modern NN O O
humans NN O O
and NN O O
suggest NN O O
that NN O O
the NN O O
rare NN O O
ancestral NN O O
DM NN O B-Disease
mutation NN O O
event NN O O
may NN O O
have NN O O
occurred NN O O
after NN O O
the NN O O
migration NN O O
from NN O O
Africa NN O O
, NN O O
hence NN O O
the NN O O
absence NN O O
of NN O O
DM NN O B-Disease
in NN O O
sub NN O O
- NN O O
Saharan NN O O
Negroid NN O O
peoples NN O O
. NN O O
. NN O O

Discordant NN O O
clinical NN O O
outcome NN O O
in NN O O
myotonic NN O B-Disease
dystrophy NN O I-Disease
relatives NN O O
showing NN O O
( NN O O
CTG NN O O
) NN O O
n NN O O
> NN O O
700 NN O O
repeats NN O O
. NN O O

A NN O O
myotonic NN O B-Disease
dystrophy NN O I-Disease
( NN O O
DM NN O B-Disease
) NN O O
family NN O O
is NN O O
described NN O O
in NN O O
which NN O O
discordant NN O O
DM NN O B-Disease
phenotypes NN O O
were NN O O
found NN O O
in NN O O
the NN O O
children NN O O
of NN O O
two NN O O
affected NN O O
sisters NN O O
with NN O O
similar NN O O
CTG NN O O
expansion NN O O
and NN O O
clinical NN O O
manifestations NN O O
. NN O O

In NN O O
this NN O O
family NN O O
, NN O O
congenital NN O O
as NN O O
well NN O O
as NN O O
early NN O O
severe NN O O
childhood NN O O
and NN O O
later NN O O
childhood NN O O
onset NN O O
DM NN O B-Disease
coexist NN O O
. NN O O

This NN O O
observation NN O O
strengthens NN O O
the NN O O
limited NN O O
ability NN O O
of NN O O
lymphocytes NN O O
CTG NN O O
repeat NN O O
number NN O O
analysis NN O O
in NN O O
predicting NN O O
genotype NN O O
- NN O O
phenotype NN O O
correlations NN O O
in NN O O
DM NN O B-Disease
patients NN O O
. NN O O
. NN O O

Purification NN O O
of NN O O
human NN O O
very NN O O
- NN O O
long NN O O
- NN O O
chain NN O O
acyl NN O O
- NN O O
coenzyme NN O O
A NN O O
dehydrogenase NN O O
and NN O O
characterization NN O O
of NN O O
its NN O O
deficiency NN O O
in NN O O
seven NN O O
patients NN O O
. NN O O

Mitochondrial NN O O
very NN O O
- NN O O
long NN O O
- NN O O
chain NN O O
acyl NN O O
- NN O O
coenzyme NN O O
A NN O O
dehydrogenase NN O O
( NN O O
VLCAD NN O O
) NN O O
was NN O O
purified NN O O
from NN O O
human NN O O
liver NN O O
. NN O O

The NN O O
molecular NN O O
masses NN O O
of NN O O
the NN O O
native NN O O
enzyme NN O O
and NN O O
the NN O O
subunit NN O O
were NN O O
estimated NN O O
to NN O O
be NN O O
154 NN O O
and NN O O
70 NN O O
kD NN O O
, NN O O
respectively NN O O
. NN O O

The NN O O
enzyme NN O O
was NN O O
found NN O O
to NN O O
catalyze NN O O
the NN O O
major NN O O
part NN O O
of NN O O
mitochondrial NN O O
palmitoylcoenzyme NN O O
A NN O O
dehydrogenation NN O O
in NN O O
liver NN O O
, NN O O
heart NN O O
, NN O O
skeletal NN O O
muscle NN O O
, NN O O
and NN O O
skin NN O O
fibroblasts NN O O
( NN O O
89 NN O O
- NN O O
97 NN O O
, NN O O
86 NN O O
- NN O O
99 NN O O
, NN O O
96 NN O O
- NN O O
99 NN O O
, NN O O
and NN O O
78 NN O O
- NN O O
87 NN O O
% NN O O
, NN O O
respectively NN O O
) NN O O
. NN O O

Skin NN O O
fibroblasts NN O O
from NN O O
26 NN O O
patients NN O O
suspected NN O O
of NN O O
having NN O O
a NN O O
disorder NN O O
of NN O O
mitochondrial NN O O
beta NN O O
- NN O O
oxidation NN O O
were NN O O
analyzed NN O O
for NN O O
VLCAD NN O O
protein NN O O
using NN O O
immunoblotting NN O O
, NN O O
and NN O O
7 NN O O
of NN O O
them NN O O
contained NN O O
undetectable NN O O
or NN O O
trace NN O O
levels NN O O
of NN O O
the NN O O
enzyme NN O O
. NN O O

The NN O O
seven NN O O
deficient NN O O
fibroblast NN O O
lines NN O O
were NN O O
characterized NN O O
by NN O O
measuring NN O O
acyl NN O O
- NN O O
coenzyme NN O O
A NN O O
dehydrogenation NN O O
activities NN O O
, NN O O
overall NN O O
palmitic NN O O
acid NN O O
oxidation NN O O
, NN O O
and NN O O
VLCAD NN O O
protein NN O O
synthesis NN O O
using NN O O
pulse NN O O
- NN O O
chase NN O O
, NN O O
further NN O O
confirming NN O O
the NN O O
diagnosis NN O O
of NN O O
VLCAD NN O B-Disease
deficiency NN O I-Disease
. NN O O

These NN O O
results NN O O
suggested NN O O
the NN O O
heterogenous NN O O
nature NN O O
of NN O O
the NN O O
mutations NN O O
causing NN O O
the NN O O
deficiency NN O O
in NN O O
the NN O O
seven NN O O
patients NN O O
. NN O O

Clinically NN O O
, NN O O
all NN O O
patients NN O O
with NN O O
VLCAD NN O B-Disease
deficiency NN O I-Disease
exhibited NN O O
cardiac NN O B-Disease
disease NN O I-Disease
. NN O O

At NN O O
least NN O O
four NN O O
of NN O O
them NN O O
presented NN O O
with NN O O
hypertrophic NN O B-Disease
cardiomyopathy NN O I-Disease
. NN O O

This NN O O
frequency NN O O
( NN O O
> NN O O
57 NN O O
% NN O O
) NN O O
was NN O O
much NN O O
higher NN O O
than NN O O
that NN O O
observed NN O O
in NN O O
patients NN O O
with NN O O
other NN O O
disorders NN O O
of NN O O
mitochondrial NN O O
long NN O O
- NN O O
chain NN O O
fatty NN O O
acid NN O O
oxidation NN O O
that NN O O
may NN O O
be NN O O
accompanied NN O O
by NN O O
cardiac NN O B-Disease
disease NN O I-Disease
in NN O O
infants NN O O
. NN O O
. NN O O

Hereditary NN O B-Disease
deficiency NN O I-Disease
of NN O I-Disease
the NN O I-Disease
fifth NN O I-Disease
component NN O I-Disease
of NN O I-Disease
complement NN O I-Disease
in NN O O
man NN O O
. NN O O

II NN O O
. NN O O

Biological NN O O
properties NN O O
of NN O O
C5 NN O B-Disease
- NN O I-Disease
deficient NN O I-Disease
human NN O O
serum NN O O
. NN O O

The NN O O
first NN O O
known NN O O
human NN O O
kindred NN O O
with NN O O
hereditary NN O B-Disease
deficiency NN O I-Disease
of NN O I-Disease
the NN O I-Disease
fifth NN O I-Disease
component NN O I-Disease
of NN O I-Disease
complement NN O I-Disease
( NN O O
C5 NN O O
) NN O O
was NN O O
documented NN O O
in NN O O
the NN O O
accompanying NN O O
report NN O O
. NN O O

This NN O O
study NN O O
examines NN O O
several NN O O
biological NN O O
properties NN O O
of NN O O
C5 NN O B-Disease
- NN O I-Disease
deficient NN O I-Disease
( NN O O
C5D NN O B-Disease
) NN O O
human NN O O
serum NN O O
, NN O O
particularly NN O O
sera NN O O
obtained NN O O
from NN O O
two NN O O
C5D NN O B-Disease
homozygotes NN O O
. NN O O

The NN O O
proband NN O O
, NN O O
who NN O O
has NN O O
inactive NN O O
systemic NN O B-Disease
lupus NN O I-Disease
erythematosus NN O I-Disease
is NN O O
completely NN O O
lacking NN O O
C5 NN O O
, NN O O
while NN O O
her NN O O
healthy NN O O
half NN O O
- NN O O
sister NN O O
has NN O O
1 NN O O
- NN O O
2 NN O O
% NN O O
of NN O O
normal NN O O
levels NN O O
. NN O O

Both NN O O
sera NN O O
were NN O O
severely NN O O
impaired NN O O
in NN O O
their NN O O
ability NN O O
to NN O O
generate NN O O
chemotactic NN O O
activity NN O O
for NN O O
normal NN O O
human NN O O
neutrophils NN O O
upon NN O O
incubation NN O O
with NN O O
aggregated NN O O
human NN O O
gamma NN O O
- NN O O
globulin NN O O
or NN O O
Escherichia NN O O
coli NN O O
endotoxin NN O O
. NN O O

This NN O O
function NN O O
was NN O O
fully NN O O
restored NN O O
in NN O O
the NN O O
siblings NN O O
serum NN O O
, NN O O
and NN O O
substantially NN O O
improved NN O O
in NN O O
the NN O O
probands NN O O
serum NN O O
, NN O O
by NN O O
addition NN O O
of NN O O
highly NN O O
purified NN O O
human NN O O
C5 NN O O
to NN O O
normal NN O O
serum NN O O
concentrations NN O O
. NN O O

Sera NN O O
from NN O O
eight NN O O
family NN O O
members NN O O
who NN O O
were NN O O
apparently NN O O
heterozygous NN O O
for NN O O
C5 NN O B-Disease
deficiency NN O I-Disease
gave NN O O
normal NN O O
chemotactic NN O O
scores NN O O
. NN O O

The NN O O
ability NN O O
of NN O O
C5D NN O B-Disease
serum NN O O
to NN O O
opsonize NN O O
Saccharomyces NN O O
cerevisiae NN O O
( NN O O
bakers NN O O
yeast NN O O
) NN O O
or NN O O
Candida NN O O
albicans NN O O
for NN O O
ingestion NN O O
by NN O O
normal NN O O
neutrophils NN O O
was NN O O
completely NN O O
normal NN O O
. NN O O

In NN O O
addition NN O O
, NN O O
C5D NN O B-Disease
serum NN O O
was NN O O
capable NN O O
of NN O O
promoting NN O O
normal NN O O
phagocytosis NN O O
and NN O O
intracellular NN O O
killing NN O O
of NN O O
Staphylococcus NN O O
aureus NN O O
. NN O O

The NN O O
probands NN O O
serum NN O O
was NN O O
incapable NN O O
of NN O O
mediating NN O O
lysis NN O O
of NN O O
erythrocytes NN O O
from NN O O
a NN O O
patient NN O O
with NN O O
paroxysmal NN O B-Disease
nocturnal NN O I-Disease
hemoglobinuria NN O I-Disease
in NN O O
both NN O O
the NN O O
sucrose NN O O
hemolysia NN O O
and NN O O
acid NN O O
hemolysis NN O O
tests NN O O
, NN O O
and NN O O
also NN O O
lacked NN O O
bactericidal NN O O
activity NN O O
against NN O O
sensitized NN O O
or NN O O
unsensitized NN O O
Salmonella NN O O
typhi NN O O
. NN O O

The NN O O
siblings NN O O
serum NN O O
, NN O O
containing NN O O
only NN O O
1 NN O O
- NN O O
2 NN O O
% NN O O
of NN O O
normal NN O O
C5 NN O O
, NN O O
effectively NN O O
lysed NN O O
S NN O O
. NN O O
typhi NN O O
, NN O O
but NN O O
only NN O O
at NN O O
eightfold NN O O
lower NN O O
serum NN O O
dilutions NN O O
as NN O O
compared NN O O
to NN O O
normals NN O O
. NN O O

These NN O O
findings NN O O
underscore NN O O
the NN O O
critical NN O O
role NN O O
of NN O O
C5 NN O O
in NN O O
the NN O O
generation NN O O
of NN O O
chemotactic NN O O
activity NN O O
and NN O O
in NN O O
cytolytic NN O O
reactions NN O O
, NN O O
as NN O O
opposed NN O O
to NN O O
a NN O O
nonobligatory NN O O
or NN O O
minimal NN O O
role NN O O
in NN O O
opsonization NN O O
, NN O O
at NN O O
least NN O O
for NN O O
the NN O O
organisms NN O O
under NN O O
study NN O O
. NN O O
. NN O O

Human NN O O
peroxisomal NN O O
targeting NN O O
signal NN O O
- NN O O
1 NN O O
receptor NN O O
restores NN O O
peroxisomal NN O O
protein NN O O
import NN O O
in NN O O
cells NN O O
from NN O O
patients NN O O
with NN O O
fatal NN O O
peroxisomal NN O B-Disease
disorders NN O I-Disease
. NN O O

Two NN O O
peroxisomal NN O O
targeting NN O O
signals NN O O
, NN O O
PTS1 NN O O
and NN O O
PTS2 NN O O
, NN O O
are NN O O
involved NN O O
in NN O O
the NN O O
import NN O O
of NN O O
proteins NN O O
into NN O O
the NN O O
peroxisome NN O O
matrix NN O O
. NN O O

Human NN O O
patients NN O O
with NN O O
fatal NN O O
generalized NN O O
peroxisomal NN O B-Disease
deficiency NN O I-Disease
disorders NN O I-Disease
fall NN O O
into NN O O
at NN O O
least NN O O
nine NN O O
genetic NN O O
complementation NN O O
groups NN O O
. NN O O

Cells NN O O
from NN O O
many NN O O
of NN O O
these NN O O
patients NN O O
are NN O O
deficient NN O O
in NN O O
the NN O O
import NN O O
of NN O O
PTS1 NN O O
- NN O O
containing NN O O
proteins NN O O
, NN O O
but NN O O
the NN O O
causes NN O O
of NN O O
the NN O O
protein NN O O
- NN O O
import NN O O
defect NN O O
in NN O O
these NN O O
patients NN O O
are NN O O
unknown NN O O
. NN O O

We NN O O
have NN O O
cloned NN O O
and NN O O
sequenced NN O O
the NN O O
human NN O O
cDNA NN O O
homologue NN O O
( NN O O
PTS1R NN O O
) NN O O
of NN O O
the NN O O
Pichia NN O O
pastoris NN O O
PAS8 NN O O
gene NN O O
, NN O O
the NN O O
PTS1 NN O O
receptor NN O O
( NN O O
McCollum NN O O
, NN O O
D NN O O
. NN O O
, NN O O
E NN O O
. NN O O
Monosov NN O O
, NN O O
and NN O O
S NN O O
. NN O O
Subramani NN O O
. NN O O
1993 NN O O
. NN O O
J NN O O
. NN O O
Cell NN O O
Biol NN O O
. NN O O
121 NN O O
761 NN O O
- NN O O
774 NN O O
) NN O O
. NN O O

The NN O O
PTS1R NN O O
mRNA NN O O
is NN O O
expressed NN O O
in NN O O
all NN O O
human NN O O
tissues NN O O
examined NN O O
. NN O O

Antibodies NN O O
to NN O O
the NN O O
human NN O O
PTS1R NN O O
recognize NN O O
this NN O O
protein NN O O
in NN O O
human NN O O
, NN O O
monkey NN O O
, NN O O
rat NN O O
, NN O O
and NN O O
hamster NN O O
cells NN O O
. NN O O

The NN O O
protein NN O O
is NN O O
localized NN O O
mainly NN O O
in NN O O
the NN O O
cytosol NN O O
but NN O O
is NN O O
also NN O O
found NN O O
to NN O O
be NN O O
associated NN O O
with NN O O
peroxisomes NN O O
. NN O O

Part NN O O
of NN O O
the NN O O
peroxisomal NN O O
PTS1R NN O O
protein NN O O
is NN O O
tightly NN O O
bound NN O O
to NN O O
the NN O O
peroxisomal NN O O
membrane NN O O
. NN O O

Antibodies NN O O
to NN O O
PTS1R NN O O
inhibit NN O O
peroxisomal NN O O
protein NN O O
- NN O O
import NN O O
of NN O O
PTS1 NN O O
- NN O O
containing NN O O
proteins NN O O
in NN O O
a NN O O
permeabilized NN O O
CHO NN O O
cell NN O O
system NN O O
. NN O O

In NN O O
vitro NN O O
- NN O O
translated NN O O
PTS1R NN O O
protein NN O O
specifically NN O O
binds NN O O
a NN O O
serine NN O O
- NN O O
lysine NN O O
- NN O O
leucine NN O O
- NN O O
peptide NN O O
. NN O O

A NN O O
PAS8 NN O O
- NN O O
PTS1R NN O O
fusion NN O O
protein NN O O
complements NN O O
the NN O O
P NN O O
. NN O O
pastoris NN O O
pas8 NN O O
mutant NN O O
. NN O O

The NN O O
PTS1R NN O O
cDNA NN O O
also NN O O
complements NN O O
the NN O O
PTS1 NN O B-Disease
protein NN O I-Disease
- NN O I-Disease
import NN O I-Disease
defect NN O I-Disease
in NN O O
skin NN O O
fibroblasts NN O O
from NN O O
patients NN O O
- NN O O
- NN O O
belonging NN O O
to NN O O
complementation NN O O
group NN O O
two NN O O
- NN O O
- NN O O
diagnosed NN O O
as NN O O
having NN O O
neonatal NN O B-Disease
adrenoleukodystrophy NN O I-Disease
or NN O O
Zellweger NN O B-Disease
syndrome NN O I-Disease
. NN O O

The NN O O
PTS1R NN O O
gene NN O O
has NN O O
been NN O O
localized NN O O
to NN O O
a NN O O
chromosomal NN O O
location NN O O
where NN O O
no NN O O
other NN O O
peroxisomal NN O B-Disease
disorder NN O I-Disease
genes NN O O
are NN O O
known NN O O
to NN O O
map NN O O
. NN O O

Our NN O O
findings NN O O
represent NN O O
the NN O O
only NN O O
case NN O O
in NN O O
which NN O O
the NN O O
molecular NN O O
basis NN O O
of NN O O
the NN O O
protein NN O B-Disease
- NN O I-Disease
import NN O I-Disease
deficiency NN O I-Disease
in NN O O
human NN O O
peroxisomal NN O B-Disease
disorders NN O I-Disease
is NN O O
understood NN O O
. NN O O

Spectrum NN O O
of NN O O
germline NN O O
mutations NN O O
in NN O O
the NN O O
RB1 NN O O
gene NN O O
: NN O O
a NN O O
study NN O O
of NN O O
232 NN O O
patients NN O O
with NN O O
hereditary NN O B-Disease
and NN O I-Disease
non NN O I-Disease
hereditary NN O I-Disease
retinoblastoma NN O I-Disease
. NN O O

Germline NN O O
mutations NN O O
in NN O O
the NN O O
RB1 NN O O
gene NN O O
confer NN O O
hereditary NN O O
predisposition NN O O
to NN O O
retinoblastoma NN O B-Disease
. NN O O

We NN O O
have NN O O
performed NN O O
a NN O O
mutation NN O O
survey NN O O
of NN O O
the NN O O
RB1 NN O O
gene NN O O
in NN O O
232 NN O O
patients NN O O
with NN O O
hereditary NN O B-Disease
or NN O I-Disease
non NN O I-Disease
hereditary NN O I-Disease
retinoblastoma NN O I-Disease
. NN O O

We NN O O
systematically NN O O
explored NN O O
all NN O O
27 NN O O
exons NN O O
and NN O O
flanking NN O O
sequences NN O O
as NN O O
well NN O O
as NN O O
the NN O O
promotor NN O O
. NN O O

All NN O O
types NN O O
of NN O O
point NN O O
mutations NN O O
are NN O O
represented NN O O
and NN O O
are NN O O
found NN O O
unequally NN O O
distributed NN O O
along NN O O
the NN O O
RB1 NN O O
gene NN O O
sequence NN O O
. NN O O

In NN O O
the NN O O
population NN O O
we NN O O
studied NN O O
, NN O O
exons NN O O
3 NN O O
, NN O O
8 NN O O
, NN O O
18 NN O O
and NN O O
19 NN O O
are NN O O
preferentially NN O O
altered NN O O
. NN O O

The NN O O
range NN O O
of NN O O
frequency NN O O
of NN O O
detection NN O O
of NN O O
germline NN O O
mutations NN O O
is NN O O
about NN O O
20 NN O O
% NN O O
, NN O O
indicating NN O O
that NN O O
other NN O O
mechanisms NN O O
of NN O O
inactivation NN O O
of NN O O
RB1 NN O O
should NN O O
be NN O O
involved NN O O
. NN O O

The NN O O
spectrum NN O O
of NN O O
mutations NN O O
presented NN O O
here NN O O
should NN O O
help NN O O
to NN O O
improve NN O O
the NN O O
clinical NN O O
management NN O O
of NN O O
retinoblastoma NN O B-Disease
and NN O O
to NN O O
understand NN O O
the NN O O
molecular NN O O
mechanisms NN O O
leading NN O O
to NN O O
tumorigenesis NN O O
. NN O O
. NN O O

Aniridia NN O B-Disease
- NN O O
associated NN O O
cytogenetic NN O O
rearrangements NN O O
suggest NN O O
that NN O O
a NN O O
position NN O O
effect NN O O
may NN O O
cause NN O O
the NN O O
mutant NN O O
phenotype NN O O
. NN O O

Current NN O O
evidence NN O O
suggests NN O O
that NN O O
aniridia NN O B-Disease
( NN O O
absence NN O B-Disease
of NN O I-Disease
iris NN O I-Disease
) NN O O
is NN O O
caused NN O O
by NN O O
loss NN O O
of NN O O
function NN O O
of NN O O
one NN O O
copy NN O O
of NN O O
the NN O O
PAX6 NN O O
gene NN O O
, NN O O
which NN O O
maps NN O O
to NN O O
11p13 NN O O
. NN O O

We NN O O
present NN O O
the NN O O
further NN O O
characterisation NN O O
of NN O O
two NN O O
aniridia NN O B-Disease
pedigrees NN O O
in NN O O
which NN O O
the NN O O
disease NN O O
segregates NN O O
with NN O O
chromosomal NN O O
rearrangements NN O O
which NN O O
involve NN O O
11p13 NN O O
but NN O O
do NN O O
not NN O O
disrupt NN O O
the NN O O
PAX6 NN O O
gene NN O O
. NN O O

We NN O O
have NN O O
isolated NN O O
three NN O O
human NN O O
YAC NN O O
clones NN O O
which NN O O
encompass NN O O
the NN O O
PAX6 NN O O
locus NN O O
and NN O O
we NN O O
have NN O O
used NN O O
these NN O O
to NN O O
show NN O O
that NN O O
in NN O O
both NN O O
cases NN O O
the NN O O
chromosomal NN O O
breakpoint NN O O
is NN O O
at NN O O
least NN O O
85 NN O O
kb NN O O
distal NN O O
of NN O O
the NN O O
3 NN O O
end NN O O
of NN O O
PAX6 NN O O
. NN O O

In NN O O
addition NN O O
, NN O O
the NN O O
open NN O O
reading NN O O
frame NN O O
of NN O O
PAX6 NN O O
is NN O O
apparently NN O O
free NN O O
of NN O O
mutations NN O O
. NN O O

We NN O O
propose NN O O
that NN O O
the NN O O
PAX6 NN O O
gene NN O O
on NN O O
the NN O O
rearranged NN O O
chromosome NN O O
11 NN O O
is NN O O
in NN O O
an NN O O
inappropriate NN O O
chromatin NN O O
environment NN O O
for NN O O
normal NN O O
expression NN O O
and NN O O
therefore NN O O
that NN O O
a NN O O
position NN O O
effect NN O O
is NN O O
the NN O O
underlying NN O O
mechanism NN O O
of NN O O
disease NN O O
in NN O O
these NN O O
families NN O O
. NN O O
. NN O O

Somatic NN O O
mutations NN O O
in NN O O
the NN O O
BRCA1 NN O O
gene NN O O
in NN O O
sporadic NN O B-Disease
ovarian NN O I-Disease
tumours NN O I-Disease
. NN O O

The NN O O
BRCA1 NN O O
gene NN O O
on NN O O
chromosome NN O O
17q21 NN O O
is NN O O
responsible NN O O
for NN O O
an NN O O
autosomal NN O B-Disease
dominant NN O I-Disease
syndrome NN O I-Disease
of NN O O
increased NN O O
susceptibility NN O O
to NN O O
breast NN O B-Disease
and NN O I-Disease
ovarian NN O I-Disease
cancer NN O I-Disease
but NN O O
no NN O O
somatic NN O O
mutations NN O O
in NN O O
tumours NN O B-Disease
have NN O O
yet NN O O
been NN O O
described NN O O
. NN O O

To NN O O
study NN O O
the NN O O
potential NN O O
role NN O O
of NN O O
BRCA1 NN O O
in NN O O
sporadic NN O O
carcinogenesis NN O O
, NN O O
we NN O O
analysed NN O O
the NN O O
genomic NN O O
DNA NN O O
of NN O O
tumour NN O B-Disease
and NN O O
normal NN O O
fractions NN O O
of NN O O
47 NN O O
ovarian NN O B-Disease
cancers NN O I-Disease
for NN O O
mutations NN O O
in NN O O
BRCA1 NN O O
using NN O O
the NN O O
single NN O O
- NN O O
strand NN O O
conformation NN O O
polymorphism NN O O
technique NN O O
. NN O O

We NN O O
now NN O O
describe NN O O
somatic NN O O
mutations NN O O
in NN O O
the NN O O
DNA NN O O
of NN O O
four NN O O
tumours NN O B-Disease
which NN O O
also NN O O
had NN O O
loss NN O O
of NN O O
heterozygosity NN O O
( NN O O
LOH NN O O
) NN O O
at NN O O
a NN O O
BRCA1 NN O O
intragenic NN O O
marker NN O O
. NN O O

Our NN O O
data NN O O
support NN O O
a NN O O
tumour NN O B-Disease
suppressor NN O O
mechanism NN O O
for NN O O
BRCA1 NN O O
; NN O O
somatic NN O O
mutations NN O O
and NN O O
LOH NN O O
may NN O O
result NN O O
in NN O O
inactivation NN O O
of NN O O
BRCA1 NN O O
in NN O O
at NN O O
least NN O O
a NN O O
small NN O O
number NN O O
of NN O O
ovarian NN O B-Disease
cancers NN O I-Disease
. NN O O
. NN O O

Decreased NN O O
expression NN O O
of NN O O
BRCA1 NN O O
accelerates NN O O
growth NN O O
and NN O O
is NN O O
often NN O O
present NN O O
during NN O O
sporadic NN O B-Disease
breast NN O I-Disease
cancer NN O I-Disease
progression NN O O
. NN O O

We NN O O
have NN O O
characterized NN O O
expression NN O O
of NN O O
the NN O O
familial NN O B-Disease
breast NN O I-Disease
and NN O I-Disease
ovarian NN O I-Disease
cancer NN O I-Disease
gene NN O O
, NN O O
BRCA1 NN O O
, NN O O
in NN O O
cases NN O O
of NN O O
non NN O B-Disease
- NN O I-Disease
hereditary NN O I-Disease
( NN O I-Disease
sporadic NN O I-Disease
) NN O I-Disease
breast NN O I-Disease
cancer NN O I-Disease
and NN O O
analyzed NN O O
the NN O O
effect NN O O
of NN O O
antisense NN O O
inhibition NN O O
of NN O O
BRCA1 NN O O
on NN O O
the NN O O
proliferative NN O O
rate NN O O
of NN O O
mammary NN O O
epithelial NN O O
cells NN O O
. NN O O

BRCA1 NN O O
mRNA NN O O
levels NN O O
are NN O O
markedly NN O O
decreased NN O O
during NN O O
the NN O O
transition NN O O
from NN O O
carcinoma NN O B-Disease
in NN O I-Disease
situ NN O I-Disease
to NN O O
invasive NN O B-Disease
cancer NN O I-Disease
. NN O O

Experimental NN O O
inhibition NN O O
of NN O O
BRCA1 NN O O
expression NN O O
with NN O O
antisense NN O O
oligonucleotides NN O O
produced NN O O
accelerated NN O O
growth NN O O
of NN O O
normal NN O O
and NN O O
malignant NN O O
mammary NN O O
cells NN O O
, NN O O
but NN O O
had NN O O
no NN O O
effect NN O O
on NN O O
non NN O O
- NN O O
mammary NN O O
epithelial NN O O
cells NN O O
. NN O O

These NN O O
studies NN O O
suggest NN O O
that NN O O
BRCA1 NN O O
may NN O O
normally NN O O
serve NN O O
as NN O O
a NN O O
negative NN O O
regulator NN O O
of NN O O
mammary NN O O
epithelial NN O O
cell NN O O
growth NN O O
whose NN O O
function NN O O
is NN O O
compromised NN O O
in NN O O
breast NN O B-Disease
cancer NN O I-Disease
either NN O O
by NN O O
direct NN O O
mutation NN O O
or NN O O
alterations NN O O
in NN O O
gene NN O O
expression NN O O
. NN O O
. NN O O

Additional NN O O
case NN O O
of NN O O
female NN O O
monozygotic NN O O
twins NN O O
discordant NN O O
for NN O O
the NN O O
clinical NN O O
manifestations NN O O
of NN O O
Duchenne NN O B-Disease
muscular NN O I-Disease
dystrophy NN O I-Disease
due NN O O
to NN O O
opposite NN O O
X NN O O
- NN O O
chromosome NN O O
inactivation NN O O
. NN O O

A NN O O
pair NN O O
of NN O O
female NN O O
monozygotic NN O O
( NN O O
MZ NN O O
) NN O O
twins NN O O
, NN O O
heterozygous NN O O
carriers NN O O
for NN O O
a NN O O
deletion NN O O
in NN O O
the NN O O
DMD NN O B-Disease
gene NN O O
and NN O O
discordant NN O O
for NN O O
the NN O O
clinical NN O O
manifestations NN O O
of NN O O
Duchenne NN O B-Disease
muscular NN O I-Disease
dystrophy NN O I-Disease
, NN O O
were NN O O
analyzed NN O O
by NN O O
molecular NN O O
studies NN O O
, NN O O
in NN O O
situ NN O O
hybridization NN O O
, NN O O
and NN O O
methylation NN O O
pattern NN O O
of NN O O
X NN O O
chromosomes NN O O
to NN O O
search NN O O
for NN O O
opposite NN O O
X NN O O
inactivation NN O O
as NN O O
an NN O O
explanation NN O O
of NN O O
their NN O O
clinical NN O O
discordance NN O O
. NN O O

Results NN O O
in NN O O
lymphocytes NN O O
and NN O O
skin NN O O
fibroblast NN O O
cell NN O O
lines NN O O
suggest NN O O
a NN O O
partial NN O O
mirror NN O O
inactivation NN O O
with NN O O
the NN O O
normal NN O O
X NN O O
chromosome NN O O
preferentially NN O O
active NN O O
in NN O O
the NN O O
unaffected NN O O
twin NN O O
, NN O O
and NN O O
the NN O O
maternal NN O O
deleted NN O O
X NN O O
chromosome NN O O
preferentially NN O O
active NN O O
in NN O O
the NN O O
affected NN O O
twin NN O O
. NN O O

A NN O O
review NN O O
shows NN O O
that NN O O
MZ NN O O
female NN O O
twins NN O O
discordant NN O O
for NN O O
X NN O B-Disease
- NN O I-Disease
linked NN O I-Disease
diseases NN O I-Disease
are NN O O
not NN O O
uncommon NN O O
. NN O O

Twinning NN O O
and NN O O
X NN O O
inactivation NN O O
may NN O O
be NN O O
interrelated NN O O
and NN O O
could NN O O
explain NN O O
the NN O O
female NN O O
twins NN O O
discordant NN O O
for NN O O
X NN O O
- NN O O
linked NN O O
traits NN O O
. NN O O
. NN O O

X NN O B-Disease
- NN O I-Disease
linked NN O I-Disease
adrenoleukodystrophy NN O I-Disease
( NN O O
ALD NN O B-Disease
) NN O O
: NN O O
a NN O O
novel NN O O
mutation NN O O
of NN O O
the NN O O
ALD NN O B-Disease
gene NN O O
in NN O O
6 NN O O
members NN O O
of NN O O
a NN O O
family NN O O
presenting NN O O
with NN O O
5 NN O O
different NN O O
phenotypes NN O O
. NN O O

Fragments NN O O
of NN O O
the NN O O
adrenoleukodystrophy NN O B-Disease
( NN O O
ALD NN O B-Disease
) NN O O
cDNA NN O O
from NN O O
a NN O O
patient NN O O
with NN O O
adolescent NN O B-Disease
ALD NN O I-Disease
were NN O O
amplified NN O O
by NN O O
polymerase NN O O
chain NN O O
reaction NN O O
and NN O O
subcloned NN O O
. NN O O

Bidirectional NN O O
sequencing NN O O
of NN O O
the NN O O
entire NN O O
coding NN O O
ALD NN O B-Disease
gene NN O O
disclosed NN O O
a NN O O
cytosine NN O O
to NN O O
guanine NN O O
transversion NN O O
at NN O O
nucleotide NN O O
1451 NN O O
in NN O O
exon NN O O
five NN O O
, NN O O
resulting NN O O
in NN O O
substitution NN O O
of NN O O
proline NN O O
484 NN O O
by NN O O
arginine NN O O
. NN O O

Five NN O O
of NN O O
nine NN O O
siblings NN O O
of NN O O
the NN O O
patient NN O O
, NN O O
comprising NN O O
two NN O O
cerebral NN O B-Disease
ALD NN O I-Disease
, NN O O
one NN O O
adrenomyeloneuropathy NN O B-Disease
, NN O O
one NN O O
Addison NN O B-Disease
only NN O I-Disease
as NN O O
well NN O O
as NN O O
the NN O O
symptomatic NN O O
mother NN O O
( NN O O
all NN O O
accumulating NN O O
very NN O O
long NN O O
chain NN O O
fatty NN O O
acids NN O O
) NN O O
carried NN O O
this NN O O
mutation NN O O
, NN O O
which NN O O
was NN O O
not NN O O
found NN O O
in NN O O
the NN O O
unaffected NN O O
persons NN O O
, NN O O
in NN O O
five NN O O
unrelated NN O O
ALD NN O B-Disease
patients NN O O
, NN O O
and NN O O
in NN O O
twenty NN O O
controls NN O O
. NN O O

We NN O O
propose NN O O
that NN O O
this NN O O
missense NN O O
mutation NN O O
generated NN O O
the NN O O
disease NN O O
per NN O O
se NN O O
as NN O O
well NN O O
as NN O O
the NN O O
metabolic NN O O
defect NN O O
; NN O O
the NN O O
different NN O O
phenotypes NN O O
, NN O O
however NN O O
, NN O O
must NN O O
have NN O O
originated NN O O
by NN O O
means NN O O
of NN O O
additional NN O O
pathogenetic NN O O
factors NN O O
. NN O O
. NN O O

Novel NN O O
mutation NN O O
at NN O O
the NN O O
initiation NN O O
codon NN O O
in NN O O
the NN O O
Norrie NN O B-Disease
disease NN O I-Disease
gene NN O O
in NN O O
two NN O O
Japanese NN O O
families NN O O
. NN O O

We NN O O
have NN O O
identified NN O O
a NN O O
new NN O O
mutation NN O O
of NN O O
Norrie NN O B-Disease
disease NN O I-Disease
( NN O O
ND NN O B-Disease
) NN O O
gene NN O O
in NN O O
two NN O O
Japanese NN O O
males NN O O
from NN O O
unrelated NN O O
families NN O O
; NN O O
they NN O O
showed NN O O
typical NN O O
ocular NN O O
features NN O O
of NN O O
ND NN O B-Disease
but NN O O
no NN O O
mental NN O B-Disease
retardation NN O I-Disease
or NN O O
hearing NN O B-Disease
impairment NN O I-Disease
. NN O O

A NN O O
mutation NN O O
was NN O O
found NN O O
in NN O O
both NN O O
patients NN O O
at NN O O
the NN O O
initiation NN O O
codon NN O O
of NN O O
exon NN O O
2 NN O O
of NN O O
the NN O O
ND NN O B-Disease
gene NN O O
( NN O O
ATG NN O O
to NN O O
GTG NN O O
) NN O O
, NN O O
with NN O O
otherwise NN O O
normal NN O O
nucleotide NN O O
sequences NN O O
. NN O O

Their NN O O
mothers NN O O
had NN O O
the NN O O
normal NN O O
and NN O O
mutant NN O O
types NN O O
of NN O O
the NN O O
gene NN O O
, NN O O
which NN O O
was NN O O
expected NN O O
for NN O O
heterozygotes NN O O
of NN O O
the NN O O
disease NN O O
. NN O O

The NN O O
mutation NN O O
of NN O O
the NN O O
initiation NN O O
codon NN O O
would NN O O
cause NN O O
the NN O O
failure NN O O
of NN O O
ND NN O B-Disease
gene NN O O
expression NN O O
or NN O O
a NN O O
defect NN O O
in NN O O
translation NN O O
thereby NN O O
truncating NN O O
the NN O O
amino NN O O
terminus NN O O
of NN O O
ND NN O B-Disease
protein NN O O
. NN O O

In NN O O
view NN O O
of NN O O
the NN O O
rarity NN O O
and NN O O
marked NN O O
heterogeneity NN O O
of NN O O
mutations NN O O
in NN O O
the NN O O
ND NN O B-Disease
gene NN O O
, NN O O
the NN O O
present NN O O
apparently NN O O
unrelated NN O O
Japanese NN O O
families NN O O
who NN O O
have NN O O
lived NN O O
in NN O O
the NN O O
same NN O O
area NN O O
for NN O O
over NN O O
two NN O O
centuries NN O O
presumably NN O O
share NN O O
the NN O O
origin NN O O
of NN O O
the NN O O
mutation NN O O
. NN O O
. NN O O

Anticipation NN O O
resulting NN O O
in NN O O
elimination NN O O
of NN O O
the NN O O
myotonic NN O B-Disease
dystrophy NN O I-Disease
gene NN O O
: NN O O
a NN O O
follow NN O O
up NN O O
study NN O O
of NN O O
one NN O O
extended NN O O
family NN O O
. NN O O

We NN O O
have NN O O
re NN O O
- NN O O
examined NN O O
an NN O O
extended NN O O
myotonic NN O B-Disease
dystrophy NN O I-Disease
( NN O O
DM NN O B-Disease
) NN O O
family NN O O
, NN O O
previously NN O O
described NN O O
in NN O O
1955 NN O O
, NN O O
in NN O O
order NN O O
to NN O O
study NN O O
the NN O O
long NN O O
term NN O O
effects NN O O
of NN O O
anticipation NN O O
in NN O O
DM NN O B-Disease
and NN O O
in NN O O
particular NN O O
the NN O O
implications NN O O
for NN O O
families NN O O
affected NN O O
by NN O O
this NN O O
disease NN O O
. NN O O

This NN O O
follow NN O O
up NN O O
study NN O O
provides NN O O
data NN O O
on NN O O
35 NN O O
gene NN O O
carriers NN O O
and NN O O
46 NN O O
asymptomatic NN O O
at NN O O
risk NN O O
family NN O O
members NN O O
in NN O O
five NN O O
generations NN O O
. NN O O

Clinical NN O O
anticipation NN O O
, NN O O
defined NN O O
as NN O O
the NN O O
cascade NN O O
of NN O O
mild NN O O
, NN O O
adult NN O O
, NN O O
childhood NN O O
, NN O O
or NN O O
congenital NN O B-Disease
disease NN O I-Disease
in NN O O
subsequent NN O O
generations NN O O
, NN O O
appeared NN O O
to NN O O
be NN O O
a NN O O
relentless NN O O
process NN O O
, NN O O
occurring NN O O
in NN O O
all NN O O
affected NN O O
branches NN O O
of NN O O
the NN O O
family NN O O
. NN O O

The NN O O
cascade NN O O
was NN O O
found NN O O
to NN O O
proceed NN O O
asynchronously NN O O
in NN O O
the NN O O
different NN O O
branches NN O O
, NN O O
mainly NN O O
because NN O O
of NN O O
an NN O O
unequal NN O O
number NN O O
of NN O O
generations NN O O
with NN O O
mild NN O O
disease NN O O
. NN O O

The NN O O
transition NN O O
from NN O O
the NN O O
mild NN O O
to NN O O
the NN O O
adult NN O O
type NN O O
was NN O O
associated NN O O
with NN O O
transmission NN O O
through NN O O
a NN O O
male NN O O
parent NN O O
. NN O O

Stable NN O O
transmission NN O O
of NN O O
the NN O O
asymptomatic NN O O
/ NN O O
mild NN O O
phenotype NN O O
showed NN O O
a NN O O
female NN O O
transmission NN O O
bias NN O O
. NN O O

We NN O O
further NN O O
examined NN O O
the NN O O
extent NN O O
and NN O O
causes NN O O
of NN O O
gene NN O O
loss NN O O
in NN O O
this NN O O
pedigree NN O O
. NN O O

Gene NN O O
loss NN O O
in NN O O
the NN O O
patient NN O O
group NN O O
was NN O O
complete NN O O
, NN O O
owing NN O O
to NN O O
infertility NN O B-Disease
of NN O O
the NN O O
male NN O O
patients NN O O
with NN O O
adult NN O O
onset NN O O
disease NN O O
and NN O O
the NN O O
fact NN O O
that NN O O
mentally NN O B-Disease
retarded NN O I-Disease
patients NN O O
did NN O O
not NN O O
procreate NN O O
. NN O O

Out NN O O
of NN O O
the NN O O
46 NN O O
at NN O O
risk NN O O
subjects NN O O
in NN O O
the NN O O
two NN O O
youngest NN O O
generations NN O O
, NN O O
only NN O O
one NN O O
was NN O O
found NN O O
to NN O O
have NN O O
a NN O O
full NN O O
mutation NN O O
. NN O O

This NN O O
is NN O O
the NN O O
only NN O O
subject NN O O
who NN O O
may NN O O
transmit NN O O
the NN O O
gene NN O O
to NN O O
the NN O O
sixth NN O O
generation NN O O
. NN O O

No NN O O
protomutation NN O O
carriers NN O O
were NN O O
found NN O O
in NN O O
the NN O O
fourth NN O O
and NN O O
fifth NN O O
generations NN O O
. NN O O

Therefore NN O O
it NN O O
is NN O O
highly NN O O
probable NN O O
that NN O O
the NN O O
DM NN O B-Disease
gene NN O O
will NN O O
be NN O O
eliminated NN O O
from NN O O
this NN O O
pedigree NN O O
within NN O O
one NN O O
generation NN O O
. NN O O

The NN O O
high NN O O
population NN O O
frequency NN O O
of NN O O
DM NN O B-Disease
can NN O O
at NN O O
present NN O O
not NN O O
be NN O O
explained NN O O
by NN O O
the NN O O
contribution NN O O
of NN O O
asymptomatic NN O O
cases NN O O
in NN O O
the NN O O
younger NN O O
generations NN O O
of NN O O
known NN O O
families NN O O
, NN O O
but NN O O
is NN O O
probably NN O O
caused NN O O
by NN O O
the NN O O
events NN O O
in NN O O
the NN O O
ancestral NN O O
generations NN O O
. NN O O
. NN O O

The NN O O
gene NN O O
for NN O O
spinal NN O B-Disease
cerebellar NN O I-Disease
ataxia NN O I-Disease
3 NN O O
( NN O O
SCA3 NN O O
) NN O O
is NN O O
located NN O O
in NN O O
a NN O O
region NN O O
of NN O O
approximately NN O O
3 NN O O
cM NN O O
on NN O O
chromosome NN O O
14q24 NN O O
. NN O O
3 NN O O
- NN O O
q32 NN O O
. NN O O
2 NN O O
. NN O O

SCA3 NN O O
, NN O O
the NN O O
gene NN O O
for NN O O
spinal NN O B-Disease
cerebellar NN O I-Disease
ataxia NN O I-Disease
3 NN O O
, NN O O
was NN O O
recently NN O O
mapped NN O O
to NN O O
a NN O O
15 NN O O
- NN O O
cM NN O O
interval NN O O
between NN O O
D14S67 NN O O
and NN O O
D14S81 NN O O
on NN O O
chromosome NN O O
14q NN O O
, NN O O
by NN O O
linkage NN O O
analysis NN O O
in NN O O
two NN O O
families NN O O
of NN O O
French NN O O
ancestry NN O O
. NN O O

The NN O O
SCA3 NN O O
candidate NN O O
region NN O O
has NN O O
now NN O O
been NN O O
refined NN O O
by NN O O
linkage NN O O
analysis NN O O
with NN O O
four NN O O
new NN O O
microsatellite NN O O
markers NN O O
( NN O O
D14S256 NN O O
, NN O O
D14S291 NN O O
, NN O O
D14S280 NN O O
, NN O O
and NN O O
AFM343vf1 NN O O
) NN O O
in NN O O
the NN O O
same NN O O
two NN O O
families NN O O
, NN O O
in NN O O
which NN O O
19 NN O O
additional NN O O
individuals NN O O
were NN O O
genotyped NN O O
, NN O O
and NN O O
in NN O O
a NN O O
third NN O O
French NN O O
family NN O O
. NN O O

Combined NN O O
two NN O O
- NN O O
point NN O O
linkage NN O O
analyses NN O O
show NN O O
that NN O O
the NN O O
new NN O O
markers NN O O
, NN O O
D14S280 NN O O
and NN O O
AFM343vf1 NN O O
, NN O O
are NN O O
tightly NN O O
linked NN O O
to NN O O
the NN O O
SCA3 NN O O
locus NN O O
, NN O O
with NN O O
maximal NN O O
lod NN O O
scores NN O O
, NN O O
at NN O O
recombination NN O O
fraction NN O O
, NN O O
( NN O O
theta NN O O
) NN O O
= NN O O
. NN O O

00 NN O O
, NN O O
of NN O O
7 NN O O
. NN O O

05 NN O O
and NN O O
13 NN O O
. NN O O

70 NN O O
, NN O O
respectively NN O O
. NN O O

Combined NN O O
multipoint NN O O
and NN O O
recombinant NN O O
haplotype NN O O
analyses NN O O
localize NN O O
the NN O O
SCA3 NN O O
locus NN O O
to NN O O
a NN O O
3 NN O O
- NN O O
cM NN O O
interval NN O O
flanked NN O O
by NN O O
D14S291 NN O O
and NN O O
D14S81 NN O O
. NN O O

The NN O O
same NN O O
allele NN O O
for NN O O
D14S280 NN O O
segregates NN O O
with NN O O
the NN O O
disease NN O O
locus NN O O
in NN O O
the NN O O
three NN O O
kindreds NN O O
. NN O O

This NN O O
allele NN O O
is NN O O
frequent NN O O
in NN O O
the NN O O
French NN O O
population NN O O
, NN O O
however NN O O
, NN O O
and NN O O
linkage NN O O
disequilibrium NN O O
is NN O O
not NN O O
clearly NN O O
established NN O O
. NN O O

The NN O O
SCA3 NN O O
locus NN O O
remains NN O O
within NN O O
the NN O O
29 NN O O
- NN O O
cM NN O O
region NN O O
on NN O O
14q24 NN O O
. NN O O

3 NN O O
- NN O O
q32 NN O O
. NN O O

2 NN O O
containing NN O O
the NN O O
gene NN O O
for NN O O
the NN O O
Machado NN O B-Disease
- NN O I-Disease
Joseph NN O I-Disease
disease NN O I-Disease
, NN O O
which NN O O
is NN O O
clinically NN O O
related NN O O
to NN O O
the NN O O
phenotype NN O O
determined NN O O
by NN O O
SCA3 NN O O
, NN O O
but NN O O
it NN O O
cannot NN O O
yet NN O O
be NN O O
concluded NN O O
that NN O O
both NN O O
diseases NN O O
result NN O O
from NN O O
alterations NN O O
of NN O O
the NN O O
same NN O O
gene NN O O

An NN O O
evaluation NN O O
of NN O O
genetic NN O O
heterogeneity NN O O
in NN O O
145 NN O O
breast NN O B-Disease
- NN O I-Disease
ovarian NN O I-Disease
cancer NN O I-Disease
families NN O O
. NN O O

Breast NN O B-Disease
Cancer NN O I-Disease
Linkage NN O O
Consortium NN O O
. NN O O

The NN O O
breast NN O B-Disease
- NN O I-Disease
ovary NN O I-Disease
cancer NN O I-Disease
- NN O I-Disease
family NN O I-Disease
syndrome NN O I-Disease
is NN O O
a NN O O
dominant NN O O
predisposition NN O O
to NN O O
cancer NN O B-Disease
of NN O I-Disease
the NN O I-Disease
breast NN O I-Disease
and NN O I-Disease
ovaries NN O I-Disease
which NN O O
has NN O O
been NN O O
mapped NN O O
to NN O O
chromosome NN O O
region NN O O
17q12 NN O O
- NN O O
q21 NN O O
. NN O O

The NN O O
majority NN O O
, NN O O
but NN O O
not NN O O
all NN O O
, NN O O
of NN O O
breast NN O B-Disease
- NN O I-Disease
ovary NN O I-Disease
cancer NN O I-Disease
families NN O O
show NN O O
linkage NN O O
to NN O O
this NN O O
susceptibility NN O O
locus NN O O
, NN O O
designated NN O O
BRCA1 NN O O
. NN O O

We NN O O
report NN O O
here NN O O
the NN O O
results NN O O
of NN O O
a NN O O
linkage NN O O
analysis NN O O
of NN O O
145 NN O O
families NN O O
with NN O O
both NN O O
breast NN O B-Disease
and NN O I-Disease
ovarian NN O I-Disease
cancer NN O I-Disease
. NN O O

These NN O O
families NN O O
contain NN O O
either NN O O
a NN O O
total NN O O
of NN O O
three NN O O
or NN O O
more NN O O
cases NN O O
of NN O O
early NN O O
- NN O O
onset NN O O
( NN O O
before NN O O
age NN O O
60 NN O O
years NN O O
) NN O O
breast NN O B-Disease
cancer NN O I-Disease
or NN O O
ovarian NN O B-Disease
cancer NN O I-Disease
. NN O O

All NN O O
families NN O O
contained NN O O
at NN O O
least NN O O
one NN O O
case NN O O
of NN O O
ovarian NN O B-Disease
cancer NN O I-Disease
. NN O O

Overall NN O O
, NN O O
an NN O O
estimated NN O O
76 NN O O
% NN O O
of NN O O
the NN O O
145 NN O O
families NN O O
are NN O O
linked NN O O
to NN O O
the NN O O
BRCA1 NN O O
locus NN O O
. NN O O

None NN O O
of NN O O
the NN O O
13 NN O O
families NN O O
with NN O O
cases NN O O
of NN O O
male NN O B-Disease
breast NN O I-Disease
cancer NN O I-Disease
appear NN O O
to NN O O
be NN O O
linked NN O O
, NN O O
but NN O O
it NN O O
is NN O O
estimated NN O O
that NN O O
92 NN O O
% NN O O
( NN O O
95 NN O O
% NN O O
confidence NN O O
interval NN O O
76 NN O O
% NN O O
- NN O O
100 NN O O
% NN O O
) NN O O
of NN O O
families NN O O
with NN O O
no NN O O
male NN O B-Disease
breast NN O I-Disease
cancer NN O I-Disease
and NN O O
with NN O O
two NN O O
or NN O O
more NN O O
ovarian NN O B-Disease
cancers NN O I-Disease
are NN O O
linked NN O O
to NN O O
BRCA1 NN O O
. NN O O

These NN O O
data NN O O
suggest NN O O
that NN O O
the NN O O
breast NN O B-Disease
- NN O I-Disease
ovarian NN O I-Disease
cancer NN O I-Disease
- NN O I-Disease
family NN O I-Disease
syndrome NN O I-Disease
is NN O O
genetically NN O O
heterogeneous NN O O
. NN O O

However NN O O
, NN O O
the NN O O
large NN O O
majority NN O O
of NN O O
families NN O O
with NN O O
early NN O O
- NN O O
onset NN O O
breast NN O B-Disease
cancer NN O I-Disease
and NN O O
with NN O O
two NN O O
or NN O O
more NN O O
cases NN O O
of NN O O
ovarian NN O B-Disease
cancer NN O I-Disease
are NN O O
likely NN O O
to NN O O
be NN O O
due NN O O
to NN O O
BRCA1 NN O O
mutations NN O O
. NN O O
. NN O O

Molecular NN O O
basis NN O O
of NN O O
essential NN O B-Disease
fructosuria NN O I-Disease
: NN O O
molecular NN O O
cloning NN O O
and NN O O
mutational NN O O
analysis NN O O
of NN O O
human NN O O
ketohexokinase NN O O
( NN O O
fructokinase NN O O
) NN O O
. NN O O

Essential NN O B-Disease
fructosuria NN O I-Disease
is NN O O
one NN O O
of NN O O
the NN O O
oldest NN O O
known NN O O
inborn NN O B-Disease
errors NN O I-Disease
of NN O I-Disease
metabolism NN O I-Disease
. NN O O

It NN O O
is NN O O
a NN O O
benign NN O O
condition NN O O
which NN O O
is NN O O
believed NN O O
to NN O O
result NN O O
from NN O O
deficiency NN O B-Disease
of NN O I-Disease
hepatic NN O I-Disease
fructokinase NN O I-Disease
( NN O O
ketohexokinase NN O O
, NN O O
KHK NN O O
, NN O O
E NN O O
. NN O O
C NN O O
. NN O O
2 NN O O
. NN O O
7 NN O O
. NN O O
1 NN O O
. NN O O
3 NN O O
) NN O O
. NN O O

This NN O O
enzyme NN O O
catalyses NN O O
the NN O O
first NN O O
step NN O O
of NN O O
metabolism NN O O
of NN O O
dietary NN O O
fructose NN O O
, NN O O
conversion NN O O
of NN O O
fructose NN O O
to NN O O
fructose NN O O
- NN O O
1 NN O O
- NN O O
phosphate NN O O
. NN O O

Despite NN O O
the NN O O
early NN O O
recognition NN O O
of NN O O
this NN O O
disorder NN O O
, NN O O
the NN O O
primary NN O O
structure NN O O
of NN O O
human NN O O
KHK NN O O
and NN O O
the NN O O
molecular NN O O
basis NN O O
of NN O O
essential NN O B-Disease
fructosuria NN O I-Disease
have NN O O
not NN O O
been NN O O
previously NN O O
defined NN O O
. NN O O

In NN O O
this NN O O
report NN O O
, NN O O
the NN O O
isolation NN O O
and NN O O
sequencing NN O O
of NN O O
full NN O O
- NN O O
length NN O O
cDNA NN O O
clones NN O O
encoding NN O O
human NN O O
ketohexokinase NN O O
are NN O O
described NN O O
. NN O O

Alternative NN O O
mRNA NN O O
species NN O O
and NN O O
alternative NN O O
KHK NN O O
isozymes NN O O
are NN O O
produced NN O O
by NN O O
alternative NN O O
polyadenylation NN O O
and NN O O
splicing NN O O
of NN O O
the NN O O
KHK NN O O
gene NN O O
. NN O O

The NN O O
KHK NN O O
proteins NN O O
show NN O O
a NN O O
high NN O O
level NN O O
of NN O O
sequence NN O O
conservation NN O O
relative NN O O
to NN O O
rat NN O O
KHK NN O O
. NN O O

Direct NN O O
evidence NN O O
that NN O O
mutation NN O O
of NN O O
the NN O O
KHK NN O O
structural NN O O
gene NN O O
is NN O O
the NN O O
cause NN O O
of NN O O
essential NN O B-Disease
fructosuria NN O I-Disease
was NN O O
also NN O O
obtained NN O O
. NN O O

In NN O O
a NN O O
well NN O O
- NN O O
characterized NN O O
family NN O O
, NN O O
in NN O O
which NN O O
three NN O O
of NN O O
eight NN O O
siblings NN O O
have NN O O
fructosuria NN O B-Disease
, NN O O
all NN O O
affected NN O O
individuals NN O O
are NN O O
compound NN O O
heterozygotes NN O O
for NN O O
two NN O O
mutations NN O O
Gly40Arg NN O O
and NN O O
Ala43Thr NN O O
. NN O O

Both NN O O
mutations NN O O
result NN O O
from NN O O
G NN O O
- NN O O
- NN O O
> NN O O
A NN O O
transitions NN O O
, NN O O
and NN O O
each NN O O
alters NN O O
the NN O O
same NN O O
conserved NN O O
region NN O O
of NN O O
the NN O O
KHK NN O O
protein NN O O
. NN O O

Neither NN O O
mutation NN O O
was NN O O
seen NN O O
in NN O O
a NN O O
sample NN O O
of NN O O
52 NN O O
unrelated NN O O
control NN O O
individuals NN O O
. NN O O

An NN O O
additional NN O O
conservative NN O O
amino NN O O
acid NN O O
change NN O O
( NN O O
Val49IIe NN O O
) NN O O
was NN O O
present NN O O
on NN O O
the NN O O
KHK NN O O
allele NN O O
bearing NN O O
Ala43Thr NN O O

Homozygous NN O O
presence NN O O
of NN O O
the NN O O
crossover NN O O
( NN O O
fusion NN O O
gene NN O O
) NN O O
mutation NN O O
identified NN O O
in NN O O
a NN O O
type NN O B-Disease
II NN O I-Disease
Gaucher NN O I-Disease
disease NN O I-Disease
fetus NN O O
: NN O O
is NN O O
this NN O O
analogous NN O O
to NN O O
the NN O O
Gaucher NN O O
knock NN O O
- NN O O
out NN O O
mouse NN O O
model NN O O
? NN O O

Gaucher NN O B-Disease
disease NN O I-Disease
( NN O O
GD NN O B-Disease
) NN O O
is NN O O
an NN O O
inherited NN O O
deficiency NN O B-Disease
of NN O I-Disease
beta NN O I-Disease
- NN O I-Disease
glucocerebrosidase NN O I-Disease
( NN O O
EC NN O O
3 NN O O
. NN O O
1 NN O O
. NN O O
2 NN O O
. NN O O
45 NN O O
, NN O O
gene NN O O
symbol NN O O
GBA NN O O
) NN O O
. NN O O

In NN O O
type NN O B-Disease
I NN O I-Disease
GD NN O I-Disease
, NN O O
the NN O O
CNS NN O O
is NN O O
not NN O O
involved NN O O
( NN O O
nonneuronopathic NN O O
) NN O O
, NN O O
whereas NN O O
in NN O O
type NN O B-Disease
II NN O I-Disease
GD NN O I-Disease
( NN O O
acute NN O O
neuronopathic NN O O
) NN O O
CNS NN O O
involvement NN O O
is NN O O
early NN O O
and NN O O
rapidly NN O O
progressive NN O O
, NN O O
while NN O O
in NN O O
type NN O B-Disease
III NN O I-Disease
GD NN O I-Disease
( NN O O
subacute NN O O
neuronopathic NN O O
) NN O O
CNS NN O O
involvement NN O O
occurs NN O O
later NN O O
and NN O O
is NN O O
slowly NN O O
progressive NN O O
. NN O O

The NN O O
T6433C NN O O
( NN O O
L444P NN O O
) NN O O
substitution NN O O
is NN O O
prevalent NN O O
in NN O O
type NN O B-Disease
GD NN O I-Disease
II NN O I-Disease
. NN O O

It NN O O
may NN O O
occur NN O O
alone NN O O
as NN O O
a NN O O
single NN O O
base NN O O
- NN O O
pair NN O O
mutation NN O O
but NN O O
often NN O O
is NN O O
found NN O O
as NN O O
part NN O O
of NN O O
a NN O O
complex NN O O
allele NN O O
containing NN O O
additional NN O O
GBA NN O O
nucleotide NN O O
substitutions NN O O
, NN O O
G6468C NN O O
( NN O O
A456P NN O O
) NN O O
and NN O O
G6482C NN O O
( NN O O
V460V NN O O
) NN O O
, NN O O
without NN O O
( NN O O
recNciI NN O O
) NN O O
or NN O O
with NN O O
( NN O O
recTL NN O O
) NN O O
G5957C NN O O
( NN O O
D409H NN O O
) NN O O
. NN O O

This NN O O
complex NN O O
allele NN O O
is NN O O
presumed NN O O
to NN O O
have NN O O
formed NN O O
by NN O O
recombination NN O O
( NN O O
crossover NN O O
, NN O O
fusion NN O O
) NN O O
of NN O O
the NN O O
structural NN O O
gene NN O O
with NN O O
the NN O O
pseudogene NN O O
, NN O O
which NN O O
contains NN O O
the NN O O
mutated NN O O
sequences NN O O
. NN O O

Two NN O O
complex NN O O
alleles NN O O
have NN O O
never NN O O
been NN O O
demonstrated NN O O
to NN O O
coexist NN O O
in NN O O
any NN O O
individual NN O O
. NN O O

We NN O O
devised NN O O
a NN O O
selective NN O O
PCR NN O O
method NN O O
for NN O O
the NN O O
specific NN O O
amplification NN O O
of NN O O
the NN O O
normal NN O O
and NN O O
/ NN O O
or NN O O
fusion NN O O
gene NN O O
. NN O O

Using NN O O
this NN O O
procedure NN O O
we NN O O
demonstrated NN O O
the NN O O
fusion NN O O
gene NN O O
in NN O O
homozygous NN O O
form NN O O
for NN O O
the NN O O
first NN O O
time NN O O
, NN O O
in NN O O
a NN O O
Macedonian NN O O
/ NN O O
Ashkenazi NN O O
Jewish NN O O
GD NN O B-Disease
type NN O I-Disease
II NN O I-Disease
fetus NN O O
. NN O O

Both NN O O
parents NN O O
were NN O O
carriers NN O O
of NN O O
the NN O O
recombination NN O O
. NN O O

This NN O O
was NN O O
confirmed NN O O
by NN O O
direct NN O O
sequence NN O O
analysis NN O O
. NN O O

A NN O O
previous NN O O
conceptus NN O O
in NN O O
this NN O O
family NN O O
was NN O O
stillborn NN O B-Disease
at NN O O
36 NN O O
weeks NN O O
, NN O O
with NN O O
features NN O O
of NN O O
severe NN O O
type NN O B-Disease
II NN O I-Disease
GD NN O I-Disease
. NN O O

Neonates NN O O
showing NN O O
a NN O O
severe NN O O
clinical NN O O
phenotype NN O O
, NN O O
analogous NN O O
to NN O O
the NN O O
early NN O O
neonatal NN O O
lethal NN O O
disease NN O O
occurring NN O O
in NN O O
mice NN O O
homozygous NN O O
for NN O O
a NN O O
null NN O O
allele NN O O
produced NN O O
by NN O O
targeted NN O O
disruption NN O O
of NN O O
GBA NN O O
, NN O O
have NN O O
been NN O O
described NN O O
elsewhere NN O O
, NN O O
but NN O O
the NN O O
specific NN O O
mutations NN O O
in NN O O
these NN O O
cases NN O O
have NN O O
not NN O O
yet NN O O
been NN O O
characterized NN O O
. NN O O

( NN O O
ABSTRACT NN O O
TRUNCATED NN O O
AT NN O O
250 NN O O
WORDS NN O O
) NN O O

Late NN O O
infantile NN O O
metachromatic NN O B-Disease
leukodystrophy NN O I-Disease
in NN O O
Israel NN O O
. NN O O

Metachromatic NN O B-Disease
Leukodystrophy NN O I-Disease
( NN O O
MLD NN O B-Disease
) NN O O
is NN O O
a NN O O
neurodegenerative NN O B-Disease
disease NN O I-Disease
in NN O O
which NN O O
the NN O O
lysosomal NN O O
enzyme NN O O
, NN O O
Aryl NN O O
sulfatase NN O O
A NN O O
( NN O O
ARSA NN O O
) NN O O
is NN O O
deficient NN O O
. NN O O

The NN O O
disease NN O O
is NN O O
inherited NN O O
as NN O O
an NN O O
autosomal NN O O
recessive NN O O
trait NN O O
and NN O O
its NN O O
frequency NN O O
is NN O O
estimated NN O O
to NN O O
be NN O O
1 NN O O
/ NN O O
40 NN O O
, NN O O
000 NN O O
live NN O O
births NN O O
. NN O O

The NN O O
gene NN O O
of NN O O
ARSA NN O O
has NN O O
been NN O O
cloned NN O O
and NN O O
up NN O O
to NN O O
now NN O O
eight NN O O
mutations NN O O
causing NN O O
MLD NN O B-Disease
have NN O O
been NN O O
reported NN O O
. NN O O

Another NN O O
mutation NN O O
, NN O O
PD NN O O
, NN O O
leads NN O O
to NN O O
the NN O O
deficiency NN O O
of NN O O
the NN O O
enzyme NN O O
in NN O O
vitro NN O O
( NN O O
pseudodeficiency NN O O
) NN O O
without NN O O
any NN O O
known NN O O
clinical NN O O
effect NN O O
. NN O O

The NN O O
PD NN O O
mutation NN O O
is NN O O
frequent NN O O
in NN O O
all NN O O
populations NN O O
. NN O O

In NN O O
Israel NN O O
, NN O O
late NN O O
infantile NN O O
MLD NN O B-Disease
was NN O O
found NN O O
to NN O O
be NN O O
very NN O O
frequent NN O O
in NN O O
a NN O O
small NN O O
Jewish NN O O
isolate NN O O
, NN O O
the NN O O
Habbanite NN O O
Jews NN O O
( NN O O
1 NN O O
/ NN O O
75 NN O O
live NN O O
births NN O O
) NN O O
. NN O O

The NN O O
molecular NN O O
analysis NN O O
demonstrated NN O O
that NN O O
in NN O O
the NN O O
Habbanite NN O O
population NN O O
, NN O O
the NN O O
mutation NN O O
occurred NN O O
on NN O O
an NN O O
allele NN O O
with NN O O
the NN O O
PD NN O O
mutation NN O O
. NN O O

The NN O O
loss NN O O
of NN O O
ARSA NN O O
activity NN O O
is NN O O
due NN O O
to NN O O
a NN O O
point NN O O
mutation NN O O
C NN O O
> NN O O
T NN O O
leading NN O O
to NN O O
a NN O O
change NN O O
of NN O O
proline NN O O
to NN O O
leucine NN O O
. NN O O

MLD NN O B-Disease
is NN O O
also NN O O
frequent NN O O
among NN O O
Moslem NN O O
Arabs NN O O
in NN O O
Jerusalem NN O O
. NN O O

The NN O O
mutation NN O O
is NN O O
a NN O O
transition NN O O
G NN O O
> NN O O
A NN O O
destroying NN O O
the NN O O
splice NN O O
donor NN O O
site NN O O
of NN O O
exon NN O O
2 NN O O
. NN O O

This NN O O
mutation NN O O
has NN O O
been NN O O
reported NN O O
in NN O O
patients NN O O
with NN O O
the NN O O
late NN O O
infantile NN O O
MLD NN O B-Disease
from NN O O
different NN O O
ethnic NN O O
groups NN O O
. NN O O

The NN O O
Christian NN O O
Arabs NN O O
in NN O O
Israel NN O O
also NN O O
have NN O O
a NN O O
high NN O O
incidence NN O O
of NN O O
the NN O O
disease NN O O
( NN O O
1 NN O O
/ NN O O
10 NN O O
, NN O O
000 NN O O
live NN O O
births NN O O
) NN O O
; NN O O
the NN O O
mutation NN O O
in NN O O
this NN O O
population NN O O
is NN O O
still NN O O
unknown NN O O
. NN O O

Knowledge NN O O
of NN O O
the NN O O
different NN O O
mutations NN O O
causing NN O O
MLD NN O B-Disease
in NN O O
these NN O O
defined NN O O
populations NN O O
will NN O O
allow NN O O
a NN O O
carrier NN O O
screening NN O O
program NN O O
to NN O O
be NN O O
carried NN O O
out NN O O
and NN O O
prevent NN O O
the NN O O
birth NN O O
of NN O O
additional NN O O
affected NN O O
children NN O O
. NN O O
. NN O O

A NN O O
single NN O O
amino NN O O
acid NN O O
substitution NN O O
( NN O O
G103D NN O O
) NN O O
in NN O O
the NN O O
type NN O O
II NN O O
collagen NN O O
triple NN O O
helix NN O O
produces NN O O
Kniest NN O B-Disease
dysplasia NN O I-Disease
. NN O O

Kniest NN O B-Disease
dysplasia NN O I-Disease
is NN O O
a NN O O
moderately NN O O
severe NN O O
chondrodysplasia NN O B-Disease
phenotype NN O O
that NN O O
results NN O O
from NN O O
mutations NN O O
in NN O O
the NN O O
gene NN O O
for NN O O
type NN O O
II NN O O
collagen NN O O
, NN O O
COL2A1 NN O O
. NN O O

Characteristics NN O O
of NN O O
the NN O O
disorder NN O O
include NN O O
a NN O O
short NN O B-Disease
trunk NN O I-Disease
and NN O I-Disease
extremities NN O I-Disease
, NN O O
mid NN O B-Disease
- NN O I-Disease
face NN O I-Disease
hypoplasia NN O I-Disease
, NN O O
cleft NN O B-Disease
palate NN O I-Disease
, NN O O
myopia NN O B-Disease
, NN O O
retinal NN O B-Disease
detachment NN O I-Disease
, NN O O
and NN O O
hearing NN O B-Disease
loss NN O I-Disease
. NN O O

Recently NN O O
, NN O O
deletions NN O O
of NN O O
all NN O O
or NN O O
part NN O O
of NN O O
exon NN O O
12 NN O O
have NN O O
been NN O O
identified NN O O
in NN O O
individuals NN O O
with NN O O
Kniest NN O B-Disease
dysplasia NN O I-Disease
, NN O O
suggesting NN O O
that NN O O
mutations NN O O
within NN O O
this NN O O
region NN O O
of NN O O
the NN O O
protein NN O O
may NN O O
primarily NN O O
result NN O O
in NN O O
the NN O O
Kniest NN O B-Disease
dysplasia NN O I-Disease
phenotype NN O O
. NN O O

We NN O O
used NN O O
SSCP NN O O
to NN O O
analyze NN O O
an NN O O
amplified NN O O
genomic NN O O
DNA NN O O
fragment NN O O
containing NN O O
exon NN O O
12 NN O O
from NN O O
seven NN O O
individuals NN O O
with NN O O
Kniest NN O B-Disease
dysplasia NN O I-Disease
. NN O O

An NN O O
abnormality NN O O
was NN O O
identified NN O O
in NN O O
one NN O O
patient NN O O
. NN O O

DNA NN O O
sequence NN O O
analysis NN O O
demonstrated NN O O
that NN O O
the NN O O
patient NN O O
was NN O O
heterozygous NN O O
for NN O O
a NN O O
G NN O O
to NN O O
A NN O O
transition NN O O
that NN O O
implied NN O O
substitution NN O O
of NN O O
glycine103 NN O O
of NN O O
the NN O O
triple NN O O
helical NN O O
domain NN O O
by NN O O
aspartate NN O O
. NN O O

The NN O O
mutation NN O O
was NN O O
not NN O O
observed NN O O
in NN O O
DNA NN O O
from NN O O
either NN O O
of NN O O
the NN O O
clinically NN O O
unaffected NN O O
parents NN O O
of NN O O
the NN O O
proband NN O O
. NN O O

Protein NN O O
microsequencing NN O O
demonstrated NN O O
expression NN O O
of NN O O
the NN O O
abnormal NN O O
allele NN O O
in NN O O
cartilage NN O O
. NN O O

These NN O O
data NN O O
demonstrate NN O O
that NN O O
point NN O O
mutations NN O O
which NN O O
result NN O O
in NN O O
single NN O O
amino NN O O
acid NN O O
substitutions NN O O
can NN O O
produce NN O O
Kniest NN O B-Disease
dysplasia NN O I-Disease
and NN O O
further NN O O
support NN O O
the NN O O
hypothesis NN O O
that NN O O
alteration NN O O
of NN O O
a NN O O
domain NN O O
, NN O O
which NN O O
includes NN O O
the NN O O
region NN O O
encoded NN O O
by NN O O
exon NN O O
12 NN O O
, NN O O
in NN O O
the NN O O
type NN O O
II NN O O
collagen NN O O
protein NN O O
leads NN O O
to NN O O
this NN O O
disorder NN O O
. NN O O
. NN O O

CAG NN O O
expansions NN O O
in NN O O
a NN O O
novel NN O O
gene NN O O
for NN O O
Machado NN O B-Disease
- NN O I-Disease
Joseph NN O I-Disease
disease NN O I-Disease
at NN O O
chromosome NN O O
14q32 NN O O
. NN O O
1 NN O O
. NN O O

We NN O O
have NN O O
identified NN O O
a NN O O
novel NN O O
gene NN O O
containing NN O O
CAG NN O O
repeats NN O O
and NN O O
mapped NN O O
it NN O O
to NN O O
chromosome NN O O
14q32 NN O O
. NN O O

1 NN O O
, NN O O
the NN O O
genetic NN O O
locus NN O O
for NN O O
Machado NN O B-Disease
- NN O I-Disease
Joseph NN O I-Disease
disease NN O I-Disease
( NN O O
MJD NN O B-Disease
) NN O O
. NN O O

In NN O O
normal NN O O
individuals NN O O
the NN O O
gene NN O O
contains NN O O
between NN O O
13 NN O O
and NN O O
36 NN O O
CAG NN O O
repeats NN O O
, NN O O
whereas NN O O
most NN O O
of NN O O
the NN O O
clinically NN O O
diagnosed NN O O
patients NN O O
and NN O O
all NN O O
of NN O O
the NN O O
affected NN O O
members NN O O
of NN O O
a NN O O
family NN O O
with NN O O
the NN O O
clinical NN O O
and NN O O
pathological NN O O
diagnosis NN O O
of NN O O
MJD NN O B-Disease
show NN O O
expansion NN O O
of NN O O
the NN O O
repeat NN O O
- NN O O
number NN O O
( NN O O
from NN O O
68 NN O O
- NN O O
79 NN O O
) NN O O
. NN O O

Southern NN O O
blot NN O O
analyses NN O O
and NN O O
genomic NN O O
cloning NN O O
demonstrates NN O O
the NN O O
existence NN O O
of NN O O
related NN O O
genes NN O O
. NN O O

These NN O O
results NN O O
raise NN O O
the NN O O
possibility NN O O
that NN O O
similar NN O O
abnormalities NN O O
in NN O O
related NN O O
genes NN O O
may NN O O
give NN O O
rise NN O O
to NN O O
diseases NN O O
similar NN O O
to NN O O
MJD NN O B-Disease
. NN O O

Mutations NN O O
in NN O O
the NN O O
BRCA1 NN O O
gene NN O O
in NN O O
families NN O O
with NN O O
early NN O O
- NN O O
onset NN O O
breast NN O B-Disease
and NN O I-Disease
ovarian NN O I-Disease
cancer NN O I-Disease
. NN O O

We NN O O
analysed NN O O
50 NN O O
probands NN O O
with NN O O
a NN O O
family NN O O
history NN O O
of NN O O
breast NN O B-Disease
and NN O I-Disease
/ NN O I-Disease
or NN O I-Disease
ovarian NN O I-Disease
cancer NN O I-Disease
for NN O O
germline NN O O
mutations NN O O
in NN O O
the NN O O
coding NN O O
region NN O O
of NN O O
the NN O O
BRCA1 NN O O
candidate NN O O
gene NN O O
, NN O O
using NN O O
single NN O O
- NN O O
strand NN O O
conformation NN O O
polymorphism NN O O
( NN O O
SSCP NN O O
) NN O O
analysis NN O O
on NN O O
PCR NN O O
- NN O O
amplified NN O O
genomic NN O O
DNA NN O O
. NN O O

A NN O O
total NN O O
of NN O O
eight NN O O
putative NN O O
disease NN O O
- NN O O
causing NN O O
alterations NN O O
were NN O O
identified NN O O
four NN O O
of NN O O
these NN O O
are NN O O
frameshifts NN O O
and NN O O
two NN O O
are NN O O
nonsense NN O O
mutations NN O O
. NN O O

In NN O O
addition NN O O
, NN O O
we NN O O
found NN O O
two NN O O
missense NN O O
mutations NN O O
, NN O O
one NN O O
of NN O O
which NN O O
changes NN O O
the NN O O
final NN O O
cysteine NN O O
of NN O O
the NN O O
BRCA1 NN O O
zinc NN O O
finger NN O O
motif NN O O
to NN O O
glycine NN O O
. NN O O

These NN O O
data NN O O
are NN O O
consistent NN O O
with NN O O
a NN O O
tumour NN O B-Disease
suppressor NN O O
model NN O O
, NN O O
and NN O O
support NN O O
the NN O O
notion NN O O
that NN O O
this NN O O
candidate NN O O
gene NN O O
is NN O O
in NN O O
fact NN O O
BRCA1 NN O O
. NN O O

The NN O O
heterogeneity NN O O
of NN O O
mutations NN O O
, NN O O
coupled NN O O
with NN O O
the NN O O
large NN O O
size NN O O
of NN O O
the NN O O
gene NN O O
, NN O O
indicates NN O O
that NN O O
clinical NN O O
application NN O O
of NN O O
BRCA1 NN O O
mutation NN O O
testing NN O O
will NN O O
be NN O O
technically NN O O
challenging NN O O
. NN O O
. NN O O

Confirmation NN O O
of NN O O
BRCA1 NN O O
by NN O O
analysis NN O O
of NN O O
germline NN O O
mutations NN O O
linked NN O O
to NN O O
breast NN O B-Disease
and NN O I-Disease
ovarian NN O I-Disease
cancer NN O I-Disease
in NN O O
ten NN O O
families NN O O
. NN O O

We NN O O
provide NN O O
genetic NN O O
evidence NN O O
supporting NN O O
the NN O O
identity NN O O
of NN O O
the NN O O
candidate NN O O
gene NN O O
for NN O O
BRCA1 NN O O
through NN O O
the NN O O
characterization NN O O
of NN O O
germline NN O O
mutations NN O O
in NN O O
63 NN O O
breast NN O B-Disease
cancer NN O I-Disease
patients NN O O
and NN O O
10 NN O O
ovarian NN O B-Disease
cancer NN O I-Disease
patients NN O O
in NN O O
ten NN O O
families NN O O
with NN O O
cancer NN O B-Disease
linked NN O O
to NN O O
chromosome NN O O
17q21 NN O O
. NN O O

Nine NN O O
different NN O O
mutations NN O O
were NN O O
detected NN O O
by NN O O
screening NN O O
BRCA1 NN O O
DNA NN O O
and NN O O
RNA NN O O
by NN O O
single NN O O
- NN O O
strand NN O O
conformation NN O O
polymorphism NN O O
analysis NN O O
and NN O O
direct NN O O
sequencing NN O O
. NN O O

Seven NN O O
mutations NN O O
lead NN O O
to NN O O
protein NN O O
truncations NN O O
at NN O O
sites NN O O
throughout NN O O
the NN O O
gene NN O O
. NN O O

One NN O O
missense NN O O
mutation NN O O
( NN O O
which NN O O
occurred NN O O
independently NN O O
in NN O O
two NN O O
families NN O O
) NN O O
leads NN O O
to NN O O
loss NN O O
of NN O O
a NN O O
cysteine NN O O
in NN O O
the NN O O
zinc NN O O
binding NN O O
domain NN O O
. NN O O

An NN O O
intronic NN O O
single NN O O
basepair NN O O
substitution NN O O
destroys NN O O
an NN O O
acceptor NN O O
site NN O O
and NN O O
activates NN O O
a NN O O
cryptic NN O O
splice NN O O
site NN O O
, NN O O
leading NN O O
to NN O O
a NN O O
59 NN O O
basepair NN O O
insertion NN O O
and NN O O
chain NN O O
termination NN O O
. NN O O

The NN O O
four NN O O
families NN O O
with NN O O
both NN O O
breast NN O B-Disease
and NN O I-Disease
ovarian NN O I-Disease
cancer NN O I-Disease
had NN O O
chain NN O O
termination NN O O
mutations NN O O
in NN O O
the NN O O
N NN O O
- NN O O
terminal NN O O
half NN O O
of NN O O
the NN O O
protein NN O O
. NN O O
. NN O O

High NN O O
resolution NN O O
genetic NN O O
analysis NN O O
suggests NN O O
one NN O O
ancestral NN O O
predisposing NN O O
haplotype NN O O
for NN O O
the NN O O
origin NN O O
of NN O O
the NN O O
myotonic NN O B-Disease
dystrophy NN O I-Disease
mutation NN O O
. NN O O

The NN O O
mutation NN O O
causing NN O O
myotonic NN O B-Disease
dystrophy NN O I-Disease
( NN O O
DM NN O B-Disease
) NN O O
has NN O O
been NN O O
identified NN O O
as NN O O
an NN O O
amplification NN O O
of NN O O
an NN O O
unstable NN O O
trinucleotide NN O O
( NN O O
CTG NN O O
) NN O O
n NN O O
repeat NN O O
in NN O O
over NN O O
99 NN O O
% NN O O
of NN O O
the NN O O
global NN O O
DM NN O B-Disease
population NN O O
. NN O O

It NN O O
is NN O O
in NN O O
complete NN O O
linkage NN O O
disequilibrium NN O O
with NN O O
an NN O O
Alu NN O O
element NN O O
polymorphism NN O O
within NN O O
the NN O O
DM NN O B-Disease
kinase NN O O
gene NN O O
, NN O O
suggesting NN O O
that NN O O
DM NN O B-Disease
is NN O O
a NN O O
consequence NN O O
of NN O O
one NN O O
or NN O O
few NN O O
ancestral NN O O
mutations NN O O
. NN O O

A NN O O
recent NN O O
analysis NN O O
utilizing NN O O
this NN O O
polymorphism NN O O
as NN O O
well NN O O
as NN O O
a NN O O
flanking NN O O
dinucleotide NN O O
marker NN O O
, NN O O
suggested NN O O
that NN O O
similar NN O O
to NN O O
Fragile NN O B-Disease
X NN O I-Disease
syndrome NN O I-Disease
, NN O O
DM NN O B-Disease
exhibited NN O O
a NN O O
founder NN O O
effect NN O O
( NN O O
Imbert NN O O
et NN O O
al NN O O
. NN O O
, NN O O
1993 NN O O
Nature NN O O
Genet NN O O
. NN O O
4 NN O O
, NN O O
72 NN O O
- NN O O
76 NN O O
) NN O O
. NN O O

In NN O O
contrast NN O O
, NN O O
the NN O O
low NN O O
reproductive NN O O
fitness NN O O
of NN O O
individuals NN O O
with NN O O
congenital NN O O
DM NN O B-Disease
( NN O O
the NN O O
endpoint NN O O
of NN O O
genetic NN O O
anticipation NN O O
in NN O O
myotonic NN O B-Disease
dystrophy NN O I-Disease
) NN O O
suggests NN O O
a NN O O
higher NN O O
rate NN O O
of NN O O
new NN O O
mutations NN O O
. NN O O

We NN O O
present NN O O
a NN O O
high NN O O
resolution NN O O
genetic NN O O
analysis NN O O
of NN O O
the NN O O
DM NN O B-Disease
locus NN O O
using NN O O
PCR NN O O
based NN O O
assays NN O O
of NN O O
nine NN O O
polymorphisms NN O O
, NN O O
spanning NN O O
a NN O O
physical NN O O
distance NN O O
of NN O O
30 NN O O
kb NN O O
, NN O O
within NN O O
and NN O O
immediately NN O O
flanking NN O O
the NN O O
DM NN O B-Disease
kinase NN O O
gene NN O O
. NN O O

The NN O O
persistent NN O O
complete NN O O
allelic NN O O
association NN O O
of NN O O
the NN O O
DM NN O B-Disease
mutation NN O O
with NN O O
all NN O O
these NN O O
polymorphisms NN O O
provides NN O O
further NN O O
support NN O O
to NN O O
previous NN O O
observations NN O O
and NN O O
suggests NN O O
more NN O O
strongly NN O O
that NN O O
the NN O O
DM NN O B-Disease
mutation NN O O
occurred NN O O
on NN O O
the NN O O
background NN O O
of NN O O
a NN O O
particular NN O O
haplotype NN O O
in NN O O
which NN O O
the NN O O
( NN O O
CTG NN O O
) NN O O
n NN O O
repeat NN O O
became NN O O
inherently NN O O
unstable NN O O
and NN O O
therefore NN O O
predisposed NN O O
to NN O O
amplification NN O O
. NN O O

Genetic NN O O
instability NN O O
in NN O O
human NN O O
ovarian NN O B-Disease
cancer NN O I-Disease
cell NN O O
lines NN O O
. NN O O

We NN O O
have NN O O
analyzed NN O O
the NN O O
stability NN O O
of NN O O
microsatellites NN O O
in NN O O
cell NN O O
lines NN O O
derived NN O O
from NN O O
human NN O O
ovarian NN O B-Disease
cancers NN O I-Disease
and NN O O
found NN O O
that NN O O
5 NN O O
out NN O O
of NN O O
10 NN O O
of NN O O
the NN O O
ovarian NN O B-Disease
tumor NN O I-Disease
cell NN O O
lines NN O O
are NN O O
genetically NN O O
unstable NN O O
at NN O O
the NN O O
majority NN O O
of NN O O
the NN O O
loci NN O O
analyzed NN O O
. NN O O

In NN O O
clones NN O O
and NN O O
subclones NN O O
derived NN O O
serially NN O O
from NN O O
one NN O O
of NN O O
these NN O O
cell NN O O
lines NN O O
( NN O O
2774 NN O O
; NN O O
serous NN O B-Disease
cystadenocarcinoma NN O I-Disease
) NN O O
, NN O O
a NN O O
very NN O O
high NN O O
proportion NN O O
of NN O O
microsatellites NN O O
distributed NN O O
in NN O O
many NN O O
different NN O O
regions NN O O
of NN O O
the NN O O
genome NN O O
change NN O O
their NN O O
size NN O O
in NN O O
a NN O O
mercurial NN O O
fashion NN O O
. NN O O

We NN O O
conclude NN O O
that NN O O
genomic NN O O
instability NN O O
in NN O O
ovarian NN O B-Disease
tumors NN O I-Disease
is NN O O
a NN O O
dynamic NN O O
and NN O O
ongoing NN O O
process NN O O
whose NN O O
high NN O O
frequency NN O O
may NN O O
have NN O O
been NN O O
previously NN O O
underestimated NN O O
by NN O O
PCR NN O O
- NN O O
based NN O O
allelotyping NN O O
of NN O O
bulk NN O O
tumor NN O B-Disease
tissue NN O O
. NN O O

We NN O O
have NN O O
identified NN O O
the NN O O
source NN O O
of NN O O
the NN O O
genetic NN O O
instability NN O O
in NN O O
one NN O O
ovarian NN O B-Disease
tumor NN O I-Disease
as NN O O
a NN O O
point NN O O
mutation NN O O
( NN O O
R524P NN O O
) NN O O
in NN O O
the NN O O
human NN O O
mismatch NN O O
- NN O O
repair NN O O
gene NN O O
MSH2 NN O O
( NN O O
Salmonella NN O O
MutS NN O O
homologue NN O O
) NN O O
, NN O O
which NN O O
has NN O O
recently NN O O
been NN O O
shown NN O O
to NN O O
be NN O O
involved NN O O
in NN O O
hereditary NN O B-Disease
nonpolyposis NN O I-Disease
colorectal NN O I-Disease
cancer NN O I-Disease
. NN O O

Patient NN O O
2774 NN O O
was NN O O
a NN O O
38 NN O O
- NN O O
year NN O O
- NN O O
old NN O O
heterozygote NN O O
, NN O O
and NN O O
her NN O O
normal NN O O
tissue NN O O
carried NN O O
both NN O O
mutant NN O O
and NN O O
wild NN O O
- NN O O
type NN O O
alleles NN O O
of NN O O
the NN O O
human NN O O
MSH2 NN O O
gene NN O O
. NN O O

However NN O O
the NN O O
wild NN O O
- NN O O
type NN O O
allele NN O O
was NN O O
lost NN O O
at NN O O
some NN O O
point NN O O
early NN O O
during NN O O
tumorigenesis NN O O
so NN O O
that NN O O
DNA NN O O
isolated NN O O
either NN O O
from NN O O
the NN O O
patients NN O O
ovarian NN O B-Disease
tumor NN O I-Disease
or NN O O
from NN O O
the NN O O
2774 NN O O
cell NN O O
line NN O O
carries NN O O
only NN O O
the NN O O
mutant NN O O
allele NN O O
of NN O O
the NN O O
human NN O O
MSH2 NN O O
gene NN O O
. NN O O

The NN O O
genetic NN O O
instability NN O O
observed NN O O
in NN O O
the NN O O
tumor NN O B-Disease
and NN O O
cell NN O O
line NN O O
DNA NN O O
, NN O O
together NN O O
with NN O O
the NN O O
germ NN O O
- NN O O
line NN O O
mutation NN O O
in NN O O
a NN O O
mismatch NN O O
- NN O O
repair NN O O
gene NN O O
, NN O O
suggest NN O O
that NN O O
the NN O O
MSH2 NN O O
gene NN O O
is NN O O
involved NN O O
in NN O O
the NN O O
onset NN O O
and NN O O
/ NN O O
or NN O O
progression NN O O
in NN O O
a NN O O
subset NN O O
of NN O O
ovarian NN O B-Disease
cancer NN O I-Disease
. NN O O
. NN O O

BRCA1 NN O O
mutations NN O O
in NN O O
primary NN O O
breast NN O B-Disease
and NN O I-Disease
ovarian NN O I-Disease
carcinomas NN O I-Disease
. NN O O

Loss NN O O
of NN O O
heterozygosity NN O O
data NN O O
from NN O O
familial NN O B-Disease
tumors NN O I-Disease
suggest NN O O
that NN O O
BRCA1 NN O O
, NN O O
a NN O O
gene NN O O
that NN O O
confers NN O O
susceptibility NN O O
to NN O O
ovarian NN O B-Disease
and NN O I-Disease
early NN O I-Disease
- NN O I-Disease
onset NN O I-Disease
breast NN O B-Disease
cancer NN O I-Disease
, NN O O
encodes NN O O
a NN O O
tumor NN O B-Disease
suppressor NN O O
. NN O O

The NN O O
BRCA1 NN O O
region NN O O
is NN O O
also NN O O
subject NN O O
to NN O O
allelic NN O O
loss NN O O
in NN O O
sporadic NN O B-Disease
breast NN O I-Disease
and NN O I-Disease
ovarian NN O I-Disease
cancers NN O I-Disease
, NN O O
an NN O O
indication NN O O
that NN O O
BRCA1 NN O O
mutations NN O O
may NN O O
occur NN O O
somatically NN O O
in NN O O
these NN O O
tumors NN O B-Disease
. NN O O

The NN O O
BRCA1 NN O O
coding NN O O
region NN O O
was NN O O
examined NN O O
for NN O O
mutations NN O O
in NN O O
primary NN O O
breast NN O B-Disease
and NN O I-Disease
ovarian NN O I-Disease
tumors NN O I-Disease
that NN O O
show NN O O
allele NN O O
loss NN O O
at NN O O
the NN O O
BRCA1 NN O O
locus NN O O
. NN O O

Mutations NN O O
were NN O O
detected NN O O
in NN O O
3 NN O O
of NN O O
32 NN O O
breast NN O O
and NN O O
1 NN O O
of NN O O
12 NN O O
ovarian NN O B-Disease
carcinomas NN O I-Disease
; NN O O
all NN O O
four NN O O
mutations NN O O
were NN O O
germline NN O O
alterations NN O O
and NN O O
occurred NN O O
in NN O O
early NN O O
- NN O O
onset NN O O
cancers NN O B-Disease
. NN O O

These NN O O
results NN O O
suggest NN O O
that NN O O
mutation NN O O
of NN O O
BRCA1 NN O O
may NN O O
not NN O O
be NN O O
critical NN O O
in NN O O
the NN O O
development NN O O
of NN O O
the NN O O
majority NN O O
of NN O O
breast NN O B-Disease
and NN O I-Disease
ovarian NN O I-Disease
cancers NN O I-Disease
that NN O O
arise NN O O
in NN O O
the NN O O
absence NN O O
of NN O O
a NN O O
mutant NN O O
germline NN O O
allele NN O O
. NN O O
. NN O O

PAX6 NN O O
gene NN O O
dosage NN O O
effect NN O O
in NN O O
a NN O O
family NN O O
with NN O O
congenital NN O B-Disease
cataracts NN O I-Disease
, NN O O
aniridia NN O B-Disease
, NN O O
anophthalmia NN O B-Disease
and NN O O
central NN O B-Disease
nervous NN O I-Disease
system NN O I-Disease
defects NN O I-Disease
. NN O O

The NN O O
human NN O O
eye NN O O
malformation NN O O
aniridia NN O B-Disease
results NN O O
from NN O O
haploinsufficiency NN O B-Disease
of NN O I-Disease
PAX6 NN O I-Disease
, NN O O
a NN O O
paired NN O O
box NN O O
DNA NN O O
- NN O O
binding NN O O
protein NN O O
. NN O O

To NN O O
study NN O O
this NN O O
dosage NN O O
effect NN O O
, NN O O
we NN O O
characterized NN O O
two NN O O
PAX6 NN O O
mutations NN O O
in NN O O
a NN O O
family NN O O
segregating NN O O
aniridia NN O B-Disease
and NN O O
a NN O O
milder NN O O
syndrome NN O O
consisting NN O O
of NN O O
congenital NN O B-Disease
cataracts NN O I-Disease
and NN O O
late NN O O
onset NN O O
corneal NN O B-Disease
dystrophy NN O I-Disease
. NN O O

The NN O O
nonsense NN O O
mutations NN O O
, NN O O
at NN O O
codons NN O O
103 NN O O
and NN O O
353 NN O O
, NN O O
truncate NN O O
PAX6 NN O O
within NN O O
the NN O O
N NN O O
- NN O O
terminal NN O O
paired NN O O
and NN O O
C NN O O
- NN O O
terminal NN O O
PST NN O O
domains NN O O
, NN O O
respectively NN O O
. NN O O

The NN O O
wild NN O O
- NN O O
type NN O O
PST NN O O
domain NN O O
activates NN O O
transcription NN O O
autonomously NN O O
and NN O O
the NN O O
mutant NN O O
form NN O O
has NN O O
partial NN O O
activity NN O O
. NN O O

A NN O O
compound NN O O
heterozygote NN O O
had NN O O
severe NN O O
craniofacial NN O B-Disease
and NN O I-Disease
central NN O I-Disease
nervous NN O I-Disease
system NN O I-Disease
defects NN O I-Disease
and NN O O
no NN O B-Disease
eyes NN O I-Disease
. NN O O

The NN O O
pattern NN O O
of NN O O
malformations NN O O
is NN O O
similar NN O O
to NN O O
that NN O O
in NN O O
homozygous NN O O
Sey NN O O
mice NN O O
and NN O O
suggests NN O O
a NN O O
critical NN O O
role NN O O
for NN O O
PAX6 NN O O
in NN O O
controlling NN O O
the NN O O
migration NN O O
and NN O O
differentiation NN O O
of NN O O
specific NN O O
neuronal NN O O
progenitor NN O O
cells NN O O
in NN O O
the NN O O
brain NN O O
. NN O O
. NN O O

A NN O O
physical NN O O
map NN O O
and NN O O
candidate NN O O
genes NN O O
in NN O O
the NN O O
BRCA1 NN O O
region NN O O
on NN O O
chromosome NN O O
17q12 NN O O
- NN O O
21 NN O O
. NN O O

We NN O O
have NN O O
constructed NN O O
a NN O O
physical NN O O
map NN O O
of NN O O
a NN O O
4 NN O O
cM NN O O
region NN O O
on NN O O
chromosome NN O O
17q12 NN O O
- NN O O
21 NN O O
that NN O O
contains NN O O
the NN O O
hereditary NN O B-Disease
breast NN O I-Disease
and NN O I-Disease
ovarian NN O I-Disease
cancer NN O I-Disease
gene NN O O
BRCA1 NN O O
. NN O O

The NN O O
map NN O O
comprises NN O O
a NN O O
contig NN O O
of NN O O
137 NN O O
overlapping NN O O
yeast NN O O
artificial NN O O
chromosomes NN O O
and NN O O
P1 NN O O
clones NN O O
, NN O O
onto NN O O
which NN O O
we NN O O
have NN O O
placed NN O O
112 NN O O
PCR NN O O
markers NN O O
. NN O O

We NN O O
have NN O O
localized NN O O
more NN O O
than NN O O
20 NN O O
genes NN O O
on NN O O
this NN O O
map NN O O
, NN O O
ten NN O O
of NN O O
which NN O O
had NN O O
not NN O O
been NN O O
mapped NN O O
to NN O O
the NN O O
region NN O O
previously NN O O
, NN O O
and NN O O
have NN O O
isolated NN O O
30 NN O O
cDNA NN O O
clones NN O O
representing NN O O
partial NN O O
sequences NN O O
of NN O O
as NN O O
yet NN O O
unidentified NN O O
genes NN O O
. NN O O

Two NN O O
genes NN O O
that NN O O
lie NN O O
within NN O O
a NN O O
narrow NN O O
region NN O O
defined NN O O
by NN O O
meiotic NN O O
breakpoints NN O O
in NN O O
BRCA1 NN O O
patients NN O O
have NN O O
been NN O O
sequenced NN O O
in NN O O
breast NN O B-Disease
cancer NN O I-Disease
patients NN O O
without NN O O
revealing NN O O
any NN O O
deleterious NN O O
mutations NN O O
. NN O O

These NN O O
new NN O O
reagents NN O O
should NN O O
facilitate NN O O
the NN O O
identification NN O O
of NN O O
BRCA1 NN O O
. NN O O
. NN O O

The NN O O
LEC NN O O
rat NN O O
has NN O O
a NN O O
deletion NN O O
in NN O O
the NN O O
copper NN O O
transporting NN O O
ATPase NN O O
gene NN O O
homologous NN O O
to NN O O
the NN O O
Wilson NN O B-Disease
disease NN O I-Disease
gene NN O O
. NN O O

The NN O O
Long NN O O
- NN O O
Evans NN O O
Cinnamon NN O O
( NN O O
LEC NN O O
) NN O O
rat NN O O
shows NN O O
similarity NN O O
to NN O O
Wilson NN O B-Disease
disease NN O I-Disease
in NN O O
many NN O O
clinical NN O O
and NN O O
biochemical NN O O
features NN O O
. NN O O

We NN O O
have NN O O
cloned NN O O
cDNAs NN O O
for NN O O
the NN O O
rat NN O O
gene NN O O
( NN O O
Atp7b NN O O
) NN O O
homologous NN O O
to NN O O
the NN O O
human NN O O
Wilson NN O B-Disease
disease NN O I-Disease
gene NN O O
( NN O O
ATP7B NN O O
) NN O O
and NN O O
have NN O O
used NN O O
them NN O O
to NN O O
identify NN O O
a NN O O
partial NN O O
deletion NN O O
in NN O O
the NN O O
Atp7b NN O O
gene NN O O
in NN O O
the NN O O
LEC NN O O
rat NN O O
. NN O O

The NN O O
deletion NN O O
removes NN O O
at NN O O
least NN O O
900 NN O O
bp NN O O
of NN O O
the NN O O
coding NN O O
region NN O O
at NN O O
the NN O O
3 NN O O
end NN O O
, NN O O
includes NN O O
the NN O O
crucial NN O O
ATP NN O O
binding NN O O
domain NN O O
and NN O O
extends NN O O
downstream NN O O
of NN O O
the NN O O
gene NN O O
. NN O O

Our NN O O
results NN O O
provide NN O O
convincing NN O O
evidence NN O O
for NN O O
defining NN O O
the NN O O
LEC NN O O
rat NN O O
as NN O O
an NN O O
animal NN O O
model NN O O
for NN O O
Wilson NN O B-Disease
disease NN O I-Disease
. NN O O

This NN O O
model NN O O
will NN O O
be NN O O
important NN O O
for NN O O
studying NN O O
liver NN O O
pathophysiology NN O O
, NN O O
for NN O O
developing NN O O
therapy NN O O
for NN O O
Wilson NN O B-Disease
disease NN O I-Disease
and NN O O
for NN O O
studying NN O O
the NN O O
pathway NN O O
of NN O O
copper NN O O
transport NN O O
and NN O O
its NN O O
possible NN O O
interaction NN O O
with NN O O
other NN O O
heavy NN O O
metals NN O O
. NN O O
. NN O O

Genomic NN O O
organization NN O O
of NN O O
the NN O O
adrenoleukodystrophy NN O B-Disease
gene NN O O
. NN O O

Adrenoleukodystrophy NN O B-Disease
( NN O O
ALD NN O B-Disease
) NN O O
, NN O O
the NN O O
most NN O O
frequent NN O O
peroxisomal NN O B-Disease
disorder NN O I-Disease
, NN O O
is NN O O
a NN O O
severe NN O O
neurodegenerative NN O B-Disease
disease NN O I-Disease
associated NN O O
with NN O O
an NN O O
impairment NN O B-Disease
of NN O I-Disease
very NN O I-Disease
long NN O I-Disease
chain NN O I-Disease
fatty NN O I-Disease
acids NN O I-Disease
beta NN O I-Disease
- NN O I-Disease
oxidation NN O I-Disease
. NN O O

We NN O O
have NN O O
recently NN O O
identified NN O O
by NN O O
positional NN O O
cloning NN O O
the NN O O
gene NN O O
responsible NN O O
for NN O O
ALD NN O B-Disease
, NN O O
located NN O O
in NN O O
Xq28 NN O O
. NN O O

It NN O O
encodes NN O O
a NN O O
new NN O O
member NN O O
of NN O O
the NN O O
" NN O O
ABC NN O O
" NN O O
superfamily NN O O
of NN O O
membrane NN O O
- NN O O
associated NN O O
transporters NN O O
that NN O O
shows NN O O
, NN O O
in NN O O
particular NN O O
, NN O O
significant NN O O
homology NN O O
to NN O O
the NN O O
70 NN O O
- NN O O
kDa NN O O
peroxisomal NN O O
membrane NN O O
protein NN O O
( NN O O
PMP70 NN O O
) NN O O
. NN O O

We NN O O
report NN O O
here NN O O
a NN O O
detailed NN O O
characterization NN O O
of NN O O
the NN O O
ALD NN O B-Disease
gene NN O O
structure NN O O
. NN O O

It NN O O
extends NN O O
over NN O O
21 NN O O
kb NN O O
and NN O O
consists NN O O
of NN O O
10 NN O O
exons NN O O
. NN O O

To NN O O
facilitate NN O O
the NN O O
detection NN O O
of NN O O
mutations NN O O
in NN O O
ALD NN O B-Disease
patients NN O O
, NN O O
we NN O O
have NN O O
determined NN O O
the NN O O
intronic NN O O
sequences NN O O
flanking NN O O
the NN O O
exons NN O O
as NN O O
well NN O O
as NN O O
the NN O O
sequence NN O O
of NN O O
the NN O O
3 NN O O
untranslated NN O O
region NN O O
and NN O O
of NN O O
the NN O O
immediate NN O O
5 NN O O
promoter NN O O
region NN O O
. NN O O

Sequences NN O O
present NN O O
in NN O O
distal NN O O
exons NN O O
cross NN O O
- NN O O
hybridize NN O O
strongly NN O O
to NN O O
additional NN O O
sequences NN O O
in NN O O
the NN O O
human NN O O
genome NN O O
. NN O O

The NN O O
ALD NN O B-Disease
gene NN O O
has NN O O
been NN O O
positioned NN O O
on NN O O
a NN O O
pulsed NN O O
- NN O O
field NN O O
map NN O O
between NN O O
DXS15 NN O O
and NN O O
the NN O O
L1CAM NN O O
gene NN O O
, NN O O
about NN O O
650 NN O O
kb NN O O
upstream NN O O
from NN O O
the NN O O
color NN O O
pigment NN O O
genes NN O O
. NN O O

The NN O O
frequent NN O O
occurrence NN O O
of NN O O
color NN O O
vision NN O O
anomalies NN O O
observed NN O O
in NN O O
patients NN O O
with NN O O
adrenomyeloneuropathy NN O B-Disease
( NN O O
the NN O O
adult NN O O
onset NN O O
form NN O O
of NN O O
ALD NN O B-Disease
) NN O O
thus NN O O
does NN O O
not NN O O
represent NN O O
a NN O O
contiguous NN O B-Disease
gene NN O I-Disease
syndrome NN O I-Disease
but NN O O
a NN O O
secondary NN O O
manifestation NN O O
of NN O O
ALD NN O B-Disease
. NN O O
. NN O O

The NN O O
murine NN O O
homologues NN O O
of NN O O
the NN O O
Huntington NN O B-Disease
disease NN O I-Disease
gene NN O O
( NN O O
Hdh NN O O
) NN O O
and NN O O
the NN O O
alpha NN O O
- NN O O
adducin NN O O
gene NN O O
( NN O O
Add1 NN O O
) NN O O
map NN O O
to NN O O
mouse NN O O
chromosome NN O O
5 NN O O
within NN O O
a NN O O
region NN O O
of NN O O
conserved NN O O
synteny NN O O
with NN O O
human NN O O
chromosome NN O O
4p16 NN O O
. NN O O
3 NN O O
. NN O O

Huntington NN O B-Disease
disease NN O I-Disease
( NN O O
HD NN O B-Disease
) NN O O
is NN O O
a NN O O
severe NN O O
autosomal NN O B-Disease
dominant NN O I-Disease
neurodegenerative NN O I-Disease
disorder NN O I-Disease
associated NN O O
with NN O O
a NN O O
novel NN O O
gene NN O O
( NN O O
IT15 NN O O
) NN O O
. NN O O

Recently NN O O
, NN O O
we NN O O
reported NN O O
the NN O O
cloning NN O O
of NN O O
Hdh NN O O
, NN O O
the NN O O
murine NN O O
homologue NN O O
of NN O O
IT15 NN O O
. NN O O

Here NN O O
, NN O O
using NN O O
an NN O O
interspecific NN O O
backcross NN O O
, NN O O
we NN O O
have NN O O
mapped NN O O
both NN O O
Hdh NN O O
and NN O O
the NN O O
mouse NN O O
homologue NN O O
of NN O O
human NN O O
alpha NN O O
- NN O O
adducin NN O O
( NN O O
Add1 NN O O
) NN O O
, NN O O
a NN O O
membrane NN O O
- NN O O
associated NN O O
cytoskeletal NN O O
protein NN O O
gene NN O O
. NN O O

Both NN O O
of NN O O
these NN O O
genes NN O O
map NN O O
in NN O O
the NN O O
same NN O O
position NN O O
on NN O O
mouse NN O O
chromosome NN O O
5 NN O O
in NN O O
a NN O O
region NN O O
associated NN O O
with NN O O
ancestral NN O O
chromosomal NN O O
rearrangements NN O O
and NN O O
show NN O O
no NN O O
recombination NN O O
with NN O O
D5H4S43 NN O O
, NN O O
D5H4S115 NN O O
, NN O O
and NN O O
D5H4S62 NN O O
, NN O O
the NN O O
murine NN O O
homologues NN O O
of NN O O
D4S43 NN O O
, NN O O
D4S115 NN O O
, NN O O
and NN O O
D4S62 NN O O
, NN O O
respectively NN O O
. NN O O

Further NN O O
mapping NN O O
studies NN O O
of NN O O
humans NN O O
, NN O O
mice NN O O
, NN O O
and NN O O
other NN O O
mammalian NN O O
species NN O O
should NN O O
reveal NN O O
the NN O O
nature NN O O
of NN O O
the NN O O
rearrangements NN O O
affecting NN O O
this NN O O
chromosomal NN O O
segment NN O O
during NN O O
mammalian NN O O
evolution NN O O
. NN O O
. NN O O

Genetic NN O O
cholesteryl NN O B-Disease
ester NN O I-Disease
transfer NN O I-Disease
protein NN O I-Disease
deficiency NN O I-Disease
caused NN O O
by NN O O
two NN O O
prevalent NN O O
mutations NN O O
as NN O O
a NN O O
major NN O O
determinant NN O O
of NN O O
increased NN O O
levels NN O O
of NN O O
high NN O O
density NN O O
lipoprotein NN O O
cholesterol NN O O
. NN O O

Genetic NN O O
determinants NN O O
of NN O O
HDL NN O O
cholesterol NN O O
( NN O O
HDL NN O O
- NN O O
C NN O O
) NN O O
levels NN O O
in NN O O
the NN O O
general NN O O
population NN O O
are NN O O
poorly NN O O
understood NN O O
. NN O O

We NN O O
previously NN O O
described NN O O
plasma NN O O
cholesteryl NN O B-Disease
ester NN O I-Disease
transfer NN O I-Disease
protein NN O I-Disease
( NN O I-Disease
CETP NN O I-Disease
) NN O I-Disease
deficiency NN O I-Disease
due NN O O
to NN O O
an NN O O
intron NN O O
14 NN O O
G NN O O
( NN O O
+ NN O O
1 NN O O
) NN O O
- NN O O
to NN O O
- NN O O
A NN O O
mutation NN O O
( NN O O
Int14 NN O O
A NN O O
) NN O O
in NN O O
several NN O O
families NN O O
with NN O O
very NN O O
high NN O O
HDL NN O O
- NN O O
C NN O O
levels NN O O
in NN O O
Japan NN O O
. NN O O

Subjects NN O O
with NN O O
HDL NN O O
- NN O O
C NN O O
> NN O O
or NN O O
= NN O O
100 NN O O
mg NN O O
/ NN O O
dl NN O O
( NN O O
n NN O O
= NN O O
130 NN O O
) NN O O
were NN O O
screened NN O O
by NN O O
PCR NN O O
single NN O O
strand NN O O
conformational NN O O
polymorphism NN O O
analysis NN O O
of NN O O
the NN O O
CETP NN O O
gene NN O O
. NN O O

Two NN O O
other NN O O
mutations NN O O
were NN O O
identified NN O O
by NN O O
DNA NN O O
sequencing NN O O
or NN O O
primer NN O O
- NN O O
mediated NN O O
restriction NN O O
map NN O O
modification NN O O
of NN O O
PCR NN O O
products NN O O
a NN O O
novel NN O O
intron NN O O
14 NN O O
splice NN O O
donor NN O O
site NN O O
mutation NN O O
caused NN O O
by NN O O
a NN O O
T NN O O
insertion NN O O
at NN O O
position NN O O
+ NN O O
3 NN O O
from NN O O
the NN O O
exon14 NN O O
/ NN O O
intron14 NN O O
boundary NN O O
( NN O O
Int14 NN O O
T NN O O
) NN O O
and NN O O
a NN O O
missense NN O O
mutation NN O O
( NN O O
Asp442 NN O O
to NN O O
Gly NN O O
) NN O O
within NN O O
exon NN O O
15 NN O O
( NN O O
D442G NN O O
) NN O O
. NN O O

The NN O O
Int14 NN O O
T NN O O
mutation NN O O
was NN O O
only NN O O
found NN O O
in NN O O
one NN O O
family NN O O
. NN O O

However NN O O
, NN O O
the NN O O
D442G NN O O
and NN O O
Int14 NN O O
A NN O O
mutations NN O O
were NN O O
highly NN O O
prevalent NN O O
in NN O O
subjects NN O O
with NN O O
HDL NN O O
- NN O O
C NN O O
> NN O O
or NN O O
= NN O O
60 NN O O
mg NN O O
/ NN O O
dl NN O O
, NN O O
with NN O O
combined NN O O
allele NN O O
frequencies NN O O
of NN O O
9 NN O O
% NN O O
, NN O O
12 NN O O
% NN O O
, NN O O
21 NN O O
% NN O O
and NN O O
43 NN O O
% NN O O
for NN O O
HDL NN O O
- NN O O
C NN O O
60 NN O O
- NN O O
79 NN O O
, NN O O
80 NN O O
- NN O O
99 NN O O
, NN O O
100 NN O O
- NN O O
119 NN O O
, NN O O
and NN O O
> NN O O
or NN O O
= NN O O
120 NN O O
mg NN O O
/ NN O O
dl NN O O
, NN O O
respectively NN O O
. NN O O

Furthermore NN O O
, NN O O
prevalences NN O O
of NN O O
the NN O O
D442G NN O O
and NN O O
Int14 NN O O
A NN O O
mutations NN O O
were NN O O
extremely NN O O
high NN O O
in NN O O
a NN O O
general NN O O
sample NN O O
of NN O O
Japanese NN O O
men NN O O
( NN O O
n NN O O
= NN O O
236 NN O O
) NN O O
, NN O O
with NN O O
heterozygote NN O O
frequencies NN O O
of NN O O
7 NN O O
% NN O O
and NN O O
2 NN O O
% NN O O
, NN O O
respectively NN O O
. NN O O

These NN O O
two NN O O
mutations NN O O
accounted NN O O
for NN O O
about NN O O
10 NN O O
% NN O O
of NN O O
the NN O O
total NN O O
variance NN O O
of NN O O
HDL NN O O
- NN O O
C NN O O
in NN O O
this NN O O
population NN O O
. NN O O

The NN O O
phenotype NN O O
in NN O O
a NN O O
genetic NN O O
compound NN O O
heterozygote NN O O
( NN O O
Int14 NN O O
T NN O O
and NN O O
Int14 NN O O
A NN O O
) NN O O
was NN O O
similar NN O O
to NN O O
that NN O O
of NN O O
Int14 NN O O
A NN O O
homozygotes NN O O
( NN O O
no NN O O
detectable NN O O
CETP NN O O
and NN O O
markedly NN O O
increased NN O O
HDL NN O O
- NN O O
C NN O O
) NN O O
, NN O O
indicating NN O O
that NN O O
the NN O O
Int14 NN O O
T NN O O
produces NN O O
a NN O O
null NN O O
allele NN O O
. NN O O

In NN O O
four NN O O
D442G NN O O
homozygotes NN O O
, NN O O
mean NN O O
HDL NN O O
- NN O O
C NN O O
levels NN O O
( NN O O
86 NN O O
+ NN O O
/ NN O O
- NN O O
26 NN O O
mg NN O O
/ NN O O
dl NN O O
) NN O O
were NN O O
lower NN O O
than NN O O
in NN O O
Int14 NN O O
A NN O O
homozygotes NN O O
( NN O O
158 NN O O
+ NN O O
/ NN O O
- NN O O
35 NN O O
mg NN O O
/ NN O O
dl NN O O
) NN O O
, NN O O
reflecting NN O O
residual NN O O
CETP NN O O
activity NN O O
in NN O O
plasma NN O O
. NN O O

In NN O O
47 NN O O
D442G NN O O
heterozygotes NN O O
, NN O O
mean NN O O
HDL NN O O
- NN O O
C NN O O
levels NN O O
were NN O O
91 NN O O
+ NN O O
/ NN O O
- NN O O
23 NN O O
mg NN O O
/ NN O O
dl NN O O
, NN O O
similar NN O O
to NN O O
the NN O O
level NN O O
in NN O O
D442G NN O O
homozygotes NN O O
, NN O O
and NN O O
significantly NN O O
greater NN O O
than NN O O
mean NN O O
HDL NN O O
- NN O O
C NN O O
levels NN O O
in NN O O
Int14 NN O O
A NN O O
heterozygotes NN O O
( NN O O
69 NN O O
+ NN O O
/ NN O O
- NN O O
15 NN O O
mg NN O O
/ NN O O
dl NN O O
) NN O O
. NN O O

Thus NN O O
, NN O O
the NN O O
D442G NN O O
mutation NN O O
acts NN O O
differently NN O O
to NN O O
the NN O O
null NN O O
mutations NN O O
with NN O O
weaker NN O O
effects NN O O
on NN O O
HDL NN O O
in NN O O
the NN O O
homozygous NN O O
state NN O O
and NN O O
stronger NN O O
effects NN O O
in NN O O
the NN O O
heterozygotes NN O O
, NN O O
suggesting NN O O
dominant NN O O
expression NN O O
of NN O O
a NN O O
partially NN O O
defective NN O O
allele NN O O
. NN O O

CETP NN O B-Disease
deficiency NN O I-Disease
, NN O O
reflecting NN O O
two NN O O
prevalent NN O O
mutations NN O O
( NN O O
D442G NN O O
and NN O O
Int14 NN O O
A NN O O
) NN O O
, NN O O
is NN O O
the NN O O
first NN O O
example NN O O
of NN O O
a NN O O
genetic NN O B-Disease
deficiency NN O I-Disease
state NN O O
which NN O O
is NN O O
sufficiently NN O O
common NN O O
to NN O O
explain NN O O
a NN O O
significant NN O O
fraction NN O O
of NN O O
the NN O O
variation NN O O
in NN O O
HDL NN O O
- NN O O
C NN O O
in NN O O
the NN O O
general NN O O
population NN O O
. NN O O
. NN O O

Treatment NN O O
of NN O O
cerebrotendinous NN O B-Disease
xanthomatosis NN O I-Disease
: NN O O
effects NN O O
of NN O O
chenodeoxycholic NN O O
acid NN O O
, NN O O
pravastatin NN O O
, NN O O
and NN O O
combined NN O O
use NN O O
. NN O O

Treatments NN O O
by NN O O
oral NN O O
administration NN O O
of NN O O
chenodeoxycholic NN O O
acid NN O O
( NN O O
CDCA NN O O
) NN O O
alone NN O O
, NN O O
3 NN O O
- NN O O
hydroxy NN O O
- NN O O
3 NN O O
- NN O O
methylglutaryl NN O O
( NN O O
HMG NN O O
) NN O O
CoA NN O O
reductase NN O O
inhibitor NN O O
( NN O O
pravastatin NN O O
) NN O O
alone NN O O
, NN O O
and NN O O
combination NN O O
of NN O O
the NN O O
two NN O O
drugs NN O O
were NN O O
attempted NN O O
for NN O O
7 NN O O
patients NN O O
with NN O O
cerebrotendinous NN O B-Disease
xanthomatosis NN O I-Disease
( NN O O
CTX NN O B-Disease
) NN O O
. NN O O

CDCA NN O O
treatment NN O O
at NN O O
a NN O O
dose NN O O
of NN O O
300 NN O O
mg NN O O
/ NN O O
day NN O O
reduced NN O O
serum NN O O
cholestanol NN O O
( NN O O
67 NN O O
. NN O O
3 NN O O
% NN O O
reduction NN O O
) NN O O
, NN O O
lathosterol NN O O
( NN O O
50 NN O O
. NN O O
8 NN O O
% NN O O
) NN O O
, NN O O
campesterol NN O O
( NN O O
61 NN O O
. NN O O
7 NN O O
% NN O O
) NN O O
and NN O O
sitosterol NN O O
( NN O O
12 NN O O
. NN O O
7 NN O O
% NN O O
) NN O O
. NN O O

However NN O O
, NN O O
the NN O O
sera NN O O
of NN O O
the NN O O
patients NN O O
changed NN O O
to NN O O
be NN O O
" NN O O
atherogenic NN O O
" NN O O
; NN O O
total NN O O
cholesterol NN O O
, NN O O
triglyceride NN O O
and NN O O
low NN O O
- NN O O
density NN O O
lipoprotein NN O O
( NN O O
LDL NN O O
) NN O O
- NN O O
cholesterol NN O O
were NN O O
increased NN O O
, NN O O
while NN O O
high NN O O
- NN O O
density NN O O
lipoprotein NN O O
( NN O O
HDL NN O O
) NN O O
- NN O O
cholesterol NN O O
was NN O O
decreased NN O O
. NN O O

Contrarily NN O O
, NN O O
pravastatin NN O O
at NN O O
a NN O O
dose NN O O
of NN O O
10 NN O O
mg NN O O
/ NN O O
day NN O O
improved NN O O
the NN O O
sera NN O O
of NN O O
the NN O O
patients NN O O
to NN O O
be NN O O
markedly NN O O
" NN O O
anti NN O O
- NN O O
atherogenic NN O O
" NN O O
, NN O O
but NN O O
the NN O O
reductions NN O O
of NN O O
cholestanol NN O O
( NN O O
30 NN O O
. NN O O
4 NN O O
% NN O O
) NN O O
, NN O O
lathosterol NN O O
( NN O O
44 NN O O
. NN O O
0 NN O O
% NN O O
) NN O O
, NN O O
campesterol NN O O
( NN O O
22 NN O O
. NN O O
9 NN O O
% NN O O
) NN O O
and NN O O
sitosterol NN O O
( NN O O
9 NN O O
. NN O O
6 NN O O
% NN O O
) NN O O
were NN O O
inadequate NN O O
. NN O O

Combined NN O O
treatment NN O O
with NN O O
CDCA NN O O
and NN O O
pravastatin NN O O
showed NN O O
good NN O O
overlapping NN O O
of NN O O
the NN O O
effects NN O O
of NN O O
each NN O O
drug NN O O
alone NN O O
. NN O O

The NN O O
sera NN O O
of NN O O
the NN O O
patients NN O O
were NN O O
apparently NN O O
more NN O O
" NN O O
anti NN O O
- NN O O
atherogenic NN O O
" NN O O
than NN O O
those NN O O
after NN O O
CDCA NN O O
treatment NN O O
. NN O O

Serum NN O O
cholestanol NN O O
concentration NN O O
was NN O O
still NN O O
2 NN O O
. NN O O

7 NN O O
times NN O O
higher NN O O
than NN O O
in NN O O
controls NN O O
, NN O O
but NN O O
the NN O O
serum NN O O
lathosterol NN O O
level NN O O
was NN O O
within NN O O
the NN O O
normal NN O O
range NN O O
, NN O O
indicating NN O O
that NN O O
the NN O O
enhancement NN O O
of NN O O
overall NN O O
cholesterol NN O O
synthesis NN O O
in NN O O
the NN O O
patients NN O O
was NN O O
sufficiently NN O O
suppressed NN O O
. NN O O

Plant NN O O
sterol NN O O
levels NN O O
were NN O O
also NN O O
within NN O O
the NN O O
normal NN O O
range NN O O
. NN O O

The NN O O
combination NN O O
of NN O O
CDCA NN O O
and NN O O
pravastatin NN O O
was NN O O
a NN O O
good NN O O
treatment NN O O
for NN O O
CTX NN O B-Disease
, NN O O
based NN O O
on NN O O
the NN O O
improvement NN O O
of NN O O
serum NN O O
lipoprotein NN O O
metabolism NN O O
, NN O O
the NN O O
suppression NN O O
of NN O O
cholesterol NN O O
synthesis NN O O
, NN O O
and NN O O
reductions NN O O
of NN O O
cholestanol NN O O
and NN O O
plant NN O O
sterol NN O O
levels NN O O
. NN O O

In NN O O
all NN O O
of NN O O
7 NN O O
patients NN O O
, NN O O
the NN O O
progression NN O O
of NN O O
disease NN O O
was NN O O
arrested NN O O
, NN O O
but NN O O
dramatic NN O O
effects NN O O
on NN O O
clinical NN O O
manifestations NN O O
, NN O O
xanthoma NN O B-Disease
, NN O O
and NN O O
electrophysiological NN O O
findings NN O O
could NN O O
not NN O O
be NN O O
found NN O O
after NN O O
the NN O O
treatment NN O O
of NN O O
these NN O O
drugs NN O O

Mutation NN O O
spectrum NN O O
in NN O O
the NN O O
CHM NN O B-Disease
gene NN O O
of NN O O
Danish NN O O
and NN O O
Swedish NN O O
choroideremia NN O B-Disease
patients NN O O
. NN O O

The NN O O
recent NN O O
isolation NN O O
of NN O O
the NN O O
complete NN O O
open NN O O
reading NN O O
frame NN O O
of NN O O
the NN O O
choroideremia NN O B-Disease
( NN O O
CHM NN O B-Disease
) NN O O
gene NN O O
and NN O O
the NN O O
characterization NN O O
of NN O O
the NN O O
exon NN O O
- NN O O
intron NN O O
boundaries NN O O
has NN O O
paved NN O O
the NN O O
way NN O O
to NN O O
mutation NN O O
detection NN O O
in NN O O
patients NN O O
with NN O O
classical NN O O
choroideremia NN O B-Disease
. NN O O

We NN O O
have NN O O
performed NN O O
mutation NN O O
screening NN O O
in NN O O
patients NN O O
from NN O O
15 NN O O
Danish NN O O
and NN O O
Swedish NN O O
families NN O O
by NN O O
using NN O O
Southern NN O O
blot NN O O
hybridization NN O O
and NN O O
the NN O O
polymerase NN O O
chain NN O O
reaction NN O O
single NN O O
- NN O O
strand NN O O
conformation NN O O
polymorphism NN O O
( NN O O
PCR NN O O
- NN O O
SSCP NN O O
) NN O O
technique NN O O
. NN O O

Causative NN O O
mutations NN O O
in NN O O
the NN O O
CHM NN O B-Disease
gene NN O O
were NN O O
detected NN O O
in NN O O
at NN O O
least NN O O
12 NN O O
families NN O O
, NN O O
indicating NN O O
that NN O O
a NN O O
substantial NN O O
part NN O O
of NN O O
the NN O O
mutations NN O O
can NN O O
be NN O O
identified NN O O
by NN O O
this NN O O
approach NN O O
. NN O O

In NN O O
four NN O O
of NN O O
these NN O O
families NN O O
deletions NN O O
of NN O O
different NN O O
sizes NN O O
were NN O O
found NN O O
. NN O O

Thus NN O O
, NN O O
in NN O O
one NN O O
patient NN O O
, NN O O
the NN O O
deletion NN O O
resulted NN O O
in NN O O
the NN O O
absence NN O O
of NN O O
only NN O O
one NN O O
exon NN O O
, NN O O
while NN O O
in NN O O
another NN O O
the NN O O
deletion NN O O
comprised NN O O
the NN O O
entire NN O O
CHM NN O B-Disease
gene NN O O
. NN O O

Mapping NN O O
of NN O O
the NN O O
deletion NN O O
endpoints NN O O
in NN O O
these NN O O
four NN O O
patients NN O O
and NN O O
in NN O O
another NN O O
11 NN O O
male NN O O
patients NN O O
with NN O O
sizeable NN O O
deletions NN O O
enabled NN O O
us NN O O
to NN O O
construct NN O O
a NN O O
very NN O O
detailed NN O O
map NN O O
of NN O O
intervals NN O O
2 NN O O
and NN O O
3 NN O O
of NN O O
Xq21 NN O O
. NN O O

In NN O O
the NN O O
remaining NN O O
11 NN O O
Danish NN O O
and NN O O
Swedish NN O O
families NN O O
at NN O O
least NN O O
8 NN O O
causative NN O O
mutations NN O O
were NN O O
found NN O O
by NN O O
PCR NN O O
- NN O O
SSCP NN O O
analysis NN O O
and NN O O
direct NN O O
sequencing NN O O
. NN O O

Interestingly NN O O
, NN O O
all NN O O
CHM NN O B-Disease
gene NN O O
mutations NN O O
detected NN O O
thus NN O O
far NN O O
in NN O O
choroideremia NN O B-Disease
patients NN O O
give NN O O
rise NN O O
to NN O O
the NN O O
introduction NN O O
of NN O O
a NN O O
premature NN O O
stop NN O O
codon NN O O
. NN O O
. NN O O

Predominance NN O O
of NN O O
the NN O O
adrenomyeloneuropathy NN O B-Disease
phenotype NN O O
of NN O O
X NN O B-Disease
- NN O I-Disease
linked NN O I-Disease
adrenoleukodystrophy NN O I-Disease
in NN O O
The NN O O
Netherlands NN O O
: NN O O
a NN O O
survey NN O O
of NN O O
30 NN O O
kindreds NN O O
. NN O O

X NN O B-Disease
- NN O I-Disease
linked NN O I-Disease
adrenoleukodystrophy NN O I-Disease
( NN O O
X NN O B-Disease
- NN O I-Disease
ALD NN O I-Disease
) NN O O
is NN O O
an NN O O
inherited NN O B-Disease
disorder NN O I-Disease
of NN O O
peroxisomal NN O O
beta NN O O
- NN O O
oxidation NN O O
associated NN O O
with NN O O
accumulation NN O O
of NN O O
saturated NN O O
very NN O O
long NN O O
- NN O O
chain NN O O
fatty NN O O
acids NN O O
, NN O O
which NN O O
results NN O O
in NN O O
central NN O O
and NN O O
peripheral NN O O
demyelination NN O B-Disease
and NN O O
in NN O O
impaired NN O B-Disease
function NN O I-Disease
of NN O I-Disease
adrenal NN O I-Disease
cortex NN O I-Disease
and NN O I-Disease
testes NN O I-Disease
. NN O O

The NN O O
phenotypic NN O O
expression NN O O
is NN O O
highly NN O O
variable NN O O
, NN O O
childhood NN O B-Disease
cerebral NN O I-Disease
ALD NN O I-Disease
( NN O O
CCALD NN O B-Disease
) NN O O
and NN O O
adrenomyeloneuropathy NN O B-Disease
( NN O O
AMN NN O B-Disease
) NN O O
being NN O O
the NN O O
main NN O O
variants NN O O
. NN O O

We NN O O
explored NN O O
the NN O O
30 NN O O
Dutch NN O O
kindreds NN O O
well NN O O
known NN O O
to NN O O
the NN O O
Dutch NN O O
X NN O B-Disease
- NN O I-Disease
ALD NN O I-Disease
/ NN O O
AMN NN O B-Disease
Study NN O O
Group NN O O
and NN O O
phenotyped NN O O
77 NN O O
male NN O O
patients NN O O
35 NN O O
( NN O O
46 NN O O
% NN O O
) NN O O
had NN O O
AMN NN O B-Disease
and NN O O
24 NN O O
( NN O O
31 NN O O
% NN O O
) NN O O
CCALD NN O B-Disease
or NN O O
adolescent NN O B-Disease
cerebral NN O I-Disease
ALD NN O I-Disease
( NN O O
AdolCALD NN O B-Disease
) NN O O
. NN O O

These NN O O
percentages NN O O
differ NN O O
significantly NN O O
from NN O O
previous NN O O
reports NN O O
, NN O O
in NN O O
which NN O O
25 NN O O
to NN O O
28 NN O O
% NN O O
of NN O O
the NN O O
patients NN O O
developed NN O O
AMN NN O B-Disease
and NN O O
53 NN O O
to NN O O
57 NN O O
% NN O O
CCALD NN O B-Disease
or NN O O
AdolCALD NN O B-Disease
. NN O O

Our NN O O
findings NN O O
indicate NN O O
that NN O O
- NN O O
- NN O O
at NN O O
least NN O O
in NN O O
the NN O O
Netherlands NN O O
- NN O O
- NN O O
AMN NN O B-Disease
may NN O O
be NN O O
the NN O O
most NN O O
frequent NN O O
phenotype NN O O
of NN O O
X NN O B-Disease
- NN O I-Disease
ALD NN O I-Disease
. NN O O
. NN O O

Adrenoleukodystrophy NN O B-Disease
gene NN O O
encodes NN O O
an NN O O
80 NN O O
kDa NN O O
membrane NN O O
protein NN O O
. NN O O

An NN O O
antibody NN O O
against NN O O
the NN O O
synthetic NN O O
C NN O O
- NN O O
terminal NN O O
peptides NN O O
deduced NN O O
from NN O O
the NN O O
cDNA NN O O
of NN O O
the NN O O
gene NN O O
responsible NN O O
for NN O O
X NN O B-Disease
- NN O I-Disease
linked NN O I-Disease
adrenoleukodystrophy NN O I-Disease
( NN O O
ALD NN O B-Disease
) NN O O
was NN O O
produced NN O O
to NN O O
characterize NN O O
the NN O O
product NN O O
of NN O O
the NN O O
ALD NN O B-Disease
gene NN O O
. NN O O

The NN O O
antibody NN O O
reacted NN O O
with NN O O
the NN O O
80 NN O O
kDa NN O O
band NN O O
protein NN O O
in NN O O
control NN O O
fibroblasts NN O O
, NN O O
while NN O O
no NN O O
bands NN O O
were NN O O
detected NN O O
in NN O O
the NN O O
fibroblasts NN O O
from NN O O
a NN O O
patient NN O O
with NN O O
ALD NN O B-Disease
( NN O O
# NN O O
163 NN O O
) NN O O
, NN O O
in NN O O
which NN O O
mRNA NN O O
of NN O O
the NN O O
ALD NN O B-Disease
gene NN O O
was NN O O
undetectable NN O O
based NN O O
on NN O O
Northern NN O O
blot NN O O
analysis NN O O
. NN O O

The NN O O
293T NN O O
cells NN O O
transfected NN O O
with NN O O
the NN O O
full NN O O
- NN O O
coding NN O O
cDNA NN O O
inserted NN O O
in NN O O
the NN O O
expression NN O O
vector NN O O
produced NN O O
a NN O O
new NN O O
80 NN O O
kDa NN O O
protein NN O O
, NN O O
as NN O O
detected NN O O
by NN O O
Western NN O O
blot NN O O
. NN O O

In NN O O
an NN O O
immunocytological NN O O
study NN O O
, NN O O
the NN O O
staining NN O O
was NN O O
in NN O O
a NN O O
punctate NN O O
pattern NN O O
, NN O O
in NN O O
the NN O O
normal NN O O
fibroblasts NN O O
. NN O O

However NN O O
, NN O O
there NN O O
was NN O O
no NN O O
punctate NN O O
staining NN O O
in NN O O
the NN O O
# NN O O
163 NN O O
cells NN O O
. NN O O

These NN O O
data NN O O
thus NN O O
indicate NN O O
that NN O O
the NN O O
ALD NN O B-Disease
gene NN O O
encodes NN O O
an NN O O
80 NN O O
kDa NN O O
membrane NN O O
protein NN O O
. NN O O
. NN O O

Isolation NN O O
of NN O O
the NN O O
gene NN O O
for NN O O
McLeod NN O B-Disease
syndrome NN O I-Disease
that NN O O
encodes NN O O
a NN O O
novel NN O O
membrane NN O O
transport NN O O
protein NN O O
. NN O O

McLeod NN O B-Disease
syndrome NN O I-Disease
is NN O O
an NN O O
X NN O B-Disease
- NN O I-Disease
linked NN O I-Disease
multisystem NN O I-Disease
disorder NN O I-Disease
characterized NN O O
by NN O O
abnormalities NN O O
in NN O O
the NN O O
neuromuscular NN O O
and NN O O
hematopoietic NN O O
systems NN O O
. NN O O

We NN O O
have NN O O
assembled NN O O
a NN O O
cosmid NN O O
contig NN O O
of NN O O
360 NN O O
kb NN O O
that NN O O
encompasses NN O O
the NN O O
McLeod NN O B-Disease
gene NN O O
locus NN O O
. NN O O

A NN O O
50 NN O O
kb NN O O
deletion NN O O
was NN O O
detected NN O O
by NN O O
screening NN O O
DNA NN O O
from NN O O
patients NN O O
with NN O O
radiolabeled NN O O
whole NN O O
cosmids NN O O
, NN O O
and NN O O
two NN O O
transcription NN O O
units NN O O
were NN O O
identified NN O O
within NN O O
this NN O O
deletion NN O O
. NN O O

The NN O O
mRNA NN O O
expression NN O O
pattern NN O O
of NN O O
one NN O O
of NN O O
them NN O O
, NN O O
designated NN O O
as NN O O
XK NN O O
, NN O O
correlates NN O O
closely NN O O
to NN O O
the NN O O
McLeod NN O B-Disease
phenotype NN O O
. NN O O

XK NN O O
encodes NN O O
a NN O O
novel NN O O
protein NN O O
with NN O O
structural NN O O
characteristics NN O O
of NN O O
prokaryotic NN O O
and NN O O
eukaryotic NN O O
membrane NN O O
transport NN O O
proteins NN O O
. NN O O

Nucleotide NN O O
sequence NN O O
analysis NN O O
of NN O O
XK NN O O
from NN O O
two NN O O
unrelated NN O O
McLeod NN O B-Disease
patients NN O O
has NN O O
identified NN O O
point NN O O
mutations NN O O
at NN O O
conserved NN O O
splice NN O O
donor NN O O
and NN O O
acceptor NN O O
sites NN O O
. NN O O

These NN O O
findings NN O O
provide NN O O
direct NN O O
evidence NN O O
that NN O O
XK NN O O
is NN O O
responsible NN O O
for NN O O
McLeod NN O B-Disease
syndrome NN O I-Disease
. NN O O
. NN O O

X NN O B-Disease
- NN O I-Disease
linked NN O I-Disease
spastic NN O I-Disease
paraplegia NN O I-Disease
and NN O O
Pelizaeus NN O B-Disease
- NN O I-Disease
Merzbacher NN O I-Disease
disease NN O I-Disease
are NN O O
allelic NN O B-Disease
disorders NN O I-Disease
at NN O O
the NN O O
proteolipid NN O O
protein NN O O
locus NN O O
. NN O O

Three NN O O
forms NN O O
of NN O O
X NN O B-Disease
- NN O I-Disease
linked NN O I-Disease
spastic NN O I-Disease
paraplegia NN O I-Disease
( NN O O
SPG NN O B-Disease
) NN O O
have NN O O
been NN O O
defined NN O O
. NN O O

One NN O O
locus NN O O
( NN O O
SPG NN O O
1 NN O O
) NN O O
maps NN O O
to NN O O
Xq28 NN O O
while NN O O
two NN O O
clinically NN O O
distinct NN O O
forms NN O O
map NN O O
to NN O O
Xq22 NN O O
( NN O O
SPG2 NN O O
) NN O O
. NN O O

A NN O O
rare NN O O
X NN O B-Disease
- NN O I-Disease
linked NN O I-Disease
dysmyelinating NN O I-Disease
disorder NN O I-Disease
of NN O O
the NN O O
central NN O O
nervous NN O O
system NN O O
, NN O O
Pelizaeus NN O B-Disease
- NN O I-Disease
Merzbacher NN O I-Disease
disease NN O I-Disease
( NN O O
PMD NN O B-Disease
) NN O O
, NN O O
has NN O O
also NN O O
been NN O O
mapped NN O O
to NN O O
Xq21 NN O O
- NN O O
q22 NN O O
, NN O O
and NN O O
is NN O O
caused NN O O
by NN O O
mutations NN O O
in NN O O
the NN O O
proteolipid NN O O
protein NN O O
gene NN O O
( NN O O
PLP NN O O
) NN O O
which NN O O
encodes NN O O
two NN O O
myelin NN O O
proteins NN O O
, NN O O
PLP NN O O
and NN O O
DM20 NN O O
. NN O O

While NN O O
narrowing NN O O
the NN O O
genetic NN O O
interval NN O O
containing NN O O
SPG2 NN O O
in NN O O
a NN O O
large NN O O
pedigree NN O O
, NN O O
we NN O O
found NN O O
that NN O O
PLP NN O O
was NN O O
the NN O O
closest NN O O
marker NN O O
to NN O O
the NN O O
disease NN O O
locus NN O O
, NN O O
implicating NN O O
PLP NN O O
as NN O O
a NN O O
possible NN O O
candidate NN O O
gene NN O O
. NN O O

We NN O O
have NN O O
found NN O O
that NN O O
a NN O O
point NN O O
mutation NN O O
( NN O O
His139Tyr NN O O
) NN O O
in NN O O
exon NN O O
3B NN O O
of NN O O
an NN O O
affected NN O O
male NN O O
produces NN O O
a NN O O
mutant NN O O
PLP NN O O
but NN O O
a NN O O
normal NN O O
DM20 NN O O
, NN O O
and NN O O
segregates NN O O
with NN O O
the NN O O
disease NN O O
( NN O O
Zmax NN O O
= NN O O
6 NN O O
. NN O O
63 NN O O
, NN O O
theta NN O O
= NN O O
0 NN O O
. NN O O
00 NN O O
) NN O O
. NN O O

It NN O O
appears NN O O
, NN O O
therefore NN O O
, NN O O
that NN O O
SPG2 NN O O
and NN O O
PMD NN O B-Disease
are NN O O
allelic NN O B-Disease
disorders NN O I-Disease

Canavan NN O B-Disease
disease NN O I-Disease
: NN O O
mutations NN O O
among NN O O
Jewish NN O O
and NN O O
non NN O O
- NN O O
Jewish NN O O
patients NN O O
. NN O O

Canavan NN O B-Disease
disease NN O I-Disease
is NN O O
an NN O O
autosomal NN O B-Disease
recessive NN O I-Disease
leukodystrophy NN O I-Disease
caused NN O O
by NN O O
the NN O O
deficiency NN O B-Disease
of NN O I-Disease
aspartoacylase NN O I-Disease
( NN O O
ASPA NN O O
) NN O O
. NN O O

Sixty NN O O
- NN O O
four NN O O
probands NN O O
were NN O O
analyzed NN O O
for NN O O
mutations NN O O
in NN O O
the NN O O
ASPA NN O O
gene NN O O
. NN O O

Three NN O O
point NN O O
mutations NN O O
- NN O O
- NN O O
693C NN O O
- NN O O
- NN O O
> NN O O
A NN O O
, NN O O
854A NN O O
- NN O O
- NN O O
> NN O O
C NN O O
, NN O O
and NN O O
914C NN O O
- NN O O
- NN O O
> NN O O
A NN O O
- NN O O
- NN O O
were NN O O
identified NN O O
in NN O O
the NN O O
coding NN O O
sequence NN O O
. NN O O

The NN O O
693C NN O O
- NN O O
- NN O O
> NN O O
A NN O O
and NN O O
914C NN O O
- NN O O
- NN O O
> NN O O
A NN O O
base NN O O
changes NN O O
, NN O O
resulting NN O O
in NN O O
nonsense NN O O
tyr231 NN O O
- NN O O
- NN O O
> NN O O
ter NN O O
and NN O O
missense NN O O
ala305 NN O O
- NN O O
- NN O O
> NN O O
glu NN O O
mutations NN O O
, NN O O
respectively NN O O
, NN O O
lead NN O O
to NN O O
complete NN O O
loss NN O O
of NN O O
ASPA NN O O
activity NN O O
in NN O O
in NN O O
vitro NN O O
expression NN O O
studies NN O O
. NN O O

The NN O O
854A NN O O
- NN O O
- NN O O
> NN O O
C NN O O
transversion NN O O
converted NN O O
glu NN O O
to NN O O
ala NN O O
in NN O O
codon NN O O
285 NN O O
. NN O O

The NN O O
glu285 NN O O
- NN O O
- NN O O
> NN O O
ala NN O O
mutant NN O O
ASPA NN O O
has NN O O
2 NN O O
. NN O O

5 NN O O
% NN O O
of NN O O
the NN O O
activity NN O O
expressed NN O O
by NN O O
the NN O O
wild NN O O
- NN O O
type NN O O
enzyme NN O O
. NN O O

A NN O O
fourth NN O O
mutation NN O O
, NN O O
433 NN O O
- NN O O
- NN O O
2 NN O O
( NN O O
A NN O O
- NN O O
- NN O O
> NN O O
G NN O O
) NN O O
transition NN O O
, NN O O
was NN O O
identified NN O O
at NN O O
the NN O O
splice NN O O
- NN O O
acceptor NN O O
site NN O O
in NN O O
intron NN O O
2 NN O O
. NN O O

The NN O O
splice NN O O
- NN O O
site NN O O
mutation NN O O
would NN O O
lead NN O O
to NN O O
skipping NN O O
of NN O O
exon NN O O
3 NN O O
, NN O O
accompanied NN O O
by NN O O
a NN O O
frameshift NN O O
, NN O O
and NN O O
thus NN O O
would NN O O
produce NN O O
aberrant NN O O
ASPA NN O O
. NN O O

Of NN O O
the NN O O
128 NN O O
unrelated NN O O
Canavan NN O B-Disease
chromosomes NN O O
analyzed NN O O
, NN O O
88 NN O O
were NN O O
from NN O O
probands NN O O
of NN O O
Ashkenazi NN O O
Jewish NN O O
descent NN O O
. NN O O

The NN O O
glu285 NN O O
- NN O O
- NN O O
> NN O O
ala NN O O
mutation NN O O
was NN O O
predominant NN O O
( NN O O
82 NN O O
. NN O O
9 NN O O
% NN O O
) NN O O
in NN O O
this NN O O
population NN O O
, NN O O
followed NN O O
by NN O O
the NN O O
tyr231 NN O O
- NN O O
- NN O O
> NN O O
ter NN O O
( NN O O
14 NN O O
. NN O O
8 NN O O
% NN O O
) NN O O
and NN O O
433 NN O O
- NN O O
- NN O O
2 NN O O
( NN O O
A NN O O
- NN O O
- NN O O
> NN O O
G NN O O
) NN O O
( NN O O
1 NN O O
. NN O O
1 NN O O
% NN O O
) NN O O
mutations NN O O
. NN O O

The NN O O
three NN O O
mutations NN O O
account NN O O
for NN O O
98 NN O O
. NN O O

8 NN O O
% NN O O
of NN O O
the NN O O
Canavan NN O B-Disease
chromosomes NN O O
of NN O O
Ashkenazi NN O O
Jewish NN O O
origin NN O O
. NN O O

The NN O O
ala305 NN O O
- NN O O
- NN O O
> NN O O
glu NN O O
mutation NN O O
was NN O O
found NN O O
exclusively NN O O
in NN O O
non NN O O
- NN O O
Jewish NN O O
probands NN O O
of NN O O
European NN O O
descent NN O O
and NN O O
constituted NN O O
60 NN O O
% NN O O
of NN O O
the NN O O
40 NN O O
mutant NN O O
chromosomes NN O O
. NN O O

Predominant NN O O
occurrence NN O O
of NN O O
certain NN O O
mutations NN O O
among NN O O
Ashkenazi NN O O
Jewish NN O O
and NN O O
non NN O O
- NN O O
Jewish NN O O
patients NN O O
with NN O O
Canavan NN O B-Disease
disease NN O I-Disease
would NN O O
suggest NN O O
a NN O O
founding NN O O
- NN O O
father NN O O
effect NN O O
in NN O O
propagation NN O O
of NN O O
these NN O O
mutant NN O O
chromosomes NN O O

Intelligence NN O O
quotient NN O O
profile NN O O
in NN O O
myotonic NN O B-Disease
dystrophy NN O I-Disease
, NN O O
intergenerational NN O O
deficit NN O O
, NN O O
and NN O O
correlation NN O O
with NN O O
CTG NN O O
amplification NN O O
. NN O O

An NN O O
abbreviated NN O O
Wechsler NN O O
Adult NN O O
Intelligence NN O O
Scale NN O O
Revised NN O O
( NN O O
WAIS NN O O
- NN O O
R NN O O
) NN O O
was NN O O
used NN O O
to NN O O
assess NN O O
verbal NN O O
and NN O O
arithmetical NN O O
cognitive NN O O
performance NN O O
in NN O O
55 NN O O
subjects NN O O
with NN O O
myotonic NN O B-Disease
dystrophy NN O I-Disease
( NN O O
DM NN O B-Disease
) NN O O
, NN O O
covering NN O O
all NN O O
grades NN O O
of NN O O
disease NN O O
severity NN O O
, NN O O
and NN O O
31 NN O O
controls NN O O
at NN O O
50 NN O O
% NN O O
risk NN O O
of NN O O
inheriting NN O O
DM NN O B-Disease
. NN O O

Scaled NN O O
scores NN O O
from NN O O
the NN O O
assessment NN O O
were NN O O
converted NN O O
into NN O O
an NN O O
intelligence NN O O
quotient NN O O
( NN O O
IQ NN O O
) NN O O
estimation NN O O
on NN O O
each NN O O
person NN O O
. NN O O

Significant NN O O
IQ NN O O
differences NN O O
were NN O O
found NN O O
between NN O O
( NN O O
1 NN O O
) NN O O
all NN O O
55 NN O O
DM NN O B-Disease
subjects NN O O
( NN O O
mean NN O O
90 NN O O
. NN O O
2 NN O O
, NN O O
SD NN O O
16 NN O O
. NN O O
1 NN O O
) NN O O
and NN O O
31 NN O O
controls NN O O
( NN O O
102 NN O O
. NN O O
6 NN O O
, NN O O
SD NN O O
9 NN O O
. NN O O
4 NN O O
) NN O O
, NN O O
with NN O O
no NN O O
sex NN O O
differences NN O O
in NN O O
either NN O O
group NN O O
; NN O O
( NN O O
2 NN O O
) NN O O
15 NN O O
affected NN O O
parents NN O O
( NN O O
99 NN O O
. NN O O
3 NN O O
, NN O O
SD NN O O
12 NN O O
. NN O O
2 NN O O
) NN O O
and NN O O
their NN O O
affected NN O O
children NN O O
( NN O O
88 NN O O
. NN O O
1 NN O O
, NN O O
SD NN O O
17 NN O O
. NN O O
2 NN O O
) NN O O
, NN O O
where NN O O
significance NN O O
was NN O O
dependent NN O O
on NN O O
parental NN O O
sex NN O O
being NN O O
female NN O O
; NN O O
and NN O O
( NN O O
3 NN O O
) NN O O
15 NN O O
pairs NN O O
of NN O O
affected NN O O
sibs NN O O
( NN O O
89 NN O O
. NN O O
6 NN O O
, NN O O
SD NN O O
13 NN O O
. NN O O
2 NN O O
) NN O O
and NN O O
their NN O O
normal NN O O
sibs NN O O
( NN O O
100 NN O O
. NN O O
2 NN O O
, NN O O
SD NN O O
7 NN O O
. NN O O
6 NN O O
) NN O O
. NN O O

IQ NN O O
steadily NN O O
declined NN O O
as NN O O
( NN O O
1 NN O O
) NN O O
the NN O O
age NN O O
of NN O O
onset NN O O
of NN O O
signs NN O O
and NN O O
symptoms NN O O
decreased NN O O
, NN O O
and NN O O
( NN O O
2 NN O O
) NN O O
the NN O O
CTG NN O O
expansion NN O O
size NN O O
increased NN O O
. NN O O

The NN O O
correlation NN O O
appeared NN O O
to NN O O
be NN O O
more NN O O
linear NN O O
with NN O O
age NN O O
of NN O O
onset NN O O
. NN O O

The NN O O
correlation NN O O
of NN O O
IQ NN O O
difference NN O O
and NN O O
CTG NN O O
expansion NN O O
difference NN O O
in NN O O
both NN O O
the NN O O
DM NN O B-Disease
parent NN O O
- NN O O
child NN O O
pairs NN O O
and NN O O
normal NN O O
sib NN O O
- NN O O
affected NN O O
sib NN O O
pairs NN O O
was NN O O
poor NN O O
, NN O O
indicating NN O O
that NN O O
CTG NN O O
expansion NN O O
is NN O O
not NN O O
a NN O O
reliable NN O O
predictor NN O O
of NN O O
IQ NN O O
either NN O O
in NN O O
individual NN O O
persons NN O O
or NN O O
families NN O O
. NN O O

Further NN O O
analysis NN O O
of NN O O
cognitive NN O O
function NN O O
in NN O O
DM NN O B-Disease
is NN O O
required NN O O
to NN O O
clarify NN O O
specific NN O O
deficits NN O O
characteristic NN O O
of NN O O
this NN O O
patient NN O O
group NN O O

Adenomatous NN O B-Disease
polyposis NN O I-Disease
coli NN O I-Disease
and NN O O
a NN O O
cytogenetic NN O O
deletion NN O O
of NN O O
chromosome NN O O
5 NN O O
resulting NN O O
from NN O O
a NN O O
maternal NN O O
intrachromosomal NN O O
insertion NN O O
. NN O O

We NN O O
present NN O O
the NN O O
clinical NN O O
and NN O O
laboratory NN O O
findings NN O O
in NN O O
an NN O O
institutionalised NN O O
adult NN O O
patient NN O O
originally NN O O
referred NN O O
for NN O O
autism NN O B-Disease
. NN O O

A NN O O
high NN O O
risk NN O O
of NN O O
colorectal NN O B-Disease
cancer NN O I-Disease
was NN O O
predicted NN O O
when NN O O
an NN O O
interstitial NN O O
deletion NN O O
of NN O O
the NN O O
long NN O O
arm NN O O
of NN O O
chromosome NN O O
5 NN O O
, NN O O
del NN O O
( NN O O
5 NN O O
) NN O O
( NN O O
q15q22 NN O O
. NN O O
3 NN O O
) NN O O
, NN O O
was NN O O
detected NN O O
in NN O O
her NN O O
lymphocytes NN O O
and NN O O
deletion NN O O
of NN O O
the NN O O
MCC NN O O
and NN O O
APC NN O B-Disease
genes NN O O
confirmed NN O O
by NN O O
molecular NN O O
analysis NN O O
. NN O O

Adenomatous NN O B-Disease
polyposis NN O I-Disease
coli NN O I-Disease
and NN O O
carcinoma NN O B-Disease
of NN O I-Disease
the NN O I-Disease
rectum NN O I-Disease
were NN O O
subsequently NN O O
diagnosed NN O O
in NN O O
the NN O O
patient NN O O
. NN O O

She NN O O
was NN O O
profoundly NN O O
mentally NN O B-Disease
retarded NN O I-Disease
, NN O O
autistic NN O B-Disease
, NN O O
and NN O O
had NN O O
minor NN O O
dysmorphic NN O B-Disease
features NN O I-Disease
consistent NN O O
with NN O O
those NN O O
of NN O O
previous NN O O
patients NN O O
with NN O O
similar NN O O
deletions NN O O
. NN O O

The NN O O
deletion NN O O
arose NN O O
as NN O O
a NN O O
result NN O O
of NN O O
recombination NN O O
within NN O O
the NN O O
small NN O O
insertion NN O O
loop NN O O
formed NN O O
at NN O O
meiosis NN O O
by NN O O
the NN O O
direct NN O O
insertion NN O O
( NN O O
dir NN O O
ins NN O O
( NN O O
5 NN O O
) NN O O
( NN O O
q22 NN O O
. NN O O
3q14 NN O O
. NN O O
2q15 NN O O
) NN O O
) NN O O
found NN O O
in NN O O
the NN O O
patients NN O O
mother NN O O
. NN O O

This NN O O
family NN O O
further NN O O
confirms NN O O
the NN O O
cytogenetic NN O O
mapping NN O O
of NN O O
both NN O O
MCC NN O O
and NN O O
APC NN O B-Disease
genes NN O O
to NN O O
5q22 NN O O
and NN O O
comparison NN O O
with NN O O
other NN O O
recent NN O O
cases NN O O
suggests NN O O
that NN O O
both NN O O
genes NN O O
and NN O O
their NN O O
closely NN O O
linked NN O O
markers NN O O
lie NN O O
within NN O O
the NN O O
5q22 NN O O
. NN O O

1 NN O O
subband NN O O

Familial NN O B-Disease
male NN O I-Disease
breast NN O I-Disease
cancer NN O I-Disease
is NN O O
not NN O O
linked NN O O
to NN O O
the NN O O
BRCA1 NN O O
locus NN O O
on NN O O
chromosome NN O O
17q NN O O
. NN O O

Breast NN O B-Disease
cancer NN O I-Disease
in NN O O
men NN O O
is NN O O
about NN O O
a NN O O
hundredfold NN O O
less NN O O
common NN O O
than NN O O
in NN O O
women NN O O
and NN O O
this NN O O
has NN O O
hindered NN O O
research NN O O
into NN O O
its NN O O
genetic NN O O
basis NN O O
. NN O O

We NN O O
have NN O O
examined NN O O
22 NN O O
families NN O O
with NN O O
at NN O O
least NN O O
one NN O O
case NN O O
of NN O O
male NN O B-Disease
breast NN O I-Disease
cancer NN O I-Disease
for NN O O
linkage NN O O
to NN O O
the NN O O
hereditary NN O B-Disease
breast NN O I-Disease
and NN O I-Disease
ovarian NN O I-Disease
cancer NN O I-Disease
locus NN O O
, NN O O
BRCA1 NN O O
, NN O O
on NN O O
chromosome NN O O
17q NN O O
. NN O O

We NN O O
found NN O O
strong NN O O
evidence NN O O
against NN O O
linkage NN O O
to NN O O
BRCA1 NN O O
( NN O O
lod NN O O
score NN O O
- NN O O
16 NN O O
. NN O O
63 NN O O
) NN O O
and NN O O
the NN O O
best NN O O
estimate NN O O
of NN O O
the NN O O
proportion NN O O
of NN O O
linked NN O O
families NN O O
was NN O O
0 NN O O
% NN O O
( NN O O
95 NN O O
% NN O O
CI NN O O
0 NN O O
- NN O O
18 NN O O
% NN O O
) NN O O
. NN O O

Our NN O O
results NN O O
indicate NN O O
that NN O O
there NN O O
is NN O O
a NN O O
gene NN O O
( NN O O
s NN O O
) NN O O
other NN O O
than NN O O
BRCA1 NN O O
which NN O O
predisposes NN O O
to NN O O
early NN O O
- NN O O
onset NN O O
breast NN O B-Disease
cancer NN O I-Disease
in NN O O
women NN O O
and NN O O
which NN O O
confers NN O O
a NN O O
higher NN O O
risk NN O O
of NN O O
male NN O B-Disease
breast NN O I-Disease
cancer NN O I-Disease
. NN O O

Identification NN O O
of NN O O
additional NN O O
pedigrees NN O O
that NN O O
include NN O O
cases NN O O
of NN O O
male NN O B-Disease
breast NN O I-Disease
cancer NN O I-Disease
may NN O O
therefore NN O O
facilitate NN O O
the NN O O
mapping NN O O
and NN O O
isolation NN O O
of NN O O
this NN O O
gene NN O O
. NN O O

The NN O O
EWS NN O O
gene NN O O
, NN O O
involved NN O O
in NN O O
Ewing NN O B-Disease
family NN O I-Disease
of NN O I-Disease
tumors NN O I-Disease
, NN O O
malignant NN O B-Disease
melanoma NN O I-Disease
of NN O I-Disease
soft NN O I-Disease
parts NN O I-Disease
and NN O O
desmoplastic NN O B-Disease
small NN O I-Disease
round NN O I-Disease
cell NN O I-Disease
tumors NN O I-Disease
, NN O O
codes NN O O
for NN O O
an NN O O
RNA NN O O
binding NN O O
protein NN O O
with NN O O
novel NN O O
regulatory NN O O
domains NN O O
. NN O O

The NN O O
EWS NN O O
gene NN O O
, NN O O
which NN O O
maps NN O O
to NN O O
band NN O O
q12 NN O O
of NN O O
human NN O O
chromosome NN O O
22 NN O O
, NN O O
is NN O O
involved NN O O
in NN O O
a NN O O
wide NN O O
variety NN O O
of NN O O
human NN O O
solid NN O B-Disease
tumors NN O I-Disease
including NN O O
Ewing NN O B-Disease
sarcoma NN O I-Disease
, NN O O
related NN O O
primitive NN O O
neuroectodermal NN O B-Disease
tumors NN O I-Disease
, NN O O
malignant NN O B-Disease
melanoma NN O I-Disease
of NN O I-Disease
soft NN O I-Disease
parts NN O I-Disease
and NN O O
desmoplastic NN O B-Disease
small NN O I-Disease
round NN O I-Disease
cell NN O I-Disease
tumors NN O I-Disease
. NN O O

In NN O O
these NN O O
tumors NN O B-Disease
, NN O O
the NN O O
EWS NN O O
is NN O O
fused NN O O
to NN O O
genes NN O O
encoding NN O O
transcriptional NN O O
activators NN O O
/ NN O O
repressors NN O O
, NN O O
like NN O O
Fli NN O O
- NN O O
1 NN O O
or NN O O
erg NN O O
or NN O O
ATF NN O O
1 NN O O
or NN O O
wt1 NN O O
. NN O O

To NN O O
better NN O O
understand NN O O
the NN O O
function NN O O
of NN O O
the NN O O
EWS NN O O
protein NN O O
, NN O O
we NN O O
cloned NN O O
the NN O O
EWS NN O O
cDNA NN O O
. NN O O

Sequence NN O O
analysis NN O O
of NN O O
this NN O O
cDNA NN O O
revealed NN O O
differential NN O O
splicing NN O O
involving NN O O
two NN O O
exons NN O O
encoding NN O O
72 NN O O
amino NN O O
acids NN O O
. NN O O

Both NN O O
alternatively NN O O
spliced NN O O
transcripts NN O O
, NN O O
EWS NN O O
and NN O O
EWS NN O O
- NN O O
b NN O O
, NN O O
are NN O O
expressed NN O O
in NN O O
a NN O O
variety NN O O
of NN O O
cells NN O O
. NN O O

Because NN O O
EWS NN O O
proteins NN O O
contain NN O O
putative NN O O
conserved NN O O
RNA NN O O
binding NN O O
motifs NN O O
, NN O O
we NN O O
studied NN O O
the NN O O
RNA NN O O
binding NN O O
properties NN O O
of NN O O
the NN O O
EWS NN O O
protein NN O O
. NN O O

The NN O O
EWS NN O O
- NN O O
b NN O O
protein NN O O
binds NN O O
to NN O O
RNA NN O O
in NN O O
vitro NN O O
and NN O O
, NN O O
specifically NN O O
, NN O O
to NN O O
poly NN O O
G NN O O
and NN O O
poly NN O O
U NN O O
. NN O O

The NN O O
RNA NN O O
binding NN O O
activity NN O O
was NN O O
localized NN O O
to NN O O
the NN O O
carboxy NN O O
terminal NN O O
86 NN O O
amino NN O O
acids NN O O
, NN O O
which NN O O
constitute NN O O
RGG NN O O
box NN O O
. NN O O

Thus NN O O
the NN O O
amino NN O O
terminal NN O O
domain NN O O
of NN O O
EWS NN O O
( NN O O
NTD NN O O
- NN O O
EWS NN O O
) NN O O
, NN O O
which NN O O
is NN O O
involved NN O O
in NN O O
chromosome NN O O
translocation NN O O
may NN O O
regulate NN O O
the NN O O
specificity NN O O
of NN O O
RNA NN O O
binding NN O O
activity NN O O
of NN O O
EWS NN O O
. NN O O

An NN O O
EWS NN O O
- NN O O
erg NN O O
chimeric NN O O
protein NN O O
, NN O O
which NN O O
is NN O O
found NN O O
in NN O O
Ewings NN O B-Disease
sarcoma NN O I-Disease
cells NN O O
, NN O O
functions NN O O
as NN O O
a NN O O
transcriptional NN O O
activator NN O O
. NN O O

Mutational NN O O
analysis NN O O
of NN O O
EWS NN O O
- NN O O
erg NN O O
chimeric NN O O
protein NN O O
revealed NN O O
that NN O O
NTD NN O O
- NN O O
EWS NN O O
functions NN O O
as NN O O
a NN O O
regulatory NN O O
domain NN O O
for NN O O
the NN O O
transcriptional NN O O
activation NN O O
properties NN O O
of NN O O
EWS NN O O
- NN O O
erg NN O O
chimeric NN O O
protein NN O O
. NN O O
. NN O O

Canavan NN O B-Disease
disease NN O I-Disease
: NN O O
genomic NN O O
organization NN O O
and NN O O
localization NN O O
of NN O O
human NN O O
ASPA NN O O
to NN O O
17p13 NN O O
- NN O O
ter NN O O
and NN O O
conservation NN O O
of NN O O
the NN O O
ASPA NN O O
gene NN O O
during NN O O
evolution NN O O
. NN O O

Canavan NN O B-Disease
disease NN O I-Disease
, NN O O
or NN O O
spongy NN O B-Disease
degeneration NN O I-Disease
of NN O I-Disease
the NN O I-Disease
brain NN O I-Disease
, NN O O
is NN O O
a NN O O
severe NN O O
leukodystrophy NN O B-Disease
caused NN O O
by NN O O
the NN O O
deficiency NN O B-Disease
of NN O I-Disease
aspartoacylase NN O I-Disease
( NN O O
ASPA NN O O
) NN O O
. NN O O

Recently NN O O
, NN O O
a NN O O
missense NN O O
mutation NN O O
was NN O O
identified NN O O
in NN O O
human NN O O
ASPA NN O O
coding NN O O
sequence NN O O
from NN O O
patients NN O O
with NN O O
Canavan NN O B-Disease
disease NN O I-Disease
. NN O O

The NN O O
human NN O O
ASPA NN O O
gene NN O O
has NN O O
been NN O O
cloned NN O O
and NN O O
found NN O O
to NN O O
span NN O O
29 NN O O
kb NN O O
of NN O O
the NN O O
genome NN O O
. NN O O

Human NN O O
aspartoacylase NN O O
is NN O O
coded NN O O
by NN O O
six NN O O
exons NN O O
intervened NN O O
by NN O O
five NN O O
introns NN O O
. NN O O

The NN O O
exons NN O O
vary NN O O
from NN O O
94 NN O O
( NN O O
exon NN O O
III NN O O
) NN O O
to NN O O
514 NN O O
( NN O O
exon NN O O
VI NN O O
) NN O O
bases NN O O
. NN O O

The NN O O
exon NN O O
/ NN O O
intron NN O O
splice NN O O
junction NN O O
sites NN O O
follow NN O O
the NN O O
gt NN O O
/ NN O O
ag NN O O
consensus NN O O
sequence NN O O
rule NN O O
. NN O O

Southern NN O O
blot NN O O
analysis NN O O
of NN O O
genomic NN O O
DNA NN O O
from NN O O
human NN O O
/ NN O O
mouse NN O O
somatic NN O O
cell NN O O
hybrid NN O O
cell NN O O
lines NN O O
localized NN O O
ASPA NN O O
to NN O O
human NN O O
chromosome NN O O
17 NN O O
. NN O O

The NN O O
human NN O O
ASPA NN O O
locus NN O O
was NN O O
further NN O O
mapped NN O O
in NN O O
the NN O O
17p13 NN O O
- NN O O
ter NN O O
region NN O O
by NN O O
fluorescence NN O O
in NN O O
situ NN O O
hybridization NN O O
. NN O O

The NN O O
bovine NN O O
aspa NN O O
gene NN O O
has NN O O
also NN O O
been NN O O
cloned NN O O
, NN O O
and NN O O
its NN O O
exon NN O O
/ NN O O
intron NN O O
organization NN O O
is NN O O
identical NN O O
to NN O O
that NN O O
of NN O O
the NN O O
human NN O O
gene NN O O
. NN O O

The NN O O
500 NN O O
- NN O O
base NN O O
sequence NN O O
upstream NN O O
of NN O O
the NN O O
initiator NN O O
ATG NN O O
codon NN O O
in NN O O
the NN O O
human NN O O
gene NN O O
and NN O O
that NN O O
in NN O O
the NN O O
bovine NN O O
gene NN O O
are NN O O
77 NN O O
% NN O O
identical NN O O
. NN O O

Human NN O O
ASPA NN O O
coding NN O O
sequences NN O O
cross NN O O
- NN O O
hybridize NN O O
with NN O O
genomic NN O O
DNA NN O O
from NN O O
yeast NN O O
, NN O O
chicken NN O O
, NN O O
rabbit NN O O
, NN O O
cow NN O O
, NN O O
dog NN O O
, NN O O
mouse NN O O
, NN O O
rat NN O O
, NN O O
and NN O O
monkey NN O O
. NN O O

The NN O O
specificity NN O O
of NN O O
cross NN O O
- NN O O
species NN O O
hybridization NN O O
of NN O O
coding NN O O
sequences NN O O
suggests NN O O
that NN O O
aspartoacylase NN O O
has NN O O
been NN O O
conserved NN O O
during NN O O
evolution NN O O
. NN O O

It NN O O
should NN O O
now NN O O
be NN O O
possible NN O O
to NN O O
identify NN O O
mutations NN O O
in NN O O
the NN O O
noncoding NN O O
genomic NN O O
sequences NN O O
that NN O O
lead NN O O
to NN O O
Canavan NN O B-Disease
disease NN O I-Disease
and NN O O
to NN O O
study NN O O
the NN O O
regulation NN O O
of NN O O
ASPA NN O O
. NN O O
. NN O O

Myotonic NN O B-Disease
dystrophy NN O I-Disease
: NN O O
size NN O O
- NN O O
and NN O O
sex NN O O
- NN O O
dependent NN O O
dynamics NN O O
of NN O O
CTG NN O O
meiotic NN O O
instability NN O O
, NN O O
and NN O O
somatic NN O O
mosaicism NN O O
. NN O O

Myotonic NN O B-Disease
dystrophy NN O I-Disease
( NN O O
DM NN O B-Disease
) NN O O
is NN O O
a NN O O
progressive NN O O
neuromuscular NN O B-Disease
disorder NN O I-Disease
which NN O O
results NN O O
from NN O O
elongations NN O O
of NN O O
an NN O O
unstable NN O O
( NN O O
CTG NN O O
) NN O O
n NN O O
repeat NN O O
, NN O O
located NN O O
in NN O O
the NN O O
3 NN O O
untranslated NN O O
region NN O O
of NN O O
the NN O O
DM NN O B-Disease
gene NN O O
. NN O O

A NN O O
correlation NN O O
has NN O O
been NN O O
demonstrated NN O O
between NN O O
the NN O O
increase NN O O
in NN O O
the NN O O
repeat NN O O
number NN O O
of NN O O
this NN O O
sequence NN O O
and NN O O
the NN O O
severity NN O O
of NN O O
the NN O O
disease NN O O
. NN O O

However NN O O
, NN O O
the NN O O
clinical NN O O
status NN O O
of NN O O
patients NN O O
cannot NN O O
be NN O O
unambiguously NN O O
ascertained NN O O
solely NN O O
on NN O O
the NN O O
basis NN O O
of NN O O
the NN O O
number NN O O
of NN O O
CTG NN O O
repeats NN O O
. NN O O

Moreover NN O O
, NN O O
the NN O O
exclusive NN O O
maternal NN O O
inheritance NN O O
of NN O O
the NN O O
congenital NN O O
form NN O O
remains NN O O
unexplained NN O O
. NN O O

Our NN O O
observation NN O O
of NN O O
differently NN O O
sized NN O O
repeats NN O O
in NN O O
various NN O O
DM NN O B-Disease
tissues NN O O
from NN O O
the NN O O
same NN O O
individual NN O O
may NN O O
explain NN O O
why NN O O
the NN O O
size NN O O
of NN O O
the NN O O
mutation NN O O
observed NN O O
in NN O O
lymphocytes NN O O
does NN O O
not NN O O
necessarily NN O O
correlate NN O O
with NN O O
the NN O O
severity NN O O
and NN O O
nature NN O O
of NN O O
symptoms NN O O
. NN O O

Through NN O O
a NN O O
molecular NN O O
and NN O O
genetic NN O O
study NN O O
of NN O O
142 NN O O
families NN O O
including NN O O
418 NN O O
DM NN O B-Disease
patients NN O O
, NN O O
we NN O O
have NN O O
investigated NN O O
the NN O O
dynamics NN O O
of NN O O
the NN O O
CTG NN O O
repeat NN O O
meiotic NN O O
instability NN O O
. NN O O

A NN O O
positive NN O O
correlation NN O O
between NN O O
the NN O O
size NN O O
of NN O O
the NN O O
repeat NN O O
and NN O O
the NN O O
intergenerational NN O O
enlargement NN O O
was NN O O
observed NN O O
similarly NN O O
through NN O O
male NN O O
and NN O O
female NN O O
meioses NN O O
for NN O O
< NN O O
or NN O O
= NN O O
0 NN O O
. NN O O

5 NN O O
- NN O O
kb NN O O
CTG NN O O
sequences NN O O
. NN O O

Beyond NN O O
0 NN O O
. NN O O

5 NN O O
kb NN O O
, NN O O
the NN O O
intergenerational NN O O
variation NN O O
was NN O O
more NN O O
important NN O O
through NN O O
female NN O O
meioses NN O O
, NN O O
whereas NN O O
a NN O O
tendency NN O O
to NN O O
compression NN O O
was NN O O
observed NN O O
almost NN O O
exclusively NN O O
in NN O O
male NN O O
meioses NN O O
, NN O O
for NN O O
> NN O O
or NN O O
= NN O O
1 NN O O
. NN O O

5 NN O O
- NN O O
kb NN O O
fragments NN O O
. NN O O

This NN O O
implies NN O O
a NN O O
size NN O O
- NN O O
and NN O O
sex NN O O
- NN O O
dependent NN O O
meiotic NN O O
instability NN O O
. NN O O

Moreover NN O O
, NN O O
segregation NN O O
analysis NN O O
supports NN O O
the NN O O
hypothesis NN O O
of NN O O
a NN O O
maternal NN O O
as NN O O
well NN O O
as NN O O
a NN O O
familial NN O O
predisposition NN O O
for NN O O
the NN O O
occurrence NN O O
of NN O O
the NN O O
congenital NN O O
form NN O O
. NN O O

Finally NN O O
, NN O O
this NN O O
analysis NN O O
reveals NN O O
a NN O O
significant NN O O
excess NN O O
of NN O O
transmitting NN O O
grandfathers NN O O
partially NN O O
accounted NN O O
for NN O O
by NN O O
increased NN O O
fertility NN O O
in NN O O
affected NN O O
males NN O O

Illegitimate NN O O
transcription NN O O
of NN O O
the NN O O
phenylalanine NN O O
hydroxylase NN O O
gene NN O O
in NN O O
lymphocytes NN O O
for NN O O
identification NN O O
of NN O O
mutations NN O O
in NN O O
phenylketonuria NN O B-Disease
. NN O O

Taking NN O O
advantage NN O O
of NN O O
the NN O O
illegitimate NN O O
transcription NN O O
of NN O O
the NN O O
phenylalanine NN O O
hydroxylase NN O O
( NN O O
PAH NN O O
) NN O O
gene NN O O
, NN O O
we NN O O
have NN O O
been NN O O
able NN O O
to NN O O
analyse NN O O
the NN O O
PAH NN O O
cDNA NN O O
sequence NN O O
of NN O O
hyperphenylalaninemic NN O B-Disease
children NN O O
in NN O O
circulating NN O O
lymphocytes NN O O
. NN O O

Using NN O O
this NN O O
approach NN O O
, NN O O
we NN O O
have NN O O
also NN O O
identified NN O O
3 NN O O
novel NN O O
mutations NN O O
in NN O O
cDNA NN O O
from NN O O
liver NN O O
and NN O O
lymphocytes NN O O
of NN O O
two NN O O
patients NN O O
. NN O O

One NN O O
mutation NN O O
, NN O O
detected NN O O
by NN O O
the NN O O
abnormal NN O O
pattern NN O O
of NN O O
migration NN O O
of NN O O
an NN O O
amplified NN O O
fragment NN O O
, NN O O
is NN O O
a NN O O
C NN O O
to NN O O
T NN O O
transition NN O O
in NN O O
the NN O O
splice NN O O
acceptor NN O O
site NN O O
of NN O O
intron NN O O
10 NN O O
, NN O O
which NN O O
resulted NN O O
in NN O O
the NN O O
skipping NN O O
of NN O O
exon NN O O
11 NN O O
with NN O O
the NN O O
premature NN O O
termination NN O O
of NN O O
RNA NN O O
translation NN O O
downstream NN O O
from NN O O
exon NN O O
12 NN O O
( NN O O
- NN O O
3 NN O O
IVS10 NN O O
) NN O O
. NN O O

The NN O O
other NN O O
two NN O O
mutations NN O O
are NN O O
missense NN O O
mutations NN O O
in NN O O
exons NN O O
10 NN O O
and NN O O
11 NN O O
( NN O O
respectively NN O O
, NN O O
L333F NN O O
and NN O O
E390G NN O O
) NN O O
. NN O O

The NN O O
present NN O O
study NN O O
supports NN O O
the NN O O
view NN O O
that NN O O
circulating NN O O
lymphocytes NN O O
give NN O O
easy NN O O
access NN O O
to NN O O
PAH NN O O
gene NN O O
transcripts NN O O
whose NN O O
nucleotide NN O O
sequence NN O O
is NN O O
identical NN O O
to NN O O
that NN O O
reported NN O O
in NN O O
liver NN O O
and NN O O
therefore NN O O
represent NN O O
a NN O O
useful NN O O
tool NN O O
for NN O O
molecular NN O O
genetic NN O O
studies NN O O
in NN O O
phenylketonuria NN O B-Disease
. NN O O
. NN O O

High NN O O
residual NN O O
arylsulfatase NN O O
A NN O O
( NN O O
ARSA NN O O
) NN O O
activity NN O O
in NN O O
a NN O O
patient NN O O
with NN O O
late NN O B-Disease
- NN O I-Disease
infantile NN O I-Disease
metachromatic NN O I-Disease
leukodystrophy NN O I-Disease
. NN O O

We NN O O
identified NN O O
a NN O O
patient NN O O
suffering NN O O
from NN O O
late NN O B-Disease
- NN O I-Disease
infantile NN O I-Disease
metachromatic NN O I-Disease
leukodystrophy NN O I-Disease
( NN O O
MLD NN O B-Disease
) NN O O
who NN O O
has NN O O
a NN O O
residual NN O O
arylsulfatase NN O O
A NN O O
( NN O O
ARSA NN O O
) NN O O
activity NN O O
of NN O O
about NN O O
10 NN O O
% NN O O
. NN O O

Fibroblasts NN O O
of NN O O
the NN O O
patient NN O O
show NN O O
significant NN O O
sulfatide NN O O
degradation NN O O
activity NN O O
exceeding NN O O
that NN O O
of NN O O
adult NN O B-Disease
MLD NN O I-Disease
patients NN O O
. NN O O

Analysis NN O O
of NN O O
the NN O O
ARSA NN O O
gene NN O O
in NN O O
this NN O O
patient NN O O
revealed NN O O
heterozygosity NN O O
for NN O O
two NN O O
new NN O O
mutant NN O O
alleles NN O O
in NN O O
one NN O O
allele NN O O
, NN O O
deletion NN O O
of NN O O
C NN O O
447 NN O O
in NN O O
exon NN O O
2 NN O O
leads NN O O
to NN O O
a NN O O
frameshift NN O O
and NN O O
to NN O O
a NN O O
premature NN O O
stop NN O O
codon NN O O
at NN O O
amino NN O O
acid NN O O
position NN O O
105 NN O O
; NN O O
in NN O O
the NN O O
second NN O O
allele NN O O
, NN O O
a NN O O
G NN O O
- NN O O
- NN O O
> NN O O
A NN O O
transition NN O O
in NN O O
exon NN O O
5 NN O O
causes NN O O
a NN O O
Gly309 NN O O
- NN O O
- NN O O
> NN O O
Ser NN O O
substitution NN O O
. NN O O

Transient NN O O
expression NN O O
of NN O O
the NN O O
mutant NN O O
Ser309 NN O O
- NN O O
ARSA NN O O
resulted NN O O
in NN O O
only NN O O
13 NN O O
% NN O O
enzyme NN O O
activity NN O O
of NN O O
that NN O O
observed NN O O
in NN O O
cells NN O O
expressing NN O O
normal NN O O
ARSA NN O O
. NN O O

The NN O O
mutant NN O O
ARSA NN O O
is NN O O
correctly NN O O
targeted NN O O
to NN O O
the NN O O
lysosomes NN O O
but NN O O
is NN O O
unstable NN O O
. NN O O

These NN O O
findings NN O O
are NN O O
in NN O O
contrast NN O O
to NN O O
previous NN O O
results NN O O
showing NN O O
that NN O O
the NN O O
late NN O B-Disease
- NN O I-Disease
infantile NN O I-Disease
type NN O I-Disease
of NN O I-Disease
MLD NN O I-Disease
is NN O O
always NN O O
associated NN O O
with NN O O
the NN O O
complete NN O O
absence NN O O
of NN O O
ARSA NN O O
activity NN O O
. NN O O

The NN O O
expression NN O O
of NN O O
the NN O O
mutant NN O O
ARSA NN O O
protein NN O O
may NN O O
be NN O O
influenced NN O O
by NN O O
particular NN O O
features NN O O
of NN O O
oligodendrocytes NN O O
, NN O O
such NN O O
that NN O O
the NN O O
level NN O O
of NN O O
mutant NN O O
enzyme NN O O
is NN O O
lower NN O O
in NN O O
these NN O O
cells NN O O
than NN O O
in NN O O
others NN O O
. NN O O
. NN O O

An NN O O
arylsulfatase NN O O
A NN O O
( NN O O
ARSA NN O O
) NN O O
missense NN O O
mutation NN O O
( NN O O
T274M NN O O
) NN O O
causing NN O O
late NN O B-Disease
- NN O I-Disease
infantile NN O I-Disease
metachromatic NN O I-Disease
leukodystrophy NN O I-Disease
. NN O O

Metachromatic NN O B-Disease
leukodystrophy NN O I-Disease
( NN O O
MLD NN O B-Disease
) NN O O
is NN O O
an NN O O
autosomal NN O B-Disease
recessive NN O I-Disease
lysosomal NN O I-Disease
storage NN O I-Disease
disorder NN O I-Disease
caused NN O O
by NN O O
a NN O O
deficiency NN O B-Disease
of NN O I-Disease
arylsulfatase NN O I-Disease
A NN O I-Disease
( NN O O
ARSA NN O O
; NN O O
EC NN O O
3 NN O O
. NN O O
1 NN O O
. NN O O
6 NN O O
. NN O O
8 NN O O
) NN O O
. NN O O

The NN O O
8 NN O O
ARSA NN O O
exons NN O O
and NN O O
adjacent NN O O
intron NN O O
boundaries NN O O
from NN O O
a NN O O
patient NN O O
with NN O O
late NN O B-Disease
- NN O I-Disease
infantile NN O I-Disease
metachromatic NN O I-Disease
leukodystrophy NN O I-Disease
were NN O O
polymerase NN O O
chain NN O O
reaction NN O O
( NN O O
PCR NN O O
) NN O O
amplified NN O O
in NN O O
seven NN O O
discrete NN O O
reactions NN O O
. NN O O

Amplified NN O O
ARSA NN O O
exons NN O O
were NN O O
analysed NN O O
for NN O O
the NN O O
presence NN O O
of NN O O
sequence NN O O
alterations NN O O
by NN O O
single NN O O
- NN O O
strand NN O O
conformation NN O O
polymorphism NN O O
analysis NN O O
, NN O O
followed NN O O
by NN O O
direct NN O O
sequencing NN O O
of NN O O
PCR NN O O
products NN O O
. NN O O

The NN O O
patient NN O O
was NN O O
found NN O O
to NN O O
be NN O O
homozygous NN O O
for NN O O
a NN O O
C NN O O
- NN O O
- NN O O
> NN O O
T NN O O
transition NN O O
in NN O O
exon NN O O
IV NN O O
that NN O O
results NN O O
in NN O O
the NN O O
substitution NN O O
of NN O O
a NN O O
highly NN O O
conserved NN O O
threonine NN O O
residue NN O O
at NN O O
amino NN O O
acid NN O O
274 NN O O
with NN O O
a NN O O
methionine NN O O
( NN O O
T274M NN O O
) NN O O
. NN O O

Analysis NN O O
of NN O O
a NN O O
further NN O O
29 NN O O
MLD NN O B-Disease
patients NN O O
revealed NN O O
the NN O O
presence NN O O
of NN O O
five NN O O
additional NN O O
homozygotes NN O O
for NN O O
T274M NN O O
. NN O O

All NN O O
6 NN O O
T274M NN O O
homozygotes NN O O
( NN O O
representing NN O O
four NN O O
families NN O O
) NN O O
were NN O O
of NN O O
Lebanese NN O O
descent NN O O
, NN O O
and NN O O
all NN O O
were NN O O
known NN O O
to NN O O
be NN O O
the NN O O
result NN O O
of NN O O
consanguineous NN O O
marriages NN O O
. NN O O

The NN O O
altered NN O O
amino NN O O
acid NN O O
is NN O O
rigidly NN O O
conserved NN O O
among NN O O
10 NN O O
sulfatases NN O O
from NN O O
Escherichia NN O O
coli NN O O
to NN O O
humans NN O O
; NN O O
therefore NN O O
, NN O O
it NN O O
is NN O O
most NN O O
likely NN O O
that NN O O
the NN O O
resultant NN O O
mutant NN O O
protein NN O O
will NN O O
have NN O O
little NN O O
or NN O O
no NN O O
enzyme NN O O
activity NN O O
. NN O O

This NN O O
is NN O O
consistent NN O O
with NN O O
the NN O O
very NN O O
low NN O O
ARSA NN O O
activity NN O O
measured NN O O
in NN O O
these NN O O
patients NN O O
and NN O O
their NN O O
uniformly NN O O
severe NN O O
clinical NN O O
presentation NN O O

Mutations NN O O
in NN O O
the NN O O
PAX6 NN O O
gene NN O O
in NN O O
patients NN O O
with NN O O
hereditary NN O O
aniridia NN O B-Disease
. NN O O

The NN O O
14 NN O O
exons NN O O
of NN O O
the NN O O
PAX6 NN O O
gene NN O O
have NN O O
been NN O O
analysed NN O O
exon NN O O
- NN O O
by NN O O
- NN O O
exon NN O O
using NN O O
SSCP NN O O
in NN O O
6 NN O O
aniridia NN O B-Disease
families NN O O
. NN O O

In NN O O
each NN O O
family NN O O
band NN O O
shifts NN O O
were NN O O
observed NN O O
on NN O O
the NN O O
SSCP NN O O
gels NN O O
for NN O O
only NN O O
one NN O O
exon NN O O
and NN O O
direct NN O O
PCR NN O O
- NN O O
sequencing NN O O
revealed NN O O
mutations NN O O
in NN O O
each NN O O
case NN O O
. NN O O

Two NN O O
mutations NN O O
involved NN O O
C NN O O
- NN O O
- NN O O
> NN O O
T NN O O
transitions NN O O
in NN O O
CGAarg NN O O
codons NN O O
in NN O O
exons NN O O
9 NN O O
and NN O O
11 NN O O
. NN O O

Another NN O O
C NN O O
- NN O O
- NN O O
> NN O O
T NN O O
transition NN O O
converted NN O O
a NN O O
CAG NN O O
- NN O O
glutamine NN O O
to NN O O
a NN O O
TAG NN O O
- NN O O
stop NN O O
in NN O O
exon NN O O
7 NN O O
. NN O O

Small NN O O
insertions NN O O
created NN O O
frameshifts NN O O
which NN O O
produced NN O O
downstream NN O O
stop NN O O
codons NN O O
in NN O O
another NN O O
two NN O O
patients NN O O
and NN O O
an NN O O
A NN O O
- NN O O
- NN O O
> NN O O
T NN O O
mutation NN O O
disrupted NN O O
the NN O O
splice NN O O
donor NN O O
site NN O O
of NN O O
exon NN O O
5 NN O O
in NN O O
the NN O O
remaining NN O O
family NN O O
. NN O O

Thus NN O O
, NN O O
complete NN O O
inactivation NN O O
of NN O O
the NN O O
PAX6 NN O O
gene NN O O
is NN O O
predicted NN O O
in NN O O
all NN O O
cases NN O O
. NN O O

Analysis NN O O
of NN O O
other NN O O
affected NN O O
members NN O O
of NN O O
the NN O O
families NN O O
showed NN O O
that NN O O
, NN O O
in NN O O
each NN O O
case NN O O
, NN O O
all NN O O
affected NN O O
individuals NN O O
carried NN O O
the NN O O
same NN O O
family NN O O
- NN O O
specific NN O O
mutation NN O O
. NN O O

One NN O O
polymorphism NN O O
was NN O O
found NN O O
in NN O O
exon NN O O
7 NN O O
. NN O O

This NN O O
data NN O O
strongly NN O O
supports NN O O
the NN O O
candidature NN O O
of NN O O
PAX6 NN O O
as NN O O
the NN O O
gene NN O O
responsible NN O O
for NN O O
hereditary NN O O
aniridia NN O B-Disease
. NN O O
. NN O O

Three NN O O
novel NN O O
mutations NN O O
in NN O O
five NN O O
unrelated NN O O
subjects NN O O
with NN O O
hereditary NN O O
protein NN O B-Disease
S NN O I-Disease
deficiency NN O I-Disease
type NN O I-Disease
I NN O I-Disease
. NN O O

A NN O O
panel NN O O
of NN O O
eight NN O O
unrelated NN O O
subjects NN O O
with NN O O
inherited NN O O
type NN O B-Disease
I NN O I-Disease
protein NN O I-Disease
S NN O I-Disease
deficiency NN O I-Disease
was NN O O
screened NN O O
for NN O O
mutations NN O O
in NN O O
the NN O O
PROS1 NN O O
gene NN O O
. NN O O

In NN O O
five NN O O
subjects NN O O
an NN O O
abnormality NN O O
was NN O O
found NN O O
but NN O O
mutations NN O O
were NN O O
not NN O O
detected NN O O
in NN O O
the NN O O
remaining NN O O
three NN O O
subjects NN O O
. NN O O

Two NN O O
subjects NN O O
shared NN O O
a NN O O
G NN O O
- NN O O
- NN O O
> NN O O
A NN O O
transition NN O O
at NN O O
position NN O O
+ NN O O
5 NN O O
of NN O O
the NN O O
donor NN O O
splice NN O O
site NN O O
consensus NN O O
sequence NN O O
of NN O O
intron NN O O
10 NN O O
. NN O O

Also NN O O
in NN O O
two NN O O
subjects NN O O
an NN O O
A NN O O
- NN O O
- NN O O
> NN O O
T NN O O
transversion NN O O
was NN O O
detected NN O O
in NN O O
the NN O O
stopcodon NN O O
of NN O O
the NN O O
PROS1 NN O O
gene NN O O
; NN O O
this NN O O
transversion NN O O
predicts NN O O
a NN O O
protein NN O O
S NN O O
molecule NN O O
that NN O O
is NN O O
extended NN O O
by NN O O
14 NN O O
amino NN O O
acids NN O O
. NN O O

The NN O O
fifth NN O O
subject NN O O
was NN O O
found NN O O
to NN O O
possess NN O O
two NN O O
sequence NN O O
abnormalities NN O O
. NN O O

One NN O O
allele NN O O
carried NN O O
a NN O O
G NN O O
- NN O O
- NN O O
> NN O O
A NN O O
transition NN O O
near NN O O
the NN O O
donor NN O O
splice NN O O
junction NN O O
of NN O O
intron NN O O
2 NN O O
, NN O O
but NN O O
this NN O O
abnormality NN O O
is NN O O
probably NN O O
neutral NN O O
, NN O O
since NN O O
it NN O O
was NN O O
inherited NN O O
from NN O O
the NN O O
parent NN O O
with NN O O
normal NN O O
protein NN O O
S NN O O
antigen NN O O
levels NN O O
. NN O O

In NN O O
the NN O O
other NN O O
allele NN O O
a NN O O
single NN O O
T NN O O
insertion NN O O
in NN O O
codon NN O O
- NN O O
25 NN O O
was NN O O
found NN O O
. NN O O

Analysis NN O O
of NN O O
platelet NN O O
RNA NN O O
showed NN O O
that NN O O
only NN O O
the NN O O
mRNA NN O O
with NN O O
the NN O O
A NN O O
- NN O O
- NN O O
> NN O O
T NN O O
mutation NN O O
in NN O O
the NN O O
stopcodon NN O O
is NN O O
present NN O O
in NN O O
amounts NN O O
comparable NN O O
to NN O O
wildtype NN O O
RNA NN O O
. NN O O

mRNA NN O O
from NN O O
the NN O O
alleles NN O O
with NN O O
the NN O O
other NN O O
two NN O O
mutations NN O O
was NN O O
either NN O O
undetectable NN O O
or NN O O
present NN O O
in NN O O
greatly NN O O
reduced NN O O
amounts NN O O
. NN O O

The NN O O
latter NN O O
indicates NN O O
that NN O O
a NN O O
mRNA NN O O
based NN O O
approach NN O O
is NN O O
not NN O O
feasible NN O O
for NN O O
the NN O O
genetic NN O O
analysis NN O O
of NN O O
protein NN O B-Disease
S NN O I-Disease
deficiency NN O I-Disease
type NN O I-Disease
I NN O I-Disease
. NN O O
. NN O O

Characteristics NN O O
of NN O O
intergenerational NN O O
contractions NN O O
of NN O O
the NN O O
CTG NN O O
repeat NN O O
in NN O O
myotonic NN O B-Disease
dystrophy NN O I-Disease
. NN O O

In NN O O
myotonic NN O B-Disease
dystrophy NN O I-Disease
( NN O O
DM NN O B-Disease
) NN O O
, NN O O
the NN O O
size NN O O
of NN O O
a NN O O
CTG NN O O
repeat NN O O
in NN O O
the NN O O
DM NN O B-Disease
kinase NN O O
gene NN O O
generally NN O O
increases NN O O
in NN O O
successive NN O O
generations NN O O
with NN O O
clinical NN O O
evidence NN O O
of NN O O
anticipation NN O O
. NN O O

However NN O O
, NN O O
there NN O O
have NN O O
also NN O O
been NN O O
cases NN O O
with NN O O
an NN O O
intergenerational NN O O
contraction NN O O
of NN O O
the NN O O
repeat NN O O
. NN O O

We NN O O
examined NN O O
1 NN O O
, NN O O
489 NN O O
DM NN O B-Disease
parent NN O O
- NN O O
offspring NN O O
pairs NN O O
, NN O O
of NN O O
which NN O O
95 NN O O
( NN O O
6 NN O O
. NN O O
4 NN O O
% NN O O
) NN O O
showed NN O O
such NN O O
contractions NN O O
in NN O O
peripheral NN O O
blood NN O O
leukocytes NN O O
( NN O O
PBL NN O O
) NN O O
. NN O O

In NN O O
56 NN O O
of NN O O
the NN O O
95 NN O O
pairs NN O O
, NN O O
clinical NN O O
data NN O O
allowed NN O O
an NN O O
analysis NN O O
of NN O O
their NN O O
anticipation NN O O
status NN O O
. NN O O

It NN O O
is NN O O
surprising NN O O
that NN O O
anticipation NN O O
occurred NN O O
in NN O O
27 NN O O
( NN O O
48 NN O O
% NN O O
) NN O O
of NN O O
these NN O O
56 NN O O
pairs NN O O
, NN O O
while NN O O
none NN O O
clearly NN O O
showed NN O O
a NN O O
later NN O O
onset NN O O
of NN O O
DM NN O B-Disease
in NN O O
the NN O O
symptomatic NN O O
offspring NN O O
. NN O O

The NN O O
contraction NN O O
occurred NN O O
in NN O O
76 NN O O
( NN O O
10 NN O O
% NN O O
) NN O O
of NN O O
753 NN O O
paternal NN O O
transmissions NN O O
and NN O O
in NN O O
19 NN O O
( NN O O
3 NN O O
% NN O O
) NN O O
of NN O O
736 NN O O
maternal NN O O
transmissions NN O O
. NN O O

Anticipation NN O O
was NN O O
observed NN O O
more NN O O
frequently NN O O
in NN O O
maternal NN O O
( NN O O
85 NN O O
% NN O O
) NN O O
than NN O O
in NN O O
paternal NN O O
( NN O O
37 NN O O
% NN O O
) NN O O
transmissions NN O O
( NN O O
P NN O O
< NN O O
. NN O O
001 NN O O
) NN O O
. NN O O

The NN O O
parental NN O O
repeat NN O O
size NN O O
correlated NN O O
with NN O O
the NN O O
size NN O O
of NN O O
intergenerational NN O O
contraction NN O O
( NN O O
r2 NN O O
= NN O O
. NN O O
50 NN O O
, NN O O
P NN O O
< NN O O
< NN O O
. NN O O
001 NN O O
) NN O O
, NN O O
and NN O O
the NN O O
slope NN O O
of NN O O
linear NN O O
regression NN O O
was NN O O
steeper NN O O
in NN O O
paternal NN O O
( NN O O
- NN O O
. NN O O
62 NN O O
) NN O O
than NN O O
in NN O O
maternal NN O O
( NN O O
- NN O O
. NN O O
30 NN O O
) NN O O
transmissions NN O O
( NN O O
P NN O O
< NN O O
< NN O O
. NN O O
001 NN O O
) NN O O
. NN O O

Sixteen NN O O
DM NN O B-Disease
parents NN O O
had NN O O
multiple NN O O
DM NN O B-Disease
offspring NN O O
with NN O O
the NN O O
CTG NN O O
repeat NN O O
contractions NN O O
. NN O O

This NN O O
frequency NN O O
was NN O O
higher NN O O
than NN O O
the NN O O
frequency NN O O
expected NN O O
from NN O O
the NN O O
probability NN O O
of NN O O
the NN O O
repeat NN O O
contractions NN O O
( NN O O
6 NN O O
. NN O O
4 NN O O
% NN O O
) NN O O
and NN O O
the NN O O
size NN O O
of NN O O
DM NN O B-Disease
sib NN O O
population NN O O
( NN O O
1 NN O O
. NN O O
54 NN O O
DM NN O B-Disease
offspring NN O O
per NN O O
DM NN O B-Disease
parent NN O O
, NN O O
in NN O O
968 NN O O
DM NN O B-Disease
parents NN O O
) NN O O
. NN O O

We NN O O
conclude NN O O
that NN O O
( NN O O
1 NN O O
) NN O O
intergenerational NN O O
contractions NN O O
of NN O O
the NN O O
CTG NN O O
repeat NN O O
in NN O O
leukocyte NN O O
DNA NN O O
frequently NN O O
accompanies NN O O
apparent NN O O
anticipation NN O O
, NN O O
especially NN O O
when NN O O
DM NN O B-Disease
is NN O O
maternally NN O O
transmitted NN O O
, NN O O
and NN O O
( NN O O
2 NN O O
) NN O O
the NN O O
paternal NN O O
origin NN O O
of NN O O
the NN O O
repeat NN O O
and NN O O
the NN O O
presence NN O O
of NN O O
the NN O O
repeat NN O O
contraction NN O O
in NN O O
a NN O O
sibling NN O O
increase NN O O
the NN O O
probability NN O O
of NN O O
the NN O O
CTG NN O O
repeat NN O O
contraction NN O O

Gonosomal NN O O
mosaicism NN O O
in NN O O
myotonic NN O B-Disease
dystrophy NN O I-Disease
patients NN O O
: NN O O
involvement NN O O
of NN O O
mitotic NN O O
events NN O O
in NN O O
( NN O O
CTG NN O O
) NN O O
n NN O O
repeat NN O O
variation NN O O
and NN O O
selection NN O O
against NN O O
extreme NN O O
expansion NN O O
in NN O O
sperm NN O O
. NN O O

Myotonic NN O B-Disease
dystrophy NN O I-Disease
( NN O O
DM NN O B-Disease
) NN O O
is NN O O
caused NN O O
by NN O O
abnormal NN O O
expansion NN O O
of NN O O
a NN O O
polymorphic NN O O
( NN O O
CTG NN O O
) NN O O
n NN O O
repeat NN O O
, NN O O
located NN O O
in NN O O
the NN O O
DM NN O B-Disease
protein NN O O
kinase NN O O
gene NN O O
. NN O O

We NN O O
determined NN O O
the NN O O
( NN O O
CTG NN O O
) NN O O
n NN O O
repeat NN O O
lengths NN O O
in NN O O
a NN O O
broad NN O O
range NN O O
of NN O O
tissue NN O O
DNAs NN O O
from NN O O
patients NN O O
with NN O O
mild NN O O
, NN O O
classical NN O O
, NN O O
or NN O O
congenital NN O O
manifestation NN O O
of NN O O
DM NN O B-Disease
. NN O O

Differences NN O O
in NN O O
the NN O O
repeat NN O O
length NN O O
were NN O O
seen NN O O
in NN O O
somatic NN O O
tissues NN O O
from NN O O
single NN O O
DM NN O B-Disease
individuals NN O O
and NN O O
twins NN O O
. NN O O

Repeats NN O O
appeared NN O O
to NN O O
expand NN O O
to NN O O
a NN O O
similar NN O O
extent NN O O
in NN O O
tissues NN O O
originating NN O O
from NN O O
the NN O O
same NN O O
embryonal NN O O
origin NN O O
. NN O O

In NN O O
most NN O O
male NN O O
patients NN O O
carrying NN O O
intermediate NN O O
- NN O O
or NN O O
small NN O O
- NN O O
sized NN O O
expansions NN O O
in NN O O
blood NN O O
, NN O O
the NN O O
repeat NN O O
lengths NN O O
covered NN O O
a NN O O
markedly NN O O
wider NN O O
range NN O O
in NN O O
sperm NN O O
. NN O O

In NN O O
contrast NN O O
, NN O O
male NN O O
patients NN O O
with NN O O
large NN O O
allele NN O O
expansions NN O O
in NN O O
blood NN O O
( NN O O
> NN O O
700 NN O O
CTGs NN O O
) NN O O
had NN O O
similar NN O O
or NN O O
smaller NN O O
repeats NN O O
in NN O O
sperm NN O O
, NN O O
when NN O O
detectable NN O O
. NN O O

Sperm NN O O
alleles NN O O
with NN O O
> NN O O
1 NN O O
, NN O O
000 NN O O
CTGs NN O O
were NN O O
not NN O O
seen NN O O
. NN O O

We NN O O
conclude NN O O
that NN O O
DM NN O B-Disease
patients NN O O
can NN O O
be NN O O
considered NN O O
gonosomal NN O O
mosaics NN O O
, NN O O
i NN O O
. NN O O

e NN O O
e NN O O
. NN O O
, NN O O
combined NN O O
somatic NN O O
and NN O O
germ NN O O
- NN O O
line NN O O
tissue NN O O
mosaics NN O O
. NN O O

Most NN O O
remarkably NN O O
, NN O O
we NN O O
observed NN O O
multiple NN O O
cases NN O O
where NN O O
the NN O O
length NN O O
distributions NN O O
of NN O O
intermediate NN O O
- NN O O
or NN O O
small NN O O
- NN O O
sized NN O O
alleles NN O O
in NN O O
fathers NN O O
sperm NN O O
were NN O O
significantly NN O O
different NN O O
from NN O O
that NN O O
in NN O O
their NN O O
offsprings NN O O
blood NN O O
. NN O O

Our NN O O
combined NN O O
findings NN O O
indicate NN O O
that NN O O
intergenerational NN O O
length NN O O
changes NN O O
in NN O O
the NN O O
unstable NN O O
CTG NN O O
repeat NN O O
are NN O O
most NN O O
likely NN O O
to NN O O
occur NN O O
during NN O O
early NN O O
embryonic NN O O
mitotic NN O O
divisions NN O O
in NN O O
both NN O O
somatic NN O O
and NN O O
germ NN O O
- NN O O
line NN O O
tissue NN O O
formation NN O O
. NN O O

Both NN O O
the NN O O
initial NN O O
CTG NN O O
length NN O O
, NN O O
the NN O O
overall NN O O
number NN O O
of NN O O
cell NN O O
divisions NN O O
involved NN O O
in NN O O
tissue NN O O
formation NN O O
, NN O O
and NN O O
perhaps NN O O
a NN O O
specific NN O O
selection NN O O
process NN O O
in NN O O
spermatogenesis NN O O
may NN O O
influence NN O O
the NN O O
dynamics NN O O
of NN O O
this NN O O
process NN O O
. NN O O

A NN O O
model NN O O
explaining NN O O
mitotic NN O O
instability NN O O
and NN O O
sex NN O O
- NN O O
dependent NN O O
segregation NN O O
phenomena NN O O
in NN O O
DM NN O B-Disease
manifestation NN O O
is NN O O
discussed NN O O

Regionally NN O O
clustered NN O O
APC NN O B-Disease
mutations NN O O
are NN O O
associated NN O O
with NN O O
a NN O O
severe NN O O
phenotype NN O O
and NN O O
occur NN O O
at NN O O
a NN O O
high NN O O
frequency NN O O
in NN O O
new NN O O
mutation NN O O
cases NN O O
of NN O O
adenomatous NN O B-Disease
polyposis NN O I-Disease
coli NN O I-Disease
. NN O O

Germline NN O O
mutation NN O O
in NN O O
APC NN O O
at NN O O
5q21 NN O O
- NN O O
22 NN O O
results NN O O
in NN O O
the NN O O
dominantly NN O O
inherited NN O O
syndrome NN O O
adenomatous NN O B-Disease
polyposis NN O I-Disease
coli NN O I-Disease
( NN O O
APC NN O B-Disease
) NN O O
. NN O O

Somatic NN O O
mutation NN O O
in NN O O
this NN O O
gene NN O O
is NN O O
an NN O O
early NN O O
event NN O O
in NN O O
colorectal NN O O
tumourigenesis NN O O
. NN O O

Both NN O O
types NN O O
of NN O O
mutation NN O O
are NN O O
concentrated NN O O
in NN O O
the NN O O
5 NN O O
half NN O O
of NN O O
exon NN O O
15 NN O O
. NN O O

We NN O O
have NN O O
used NN O O
single NN O O
strand NN O O
conformational NN O O
polymorphism NN O O
( NN O O
SSCP NN O O
) NN O O
and NN O O
heteroduplex NN O O
analysis NN O O
to NN O O
screen NN O O
for NN O O
variants NN O O
in NN O O
this NN O O
region NN O O
of NN O O
the NN O O
gene NN O O
in NN O O
a NN O O
total NN O O
of NN O O
45 NN O O
affected NN O O
but NN O O
unrelated NN O O
individuals NN O O
. NN O O

Eighteen NN O O
patients NN O O
had NN O O
no NN O O
family NN O O
history NN O O
of NN O O
the NN O O
disease NN O O
; NN O O
of NN O O
these NN O O
11 NN O O
were NN O O
classified NN O O
as NN O O
having NN O O
a NN O O
severe NN O O
phenotype NN O O
, NN O O
based NN O O
on NN O O
an NN O O
early NN O O
age NN O O
at NN O O
presentation NN O O
or NN O O
cancer NN O B-Disease
development NN O O
. NN O O

This NN O O
compared NN O O
with NN O O
6 NN O O
of NN O O
27 NN O O
familial NN O O
cases NN O O
. NN O O

A NN O O
5 NN O O
bp NN O O
deletion NN O O
at NN O O
codon NN O O
1309 NN O O
reported NN O O
to NN O O
occur NN O O
in NN O O
10 NN O O
- NN O O
15 NN O O
% NN O O
of NN O O
unselected NN O O
APC NN O B-Disease
patients NN O O
worldwide NN O O
, NN O O
was NN O O
found NN O O
in NN O O
5 NN O O
of NN O O
the NN O O
18 NN O O
new NN O O
mutation NN O O
cases NN O O
and NN O O
4 NN O O
of NN O O
the NN O O
27 NN O O
familial NN O O
cases NN O O
all NN O O
nine NN O O
were NN O O
classed NN O O
as NN O O
severe NN O O
. NN O O

A NN O O
further NN O O
3 NN O O
new NN O O
mutations NN O O
and NN O O
1 NN O O
familial NN O O
mutation NN O O
were NN O O
located NN O O
downstream NN O O
from NN O O
codon NN O O
1309 NN O O
, NN O O
these NN O O
individuals NN O O
similarly NN O O
being NN O O
classed NN O O
as NN O O
phenotypically NN O O
severe NN O O
. NN O O

In NN O O
contrast NN O O
all NN O O
of NN O O
the NN O O
APC NN O B-Disease
mutations NN O O
detected NN O O
in NN O O
affected NN O O
individuals NN O O
with NN O O
an NN O O
average NN O O
phenotype NN O O
were NN O O
located NN O O
prior NN O O
to NN O O
codon NN O O
1309 NN O O
. NN O O

The NN O O
frequent NN O O
association NN O O
of NN O O
a NN O O
severe NN O O
phenotype NN O O
with NN O O
fresh NN O O
mutation NN O O
may NN O O
explain NN O O
the NN O O
apparent NN O O
conflict NN O O
of NN O O
a NN O O
high NN O O
mutation NN O O
rate NN O O
( NN O O
20 NN O O
- NN O O
30 NN O O
% NN O O
) NN O O
in NN O O
a NN O O
condition NN O O
, NN O O
which NN O O
on NN O O
average NN O O
, NN O O
is NN O O
lethal NN O O
at NN O O
a NN O O
post NN O O
- NN O O
reproductive NN O O
age NN O O
. NN O O
. NN O O

Mutations NN O O
at NN O O
the NN O O
PAX6 NN O O
locus NN O O
are NN O O
found NN O O
in NN O O
heterogeneous NN O O
anterior NN O B-Disease
segment NN O I-Disease
malformations NN O I-Disease
including NN O O
Peters NN O B-Disease
' NN O I-Disease
anomaly NN O I-Disease
. NN O O

Mutation NN O O
or NN O O
deletion NN O O
of NN O O
the NN O O
PAX6 NN O O
gene NN O O
underlies NN O O
many NN O O
cases NN O O
of NN O O
aniridia NN O B-Disease
. NN O O

Three NN O O
lines NN O O
of NN O O
evidence NN O O
now NN O O
converge NN O O
to NN O O
implicate NN O O
PAX6 NN O O
more NN O O
widely NN O O
in NN O O
anterior NN O B-Disease
segment NN O I-Disease
malformations NN O I-Disease
including NN O O
Peters NN O B-Disease
anomaly NN O I-Disease
. NN O O

First NN O O
, NN O O
a NN O O
child NN O O
with NN O O
Peters NN O B-Disease
anomaly NN O I-Disease
is NN O O
deleted NN O O
for NN O O
one NN O O
copy NN O O
of NN O O
PAX6 NN O O
. NN O O

Second NN O O
, NN O O
affected NN O O
members NN O O
of NN O O
a NN O O
family NN O O
with NN O O
dominantly NN O O
inherited NN O O
anterior NN O B-Disease
segment NN O I-Disease
malformations NN O I-Disease
, NN O O
including NN O O
Peters NN O B-Disease
anomaly NN O I-Disease
are NN O O
heterozygous NN O O
for NN O O
an NN O O
R26G NN O O
mutation NN O O
in NN O O
the NN O O
PAX6 NN O O
paired NN O O
box NN O O
. NN O O

Third NN O O
, NN O O
a NN O O
proportion NN O O
of NN O O
Sey NN O O
/ NN O O
+ NN O O
Smalleye NN O O
mice NN O O
, NN O O
heterozygous NN O O
for NN O O
a NN O O
nonsense NN O O
mutation NN O O
in NN O O
murine NN O O
Pax NN O O
- NN O O
6 NN O O
, NN O O
have NN O O
an NN O O
ocular NN O O
phenotype NN O O
resembling NN O O
Peters NN O B-Disease
anomaly NN O I-Disease
. NN O O

We NN O O
therefore NN O O
propose NN O O
that NN O O
a NN O O
variety NN O O
of NN O O
anterior NN O B-Disease
segment NN O I-Disease
anomalies NN O I-Disease
may NN O O
be NN O O
associated NN O O
with NN O O
PAX6 NN O O
mutations NN O O
. NN O O
. NN O O

Huntington NN O B-Disease
disease NN O I-Disease
without NN O O
CAG NN O O
expansion NN O O
: NN O O
phenocopies NN O O
or NN O O
errors NN O O
in NN O O
assignment NN O O
? NN O O

Huntington NN O B-Disease
disease NN O I-Disease
( NN O O
HD NN O B-Disease
) NN O O
has NN O O
been NN O O
shown NN O O
to NN O O
be NN O O
associated NN O O
with NN O O
an NN O O
expanded NN O O
CAG NN O O
repeat NN O O
within NN O O
a NN O O
novel NN O O
gene NN O O
on NN O O
4p16 NN O O
. NN O O

3 NN O O
( NN O O
IT15 NN O O
) NN O O
. NN O O

A NN O O
total NN O O
of NN O O
30 NN O O
of NN O O
1 NN O O
, NN O O
022 NN O O
affected NN O O
persons NN O O
( NN O O
2 NN O O
. NN O O
9 NN O O
% NN O O
of NN O O
our NN O O
cohort NN O O
) NN O O
did NN O O
not NN O O
have NN O O
an NN O O
expanded NN O O
CAG NN O O
in NN O O
the NN O O
disease NN O O
range NN O O
. NN O O

The NN O O
reasons NN O O
for NN O O
not NN O O
observing NN O O
expansion NN O O
in NN O O
affected NN O O
individuals NN O O
are NN O O
important NN O O
for NN O O
determining NN O O
the NN O O
sensitivity NN O O
of NN O O
using NN O O
repeat NN O O
length NN O O
both NN O O
for NN O O
diagnosis NN O O
of NN O O
affected NN O O
patients NN O O
and NN O O
for NN O O
predictive NN O O
testing NN O O
programs NN O O
and NN O O
may NN O O
have NN O O
biological NN O O
relevance NN O O
for NN O O
the NN O O
understanding NN O O
of NN O O
the NN O O
molecular NN O O
mechanism NN O O
underlying NN O O
HD NN O B-Disease
. NN O O

Here NN O O
we NN O O
show NN O O
that NN O O
the NN O O
majority NN O O
( NN O O
18 NN O O
) NN O O
of NN O O
the NN O O
individuals NN O O
with NN O O
normal NN O O
sized NN O O
alleles NN O O
represent NN O O
misdiagnosis NN O O
, NN O O
sample NN O O
mix NN O O
- NN O O
up NN O O
, NN O O
or NN O O
clerical NN O O
error NN O O
. NN O O

The NN O O
remaining NN O O
12 NN O O
patients NN O O
represent NN O O
possible NN O O
phenocopies NN O O
for NN O O
HD NN O B-Disease
. NN O O

In NN O O
at NN O O
least NN O O
four NN O O
cases NN O O
, NN O O
family NN O O
studies NN O O
of NN O O
these NN O O
phenocopies NN O O
excluded NN O O
4p16 NN O O
. NN O O

3 NN O O
as NN O O
the NN O O
region NN O O
responsible NN O O
for NN O O
the NN O O
phenotype NN O O
. NN O O

Mutations NN O O
in NN O O
the NN O O
HD NN O B-Disease
gene NN O O
that NN O O
are NN O O
other NN O O
than NN O O
CAG NN O O
expansion NN O O
have NN O O
not NN O O
been NN O O
excluded NN O O
for NN O O
the NN O O
remaining NN O O
eight NN O O
cases NN O O
; NN O O
however NN O O
, NN O O
in NN O O
as NN O O
many NN O O
as NN O O
seven NN O O
of NN O O
these NN O O
persons NN O O
, NN O O
retrospective NN O O
review NN O O
of NN O O
these NN O O
patients NN O O
clinical NN O O
features NN O O
identified NN O O
characteristics NN O O
not NN O O
typical NN O O
for NN O O
HD NN O B-Disease
. NN O O

This NN O O
study NN O O
shows NN O O
that NN O O
on NN O O
rare NN O O
occasions NN O O
mutations NN O O
in NN O O
other NN O O
, NN O O
as NN O O
- NN O O
yet NN O O
- NN O O
undefined NN O O
genes NN O O
can NN O O
present NN O O
with NN O O
a NN O O
clinical NN O O
phenotype NN O O
very NN O O
similar NN O O
to NN O O
that NN O O
of NN O O
HD NN O B-Disease

Frequent NN O O
detection NN O O
of NN O O
codon NN O O
877 NN O O
mutation NN O O
in NN O O
the NN O O
androgen NN O O
receptor NN O O
gene NN O O
in NN O O
advanced NN O B-Disease
prostate NN O I-Disease
cancers NN O I-Disease
. NN O O

Prostatic NN O O
tissue NN O O
specimens NN O O
derived NN O O
from NN O O
transurethral NN O O
resections NN O O
of NN O O
patients NN O O
with NN O O
metastatic NN O B-Disease
prostate NN O I-Disease
cancer NN O I-Disease
were NN O O
analyzed NN O O
for NN O O
genetic NN O O
alterations NN O O
in NN O O
the NN O O
hormone NN O O
- NN O O
binding NN O O
domain NN O O
of NN O O
the NN O O
androgen NN O O
receptor NN O O
( NN O O
AR NN O O
) NN O O
gene NN O O
. NN O O

Direct NN O O
sequencing NN O O
of NN O O
the NN O O
polymerase NN O O
chain NN O O
reaction NN O O
- NN O O
derived NN O O
DNAs NN O O
of NN O O
6 NN O O
of NN O O
24 NN O O
specimens NN O O
revealed NN O O
a NN O O
codon NN O O
877 NN O O
mutation NN O O
( NN O O
ACT NN O O
- NN O O
- NN O O
> NN O O
GCT NN O O
, NN O O
Thr NN O O
- NN O O
- NN O O
> NN O O
Ala NN O O
) NN O O
in NN O O
the NN O O
hormone NN O O
- NN O O
binding NN O O
domain NN O O
of NN O O
the NN O O
AR NN O O
gene NN O O
. NN O O

This NN O O
same NN O O
AR NN O O
mutation NN O O
has NN O O
been NN O O
reported NN O O
previously NN O O
in NN O O
a NN O O
metastatic NN O B-Disease
prostate NN O I-Disease
cancer NN O I-Disease
cell NN O O
line NN O O
, NN O O
LNCaP NN O O
, NN O O
where NN O O
this NN O O
mutation NN O O
confers NN O O
upon NN O O
the NN O O
AR NN O O
an NN O O
altered NN O O
ligand NN O O
- NN O O
binding NN O O
specificity NN O O
which NN O O
is NN O O
stimulated NN O O
by NN O O
estrogens NN O O
, NN O O
progestagens NN O O
, NN O O
and NN O O
antiandrogens NN O O
. NN O O

It NN O O
is NN O O
possible NN O O
that NN O O
analogous NN O O
to NN O O
an NN O O
activated NN O O
/ NN O O
altered NN O O
growth NN O O
factor NN O O
receptor NN O O
oncogene NN O O
, NN O O
codon NN O O
877 NN O O
mutant NN O O
AR NN O O
with NN O O
altered NN O O
ligand NN O O
binding NN O O
may NN O O
provide NN O O
a NN O O
selective NN O O
growth NN O O
advantage NN O O
in NN O O
the NN O O
genesis NN O O
of NN O O
a NN O O
subset NN O O
of NN O O
advanced NN O B-Disease
prostate NN O I-Disease
cancer NN O I-Disease
. NN O O

Although NN O O
estrogens NN O O
are NN O O
used NN O O
infrequently NN O O
, NN O O
antiandrogens NN O O
are NN O O
used NN O O
increasingly NN O O
in NN O O
hormonal NN O O
therapy NN O O
for NN O O
patients NN O O
with NN O O
advanced NN O B-Disease
prostate NN O I-Disease
cancer NN O I-Disease
. NN O O

The NN O O
stimulatory NN O O
effect NN O O
of NN O O
these NN O O
therapeutic NN O O
agents NN O O
on NN O O
the NN O O
codon NN O O
877 NN O O
mutant NN O O
AR NN O O
further NN O O
suggests NN O O
that NN O O
this NN O O
frequently NN O O
observed NN O O
AR NN O O
mutation NN O O
may NN O O
contribute NN O O
to NN O O
the NN O O
treatment NN O O
refractory NN O O
disease NN O O
. NN O O
. NN O O

The NN O O
human NN O O
gene NN O O
for NN O O
alkaptonuria NN O B-Disease
( NN O O
AKU NN O B-Disease
) NN O O
maps NN O O
to NN O O
chromosome NN O O
3q NN O O
. NN O O

Alkaptonuria NN O B-Disease
( NN O O
AKU NN O B-Disease
; NN O O
McKusick NN O O
no NN O O
. NN O O
203500 NN O O
) NN O O
is NN O O
a NN O O
rare NN O O
autosomal NN O B-Disease
recessive NN O I-Disease
disorder NN O I-Disease
caused NN O O
by NN O O
the NN O O
lack NN O O
of NN O O
homogentisic NN O O
acid NN O O
oxidase NN O O
activity NN O O
. NN O O

Patients NN O O
excrete NN O O
large NN O O
amounts NN O O
of NN O O
homogentisic NN O O
acid NN O O
in NN O O
their NN O O
urine NN O O
and NN O O
a NN O O
black NN O O
ochronotic NN O O
pigment NN O O
is NN O O
deposited NN O O
in NN O O
their NN O O
cartilage NN O O
and NN O O
collagenous NN O O
tissues NN O O
. NN O O

Ochronosis NN O B-Disease
is NN O O
the NN O O
predominant NN O O
clinical NN O O
complication NN O O
of NN O O
the NN O O
disease NN O O
leading NN O O
to NN O O
ochronotic NN O B-Disease
arthropathy NN O I-Disease
, NN O O
dark NN O O
urine NN O O
, NN O O
pigment NN O O
changes NN O O
of NN O O
the NN O O
skin NN O O
, NN O O
and NN O O
other NN O O
clinical NN O O
features NN O O
. NN O O

A NN O O
mutation NN O O
causing NN O O
alkaptonuria NN O B-Disease
in NN O O
the NN O O
mouse NN O O
has NN O O
mapped NN O O
to NN O O
chromosome NN O O
16 NN O O
. NN O O

Considering NN O O
conserved NN O O
synteny NN O O
, NN O O
we NN O O
were NN O O
able NN O O
to NN O O
map NN O O
the NN O O
human NN O O
gene NN O O
to NN O O
chromosome NN O O
3q NN O O
in NN O O
six NN O O
alkaptonuria NN O B-Disease
pedigrees NN O O
of NN O O
Slovak NN O O
origin NN O O
. NN O O
. NN O O

Structure NN O O
of NN O O
the NN O O
human NN O O
Na NN O O
+ NN O O
/ NN O O
glucose NN O O
cotransporter NN O O
gene NN O O
SGLT1 NN O O
. NN O O

Intestinal NN O O
uptake NN O O
of NN O O
dietary NN O O
glucose NN O O
and NN O O
galactose NN O O
is NN O O
mediated NN O O
by NN O O
the NN O O
SGLT1 NN O O
Na NN O O
+ NN O O
/ NN O O
glucose NN O O
cotransporter NN O O
of NN O O
the NN O O
brush NN O O
border NN O O
. NN O O

An NN O O
SGLT1 NN O O
missense NN O O
mutation NN O O
underlies NN O O
hereditary NN O B-Disease
glucose NN O I-Disease
/ NN O I-Disease
galactose NN O I-Disease
malabsorption NN O I-Disease
, NN O O
characterized NN O O
by NN O O
potentially NN O O
fatal NN O O
diarrhea NN O B-Disease
; NN O O
conversely NN O O
, NN O O
oral NN O O
rehydration NN O O
therapy NN O O
exploits NN O O
normal NN O O
transport NN O O
to NN O O
alleviate NN O O
life NN O O
- NN O O
threatening NN O O
diarrhea NN O B-Disease
of NN O O
infectious NN O O
origin NN O O
. NN O O

We NN O O
have NN O O
mapped NN O O
the NN O O
entire NN O O
human NN O O
SGLT1 NN O O
Na NN O O
+ NN O O
/ NN O O
glucose NN O O
cotransporter NN O O
gene NN O O
from NN O O
cosmid NN O O
and NN O O
lambda NN O O
phage NN O O
clones NN O O
representing NN O O
a NN O O
genomic NN O O
region NN O O
of NN O O
112 NN O O
kilobases NN O O
. NN O O

Transcription NN O O
initiation NN O O
occurred NN O O
from NN O O
a NN O O
site NN O O
27 NN O O
base NN O O
pairs NN O O
3 NN O O
of NN O O
a NN O O
TATAA NN O O
sequence NN O O
. NN O O

All NN O O
exon NN O O
- NN O O
flanking NN O O
regions NN O O
were NN O O
sequenced NN O O
, NN O O
and NN O O
the NN O O
entire NN O O
112 NN O O
- NN O O
kilobase NN O O
region NN O O
mapped NN O O
with NN O O
four NN O O
restriction NN O O
enzymes NN O O
. NN O O

SGLT1 NN O O
is NN O O
comprised NN O O
of NN O O
15 NN O O
exons NN O O
( NN O O
spanning NN O O
72 NN O O
kilobases NN O O
) NN O O
; NN O O
a NN O O
possible NN O O
evolutionary NN O O
origin NN O O
from NN O O
a NN O O
six NN O O
- NN O O
membrane NN O O
- NN O O
span NN O O
ancestral NN O O
precursor NN O O
via NN O O
a NN O O
gene NN O O
duplication NN O O
event NN O O
is NN O O
suggested NN O O
from NN O O
comparison NN O O
of NN O O
exons NN O O
against NN O O
protein NN O O
secondary NN O O
structure NN O O
and NN O O
from NN O O
sequence NN O O
considerations NN O O
. NN O O

A NN O O
new NN O O
missense NN O O
mutation NN O O
in NN O O
exon NN O O
1 NN O O
causing NN O O
glucose NN O B-Disease
/ NN O I-Disease
galactose NN O I-Disease
malabsorption NN O I-Disease
is NN O O
also NN O O
described NN O O
. NN O O

This NN O O
is NN O O
the NN O O
first NN O O
Na NN O O
( NN O O
+ NN O O
) NN O O
- NN O O
dependent NN O O
cotransporter NN O O
gene NN O O
structure NN O O
reported NN O O
. NN O O

These NN O O
data NN O O
facilitate NN O O
the NN O O
search NN O O
for NN O O
new NN O O
glucose NN O B-Disease
/ NN O I-Disease
galactose NN O I-Disease
malabsorption NN O I-Disease
- NN O O
related NN O O
mutations NN O O
in NN O O
this NN O O
important NN O O
gene NN O O
and NN O O
provide NN O O
a NN O O
basis NN O O
for NN O O
future NN O O
evolutionary NN O O
comparisons NN O O
with NN O O
other NN O O
Na NN O O
( NN O O
+ NN O O
) NN O O
- NN O O
dependent NN O O
cotransporters NN O O
. NN O O
. NN O O

Four NN O O
novel NN O O
PEPD NN O O
alleles NN O O
causing NN O O
prolidase NN O B-Disease
deficiency NN O I-Disease
. NN O O

Mutations NN O O
at NN O O
the NN O O
PEPD NN O O
locus NN O O
cause NN O O
prolidase NN O B-Disease
deficiency NN O I-Disease
( NN O O
McKusick NN O O
170100 NN O O
) NN O O
, NN O O
a NN O O
rare NN O O
autosomal NN O B-Disease
recessive NN O I-Disease
disorder NN O I-Disease
characterized NN O O
by NN O O
iminodipeptiduria NN O B-Disease
, NN O O
skin NN O B-Disease
ulcers NN O I-Disease
, NN O O
mental NN O B-Disease
retardation NN O I-Disease
, NN O O
and NN O O
recurrent NN O O
infections NN O O
. NN O O

Four NN O O
PEPD NN O O
mutations NN O O
from NN O O
five NN O O
severely NN O O
affected NN O O
individuals NN O O
were NN O O
characterized NN O O
by NN O O
analysis NN O O
of NN O O
reverse NN O O
- NN O O
transcribed NN O O
, NN O O
PCR NN O O
- NN O O
amplified NN O O
( NN O O
RT NN O O
- NN O O
PCR NN O O
) NN O O
cDNA NN O O
. NN O O

We NN O O
used NN O O
SSCP NN O O
analysis NN O O
on NN O O
four NN O O
overlapping NN O O
cDNA NN O O
fragments NN O O
covering NN O O
the NN O O
entire NN O O
coding NN O O
region NN O O
of NN O O
the NN O O
PEPD NN O O
gene NN O O
and NN O O
detected NN O O
abnormal NN O O
SSCP NN O O
bands NN O O
for NN O O
the NN O O
fragment NN O O
spanning NN O O
all NN O O
or NN O O
part NN O O
of NN O O
exons NN O O
13 NN O O
- NN O O
15 NN O O
in NN O O
three NN O O
of NN O O
the NN O O
probands NN O O
. NN O O

Direct NN O O
sequencing NN O O
of NN O O
the NN O O
mutant NN O O
cDNAs NN O O
showed NN O O
a NN O O
G NN O O
- NN O O
- NN O O
> NN O O
A NN O O
, NN O O
1342 NN O O
substitution NN O O
( NN O O
G448R NN O O
) NN O O
in NN O O
two NN O O
patients NN O O
and NN O O
a NN O O
3 NN O O
- NN O O
bp NN O O
deletion NN O O
( NN O O
delta NN O O
E452 NN O O
or NN O O
delta NN O O
E453 NN O O
) NN O O
in NN O O
another NN O O
. NN O O

In NN O O
the NN O O
other NN O O
two NN O O
probands NN O O
the NN O O
amplified NN O O
products NN O O
were NN O O
of NN O O
reduced NN O O
size NN O O
. NN O O

Direct NN O O
sequencing NN O O
of NN O O
these NN O O
mutant NN O O
cDNAs NN O O
revealed NN O O
a NN O O
deletion NN O O
of NN O O
exon NN O O
5 NN O O
in NN O O
one NN O O
patient NN O O
and NN O O
of NN O O
exon NN O O
7 NN O O
in NN O O
the NN O O
other NN O O
. NN O O

Intronic NN O O
sequences NN O O
flanking NN O O
exons NN O O
5 NN O O
and NN O O
7 NN O O
were NN O O
identified NN O O
using NN O O
inverse NN O O
PCR NN O O
followed NN O O
by NN O O
direct NN O O
sequencing NN O O
. NN O O

Conventional NN O O
PCR NN O O
and NN O O
direct NN O O
sequencing NN O O
then NN O O
established NN O O
the NN O O
intron NN O O
- NN O O
exon NN O O
borders NN O O
of NN O O
the NN O O
mutant NN O O
genomic NN O O
DNA NN O O
revealing NN O O
two NN O O
splice NN O O
acceptor NN O O
mutations NN O O
a NN O O
G NN O O
- NN O O
- NN O O
> NN O O
C NN O O
substitution NN O O
at NN O O
position NN O O
- NN O O
1 NN O O
of NN O O
intron NN O O
4 NN O O
and NN O O
an NN O O
A NN O O
- NN O O
- NN O O
> NN O O
G NN O O
substitution NN O O
at NN O O
position NN O O
- NN O O
2 NN O O
of NN O O
intron NN O O
6 NN O O
. NN O O

Our NN O O
results NN O O
indicate NN O O
that NN O O
the NN O O
severe NN O O
form NN O O
of NN O O
prolidase NN O B-Disease
deficiency NN O I-Disease
is NN O O
caused NN O O
by NN O O
multiple NN O O
PEPD NN O O
alleles NN O O
. NN O O

In NN O O
this NN O O
report NN O O
we NN O O
attempt NN O O
to NN O O
begin NN O O
the NN O O
process NN O O
of NN O O
describing NN O O
these NN O O
alleles NN O O
and NN O O
cataloging NN O O
their NN O O
phenotypic NN O O
expression NN O O
. NN O O
. NN O O

Recombinations NN O O
in NN O O
individuals NN O O
homozygous NN O O
by NN O O
descent NN O O
localize NN O O
the NN O O
Friedreich NN O B-Disease
ataxia NN O I-Disease
locus NN O O
in NN O O
a NN O O
cloned NN O O
450 NN O O
- NN O O
kb NN O O
interval NN O O
. NN O O

The NN O O
locus NN O O
for NN O O
Friedreich NN O B-Disease
ataxia NN O I-Disease
( NN O O
FRDA NN O B-Disease
) NN O O
, NN O O
a NN O O
severe NN O O
neurodegenerative NN O B-Disease
disease NN O I-Disease
, NN O O
is NN O O
tightly NN O O
linked NN O O
to NN O O
markers NN O O
D9S5 NN O O
and NN O O
D9S15 NN O O
, NN O O
and NN O O
analysis NN O O
of NN O O
rare NN O O
recombination NN O O
events NN O O
has NN O O
suggested NN O O
the NN O O
order NN O O
cen NN O O
- NN O O
FRDA NN O O
- NN O O
D9S5 NN O O
- NN O O
D9S15 NN O O
- NN O O
qter NN O O
. NN O O

We NN O O
report NN O O
here NN O O
the NN O O
construction NN O O
of NN O O
a NN O O
YAC NN O O
contig NN O O
extending NN O O
800 NN O O
kb NN O O
centromeric NN O O
to NN O O
D9S5 NN O O
and NN O O
the NN O O
isolation NN O O
of NN O O
five NN O O
new NN O O
microsatellite NN O O
markers NN O O
from NN O O
this NN O O
region NN O O
. NN O O

In NN O O
order NN O O
to NN O O
map NN O O
these NN O O
markers NN O O
with NN O O
respect NN O O
to NN O O
the NN O O
FRDA NN O B-Disease
locus NN O O
, NN O O
all NN O O
within NN O O
a NN O O
1 NN O O
- NN O O
cM NN O O
confidence NN O O
interval NN O O
, NN O O
we NN O O
sought NN O O
to NN O O
increase NN O O
the NN O O
genetic NN O O
information NN O O
of NN O O
available NN O O
FRDA NN O B-Disease
families NN O O
by NN O O
considering NN O O
homozygosity NN O O
by NN O O
descent NN O O
and NN O O
association NN O O
with NN O O
founder NN O O
haplotypes NN O O
in NN O O
isolated NN O O
populations NN O O
. NN O O

This NN O O
approach NN O O
allowed NN O O
us NN O O
to NN O O
identify NN O O
one NN O O
phase NN O O
- NN O O
known NN O O
recombination NN O O
and NN O O
one NN O O
probable NN O O
historic NN O O
recombination NN O O
on NN O O
haplotypes NN O O
from NN O O
Reunion NN O O
Island NN O O
patients NN O O
, NN O O
both NN O O
of NN O O
which NN O O
place NN O O
three NN O O
of NN O O
the NN O O
five NN O O
markers NN O O
proximal NN O O
to NN O O
FRDA NN O B-Disease
. NN O O

This NN O O
represents NN O O
the NN O O
first NN O O
identification NN O O
of NN O O
close NN O O
FRDA NN O B-Disease
flanking NN O O
markers NN O O
on NN O O
the NN O O
centromeric NN O O
side NN O O
. NN O O

The NN O O
two NN O O
other NN O O
markers NN O O
allowed NN O O
us NN O O
to NN O O
narrow NN O O
the NN O O
breakpoint NN O O
of NN O O
a NN O O
previously NN O O
identified NN O O
distal NN O O
recombination NN O O
that NN O O
is NN O O
> NN O O
180 NN O O
kb NN O O
from NN O O
D9S5 NN O O
( NN O O
26P NN O O
) NN O O
. NN O O

Taken NN O O
together NN O O
, NN O O
the NN O O
results NN O O
place NN O O
the NN O O
FRDA NN O B-Disease
locus NN O O
in NN O O
a NN O O
450 NN O O
- NN O O
kb NN O O
interval NN O O
, NN O O
which NN O O
is NN O O
small NN O O
enough NN O O
for NN O O
direct NN O O
search NN O O
of NN O O
candidate NN O O
genes NN O O
. NN O O

A NN O O
detailed NN O O
rare NN O O
cutter NN O O
restriction NN O O
map NN O O
and NN O O
a NN O O
cosmid NN O O
contig NN O O
covering NN O O
this NN O O
interval NN O O
were NN O O
constructed NN O O
and NN O O
should NN O O
facilitate NN O O
the NN O O
search NN O O
of NN O O
genes NN O O
in NN O O
this NN O O
region NN O O
. NN O O
. NN O O

Investigation NN O O
of NN O O
thermoregulatory NN O O
characteristics NN O O
in NN O O
patients NN O O
with NN O O
Prader NN O B-Disease
- NN O I-Disease
Willi NN O I-Disease
syndrome NN O I-Disease
. NN O O

A NN O O
survey NN O O
instrument NN O O
is NN O O
used NN O O
to NN O O
assess NN O O
temperature NN O O
regulation NN O O
characteristics NN O O
in NN O O
children NN O O
with NN O O
Prader NN O B-Disease
- NN O I-Disease
Willi NN O I-Disease
syndrome NN O I-Disease
( NN O O
PWS NN O B-Disease
) NN O O
compared NN O O
to NN O O
3 NN O O
control NN O O
groups NN O O
sibs NN O O
of NN O O
PWS NN O B-Disease
patients NN O O
( NN O O
SIB NN O O
) NN O O
, NN O O
neurodevelopmentally NN O B-Disease
handicapped NN O I-Disease
children NN O O
( NN O O
ND NN O O
) NN O O
, NN O O
and NN O O
age NN O O
and NN O O
gender NN O O
matched NN O O
well NN O O
children NN O O
( NN O O
WC NN O O
) NN O O
. NN O O

Significant NN O O
differences NN O O
were NN O O
found NN O O
between NN O O
PWS NN O B-Disease
patients NN O O
, NN O O
SIB NN O O
controls NN O O
, NN O O
and NN O O
WC NN O O
controls NN O O
in NN O O
the NN O O
prevalence NN O O
of NN O O
febrile NN O O
convulsions NN O O
, NN O O
fever NN O O
- NN O O
associated NN O O
symptoms NN O O
, NN O O
and NN O O
temperature NN O O
less NN O O
than NN O O
94 NN O O
degrees NN O O
F NN O O
. NN O O

No NN O O
differences NN O O
were NN O O
noted NN O O
in NN O O
any NN O O
variable NN O O
between NN O O
the NN O O
PWS NN O B-Disease
patients NN O O
and NN O O
the NN O O
ND NN O O
controls NN O O
, NN O O
suggesting NN O O
that NN O O
these NN O O
abnormalities NN O O
are NN O O
not NN O O
unique NN O O
to NN O O
PWS NN O B-Disease
, NN O O
but NN O O
can NN O O
occur NN O O
in NN O O
any NN O O
neurodevelopmentally NN O B-Disease
handicapped NN O I-Disease
individual NN O O
, NN O O
further NN O O
suggesting NN O O
these NN O O
do NN O O
not NN O O
necessarily NN O O
reflect NN O O
syndrome NN O O
- NN O O
specific NN O O
hypothalamic NN O B-Disease
abnormalities NN O I-Disease
. NN O O
. NN O O

Phenotypic NN O O
variation NN O O
including NN O O
retinitis NN O B-Disease
pigmentosa NN O I-Disease
, NN O O
pattern NN O B-Disease
dystrophy NN O I-Disease
, NN O O
and NN O O
fundus NN O B-Disease
flavimaculatus NN O I-Disease
in NN O O
a NN O O
single NN O O
family NN O O
with NN O O
a NN O O
deletion NN O O
of NN O O
codon NN O O
153 NN O O
or NN O O
154 NN O O
of NN O O
the NN O O
peripherin NN O O
/ NN O O
RDS NN O O
gene NN O O
. NN O O

BACKGROUND NN O O
AND NN O O
OBJECTIVES NN O O
Mutations NN O O
of NN O O
the NN O O
peripherin NN O O
/ NN O O
RDS NN O O
gene NN O O
have NN O O
been NN O O
reported NN O O
in NN O O
autosomal NN O B-Disease
dominant NN O I-Disease
retinitis NN O I-Disease
pigmentosa NN O I-Disease
, NN O O
pattern NN O O
macular NN O B-Disease
dystrophy NN O I-Disease
, NN O O
and NN O O
retinitis NN O B-Disease
punctata NN O I-Disease
albescens NN O I-Disease
. NN O O

We NN O O
report NN O O
herein NN O O
the NN O O
occurrence NN O O
of NN O O
three NN O O
separate NN O O
phenotypes NN O O
within NN O O
a NN O O
single NN O O
family NN O O
with NN O O
a NN O O
novel NN O O
3 NN O O
- NN O O
base NN O O
pair NN O O
deletion NN O O
of NN O O
codon NN O O
153 NN O O
or NN O O
154 NN O O
of NN O O
the NN O O
peripherin NN O O
/ NN O O
RDS NN O O
gene NN O O
. NN O O

DESIGN NN O O
Case NN O O
reports NN O O
with NN O O
clinical NN O O
features NN O O
, NN O O
fluorescein NN O O
angiography NN O O
, NN O O
kinetic NN O O
perimetry NN O O
, NN O O
electrophysiological NN O O
studies NN O O
, NN O O
and NN O O
molecular NN O O
genetics NN O O
. NN O O

SETTING NN O O
University NN O O
medical NN O O
centers NN O O
. NN O O

PATIENTS NN O O
A NN O O
75 NN O O
- NN O O
year NN O O
- NN O O
old NN O O
woman NN O O
, NN O O
her NN O O
two NN O O
daughters NN O O
( NN O O
aged NN O O
44 NN O O
and NN O O
50 NN O O
years NN O O
) NN O O
, NN O O
and NN O O
her NN O O
49 NN O O
- NN O O
year NN O O
- NN O O
old NN O O
son NN O O
were NN O O
screened NN O O
for NN O O
peripherin NN O O
/ NN O O
RDS NN O O
mutations NN O O
because NN O O
of NN O O
the NN O O
presence NN O O
of NN O O
multiple NN O O
phenotypes NN O O
within NN O O
the NN O O
same NN O O
family NN O O
. NN O O

RESULTS NN O O
The NN O O
mother NN O O
presented NN O O
at NN O O
age NN O O
63 NN O O
years NN O O
with NN O O
a NN O O
profoundly NN O O
abnormal NN O O
electroretinogram NN O O
( NN O O
ERG NN O O
) NN O O
and NN O O
adult NN O O
- NN O O
onset NN O O
retinitis NN O B-Disease
pigmentosa NN O I-Disease
that NN O O
progressed NN O O
dramatically NN O O
over NN O O
12 NN O O
years NN O O
, NN O O
with NN O O
marked NN O O
loss NN O O
of NN O O
peripheral NN O O
visual NN O O
field NN O O
. NN O O

One NN O O
daughter NN O O
developed NN O O
pattern NN O B-Disease
macular NN O I-Disease
dystrophy NN O I-Disease
at NN O O
age NN O O
31 NN O O
years NN O O
. NN O O

At NN O O
age NN O O
44 NN O O
years NN O O
, NN O O
her NN O O
ERG NN O O
was NN O O
moderately NN O O
abnormal NN O O
but NN O O
her NN O O
clinical NN O O
disease NN O O
was NN O O
limited NN O O
to NN O O
the NN O O
macula NN O O
. NN O O

Another NN O O
daughter NN O O
presented NN O O
at NN O O
age NN O O
42 NN O O
years NN O O
with NN O O
macular NN O B-Disease
degeneration NN O I-Disease
and NN O O
over NN O O
10 NN O O
years NN O O
developed NN O O
the NN O O
clinical NN O O
picture NN O O
of NN O O
fundus NN O B-Disease
flavimaculatus NN O I-Disease
. NN O O

Her NN O O
peripheral NN O O
visual NN O O
field NN O O
was NN O O
preserved NN O O
but NN O O
her NN O O
ERG NN O O
was NN O O
moderately NN O O
abnormal NN O O
. NN O O

The NN O O
son NN O O
had NN O O
onset NN O O
of NN O O
macular NN O B-Disease
degeneration NN O I-Disease
at NN O O
age NN O O
44 NN O O
years NN O O
. NN O O

Pericentral NN O B-Disease
scotomas NN O I-Disease
were NN O O
present NN O O
and NN O O
the NN O O
ERG NN O O
was NN O O
markedly NN O O
abnormal NN O O
. NN O O

Fluorescein NN O O
angiography NN O O
revealed NN O O
punctate NN O O
pigment NN O O
epithelial NN O O
transmission NN O O
defects NN O O
. NN O O

CONCLUSIONS NN O O
A NN O O
3 NN O O
- NN O O
base NN O O
pair NN O O
deletion NN O O
of NN O O
codon NN O O
153 NN O O
or NN O O
154 NN O O
of NN O O
the NN O O
peripherin NN O O
/ NN O O
RDS NN O O
gene NN O O
can NN O O
produce NN O O
clinically NN O O
disparate NN O O
phenotypes NN O O
even NN O O
within NN O O
the NN O O
same NN O O
family NN O O
. NN O O
. NN O O

Assignment NN O O
of NN O O
the NN O O
human NN O O
Na NN O O
+ NN O O
/ NN O O
glucose NN O O
cotransporter NN O O
gene NN O O
SGLT1 NN O O
to NN O O
chromosome NN O O
22q13 NN O O
. NN O O
1 NN O O
. NN O O

The NN O O
Na NN O O
+ NN O O
/ NN O O
glucose NN O O
cotransporter NN O O
gene NN O O
SGLT1 NN O O
encodes NN O O
the NN O O
primary NN O O
carrier NN O O
protein NN O O
responsible NN O O
for NN O O
the NN O O
uptake NN O O
of NN O O
the NN O O
dietary NN O O
sugars NN O O
glucose NN O O
and NN O O
galactose NN O O
from NN O O
the NN O O
intestinal NN O O
lumen NN O O
. NN O O

SGLT1 NN O O
transport NN O O
activity NN O O
is NN O O
currently NN O O
exploited NN O O
in NN O O
oral NN O O
rehydration NN O O
therapy NN O O
. NN O O

The NN O O
75 NN O O
- NN O O
kDa NN O O
glycoprotein NN O O
is NN O O
localized NN O O
in NN O O
the NN O O
brush NN O O
border NN O O
of NN O O
the NN O O
intestinal NN O O
epithelium NN O O
and NN O O
is NN O O
predicted NN O O
to NN O O
comprise NN O O
12 NN O O
membrane NN O O
spans NN O O
. NN O O

In NN O O
two NN O O
patients NN O O
with NN O O
the NN O O
autosomal NN O B-Disease
recessive NN O I-Disease
disease NN O I-Disease
glucose NN O I-Disease
/ NN O I-Disease
galactose NN O I-Disease
malabsorption NN O I-Disease
, NN O O
the NN O O
underlying NN O O
cause NN O O
was NN O O
found NN O O
to NN O O
be NN O O
a NN O O
missense NN O O
mutation NN O O
in NN O O
SGLT1 NN O O
, NN O O
and NN O O
the NN O O
Asp28 NN O O
- NN O O
- NN O O
> NN O O
Asn NN O O
change NN O O
was NN O O
demonstrated NN O O
in NN O O
vitro NN O O
to NN O O
eliminate NN O O
SGLT1 NN O O
transport NN O O
activity NN O O
. NN O O

The NN O O
SGLT1 NN O O
gene NN O O
was NN O O
previously NN O O
shown NN O O
to NN O O
reside NN O O
on NN O O
the NN O O
distal NN O O
q NN O O
arm NN O O
of NN O O
chromosome NN O O
22 NN O O
( NN O O
11 NN O O
. NN O O
2 NN O O
- NN O O
- NN O O
> NN O O
qter NN O O
) NN O O
. NN O O

We NN O O
have NN O O
used NN O O
a NN O O
cosmid NN O O
probe NN O O
for NN O O
fluorescence NN O O
in NN O O
situ NN O O
hybridization NN O O
, NN O O
which NN O O
refines NN O O
the NN O O
localization NN O O
to NN O O
22q13 NN O O
. NN O O

1 NN O O
, NN O O
and NN O O
provide NN O O
an NN O O
example NN O O
of NN O O
the NN O O
utility NN O O
of NN O O
the NN O O
SGLT1 NN O O
probe NN O O
as NN O O
a NN O O
diagnostic NN O O
for NN O O
genetic NN O B-Disease
diseases NN O I-Disease
associated NN O O
with NN O O
translocations NN O O
of NN O O
chromosome NN O O
22 NN O O
. NN O O

Restriction NN O O
of NN O O
ocular NN O O
fundus NN O O
lesions NN O O
to NN O O
a NN O O
specific NN O O
subgroup NN O O
of NN O O
APC NN O B-Disease
mutations NN O O
in NN O O
adenomatous NN O B-Disease
polyposis NN O I-Disease
coli NN O I-Disease
patients NN O O
. NN O O

In NN O O
humans NN O O
, NN O O
alteration NN O O
of NN O O
the NN O O
tumor NN O B-Disease
suppressor NN O O
gene NN O O
, NN O O
APC NN O B-Disease
, NN O O
causes NN O O
adenomatous NN O B-Disease
polyposis NN O I-Disease
coli NN O I-Disease
, NN O O
a NN O O
condition NN O O
causing NN O O
predisposition NN O O
to NN O O
colorectal NN O B-Disease
cancer NN O I-Disease
. NN O O

The NN O O
syndrome NN O O
inconsistently NN O O
associates NN O O
characteristic NN O O
patches NN O O
of NN O O
congenital NN O B-Disease
hypertrophy NN O I-Disease
of NN O I-Disease
the NN O I-Disease
retinal NN O I-Disease
pigment NN O I-Disease
epithelium NN O I-Disease
( NN O O
CHRPE NN O B-Disease
) NN O O
. NN O O

Ocular NN O O
examination NN O O
revealed NN O O
that NN O O
patients NN O O
expressing NN O O
CHRPE NN O B-Disease
tend NN O O
to NN O O
cluster NN O O
within NN O O
specific NN O O
families NN O O
. NN O O

The NN O O
exact NN O O
APC NN O B-Disease
mutation NN O O
was NN O O
identified NN O O
in NN O O
42 NN O O
unrelated NN O O
patients NN O O
. NN O O

In NN O O
all NN O O
cases NN O O
these NN O O
mutations NN O O
were NN O O
predicted NN O O
to NN O O
lead NN O O
to NN O O
the NN O O
synthesis NN O O
of NN O O
a NN O O
truncated NN O O
protein NN O O
. NN O O

The NN O O
extent NN O O
of NN O O
CHRPE NN O B-Disease
was NN O O
found NN O O
to NN O O
be NN O O
dependent NN O O
on NN O O
the NN O O
position NN O O
of NN O O
the NN O O
mutation NN O O
along NN O O
the NN O O
coding NN O O
sequence NN O O
. NN O O

CHRPE NN O B-Disease
lesions NN O O
are NN O O
almost NN O O
always NN O O
absent NN O O
if NN O O
the NN O O
mutation NN O O
occurs NN O O
before NN O O
exon NN O O
9 NN O O
, NN O O
but NN O O
are NN O O
systematically NN O O
present NN O O
if NN O O
it NN O O
occurs NN O O
after NN O O
this NN O O
exon NN O O
. NN O O

Thus NN O O
, NN O O
the NN O O
range NN O O
of NN O O
phenotypic NN O O
expression NN O O
observed NN O O
among NN O O
affected NN O O
patients NN O O
may NN O O
result NN O O
in NN O O
part NN O O
from NN O O
different NN O O
allelic NN O O
manifestations NN O O
of NN O O
APC NN O B-Disease
mutations NN O O
. NN O O
. NN O O

The NN O O
effects NN O O
of NN O O
dystrophin NN O O
gene NN O O
mutations NN O O
on NN O O
the NN O O
ERG NN O O
in NN O O
mice NN O O
and NN O O
humans NN O O
. NN O O

PURPOSE NN O O
. NN O O

The NN O O
authors NN O O
earlier NN O O
findings NN O O
of NN O O
a NN O O
negative NN O O
electroretinogram NN O O
( NN O O
ERG NN O O
) NN O O
in NN O O
a NN O O
boy NN O O
with NN O O
Duchenne NN O B-Disease
muscular NN O I-Disease
dystrophy NN O I-Disease
( NN O O
DMD NN O B-Disease
) NN O O
led NN O O
them NN O O
to NN O O
investigate NN O O
dystrophin NN O O
gene NN O O
deletions NN O O
and NN O O
ERGs NN O O
in NN O O
five NN O O
boys NN O O
with NN O O
DMD NN O B-Disease
. NN O O

The NN O O
authors NN O O
wanted NN O O
to NN O O
determined NN O O
whether NN O O
there NN O O
were NN O O
similar NN O O
ERG NN O O
findings NN O O
in NN O O
an NN O O
animal NN O O
model NN O O
for NN O O
DMD NN O B-Disease
, NN O O
the NN O O
mdx NN O O
mouse NN O O
. NN O O

METHODS NN O O
. NN O O

Ganzfeld NN O O
ERGs NN O O
were NN O O
recorded NN O O
in NN O O
five NN O O
boys NN O O
with NN O O
DMD NN O B-Disease
after NN O O
a NN O O
complete NN O O
ophthalmic NN O O
examination NN O O
. NN O O

The NN O O
dystrophin NN O O
gene NN O O
was NN O O
analyzed NN O O
by NN O O
Southern NN O O
blot NN O O
hybridization NN O O
. NN O O

ERGs NN O O
were NN O O
recorded NN O O
in NN O O
anesthetized NN O O
mdx NN O O
and NN O O
control NN O O
mice NN O O
with NN O O
a NN O O
modified NN O O
Grass NN O O
photostimulator NN O O
( NN O O
Grass NN O O
Instrument NN O O
Company NN O O
, NN O O
Quincy NN O O
, NN O O
MA NN O O
) NN O O
. NN O O

RESULTS NN O O
. NN O O

Ophthalmic NN O O
examinations NN O O
in NN O O
all NN O O
five NN O O
boys NN O O
had NN O O
normal NN O O
findings NN O O
, NN O O
yet NN O O
an NN O O
abnormal NN O O
negative NN O O
ERG NN O O
was NN O O
recorded NN O O
for NN O O
each NN O O
subject NN O O
. NN O O

The NN O O
subjects NN O O
gene NN O O
deletions NN O O
were NN O O
variable NN O O
, NN O O
ranging NN O O
from NN O O
large NN O O
deletions NN O O
to NN O O
no NN O O
detectable NN O O
deletions NN O O
. NN O O

The NN O O
ERGs NN O O
of NN O O
the NN O O
mdx NN O O
mice NN O O
were NN O O
normal NN O O
and NN O O
did NN O O
not NN O O
differ NN O O
significantly NN O O
from NN O O
those NN O O
of NN O O
the NN O O
control NN O O
mice NN O O
. NN O O

CONCLUSIONS NN O O
. NN O O

The NN O O
authors NN O O
believe NN O O
the NN O O
unique NN O O
ERG NN O O
recorded NN O O
for NN O O
the NN O O
human NN O O
subjects NN O O
is NN O O
a NN O O
manifestation NN O O
of NN O O
DMD NN O B-Disease
associated NN O O
with NN O O
defects NN O O
at NN O O
the NN O O
dystrophin NN O O
gene NN O O
locus NN O O
and NN O O
represents NN O O
a NN O O
new NN O O
clinical NN O O
entity NN O O
. NN O O

The NN O O
ERG NN O O
of NN O O
the NN O O
mdx NN O O
mouse NN O O
may NN O O
be NN O O
spared NN O O
for NN O O
several NN O O
reasons NN O O
, NN O O
including NN O O
milder NN O O
effects NN O O
of NN O O
the NN O O
mouse NN O O
gene NN O O
defect NN O O
, NN O O
differences NN O O
in NN O O
muscle NN O O
and NN O O
retinal NN O O
gene NN O O
product NN O O
, NN O O
or NN O O
species NN O O
differences NN O O
in NN O O
the NN O O
biochemical NN O O
role NN O O
of NN O O
dystrophin NN O O
. NN O O

The NN O O
ERG NN O O
shows NN O O
promise NN O O
of NN O O
becoming NN O O
a NN O O
noninvasive NN O O
diagnostic NN O O
tool NN O O
for NN O O
DMD NN O B-Disease
and NN O O
its NN O O
milder NN O O
allelic NN O O
forms NN O O
. NN O O
. NN O O

Association NN O O
of NN O O
the NN O O
APC NN O B-Disease
tumor NN O I-Disease
suppressor NN O O
protein NN O O
with NN O O
catenins NN O O
. NN O O

Mutations NN O O
of NN O O
APC NN O O
appear NN O O
to NN O O
initiate NN O O
sporadic NN O O
and NN O O
inherited NN O O
forms NN O O
of NN O O
human NN O O
colorectal NN O B-Disease
cancer NN O I-Disease
. NN O O

Although NN O O
these NN O O
mutations NN O O
have NN O O
been NN O O
well NN O O
characterized NN O O
, NN O O
little NN O O
is NN O O
known NN O O
about NN O O
the NN O O
function NN O O
of NN O O
the NN O O
APC NN O B-Disease
gene NN O O
product NN O O
. NN O O

Two NN O O
cellular NN O O
proteins NN O O
that NN O O
associate NN O O
with NN O O
APC NN O B-Disease
were NN O O
identified NN O O
by NN O O
nucleotide NN O O
sequence NN O O
analysis NN O O
and NN O O
peptide NN O O
mapping NN O O
as NN O O
the NN O O
E NN O O
- NN O O
cadherin NN O O
- NN O O
associated NN O O
proteins NN O O
alpha NN O O
- NN O O
and NN O O
beta NN O O
- NN O O
catenin NN O O
. NN O O

A NN O O
27 NN O O
- NN O O
residue NN O O
fragment NN O O
of NN O O
APC NN O O
containing NN O O
a NN O O
15 NN O O
- NN O O
amino NN O O
acid NN O O
repeat NN O O
was NN O O
sufficient NN O O
for NN O O
the NN O O
interaction NN O O
with NN O O
the NN O O
catenins NN O O
. NN O O

These NN O O
results NN O O
suggest NN O O
an NN O O
important NN O O
link NN O O
between NN O O
tumor NN O B-Disease
initiation NN O O
and NN O O
cell NN O O
adhesion NN O O
. NN O O
. NN O O

Difference NN O O
in NN O O
methylation NN O O
patterns NN O O
within NN O O
the NN O O
D15S9 NN O O
region NN O O
of NN O O
chromosome NN O O
15q11 NN O O
- NN O O
13 NN O O
in NN O O
first NN O O
cousins NN O O
with NN O O
Angelman NN O B-Disease
syndrome NN O I-Disease
and NN O O
Prader NN O B-Disease
- NN O I-Disease
Willi NN O I-Disease
syndrome NN O I-Disease
. NN O O

Abnormalities NN O O
of NN O O
chromosome NN O O
region NN O O
15q11 NN O O
- NN O O
13 NN O O
are NN O O
associated NN O O
with NN O O
Angelman NN O B-Disease
syndrome NN O I-Disease
( NN O O
AS NN O B-Disease
) NN O O
and NN O O
Prader NN O B-Disease
- NN O I-Disease
Willi NN O I-Disease
syndrome NN O I-Disease
( NN O O
PWS NN O B-Disease
) NN O O
. NN O O

Differences NN O O
between NN O O
the NN O O
methylation NN O O
patterns NN O O
of NN O O
the NN O O
region NN O O
of NN O O
chromosome NN O O
15q11 NN O O
- NN O O
13 NN O O
which NN O O
hybridizes NN O O
to NN O O
the NN O O
highly NN O O
conserved NN O O
DNA NN O O
, NN O O
DN34 NN O O
, NN O O
in NN O O
normal NN O O
individuals NN O O
and NN O O
in NN O O
patients NN O O
with NN O O
AS NN O B-Disease
and NN O O
PWS NN O B-Disease
have NN O O
been NN O O
described NN O O
. NN O O

We NN O O
report NN O O
on NN O O
a NN O O
family NN O O
in NN O O
which NN O O
first NN O O
cousins NN O O
are NN O O
affected NN O O
by NN O O
AS NN O B-Disease
and NN O O
PWS NN O B-Disease
as NN O O
a NN O O
result NN O O
of NN O O
a NN O O
familial NN O O
paracentric NN O O
inversion NN O O
of NN O O
15q11 NN O O
- NN O O
q13 NN O O
. NN O O

The NN O O
results NN O O
of NN O O
the NN O O
studies NN O O
on NN O O
this NN O O
family NN O O
demonstrate NN O O
the NN O O
differences NN O O
in NN O O
the NN O O
methylation NN O O
patterns NN O O
in NN O O
the NN O O
2 NN O O
conditions NN O O
and NN O O
the NN O O
phenomenon NN O O
of NN O O
genomic NN O O
imprinting NN O O
, NN O O
whereby NN O O
genetic NN O O
information NN O O
is NN O O
expressed NN O O
differently NN O O
dependent NN O O
on NN O O
the NN O O
parent NN O O
of NN O O
origin NN O O
. NN O O
. NN O O

Haplotype NN O O
studies NN O O
in NN O O
Wilson NN O B-Disease
disease NN O I-Disease
. NN O O

In NN O O
51 NN O O
families NN O O
with NN O O
Wilson NN O B-Disease
disease NN O I-Disease
, NN O O
we NN O O
have NN O O
studied NN O O
DNA NN O O
haplotypes NN O O
of NN O O
dinucleotide NN O O
repeat NN O O
polymorphisms NN O O
( NN O O
CA NN O O
repeats NN O O
) NN O O
in NN O O
the NN O O
13q14 NN O O
. NN O O

3 NN O O
region NN O O
, NN O O
to NN O O
examine NN O O
these NN O O
markers NN O O
for NN O O
association NN O O
with NN O O
the NN O O
Wilson NN O B-Disease
disease NN O I-Disease
gene NN O O
( NN O O
WND NN O B-Disease
) NN O O
. NN O O

In NN O O
addition NN O O
to NN O O
a NN O O
marker NN O O
( NN O O
D13S133 NN O O
) NN O O
described NN O O
elsewhere NN O O
, NN O O
we NN O O
have NN O O
developed NN O O
three NN O O
new NN O O
highly NN O O
polymorphic NN O O
markers NN O O
( NN O O
D13S314 NN O O
, NN O O
D13S315 NN O O
, NN O O
and NN O O
D13S316 NN O O
) NN O O
close NN O O
to NN O O
the NN O O
WND NN O B-Disease
locus NN O O
. NN O O

We NN O O
have NN O O
examined NN O O
the NN O O
distribution NN O O
of NN O O
marker NN O O
alleles NN O O
at NN O O
the NN O O
loci NN O O
studied NN O O
and NN O O
have NN O O
found NN O O
that NN O O
D13S314 NN O O
, NN O O
D13S133 NN O O
, NN O O
and NN O O
D13S316 NN O O
each NN O O
show NN O O
nonrandom NN O O
distribution NN O O
on NN O O
chromosomes NN O O
carrying NN O O
the NN O O
WND NN O B-Disease
mutation NN O O
. NN O O

We NN O O
have NN O O
studied NN O O
haplotypes NN O O
of NN O O
these NN O O
three NN O O
markers NN O O
and NN O O
have NN O O
found NN O O
that NN O O
there NN O O
are NN O O
highly NN O O
significant NN O O
differences NN O O
between NN O O
WND NN O B-Disease
and NN O O
normal NN O O
haplotypes NN O O
in NN O O
northern NN O O
European NN O O
families NN O O
. NN O O

These NN O O
findings NN O O
have NN O O
important NN O O
implications NN O O
for NN O O
mutation NN O O
detection NN O O
and NN O O
molecular NN O O
diagnosis NN O O
in NN O O
families NN O O
with NN O O
Wilson NN O B-Disease
disease NN O I-Disease
. NN O O

Genetic NN O O
analysis NN O O
of NN O O
the NN O O
BRCA1 NN O O
region NN O O
in NN O O
a NN O O
large NN O O
breast NN O O
/ NN O O
ovarian NN O O
family NN O O
: NN O O
refinement NN O O
of NN O O
the NN O O
minimal NN O O
region NN O O
containing NN O O
BRCA1 NN O O
. NN O O

We NN O O
have NN O O
analyzed NN O O
a NN O O
single NN O O
multi NN O O
- NN O O
affected NN O O
breast NN O B-Disease
/ NN O I-Disease
ovarian NN O I-Disease
cancer NN O I-Disease
pedigree NN O O
( NN O O
BOV3 NN O O
) NN O O
and NN O O
have NN O O
shown NN O O
consistent NN O O
inheritance NN O O
of NN O O
markers NN O O
on NN O O
chromosome NN O O
17q NN O O
with NN O O
the NN O O
disease NN O O
confirming NN O O
that NN O O
this NN O O
family NN O O
is NN O O
due NN O O
to NN O O
the NN O O
BRCA1 NN O O
gene NN O O
. NN O O

Analysis NN O O
of NN O O
17q NN O O
haplotypes NN O O
shows NN O O
a NN O O
recombination NN O O
event NN O O
in NN O O
a NN O O
bilateral NN O O
breast NN O B-Disease
cancer NN O I-Disease
case NN O O
which NN O O
suggests NN O O
that NN O O
the NN O O
BRCA1 NN O O
gene NN O O
lies NN O O
distal NN O O
to NN O O
D17S857 NN O O
; NN O O
D17S857 NN O O
is NN O O
thus NN O O
the NN O O
new NN O O
proximal NN O O
boundary NN O O
for NN O O
the NN O O
region NN O O
containing NN O O
BRCA1 NN O O
. NN O O

Combining NN O O
this NN O O
information NN O O
with NN O O
previously NN O O
published NN O O
mapping NN O O
information NN O O
suggests NN O O
that NN O O
BRCA1 NN O O
is NN O O
contained NN O O
in NN O O
a NN O O
region NN O O
estimated NN O O
at NN O O
1 NN O O
- NN O O
1 NN O O
. NN O O

5 NN O O
Mb NN O O
in NN O O
length NN O O
. NN O O

All NN O O
seven NN O O
breast NN O B-Disease
tumour NN O I-Disease
/ NN O O
blood NN O O
pairs NN O O
examined NN O O
from NN O O
this NN O O
family NN O O
show NN O O
loss NN O O
of NN O O
heterozygosity NN O O
in NN O O
the NN O O
tumours NN O B-Disease
. NN O O

The NN O O
allel NN O O
retained NN O O
in NN O O
each NN O O
tumour NN O B-Disease
was NN O O
from NN O O
the NN O O
disease NN O O
- NN O O
bearing NN O O
chromosome NN O O
implicating NN O O
BRCA1 NN O O
as NN O O
a NN O O
tumour NN O B-Disease
suppressor NN O O
gene NN O O
. NN O O

We NN O O
have NN O O
sequenced NN O O
the NN O O
17 NN O O
beta NN O O
- NN O O
oestradiol NN O O
dehydrogenase NN O O
genes NN O O
( NN O O
EDH17B1 NN O O
and NN O O
EDH17B2 NN O O
) NN O O
which NN O O
have NN O O
been NN O O
suggested NN O O
as NN O O
candidate NN O O
genes NN O O
for NN O O
BRCA1 NN O O
in NN O O
four NN O O
members NN O O
of NN O O
this NN O O
family NN O O
. NN O O

No NN O O
germline NN O O
mutations NN O O
were NN O O
detected NN O O
. NN O O

Myotonic NN O B-Disease
dystrophy NN O I-Disease
kinase NN O O
is NN O O
a NN O O
component NN O O
of NN O O
neuromuscular NN O O
junctions NN O O
. NN O O

The NN O O
clinical NN O O
manifestation NN O O
of NN O O
myotonic NN O B-Disease
dystrophy NN O I-Disease
( NN O O
DM NN O B-Disease
) NN O O
is NN O O
correlated NN O O
to NN O O
the NN O O
extent NN O O
of NN O O
expansion NN O O
of NN O O
an NN O O
unstable NN O O
[ NN O O
CTG NN O O
] NN O O
n NN O O
DNA NN O O
motif NN O O
. NN O O

Recent NN O O
studies NN O O
have NN O O
demonstrated NN O O
that NN O O
this NN O O
trinucleotide NN O O
motif NN O O
forms NN O O
part NN O O
of NN O O
the NN O O
last NN O O
, NN O O
3 NN O O
untranslated NN O O
exon NN O O
of NN O O
a NN O O
gene NN O O
which NN O O
potentially NN O O
encodes NN O O
multiple NN O O
protein NN O O
isoforms NN O O
of NN O O
a NN O O
serine NN O O
/ NN O O
threonine NN O O
protein NN O O
kinase NN O O
( NN O O
myotonic NN O B-Disease
dystrophy NN O I-Disease
protein NN O O
kinase NN O O
, NN O O
DM NN O O
- NN O O
PK NN O O
) NN O O
. NN O O

We NN O O
report NN O O
here NN O O
on NN O O
the NN O O
development NN O O
of NN O O
antisera NN O O
against NN O O
synthetic NN O O
DM NN O O
- NN O O
PK NN O O
peptide NN O O
antigens NN O O
and NN O O
their NN O O
use NN O O
in NN O O
biochemical NN O O
and NN O O
histochemical NN O O
studies NN O O
. NN O O

Immunoreactive NN O O
DM NN O O
- NN O O
kinase NN O O
protein NN O O
of NN O O
53 NN O O
kD NN O O
is NN O O
present NN O O
at NN O O
low NN O O
levels NN O O
in NN O O
skeletal NN O O
and NN O O
cardiac NN O O
muscle NN O O
extracts NN O O
of NN O O
DM NN O B-Disease
patients NN O O
and NN O O
normal NN O O
controls NN O O
. NN O O

Immunohistochemical NN O O
staining NN O O
revealed NN O O
that NN O O
DM NN O O
- NN O O
PK NN O O
is NN O O
localised NN O O
prominently NN O O
at NN O O
sites NN O O
of NN O O
neuromuscular NN O O
and NN O O
myotendinous NN O O
junctions NN O O
( NN O O
NMJs NN O O
and NN O O
MTJs NN O O
) NN O O
of NN O O
human NN O O
and NN O O
rodent NN O O
skeletal NN O O
muscles NN O O
. NN O O

Furthermore NN O O
, NN O O
very NN O O
low NN O O
levels NN O O
of NN O O
immunoreactive NN O O
DM NN O O
- NN O O
PK NN O O
protein NN O O
are NN O O
present NN O O
in NN O O
the NN O O
sarcoplasm NN O O
of NN O O
predominantly NN O O
type NN O O
I NN O O
fibres NN O O
in NN O O
various NN O O
muscles NN O O
. NN O O

Strikingly NN O O
, NN O O
presence NN O O
of NN O O
the NN O O
protein NN O O
can NN O O
also NN O O
be NN O O
demonstrated NN O O
for NN O O
NMJs NN O O
of NN O O
muscular NN O O
tissues NN O O
of NN O O
adult NN O O
and NN O O
congenital NN O O
cases NN O O
of NN O O
DM NN O B-Disease
, NN O O
with NN O O
no NN O O
gross NN O O
changes NN O O
in NN O O
structural NN O O
organisation NN O O
. NN O O

Our NN O O
findings NN O O
provide NN O O
a NN O O
basis NN O O
for NN O O
further NN O O
characterisation NN O O
of NN O O
the NN O O
role NN O O
of NN O O
the NN O O
kinase NN O O
in NN O O
protein NN O O
assembly NN O O
processes NN O O
or NN O O
signal NN O O
mediation NN O O
at NN O O
synaptic NN O O
sites NN O O
and NN O O
ultimately NN O O
for NN O O
the NN O O
understanding NN O O
of NN O O
the NN O O
complex NN O O
pathophysiology NN O O
of NN O O
DM NN O B-Disease
. NN O O
. NN O O

Markedly NN O O
accelerated NN O O
catabolism NN O O
of NN O O
apolipoprotein NN O O
A NN O O
- NN O O
II NN O O
( NN O O
ApoA NN O O
- NN O O
II NN O O
) NN O O
and NN O O
high NN O O
density NN O O
lipoproteins NN O O
containing NN O O
ApoA NN O O
- NN O O
II NN O O
in NN O O
classic NN O O
lecithin NN O O
: NN O O
cholesterol NN O B-Disease
acyltransferase NN O I-Disease
deficiency NN O I-Disease
and NN O O
fish NN O B-Disease
- NN O I-Disease
eye NN O I-Disease
disease NN O I-Disease
. NN O O

Classic NN O B-Disease
( NN O I-Disease
complete NN O I-Disease
) NN O I-Disease
lecithin NN O I-Disease
cholesterol NN O I-Disease
acyltransferase NN O I-Disease
( NN O I-Disease
LCAT NN O I-Disease
) NN O I-Disease
deficiency NN O I-Disease
and NN O O
Fish NN O B-Disease
- NN O I-Disease
eye NN O I-Disease
disease NN O I-Disease
( NN O O
partial NN O B-Disease
LCAT NN O I-Disease
deficiency NN O I-Disease
) NN O O
are NN O O
genetic NN O O
syndromes NN O O
associated NN O O
with NN O O
markedly NN O O
decreased NN O O
plasma NN O O
levels NN O O
of NN O O
high NN O O
density NN O O
lipoprotein NN O O
( NN O O
HDL NN O O
) NN O O
cholesterol NN O O
but NN O O
not NN O O
with NN O O
an NN O O
increased NN O O
risk NN O O
of NN O O
atherosclerotic NN O B-Disease
cardiovascular NN O I-Disease
disease NN O I-Disease
. NN O O

We NN O O
investigated NN O O
the NN O O
metabolism NN O O
of NN O O
the NN O O
HDL NN O O
apolipoproteins NN O O
( NN O O
apo NN O O
) NN O O
apoA NN O O
- NN O O
I NN O O
and NN O O
apoA NN O O
- NN O O
II NN O O
in NN O O
a NN O O
total NN O O
of NN O O
five NN O O
patients NN O O
with NN O O
LCAT NN O B-Disease
deficiency NN O I-Disease
, NN O O
one NN O O
with NN O O
classic NN O B-Disease
LCAT NN O I-Disease
deficiency NN O I-Disease
and NN O O
four NN O O
with NN O O
Fish NN O B-Disease
- NN O I-Disease
eye NN O I-Disease
disease NN O I-Disease
. NN O O

Plasma NN O O
levels NN O O
of NN O O
apoA NN O O
- NN O O
II NN O O
were NN O O
decreased NN O O
to NN O O
a NN O O
proportionately NN O O
greater NN O O
extent NN O O
( NN O O
23 NN O O
% NN O O
of NN O O
normal NN O O
) NN O O
than NN O O
apoA NN O O
- NN O O
I NN O O
( NN O O
30 NN O O
% NN O O
of NN O O
normal NN O O
) NN O O
. NN O O

In NN O O
addition NN O O
, NN O O
plasma NN O O
concentrations NN O O
of NN O O
HDL NN O O
particles NN O O
containing NN O O
both NN O O
apoA NN O O
- NN O O
I NN O O
and NN O O
apoA NN O O
- NN O O
II NN O O
( NN O O
LpA NN O O
- NN O O
I NN O O
A NN O O
- NN O O
II NN O O
) NN O O
were NN O O
much NN O O
lower NN O O
( NN O O
18 NN O O
% NN O O
of NN O O
normal NN O O
) NN O O
than NN O O
those NN O O
of NN O O
particles NN O O
containing NN O O
only NN O O
apoA NN O O
- NN O O
I NN O O
( NN O O
LpA NN O O
- NN O O
I NN O O
) NN O O
( NN O O
51 NN O O
% NN O O
of NN O O
normal NN O O
) NN O O
. NN O O

The NN O O
metabolic NN O O
basis NN O O
for NN O O
the NN O O
low NN O O
levels NN O O
of NN O O
apoA NN O O
- NN O O
II NN O O
and NN O O
LpA NN O O
- NN O O
I NN O O
A NN O O
- NN O O
II NN O O
was NN O O
investigated NN O O
in NN O O
all NN O O
five NN O O
patients NN O O
using NN O O
both NN O O
exogenous NN O O
radiotracer NN O O
and NN O O
endogenous NN O O
stable NN O O
isotope NN O O
labeling NN O O
techniques NN O O
. NN O O

The NN O O
mean NN O O
plasma NN O O
residence NN O O
time NN O O
of NN O O
apoA NN O O
- NN O O
I NN O O
was NN O O
decreased NN O O
at NN O O
2 NN O O
. NN O O

08 NN O O
+ NN O O
/ NN O O
- NN O O
0 NN O O
. NN O O

27 NN O O
d NN O O
( NN O O
controls NN O O
4 NN O O
. NN O O
74 NN O O
+ NN O O
/ NN O O
- NN O O
0 NN O O
. NN O O
65 NN O O
days NN O O
) NN O O
; NN O O
however NN O O
, NN O O
the NN O O
residence NN O O
time NN O O
of NN O O
apoA NN O O
- NN O O
II NN O O
was NN O O
even NN O O
shorter NN O O
at NN O O
1 NN O O
. NN O O

66 NN O O
+ NN O O
/ NN O O
- NN O O
0 NN O O
. NN O O

24 NN O O
d NN O O
( NN O O
controls NN O O
5 NN O O
. NN O O
25 NN O O
+ NN O O
/ NN O O
- NN O O
0 NN O O
. NN O O
61 NN O O
d NN O O
) NN O O
. NN O O

In NN O O
addition NN O O
, NN O O
the NN O O
catabolism NN O O
of NN O O
apoA NN O O
- NN O O
I NN O O
in NN O O
LpA NN O O
- NN O O
I NN O O
A NN O O
- NN O O
II NN O O
was NN O O
substantially NN O O
faster NN O O
than NN O O
that NN O O
of NN O O
apoA NN O O
- NN O O
I NN O O
in NN O O
LpA NN O O
- NN O O
I NN O O
. NN O O

In NN O O
summary NN O O
, NN O O
genetic NN O O
syndromes NN O O
of NN O O
either NN O O
complete NN O B-Disease
or NN O I-Disease
partial NN O I-Disease
LCAT NN O I-Disease
deficiency NN O I-Disease
result NN O O
in NN O O
low NN O O
levels NN O O
of NN O O
HDL NN O O
through NN O O
preferential NN O O
hypercatabolism NN O O
of NN O O
apoA NN O O
- NN O O
II NN O O
and NN O O
HDL NN O O
particles NN O O
containing NN O O
apoA NN O O
- NN O O
II NN O O
. NN O O

Because NN O O
LpA NN O O
- NN O O
I NN O O
has NN O O
been NN O O
proposed NN O O
to NN O O
be NN O O
more NN O O
protective NN O O
than NN O O
LpA NN O O
- NN O O
I NN O O
A NN O O
- NN O O
II NN O O
against NN O O
atherosclerosis NN O B-Disease
, NN O O
this NN O O
selective NN O O
effect NN O O
on NN O O
the NN O O
metabolism NN O O
of NN O O
LpA NN O O
- NN O O
I NN O O
A NN O O
- NN O O
II NN O O
may NN O O
provide NN O O
a NN O O
potential NN O O
explanation NN O O
why NN O O
patients NN O O
with NN O O
classic NN O B-Disease
LCAT NN O I-Disease
deficiency NN O I-Disease
and NN O O
Fish NN O B-Disease
- NN O I-Disease
eye NN O I-Disease
disease NN O I-Disease
are NN O O
not NN O O
at NN O O
increased NN O O
risk NN O O
for NN O O
premature NN O O
atherosclerosis NN O B-Disease
despite NN O O
markedly NN O O
decreased NN O O
levels NN O O
of NN O O
HDL NN O O
cholesterol NN O O
and NN O O
apoA NN O O
- NN O O
I NN O O

X NN O B-Disease
linked NN O I-Disease
recessive NN O I-Disease
thrombocytopenia NN O I-Disease
. NN O O

A NN O O
Saudi NN O O
Arab NN O O
boy NN O O
presented NN O O
in NN O O
early NN O O
childhood NN O O
with NN O O
thrombocytopenia NN O B-Disease
, NN O O
morphologically NN O O
large NN O O
and NN O O
normal NN O O
sized NN O O
platelets NN O O
, NN O O
increased NN O O
mean NN O O
platelet NN O O
volume NN O O
, NN O O
and NN O O
a NN O O
hypermegakaryocytic NN O O
bone NN O O
marrow NN O O
. NN O O

There NN O O
was NN O O
no NN O O
clinical NN O O
and NN O O
laboratory NN O O
evidence NN O O
of NN O O
any NN O O
significant NN O O
immunological NN O B-Disease
abnormalities NN O I-Disease
. NN O O

Similar NN O O
findings NN O O
in NN O O
two NN O O
other NN O O
brothers NN O O
suggested NN O O
strongly NN O O
that NN O O
they NN O O
were NN O O
all NN O O
suffering NN O O
from NN O O
an NN O O
X NN O B-Disease
linked NN O I-Disease
recessive NN O I-Disease
thrombocytopenic NN O I-Disease
disorder NN O I-Disease
. NN O O

Results NN O O
of NN O O
DNA NN O O
analysis NN O O
with NN O O
the NN O O
probe NN O O
M27 NN O O
beta NN O O
are NN O O
consistent NN O O
with NN O O
X NN O O
linkage NN O O
and NN O O
indicate NN O O
also NN O O
that NN O O
the NN O O
locus NN O O
of NN O O
the NN O O
relevant NN O O
gene NN O O
lies NN O O
close NN O O
to NN O O
or NN O O
is NN O O
identical NN O O
to NN O O
the NN O O
locus NN O O
of NN O O
the NN O O
gene NN O O
for NN O O
the NN O O
Wiskott NN O B-Disease
- NN O I-Disease
Aldrich NN O I-Disease
syndrome NN O I-Disease
( NN O O
WAS NN O B-Disease
) NN O O
. NN O O

Because NN O O
of NN O O
various NN O O
features NN O O
which NN O O
include NN O O
the NN O O
presence NN O O
of NN O O
large NN O O
and NN O O
normal NN O O
sized NN O O
platelets NN O O
( NN O O
rather NN O O
than NN O O
small NN O O
platelets NN O O
) NN O O
and NN O O
freedom NN O O
from NN O O
significant NN O O
immune NN O B-Disease
deficiencies NN O I-Disease
, NN O O
it NN O O
is NN O O
likely NN O O
that NN O O
the NN O O
X NN O B-Disease
linked NN O I-Disease
recessive NN O I-Disease
thrombocytopenia NN O I-Disease
in NN O O
this NN O O
family NN O O
is NN O O
an NN O O
isolated NN O O
entity NN O O
quite NN O O
distinct NN O O
from NN O O
the NN O O
classical NN O O
WAS NN O B-Disease
phenotype NN O O
. NN O O

However NN O O
, NN O O
a NN O O
modified NN O O
expression NN O O
of NN O O
the NN O O
WAS NN O B-Disease
gene NN O O
producing NN O O
a NN O O
mild NN O O
phenotypic NN O O
variant NN O O
cannot NN O O
be NN O O
excluded NN O O
entirely NN O O
. NN O O
. NN O O

Macular NN O B-Disease
dystrophy NN O I-Disease
associated NN O O
with NN O O
mutations NN O O
at NN O O
codon NN O O
172 NN O O
in NN O O
the NN O O
human NN O O
retinal NN O B-Disease
degeneration NN O I-Disease
slow NN O O
gene NN O O
. NN O O

BACKGROUND NN O O
Recently NN O O
, NN O O
mutations NN O O
in NN O O
the NN O O
retinal NN O B-Disease
degeneration NN O I-Disease
slow NN O O
( NN O O
rds NN O O
) NN O O
gene NN O O
which NN O O
codes NN O O
for NN O O
peripherin NN O O
- NN O O
rds NN O O
have NN O O
been NN O O
implicated NN O O
as NN O O
a NN O O
cause NN O O
of NN O O
autosomal NN O B-Disease
dominant NN O I-Disease
retinitis NN O I-Disease
pigmentosa NN O I-Disease
. NN O O

Because NN O O
this NN O O
gene NN O O
is NN O O
expressed NN O O
in NN O O
both NN O O
rods NN O O
and NN O O
cones NN O O
, NN O O
mutations NN O O
in NN O O
the NN O O
rds NN O O
gene NN O O
might NN O O
be NN O O
expected NN O O
to NN O O
cause NN O O
degeneration NN O O
affecting NN O O
either NN O O
the NN O O
scotopic NN O O
or NN O O
photopic NN O O
systems NN O O
. NN O O

Mutations NN O O
at NN O O
codon NN O O
172 NN O O
of NN O O
the NN O O
rds NN O O
gene NN O O
have NN O O
been NN O O
identified NN O O
in NN O O
three NN O O
families NN O O
with NN O O
autosomal NN O O
dominantly NN O O
inherited NN O O
, NN O O
progressive NN O O
macular NN O B-Disease
dystrophy NN O I-Disease
. NN O O

METHODS NN O O
Affected NN O O
individuals NN O O
underwent NN O O
ophthalmic NN O O
examination NN O O
, NN O O
scotopic NN O O
perimetry NN O O
, NN O O
dark NN O O
adaptometry NN O O
, NN O O
measurement NN O O
of NN O O
color NN O O
- NN O O
contrast NN O O
sensitivity NN O O
, NN O O
and NN O O
electroretinography NN O O
to NN O O
characterize NN O O
the NN O O
photoreceptor NN O O
dysfunction NN O O
. NN O O

RESULTS NN O O
In NN O O
all NN O O
but NN O O
one NN O O
affected NN O O
member NN O O
, NN O O
symptoms NN O O
of NN O O
progressive NN O O
central NN O O
visual NN O B-Disease
loss NN O I-Disease
developed NN O O
in NN O O
the NN O O
third NN O O
or NN O O
fourth NN O O
decade NN O O
of NN O O
life NN O O
accompanied NN O O
by NN O O
central NN O B-Disease
scotoma NN O I-Disease
and NN O O
well NN O O
- NN O O
demarcated NN O O
atrophy NN O B-Disease
of NN O I-Disease
the NN O I-Disease
retinal NN O I-Disease
pigment NN O I-Disease
epithelium NN O I-Disease
and NN O O
choriocapillaris NN O B-Disease
of NN O I-Disease
the NN O I-Disease
macula NN O I-Disease
. NN O O

In NN O O
general NN O O
, NN O O
cone NN O O
and NN O O
rod NN O O
thresholds NN O O
were NN O O
elevated NN O O
, NN O O
and NN O O
color NN O O
- NN O O
contrast NN O O
sensitivity NN O O
was NN O O
absent NN O O
in NN O O
the NN O O
central NN O O
visual NN O O
field NN O O
. NN O O

Peripherally NN O O
, NN O O
the NN O O
scotopic NN O O
sensitivities NN O O
were NN O O
normal NN O O
, NN O O
as NN O O
was NN O O
the NN O O
recovery NN O O
from NN O O
bleach NN O O
. NN O O

Cone NN O O
electroretinograms NN O O
were NN O O
diminished NN O O
in NN O O
amplitude NN O O
, NN O O
and NN O O
delayed NN O O
in NN O O
all NN O O
affected NN O O
adults NN O O
except NN O O
one NN O O
. NN O O

Rod NN O O
electroretinograms NN O O
were NN O O
normal NN O O
or NN O O
near NN O O
normal NN O O
in NN O O
amplitude NN O O
, NN O O
and NN O O
had NN O O
normal NN O O
implicit NN O O
times NN O O
. NN O O

Affected NN O O
asymptomatic NN O O
children NN O O
had NN O O
macular NN O O
changes NN O O
, NN O O
abnormal NN O O
color NN O O
- NN O O
contrast NN O O
sensitivity NN O O
, NN O O
and NN O O
reduced NN O O
pattern NN O O
and NN O O
cone NN O O
electroretinograms NN O O
. NN O O

CONCLUSION NN O O
These NN O O
results NN O O
indicate NN O O
that NN O O
mutations NN O O
in NN O O
the NN O O
rds NN O O
gene NN O O
can NN O O
be NN O O
expressed NN O O
as NN O O
a NN O O
macular NN O B-Disease
dystrophy NN O I-Disease
, NN O O
with NN O O
evidence NN O O
of NN O O
primary NN O O
cone NN O B-Disease
dysfunction NN O I-Disease
and NN O O
preservation NN O O
of NN O O
peripheral NN O O
rod NN O O
function NN O O
. NN O O
. NN O O

Anonymous NN O O
marker NN O O
loci NN O O
within NN O O
400 NN O O
kb NN O O
of NN O O
HLA NN O O
- NN O O
A NN O O
generate NN O O
haplotypes NN O O
in NN O O
linkage NN O O
disequilibrium NN O O
with NN O O
the NN O O
hemochromatosis NN O B-Disease
gene NN O O
( NN O O
HFE NN O O
) NN O O

The NN O O
hemochromatosis NN O B-Disease
gene NN O O
( NN O O
HFE NN O O
) NN O O
maps NN O O
to NN O O
6p21 NN O O
. NN O O

3 NN O O
and NN O O
is NN O O
less NN O O
than NN O O
1 NN O O
cM NN O O
from NN O O
the NN O O
HLA NN O O
class NN O O
I NN O O
genes NN O O
; NN O O
however NN O O
, NN O O
the NN O O
precise NN O O
physical NN O O
location NN O O
of NN O O
the NN O O
gene NN O O
has NN O O
remained NN O O
elusive NN O O
and NN O O
controversial NN O O
. NN O O

The NN O O
unambiguous NN O O
identification NN O O
of NN O O
a NN O O
crossover NN O O
event NN O O
within NN O O
hemochromatosis NN O B-Disease
families NN O O
is NN O O
very NN O O
difficult NN O O
; NN O O
it NN O O
is NN O O
particularly NN O O
hampered NN O O
by NN O O
the NN O O
variability NN O O
of NN O O
the NN O O
phenotypic NN O O
expression NN O O
as NN O O
well NN O O
as NN O O
by NN O O
the NN O O
sex NN O O
- NN O O
and NN O O
age NN O O
- NN O O
related NN O O
penetrance NN O O
of NN O O
the NN O O
disease NN O O
. NN O O

For NN O O
these NN O O
practical NN O O
considerations NN O O
, NN O O
traditional NN O O
linkage NN O O
analysis NN O O
could NN O O
prove NN O O
of NN O O
limited NN O O
value NN O O
in NN O O
further NN O O
refining NN O O
the NN O O
extrapolated NN O O
physical NN O O
position NN O O
of NN O O
HFE NN O O
. NN O O

We NN O O
therefore NN O O
embarked NN O O
upon NN O O
a NN O O
linkage NN O O
- NN O O
disequilibrium NN O O
analysis NN O O
of NN O O
HFE NN O O
and NN O O
normal NN O O
chromosomes NN O O
from NN O O
the NN O O
Brittany NN O O
population NN O O
. NN O O

In NN O O
the NN O O
present NN O O
report NN O O
, NN O O
66 NN O O
hemochromatosis NN O B-Disease
families NN O O
yielding NN O O
151 NN O O
hemochromatosis NN O B-Disease
chromosomes NN O O
and NN O O
182 NN O O
normal NN O O
chromosomes NN O O
were NN O O
RFLP NN O O
- NN O O
typed NN O O
with NN O O
a NN O O
battery NN O O
of NN O O
probes NN O O
, NN O O
including NN O O
two NN O O
newly NN O O
derived NN O O
polymorphic NN O O
markers NN O O
from NN O O
the NN O O
6 NN O O
. NN O O

7 NN O O
and NN O O
HLA NN O O
- NN O O
F NN O O
loci NN O O
located NN O O
150 NN O O
and NN O O
250 NN O O
kb NN O O
telomeric NN O O
to NN O O
HLA NN O O
- NN O O
A NN O O
, NN O O
respectively NN O O
. NN O O

The NN O O
results NN O O
suggest NN O O
a NN O O
strong NN O O
peak NN O O
of NN O O
existing NN O O
linkage NN O O
disequilibrium NN O O
focused NN O O
within NN O O
the NN O O
i82 NN O O
- NN O O
to NN O O
- NN O O
6 NN O O
. NN O O

7 NN O O
interval NN O O
( NN O O
approximately NN O O
250 NN O O
kb NN O O
) NN O O
. NN O O

The NN O O
zone NN O O
of NN O O
linkage NN O O
disequilibrium NN O O
is NN O O
flanked NN O O
by NN O O
the NN O O
i97 NN O O
locus NN O O
, NN O O
positioned NN O O
30 NN O O
kb NN O O
proximal NN O O
to NN O O
i82 NN O O
, NN O O
and NN O O
the NN O O
HLA NN O O
- NN O O
F NN O O
gene NN O O
, NN O O
found NN O O
250 NN O O
kb NN O O
distal NN O O
to NN O O
HLA NN O O
- NN O O
A NN O O
, NN O O
markers NN O O
of NN O O
which NN O O
display NN O O
no NN O O
significant NN O O
association NN O O
with NN O O
HFE NN O O
. NN O O

These NN O O
data NN O O
support NN O O
the NN O O
possibility NN O O
that NN O O
HFE NN O O
resides NN O O
within NN O O
the NN O O
400 NN O O
- NN O O
kb NN O O
expanse NN O O
of NN O O
DNA NN O O
between NN O O
i97 NN O O
and NN O O
HLA NN O O
- NN O O
F NN O O
. NN O O

Alternatively NN O O
, NN O O
the NN O O
very NN O O
tight NN O O
association NN O O
of NN O O
HLA NN O O
- NN O O
A3 NN O O
and NN O O
allele NN O O
1 NN O O
of NN O O
the NN O O
6 NN O O
. NN O O

7 NN O O
locus NN O O
, NN O O
both NN O O
of NN O O
which NN O O
are NN O O
comprised NN O O
by NN O O
the NN O O
major NN O O
ancestral NN O O
or NN O O
founder NN O O
HFE NN O O
haplotype NN O O
in NN O O
Brittany NN O O
, NN O O
supports NN O O
the NN O O
possibility NN O O
that NN O O
the NN O O
disease NN O O
gene NN O O
may NN O O
reside NN O O
immediately NN O O
telomeric NN O O
to NN O O
the NN O O
6 NN O O
. NN O O

7 NN O O
locus NN O O
within NN O O
the NN O O
linkage NN O O
- NN O O
disequilibrium NN O O
zone NN O O
. NN O O

Additionally NN O O
, NN O O
hemochromatosis NN O B-Disease
haplotypes NN O O
possessing NN O O
HLA NN O O
- NN O O
A11 NN O O
and NN O O
the NN O O
low NN O O
- NN O O
frequency NN O O
HLA NN O O
- NN O O
F NN O O
polymorphism NN O O
( NN O O
allele NN O O
2 NN O O
) NN O O
are NN O O
supportive NN O O
of NN O O
a NN O O
separate NN O O
founder NN O O
chromosome NN O O
containing NN O O
a NN O O
second NN O O
, NN O O
independently NN O O
arising NN O O
mutant NN O O
allele NN O O
. NN O O

Overall NN O O
, NN O O
the NN O O
establishment NN O O
of NN O O
a NN O O
likely NN O O
" NN O O
hemochromatosis NN O B-Disease
critical NN O O
region NN O O
" NN O O
centromeric NN O O
boundary NN O O
and NN O O
the NN O O
identification NN O O
of NN O O
a NN O O
linkage NN O O
- NN O O
disequilibrium NN O O
zone NN O O
both NN O O
significantly NN O O
contribute NN O O
to NN O O
a NN O O
reduction NN O O
in NN O O
the NN O O
amount NN O O
of NN O O
DNA NN O O
required NN O O
to NN O O
be NN O O
searched NN O O
for NN O O
novel NN O O
coding NN O O
sequences NN O O
constituting NN O O
the NN O O
HFE NN O B-Disease
defect NN O I-Disease

Genomic NN O O
structure NN O O
of NN O O
the NN O O
EWS NN O O
gene NN O O
and NN O O
its NN O O
relationship NN O O
to NN O O
EWSR1 NN O O
, NN O O
a NN O O
site NN O O
of NN O O
tumor NN O B-Disease
- NN O O
associated NN O O
chromosome NN O O
translocation NN O O
. NN O O

The NN O O
EWS NN O O
gene NN O O
has NN O O
been NN O O
identified NN O O
based NN O O
on NN O O
its NN O O
location NN O O
at NN O O
the NN O O
chromosome NN O O
22 NN O O
breakpoint NN O O
of NN O O
the NN O O
t NN O O
( NN O O
11 NN O O
; NN O O
22 NN O O
) NN O O
( NN O O
q24 NN O O
; NN O O
q12 NN O O
) NN O O
translocation NN O O
that NN O O
characterizes NN O O
Ewing NN O B-Disease
sarcoma NN O I-Disease
and NN O O
related NN O O
neuroectodermal NN O B-Disease
tumors NN O I-Disease
. NN O O

The NN O O
EWS NN O O
gene NN O O
spans NN O O
about NN O O
40 NN O O
kb NN O O
of NN O O
DNA NN O O
and NN O O
is NN O O
encoded NN O O
by NN O O
17 NN O O
exons NN O O
. NN O O

The NN O O
nucleotide NN O O
sequence NN O O
of NN O O
the NN O O
exons NN O O
is NN O O
identical NN O O
to NN O O
that NN O O
of NN O O
the NN O O
previously NN O O
described NN O O
cDNA NN O O
. NN O O

The NN O O
first NN O O
7 NN O O
exons NN O O
encode NN O O
the NN O O
N NN O O
- NN O O
terminal NN O O
domain NN O O
of NN O O
EWS NN O O
, NN O O
which NN O O
consists NN O O
of NN O O
a NN O O
repeated NN O O
degenerated NN O O
polypeptide NN O O
of NN O O
7 NN O O
to NN O O
12 NN O O
residues NN O O
rich NN O O
in NN O O
tyrosine NN O O
, NN O O
serine NN O O
, NN O O
threonine NN O O
, NN O O
glycine NN O O
, NN O O
and NN O O
glutamine NN O O
. NN O O

Exons NN O O
11 NN O O
, NN O O
12 NN O O
, NN O O
and NN O O
13 NN O O
encode NN O O
the NN O O
putative NN O O
RNA NN O O
binding NN O O
domain NN O O
. NN O O

The NN O O
three NN O O
glycine NN O O
- NN O O
and NN O O
arginine NN O O
- NN O O
rich NN O O
motifs NN O O
of NN O O
the NN O O
gene NN O O
are NN O O
mainly NN O O
encoded NN O O
by NN O O
exons NN O O
8 NN O O
- NN O O
9 NN O O
, NN O O
14 NN O O
, NN O O
and NN O O
16 NN O O
. NN O O

The NN O O
DNA NN O O
sequence NN O O
in NN O O
the NN O O
5 NN O O
region NN O O
of NN O O
the NN O O
gene NN O O
has NN O O
features NN O O
of NN O O
a NN O O
CpG NN O O
- NN O O
rich NN O O
island NN O O
and NN O O
lacks NN O O
canonical NN O O
promoter NN O O
elements NN O O
, NN O O
such NN O O
as NN O O
TATA NN O O
and NN O O
CCAAT NN O O
consensus NN O O
sequences NN O O
. NN O O

Positions NN O O
of NN O O
the NN O O
chromosome NN O O
22 NN O O
breakpoints NN O O
were NN O O
determined NN O O
for NN O O
19 NN O O
Ewing NN O B-Disease
tumors NN O I-Disease
. NN O O

They NN O O
were NN O O
localized NN O O
in NN O O
introns NN O O
7 NN O O
or NN O O
8 NN O O
in NN O O
18 NN O O
cases NN O O
and NN O O
in NN O O
intron NN O O
10 NN O O
in NN O O
1 NN O O
case NN O O
. NN O O
. NN O O

Norrie NN O B-Disease
disease NN O I-Disease
gene NN O O
: NN O O
characterization NN O O
of NN O O
deletions NN O O
and NN O O
possible NN O O
function NN O O
. NN O O

Positional NN O O
cloning NN O O
experiments NN O O
have NN O O
resulted NN O O
recently NN O O
in NN O O
the NN O O
isolation NN O O
of NN O O
a NN O O
candidate NN O O
gene NN O O
for NN O O
Norrie NN O B-Disease
disease NN O I-Disease
( NN O O
pseudoglioma NN O B-Disease
; NN O O
NDP NN O B-Disease
) NN O O
, NN O O
a NN O O
severe NN O O
X NN O B-Disease
- NN O I-Disease
linked NN O I-Disease
neurodevelopmental NN O I-Disease
disorder NN O I-Disease
. NN O O

Here NN O O
we NN O O
report NN O O
the NN O O
isolation NN O O
and NN O O
analysis NN O O
of NN O O
human NN O O
genomic NN O O
DNA NN O O
clones NN O O
encompassing NN O O
the NN O O
NDP NN O B-Disease
gene NN O O
. NN O O

The NN O O
gene NN O O
spans NN O O
28 NN O O
kb NN O O
and NN O O
consists NN O O
of NN O O
3 NN O O
exons NN O O
, NN O O
the NN O O
first NN O O
of NN O O
which NN O O
is NN O O
entirely NN O O
contained NN O O
within NN O O
the NN O O
5 NN O O
untranslated NN O O
region NN O O
. NN O O

Detailed NN O O
analysis NN O O
of NN O O
genomic NN O O
deletions NN O O
in NN O O
Norrie NN O B-Disease
patients NN O O
shows NN O O
that NN O O
they NN O O
are NN O O
heterogeneous NN O O
, NN O O
both NN O O
in NN O O
size NN O O
and NN O O
in NN O O
position NN O O
. NN O O

By NN O O
PCR NN O O
analysis NN O O
, NN O O
we NN O O
found NN O O
that NN O O
expression NN O O
of NN O O
the NN O O
NDP NN O B-Disease
gene NN O O
was NN O O
not NN O O
confined NN O O
to NN O O
the NN O O
eye NN O O
or NN O O
to NN O O
the NN O O
brain NN O O
. NN O O

An NN O O
extensive NN O O
DNA NN O O
and NN O O
protein NN O O
sequence NN O O
comparison NN O O
between NN O O
the NN O O
human NN O O
NDP NN O B-Disease
gene NN O O
and NN O O
related NN O O
genes NN O O
from NN O O
the NN O O
database NN O O
revealed NN O O
homology NN O O
with NN O O
cysteine NN O O
- NN O O
rich NN O O
protein NN O O
- NN O O
binding NN O O
domains NN O O
of NN O O
immediate NN O O
- NN O O
- NN O O
early NN O O
genes NN O O
implicated NN O O
in NN O O
the NN O O
regulation NN O O
of NN O O
cell NN O O
proliferation NN O O
. NN O O

We NN O O
propose NN O O
that NN O O
NDP NN O O
is NN O O
a NN O O
molecule NN O O
related NN O O
in NN O O
function NN O O
to NN O O
these NN O O
genes NN O O
and NN O O
may NN O O
be NN O O
involved NN O O
in NN O O
a NN O O
pathway NN O O
that NN O O
regulates NN O O
neural NN O O
cell NN O O
differentiation NN O O
and NN O O
proliferation NN O O
. NN O O
. NN O O

The NN O O
normal NN O O
Huntington NN O B-Disease
disease NN O I-Disease
( NN O O
HD NN O B-Disease
) NN O O
allele NN O O
, NN O O
or NN O O
a NN O O
closely NN O O
linked NN O O
gene NN O O
, NN O O
influences NN O O
age NN O O
at NN O O
onset NN O O
of NN O O
HD NN O B-Disease
. NN O O

We NN O O
evaluated NN O O
the NN O O
hypothesis NN O O
that NN O O
Huntington NN O B-Disease
disease NN O I-Disease
( NN O O
HD NN O B-Disease
) NN O O
is NN O O
influenced NN O O
by NN O O
the NN O O
normal NN O O
HD NN O B-Disease
allele NN O O
by NN O O
comparing NN O O
transmission NN O O
patterns NN O O
of NN O O
genetically NN O O
linked NN O O
markers NN O O
at NN O O
the NN O O
D4S10 NN O O
locus NN O O
in NN O O
the NN O O
normal NN O O
parent NN O O
against NN O O
age NN O O
at NN O O
onset NN O O
in NN O O
the NN O O
affected NN O O
offspring NN O O
. NN O O

Analysis NN O O
of NN O O
information NN O O
from NN O O
21 NN O O
sibships NN O O
in NN O O
14 NN O O
kindreds NN O O
showed NN O O
a NN O O
significant NN O O
tendency NN O O
for NN O O
sibs NN O O
who NN O O
have NN O O
similar NN O O
onset NN O O
ages NN O O
to NN O O
share NN O O
the NN O O
same NN O O
D4S10 NN O O
allele NN O O
from NN O O
the NN O O
normal NN O O
parent NN O O
. NN O O

Affected NN O O
sibs NN O O
who NN O O
inherited NN O O
different NN O O
D4S10 NN O O
alleles NN O O
from NN O O
the NN O O
normal NN O O
parent NN O O
tended NN O O
to NN O O
have NN O O
more NN O O
variable NN O O
ages NN O O
at NN O O
onset NN O O
. NN O O

These NN O O
findings NN O O
suggest NN O O
that NN O O
the NN O O
expression NN O O
of NN O O
HD NN O B-Disease
is NN O O
modulated NN O O
by NN O O
the NN O O
normal NN O O
HD NN O B-Disease
allele NN O O
or NN O O
by NN O O
a NN O O
closely NN O O
linked NN O O
locus NN O O
. NN O O
. NN O O

Further NN O O
investigation NN O O
of NN O O
the NN O O
HEXA NN O O
gene NN O O
intron NN O O
9 NN O O
donor NN O O
splice NN O O
site NN O O
mutation NN O O
frequently NN O O
found NN O O
in NN O O
non NN O O
- NN O O
Jewish NN O O
Tay NN O B-Disease
- NN O I-Disease
Sachs NN O I-Disease
disease NN O I-Disease
patients NN O O
from NN O O
the NN O O
British NN O O
Isles NN O O
. NN O O

In NN O O
a NN O O
previous NN O O
study NN O O
we NN O O
found NN O O
that NN O O
a NN O O
Tay NN O B-Disease
- NN O I-Disease
Sachs NN O I-Disease
disease NN O I-Disease
( NN O O
TSD NN O B-Disease
) NN O O
causing NN O O
mutation NN O O
in NN O O
the NN O O
intron NN O O
9 NN O O
donor NN O O
splice NN O O
site NN O O
of NN O O
the NN O O
HEXA NN O O
gene NN O O
occurs NN O O
at NN O O
high NN O O
frequency NN O O
in NN O O
non NN O O
- NN O O
Jewish NN O O
patients NN O O
and NN O O
carriers NN O O
from NN O O
the NN O O
British NN O O
Isles NN O O
. NN O O

It NN O O
was NN O O
found NN O O
more NN O O
frequently NN O O
in NN O O
subjects NN O O
of NN O O
Irish NN O O
, NN O O
Scottish NN O O
, NN O O
and NN O O
Welsh NN O O
origin NN O O
compared NN O O
with NN O O
English NN O O
origin NN O O
( NN O O
63 NN O O
% NN O O
and NN O O
31 NN O O
% NN O O
respectively NN O O
) NN O O
. NN O O

We NN O O
have NN O O
now NN O O
tested NN O O
, NN O O
in NN O O
a NN O O
blind NN O O
study NN O O
, NN O O
26 NN O O
American NN O O
TSD NN O B-Disease
carriers NN O O
and NN O O
28 NN O O
non NN O O
- NN O O
carriers NN O O
who NN O O
have NN O O
British NN O O
ancestry NN O O
for NN O O
the NN O O
intron NN O O
9 NN O O
splice NN O O
site NN O O
mutation NN O O
. NN O O

Six NN O O
of NN O O
the NN O O
carriers NN O O
and NN O O
none NN O O
of NN O O
the NN O O
controls NN O O
were NN O O
positive NN O O
for NN O O
the NN O O
mutation NN O O
. NN O O

All NN O O
six NN O O
had NN O O
Irish NN O O
ancestry NN O O
, NN O O
compared NN O O
with NN O O
nine NN O O
of NN O O
the NN O O
20 NN O O
other NN O O
( NN O O
intron NN O O
9 NN O O
mutation NN O O
negative NN O O
) NN O O
TSD NN O B-Disease
carriers NN O O
( NN O O
p NN O O
< NN O O
0 NN O O
. NN O O
05 NN O O
) NN O O
. NN O O

These NN O O
results NN O O
confirm NN O O
the NN O O
previously NN O O
found NN O O
high NN O O
frequency NN O O
of NN O O
the NN O O
intron NN O O
9 NN O O
mutation NN O O
in NN O O
non NN O O
- NN O O
Jewish NN O O
TSD NN O B-Disease
families NN O O
of NN O O
British NN O O
Isles NN O O
, NN O O
particularly NN O O
Irish NN O O
, NN O O
origin NN O O
, NN O O
and NN O O
reinforce NN O O
the NN O O
need NN O O
to NN O O
screen NN O O
such NN O O
families NN O O
for NN O O
this NN O O
mutation NN O O
. NN O O

Molecular NN O O
mechanisms NN O O
of NN O O
oncogenic NN O O
mutations NN O O
in NN O O
tumors NN O B-Disease
from NN O O
patients NN O O
with NN O O
bilateral NN O B-Disease
and NN O I-Disease
unilateral NN O I-Disease
retinoblastoma NN O I-Disease
. NN O O

The NN O O
RB1 NN O O
gene NN O O
from NN O O
12 NN O O
human NN O O
retinoblastoma NN O B-Disease
tumors NN O I-Disease
has NN O O
been NN O O
analyzed NN O O
exon NN O O
- NN O O
by NN O O
- NN O O
exon NN O O
with NN O O
the NN O O
single NN O O
- NN O O
strand NN O O
conformation NN O O
polymorphism NN O O
technique NN O O
. NN O O

Mutations NN O O
were NN O O
found NN O O
in NN O O
all NN O O
tumors NN O B-Disease
, NN O O
and NN O O
one NN O O
- NN O O
third NN O O
of NN O O
the NN O O
tumors NN O B-Disease
had NN O O
independent NN O O
mutations NN O O
in NN O O
both NN O O
alleles NN O O
neither NN O O
of NN O O
which NN O O
were NN O O
found NN O O
in NN O O
the NN O O
germ NN O O
line NN O O
, NN O O
confirming NN O O
their NN O O
true NN O O
sporadic NN O O
nature NN O O
. NN O O

In NN O O
the NN O O
remaining NN O O
two NN O O
- NN O O
thirds NN O O
of NN O O
the NN O O
tumors NN O B-Disease
only NN O O
one NN O O
mutation NN O O
was NN O O
found NN O O
, NN O O
consistent NN O O
with NN O O
the NN O O
loss NN O O
- NN O O
of NN O O
- NN O O
heterozygosity NN O O
theory NN O O
of NN O O
tumorigenesis NN O O
. NN O O

Point NN O O
mutations NN O O
, NN O O
the NN O O
majority NN O O
of NN O O
which NN O O
were NN O O
C NN O O
- NN O O
- NN O O
> NN O O
T NN O O
transitions NN O O
, NN O O
were NN O O
the NN O O
most NN O O
common NN O O
abnormality NN O O
and NN O O
usually NN O O
resulted NN O O
in NN O O
the NN O O
conversion NN O O
of NN O O
an NN O O
arginine NN O O
codon NN O O
to NN O O
a NN O O
stop NN O O
codon NN O O
. NN O O

Small NN O O
deletions NN O O
were NN O O
the NN O O
second NN O O
most NN O O
common NN O O
abnormality NN O O
and NN O O
most NN O O
often NN O O
created NN O O
a NN O O
downstream NN O O
stop NN O O
codon NN O O
as NN O O
the NN O O
result NN O O
of NN O O
a NN O O
reading NN O O
frameshift NN O O
. NN O O

Deletions NN O O
and NN O O
point NN O O
mutations NN O O
also NN O O
affected NN O O
splice NN O O
junctions NN O O
. NN O O

Direct NN O O
repeats NN O O
were NN O O
present NN O O
at NN O O
the NN O O
breakpoint NN O O
junctions NN O O
in NN O O
the NN O O
majority NN O O
of NN O O
deletions NN O O
, NN O O
supporting NN O O
a NN O O
slipped NN O O
- NN O O
mispairing NN O O
mechanism NN O O
. NN O O

Point NN O O
mutations NN O O
generally NN O O
produced NN O O
DNA NN O O
sequences NN O O
which NN O O
resulted NN O O
in NN O O
perfect NN O O
homology NN O O
with NN O O
endogenous NN O O
sequences NN O O
which NN O O
lay NN O O
within NN O O
14 NN O O
bp NN O O
. NN O O
. NN O O

PAX6 NN O O
mutations NN O O
in NN O O
aniridia NN O B-Disease
. NN O O

Aniridia NN O B-Disease
is NN O O
a NN O O
congenital NN O B-Disease
malformation NN O I-Disease
of NN O I-Disease
the NN O I-Disease
eye NN O I-Disease
, NN O O
chiefly NN O O
characterised NN O O
by NN O O
iris NN O B-Disease
hypoplasia NN O I-Disease
, NN O O
which NN O O
can NN O O
cause NN O O
blindness NN O B-Disease
. NN O O

The NN O O
PAX6 NN O O
gene NN O O
was NN O O
isolated NN O O
as NN O O
a NN O O
candidate NN O O
aniridia NN O B-Disease
gene NN O O
by NN O O
positional NN O O
cloning NN O O
from NN O O
the NN O O
smallest NN O O
region NN O O
of NN O O
overlap NN O O
of NN O O
aniridia NN O B-Disease
- NN O O
associated NN O O
deletions NN O O
. NN O O

Subsequently NN O O
PAX6 NN O O
intragenic NN O O
mutations NN O O
were NN O O
demonstrated NN O O
in NN O O
Smalleye NN O O
, NN O O
a NN O O
mouse NN O O
mutant NN O O
which NN O O
is NN O O
an NN O O
animal NN O O
model NN O O
for NN O O
aniridia NN O B-Disease
, NN O O
and NN O O
six NN O O
human NN O O
aniridia NN O B-Disease
patients NN O O
. NN O O

In NN O O
this NN O O
paper NN O O
we NN O O
describe NN O O
four NN O O
additional NN O O
PAX6 NN O O
point NN O O
mutations NN O O
in NN O O
aniridia NN O B-Disease
patients NN O O
, NN O O
both NN O O
sporadic NN O O
and NN O O
familial NN O O
. NN O O

These NN O O
mutations NN O O
highlight NN O O
regions NN O O
of NN O O
the NN O O
gene NN O O
which NN O O
are NN O O
essential NN O O
for NN O O
normal NN O O
PAX6 NN O O
function NN O O
. NN O O

In NN O O
addition NN O O
, NN O O
the NN O O
frequency NN O O
at NN O O
which NN O O
we NN O O
have NN O O
found NN O O
PAX6 NN O O
mutations NN O O
suggests NN O O
that NN O O
lesions NN O O
in NN O O
PAX6 NN O O
will NN O O
account NN O O
for NN O O
most NN O O
cases NN O O
of NN O O
aniridia NN O B-Disease
. NN O O
. NN O O

Detection NN O O
of NN O O
a NN O O
novel NN O O
arginine NN O O
vasopressin NN O O
defect NN O O
by NN O O
dideoxy NN O O
fingerprinting NN O O
. NN O O

Autosomal NN O B-Disease
dominant NN O I-Disease
neurohypophyseal NN O I-Disease
diabetes NN O I-Disease
insipidus NN O I-Disease
is NN O O
a NN O O
familial NN O O
form NN O O
of NN O O
diabetes NN O B-Disease
insipidus NN O I-Disease
. NN O O

This NN O O
disorder NN O O
is NN O O
associated NN O O
with NN O O
variable NN O O
levels NN O O
of NN O O
arginine NN O O
vasopressin NN O O
( NN O O
AVP NN O O
) NN O O
and NN O O
diabetes NN O B-Disease
insipidus NN O I-Disease
of NN O O
varying NN O O
severity NN O O
, NN O O
which NN O O
responds NN O O
to NN O O
exogenous NN O O
AVP NN O O
. NN O O

To NN O O
determine NN O O
the NN O O
molecular NN O O
basis NN O O
of NN O O
autosomal NN O B-Disease
dominant NN O I-Disease
neurohypophyseal NN O I-Disease
diabetes NN O I-Disease
insipidus NN O I-Disease
, NN O O
the NN O O
AVP NN O O
genes NN O O
of NN O O
members NN O O
of NN O O
a NN O O
large NN O O
kindred NN O O
were NN O O
analyzed NN O O
. NN O O

A NN O O
new NN O O
method NN O O
, NN O O
called NN O O
dideoxy NN O O
fingerprinting NN O O
, NN O O
was NN O O
used NN O O
to NN O O
detect NN O O
an NN O O
AVP NN O O
mutation NN O O
that NN O O
was NN O O
characterized NN O O
by NN O O
DNA NN O O
sequencing NN O O
. NN O O

The NN O O
novel NN O O
defect NN O O
found NN O O
changes NN O O
the NN O O
last NN O O
codon NN O O
of NN O O
the NN O O
AVP NN O O
signal NN O O
peptide NN O O
from NN O O
alanine NN O O
to NN O O
threonine NN O O
, NN O O
which NN O O
should NN O O
perturb NN O O
cleavage NN O O
of NN O O
mature NN O O
AVP NN O O
from NN O O
its NN O O
precursor NN O O
protein NN O O
and NN O O
inhibit NN O O
its NN O O
secretion NN O O
or NN O O
action NN O O
. NN O O
. NN O O

Germinal NN O O
mosaicism NN O O
in NN O O
a NN O O
Duchenne NN O B-Disease
muscular NN O I-Disease
dystrophy NN O I-Disease
family NN O O
: NN O O
implications NN O O
for NN O O
genetic NN O O
counselling NN O O
. NN O O

In NN O O
this NN O O
study NN O O
we NN O O
describe NN O O
a NN O O
three NN O O
- NN O O
generation NN O O
family NN O O
in NN O O
which NN O O
two NN O O
siblings NN O O
were NN O O
affected NN O O
by NN O O
Duchenne NN O B-Disease
muscular NN O I-Disease
dystrophy NN O I-Disease
( NN O O
DMD NN O B-Disease
) NN O O
. NN O O

Immunohistochemical NN O O
analysis NN O O
of NN O O
muscle NN O O
dystrophin NN O O
and NN O O
haplotype NN O O
analysis NN O O
of NN O O
the NN O O
DMD NN O B-Disease
locus NN O O
revealed NN O O
that NN O O
the NN O O
X NN O O
chromosome NN O O
carrying NN O O
the NN O O
DMD NN O B-Disease
gene NN O O
was NN O O
transmitted NN O O
from NN O O
the NN O O
healthy NN O O
maternal NN O O
grandfather NN O O
to NN O O
his NN O O
three NN O O
daughters NN O O
, NN O O
including NN O O
the NN O O
probands NN O O
mother NN O O
. NN O O

These NN O O
findings NN O O
indicate NN O O
that NN O O
the NN O O
grandfather NN O O
was NN O O
a NN O O
germinal NN O O
mosaic NN O O
for NN O O
the NN O O
DMD NN O B-Disease
gene NN O O
. NN O O

The NN O O
definition NN O O
of NN O O
the NN O O
carrier NN O O
status NN O O
in NN O O
two NN O O
possible NN O O
carriers NN O O
led NN O O
us NN O O
to NN O O
give NN O O
accurate NN O O
genetic NN O O
counselling NN O O
and NN O O
to NN O O
prevent NN O O
the NN O O
birth NN O O
of NN O O
an NN O O
affected NN O O
boy NN O O
. NN O O

The NN O O
results NN O O
of NN O O
this NN O O
study NN O O
demonstrate NN O O
the NN O O
usefulness NN O O
of NN O O
haplotype NN O O
analysis NN O O
and NN O O
immunohistochemical NN O O
muscle NN O O
dystrophin NN O O
studies NN O O
to NN O O
detect NN O O
hidden NN O O
germinal NN O O
mosaicism NN O O
and NN O O
to NN O O
improve NN O O
genetic NN O O
counselling NN O O
. NN O O
. NN O O

Genetic NN O O
mapping NN O O
of NN O O
the NN O O
breast NN O B-Disease
- NN O I-Disease
ovarian NN O I-Disease
cancer NN O I-Disease
syndrome NN O I-Disease
to NN O O
a NN O O
small NN O O
interval NN O O
on NN O O
chromosome NN O O
17q12 NN O O
- NN O O
21 NN O O
: NN O O
exclusion NN O O
of NN O O
candidate NN O O
genes NN O O
EDH17B2 NN O O
and NN O O
RARA NN O O
. NN O O

A NN O O
susceptibility NN O O
gene NN O O
for NN O O
hereditary NN O B-Disease
breast NN O I-Disease
- NN O I-Disease
ovarian NN O I-Disease
cancer NN O I-Disease
, NN O O
BRCA1 NN O O
, NN O O
has NN O O
been NN O O
assigned NN O O
by NN O O
linkage NN O O
analysis NN O O
to NN O O
chromosome NN O O
17q21 NN O O
. NN O O

Candidate NN O O
genes NN O O
in NN O O
this NN O O
region NN O O
include NN O O
EDH17B2 NN O O
, NN O O
which NN O O
encodes NN O O
estradiol NN O O
17 NN O O
beta NN O O
- NN O O
hydroxysteroid NN O O
dehydrogenase NN O O
II NN O O
( NN O O
17 NN O O
beta NN O O
- NN O O
HSD NN O O
II NN O O
) NN O O
, NN O O
and NN O O
RARA NN O O
, NN O O
the NN O O
gene NN O O
for NN O O
retinoic NN O O
acid NN O O
receptor NN O O
alpha NN O O
. NN O O

We NN O O
have NN O O
typed NN O O
22 NN O O
breast NN O B-Disease
and NN O I-Disease
breast NN O I-Disease
- NN O I-Disease
ovarian NN O I-Disease
cancer NN O I-Disease
families NN O O
with NN O O
eight NN O O
polymorphisms NN O O
from NN O O
the NN O O
chromosome NN O O
17q12 NN O O
- NN O O
21 NN O O
region NN O O
, NN O O
including NN O O
two NN O O
in NN O O
the NN O O
EDH17B2 NN O O
gene NN O O
. NN O O

Genetic NN O O
recombination NN O O
with NN O O
the NN O O
breast NN O B-Disease
cancer NN O I-Disease
trait NN O O
excludes NN O O
RARA NN O O
from NN O O
further NN O O
consideration NN O O
as NN O O
a NN O O
candidate NN O O
gene NN O O
for NN O O
BRCA1 NN O O
. NN O O

Both NN O O
BRCA1 NN O O
and NN O O
EDH17B2 NN O O
map NN O O
to NN O O
a NN O O
6 NN O O
cM NN O O
interval NN O O
( NN O O
between NN O O
THRA1 NN O O
and NN O O
D17S579 NN O O
) NN O O
and NN O O
no NN O O
recombination NN O O
was NN O O
observed NN O O
between NN O O
the NN O O
two NN O O
genes NN O O
. NN O O

However NN O O
, NN O O
direct NN O O
sequencing NN O O
of NN O O
overlapping NN O O
PCR NN O O
products NN O O
containing NN O O
the NN O O
entire NN O O
EDH17B2 NN O O
gene NN O O
in NN O O
four NN O O
unrelated NN O O
affected NN O O
women NN O O
did NN O O
not NN O O
uncover NN O O
any NN O O
sequence NN O O
variation NN O O
, NN O O
other NN O O
than NN O O
previously NN O O
described NN O O
polymorphisms NN O O
. NN O O

Mutations NN O O
in NN O O
the NN O O
EDH17B2 NN O O
gene NN O O
, NN O O
therefore NN O O
do NN O O
not NN O O
appear NN O O
to NN O O
be NN O O
responsible NN O O
for NN O O
the NN O O
hereditary NN O B-Disease
breast NN O I-Disease
- NN O I-Disease
ovarian NN O I-Disease
cancer NN O I-Disease
syndrome NN O I-Disease
. NN O O

Single NN O O
meiotic NN O O
crossovers NN O O
in NN O O
affected NN O O
women NN O O
suggest NN O O
that NN O O
BRCA1 NN O O
is NN O O
flanked NN O O
by NN O O
the NN O O
loci NN O O
RARA NN O O
and NN O O
D17S78 NN O O
. NN O O
. NN O O

A NN O O
missense NN O O
mutation NN O O
in NN O O
the NN O O
cholesteryl NN O O
ester NN O O
transfer NN O O
protein NN O O
gene NN O O
with NN O O
possible NN O O
dominant NN O O
effects NN O O
on NN O O
plasma NN O O
high NN O O
density NN O O
lipoproteins NN O O
. NN O O

Plasma NN O O
HDL NN O O
are NN O O
a NN O O
negative NN O O
risk NN O O
factor NN O O
for NN O O
atherosclerosis NN O B-Disease
. NN O O

Cholesteryl NN O O
ester NN O O
transfer NN O O
protein NN O O
( NN O O
CETP NN O O
; NN O O
476 NN O O
amino NN O O
acids NN O O
) NN O O
transfers NN O O
cholesteryl NN O O
ester NN O O
from NN O O
HDL NN O O
to NN O O
other NN O O
lipoproteins NN O O
. NN O O

Subjects NN O O
with NN O O
homozygous NN O O
CETP NN O B-Disease
deficiency NN O I-Disease
caused NN O O
by NN O O
a NN O O
gene NN O O
splicing NN O O
defect NN O O
have NN O O
markedly NN O O
elevated NN O O
HDL NN O O
; NN O O
however NN O O
, NN O O
heterozygotes NN O O
have NN O O
only NN O O
mild NN O O
increases NN O O
in NN O O
HDL NN O O
. NN O O

We NN O O
describe NN O O
two NN O O
probands NN O O
with NN O O
a NN O O
CETP NN O O
missense NN O O
mutation NN O O
( NN O O
442 NN O O
D NN O O
G NN O O
) NN O O
. NN O O

Although NN O O
heterozygous NN O O
, NN O O
they NN O O
have NN O O
threefold NN O O
increases NN O O
in NN O O
HDL NN O O
concentration NN O O
and NN O O
markedly NN O O
decreased NN O O
plasma NN O O
CETP NN O O
mass NN O O
and NN O O
activity NN O O
, NN O O
suggesting NN O O
that NN O O
the NN O O
mutation NN O O
has NN O O
dominant NN O O
effects NN O O
on NN O O
CETP NN O O
and NN O O
HDL NN O O
in NN O O
vivo NN O O
. NN O O

Cellular NN O O
expression NN O O
of NN O O
mutant NN O O
cDNA NN O O
results NN O O
in NN O O
secretion NN O O
of NN O O
only NN O O
30 NN O O
% NN O O
of NN O O
wild NN O O
type NN O O
CETP NN O O
activity NN O O
. NN O O

Moreover NN O O
, NN O O
coexpression NN O O
of NN O O
wild NN O O
type NN O O
and NN O O
mutant NN O O
cDNAs NN O O
leads NN O O
to NN O O
inhibition NN O O
of NN O O
wild NN O O
type NN O O
secretion NN O O
and NN O O
activity NN O O
. NN O O

The NN O O
dominant NN O O
effects NN O O
of NN O O
the NN O O
CETP NN O O
missense NN O O
mutation NN O O
during NN O O
cellular NN O O
expression NN O O
probably NN O O
explains NN O O
why NN O O
the NN O O
probands NN O O
have NN O O
markedly NN O O
increased NN O O
HDL NN O O
in NN O O
the NN O O
heterozygous NN O O
state NN O O
, NN O O
and NN O O
suggests NN O O
that NN O O
the NN O O
active NN O O
molecular NN O O
species NN O O
of NN O O
CETP NN O O
may NN O O
be NN O O
multimeric NN O O
. NN O O
. NN O O

Familial NN O B-Disease
Mediterranean NN O I-Disease
fever NN O I-Disease
in NN O O
the NN O O
colchicine NN O O
era NN O O
: NN O O
the NN O O
fate NN O O
of NN O O
one NN O O
family NN O O
. NN O O

In NN O O
order NN O O
to NN O O
demonstrate NN O O
the NN O O
effect NN O O
of NN O O
prophylactic NN O O
colchicine NN O O
treatment NN O O
on NN O O
the NN O O
natural NN O O
history NN O O
of NN O O
familial NN O B-Disease
Mediterranean NN O I-Disease
fever NN O I-Disease
( NN O O
FMF NN O B-Disease
) NN O O
, NN O O
a NN O O
family NN O O
is NN O O
presented NN O O
with NN O O
6 NN O O
out NN O O
of NN O O
9 NN O O
siblings NN O O
affected NN O O
by NN O O
FMF NN O B-Disease
. NN O O

Each NN O O
patient NN O O
represents NN O O
a NN O O
different NN O O
stage NN O O
of NN O O
the NN O O
amyloidotic NN O B-Disease
kidney NN O I-Disease
disease NN O I-Disease
of NN O O
FMF NN O B-Disease
and NN O O
the NN O O
effect NN O O
of NN O O
continuous NN O O
colchicine NN O O
treatment NN O O
on NN O O
its NN O O
course NN O O
. NN O O

Considered NN O O
together NN O O
, NN O O
the NN O O
members NN O O
of NN O O
this NN O O
family NN O O
present NN O O
an NN O O
almost NN O O
complete NN O O
clinical NN O O
, NN O O
genetic NN O O
, NN O O
and NN O O
behavioral NN O O
picture NN O O
of NN O O
the NN O O
disease NN O O
. NN O O
. NN O O

Detection NN O O
of NN O O
a NN O O
new NN O O
submicroscopic NN O O
Norrie NN O B-Disease
disease NN O I-Disease
deletion NN O O
interval NN O O
with NN O O
a NN O O
novel NN O O
DNA NN O O
probe NN O O
isolated NN O O
by NN O O
differential NN O O
Alu NN O O
PCR NN O O
fingerprint NN O O
cloning NN O O
. NN O O

Differential NN O O
Alu NN O O
PCR NN O O
fingerprint NN O O
cloning NN O O
was NN O O
used NN O O
to NN O O
isolate NN O O
a NN O O
DNA NN O O
probe NN O O
from NN O O
the NN O O
Xp11 NN O O
. NN O O

4 NN O O
- NN O O
- NN O O
> NN O O
p11 NN O O
. NN O O

21 NN O O
region NN O O
of NN O O
the NN O O
human NN O O
X NN O O
chromosome NN O O
. NN O O

This NN O O
novel NN O O
sequence NN O O
, NN O O
cpXr318 NN O O
( NN O O
DXS742 NN O O
) NN O O
, NN O O
detects NN O O
a NN O O
new NN O O
submicroscopic NN O O
deletion NN O O
interval NN O O
at NN O O
the NN O O
Norrie NN O B-Disease
disease NN O I-Disease
locus NN O O
( NN O O
NDP NN O O
) NN O O
. NN O O

Combining NN O O
our NN O O
data NN O O
with NN O O
the NN O O
consensus NN O O
genetic NN O O
map NN O O
of NN O O
the NN O O
proximal NN O O
short NN O O
arm NN O O
of NN O O
the NN O O
X NN O O
chromosome NN O O
, NN O O
we NN O O
propose NN O O
the NN O O
physical NN O O
order NN O O
Xcen NN O O
- NN O O
DXS14 NN O O
- NN O O
DXS255 NN O O
- NN O O
( NN O O
DXS426 NN O O
, NN O O
TIMP NN O O
) NN O O
- NN O O
( NN O O
DXS742 NN O O
- NN O O
( NN O O
[ NN O O
MAOB NN O O
- NN O O
MAOA NN O O
- NN O O
DXS7 NN O O
] NN O O
, NN O O
NDP NN O O
) NN O O
- NN O O
DXS77 NN O O
- NN O O
DXS228 NN O O
) NN O O
- NN O O
DXS209 NN O O
- NN O O
DXS148 NN O O
- NN O O
DXS196 NN O O
- NN O O
+ NN O O
+ NN O O
+ NN O O
Xpter NN O O
. NN O O

The NN O O
cpXr318 NN O O
probe NN O O
and NN O O
a NN O O
subclone NN O O
from NN O O
a NN O O
cosmid NN O O
corresponding NN O O
to NN O O
the NN O O
DXS7 NN O O
locus NN O O
were NN O O
converted NN O O
into NN O O
sequence NN O O
- NN O O
tagged NN O O
sites NN O O
. NN O O

Finally NN O O
, NN O O
DXS742 NN O O
, NN O O
DSX7 NN O O
, NN O O
DXS77 NN O O
, NN O O
and NN O O
MAOA NN O O
were NN O O
integrated NN O O
into NN O O
a NN O O
physical NN O O
map NN O O
spanning NN O O
the NN O O
Norrie NN O B-Disease
disease NN O I-Disease
locus NN O O

Putative NN O O
X NN O B-Disease
- NN O I-Disease
linked NN O I-Disease
adrenoleukodystrophy NN O I-Disease
gene NN O O
shares NN O O
unexpected NN O O
homology NN O O
with NN O O
ABC NN O O
transporters NN O O
. NN O O

Adrenoleukodystrophy NN O B-Disease
( NN O O
ALD NN O B-Disease
) NN O O
is NN O O
an NN O O
X NN O B-Disease
- NN O I-Disease
linked NN O I-Disease
disease NN O I-Disease
affecting NN O O
1 NN O O
/ NN O O
20 NN O O
, NN O O
000 NN O O
males NN O O
either NN O O
as NN O O
cerebral NN O B-Disease
ALD NN O I-Disease
in NN O O
childhood NN O O
or NN O O
as NN O O
adrenomyeloneuropathy NN O B-Disease
( NN O O
AMN NN O B-Disease
) NN O O
in NN O O
adults NN O O
. NN O O

Childhood NN O O
ALD NN O B-Disease
is NN O O
the NN O O
more NN O O
severe NN O O
form NN O O
, NN O O
with NN O O
onset NN O O
of NN O O
neurological NN O O
symptoms NN O O
between NN O O
5 NN O O
- NN O O
12 NN O O
years NN O O
of NN O O
age NN O O
. NN O O

Central NN O B-Disease
nervous NN O I-Disease
system NN O I-Disease
demyelination NN O I-Disease
progresses NN O O
rapidly NN O O
and NN O O
death NN O O
occurs NN O O
within NN O O
a NN O O
few NN O O
years NN O O
. NN O O

AMN NN O B-Disease
is NN O O
a NN O O
milder NN O O
form NN O O
of NN O O
the NN O O
disease NN O O
with NN O O
onset NN O O
at NN O O
15 NN O O
- NN O O
30 NN O O
years NN O O
of NN O O
age NN O O
and NN O O
a NN O O
more NN O O
progressive NN O O
course NN O O
. NN O O

Adrenal NN O B-Disease
insufficiency NN O I-Disease
( NN O O
Addisons NN O B-Disease
disease NN O I-Disease
) NN O O
may NN O O
remain NN O O
the NN O O
only NN O O
clinical NN O O
manifestation NN O O
of NN O O
ALD NN O B-Disease
. NN O O

The NN O O
principal NN O O
biochemical NN O O
abnormality NN O O
of NN O O
ALD NN O B-Disease
is NN O O
the NN O O
accumulation NN O O
of NN O O
very NN O O
- NN O O
long NN O O
- NN O O
chain NN O O
fatty NN O O
acids NN O O
( NN O O
VLCFA NN O O
) NN O O
because NN O O
of NN O O
impaired NN O O
beta NN O O
- NN O O
oxidation NN O O
in NN O O
peroxisomes NN O O
. NN O O

The NN O O
normal NN O O
oxidation NN O O
of NN O O
VLCFA NN O O
- NN O O
CoA NN O O
in NN O O
patients NN O O
fibroblasts NN O O
suggested NN O O
that NN O O
the NN O O
gene NN O O
coding NN O O
for NN O O
the NN O O
VLCFA NN O O
- NN O O
CoA NN O O
synthetase NN O O
could NN O O
be NN O O
a NN O O
candidate NN O O
gene NN O O
for NN O O
ALD NN O B-Disease
. NN O O

Here NN O O
we NN O O
use NN O O
positional NN O O
cloning NN O O
to NN O O
identify NN O O
a NN O O
gene NN O O
partially NN O O
deleted NN O O
in NN O O
6 NN O O
of NN O O
85 NN O O
independent NN O O
patients NN O O
with NN O O
ALD NN O B-Disease
. NN O O

In NN O O
familial NN O O
cases NN O O
, NN O O
the NN O O
deletions NN O O
segregated NN O O
with NN O O
the NN O O
disease NN O O
. NN O O

An NN O O
identical NN O O
deletion NN O O
was NN O O
detected NN O O
in NN O O
two NN O O
brothers NN O O
presenting NN O O
with NN O O
different NN O O
clinical NN O O
ALD NN O B-Disease
phenotypes NN O O
. NN O O

Candidate NN O O
exons NN O O
were NN O O
identified NN O O
by NN O O
computer NN O O
analysis NN O O
of NN O O
genomic NN O O
sequences NN O O
and NN O O
used NN O O
to NN O O
isolate NN O O
complementary NN O O
DNAs NN O O
by NN O O
exon NN O O
connection NN O O
and NN O O
screening NN O O
of NN O O
cDNA NN O O
libraries NN O O
. NN O O

The NN O O
deduced NN O O
protein NN O O
sequence NN O O
shows NN O O
significant NN O O
sequence NN O O
identity NN O O
to NN O O
a NN O O
peroxisomal NN O O
membrane NN O O
protein NN O O
of NN O O
M NN O O
( NN O O
r NN O O
) NN O O
70K NN O O
that NN O O
is NN O O
involved NN O O
in NN O O
peroxisome NN O O
biogenesis NN O O
and NN O O
belongs NN O O
to NN O O
the NN O O
ATP NN O O
- NN O O
binding NN O O
cassette NN O O
superfamily NN O O
of NN O O
transporters NN O O
. NN O O
. NN O O

Targeted NN O O
modification NN O O
of NN O O
the NN O O
apolipoprotein NN O O
B NN O O
gene NN O O
results NN O O
in NN O O
hypobetalipoproteinemia NN O B-Disease
and NN O O
developmental NN O B-Disease
abnormalities NN O I-Disease
in NN O O
mice NN O O
. NN O O

Familial NN O B-Disease
hypobetalipoproteinemia NN O I-Disease
is NN O O
an NN O O
autosomal NN O B-Disease
codominant NN O I-Disease
disorder NN O I-Disease
resulting NN O O
in NN O O
a NN O O
dramatic NN O O
reduction NN O O
in NN O O
plasma NN O O
concentrations NN O O
of NN O O
apolipoprotein NN O O
( NN O O
apo NN O O
) NN O O
B NN O O
, NN O O
cholesterol NN O O
, NN O O
and NN O O
beta NN O O
- NN O O
migrating NN O O
lipoproteins NN O O
. NN O O

A NN O O
benefit NN O O
of NN O O
hypobetalipoproteinemia NN O B-Disease
is NN O O
that NN O O
mildly NN O O
affected NN O O
individuals NN O O
may NN O O
be NN O O
protected NN O O
from NN O O
coronary NN O B-Disease
vascular NN O I-Disease
disease NN O I-Disease
. NN O O

We NN O O
have NN O O
used NN O O
gene NN O O
targeting NN O O
to NN O O
generate NN O O
mice NN O O
with NN O O
a NN O O
modified NN O O
Apob NN O O
allele NN O O
. NN O O

Mice NN O O
containing NN O O
this NN O O
allele NN O O
display NN O O
all NN O O
of NN O O
the NN O O
hallmarks NN O O
of NN O O
human NN O O
hypobetalipoproteinemia NN O B-Disease
they NN O O
produce NN O O
a NN O O
truncated NN O O
apoB NN O O
protein NN O O
, NN O O
apoB70 NN O O
, NN O O
and NN O O
have NN O O
markedly NN O O
decreased NN O O
plasma NN O O
concentrations NN O O
of NN O O
apoB NN O O
, NN O O
beta NN O O
- NN O O
lipoproteins NN O O
, NN O O
and NN O O
total NN O O
cholesterol NN O O
. NN O O

In NN O O
addition NN O O
, NN O O
the NN O O
mice NN O O
manifest NN O O
several NN O O
characteristics NN O O
that NN O O
are NN O O
occasionally NN O O
observed NN O O
in NN O O
human NN O O
hypobetalipoproteinemia NN O B-Disease
, NN O O
including NN O O
reduced NN O O
plasma NN O O
triglyceride NN O O
concentrations NN O O
, NN O O
fasting NN O O
chylomicronemia NN O B-Disease
, NN O O
and NN O O
reduced NN O O
high NN O O
density NN O O
lipoprotein NN O O
cholesterol NN O O
. NN O O

An NN O O
unexpected NN O O
finding NN O O
is NN O O
that NN O O
the NN O O
modified NN O O
Apob NN O O
allele NN O O
is NN O O
strongly NN O O
associated NN O O
with NN O O
exencephalus NN O B-Disease
and NN O O
hydrocephalus NN O B-Disease
. NN O O

These NN O O
mice NN O O
should NN O O
help NN O O
increase NN O O
our NN O O
understanding NN O O
of NN O O
hypobetalipoproteinemia NN O B-Disease
, NN O O
atherogenesis NN O B-Disease
, NN O O
and NN O O
the NN O O
etiology NN O O
of NN O O
exencephalus NN O B-Disease
and NN O O
hydrocephalus NN O B-Disease
. NN O O
. NN O O

A NN O O
novel NN O O
disease NN O O
with NN O O
deficiency NN O B-Disease
of NN O I-Disease
mitochondrial NN O I-Disease
very NN O I-Disease
- NN O I-Disease
long NN O I-Disease
- NN O I-Disease
chain NN O I-Disease
acyl NN O I-Disease
- NN O I-Disease
CoA NN O I-Disease
dehydrogenase NN O I-Disease
. NN O O

Palmitoyl NN O O
- NN O O
CoA NN O O
dehydrogenase NN O O
activity NN O O
in NN O O
skin NN O O
fibroblasts NN O O
from NN O O
seven NN O O
patients NN O O
with NN O O
unidentified NN O O
defects NN O O
of NN O O
fatty NN O O
acid NN O O
oxidation NN O O
was NN O O
measured NN O O
in NN O O
the NN O O
presence NN O O
and NN O O
absence NN O O
of NN O O
antibodies NN O O
against NN O O
medium NN O O
- NN O O
chain NN O O
, NN O O
long NN O O
- NN O O
chain NN O O
, NN O O
and NN O O
very NN O O
- NN O O
long NN O O
- NN O O
chain NN O O
acyl NN O O
- NN O O
CoA NN O O
dehydrogenases NN O O
( NN O O
VLCAD NN O O
) NN O O
. NN O O

Two NN O O
of NN O O
the NN O O
patients NN O O
, NN O O
4 NN O O
- NN O O
5 NN O O
month NN O O
old NN O O
boys NN O O
, NN O O
were NN O O
found NN O O
to NN O O
have NN O O
a NN O O
novel NN O O
disease NN O O
, NN O O
VLCAD NN O B-Disease
deficiency NN O I-Disease
, NN O O
as NN O O
judged NN O O
from NN O O
the NN O O
results NN O O
of NN O O
very NN O O
low NN O O
palmitoyl NN O O
- NN O O
CoA NN O O
dehydrogenase NN O O
activity NN O O
and NN O O
the NN O O
lack NN O O
of NN O O
immunoreactivity NN O O
toward NN O O
antibody NN O O
raised NN O O
to NN O O
purified NN O O
VLCAD NN O O
. NN O O
. NN O O

Molecular NN O O
characterization NN O O
of NN O O
glucose NN O B-Disease
- NN O I-Disease
6 NN O I-Disease
- NN O I-Disease
phosphate NN O I-Disease
dehydrogenase NN O I-Disease
( NN O I-Disease
G6PD NN O I-Disease
) NN O I-Disease
deficiency NN O I-Disease
in NN O O
patients NN O O
of NN O O
Chinese NN O O
descent NN O O
and NN O O
identification NN O O
of NN O O
new NN O O
base NN O O
substitutions NN O O
in NN O O
the NN O O
human NN O O
G6PD NN O O
gene NN O O
. NN O O

The NN O O
underlying NN O O
DNA NN O O
changes NN O O
associated NN O O
with NN O O
glucose NN O B-Disease
- NN O I-Disease
6 NN O I-Disease
- NN O I-Disease
phosphate NN O I-Disease
dehydrogenase NN O I-Disease
( NN O I-Disease
G6PD NN O I-Disease
) NN O I-Disease
- NN O I-Disease
deficient NN O I-Disease
Asians NN O O
have NN O O
not NN O O
been NN O O
extensively NN O O
investigated NN O O
. NN O O

To NN O O
fill NN O O
this NN O O
gap NN O O
, NN O O
we NN O O
sequenced NN O O
the NN O O
G6PD NN O O
gene NN O O
of NN O O
43 NN O O
G6PD NN O B-Disease
- NN O I-Disease
deficient NN O I-Disease
Chinese NN O O
whose NN O O
G6PD NN O O
was NN O O
well NN O O
characterized NN O O
biochemically NN O O
. NN O O

DNA NN O O
samples NN O O
were NN O O
obtained NN O O
from NN O O
peripheral NN O O
blood NN O O
of NN O O
these NN O O
individuals NN O O
for NN O O
sequencing NN O O
using NN O O
a NN O O
direct NN O O
polymerase NN O O
chain NN O O
reaction NN O O
( NN O O
PCR NN O O
) NN O O
sequencing NN O O
procedure NN O O
. NN O O

From NN O O
these NN O O
43 NN O O
samples NN O O
, NN O O
we NN O O
have NN O O
identified NN O O
five NN O O
different NN O O
types NN O O
of NN O O
nucleotide NN O O
substitutions NN O O
in NN O O
the NN O O
G6PD NN O O
gene NN O O
at NN O O
cDNA NN O O
1388 NN O O
from NN O O
G NN O O
to NN O O
A NN O O
( NN O O
Arg NN O O
to NN O O
His NN O O
) NN O O
; NN O O
at NN O O
cDNA NN O O
1376 NN O O
from NN O O
G NN O O
to NN O O
T NN O O
( NN O O
Arg NN O O
to NN O O
Leu NN O O
) NN O O
; NN O O
at NN O O
cDNA NN O O
1024 NN O O
from NN O O
C NN O O
to NN O O
T NN O O
( NN O O
Leu NN O O
to NN O O
Phe NN O O
) NN O O
; NN O O
at NN O O
cDNA NN O O
392 NN O O
from NN O O
G NN O O
to NN O O
T NN O O
( NN O O
Gly NN O O
to NN O O
Val NN O O
) NN O O
; NN O O
at NN O O
cDNA NN O O
95 NN O O
from NN O O
A NN O O
to NN O O
G NN O O
( NN O O
His NN O O
to NN O O
Arg NN O O
) NN O O
. NN O O

These NN O O
five NN O O
nucleotide NN O O
substitutions NN O O
account NN O O
for NN O O
over NN O O
83 NN O O
% NN O O
of NN O O
our NN O O
43 NN O O
G6PD NN O B-Disease
- NN O I-Disease
deficient NN O I-Disease
samples NN O O
and NN O O
these NN O O
substitutions NN O O
have NN O O
not NN O O
been NN O O
reported NN O O
in NN O O
non NN O O
- NN O O
Asians NN O O
. NN O O

The NN O O
substitutions NN O O
found NN O O
at NN O O
cDNA NN O O
392 NN O O
and NN O O
cDNA NN O O
1024 NN O O
are NN O O
new NN O O
findings NN O O
. NN O O

The NN O O
substitutions NN O O
at NN O O
cDNA NN O O
1376 NN O O
and NN O O
1388 NN O O
account NN O O
for NN O O
over NN O O
50 NN O O
% NN O O
of NN O O
the NN O O
43 NN O O
samples NN O O
examined NN O O
indicating NN O O
a NN O O
high NN O O
prevalence NN O O
of NN O O
these NN O O
two NN O O
alleles NN O O
among NN O O
G6PD NN O B-Disease
- NN O I-Disease
deficient NN O I-Disease
Chinese NN O O
. NN O O

Our NN O O
findings NN O O
add NN O O
support NN O O
to NN O O
the NN O O
notion NN O O
that NN O O
diverse NN O O
point NN O O
mutations NN O O
may NN O O
account NN O O
largely NN O O
for NN O O
much NN O O
of NN O O
the NN O O
phenotypic NN O O
heterogeneity NN O O
of NN O O
G6PD NN O B-Disease
deficiency NN O I-Disease
. NN O O
. NN O O

Identification NN O O
of NN O O
mutations NN O O
in NN O O
Danish NN O O
choroideremia NN O B-Disease
families NN O O
. NN O O

We NN O O
have NN O O
searched NN O O
for NN O O
mutations NN O O
in NN O O
the NN O O
choroideremia NN O B-Disease
gene NN O O
( NN O O
CHM NN O B-Disease
) NN O O
in NN O O
patients NN O O
from NN O O
12 NN O O
Danish NN O O
families NN O O
in NN O O
which NN O O
CHM NN O B-Disease
is NN O O
segregating NN O O
. NN O O

Employing NN O O
polymerase NN O O
chain NN O O
reaction NN O O
( NN O O
PCR NN O O
) NN O O
, NN O O
single NN O O
strand NN O O
conformation NN O O
polymorphism NN O O
( NN O O
SSCP NN O O
) NN O O
analysis NN O O
, NN O O
and NN O O
direct NN O O
DNA NN O O
sequencing NN O O
, NN O O
different NN O O
mutations NN O O
have NN O O
been NN O O
identified NN O O
in NN O O
6 NN O O
patients NN O O
. NN O O

All NN O O
the NN O O
mutations NN O O
will NN O O
interfere NN O O
with NN O O
the NN O O
correct NN O O
translation NN O O
of NN O O
the NN O O
mRNA NN O O
predicting NN O O
a NN O O
truncated NN O O
protein NN O O
or NN O O
no NN O O
gene NN O O
product NN O O
at NN O O
all NN O O
. NN O O
. NN O O

Structure NN O O
and NN O O
genomic NN O O
sequence NN O O
of NN O O
the NN O O
myotonic NN O B-Disease
dystrophy NN O I-Disease
( NN O O
DM NN O B-Disease
kinase NN O O
) NN O O
gene NN O O
. NN O O

The NN O O
mutation NN O O
causing NN O O
myotonic NN O B-Disease
dystrophy NN O I-Disease
( NN O O
DM NN O B-Disease
) NN O O
has NN O O
recently NN O O
been NN O O
identified NN O O
as NN O O
an NN O O
unstable NN O O
CTG NN O O
trinucleotide NN O O
repeat NN O O
located NN O O
in NN O O
the NN O O
3 NN O O
untranslated NN O O
region NN O O
of NN O O
a NN O O
gene NN O O
encoding NN O O
for NN O O
a NN O O
protein NN O O
with NN O O
putative NN O O
serine NN O O
- NN O O
threonine NN O O
protein NN O O
kinase NN O O
activity NN O O
. NN O O

In NN O O
this NN O O
report NN O O
we NN O O
present NN O O
the NN O O
genomic NN O O
sequences NN O O
of NN O O
the NN O O
human NN O O
and NN O O
murine NN O O
DM NN O B-Disease
kinase NN O O
gene NN O O
. NN O O

A NN O O
comparison NN O O
of NN O O
these NN O O
sequences NN O O
with NN O O
each NN O O
other NN O O
and NN O O
with NN O O
known NN O O
cDNA NN O O
sequences NN O O
from NN O O
both NN O O
species NN O O
, NN O O
led NN O O
us NN O O
to NN O O
predict NN O O
a NN O O
translation NN O O
initiation NN O O
codon NN O O
, NN O O
as NN O O
well NN O O
as NN O O
determine NN O O
the NN O O
organization NN O O
of NN O O
the NN O O
DM NN O B-Disease
kinase NN O O
gene NN O O
. NN O O

Several NN O O
polymorphisms NN O O
within NN O O
the NN O O
human NN O O
DM NN O B-Disease
kinase NN O O
gene NN O O
have NN O O
been NN O O
identified NN O O
, NN O O
and NN O O
PCR NN O O
assays NN O O
to NN O O
detect NN O O
two NN O O
of NN O O
these NN O O
are NN O O
described NN O O
. NN O O

The NN O O
complete NN O O
sequence NN O O
and NN O O
characterization NN O O
of NN O O
the NN O O
structure NN O O
of NN O O
the NN O O
DM NN O B-Disease
kinase NN O O
gene NN O O
, NN O O
as NN O O
well NN O O
as NN O O
the NN O O
identification NN O O
of NN O O
novel NN O O
polymorphisms NN O O
within NN O O
the NN O O
gene NN O O
, NN O O
represent NN O O
an NN O O
important NN O O
step NN O O
in NN O O
a NN O O
further NN O O
understanding NN O O
of NN O O
the NN O O
genetics NN O O
of NN O O
myotonic NN O B-Disease
dystrophy NN O I-Disease
and NN O O
the NN O O
molecular NN O O
biology NN O O
of NN O O
the NN O O
gene NN O O
. NN O O
. NN O O

Autosomal NN O O
recessive NN O O
transmission NN O O
of NN O O
hemophilia NN O B-Disease
A NN O I-Disease
due NN O O
to NN O O
a NN O O
von NN O B-Disease
Willebrand NN O I-Disease
factor NN O O
mutation NN O O
. NN O O

The NN O O
differential NN O O
diagnosis NN O O
of NN O O
the NN O O
genetic NN O B-Disease
bleeding NN O I-Disease
disorders NN O I-Disease
, NN O O
hemophilia NN O B-Disease
A NN O I-Disease
and NN O O
von NN O B-Disease
Willebrand NN O I-Disease
disease NN O I-Disease
, NN O O
is NN O O
occasionally NN O O
confounded NN O O
by NN O O
the NN O O
close NN O O
molecular NN O O
relationship NN O O
of NN O O
coagulation NN O O
factor NN O O
VIII NN O O
and NN O O
von NN O B-Disease
Willebrand NN O I-Disease
factor NN O O
( NN O O
vWF NN O O
) NN O O
. NN O O

This NN O O
report NN O O
describes NN O O
the NN O O
autosomal NN O O
inheritance NN O O
of NN O O
a NN O O
hemophilia NN O B-Disease
A NN O I-Disease
phenotype NN O O
due NN O O
to NN O O
a NN O O
mutation NN O O
of NN O O
vWF NN O O
that NN O O
results NN O O
in NN O O
defective NN O O
factor NN O O
VIII NN O O
binding NN O O
. NN O O

The NN O O
proband NN O O
was NN O O
a NN O O
female NN O O
patient NN O O
with NN O O
low NN O O
levels NN O O
of NN O O
factor NN O O
VIII NN O O
activity NN O O
. NN O O

Polymerase NN O O
chain NN O O
reaction NN O O
( NN O O
PCR NN O O
) NN O O
amplification NN O O
and NN O O
DNA NN O O
sequencing NN O O
were NN O O
employed NN O O
to NN O O
examine NN O O
exons NN O O
encoding NN O O
the NN O O
putative NN O O
factor NN O O
VIII NN O O
binding NN O O
domain NN O O
of NN O O
vWF NN O O
. NN O O

The NN O O
patient NN O O
was NN O O
found NN O O
to NN O O
be NN O O
homozygous NN O O
for NN O O
a NN O O
single NN O O
point NN O O
mutation NN O O
causing NN O O
a NN O O
Thr NN O O
- NN O O
- NN O O
> NN O O
Met NN O O
substitution NN O O
at NN O O
amino NN O O
acid NN O O
position NN O O
28 NN O O
in NN O O
the NN O O
mature NN O O
vWF NN O O
subunit NN O O
. NN O O

The NN O O
phenotypic NN O O
expression NN O O
of NN O O
the NN O O
mutation NN O O
was NN O O
determined NN O O
to NN O O
be NN O O
recessive NN O O
because NN O O
heterozygous NN O O
family NN O O
members NN O O
were NN O O
clinically NN O O
unaffected NN O O
. NN O O

Recombinant NN O O
vWF NN O O
containing NN O O
the NN O O
observed NN O O
amino NN O O
acid NN O O
substitution NN O O
was NN O O
expressed NN O O
in NN O O
COS NN O O
- NN O O
1 NN O O
cells NN O O
. NN O O

The NN O O
mutant NN O O
vWF NN O O
was NN O O
processed NN O O
and NN O O
secreted NN O O
normally NN O O
, NN O O
and NN O O
was NN O O
functionally NN O O
equivalent NN O O
to NN O O
wild NN O O
- NN O O
type NN O O
vWF NN O O
in NN O O
its NN O O
ability NN O O
to NN O O
bind NN O O
to NN O O
platelets NN O O
. NN O O

However NN O O
, NN O O
the NN O O
mutant NN O O
failed NN O O
to NN O O
bind NN O O
factor NN O O
VIII NN O O
, NN O O
demonstrating NN O O
that NN O O
the NN O O
mutation NN O O
was NN O O
functionally NN O O
related NN O O
to NN O O
the NN O O
observed NN O O
hemophilia NN O B-Disease
phenotype NN O O
. NN O O

The NN O O
family NN O O
we NN O O
describe NN O O
demonstrates NN O O
the NN O O
recessive NN O O
inheritance NN O O
of NN O O
a NN O O
recently NN O O
recognized NN O O
class NN O O
of NN O O
genetic NN O O
bleeding NN O O
disorders NN O O
, NN O O
we NN O O
call NN O O
" NN O O
autosomal NN O O
hemophilia NN O B-Disease
. NN O O

" NN O O
We NN O O
conclude NN O O
that NN O O
vWF NN O O
mutation NN O O
may NN O O
be NN O O
an NN O O
under NN O O
recognized NN O O
cause NN O O
of NN O O
hemophilia NN O B-Disease
, NN O O
especially NN O O
in NN O O
cases NN O O
where NN O O
the NN O O
inheritance NN O O
pattern NN O O
is NN O O
not NN O O
consistent NN O O
with NN O O
X NN O O
- NN O O
linked NN O O
transmission NN O O
. NN O O

Somatic NN O O
von NN O B-Disease
Hippel NN O I-Disease
- NN O I-Disease
Lindau NN O I-Disease
mutation NN O O
in NN O O
clear NN O O
cell NN O O
papillary NN O B-Disease
cystadenoma NN O I-Disease
of NN O I-Disease
the NN O I-Disease
epididymis NN O I-Disease
. NN O O

Papillary NN O B-Disease
cystadenoma NN O I-Disease
of NN O I-Disease
the NN O I-Disease
epididymis NN O I-Disease
is NN O O
an NN O O
uncommon NN O O
benign NN O O
lesion NN O O
that NN O O
may NN O O
occur NN O O
sporadically NN O O
or NN O O
as NN O O
a NN O O
manifestation NN O O
of NN O O
von NN O B-Disease
Hippel NN O I-Disease
- NN O I-Disease
Lindau NN O I-Disease
( NN O I-Disease
VHL NN O I-Disease
) NN O I-Disease
disease NN O I-Disease
. NN O O

Neither NN O O
immunohistochemical NN O O
studies NN O O
nor NN O O
molecular NN O O
genetic NN O O
analyses NN O O
of NN O O
the NN O O
VHL NN O B-Disease
gene NN O O
have NN O O
been NN O O
reported NN O O
previously NN O O
for NN O O
this NN O O
lesion NN O O
. NN O O

The NN O O
authors NN O O
describe NN O O
two NN O O
cases NN O O
of NN O O
clear NN O O
cell NN O O
papillary NN O B-Disease
cystadenoma NN O I-Disease
of NN O I-Disease
the NN O I-Disease
epididymis NN O I-Disease
, NN O O
both NN O O
of NN O O
which NN O O
were NN O O
initially NN O O
confused NN O O
with NN O O
metastatic NN O B-Disease
renal NN O I-Disease
cell NN O I-Disease
carcinoma NN O I-Disease
. NN O O

Both NN O O
lesions NN O O
showed NN O O
positive NN O O
immunohistochemical NN O O
staining NN O O
for NN O O
low NN O O
and NN O O
intermediate NN O O
molecular NN O O
weight NN O O
keratins NN O O
( NN O O
Cam NN O O
5 NN O O
. NN O O
2 NN O O
and NN O O
AE1 NN O O
/ NN O O
AE3 NN O O
) NN O O
, NN O O
EMA NN O O
, NN O O
vimentin NN O O
, NN O O
alpha NN O O
1 NN O O
- NN O O
antitrypsin NN O O
, NN O O
and NN O O
alpha NN O O
1 NN O O
- NN O O
antichymotrypsin NN O O
. NN O O

Each NN O O
was NN O O
negative NN O O
for NN O O
CEA NN O O
. NN O O

Because NN O O
clear NN O O
cell NN O O
papillary NN O B-Disease
cystadenoma NN O I-Disease
is NN O O
similar NN O O
to NN O O
renal NN O B-Disease
cell NN O I-Disease
carcinoma NN O I-Disease
histologically NN O O
, NN O O
and NN O O
because NN O O
both NN O O
occur NN O O
as NN O O
components NN O O
of NN O O
the NN O O
von NN O B-Disease
Hippel NN O I-Disease
- NN O I-Disease
Lindau NN O I-Disease
disease NN O I-Disease
complex NN O O
, NN O O
the NN O O
authors NN O O
analyzed NN O O
both NN O O
cases NN O O
for NN O O
the NN O O
presence NN O O
of NN O O
mutations NN O O
in NN O O
the NN O O
VHL NN O B-Disease
gene NN O O
. NN O O

A NN O O
somatic NN O O
VHL NN O B-Disease
gene NN O O
mutation NN O O
was NN O O
detected NN O O
in NN O O
one NN O O
of NN O O
the NN O O
two NN O O
tumors NN O B-Disease
by NN O O
polymerase NN O O
chain NN O O
reaction NN O O
followed NN O O
by NN O O
single NN O O
- NN O O
strand NN O O
conformation NN O O
polymorphism NN O O
analysis NN O O
. NN O O

Direct NN O O
sequencing NN O O
revealed NN O O
a NN O O
cytosine NN O O
to NN O O
thymine NN O O
transition NN O O
at NN O O
nucleotide NN O O
694 NN O O
, NN O O
resulting NN O O
in NN O O
the NN O O
replacement NN O O
of NN O O
an NN O O
arginine NN O O
with NN O O
a NN O O
stop NN O O
codon NN O O
after NN O O
the NN O O
sixth NN O O
amino NN O O
acid NN O O
of NN O O
exon NN O O
3 NN O O
. NN O O

As NN O O
the NN O O
VHL NN O B-Disease
gene NN O O
is NN O O
believed NN O O
to NN O O
function NN O O
as NN O O
a NN O O
tumor NN O B-Disease
suppressor NN O O
gene NN O O
, NN O O
VHL NN O B-Disease
gene NN O O
mutations NN O O
may NN O O
play NN O O
a NN O O
role NN O O
in NN O O
the NN O O
initiation NN O O
of NN O O
tumorigenesis NN O O
in NN O O
sporadic NN O O
cystadenomas NN O B-Disease
of NN O I-Disease
the NN O I-Disease
epididymis NN O I-Disease
. NN O O

Identification NN O O
of NN O O
WASP NN O O
mutations NN O O
in NN O O
patients NN O O
with NN O O
Wiskott NN O B-Disease
- NN O I-Disease
Aldrich NN O I-Disease
syndrome NN O I-Disease
and NN O O
isolated NN O B-Disease
thrombocytopenia NN O I-Disease
reveals NN O O
allelic NN O O
heterogeneity NN O O
at NN O O
the NN O O
WAS NN O B-Disease
locus NN O O
. NN O O

Mutation NN O O
in NN O O
the NN O O
gene NN O O
encoding NN O O
the NN O O
recently NN O O
isolated NN O O
WASP NN O O
protein NN O O
has NN O O
now NN O O
been NN O O
identified NN O O
as NN O O
the NN O O
genetic NN O B-Disease
defect NN O I-Disease
responsible NN O O
for NN O O
the NN O O
X NN O B-Disease
- NN O I-Disease
linked NN O I-Disease
Wiskott NN O I-Disease
- NN O I-Disease
Aldrich NN O I-Disease
syndrome NN O I-Disease
( NN O O
WAS NN O B-Disease
) NN O O
, NN O O
a NN O O
primary NN O O
immunodeficiency NN O B-Disease
disease NN O I-Disease
associated NN O O
with NN O O
extensive NN O O
phenotypic NN O O
variability NN O O
. NN O O

To NN O O
elucidate NN O O
the NN O O
range NN O O
of NN O O
WASP NN O O
mutations NN O O
responsible NN O O
for NN O O
WAS NN O B-Disease
, NN O O
we NN O O
used NN O O
PCR NN O O
- NN O O
SSCP NN O O
analysis NN O O
to NN O O
screen NN O O
for NN O O
WASP NN O O
gene NN O O
mutation NN O O
in NN O O
19 NN O O
unrelated NN O O
boys NN O O
with NN O O
the NN O O
diagnosis NN O O
of NN O O
classical NN O O
or NN O O
attenuated NN O O
WAS NN O B-Disease
or NN O O
isolated NN O B-Disease
thrombocytopenia NN O I-Disease
. NN O O

All NN O O
19 NN O O
patients NN O O
had NN O O
WASP NN O O
mutations NN O O
, NN O O
each NN O O
of NN O O
which NN O O
localized NN O O
to NN O O
the NN O O
initial NN O O
three NN O O
or NN O O
terminal NN O O
three NN O O
exons NN O O
of NN O O
the NN O O
gene NN O O
, NN O O
and NN O O
the NN O O
majority NN O O
of NN O O
which NN O O
were NN O O
unique NN O O
in NN O O
each NN O O
case NN O O
. NN O O

However NN O O
, NN O O
a NN O O
missense NN O O
mutation NN O O
which NN O O
results NN O O
in NN O O
substitution NN O O
of NN O O
the NN O O
arginine NN O O
at NN O O
WAS NN O B-Disease
codon NN O O
86 NN O O
was NN O O
identified NN O O
in NN O O
three NN O O
boys NN O O
with NN O O
severe NN O O
WAS NN O B-Disease
as NN O O
well NN O O
as NN O O
in NN O O
one NN O O
boy NN O O
presenting NN O O
with NN O O
thrombocytopenia NN O B-Disease
alone NN O O
. NN O O

While NN O O
the NN O O
three NN O O
mutations NN O O
found NN O O
in NN O O
the NN O O
isolated NN O B-Disease
thrombocytopenia NN O I-Disease
patients NN O O
leave NN O O
the NN O O
reading NN O O
frame NN O O
intact NN O O
, NN O O
about NN O O
one NN O O
- NN O O
half NN O O
of NN O O
the NN O O
gene NN O O
alterations NN O O
detected NN O O
in NN O O
both NN O O
severe NN O O
and NN O O
attenuated NN O O
WAS NN O B-Disease
patients NN O O
result NN O O
in NN O O
frameshifted NN O O
transcript NN O O
and NN O O
premature NN O O
translation NN O O
termination NN O O
. NN O O

These NN O O
findings NN O O
therefore NN O O
confirm NN O O
the NN O O
association NN O O
of NN O O
WAS NN O B-Disease
with NN O O
WASP NN O O
mutation NN O O
and NN O O
identify NN O O
WASP NN O O
mutation NN O O
as NN O O
a NN O O
cause NN O O
for NN O O
isolated NN O O
congenital NN O B-Disease
thrombocytopenia NN O I-Disease
in NN O O
males NN O O
. NN O O

While NN O O
the NN O O
WASP NN O O
gene NN O O
defects NN O O
responsible NN O O
for NN O O
isolated NN O B-Disease
thrombocytopenia NN O I-Disease
and NN O O
other NN O O
mild NN O O
presentations NN O O
of NN O O
WAS NN O B-Disease
do NN O O
not NN O O
appear NN O O
distinct NN O O
from NN O O
those NN O O
resulting NN O O
in NN O O
severe NN O O
WAS NN O B-Disease
, NN O O
these NN O O
data NN O O
indicate NN O O
that NN O O
analysis NN O O
of NN O O
WASP NN O O
gene NN O O
mutation NN O O
provides NN O O
a NN O O
valuable NN O O
tool NN O O
for NN O O
distinguishing NN O O
the NN O O
spectrum NN O O
of NN O O
WAS NN O B-Disease
patients NN O O
and NN O O
the NN O O
subset NN O O
of NN O O
males NN O O
with NN O O
isolated NN O B-Disease
thrombocytopenia NN O I-Disease
who NN O O
represent NN O O
mild NN O O
cases NN O O
of NN O O
WAS NN O B-Disease
. NN O O
. NN O O

WASP NN O O
gene NN O O
mutations NN O O
in NN O O
Wiskott NN O B-Disease
- NN O I-Disease
Aldrich NN O I-Disease
syndrome NN O I-Disease
and NN O O
X NN O B-Disease
- NN O I-Disease
linked NN O I-Disease
thrombocytopenia NN O I-Disease
. NN O O

The NN O O
WASP NN O O
gene NN O O
has NN O O
been NN O O
recently NN O O
cloned NN O O
from NN O O
Xp11 NN O O
. NN O O

23 NN O O
and NN O O
shown NN O O
to NN O O
be NN O O
mutated NN O O
in NN O O
three NN O O
patients NN O O
with NN O O
the NN O O
Wiskott NN O B-Disease
- NN O I-Disease
Aldrich NN O I-Disease
syndrome NN O I-Disease
( NN O O
WAS NN O B-Disease
) NN O O
. NN O O

We NN O O
have NN O O
developed NN O O
a NN O O
screening NN O O
protocol NN O O
for NN O O
identifying NN O O
WASP NN O O
gene NN O O
alterations NN O O
in NN O O
genomic NN O O
DNA NN O O
and NN O O
have NN O O
identified NN O O
a NN O O
spectrum NN O O
of NN O O
novel NN O O
mutations NN O O
in NN O O
12 NN O O
additional NN O O
unrelated NN O O
families NN O O
. NN O O

These NN O O
missense NN O O
, NN O O
nonsense NN O O
and NN O O
frameshift NN O O
mutations NN O O
involve NN O O
eight NN O O
of NN O O
the NN O O
12 NN O O
exons NN O O
of NN O O
the NN O O
gene NN O O
. NN O O

Two NN O O
mutations NN O O
creating NN O O
premature NN O O
termination NN O O
codons NN O O
were NN O O
associated NN O O
with NN O O
lack NN O O
of NN O O
detectable NN O O
mRNA NN O O
on NN O O
Northern NN O O
blots NN O O
. NN O O

Four NN O O
amino NN O O
acid NN O O
substitutions NN O O
, NN O O
Leu27Phe NN O O
, NN O O
Thr48Ile NN O O
, NN O O
Val75Met NN O O
and NN O O
Arg477Lys NN O O
, NN O O
were NN O O
found NN O O
in NN O O
patients NN O O
with NN O O
congenital NN O B-Disease
thrombocytopenia NN O I-Disease
and NN O O
no NN O O
clinically NN O O
evident NN O O
immune NN O O
defect NN O O
indicating NN O O
that NN O O
the NN O O
WASP NN O O
gene NN O O
is NN O O
the NN O O
site NN O O
for NN O O
mutations NN O O
in NN O O
X NN O B-Disease
- NN O I-Disease
linked NN O I-Disease
thrombocytopenia NN O I-Disease
as NN O O
well NN O O
as NN O O
in NN O O
WAS NN O B-Disease
. NN O O

A NN O O
T NN O O
- NN O O
cell NN O O
line NN O O
from NN O O
a NN O O
WAS NN O B-Disease
patient NN O O
contained NN O O
two NN O O
independent NN O O
DNA NN O O
alterations NN O O
, NN O O
a NN O O
constitutional NN O O
frameshift NN O O
mutation NN O O
, NN O O
also NN O O
present NN O O
in NN O O
peripheral NN O O
blood NN O O
leukocytes NN O O
from NN O O
the NN O O
patient NN O O
, NN O O
and NN O O
compensatory NN O O
splice NN O O
site NN O O
mutation NN O O
unique NN O O
to NN O O
the NN O O
cell NN O O
line NN O O
. NN O O

The NN O O
distribution NN O O
of NN O O
eight NN O O
missense NN O O
mutations NN O O
provides NN O O
valuable NN O O
information NN O O
on NN O O
amino NN O O
acids NN O O
which NN O O
are NN O O
essential NN O O
for NN O O
normal NN O O
protein NN O O
function NN O O
, NN O O
and NN O O
suggests NN O O
that NN O O
sites NN O O
in NN O O
the NN O O
first NN O O
two NN O O
exons NN O O
are NN O O
hot NN O O
- NN O O
spots NN O O
for NN O O
mutation NN O O
. NN O O

Evidence NN O O
for NN O O
inter NN O O
- NN O O
generational NN O O
instability NN O O
in NN O O
the NN O O
CAG NN O O
repeat NN O O
in NN O O
the NN O O
MJD1 NN O O
gene NN O O
and NN O O
for NN O O
conserved NN O O
haplotypes NN O O
at NN O O
flanking NN O O
markers NN O O
amongst NN O O
Japanese NN O O
and NN O O
Caucasian NN O O
subjects NN O O
with NN O O
Machado NN O B-Disease
- NN O I-Disease
Joseph NN O I-Disease
disease NN O I-Disease
. NN O O

The NN O O
size NN O O
of NN O O
the NN O O
( NN O O
CAG NN O O
) NN O O
n NN O O
repeat NN O O
array NN O O
in NN O O
the NN O O
3 NN O O
' NN O O
end NN O O
of NN O O
the NN O O
MJD1 NN O O
gene NN O O
and NN O O
the NN O O
haplotype NN O O
at NN O O
a NN O O
series NN O O
of NN O O
microsatellite NN O O
markers NN O O
surrounding NN O O
the NN O O
MJD1 NN O O
gene NN O O
were NN O O
examined NN O O
in NN O O
a NN O O
large NN O O
cohort NN O O
of NN O O
Japanese NN O O
and NN O O
Caucasian NN O O
subjects NN O O
affected NN O O
with NN O O
Machado NN O B-Disease
- NN O I-Disease
Joseph NN O I-Disease
disease NN O I-Disease
( NN O O
MJD NN O B-Disease
) NN O O
. NN O O

Our NN O O
data NN O O
provide NN O O
five NN O O
novel NN O O
observations NN O O
. NN O O

First NN O O
, NN O O
MJD NN O B-Disease
is NN O O
associated NN O O
with NN O O
expansion NN O O
fo NN O O
the NN O O
array NN O O
from NN O O
the NN O O
normal NN O O
range NN O O
of NN O O
14 NN O O
- NN O O
37 NN O O
repeats NN O O
to NN O O
68 NN O O
- NN O O
84 NN O O
repeats NN O O
in NN O O
most NN O O
Japanese NN O O
and NN O O
Caucasian NN O O
subjects NN O O
, NN O O
but NN O O
no NN O O
subjects NN O O
were NN O O
observed NN O O
with NN O O
expansions NN O O
intermediate NN O O
in NN O O
size NN O O
between NN O O
those NN O O
of NN O O
the NN O O
normal NN O O
and NN O O
MJD NN O B-Disease
affected NN O O
groups NN O O
. NN O O

Second NN O O
, NN O O
the NN O O
expanded NN O O
allele NN O O
associated NN O O
with NN O O
MJD NN O B-Disease
displays NN O O
inter NN O O
- NN O O
generational NN O O
instability NN O O
, NN O O
particularly NN O O
in NN O O
male NN O O
meioses NN O O
, NN O O
and NN O O
this NN O O
instability NN O O
was NN O O
associated NN O O
with NN O O
the NN O O
clinical NN O O
phenomenon NN O O
of NN O O
anticipation NN O O
. NN O O

Third NN O O
, NN O O
the NN O O
size NN O O
of NN O O
the NN O O
expanded NN O O
allele NN O O
is NN O O
not NN O O
only NN O O
inversely NN O O
correlated NN O O
with NN O O
the NN O O
age NN O O
- NN O O
of NN O O
- NN O O
onset NN O O
of NN O O
MJD NN O B-Disease
( NN O O
r NN O O
= NN O O
- NN O O
0 NN O O
. NN O O
738 NN O O
, NN O O
p NN O O
< NN O O
0 NN O O
. NN O O
001 NN O O
) NN O O
, NN O O
but NN O O
is NN O O
also NN O O
correlated NN O O
with NN O O
the NN O O
frequency NN O O
of NN O O
other NN O O
clinical NN O O
features NN O O
[ NN O O
e NN O O
. NN O O
g NN O O
. NN O O
pseudoexophthalmos NN O O
and NN O O
pyramidal NN O O
signs NN O O
were NN O O
more NN O O
frequent NN O O
in NN O O
subjects NN O O
with NN O O
large NN O O
repeats NN O O
( NN O O
p NN O O
< NN O O
0 NN O O
. NN O O
001 NN O O
and NN O O
p NN O O
< NN O O
0 NN O O
. NN O O
05 NN O O
respectively NN O O
) NN O O
] NN O O
. NN O O

Fourth NN O O
, NN O O
the NN O O
disease NN O O
phenotype NN O O
is NN O O
significantly NN O O
more NN O O
severe NN O O
and NN O O
had NN O O
an NN O O
early NN O O
age NN O O
of NN O O
onset NN O O
( NN O O
16 NN O O
years NN O O
) NN O O
in NN O O
a NN O O
subject NN O O
homozygous NN O O
for NN O O
the NN O O
expanded NN O O
allele NN O O
, NN O O
which NN O O
contrasts NN O O
with NN O O
Huntington NN O B-Disease
disease NN O I-Disease
and NN O O
suggests NN O O
that NN O O
the NN O O
expanded NN O O
allele NN O O
in NN O O
the NN O O
MJD1 NN O O
gene NN O O
could NN O O
exert NN O O
its NN O O
effect NN O O
either NN O O
by NN O O
a NN O O
dominant NN O O
negative NN O O
effect NN O O
( NN O O
putatively NN O O
excluded NN O O
in NN O O
HD NN O B-Disease
) NN O O
or NN O O
by NN O O
a NN O O
gain NN O O
of NN O O
function NN O O
effect NN O O
as NN O O
proposed NN O O
for NN O O
HD NN O B-Disease
. NN O O

Finally NN O O
, NN O O
Japanese NN O O
and NN O O
Caucasian NN O O
subjects NN O O
affected NN O O
with NN O O
MJD NN O B-Disease
share NN O O
haplotypes NN O O
at NN O O
several NN O O
markers NN O O
surrounding NN O O
the NN O O
MJD1 NN O O
gene NN O O
, NN O O
which NN O O
are NN O O
uncommon NN O O
in NN O O
the NN O O
normal NN O O
Japanese NN O O
and NN O O
Caucasian NN O O
population NN O O
, NN O O
and NN O O
which NN O O
suggests NN O O
the NN O O
existence NN O O
either NN O O
of NN O O
common NN O O
founders NN O O
in NN O O
these NN O O
populations NN O O
or NN O O
of NN O O
chromosomes NN O O
susceptible NN O O
to NN O O
pathologic NN O O
expansion NN O O
of NN O O
the NN O O
CAG NN O O
repeat NN O O
in NN O O
the NN O O
MJD1 NN O O
gene NN O O
. NN O O

A NN O O
4 NN O O
- NN O O
megabase NN O O
YAC NN O O
contig NN O O
that NN O O
spans NN O O
the NN O O
Langer NN O B-Disease
- NN O I-Disease
Giedion NN O I-Disease
syndrome NN O I-Disease
region NN O O
on NN O O
human NN O O
chromosome NN O O
8q24 NN O O
. NN O O
1 NN O O
: NN O O
use NN O O
in NN O O
refining NN O O
the NN O O
location NN O O
of NN O O
the NN O O
trichorhinophalangeal NN O B-Disease
syndrome NN O I-Disease
and NN O O
multiple NN O O
exostoses NN O O
genes NN O O
( NN O O
TRPS1 NN O O
and NN O O
EXT1 NN O O
) NN O O
. NN O O

We NN O O
have NN O O
constructed NN O O
a NN O O
physical NN O O
map NN O O
covering NN O O
over NN O O
4 NN O O
Mb NN O O
of NN O O
human NN O O
chromosome NN O O
8q24 NN O O
. NN O O

1 NN O O
and NN O O
used NN O O
this NN O O
map NN O O
to NN O O
refine NN O O
the NN O O
locations NN O O
of NN O O
the NN O O
genes NN O O
responsible NN O O
for NN O O
Langer NN O B-Disease
- NN O I-Disease
Giedion NN O I-Disease
syndrome NN O I-Disease
. NN O O

The NN O O
map NN O O
is NN O O
composed NN O O
of NN O O
overlapping NN O O
YAC NN O O
clones NN O O
that NN O O
were NN O O
identified NN O O
and NN O O
ordered NN O O
in NN O O
relation NN O O
to NN O O
sequence NN O O
tagged NN O O
sites NN O O
mapped NN O O
to NN O O
the NN O O
Langer NN O O
- NN O O
Giedion NN O O
chromosomal NN O O
region NN O O
on NN O O
somatic NN O O
cell NN O O
hybrids NN O O
. NN O O

The NN O O
minimal NN O O
region NN O O
of NN O O
overlap NN O O
of NN O O
Langer NN O B-Disease
- NN O I-Disease
Giedion NN O I-Disease
syndrome NN O I-Disease
deletions NN O O
, NN O O
previously NN O O
identified NN O O
by NN O O
analysis NN O O
of NN O O
15 NN O O
patients NN O O
, NN O O
was NN O O
placed NN O O
on NN O O
the NN O O
map NN O O
by NN O O
analysis NN O O
of NN O O
2 NN O O
patients NN O O
whose NN O O
deletions NN O O
define NN O O
the NN O O
endpoints NN O O
. NN O O

The NN O O
chromosome NN O O
8 NN O O
breakpoint NN O O
of NN O O
a NN O O
balanced NN O O
t NN O O
( NN O O
8 NN O O
; NN O O
9 NN O O
) NN O O
( NN O O
q24 NN O O
. NN O O
11 NN O O
; NN O O
q33 NN O O
. NN O O
3 NN O O
) NN O O
translocation NN O O
from NN O O
a NN O O
patient NN O O
with NN O O
trichorhinophalangeal NN O B-Disease
syndrome NN O I-Disease
( NN O O
TRPS NN O B-Disease
I NN O O
) NN O O
was NN O O
found NN O O
to NN O O
be NN O O
located NN O O
just NN O O
within NN O O
the NN O O
proximal NN O O
end NN O O
of NN O O
the NN O O
minimal NN O O
deletion NN O O
region NN O O
. NN O O

A NN O O
deletion NN O O
of NN O O
8q24 NN O O
. NN O O

11 NN O O
- NN O O
q24 NN O O
. NN O O

3 NN O O
in NN O O
a NN O O
patient NN O O
with NN O O
multiple NN O O
exostoses NN O O
was NN O O
found NN O O
to NN O O
overlap NN O O
the NN O O
distal NN O O
end NN O O
of NN O O
the NN O O
LGS NN O B-Disease
deletion NN O O
region NN O O
, NN O O
indicating NN O O
that NN O O
the NN O O
EXT1 NN O O
gene NN O O
is NN O O
distal NN O O
to NN O O
the NN O O
TRPS1 NN O O
gene NN O O
and NN O O
supporting NN O O
the NN O O
hypothesis NN O O
that NN O O
Langer NN O B-Disease
- NN O I-Disease
Giedion NN O I-Disease
syndrome NN O I-Disease
is NN O O
due NN O O
to NN O O
loss NN O O
of NN O O
functional NN O O
copies NN O O
of NN O O
both NN O O
the NN O O
TRPS1 NN O O
and NN O O
the NN O O
EXT1 NN O O
genes NN O O

BRCA1 NN O O
mutations NN O O
in NN O O
a NN O O
population NN O O
- NN O O
based NN O O
sample NN O O
of NN O O
young NN O O
women NN O O
with NN O O
breast NN O B-Disease
cancer NN O I-Disease
. NN O O

BACKGROUND NN O O
. NN O O

Inherited NN O O
mutations NN O O
in NN O O
the NN O O
BRCA1 NN O O
gene NN O O
are NN O O
associated NN O O
with NN O O
a NN O O
high NN O O
risk NN O O
of NN O O
breast NN O B-Disease
and NN O I-Disease
ovarian NN O I-Disease
cancer NN O I-Disease
in NN O O
some NN O O
families NN O O
. NN O O

However NN O O
, NN O O
little NN O O
is NN O O
known NN O O
about NN O O
the NN O O
contribution NN O O
of NN O O
BRCA1 NN O O
mutations NN O O
to NN O O
breast NN O B-Disease
cancer NN O I-Disease
in NN O O
the NN O O
general NN O O
population NN O O
. NN O O

We NN O O
analyzed NN O O
DNA NN O O
samples NN O O
from NN O O
women NN O O
enrolled NN O O
in NN O O
a NN O O
population NN O O
- NN O O
based NN O O
study NN O O
of NN O O
early NN O O
- NN O O
onset NN O O
breast NN O B-Disease
cancer NN O I-Disease
to NN O O
assess NN O O
the NN O O
spectrum NN O O
and NN O O
frequency NN O O
of NN O O
germ NN O O
- NN O O
line NN O O
BRCA1 NN O O
mutations NN O O
in NN O O
young NN O O
women NN O O
with NN O O
breast NN O B-Disease
cancer NN O I-Disease
. NN O O

METHODS NN O O
. NN O O

We NN O O
studied NN O O
80 NN O O
women NN O O
in NN O O
whom NN O O
breast NN O B-Disease
cancer NN O I-Disease
was NN O O
diagnosed NN O O
before NN O O
the NN O O
age NN O O
of NN O O
35 NN O O
, NN O O
and NN O O
who NN O O
were NN O O
not NN O O
selected NN O O
on NN O O
the NN O O
basis NN O O
of NN O O
family NN O O
history NN O O
. NN O O

Genomic NN O O
DNA NN O O
was NN O O
studied NN O O
for NN O O
BRCA1 NN O O
mutations NN O O
by NN O O
analysis NN O O
involving NN O O
single NN O O
- NN O O
strand NN O O
conformation NN O O
polymorphisms NN O O
and NN O O
with NN O O
allele NN O O
- NN O O
specific NN O O
assays NN O O
. NN O O

Alterations NN O O
were NN O O
defined NN O O
by NN O O
DNA NN O O
sequencing NN O O
. NN O O

RESULTS NN O O
. NN O O

Germ NN O O
- NN O O
line NN O O
BRCA1 NN O O
mutations NN O O
were NN O O
identified NN O O
in NN O O
6 NN O O
of NN O O
the NN O O
80 NN O O
women NN O O
. NN O O

Four NN O O
additional NN O O
rare NN O O
sequence NN O O
variants NN O O
of NN O O
unknown NN O O
functional NN O O
importance NN O O
were NN O O
also NN O O
identified NN O O
. NN O O

Two NN O O
of NN O O
the NN O O
mutations NN O O
and NN O O
three NN O O
of NN O O
the NN O O
rare NN O O
sequence NN O O
variants NN O O
were NN O O
found NN O O
among NN O O
the NN O O
39 NN O O
women NN O O
who NN O O
reported NN O O
no NN O O
family NN O O
history NN O O
of NN O O
breast NN O B-Disease
or NN O I-Disease
ovarian NN O I-Disease
cancer NN O I-Disease
. NN O O

None NN O O
of NN O O
the NN O O
mutations NN O O
and NN O O
only NN O O
one NN O O
of NN O O
the NN O O
rare NN O O
variants NN O O
was NN O O
identified NN O O
in NN O O
a NN O O
reference NN O O
population NN O O
of NN O O
73 NN O O
unrelated NN O O
subjects NN O O
. NN O O

CONCLUSIONS NN O O
. NN O O

Alterations NN O O
in NN O O
BRCA1 NN O O
were NN O O
identified NN O O
in NN O O
approximately NN O O
10 NN O O
percent NN O O
of NN O O
this NN O O
cohort NN O O
of NN O O
young NN O O
women NN O O
with NN O O
breast NN O B-Disease
cancer NN O I-Disease
. NN O O

The NN O O
risk NN O O
of NN O O
harboring NN O O
a NN O O
mutation NN O O
was NN O O
not NN O O
limited NN O O
to NN O O
women NN O O
with NN O O
family NN O O
histories NN O O
of NN O O
breast NN O B-Disease
or NN O I-Disease
ovarian NN O I-Disease
cancer NN O I-Disease
. NN O O

These NN O O
results NN O O
represent NN O O
a NN O O
minimal NN O O
estimate NN O O
of NN O O
the NN O O
frequency NN O O
of NN O O
BRCA1 NN O O
mutations NN O O
in NN O O
this NN O O
population NN O O
. NN O O

Comprehensive NN O O
methods NN O O
of NN O O
identifying NN O O
BRCA1 NN O O
mutations NN O O
and NN O O
understanding NN O O
their NN O O
importance NN O O
will NN O O
be NN O O
needed NN O O
before NN O O
testing NN O O
of NN O O
women NN O O
in NN O O
the NN O O
general NN O O
population NN O O
can NN O O
be NN O O
undertaken NN O O
. NN O O
. NN O O

Novel NN O O
inherited NN O O
mutations NN O O
and NN O O
variable NN O O
expressivity NN O O
of NN O O
BRCA1 NN O O
alleles NN O O
, NN O O
including NN O O
the NN O O
founder NN O O
mutation NN O O
185delAG NN O O
in NN O O
Ashkenazi NN O O
Jewish NN O O
families NN O O
. NN O O

Thirty NN O O
- NN O O
seven NN O O
families NN O O
with NN O O
four NN O O
or NN O O
more NN O O
cases NN O O
of NN O O
breast NN O B-Disease
cancer NN O I-Disease
or NN O O
breast NN O B-Disease
and NN O I-Disease
ovarian NN O I-Disease
cancer NN O I-Disease
were NN O O
analyzed NN O O
for NN O O
mutations NN O O
in NN O O
BRCA1 NN O O
. NN O O

Twelve NN O O
different NN O O
germ NN O O
- NN O O
line NN O O
mutations NN O O
, NN O O
four NN O O
novel NN O O
and NN O O
eight NN O O
previously NN O O
observed NN O O
, NN O O
were NN O O
detected NN O O
in NN O O
16 NN O O
families NN O O
. NN O O

Five NN O O
families NN O O
of NN O O
Ashkenazi NN O O
Jewish NN O O
descent NN O O
carried NN O O
the NN O O
185delAG NN O O
mutation NN O O
and NN O O
shared NN O O
the NN O O
same NN O O
haplotype NN O O
at NN O O
eight NN O O
polymorphic NN O O
markers NN O O
spanning NN O O
approximately NN O O
850 NN O O
kb NN O O
at NN O O
BRCA1 NN O O
. NN O O

Expressivity NN O O
of NN O O
185delAG NN O O
in NN O O
these NN O O
families NN O O
varied NN O O
, NN O O
from NN O O
early NN O O
- NN O O
onset NN O O
breast NN O B-Disease
cancer NN O I-Disease
without NN O O
ovarian NN O B-Disease
cancer NN O I-Disease
. NN O O

Mutation NN O O
4184delTCAA NN O O
occurred NN O O
independently NN O O
in NN O O
two NN O O
families NN O O
. NN O O

In NN O O
one NN O O
family NN O O
, NN O O
penetrance NN O O
was NN O O
complete NN O O
, NN O O
with NN O O
females NN O O
developing NN O O
early NN O O
- NN O O
onset NN O O
breast NN O B-Disease
cancer NN O I-Disease
or NN O O
ovarian NN O B-Disease
cancer NN O I-Disease
and NN O O
the NN O O
male NN O O
carrier NN O O
developing NN O O
prostatic NN O B-Disease
cancer NN O I-Disease
, NN O O
whereas NN O O
, NN O O
in NN O O
the NN O O
other NN O O
family NN O O
, NN O O
penetrance NN O O
was NN O O
incomplete NN O O
and NN O O
only NN O O
breast NN O B-Disease
cancer NN O I-Disease
occurred NN O O
, NN O O
diagnosed NN O O
at NN O O
ages NN O O
38 NN O O
- NN O O
81 NN O O
years NN O O
. NN O O

Two NN O O
novel NN O O
nonsense NN O O
mutations NN O O
led NN O O
to NN O O
the NN O O
loss NN O O
of NN O O
mutant NN O O
BRCA1 NN O O
transcript NN O O
in NN O O
families NN O O
with NN O O
10 NN O O
and NN O O
6 NN O O
cases NN O O
of NN O O
early NN O O
- NN O O
onset NN O O
breast NN O B-Disease
cancer NN O I-Disease
and NN O O
ovarian NN O B-Disease
cancer NN O I-Disease
. NN O O

A NN O O
665 NN O O
- NN O O
nt NN O O
segment NN O O
of NN O O
the NN O O
BRCA1 NN O O
3 NN O O
- NN O O
UTR NN O O
and NN O O
1 NN O O
. NN O O

3 NN O O
kb NN O O
of NN O O
genomic NN O O
sequence NN O O
including NN O O
the NN O O
putative NN O O
promoter NN O O
region NN O O
were NN O O
invariant NN O O
by NN O O
single NN O O
- NN O O
strand NN O O
conformation NN O O
analysis NN O O
in NN O O
13 NN O O
families NN O O
without NN O O
coding NN O O
- NN O O
sequence NN O O
mutations NN O O
. NN O O

Overall NN O O
in NN O O
our NN O O
series NN O O
, NN O O
BRCA1 NN O O
mutations NN O O
have NN O O
been NN O O
detected NN O O
in NN O O
26 NN O O
families NN O O
16 NN O O
with NN O O
positive NN O O
BRCA1 NN O O
lod NN O O
scores NN O O
, NN O O
7 NN O O
with NN O O
negative NN O O
lod NN O O
scores NN O O
( NN O O
reflecting NN O O
multiple NN O O
sporadic NN O O
breast NN O B-Disease
cancers NN O I-Disease
) NN O O
, NN O O
and NN O O
3 NN O O
not NN O O
tested NN O O
for NN O O
linkage NN O O
. NN O O

Three NN O O
other NN O O
families NN O O
have NN O O
positive NN O O
lod NN O O
scores NN O O
for NN O O
linkage NN O O
to NN O O
BRCA2 NN O O
, NN O O
but NN O O
13 NN O O
families NN O O
without NN O O
detected NN O O
BRCA1 NN O O
mutations NN O O
have NN O O
negative NN O O
lod NN O O
scores NN O O
for NN O O
both NN O O
BRCA1 NN O O
and NN O O
BRCA2 NN O O
. NN O O

A NN O O
new NN O O
glucose NN O O
- NN O O
6 NN O O
- NN O O
phosphate NN O O
dehydrogenase NN O O
variant NN O O
, NN O O
G6PD NN O O
Orissa NN O O
( NN O O
44 NN O O
Ala NN O O
- NN O O
- NN O O
> NN O O
Gly NN O O
) NN O O
, NN O O
is NN O O
the NN O O
major NN O O
polymorphic NN O O
variant NN O O
in NN O O
tribal NN O O
populations NN O O
in NN O O
India NN O O
. NN O O

Deficiency NN O B-Disease
of NN O I-Disease
glucose NN O I-Disease
- NN O I-Disease
6 NN O I-Disease
- NN O I-Disease
phosphate NN O I-Disease
dehydrogenase NN O I-Disease
( NN O O
G6PD NN O O
) NN O O
is NN O O
usually NN O O
found NN O O
at NN O O
high NN O O
frequencies NN O O
in NN O O
areas NN O O
of NN O O
the NN O O
world NN O O
where NN O O
malaria NN O B-Disease
has NN O O
been NN O O
endemic NN O O
. NN O O

The NN O O
frequency NN O O
and NN O O
genetic NN O O
basis NN O O
of NN O O
G6PD NN O B-Disease
deficiency NN O I-Disease
have NN O O
been NN O O
studied NN O O
in NN O O
Africa NN O O
, NN O O
around NN O O
the NN O O
Mediterranean NN O O
, NN O O
and NN O O
in NN O O
the NN O O
Far NN O O
East NN O O
, NN O O
but NN O O
little NN O O
such NN O O
information NN O O
is NN O O
available NN O O
about NN O O
the NN O O
situation NN O O
in NN O O
India NN O O
. NN O O

To NN O O
determine NN O O
the NN O O
extent NN O O
of NN O O
heterogeneity NN O O
of NN O O
G6PD NN O O
, NN O O
we NN O O
have NN O O
studied NN O O
several NN O O
different NN O O
Indian NN O O
populations NN O O
by NN O O
screening NN O O
for NN O O
G6PD NN O B-Disease
deficiency NN O I-Disease
, NN O O
followed NN O O
by NN O O
molecular NN O O
analysis NN O O
of NN O O
deficient NN O O
alleles NN O O
. NN O O

The NN O O
frequency NN O O
of NN O O
G6PD NN O B-Disease
deficiency NN O I-Disease
varies NN O O
between NN O O
3 NN O O
% NN O O
and NN O O
15 NN O O
% NN O O
in NN O O
different NN O O
tribal NN O O
and NN O O
urban NN O O
groups NN O O
. NN O O

Remarkably NN O O
, NN O O
a NN O O
previously NN O O
unreported NN O O
deficient NN O O
variant NN O O
, NN O O
G6PD NN O O
Orissa NN O O
( NN O O
44 NN O O
Ala NN O O
- NN O O
- NN O O
> NN O O
Gly NN O O
) NN O O
, NN O O
is NN O O
responsible NN O O
for NN O O
most NN O O
of NN O O
the NN O O
G6PD NN O B-Disease
deficiency NN O I-Disease
in NN O O
tribal NN O O
Indian NN O O
populations NN O O
but NN O O
is NN O O
not NN O O
found NN O O
in NN O O
urban NN O O
populations NN O O
, NN O O
where NN O O
most NN O O
of NN O O
the NN O O
G6PD NN O B-Disease
deficiency NN O I-Disease
is NN O O
due NN O O
to NN O O
the NN O O
G6PD NN O O
Mediterranean NN O O
( NN O O
188 NN O O
Ser NN O O
- NN O O
- NN O O
> NN O O
Phe NN O O
) NN O O
variant NN O O
. NN O O

The NN O O
KmNADP NN O O
of NN O O
G6PD NN O O
Orissa NN O O
is NN O O
fivefold NN O O
higher NN O O
than NN O O
that NN O O
of NN O O
the NN O O
normal NN O O
enzyme NN O O
. NN O O

This NN O O
may NN O O
be NN O O
due NN O O
to NN O O
the NN O O
fact NN O O
that NN O O
the NN O O
alanine NN O O
residue NN O O
that NN O O
is NN O O
replaced NN O O
by NN O O
glycine NN O O
is NN O O
part NN O O
of NN O O
a NN O O
putative NN O O
coenzyme NN O O
- NN O O
binding NN O O
site NN O O
. NN O O
. NN O O

Evidence NN O O
for NN O O
linkage NN O O
of NN O O
bipolar NN O B-Disease
disorder NN O I-Disease
to NN O O
chromosome NN O O
18 NN O O
with NN O O
a NN O O
parent NN O O
- NN O O
of NN O O
- NN O O
origin NN O O
effect NN O O
. NN O O

A NN O O
susceptibility NN O O
gene NN O O
on NN O O
chromosome NN O O
18 NN O O
and NN O O
a NN O O
parent NN O O
- NN O O
of NN O O
- NN O O
origin NN O O
effect NN O O
have NN O O
been NN O O
suggested NN O O
for NN O O
bipolar NN O B-Disease
affective NN O I-Disease
disorder NN O I-Disease
( NN O O
BPAD NN O B-Disease
) NN O O
. NN O O

We NN O O
have NN O O
studied NN O O
28 NN O O
nuclear NN O O
families NN O O
selected NN O O
for NN O O
apparent NN O O
unilineal NN O O
transmission NN O O
of NN O O
the NN O O
BPAD NN O B-Disease
phenotype NN O O
, NN O O
by NN O O
using NN O O
31 NN O O
polymorphic NN O O
markers NN O O
spanning NN O O
chromosome NN O O
18 NN O O
. NN O O

Evidence NN O O
for NN O O
linkage NN O O
was NN O O
tested NN O O
with NN O O
affected NN O O
- NN O O
sib NN O O
- NN O O
pair NN O O
and NN O O
LOD NN O O
score NN O O
methods NN O O
under NN O O
two NN O O
definitions NN O O
of NN O O
the NN O O
affected NN O O
phenotype NN O O
. NN O O

The NN O O
affected NN O O
- NN O O
sibpair NN O O
analyses NN O O
indicated NN O O
excess NN O O
allele NN O O
sharing NN O O
for NN O O
markers NN O O
on NN O O
18p NN O O
within NN O O
the NN O O
region NN O O
reported NN O O
previously NN O O
. NN O O

The NN O O
greatest NN O O
sharing NN O O
was NN O O
at NN O O
D18S37 NN O O
64 NN O O
% NN O O
in NN O O
bipolar NN O O
and NN O O
recurrent NN O O
unipolar NN O O
( NN O O
RUP NN O O
) NN O O
sib NN O O
pairs NN O O
( NN O O
P NN O O
= NN O O
. NN O O
0006 NN O O
) NN O O
. NN O O

In NN O O
addition NN O O
, NN O O
excess NN O O
sharing NN O O
of NN O O
the NN O O
paternally NN O O
, NN O O
but NN O O
not NN O O
maternally NN O O
, NN O O
transmitted NN O O
alleles NN O O
was NN O O
observed NN O O
at NN O O
three NN O O
markers NN O O
on NN O O
18q NN O O
at NN O O
D18S41 NN O O
, NN O O
51 NN O O
bipolar NN O O
and NN O O
RUP NN O O
sib NN O O
pairs NN O O
were NN O O
concordant NN O O
for NN O O
paternally NN O O
transmitted NN O O
alleles NN O O
, NN O O
and NN O O
21 NN O O
pairs NN O O
were NN O O
discordant NN O O
( NN O O
P NN O O
= NN O O
0004 NN O O
) NN O O
. NN O O

The NN O O
evidence NN O O
for NN O O
linkage NN O O
to NN O O
loci NN O O
on NN O O
both NN O O
18p NN O O
and NN O O
18q NN O O
was NN O O
strongest NN O O
in NN O O
the NN O O
11 NN O O
paternal NN O O
pedigrees NN O O
, NN O O
i NN O O
. NN O O

e NN O O
e NN O O
. NN O O
, NN O O
those NN O O
in NN O O
which NN O O
the NN O O
father NN O O
or NN O O
one NN O O
of NN O O
the NN O O
fathers NN O O
sibs NN O O
is NN O O
affected NN O O
. NN O O

In NN O O
these NN O O
pedigrees NN O O
, NN O O
the NN O O
greatest NN O O
allele NN O O
sharing NN O O
( NN O O
81 NN O O
% NN O O
; NN O O
P NN O O
= NN O O
. NN O O
00002 NN O O
) NN O O
and NN O O
the NN O O
highest NN O O
LOD NN O O
score NN O O
( NN O O
3 NN O O
. NN O O
51 NN O O
; NN O O
phi NN O O
= NN O O
0 NN O O
. NN O O
0 NN O O
) NN O O
were NN O O
observed NN O O
at NN O O
D18S41 NN O O
. NN O O

Our NN O O
results NN O O
provide NN O O
further NN O O
support NN O O
for NN O O
linkage NN O O
of NN O O
BPAD NN O B-Disease
to NN O O
chromosome NN O O
18 NN O O
and NN O O
the NN O O
first NN O O
molecular NN O O
evidence NN O O
for NN O O
a NN O O
parent NN O O
- NN O O
of NN O O
- NN O O
origin NN O O
effect NN O O
operating NN O O
in NN O O
this NN O O
disorder NN O O
. NN O O

The NN O O
number NN O O
of NN O O
loci NN O O
involved NN O O
, NN O O
and NN O O
their NN O O
precise NN O O
location NN O O
, NN O O
require NN O O
further NN O O
study NN O O

A NN O O
prevalent NN O O
mutation NN O O
for NN O O
galactosemia NN O B-Disease
among NN O O
black NN O O
Americans NN O O
. NN O O

OBJECTIVE NN O O
To NN O O
define NN O O
the NN O O
mutation NN O O
causing NN O O
galactosemia NN O B-Disease
in NN O O
patients NN O O
of NN O O
black NN O O
American NN O O
origin NN O O
who NN O O
have NN O O
no NN O O
galactose NN O O
- NN O O
1 NN O O
- NN O O
phosphate NN O O
uridyltransferase NN O O
( NN O O
GALT NN O O
) NN O O
activity NN O O
in NN O O
erythrocytes NN O O
but NN O O
good NN O O
clinical NN O O
outcome NN O O
. NN O O

METHODS NN O O
We NN O O
discovered NN O O
a NN O O
mutation NN O O
caused NN O O
by NN O O
a NN O O
C NN O O
- NN O O
- NN O O
> NN O O
T NN O O
transition NN O O
at NN O O
base NN O O
- NN O O
pair NN O O
1158 NN O O
of NN O O
the NN O O
GALT NN O O
gene NN O O
that NN O O
results NN O O
in NN O O
a NN O O
serine NN O O
- NN O O
to NN O O
- NN O O
leucine NN O O
substitution NN O O
at NN O O
codon NN O O
135 NN O O
( NN O O
S135L NN O O
) NN O O
. NN O O

We NN O O
developed NN O O
a NN O O
method NN O O
with NN O O
which NN O O
to NN O O
screen NN O O
populations NN O O
for NN O O
its NN O O
prevalence NN O O
. NN O O

We NN O O
compared NN O O
galactose NN O O
- NN O O
1 NN O O
- NN O O
phosphate NN O O
uridyltransferase NN O O
among NN O O
erythrocytes NN O O
, NN O O
leukocytes NN O O
, NN O O
and NN O O
transformed NN O O
lymphoblasts NN O O
, NN O O
as NN O O
well NN O O
as NN O O
total NN O O
body NN O O
oxidation NN O O
of NN O O
D NN O O
- NN O O
( NN O O
13C NN O O
) NN O O
- NN O O
galactose NN O O
to NN O O
13CO2 NN O O
among NN O O
three NN O O
genotypes NN O O
for NN O O
GALT NN O O
( NN O O
S135L NN O O
/ NN O O
S135L NN O O
, NN O O
Q188R NN O O
/ NN O O
Q188R NN O O
, NN O O
and NN O O
Normal NN O O
/ NN O O
Normal NN O O
) NN O O
. NN O O

RESULTS NN O O
We NN O O
found NN O O
a NN O O
48 NN O O
% NN O O
prevalence NN O O
of NN O O
the NN O O
S135L NN O O
mutation NN O O
among NN O O
17 NN O O
black NN O O
American NN O O
patients NN O O
with NN O O
classic NN O B-Disease
galactosemia NN O I-Disease
and NN O O
a NN O O
1 NN O O
% NN O O
prevalence NN O O
in NN O O
a NN O O
population NN O O
of NN O O
50 NN O O
black NN O O
Americans NN O O
without NN O O
galactosemia NN O B-Disease
. NN O O

The NN O O
S135L NN O O
mutation NN O O
was NN O O
not NN O O
found NN O O
in NN O O
84 NN O O
white NN O O
patients NN O O
with NN O O
G NN O O
/ NN O O
G NN O O
galactosemia NN O B-Disease
nor NN O O
in NN O O
87 NN O O
white NN O O
control NN O O
subjects NN O O
without NN O O
galactosemia NN O B-Disease
. NN O O

We NN O O
found NN O O
normal NN O O
whole NN O O
body NN O O
oxidation NN O O
of NN O O
D NN O O
- NN O O
( NN O O
13C NN O O
) NN O O
- NN O O
galactose NN O O
by NN O O
the NN O O
patient NN O O
homozygous NN O O
for NN O O
S135L NN O O
and NN O O
various NN O O
degrees NN O O
of NN O O
enzyme NN O O
impairment NN O O
among NN O O
different NN O O
tissues NN O O
. NN O O

CONCLUSIONS NN O O
The NN O O
S135L NN O O
mutation NN O O
in NN O O
the NN O O
GALT NN O O
gene NN O O
is NN O O
a NN O O
prevalent NN O O
cause NN O O
of NN O O
galactosemia NN O B-Disease
among NN O O
black NN O O
patients NN O O
. NN O O

Because NN O O
GALT NN O O
activity NN O O
varies NN O O
in NN O O
different NN O O
tissues NN O O
of NN O O
patients NN O O
homozygous NN O O
for NN O O
S135L NN O O
, NN O O
they NN O O
may NN O O
have NN O O
a NN O O
better NN O O
clinical NN O O
outcome NN O O
than NN O O
patients NN O O
who NN O O
are NN O O
homozygous NN O O
for NN O O
Q188R NN O O
when NN O O
both NN O O
are NN O O
treated NN O O
from NN O O
infancy NN O O
. NN O O
. NN O O

A NN O O
high NN O O
incidence NN O O
of NN O O
BRCA1 NN O O
mutations NN O O
in NN O O
20 NN O O
breast NN O B-Disease
- NN O I-Disease
ovarian NN O I-Disease
cancer NN O I-Disease
families NN O O
. NN O O

We NN O O
have NN O O
analyzed NN O O
20 NN O O
breast NN O B-Disease
- NN O I-Disease
ovarian NN O I-Disease
cancer NN O I-Disease
families NN O O
, NN O O
the NN O O
majority NN O O
of NN O O
which NN O O
show NN O O
positive NN O O
evidence NN O O
of NN O O
linkage NN O O
to NN O O
chromosome NN O O
17q12 NN O O
for NN O O
germ NN O O
- NN O O
line NN O O
mutations NN O O
in NN O O
the NN O O
BRCA1 NN O O
gene NN O O
. NN O O

BRCA1 NN O O
mutations NN O O
cosegregating NN O O
with NN O O
breast NN O B-Disease
and NN O I-Disease
ovarian NN O I-Disease
cancer NN O I-Disease
susceptibility NN O O
were NN O O
identified NN O O
in NN O O
16 NN O O
families NN O O
, NN O O
including NN O O
1 NN O O
family NN O O
with NN O O
a NN O O
case NN O O
of NN O O
male NN O B-Disease
breast NN O I-Disease
cancer NN O I-Disease
. NN O O

Nine NN O O
of NN O O
these NN O O
mutations NN O O
have NN O O
not NN O O
been NN O O
reported NN O O
previously NN O O
. NN O O

The NN O O
majority NN O O
of NN O O
mutations NN O O
were NN O O
found NN O O
to NN O O
generate NN O O
a NN O O
premature NN O O
stop NN O O
codon NN O O
leading NN O O
to NN O O
the NN O O
formation NN O O
of NN O O
a NN O O
truncated NN O O
BRCA1 NN O O
protein NN O O
of NN O O
2 NN O O
% NN O O
- NN O O
88 NN O O
% NN O O
of NN O O
the NN O O
expected NN O O
normal NN O O
length NN O O
. NN O O

Two NN O O
mutations NN O O
altered NN O O
the NN O O
RING NN O O
finger NN O O
domain NN O O
. NN O O

Sequencing NN O O
of NN O O
genomic NN O O
DNA NN O O
led NN O O
to NN O O
the NN O O
identification NN O O
of NN O O
a NN O O
mutation NN O O
in NN O O
the NN O O
coding NN O O
region NN O O
of NN O O
BRCA1 NN O O
in NN O O
12 NN O O
families NN O O
, NN O O
and NN O O
cDNA NN O O
analysis NN O O
revealed NN O O
an NN O O
abnormal NN O O
or NN O O
missing NN O O
BRCA1 NN O O
transcript NN O O
in NN O O
4 NN O O
of NN O O
the NN O O
8 NN O O
remaining NN O O
families NN O O
. NN O O

A NN O O
total NN O O
of NN O O
eight NN O O
mutations NN O O
were NN O O
associated NN O O
with NN O O
a NN O O
reduced NN O O
quantity NN O O
of NN O O
BRCA1 NN O O
transcript NN O O
. NN O O

We NN O O
were NN O O
unable NN O O
to NN O O
detect NN O O
BRCA1 NN O O
mutations NN O O
in NN O O
4 NN O O
of NN O O
the NN O O
20 NN O O
families NN O O
, NN O O
but NN O O
only NN O O
1 NN O O
of NN O O
these NN O O
was NN O O
clearly NN O O
linked NN O O
to NN O O
BRCA1 NN O O
. NN O O

It NN O O
is NN O O
expected NN O O
that NN O O
the NN O O
majority NN O O
of NN O O
clear NN O O
examples NN O O
of NN O O
the NN O O
breast NN O B-Disease
- NN O I-Disease
ovarian NN O I-Disease
syndrome NN O I-Disease
will NN O O
be NN O O
associated NN O O
with NN O O
germ NN O O
- NN O O
line NN O O
mutations NN O O
in NN O O
the NN O O
coding NN O O
region NN O O
of NN O O
BRCA1 NN O O
. NN O O
. NN O O

Brca1 NN O B-Disease
deficiency NN O I-Disease
results NN O O
in NN O O
early NN O O
embryonic NN O B-Disease
lethality NN O I-Disease
characterized NN O O
by NN O O
neuroepithelial NN O B-Disease
abnormalities NN O I-Disease
. NN O O

The NN O O
breast NN O B-Disease
and NN O I-Disease
ovarian NN O I-Disease
cancer NN O I-Disease
susceptibility NN O O
gene NN O O
, NN O O
BRCA1 NN O O
, NN O O
has NN O O
been NN O O
cloned NN O O
and NN O O
shown NN O O
to NN O O
encode NN O O
a NN O O
zinc NN O O
- NN O O
finger NN O O
protein NN O O
of NN O O
unknown NN O O
function NN O O
. NN O O

Mutations NN O O
in NN O O
BRCA1 NN O O
account NN O O
for NN O O
at NN O O
least NN O O
80 NN O O
% NN O O
of NN O O
families NN O O
with NN O O
both NN O O
breast NN O B-Disease
and NN O I-Disease
ovarian NN O I-Disease
cancer NN O I-Disease
, NN O O
as NN O O
well NN O O
as NN O O
some NN O O
non NN O O
- NN O O
familial NN O O
sporadic NN O O
ovarian NN O B-Disease
cancers NN O I-Disease
. NN O O

The NN O O
loss NN O O
of NN O O
wild NN O O
- NN O O
type NN O O
BRCA1 NN O O
in NN O O
tumours NN O B-Disease
of NN O O
individuals NN O O
carrying NN O O
one NN O O
nonfunctional NN O O
BRCA1 NN O O
allele NN O O
suggests NN O O
that NN O O
BRCA1 NN O O
encodes NN O O
a NN O O
tumour NN O B-Disease
suppressor NN O O
that NN O O
may NN O O
inhibit NN O O
the NN O O
proliferation NN O O
of NN O O
mammary NN O O
epithelial NN O O
cells NN O O
. NN O O

To NN O O
examine NN O O
the NN O O
role NN O O
of NN O O
BRCA1 NN O O
in NN O O
normal NN O O
tissue NN O O
growth NN O O
and NN O O
differentiation NN O O
, NN O O
and NN O O
to NN O O
generate NN O O
a NN O O
potential NN O O
model NN O O
for NN O O
the NN O O
cancer NN O B-Disease
susceptibility NN O O
associated NN O O
with NN O O
loss NN O O
of NN O O
BRCA1 NN O O
function NN O O
, NN O O
we NN O O
have NN O O
created NN O O
a NN O O
mouse NN O O
line NN O O
carrying NN O O
a NN O O
mutation NN O O
in NN O O
one NN O O
Brca1 NN O O
allele NN O O
. NN O O

Analysis NN O O
of NN O O
mice NN O O
homozygous NN O O
for NN O O
the NN O O
mutant NN O O
allele NN O O
indicate NN O O
that NN O O
Brca1 NN O O
is NN O O
critical NN O O
for NN O O
normal NN O O
development NN O O
, NN O O
as NN O O
these NN O O
mice NN O O
died NN O O
in NN O O
utero NN O O
between NN O O
10 NN O O
and NN O O
13 NN O O
days NN O O
of NN O O
gestation NN O O
( NN O O
E10 NN O O
- NN O O
E13 NN O O
) NN O O
. NN O O

Abnormalities NN O O
in NN O O
Brca1 NN O B-Disease
- NN O I-Disease
deficient NN O I-Disease
embryos NN O O
were NN O O
most NN O O
evident NN O O
in NN O O
the NN O O
neural NN O O
tube NN O O
, NN O O
with NN O O
40 NN O O
% NN O O
of NN O O
the NN O O
embryos NN O O
presenting NN O O
with NN O O
varying NN O O
degrees NN O O
of NN O O
spina NN O B-Disease
bifida NN O I-Disease
and NN O O
anencephaly NN O B-Disease
. NN O O

In NN O O
addition NN O O
, NN O O
the NN O O
neuroepithelium NN O O
in NN O O
Brca1 NN O B-Disease
- NN O I-Disease
deficient NN O I-Disease
embryos NN O O
appeared NN O O
disorganized NN O O
, NN O O
with NN O O
signs NN O O
of NN O O
both NN O O
rapid NN O O
proliferation NN O O
and NN O O
excessive NN O O
cell NN O O
death NN O O
. NN O O
. NN O O

Identification NN O O
of NN O O
mutations NN O O
in NN O O
the NN O O
ALD NN O O
- NN O O
gene NN O O
of NN O O
20 NN O O
families NN O O
with NN O O
adrenoleukodystrophy NN O B-Disease
/ NN O O
adrenomyeloneuropathy NN O B-Disease
. NN O O

Adrenoleukodystrophy NN O B-Disease
( NN O O
ALD NN O B-Disease
) NN O O
, NN O O
an NN O O
X NN O B-Disease
- NN O I-Disease
linked NN O I-Disease
inherited NN O I-Disease
metabolic NN O I-Disease
disorder NN O I-Disease
, NN O O
is NN O O
the NN O O
most NN O O
frequent NN O O
inborn NN O B-Disease
peroxisomal NN O I-Disease
disease NN O I-Disease
. NN O O

It NN O O
leads NN O O
to NN O O
demyelination NN O B-Disease
in NN O I-Disease
the NN O I-Disease
central NN O I-Disease
and NN O I-Disease
peripheral NN O I-Disease
nervous NN O I-Disease
system NN O I-Disease
. NN O O

Defective NN O O
beta NN O O
- NN O O
oxidation NN O O
of NN O O
saturated NN O O
very NN O O
long NN O O
chain NN O O
fatty NN O O
acids NN O O
( NN O O
VLCFAs NN O O
; NN O O
C22 NN O O
0 NN O O
- NN O O
C26 NN O O
0 NN O O
) NN O O
in NN O O
peroxisomes NN O O
has NN O O
been NN O O
shown NN O O
to NN O O
lead NN O O
to NN O O
an NN O O
accumulation NN O O
of NN O O
VLCFAs NN O O
in NN O O
leukoid NN O O
areas NN O O
of NN O O
the NN O O
central NN O O
nervous NN O O
system NN O O
, NN O O
peripheral NN O O
nerves NN O O
, NN O O
adrenal NN O O
gland NN O O
, NN O O
and NN O O
blood NN O O
. NN O O

The NN O O
ALD NN O B-Disease
gene NN O O
has NN O O
been NN O O
recently NN O O
identified NN O O
and NN O O
encodes NN O O
a NN O O
745 NN O O
- NN O O
amino NN O O
- NN O O
acid NN O O
protein NN O O
. NN O O

We NN O O
screened NN O O
patients NN O O
with NN O O
adrenoleukodystrophy NN O B-Disease
/ NN O O
adrenomyeloneuropathy NN O B-Disease
( NN O O
ALD NN O B-Disease
/ NN O O
AMN NN O B-Disease
) NN O O
from NN O O
20 NN O O
kindreds NN O O
for NN O O
mutations NN O O
in NN O O
the NN O O
ALD NN O B-Disease
gene NN O O
. NN O O

Eleven NN O O
missense NN O O
and NN O O
two NN O O
nonsense NN O O
mutations NN O O
, NN O O
five NN O O
deletions NN O O
, NN O O
and NN O O
one NN O O
insertion NN O O
were NN O O
detected NN O O
by NN O O
direct NN O O
sequencing NN O O
of NN O O
eight NN O O
reverse NN O O
transcribed NN O O
fragments NN O O
of NN O O
the NN O O
ALD NN O B-Disease
- NN O O
gene NN O O
mRNA NN O O
. NN O O

Four NN O O
mutations NN O O
could NN O O
be NN O O
shown NN O O
to NN O O
be NN O O
de NN O O
novo NN O O
. NN O O

All NN O O
mutations NN O O
could NN O O
be NN O O
confirmed NN O O
in NN O O
carriers NN O O
by NN O O
sequencing NN O O
genomic NN O O
DNA NN O O
. NN O O

No NN O O
correlation NN O O
between NN O O
the NN O O
type NN O O
of NN O O
mutation NN O O
and NN O O
the NN O O
severity NN O O
of NN O O
the NN O O
phenotype NN O O
could NN O O
be NN O O
observed NN O O
. NN O O

The NN O O
mutations NN O O
were NN O O
not NN O O
detected NN O O
in NN O O
the NN O O
ALD NN O B-Disease
gene NN O O
of NN O O
30 NN O O
healthy NN O O
persons NN O O
. NN O O
. NN O O

The NN O O
murine NN O O
homolog NN O O
of NN O O
the NN O O
human NN O O
breast NN O B-Disease
and NN O I-Disease
ovarian NN O I-Disease
cancer NN O I-Disease
susceptibility NN O O
gene NN O O
Brca1 NN O O
maps NN O O
to NN O O
mouse NN O O
chromosome NN O O
11D NN O O
. NN O O

The NN O O
recently NN O O
cloned NN O O
human NN O O
breast NN O B-Disease
and NN O I-Disease
ovarian NN O I-Disease
cancer NN O I-Disease
susceptibility NN O O
gene NN O O
, NN O O
BRCA1 NN O O
, NN O O
is NN O O
located NN O O
on NN O O
human NN O O
chromosome NN O O
17q21 NN O O
. NN O O

We NN O O
have NN O O
isolated NN O O
murine NN O O
genomic NN O O
clones NN O O
containing NN O O
Brca1 NN O O
as NN O O
a NN O O
first NN O O
step NN O O
in NN O O
generating NN O O
a NN O O
mouse NN O O
model NN O O
for NN O O
the NN O O
loss NN O O
of NN O O
BRCA1 NN O O
function NN O O
. NN O O

A NN O O
mouse NN O O
genomic NN O O
library NN O O
was NN O O
screened NN O O
using NN O O
probes NN O O
corresponding NN O O
to NN O O
exon NN O O
11 NN O O
of NN O O
the NN O O
human NN O O
BRCA1 NN O O
gene NN O O
. NN O O

Two NN O O
overlapping NN O O
mouse NN O O
clones NN O O
were NN O O
identified NN O O
that NN O O
hybridized NN O O
to NN O O
human NN O O
BRCA1 NN O O
exons NN O O
9 NN O O
- NN O O
12 NN O O
. NN O O

Sequence NN O O
analysis NN O O
of NN O O
1 NN O O
. NN O O

4 NN O O
kb NN O O
of NN O O
the NN O O
region NN O O
of NN O O
these NN O O
clones NN O O
corresponding NN O O
to NN O O
part NN O O
of NN O O
human NN O O
exon NN O O
11 NN O O
revealed NN O O
72 NN O O
% NN O O
nucleic NN O O
acid NN O O
identity NN O O
but NN O O
only NN O O
50 NN O O
% NN O O
amino NN O O
acid NN O O
identity NN O O
with NN O O
the NN O O
human NN O O
gene NN O O
. NN O O

The NN O O
longest NN O O
of NN O O
the NN O O
mouse NN O O
Brca1 NN O O
genomic NN O O
clones NN O O
maps NN O O
to NN O O
chromosome NN O O
11D NN O O
, NN O O
as NN O O
determined NN O O
by NN O O
two NN O O
- NN O O
color NN O O
fluorescence NN O O
in NN O O
situ NN O O
hybridization NN O O
. NN O O

The NN O O
synteny NN O O
to NN O O
human NN O O
chromosome NN O O
17 NN O O
was NN O O
confirmed NN O O
by NN O O
cohybridization NN O O
with NN O O
the NN O O
mouse NN O O
probe NN O O
for NN O O
the NN O O
NF1 NN O O
- NN O O
gene NN O O
. NN O O

This NN O O
comparative NN O O
study NN O O
confirms NN O O
that NN O O
the NN O O
relative NN O O
location NN O O
of NN O O
the NN O O
BRCA1 NN O O
gene NN O O
has NN O O
been NN O O
conserved NN O O
between NN O O
mice NN O O
and NN O O
humans NN O O
. NN O O

Atelosteogenesis NN O B-Disease
type NN O I-Disease
II NN O I-Disease
is NN O O
caused NN O O
by NN O O
mutations NN O O
in NN O O
the NN O O
diastrophic NN O B-Disease
dysplasia NN O I-Disease
sulfate NN O O
- NN O O
transporter NN O O
gene NN O O
( NN O O
DTDST NN O O
) NN O O
: NN O O
evidence NN O O
for NN O O
a NN O O
phenotypic NN O O
series NN O O
involving NN O O
three NN O O
chondrodysplasias NN O B-Disease
. NN O O

Atelosteogenesis NN O B-Disease
type NN O I-Disease
II NN O I-Disease
( NN O O
AO NN O B-Disease
II NN O I-Disease
) NN O O
is NN O O
a NN O O
neonatally NN O O
lethal NN O O
chondrodysplasia NN O B-Disease
whose NN O O
clinical NN O O
and NN O O
histological NN O O
characteristics NN O O
resemble NN O O
those NN O O
of NN O O
another NN O O
chondrodysplasia NN O B-Disease
, NN O O
the NN O O
much NN O O
less NN O O
severe NN O O
diastrophic NN O B-Disease
dysplasia NN O I-Disease
( NN O O
DTD NN O B-Disease
) NN O O
. NN O O

The NN O O
similarity NN O O
suggests NN O O
a NN O O
shared NN O O
pathogenesis NN O O
involving NN O O
lesions NN O O
in NN O O
the NN O O
same NN O O
biochemical NN O O
pathway NN O O
and NN O O
perhaps NN O O
the NN O O
same NN O O
gene NN O O
. NN O O

DTD NN O B-Disease
is NN O O
caused NN O O
by NN O O
mutations NN O O
in NN O O
the NN O O
recently NN O O
identified NN O O
diastrophic NN O B-Disease
dysplasia NN O I-Disease
sulfate NN O O
- NN O O
transporter NN O O
gene NN O O
( NN O O
DTDST NN O O
) NN O O
. NN O O

Here NN O O
, NN O O
we NN O O
report NN O O
that NN O O
AOII NN O B-Disease
patients NN O O
also NN O O
have NN O O
DTDST NN O O
mutations NN O O
, NN O O
which NN O O
lead NN O O
to NN O O
defective NN O O
uptake NN O O
of NN O O
inorganic NN O O
sulfate NN O O
and NN O O
insufficient NN O O
sulfation NN O O
of NN O O
macromolecules NN O O
by NN O O
patient NN O O
mesenchymal NN O O
cells NN O O
in NN O O
vitro NN O O
. NN O O

Together NN O O
with NN O O
our NN O O
recent NN O O
observation NN O O
that NN O O
a NN O O
third NN O O
even NN O O
more NN O O
severe NN O O
chondrodysplasia NN O B-Disease
, NN O O
achondrogenesis NN O O
type NN O O
IB NN O O
, NN O O
is NN O O
also NN O O
caused NN O O
by NN O O
mutations NN O O
in NN O O
DTDST NN O O
, NN O O
these NN O O
results NN O O
demonstrate NN O O
a NN O O
phenotypic NN O O
series NN O O
of NN O O
three NN O O
chondrodysplasias NN O B-Disease
of NN O O
increasing NN O O
severity NN O O
caused NN O O
by NN O O
lesions NN O O
in NN O O
a NN O O
single NN O O
sulfate NN O O
- NN O O
transporter NN O O
gene NN O O
. NN O O

The NN O O
severity NN O O
of NN O O
the NN O O
phenotype NN O O
appears NN O O
to NN O O
be NN O O
correlated NN O O
with NN O O
the NN O O
predicted NN O O
effect NN O O
of NN O O
the NN O O
mutations NN O O
on NN O O
the NN O O
residual NN O O
activity NN O O
of NN O O
the NN O O
DTDST NN O O
protein NN O O
. NN O O
. NN O O

Haplotype NN O O
and NN O O
phenotype NN O O
analysis NN O O
of NN O O
six NN O O
recurrent NN O O
BRCA1 NN O O
mutations NN O O
in NN O O
61 NN O O
families NN O O
: NN O O
results NN O O
of NN O O
an NN O O
international NN O O
study NN O O
. NN O O

Several NN O O
BRCA1 NN O O
mutations NN O O
have NN O O
now NN O O
been NN O O
found NN O O
to NN O O
occur NN O O
in NN O O
geographically NN O O
diverse NN O O
breast NN O B-Disease
and NN O I-Disease
ovarian NN O I-Disease
cancer NN O I-Disease
families NN O O
. NN O O

To NN O O
investigate NN O O
mutation NN O O
origin NN O O
and NN O O
mutation NN O O
- NN O O
specific NN O O
phenotypes NN O O
due NN O O
to NN O O
BRCA1 NN O O
, NN O O
we NN O O
constructed NN O O
a NN O O
haplotype NN O O
of NN O O
nine NN O O
polymorphic NN O O
markers NN O O
within NN O O
or NN O O
immediately NN O O
flanking NN O O
the NN O O
BRCA1 NN O O
locus NN O O
in NN O O
a NN O O
set NN O O
of NN O O
61 NN O O
breast NN O B-Disease
/ NN O I-Disease
ovarian NN O I-Disease
cancer NN O I-Disease
families NN O O
selected NN O O
for NN O O
having NN O O
one NN O O
of NN O O
six NN O O
recurrent NN O O
BRCA1 NN O O
mutations NN O O
. NN O O

Tests NN O O
of NN O O
both NN O O
mutations NN O O
and NN O O
family NN O O
- NN O O
specific NN O O
differences NN O O
in NN O O
age NN O O
at NN O O
diagnosis NN O O
were NN O O
not NN O O
significant NN O O
. NN O O

A NN O O
comparison NN O O
of NN O O
the NN O O
six NN O O
mutations NN O O
in NN O O
the NN O O
relative NN O O
proportions NN O O
of NN O O
cases NN O O
of NN O O
breast NN O B-Disease
and NN O I-Disease
ovarian NN O I-Disease
cancer NN O I-Disease
was NN O O
suggestive NN O O
of NN O O
an NN O O
effect NN O O
( NN O O
P NN O O
= NN O O
. NN O O
069 NN O O
) NN O O
, NN O O
with NN O O
57 NN O O
% NN O O
of NN O O
women NN O O
presumed NN O O
affected NN O O
because NN O O
of NN O O
the NN O O
1294 NN O O
del NN O O
40 NN O O
BRCA1 NN O O
mutation NN O O
having NN O O
ovarian NN O B-Disease
cancer NN O I-Disease
, NN O O
compared NN O O
with NN O O
14 NN O O
% NN O O
of NN O O
affected NN O O
women NN O O
with NN O O
the NN O O
splice NN O O
- NN O O
site NN O O
mutation NN O O
in NN O O
intron NN O O
5 NN O O
of NN O O
BRCA1 NN O O
. NN O O

For NN O O
the NN O O
BRCA1 NN O O
mutations NN O O
studied NN O O
here NN O O
, NN O O
the NN O O
individual NN O O
mutations NN O O
are NN O O
estimated NN O O
to NN O O
have NN O O
arisen NN O O
9 NN O O
- NN O O
170 NN O O
generations NN O O
ago NN O O
. NN O O

In NN O O
general NN O O
, NN O O
a NN O O
high NN O O
degree NN O O
of NN O O
haplotype NN O O
conservation NN O O
across NN O O
the NN O O
region NN O O
was NN O O
observed NN O O
, NN O O
with NN O O
haplotype NN O O
differences NN O O
most NN O O
often NN O O
due NN O O
to NN O O
mutations NN O O
in NN O O
the NN O O
short NN O O
- NN O O
tandem NN O O
- NN O O
repeat NN O O
markers NN O O
, NN O O
although NN O O
some NN O O
likely NN O O
instances NN O O
of NN O O
recombination NN O O
also NN O O
were NN O O
observed NN O O
. NN O O

For NN O O
several NN O O
of NN O O
the NN O O
instances NN O O
, NN O O
there NN O O
was NN O O
evidence NN O O
for NN O O
multiple NN O O
, NN O O
independent NN O O
, NN O O
BRCA1 NN O O
mutational NN O O
events NN O O
. NN O O

Isolation NN O O
of NN O O
the NN O O
mouse NN O O
homologue NN O O
of NN O O
BRCA1 NN O O
and NN O O
genetic NN O O
mapping NN O O
to NN O O
mouse NN O O
chromosome NN O O
11 NN O O
. NN O O

The NN O O
BRCA1 NN O O
gene NN O O
is NN O O
in NN O O
large NN O O
part NN O O
responsible NN O O
for NN O O
hereditary NN O B-Disease
human NN O I-Disease
breast NN O I-Disease
and NN O I-Disease
ovarian NN O I-Disease
cancer NN O I-Disease
. NN O O

Here NN O O
we NN O O
report NN O O
the NN O O
isolation NN O O
of NN O O
the NN O O
murine NN O O
Brca1 NN O O
homologue NN O O
cDNA NN O O
clones NN O O
. NN O O

In NN O O
addition NN O O
, NN O O
we NN O O
identified NN O O
genomic NN O O
P1 NN O O
clones NN O O
that NN O O
contain NN O O
most NN O O
, NN O O
if NN O O
not NN O O
all NN O O
, NN O O
of NN O O
the NN O O
mouse NN O O
Brca1 NN O O
locus NN O O
. NN O O

DNA NN O O
sequence NN O O
analysis NN O O
revealed NN O O
that NN O O
the NN O O
mouse NN O O
and NN O O
human NN O O
coding NN O O
regions NN O O
are NN O O
75 NN O O
% NN O O
identical NN O O
at NN O O
the NN O O
nucleotide NN O O
level NN O O
while NN O O
the NN O O
predicted NN O O
amino NN O O
acid NN O O
identity NN O O
is NN O O
only NN O O
58 NN O O
% NN O O
. NN O O

A NN O O
DNA NN O O
sequence NN O O
variant NN O O
in NN O O
the NN O O
Brca1 NN O O
locus NN O O
was NN O O
identified NN O O
and NN O O
used NN O O
to NN O O
map NN O O
this NN O O
gene NN O O
on NN O O
a NN O O
( NN O O
Mus NN O O
m NN O O
. NN O O
musculus NN O O
Czech NN O O
II NN O O
x NN O O
C57BL NN O O
/ NN O O
KsJ NN O O
) NN O O
F1 NN O O
x NN O O
C57BL NN O O
/ NN O O
KsJ NN O O
intersubspecific NN O O
backcross NN O O
to NN O O
distal NN O O
mouse NN O O
chromosome NN O O
11 NN O O
. NN O O

The NN O O
mapping NN O O
of NN O O
this NN O O
gene NN O O
to NN O O
a NN O O
region NN O O
highly NN O O
syntenic NN O O
with NN O O
human NN O O
chromosome NN O O
17 NN O O
, NN O O
coupled NN O O
with NN O O
Southern NN O O
and NN O O
Northern NN O O
analyses NN O O
, NN O O
confirms NN O O
that NN O O
we NN O O
isolated NN O O
the NN O O
murine NN O O
Brca1 NN O O
homologue NN O O
rather NN O O
than NN O O
a NN O O
related NN O O
RING NN O O
finger NN O O
gene NN O O
. NN O O

The NN O O
isolation NN O O
of NN O O
the NN O O
mouse NN O O
Brca1 NN O O
homologue NN O O
will NN O O
facilitate NN O O
the NN O O
creation NN O O
of NN O O
mouse NN O O
models NN O O
for NN O O
germline NN O O
BRCA1 NN O B-Disease
defects NN O I-Disease
. NN O O
. NN O O

Emerin NN O B-Disease
deficiency NN O I-Disease
at NN O O
the NN O O
nuclear NN O O
membrane NN O O
in NN O O
patients NN O O
with NN O O
Emery NN O B-Disease
- NN O I-Disease
Dreifuss NN O I-Disease
muscular NN O I-Disease
dystrophy NN O I-Disease
. NN O O

Mutations NN O O
in NN O O
the NN O O
STA NN O O
gene NN O O
at NN O O
the NN O O
Xq28 NN O O
locus NN O O
have NN O O
been NN O O
found NN O O
in NN O O
patients NN O O
with NN O O
X NN O B-Disease
- NN O I-Disease
linked NN O I-Disease
Emery NN O I-Disease
- NN O I-Disease
Dreifuss NN O I-Disease
muscular NN O I-Disease
dystrophy NN O I-Disease
( NN O O
EDMD NN O B-Disease
) NN O O
. NN O O

This NN O O
gene NN O O
encodes NN O O
a NN O O
hitherto NN O O
unknown NN O O
protein NN O O
named NN O O
emerin NN O O
. NN O O

To NN O O
elucidate NN O O
the NN O O
subcellular NN O O
localization NN O O
of NN O O
emerin NN O O
, NN O O
we NN O O
raised NN O O
two NN O O
antisera NN O O
against NN O O
synthetic NN O O
peptide NN O O
fragments NN O O
predicted NN O O
from NN O O
emerin NN O O
cDNA NN O O
. NN O O

Using NN O O
both NN O O
antisera NN O O
, NN O O
we NN O O
found NN O O
positive NN O O
nuclear NN O O
membrane NN O O
staining NN O O
in NN O O
skeletal NN O O
, NN O O
cardiac NN O O
and NN O O
smooth NN O O
muscles NN O O
in NN O O
the NN O O
normal NN O O
controls NN O O
and NN O O
in NN O O
patients NN O O
with NN O O
neuromuscular NN O B-Disease
diseases NN O I-Disease
other NN O O
than NN O O
EDMD NN O B-Disease
. NN O O

In NN O O
contrast NN O O
, NN O O
a NN O O
deficiency NN O O
in NN O O
immunofluorescent NN O O
staining NN O O
of NN O O
skeletal NN O O
and NN O O
cardiac NN O O
muscle NN O O
from NN O O
EDMD NN O B-Disease
patients NN O O
was NN O O
observed NN O O
. NN O O

A NN O O
34 NN O O
kD NN O O
protein NN O O
is NN O O
immunoreactive NN O O
with NN O O
the NN O O
antisera NN O O
- NN O O
- NN O O
the NN O O
protein NN O O
is NN O O
equivalent NN O O
to NN O O
that NN O O
predicted NN O O
for NN O O
emerin NN O O
. NN O O

Together NN O O
, NN O O
our NN O O
findings NN O O
suggest NN O O
the NN O O
specific NN O O
deficiency NN O B-Disease
of NN O I-Disease
emerin NN O I-Disease
in NN O O
the NN O O
nuclear NN O O
membrane NN O O
of NN O O
muscle NN O O
cells NN O O
in NN O O
patients NN O O
with NN O O
EDMD NN O B-Disease
. NN O O
. NN O O

Growth NN O B-Disease
retardation NN O I-Disease
and NN O O
tumour NN O B-Disease
inhibition NN O O
by NN O O
BRCA1 NN O O
. NN O O

Inherited NN O O
mutations NN O O
in NN O O
BRCA1 NN O O
predispose NN O O
to NN O O
breast NN O B-Disease
and NN O I-Disease
ovarian NN O I-Disease
cancer NN O I-Disease
, NN O O
but NN O O
the NN O O
role NN O O
of NN O O
BRCA1 NN O O
in NN O O
sporadic NN O O
breast NN O B-Disease
and NN O I-Disease
ovarian NN O I-Disease
cancer NN O I-Disease
has NN O O
previously NN O O
been NN O O
elusive NN O O
. NN O O

Here NN O O
, NN O O
we NN O O
show NN O O
that NN O O
retroviral NN O O
transfer NN O O
of NN O O
the NN O O
wild NN O O
- NN O O
type NN O O
BRCA1 NN O O
gene NN O O
inhibits NN O O
growth NN O O
in NN O O
vitro NN O O
of NN O O
all NN O O
breast NN O B-Disease
and NN O I-Disease
ovarian NN O I-Disease
cancer NN O I-Disease
cell NN O O
lines NN O O
tested NN O O
, NN O O
but NN O O
not NN O O
colon NN O B-Disease
or NN O I-Disease
lung NN O I-Disease
cancer NN O I-Disease
cells NN O O
or NN O O
fibroblasts NN O O
. NN O O

Mutant NN O O
BRCA1 NN O O
has NN O O
no NN O O
effect NN O O
on NN O O
growth NN O O
of NN O O
breast NN O B-Disease
cancer NN O I-Disease
cells NN O O
; NN O O
ovarian NN O B-Disease
cancer NN O I-Disease
cell NN O O
growth NN O O
is NN O O
not NN O O
affected NN O O
by NN O O
BRCA1 NN O O
mutations NN O O
in NN O O
the NN O O
5 NN O O
portion NN O O
of NN O O
the NN O O
gene NN O O
, NN O O
but NN O O
is NN O O
inhibited NN O O
by NN O O
3 NN O O
BRCA1 NN O O
mutations NN O O
. NN O O

Development NN O O
of NN O O
MCF NN O B-Disease
- NN O I-Disease
7 NN O I-Disease
tumours NN O I-Disease
in NN O O
nude NN O O
mice NN O O
is NN O O
inhibited NN O O
when NN O O
MCF NN O O
- NN O O
7 NN O O
cells NN O O
are NN O O
transfected NN O O
with NN O O
wild NN O O
- NN O O
type NN O O
, NN O O
but NN O O
not NN O O
mutant NN O O
, NN O O
BRCA1 NN O O
. NN O O

Most NN O O
importantly NN O O
, NN O O
among NN O O
mice NN O O
with NN O O
established NN O O
MCF NN O B-Disease
- NN O I-Disease
7 NN O I-Disease
tumours NN O I-Disease
, NN O O
peritoneal NN O O
treatment NN O O
with NN O O
a NN O O
retroviral NN O O
vector NN O O
expressing NN O O
wild NN O O
- NN O O
type NN O O
BRCA1 NN O O
significantly NN O O
inhibits NN O O
tumour NN O B-Disease
growth NN O O
and NN O O
increased NN O O
survival NN O O
. NN O O
. NN O O


-DOCSTART- -X- -X- O

BRCA1 NN O O
is NN O O
secreted NN O O
and NN O O
exhibits NN O O
properties NN O O
of NN O O
a NN O O
granin NN O O
. NN O O

Germline NN O O
mutations NN O O
in NN O O
BRCA1 NN O O
are NN O O
responsible NN O O
for NN O O
most NN O O
cases NN O O
of NN O O
inherited NN O B-Disease
breast NN O I-Disease
and NN O I-Disease
ovarian NN O I-Disease
cancer NN O I-Disease
. NN O O

However NN O O
, NN O O
the NN O O
function NN O O
of NN O O
the NN O O
BRCA1 NN O O
protein NN O O
has NN O O
remained NN O O
elusive NN O O
. NN O O

We NN O O
now NN O O
show NN O O
that NN O O
BRCA1 NN O O
encodes NN O O
a NN O O
190 NN O O
- NN O O
kD NN O O
protein NN O O
with NN O O
sequence NN O O
homology NN O O
and NN O O
biochemical NN O O
analogy NN O O
to NN O O
the NN O O
granin NN O O
protein NN O O
family NN O O
. NN O O

Interestingly NN O O
, NN O O
BRCA2 NN O O
also NN O O
includes NN O O
a NN O O
motif NN O O
similar NN O O
to NN O O
the NN O O
granin NN O O
consensus NN O O
at NN O O
the NN O O
C NN O O
terminus NN O O
of NN O O
the NN O O
protein NN O O
. NN O O

Both NN O O
BRCA1 NN O O
and NN O O
the NN O O
granins NN O O
localize NN O O
to NN O O
secretory NN O O
vesicles NN O O
, NN O O
are NN O O
secreted NN O O
by NN O O
a NN O O
regulated NN O O
pathway NN O O
, NN O O
are NN O O
post NN O O
- NN O O
translationally NN O O
glycosylated NN O O
and NN O O
are NN O O
responsive NN O O
to NN O O
hormones NN O O
. NN O O

As NN O O
a NN O O
regulated NN O O
secretory NN O O
protein NN O O
, NN O O
BRCA1 NN O O
appears NN O O
to NN O O
function NN O O
by NN O O
a NN O O
mechanism NN O O
not NN O O
previously NN O O
described NN O O
for NN O O
tumour NN O B-Disease
suppressor NN O O
gene NN O O
products NN O O
. NN O O
. NN O O

Ovarian NN O B-Disease
cancer NN O I-Disease
risk NN O O
in NN O O
BRCA1 NN O O
carriers NN O O
is NN O O
modified NN O O
by NN O O
the NN O O
HRAS1 NN O O
variable NN O O
number NN O O
of NN O O
tandem NN O O
repeat NN O O
( NN O O
VNTR NN O O
) NN O O
locus NN O O
. NN O O

Women NN O O
who NN O O
carry NN O O
a NN O O
mutation NN O O
in NN O O
the NN O O
BRCA1 NN O O
gene NN O O
( NN O O
on NN O O
chromosome NN O O
17q21 NN O O
) NN O O
, NN O O
have NN O O
an NN O O
80 NN O O
% NN O O
risk NN O O
of NN O O
breast NN O B-Disease
cancer NN O I-Disease
and NN O O
a NN O O
40 NN O O
% NN O O
risk NN O O
of NN O O
ovarian NN O B-Disease
cancer NN O I-Disease
by NN O O
the NN O O
age NN O O
of NN O O
70 NN O O
( NN O O
ref NN O O
. NN O O
1 NN O O
) NN O O
. NN O O

The NN O O
variable NN O O
penetrance NN O O
of NN O O
BRCA1 NN O O
suggests NN O O
that NN O O
other NN O O
genetic NN O O
and NN O O
non NN O O
- NN O O
genetic NN O O
factors NN O O
play NN O O
a NN O O
role NN O O
in NN O O
tumourigenesis NN O O
in NN O O
these NN O O
individuals NN O O
. NN O O

The NN O O
HRAS1 NN O O
variable NN O O
number NN O O
of NN O O
tandem NN O O
repeats NN O O
( NN O O
VNTR NN O O
) NN O O
polymorphism NN O O
, NN O O
located NN O O
1 NN O O
kilobase NN O O
( NN O O
kb NN O O
) NN O O
downstream NN O O
of NN O O
the NN O O
HRAS1 NN O O
proto NN O O
- NN O O
oncogene NN O O
( NN O O
chromosome NN O O
11p15 NN O O
. NN O O
5 NN O O
) NN O O
is NN O O
one NN O O
possible NN O O
genetic NN O O
modifier NN O O
of NN O O
cancer NN O B-Disease
penetrance NN O O
. NN O O

Individuals NN O O
who NN O O
have NN O O
rare NN O O
alleles NN O O
of NN O O
the NN O O
VNTR NN O O
have NN O O
an NN O O
increased NN O O
risk NN O O
of NN O O
certain NN O O
types NN O O
of NN O O
cancers NN O B-Disease
, NN O O
including NN O O
breast NN O B-Disease
cancer NN O I-Disease
( NN O O
2 NN O O
- NN O O
4 NN O O
) NN O O
. NN O O

To NN O O
investigate NN O O
whether NN O O
the NN O O
presence NN O O
of NN O O
rare NN O O
HRAS1 NN O O
alleles NN O O
increases NN O O
susceptibility NN O O
to NN O O
hereditary NN O B-Disease
breast NN O I-Disease
and NN O I-Disease
ovarian NN O I-Disease
cancer NN O I-Disease
, NN O O
we NN O O
have NN O O
typed NN O O
a NN O O
panel NN O O
of NN O O
307 NN O O
female NN O O
BRCA1 NN O O
carriers NN O O
at NN O O
this NN O O
locus NN O O
using NN O O
a NN O O
PCR NN O O
- NN O O
based NN O O
technique NN O O
. NN O O

The NN O O
risk NN O O
for NN O O
ovarian NN O B-Disease
cancer NN O I-Disease
was NN O O
2 NN O O
. NN O O

11 NN O O
times NN O O
greater NN O O
for NN O O
BRCA1 NN O O
carriers NN O O
harbouring NN O O
one NN O O
or NN O O
two NN O O
rare NN O O
HRAS1 NN O O
alleles NN O O
, NN O O
compared NN O O
to NN O O
carriers NN O O
with NN O O
only NN O O
common NN O O
alleles NN O O
( NN O O
P NN O O
= NN O O
0 NN O O
. NN O O
015 NN O O
) NN O O
. NN O O

The NN O O
magnitude NN O O
of NN O O
the NN O O
relative NN O O
risk NN O O
associated NN O O
with NN O O
a NN O O
rare NN O O
HRAS1 NN O O
allele NN O O
was NN O O
not NN O O
altered NN O O
by NN O O
adjusting NN O O
for NN O O
the NN O O
other NN O O
known NN O O
risk NN O O
factors NN O O
for NN O O
hereditary NN O B-Disease
ovarian NN O I-Disease
cancer NN O I-Disease
( NN O O
5 NN O O
) NN O O
. NN O O

Susceptibility NN O O
to NN O O
breast NN O B-Disease
cancer NN O I-Disease
did NN O O
not NN O O
appear NN O O
to NN O O
be NN O O
affected NN O O
by NN O O
the NN O O
presence NN O O
of NN O O
rare NN O O
HRAS1 NN O O
alleles NN O O
. NN O O

This NN O O
study NN O O
is NN O O
the NN O O
first NN O O
to NN O O
show NN O O
the NN O O
effect NN O O
of NN O O
a NN O O
modifying NN O O
gene NN O O
on NN O O
the NN O O
penetrance NN O O
of NN O O
an NN O O
inherited NN O B-Disease
cancer NN O I-Disease
syndrome NN O I-Disease

A NN O O
novel NN O O
homeodomain NN O O
- NN O O
encoding NN O O
gene NN O O
is NN O O
associated NN O O
with NN O O
a NN O O
large NN O O
CpG NN O O
island NN O O
interrupted NN O O
by NN O O
the NN O O
myotonic NN O B-Disease
dystrophy NN O I-Disease
unstable NN O O
( NN O O
CTG NN O O
) NN O O
n NN O O
repeat NN O O
. NN O O

Myotonic NN O B-Disease
dystrophy NN O I-Disease
( NN O O
DM NN O B-Disease
) NN O O
is NN O O
associated NN O O
with NN O O
a NN O O
( NN O O
CTG NN O O
) NN O O
n NN O O
trinucleotide NN O O
repeat NN O O
expansion NN O O
in NN O O
the NN O O
3 NN O O
- NN O O
untranslated NN O O
region NN O O
of NN O O
a NN O O
protein NN O O
kinase NN O O
- NN O O
encoding NN O O
gene NN O O
, NN O O
DMPK NN O O
, NN O O
which NN O O
maps NN O O
to NN O O
chromosome NN O O
19q13 NN O O
. NN O O

3 NN O O
. NN O O

Characterisation NN O O
of NN O O
the NN O O
expression NN O O
of NN O O
this NN O O
gene NN O O
in NN O O
patient NN O O
tissues NN O O
has NN O O
thus NN O O
far NN O O
generated NN O O
conflicting NN O O
data NN O O
on NN O O
alterations NN O O
in NN O O
the NN O O
steady NN O O
state NN O O
levels NN O O
of NN O O
DMPK NN O O
mRNA NN O O
, NN O O
and NN O O
on NN O O
the NN O O
final NN O O
DMPK NN O O
protein NN O O
levels NN O O
in NN O O
the NN O O
presence NN O O
of NN O O
the NN O O
expansion NN O O
. NN O O

The NN O O
DM NN O B-Disease
region NN O O
of NN O O
chromosome NN O O
19 NN O O
is NN O O
gene NN O O
rich NN O O
, NN O O
and NN O O
it NN O O
is NN O O
possible NN O O
that NN O O
the NN O O
repeat NN O O
expansion NN O O
may NN O O
lead NN O O
to NN O O
dysfunction NN O O
of NN O O
a NN O O
number NN O O
of NN O O
transcription NN O O
units NN O O
in NN O O
the NN O O
vicinity NN O O
, NN O O
perhaps NN O O
as NN O O
a NN O O
consequence NN O O
of NN O O
chromatin NN O O
disruption NN O O
. NN O O

We NN O O
have NN O O
searched NN O O
for NN O O
genes NN O O
associated NN O O
with NN O O
a NN O O
CpG NN O O
island NN O O
at NN O O
the NN O O
3 NN O O
end NN O O
of NN O O
DMPK NN O O
. NN O O

Sequencing NN O O
of NN O O
this NN O O
region NN O O
shows NN O O
that NN O O
the NN O O
island NN O O
extends NN O O
over NN O O
3 NN O O
. NN O O

5 NN O O
kb NN O O
and NN O O
is NN O O
interrupted NN O O
by NN O O
the NN O O
( NN O O
CTG NN O O
) NN O O
n NN O O
repeat NN O O
. NN O O

Comparison NN O O
of NN O O
genomic NN O O
sequences NN O O
downstream NN O O
( NN O O
centromeric NN O O
) NN O O
of NN O O
the NN O O
repeat NN O O
in NN O O
human NN O O
and NN O O
mouse NN O O
identified NN O O
regions NN O O
of NN O O
significant NN O O
homology NN O O
. NN O O

These NN O O
correspond NN O O
to NN O O
exons NN O O
of NN O O
a NN O O
gene NN O O
predicted NN O O
to NN O O
encode NN O O
a NN O O
homeodomain NN O O
protein NN O O
. NN O O

RT NN O O
- NN O O
PCR NN O O
analysis NN O O
shows NN O O
that NN O O
this NN O O
gene NN O O
, NN O O
which NN O O
we NN O O
have NN O O
called NN O O
DM NN O B-Disease
locus NN O O
- NN O O
associated NN O O
homeodomain NN O O
protein NN O O
( NN O O
DMAHP NN O O
) NN O O
, NN O O
is NN O O
expressed NN O O
in NN O O
a NN O O
number NN O O
of NN O O
human NN O O
tissues NN O O
, NN O O
including NN O O
skeletal NN O O
muscle NN O O
, NN O O
heart NN O O
and NN O O
brain NN O O
. NN O O

Germline NN O O
mutations NN O O
in NN O O
the NN O O
RB1 NN O O
gene NN O O
in NN O O
patients NN O O
with NN O O
hereditary NN O B-Disease
retinoblastoma NN O I-Disease
. NN O O

We NN O O
have NN O O
analyzed NN O O
the NN O O
27 NN O O
exons NN O O
and NN O O
the NN O O
promoter NN O O
region NN O O
of NN O O
the NN O O
RB1 NN O O
gene NN O O
in NN O O
familial NN O B-Disease
or NN O I-Disease
sporadic NN O I-Disease
bilateral NN O I-Disease
retinoblastoma NN O I-Disease
by NN O O
using NN O O
single NN O O
- NN O O
strand NN O O
conformation NN O O
polymorphism NN O O
analysis NN O O
. NN O O

For NN O O
improvement NN O O
over NN O O
previous NN O O
studies NN O O
, NN O O
a NN O O
new NN O O
set NN O O
of NN O O
primers NN O O
has NN O O
been NN O O
designed NN O O
, NN O O
which NN O O
allow NN O O
for NN O O
amplification NN O O
of NN O O
the NN O O
coding NN O O
and NN O O
splicing NN O O
sequences NN O O
only NN O O
. NN O O

The NN O O
positioning NN O O
of NN O O
the NN O O
polymerase NN O O
chain NN O O
reaction NN O O
( NN O O
PCR NN O O
) NN O O
primers NN O O
was NN O O
such NN O O
that NN O O
the NN O O
resulting NN O O
PCR NN O O
products NN O O
were NN O O
of NN O O
different NN O O
sizes NN O O
, NN O O
which NN O O
enabled NN O O
us NN O O
to NN O O
analyze NN O O
two NN O O
different NN O O
exons NN O O
simultaneously NN O O
and NN O O
still NN O O
distinguish NN O O
between NN O O
the NN O O
banding NN O O
profiles NN O O
for NN O O
both NN O O
( NN O O
biplex NN O O
analysis NN O O
) NN O O
. NN O O

By NN O O
using NN O O
this NN O O
approach NN O O
, NN O O
we NN O O
were NN O O
able NN O O
to NN O O
identify NN O O
mutation NN O O
in NN O O
22 NN O O
new NN O O
patients NN O O
, NN O O
but NN O O
the NN O O
overall NN O O
efficiency NN O O
of NN O O
the NN O O
procedure NN O O
when NN O O
we NN O O
used NN O O
a NN O O
single NN O O
- NN O O
pass NN O O
regimen NN O O
was NN O O
only NN O O
48 NN O O
% NN O O
. NN O O

The NN O O
mutations NN O O
were NN O O
small NN O O
insertions NN O O
and NN O O
deletions NN O O
and NN O O
point NN O O
mutations NN O O
in NN O O
roughly NN O O
equal NN O O
proportions NN O O
. NN O O
. NN O O

Type NN O B-Disease
II NN O I-Disease
human NN O I-Disease
complement NN O I-Disease
C2 NN O I-Disease
deficiency NN O I-Disease
. NN O O

Allele NN O O
- NN O O
specific NN O O
amino NN O O
acid NN O O
substitutions NN O O
( NN O O
Ser189 NN O O
- NN O O
- NN O O
> NN O O
Phe NN O O
; NN O O
Gly444 NN O O
- NN O O
- NN O O
> NN O O
Arg NN O O
) NN O O
cause NN O O
impaired NN O O
C2 NN O O
secretion NN O O
. NN O O

Type NN O B-Disease
II NN O I-Disease
complement NN O I-Disease
protein NN O I-Disease
C2 NN O I-Disease
deficiency NN O I-Disease
is NN O O
characterized NN O O
by NN O O
a NN O O
selective NN O O
block NN O O
in NN O O
C2 NN O O
secretion NN O O
. NN O O

The NN O O
Type NN O O
II NN O O
C2 NN O O
null NN O O
allele NN O O
( NN O O
C2Q0 NN O O
) NN O O
is NN O O
linked NN O O
to NN O O
two NN O O
major NN O O
histocompatibility NN O O
haplotypes NN O O
( NN O O
MHC NN O O
) NN O O
that NN O O
differ NN O O
from NN O O
the NN O O
MHC NN O O
of NN O O
the NN O O
more NN O O
common NN O O
Type NN O B-Disease
I NN O I-Disease
C2 NN O I-Disease
deficiency NN O I-Disease
. NN O O

To NN O O
determine NN O O
the NN O O
molecular NN O O
basis NN O O
of NN O O
Type NN O B-Disease
II NN O I-Disease
deficiency NN O I-Disease
the NN O O
two NN O O
Type NN O O
II NN O O
C2Q0 NN O O
genes NN O O
were NN O O
isolated NN O O
and NN O O
transfected NN O O
separately NN O O
into NN O O
L NN O O
- NN O O
cells NN O O
. NN O O

Subsequent NN O O
molecular NN O O
biology NN O O
, NN O O
biosynthetic NN O O
, NN O O
and NN O O
immunofluorescence NN O O
studies NN O O
demonstrated NN O O
that NN O O
C2 NN O O
secretion NN O O
is NN O O
impaired NN O O
in NN O O
Type NN O B-Disease
II NN O I-Disease
C2 NN O I-Disease
deficiency NN O I-Disease
because NN O O
of NN O O
different NN O O
missense NN O O
mutations NN O O
at NN O O
highly NN O O
conserved NN O O
residues NN O O
in NN O O
each NN O O
of NN O O
the NN O O
C2Q0 NN O O
alleles NN O O
. NN O O

One NN O O
is NN O O
in NN O O
exon NN O O
5 NN O O
( NN O O
nucleotide NN O O
C566 NN O O
- NN O O
- NN O O
> NN O O
T NN O O
; NN O O
Ser189 NN O O
- NN O O
- NN O O
> NN O O
Phe NN O O
) NN O O
of NN O O
the NN O O
C2Q0 NN O O
gene NN O O
linked NN O O
to NN O O
the NN O O
MHC NN O O
haplotype NN O O
A11 NN O O
, NN O O
B35 NN O O
, NN O O
DRw1 NN O O
, NN O O
BFS NN O O
, NN O O
C4A0B1 NN O O
. NN O O

The NN O O
other NN O O
is NN O O
in NN O O
exon NN O O
11 NN O O
( NN O O
G1930 NN O O
- NN O O
- NN O O
> NN O O
A NN O O
; NN O O
Gly444 NN O O
- NN O O
- NN O O
> NN O O
Arg NN O O
) NN O O
of NN O O
the NN O O
C2Q0 NN O O
gene NN O O
linked NN O O
to NN O O
the NN O O
MHC NN O O
haplotype NN O O
A2 NN O O
, NN O O
B5 NN O O
, NN O O
DRw4 NN O O
, NN O O
BFS NN O O
, NN O O
C4A3B1 NN O O
. NN O O

Each NN O O
mutant NN O O
C2 NN O O
gene NN O O
product NN O O
is NN O O
retained NN O O
early NN O O
in NN O O
the NN O O
secretory NN O O
pathway NN O O
. NN O O

These NN O O
mutants NN O O
provide NN O O
models NN O O
for NN O O
elucidating NN O O
the NN O O
C2 NN O O
secretory NN O O
pathway NN O O
. NN O O
. NN O O

Defective NN O O
dimerization NN O O
of NN O O
von NN O B-Disease
Willebrand NN O I-Disease
factor NN O O
subunits NN O O
due NN O O
to NN O O
a NN O O
Cys NN O O
- NN O O
> NN O O
Arg NN O O
mutation NN O O
in NN O O
type NN O B-Disease
IID NN O I-Disease
von NN O I-Disease
Willebrand NN O I-Disease
disease NN O I-Disease
. NN O O

The NN O O
same NN O O
heterozygous NN O O
T NN O O
- NN O O
> NN O O
C NN O O
transition NN O O
at NN O O
nt NN O O
8567 NN O O
of NN O O
the NN O O
von NN O B-Disease
Willebrand NN O I-Disease
factor NN O O
( NN O O
vWF NN O O
) NN O O
transcript NN O O
was NN O O
found NN O O
in NN O O
two NN O O
unrelated NN O O
patients NN O O
with NN O O
type NN O B-Disease
IID NN O I-Disease
von NN O I-Disease
Willebrand NN O I-Disease
disease NN O I-Disease
, NN O O
with NN O O
no NN O O
other NN O O
apparent NN O O
abnormality NN O O
. NN O O

In NN O O
one NN O O
family NN O O
, NN O O
both NN O O
alleles NN O O
were NN O O
normal NN O O
in NN O O
the NN O O
parents NN O O
and NN O O
one NN O O
sister NN O O
; NN O O
thus NN O O
, NN O O
the NN O O
mutation NN O O
originated NN O O
de NN O O
novo NN O O
in NN O O
the NN O O
proposita NN O O
. NN O O

The NN O O
second NN O O
patient NN O O
also NN O O
had NN O O
asymptomatic NN O O
parents NN O O
who NN O O
, NN O O
however NN O O
, NN O O
were NN O O
not NN O O
available NN O O
for NN O O
study NN O O
. NN O O

The NN O O
structural NN O O
consequences NN O O
of NN O O
the NN O O
identified NN O O
mutation NN O O
, NN O O
resulting NN O O
in NN O O
the NN O O
CyS2010 NN O O
- NN O O
> NN O O
Arg NN O O
substitution NN O O
, NN O O
were NN O O
evaluated NN O O
by NN O O
expression NN O O
of NN O O
the NN O O
vWF NN O O
carboxyl NN O O
- NN O O
terminal NN O O
domain NN O O
containing NN O O
residues NN O O
1366 NN O O
- NN O O
2050 NN O O
. NN O O

Insect NN O O
cells NN O O
infected NN O O
with NN O O
recombinant NN O O
baculovirus NN O O
expressing NN O O
normal NN O O
vWF NN O O
sequence NN O O
secreted NN O O
a NN O O
disulfide NN O O
linked NN O O
dimeric NN O O
molecule NN O O
with NN O O
an NN O O
apparent NN O O
molecular NN O O
mass NN O O
of NN O O
150 NN O O
kDa NN O O
before NN O O
reduction NN O O
, NN O O
yielding NN O O
a NN O O
single NN O O
band NN O O
of NN O O
80 NN O O
kDa NN O O
after NN O O
disulfide NN O O
bond NN O O
reduction NN O O
. NN O O

In NN O O
contrast NN O O
, NN O O
cells NN O O
expressing NN O O
the NN O O
mutant NN O O
fragment NN O O
secreted NN O O
a NN O O
monomeric NN O O
molecule NN O O
of NN O O
apparent NN O O
molecular NN O O
mass NN O O
of NN O O
80 NN O O
kDa NN O O
, NN O O
which NN O O
remained NN O O
unchanged NN O O
after NN O O
reduction NN O O
. NN O O

We NN O O
conclude NN O O
that NN O O
CyS2010 NN O O
is NN O O
essential NN O O
for NN O O
normal NN O O
dimerization NN O O
of NN O O
vWF NN O O
subunits NN O O
through NN O O
disulfide NN O O
bonding NN O O
of NN O O
carboxyl NN O O
- NN O O
terminal NN O O
domains NN O O
and NN O O
that NN O O
a NN O O
heterozygous NN O O
mutation NN O O
in NN O O
the NN O O
corresponding NN O O
codon NN O O
is NN O O
responsible NN O O
for NN O O
defective NN O O
multimer NN O O
formation NN O O
in NN O O
type NN O B-Disease
IID NN O I-Disease
von NN O I-Disease
Willebrand NN O I-Disease
disease NN O I-Disease
. NN O O
. NN O O

Wiskott NN O B-Disease
- NN O I-Disease
Aldrich NN O I-Disease
syndrome NN O I-Disease
protein NN O O
, NN O O
a NN O O
novel NN O O
effector NN O O
for NN O O
the NN O O
GTPase NN O O
CDC42Hs NN O O
, NN O O
is NN O O
implicated NN O O
in NN O O
actin NN O O
polymerization NN O O
. NN O O

The NN O O
Rho NN O O
family NN O O
of NN O O
GTPases NN O O
control NN O O
diverse NN O O
biological NN O O
processes NN O O
, NN O O
including NN O O
cell NN O O
morphology NN O O
and NN O O
mitogenesis NN O O
. NN O O

We NN O O
have NN O O
identified NN O O
WASP NN O O
, NN O O
the NN O O
protein NN O O
that NN O O
is NN O O
defective NN O O
in NN O O
Wiskott NN O B-Disease
- NN O I-Disease
Aldrich NN O I-Disease
syndrome NN O I-Disease
( NN O O
WAS NN O B-Disease
) NN O O
, NN O O
as NN O O
a NN O O
novel NN O O
effector NN O O
for NN O O
CDC42Hs NN O O
, NN O O
but NN O O
not NN O O
for NN O O
the NN O O
other NN O O
Rho NN O O
family NN O O
members NN O O
, NN O O
Rac NN O O
and NN O O
Rho NN O O
. NN O O

This NN O O
interaction NN O O
is NN O O
dependent NN O O
on NN O O
the NN O O
presence NN O O
of NN O O
the NN O O
G NN O O
protein NN O O
- NN O O
binding NN O O
domain NN O O
. NN O O

Cellular NN O O
expression NN O O
of NN O O
epitope NN O O
- NN O O
tagged NN O O
WASP NN O O
produces NN O O
clusters NN O O
of NN O O
WASP NN O O
that NN O O
are NN O O
highly NN O O
enriched NN O O
in NN O O
polymerized NN O O
actin NN O O
. NN O O

This NN O O
clustering NN O O
is NN O O
not NN O O
observed NN O O
with NN O O
a NN O O
C NN O O
- NN O O
terminally NN O O
deleted NN O O
WASP NN O O
and NN O O
is NN O O
inhibited NN O O
by NN O O
coexpression NN O O
with NN O O
dominant NN O O
negative NN O O
CDC42Hs NN O O
- NN O O
N17 NN O O
, NN O O
but NN O O
not NN O O
with NN O O
dominant NN O O
negative NN O O
forms NN O O
of NN O O
Rac NN O O
or NN O O
Rho NN O O
. NN O O

Thus NN O O
, NN O O
WASP NN O O
provides NN O O
a NN O O
novel NN O O
link NN O O
between NN O O
CDC42Hs NN O O
and NN O O
the NN O O
actin NN O O
cytoskeleton NN O O
, NN O O
which NN O O
suggests NN O O
a NN O O
molecular NN O O
mechanism NN O O
for NN O O
many NN O O
of NN O O
the NN O O
cellular NN O O
abnormalities NN O O
in NN O O
WAS NN O B-Disease
. NN O O

The NN O O
WASP NN O O
sequence NN O O
contains NN O O
two NN O O
novel NN O O
domains NN O O
that NN O O
are NN O O
homologous NN O O
to NN O O
other NN O O
proteins NN O O
involved NN O O
in NN O O
action NN O O
organization NN O O
. NN O O
. NN O O

X NN O B-Disease
- NN O I-Disease
linked NN O I-Disease
adrenoleukodystrophy NN O I-Disease
is NN O O
a NN O O
frequent NN O O
cause NN O O
of NN O O
idiopathic NN O O
Addison NN O B-Disease
' NN O I-Disease
s NN O I-Disease
disease NN O I-Disease
in NN O O
young NN O O
adult NN O O
male NN O O
patients NN O O
. NN O O

X NN O B-Disease
- NN O I-Disease
Linked NN O I-Disease
adrenoleukodystrophy NN O I-Disease
( NN O O
ALD NN O B-Disease
) NN O O
is NN O O
a NN O O
genetic NN O B-Disease
disease NN O I-Disease
associated NN O O
with NN O O
demyelination NN O B-Disease
of NN O I-Disease
the NN O I-Disease
central NN O I-Disease
nervous NN O I-Disease
system NN O I-Disease
, NN O O
adrenal NN O B-Disease
insufficiency NN O I-Disease
, NN O O
and NN O O
accumulation NN O O
of NN O O
very NN O O
long NN O O
chain NN O O
fatty NN O O
acids NN O O
in NN O O
tissue NN O O
and NN O O
body NN O O
fluids NN O O
. NN O O

ALD NN O B-Disease
is NN O O
due NN O O
to NN O O
mutation NN O O
of NN O O
a NN O O
gene NN O O
located NN O O
in NN O O
Xq28 NN O O
that NN O O
encodes NN O O
a NN O O
peroxisomal NN O O
transporter NN O O
protein NN O O
of NN O O
unknown NN O O
function NN O O
. NN O O

The NN O O
most NN O O
common NN O O
phenotype NN O O
of NN O O
ALD NN O B-Disease
is NN O O
the NN O O
cerebral NN O O
form NN O O
( NN O O
45 NN O O
% NN O O
) NN O O
that NN O O
develops NN O O
in NN O O
boys NN O O
between NN O O
5 NN O O
- NN O O
12 NN O O
yr NN O O
. NN O O

Adrenomyeloneuropathy NN O B-Disease
( NN O O
AMN NN O B-Disease
) NN O O
involves NN O O
the NN O O
spinal NN O O
cord NN O O
and NN O O
peripheral NN O O
nerves NN O O
in NN O O
young NN O O
adults NN O O
( NN O O
35 NN O O
% NN O O
) NN O O
. NN O O

Adrenal NN O B-Disease
insufficiency NN O I-Disease
( NN O O
Addisons NN O B-Disease
disease NN O I-Disease
) NN O O
is NN O O
frequently NN O O
associated NN O O
with NN O O
AMN NN O B-Disease
or NN O O
cerebral NN O B-Disease
ALD NN O I-Disease
and NN O O
may NN O O
remain NN O O
the NN O O
only NN O O
clinical NN O O
expression NN O O
of NN O O
ALD NN O B-Disease
( NN O O
8 NN O O
% NN O O
of NN O O
cases NN O O
) NN O O
. NN O O

The NN O O
prevalence NN O O
of NN O O
ALD NN O B-Disease
among NN O O
adults NN O O
with NN O O
Addisons NN O B-Disease
disease NN O I-Disease
remains NN O O
unknown NN O O
. NN O O

To NN O O
evaluate NN O O
this NN O O
prevalence NN O O
, NN O O
we NN O O
performed NN O O
biochemical NN O O
analysis NN O O
of NN O O
very NN O O
long NN O O
chain NN O O
fatty NN O O
acids NN O O
in NN O O
14 NN O O
male NN O O
patients NN O O
( NN O O
age NN O O
ranging NN O O
from NN O O
12 NN O O
- NN O O
45 NN O O
yr NN O O
at NN O O
diagnosis NN O O
) NN O O
previously NN O O
diagnosed NN O O
as NN O O
having NN O O
primary NN O O
idiopathic NN O O
adrenocortical NN O B-Disease
insufficiency NN O I-Disease
. NN O O

In NN O O
5 NN O O
of NN O O
14 NN O O
patients NN O O
( NN O O
35 NN O O
% NN O O
) NN O O
, NN O O
elevated NN O O
plasma NN O O
concentrations NN O O
of NN O O
very NN O O
long NN O O
chain NN O O
fatty NN O O
acids NN O O
were NN O O
detected NN O O
. NN O O

None NN O O
of NN O O
these NN O O
patients NN O O
had NN O O
adrenocortical NN O O
antibodies NN O O
. NN O O

By NN O O
electrophysiological NN O O
tests NN O O
and NN O O
magnetic NN O O
resonance NN O O
imaging NN O O
it NN O O
was NN O O
determined NN O O
that NN O O
two NN O O
patients NN O O
had NN O O
cerebral NN O B-Disease
ALD NN O I-Disease
, NN O O
one NN O O
had NN O O
adrenomyeloneuropathy NN O B-Disease
with NN O O
cerebral NN O O
involvement NN O O
, NN O O
and NN O O
two NN O O
had NN O O
preclinical NN O O
AMN NN O B-Disease
. NN O O

Our NN O O
data NN O O
support NN O O
the NN O O
hypothesis NN O O
that NN O O
ALD NN O B-Disease
is NN O O
a NN O O
frequent NN O O
cause NN O O
of NN O O
idiopathic NN O O
Addisons NN O B-Disease
disease NN O I-Disease
in NN O O
children NN O O
and NN O O
adults NN O O
. NN O O
. NN O O

Tumor NN O B-Disease
suppression NN O O
and NN O O
apoptosis NN O O
of NN O O
human NN O O
prostate NN O B-Disease
carcinoma NN O I-Disease
mediated NN O O
by NN O O
a NN O O
genetic NN O O
locus NN O O
within NN O O
human NN O O
chromosome NN O O
10pter NN O O
- NN O O
q11 NN O O
. NN O O

Prostate NN O B-Disease
cancer NN O I-Disease
is NN O O
the NN O O
second NN O O
leading NN O O
cause NN O O
of NN O O
male NN O O
cancer NN O B-Disease
deaths NN O O
in NN O O
the NN O O
United NN O O
States NN O O
. NN O O

Yet NN O O
, NN O O
despite NN O O
a NN O O
large NN O O
international NN O O
effort NN O O
, NN O O
little NN O O
is NN O O
known NN O O
about NN O O
the NN O O
molecular NN O O
mechanisms NN O O
that NN O O
underlie NN O O
this NN O O
devastating NN O O
disease NN O O
. NN O O

Prostate NN O O
secretory NN O O
epithelial NN O O
cells NN O O
and NN O O
androgen NN O O
- NN O O
dependent NN O O
prostate NN O B-Disease
carcinomas NN O I-Disease
undergo NN O O
apoptosis NN O O
in NN O O
response NN O O
to NN O O
androgen NN O O
deprivation NN O O
and NN O O
, NN O O
furthermore NN O O
, NN O O
most NN O O
prostate NN O B-Disease
carcinomas NN O I-Disease
become NN O O
androgen NN O O
independent NN O O
and NN O O
refractory NN O O
to NN O O
further NN O O
therapeutic NN O O
manipulations NN O O
during NN O O
disease NN O O
progression NN O O
. NN O O

Definition NN O O
of NN O O
the NN O O
genetic NN O O
events NN O O
that NN O O
trigger NN O O
apoptosis NN O O
in NN O O
the NN O O
prostate NN O O
could NN O O
provide NN O O
important NN O O
insights NN O O
into NN O O
critical NN O O
pathways NN O O
in NN O O
normal NN O O
development NN O O
as NN O O
well NN O O
as NN O O
elucidate NN O O
the NN O O
perturbations NN O O
of NN O O
those NN O O
key NN O O
pathways NN O O
in NN O O
neoplastic NN O O
transformation NN O O
. NN O O

We NN O O
report NN O O
the NN O O
functional NN O O
definition NN O O
of NN O O
a NN O O
novel NN O O
genetic NN O O
locus NN O O
within NN O O
human NN O O
chromosome NN O O
10pter NN O O
- NN O O
q11 NN O O
that NN O O
mediates NN O O
both NN O O
in NN O O
vivo NN O O
tumor NN O O
suppression NN O O
and NN O O
in NN O O
vitro NN O O
apoptosis NN O O
of NN O O
prostatic NN O B-Disease
adenocarcinoma NN O I-Disease
cells NN O O
. NN O O

A NN O O
defined NN O O
fragment NN O O
of NN O O
human NN O O
chromosome NN O O
10 NN O O
was NN O O
transferred NN O O
via NN O O
microcell NN O O
fusion NN O O
into NN O O
a NN O O
prostate NN O B-Disease
adenocarcinoma NN O I-Disease
cell NN O O
line NN O O
. NN O O

Microcell NN O O
hybrids NN O O
containing NN O O
only NN O O
the NN O O
region NN O O
10pter NN O O
- NN O O
q11 NN O O
were NN O O
suppressed NN O O
for NN O O
tumorigenicity NN O O
following NN O O
injection NN O O
of NN O O
microcell NN O O
hybrids NN O O
into NN O O
nude NN O O
mice NN O O
. NN O O

Furthermore NN O O
, NN O O
the NN O O
complemented NN O O
hybrids NN O O
undergo NN O O
programmed NN O O
cell NN O O
death NN O O
in NN O O
vitro NN O O
via NN O O
a NN O O
mechanism NN O O
that NN O O
does NN O O
not NN O O
require NN O O
nuclear NN O O
localization NN O O
of NN O O
p53 NN O O
. NN O O

These NN O O
data NN O O
functionally NN O O
define NN O O
a NN O O
novel NN O O
genetic NN O O
locus NN O O
, NN O O
designated NN O O
PAC1 NN O O
, NN O O
for NN O O
prostate NN O O
adenocarcinoma NN O O
1 NN O O
, NN O O
involved NN O O
in NN O O
tumor NN O O
suppression NN O O
of NN O O
human NN O O
prostate NN O B-Disease
carcinoma NN O I-Disease
and NN O O
furthermore NN O O
strongly NN O O
suggest NN O O
that NN O O
the NN O O
cell NN O O
death NN O O
pathway NN O O
can NN O O
be NN O O
functionally NN O O
restored NN O O
in NN O O
prostatic NN O B-Disease
adenocarcinoma NN O I-Disease
. NN O O
. NN O O

Low NN O O
incidence NN O O
of NN O O
BRCA2 NN O O
mutations NN O O
in NN O O
breast NN O B-Disease
carcinoma NN O I-Disease
and NN O O
other NN O O
cancers NN O B-Disease
. NN O O

Inherited NN O O
mutant NN O O
alleles NN O O
of NN O O
familial NN O O
tumour NN O B-Disease
suppressor NN O O
genes NN O O
predispose NN O O
individuals NN O O
to NN O O
particular NN O O
types NN O O
of NN O O
cancer NN O B-Disease
. NN O O

In NN O O
addition NN O O
to NN O O
an NN O O
involvement NN O O
in NN O O
inherited NN O O
susceptibility NN O O
to NN O O
cancer NN O B-Disease
, NN O O
these NN O O
tumour NN O B-Disease
suppressor NN O O
genes NN O O
are NN O O
targets NN O O
for NN O O
somatic NN O O
mutations NN O O
in NN O O
sporadic NN O B-Disease
cancers NN O I-Disease
of NN O O
the NN O O
same NN O O
type NN O O
found NN O O
in NN O O
the NN O O
familial NN O O
forms NN O O
. NN O O

An NN O O
exception NN O O
is NN O O
BRCA1 NN O O
, NN O O
which NN O O
contributes NN O O
to NN O O
a NN O O
significant NN O O
fraction NN O O
of NN O O
familial NN O B-Disease
breast NN O I-Disease
and NN O I-Disease
ovarian NN O I-Disease
cancer NN O I-Disease
, NN O O
but NN O O
undergoes NN O O
mutation NN O O
at NN O O
very NN O O
low NN O O
rates NN O O
in NN O O
sporadic NN O B-Disease
breast NN O I-Disease
and NN O I-Disease
ovarian NN O I-Disease
cancers NN O I-Disease
. NN O O

This NN O O
finding NN O O
suggests NN O O
that NN O O
other NN O O
genes NN O O
may NN O O
be NN O O
the NN O O
principal NN O O
targets NN O O
for NN O O
somatic NN O O
mutation NN O O
in NN O O
breast NN O B-Disease
carcinoma NN O I-Disease
. NN O O

A NN O O
second NN O O
, NN O O
recently NN O O
identified NN O O
familial NN O B-Disease
breast NN O I-Disease
cancer NN O I-Disease
gene NN O O
, NN O O
BRCA2 NN O O
( NN O O
refs NN O O
5 NN O O
- NN O O
8 NN O O
) NN O O
, NN O O
accounts NN O O
for NN O O
a NN O O
proportion NN O O
of NN O O
breast NN O B-Disease
cancer NN O I-Disease
roughly NN O O
equal NN O O
to NN O O
BRCA1 NN O O
. NN O O

Like NN O O
BRCA1 NN O O
, NN O O
BRCA2 NN O O
behaves NN O O
as NN O O
a NN O O
dominantly NN O O
inherited NN O O
tumour NN O B-Disease
suppressor NN O O
gene NN O O
. NN O O

Individuals NN O O
who NN O O
inherit NN O O
one NN O O
mutant NN O O
allele NN O O
are NN O O
at NN O O
increased NN O O
risk NN O O
for NN O O
breast NN O B-Disease
cancer NN O I-Disease
, NN O O
and NN O O
the NN O O
tumours NN O B-Disease
they NN O O
develop NN O O
lose NN O O
the NN O O
wild NN O O
- NN O O
type NN O O
allele NN O O
by NN O O
heterozygous NN O O
deletion NN O O
. NN O O

The NN O O
BRCA2 NN O O
coding NN O O
sequence NN O O
is NN O O
huge NN O O
, NN O O
composed NN O O
of NN O O
26 NN O O
exons NN O O
that NN O O
span NN O O
10 NN O O
, NN O O
443 NN O O
bp NN O O
. NN O O

Here NN O O
we NN O O
investigate NN O O
the NN O O
rate NN O O
of NN O O
BRCA2 NN O O
mutation NN O O
in NN O O
sporadic NN O B-Disease
breast NN O I-Disease
cancers NN O I-Disease
and NN O O
in NN O O
a NN O O
set NN O O
of NN O O
cell NN O O
lines NN O O
that NN O O
represent NN O O
twelve NN O O
other NN O O
tumour NN O B-Disease
types NN O O
. NN O O

Surprisingly NN O O
, NN O O
mutations NN O O
in NN O O
BRCA2 NN O O
are NN O O
infrequent NN O O
in NN O O
cancers NN O B-Disease
including NN O O
breast NN O B-Disease
carcinoma NN O I-Disease
. NN O O

However NN O O
, NN O O
a NN O O
probable NN O O
germline NN O O
mutation NN O O
in NN O O
a NN O O
pancreatic NN O B-Disease
tumour NN O I-Disease
cell NN O O
line NN O O
suggests NN O O
a NN O O
role NN O O
for NN O O
BRCA2 NN O O
in NN O O
susceptibility NN O O
to NN O O
pancreatic NN O B-Disease
cancer NN O I-Disease
. NN O O
. NN O O

Founding NN O O
BRCA1 NN O O
mutations NN O O
in NN O O
hereditary NN O B-Disease
breast NN O I-Disease
and NN O I-Disease
ovarian NN O I-Disease
cancer NN O I-Disease
in NN O O
southern NN O O
Sweden NN O O
. NN O O

Nine NN O O
different NN O O
germ NN O O
- NN O O
line NN O O
mutations NN O O
in NN O O
the NN O O
BRCA1 NN O O
breast NN O B-Disease
and NN O I-Disease
ovarian NN O I-Disease
cancer NN O I-Disease
susceptibility NN O O
gene NN O O
were NN O O
identified NN O O
in NN O O
15 NN O O
of NN O O
47 NN O O
kindreds NN O O
from NN O O
southern NN O O
Sweden NN O O
, NN O O
by NN O O
use NN O O
of NN O O
SSCP NN O O
and NN O O
heteroduplex NN O O
analysis NN O O
of NN O O
all NN O O
exons NN O O
and NN O O
flanking NN O O
intron NN O O
region NN O O
and NN O O
by NN O O
a NN O O
protein NN O O
- NN O O
truncation NN O O
test NN O O
for NN O O
exon NN O O
11 NN O O
, NN O O
followed NN O O
by NN O O
direct NN O O
sequencing NN O O
. NN O O

All NN O O
but NN O O
one NN O O
of NN O O
the NN O O
mutations NN O O
are NN O O
predicted NN O O
to NN O O
give NN O O
rise NN O O
to NN O O
premature NN O O
translation NN O O
termination NN O O
and NN O O
include NN O O
seven NN O O
frameshift NN O O
insertions NN O O
or NN O O
deletions NN O O
, NN O O
a NN O O
nonsense NN O O
mutation NN O O
, NN O O
and NN O O
a NN O O
splice NN O O
acceptor NN O O
site NN O O
mutation NN O O
. NN O O

The NN O O
remaining NN O O
mutation NN O O
is NN O O
a NN O O
missense NN O O
mutation NN O O
( NN O O
Cys61Gly NN O O
) NN O O
in NN O O
the NN O O
zinc NN O O
- NN O O
binding NN O O
motif NN O O
. NN O O

Four NN O O
novel NN O O
Swedish NN O O
founding NN O O
mutations NN O O
were NN O O
identified NN O O
the NN O O
nucleotide NN O O
2595 NN O O
deletion NN O O
A NN O O
was NN O O
found NN O O
in NN O O
five NN O O
families NN O O
, NN O O
the NN O O
C NN O O
1806 NN O O
T NN O O
nonsense NN O O
mutation NN O O
in NN O O
three NN O O
families NN O O
, NN O O
the NN O O
3166 NN O O
insertion NN O O
TGAGA NN O O
in NN O O
three NN O O
families NN O O
, NN O O
and NN O O
the NN O O
nucleotide NN O O
1201 NN O O
deletion NN O O
11 NN O O
in NN O O
two NN O O
families NN O O
. NN O O

Analysis NN O O
of NN O O
the NN O O
intragenic NN O O
polymorphism NN O O
D17S855 NN O O
supports NN O O
common NN O O
origins NN O O
of NN O O
the NN O O
mutations NN O O
. NN O O

Eleven NN O O
of NN O O
the NN O O
15 NN O O
kindreds NN O O
manifesting NN O O
BRCA1 NN O O
mutations NN O O
were NN O O
breast NN O B-Disease
- NN O I-Disease
ovarian NN O I-Disease
cancer NN O I-Disease
families NN O O
, NN O O
several NN O O
of NN O O
them NN O O
with NN O O
a NN O O
predominant NN O O
ovarian NN O B-Disease
cancer NN O I-Disease
phenotype NN O O
. NN O O

The NN O O
set NN O O
of NN O O
32 NN O O
families NN O O
in NN O O
which NN O O
no NN O O
BRCA1 NN O O
alterations NN O O
were NN O O
detected NN O O
included NN O O
1 NN O O
breast NN O B-Disease
- NN O I-Disease
ovarian NN O I-Disease
cancer NN O I-Disease
kindred NN O O
manifesting NN O O
clear NN O O
linkage NN O O
to NN O O
the NN O O
BRCA1 NN O O
region NN O O
and NN O O
loss NN O O
of NN O O
the NN O O
wild NN O O
- NN O O
type NN O O
chromosome NN O O
in NN O O
associated NN O O
tumors NN O B-Disease
. NN O O

Other NN O O
tumor NN O B-Disease
types NN O O
found NN O O
in NN O O
BRCA1 NN O O
mutation NN O O
/ NN O O
haplotype NN O O
carriers NN O O
included NN O O
prostatic NN O B-Disease
, NN O I-Disease
pancreas NN O I-Disease
, NN O I-Disease
skin NN O I-Disease
, NN O I-Disease
and NN O I-Disease
lung NN O I-Disease
cancer NN O I-Disease
, NN O O
a NN O O
malignant NN O B-Disease
melanoma NN O I-Disease
, NN O O
an NN O O
oligodendroglioma NN O B-Disease
, NN O O
and NN O O
a NN O O
carcinosarcoma NN O B-Disease
. NN O O

In NN O O
all NN O O
, NN O O
12 NN O O
of NN O O
16 NN O O
kindreds NN O O
manifesting NN O O
BRCA1 NN O O
mutation NN O O
or NN O O
linkage NN O O
contained NN O O
ovarian NN O B-Disease
cancer NN O I-Disease
, NN O O
as NN O O
compared NN O O
with NN O O
only NN O O
6 NN O O
of NN O O
the NN O O
remaining NN O O
31 NN O O
families NN O O
( NN O O
P NN O O
< NN O O
. NN O O
001 NN O O
) NN O O
. NN O O

The NN O O
present NN O O
study NN O O
confirms NN O O
the NN O O
involvement NN O O
of NN O O
BRCA1 NN O O
in NN O O
disease NN O O
predisposition NN O O
for NN O O
a NN O O
subset NN O O
of NN O O
hereditary NN O B-Disease
breast NN O I-Disease
cancer NN O I-Disease
families NN O O
often NN O O
characterized NN O O
by NN O O
ovarian NN O B-Disease
cancers NN O I-Disease
. NN O O

Rapid NN O O
detection NN O O
of NN O O
regionally NN O O
clustered NN O O
germ NN O O
- NN O O
line NN O O
BRCA1 NN O O
mutations NN O O
by NN O O
multiplex NN O O
heteroduplex NN O O
analysis NN O O
. NN O O

UKCCCR NN O O
Familial NN O O
Ovarian NN O B-Disease
Cancer NN O I-Disease
Study NN O O
Group NN O O
. NN O O

Germ NN O O
- NN O O
line NN O O
mutations NN O O
of NN O O
the NN O O
BRCA1 NN O O
gene NN O O
are NN O O
responsible NN O O
for NN O O
a NN O O
substantial NN O O
proportion NN O O
of NN O O
families NN O O
with NN O O
multiple NN O O
cases NN O O
of NN O O
early NN O O
- NN O O
onset NN O O
breast NN O B-Disease
and NN O I-Disease
/ NN O I-Disease
or NN O I-Disease
ovarian NN O I-Disease
cancer NN O I-Disease
. NN O O

Since NN O O
the NN O O
isolation NN O O
of NN O O
BRCA1 NN O O
last NN O O
year NN O O
, NN O O
> NN O O
65 NN O O
distinct NN O O
mutations NN O O
scattered NN O O
throughout NN O O
the NN O O
coding NN O O
region NN O O
have NN O O
been NN O O
detected NN O O
, NN O O
making NN O O
analysis NN O O
of NN O O
the NN O O
gene NN O O
time NN O O
consuming NN O O
and NN O O
technically NN O O
challenging NN O O
. NN O O

We NN O O
have NN O O
developed NN O O
a NN O O
multiplex NN O O
heteroduplex NN O O
analysis NN O O
that NN O O
is NN O O
designed NN O O
to NN O O
analyze NN O O
one NN O O
- NN O O
quarter NN O O
of NN O O
the NN O O
coding NN O O
sequence NN O O
in NN O O
a NN O O
single NN O O
- NN O O
step NN O O
screening NN O O
procedure NN O O
and NN O O
that NN O O
will NN O O
detect NN O O
approximately NN O O
50 NN O O
% NN O O
of NN O O
all NN O O
BRCA1 NN O O
mutations NN O O
so NN O O
far NN O O
reported NN O O
in NN O O
breast NN O B-Disease
/ NN O I-Disease
ovarian NN O I-Disease
cancer NN O I-Disease
families NN O O
. NN O O

We NN O O
have NN O O
used NN O O
this NN O O
technique NN O O
to NN O O
analyze NN O O
BRCA1 NN O O
in NN O O
162 NN O O
families NN O O
with NN O O
a NN O O
history NN O O
of NN O O
breast NN O B-Disease
and NN O I-Disease
/ NN O I-Disease
or NN O I-Disease
ovarian NN O I-Disease
cancer NN O I-Disease
and NN O O
identified NN O O
12 NN O O
distinct NN O O
mutations NN O O
in NN O O
35 NN O O
families NN O O
. NN O O
. NN O O

A NN O O
previously NN O O
undescribed NN O O
mutation NN O O
within NN O O
the NN O O
tetramerisation NN O O
domain NN O O
of NN O O
TP53 NN O O
in NN O O
a NN O O
family NN O O
with NN O O
Li NN O B-Disease
- NN O I-Disease
Fraumeni NN O I-Disease
syndrome NN O I-Disease
. NN O O

We NN O O
report NN O O
details NN O O
of NN O O
a NN O O
family NN O O
with NN O O
classic NN O O
Li NN O B-Disease
- NN O I-Disease
Fraumeni NN O I-Disease
syndrome NN O I-Disease
in NN O O
which NN O O
there NN O O
is NN O O
a NN O O
mutation NN O O
in NN O O
codon NN O O
344 NN O O
of NN O O
the NN O O
tumour NN O B-Disease
suppressor NN O O
gene NN O O
TP53 NN O O
. NN O O

Codon NN O O
344 NN O O
is NN O O
a NN O O
key NN O O
residue NN O O
within NN O O
the NN O O
tetramerisation NN O O
domain NN O O
, NN O O
and NN O O
the NN O O
amino NN O O
acid NN O O
substitution NN O O
of NN O O
a NN O O
proline NN O O
for NN O O
a NN O O
leucine NN O O
is NN O O
predicted NN O O
to NN O O
have NN O O
profound NN O O
implications NN O O
for NN O O
tetramerisation NN O O
and NN O O
potentially NN O O
DNA NN O O
binding NN O O
. NN O O

This NN O O
is NN O O
the NN O O
first NN O O
report NN O O
of NN O O
a NN O O
mutation NN O O
at NN O O
this NN O O
residue NN O O
in NN O O
either NN O O
sporadic NN O B-Disease
tumours NN O I-Disease
or NN O O
in NN O O
the NN O O
germline NN O O
and NN O O
the NN O O
first NN O O
report NN O O
of NN O O
a NN O O
germline NN O O
mutation NN O O
within NN O O
the NN O O
tetramerisation NN O O
domain NN O O
. NN O O

The NN O O
family NN O O
does NN O O
not NN O O
appear NN O O
to NN O O
be NN O O
remarkable NN O O
in NN O O
the NN O O
spectrum NN O O
of NN O O
tumours NN O B-Disease
, NN O O
and NN O O
there NN O O
is NN O O
loss NN O O
of NN O O
the NN O O
wild NN O O
- NN O O
type NN O O
allele NN O O
in NN O O
a NN O O
leiomyosarcoma NN O B-Disease
from NN O O
the NN O O
proband NN O O
. NN O O

A NN O O
cell NN O O
line NN O O
has NN O O
been NN O O
established NN O O
from NN O O
the NN O O
tumour NN O B-Disease
of NN O O
the NN O O
proband NN O O
and NN O O
cytogenetic NN O O
and NN O O
molecular NN O O
studies NN O O
carried NN O O
out NN O O
, NN O O
providing NN O O
an NN O O
extensive NN O O
analysis NN O O
in NN O O
this NN O O
family NN O O
. NN O O
. NN O O

The NN O O
spectrum NN O O
of NN O O
RB1 NN O O
germ NN O O
- NN O O
line NN O O
mutations NN O O
in NN O O
hereditary NN O B-Disease
retinoblastoma NN O I-Disease
. NN O O

We NN O O
have NN O O
searched NN O O
for NN O O
germ NN O O
- NN O O
line NN O O
RB1 NN O O
mutations NN O O
in NN O O
119 NN O O
patients NN O O
with NN O O
hereditary NN O B-Disease
retinoblastoma NN O I-Disease
. NN O O

Previous NN O O
investigations NN O O
by NN O O
Southern NN O O
blot NN O O
hybridization NN O O
and NN O O
PCR NN O O
fragment NN O O
- NN O O
length NN O O
analysis NN O O
had NN O O
revealed NN O O
mutations NN O O
in NN O O
48 NN O O
patients NN O O
. NN O O

Here NN O O
we NN O O
report NN O O
on NN O O
the NN O O
analysis NN O O
of NN O O
the NN O O
remaining NN O O
71 NN O O
patients NN O O
. NN O O

By NN O O
applying NN O O
heteroduplex NN O O
analysis NN O O
, NN O O
nonisotopic NN O O
SSCP NN O O
, NN O O
and NN O O
direct NN O O
sequencing NN O O
, NN O O
we NN O O
detected NN O O
germ NN O O
- NN O O
line NN O O
mutations NN O O
resulting NN O O
in NN O O
premature NN O O
termination NN O O
codons NN O O
or NN O O
disruption NN O O
of NN O O
splice NN O O
signals NN O O
in NN O O
51 NN O O
( NN O O
72 NN O O
% NN O O
) NN O O
of NN O O
the NN O O
71 NN O O
patients NN O O
. NN O O

Four NN O O
patients NN O O
also NN O O
showed NN O O
rare NN O O
sequence NN O O
variants NN O O
. NN O O

No NN O O
region NN O O
of NN O O
the NN O O
RB1 NN O O
gene NN O O
was NN O O
preferentially NN O O
involved NN O O
in NN O O
single NN O O
base NN O O
substitutions NN O O
. NN O O

Recurrent NN O O
transitions NN O O
were NN O O
observed NN O O
at NN O O
most NN O O
of NN O O
the NN O O
14 NN O O
codons NN O O
within NN O O
the NN O O
RB1 NN O O
. NN O O

No NN O O
mutation NN O O
was NN O O
observed NN O O
in NN O O
exons NN O O
25 NN O O
- NN O O
27 NN O O
, NN O O
although NN O O
this NN O O
region NN O O
contains NN O O
two NN O O
CGA NN O O
codons NN O O
. NN O O

This NN O O
suggests NN O O
that NN O O
mutations NN O O
within NN O O
the NN O O
3 NN O O
- NN O O
terminal NN O O
region NN O O
of NN O O
the NN O O
RB1 NN O O
gene NN O O
may NN O O
not NN O O
be NN O O
oncogenic NN O O
. NN O O

When NN O O
these NN O O
data NN O O
were NN O O
combined NN O O
with NN O O
the NN O O
results NN O O
of NN O O
our NN O O
previous NN O O
investigations NN O O
, NN O O
mutations NN O O
were NN O O
identified NN O O
in NN O O
a NN O O
total NN O O
of NN O O
99 NN O O
( NN O O
83 NN O O
% NN O O
) NN O O
of NN O O
119 NN O O
patients NN O O
. NN O O

The NN O O
spectrum NN O O
comprises NN O O
15 NN O O
% NN O O
large NN O O
deletions NN O O
, NN O O
26 NN O O
% NN O O
small NN O O
length NN O O
alterations NN O O
, NN O O
and NN O O
42 NN O O
% NN O O
base NN O O
substitutions NN O O
. NN O O

No NN O O
correlation NN O O
between NN O O
the NN O O
location NN O O
of NN O O
frameshift NN O O
or NN O O
nonsense NN O O
mutations NN O O
and NN O O
phenotypic NN O O
features NN O O
, NN O O
including NN O O
age NN O O
at NN O O
diagnosis NN O O
, NN O O
the NN O O
number NN O O
of NN O O
tumor NN O B-Disease
foci NN O O
, NN O O
and NN O O
manifestation NN O O
of NN O O
nonocular NN O B-Disease
tumors NN O I-Disease
was NN O O
observed NN O O
. NN O O
. NN O O

Phenotypic NN O O
characterization NN O O
of NN O O
individuals NN O O
with NN O O
30 NN O O
- NN O O
40 NN O O
CAG NN O O
repeats NN O O
in NN O O
the NN O O
Huntington NN O B-Disease
disease NN O I-Disease
( NN O O
HD NN O B-Disease
) NN O O
gene NN O O
reveals NN O O
HD NN O B-Disease
cases NN O O
with NN O O
36 NN O O
repeats NN O O
and NN O O
apparently NN O O
normal NN O O
elderly NN O O
individuals NN O O
with NN O O
36 NN O O
- NN O O
39 NN O O
repeats NN O O
. NN O O

Abnormal NN O O
CAG NN O O
expansions NN O O
in NN O O
the NN O O
IT NN O O
- NN O O
15 NN O O
gene NN O O
are NN O O
associated NN O O
with NN O O
Huntington NN O B-Disease
disease NN O I-Disease
( NN O O
HD NN O B-Disease
) NN O O
. NN O O

In NN O O
the NN O O
diagnostic NN O O
setting NN O O
it NN O O
is NN O O
necessary NN O O
to NN O O
define NN O O
the NN O O
limits NN O O
of NN O O
the NN O O
CAG NN O O
size NN O O
ranges NN O O
on NN O O
normal NN O O
and NN O O
HD NN O B-Disease
- NN O O
associated NN O O
chromosomes NN O O
. NN O O

Most NN O O
large NN O O
analyses NN O O
that NN O O
defined NN O O
the NN O O
limits NN O O
of NN O O
the NN O O
normal NN O O
and NN O O
pathological NN O O
size NN O O
ranges NN O O
employed NN O O
PCR NN O O
assays NN O O
, NN O O
which NN O O
included NN O O
the NN O O
CAG NN O O
repeats NN O O
and NN O O
a NN O O
CCG NN O O
repeat NN O O
tract NN O O
that NN O O
was NN O O
thought NN O O
to NN O O
be NN O O
invariant NN O O
. NN O O

Many NN O O
of NN O O
these NN O O
experiments NN O O
found NN O O
an NN O O
overlap NN O O
between NN O O
the NN O O
normal NN O O
and NN O O
disease NN O O
size NN O O
ranges NN O O
. NN O O

Subsequent NN O O
findings NN O O
that NN O O
the NN O O
CCG NN O O
repeats NN O O
vary NN O O
by NN O O
8 NN O O
trinucleotide NN O O
lengths NN O O
suggested NN O O
that NN O O
the NN O O
limits NN O O
of NN O O
the NN O O
normal NN O O
and NN O O
disease NN O O
size NN O O
ranges NN O O
should NN O O
be NN O O
reevaluated NN O O
with NN O O
assays NN O O
that NN O O
exclude NN O O
the NN O O
CCG NN O O
polymorphism NN O O
. NN O O

Since NN O O
patients NN O O
with NN O O
between NN O O
30 NN O O
and NN O O
40 NN O O
repeats NN O O
are NN O O
rare NN O O
, NN O O
a NN O O
consortium NN O O
was NN O O
assembled NN O O
to NN O O
collect NN O O
such NN O O
individuals NN O O
. NN O O

All NN O O
178 NN O O
samples NN O O
were NN O O
reanalyzed NN O O
in NN O O
Cambridge NN O O
by NN O O
using NN O O
assays NN O O
specific NN O O
for NN O O
the NN O O
CAG NN O O
repeats NN O O
. NN O O

We NN O O
have NN O O
optimized NN O O
methods NN O O
for NN O O
reliable NN O O
sizing NN O O
of NN O O
CAG NN O O
repeats NN O O
and NN O O
show NN O O
cases NN O O
that NN O O
demonstrate NN O O
the NN O O
dangers NN O O
of NN O O
using NN O O
PCR NN O O
assays NN O O
that NN O O
include NN O O
both NN O O
the NN O O
CAG NN O O
and NN O O
CCG NN O O
polymorphisms NN O O
. NN O O

Seven NN O O
HD NN O B-Disease
patients NN O O
had NN O O
36 NN O O
repeats NN O O
, NN O O
which NN O O
confirms NN O O
that NN O O
this NN O O
allele NN O O
is NN O O
associated NN O O
with NN O O
disease NN O O
. NN O O

Individuals NN O O
without NN O O
apparent NN O O
symptoms NN O O
or NN O O
signs NN O O
of NN O O
HD NN O B-Disease
were NN O O
found NN O O
at NN O O
36 NN O O
repeats NN O O
( NN O O
aged NN O O
74 NN O O
, NN O O
78 NN O O
, NN O O
79 NN O O
, NN O O
and NN O O
87 NN O O
years NN O O
) NN O O
, NN O O
37 NN O O
repeats NN O O
( NN O O
aged NN O O
69 NN O O
years NN O O
) NN O O
, NN O O
38 NN O O
repeats NN O O
( NN O O
aged NN O O
69 NN O O
and NN O O
90 NN O O
years NN O O
) NN O O
, NN O O
and NN O O
39 NN O O
repeats NN O O
( NN O O
aged NN O O
67 NN O O
, NN O O
90 NN O O
, NN O O
and NN O O
95 NN O O
years NN O O
) NN O O
. NN O O

The NN O O
detailed NN O O
case NN O O
histories NN O O
of NN O O
an NN O O
exceptional NN O O
case NN O O
from NN O O
this NN O O
series NN O O
will NN O O
be NN O O
presented NN O O
a NN O O
95 NN O O
- NN O O
year NN O O
- NN O O
old NN O O
man NN O O
with NN O O
39 NN O O
repeats NN O O
who NN O O
did NN O O
not NN O O
have NN O O
classical NN O O
features NN O O
of NN O O
HD NN O B-Disease
. NN O O

The NN O O
apparently NN O O
healthy NN O O
survival NN O O
into NN O O
old NN O O
age NN O O
of NN O O
some NN O O
individuals NN O O
with NN O O
36 NN O O
- NN O O
39 NN O O
repeats NN O O
suggests NN O O
that NN O O
the NN O O
HD NN O B-Disease
mutation NN O O
may NN O O
not NN O O
always NN O O
be NN O O
fully NN O O
penetrant NN O O
. NN O O
. NN O O

Identification NN O O
and NN O O
expression NN O O
of NN O O
eight NN O O
novel NN O O
mutations NN O O
among NN O O
non NN O O
- NN O O
Jewish NN O O
patients NN O O
with NN O O
Canavan NN O B-Disease
disease NN O I-Disease
. NN O O

Canavan NN O B-Disease
disease NN O I-Disease
is NN O O
inherited NN O O
as NN O O
an NN O O
autosomal NN O O
recessive NN O O
trait NN O O
that NN O O
is NN O O
caused NN O O
by NN O O
the NN O O
deficiency NN O B-Disease
of NN O I-Disease
aspartoacylase NN O I-Disease
( NN O O
ASPA NN O O
) NN O O
. NN O O

The NN O O
majority NN O O
of NN O O
patients NN O O
with NN O O
Canavan NN O B-Disease
disease NN O I-Disease
are NN O O
from NN O O
an NN O O
Ashkenazi NN O O
Jewish NN O O
background NN O O
. NN O O

Mutations NN O O
in NN O O
ASPA NN O O
that NN O O
lead NN O O
to NN O O
loss NN O O
of NN O O
enzymatic NN O O
activity NN O O
have NN O O
been NN O O
identified NN O O
, NN O O
and NN O O
E285A NN O O
and NN O O
Y231X NN O O
are NN O O
the NN O O
two NN O O
predominant NN O O
mutations NN O O
that NN O O
account NN O O
for NN O O
97 NN O O
% NN O O
of NN O O
the NN O O
mutant NN O O
chromosomes NN O O
in NN O O
Ashkenazi NN O O
Jewish NN O O
patients NN O O
. NN O O

The NN O O
current NN O O
study NN O O
was NN O O
aimed NN O O
at NN O O
finding NN O O
the NN O O
molecular NN O O
basis NN O O
of NN O O
Canavan NN O B-Disease
disease NN O I-Disease
in NN O O
25 NN O O
independent NN O O
patients NN O O
of NN O O
non NN O O
- NN O O
Jewish NN O O
background NN O O
. NN O O

Eight NN O O
novel NN O O
and NN O O
three NN O O
previously NN O O
characterized NN O O
mutations NN O O
accounted NN O O
for NN O O
80 NN O O
% NN O O
( NN O O
40 NN O O
/ NN O O
50 NN O O
) NN O O
of NN O O
mutant NN O O
chromosomes NN O O
. NN O O

The NN O O
A305E NN O O
missense NN O O
mutation NN O O
accounted NN O O
for NN O O
48 NN O O
% NN O O
( NN O O
24 NN O O
/ NN O O
50 NN O O
) NN O O
of NN O O
mutant NN O O
chromosomes NN O O
in NN O O
patients NN O O
of NN O O
western NN O O
European NN O O
descent NN O O
, NN O O
while NN O O
the NN O O
two NN O O
predominant NN O O
Jewish NN O O
mutations NN O O
each NN O O
accounted NN O O
for NN O O
a NN O O
single NN O O
mutant NN O O
chromosome NN O O
. NN O O

The NN O O
eight NN O O
novel NN O O
mutations NN O O
identified NN O O
included NN O O
1 NN O O
- NN O O
and NN O O
4 NN O O
- NN O O
bp NN O O
deletions NN O O
( NN O O
32 NN O O
deltaT NN O O
and NN O O
876 NN O O
deltaAGAA NN O O
, NN O O
respectively NN O O
) NN O O
and NN O O
I16T NN O O
, NN O O
G27R NN O O
, NN O O
D114E NN O O
, NN O O
G123E NN O O
, NN O O
C152Y NN O O
, NN O O
and NN O O
R168C NN O O
missense NN O O
mutations NN O O
. NN O O

The NN O O
homozygous NN O O
32 NN O O
deltaT NN O O
deletion NN O O
was NN O O
identified NN O O
in NN O O
the NN O O
only NN O O
known NN O O
patient NN O O
of NN O O
African NN O O
- NN O O
American NN O O
origin NN O O
with NN O O
Canavan NN O B-Disease
disease NN O I-Disease
. NN O O

The NN O O
heterozygosity NN O O
for NN O O
876 NN O O
deltaAGAA NN O O
mutation NN O O
was NN O O
identified NN O O
in NN O O
three NN O O
independent NN O O
patients NN O O
from NN O O
England NN O O
. NN O O

Six NN O O
single NN O O
- NN O O
base NN O O
changes NN O O
leading NN O O
to NN O O
missense NN O O
mutations NN O O
were NN O O
identified NN O O
in NN O O
patients NN O O
from NN O O
Turkey NN O O
( NN O O
D114E NN O O
, NN O O
R168C NN O O
) NN O O
, NN O O
The NN O O
Netherlands NN O O
( NN O O
I16T NN O O
) NN O O
, NN O O
Germany NN O O
( NN O O
G27R NN O O
) NN O O
, NN O O
Ireland NN O O
( NN O O
C152Y NN O O
) NN O O
, NN O O
and NN O O
Canada NN O O
( NN O O
G123E NN O O
) NN O O
. NN O O

A NN O O
PCR NN O O
- NN O O
based NN O O
protocol NN O O
is NN O O
described NN O O
that NN O O
was NN O O
used NN O O
to NN O O
introduce NN O O
mutations NN O O
in NN O O
wild NN O O
- NN O O
type NN O O
cDNA NN O O
. NN O O

In NN O O
vitro NN O O
expression NN O O
of NN O O
mutant NN O O
cDNA NN O O
clones NN O O
demonstrated NN O O
that NN O O
all NN O O
of NN O O
these NN O O
mutations NN O O
led NN O O
to NN O O
a NN O O
deficiency NN O B-Disease
of NN O I-Disease
ASPA NN O I-Disease
and NN O O
should NN O O
therefore NN O O
result NN O O
in NN O O
Canavan NN O B-Disease
disease NN O I-Disease
. NN O O
. NN O O

Identification NN O O
and NN O O
chromosomal NN O O
localization NN O O
of NN O O
Atm NN O O
, NN O O
the NN O O
mouse NN O O
homolog NN O O
of NN O O
the NN O O
ataxia NN O B-Disease
- NN O I-Disease
telangiectasia NN O I-Disease
gene NN O O
. NN O O

Atm NN O O
, NN O O
the NN O O
mouse NN O O
homolog NN O O
of NN O O
the NN O O
human NN O O
ATM NN O O
gene NN O O
defective NN O O
in NN O O
ataxia NN O B-Disease
- NN O I-Disease
telangiectasia NN O I-Disease
( NN O O
A NN O B-Disease
- NN O I-Disease
T NN O I-Disease
) NN O O
, NN O O
has NN O O
been NN O O
identified NN O O
. NN O O

The NN O O
entire NN O O
coding NN O O
sequence NN O O
of NN O O
the NN O O
Atm NN O O
transcript NN O O
was NN O O
cloned NN O O
and NN O O
found NN O O
to NN O O
contain NN O O
an NN O O
open NN O O
reading NN O O
frame NN O O
encoding NN O O
a NN O O
protein NN O O
of NN O O
3066 NN O O
amino NN O O
acids NN O O
with NN O O
84 NN O O
% NN O O
overall NN O O
identity NN O O
and NN O O
91 NN O O
% NN O O
similarity NN O O
to NN O O
the NN O O
human NN O O
ATM NN O O
protein NN O O
. NN O O

Variable NN O O
levels NN O O
of NN O O
expression NN O O
of NN O O
Atm NN O O
were NN O O
observed NN O O
in NN O O
different NN O O
tissues NN O O
. NN O O

Fluorescence NN O O
in NN O O
situ NN O O
hybridization NN O O
and NN O O
linkage NN O O
analysis NN O O
located NN O O
the NN O O
Atm NN O O
gene NN O O
on NN O O
mouse NN O O
chromosome NN O O
9 NN O O
, NN O O
band NN O O
9C NN O O
, NN O O
in NN O O
a NN O O
region NN O O
homologous NN O O
to NN O O
the NN O O
ATM NN O O
region NN O O
on NN O O
human NN O O
chromosome NN O O
11q22 NN O O
- NN O O
q23 NN O O
. NN O O
. NN O O

The NN O O
mouse NN O O
homolog NN O O
of NN O O
the NN O O
Wiskott NN O B-Disease
- NN O I-Disease
Aldrich NN O I-Disease
syndrome NN O I-Disease
protein NN O O
( NN O O
WASP NN O O
) NN O O
gene NN O O
is NN O O
highly NN O O
conserved NN O O
and NN O O
maps NN O O
near NN O O
the NN O O
scurfy NN O O
( NN O O
sf NN O O
) NN O O
mutation NN O O
on NN O O
the NN O O
X NN O O
chromosome NN O O
. NN O O

The NN O O
mouse NN O O
WASP NN O O
gene NN O O
, NN O O
the NN O O
homolog NN O O
of NN O O
the NN O O
gene NN O O
mutated NN O O
in NN O O
Wiskott NN O B-Disease
- NN O I-Disease
Aldrich NN O I-Disease
syndrome NN O I-Disease
, NN O O
has NN O O
been NN O O
isolated NN O O
and NN O O
sequenced NN O O
. NN O O
the NN O O
predicted NN O O
amino NN O O
acid NN O O
sequence NN O O
is NN O O
86 NN O O
% NN O O
identical NN O O
to NN O O
the NN O O
human NN O O
WASP NN O O
sequence NN O O
. NN O O

A NN O O
distinct NN O O
feature NN O O
of NN O O
the NN O O
mouse NN O O
gene NN O O
is NN O O
an NN O O
expanded NN O O
polymorphic NN O O
GGA NN O O
trinucleotide NN O O
repeat NN O O
that NN O O
codes NN O O
for NN O O
polyglycine NN O O
and NN O O
varies NN O O
from NN O O
15 NN O O
to NN O O
17 NN O O
triplets NN O O
in NN O O
different NN O O
Mus NN O O
musculus NN O O
strains NN O O
. NN O O

The NN O O
genomic NN O O
structure NN O O
of NN O O
the NN O O
mouse NN O O
WASP NN O O
gene NN O O
is NN O O
expressed NN O O
as NN O O
an NN O O
approximately NN O O
2 NN O O
. NN O O

4 NN O O
- NN O O
kb NN O O
mRNA NN O O
in NN O O
thymus NN O O
and NN O O
spleen NN O O
. NN O O

Chromosomal NN O O
mapping NN O O
in NN O O
an NN O O
interspecific NN O O
M NN O O
. NN O O

Musculus NN O O
/ NN O O
M NN O O
. NN O O
spretus NN O O
backcross NN O O
placed NN O O
the NN O O
Wasp NN O O
locus NN O O
near NN O O
the NN O O
centromere NN O O
of NN O O
the NN O O
mouse NN O O
X NN O O
chromosome NN O O
, NN O O
inseparable NN O O
from NN O O
Gata1 NN O O
, NN O O
Tcfe3 NN O O
, NN O O
and NN O O
scurfy NN O O
( NN O O
sf NN O O
) NN O O
. NN O O

This NN O O
localization NN O O
makes NN O O
Wasp NN O O
a NN O O
candidate NN O O
for NN O O
involvement NN O O
in NN O O
scurfy NN O O
, NN O O
a NN O O
T NN O O
cell NN O O
- NN O O
mediated NN O O
fatal NN O B-Disease
lymphoreticular NN O I-Disease
disease NN O I-Disease
of NN O O
mice NN O O
that NN O O
has NN O O
previously NN O O
been NN O O
proposed NN O O
as NN O O
a NN O O
mouse NN O O
homolog NN O O
of NN O O
Wiskott NN O B-Disease
- NN O I-Disease
Aldrich NN O I-Disease
syndrome NN O I-Disease
. NN O O

Northern NN O O
analysis NN O O
of NN O O
sf NN O O
tissue NN O O
samples NN O O
indicated NN O O
the NN O O
presence NN O O
of NN O O
WASP NN O O
mRNA NN O O
in NN O O
liver NN O O
and NN O O
skin NN O O
, NN O O
presumably NN O O
as NN O O
a NN O O
consequence NN O O
of NN O O
lymphocytic NN O O
infiltration NN O O
, NN O O
but NN O O
non NN O O
abnormalities NN O O
in NN O O
the NN O O
amount NN O O
or NN O O
size NN O O
of NN O O
mRNA NN O O
present NN O O
. NN O O

Colchicine NN O O
in NN O O
breast NN O O
milk NN O O
of NN O O
patients NN O O
with NN O O
familial NN O B-Disease
Mediterranean NN O I-Disease
fever NN O I-Disease
. NN O O

OBJECTIVE NN O O
. NN O O

To NN O O
clarify NN O O
whether NN O O
colchicine NN O O
is NN O O
excreted NN O O
in NN O O
breast NN O O
milk NN O O
, NN O O
and NN O O
to NN O O
compare NN O O
its NN O O
concentrations NN O O
in NN O O
the NN O O
serum NN O O
and NN O O
breast NN O O
milk NN O O
of NN O O
lactating NN O O
women NN O O
who NN O O
have NN O O
familial NN O B-Disease
Mediterranean NN O I-Disease
fever NN O I-Disease
( NN O O
FMF NN O B-Disease
) NN O O
. NN O O

METHODS NN O O
. NN O O

Using NN O O
a NN O O
specific NN O O
radioimmunoassay NN O O
, NN O O
we NN O O
determined NN O O
colchicine NN O O
concentrations NN O O
in NN O O
the NN O O
serum NN O O
and NN O O
breast NN O O
milk NN O O
of NN O O
4 NN O O
patients NN O O
at NN O O
various NN O O
time NN O O
points NN O O
, NN O O
following NN O O
oral NN O O
administration NN O O
of NN O O
the NN O O
drug NN O O
. NN O O

The NN O O
study NN O O
evaluated NN O O
4 NN O O
patients NN O O
with NN O O
FMF NN O B-Disease
who NN O O
had NN O O
been NN O O
taking NN O O
colchicine NN O O
on NN O O
a NN O O
long NN O O
- NN O O
term NN O O
basis NN O O
. NN O O

RESULTS NN O O
. NN O O

Colchicine NN O O
was NN O O
found NN O O
to NN O O
be NN O O
excreted NN O O
in NN O O
breast NN O O
milk NN O O
. NN O O

Its NN O O
levels NN O O
ranged NN O O
between NN O O
1 NN O O
. NN O O

9 NN O O
and NN O O
8 NN O O
. NN O O

6 NN O O
ng NN O O
/ NN O O
ml NN O O
, NN O O
which NN O O
were NN O O
similar NN O O
to NN O O
those NN O O
found NN O O
in NN O O
the NN O O
serum NN O O
( NN O O
parallel NN O O
concentration NN O O
time NN O O
curves NN O O
) NN O O
. NN O O

However NN O O
, NN O O
there NN O O
appeared NN O O
to NN O O
be NN O O
a NN O O
considerable NN O O
variation NN O O
in NN O O
colchicine NN O O
milk NN O O
concentration NN O O
among NN O O
the NN O O
different NN O O
patients NN O O
, NN O O
which NN O O
might NN O O
be NN O O
related NN O O
to NN O O
individual NN O O
breast NN O O
milk NN O O
composition NN O O
and NN O O
, NN O O
possibly NN O O
, NN O O
to NN O O
other NN O O
nutritional NN O O
or NN O O
metabolic NN O O
factors NN O O
. NN O O

CONCLUSION NN O O
. NN O O

The NN O O
extensive NN O O
peripheral NN O O
tissue NN O O
binding NN O O
and NN O O
relatively NN O O
low NN O O
concentration NN O O
of NN O O
colchicine NN O O
in NN O O
breast NN O O
milk NN O O
suggests NN O O
that NN O O
the NN O O
amount NN O O
ingested NN O O
by NN O O
the NN O O
infant NN O O
is NN O O
small NN O O
. NN O O

Furthermore NN O O
, NN O O
based NN O O
on NN O O
our NN O O
clinical NN O O
experience NN O O
, NN O O
nursing NN O O
appears NN O O
to NN O O
be NN O O
safe NN O O
for NN O O
lactating NN O O
women NN O O
with NN O O
FMF NN O B-Disease
who NN O O
continue NN O O
to NN O O
take NN O O
colchicine NN O O
. NN O O

Abnormal NN O O
myotonic NN O B-Disease
dystrophy NN O I-Disease
protein NN O O
kinase NN O O
levels NN O O
produce NN O O
only NN O O
mild NN O O
myopathy NN O B-Disease
in NN O O
mice NN O O
. NN O O

Myotonic NN O B-Disease
dystrophy NN O I-Disease
( NN O O
DM NN O B-Disease
) NN O O
is NN O O
commonly NN O O
associated NN O O
with NN O O
CTG NN O O
repeat NN O O
expansions NN O O
within NN O O
the NN O O
gene NN O O
for NN O O
DM NN O O
- NN O O
protein NN O O
kinase NN O O
( NN O O
DMPK NN O O
) NN O O
. NN O O

The NN O O
effect NN O O
of NN O O
altered NN O O
expression NN O O
levels NN O O
of NN O O
DMPK NN O O
, NN O O
which NN O O
is NN O O
ubiquitously NN O O
expressed NN O O
in NN O O
all NN O O
muscle NN O O
cell NN O O
lineages NN O O
during NN O O
development NN O O
, NN O O
was NN O O
examined NN O O
by NN O O
disrupting NN O O
the NN O O
endogenous NN O O
Dmpk NN O O
gene NN O O
and NN O O
overexpressing NN O O
a NN O O
normal NN O O
human NN O O
DMPK NN O O
transgene NN O O
in NN O O
mice NN O O
. NN O O

Nullizygous NN O O
( NN O O
- NN O O
/ NN O O
- NN O O
) NN O O
mice NN O O
showed NN O O
only NN O O
inconsistent NN O O
and NN O O
minor NN O O
size NN O O
changes NN O O
in NN O O
head NN O O
and NN O O
neck NN O O
muscle NN O O
fibres NN O O
at NN O O
older NN O O
age NN O O
, NN O O
animals NN O O
with NN O O
the NN O O
highest NN O O
DMPK NN O O
transgene NN O O
expression NN O O
showed NN O O
hypertrophic NN O B-Disease
cardiomyopathy NN O I-Disease
and NN O O
enhanced NN O O
neonatal NN O O
mortality NN O O
. NN O O

However NN O O
, NN O O
both NN O O
models NN O O
lack NN O O
other NN O O
frequent NN O O
DM NN O B-Disease
symptoms NN O O
including NN O O
the NN O O
fibre NN O O
- NN O O
type NN O O
dependent NN O O
atrophy NN O B-Disease
, NN O O
myotonia NN O B-Disease
, NN O O
cataract NN O B-Disease
and NN O O
male NN O B-Disease
- NN O I-Disease
infertility NN O I-Disease
. NN O O

These NN O O
results NN O O
strengthen NN O O
the NN O O
contention NN O O
that NN O O
simple NN O O
loss NN O O
- NN O O
or NN O O
gain NN O O
- NN O O
of NN O O
- NN O O
expression NN O O
of NN O O
DMPK NN O O
is NN O O
not NN O O
the NN O O
only NN O O
crucial NN O O
requirement NN O O
for NN O O
development NN O O
of NN O O
the NN O O
disease NN O O
. NN O O
. NN O O

Mice NN O O
lacking NN O O
the NN O O
myotonic NN O B-Disease
dystrophy NN O I-Disease
protein NN O O
kinase NN O O
develop NN O O
a NN O O
late NN O O
onset NN O O
progressive NN O O
myopathy NN O B-Disease
. NN O O

Myotonic NN O B-Disease
dystrophy NN O I-Disease
( NN O O
DM NN O B-Disease
) NN O O
is NN O O
an NN O O
autosomal NN O B-Disease
dominant NN O I-Disease
disorder NN O I-Disease
resulting NN O O
from NN O O
the NN O O
expansion NN O O
of NN O O
a NN O O
CTG NN O O
repeat NN O O
in NN O O
the NN O O
3 NN O O
untranslated NN O O
region NN O O
of NN O O
a NN O O
putative NN O O
protein NN O O
kinase NN O O
( NN O O
DMPK NN O O
) NN O O
. NN O O

To NN O O
elucidate NN O O
the NN O O
role NN O O
of NN O O
DMPK NN O O
in NN O O
DM NN O B-Disease
pathogenesis NN O O
we NN O O
have NN O O
developed NN O O
Dmpk NN O B-Disease
deficient NN O I-Disease
( NN O O
Dmpk NN O O
- NN O O
/ NN O O
- NN O O
) NN O O
mice NN O O
. NN O O

Dmpk NN O O
- NN O O
/ NN O O
- NN O O
mice NN O O
develop NN O O
a NN O O
late NN O O
- NN O O
onset NN O O
, NN O O
progressive NN O B-Disease
skeletal NN O I-Disease
myopathy NN O I-Disease
that NN O O
shares NN O O
some NN O O
pathological NN O O
features NN O O
with NN O O
DM NN O B-Disease
. NN O O

Muscles NN O O
from NN O O
mature NN O O
mice NN O O
show NN O O
variation NN O O
in NN O O
fibre NN O O
size NN O O
, NN O O
increased NN O O
fibre NN O B-Disease
degeneration NN O I-Disease
and NN O O
fibrosis NN O B-Disease
. NN O O

Adult NN O O
Dmpk NN O O
- NN O O
/ NN O O
- NN O O
mice NN O O
show NN O O
ultrastructural NN O O
changes NN O O
in NN O O
muscle NN O O
and NN O O
a NN O O
50 NN O O
% NN O O
decrease NN O O
in NN O O
force NN O O
generation NN O O
compared NN O O
to NN O O
young NN O O
mice NN O O
. NN O O

Our NN O O
results NN O O
indicate NN O O
that NN O O
DMPK NN O O
may NN O O
be NN O O
necessary NN O O
for NN O O
the NN O O
maintenance NN O O
of NN O O
skeletal NN O O
muscle NN O O
structure NN O O
and NN O O
function NN O O
and NN O O
suggest NN O O
that NN O O
a NN O O
decrease NN O O
in NN O O
DMPK NN O O
levels NN O O
may NN O O
contribute NN O O
to NN O O
DM NN O B-Disease
pathology NN O O
. NN O O
. NN O O

The NN O O
tumor NN O B-Disease
suppressor NN O O
gene NN O O
Brca1 NN O O
is NN O O
required NN O O
for NN O O
embryonic NN O O
cellular NN O O
proliferation NN O O
in NN O O
the NN O O
mouse NN O O
. NN O O

Mutations NN O O
of NN O O
the NN O O
BRCA1 NN O O
gone NN O O
in NN O O
humans NN O O
are NN O O
associated NN O O
with NN O O
predisposition NN O O
to NN O O
breast NN O B-Disease
and NN O I-Disease
ovarian NN O I-Disease
cancers NN O I-Disease
. NN O O

We NN O O
show NN O O
here NN O O
that NN O O
Brca1 NN O O
+ NN O O
/ NN O O
- NN O O
mice NN O O
are NN O O
normal NN O O
and NN O O
fertile NN O O
and NN O O
lack NN O O
tumors NN O B-Disease
by NN O O
age NN O O
eleven NN O O
months NN O O
. NN O O

Homozygous NN O O
Brca1 NN O O
( NN O O
5 NN O O
- NN O O
6 NN O O
) NN O O
mutant NN O O
mice NN O O
die NN O O
before NN O O
day NN O O
7 NN O O
. NN O O

5 NN O O
of NN O O
embryogenesis NN O O
. NN O O

Mutant NN O O
embryos NN O O
are NN O O
poorly NN O O
developed NN O O
, NN O O
with NN O O
no NN O O
evidence NN O O
of NN O O
mesoderm NN O O
formation NN O O
. NN O O

The NN O O
extraembryonic NN O O
region NN O O
is NN O O
abnormal NN O O
, NN O O
but NN O O
aggregation NN O O
with NN O O
wild NN O O
- NN O O
type NN O O
tetraploid NN O O
embryos NN O O
does NN O O
not NN O O
rescue NN O O
the NN O O
lethality NN O O
. NN O O

In NN O O
vivo NN O O
, NN O O
mutant NN O O
embryos NN O O
do NN O O
not NN O O
exhibit NN O O
increased NN O O
apoptosis NN O O
but NN O O
show NN O O
reduced NN O O
cell NN O O
proliferation NN O O
accompanied NN O O
by NN O O
decreased NN O O
expression NN O O
of NN O O
cyclin NN O O
E NN O O
and NN O O
mdm NN O O
- NN O O
2 NN O O
, NN O O
a NN O O
regulator NN O O
of NN O O
p53 NN O O
activity NN O O
. NN O O

The NN O O
expression NN O O
of NN O O
cyclin NN O O
- NN O O
dependent NN O O
kinase NN O O
inhibitor NN O O
p21 NN O O
is NN O O
dramatically NN O O
increased NN O O
in NN O O
the NN O O
mutant NN O O
embryos NN O O
. NN O O

Buttressing NN O O
these NN O O
in NN O O
vivo NN O O
observations NN O O
is NN O O
the NN O O
fact NN O O
that NN O O
mutant NN O O
blastocyst NN O O
growth NN O O
is NN O O
grossly NN O O
impaired NN O O
in NN O O
vitro NN O O
. NN O O

Thus NN O O
, NN O O
the NN O O
death NN O O
of NN O O
Brca1 NN O O
( NN O O
5 NN O O
- NN O O
6 NN O O
) NN O O
mutant NN O O
embryos NN O O
prior NN O O
to NN O O
gastrulation NN O O
may NN O O
be NN O O
due NN O O
to NN O O
a NN O O
failure NN O O
of NN O O
the NN O O
proliferative NN O O
burst NN O O
required NN O O
for NN O O
the NN O O
development NN O O
of NN O O
the NN O O
different NN O O
germ NN O O
layers NN O O
. NN O O

Increased NN O O
coronary NN O B-Disease
heart NN O I-Disease
disease NN O I-Disease
in NN O O
Japanese NN O O
- NN O O
American NN O O
men NN O O
with NN O O
mutation NN O O
in NN O O
the NN O O
cholesteryl NN O O
ester NN O O
transfer NN O O
protein NN O O
gene NN O O
despite NN O O
increased NN O O
HDL NN O O
levels NN O O
. NN O O

Plasma NN O O
high NN O O
density NN O O
lipoprotein NN O O
( NN O O
HDL NN O O
) NN O O
levels NN O O
are NN O O
strongly NN O O
genetically NN O O
determined NN O O
and NN O O
show NN O O
a NN O O
general NN O O
inverse NN O O
relationship NN O O
with NN O O
coronary NN O B-Disease
heart NN O I-Disease
disease NN O I-Disease
( NN O O
CHD NN O B-Disease
) NN O O
. NN O O

The NN O O
cholesteryl NN O O
ester NN O O
transfer NN O O
protein NN O O
( NN O O
CETP NN O O
) NN O O
mediates NN O O
the NN O O
transfer NN O O
of NN O O
cholesteryl NN O O
esters NN O O
from NN O O
HDL NN O O
to NN O O
other NN O O
lipoproteins NN O O
and NN O O
is NN O O
a NN O O
key NN O O
participant NN O O
in NN O O
the NN O O
reverse NN O O
transport NN O O
of NN O O
cholesterol NN O O
from NN O O
the NN O O
periphery NN O O
to NN O O
the NN O O
liver NN O O
. NN O O

A NN O O
high NN O O
prevalence NN O O
of NN O O
two NN O O
different NN O O
CETP NN O O
gene NN O O
mutations NN O O
( NN O O
D442G NN O O
, NN O O
5 NN O O
. NN O O
1 NN O O
% NN O O
; NN O O
intron NN O O
14G NN O O
A NN O O
, NN O O
0 NN O O
. NN O O
5 NN O O
% NN O O
) NN O O
, NN O O
was NN O O
found NN O O
in NN O O
3 NN O O
, NN O O
469 NN O O
men NN O O
of NN O O
Japanese NN O O
ancestry NN O O
in NN O O
the NN O O
Honolulu NN O O
Heart NN O O
Program NN O O
and NN O O
mutations NN O O
were NN O O
associated NN O O
with NN O O
decreased NN O O
CETP NN O O
( NN O O
- NN O O
35 NN O O
% NN O O
) NN O O
and NN O O
increased NN O O
HDL NN O O
chol NN O O
levels NN O O
( NN O O
+ NN O O
10 NN O O
% NN O O
for NN O O
D442G NN O O
) NN O O
. NN O O

However NN O O
, NN O O
the NN O O
overall NN O O
prevalence NN O O
of NN O O
definite NN O O
CHD NN O B-Disease
was NN O O
21 NN O O
% NN O O
in NN O O
men NN O O
with NN O O
mutations NN O O
and NN O O
16 NN O O
% NN O O
in NN O O
men NN O O
without NN O O
mutations NN O O
. NN O O

The NN O O
relative NN O O
risk NN O O
( NN O O
RR NN O O
) NN O O
of NN O O
CHD NN O B-Disease
was NN O O
1 NN O O
. NN O O

43 NN O O
in NN O O
men NN O O
with NN O O
mutations NN O O
( NN O O
P NN O O
< NN O O
. NN O O
05 NN O O
) NN O O
; NN O O
after NN O O
adjustment NN O O
for NN O O
CHD NN O B-Disease
risk NN O O
factors NN O O
, NN O O
the NN O O
RR NN O O
was NN O O
1 NN O O
. NN O O

55 NN O O
( NN O O
P NN O O
= NN O O
. NN O O
02 NN O O
) NN O O
; NN O O
after NN O O
additional NN O O
adjustment NN O O
for NN O O
HDL NN O O
levels NN O O
, NN O O
the NN O O
RR NN O O
was NN O O
1 NN O O
. NN O O

68 NN O O
( NN O O
P NN O O
= NN O O
. NN O O
008 NN O O
) NN O O
. NN O O

Similar NN O O
RR NN O O
values NN O O
were NN O O
obtained NN O O
for NN O O
the NN O O
D442G NN O O
mutation NN O O
alone NN O O
. NN O O

Increased NN O O
CHD NN O B-Disease
in NN O O
men NN O O
with NN O O
mutations NN O O
was NN O O
primarily NN O O
observed NN O O
for NN O O
HDL NN O O
chol NN O O
41 NN O O
- NN O O
60 NN O O
mg NN O O
/ NN O O
dl NN O O
; NN O O
for NN O O
HDL NN O O
chol NN O O
> NN O O
60 NN O O
mg NN O O
/ NN O O
dl NN O O
men NN O O
with NN O O
and NN O O
without NN O O
mutations NN O O
had NN O O
low NN O O
CHD NN O B-Disease
prevalence NN O O
. NN O O

Thus NN O O
, NN O O
genetic NN O O
CETP NN O B-Disease
deficiency NN O I-Disease
appears NN O O
to NN O O
be NN O O
an NN O O
independent NN O O
risk NN O O
factor NN O O
for NN O O
CHD NN O B-Disease
, NN O O
primarily NN O O
due NN O O
to NN O O
increased NN O O
CHD NN O B-Disease
prevalence NN O O
in NN O O
men NN O O
with NN O O
the NN O O
D442G NN O O
mutation NN O O
and NN O O
HDL NN O O
cholesterol NN O O
between NN O O
41 NN O O
and NN O O
60 NN O O
mg NN O O
/ NN O O
dl NN O O
. NN O O

The NN O O
findings NN O O
suggest NN O O
that NN O O
both NN O O
HDL NN O O
concentration NN O O
and NN O O
the NN O O
dynamics NN O O
of NN O O
cholesterol NN O O
transport NN O O
through NN O O
HDL NN O O
( NN O O
i NN O O
. NN O O
e NN O O
. NN O O
, NN O O
reverse NN O O
cholesterol NN O O
transport NN O O
) NN O O
determine NN O O
the NN O O
anti NN O O
- NN O O
atherogenicity NN O O
of NN O O
the NN O O
HDL NN O O
fraction NN O O
. NN O O

Mapping NN O O
the NN O O
homolog NN O O
of NN O O
the NN O O
human NN O O
Rb1 NN O O
gene NN O O
to NN O O
chromosome NN O O
14 NN O O
of NN O O
higher NN O O
primates NN O O
. NN O O

The NN O O
Rb1 NN O O
gene NN O O
has NN O O
been NN O O
implicated NN O O
with NN O O
retinoblastoma NN O B-Disease
and NN O O
is NN O O
located NN O O
on NN O O
human NN O O
Chromosome NN O O
( NN O O
Chr NN O O
) NN O O
13q14 NN O O
. NN O O

2 NN O O
2 NN O O
. NN O O

A NN O O
unique NN O O
sequence NN O O
human NN O O
Rb1 NN O O
cosmid NN O O
DNA NN O O
probe NN O O
has NN O O
been NN O O
used NN O O
to NN O O
localize NN O O
this NN O O
region NN O O
on NN O O
apes NN O O
Chr NN O O
14 NN O O
by NN O O
the NN O O
FISH NN O O
technique NN O O
. NN O O

The NN O O
conservation NN O O
of NN O O
the NN O O
Rb1 NN O O
gene NN O O
in NN O O
higher NN O O
primates NN O O
at NN O O
the NN O O
corresponding NN O O
equivalent NN O O
chromosome NN O O
locus NN O O
( NN O O
14q14 NN O O
) NN O O
of NN O O
the NN O O
human NN O O
may NN O O
serve NN O O
as NN O O
a NN O O
phylogenetic NN O O
marker NN O O
to NN O O
further NN O O
trace NN O O
the NN O O
evolutionary NN O O
pathway NN O O
of NN O O
human NN O O
descent NN O O
. NN O O

Wiskott NN O B-Disease
- NN O I-Disease
Aldrich NN O I-Disease
syndrome NN O I-Disease
: NN O O
no NN O O
strict NN O O
genotype NN O O
- NN O O
phenotype NN O O
correlations NN O O
but NN O O
clustering NN O O
of NN O O
missense NN O O
mutations NN O O
in NN O O
the NN O O
amino NN O O
- NN O O
terminal NN O O
part NN O O
of NN O O
the NN O O
WASP NN O O
gene NN O O
product NN O O
. NN O O

The NN O O
Wiskott NN O B-Disease
- NN O I-Disease
Aldrich NN O I-Disease
syndrome NN O I-Disease
protein NN O O
( NN O O
WASP NN O O
) NN O O
gene NN O O
was NN O O
found NN O O
to NN O O
be NN O O
mutated NN O O
in NN O O
patients NN O O
presenting NN O O
with NN O O
WAS NN O B-Disease
and NN O O
in NN O O
patients NN O O
showing NN O O
X NN O B-Disease
- NN O I-Disease
linked NN O I-Disease
thrombocytopenia NN O I-Disease
. NN O O

Mutation NN O O
analysis NN O O
in NN O O
19 NN O O
families NN O O
of NN O O
German NN O O
, NN O O
Swiss NN O O
and NN O O
Turkish NN O O
descent NN O O
by NN O O
single NN O O
- NN O O
strand NN O O
conformation NN O O
polymorphism NN O O
and NN O O
sequencing NN O O
resulted NN O O
in NN O O
the NN O O
detection NN O O
of NN O O
seven NN O O
novel NN O O
and NN O O
10 NN O O
known NN O O
mutations NN O O
. NN O O

A NN O O
striking NN O O
clustering NN O O
of NN O O
missense NN O O
mutations NN O O
in NN O O
the NN O O
first NN O O
four NN O O
exons NN O O
contrasted NN O O
with NN O O
a NN O O
random NN O O
distribution NN O O
of NN O O
nonsense NN O O
mutations NN O O
. NN O O

More NN O O
than NN O O
85 NN O O
% NN O O
of NN O O
all NN O O
known NN O O
missense NN O O
mutations NN O O
were NN O O
localized NN O O
in NN O O
the NN O O
amino NN O O
- NN O O
terminal NN O O
stretch NN O O
of NN O O
the NN O O
WASP NN O O
gene NN O O
product NN O O
; NN O O
this NN O O
region NN O O
contained NN O O
a NN O O
mutational NN O O
hot NN O O
spot NN O O
at NN O O
codon NN O O
86 NN O O
. NN O O

No NN O O
genotype NN O O
- NN O O
phenotype NN O O
correlation NN O O
emerged NN O O
after NN O O
a NN O O
comparison NN O O
of NN O O
the NN O O
identified NN O O
mutations NN O O
with NN O O
the NN O O
resulting NN O O
clinical NN O O
picture NN O O
for NN O O
a NN O O
classical NN O O
WAS NN O B-Disease
phenotype NN O O
. NN O O

A NN O O
substitution NN O O
at NN O O
codon NN O O
86 NN O O
resulted NN O O
in NN O O
an NN O O
extremely NN O O
variable NN O O
expression NN O O
of NN O O
the NN O O
disease NN O O
in NN O O
a NN O O
large NN O O
Swiss NN O O
family NN O O
. NN O O

An NN O O
extended NN O O
homology NN O O
search NN O O
revealed NN O O
a NN O O
distant NN O O
relationship NN O O
of NN O O
this NN O O
stretch NN O O
to NN O O
the NN O O
vasodilator NN O O
- NN O O
stimulated NN O O
phosphoprotein NN O O
( NN O O
VASP NN O O
) NN O O
, NN O O
which NN O O
is NN O O
involved NN O O
in NN O O
the NN O O
maintenance NN O O
of NN O O
cyto NN O O
- NN O O
architecture NN O O
by NN O O
interacting NN O O
with NN O O
actin NN O O
- NN O O
like NN O O
filaments NN O O
. NN O O
. NN O O

Influence NN O O
of NN O O
PAX6 NN O O
gene NN O O
dosage NN O O
on NN O O
development NN O O
: NN O O
overexpression NN O O
causes NN O O
severe NN O O
eye NN O B-Disease
abnormalities NN O I-Disease
. NN O O

Aniridia NN O B-Disease
in NN O O
man NN O O
and NN O O
Small NN O O
eye NN O O
in NN O O
mice NN O O
are NN O O
semidominant NN O B-Disease
developmental NN O I-Disease
disorders NN O I-Disease
caused NN O O
by NN O O
mutations NN O O
within NN O O
the NN O O
paired NN O O
box NN O O
gene NN O O
PAX6 NN O O
. NN O O

Whereas NN O O
heterozygotes NN O O
suffer NN O O
from NN O O
iris NN O B-Disease
hypoplasia NN O I-Disease
, NN O O
homozygous NN O O
mice NN O O
lack NN O O
eyes NN O O
and NN O O
nasal NN O O
cavities NN O O
and NN O O
exhibit NN O O
brain NN O B-Disease
abnormalities NN O I-Disease
. NN O O

To NN O O
investigate NN O O
the NN O O
role NN O O
of NN O O
gene NN O O
dosage NN O O
in NN O O
more NN O O
detail NN O O
, NN O O
we NN O O
have NN O O
generated NN O O
yeast NN O O
artificial NN O O
chromosome NN O O
transgenic NN O O
mice NN O O
carrying NN O O
the NN O O
human NN O O
PAX6 NN O O
locus NN O O
. NN O O

When NN O O
crossed NN O O
onto NN O O
the NN O O
Small NN O O
eye NN O O
background NN O O
, NN O O
the NN O O
transgene NN O O
rescues NN O O
the NN O O
mutant NN O O
phenotype NN O O
. NN O O

Strikingly NN O O
, NN O O
mice NN O O
carrying NN O O
multiple NN O O
copies NN O O
on NN O O
a NN O O
wild NN O O
- NN O O
type NN O O
background NN O O
show NN O O
specific NN O O
developmental NN O B-Disease
abnormalities NN O I-Disease
of NN O I-Disease
the NN O I-Disease
eye NN O I-Disease
, NN O O
but NN O O
not NN O O
of NN O O
other NN O O
tissues NN O O
expressing NN O O
the NN O O
gene NN O O
. NN O O

Thus NN O O
, NN O O
at NN O O
least NN O O
five NN O O
different NN O O
eye NN O O
phenotypes NN O O
are NN O O
associated NN O O
with NN O O
changes NN O O
in NN O O
PAX6 NN O O
expression NN O O
. NN O O

We NN O O
provide NN O O
evidence NN O O
that NN O O
not NN O O
only NN O O
reduced NN O O
, NN O O
but NN O O
also NN O O
increased NN O O
levels NN O O
of NN O O
transcriptional NN O O
regulators NN O O
can NN O O
cause NN O O
developmental NN O B-Disease
defects NN O I-Disease
. NN O O
. NN O O

Heterodimer NN O O
formation NN O O
and NN O O
activity NN O O
in NN O O
the NN O O
human NN O O
enzyme NN O O
galactose NN O O
- NN O O
1 NN O O
- NN O O
phosphate NN O O
uridylyltransferase NN O O
. NN O O

One NN O O
of NN O O
the NN O O
fundamental NN O O
questions NN O O
concerning NN O O
expression NN O O
and NN O O
function NN O O
of NN O O
dimeric NN O O
enzymes NN O O
involves NN O O
the NN O O
impact NN O O
of NN O O
naturally NN O O
occurring NN O O
mutations NN O O
on NN O O
subunit NN O O
assembly NN O O
and NN O O
heterodimer NN O O
activity NN O O
. NN O O

This NN O O
question NN O O
is NN O O
of NN O O
particular NN O O
interest NN O O
for NN O O
the NN O O
human NN O O
enzyme NN O O
galactose NN O O
- NN O O
l NN O O
- NN O O
phosphate NN O O
uridylyl NN O O
- NN O O
transferase NN O O
( NN O O
GALT NN O O
) NN O O
, NN O O
impairment NN O O
of NN O O
which NN O O
results NN O O
in NN O O
the NN O O
inherited NN O B-Disease
metabolic NN O I-Disease
disorder NN O I-Disease
galactosemia NN O B-Disease
, NN O O
because NN O O
many NN O O
if NN O O
not NN O O
most NN O O
patients NN O O
studied NN O O
to NN O O
date NN O O
are NN O O
compound NN O O
heterozygotes NN O O
rather NN O O
than NN O O
true NN O O
molecular NN O O
homozygotes NN O O
. NN O O

Furthermore NN O O
, NN O O
the NN O O
broad NN O O
range NN O O
of NN O O
phenotypic NN O O
severity NN O O
observed NN O O
in NN O O
these NN O O
patients NN O O
raises NN O O
the NN O O
possibility NN O O
that NN O O
allelic NN O O
combination NN O O
, NN O O
not NN O O
just NN O O
allelic NN O O
constitution NN O O
, NN O O
may NN O O
play NN O O
some NN O O
role NN O O
in NN O O
determining NN O O
outcome NN O O
. NN O O

In NN O O
the NN O O
work NN O O
described NN O O
herein NN O O
, NN O O
we NN O O
have NN O O
selected NN O O
two NN O O
distinct NN O O
naturally NN O O
occurring NN O O
null NN O O
mutations NN O O
of NN O O
GALT NN O O
, NN O O
Q188R NN O O
and NN O O
R333W NN O O
, NN O O
and NN O O
asked NN O O
the NN O O
questions NN O O
( NN O O
i NN O O
) NN O O
what NN O O
are NN O O
the NN O O
impacts NN O O
of NN O O
these NN O O
mutations NN O O
on NN O O
subunit NN O O
assembly NN O O
, NN O O
and NN O O
( NN O O
ii NN O O
) NN O O
if NN O O
heterodimers NN O O
do NN O O
form NN O O
, NN O O
are NN O O
they NN O O
active NN O O
? NN O O

To NN O O
answer NN O O
these NN O O
questions NN O O
, NN O O
we NN O O
have NN O O
established NN O O
a NN O O
yeast NN O O
system NN O O
for NN O O
the NN O O
coexpression NN O O
of NN O O
epitope NN O O
- NN O O
tagged NN O O
alleles NN O O
of NN O O
human NN O O
GALT NN O O
and NN O O
investigated NN O O
both NN O O
the NN O O
extent NN O O
of NN O O
specific NN O O
GALT NN O O
subunit NN O O
interactions NN O O
and NN O O
the NN O O
activity NN O O
of NN O O
defined NN O O
heterodimer NN O O
pools NN O O
. NN O O

We NN O O
have NN O O
found NN O O
that NN O O
both NN O O
homodimers NN O O
and NN O O
heterodimers NN O O
do NN O O
form NN O O
involving NN O O
each NN O O
of NN O O
the NN O O
mutant NN O O
subunits NN O O
tested NN O O
and NN O O
that NN O O
both NN O O
heterodimer NN O O
pools NN O O
retain NN O O
substantial NN O O
enzymatic NN O O
activity NN O O
. NN O O

These NN O O
results NN O O
are NN O O
significant NN O O
not NN O O
only NN O O
in NN O O
terms NN O O
of NN O O
their NN O O
implications NN O O
for NN O O
furthering NN O O
our NN O O
understanding NN O O
of NN O O
galactosemia NN O B-Disease
and NN O O
GALT NN O O
holoenzyme NN O O
structure NN O O
- NN O O
function NN O O
relationships NN O O
but NN O O
also NN O O
because NN O O
the NN O O
system NN O O
described NN O O
may NN O O
serve NN O O
as NN O O
a NN O O
model NN O O
for NN O O
similar NN O O
studies NN O O
of NN O O
other NN O O
complexes NN O O
composed NN O O
of NN O O
multiple NN O O
subunits NN O O
. NN O O
. NN O O

Cleavage NN O O
of NN O O
huntingtin NN O O
by NN O O
apopain NN O O
, NN O O
a NN O O
proapoptotic NN O O
cysteine NN O O
protease NN O O
, NN O O
is NN O O
modulated NN O O
by NN O O
the NN O O
polyglutamine NN O O
tract NN O O
. NN O O

Apoptosis NN O O
has NN O O
recently NN O O
been NN O O
recognized NN O O
as NN O O
a NN O O
mode NN O O
of NN O O
cell NN O O
death NN O O
in NN O O
Huntington NN O B-Disease
disease NN O I-Disease
( NN O O
HD NN O B-Disease
) NN O O
. NN O O

Apopain NN O O
, NN O O
a NN O O
human NN O O
counterpart NN O O
of NN O O
the NN O O
nematode NN O O
cysteine NN O O
protease NN O O
death NN O O
- NN O O
gene NN O O
product NN O O
, NN O O
CED NN O O
- NN O O
3 NN O O
, NN O O
has NN O O
a NN O O
key NN O O
role NN O O
in NN O O
proteolytic NN O O
events NN O O
leading NN O O
to NN O O
apoptosis NN O O
. NN O O

Here NN O O
we NN O O
show NN O O
that NN O O
apoptotic NN O O
extracts NN O O
and NN O O
apopain NN O O
itself NN O O
specifically NN O O
cleave NN O O
the NN O O
HD NN O B-Disease
gene NN O O
product NN O O
, NN O O
huntingtin NN O O
. NN O O

The NN O O
rate NN O O
of NN O O
cleavage NN O O
increases NN O O
with NN O O
the NN O O
length NN O O
of NN O O
the NN O O
huntingtin NN O O
polyglutamine NN O O
tract NN O O
, NN O O
providing NN O O
an NN O O
explanation NN O O
for NN O O
the NN O O
gain NN O O
- NN O O
of NN O O
- NN O O
function NN O O
associated NN O O
with NN O O
CAG NN O O
expansion NN O O
. NN O O

Our NN O O
results NN O O
show NN O O
that NN O O
huntingtin NN O O
is NN O O
cleaved NN O O
by NN O O
cysteine NN O O
proteases NN O O
and NN O O
suggest NN O O
that NN O O
HD NN O B-Disease
might NN O O
be NN O O
a NN O O
disorder NN O B-Disease
of NN O I-Disease
inappropriate NN O I-Disease
apoptosis NN O I-Disease
. NN O O
. NN O O

The NN O O
5 NN O O
' NN O O
end NN O O
of NN O O
the NN O O
BRCA1 NN O O
gene NN O O
lies NN O O
within NN O O
a NN O O
duplicated NN O O
region NN O O
of NN O O
human NN O O
chromosome NN O O
17q21 NN O O
. NN O O

To NN O O
begin NN O O
to NN O O
address NN O O
the NN O O
hypothesis NN O O
that NN O O
abnormal NN O O
regulation NN O O
of NN O O
the NN O O
breast NN O B-Disease
/ NN O I-Disease
ovarian NN O I-Disease
cancer NN O I-Disease
susceptibility NN O O
gene NN O O
BRCA1 NN O O
is NN O O
a NN O O
critical NN O O
step NN O O
in NN O O
sporadic NN O O
breast NN O O
/ NN O O
ovarian NN O O
tumorigenesis NN O O
, NN O O
we NN O O
have NN O O
determined NN O O
the NN O O
detailed NN O O
structure NN O O
of NN O O
the NN O O
BRCA1 NN O O
genomic NN O O
region NN O O
. NN O O

We NN O O
show NN O O
that NN O O
this NN O O
region NN O O
of NN O O
the NN O O
genome NN O O
contains NN O O
a NN O O
tandem NN O O
duplication NN O O
of NN O O
approximately NN O O
30 NN O O
kilobases NN O O
, NN O O
which NN O O
results NN O O
in NN O O
two NN O O
copies NN O O
of NN O O
BRCA1 NN O O
exons NN O O
1 NN O O
and NN O O
2 NN O O
, NN O O
of NN O O
exons NN O O
1 NN O O
and NN O O
3 NN O O
of NN O O
the NN O O
adjacent NN O O
1A1 NN O O
- NN O O
3B NN O O
gene NN O O
and NN O O
of NN O O
the NN O O
previously NN O O
reported NN O O
295 NN O O
base NN O O
pair NN O O
intergenic NN O O
region NN O O
. NN O O

Sequence NN O O
analysis NN O O
of NN O O
the NN O O
duplicated NN O O
exons NN O O
of NN O O
BRCA1 NN O O
and NN O O
1A1 NN O O
- NN O O
3B NN O O
and NN O O
flanking NN O O
genomic NN O O
DNA NN O O
reveals NN O O
maintenance NN O O
of NN O O
the NN O O
intron NN O O
- NN O O
exon NN O O
structure NN O O
and NN O O
a NN O O
high NN O O
degree NN O O
of NN O O
nucleotide NN O O
sequence NN O O
identity NN O O
, NN O O
suggesting NN O O
that NN O O
these NN O O
are NN O O
non NN O O
- NN O O
processed NN O O
pseudogenes NN O O
and NN O O
that NN O O
the NN O O
duplication NN O O
is NN O O
a NN O O
recent NN O O
event NN O O
in NN O O
evolutionary NN O O
terms NN O O
. NN O O

We NN O O
also NN O O
show NN O O
that NN O O
a NN O O
processed NN O O
pseudogene NN O O
of NN O O
the NN O O
acidic NN O O
ribosomal NN O O
phosphoprotein NN O O
P1 NN O O
( NN O O
ARPP1 NN O O
) NN O O
is NN O O
inserted NN O O
directly NN O O
upstream NN O O
of NN O O
pseudo NN O O
- NN O O
BRCA1 NN O O
exon NN O O
1A NN O O
. NN O O

We NN O O
believe NN O O
that NN O O
these NN O O
findings NN O O
could NN O O
not NN O O
only NN O O
confound NN O O
BRCA1 NN O O
mutation NN O O
analysis NN O O
, NN O O
but NN O O
could NN O O
have NN O O
implications NN O O
for NN O O
the NN O O
normal NN O O
and NN O O
abnormal NN O O
regulation NN O O
of NN O O
BRCA1 NN O O
transcription NN O O
, NN O O
translation NN O O
and NN O O
function NN O O
. NN O O
. NN O O

Deletion NN O O
of NN O O
small NN O O
nuclear NN O O
ribonucleoprotein NN O O
polypeptide NN O O
N NN O O
( NN O O
SNRPN NN O O
) NN O O
in NN O O
Prader NN O B-Disease
- NN O I-Disease
Willi NN O I-Disease
syndrome NN O I-Disease
detected NN O O
by NN O O
fluorescence NN O O
in NN O O
situ NN O O
hybridization NN O O
: NN O O
two NN O O
sibs NN O O
with NN O O
the NN O O
typical NN O O
phenotype NN O O
without NN O O
a NN O O
cytogenetic NN O O
deletion NN O O
in NN O O
chromosome NN O O
15q NN O O
. NN O O

The NN O O
small NN O O
nuclear NN O O
ribonucleoprotein NN O O
polypeptide NN O O
N NN O O
( NN O O
SNRPN NN O O
) NN O O
gene NN O O
is NN O O
regarded NN O O
as NN O O
one NN O O
of NN O O
the NN O O
candidates NN O O
for NN O O
Prader NN O B-Disease
- NN O I-Disease
Willi NN O I-Disease
syndrome NN O I-Disease
( NN O O
PWS NN O B-Disease
) NN O O
. NN O O

We NN O O
describe NN O O
two NN O O
sibs NN O O
with NN O O
typical NN O O
PWS NN O B-Disease
presenting NN O O
deletion NN O O
of NN O O
SNRPN NN O O
detected NN O O
by NN O O
fluorescence NN O O
in NN O O
situ NN O O
hybridization NN O O
( NN O O
FISH NN O O
) NN O O
. NN O O

Neither NN O O
a NN O O
cytogenetically NN O O
detectable NN O O
15q12 NN O O
deletion NN O O
nor NN O O
a NN O O
deletion NN O O
for NN O O
the NN O O
D15S11 NN O O
, NN O O
D15S10 NN O O
, NN O O
and NN O O
GABRB3 NN O O
cosmid NN O O
probes NN O O
were NN O O
found NN O O
in NN O O
either NN O O
patient NN O O
. NN O O

This NN O O
implies NN O O
a NN O O
smaller NN O O
deletion NN O O
limited NN O O
to NN O O
the NN O O
PWS NN O B-Disease
critical NN O O
region NN O O
. NN O O

FISH NN O O
with NN O O
a NN O O
SNRPN NN O O
probe NN O O
will NN O O
permit NN O O
analysis NN O O
of NN O O
PWS NN O B-Disease
patients NN O O
with NN O O
limited NN O O
deletions NN O O
not NN O O
detectable NN O O
with NN O O
other NN O O
probes NN O O
. NN O O
. NN O O

Expression NN O O
of NN O O
the NN O O
von NN O B-Disease
Hippel NN O I-Disease
- NN O I-Disease
Lindau NN O I-Disease
disease NN O I-Disease
tumour NN O I-Disease
suppressor NN O O
gene NN O O
during NN O O
human NN O O
embryogenesis NN O O
. NN O O

The NN O O
von NN O B-Disease
Hippel NN O I-Disease
- NN O I-Disease
Lindau NN O I-Disease
( NN O I-Disease
VHL NN O I-Disease
) NN O I-Disease
disease NN O I-Disease
product NN O O
is NN O O
thought NN O O
to NN O O
down NN O O
- NN O O
regulate NN O O
transcription NN O O
by NN O O
antagonizing NN O O
elongin NN O O
- NN O O
enhanced NN O O
transcriptional NN O O
elongation NN O O
. NN O O

Germline NN O O
VHL NN O B-Disease
gene NN O O
mutations NN O O
predispose NN O O
to NN O O
the NN O O
development NN O O
of NN O O
retinal NN O B-Disease
, NN O I-Disease
cerebellar NN O I-Disease
and NN O I-Disease
spinal NN O I-Disease
haemangioblastomas NN O I-Disease
, NN O O
renal NN O B-Disease
cell NN O I-Disease
carcinoma NN O I-Disease
and NN O O
phaeochromocytoma NN O B-Disease
. NN O O

In NN O O
addition NN O O
, NN O O
somatic NN O O
Inactivation NN O O
of NN O O
the NN O O
VHL NN O B-Disease
gene NN O O
is NN O O
frequent NN O O
in NN O O
sporadic NN O B-Disease
renal NN O I-Disease
cell NN O I-Disease
carcinoma NN O I-Disease
and NN O O
haemangioblastoma NN O B-Disease
. NN O O

Regulation NN O O
of NN O O
transcript NN O O
elongation NN O O
is NN O O
an NN O O
important NN O O
control NN O O
mechanism NN O O
for NN O O
gene NN O O
expression NN O O
and NN O O
the NN O O
VHL NN O B-Disease
gene NN O O
might NN O O
modify NN O O
the NN O O
expression NN O O
of NN O O
proto NN O O
- NN O O
oncogenes NN O O
and NN O O
growth NN O O
suppressor NN O O
genes NN O O
during NN O O
embryogenesis NN O O
. NN O O

We NN O O
therefore NN O O
investigated NN O O
the NN O O
expression NN O O
of NN O O
VHL NN O B-Disease
mRNA NN O O
during NN O O
human NN O O
embryogenesis NN O O
by NN O O
in NN O O
situ NN O O
hybridization NN O O
studies NN O O
at NN O O
4 NN O O
, NN O O
6 NN O O
and NN O O
10 NN O O
weeks NN O O
post NN O O
conception NN O O
. NN O O

Although NN O O
VHL NN O B-Disease
mRNA NN O O
was NN O O
expressed NN O O
in NN O O
all NN O O
three NN O O
germ NN O O
layers NN O O
, NN O O
strong NN O O
expression NN O O
was NN O O
noted NN O O
in NN O O
the NN O O
central NN O O
nervous NN O O
system NN O O
, NN O O
kidneys NN O O
, NN O O
testis NN O O
and NN O O
lung NN O O
. NN O O

Within NN O O
the NN O O
kidney NN O O
, NN O O
VHL NN O B-Disease
mRNA NN O O
was NN O O
differentially NN O O
expressed NN O O
within NN O O
renal NN O O
tubules NN O O
suggesting NN O O
that NN O O
the NN O O
VHL NN O B-Disease
gene NN O O
product NN O O
may NN O O
have NN O O
a NN O O
specific NN O O
role NN O O
in NN O O
kidney NN O O
development NN O O
. NN O O

Two NN O O
alternatively NN O O
spliced NN O O
VHL NN O B-Disease
mRNAs NN O O
characterized NN O O
by NN O O
inclusion NN O O
( NN O O
isoform NN O O
I NN O O
) NN O O
or NN O O
exclusion NN O O
( NN O O
isoform NN O O
II NN O O
) NN O O
of NN O O
exon NN O O
2 NN O O
are NN O O
transcribed NN O O
in NN O O
adult NN O O
tissues NN O O
. NN O O

To NN O O
investigate NN O O
if NN O O
the NN O O
two NN O O
isoforms NN O O
are NN O O
differentially NN O O
expressed NN O O
during NN O O
embryogenesis NN O O
, NN O O
VHL NN O B-Disease
mRNA NN O O
was NN O O
reverse NN O O
transcribed NN O O
from NN O O
13 NN O O
fetal NN O O
tissues NN O O
( NN O O
8 NN O O
- NN O O
10 NN O O
weeks NN O O
gestation NN O O
) NN O O
. NN O O

The NN O O
quantitative NN O O
distribution NN O O
of NN O O
VHL NN O B-Disease
mRNA NN O O
within NN O O
fetal NN O O
tissues NN O O
reflected NN O O
that NN O O
seen NN O O
by NN O O
in NN O O
situ NN O O
hybridization NN O O
and NN O O
the NN O O
ratio NN O O
of NN O O
the NN O O
two NN O O
VHL NN O B-Disease
isoforms NN O O
was NN O O
similar NN O O
between NN O O
tissues NN O O
. NN O O

Although NN O O
the NN O O
genes NN O O
regulated NN O O
by NN O O
the NN O O
VHL NN O B-Disease
gene NN O O
product NN O O
have NN O O
not NN O O
yet NN O O
been NN O O
identified NN O O
, NN O O
our NN O O
findings NN O O
are NN O O
compatible NN O O
with NN O O
the NN O O
hypothesis NN O O
that NN O O
VHL NN O B-Disease
- NN O O
mediated NN O O
control NN O O
of NN O O
transcriptional NN O O
elongation NN O O
may NN O O
have NN O O
a NN O O
role NN O O
in NN O O
normal NN O O
human NN O O
development NN O O
. NN O O
. NN O O

Genetic NN O O
heterogeneity NN O O
in NN O O
hereditary NN O B-Disease
breast NN O I-Disease
cancer NN O I-Disease
: NN O O
role NN O O
of NN O O
BRCA1 NN O O
and NN O O
BRCA2 NN O O
. NN O O

The NN O O
common NN O O
hereditary NN O O
forms NN O O
of NN O O
breast NN O B-Disease
cancer NN O I-Disease
have NN O O
been NN O O
largely NN O O
attributed NN O O
to NN O O
the NN O O
inheritance NN O O
of NN O O
mutations NN O O
in NN O O
the NN O O
BRCA1 NN O O
or NN O O
BRCA2 NN O O
genes NN O O
. NN O O

However NN O O
, NN O O
it NN O O
is NN O O
not NN O O
yet NN O O
clear NN O O
what NN O O
proportion NN O O
of NN O O
hereditary NN O B-Disease
breast NN O I-Disease
cancer NN O I-Disease
is NN O O
explained NN O O
by NN O O
BRCA1 NN O O
and NN O O
BRCA2 NN O O
or NN O O
by NN O O
some NN O O
other NN O O
unidentified NN O O
susceptibility NN O O
gene NN O O
( NN O O
s NN O O
) NN O O
. NN O O

We NN O O
describe NN O O
the NN O O
proportion NN O O
of NN O O
hereditary NN O B-Disease
breast NN O I-Disease
cancer NN O I-Disease
explained NN O O
by NN O O
BRCA1 NN O O
or NN O O
BRCA2 NN O O
in NN O O
a NN O O
sample NN O O
of NN O O
North NN O O
American NN O O
hereditary NN O B-Disease
breast NN O I-Disease
cancers NN O I-Disease
and NN O O
assess NN O O
the NN O O
evidence NN O O
for NN O O
additional NN O O
susceptibility NN O O
genes NN O O
that NN O O
may NN O O
confer NN O O
hereditary NN O B-Disease
breast NN O I-Disease
or NN O I-Disease
ovarian NN O I-Disease
cancer NN O I-Disease
risk NN O O
. NN O O

Twenty NN O O
- NN O O
three NN O O
families NN O O
were NN O O
identified NN O O
through NN O O
two NN O O
high NN O O
- NN O O
risk NN O O
breast NN O B-Disease
cancer NN O I-Disease
research NN O O
programs NN O O
. NN O O

Genetic NN O O
analysis NN O O
was NN O O
undertaken NN O O
to NN O O
establish NN O O
linkage NN O O
between NN O O
the NN O O
breast NN O B-Disease
or NN O I-Disease
ovarian NN O I-Disease
cancer NN O I-Disease
cases NN O O
and NN O O
markers NN O O
on NN O O
chromosomes NN O O
17q NN O O
( NN O O
BRCA1 NN O O
) NN O O
and NN O O
13q NN O O
( NN O O
BRCA2 NN O O
) NN O O
. NN O O

Mutation NN O O
analysis NN O O
in NN O O
the NN O O
BRCA1 NN O O
and NN O O
BRCA2 NN O O
genes NN O O
was NN O O
also NN O O
undertaken NN O O
in NN O O
all NN O O
families NN O O
. NN O O

The NN O O
pattern NN O O
of NN O O
hereditary NN O B-Disease
cancer NN O I-Disease
in NN O O
14 NN O O
( NN O O
61 NN O O
% NN O O
) NN O O
of NN O O
the NN O O
23 NN O O
families NN O O
studied NN O O
was NN O O
attributed NN O O
to NN O O
BRCA1 NN O O
by NN O O
a NN O O
combination NN O O
of NN O O
linkage NN O O
and NN O O
mutation NN O O
analyses NN O O
. NN O O

No NN O O
families NN O O
were NN O O
attributed NN O O
to NN O O
BRCA2 NN O O
. NN O O

Five NN O O
families NN O O
( NN O O
22 NN O O
% NN O O
) NN O O
provided NN O O
evidence NN O O
against NN O O
linkage NN O O
to NN O O
both NN O O
BRCA1 NN O O
and NN O O
BRCA2 NN O O
. NN O O

No NN O O
BRCA1 NN O O
or NN O O
BRCA2 NN O O
mutations NN O O
were NN O O
detected NN O O
in NN O O
these NN O O
five NN O O
families NN O O
. NN O O

The NN O O
BRCA1 NN O O
or NN O O
BRCA2 NN O O
status NN O O
of NN O O
four NN O O
families NN O O
( NN O O
17 NN O O
% NN O O
) NN O O
could NN O O
not NN O O
be NN O O
determined NN O O
. NN O O

BRCA1 NN O O
and NN O O
BRCA2 NN O O
probably NN O O
explain NN O O
the NN O O
majority NN O O
of NN O O
hereditary NN O B-Disease
breast NN O I-Disease
cancer NN O I-Disease
that NN O O
exists NN O O
in NN O O
the NN O O
North NN O O
American NN O O
population NN O O
. NN O O

However NN O O
, NN O O
one NN O O
or NN O O
more NN O O
additional NN O O
genes NN O O
may NN O O
yet NN O O
be NN O O
found NN O O
that NN O O
explain NN O O
some NN O O
proportion NN O O
of NN O O
hereditary NN O B-Disease
breast NN O I-Disease
cancer NN O I-Disease
. NN O O
. NN O O

An NN O O
intronic NN O O
mutation NN O O
in NN O O
a NN O O
lariat NN O O
branchpoint NN O O
sequence NN O O
is NN O O
a NN O O
direct NN O O
cause NN O O
of NN O O
an NN O O
inherited NN O B-Disease
human NN O I-Disease
disorder NN O I-Disease
( NN O O
fish NN O B-Disease
- NN O I-Disease
eye NN O I-Disease
disease NN O I-Disease
) NN O O
. NN O O

The NN O O
first NN O O
step NN O O
in NN O O
the NN O O
splicing NN O O
of NN O O
an NN O O
intron NN O O
from NN O O
nuclear NN O O
precursors NN O O
of NN O O
mRNA NN O O
results NN O O
in NN O O
the NN O O
formation NN O O
of NN O O
a NN O O
lariat NN O O
structure NN O O
. NN O O

A NN O O
distinct NN O O
intronic NN O O
nucleotide NN O O
sequence NN O O
, NN O O
known NN O O
as NN O O
the NN O O
branchpoint NN O O
region NN O O
, NN O O
plays NN O O
a NN O O
central NN O O
role NN O O
in NN O O
this NN O O
process NN O O
. NN O O

We NN O O
here NN O O
describe NN O O
a NN O O
point NN O O
mutation NN O O
in NN O O
such NN O O
a NN O O
sequence NN O O
. NN O O

Three NN O O
sisters NN O O
were NN O O
shown NN O O
to NN O O
suffer NN O O
from NN O O
fish NN O B-Disease
- NN O I-Disease
eye NN O I-Disease
disease NN O I-Disease
( NN O O
FED NN O B-Disease
) NN O O
, NN O O
a NN O O
disorder NN O O
which NN O O
is NN O O
caused NN O O
by NN O O
mutations NN O O
in NN O O
the NN O O
gene NN O O
coding NN O O
for NN O O
lecithin NN O O
cholesterol NN O O
acyltransferase NN O O
( NN O O
LCAT NN O O
) NN O O
. NN O O

Sequencing NN O O
of NN O O
the NN O O
LCAT NN O O
gene NN O O
of NN O O
all NN O O
three NN O O
probands NN O O
revealed NN O O
compound NN O O
heterozygosity NN O O
for NN O O
a NN O O
missense NN O O
mutation NN O O
in NN O O
exon NN O O
4 NN O O
which NN O O
is NN O O
reported NN O O
to NN O O
underlie NN O O
the NN O O
FED NN O B-Disease
phenotype NN O O
, NN O O
and NN O O
a NN O O
point NN O O
mutation NN O O
located NN O O
in NN O O
intron NN O O
4 NN O O
( NN O O
IVS4 NN O O
T NN O O
- NN O O
22C NN O O
) NN O O
. NN O O

By NN O O
performing NN O O
in NN O O
vitro NN O O
expression NN O O
of NN O O
LCAT NN O O
minigenes NN O O
and NN O O
reverse NN O O
transcriptase NN O O
PCR NN O O
on NN O O
mRNA NN O O
isolated NN O O
from NN O O
leukocytes NN O O
of NN O O
the NN O O
patient NN O O
, NN O O
this NN O O
gene NN O O
defect NN O O
was NN O O
shown NN O O
to NN O O
cause NN O O
a NN O O
null NN O O
allele NN O O
as NN O O
the NN O O
result NN O O
of NN O O
complete NN O O
intron NN O O
retention NN O O
. NN O O

In NN O O
conclusion NN O O
, NN O O
we NN O O
demonstrated NN O O
that NN O O
a NN O O
point NN O O
mutation NN O O
in NN O O
a NN O O
lariat NN O O
branchpoint NN O O
consensus NN O O
sequence NN O O
causes NN O O
a NN O O
null NN O O
allele NN O O
in NN O O
a NN O O
patient NN O O
with NN O O
FED NN O B-Disease
. NN O O

In NN O O
addition NN O O
, NN O O
our NN O O
finding NN O O
illustrates NN O O
the NN O O
importance NN O O
of NN O O
this NN O O
sequence NN O O
for NN O O
normal NN O O
human NN O O
mRNA NN O O
processing NN O O
. NN O O

Finally NN O O
, NN O O
this NN O O
report NN O O
provides NN O O
a NN O O
widely NN O O
applicable NN O O
strategy NN O O
which NN O O
ensures NN O O
fast NN O O
and NN O O
effective NN O O
screening NN O O
for NN O O
intronic NN O O
defects NN O O
that NN O O
underlie NN O O
differential NN O O
gene NN O O
expression NN O O
. NN O O
. NN O O

Mutations NN O O
associated NN O O
with NN O O
variant NN O O
phenotypes NN O O
in NN O O
ataxia NN O B-Disease
- NN O I-Disease
telangiectasia NN O I-Disease
. NN O O

We NN O O
have NN O O
identified NN O O
14 NN O O
families NN O O
with NN O O
ataxia NN O B-Disease
- NN O I-Disease
telangiectasia NN O I-Disease
( NN O O
A NN O B-Disease
- NN O I-Disease
T NN O I-Disease
) NN O O
in NN O O
which NN O O
mutation NN O O
of NN O O
the NN O O
ATM NN O O
gene NN O O
is NN O O
associated NN O O
with NN O O
a NN O O
less NN O O
severe NN O O
clinical NN O O
and NN O O
cellular NN O O
phenotype NN O O
( NN O O
approximately NN O O
10 NN O O
% NN O O
- NN O O
15 NN O O
% NN O O
of NN O O
A NN O B-Disease
- NN O I-Disease
T NN O I-Disease
families NN O O
identified NN O O
in NN O O
the NN O O
United NN O O
Kingdom NN O O
) NN O O
. NN O O

In NN O O
10 NN O O
of NN O O
these NN O O
families NN O O
, NN O O
all NN O O
the NN O O
homozygotes NN O O
have NN O O
a NN O O
137 NN O O
- NN O O
bp NN O O
insertion NN O O
in NN O O
their NN O O
cDNA NN O O
caused NN O O
by NN O O
a NN O O
point NN O O
mutation NN O O
in NN O O
a NN O O
sequence NN O O
resembling NN O O
a NN O O
splice NN O O
- NN O O
donor NN O O
site NN O O
. NN O O

The NN O O
second NN O O
A NN O B-Disease
- NN O I-Disease
T NN O I-Disease
allele NN O O
has NN O O
a NN O O
different NN O O
mutation NN O O
in NN O O
each NN O O
patient NN O O
. NN O O

We NN O O
show NN O O
that NN O O
the NN O O
less NN O O
severe NN O O
phenotype NN O O
in NN O O
these NN O O
patients NN O O
is NN O O
caused NN O O
by NN O O
some NN O O
degree NN O O
of NN O O
normal NN O O
splicing NN O O
, NN O O
which NN O O
occurs NN O O
as NN O O
an NN O O
alternative NN O O
product NN O O
from NN O O
the NN O O
insertion NN O O
- NN O O
containing NN O O
allele NN O O
. NN O O

The NN O O
level NN O O
of NN O O
the NN O O
137 NN O O
- NN O O
bp NN O O
PCR NN O O
product NN O O
containing NN O O
the NN O O
insertion NN O O
was NN O O
lowest NN O O
in NN O O
two NN O O
patients NN O O
who NN O O
showed NN O O
a NN O O
later NN O O
onset NN O O
of NN O O
cerebellar NN O B-Disease
ataxia NN O I-Disease
. NN O O

A NN O O
further NN O O
four NN O O
families NN O O
who NN O O
do NN O O
not NN O O
have NN O O
this NN O O
insertion NN O O
have NN O O
been NN O O
identified NN O O
. NN O O

Mutations NN O O
detected NN O O
in NN O O
two NN O O
of NN O O
four NN O O
of NN O O
these NN O O
are NN O O
missense NN O O
mutations NN O O
, NN O O
normally NN O O
rare NN O O
in NN O O
A NN O B-Disease
- NN O I-Disease
T NN O I-Disease
patients NN O O
. NN O O

The NN O O
demonstration NN O O
of NN O O
mutations NN O O
giving NN O O
rise NN O O
to NN O O
a NN O O
slightly NN O O
milder NN O O
phenotype NN O O
in NN O O
A NN O B-Disease
- NN O I-Disease
T NN O I-Disease
raises NN O O
the NN O O
interesting NN O O
question NN O O
of NN O O
what NN O O
range NN O O
of NN O O
phenotypes NN O O
might NN O O
occur NN O O
in NN O O
individuals NN O O
in NN O O
whom NN O O
both NN O O
mutations NN O O
are NN O O
milder NN O O
. NN O O

One NN O O
possibility NN O O
might NN O O
be NN O O
that NN O O
individuals NN O O
who NN O O
are NN O O
compound NN O O
heterozygotes NN O O
for NN O O
ATM NN O O
mutations NN O O
are NN O O
more NN O O
common NN O O
than NN O O
we NN O O
realize NN O O
. NN O O
. NN O O

Mutation NN O O
of NN O O
the NN O O
VHL NN O O
gene NN O O
is NN O O
associated NN O O
exclusively NN O O
with NN O O
the NN O O
development NN O O
of NN O O
non NN O B-Disease
- NN O I-Disease
papillary NN O I-Disease
renal NN O I-Disease
cell NN O I-Disease
carcinomas NN O I-Disease
. NN O O

To NN O O
define NN O O
the NN O O
possible NN O O
role NN O O
of NN O O
the NN O O
VHL NN O B-Disease
gene NN O O
in NN O O
the NN O O
development NN O O
of NN O O
sporadic NN O B-Disease
renal NN O I-Disease
cell NN O I-Disease
carcinomas NN O I-Disease
, NN O O
91 NN O O
different NN O O
parenchymal NN O B-Disease
tumours NN O I-Disease
of NN O I-Disease
the NN O I-Disease
kidney NN O I-Disease
have NN O O
been NN O O
investigated NN O O
for NN O O
mutation NN O O
of NN O O
the NN O O
VHL NN O B-Disease
gene NN O O
by NN O O
single NN O O
strand NN O O
conformation NN O O
polymorphism NN O O
( NN O O
SSCP NN O O
) NN O O
and NN O O
/ NN O O
or NN O O
heteroduplex NN O O
( NN O O
HD NN O O
) NN O O
techniques NN O O
. NN O O

Chromosome NN O O
3p NN O O
deletion NN O O
was NN O O
detected NN O O
in NN O O
98 NN O O
per NN O O
cent NN O O
of NN O O
non NN O B-Disease
- NN O I-Disease
papillary NN O I-Disease
renal NN O I-Disease
cell NN O I-Disease
carcinomas NN O I-Disease
and NN O O
in NN O O
25 NN O O
per NN O O
cent NN O O
of NN O O
chromophobe NN O O
renal NN O B-Disease
cell NN O I-Disease
carcinomas NN O I-Disease
. NN O O

In NN O O
22 NN O O
of NN O O
the NN O O
43 NN O O
non NN O B-Disease
- NN O I-Disease
papillary NN O I-Disease
renal NN O I-Disease
cell NN O I-Disease
carcinomas NN O I-Disease
, NN O O
abnormally NN O O
migrating NN O O
DNA NN O O
bands NN O O
were NN O O
detected NN O O
by NN O O
SSCP NN O O
and NN O O
/ NN O O
or NN O O
HD NN O O
analysis NN O O
. NN O O

No NN O O
mobility NN O O
shift NN O O
was NN O O
seen NN O O
in NN O O
any NN O O
of NN O O
the NN O O
23 NN O O
chromophobe NN O O
renal NN O B-Disease
cell NN O I-Disease
carcinomas NN O I-Disease
. NN O O

In NN O O
addition NN O O
, NN O O
15 NN O O
papillary NN O B-Disease
renal NN O I-Disease
cell NN O I-Disease
tumours NN O I-Disease
and NN O O
ten NN O O
renal NN O B-Disease
oncocytomas NN O I-Disease
, NN O O
which NN O O
are NN O O
characterized NN O O
by NN O O
genetic NN O O
changes NN O O
other NN O O
than NN O O
loss NN O O
of NN O O
chromosome NN O O
3p NN O O
sequences NN O O
, NN O O
were NN O O
analysed NN O O
for NN O O
mutation NN O O
of NN O O
the NN O O
VHL NN O B-Disease
gene NN O O
. NN O O

None NN O O
of NN O O
these NN O O
tumours NN O B-Disease
showed NN O O
abnormal NN O O
migration NN O O
patterns NN O O
. NN O O

The NN O O
results NN O O
indicate NN O O
that NN O O
mutation NN O O
of NN O O
the NN O O
VHL NN O B-Disease
gene NN O O
is NN O O
associated NN O O
exclusively NN O O
with NN O O
the NN O O
development NN O O
of NN O O
non NN O B-Disease
- NN O I-Disease
papillary NN O I-Disease
renal NN O I-Disease
cell NN O I-Disease
carcinoma NN O I-Disease
. NN O O
. NN O O

The NN O O
Emery NN O B-Disease
- NN O I-Disease
Dreifuss NN O I-Disease
muscular NN O I-Disease
dystrophy NN O I-Disease
protein NN O O
, NN O O
emerin NN O O
, NN O O
is NN O O
a NN O O
nuclear NN O O
membrane NN O O
protein NN O O
. NN O O

A NN O O
large NN O O
fragment NN O O
of NN O O
emerin NN O O
cDNA NN O O
was NN O O
prepared NN O O
by NN O O
PCR NN O O
and NN O O
expressed NN O O
as NN O O
a NN O O
recombinant NN O O
protein NN O O
in NN O O
Escherichia NN O O
coli NN O O
. NN O O

Using NN O O
this NN O O
as NN O O
immunogen NN O O
, NN O O
we NN O O
prepared NN O O
a NN O O
panel NN O O
of NN O O
12 NN O O
monoclonal NN O O
antibodies NN O O
which NN O O
recognise NN O O
at NN O O
least NN O O
four NN O O
different NN O O
epitopes NN O O
on NN O O
emerin NN O O
in NN O O
order NN O O
to NN O O
ensure NN O O
that NN O O
emerin NN O O
can NN O O
be NN O O
distinguished NN O O
from NN O O
non NN O O
- NN O O
specific NN O O
cross NN O O
- NN O O
reacting NN O O
proteins NN O O
. NN O O

All NN O O
the NN O O
mAbs NN O O
recognised NN O O
a NN O O
34 NN O O
kDa NN O O
protein NN O O
in NN O O
all NN O O
tissues NN O O
tested NN O O
, NN O O
though NN O O
minor NN O O
emerin NN O O
- NN O O
related NN O O
bands NN O O
were NN O O
also NN O O
detected NN O O
in NN O O
some NN O O
tissues NN O O
. NN O O

Immunofluorescence NN O O
microscopy NN O O
showed NN O O
that NN O O
emerin NN O O
is NN O O
located NN O O
at NN O O
the NN O O
nuclear NN O O
rim NN O O
in NN O O
all NN O O
tissues NN O O
examined NN O O
. NN O O

A NN O O
muscle NN O O
biopsy NN O O
from NN O O
an NN O O
Emery NN O B-Disease
- NN O I-Disease
Dreifuss NN O I-Disease
muscular NN O I-Disease
dystrophy NN O I-Disease
( NN O O
EMDM NN O B-Disease
) NN O O
patient NN O O
showed NN O O
complete NN O O
absence NN O O
of NN O O
emerin NN O O
by NN O O
both NN O O
Western NN O O
blotting NN O O
and NN O O
immunohistochemistry NN O O
, NN O O
suggesting NN O O
a NN O O
simple NN O O
diagnostic NN O O
antibody NN O O
test NN O O
for NN O O
EDMD NN O B-Disease
families NN O O
. NN O O

Biochemical NN O O
fractionation NN O O
of NN O O
brain NN O O
and NN O O
liver NN O O
tissues NN O O
showed NN O O
that NN O O
emerin NN O O
was NN O O
present NN O O
in NN O O
nuclei NN O O
purified NN O O
by NN O O
centrifugation NN O O
through NN O O
65 NN O O
% NN O O
sucrose NN O O
and NN O O
was NN O O
absent NN O O
from NN O O
soluble NN O O
fractions NN O O
( NN O O
post NN O O
- NN O O
100 NN O O
, NN O O
000 NN O O
g NN O O
) NN O O
. NN O O

From NN O O
these NN O O
results NN O O
, NN O O
together NN O O
with NN O O
sequence NN O O
and NN O O
structural NN O O
homologies NN O O
between NN O O
emerin NN O O
, NN O O
thymopoietins NN O O
and NN O O
the NN O O
nuclear NN O O
lamina NN O O
- NN O O
associated NN O O
protein NN O O
, NN O O
LAP2 NN O O
, NN O O
we NN O O
suggest NN O O
that NN O O
emerin NN O O
will NN O O
prove NN O O
to NN O O
be NN O O
one NN O O
member NN O O
of NN O O
a NN O O
family NN O O
of NN O O
inner NN O O
nuclear NN O O
membrane NN O O
proteins NN O O
. NN O O
. NN O O

Mutation NN O O
of NN O O
MSH3 NN O O
in NN O O
endometrial NN O B-Disease
cancer NN O I-Disease
and NN O O
evidence NN O O
for NN O O
its NN O O
functional NN O O
role NN O O
in NN O O
heteroduplex NN O O
repair NN O O
. NN O O

Many NN O O
human NN O O
tumours NN O B-Disease
have NN O O
length NN O O
alterations NN O O
in NN O O
repetitive NN O O
sequence NN O O
elements NN O O
. NN O O

Although NN O O
this NN O O
microsatellite NN O B-Disease
instability NN O I-Disease
has NN O O
been NN O O
attributed NN O O
to NN O O
mutations NN O O
in NN O O
four NN O O
DNA NN O O
mismatch NN O O
repair NN O O
genes NN O O
in NN O O
hereditary NN O B-Disease
nonpolyposis NN O I-Disease
colorectal NN O I-Disease
cancer NN O I-Disease
( NN O O
HNPCC NN O B-Disease
) NN O O
kindreds NN O O
, NN O O
many NN O O
sporadic NN O B-Disease
tumours NN O I-Disease
exhibit NN O O
instability NN O O
but NN O O
no NN O O
detectable NN O O
mutations NN O O
in NN O O
these NN O O
genes NN O O
. NN O O

It NN O O
is NN O O
therefore NN O O
of NN O O
interest NN O O
to NN O O
identify NN O O
other NN O O
genes NN O O
that NN O O
contribute NN O O
to NN O O
this NN O O
instability NN O O
. NN O O

In NN O O
yeast NN O O
, NN O O
mutations NN O O
in NN O O
several NN O O
genes NN O O
, NN O O
including NN O O
RTH NN O O
and NN O O
MSH3 NN O O
, NN O O
cause NN O O
microsatellite NN O O
instability NN O O
. NN O O

Thus NN O O
, NN O O
we NN O O
screened NN O O
16 NN O O
endometrial NN O B-Disease
carcinomas NN O I-Disease
with NN O O
microsatellite NN O O
instability NN O O
for NN O O
alterations NN O O
in NN O O
FEN1 NN O O
( NN O O
the NN O O
human NN O O
homolog NN O O
of NN O O
RTH NN O O
) NN O O
and NN O O
in NN O O
MSH3 NN O O
( NN O O
refs NN O O
12 NN O O
- NN O O
14 NN O O
) NN O O
. NN O O

Although NN O O
we NN O O
found NN O O
no NN O O
FEN1 NN O O
mutations NN O O
, NN O O
a NN O O
frameshift NN O O
mutation NN O O
in NN O O
MSH3 NN O O
was NN O O
observed NN O O
in NN O O
an NN O O
endometrial NN O B-Disease
carcinoma NN O I-Disease
and NN O O
in NN O O
an NN O O
endometrial NN O B-Disease
carcinoma NN O I-Disease
cell NN O O
line NN O O
. NN O O

Extracts NN O O
of NN O O
the NN O O
cell NN O O
line NN O O
were NN O O
deficient NN O O
in NN O O
repair NN O O
of NN O O
DNA NN O O
substrates NN O O
containing NN O O
mismatches NN O O
or NN O O
extra NN O O
nucleotides NN O O
. NN O O

Introducing NN O O
chromosome NN O O
5 NN O O
, NN O O
encoding NN O O
the NN O O
MSH3 NN O O
gene NN O O
, NN O O
into NN O O
the NN O O
mutant NN O O
cell NN O O
line NN O O
increased NN O O
the NN O O
stability NN O O
of NN O O
some NN O O
but NN O O
not NN O O
all NN O O
microsatellites NN O O
. NN O O

Extracts NN O O
of NN O O
these NN O O
cells NN O O
repaired NN O O
certain NN O O
substrates NN O O
containing NN O O
extra NN O O
nucleotides NN O O
, NN O O
but NN O O
were NN O O
deficient NN O O
in NN O O
repair NN O O
of NN O O
those NN O O
containing NN O O
mismatches NN O O
or NN O O
other NN O O
extra NN O O
nucleotides NN O O
. NN O O

A NN O O
subsequent NN O O
search NN O O
revealed NN O O
a NN O O
second NN O O
gene NN O O
mutation NN O O
in NN O O
HHUA NN O O
cells NN O O
, NN O O
a NN O O
missense NN O O
mutation NN O O
in NN O O
the NN O O
MSH6 NN O O
gene NN O O
. NN O O

Together NN O O
the NN O O
data NN O O
suggest NN O O
that NN O O
the NN O O
MSH3 NN O O
gene NN O O
encodes NN O O
a NN O O
product NN O O
that NN O O
functions NN O O
in NN O O
repair NN O O
of NN O O
some NN O O
but NN O O
not NN O O
all NN O O
pre NN O O
- NN O O
mutational NN O O
intermediates NN O O
, NN O O
its NN O O
mutation NN O O
in NN O O
tumours NN O B-Disease
can NN O O
result NN O O
in NN O O
genomic NN O O
instability NN O O
and NN O O
, NN O O
as NN O O
in NN O O
yeast NN O O
, NN O O
MSH3 NN O O
and NN O O
MSH6 NN O O
are NN O O
partially NN O O
redundant NN O O
for NN O O
mismatch NN O O
repair NN O O
. NN O O
. NN O O

Comparative NN O O
genome NN O O
mapping NN O O
of NN O O
the NN O O
ataxia NN O B-Disease
- NN O I-Disease
telangiectasia NN O I-Disease
region NN O O
in NN O O
mouse NN O O
, NN O O
rat NN O O
, NN O O
and NN O O
Syrian NN O O
hamster NN O O
. NN O O

Chromosomal NN O O
locations NN O O
of NN O O
the NN O O
Atm NN O O
( NN O O
ataxia NN O B-Disease
- NN O I-Disease
telangiectasia NN O I-Disease
( NN O O
AT NN O B-Disease
) NN O O
- NN O O
mutated NN O O
) NN O O
and NN O O
Acat1 NN O O
( NN O O
mitochondrial NN O O
acetoacetyl NN O O
- NN O O
CoA NN O O
thiolase NN O O
) NN O O
genes NN O O
in NN O O
mouse NN O O
, NN O O
rat NN O O
, NN O O
and NN O O
Syrian NN O O
hamster NN O O
were NN O O
determined NN O O
by NN O O
direct NN O O
R NN O O
- NN O O
banding NN O O
FISH NN O O
. NN O O

Both NN O O
genes NN O O
were NN O O
colocalized NN O O
to NN O O
the NN O O
C NN O O
- NN O O
D NN O O
band NN O O
of NN O O
mouse NN O O
chromosome NN O O
9 NN O O
, NN O O
the NN O O
proximal NN O O
end NN O O
of NN O O
q24 NN O O
. NN O O

1 NN O O
of NN O O
rat NN O O
chromosome NN O O
8 NN O O
, NN O O
and NN O O
qa4 NN O O
- NN O O
qa5 NN O O
of NN O O
Syrian NN O O
hamster NN O O
chromosome NN O O
12 NN O O
. NN O O

The NN O O
regions NN O O
in NN O O
the NN O O
mouse NN O O
and NN O O
rat NN O O
were NN O O
homologous NN O O
to NN O O
human NN O O
chromosome NN O O
11q NN O O
. NN O O

Fine NN O O
genetic NN O O
linkage NN O O
mapping NN O O
of NN O O
the NN O O
mouse NN O O
AT NN O B-Disease
region NN O O
was NN O O
performed NN O O
using NN O O
the NN O O
interspecific NN O O
backcross NN O O
mice NN O O
. NN O O

Atm NN O O
, NN O O
Acat1 NN O O
, NN O O
and NN O O
Npat NN O O
, NN O O
which NN O O
is NN O O
a NN O O
new NN O O
gene NN O O
isolated NN O O
from NN O O
the NN O O
AT NN O O
region NN O O
, NN O O
and NN O O
12 NN O O
flanking NN O O
microsatellite NN O O
DNA NN O O
markers NN O O
were NN O O
examined NN O O
. NN O O

No NN O O
recombinations NN O O
were NN O O
found NN O O
among NN O O
the NN O O
Atm NN O O
, NN O O
Npat NN O O
, NN O O
Acat1 NN O O
, NN O O
and NN O O
D9Mit6 NN O O
loci NN O O
, NN O O
and NN O O
these NN O O
loci NN O O
were NN O O
mapped NN O O
2 NN O O
. NN O O

0 NN O O
cM NN O O
distal NN O O
to NN O O
D9Mit99 NN O O
and NN O O
1 NN O O
. NN O O

3 NN O O
cM NN O O
proximal NN O O
to NN O O
D9Mit102 NN O O
. NN O O

Comparison NN O O
of NN O O
the NN O O
linkage NN O O
map NN O O
of NN O O
mouse NN O O
chromosome NN O O
9 NN O O
( NN O O
MMU9 NN O O
) NN O O
and NN O O
that NN O O
of NN O O
human NN O O
chromosome NN O O
11 NN O O
( NN O O
HSA11 NN O O
) NN O O
indicates NN O O
that NN O O
there NN O O
is NN O O
a NN O O
chromosomal NN O O
rearrangement NN O O
due NN O O
to NN O O
an NN O O
inversion NN O O
between NN O O
Ets1 NN O O
and NN O O
Atm NN O O
- NN O O
Npat NN O O
- NN O O
Acat1 NN O O
and NN O O
that NN O O
the NN O O
inversion NN O O
of NN O O
MMU9 NN O O
originated NN O O
from NN O O
the NN O O
chromosomal NN O O
breakage NN O O
at NN O O
the NN O O
boundary NN O O
between NN O O
Gria4 NN O O
and NN O O
Atm NN O O
- NN O O
Npat NN O O
- NN O O
Acat1 NN O O
on NN O O
HSA11 NN O O
. NN O O

This NN O O
type NN O O
of NN O O
inversion NN O O
appeared NN O O
to NN O O
be NN O O
conserved NN O O
in NN O O
the NN O O
three NN O O
rodent NN O O
species NN O O
, NN O O
mouse NN O O
, NN O O
rat NN O O
, NN O O
and NN O O
Syrian NN O O
hamster NN O O
, NN O O
using NN O O
additional NN O O
comparative NN O O
mapping NN O O
data NN O O
with NN O O
the NN O O
Rck NN O O
gene NN O O

An NN O O
animal NN O O
model NN O O
for NN O O
Norrie NN O B-Disease
disease NN O I-Disease
( NN O O
ND NN O B-Disease
) NN O O
: NN O O
gene NN O O
targeting NN O O
of NN O O
the NN O O
mouse NN O O
ND NN O B-Disease
gene NN O O
. NN O O

In NN O O
order NN O O
to NN O O
elucidate NN O O
the NN O O
cellular NN O O
and NN O O
molecular NN O O
processes NN O O
which NN O O
are NN O O
involved NN O O
in NN O O
Norrie NN O B-Disease
disease NN O I-Disease
( NN O O
ND NN O B-Disease
) NN O O
, NN O O
we NN O O
have NN O O
used NN O O
gene NN O O
targeting NN O O
technology NN O O
to NN O O
generate NN O O
ND NN O B-Disease
mutant NN O O
mice NN O O
. NN O O

The NN O O
murine NN O O
homologue NN O O
of NN O O
the NN O O
ND NN O B-Disease
gene NN O O
was NN O O
cloned NN O O
and NN O O
shown NN O O
to NN O O
encode NN O O
a NN O O
polypeptide NN O O
that NN O O
shares NN O O
94 NN O O
% NN O O
of NN O O
the NN O O
amino NN O O
acid NN O O
sequence NN O O
with NN O O
its NN O O
human NN O O
counterpart NN O O
. NN O O

RNA NN O O
in NN O O
situ NN O O
hybridization NN O O
revealed NN O O
expression NN O O
in NN O O
retina NN O O
, NN O O
brain NN O O
and NN O O
the NN O O
olfactory NN O O
bulb NN O O
and NN O O
epithelium NN O O
of NN O O
2 NN O O
week NN O O
old NN O O
mice NN O O
. NN O O

Hemizygous NN O O
mice NN O O
carrying NN O O
a NN O O
replacement NN O O
mutation NN O O
in NN O O
exon NN O O
2 NN O O
of NN O O
the NN O O
ND NN O B-Disease
gene NN O O
developed NN O O
retrolental NN O O
structures NN O O
in NN O O
the NN O O
vitreous NN O O
body NN O O
and NN O O
showed NN O O
an NN O O
overall NN O O
disorganization NN O O
of NN O O
the NN O O
retinal NN O O
ganglion NN O O
cell NN O O
layer NN O O
. NN O O

The NN O O
outer NN O O
plexiform NN O O
layer NN O O
disappears NN O O
occasionally NN O O
, NN O O
resulting NN O O
in NN O O
a NN O O
juxtaposed NN O O
inner NN O O
and NN O O
outer NN O O
nuclear NN O O
layer NN O O
. NN O O

At NN O O
the NN O O
same NN O O
regions NN O O
, NN O O
the NN O O
outer NN O O
segments NN O O
of NN O O
the NN O O
photoreceptor NN O O
cell NN O O
layer NN O O
are NN O O
no NN O O
longer NN O O
present NN O O
. NN O O

These NN O O
ocular NN O O
findings NN O O
are NN O O
consistent NN O O
with NN O O
observations NN O O
in NN O O
ND NN O B-Disease
patients NN O O
and NN O O
the NN O O
generated NN O O
mouse NN O O
line NN O O
provides NN O O
a NN O O
faithful NN O O
model NN O O
for NN O O
study NN O O
of NN O O
early NN O O
pathogenic NN O O
events NN O O
in NN O O
this NN O O
severe NN O O
X NN O B-Disease
- NN O I-Disease
linked NN O I-Disease
recessive NN O I-Disease
neurological NN O I-Disease
disorder NN O I-Disease
. NN O O
. NN O O

The NN O O
hybrid NN O O
PAX3 NN O O
- NN O O
FKHR NN O O
fusion NN O O
protein NN O O
of NN O O
alveolar NN O B-Disease
rhabdomyosarcoma NN O I-Disease
transforms NN O O
fibroblasts NN O O
in NN O O
culture NN O O
. NN O O

Pediatric NN O B-Disease
alveolar NN O I-Disease
rhabdomyosarcoma NN O I-Disease
is NN O O
characterized NN O O
by NN O O
a NN O O
chromosomal NN O O
translocation NN O O
that NN O O
fuses NN O O
parts NN O O
of NN O O
the NN O O
PAX3 NN O O
and NN O O
FKHR NN O O
genes NN O O
. NN O O

PAX3 NN O O
codes NN O O
for NN O O
a NN O O
transcriptional NN O O
regulator NN O O
that NN O O
controls NN O O
developmental NN O O
programs NN O O
, NN O O
and NN O O
FKHR NN O O
codes NN O O
for NN O O
a NN O O
forkhead NN O O
- NN O O
winged NN O O
helix NN O O
protein NN O O
, NN O O
also NN O O
a NN O O
likely NN O O
transcription NN O O
factor NN O O
. NN O O

The NN O O
PAX3 NN O O
- NN O O
FKHR NN O O
fusion NN O O
product NN O O
retains NN O O
the NN O O
DNA NN O O
binding NN O O
domains NN O O
of NN O O
the NN O O
PAX3 NN O O
protein NN O O
and NN O O
the NN O O
putative NN O O
activator NN O O
domain NN O O
of NN O O
the NN O O
FKHR NN O O
protein NN O O
. NN O O

The NN O O
PAX3 NN O O
- NN O O
FKHR NN O O
protein NN O O
has NN O O
been NN O O
shown NN O O
to NN O O
function NN O O
as NN O O
a NN O O
transcriptional NN O O
activator NN O O
. NN O O

Using NN O O
the NN O O
RCAS NN O O
retroviral NN O O
vector NN O O
, NN O O
we NN O O
have NN O O
introduced NN O O
the NN O O
PAX3 NN O O
- NN O O
FKHR NN O O
gene NN O O
into NN O O
chicken NN O O
embryo NN O O
fibroblasts NN O O
. NN O O

Expression NN O O
of NN O O
the NN O O
PAX3 NN O O
- NN O O
FKHR NN O O
protein NN O O
in NN O O
these NN O O
cells NN O O
leads NN O O
to NN O O
transformation NN O O
the NN O O
cells NN O O
become NN O O
enlarged NN O O
, NN O O
grow NN O O
tightly NN O O
packed NN O O
and NN O O
in NN O O
multiple NN O O
layers NN O O
, NN O O
and NN O O
acquire NN O O
the NN O O
ability NN O O
for NN O O
anchorage NN O O
- NN O O
independent NN O O
growth NN O O
. NN O O

This NN O O
cellular NN O O
transformation NN O O
in NN O O
vitro NN O O
will NN O O
facilitate NN O O
studies NN O O
on NN O O
the NN O O
mechanism NN O O
of NN O O
PAX3 NN O O
- NN O O
FKHR NN O O
- NN O O
induced NN O O
oncogenesis NN O O
. NN O O
. NN O O

Somatic NN O O
- NN O O
cell NN O O
selection NN O O
is NN O O
a NN O O
major NN O O
determinant NN O O
of NN O O
the NN O O
blood NN O O
- NN O O
cell NN O O
phenotype NN O O
in NN O O
heterozygotes NN O O
for NN O O
glucose NN O O
- NN O O
6 NN O O
- NN O O
phosphate NN O O
dehydrogenase NN O O
mutations NN O O
causing NN O O
severe NN O O
enzyme NN O B-Disease
deficiency NN O I-Disease
. NN O O

X NN O O
- NN O O
chromosome NN O O
inactivation NN O O
in NN O O
mammals NN O O
is NN O O
regarded NN O O
as NN O O
an NN O O
essentially NN O O
random NN O O
process NN O O
, NN O O
but NN O O
the NN O O
resulting NN O O
somatic NN O O
- NN O O
cell NN O O
mosaicism NN O O
creates NN O O
the NN O O
opportunity NN O O
for NN O O
cell NN O O
selection NN O O
. NN O O

In NN O O
most NN O O
people NN O O
with NN O O
red NN O O
- NN O O
blood NN O O
- NN O O
cell NN O O
glucose NN O B-Disease
- NN O I-Disease
6 NN O I-Disease
- NN O I-Disease
phosphate NN O I-Disease
dehydrogenase NN O I-Disease
( NN O I-Disease
G6PD NN O I-Disease
) NN O I-Disease
deficiency NN O I-Disease
, NN O O
the NN O O
enzyme NN O O
- NN O O
deficient NN O O
phenotype NN O O
is NN O O
only NN O O
moderately NN O O
expressed NN O O
in NN O O
nucleated NN O O
cells NN O O
. NN O O

However NN O O
, NN O O
in NN O O
a NN O O
small NN O O
subset NN O O
of NN O O
hemizygous NN O O
males NN O O
who NN O O
suffer NN O O
from NN O O
chronic NN O B-Disease
nonspherocytic NN O I-Disease
hemolytic NN O I-Disease
anemia NN O I-Disease
, NN O O
the NN O O
underlying NN O O
mutations NN O O
( NN O O
designated NN O O
class NN O O
I NN O O
) NN O O
cause NN O O
more NN O O
- NN O O
severe NN O O
G6PD NN O B-Disease
deficiency NN O I-Disease
, NN O O
and NN O O
this NN O O
might NN O O
provide NN O O
an NN O O
opportunity NN O O
for NN O O
selection NN O O
in NN O O
heterozygous NN O O
females NN O O
during NN O O
development NN O O
. NN O O

In NN O O
order NN O O
to NN O O
test NN O O
this NN O O
possibility NN O O
we NN O O
have NN O O
analyzed NN O O
four NN O O
heterozygotes NN O O
for NN O O
class NN O O
I NN O O
G6PD NN O O
mutations NN O O
two NN O O
with NN O O
G6PD NN O O
Portici NN O O
( NN O O
1178G NN O O
- NN O O
- NN O O
> NN O O
A NN O O
) NN O O
and NN O O
two NN O O
with NN O O
G6PD NN O O
Bari NN O O
( NN O O
1187C NN O O
- NN O O
- NN O O
> NN O O
T NN O O
) NN O O
. NN O O

We NN O O
found NN O O
that NN O O
in NN O O
fractionated NN O O
blood NN O O
cell NN O O
types NN O O
( NN O O
including NN O O
erythroid NN O O
, NN O O
myeloid NN O O
, NN O O
and NN O O
lymphoid NN O O
cell NN O O
lineages NN O O
) NN O O
there NN O O
was NN O O
a NN O O
significant NN O O
excess NN O O
of NN O O
G6PD NN O O
- NN O O
normal NN O O
cells NN O O
. NN O O

The NN O O
significant NN O O
concordance NN O O
that NN O O
we NN O O
have NN O O
observed NN O O
in NN O O
the NN O O
degree NN O O
of NN O O
imbalance NN O O
in NN O O
the NN O O
different NN O O
blood NN O O
- NN O O
cell NN O O
lineages NN O O
indicates NN O O
that NN O O
a NN O O
selective NN O O
mechanism NN O O
is NN O O
likely NN O O
to NN O O
operate NN O O
at NN O O
the NN O O
level NN O O
of NN O O
pluripotent NN O O
blood NN O O
stem NN O O
cells NN O O
. NN O O

Thus NN O O
, NN O O
it NN O O
appears NN O O
that NN O O
severe NN O O
G6PD NN O B-Disease
deficiency NN O I-Disease
affects NN O O
adversely NN O O
the NN O O
proliferation NN O O
or NN O O
the NN O O
survival NN O O
of NN O O
nucleated NN O O
blood NN O O
cells NN O O
and NN O O
that NN O O
this NN O O
phenotypic NN O O
characteristic NN O O
is NN O O
critical NN O O
during NN O O
hematopoiesis NN O O
. NN O O
. NN O O

Analysis NN O O
of NN O O
meiotic NN O O
segregation NN O O
, NN O O
using NN O O
single NN O O
- NN O O
sperm NN O O
typing NN O O
: NN O O
meiotic NN O O
drive NN O O
at NN O O
the NN O O
myotonic NN O B-Disease
dystrophy NN O I-Disease
locus NN O O
. NN O O

Meiotic NN O O
drive NN O O
at NN O O
the NN O O
myotonic NN O B-Disease
dystrophy NN O I-Disease
( NN O O
DM NN O B-Disease
) NN O O
locus NN O O
has NN O O
recently NN O O
been NN O O
suggested NN O O
as NN O O
being NN O O
responsible NN O O
for NN O O
maintaining NN O O
the NN O O
frequency NN O O
, NN O O
in NN O O
the NN O O
human NN O O
population NN O O
, NN O O
of NN O O
DM NN O B-Disease
chromosomes NN O O
capable NN O O
of NN O O
expansion NN O O
to NN O O
the NN O O
disease NN O O
state NN O O
. NN O O

In NN O O
order NN O O
to NN O O
test NN O O
this NN O O
hypothesis NN O O
, NN O O
we NN O O
have NN O O
studied NN O O
samples NN O O
of NN O O
single NN O O
sperm NN O O
from NN O O
three NN O O
individuals NN O O
heterozygous NN O O
at NN O O
the NN O O
DM NN O B-Disease
locus NN O O
, NN O O
each NN O O
with NN O O
one NN O O
allele NN O O
larger NN O O
and NN O O
one NN O O
allele NN O O
smaller NN O O
than NN O O
19 NN O O
CTG NN O O
repeats NN O O
. NN O O

To NN O O
guard NN O O
against NN O O
the NN O O
possible NN O O
problem NN O O
of NN O O
differential NN O O
PCR NN O O
amplification NN O O
rates NN O O
based NN O O
on NN O O
the NN O O
lengths NN O O
of NN O O
the NN O O
alleles NN O O
, NN O O
the NN O O
sperm NN O O
were NN O O
also NN O O
typed NN O O
at NN O O
another NN O O
closely NN O O
linked NN O O
marker NN O O
whose NN O O
allele NN O O
size NN O O
was NN O O
unrelated NN O O
to NN O O
the NN O O
allele NN O O
size NN O O
at NN O O
the NN O O
DM NN O B-Disease
locus NN O O
. NN O O

Using NN O O
statistical NN O O
models NN O O
specifically NN O O
designed NN O O
to NN O O
study NN O O
single NN O O
- NN O O
sperm NN O O
segregation NN O O
data NN O O
, NN O O
we NN O O
find NN O O
no NN O O
evidence NN O O
of NN O O
meiotic NN O O
segregation NN O O
distortion NN O O
. NN O O

The NN O O
upper NN O O
limit NN O O
of NN O O
the NN O O
two NN O O
- NN O O
sided NN O O
95 NN O O
% NN O O
confidence NN O O
interval NN O O
for NN O O
the NN O O
estimate NN O O
of NN O O
the NN O O
common NN O O
segregation NN O O
probability NN O O
for NN O O
the NN O O
three NN O O
donors NN O O
is NN O O
at NN O O
or NN O O
below NN O O
. NN O O

515 NN O O
for NN O O
all NN O O
models NN O O
considered NN O O
, NN O O
and NN O O
no NN O O
statistically NN O O
significant NN O O
difference NN O O
from NN O O
. NN O O

5 NN O O
is NN O O
detected NN O O
in NN O O
any NN O O
of NN O O
the NN O O
models NN O O
. NN O O

This NN O O
suggests NN O O
that NN O O
any NN O O
greater NN O O
amount NN O O
of NN O O
segregation NN O O
distortion NN O O
at NN O O
the NN O O
myotonic NN O B-Disease
dystrophy NN O I-Disease
locus NN O O
must NN O O
result NN O O
from NN O O
events NN O O
following NN O O
sperm NN O O
ejaculation NN O O
. NN O O

LPP NN O O
, NN O O
the NN O O
preferred NN O O
fusion NN O O
partner NN O O
gene NN O O
of NN O O
HMGIC NN O O
in NN O O
lipomas NN O B-Disease
, NN O O
is NN O O
a NN O O
novel NN O O
member NN O O
of NN O O
the NN O O
LIM NN O O
protein NN O O
gene NN O O
family NN O O
. NN O O

A NN O O
major NN O O
cytogenetic NN O O
subgroup NN O O
of NN O O
lipomas NN O B-Disease
is NN O O
characterized NN O O
by NN O O
recurrent NN O O
chromosome NN O O
aberrations NN O O
, NN O O
mainly NN O O
translocations NN O O
, NN O O
that NN O O
involve NN O O
chromosome NN O O
segment NN O O
12q13 NN O O
- NN O O
q15 NN O O
. NN O O

Multiple NN O O
chromosomes NN O O
have NN O O
been NN O O
found NN O O
as NN O O
the NN O O
translocation NN O O
partners NN O O
of NN O O
chromosome NN O O
12 NN O O
but NN O O
3q27 NN O O
- NN O O
q28 NN O O
is NN O O
preferentially NN O O
involved NN O O
. NN O O

In NN O O
previous NN O O
studies NN O O
, NN O O
it NN O O
has NN O O
been NN O O
shown NN O O
that NN O O
the NN O O
high NN O O
mobility NN O O
group NN O O
( NN O O
HMG NN O O
) NN O O
protein NN O O
gene NN O O
HMGIC NN O O
at NN O O
12q15 NN O O
is NN O O
consistently NN O O
rearranged NN O O
as NN O O
a NN O O
consequence NN O O
of NN O O
these NN O O
translocations NN O O
. NN O O

Here NN O O
, NN O O
we NN O O
report NN O O
the NN O O
identification NN O O
and NN O O
characterization NN O O
of NN O O
the NN O O
chromosome NN O O
3 NN O O
- NN O O
derived NN O O
translocation NN O O
partner NN O O
gene NN O O
, NN O O
which NN O O
we NN O O
have NN O O
designated NN O O
LPP NN O O
( NN O O
lipoma NN O B-Disease
preferred NN O O
partner NN O O
gene NN O O
) NN O O
. NN O O

Using NN O O
3 NN O O
- NN O O
RACE NN O O
analysis NN O O
of NN O O
HMGIC NN O O
fusion NN O O
transcripts NN O O
in NN O O
lipoma NN O B-Disease
cell NN O O
line NN O O
Li NN O O
- NN O O
501 NN O O
/ NN O O
SV40 NN O O
, NN O O
ectopic NN O O
genetic NN O O
sequences NN O O
were NN O O
obtained NN O O
, NN O O
which NN O O
by NN O O
CASH NN O O
( NN O O
chromosome NN O O
assignment NN O O
using NN O O
somatic NN O O
cell NN O O
hybrids NN O O
) NN O O
and NN O O
FISH NN O O
( NN O O
fluorescence NN O O
in NN O O
situ NN O O
hybridization NN O O
) NN O O
analysis NN O O
were NN O O
found NN O O
to NN O O
originate NN O O
from NN O O
chromosome NN O O
segment NN O O
3q27 NN O O
- NN O O
q28 NN O O
. NN O O

In NN O O
Northern NN O O
blot NN O O
analysis NN O O
, NN O O
an NN O O
mRNA NN O O
of NN O O
over NN O O
10 NN O O
kb NN O O
was NN O O
detected NN O O
by NN O O
these NN O O
ectopic NN O O
sequences NN O O
in NN O O
a NN O O
variety NN O O
of NN O O
human NN O O
tissues NN O O
but NN O O
not NN O O
in NN O O
brain NN O O
and NN O O
peripheral NN O O
blood NN O O
leukocytes NN O O
. NN O O

Upon NN O O
partial NN O O
cDNA NN O O
cloning NN O O
, NN O O
features NN O O
of NN O O
the NN O O
genetic NN O O
organization NN O O
of NN O O
LPP NN O O
were NN O O
established NN O O
. NN O O

The NN O O
gene NN O O
was NN O O
found NN O O
to NN O O
span NN O O
a NN O O
genomic NN O O
region NN O O
of NN O O
over NN O O
400 NN O O
kb NN O O
. NN O O

Nucleotide NN O O
sequence NN O O
analysis NN O O
of NN O O
a NN O O
composite NN O O
cDNA NN O O
of NN O O
LPP NN O O
revealed NN O O
an NN O O
open NN O O
reading NN O O
frame NN O O
of NN O O
1836 NN O O
nucleotides NN O O
encoding NN O O
a NN O O
proline NN O O
- NN O O
rich NN O O
protein NN O O
containing NN O O
a NN O O
leucine NN O O
- NN O O
zipper NN O O
motif NN O O
in NN O O
its NN O O
amino NN O O
- NN O O
terminal NN O O
region NN O O
and NN O O
three NN O O
LIM NN O O
domains NN O O
in NN O O
its NN O O
carboxy NN O O
- NN O O
terminal NN O O
region NN O O
. NN O O

The NN O O
LPP NN O O
- NN O O
encoded NN O O
protein NN O O
should NN O O
be NN O O
classified NN O O
as NN O O
a NN O O
novel NN O O
member NN O O
of NN O O
the NN O O
group NN O O
3 NN O O
proteins NN O O
of NN O O
the NN O O
LIM NN O O
protein NN O O
gene NN O O
family NN O O
. NN O O

Using NN O O
reverse NN O O
transcriptase NN O O
combined NN O O
with NN O O
polymerase NN O O
chain NN O O
reactions NN O O
in NN O O
the NN O O
analysis NN O O
of NN O O
a NN O O
number NN O O
of NN O O
lipoma NN O B-Disease
cell NN O O
lines NN O O
and NN O O
primary NN O B-Disease
lipomas NN O I-Disease
, NN O O
it NN O O
appeared NN O O
that NN O O
LPP NN O O
is NN O O
frequently NN O O
rearranged NN O O
also NN O O
in NN O O
cases NN O O
without NN O O
a NN O O
cytogenetically NN O O
detectable NN O O
involvement NN O O
of NN O O
3q27 NN O O
- NN O O
q28 NN O O
. NN O O

Two NN O O
alternative NN O O
HMGIC NN O O
/ NN O O
LPP NN O O
hybrid NN O O
transcripts NN O O
have NN O O
been NN O O
detected NN O O
; NN O O
the NN O O
difference NN O O
between NN O O
them NN O O
is NN O O
mainly NN O O
the NN O O
presence NN O O
of NN O O
either NN O O
two NN O O
or NN O O
three NN O O
LIM NN O O
domains NN O O
in NN O O
the NN O O
predicted NN O O
HMGI NN O O
- NN O O
C NN O O
/ NN O O
LPP NN O O
fusion NN O O
proteins NN O O
. NN O O
. NN O O

Absence NN O O
of NN O O
disease NN O O
phenotype NN O O
and NN O O
intergenerational NN O O
stability NN O O
of NN O O
the NN O O
CAG NN O O
repeat NN O O
in NN O O
transgenic NN O O
mice NN O O
expressing NN O O
the NN O O
human NN O O
Huntington NN O B-Disease
disease NN O I-Disease
transcript NN O O
. NN O O

The NN O O
mutation NN O O
underlying NN O O
Huntington NN O B-Disease
disease NN O I-Disease
( NN O O
HD NN O B-Disease
) NN O O
is NN O O
CAG NN O O
expansion NN O O
in NN O O
the NN O O
first NN O O
exon NN O O
of NN O O
the NN O O
HD NN O B-Disease
gene NN O O
. NN O O

In NN O O
order NN O O
to NN O O
investigate NN O O
the NN O O
role NN O O
of NN O O
CAG NN O O
expansion NN O O
in NN O O
the NN O O
pathogenesis NN O O
of NN O O
HD NN O B-Disease
, NN O O
we NN O O
have NN O O
produced NN O O
transgenic NN O O
mice NN O O
containing NN O O
the NN O O
full NN O O
length NN O O
human NN O O
HD NN O B-Disease
cDNA NN O O
with NN O O
44 NN O O
CAG NN O O
repeats NN O O
. NN O O

By NN O O
1 NN O O
year NN O O
, NN O O
these NN O O
mice NN O O
have NN O O
no NN O O
behavioral NN O B-Disease
abnormalities NN O I-Disease
and NN O O
morphometric NN O O
analysis NN O O
at NN O O
6 NN O O
( NN O O
one NN O O
animal NN O O
) NN O O
and NN O O
9 NN O O
( NN O O
two NN O O
animals NN O O
) NN O O
months NN O O
age NN O O
revealed NN O O
no NN O O
changes NN O O
. NN O O

Despite NN O O
high NN O O
levels NN O O
of NN O O
mRNA NN O O
expression NN O O
, NN O O
there NN O O
was NN O O
no NN O O
evidence NN O O
of NN O O
the NN O O
HD NN O B-Disease
gene NN O O
product NN O O
in NN O O
any NN O O
of NN O O
these NN O O
transgenic NN O O
mice NN O O
. NN O O

In NN O O
vitro NN O O
transfection NN O O
studies NN O O
indicated NN O O
that NN O O
the NN O O
inclusion NN O O
of NN O O
120 NN O O
bp NN O O
of NN O O
the NN O O
5 NN O O
UTR NN O O
in NN O O
the NN O O
cDNA NN O O
construct NN O O
and NN O O
the NN O O
presence NN O O
of NN O O
a NN O O
frameshift NN O O
mutation NN O O
at NN O O
nucleotide NN O O
2349 NN O O
prevented NN O O
expression NN O O
of NN O O
the NN O O
HD NN O B-Disease
cDNA NN O O
. NN O O

These NN O O
findings NN O O
suggest NN O O
that NN O O
the NN O O
pathogenesis NN O O
of NN O O
HD NN O B-Disease
is NN O O
not NN O O
mediated NN O O
through NN O O
DNA NN O O
- NN O O
protein NN O O
interaction NN O O
and NN O O
that NN O O
presence NN O O
of NN O O
the NN O O
RNA NN O O
transcript NN O O
with NN O O
an NN O O
expanded NN O O
CAG NN O O
repeat NN O O
is NN O O
insufficient NN O O
to NN O O
cause NN O O
the NN O O
disease NN O O
. NN O O

Rather NN O O
, NN O O
translation NN O O
of NN O O
the NN O O
CAG NN O O
is NN O O
crucial NN O O
for NN O O
the NN O O
pathogenesis NN O O
of NN O O
HD NN O B-Disease
. NN O O

In NN O O
contrast NN O O
to NN O O
that NN O O
seen NN O O
in NN O O
humans NN O O
, NN O O
the NN O O
CAG NN O O
repeat NN O O
in NN O O
these NN O O
mice NN O O
was NN O O
remarkably NN O O
stable NN O O
in NN O O
97 NN O O
meioses NN O O
. NN O O

This NN O O
suggests NN O O
that NN O O
genomic NN O O
sequences NN O O
may NN O O
play NN O O
a NN O O
critical NN O O
role NN O O
in NN O O
influencing NN O O
repeat NN O O
instability NN O O
. NN O O
. NN O O

FISH NN O O
studies NN O O
in NN O O
a NN O O
patient NN O O
with NN O O
sporadic NN O B-Disease
aniridia NN O I-Disease
and NN O O
t NN O O
( NN O O
7 NN O O
; NN O O
11 NN O O
) NN O O
( NN O O
q31 NN O O
. NN O O
2 NN O O
; NN O O
p13 NN O O
) NN O O
. NN O O

A NN O O
2 NN O O
year NN O O
old NN O O
female NN O O
presenting NN O O
with NN O O
bilateral NN O B-Disease
sporadic NN O I-Disease
aniridia NN O I-Disease
was NN O O
found NN O O
to NN O O
have NN O O
an NN O O
apparently NN O O
balanced NN O O
reciprocal NN O O
translocation NN O O
with NN O O
a NN O O
chromosome NN O O
11 NN O O
breakpoint NN O O
within NN O O
band NN O O
p13 NN O O
. NN O O

Fluorescence NN O O
in NN O O
situ NN O O
hybridisation NN O O
( NN O O
FISH NN O O
) NN O O
studies NN O O
with NN O O
distal NN O O
11p13 NN O O
specific NN O O
cosmids NN O O
showed NN O O
that NN O O
the NN O O
chromosome NN O O
11 NN O O
breakpoint NN O O
lay NN O O
between NN O O
the NN O O
aniridia NN O B-Disease
( NN O O
PAX6 NN O O
) NN O O
locus NN O O
and NN O O
a NN O O
region NN O O
approximately NN O O
100 NN O O
kb NN O O
distal NN O O
to NN O O
PAX6 NN O O
defined NN O O
by NN O O
the NN O O
cosmid NN O O
FO2121 NN O O
. NN O O

Although NN O O
this NN O O
patient NN O O
did NN O O
not NN O O
have NN O O
a NN O O
detectable NN O O
deletion NN O O
within NN O O
PAX6 NN O O
, NN O O
her NN O O
aniridia NN O B-Disease
may NN O O
have NN O O
resulted NN O O
from NN O O
a NN O O
disruption NN O O
of NN O O
the NN O O
distal NN O O
chromatin NN O O
domain NN O O
containing NN O O
either NN O O
enhancers NN O O
or NN O O
regulators NN O O
for NN O O
PAX6 NN O O
. NN O O

This NN O O
case NN O O
may NN O O
therefore NN O O
be NN O O
another NN O O
example NN O O
of NN O O
aniridia NN O B-Disease
caused NN O O
by NN O O
a NN O O
position NN O O
effect NN O O
as NN O O
recently NN O O
described NN O O
in NN O O
two NN O O
familial NN O B-Disease
aniridia NN O I-Disease
patients NN O O
in NN O O
which NN O O
the NN O O
phenotype NN O O
cosegregated NN O O
with NN O O
chromosome NN O B-Disease
abnormalities NN O I-Disease
with NN O O
11p13 NN O O
breakpoints NN O O
. NN O O
. NN O O

Muscle NN O O
expression NN O O
of NN O O
glucose NN O B-Disease
- NN O I-Disease
6 NN O I-Disease
- NN O I-Disease
phosphate NN O I-Disease
dehydrogenase NN O I-Disease
deficiency NN O I-Disease
in NN O O
different NN O O
variants NN O O
. NN O O

Muscle NN O O
expression NN O O
of NN O O
G6PD NN O B-Disease
deficiency NN O I-Disease
has NN O O
been NN O O
investigated NN O O
in NN O O
Mediterranean NN O O
, NN O O
Seattle NN O O
- NN O O
like NN O O
and NN O O
A NN O O
- NN O O
variants NN O O
. NN O O

G6PD NN O O
activity NN O O
was NN O O
detected NN O O
in NN O O
samples NN O O
obtained NN O O
from NN O O
biopsies NN O O
on NN O O
the NN O O
quadriceps NN O O
muscle NN O O
of NN O O
seven NN O O
males NN O O
and NN O O
one NN O O
female NN O O
. NN O O

The NN O O
type NN O O
of NN O O
genetic NN O O
variant NN O O
was NN O O
determined NN O O
by NN O O
molecular NN O O
analysis NN O O
of NN O O
DNA NN O O
, NN O O
extracted NN O O
from NN O O
blood NN O O
samples NN O O
. NN O O

All NN O O
variants NN O O
showed NN O O
the NN O O
enzyme NN O O
defect NN O O
in NN O O
muscle NN O O
. NN O O

A NN O O
statistically NN O O
significant NN O O
relationship NN O O
was NN O O
found NN O O
in NN O O
the NN O O
activity NN O O
of NN O O
G6PD NN O O
between NN O O
erythrocytes NN O O
and NN O O
muscle NN O O
of NN O O
the NN O O
male NN O O
subjects NN O O
( NN O O
r NN O O
= NN O O
0 NN O O
. NN O O
968 NN O O
; NN O O
p NN O O
= NN O O
0 NN O O
. NN O O
00008 NN O O
) NN O O
. NN O O

The NN O O
equation NN O O
for NN O O
the NN O O
best NN O O
fit NN O O
line NN O O
was NN O O
Y NN O O
= NN O O
0 NN O O
. NN O O

390X NN O O
+ NN O O
0 NN O O
. NN O O

198 NN O O
198 NN O O
. NN O O

The NN O O
results NN O O
suggest NN O O
that NN O O
, NN O O
for NN O O
a NN O O
given NN O O
variant NN O O
, NN O O
the NN O O
extent NN O O
of NN O O
the NN O O
enzyme NN O O
defect NN O O
in NN O O
muscle NN O O
may NN O O
be NN O O
determined NN O O
, NN O O
using NN O O
this NN O O
equation NN O O
, NN O O
from NN O O
the NN O O
G6PD NN O O
activity NN O O
of NN O O
erythrocytes NN O O

Gene NN O O
therapy NN O O
for NN O O
phenylketonuria NN O B-Disease
. NN O O

Classical NN O O
phenylketonuria NN O B-Disease
( NN O O
PKU NN O B-Disease
) NN O O
is NN O O
an NN O O
autosomal NN O B-Disease
recessive NN O I-Disease
disorder NN O I-Disease
caused NN O O
by NN O O
a NN O O
deficiency NN O B-Disease
of NN O I-Disease
hepatic NN O I-Disease
phenylalanine NN O I-Disease
hydroxylase NN O I-Disease
( NN O O
PAH NN O O
) NN O O
. NN O O

Limitations NN O O
of NN O O
the NN O O
current NN O O
dietary NN O O
treatment NN O O
for NN O O
PKU NN O B-Disease
have NN O O
led NN O O
to NN O O
the NN O O
development NN O O
of NN O O
potential NN O O
treatments NN O O
based NN O O
on NN O O
somatic NN O O
gene NN O O
transfer NN O O
. NN O O

Three NN O O
different NN O O
vector NN O O
systems NN O O
have NN O O
been NN O O
examined NN O O
. NN O O

Vectors NN O O
derived NN O O
from NN O O
a NN O O
recombinant NN O O
retrovirus NN O O
or NN O O
a NN O O
DNA NN O O
/ NN O O
protein NN O O
complex NN O O
can NN O O
efficiently NN O O
transduce NN O O
the NN O O
PAH NN O O
cDNA NN O O
into NN O O
PAH NN O B-Disease
- NN O I-Disease
deficient NN O I-Disease
hepatocytes NN O O
in NN O O
vitro NN O O
, NN O O
but NN O O
the NN O O
application NN O O
of NN O O
these NN O O
vector NN O O
systems NN O O
is NN O O
presently NN O O
limited NN O O
by NN O O
their NN O O
low NN O O
transduction NN O O
efficiency NN O O
in NN O O
vivo NN O O
. NN O O

In NN O O
contrast NN O O
, NN O O
a NN O O
vector NN O O
derived NN O O
from NN O O
a NN O O
recombinant NN O O
adenovirus NN O O
can NN O O
restore NN O O
10 NN O O
% NN O O
- NN O O
80 NN O O
% NN O O
of NN O O
normal NN O O
hepatic NN O O
PAH NN O O
activity NN O O
into NN O O
PAH NN O B-Disease
- NN O I-Disease
deficient NN O I-Disease
mice NN O O
, NN O O
which NN O O
completely NN O O
normalizes NN O O
serum NN O O
phenylalanine NN O O
levels NN O O
. NN O O

This NN O O
treatment NN O O
is NN O O
transient NN O O
and NN O O
cannot NN O O
be NN O O
effectively NN O O
re NN O O
- NN O O
administered NN O O
due NN O O
to NN O O
the NN O O
presence NN O O
of NN O O
neutralizing NN O O
antibodies NN O O
directed NN O O
against NN O O
the NN O O
recombinant NN O O
adenoviral NN O O
vector NN O O
. NN O O

However NN O O
, NN O O
these NN O O
findings NN O O
suggest NN O O
that NN O O
PKU NN O B-Disease
can NN O O
be NN O O
completely NN O O
corrected NN O O
by NN O O
somatic NN O O
gene NN O O
therapy NN O O
, NN O O
and NN O O
provide NN O O
some NN O O
direction NN O O
for NN O O
the NN O O
future NN O O
development NN O O
of NN O O
adenoviral NN O O
vectors NN O O
. NN O O
. NN O O

Exon NN O O
- NN O O
intron NN O O
structure NN O O
of NN O O
the NN O O
human NN O O
neuronal NN O O
nicotinic NN O O
acetylcholine NN O O
receptor NN O O
alpha NN O O
4 NN O O
subunit NN O O
( NN O O
CHRNA4 NN O O
) NN O O
. NN O O

The NN O O
human NN O O
neuronal NN O O
nicotinic NN O O
acetylcholine NN O O
receptor NN O O
alpha NN O O
4 NN O O
subunit NN O O
gene NN O O
( NN O O
CHRNA4 NN O O
) NN O O
is NN O O
located NN O O
in NN O O
the NN O O
candidate NN O O
region NN O O
for NN O O
three NN O O
different NN O O
phenotypes NN O O
benign NN O B-Disease
familial NN O I-Disease
neonatal NN O I-Disease
convulsions NN O I-Disease
, NN O O
autosomal NN O B-Disease
dominant NN O I-Disease
nocturnal NN O I-Disease
frontal NN O I-Disease
lobe NN O I-Disease
epilepsy NN O I-Disease
, NN O O
and NN O O
low NN O O
- NN O O
voltage NN O O
EEG NN O O
. NN O O

Recently NN O O
, NN O O
a NN O O
missense NN O O
mutation NN O O
in NN O O
transmembrane NN O O
domain NN O O
2 NN O O
of NN O O
CHRNA4 NN O O
was NN O O
found NN O O
to NN O O
be NN O O
associated NN O O
with NN O O
autosomal NN O B-Disease
dominant NN O I-Disease
nocturnal NN O I-Disease
frontal NN O I-Disease
lobe NN O I-Disease
epilepsy NN O I-Disease
in NN O O
one NN O O
extended NN O O
pedigree NN O O
. NN O O

We NN O O
have NN O O
determined NN O O
the NN O O
genomic NN O O
organization NN O O
of NN O O
CHRNA4 NN O O
, NN O O
which NN O O
consists NN O O
of NN O O
six NN O O
exons NN O O
distributed NN O O
over NN O O
approximately NN O O
17 NN O O
kb NN O O
of NN O O
genomic NN O O
DNA NN O O
. NN O O

The NN O O
nucleotide NN O O
sequence NN O O
obtained NN O O
from NN O O
the NN O O
genomic NN O O
regions NN O O
adjacent NN O O
to NN O O
the NN O O
exon NN O O
boundaries NN O O
enabled NN O O
us NN O O
to NN O O
develop NN O O
a NN O O
set NN O O
of NN O O
primer NN O O
pairs NN O O
for NN O O
PCR NN O O
amplification NN O O
of NN O O
the NN O O
complete NN O O
coding NN O O
region NN O O
. NN O O

The NN O O
sequence NN O O
analysis NN O O
provides NN O O
the NN O O
basis NN O O
for NN O O
a NN O O
comprehensive NN O O
mutation NN O O
screening NN O O
of NN O O
CHRNA4 NN O O
in NN O O
the NN O O
above NN O O
- NN O O
mentioned NN O O
phenotypes NN O O
and NN O O
possibly NN O O
in NN O O
other NN O O
types NN O O
of NN O O
idiopathic NN O B-Disease
epilepsies NN O I-Disease
. NN O O
. NN O O

Ashkenazi NN O O
Jewish NN O O
population NN O O
frequencies NN O O
for NN O O
common NN O O
mutations NN O O
in NN O O
BRCA1 NN O O
and NN O O
BRCA2 NN O O
. NN O O

BRCA1 NN O O
and NN O O
BRCA2 NN O O
are NN O O
the NN O O
two NN O O
major NN O O
identified NN O O
causes NN O O
of NN O O
inherited NN O B-Disease
breast NN O I-Disease
cancer NN O I-Disease
, NN O O
with NN O O
mutations NN O O
in NN O O
either NN O O
gene NN O O
conferring NN O O
up NN O O
to NN O O
80 NN O O
- NN O O
90 NN O O
% NN O O
lifetime NN O O
risk NN O O
of NN O O
breast NN O B-Disease
cancer NN O I-Disease
in NN O O
carrier NN O O
females NN O O
. NN O O

Mutations NN O O
in NN O O
BRCA1 NN O O
account NN O O
for NN O O
approximately NN O O
45 NN O O
% NN O O
of NN O O
familial NN O B-Disease
breast NN O I-Disease
cancer NN O I-Disease
and NN O O
90 NN O O
% NN O O
of NN O O
inherited NN O B-Disease
breast NN O I-Disease
/ NN O I-Disease
ovarian NN O I-Disease
cancer NN O I-Disease
, NN O O
whereas NN O O
mutations NN O O
in NN O O
BRCA2 NN O O
account NN O O
for NN O O
a NN O O
comparable NN O O
percentage NN O O
of NN O O
inherited NN O B-Disease
breast NN O I-Disease
cancer NN O I-Disease
cases NN O O
. NN O O

Over NN O O
85 NN O O
distinct NN O O
BRCA1 NN O O
mutations NN O O
and NN O O
a NN O O
growing NN O O
list NN O O
of NN O O
BRCA2 NN O O
mutations NN O O
have NN O O
been NN O O
identified NN O O
, NN O O
with NN O O
the NN O O
majority NN O O
resulting NN O O
in NN O O
protein NN O O
truncation NN O O
. NN O O

A NN O O
specific NN O O
BRCA1 NN O O
mutation NN O O
, NN O O
185delAG NN O O
, NN O O
has NN O O
a NN O O
reported NN O O
increased NN O O
carrier NN O O
frequency NN O O
of NN O O
approximately NN O O
0 NN O O
. NN O O

9 NN O O
% NN O O
in NN O O
the NN O O
Ashkenazi NN O O
Jewish NN O O
population NN O O
, NN O O
but NN O O
is NN O O
also NN O O
found NN O O
in NN O O
rare NN O O
non NN O O
- NN O O
Jewish NN O O
patients NN O O
with NN O O
a NN O O
different NN O O
haplotype NN O O
. NN O O

The NN O O
6174delT NN O O
mutation NN O O
in NN O O
BRCA2 NN O O
was NN O O
recently NN O O
identified NN O O
as NN O O
a NN O O
frequent NN O O
mutation NN O O
in NN O O
8 NN O O
out NN O O
of NN O O
107 NN O O
Ashkenazi NN O O
Jewish NN O O
women NN O O
diagnosed NN O O
with NN O O
breast NN O B-Disease
cancer NN O I-Disease
by NN O O
age NN O O
50 NN O O
( NN O O
ref NN O O
. NN O O
8 NN O O
) NN O O
, NN O O
as NN O O
well NN O O
as NN O O
in NN O O
three NN O O
Ashkenazi NN O O
male NN O B-Disease
breast NN O I-Disease
cancer NN O I-Disease
patients NN O O
. NN O O

We NN O O
have NN O O
conducted NN O O
a NN O O
large NN O O
- NN O O
scale NN O O
population NN O O
study NN O O
to NN O O
investigate NN O O
the NN O O
prevalence NN O O
of NN O O
specific NN O O
BRCA1 NN O O
and NN O O
BRCA2 NN O O
mutations NN O O
in NN O O
Ashkenazi NN O O
Jewish NN O O
individuals NN O O
who NN O O
were NN O O
unselected NN O O
for NN O O
breast NN O B-Disease
cancer NN O I-Disease
. NN O O

BRCA1 NN O O
mutation NN O O
screening NN O O
on NN O O
approximately NN O O
3 NN O O
, NN O O
000 NN O O
Ashkenazi NN O O
Jewish NN O O
samples NN O O
determined NN O O
a NN O O
carrier NN O O
frequency NN O O
of NN O O
1 NN O O
. NN O O

09 NN O O
% NN O O
for NN O O
the NN O O
185delAG NN O O
mutation NN O O
and NN O O
0 NN O O
. NN O O

13 NN O O
% NN O O
for NN O O
the NN O O
5382insC NN O O
mutation NN O O
. NN O O

BRCA2 NN O O
analysis NN O O
on NN O O
3 NN O O
, NN O O
085 NN O O
individuals NN O O
from NN O O
the NN O O
same NN O O
population NN O O
showed NN O O
a NN O O
carrier NN O O
frequency NN O O
of NN O O
1 NN O O
. NN O O

52 NN O O
% NN O O
for NN O O
the NN O O
6174delT NN O O
mutation NN O O
. NN O O

This NN O O
expanded NN O O
population NN O O
- NN O O
based NN O O
study NN O O
confirms NN O O
that NN O O
the NN O O
BRCA1 NN O O
185delAG NN O O
mutation NN O O
and NN O O
the NN O O
BRCA2 NN O O
6174delT NN O O
mutation NN O O
constitute NN O O
the NN O O
two NN O O
most NN O O
frequent NN O O
mutation NN O O
alleles NN O O
predisposing NN O O
to NN O O
hereditary NN O B-Disease
breast NN O I-Disease
cancer NN O I-Disease
among NN O O
the NN O O
Ashkenazim NN O O
, NN O O
and NN O O
suggests NN O O
a NN O O
relatively NN O O
lower NN O O
penetrance NN O O
for NN O O
the NN O O
6174delT NN O O
mutation NN O O
in NN O O
BRCA2 NN O O

Dual NN O O
roles NN O O
of NN O O
ATM NN O O
in NN O O
the NN O O
cellular NN O O
response NN O O
to NN O O
radiation NN O O
and NN O O
in NN O O
cell NN O O
growth NN O O
control NN O O
. NN O O

The NN O O
gene NN O O
mutated NN O O
in NN O O
ataxia NN O B-Disease
- NN O I-Disease
telangiectasia NN O I-Disease
( NN O O
AT NN O B-Disease
) NN O O
patients NN O O
, NN O O
denoted NN O O
ATM NN O O
, NN O O
encodes NN O O
a NN O O
putative NN O O
protein NN O O
or NN O O
lipid NN O O
kinase NN O O
. NN O O

To NN O O
elucidate NN O O
the NN O O
functions NN O O
of NN O O
ATM NN O O
, NN O O
we NN O O
disrupted NN O O
the NN O O
mouse NN O O
ATM NN O O
gene NN O O
through NN O O
homologous NN O O
recombination NN O O
in NN O O
mice NN O O
. NN O O

Consistent NN O O
with NN O O
cellular NN O O
defects NN O O
of NN O O
AT NN O B-Disease
patients NN O O
, NN O O
the NN O O
ATM NN O O
- NN O O
/ NN O O
- NN O O
cells NN O O
are NN O O
hypersensitive NN O O
to NN O O
gamma NN O O
- NN O O
irradiation NN O O
and NN O O
defective NN O O
in NN O O
cell NN O O
- NN O O
cycle NN O O
arrest NN O O
following NN O O
radiation NN O O
, NN O O
correlating NN O O
with NN O O
a NN O O
defective NN O O
up NN O O
- NN O O
regulation NN O O
of NN O O
p53 NN O O
. NN O O

In NN O O
addition NN O O
, NN O O
ATM NN O O
- NN O O
/ NN O O
- NN O O
mouse NN O O
thymocytes NN O O
are NN O O
more NN O O
resistant NN O O
to NN O O
apoptosis NN O O
induced NN O O
by NN O O
gamma NN O O
- NN O O
irradiation NN O O
than NN O O
normal NN O O
thymocytes NN O O
. NN O O

ATM NN O O
- NN O O
/ NN O O
- NN O O
fibroblasts NN O O
are NN O O
inefficient NN O O
in NN O O
G1 NN O O
to NN O O
S NN O O
- NN O O
phase NN O O
progression NN O O
following NN O O
serum NN O O
stimulation NN O O
and NN O O
senesce NN O O
after NN O O
only NN O O
a NN O O
few NN O O
passages NN O O
in NN O O
culture NN O O
. NN O O

They NN O O
have NN O O
an NN O O
increased NN O O
constitutive NN O O
level NN O O
of NN O O
p21CP1 NN O O
/ NN O O
WAF1 NN O O
. NN O O

The NN O O
ATM NN O O
protein NN O O
is NN O O
therefore NN O O
critical NN O O
both NN O O
for NN O O
cellular NN O O
responses NN O O
to NN O O
ionizing NN O O
radiation NN O O
and NN O O
for NN O O
normal NN O O
cell NN O O
- NN O O
cycle NN O O
progression NN O O
. NN O O

ATM NN O O
+ NN O O
/ NN O O
- NN O O
fibroblasts NN O O
and NN O O
thymocytes NN O O
showed NN O O
intermediately NN O O
defective NN O O
responses NN O O
to NN O O
irradiation NN O O
but NN O O
no NN O O
growth NN O O
defect NN O O
, NN O O
suggesting NN O O
that NN O O
the NN O O
increased NN O O
cancer NN O B-Disease
risk NN O O
of NN O O
AT NN O B-Disease
heterozygotes NN O O
could NN O O
be NN O O
attributable NN O O
to NN O O
poor NN O O
checkpoint NN O O
function NN O O
. NN O O
. NN O O

Targeted NN O O
disruption NN O O
of NN O O
ATM NN O O
leads NN O O
to NN O O
growth NN O B-Disease
retardation NN O I-Disease
, NN O O
chromosomal NN O B-Disease
fragmentation NN O I-Disease
during NN O I-Disease
meiosis NN O I-Disease
, NN O O
immune NN O B-Disease
defects NN O I-Disease
, NN O O
and NN O O
thymic NN O B-Disease
lymphoma NN O I-Disease
. NN O O

ATM NN O O
, NN O O
the NN O O
gene NN O O
mutated NN O O
in NN O O
the NN O O
inherited NN O B-Disease
human NN O I-Disease
disease NN O I-Disease
ataxia NN O B-Disease
- NN O I-Disease
telangiectasia NN O I-Disease
, NN O O
is NN O O
a NN O O
member NN O O
of NN O O
a NN O O
family NN O O
of NN O O
kinases NN O O
involved NN O O
in NN O O
DNA NN O O
metabolism NN O O
and NN O O
cell NN O O
- NN O O
cycle NN O O
checkpoint NN O O
control NN O O
. NN O O

To NN O O
help NN O O
clarify NN O O
the NN O O
physiological NN O O
roles NN O O
of NN O O
the NN O O
ATM NN O O
protein NN O O
, NN O O
we NN O O
disrupted NN O O
the NN O O
ATM NN O O
gene NN O O
in NN O O
mice NN O O
through NN O O
homologous NN O O
recombination NN O O
. NN O O

Initial NN O O
evaluation NN O O
of NN O O
the NN O O
ATM NN O O
knockout NN O O
animals NN O O
indicates NN O O
that NN O O
inactivation NN O O
of NN O O
the NN O O
mouse NN O O
ATM NN O O
gene NN O O
recreates NN O O
much NN O O
of NN O O
the NN O O
phenotype NN O O
of NN O O
ataxia NN O B-Disease
- NN O I-Disease
telangiectasia NN O I-Disease
. NN O O

The NN O O
homozygous NN O O
mutant NN O O
( NN O O
ATM NN O O
- NN O O
/ NN O O
- NN O O
) NN O O
mice NN O O
are NN O O
viable NN O O
, NN O O
growth NN O O
- NN O O
retarded NN O O
, NN O O
and NN O O
infertile NN O O
. NN O O

The NN O O
infertility NN O B-Disease
of NN O O
ATM NN O O
- NN O O
/ NN O O
- NN O O
mice NN O O
results NN O O
from NN O O
meiotic NN O O
failure NN O O
. NN O O

Meiosis NN O O
is NN O O
arrested NN O O
at NN O O
the NN O O
zygotene NN O O
/ NN O O
pachytene NN O O
stage NN O O
of NN O O
prophase NN O O
I NN O O
as NN O O
a NN O O
result NN O O
of NN O O
abnormal NN O O
chromosomal NN O O
synapsis NN O O
and NN O O
subsequent NN O O
chromosome NN O O
fragmentation NN O O
. NN O O

Immune NN O B-Disease
defects NN O I-Disease
also NN O O
are NN O O
evident NN O O
in NN O O
ATM NN O O
- NN O O
/ NN O O
- NN O O
mice NN O O
, NN O O
including NN O O
reduced NN O O
numbers NN O O
of NN O O
B220 NN O O
+ NN O O
CD43 NN O O
- NN O O
pre NN O O
- NN O O
B NN O O
cells NN O O
, NN O O
thymocytes NN O O
, NN O O
and NN O O
peripheral NN O O
T NN O O
cells NN O O
, NN O O
as NN O O
well NN O O
as NN O O
functional NN O O
impairment NN O O
of NN O O
T NN O O
- NN O O
cell NN O O
- NN O O
dependent NN O O
immune NN O O
responses NN O O
. NN O O

The NN O O
cerebella NN O O
of NN O O
ATM NN O O
- NN O O
/ NN O O
- NN O O
mice NN O O
appear NN O O
normal NN O O
by NN O O
histologic NN O O
examination NN O O
at NN O O
3 NN O O
to NN O O
4 NN O O
months NN O O
and NN O O
the NN O O
mice NN O O
have NN O O
no NN O O
gross NN O O
behavioral NN O B-Disease
abnormalities NN O I-Disease
. NN O O

The NN O O
majority NN O O
of NN O O
mutant NN O O
mice NN O O
rapidly NN O O
develop NN O O
thymic NN O B-Disease
lymphomas NN O I-Disease
and NN O O
die NN O O
before NN O O
4 NN O O
months NN O O
of NN O O
age NN O O
. NN O O

These NN O O
findings NN O O
indicate NN O O
that NN O O
the NN O O
ATM NN O O
gene NN O O
product NN O O
plays NN O O
an NN O O
essential NN O O
role NN O O
in NN O O
a NN O O
diverse NN O O
group NN O O
of NN O O
cellular NN O O
processes NN O O
, NN O O
including NN O O
meiosis NN O O
, NN O O
the NN O O
normal NN O O
growth NN O O
of NN O O
somatic NN O O
tissues NN O O
, NN O O
immune NN O O
development NN O O
, NN O O
and NN O O
tumor NN O B-Disease
suppression NN O O
. NN O O
. NN O O

Cloning NN O O
and NN O O
characterization NN O O
of NN O O
human NN O O
very NN O O
- NN O O
long NN O O
- NN O O
chain NN O O
acyl NN O O
- NN O O
CoA NN O O
dehydrogenase NN O O
cDNA NN O O
, NN O O
chromosomal NN O O
assignment NN O O
of NN O O
the NN O O
gene NN O O
and NN O O
identification NN O O
in NN O O
four NN O O
patients NN O O
of NN O O
nine NN O O
different NN O O
mutations NN O O
within NN O O
the NN O O
VLCAD NN O O
gene NN O O
. NN O O

Very NN O O
- NN O O
long NN O O
- NN O O
chain NN O O
acyl NN O O
- NN O O
CoA NN O O
dehydrogenase NN O O
( NN O O
VLCAD NN O O
) NN O O
is NN O O
one NN O O
of NN O O
four NN O O
straight NN O O
- NN O O
chain NN O O
acyl NN O O
- NN O O
CoA NN O O
dehydrogenase NN O O
( NN O O
ACD NN O O
) NN O O
enzymes NN O O
, NN O O
which NN O O
are NN O O
all NN O O
nuclear NN O O
encoded NN O O
mitochondrial NN O O
flavoproteins NN O O
catalyzing NN O O
the NN O O
initial NN O O
step NN O O
in NN O O
fatty NN O O
acid NN O O
beta NN O O
- NN O O
oxidation NN O O
. NN O O

We NN O O
have NN O O
used NN O O
the NN O O
very NN O O
fast NN O O
, NN O O
Rapid NN O O
Amplification NN O O
of NN O O
cDNA NN O O
Ends NN O O
( NN O O
RACE NN O O
) NN O O
based NN O O
strategy NN O O
to NN O O
obtain NN O O
the NN O O
sequence NN O O
of NN O O
cDNAs NN O O
encoding NN O O
human NN O O
VLCAD NN O O
from NN O O
placenta NN O O
and NN O O
fibroblasts NN O O
. NN O O

Alignment NN O O
of NN O O
the NN O O
predicted NN O O
amino NN O O
acid NN O O
sequence NN O O
of NN O O
human NN O O
VLCAD NN O O
with NN O O
those NN O O
of NN O O
the NN O O
other NN O O
human NN O O
ACD NN O O
enzymes NN O O
revealed NN O O
extensive NN O O
sequence NN O O
homology NN O O
. NN O O

Moreover NN O O
, NN O O
human NN O O
VLCAD NN O O
and NN O O
human NN O O
acyl NN O O
- NN O O
CoA NN O O
oxidase NN O O
showed NN O O
extensive NN O O
sequence NN O O
homology NN O O
corroborating NN O O
the NN O O
notion NN O O
that NN O O
these NN O O
genes NN O O
are NN O O
evolutionarily NN O O
related NN O O
. NN O O

Southern NN O O
blot NN O O
analysis NN O O
of NN O O
genomic NN O O
DNA NN O O
from NN O O
hybrid NN O O
cell NN O O
lines NN O O
was NN O O
used NN O O
to NN O O
localize NN O O
the NN O O
VLCAD NN O O
gene NN O O
to NN O O
human NN O O
chromosome NN O O
17p11 NN O O
. NN O O

2 NN O O
- NN O O
p11 NN O O
. NN O O

13105 NN O O
. NN O O

Using NN O O
Northern NN O O
and NN O O
Western NN O O
blot NN O O
analysis NN O O
to NN O O
investigate NN O O
the NN O O
tissue NN O O
specific NN O O
distribution NN O O
of NN O O
VLCAD NN O O
mRNA NN O O
and NN O O
protein NN O O
in NN O O
several NN O O
human NN O O
tissues NN O O
we NN O O
showed NN O O
that NN O O
VLCAD NN O O
is NN O O
most NN O O
abundant NN O O
in NN O O
heart NN O O
and NN O O
skeletal NN O O
muscle NN O O
. NN O O

This NN O O
agrees NN O O
well NN O O
with NN O O
the NN O O
fact NN O O
that NN O O
cardiac NN O O
and NN O O
muscle NN O O
symptoms NN O O
are NN O O
characteristic NN O O
for NN O O
patients NN O O
with NN O O
VLCAD NN O B-Disease
deficiency NN O I-Disease
. NN O O

Northern NN O O
blot NN O O
analysis NN O O
and NN O O
sequencing NN O O
of NN O O
cloned NN O O
PCR NN O O
amplified NN O O
VLCAD NN O O
cDNA NN O O
from NN O O
four NN O O
unrelated NN O O
patients NN O O
with NN O O
VLCAD NN O B-Disease
deficiency NN O I-Disease
showed NN O O
that NN O O
VLCAD NN O O
mRNA NN O O
was NN O O
undetectable NN O O
in NN O O
one NN O O
patient NN O O
and NN O O
that NN O O
the NN O O
other NN O O
three NN O O
have NN O O
mutations NN O O
in NN O O
both NN O O
VLCAD NN O O
alleles NN O O
. NN O O

Western NN O O
blot NN O O
analysis NN O O
of NN O O
patient NN O O
fibroblasts NN O O
showed NN O O
that NN O O
the NN O O
identified NN O O
mutations NN O O
result NN O O
in NN O O
severely NN O O
reduced NN O O
amounts NN O O
of NN O O
VLCAD NN O O
protein NN O O
. NN O O

Molecular NN O O
bases NN O O
of NN O O
combined NN O B-Disease
subtotal NN O I-Disease
deficiencies NN O I-Disease
of NN O I-Disease
C6 NN O I-Disease
and NN O I-Disease
C7 NN O I-Disease
: NN O O
their NN O O
effects NN O O
in NN O O
combination NN O O
with NN O O
other NN O O
C6 NN O B-Disease
and NN O I-Disease
C7 NN O I-Disease
deficiencies NN O I-Disease
. NN O O

Combined NN O B-Disease
subtotal NN O I-Disease
deficiency NN O I-Disease
of NN O I-Disease
C6 NN O I-Disease
and NN O I-Disease
C7 NN O I-Disease
, NN O O
in NN O O
which NN O O
both NN O O
proteins NN O O
are NN O O
expressed NN O O
at NN O O
very NN O O
low NN O O
levels NN O O
, NN O O
has NN O O
been NN O O
observed NN O O
in NN O O
homozygous NN O O
form NN O O
in NN O O
two NN O O
families NN O O
. NN O O

A NN O O
defect NN O O
at NN O O
the NN O O
5 NN O O
splice NN O O
donor NN O O
site NN O O
of NN O O
intron NN O O
15 NN O O
of NN O O
the NN O O
C6 NN O O
gene NN O O
explains NN O O
the NN O O
low NN O O
molecular NN O O
weight NN O O
of NN O O
the NN O O
C6 NN O O
protein NN O O
and NN O O
is NN O O
probably NN O O
responsible NN O O
for NN O O
its NN O O
low NN O O
expressed NN O O
concentration NN O O
. NN O O

The NN O O
C7 NN O O
defect NN O O
is NN O O
more NN O O
enigmatic NN O O
the NN O O
protein NN O O
is NN O O
of NN O O
normal NN O O
molecular NN O O
weight NN O O
, NN O O
low NN O O
circulating NN O O
concentration NN O O
, NN O O
and NN O O
altered NN O O
isoelectric NN O O
point NN O O
. NN O O

An NN O O
Arg NN O O
> NN O O
Ser NN O O
codon NN O O
substitution NN O O
in NN O O
exon NN O O
11 NN O O
is NN O O
the NN O O
only NN O O
molecular NN O O
alteration NN O O
within NN O O
the NN O O
mature NN O O
C7 NN O O
protein NN O O
. NN O O

These NN O O
defects NN O O
are NN O O
associated NN O O
with NN O O
a NN O O
characteristic NN O O
set NN O O
of NN O O
polymorphic NN O O
DNA NN O O
markers NN O O
in NN O O
the NN O O
C6 NN O O
/ NN O O
C7 NN O O
region NN O O
, NN O O
forming NN O O
a NN O O
distinct NN O O
haplotype NN O O
. NN O O

The NN O O
haplotype NN O O
has NN O O
been NN O O
found NN O O
in NN O O
combination NN O O
with NN O O
a NN O O
number NN O O
of NN O O
other NN O O
haplotypes NN O O
containing NN O O
defective NN O O
genes NN O O
that NN O O
lead NN O O
either NN O O
to NN O O
C6 NN O B-Disease
or NN O I-Disease
C7 NN O I-Disease
deficiency NN O I-Disease
, NN O O
but NN O O
with NN O O
different NN O O
consequences NN O O
. NN O O

Where NN O O
it NN O O
is NN O O
combined NN O O
with NN O O
a NN O O
C6 NN O B-Disease
- NN O I-Disease
deficient NN O I-Disease
gene NN O O
, NN O O
the NN O O
serum NN O O
C7 NN O O
levels NN O O
can NN O O
be NN O O
surprisingly NN O O
high NN O O
, NN O O
possibly NN O O
because NN O O
there NN O O
is NN O O
no NN O O
C6 NN O O
generating NN O O
C56 NN O O
to NN O O
consume NN O O
the NN O O
C7 NN O O
. NN O O

In NN O O
contrast NN O O
, NN O O
where NN O O
the NN O O
C7 NN O O
genes NN O O
are NN O O
both NN O O
defective NN O O
( NN O O
but NN O O
still NN O O
partially NN O O
functional NN O O
) NN O O
, NN O O
there NN O O
may NN O O
be NN O O
a NN O O
profound NN O O
deficit NN O O
of NN O O
circulating NN O O
C7 NN O O
because NN O O
there NN O O
is NN O O
ample NN O O
C6 NN O O
to NN O O
produce NN O O
C56 NN O O
and NN O O
consume NN O O
the NN O O
already NN O O
small NN O O
amount NN O O
of NN O O
C7 NN O O
. NN O O

Each NN O O
molecular NN O O
defect NN O O
has NN O O
also NN O O
been NN O O
found NN O O
in NN O O
isolation NN O O
and NN O O
has NN O O
the NN O O
expected NN O O
effect NN O O
. NN O O
. NN O O

Genetic NN O O
bases NN O O
of NN O O
human NN O O
complement NN O B-Disease
C7 NN O I-Disease
deficiency NN O I-Disease
. NN O O

Complement NN O B-Disease
C7 NN O I-Disease
deficiency NN O I-Disease
( NN O O
C7D NN O B-Disease
) NN O O
is NN O O
associated NN O O
frequently NN O O
with NN O O
recurrent NN O O
bacterial NN O B-Disease
infections NN O I-Disease
, NN O O
especially NN O O
meningitis NN O B-Disease
caused NN O O
by NN O O
Neisseria NN O B-Disease
meningitidis NN O I-Disease
. NN O O

We NN O O
report NN O O
in NN O O
this NN O O
work NN O O
the NN O O
molecular NN O O
bases NN O O
of NN O O
C7D NN O B-Disease
in NN O O
two NN O O
unrelated NN O O
Japanese NN O O
males NN O O
. NN O O

We NN O O
used NN O O
exon NN O O
- NN O O
specific NN O O
PCR NN O O
/ NN O O
single NN O O
- NN O O
strand NN O O
conformation NN O O
polymorphism NN O O
analysis NN O O
as NN O O
a NN O O
screening NN O O
step NN O O
for NN O O
mutations NN O O
. NN O O

Subsequent NN O O
direct NN O O
sequencing NN O O
of NN O O
the NN O O
target NN O O
exons NN O O
identified NN O O
homozygous NN O O
mutations NN O O
in NN O O
exon NN O O
16 NN O O
of NN O O
case NN O O
1 NN O O
and NN O O
in NN O O
exon NN O O
15 NN O O
of NN O O
case NN O O
2 NN O O
. NN O O

The NN O O
mutation NN O O
of NN O O
case NN O O
1 NN O O
was NN O O
a NN O O
homozygous NN O O
T NN O O
to NN O O
A NN O O
transversion NN O O
at NN O O
nucleotide NN O O
2250 NN O O
, NN O O
the NN O O
third NN O O
nucleotide NN O O
of NN O O
the NN O O
codon NN O O
TGT NN O O
for NN O O
Cys728 NN O O
, NN O O
leading NN O O
to NN O O
a NN O O
stop NN O O
codon NN O O
TGA NN O O
( NN O O
C728X NN O O
) NN O O
. NN O O

In NN O O
case NN O O
2 NN O O
, NN O O
a NN O O
homozygous NN O O
2 NN O O
- NN O O
bp NN O O
deletion NN O O
( NN O O
2137delTG NN O O
/ NN O O
2138delGT NN O O
/ NN O O
2139delTG NN O O
) NN O O
caused NN O O
a NN O O
frameshift NN O O
, NN O O
generating NN O O
a NN O O
premature NN O O
termination NN O O
codon NN O O
4 NN O O
to NN O O
6 NN O O
nucleotides NN O O
downstream NN O O
. NN O O

Family NN O O
study NN O O
in NN O O
case NN O O
1 NN O O
confirmed NN O O
the NN O O
genetic NN O O
nature NN O O
of NN O O
the NN O O
defect NN O O
. NN O O

Moreover NN O O
, NN O O
we NN O O
detected NN O O
a NN O O
novel NN O O
polymorphism NN O O
in NN O O
intron NN O O
11 NN O O
that NN O O
presumably NN O O
is NN O O
linked NN O O
to NN O O
the NN O O
mutation NN O O
responsible NN O O
for NN O O
C7D NN O B-Disease
in NN O O
case NN O O
1 NN O O
. NN O O

Our NN O O
results NN O O
indicate NN O O
that NN O O
the NN O O
pathogenesis NN O O
of NN O O
C7D NN O B-Disease
is NN O O
heterogeneous NN O O
like NN O O
most NN O O
of NN O O
the NN O O
other NN O O
deficiencies NN O B-Disease
of NN O I-Disease
complement NN O I-Disease
components NN O I-Disease
. NN O O
. NN O O

HPRT NN O B-Disease
- NN O I-Disease
APRT NN O I-Disease
- NN O I-Disease
deficient NN O I-Disease
mice NN O O
are NN O O
not NN O O
a NN O O
model NN O O
for NN O O
lesch NN O B-Disease
- NN O I-Disease
nyhan NN O I-Disease
syndrome NN O I-Disease
. NN O O

Complete NN O B-Disease
hypoxanthine NN O I-Disease
- NN O I-Disease
guanine NN O I-Disease
phosphoribosyl NN O I-Disease
- NN O I-Disease
transferase NN O I-Disease
( NN O I-Disease
HPRT NN O I-Disease
) NN O I-Disease
deficiency NN O I-Disease
in NN O O
humans NN O O
results NN O O
in NN O O
the NN O O
Lesch NN O B-Disease
- NN O I-Disease
Nyhan NN O I-Disease
syndrome NN O I-Disease
which NN O O
is NN O O
characterized NN O O
, NN O O
among NN O O
other NN O O
features NN O O
, NN O O
by NN O O
compulsive NN O O
self NN O O
- NN O O
injurious NN O O
behavior NN O O
. NN O O

HPRT NN O B-Disease
- NN O I-Disease
deficient NN O I-Disease
mice NN O O
generated NN O O
using NN O O
mouse NN O O
embryonic NN O O
stem NN O O
cells NN O O
exhibit NN O O
none NN O O
of NN O O
the NN O O
behavioral NN O O
symptoms NN O O
associated NN O O
with NN O O
the NN O O
Lesch NN O B-Disease
- NN O I-Disease
Nyhan NN O I-Disease
syndrome NN O I-Disease
. NN O O

Administration NN O O
of NN O O
drugs NN O O
that NN O O
inhibit NN O O
adenine NN O O
phosphoribosyltransferase NN O O
( NN O O
APRT NN O O
) NN O O
in NN O O
HPRT NN O B-Disease
- NN O I-Disease
deficient NN O I-Disease
mice NN O O
has NN O O
produced NN O O
the NN O O
suggestion NN O O
that NN O O
deficiency NN O B-Disease
of NN O I-Disease
APRT NN O I-Disease
in NN O O
combination NN O O
with NN O O
HPRT NN O B-Disease
- NN O I-Disease
deficiency NN O I-Disease
in NN O O
mice NN O O
may NN O O
lead NN O O
to NN O O
self NN O O
- NN O O
mutilation NN O O
behavior NN O O
[ NN O O
C NN O O
. NN O O
L NN O O
. NN O O
Wu NN O O
and NN O O
D NN O O
. NN O O
W NN O O
. NN O O
Melton NN O O
( NN O O
1993 NN O O
) NN O O
Nature NN O O
Genet NN O O
. NN O O
3 NN O O
, NN O O
235 NN O O
- NN O O
240 NN O O
] NN O O
. NN O O

To NN O O
test NN O O
this NN O O
proposition NN O O
, NN O O
we NN O O
bred NN O O
HPRT NN O B-Disease
- NN O I-Disease
APRT NN O I-Disease
- NN O I-Disease
deficient NN O I-Disease
mice NN O O
. NN O O

Although NN O O
the NN O O
doubly NN O O
- NN O O
deficient NN O O
mice NN O O
excrete NN O O
adenine NN O O
and NN O O
its NN O O
highly NN O O
insoluble NN O O
derivative NN O O
, NN O O
2 NN O O
, NN O O
8 NN O O
- NN O O
dihydroxyadenine NN O O
, NN O O
which NN O O
are NN O O
also NN O O
associated NN O O
with NN O O
human NN O O
APRT NN O B-Disease
deficiency NN O I-Disease
, NN O O
additional NN O O
abnormalities NN O O
or NN O O
any NN O O
self NN O O
- NN O O
injurious NN O O
behavior NN O O
were NN O O
not NN O O
detected NN O O
. NN O O

Thus NN O O
, NN O O
APRT NN O B-Disease
- NN O I-Disease
HPRT NN O I-Disease
- NN O I-Disease
deficient NN O I-Disease
mice NN O O
, NN O O
which NN O O
are NN O O
devoid NN O O
of NN O O
any NN O O
purine NN O O
salvage NN O O
pathways NN O O
, NN O O
show NN O O
no NN O O
novel NN O O
phenotype NN O O
and NN O O
are NN O O
not NN O O
a NN O O
model NN O O
for NN O O
the NN O O
behavioral NN O B-Disease
abnormalities NN O I-Disease
associated NN O O
with NN O O
the NN O O
Lesch NN O B-Disease
- NN O I-Disease
Nyhan NN O I-Disease
syndrome NN O I-Disease
as NN O O
previously NN O O
suggested NN O O

Somatic NN O O
alterations NN O O
of NN O O
the NN O O
DPC4 NN O O
gene NN O O
in NN O O
human NN O O
colorectal NN O B-Disease
cancers NN O I-Disease
in NN O O
vivo NN O O
. NN O O

BACKGROUND NN O O
& NN O O
AIMS NN O O
The NN O O
chromosome NN O O
region NN O O
18q21 NN O O
has NN O O
been NN O O
shown NN O O
to NN O O
be NN O O
frequently NN O O
deleted NN O O
in NN O O
colorectal NN O B-Disease
cancers NN O I-Disease
, NN O O
and NN O O
such NN O O
frequent NN O O
allelic NN O O
loss NN O O
is NN O O
a NN O O
hallmark NN O O
of NN O O
the NN O O
presence NN O O
of NN O O
a NN O O
tumor NN O O
- NN O O
suppressor NN O O
gene NN O O
. NN O O

The NN O O
DPC4 NN O O
gene NN O O
, NN O O
which NN O O
is NN O O
located NN O O
at NN O O
18q21 NN O O
, NN O O
has NN O O
been NN O O
identified NN O O
as NN O O
a NN O O
tumor NN O O
- NN O O
suppressor NN O O
gene NN O O
from NN O O
examination NN O O
of NN O O
pancreatic NN O B-Disease
cancers NN O I-Disease
. NN O O

The NN O O
aim NN O O
of NN O O
the NN O O
present NN O O
study NN O O
was NN O O
to NN O O
determine NN O O
if NN O O
it NN O O
might NN O O
also NN O O
be NN O O
altered NN O O
in NN O O
colorectal NN O B-Disease
cancers NN O I-Disease
. NN O O

METHODS NN O O
Mutation NN O O
analyses NN O O
of NN O O
the NN O O
DPC4 NN O O
gene NN O O
were NN O O
performed NN O O
on NN O O
complementary NN O O
DNA NN O O
samples NN O O
from NN O O
31 NN O O
primary NN O O
colorectal NN O B-Disease
cancer NN O I-Disease
specimens NN O O
using NN O O
a NN O O
combination NN O O
of NN O O
polymerase NN O O
chain NN O O
reaction NN O O
, NN O O
single NN O O
- NN O O
strand NN O O
conformation NN O O
polymorphism NN O O
, NN O O
and NN O O
DNA NN O O
sequencing NN O O
. NN O O

RESULTS NN O O
Four NN O O
missense NN O O
mutations NN O O
producing NN O O
amino NN O O
acid NN O O
substitutions NN O O
and NN O O
a NN O O
somatic NN O O
12 NN O O
- NN O O
base NN O O
pair NN O O
deletion NN O O
in NN O O
the NN O O
coding NN O O
region NN O O
of NN O O
the NN O O
DPC4 NN O O
gene NN O O
were NN O O
detected NN O O
in NN O O
the NN O O
31 NN O O
cancers NN O B-Disease
( NN O O
16 NN O O
% NN O O
; NN O O
5 NN O O
of NN O O
31 NN O O
) NN O O
. NN O O

CONCLUSIONS NN O O
The NN O O
DPC4 NN O O
gene NN O O
may NN O O
play NN O O
a NN O O
role NN O O
as NN O O
a NN O O
tumor NN O O
- NN O O
suppressor NN O O
gene NN O O
in NN O O
a NN O O
fraction NN O O
of NN O O
colorectal NN O B-Disease
cancers NN O I-Disease
; NN O O
however NN O O
, NN O O
while NN O O
allelic NN O O
loss NN O O
at NN O O
18q21 NN O O
is NN O O
very NN O O
often NN O O
seen NN O O
in NN O O
colorectal NN O B-Disease
cancers NN O I-Disease
, NN O O
only NN O O
a NN O O
minority NN O O
show NN O O
DPC4 NN O O
mutations NN O O
, NN O O
suggesting NN O O
that NN O O
there NN O O
might NN O O
be NN O O
another NN O O
tumor NN O O
- NN O O
suppressor NN O O
gene NN O O
in NN O O
this NN O O
chromosome NN O O
region NN O O
. NN O O
. NN O O

Pleiotropic NN O O
defects NN O O
in NN O O
ataxia NN O B-Disease
- NN O I-Disease
telangiectasia NN O I-Disease
protein NN O O
- NN O O
deficient NN O O
mice NN O O
. NN O O

We NN O O
have NN O O
generated NN O O
a NN O O
mouse NN O O
model NN O O
for NN O O
ataxia NN O B-Disease
- NN O I-Disease
telangiectasia NN O I-Disease
by NN O O
using NN O O
gene NN O O
targeting NN O O
to NN O O
generate NN O O
mice NN O O
that NN O O
do NN O O
not NN O O
express NN O O
the NN O O
Atm NN O O
protein NN O O
. NN O O

Atm NN O O
- NN O O
deficient NN O O
mice NN O O
are NN O O
retarded NN O O
in NN O O
growth NN O O
, NN O O
do NN O O
not NN O O
produce NN O O
mature NN O O
sperm NN O O
, NN O O
and NN O O
exhibit NN O O
severe NN O O
defects NN O O
in NN O O
T NN O O
cell NN O O
maturation NN O O
while NN O O
going NN O O
on NN O O
to NN O O
develop NN O O
thymomas NN O B-Disease
. NN O O

Atm NN O O
- NN O O
deficient NN O O
fibroblasts NN O O
grow NN O O
poorly NN O O
in NN O O
culture NN O O
and NN O O
display NN O O
a NN O O
high NN O O
level NN O O
of NN O O
double NN O O
- NN O O
stranded NN O O
chromosome NN O O
breaks NN O O
. NN O O

Atm NN O O
- NN O O
deficient NN O O
thymocytes NN O O
undergo NN O O
spontaneous NN O O
apoptosis NN O O
in NN O O
vitro NN O O
significantly NN O O
more NN O O
than NN O O
controls NN O O
. NN O O

Atm NN O O
- NN O O
deficient NN O O
mice NN O O
then NN O O
exhibit NN O O
many NN O O
of NN O O
the NN O O
same NN O O
symptoms NN O O
found NN O O
in NN O O
ataxia NN O B-Disease
- NN O I-Disease
telangiectasia NN O I-Disease
patients NN O O
and NN O O
in NN O O
cells NN O O
derived NN O O
from NN O O
them NN O O
. NN O O

Furthermore NN O O
, NN O O
we NN O O
demonstrate NN O O
that NN O O
the NN O O
Atm NN O O
protein NN O O
exists NN O O
as NN O O
two NN O O
discrete NN O O
molecular NN O O
species NN O O
, NN O O
and NN O O
that NN O O
loss NN O O
of NN O O
one NN O O
or NN O O
of NN O O
both NN O O
of NN O O
these NN O O
can NN O O
lead NN O O
to NN O O
the NN O O
development NN O O
of NN O O
the NN O O
disease NN O O
. NN O O
. NN O O

The NN O O
DCC NN O O
protein NN O O
and NN O O
prognosis NN O O
in NN O O
colorectal NN O B-Disease
cancer NN O I-Disease
. NN O O

BACKGROUND NN O O
Allelic NN O O
loss NN O O
of NN O O
chromosome NN O O
18q NN O O
predicts NN O O
a NN O O
poor NN O O
outcome NN O O
in NN O O
patients NN O O
with NN O O
stage NN O B-Disease
II NN O I-Disease
colorectal NN O I-Disease
cancer NN O I-Disease
. NN O O

Although NN O O
the NN O O
specific NN O O
gene NN O O
inactivated NN O O
by NN O O
this NN O O
allelic NN O O
loss NN O O
has NN O O
not NN O O
been NN O O
elucidated NN O O
, NN O O
the NN O O
DCC NN O O
( NN O O
deleted NN O O
in NN O O
colorectal NN O B-Disease
cancer NN O I-Disease
) NN O O
gene NN O O
is NN O O
a NN O O
candidate NN O O
. NN O O

We NN O O
investigated NN O O
whether NN O O
the NN O O
expression NN O O
of NN O O
the NN O O
DCC NN O O
protein NN O O
in NN O O
tumor NN O B-Disease
cells NN O O
is NN O O
a NN O O
prognostic NN O O
marker NN O O
in NN O O
colorectal NN O B-Disease
carcinoma NN O I-Disease
. NN O O

METHODS NN O O
The NN O O
expression NN O O
of NN O O
DCC NN O O
was NN O O
evaluated NN O O
immunohistochemically NN O O
in NN O O
132 NN O O
paraffin NN O O
- NN O O
embedded NN O O
samples NN O O
from NN O O
patients NN O O
with NN O O
curatively NN O O
resected NN O O
stage NN O B-Disease
II NN O I-Disease
and NN O I-Disease
III NN O I-Disease
colorectal NN O I-Disease
carcinomas NN O I-Disease
. NN O O

The NN O O
Cox NN O O
proportional NN O O
- NN O O
hazards NN O O
model NN O O
was NN O O
used NN O O
to NN O O
adjust NN O O
for NN O O
covariates NN O O
including NN O O
age NN O O
, NN O O
sex NN O O
, NN O O
tumor NN O B-Disease
site NN O O
, NN O O
degree NN O O
of NN O O
tumor NN O B-Disease
differentiation NN O O
, NN O O
and NN O O
use NN O O
of NN O O
adjuvant NN O O
therapy NN O O
. NN O O

RESULTS NN O O
The NN O O
expression NN O O
of NN O O
DCC NN O O
was NN O O
a NN O O
strong NN O O
positive NN O O
predictive NN O O
factor NN O O
for NN O O
survival NN O O
in NN O O
both NN O O
stage NN O B-Disease
II NN O I-Disease
and NN O I-Disease
stage NN O I-Disease
III NN O I-Disease
colorectal NN O I-Disease
carcinomas NN O I-Disease
. NN O O

In NN O O
patients NN O O
with NN O O
stage NN O O
II NN O O
disease NN O O
whose NN O O
tumors NN O B-Disease
expressed NN O O
DCC NN O O
, NN O O
the NN O O
five NN O O
- NN O O
year NN O O
survival NN O O
rate NN O O
was NN O O
94 NN O O
. NN O O

3 NN O O
percent NN O O
, NN O O
whereas NN O O
in NN O O
patients NN O O
with NN O O
DCC NN O B-Disease
- NN O I-Disease
negative NN O I-Disease
tumors NN O I-Disease
, NN O O
the NN O O
survival NN O O
rate NN O O
was NN O O
61 NN O O
. NN O O

6 NN O O
percent NN O O
( NN O O
P NN O O
< NN O O
0 NN O O
. NN O O
001 NN O O
) NN O O
. NN O O

In NN O O
patients NN O O
with NN O O
stage NN O B-Disease
III NN O I-Disease
disease NN O I-Disease
, NN O O
the NN O O
respective NN O O
survival NN O O
rates NN O O
were NN O O
59 NN O O
. NN O O

3 NN O O
percent NN O O
and NN O O
33 NN O O
. NN O O

2 NN O O
percent NN O O
( NN O O
P NN O O
= NN O O
0 NN O O
. NN O O
03 NN O O
) NN O O
. NN O O

CONCLUSIONS NN O O
DCC NN O O
is NN O O
a NN O O
prognostic NN O O
marker NN O O
in NN O O
patients NN O O
with NN O O
stage NN O B-Disease
II NN O I-Disease
or NN O I-Disease
stage NN O I-Disease
III NN O I-Disease
colorectal NN O I-Disease
cancer NN O I-Disease
. NN O O

In NN O O
stage NN O B-Disease
II NN O I-Disease
colorectal NN O I-Disease
carcinomas NN O I-Disease
, NN O O
the NN O O
absence NN O O
of NN O O
DCC NN O O
identifies NN O O
a NN O O
subgroup NN O O
of NN O O
patients NN O O
with NN O O
lesions NN O O
that NN O O
behave NN O O
like NN O O
stage NN O B-Disease
III NN O I-Disease
cancers NN O I-Disease
. NN O O

These NN O O
findings NN O O
may NN O O
thus NN O O
have NN O O
therapeutic NN O O
implications NN O O
in NN O O
this NN O O
group NN O O
of NN O O
patients NN O O

Association NN O O
of NN O O
anxiety NN O B-Disease
- NN O I-Disease
related NN O I-Disease
traits NN O I-Disease
with NN O O
a NN O O
polymorphism NN O O
in NN O O
the NN O O
serotonin NN O O
transporter NN O O
gene NN O O
regulatory NN O O
region NN O O
. NN O O

Transporter NN O O
- NN O O
facilitated NN O O
uptake NN O O
of NN O O
serotonin NN O O
( NN O O
5 NN O O
- NN O O
hydroxytryptamine NN O O
or NN O O
5 NN O O
- NN O O
HT NN O O
) NN O O
has NN O O
been NN O O
implicated NN O O
in NN O O
anxiety NN O B-Disease
in NN O O
humans NN O O
and NN O O
animal NN O O
models NN O O
and NN O O
is NN O O
the NN O O
site NN O O
of NN O O
action NN O O
of NN O O
widely NN O O
used NN O O
uptake NN O O
- NN O O
inhibiting NN O O
antidepressant NN O O
and NN O O
antianxiety NN O O
drugs NN O O
. NN O O

Human NN O O
5 NN O O
- NN O O
HT NN O O
transporter NN O O
( NN O O
5 NN O O
- NN O O
HTT NN O O
) NN O O
gene NN O O
transcription NN O O
is NN O O
modulated NN O O
by NN O O
a NN O O
common NN O O
polymorphism NN O O
in NN O O
its NN O O
upstream NN O O
regulatory NN O O
region NN O O
. NN O O

The NN O O
short NN O O
variant NN O O
of NN O O
the NN O O
polymorphism NN O O
reduces NN O O
the NN O O
transcriptional NN O O
efficiency NN O O
of NN O O
the NN O O
5 NN O O
- NN O O
HTT NN O O
gene NN O O
promoter NN O O
, NN O O
resulting NN O O
in NN O O
decreased NN O O
5 NN O O
- NN O O
HTT NN O O
expression NN O O
and NN O O
5 NN O O
- NN O O
HT NN O O
uptake NN O O
in NN O O
lymphoblasts NN O O
. NN O O

Association NN O O
studies NN O O
in NN O O
two NN O O
independent NN O O
samples NN O O
totaling NN O O
505 NN O O
individuals NN O O
revealed NN O O
that NN O O
the NN O O
5 NN O O
- NN O O
HTT NN O O
polymorphism NN O O
accounts NN O O
for NN O O
3 NN O O
to NN O O
4 NN O O
percent NN O O
of NN O O
total NN O O
variation NN O O
and NN O O
7 NN O O
to NN O O
9 NN O O
percent NN O O
of NN O O
inherited NN O O
variance NN O O
in NN O O
anxiety NN O B-Disease
- NN O I-Disease
related NN O I-Disease
personality NN O I-Disease
traits NN O I-Disease
in NN O O
individuals NN O O
as NN O O
well NN O O
as NN O O
sibships NN O O
. NN O O
. NN O O

Phenotypic NN O O
and NN O O
genotypic NN O O
overlap NN O O
between NN O O
atelosteogenesis NN O B-Disease
type NN O I-Disease
2 NN O I-Disease
and NN O O
diastrophic NN O B-Disease
dysplasia NN O I-Disease
. NN O O

Mutations NN O O
in NN O O
the NN O O
diastrophic NN O B-Disease
dysplasia NN O I-Disease
sulfate NN O O
transporter NN O O
gene NN O O
DTDST NN O O
have NN O O
been NN O O
associated NN O O
with NN O O
a NN O O
family NN O O
of NN O O
chondrodysplasias NN O B-Disease
that NN O O
comprises NN O O
, NN O O
in NN O O
order NN O O
of NN O O
increasing NN O O
severity NN O O
, NN O O
diastrophic NN O B-Disease
dysplasia NN O I-Disease
( NN O O
DTD NN O B-Disease
) NN O O
, NN O O
atelosteogenesis NN O B-Disease
type NN O I-Disease
2 NN O I-Disease
( NN O O
AO2 NN O B-Disease
) NN O O
, NN O O
and NN O O
achondrogenesis NN O B-Disease
type NN O I-Disease
1B NN O I-Disease
( NN O O
ACG1B NN O B-Disease
) NN O O
. NN O O

To NN O O
learn NN O O
more NN O O
about NN O O
the NN O O
molecular NN O O
basis NN O O
of NN O O
DTDST NN O B-Disease
chondrodysplasias NN O I-Disease
and NN O O
about NN O O
genotype NN O O
- NN O O
phenotype NN O O
correlations NN O O
, NN O O
we NN O O
studied NN O O
fibroblast NN O O
cultures NN O O
of NN O O
three NN O O
new NN O O
patients NN O O
one NN O O
with NN O O
AO NN O B-Disease
- NN O I-Disease
2 NN O I-Disease
, NN O O
one NN O O
with NN O O
DTD NN O B-Disease
, NN O O
and NN O O
one NN O O
with NN O O
an NN O O
intermediate NN O O
phenotype NN O O
( NN O O
AO2 NN O B-Disease
/ NN O O
DTD NN O B-Disease
) NN O O
. NN O O

Reduced NN O O
incorporation NN O O
of NN O O
inorganic NN O O
sulfate NN O O
into NN O O
macromolecules NN O O
was NN O O
found NN O O
in NN O O
all NN O O
three NN O O
. NN O O

Each NN O O
of NN O O
the NN O O
three NN O O
patients NN O O
was NN O O
found NN O O
to NN O O
be NN O O
heterozygous NN O O
for NN O O
a NN O O
c862t NN O O
transition NN O O
predicting NN O O
a NN O O
R279W NN O O
substitution NN O O
in NN O O
the NN O O
third NN O O
extracellular NN O O
loop NN O O
of NN O O
DTDST NN O O
. NN O O

In NN O O
two NN O O
patients NN O O
( NN O O
DTD NN O B-Disease
and NN O O
AO2 NN O B-Disease
/ NN O O
DTD NN O B-Disease
) NN O O
, NN O O
no NN O O
other NN O O
structural NN O O
mutation NN O O
was NN O O
found NN O O
, NN O O
but NN O O
polymerase NN O O
chain NN O O
reaction NN O O
amplification NN O O
and NN O O
single NN O O
- NN O O
strand NN O O
conformation NN O O
polymorphism NN O O
analysis NN O O
of NN O O
fibroblast NN O O
cDNA NN O O
showed NN O O
reduced NN O O
mRNA NN O O
levels NN O O
of NN O O
the NN O O
wild NN O O
- NN O O
type NN O O
DTDST NN O O
allele NN O O
these NN O O
two NN O O
patients NN O O
may NN O O
be NN O O
compound NN O O
heterozygotes NN O O
for NN O O
the NN O O
" NN O O
Finnish NN O O
" NN O O
mutation NN O O
( NN O O
as NN O O
yet NN O O
uncharacterized NN O O
at NN O O
the NN O O
DNA NN O O
level NN O O
) NN O O
, NN O O
which NN O O
causes NN O O
reduced NN O O
expression NN O O
of NN O O
DTDST NN O O
. NN O O

The NN O O
third NN O O
patient NN O O
( NN O O
with NN O O
AO2 NN O B-Disease
) NN O O
had NN O O
the NN O O
R279W NN O O
mutation NN O O
compounded NN O O
with NN O O
a NN O O
novel NN O O
mutation NN O O
, NN O O
the NN O O
deletion NN O O
of NN O O
cytosine NN O O
418 NN O O
( NN O O
delta NN O O
c418 NN O O
) NN O O
, NN O O
predicting NN O O
a NN O O
frameshift NN O O
with NN O O
premature NN O O
termination NN O O
. NN O O

Also NN O O
the NN O O
delta NN O O
c418 NN O O
allele NN O O
was NN O O
underrepresented NN O O
in NN O O
the NN O O
cDNA NN O O
, NN O O
in NN O O
accordance NN O O
with NN O O
previous NN O O
observations NN O O
that NN O O
premature NN O O
stop NN O O
codons NN O O
reduce NN O O
mRNA NN O O
levels NN O O
. NN O O

The NN O O
presence NN O O
of NN O O
the NN O O
DTDST NN O O
R279W NN O O
mutation NN O O
in NN O O
a NN O O
total NN O O
of NN O O
11 NN O O
patients NN O O
with NN O O
AO2 NN O B-Disease
or NN O O
DTD NN O B-Disease
emphasizes NN O O
the NN O O
overlap NN O O
between NN O O
these NN O O
conditions NN O O
. NN O O

This NN O O
mutation NN O O
has NN O O
not NN O O
been NN O O
found NN O O
so NN O O
far NN O O
in NN O O
8 NN O O
analyzed NN O O
ACG1B NN O B-Disease
patients NN O O
, NN O O
suggesting NN O O
that NN O O
it NN O O
allows NN O O
some NN O O
residual NN O O
activity NN O O
of NN O O
the NN O O
sulfate NN O O
transporter NN O O
. NN O O
. NN O O

Identification NN O O
of NN O O
WASP NN O O
mutations NN O O
, NN O O
mutation NN O O
hotspots NN O O
and NN O O
genotype NN O O
- NN O O
phenotype NN O O
disparities NN O O
in NN O O
24 NN O O
patients NN O O
with NN O O
the NN O O
Wiskott NN O B-Disease
- NN O I-Disease
Aldrich NN O I-Disease
syndrome NN O I-Disease
. NN O O

The NN O O
Wiskott NN O B-Disease
- NN O I-Disease
Aldrich NN O I-Disease
syndrome NN O I-Disease
( NN O O
WAS NN O B-Disease
) NN O O
, NN O O
an NN O O
X NN O B-Disease
- NN O I-Disease
linked NN O I-Disease
immunodeficiency NN O I-Disease
disease NN O I-Disease
caused NN O O
by NN O O
mutation NN O O
in NN O O
the NN O O
recently NN O O
isolated NN O O
gene NN O O
encoding NN O O
WAS NN O B-Disease
protein NN O O
( NN O O
WASP NN O O
) NN O O
, NN O O
is NN O O
known NN O O
to NN O O
be NN O O
associated NN O O
with NN O O
extensive NN O O
clinical NN O O
heterogeneity NN O O
. NN O O

Cumulative NN O O
mutation NN O O
data NN O O
have NN O O
revealed NN O O
that NN O O
WASP NN O O
genotypes NN O O
are NN O O
also NN O O
highly NN O O
variable NN O O
among NN O O
WAS NN O B-Disease
patients NN O O
, NN O O
but NN O O
the NN O O
relationship NN O O
of NN O O
phenotype NN O O
with NN O O
genotype NN O O
in NN O O
this NN O O
disease NN O O
remains NN O O
unclear NN O O
. NN O O

To NN O O
address NN O O
this NN O O
issue NN O O
we NN O O
characterized NN O O
WASP NN O O
mutations NN O O
in NN O O
24 NN O O
unrelated NN O O
WAS NN O B-Disease
patients NN O O
, NN O O
including NN O O
18 NN O O
boys NN O O
with NN O O
severe NN O O
classical NN O O
WAS NN O B-Disease
and NN O O
6 NN O O
boys NN O O
expressing NN O O
mild NN O O
forms NN O O
of NN O O
the NN O O
disease NN O O
, NN O O
and NN O O
then NN O O
examined NN O O
the NN O O
degree NN O O
of NN O O
correlation NN O O
of NN O O
these NN O O
as NN O O
well NN O O
as NN O O
all NN O O
previously NN O O
published NN O O
WASP NN O O
mutations NN O O
with NN O O
disease NN O O
severity NN O O
. NN O O

By NN O O
analysis NN O O
of NN O O
these NN O O
compiled NN O O
mutation NN O O
data NN O O
, NN O O
we NN O O
demonstrated NN O O
clustering NN O O
of NN O O
WASP NN O O
mutations NN O O
within NN O O
the NN O O
four NN O O
most NN O O
N NN O O
- NN O O
terminal NN O O
exons NN O O
of NN O O
the NN O O
gene NN O O
and NN O O
also NN O O
identified NN O O
several NN O O
sites NN O O
within NN O O
this NN O O
region NN O O
as NN O O
hotspots NN O O
for NN O O
WASP NN O O
mutation NN O O
. NN O O

These NN O O
characteristics NN O O
were NN O O
observed NN O O
, NN O O
however NN O O
, NN O O
in NN O O
both NN O O
severe NN O O
and NN O O
mild NN O O
cases NN O O
of NN O O
the NN O O
disease NN O O
. NN O O

Similarly NN O O
, NN O O
while NN O O
the NN O O
cumulative NN O O
data NN O O
revealed NN O O
a NN O O
predominance NN O O
of NN O O
missense NN O O
mutations NN O O
among NN O O
the NN O O
WASP NN O O
gene NN O O
lesions NN O O
observed NN O O
in NN O O
boys NN O O
with NN O O
isolated NN O B-Disease
thrombocytopenia NN O I-Disease
, NN O O
missense NN O O
mutations NN O O
were NN O O
not NN O O
exclusively NN O O
associated NN O O
with NN O O
milder NN O O
WAS NN O B-Disease
phenotypes NN O O
, NN O O
but NN O O
also NN O O
comprised NN O O
a NN O O
substantial NN O O
portion NN O O
( NN O O
38 NN O O
% NN O O
) NN O O
of NN O O
the NN O O
WASP NN O O
gene NN O O
defects NN O O
found NN O O
in NN O O
patients NN O O
with NN O O
severe NN O O
disease NN O O
. NN O O

These NN O O
findings NN O O
, NN O O
as NN O O
well NN O O
as NN O O
the NN O O
detection NN O O
of NN O O
identical NN O O
WASP NN O O
mutations NN O O
in NN O O
patients NN O O
with NN O O
disparate NN O O
phenotypes NN O O
, NN O O
reveal NN O O
a NN O O
lack NN O O
of NN O O
phenotype NN O O
concordance NN O O
with NN O O
genotype NN O O
in NN O O
WAS NN O B-Disease
and NN O O
thus NN O O
imply NN O O
that NN O O
phenotypic NN O O
outcome NN O O
in NN O O
this NN O O
disease NN O O
cannot NN O O
be NN O O
reliably NN O O
predicted NN O O
solely NN O O
on NN O O
the NN O O
basis NN O O
of NN O O
WASP NN O O
genotypes NN O O
. NN O O
. NN O O

Germline NN O O
mutations NN O O
in NN O O
the NN O O
3 NN O O
' NN O O
part NN O O
of NN O O
APC NN O B-Disease
exon NN O O
15 NN O O
do NN O O
not NN O O
result NN O O
in NN O O
truncated NN O O
proteins NN O O
and NN O O
are NN O O
associated NN O O
with NN O O
attenuated NN O O
adenomatous NN O B-Disease
polyposis NN O I-Disease
coli NN O I-Disease
. NN O O

Familial NN O B-Disease
adenomatous NN O I-Disease
polyposis NN O I-Disease
( NN O O
FAP NN O B-Disease
) NN O O
is NN O O
an NN O O
inherited NN O O
predisposition NN O O
to NN O O
colorectal NN O B-Disease
cancer NN O I-Disease
characterized NN O O
by NN O O
the NN O O
development NN O O
of NN O O
numerous NN O O
adenomatous NN O B-Disease
polyps NN O I-Disease
predominantly NN O O
in NN O O
the NN O O
colorectal NN O O
region NN O O
. NN O O

Germline NN O O
mutations NN O O
in NN O O
the NN O O
adenomatous NN O B-Disease
polyposis NN O I-Disease
coli NN O I-Disease
( NN O O
APC NN O B-Disease
) NN O O
gene NN O O
are NN O O
responsible NN O O
for NN O O
most NN O O
cases NN O O
of NN O O
FAP NN O B-Disease
. NN O O

Mutations NN O O
at NN O O
the NN O O
5 NN O O
end NN O O
of NN O O
APC NN O B-Disease
are NN O O
known NN O O
to NN O O
be NN O O
associated NN O O
with NN O O
a NN O O
relatively NN O O
mild NN O O
form NN O O
of NN O O
the NN O O
disease NN O O
, NN O O
called NN O O
attenuated NN O B-Disease
adenomatous NN O I-Disease
polyposis NN O I-Disease
coli NN O I-Disease
( NN O O
AAPC NN O B-Disease
) NN O O
. NN O O

We NN O O
identified NN O O
a NN O O
frameshift NN O O
mutation NN O O
in NN O O
the NN O O
3 NN O O
part NN O O
of NN O O
exon NN O O
15 NN O O
, NN O O
resulting NN O O
in NN O O
a NN O O
stop NN O O
codon NN O O
at NN O O
1862 NN O O
, NN O O
in NN O O
a NN O O
large NN O O
Dutch NN O O
kindred NN O O
with NN O O
AAPC NN O B-Disease
. NN O O

Western NN O O
blot NN O O
analysis NN O O
of NN O O
lymphoblastoid NN O O
cell NN O O
lines NN O O
derived NN O O
from NN O O
affected NN O O
family NN O O
members NN O O
from NN O O
this NN O O
kindred NN O O
, NN O O
as NN O O
well NN O O
as NN O O
from NN O O
a NN O O
previously NN O O
reported NN O O
Swiss NN O O
family NN O O
carrying NN O O
a NN O O
frameshift NN O O
mutation NN O O
at NN O O
codon NN O O
1987 NN O O
and NN O O
displaying NN O O
a NN O O
similar NN O O
attenuated NN O O
phenotype NN O O
, NN O O
showed NN O O
only NN O O
the NN O O
wild NN O O
- NN O O
type NN O O
APC NN O B-Disease
protein NN O O
. NN O O

Our NN O O
study NN O O
indicates NN O O
that NN O O
chain NN O O
- NN O O
terminating NN O O
mutations NN O O
located NN O O
in NN O O
the NN O O
3 NN O O
part NN O O
of NN O O
APC NN O B-Disease
do NN O O
not NN O O
result NN O O
in NN O O
detectable NN O O
truncated NN O O
polypeptides NN O O
and NN O O
we NN O O
hypothesize NN O O
that NN O O
this NN O O
is NN O O
likely NN O O
to NN O O
be NN O O
the NN O O
basis NN O O
for NN O O
the NN O O
observed NN O O
AAPC NN O B-Disease
phenotype NN O O
. NN O O
. NN O O

Complete NN O O
genomic NN O O
sequence NN O O
and NN O O
analysis NN O O
of NN O O
117 NN O O
kb NN O O
of NN O O
human NN O O
DNA NN O O
containing NN O O
the NN O O
gene NN O O
BRCA1 NN O O
. NN O O

Over NN O O
100 NN O O
distinct NN O O
disease NN O O
- NN O O
associated NN O O
mutations NN O O
have NN O O
been NN O O
identified NN O O
in NN O O
the NN O O
breast NN O B-Disease
- NN O I-Disease
ovarian NN O I-Disease
cancer NN O I-Disease
susceptibility NN O O
gene NN O O
BRCA1 NN O O
. NN O O

Loss NN O O
of NN O O
the NN O O
wild NN O O
- NN O O
type NN O O
allele NN O O
in NN O O
> NN O O
90 NN O O
% NN O O
of NN O O
tumors NN O B-Disease
from NN O O
patients NN O O
with NN O O
inherited NN O O
BRCA1 NN O O
mutations NN O O
indicates NN O O
tumor NN O B-Disease
suppressive NN O O
function NN O O
. NN O O

The NN O O
low NN O O
incidence NN O O
of NN O O
somatic NN O O
mutations NN O O
suggests NN O O
that NN O O
BRCA1 NN O O
inactivation NN O O
in NN O O
sporadic NN O O
tumors NN O B-Disease
occurs NN O O
by NN O O
alternative NN O O
mechanisms NN O O
, NN O O
such NN O O
as NN O O
interstitial NN O O
chromosomal NN O O
deletion NN O O
or NN O O
reduced NN O O
transcription NN O O
. NN O O

To NN O O
identify NN O O
possible NN O O
features NN O O
of NN O O
the NN O O
BRCA1 NN O O
genomic NN O O
region NN O O
that NN O O
may NN O O
contribute NN O O
to NN O O
chromosomal NN O O
instability NN O O
as NN O O
well NN O O
as NN O O
potential NN O O
transcriptional NN O O
regulatory NN O O
elements NN O O
, NN O O
a NN O O
117 NN O O
, NN O O
143 NN O O
- NN O O
bp NN O O
DNA NN O O
sequence NN O O
encompassing NN O O
BRCA1 NN O O
was NN O O
obtained NN O O
by NN O O
random NN O O
sequencing NN O O
of NN O O
four NN O O
cosmids NN O O
identified NN O O
from NN O O
a NN O O
human NN O O
chromosome NN O O
17 NN O O
specific NN O O
library NN O O
. NN O O

The NN O O
24 NN O O
exons NN O O
of NN O O
BRCA1 NN O O
span NN O O
an NN O O
81 NN O O
- NN O O
kb NN O O
region NN O O
that NN O O
has NN O O
an NN O O
unusually NN O O
high NN O O
density NN O O
of NN O O
Alu NN O O
repetitive NN O O
DNA NN O O
( NN O O
41 NN O O
. NN O O
5 NN O O
% NN O O
) NN O O
, NN O O
but NN O O
relatively NN O O
low NN O O
density NN O O
( NN O O
4 NN O O
. NN O O
8 NN O O
% NN O O
) NN O O
of NN O O
other NN O O
repetitive NN O O
sequences NN O O
. NN O O

BRCA1 NN O O
intron NN O O
lengths NN O O
range NN O O
in NN O O
size NN O O
from NN O O
403 NN O O
bp NN O O
to NN O O
9 NN O O
. NN O O

2 NN O O
kb NN O O
and NN O O
contain NN O O
the NN O O
intragenic NN O O
microsatellite NN O O
markers NN O O
D17S1323 NN O O
, NN O O
D17S1322 NN O O
, NN O O
and NN O O
D17S855 NN O O
, NN O O
which NN O O
localize NN O O
to NN O O
introns NN O O
12 NN O O
, NN O O
19 NN O O
, NN O O
and NN O O
20 NN O O
, NN O O
respectively NN O O
. NN O O

In NN O O
addition NN O O
to NN O O
BRCA1 NN O O
, NN O O
the NN O O
contig NN O O
contains NN O O
two NN O O
complete NN O O
genes NN O O
Rho7 NN O O
, NN O O
a NN O O
member NN O O
of NN O O
the NN O O
rho NN O O
family NN O O
of NN O O
GTP NN O O
binding NN O O
proteins NN O O
, NN O O
and NN O O
VAT1 NN O O
, NN O O
an NN O O
abundant NN O O
membrane NN O O
protein NN O O
of NN O O
cholinergic NN O O
synaptic NN O O
vesicles NN O O
. NN O O

Partial NN O O
sequences NN O O
of NN O O
the NN O O
1A1 NN O O
- NN O O
3B NN O O
B NN O O
- NN O O
box NN O O
protein NN O O
pseudogene NN O O
and NN O O
IFP NN O O
35 NN O O
, NN O O
an NN O O
interferon NN O O
induced NN O O
leucine NN O O
zipper NN O O
protein NN O O
, NN O O
reside NN O O
within NN O O
the NN O O
contig NN O O
. NN O O

An NN O O
L21 NN O O
ribosomal NN O O
protein NN O O
pseudogene NN O O
is NN O O
embedded NN O O
in NN O O
BRCA1 NN O O
intron NN O O
13 NN O O
. NN O O

The NN O O
order NN O O
of NN O O
genes NN O O
on NN O O
the NN O O
chromosome NN O O
is NN O O
centromere NN O O
- NN O O
1FP NN O O
35 NN O O
- NN O O
VAT1 NN O O
- NN O O
Rho7 NN O O
- NN O O
BRCA1 NN O O
- NN O O
1A1 NN O O
- NN O O
3B NN O O
- NN O O
telomere NN O O

Identification NN O O
of NN O O
a NN O O
RING NN O O
protein NN O O
that NN O O
can NN O O
interact NN O O
in NN O O
vivo NN O O
with NN O O
the NN O O
BRCA1 NN O O
gene NN O O
product NN O O
. NN O O

The NN O O
hereditary NN O B-Disease
breast NN O I-Disease
and NN O I-Disease
ovarian NN O I-Disease
cancer NN O I-Disease
gene NN O O
, NN O O
BRCA1 NN O O
, NN O O
encodes NN O O
a NN O O
large NN O O
polypeptide NN O O
that NN O O
contains NN O O
the NN O O
cysteine NN O O
- NN O O
rich NN O O
RING NN O O
motif NN O O
, NN O O
a NN O O
zinc NN O O
- NN O O
binding NN O O
domain NN O O
found NN O O
in NN O O
a NN O O
variety NN O O
of NN O O
regulatory NN O O
proteins NN O O
. NN O O

Here NN O O
we NN O O
describe NN O O
a NN O O
novel NN O O
protein NN O O
that NN O O
interacts NN O O
in NN O O
vivo NN O O
with NN O O
the NN O O
N NN O O
- NN O O
terminal NN O O
region NN O O
of NN O O
BRCA1 NN O O
. NN O O

This NN O O
BRCA1 NN O O
- NN O O
associated NN O O
RING NN O O
domain NN O O
( NN O O
BARD1 NN O O
) NN O O
protein NN O O
contains NN O O
an NN O O
N NN O O
- NN O O
terminal NN O O
RING NN O O
motif NN O O
, NN O O
three NN O O
tandem NN O O
ankyrin NN O O
repeats NN O O
, NN O O
and NN O O
a NN O O
C NN O O
- NN O O
terminal NN O O
sequence NN O O
with NN O O
significant NN O O
homology NN O O
to NN O O
the NN O O
phylogenetically NN O O
conserved NN O O
BRCT NN O O
domains NN O O
that NN O O
lie NN O O
near NN O O
the NN O O
C NN O O
terminus NN O O
of NN O O
BRCA1 NN O O
. NN O O

The NN O O
BARD1 NN O O
/ NN O O
BRCA1 NN O O
interaction NN O O
is NN O O
disrupted NN O O
by NN O O
BRCA1 NN O O
missense NN O O
mutations NN O O
that NN O O
segregate NN O O
with NN O O
breast NN O B-Disease
cancer NN O I-Disease
susceptibility NN O O
, NN O O
indicating NN O O
that NN O O
BARD1 NN O O
may NN O O
be NN O O
involved NN O O
in NN O O
mediating NN O O
tumour NN O B-Disease
suppression NN O O
by NN O O
BRCA1 NN O O
. NN O O
. NN O O

Detection NN O O
of NN O O
heterozygous NN O O
mutations NN O O
in NN O O
BRCA1 NN O O
using NN O O
high NN O O
density NN O O
oligonucleotide NN O O
arrays NN O O
and NN O O
two NN O O
- NN O O
colour NN O O
fluorescence NN O O
analysis NN O O
. NN O O

The NN O O
ability NN O O
to NN O O
scan NN O O
a NN O O
large NN O O
gene NN O O
rapidly NN O O
and NN O O
accurately NN O O
for NN O O
all NN O O
possible NN O O
heterozygous NN O O
mutations NN O O
in NN O O
large NN O O
numbers NN O O
of NN O O
patient NN O O
samples NN O O
will NN O O
be NN O O
critical NN O O
for NN O O
the NN O O
future NN O O
of NN O O
medicine NN O O
. NN O O

We NN O O
have NN O O
designed NN O O
high NN O O
- NN O O
density NN O O
arrays NN O O
consisting NN O O
of NN O O
over NN O O
96 NN O O
, NN O O
600 NN O O
oligonucleotides NN O O
20 NN O O
- NN O O
nucleotides NN O O
( NN O O
nt NN O O
) NN O O
in NN O O
length NN O O
to NN O O
screen NN O O
for NN O O
a NN O O
wide NN O O
range NN O O
of NN O O
heterozygous NN O O
mutations NN O O
in NN O O
the NN O O
3 NN O O
. NN O O

45 NN O O
- NN O O
kilobases NN O O
( NN O O
kb NN O O
) NN O O
exon NN O O
11 NN O O
of NN O O
the NN O O
hereditary NN O B-Disease
breast NN O I-Disease
and NN O I-Disease
ovarian NN O I-Disease
cancer NN O I-Disease
gene NN O O
BRCA1 NN O O
. NN O O

Reference NN O O
and NN O O
test NN O O
samples NN O O
were NN O O
co NN O O
- NN O O
hybridized NN O O
to NN O O
these NN O O
arrays NN O O
and NN O O
differences NN O O
in NN O O
hybridization NN O O
patterns NN O O
quantitated NN O O
by NN O O
two NN O O
- NN O O
colour NN O O
analysis NN O O
. NN O O

Fourteen NN O O
of NN O O
fifteen NN O O
patient NN O O
samples NN O O
with NN O O
known NN O O
mutations NN O O
were NN O O
accurately NN O O
diagnosed NN O O
, NN O O
and NN O O
no NN O O
false NN O O
positive NN O O
mutations NN O O
were NN O O
identified NN O O
in NN O O
20 NN O O
control NN O O
samples NN O O
. NN O O

Eight NN O O
single NN O O
nucleotide NN O O
polymorphisms NN O O
were NN O O
also NN O O
readily NN O O
detected NN O O
. NN O O

DNA NN O O
chip NN O O
- NN O O
based NN O O
assays NN O O
may NN O O
provide NN O O
a NN O O
valuable NN O O
new NN O O
technology NN O O
for NN O O
high NN O O
- NN O O
throughput NN O O
cost NN O O
- NN O O
efficient NN O O
detection NN O O
of NN O O
genetic NN O O
alterations NN O O
. NN O O

Autosomal NN O O
dominant NN O O
primary NN O O
hyperparathyroidism NN O B-Disease
and NN O I-Disease
jaw NN O I-Disease
tumor NN O I-Disease
syndrome NN O I-Disease
associated NN O O
with NN O O
renal NN O B-Disease
hamartomas NN O I-Disease
and NN O O
cystic NN O B-Disease
kidney NN O I-Disease
disease NN O I-Disease
: NN O O
linkage NN O O
to NN O O
1q21 NN O O
- NN O O
q32 NN O O
and NN O O
loss NN O O
of NN O O
the NN O O
wild NN O O
type NN O O
allele NN O O
in NN O O
renal NN O B-Disease
hamartomas NN O I-Disease
. NN O O

Hereditary NN O B-Disease
hyperparathyroidism NN O I-Disease
- NN O I-Disease
jaw NN O I-Disease
tumor NN O I-Disease
syndrome NN O I-Disease
( NN O O
HPT NN O B-Disease
- NN O I-Disease
JT NN O I-Disease
) NN O O
is NN O O
an NN O O
autosomal NN O B-Disease
dominant NN O I-Disease
disease NN O I-Disease
( NN O O
OMIM NN O O
145001 NN O O
) NN O O
that NN O O
has NN O O
recently NN O O
been NN O O
mapped NN O O
to NN O O
chromosomal NN O O
region NN O O
1q21 NN O O
- NN O O
q32 NN O O
( NN O O
HRPT2 NN O O
) NN O O
. NN O O

Here NN O O
we NN O O
report NN O O
two NN O O
families NN O O
with NN O O
HPT NN O B-Disease
- NN O I-Disease
JT NN O I-Disease
syndrome NN O I-Disease
in NN O O
which NN O O
adult NN O B-Disease
renal NN O I-Disease
hamartomas NN O I-Disease
or NN O O
cystic NN O B-Disease
kidney NN O I-Disease
disease NN O I-Disease
were NN O O
prominent NN O O
associated NN O O
features NN O O
, NN O O
possibly NN O O
representing NN O O
a NN O O
new NN O O
phenotypic NN O O
variant NN O O
of NN O O
the NN O O
HPT NN O B-Disease
- NN O I-Disease
JT NN O I-Disease
syndrome NN O I-Disease
. NN O O

In NN O O
the NN O O
first NN O O
family NN O O
, NN O O
renal NN O B-Disease
lesions NN O I-Disease
were NN O O
present NN O O
in NN O O
five NN O O
out NN O O
of NN O O
six NN O O
affected NN O O
individuals NN O O
, NN O O
whereas NN O O
HPT NN O B-Disease
and NN O O
JT NN O B-Disease
were NN O O
seen NN O O
in NN O O
four NN O O
and NN O O
two NN O O
cases NN O O
, NN O O
respectively NN O O
. NN O O

In NN O O
the NN O O
second NN O O
family NN O O
, NN O O
JT NN O B-Disease
was NN O O
found NN O O
in NN O O
three NN O O
of NN O O
the NN O O
five NN O O
affected NN O O
individuals NN O O
and NN O O
two NN O O
affected NN O O
members NN O O
also NN O O
exhibited NN O O
polycystic NN O B-Disease
kidney NN O I-Disease
disease NN O I-Disease
. NN O O

The NN O O
possibility NN O O
of NN O O
the NN O O
latter NN O O
cosegregating NN O O
as NN O O
a NN O O
separate NN O O
autosomal NN O O
dominant NN O O
gene NN O O
can NN O O
not NN O O
be NN O O
ruled NN O O
out NN O O
. NN O O

A NN O O
sex NN O O
- NN O O
dependent NN O O
penetrance NN O O
of NN O O
primary NN O B-Disease
HPT NN O I-Disease
, NN O O
resulting NN O O
in NN O O
predominantly NN O O
male NN O O
- NN O O
affected NN O O
cases NN O O
was NN O O
evident NN O O
in NN O O
the NN O O
two NN O O
families NN O O
. NN O O

Twenty NN O O
microsatellite NN O O
markers NN O O
in NN O O
the NN O O
HRPT2 NN O O
region NN O O
were NN O O
typed NN O O
, NN O O
in NN O O
addition NN O O
to NN O O
markers NN O O
in NN O O
the NN O O
multiple NN O B-Disease
endocrine NN O I-Disease
neoplasia NN O I-Disease
( NN O I-Disease
MEN NN O I-Disease
) NN O I-Disease
types NN O I-Disease
1 NN O I-Disease
and NN O I-Disease
2 NN O I-Disease
regions NN O O
at NN O O
11q13 NN O O
and NN O O
10q11 NN O O
. NN O O

The NN O O
disease NN O O
in NN O O
these NN O O
two NN O O
kindreds NN O O
was NN O O
linked NN O O
to NN O O
five NN O O
markers NN O O
in NN O O
the NN O O
1q21 NN O O
- NN O O
q32 NN O O
region NN O O
( NN O O
logarithm NN O O
- NN O O
of NN O O
- NN O O
odds NN O O
scores NN O O
3 NN O O
. NN O O
2 NN O O
- NN O O
4 NN O O
2 NN O O
- NN O O
4 NN O O
. NN O O
2 NN O O
) NN O O
, NN O O
whereas NN O O
linkage NN O O
to NN O O
the NN O O
MEN1 NN O B-Disease
and NN O O
MEN2 NN O B-Disease
regions NN O O
was NN O O
excluded NN O O
. NN O O

Meiotic NN O O
recombinations NN O O
detected NN O O
in NN O O
affected NN O O
individuals NN O O
placed NN O O
the NN O O
locus NN O O
telomeric NN O O
of NN O O
D1S215 NN O O
, NN O O
thus NN O O
narrowing NN O O
the NN O O
HRPT2 NN O O
region NN O O
from NN O O
> NN O O
60 NN O O
to NN O O
approximately NN O O
34 NN O O
centimorgans NN O O
. NN O O

Loss NN O O
of NN O O
heterozygosity NN O O
was NN O O
studied NN O O
in NN O O
seven NN O O
renal NN O B-Disease
hamartomas NN O I-Disease
from NN O O
two NN O O
affected NN O O
individuals NN O O
in NN O O
the NN O O
first NN O O
family NN O O
, NN O O
as NN O O
well NN O O
as NN O O
in NN O O
a NN O O
jaw NN O B-Disease
tumor NN O I-Disease
and NN O O
a NN O O
parathyroid NN O B-Disease
tumor NN O I-Disease
from NN O O
the NN O O
second NN O O
family NN O O
. NN O O

All NN O O
renal NN O B-Disease
hamartomas NN O I-Disease
showed NN O O
loss NN O O
of NN O O
heterozygosity NN O O
at NN O O
the NN O O
1q21 NN O O
- NN O O
q32 NN O O
region NN O O
. NN O O

The NN O O
losses NN O O
invariably NN O O
involved NN O O
the NN O O
wild NN O O
type NN O O
allele NN O O
derived NN O O
from NN O O
the NN O O
unaffected NN O O
parent NN O O
, NN O O
suggesting NN O O
the NN O O
inactivation NN O O
of NN O O
a NN O O
tumor NN O B-Disease
suppressor NN O O
gene NN O O
in NN O O
this NN O O
region NN O O

Independent NN O O
origin NN O O
of NN O O
single NN O O
and NN O O
double NN O O
mutations NN O O
in NN O O
the NN O O
human NN O O
glucose NN O O
6 NN O O
- NN O O
phosphate NN O O
dehydrogenase NN O O
gene NN O O
. NN O O

The NN O O
vast NN O O
majority NN O O
of NN O O
both NN O O
polymorphic NN O O
and NN O O
sporadic NN O O
G6PD NN O O
variants NN O O
are NN O O
due NN O O
to NN O O
single NN O O
missense NN O O
mutations NN O O
. NN O O

In NN O O
the NN O O
four NN O O
polymorphic NN O O
variants NN O O
that NN O O
have NN O O
two NN O O
point NN O O
mutations NN O O
, NN O O
one NN O O
of NN O O
the NN O O
mutations NN O O
is NN O O
always NN O O
376 NN O O
A NN O O
- NN O O
- NN O O
> NN O O
G NN O O
( NN O O
126 NN O O
Asn NN O O
- NN O O
- NN O O
> NN O O
Asp NN O O
) NN O O
, NN O O
which NN O O
on NN O O
its NN O O
own NN O O
gives NN O O
rise NN O O
to NN O O
the NN O O
nondeficient NN O O
polymorphic NN O O
variant NN O O
, NN O O
G6PD NN O O
A NN O O
. NN O O

In NN O O
a NN O O
study NN O O
of NN O O
G6PD NN O B-Disease
deficient NN O I-Disease
patients NN O O
who NN O O
presented NN O O
with NN O O
clinical NN O O
favism NN O B-Disease
in NN O O
Spain NN O O
, NN O O
we NN O O
have NN O O
found NN O O
a NN O O
new NN O O
polymorphic NN O O
variant NN O O
that NN O O
we NN O O
have NN O O
called NN O O
G6PD NN O O
Malaga NN O O
, NN O O
whose NN O O
only NN O O
abnormality NN O O
is NN O O
a NN O O
542 NN O O
A NN O O
- NN O O
- NN O O
> NN O O
T NN O O
( NN O O
181 NN O O
Asp NN O O
- NN O O
- NN O O
> NN O O
Val NN O O
) NN O O
mutation NN O O
. NN O O

This NN O O
is NN O O
the NN O O
same NN O O
mutation NN O O
as NN O O
previously NN O O
found NN O O
in NN O O
association NN O O
with NN O O
the NN O O
mutation NN O O
of NN O O
G6PD NN O O
A NN O O
in NN O O
the NN O O
double NN O O
mutant NN O O
, NN O O
G6PD NN O O
Santamaria NN O O
. NN O O

G6PD NN O O
Malaga NN O O
is NN O O
associated NN O O
with NN O O
enzyme NN O B-Disease
deficiency NN O I-Disease
( NN O O
class NN O O
III NN O O
) NN O O
, NN O O
and NN O O
the NN O O
enzymic NN O O
properties NN O O
of NN O O
G6PD NN O O
Malaga NN O O
and NN O O
G6PD NN O O
Santamaria NN O O
are NN O O
quite NN O O
similar NN O O
, NN O O
indicating NN O O
that NN O O
in NN O O
this NN O O
case NN O O
the NN O O
effects NN O O
of NN O O
the NN O O
two NN O O
mutations NN O O
are NN O O
additive NN O O
rather NN O O
than NN O O
synergistic NN O O
. NN O O

G6PD NN O O
Santamaria NN O O
might NN O O
have NN O O
been NN O O
produced NN O O
by NN O O
recombination NN O O
between NN O O
G6PD NN O O
A NN O O
and NN O O
G6PD NN O O
Malaga NN O O
; NN O O
however NN O O
haplotype NN O O
analysis NN O O
, NN O O
including NN O O
the NN O O
use NN O O
of NN O O
a NN O O
new NN O O
silent NN O O
polymorphism NN O O
, NN O O
suggests NN O O
that NN O O
the NN O O
same NN O O
542 NN O O
A NN O O
- NN O O
- NN O O
> NN O O
T NN O O
mutation NN O O
has NN O O
taken NN O O
place NN O O
independently NN O O
in NN O O
a NN O O
G6PD NN O O
B NN O O
gene NN O O
to NN O O
give NN O O
G6PD NN O O
Malaga NN O O
and NN O O
in NN O O
a NN O O
G6PD NN O O
A NN O O
gene NN O O
to NN O O
give NN O O
G6PD NN O O
Santamaria NN O O
. NN O O

These NN O O
findings NN O O
help NN O O
to NN O O
outline NN O O
the NN O O
relationship NN O O
and NN O O
evolution NN O O
of NN O O
mutations NN O O
in NN O O
the NN O O
human NN O O
G6PD NN O O
locus NN O O
. NN O O
. NN O O

BRCA1 NN O O
R841W NN O O
: NN O O
a NN O O
strong NN O O
candidate NN O O
for NN O O
a NN O O
common NN O O
mutation NN O O
with NN O O
moderate NN O O
phenotype NN O O
. NN O O

BRCA1 NN O O
mutations NN O O
cause NN O O
increased NN O O
risk NN O O
for NN O O
breast NN O B-Disease
and NN O I-Disease
ovarian NN O I-Disease
cancer NN O I-Disease
, NN O O
frequently NN O O
of NN O O
early NN O O
onset NN O O
. NN O O

Many NN O O
different NN O O
mutations NN O O
occur NN O O
in NN O O
BRCA1 NN O O
, NN O O
including NN O O
several NN O O
examples NN O O
of NN O O
recurrent NN O O
mutations NN O O
, NN O O
each NN O O
of NN O O
which NN O O
accounts NN O O
for NN O O
a NN O O
significant NN O O
number NN O O
of NN O O
families NN O O
with NN O O
heritable NN O O
cancer NN O B-Disease
predisposition NN O O
. NN O O

These NN O O
common NN O O
mutations NN O O
have NN O O
an NN O O
etiological NN O O
role NN O O
in NN O O
many NN O O
breast NN O B-Disease
and NN O I-Disease
ovarian NN O I-Disease
cancer NN O I-Disease
cases NN O O
and NN O O
provide NN O O
the NN O O
opportunity NN O O
to NN O O
examine NN O O
genotype NN O O
- NN O O
phenotype NN O O
correlations NN O O
and NN O O
genotype NN O O
- NN O O
environment NN O O
interactions NN O O
in NN O O
individuals NN O O
with NN O O
the NN O O
identical NN O O
BRCA1 NN O O
lesion NN O O
. NN O O

We NN O O
report NN O O
a NN O O
novel NN O O
missense NN O O
change NN O O
in NN O O
BRCA1 NN O O
, NN O O
2640 NN O O
C NN O O
- NN O O
- NN O O
> NN O O
T NN O O
( NN O O
R841W NN O O
) NN O O
, NN O O
found NN O O
in NN O O
3 NN O O
cases NN O O
from NN O O
a NN O O
subject NN O O
group NN O O
of NN O O
305 NN O O
breast NN O B-Disease
and NN O I-Disease
79 NN O I-Disease
ovarian NN O I-Disease
cancer NN O I-Disease
cases NN O O
from NN O O
Orange NN O O
County NN O O
, NN O O
CA NN O O
. NN O O

These NN O O
are NN O O
consecutive NN O O
, NN O O
population NN O O
- NN O O
based NN O O
cases NN O O
not NN O O
selected NN O O
for NN O O
age NN O O
or NN O O
family NN O O
history NN O O
. NN O O

In NN O O
all NN O O
three NN O O
cases NN O O
, NN O O
there NN O O
is NN O O
a NN O O
strong NN O O
family NN O O
history NN O O
of NN O O
breast NN O B-Disease
, NN O I-Disease
ovarian NN O I-Disease
, NN O I-Disease
or NN O I-Disease
other NN O I-Disease
cancers NN O I-Disease
possibly NN O O
related NN O O
to NN O O
a NN O O
BRCA1 NN O O
defect NN O O
and NN O O
family NN O O
members NN O O
showed NN O O
a NN O O
high NN O O
concordance NN O O
of NN O O
cancer NN O B-Disease
incidence NN O O
with NN O O
the NN O O
presence NN O O
of NN O O
R841W NN O O
. NN O O

The NN O O
age NN O O
of NN O O
cancer NN O B-Disease
onset NN O O
was NN O O
not NN O O
always NN O O
distinct NN O O
from NN O O
typical NN O O
sporadic NN O O
cases NN O O
. NN O O

Testing NN O O
of NN O O
a NN O O
sample NN O O
of NN O O
413 NN O O
unrelated NN O O
individuals NN O O
to NN O O
examine NN O O
the NN O O
hypothesis NN O O
that NN O O
R841W NN O O
might NN O O
be NN O O
a NN O O
rare NN O O
polymorphism NN O O
detected NN O O
one NN O O
additional NN O O
instance NN O O
in NN O O
a NN O O
woman NN O O
with NN O O
breast NN O B-Disease
cancer NN O I-Disease
diagnosed NN O O
at NN O O
age NN O O
77 NN O O
years NN O O
, NN O O
and NN O O
cancer NN O B-Disease
in NN O O
one NN O O
parent NN O O
. NN O O

R841W NN O O
is NN O O
likely NN O O
to NN O O
be NN O O
an NN O O
etiologically NN O O
significant NN O O
lesion NN O O
with NN O O
involvement NN O O
in NN O O
close NN O O
to NN O O
1 NN O O
% NN O O
( NN O O
95 NN O O
% NN O O
confidence NN O O
interval NN O O
of NN O O
0 NN O O
- NN O O
1 NN O O
. NN O O
7 NN O O
% NN O O
) NN O O
of NN O O
all NN O O
breast NN O B-Disease
and NN O I-Disease
ovarian NN O I-Disease
cancers NN O I-Disease
in NN O O
this NN O O
population NN O O
. NN O O

Ataxia NN O B-Disease
- NN O I-Disease
telangiectasia NN O I-Disease
: NN O O
founder NN O O
effect NN O O
among NN O O
north NN O O
African NN O O
Jews NN O O
. NN O O

The NN O O
ATM NN O O
gene NN O O
is NN O O
responsible NN O O
for NN O O
the NN O O
autosomal NN O B-Disease
recessive NN O I-Disease
disorder NN O I-Disease
ataxia NN O B-Disease
- NN O I-Disease
telangiectasia NN O I-Disease
( NN O O
A NN O B-Disease
- NN O I-Disease
T NN O I-Disease
) NN O O
, NN O O
characterized NN O O
by NN O O
cerebellar NN O B-Disease
degeneration NN O I-Disease
, NN O O
immunodeficiency NN O B-Disease
and NN O O
cancer NN O B-Disease
predisposition NN O I-Disease
. NN O O

A NN O B-Disease
- NN O I-Disease
T NN O I-Disease
carriers NN O O
were NN O O
reported NN O O
to NN O O
be NN O O
moderately NN O O
cancer NN O B-Disease
- NN O I-Disease
prone NN O I-Disease
. NN O O

A NN O O
wide NN O O
variety NN O O
of NN O O
A NN O B-Disease
- NN O I-Disease
T NN O I-Disease
mutations NN O O
, NN O O
most NN O O
of NN O O
which NN O O
are NN O O
unique NN O O
to NN O O
single NN O O
families NN O O
, NN O O
were NN O O
identified NN O O
in NN O O
various NN O O
ethnic NN O O
groups NN O O
, NN O O
precluding NN O O
carrier NN O O
screening NN O O
with NN O O
mutation NN O O
- NN O O
specific NN O O
assays NN O O
. NN O O

However NN O O
, NN O O
a NN O O
single NN O O
mutation NN O O
was NN O O
observed NN O O
in NN O O
32 NN O O
/ NN O O
33 NN O O
defective NN O O
ATM NN O O
alleles NN O O
in NN O O
Jewish NN O O
A NN O B-Disease
- NN O I-Disease
T NN O I-Disease
families NN O O
of NN O O
North NN O O
African NN O O
origin NN O O
, NN O O
coming NN O O
from NN O O
various NN O O
regions NN O O
of NN O O
Morocco NN O O
and NN O O
Tunisia NN O O
. NN O O

This NN O O
mutation NN O O
, NN O O
103C NN O O
- NN O O
- NN O O
> NN O O
T NN O O
, NN O O
results NN O O
in NN O O
a NN O O
stop NN O O
codon NN O O
at NN O O
position NN O O
35 NN O O
of NN O O
the NN O O
ATM NN O O
protein NN O O
. NN O O

In NN O O
keeping NN O O
with NN O O
the NN O O
nature NN O O
of NN O O
this NN O O
mutation NN O O
, NN O O
various NN O O
antibodies NN O O
directed NN O O
against NN O O
the NN O O
ATM NN O O
protein NN O O
failed NN O O
to NN O O
defect NN O O
this NN O O
protein NN O O
in NN O O
patient NN O O
cells NN O O
. NN O O

A NN O O
rapid NN O O
carrier NN O O
detection NN O O
assay NN O O
detected NN O O
this NN O O
mutation NN O O
in NN O O
three NN O O
out NN O O
of NN O O
488 NN O O
ATM NN O O
alleles NN O O
of NN O O
Jewish NN O O
Moroccan NN O O
or NN O O
Tunisian NN O O
origin NN O O
. NN O O

This NN O O
founder NN O O
effect NN O O
provides NN O O
a NN O O
unique NN O O
opportunity NN O O
for NN O O
population NN O O
- NN O O
based NN O O
screening NN O O
for NN O O
A NN O B-Disease
- NN O I-Disease
T NN O I-Disease
carriers NN O O
in NN O O
a NN O O
large NN O O
Jewish NN O O
community NN O O
. NN O O
. NN O O

Mutation NN O O
analysis NN O O
of NN O O
BRCA1 NN O O
and NN O O
BRCA2 NN O O
in NN O O
a NN O O
male NN O B-Disease
breast NN O I-Disease
cancer NN O I-Disease
population NN O O
. NN O O

A NN O O
population NN O O
- NN O O
based NN O O
series NN O O
of NN O O
54 NN O O
male NN O B-Disease
breast NN O I-Disease
cancer NN O I-Disease
cases NN O O
from NN O O
Southern NN O O
California NN O O
were NN O O
analyzed NN O O
for NN O O
germ NN O O
- NN O O
line NN O O
mutations NN O O
in NN O O
the NN O O
inherited NN O B-Disease
breast NN O I-Disease
/ NN O I-Disease
ovarian NN O I-Disease
cancer NN O I-Disease
genes NN O O
, NN O O
BRCA1 NN O O
and NN O O
BRCA2 NN O O
. NN O O

Nine NN O O
( NN O O
17 NN O O
% NN O O
) NN O O
of NN O O
the NN O O
patients NN O O
had NN O O
a NN O O
family NN O O
history NN O O
of NN O O
breast NN O B-Disease
and NN O I-Disease
/ NN O I-Disease
or NN O I-Disease
ovarian NN O I-Disease
cancer NN O I-Disease
in NN O O
at NN O O
least NN O O
one NN O O
first NN O O
- NN O O
degree NN O O
relative NN O O
. NN O O

A NN O O
further NN O O
seven NN O O
( NN O O
13 NN O O
% NN O O
) NN O O
of NN O O
the NN O O
patients NN O O
reported NN O O
breast NN O B-Disease
/ NN O I-Disease
ovarian NN O I-Disease
cancer NN O I-Disease
in NN O O
at NN O O
least NN O O
one NN O O
second NN O O
- NN O O
degree NN O O
relative NN O O
and NN O O
in NN O O
no NN O O
first NN O O
- NN O O
degree NN O O
relatives NN O O
. NN O O

No NN O O
germ NN O O
- NN O O
line NN O O
BRCA1 NN O O
mutations NN O O
were NN O O
found NN O O
. NN O O

Two NN O O
male NN O B-Disease
breast NN O I-Disease
cancer NN O I-Disease
patients NN O O
( NN O O
4 NN O O
% NN O O
of NN O O
the NN O O
total NN O O
) NN O O
were NN O O
found NN O O
to NN O O
carry NN O O
novel NN O O
truncating NN O O
mutations NN O O
in NN O O
the NN O O
BRCA2 NN O O
gene NN O O
. NN O O

Only NN O O
one NN O O
of NN O O
the NN O O
two NN O O
male NN O B-Disease
breast NN O I-Disease
cancer NN O I-Disease
patients NN O O
carrying NN O O
a NN O O
BRCA2 NN O O
mutation NN O O
had NN O O
a NN O O
family NN O O
history NN O O
of NN O O
cancer NN O B-Disease
, NN O O
with NN O O
one NN O O
case NN O O
of NN O O
ovarian NN O B-Disease
cancer NN O I-Disease
in NN O O
a NN O O
first NN O O
- NN O O
degree NN O O
relative NN O O
. NN O O

The NN O O
remaining NN O O
eight NN O O
cases NN O O
( NN O O
89 NN O O
% NN O O
) NN O O
of NN O O
male NN O B-Disease
breast NN O I-Disease
cancer NN O I-Disease
with NN O O
a NN O O
family NN O O
history NN O O
of NN O O
breast NN O B-Disease
/ NN O I-Disease
ovarian NN O I-Disease
cancer NN O I-Disease
in NN O O
first NN O O
- NN O O
degree NN O O
relatives NN O O
remain NN O O
unaccounted NN O O
for NN O O
by NN O O
mutations NN O O
in NN O O
either NN O O
the NN O O
BRCA1 NN O O
gene NN O O
or NN O O
the NN O O
BRCA2 NN O O
gene NN O O
. NN O O
. NN O O

Molecular NN O O
basis NN O O
for NN O O
Duarte NN O B-Disease
and NN O I-Disease
Los NN O I-Disease
Angeles NN O I-Disease
variant NN O I-Disease
galactosemia NN O I-Disease
. NN O O

Human NN O O
orythrocytes NN O O
that NN O O
are NN O O
homozygous NN O O
for NN O O
the NN O O
Duarte NN O B-Disease
enzyme NN O I-Disease
variant NN O I-Disease
of NN O I-Disease
galactosemia NN O I-Disease
( NN O O
D NN O O
/ NN O O
D NN O O
) NN O O
have NN O O
a NN O O
characteristic NN O O
isoform NN O O
on NN O O
isoelectric NN O O
focusing NN O O
and NN O O
50 NN O O
% NN O O
reduction NN O O
in NN O O
galactose NN O O
- NN O O
1 NN O O
- NN O O
phosphate NN O O
uridyltransferase NN O O
( NN O O
GALT NN O O
) NN O O
enzyme NN O O
activity NN O O
. NN O O

The NN O O
Duarte NN O O
biochemical NN O O
phenotype NN O O
has NN O O
a NN O O
molecular NN O O
genotype NN O O
of NN O O
N314D NN O O
/ NN O O
N314D NN O O
. NN O O

The NN O O
characteristic NN O O
Duarte NN O O
isoform NN O O
is NN O O
also NN O O
associated NN O O
with NN O O
a NN O O
variant NN O O
called NN O O
the NN O O
" NN O O
Los NN O O
Angeles NN O O
( NN O O
LA NN O O
) NN O O
phenotype NN O O
, NN O O
" NN O O
which NN O O
has NN O O
increased NN O O
GALT NN O O
enzyme NN O O
activity NN O O
. NN O O

We NN O O
evaluated NN O O
GALT NN O O
enzyme NN O O
activity NN O O
and NN O O
screened NN O O
the NN O O
GALT NN O O
genes NN O O
of NN O O
145 NN O O
patients NN O O
with NN O O
one NN O O
or NN O O
more NN O O
N314D NN O O
- NN O O
containing NN O O
alleles NN O O
. NN O O

We NN O O
found NN O O
seven NN O O
with NN O O
the NN O O
LA NN O O
biochemical NN O O
phenotype NN O O
, NN O O
and NN O O
all NN O O
had NN O O
a NN O O
1721C NN O O
- NN O O
- NN O O
> NN O O
T NN O O
transition NN O O
in NN O O
exon NN O O
7 NN O O
in NN O O
cis NN O O
with NN O O
the NN O O
N314D NN O O
missense NN O O
mutation NN O O
. NN O O

The NN O O
1721C NN O O
- NN O O
- NN O O
> NN O O
T NN O O
transition NN O O
is NN O O
a NN O O
neutral NN O O
polymorphism NN O O
for NN O O
leucine NN O O
at NN O O
amino NN O O
acid NN O O
218 NN O O
( NN O O
L218L NN O O
) NN O O
. NN O O

In NN O O
pedigree NN O O
analyses NN O O
, NN O O
this NN O O
1721C NN O O
- NN O O
- NN O O
> NN O O
T NN O O
transition NN O O
segregated NN O O
with NN O O
the NN O O
LA NN O O
phenotype NN O O
of NN O O
increased NN O O
GALT NN O O
activity NN O O
in NN O O
three NN O O
different NN O O
biochemical NN O O
phenotypes NN O O
( NN O O
LA NN O O
/ NN O O
N NN O O
, NN O O
LA NN O O
/ NN O O
G NN O O
, NN O O
and NN O O
LA NN O O
/ NN O O
D NN O O
) NN O O
. NN O O

To NN O O
determine NN O O
the NN O O
mechanism NN O O
for NN O O
increased NN O O
activity NN O O
of NN O O
the NN O O
LA NN O O
variant NN O O
, NN O O
we NN O O
compared NN O O
GALT NN O O
mRNA NN O O
, NN O O
protein NN O O
abundance NN O O
, NN O O
and NN O O
enzyme NN O O
thermal NN O O
stability NN O O
in NN O O
lymphoblast NN O O
cell NN O O
lines NN O O
of NN O O
D NN O O
and NN O O
LA NN O O
phenotypes NN O O
with NN O O
comparable NN O O
genotypes NN O O
. NN O O

GALT NN O O
protein NN O O
abundance NN O O
was NN O O
increased NN O O
in NN O O
LA NN O O
compared NN O O
to NN O O
D NN O O
alleles NN O O
, NN O O
but NN O O
mRNA NN O O
was NN O O
similar NN O O
among NN O O
all NN O O
genotypes NN O O
. NN O O

When NN O O
LA NN O O
/ NN O O
D NN O O
and NN O O
D NN O O
/ NN O O
D NN O O
GALT NN O O
biochemical NN O O
phenotypes NN O O
were NN O O
compared NN O O
to NN O O
N NN O O
/ NN O O
N NN O O
GALT NN O O
phenotypes NN O O
, NN O O
both NN O O
had NN O O
50 NN O O
% NN O O
, NN O O
as NN O O
compared NN O O
to NN O O
21 NN O O
% NN O O
, NN O O
reduction NN O O
in NN O O
GALT NN O O
activity NN O O
in NN O O
the NN O O
wild NN O O
type NN O O
( NN O O
N NN O O
/ NN O O
N NN O O
) NN O O
after NN O O
exposure NN O O
at NN O O
identical NN O O
initial NN O O
enzyme NN O O
activity NN O O
to NN O O
50 NN O O
degrees NN O O
C NN O O
for NN O O
15 NN O O
min NN O O
. NN O O

We NN O O
conclude NN O O
that NN O O
the NN O O
codon NN O O
change NN O O
N314D NN O O
in NN O O
cis NN O O
with NN O O
the NN O O
base NN O O
- NN O O
pair NN O O
transition NN O O
1721C NN O O
- NN O O
- NN O O
> NN O O
T NN O O
produces NN O O
the NN O O
LA NN O B-Disease
variant NN O I-Disease
of NN O I-Disease
galactosemia NN O I-Disease
and NN O O
that NN O O
this NN O O
nucleotide NN O O
change NN O O
increases NN O O
GALT NN O O
activity NN O O
by NN O O
increasing NN O O
GALT NN O O
protein NN O O
abundance NN O O
without NN O O
increasing NN O O
transcription NN O O
or NN O O
decreasing NN O O
thermal NN O O
lability NN O O
. NN O O

A NN O O
favorable NN O O
codon NN O O
bias NN O O
for NN O O
the NN O O
mutated NN O O
codon NN O O
with NN O O
consequently NN O O
increased NN O O
translation NN O O
rates NN O O
is NN O O
postulated NN O O
as NN O O
the NN O O
mechanism NN O O
. NN O O
. NN O O

The NN O O
TSG101 NN O O
tumor NN O B-Disease
susceptibility NN O O
gene NN O O
is NN O O
located NN O O
in NN O O
chromosome NN O O
11 NN O O
band NN O O
p15 NN O O
and NN O O
is NN O O
mutated NN O O
in NN O O
human NN O O
breast NN O B-Disease
cancer NN O I-Disease
. NN O O

Recent NN O O
work NN O O
has NN O O
identified NN O O
a NN O O
mouse NN O O
gene NN O O
( NN O O
tsg101 NN O O
) NN O O
whose NN O O
inactivation NN O O
in NN O O
fibroblasts NN O O
results NN O O
in NN O O
cellular NN O O
transformation NN O O
and NN O O
the NN O O
ability NN O O
to NN O O
produce NN O O
metastatic NN O B-Disease
tumors NN O I-Disease
in NN O O
nude NN O O
mice NN O O
. NN O O

Here NN O O
, NN O O
we NN O O
report NN O O
that NN O O
the NN O O
human NN O O
homolog NN O O
, NN O O
TSG101 NN O O
, NN O O
which NN O O
we NN O O
isolated NN O O
and NN O O
mapped NN O O
to NN O O
chromosome NN O O
11 NN O O
, NN O O
bands NN O O
15 NN O O
. NN O O

1 NN O O
- NN O O
15 NN O O
1 NN O O
- NN O O
15 NN O O
. NN O O

2 NN O O
, NN O O
a NN O O
region NN O O
proposed NN O O
to NN O O
contain NN O O
tumor NN O B-Disease
suppressor NN O O
gene NN O O
( NN O O
s NN O O
) NN O O
, NN O O
is NN O O
mutated NN O O
at NN O O
high NN O O
frequency NN O O
in NN O O
human NN O O
breast NN O B-Disease
cancer NN O I-Disease
. NN O O

In NN O O
7 NN O O
of NN O O
15 NN O O
uncultured NN O O
primary NN O O
human NN O O
breast NN O B-Disease
carcinomas NN O I-Disease
, NN O O
intragenic NN O O
deletions NN O O
were NN O O
shown NN O O
in NN O O
TSG101 NN O O
genomic NN O O
DNA NN O O
and NN O O
transcripts NN O O
by NN O O
gel NN O O
and NN O O
sequence NN O O
analysis NN O O
, NN O O
and NN O O
mutations NN O O
affecting NN O O
two NN O O
TSG101 NN O O
alleles NN O O
were NN O O
identified NN O O
in NN O O
four NN O O
of NN O O
these NN O O
cancers NN O B-Disease
. NN O O

No NN O O
TSG101 NN O O
defects NN O O
were NN O O
found NN O O
in NN O O
matched NN O O
normal NN O O
breast NN O O
tissue NN O O
from NN O O
the NN O O
breast NN O B-Disease
cancer NN O I-Disease
patients NN O O
. NN O O

These NN O O
findings NN O O
strongly NN O O
implicate NN O O
TSG101 NN O O
mutations NN O O
in NN O O
human NN O O
breast NN O B-Disease
cancer NN O I-Disease

Moderate NN O O
intergenerational NN O O
and NN O O
somatic NN O O
instability NN O O
of NN O O
a NN O O
55 NN O O
- NN O O
CTG NN O O
repeat NN O O
in NN O O
transgenic NN O O
mice NN O O
. NN O O

Myotonic NN O B-Disease
dystrophy NN O I-Disease
( NN O O
DM NN O B-Disease
) NN O O
is NN O O
associated NN O O
with NN O O
the NN O O
expansion NN O O
of NN O O
a NN O O
( NN O O
CTG NN O O
) NN O O
n NN O O
trinucleotide NN O O
repeat NN O O
in NN O O
the NN O O
3 NN O O
untranslated NN O O
region NN O O
( NN O O
UTR NN O O
) NN O O
of NN O O
the NN O O
DM NN O B-Disease
protein NN O O
kinase NN O O
gene NN O O
( NN O O
DMPK NN O O
) NN O O
. NN O O

The NN O O
( NN O O
CTG NN O O
) NN O O
n NN O O
repeat NN O O
is NN O O
polymorphic NN O O
and NN O O
varies NN O O
in NN O O
size NN O O
between NN O O
5 NN O O
and NN O O
37 NN O O
repeats NN O O
in NN O O
unaffected NN O O
individuals NN O O
whereas NN O O
in NN O O
affected NN O O
patients NN O O
there NN O O
are NN O O
between NN O O
50 NN O O
and NN O O
4 NN O O
, NN O O
000 NN O O
CTGs NN O O
. NN O O

The NN O O
size NN O O
of NN O O
the NN O O
( NN O O
CTG NN O O
) NN O O
n NN O O
repeat NN O O
, NN O O
which NN O O
increases NN O O
through NN O O
generations NN O O
, NN O O
generally NN O O
correlates NN O O
with NN O O
clinical NN O O
severity NN O O
and NN O O
age NN O O
of NN O O
onset NN O O
. NN O O

The NN O O
instability NN O O
of NN O O
the NN O O
CTG NN O O
repeat NN O O
appears NN O O
to NN O O
depend NN O O
on NN O O
its NN O O
size NN O O
as NN O O
well NN O O
as NN O O
on NN O O
the NN O O
sex NN O O
of NN O O
the NN O O
transmitting NN O O
parent NN O O
. NN O O

Moreover NN O O
, NN O O
mitotic NN O O
instability NN O O
analysis NN O O
of NN O O
different NN O O
human NN O O
DM NN O B-Disease
tissues NN O O
shows NN O O
length NN O O
mosaicism NN O O
between NN O O
different NN O O
cell NN O O
lineages NN O O
. NN O O

The NN O O
molecular NN O O
mechanisms NN O O
of NN O O
triplet NN O O
instability NN O O
remain NN O O
elusive NN O O
. NN O O

To NN O O
investigate NN O O
the NN O O
role NN O O
of NN O O
genomic NN O O
sequences NN O O
in NN O O
instability NN O O
, NN O O
we NN O O
produced NN O O
transgenic NN O O
mice NN O O
containing NN O O
a NN O O
45 NN O O
- NN O O
kb NN O O
genomic NN O O
segment NN O O
with NN O O
a NN O O
55 NN O O
- NN O O
CTG NN O O
repeat NN O O
cloned NN O O
from NN O O
a NN O O
mildly NN O O
affected NN O O
patient NN O O
. NN O O

In NN O O
contrast NN O O
to NN O O
other NN O O
mouse NN O O
models NN O O
containing NN O O
CAG NN O O
repeats NN O O
within NN O O
cDNAs NN O O
, NN O O
these NN O O
mice NN O O
showed NN O O
both NN O O
intergenerational NN O O
and NN O O
somatic NN O O
repeat NN O O
instability NN O O
. NN O O
. NN O O

Missense NN O O
mutations NN O O
in NN O O
the NN O O
Fas NN O O
gene NN O O
resulting NN O O
in NN O O
autoimmune NN O B-Disease
lymphoproliferative NN O I-Disease
syndrome NN O I-Disease
: NN O O
a NN O O
molecular NN O O
and NN O O
immunological NN O O
analysis NN O O
. NN O O

Programmed NN O O
cell NN O O
death NN O O
( NN O O
or NN O O
apoptosis NN O O
) NN O O
is NN O O
a NN O O
physiological NN O O
process NN O O
essential NN O O
to NN O O
the NN O O
normal NN O O
development NN O O
and NN O O
homeostatic NN O O
maintenance NN O O
of NN O O
the NN O O
immune NN O O
system NN O O
. NN O O

The NN O O
Fas NN O O
/ NN O O
Apo NN O O
- NN O O
1 NN O O
receptor NN O O
plays NN O O
a NN O O
crucial NN O O
role NN O O
in NN O O
the NN O O
regulation NN O O
of NN O O
apoptosis NN O O
, NN O O
as NN O O
demonstrated NN O O
by NN O O
lymphoproliferation NN O O
in NN O O
MRL NN O O
- NN O O
lpr NN O O
/ NN O O
lpr NN O O
mice NN O O
and NN O O
by NN O O
the NN O O
recently NN O O
described NN O O
autoimmune NN O B-Disease
lymphoproliferative NN O I-Disease
syndrome NN O I-Disease
( NN O O
ALPS NN O B-Disease
) NN O O
in NN O O
humans NN O O
, NN O O
both NN O O
of NN O O
which NN O O
are NN O O
due NN O O
to NN O O
mutations NN O O
in NN O O
the NN O O
Fas NN O O
gene NN O O
. NN O O

We NN O O
describe NN O O
a NN O O
novel NN O O
family NN O O
with NN O O
ALPS NN O B-Disease
in NN O O
which NN O O
three NN O O
affected NN O O
siblings NN O O
carry NN O O
two NN O O
distinct NN O O
missense NN O O
mutations NN O O
on NN O O
both NN O O
the NN O O
Fas NN O O
gene NN O O
alleles NN O O
and NN O O
show NN O O
lack NN O O
of NN O O
Fas NN O O
- NN O O
induced NN O O
apoptosis NN O O
. NN O O

The NN O O
children NN O O
share NN O O
common NN O O
clinical NN O O
features NN O O
including NN O O
splenomegaly NN O B-Disease
and NN O O
lymphadenopathy NN O B-Disease
, NN O O
but NN O O
only NN O O
one NN O O
developed NN O O
severe NN O O
autoimmune NN O B-Disease
manifestations NN O I-Disease
. NN O O

In NN O O
all NN O O
three NN O O
siblings NN O O
, NN O O
we NN O O
demonstrated NN O O
the NN O O
presence NN O O
of NN O O
anergic NN O O
CD3 NN O O
+ NN O O
CD4 NN O O
- NN O O
CD8 NN O O
- NN O O
( NN O O
double NN O O
negative NN O O
, NN O O
[ NN O O
DN NN O O
] NN O O
) NN O O
T NN O O
cells NN O O
; NN O O
moreover NN O O
, NN O O
a NN O O
chronic NN O O
lymphocyte NN O O
activation NN O O
was NN O O
found NN O O
, NN O O
as NN O O
demonstrated NN O O
by NN O O
the NN O O
presence NN O O
of NN O O
high NN O O
levels NN O O
of NN O O
HLA NN O O
- NN O O
DR NN O O
expression NN O O
on NN O O
peripheral NN O O
CD3 NN O O
+ NN O O
cells NN O O
and NN O O
by NN O O
the NN O O
presence NN O O
of NN O O
high NN O O
levels NN O O
of NN O O
serum NN O O
activation NN O O
markers NN O O
such NN O O
as NN O O
soluble NN O O
interleukin NN O O
- NN O O
2 NN O O
receptor NN O O
( NN O O
slL NN O O
- NN O O
2R NN O O
) NN O O
and NN O O
soluble NN O O
CD30 NN O O
( NN O O
sCD30 NN O O
) NN O O
. NN O O
. NN O O

The NN O O
ataxia NN O B-Disease
- NN O I-Disease
telangiectasia NN O I-Disease
gene NN O O
product NN O O
, NN O O
a NN O O
constitutively NN O O
expressed NN O O
nuclear NN O O
protein NN O O
that NN O O
is NN O O
not NN O O
up NN O O
- NN O O
regulated NN O O
following NN O O
genome NN O O
damage NN O O
. NN O O

The NN O O
product NN O O
of NN O O
the NN O O
ataxia NN O B-Disease
- NN O I-Disease
telangiectasia NN O I-Disease
gene NN O O
( NN O O
ATM NN O O
) NN O O
was NN O O
identified NN O O
by NN O O
using NN O O
an NN O O
antiserum NN O O
developed NN O O
to NN O O
a NN O O
peptide NN O O
corresponding NN O O
to NN O O
the NN O O
deduced NN O O
amino NN O O
acid NN O O
sequence NN O O
. NN O O

The NN O O
ATM NN O O
protein NN O O
is NN O O
a NN O O
single NN O O
, NN O O
high NN O O
- NN O O
molecular NN O O
weight NN O O
protein NN O O
predominantly NN O O
confined NN O O
to NN O O
the NN O O
nucleus NN O O
of NN O O
human NN O O
fibroblasts NN O O
, NN O O
but NN O O
is NN O O
present NN O O
in NN O O
both NN O O
nuclear NN O O
and NN O O
microsomal NN O O
fractions NN O O
from NN O O
human NN O O
lymphoblast NN O O
cells NN O O
and NN O O
peripheral NN O O
blood NN O O
lymphocytes NN O O
. NN O O

ATM NN O O
protein NN O O
levels NN O O
and NN O O
localization NN O O
remain NN O O
constant NN O O
throughout NN O O
all NN O O
stages NN O O
of NN O O
the NN O O
cell NN O O
cycle NN O O
. NN O O

Truncated NN O O
ATM NN O O
protein NN O O
was NN O O
not NN O O
detected NN O O
in NN O O
lymphoblasts NN O O
from NN O O
ataxia NN O B-Disease
- NN O I-Disease
telangiectasia NN O I-Disease
patients NN O O
homozygous NN O O
for NN O O
mutations NN O O
leading NN O O
to NN O O
premature NN O O
protein NN O O
termination NN O O
. NN O O

Exposure NN O O
of NN O O
normal NN O O
human NN O O
cells NN O O
to NN O O
gamma NN O O
- NN O O
irradiation NN O O
and NN O O
the NN O O
radiomimetic NN O O
drug NN O O
neocarzinostatin NN O O
had NN O O
no NN O O
effect NN O O
on NN O O
ATM NN O O
protein NN O O
levels NN O O
, NN O O
in NN O O
contrast NN O O
to NN O O
a NN O O
noted NN O O
rise NN O O
in NN O O
p53 NN O O
levels NN O O
over NN O O
the NN O O
same NN O O
time NN O O
interval NN O O
. NN O O

These NN O O
findings NN O O
are NN O O
consistent NN O O
with NN O O
a NN O O
role NN O O
for NN O O
the NN O O
ATM NN O O
protein NN O O
in NN O O
ensuring NN O O
the NN O O
fidelity NN O O
of NN O O
DNA NN O O
repair NN O O
and NN O O
cell NN O O
cycle NN O O
regulation NN O O
following NN O O
genome NN O O
damage NN O O
. NN O O
. NN O O

Type NN O O
III NN O O
collagen NN O O
is NN O O
crucial NN O O
for NN O O
collagen NN O O
I NN O O
fibrillogenesis NN O O
and NN O O
for NN O O
normal NN O O
cardiovascular NN O O
development NN O O
. NN O O

Type NN O O
III NN O O
collagen NN O O
is NN O O
a NN O O
fibrillar NN O O
forming NN O O
collagen NN O O
comprising NN O O
three NN O O
alpha1 NN O O
( NN O O
III NN O O
) NN O O
chains NN O O
and NN O O
is NN O O
expressed NN O O
in NN O O
early NN O O
embryos NN O O
and NN O O
throughout NN O O
embryogenesis NN O O
. NN O O

In NN O O
the NN O O
adult NN O O
, NN O O
type NN O O
III NN O O
collagen NN O O
is NN O O
a NN O O
major NN O O
component NN O O
of NN O O
the NN O O
extracellular NN O O
matrix NN O O
in NN O O
a NN O O
variety NN O O
of NN O O
internal NN O O
organs NN O O
and NN O O
skin NN O O
. NN O O

Mutations NN O O
in NN O O
the NN O O
COL3A1 NN O O
gene NN O O
have NN O O
been NN O O
implicated NN O O
as NN O O
a NN O O
cause NN O O
of NN O O
type NN O B-Disease
IV NN O I-Disease
Ehlers NN O I-Disease
- NN O I-Disease
Danlos NN O I-Disease
syndrome NN O I-Disease
, NN O O
a NN O O
disease NN O O
leading NN O O
to NN O O
aortic NN O B-Disease
rupture NN O I-Disease
in NN O O
early NN O O
adult NN O O
life NN O O
. NN O O

To NN O O
directly NN O O
study NN O O
the NN O O
role NN O O
of NN O O
Col3a1 NN O O
in NN O O
development NN O O
and NN O O
disease NN O O
, NN O O
we NN O O
have NN O O
inactivated NN O O
the NN O O
Col3a1 NN O O
gene NN O O
in NN O O
embryonic NN O O
stem NN O O
cells NN O O
by NN O O
homologous NN O O
recombination NN O O
. NN O O

The NN O O
mutated NN O O
allele NN O O
was NN O O
transmitted NN O O
through NN O O
the NN O O
mouse NN O O
germ NN O O
line NN O O
and NN O O
homozygous NN O O
mutant NN O O
animals NN O O
were NN O O
derived NN O O
from NN O O
heterozygous NN O O
intercrosses NN O O
. NN O O

About NN O O
10 NN O O
% NN O O
of NN O O
the NN O O
homozygous NN O O
mutant NN O O
animals NN O O
survived NN O O
to NN O O
adulthood NN O O
but NN O O
have NN O O
a NN O O
much NN O O
shorter NN O O
life NN O O
span NN O O
compared NN O O
with NN O O
wild NN O O
- NN O O
type NN O O
mice NN O O
. NN O O

The NN O O
major NN O O
cause NN O O
of NN O O
death NN O O
of NN O O
mutant NN O O
mice NN O O
was NN O O
rupture NN O O
of NN O O
the NN O O
major NN O O
blood NN O O
vessels NN O O
, NN O O
similar NN O O
to NN O O
patients NN O O
with NN O O
type NN O B-Disease
IV NN O I-Disease
Ehlers NN O I-Disease
- NN O I-Disease
Danlos NN O I-Disease
syndrome NN O I-Disease
. NN O O

Ultrastructural NN O O
analysis NN O O
of NN O O
tissues NN O O
from NN O O
mutant NN O O
mice NN O O
revealed NN O O
that NN O O
type NN O O
III NN O O
collagen NN O O
is NN O O
essential NN O O
for NN O O
normal NN O O
collagen NN O O
I NN O O
fibrillogenesis NN O O
in NN O O
the NN O O
cardiovascular NN O O
system NN O O
and NN O O
other NN O O
organs NN O O
. NN O O
. NN O O

Nonsense NN O O
mutation NN O O
in NN O O
exon NN O O
3 NN O O
of NN O O
the NN O O
proteolipid NN O O
protein NN O O
gene NN O O
( NN O O
PLP NN O O
) NN O O
in NN O O
a NN O O
family NN O O
with NN O O
an NN O O
unusual NN O O
form NN O O
of NN O O
Pelizaeus NN O B-Disease
- NN O I-Disease
Merzbacher NN O I-Disease
disease NN O I-Disease
. NN O O

We NN O O
report NN O O
a NN O O
G NN O O
- NN O O
- NN O O
> NN O O
A NN O O
transition NN O O
at NN O O
nucleotide NN O O
431 NN O O
of NN O O
the NN O O
proteolipid NN O O
protein NN O O
gene NN O O
( NN O O
PLP NN O O
) NN O O
results NN O O
in NN O O
a NN O O
nonsense NN O O
codon NN O O
in NN O O
a NN O O
family NN O O
with NN O O
an NN O O
unusual NN O O
form NN O O
of NN O O
Pelizaeus NN O B-Disease
- NN O I-Disease
Merzbacher NN O I-Disease
disease NN O I-Disease
( NN O O
PMD NN O B-Disease
) NN O O
. NN O O

The NN O O
mutation NN O O
, NN O O
which NN O O
creates NN O O
a NN O O
second NN O O
AluI NN O O
restriction NN O O
site NN O O
, NN O O
results NN O O
in NN O O
a NN O O
nonsense NN O O
mutation NN O O
in NN O O
PLP NN O O
. NN O O

The NN O O
clinical NN O O
picture NN O O
resembles NN O O
somewhat NN O O
that NN O O
of NN O O
X NN O B-Disease
- NN O I-Disease
linked NN O I-Disease
spastic NN O I-Disease
paraplegia NN O I-Disease
( NN O O
SPG NN O B-Disease
) NN O O
. NN O O

It NN O O
differs NN O O
from NN O O
this NN O O
and NN O O
both NN O O
the NN O O
classical NN O O
and NN O O
connatal NN O O
forms NN O O
of NN O O
PMD NN O B-Disease
in NN O O
that NN O O
it NN O O
is NN O O
relatively NN O O
mild NN O O
in NN O O
form NN O O
, NN O O
onset NN O O
is NN O O
delayed NN O O
beyond NN O O
age NN O O
2 NN O O
years NN O O
, NN O O
nystagmus NN O B-Disease
is NN O O
absent NN O O
, NN O O
tremors NN O B-Disease
are NN O O
prominent NN O O
, NN O O
mental NN O B-Disease
retardation NN O I-Disease
is NN O O
not NN O O
severe NN O O
, NN O O
some NN O O
patients NN O O
show NN O O
dementia NN O B-Disease
or NN O O
personality NN O B-Disease
disorders NN O I-Disease
, NN O O
the NN O O
disease NN O O
is NN O O
progressive NN O O
rather NN O O
than NN O O
static NN O O
in NN O O
some NN O O
, NN O O
and NN O O
several NN O O
females NN O O
show NN O O
signs NN O O
of NN O O
disease NN O O
. NN O O

The NN O O
nonsense NN O O
mutation NN O O
, NN O O
which NN O O
is NN O O
in NN O O
exon NN O O
3B NN O O
, NN O O
should NN O O
block NN O O
the NN O O
synthesis NN O O
of NN O O
normal NN O O
PLP NN O O
but NN O O
spare NN O O
DM20 NN O O
, NN O O
the NN O O
isoform NN O O
whose NN O O
persistence NN O O
has NN O O
been NN O O
associated NN O O
with NN O O
mild NN O O
forms NN O O
of NN O O
PLP NN O B-Disease
- NN O I-Disease
associated NN O I-Disease
disease NN O I-Disease
in NN O O
both NN O O
humans NN O O
and NN O O
mice NN O O
. NN O O
. NN O O

Common NN O O
BRCA1 NN O O
variants NN O O
and NN O O
susceptibility NN O O
to NN O O
breast NN O B-Disease
and NN O I-Disease
ovarian NN O I-Disease
cancer NN O I-Disease
in NN O O
the NN O O
general NN O O
population NN O O
. NN O O

Most NN O O
multiple NN O O
case NN O O
families NN O O
of NN O O
young NN O O
onset NN O O
breast NN O B-Disease
cancer NN O I-Disease
and NN O O
ovarian NN O B-Disease
cancer NN O I-Disease
are NN O O
thought NN O O
to NN O O
be NN O O
due NN O O
to NN O O
highly NN O O
penetrant NN O O
mutations NN O O
in NN O O
the NN O O
predisposing NN O O
genes NN O O
BRCA1 NN O O
and NN O O
BRCA2 NN O O
. NN O O

However NN O O
, NN O O
these NN O O
mutations NN O O
are NN O O
uncommon NN O O
in NN O O
the NN O O
population NN O O
and NN O O
they NN O O
probably NN O O
account NN O O
for NN O O
only NN O O
a NN O O
few NN O O
percent NN O O
of NN O O
all NN O O
breast NN O B-Disease
cancer NN O I-Disease
incidence NN O O
. NN O O

A NN O O
much NN O O
larger NN O O
fraction NN O O
of NN O O
breast NN O B-Disease
cancer NN O I-Disease
might NN O O
, NN O O
in NN O O
principle NN O O
, NN O O
be NN O O
due NN O O
to NN O O
common NN O O
variants NN O O
which NN O O
confer NN O O
more NN O O
modest NN O O
individual NN O O
risks NN O O
. NN O O

There NN O O
are NN O O
several NN O O
common NN O O
polymorphisms NN O O
in NN O O
the NN O O
BRCA1 NN O O
gene NN O O
which NN O O
generate NN O O
amino NN O O
acid NN O O
substitutions NN O O
. NN O O

We NN O O
have NN O O
examined NN O O
the NN O O
frequency NN O O
of NN O O
four NN O O
of NN O O
these NN O O
polymorphisms NN O O
Gln356Arg NN O O
, NN O O
Pro871Leu NN O O
, NN O O
Glu1038Gly NN O O
and NN O O
Ser1613Gly NN O O
in NN O O
large NN O O
series NN O O
of NN O O
breast NN O B-Disease
and NN O I-Disease
ovarian NN O I-Disease
cancer NN O I-Disease
cases NN O O
and NN O O
matched NN O O
controls NN O O
. NN O O

Due NN O O
to NN O O
strong NN O O
linkage NN O O
disequilibrium NN O O
, NN O O
these NN O O
four NN O O
sites NN O O
generate NN O O
only NN O O
three NN O O
haplotypes NN O O
with NN O O
a NN O O
frequency NN O O
> NN O O
1 NN O O
. NN O O

3 NN O O
% NN O O
. NN O O

The NN O O
most NN O O
common NN O O
haplotypes NN O O
, NN O O
defined NN O O
by NN O O
the NN O O
alleles NN O O
Gln356Pro871Glu1038Ser1613 NN O O
and NN O O
Gln356Leu871Gly1038Gly1613 NN O O
, NN O O
have NN O O
frequencies NN O O
of NN O O
0 NN O O
. NN O O

57 NN O O
and NN O O
0 NN O O
. NN O O

32 NN O O
respectively NN O O
, NN O O
and NN O O
these NN O O
frequencies NN O O
do NN O O
not NN O O
differ NN O O
significantly NN O O
between NN O O
patient NN O O
and NN O O
control NN O O
groups NN O O
. NN O O

Thus NN O O
the NN O O
most NN O O
common NN O O
polymorphisms NN O O
of NN O O
the NN O O
BRCA1 NN O O
gene NN O O
do NN O O
not NN O O
make NN O O
a NN O O
significant NN O O
contribution NN O O
to NN O O
breast NN O B-Disease
or NN O I-Disease
ovarian NN O I-Disease
cancer NN O I-Disease
risk NN O O
. NN O O

However NN O O
, NN O O
our NN O O
data NN O O
suggest NN O O
that NN O O
the NN O O
Arg356 NN O O
allele NN O O
may NN O O
have NN O O
a NN O O
different NN O O
genotype NN O O
distribution NN O O
in NN O O
breast NN O B-Disease
cancer NN O I-Disease
patients NN O O
from NN O O
that NN O O
in NN O O
controls NN O O
( NN O O
Arg356 NN O O
homozygotes NN O O
are NN O O
more NN O O
frequent NN O O
in NN O O
the NN O O
control NN O O
groups NN O O
, NN O O
P NN O O
= NN O O
0 NN O O
. NN O O
01 NN O O
) NN O O
, NN O O
indicating NN O O
that NN O O
it NN O O
may NN O O
be NN O O
protective NN O O
against NN O O
breast NN O B-Disease
cancer NN O I-Disease
. NN O O

If NN O O
this NN O O
finding NN O O
can NN O O
be NN O O
confirmed NN O O
, NN O O
it NN O O
may NN O O
provide NN O O
an NN O O
insight NN O O
into NN O O
the NN O O
structural NN O O
features NN O O
of NN O O
the NN O O
BRCA1 NN O O
protein NN O O
that NN O O
are NN O O
important NN O O
for NN O O
its NN O O
function NN O O
. NN O O

Kniest NN O B-Disease
dysplasia NN O I-Disease
: NN O O
Dr NN O O
. NN O O
W NN O O
. NN O O

Kniest NN O O
, NN O O
his NN O O
patient NN O O
, NN O O
the NN O O
molecular NN O O
defect NN O O
. NN O O

Kniest NN O B-Disease
dysplasia NN O I-Disease
is NN O O
a NN O O
severe NN O O
chondrodysplasia NN O B-Disease
caused NN O O
by NN O O
the NN O O
defective NN O B-Disease
formation NN O I-Disease
of NN O I-Disease
type NN O I-Disease
II NN O I-Disease
collagen NN O I-Disease
. NN O O

We NN O O
report NN O O
about NN O O
Dr NN O O
. NN O O
Kniest NN O O
, NN O O
who NN O O
first NN O O
described NN O O
the NN O O
condition NN O O
in NN O O
1952 NN O O
, NN O O
and NN O O
his NN O O
patient NN O O
, NN O O
who NN O O
, NN O O
at NN O O
the NN O O
age NN O O
of NN O O
50 NN O O
years NN O O
is NN O O
severely NN O B-Disease
handicapped NN O I-Disease
with NN O O
short NN O B-Disease
stature NN O I-Disease
, NN O O
restricted NN O B-Disease
joint NN O I-Disease
mobility NN O I-Disease
, NN O O
and NN O O
blindness NN O B-Disease
but NN O O
is NN O O
mentally NN O O
alert NN O O
and NN O O
leads NN O O
an NN O O
active NN O O
life NN O O
. NN O O

Molecular NN O O
analysis NN O O
of NN O O
the NN O O
patients NN O O
DNA NN O O
showed NN O O
a NN O O
single NN O O
base NN O O
( NN O O
G NN O O
) NN O O
deletion NN O O
involving NN O O
the NN O O
GT NN O O
dinucleotide NN O O
at NN O O
the NN O O
start NN O O
of NN O O
intron NN O O
18 NN O O
destroying NN O O
a NN O O
splice NN O O
site NN O O
of NN O O
the NN O O
COL2A1 NN O O
gene NN O O
. NN O O

This NN O O
is NN O O
in NN O O
accordance NN O O
with NN O O
molecular NN O O
findings NN O O
in NN O O
other NN O O
patients NN O O
with NN O O
Kniest NN O B-Disease
dysplasia NN O I-Disease
and NN O O
confirms NN O O
, NN O O
in NN O O
the NN O O
original NN O O
patient NN O O
, NN O O
that NN O O
the NN O O
disorder NN O O
is NN O O
caused NN O O
by NN O O
small NN O O
inframe NN O O
deletions NN O O
often NN O O
due NN O O
to NN O O
exon NN O O
skipping NN O O
as NN O O
a NN O O
result NN O O
of NN O O
COL2A1 NN O O
splice NN O O
site NN O O
mutations NN O O
. NN O O
. NN O O

Cloning NN O O
of NN O O
the NN O O
homogentisate NN O O
1 NN O O
, NN O O
2 NN O O
- NN O O
dioxygenase NN O O
gene NN O O
, NN O O
the NN O O
key NN O O
enzyme NN O O
of NN O O
alkaptonuria NN O B-Disease
in NN O O
mouse NN O O
. NN O O

We NN O O
determined NN O O
48 NN O O
amino NN O O
acid NN O O
residues NN O O
from NN O O
five NN O O
peptides NN O O
from NN O O
the NN O O
homogeneous NN O O
monomer NN O O
of NN O O
homogentisate NN O O
1 NN O O
, NN O O
2 NN O O
- NN O O
dioxygenase NN O O
( NN O O
HGO NN O O
; NN O O
E NN O O
. NN O O
C NN O O
. NN O O
1 NN O O
. NN O O
13 NN O O
. NN O O
11 NN O O
. NN O O
15 NN O O
) NN O O
of NN O O
mouse NN O O
liver NN O O
. NN O O

After NN O O
digestion NN O O
with NN O O
trypsin NN O O
, NN O O
peptides NN O O
were NN O O
separated NN O O
by NN O O
reversed NN O O
phase NN O O
chromatography NN O O
and NN O O
amino NN O O
acid NN O O
sequenced NN O O
. NN O O

The NN O O
deduced NN O O
codon NN O O
sequence NN O O
of NN O O
three NN O O
peptides NN O O
was NN O O
used NN O O
to NN O O
derive NN O O
degenerated NN O O
oligomeres NN O O
. NN O O

By NN O O
combining NN O O
these NN O O
oligos NN O O
, NN O O
we NN O O
were NN O O
able NN O O
to NN O O
amplify NN O O
fragments NN O O
from NN O O
100 NN O O
to NN O O
300 NN O O
bases NN O O
( NN O O
b NN O O
) NN O O
from NN O O
mouse NN O O
liver NN O O
cDNA NN O O
by NN O O
polymerase NN O O
chain NN O O
reaction NN O O
after NN O O
reverse NN O O
transcription NN O O
( NN O O
RT NN O O
- NN O O
PCR NN O O
) NN O O
. NN O O

A NN O O
fragment NN O O
of NN O O
200 NN O O
b NN O O
was NN O O
cloned NN O O
and NN O O
used NN O O
as NN O O
a NN O O
probe NN O O
to NN O O
screen NN O O
a NN O O
mouse NN O O
liver NN O O
cDNA NN O O
library NN O O
. NN O O

One NN O O
clone NN O O
from NN O O
this NN O O
library NN O O
contained NN O O
the NN O O
complete NN O O
cDNA NN O O
- NN O O
insert NN O O
for NN O O
HGO NN O O
as NN O O
determined NN O O
by NN O O
sequencing NN O O
. NN O O

The NN O O
cDNA NN O O
encodes NN O O
for NN O O
a NN O O
protein NN O O
of NN O O
50 NN O O
kDa NN O O
, NN O O
as NN O O
predicted NN O O
. NN O O

The NN O O
cDNA NN O O
of NN O O
mouse NN O O
HGO NN O O
has NN O O
an NN O O
overall NN O O
identity NN O O
of NN O O
41 NN O O
% NN O O
to NN O O
the NN O O
corresponding NN O O
gene NN O O
hmgA NN O O
from NN O O
Aspergillus NN O O
. NN O O

Sequence NN O O
similarities NN O O
to NN O O
human NN O O
expressed NN O O
sequence NN O O
tags NN O O
( NN O O
EST NN O O
) NN O O
clones NN O O
ranged NN O O
from NN O O
70 NN O O
% NN O O
to NN O O
20 NN O O
% NN O O
. NN O O

The NN O O
positions NN O O
of NN O O
122 NN O O
conserved NN O O
amino NN O O
acids NN O O
could NN O O
be NN O O
determined NN O O
by NN O O
multiple NN O O
sequence NN O O
alignment NN O O
. NN O O

We NN O O
identified NN O O
one NN O O
first NN O O
intron NN O O
of NN O O
928 NN O O
b NN O O
in NN O O
the NN O O
mouse NN O O
gene NN O O
. NN O O

The NN O O
gene NN O O
for NN O O
HGO NN O O
seems NN O O
to NN O O
be NN O O
expressed NN O O
in NN O O
various NN O O
tissues NN O O
, NN O O
as NN O O
shown NN O O
by NN O O
RT NN O O
- NN O O
PCR NN O O
on NN O O
different NN O O
cDNAs NN O O
. NN O O

FISH NN O O
experiments NN O O
with NN O O
the NN O O
whole NN O O
murine NN O O
cDNA NN O O
as NN O O
probe NN O O
clearly NN O O
revealed NN O O
signals NN O O
at NN O O
the NN O O
human NN O O
chromosomal NN O O
band NN O O
3q13 NN O O
. NN O O

3 NN O O
- NN O O
q21 NN O O
. NN O O

This NN O O
corresponds NN O O
well NN O O
to NN O O
the NN O O
previous NN O O
assignment NN O O
of NN O O
the NN O O
locus NN O O
for NN O O
the NN O O
human NN O O
alkaptonuria NN O B-Disease
gene NN O O
( NN O O
AKU NN O O
) NN O O
to NN O O
the NN O O
same NN O O
chromosomal NN O O
region NN O O
by NN O O
multipoint NN O O
linkage NN O O
analysis NN O O
. NN O O

We NN O O
therefore NN O O
conclude NN O O
that NN O O
the NN O O
HGO NN O O
cDNA NN O O
encodes NN O O
the NN O O
gene NN O O
responsible NN O O
for NN O O
alkaptonuria NN O B-Disease
. NN O O

PTEN NN O O
, NN O O
a NN O O
putative NN O O
protein NN O O
tyrosine NN O O
phosphatase NN O O
gene NN O O
mutated NN O O
in NN O O
human NN O O
brain NN O B-Disease
, NN O I-Disease
breast NN O I-Disease
, NN O I-Disease
and NN O I-Disease
prostate NN O I-Disease
cancer NN O I-Disease
. NN O O

Mapping NN O O
of NN O O
homozygous NN O O
deletions NN O O
on NN O O
human NN O O
chromosome NN O O
10q23 NN O O
has NN O O
led NN O O
to NN O O
the NN O O
isolation NN O O
of NN O O
a NN O O
candidate NN O O
tumor NN O B-Disease
suppressor NN O O
gene NN O O
, NN O O
PTEN NN O O
, NN O O
that NN O O
appears NN O O
to NN O O
be NN O O
mutated NN O O
at NN O O
considerable NN O O
frequency NN O O
in NN O O
human NN O O
cancers NN O B-Disease
. NN O O

In NN O O
preliminary NN O O
screens NN O O
, NN O O
mutations NN O O
of NN O O
PTEN NN O O
were NN O O
detected NN O O
in NN O O
31 NN O O
% NN O O
( NN O O
13 NN O O
/ NN O O
42 NN O O
) NN O O
of NN O O
glioblastoma NN O B-Disease
cell NN O O
lines NN O O
and NN O O
xenografts NN O O
, NN O O
100 NN O O
% NN O O
( NN O O
4 NN O O
/ NN O O
4 NN O O
) NN O O
of NN O O
prostate NN O B-Disease
cancer NN O I-Disease
cell NN O O
lines NN O O
, NN O O
6 NN O O
% NN O O
( NN O O
4 NN O O
/ NN O O
65 NN O O
) NN O O
of NN O O
breast NN O B-Disease
cancer NN O I-Disease
cell NN O O
lines NN O O
and NN O O
xenografts NN O O
, NN O O
and NN O O
17 NN O O
% NN O O
( NN O O
3 NN O O
/ NN O O
18 NN O O
) NN O O
of NN O O
primary NN O B-Disease
glioblastomas NN O I-Disease
. NN O O

The NN O O
predicted NN O O
PTEN NN O O
product NN O O
has NN O O
a NN O O
protein NN O O
tyrosine NN O O
phosphatase NN O O
domain NN O O
and NN O O
extensive NN O O
homology NN O O
to NN O O
tensin NN O O
, NN O O
a NN O O
protein NN O O
that NN O O
interacts NN O O
with NN O O
actin NN O O
filaments NN O O
at NN O O
focal NN O O
adhesions NN O O
. NN O O

These NN O O
homologies NN O O
suggest NN O O
that NN O O
PTEN NN O O
may NN O O
suppress NN O O
tumor NN O B-Disease
cell NN O O
growth NN O O
by NN O O
antagonizing NN O O
protein NN O O
tyrosine NN O O
kinases NN O O
and NN O O
may NN O O
regulate NN O O
tumor NN O B-Disease
cell NN O O
invasion NN O O
and NN O O
metastasis NN O B-Disease
through NN O O
interactions NN O O
at NN O O
focal NN O O
adhesions NN O O
. NN O O
. NN O O

Heterogeneity NN O O
in NN O O
Schwartz NN O B-Disease
- NN O I-Disease
Jampel NN O I-Disease
chondrodystrophic NN O I-Disease
myotonia NN O I-Disease
. NN O O

The NN O O
Schwartz NN O B-Disease
- NN O I-Disease
Jampel NN O I-Disease
syndrome NN O I-Disease
( NN O O
SJS NN O B-Disease
; NN O O
chondrodystrophic NN O B-Disease
myotonia NN O I-Disease
; NN O O
McK NN O O
255 NN O O
, NN O O
800 NN O O
) NN O O
is NN O O
a NN O O
recessively NN O B-Disease
inherited NN O I-Disease
condition NN O I-Disease
defined NN O O
by NN O O
myotonia NN O B-Disease
, NN O O
short NN O B-Disease
stature NN O I-Disease
, NN O O
and NN O O
bone NN O B-Disease
dysplasia NN O I-Disease
. NN O O

Genetic NN O O
linkage NN O O
between NN O O
SJS NN O B-Disease
and NN O O
chromosomal NN O O
region NN O O
1q36 NN O O
- NN O O
34 NN O O
has NN O O
been NN O O
observed NN O O
in NN O O
several NN O O
families NN O O
, NN O O
but NN O O
the NN O O
gene NN O O
has NN O O
not NN O O
yet NN O O
been NN O O
identified NN O O
. NN O O

We NN O O
studied NN O O
the NN O O
clinical NN O O
and NN O O
radiological NN O O
features NN O O
in NN O O
81 NN O O
patients NN O O
from NN O O
the NN O O
literature NN O O
and NN O O
5 NN O O
own NN O O
patients NN O O
trying NN O O
to NN O O
identify NN O O
distinct NN O O
subgroups NN O O
. NN O O

In NN O O
addition NN O O
, NN O O
we NN O O
tested NN O O
genetic NN O O
linkage NN O O
to NN O O
the NN O O
SJS NN O B-Disease
locus NN O O
on NN O O
chromosome NN O O
1 NN O O
in NN O O
one NN O O
family NN O O
with NN O O
two NN O O
affected NN O O
sibs NN O O
. NN O O

We NN O O
found NN O O
that NN O O
a NN O O
group NN O O
of NN O O
patients NN O O
have NN O O
mild NN O O
skeletal NN O O
changes NN O O
which NN O O
may NN O O
be NN O O
secondary NN O O
consequences NN O O
of NN O O
myotonia NN O B-Disease
, NN O O
while NN O O
another NN O O
group NN O O
of NN O O
patients NN O O
appear NN O O
to NN O O
have NN O O
primary NN O O
bone NN O B-Disease
dysplasia NN O I-Disease
with NN O O
myotonia NN O B-Disease
. NN O O

Within NN O O
this NN O O
latter NN O O
group NN O O
, NN O O
there NN O O
are NN O O
differences NN O O
in NN O O
age NN O O
of NN O O
manifestation NN O O
, NN O O
clinical NN O O
course NN O O
and NN O O
pattern NN O O
of NN O O
bone NN O O
changes NN O O
. NN O O

We NN O O
tentatively NN O O
isolate NN O O
three NN O O
different NN O O
types NN O O
of NN O O
SJS NN O B-Disease
type NN O I-Disease
1A NN O I-Disease
, NN O O
usually NN O O
recognized NN O O
in NN O O
childhood NN O O
, NN O O
with NN O O
moderate NN O O
bone NN O B-Disease
dysplasia NN O I-Disease
, NN O O
corresponding NN O O
to NN O O
the NN O O
original NN O O
descriptions NN O O
of NN O O
Schwartz NN O O
, NN O O
Jampel NN O O
and NN O O
Aberfeld NN O O
; NN O O
type NN O O
1B NN O O
, NN O O
similar NN O O
to NN O O
type NN O O
1A NN O O
but NN O O
recognizable NN O O
at NN O O
birth NN O O
, NN O O
with NN O O
more NN O O
pronounced NN O O
bone NN O B-Disease
dysplasia NN O I-Disease
resembling NN O O
Kniest NN O B-Disease
dysplasia NN O I-Disease
; NN O O
and NN O O
type NN O O
2 NN O O
, NN O O
manifest NN O O
at NN O O
birth NN O O
, NN O O
with NN O O
increased NN O O
mortality NN O O
and NN O O
bone NN O B-Disease
dysplasia NN O I-Disease
resembling NN O O
Pyle NN O B-Disease
disease NN O I-Disease
. NN O O

Genetic NN O O
analysis NN O O
of NN O O
the NN O O
family NN O O
with NN O O
two NN O O
sibs NN O O
affected NN O O
by NN O O
SJS NN O B-Disease
type NN O I-Disease
2 NN O I-Disease
showed NN O O
evidence NN O O
against NN O O
linkage NN O O
to NN O O
chromosome NN O O
1p36 NN O O
- NN O O
34 NN O O
. NN O O

CONCLUSIONS NN O O
SJS NN O B-Disease
is NN O O
clinically NN O O
and NN O O
radiologically NN O O
heterogeneous NN O O
. NN O O

The NN O O
causes NN O O
of NN O O
heterogeneity NN O O
are NN O O
not NN O O
known NN O O
yet NN O O
but NN O O
are NN O O
likely NN O O
to NN O O
include NN O O
both NN O O
different NN O O
mutations NN O O
at NN O O
the NN O O
SJS NN O B-Disease
locus NN O O
on NN O O
chromosome NN O O
1 NN O O
and NN O O
the NN O O
presence NN O O
of NN O O
a NN O O
second NN O O
SJS NN O B-Disease
locus NN O O
. NN O O

A NN O O
tentative NN O O
clinico NN O O
- NN O O
radiological NN O O
classification NN O O
can NN O O
be NN O O
useful NN O O
for NN O O
the NN O O
characterization NN O O
of NN O O
patients NN O O
and NN O O
the NN O O
development NN O O
of NN O O
genotype NN O O
- NN O O
phenotype NN O O
correlations NN O O
. NN O O
. NN O O

A NN O O
clinical NN O O
overview NN O O
of NN O O
WT1 NN O O
gene NN O O
mutations NN O O
. NN O O

Mutations NN O O
in NN O O
the NN O O
WT1 NN O O
gene NN O O
were NN O O
anticipated NN O O
to NN O O
explain NN O O
the NN O O
genetic NN O O
basis NN O O
of NN O O
the NN O O
childhood NN O O
kidney NN O B-Disease
cancer NN O I-Disease
, NN O O
Wilms NN O B-Disease
tumour NN O I-Disease
( NN O O
WT NN O B-Disease
) NN O O
. NN O O

Six NN O O
years NN O O
on NN O O
, NN O O
we NN O O
review NN O O
100 NN O O
reports NN O O
of NN O O
intragenic NN O O
WT1 NN O O
mutations NN O O
and NN O O
examine NN O O
the NN O O
accompanying NN O O
clinical NN O O
phenotypes NN O O
. NN O O

While NN O O
only NN O O
5 NN O O
% NN O O
of NN O O
sporadic NN O B-Disease
Wilms NN O I-Disease
tumours NN O I-Disease
have NN O O
intragenic NN O O
WT1 NN O O
mutations NN O O
, NN O O
> NN O O
90 NN O O
% NN O O
of NN O O
patients NN O O
with NN O O
the NN O O
Denys NN O B-Disease
- NN O I-Disease
Drash NN O I-Disease
syndrome NN O I-Disease
( NN O O
renal NN O B-Disease
nephropathy NN O I-Disease
, NN O O
gonadal NN O B-Disease
anomaly NN O I-Disease
, NN O O
predisposition NN O B-Disease
to NN O I-Disease
WT NN O I-Disease
) NN O O
carry NN O O
constitutional NN O O
intragenic NN O O
WT1 NN O O
mutations NN O O
. NN O O

WT1 NN O O
mutations NN O O
have NN O O
also NN O O
been NN O O
reported NN O O
in NN O O
juvenile NN O B-Disease
granulosa NN O I-Disease
cell NN O I-Disease
tumour NN O I-Disease
, NN O O
non NN O B-Disease
- NN O I-Disease
asbestos NN O I-Disease
related NN O I-Disease
mesothelioma NN O I-Disease
, NN O O
desmoplastic NN O B-Disease
small NN O I-Disease
round NN O I-Disease
cell NN O I-Disease
tumour NN O I-Disease
and NN O O
, NN O O
most NN O O
recently NN O O
, NN O O
acute NN O B-Disease
myeloid NN O I-Disease
leukemia NN O I-Disease
. NN O O
. NN O O

A NN O O
mutation NN O O
in NN O O
autosomal NN O B-Disease
dominant NN O I-Disease
myotonia NN O I-Disease
congenita NN O I-Disease
affects NN O O
pore NN O O
properties NN O O
of NN O O
the NN O O
muscle NN O O
chloride NN O O
channel NN O O
. NN O O

Autosomal NN O B-Disease
dominant NN O I-Disease
myotonia NN O I-Disease
congenita NN O I-Disease
is NN O O
an NN O O
inherited NN O B-Disease
disorder NN O I-Disease
of NN O I-Disease
skeletal NN O I-Disease
muscle NN O I-Disease
caused NN O O
by NN O O
mutations NN O O
in NN O O
a NN O O
voltage NN O O
- NN O O
gated NN O O
Cl NN O O
- NN O O
channel NN O O
gene NN O O
( NN O O
CLCN1 NN O O
, NN O O
7q35 NN O O
) NN O O
. NN O O

Here NN O O
, NN O O
we NN O O
report NN O O
that NN O O
a NN O O
mutation NN O O
predicting NN O O
the NN O O
substitution NN O O
of NN O O
Gly NN O O
230 NN O O
by NN O O
glutamic NN O O
acid NN O O
( NN O O
G230E NN O O
) NN O O
between NN O O
segments NN O O
D3 NN O O
and NN O O
D4 NN O O
dramatically NN O O
alters NN O O
the NN O O
pore NN O O
properties NN O O
of NN O O
a NN O O
recombinant NN O O
human NN O O
muscle NN O O
Cl NN O O
- NN O O
channel NN O O
( NN O O
hCIC NN O O
- NN O O
1 NN O O
) NN O O
expressed NN O O
in NN O O
a NN O O
mammalian NN O O
cell NN O O
line NN O O
( NN O O
tsA201 NN O O
) NN O O
. NN O O

The NN O O
G230E NN O O
mutation NN O O
causes NN O O
substantial NN O O
changes NN O O
in NN O O
anion NN O O
and NN O O
cation NN O O
selectivity NN O O
as NN O O
well NN O O
as NN O O
a NN O O
fundamental NN O O
change NN O O
in NN O O
rectification NN O O
of NN O O
the NN O O
current NN O O
- NN O O
voltage NN O O
relationship NN O O
. NN O O

Whereas NN O O
wild NN O O
- NN O O
type NN O O
channels NN O O
are NN O O
characterized NN O O
by NN O O
pronounced NN O O
inward NN O O
rectification NN O O
and NN O O
a NN O O
Cl NN O O
> NN O O
thiocyanate NN O O
> NN O O
Br NN O O
> NN O O
NO NN O O
( NN O O
3 NN O O
) NN O O
> NN O O
I NN O O
> NN O O
CH NN O O
( NN O O
3 NN O O
) NN O O
SO NN O O
( NN O O
3 NN O O
) NN O O
selectivity NN O O
, NN O O
G230E NN O O
exhibits NN O O
outward NN O O
rectification NN O O
at NN O O
positive NN O O
potentials NN O O
and NN O O
a NN O O
thiocyanate NN O O
> NN O O
NO NN O O
( NN O O
3 NN O O
) NN O O
> NN O O
I NN O O
> NN O O
Br NN O O
> NN O O
Cl NN O O
> NN O O
CH NN O O
( NN O O
3 NN O O
) NN O O
SO NN O O
( NN O O
3 NN O O
) NN O O
selectivity NN O O
. NN O O

Furthermore NN O O
, NN O O
the NN O O
cation NN O O
- NN O O
to NN O O
- NN O O
anion NN O O
permeability NN O O
ratio NN O O
of NN O O
the NN O O
mutant NN O O
is NN O O
much NN O O
greater NN O O
than NN O O
that NN O O
of NN O O
the NN O O
wild NN O O
- NN O O
type NN O O
channel NN O O
. NN O O

Voltage NN O O
- NN O O
dependent NN O O
blocks NN O O
by NN O O
intracellular NN O O
and NN O O
extracellular NN O O
iodide NN O O
help NN O O
to NN O O
distinguish NN O O
two NN O O
distinct NN O O
ion NN O O
binding NN O O
sites NN O O
within NN O O
the NN O O
hClC NN O O
- NN O O
1 NN O O
conduction NN O O
pathway NN O O
. NN O O

Both NN O O
binding NN O O
sites NN O O
are NN O O
preserved NN O O
in NN O O
the NN O O
mutant NN O O
but NN O O
have NN O O
decreased NN O O
affinities NN O O
for NN O O
iodide NN O O
. NN O O

These NN O O
findings NN O O
suggest NN O O
that NN O O
Gly NN O O
230 NN O O
is NN O O
critical NN O O
for NN O O
normal NN O O
ion NN O O
conductance NN O O
in NN O O
hClC NN O O
- NN O O
1 NN O O
and NN O O
that NN O O
this NN O O
residue NN O O
resides NN O O
within NN O O
the NN O O
channel NN O O
pore NN O O
. NN O O
. NN O O

The NN O O
incidence NN O O
of NN O O
PAX6 NN O O
mutation NN O O
in NN O O
patients NN O O
with NN O O
simple NN O O
aniridia NN O B-Disease
: NN O O
an NN O O
evaluation NN O O
of NN O O
mutation NN O O
detection NN O O
in NN O O
12 NN O O
cases NN O O
. NN O O

Twelve NN O O
aniridia NN O B-Disease
patients NN O O
, NN O O
five NN O O
with NN O O
a NN O O
family NN O O
history NN O O
and NN O O
seven NN O O
presumed NN O O
to NN O O
be NN O O
sporadic NN O O
, NN O O
were NN O O
exhaustively NN O O
screened NN O O
in NN O O
order NN O O
to NN O O
test NN O O
what NN O O
proportion NN O O
of NN O O
people NN O O
with NN O O
aniridia NN O B-Disease
, NN O O
uncomplicated NN O O
by NN O O
associated NN O O
anomalies NN O O
, NN O O
carry NN O O
mutations NN O O
in NN O O
the NN O O
human NN O O
PAX6 NN O O
gene NN O O
. NN O O

Mutations NN O O
were NN O O
detected NN O O
in NN O O
90 NN O O
% NN O O
of NN O O
the NN O O
cases NN O O
. NN O O

Three NN O O
mutation NN O O
detection NN O O
techniques NN O O
were NN O O
used NN O O
to NN O O
determine NN O O
if NN O O
one NN O O
method NN O O
was NN O O
superior NN O O
for NN O O
this NN O O
gene NN O O
. NN O O

The NN O O
protein NN O O
truncation NN O O
test NN O O
( NN O O
PTT NN O O
) NN O O
was NN O O
used NN O O
on NN O O
RT NN O O
- NN O O
PCR NN O O
products NN O O
, NN O O
SSCP NN O O
on NN O O
genomic NN O O
PCR NN O O
amplifications NN O O
, NN O O
and NN O O
chemical NN O O
cleavage NN O O
of NN O O
mismatch NN O O
on NN O O
both NN O O
RT NN O O
- NN O O
PCR NN O O
and NN O O
genomic NN O O
amplifications NN O O
. NN O O

For NN O O
RT NN O O
- NN O O
PCR NN O O
products NN O O
, NN O O
only NN O O
the NN O O
translated NN O O
portion NN O O
of NN O O
the NN O O
gene NN O O
was NN O O
screened NN O O
. NN O O

On NN O O
genomic NN O O
products NN O O
exons NN O O
1 NN O O
to NN O O
13 NN O O
( NN O O
including NN O O
740 NN O O
bp NN O O
of NN O O
the NN O O
3 NN O O
untranslated NN O O
sequence NN O O
and NN O O
all NN O O
intron NN O O
/ NN O O
exon NN O O
boundaries NN O O
) NN O O
were NN O O
screened NN O O
, NN O O
as NN O O
was NN O O
a NN O O
neuroretina NN O O
specific NN O O
enhancer NN O O
in NN O O
intron NN O O
4 NN O O
. NN O O

Ten NN O O
of NN O O
the NN O O
possible NN O O
12 NN O O
mutations NN O O
in NN O O
the NN O O
five NN O O
familial NN O O
cases NN O O
and NN O O
five NN O O
of NN O O
the NN O O
sporadic NN O O
patients NN O O
were NN O O
found NN O O
, NN O O
all NN O O
of NN O O
which NN O O
conformed NN O O
to NN O O
a NN O O
functional NN O O
outcome NN O O
of NN O O
haploinsufficiency NN O O
. NN O O

Five NN O O
were NN O O
splice NN O O
site NN O O
mutations NN O O
( NN O O
one NN O O
in NN O O
the NN O O
donor NN O O
site NN O O
of NN O O
intron NN O O
4 NN O O
, NN O O
two NN O O
in NN O O
the NN O O
donor NN O O
site NN O O
of NN O O
intron NN O O
6 NN O O
, NN O O
one NN O O
in NN O O
each NN O O
of NN O O
the NN O O
acceptor NN O O
sites NN O O
of NN O O
introns NN O O
8 NN O O
and NN O O
9 NN O O
) NN O O
and NN O O
five NN O O
were NN O O
nonsense NN O O
mutations NN O O
in NN O O
exons NN O O
8 NN O O
, NN O O
9 NN O O
, NN O O
10 NN O O
, NN O O
11 NN O O
, NN O O
and NN O O
12 NN O O
. NN O O

SSCP NN O O
analysis NN O O
of NN O O
individually NN O O
amplified NN O O
exons NN O O
, NN O O
with NN O O
which NN O O
nine NN O O
of NN O O
the NN O O
10 NN O O
mutations NN O O
were NN O O
seen NN O O
, NN O O
was NN O O
the NN O O
most NN O O
useful NN O O
detection NN O O
method NN O O
for NN O O
PAX6 NN O O
. NN O O
. NN O O

Insulin NN O O
gene NN O O
region NN O O
contributes NN O O
to NN O O
genetic NN O O
susceptibility NN O O
to NN O O
, NN O O
but NN O O
may NN O O
not NN O O
to NN O O
low NN O O
incidence NN O O
of NN O O
, NN O O
insulin NN O B-Disease
- NN O I-Disease
dependent NN O I-Disease
diabetes NN O I-Disease
mellitus NN O I-Disease
in NN O O
Japanese NN O O
. NN O O

In NN O O
the NN O O
Caucasian NN O O
population NN O O
, NN O O
it NN O O
has NN O O
been NN O O
demonstrated NN O O
that NN O O
the NN O O
insulin NN O O
gene NN O O
( NN O O
INS NN O O
) NN O O
region NN O O
contains NN O O
the NN O O
insulin NN O B-Disease
- NN O I-Disease
dependent NN O I-Disease
diabetes NN O I-Disease
mellitus NN O I-Disease
locus NN O O
( NN O O
IDDM2 NN O O
) NN O O
. NN O O

In NN O O
the NN O O
Japanese NN O O
population NN O O
, NN O O
however NN O O
, NN O O
there NN O O
has NN O O
been NN O O
no NN O O
report NN O O
demonstrating NN O O
the NN O O
contribution NN O O
of NN O O
IDDM2 NN O O
to NN O O
the NN O O
pathogenesis NN O O
of NN O O
IDDM NN O B-Disease
. NN O O

We NN O O
conducted NN O O
an NN O O
association NN O O
study NN O O
of NN O O
IDDM NN O B-Disease
in NN O O
a NN O O
large NN O O
number NN O O
of NN O O
Japanese NN O O
subjects NN O O
with NN O O
multiple NN O O
polymorphisms NN O O
in NN O O
INS NN O O
region NN O O
. NN O O

We NN O O
found NN O O
a NN O O
significant NN O O
association NN O O
of NN O O
the NN O O
INS NN O O
region NN O O
with NN O O
IDDM NN O B-Disease
. NN O O

Alleles NN O O
positively NN O O
associated NN O O
with NN O O
IDDM NN O B-Disease
in NN O O
INS NN O O
region NN O O
were NN O O
the NN O O
same NN O O
as NN O O
those NN O O
positively NN O O
- NN O O
associated NN O O
with NN O O
IDDM NN O B-Disease
in NN O O
Caucasian NN O O
population NN O O
, NN O O
although NN O O
positively NN O O
- NN O O
associated NN O O
alleles NN O O
are NN O O
very NN O O
common NN O O
( NN O O
allele NN O O
frequencies NN O O
> NN O O
0 NN O O
. NN O O
9 NN O O
) NN O O
in NN O O
the NN O O
Japanese NN O O
general NN O O
population NN O O
. NN O O

These NN O O
data NN O O
suggest NN O O
that NN O O
IDDM2 NN O O
is NN O O
involved NN O O
in NN O O
the NN O O
genetic NN O O
susceptibility NN O O
to NN O O
IDDM NN O B-Disease
in NN O O
Japanese NN O O
. NN O O

The NN O O
high NN O O
frequencies NN O O
of NN O O
disease NN O O
- NN O O
associated NN O O
alleles NN O O
in NN O O
the NN O O
general NN O O
population NN O O
suggest NN O O
that NN O O
IDDM2 NN O O
locus NN O O
is NN O O
not NN O O
responsible NN O O
for NN O O
the NN O O
low NN O O
incidence NN O O
of NN O O
IDDM NN O B-Disease
in NN O O
Japanese NN O O
. NN O O

The NN O O
human NN O O
complement NN O O
C9 NN O O
gene NN O O
: NN O O
identification NN O O
of NN O O
two NN O O
mutations NN O O
causing NN O O
deficiency NN O O
and NN O O
revision NN O O
of NN O O
the NN O O
gene NN O O
structure NN O O
. NN O O

The NN O O
ninth NN O O
component NN O O
of NN O O
human NN O O
complement NN O O
( NN O O
C9 NN O O
) NN O O
is NN O O
the NN O O
last NN O O
of NN O O
the NN O O
terminal NN O O
complement NN O O
components NN O O
creating NN O O
the NN O O
membrane NN O O
attack NN O O
complex NN O O
. NN O O

C9 NN O O
is NN O O
a NN O O
single NN O O
- NN O O
chain NN O O
serum NN O O
protein NN O O
that NN O O
is NN O O
encoded NN O O
by NN O O
a NN O O
gene NN O O
located NN O O
on NN O O
chromosome NN O O
5p NN O O
. NN O O

Deficiency NN O B-Disease
of NN O I-Disease
terminal NN O I-Disease
complement NN O I-Disease
components NN O I-Disease
is NN O O
generally NN O O
associated NN O O
with NN O O
recurrent NN O O
neisseria NN O B-Disease
infections NN O I-Disease
. NN O O

We NN O O
studied NN O O
a NN O O
previously NN O O
described NN O O
Swiss NN O O
family NN O O
with NN O O
inherited NN O B-Disease
C9 NN O I-Disease
deficiency NN O I-Disease
. NN O O

To NN O O
identify NN O O
the NN O O
genetic NN O O
basis NN O O
of NN O O
C9 NN O B-Disease
deficiency NN O I-Disease
, NN O O
we NN O O
developed NN O O
an NN O O
approach NN O O
using NN O O
exon NN O O
- NN O O
specific NN O O
PCR NN O O
and NN O O
direct NN O O
DNA NN O O
sequencing NN O O
. NN O O

As NN O O
a NN O O
cause NN O O
of NN O O
C9 NN O B-Disease
deficiency NN O I-Disease
, NN O O
we NN O O
found NN O O
two NN O O
different NN O O
point NN O O
mutations NN O O
, NN O O
both NN O O
generating NN O O
TGA NN O O
stop NN O O
codons NN O O
in NN O O
the NN O O
coding NN O O
sequence NN O O
. NN O O

One NN O O
mutation NN O O
, NN O O
a NN O O
C NN O O
to NN O O
A NN O O
exchange NN O O
, NN O O
was NN O O
detected NN O O
in NN O O
exon NN O O
2 NN O O
at NN O O
cDNA NN O O
position NN O O
166 NN O O
, NN O O
the NN O O
other NN O O
, NN O O
a NN O O
C NN O O
to NN O O
T NN O O
exchange NN O O
, NN O O
was NN O O
located NN O O
in NN O O
exon NN O O
4 NN O O
( NN O O
cDNA NN O O
position NN O O
464 NN O O
) NN O O
. NN O O

In NN O O
family NN O O
studies NN O O
of NN O O
three NN O O
first NN O O
- NN O O
degree NN O O
relatives NN O O
with NN O O
heterozygous NN O O
C9 NN O B-Disease
deficiency NN O I-Disease
, NN O O
we NN O O
demonstrated NN O O
that NN O O
the NN O O
two NN O O
mutations NN O O
are NN O O
segregating NN O O
independently NN O O
. NN O O

Therefore NN O O
, NN O O
these NN O O
mutations NN O O
are NN O O
sufficient NN O O
to NN O O
explain NN O O
the NN O O
complete NN O O
deficiency NN O O
of NN O O
both NN O O
the NN O O
probands NN O O
studied NN O O
. NN O O

DNA NN O O
sequencing NN O O
of NN O O
the NN O O
exon NN O O
- NN O O
intron NN O O
junctions NN O O
revealed NN O O
a NN O O
number NN O O
of NN O O
revisions NN O O
regarding NN O O
the NN O O
boundaries NN O O
between NN O O
exons NN O O
4 NN O O
, NN O O
5 NN O O
, NN O O
and NN O O
6 NN O O
as NN O O
well NN O O
as NN O O
between NN O O
exons NN O O
10 NN O O
and NN O O
11 NN O O
. NN O O

No NN O O
additional NN O O
introns NN O O
were NN O O
detected NN O O
in NN O O
exons NN O O
6 NN O O
and NN O O
10 NN O O
. NN O O

Furthermore NN O O
, NN O O
DNA NN O O
marker NN O O
studies NN O O
were NN O O
conducted NN O O
using NN O O
known NN O O
polymorphisms NN O O
of NN O O
the NN O O
C6 NN O O
, NN O O
C7 NN O O
, NN O O
and NN O O
C9 NN O O
genes NN O O
, NN O O
confirming NN O O
the NN O O
linkage NN O O
of NN O O
the NN O O
observed NN O O
C9 NN O O
mutations NN O O
with NN O O
defined NN O O
haplotypes NN O O
. NN O O
. NN O O

BRCA1 NN O O
mutations NN O O
in NN O O
women NN O O
attending NN O O
clinics NN O O
that NN O O
evaluate NN O O
the NN O O
risk NN O O
of NN O O
breast NN O B-Disease
cancer NN O I-Disease
. NN O O

BACKGROUND NN O O
To NN O O
define NN O O
the NN O O
incidence NN O O
of NN O O
BRCA1 NN O O
mutations NN O O
among NN O O
patients NN O O
seen NN O O
in NN O O
clinics NN O O
that NN O O
evaluate NN O O
the NN O O
risk NN O O
of NN O O
breast NN O B-Disease
cancer NN O I-Disease
, NN O O
we NN O O
analyzed NN O O
DNA NN O O
samples NN O O
from NN O O
women NN O O
seen NN O O
in NN O O
this NN O O
setting NN O O
and NN O O
constructed NN O O
probability NN O O
tables NN O O
to NN O O
provide NN O O
estimates NN O O
of NN O O
the NN O O
likelihood NN O O
of NN O O
finding NN O O
a NN O O
BRCA1 NN O O
mutation NN O O
in NN O O
individual NN O O
families NN O O
. NN O O

METHODS NN O O
Clinical NN O O
information NN O O
, NN O O
family NN O O
histories NN O O
, NN O O
and NN O O
blood NN O O
for NN O O
DNA NN O O
analysis NN O O
were NN O O
obtained NN O O
from NN O O
263 NN O O
women NN O O
with NN O O
breast NN O B-Disease
cancer NN O I-Disease
. NN O O

Conformation NN O O
- NN O O
sensitive NN O O
gel NN O O
electrophoresis NN O O
and NN O O
DNA NN O O
sequencing NN O O
were NN O O
used NN O O
to NN O O
identify NN O O
BRCA1 NN O O
mutations NN O O
. NN O O

RESULTS NN O O
BRCA1 NN O O
mutations NN O O
were NN O O
identified NN O O
in NN O O
16 NN O O
percent NN O O
of NN O O
women NN O O
with NN O O
a NN O O
family NN O O
history NN O O
of NN O O
breast NN O B-Disease
cancer NN O I-Disease
. NN O O

Only NN O O
7 NN O O
percent NN O O
of NN O O
women NN O O
from NN O O
families NN O O
with NN O O
a NN O O
history NN O O
of NN O O
breast NN O B-Disease
cancer NN O I-Disease
but NN O O
not NN O O
ovarian NN O B-Disease
cancer NN O I-Disease
had NN O O
BRCA1 NN O O
mutations NN O O
. NN O O

The NN O O
rates NN O O
were NN O O
higher NN O O
among NN O O
women NN O O
from NN O O
families NN O O
with NN O O
a NN O O
history NN O O
of NN O O
both NN O O
breast NN O B-Disease
and NN O I-Disease
ovarian NN O I-Disease
cancer NN O I-Disease
. NN O O

Among NN O O
family NN O O
members NN O O
, NN O O
an NN O O
average NN O O
age NN O O
of NN O O
less NN O O
than NN O O
55 NN O O
years NN O O
at NN O O
the NN O O
diagnosis NN O O
of NN O O
breast NN O B-Disease
cancer NN O I-Disease
, NN O O
the NN O O
presence NN O O
of NN O O
ovarian NN O B-Disease
cancer NN O I-Disease
, NN O O
the NN O O
presence NN O O
of NN O O
breast NN O B-Disease
and NN O I-Disease
ovarian NN O I-Disease
cancer NN O I-Disease
in NN O O
the NN O O
same NN O O
woman NN O O
, NN O O
and NN O O
Ashkenazi NN O O
Jewish NN O O
ancestry NN O O
were NN O O
all NN O O
associated NN O O
with NN O O
an NN O O
increased NN O O
risk NN O O
of NN O O
detecting NN O O
a NN O O
BRCA1 NN O O
mutation NN O O
. NN O O

No NN O O
association NN O O
was NN O O
found NN O O
between NN O O
the NN O O
presence NN O O
of NN O O
bilateral NN O O
breast NN O B-Disease
cancer NN O I-Disease
or NN O O
the NN O O
number NN O O
of NN O O
breast NN O B-Disease
cancers NN O I-Disease
in NN O O
a NN O O
family NN O O
and NN O O
the NN O O
detection NN O O
of NN O O
a NN O O
BRCA1 NN O O
mutation NN O O
, NN O O
or NN O O
between NN O O
the NN O O
position NN O O
of NN O O
the NN O O
mutation NN O O
in NN O O
the NN O O
BRCA1 NN O O
gene NN O O
and NN O O
the NN O O
presence NN O O
of NN O O
ovarian NN O B-Disease
cancer NN O I-Disease
in NN O O
a NN O O
family NN O O
. NN O O

CONCLUSIONS NN O O
Among NN O O
women NN O O
with NN O O
breast NN O B-Disease
cancer NN O I-Disease
and NN O O
a NN O O
family NN O O
history NN O O
of NN O O
the NN O O
disease NN O O
, NN O O
the NN O O
percentage NN O O
with NN O O
BRCA1 NN O O
coding NN O O
- NN O O
region NN O O
mutations NN O O
is NN O O
less NN O O
than NN O O
the NN O O
45 NN O O
percent NN O O
predicted NN O O
by NN O O
genetic NN O O
- NN O O
linkage NN O O
analysis NN O O
. NN O O

These NN O O
results NN O O
suggest NN O O
that NN O O
even NN O O
in NN O O
a NN O O
referral NN O O
clinic NN O O
specializing NN O O
in NN O O
screening NN O O
women NN O O
from NN O O
high NN O O
- NN O O
risk NN O O
families NN O O
, NN O O
the NN O O
majority NN O O
of NN O O
tests NN O O
for NN O O
BRCA1 NN O O
mutations NN O O
will NN O O
be NN O O
negative NN O O
and NN O O
therefore NN O O
uninformative NN O O
. NN O O
. NN O O

Mutations NN O O
in NN O O
the NN O O
arginine NN O O
- NN O O
rich NN O O
protein NN O O
gene NN O O
( NN O O
ARP NN O O
) NN O O
in NN O O
pancreatic NN O B-Disease
cancer NN O I-Disease
. NN O O

The NN O O
ARP NN O O
gene NN O O
encodes NN O O
a NN O O
highly NN O O
conserved NN O O
arginine NN O O
- NN O O
rich NN O O
protein NN O O
from NN O O
chromosomal NN O O
band NN O O
3p21 NN O O
. NN O O

1 NN O O
1 NN O O
. NN O O

At NN O O
the NN O O
cytogenetic NN O O
level NN O O
this NN O O
region NN O O
is NN O O
frequently NN O O
deleted NN O O
in NN O O
a NN O O
variety NN O O
of NN O O
different NN O O
solid NN O B-Disease
tumors NN O I-Disease
, NN O O
although NN O O
not NN O O
in NN O O
pancreatic NN O B-Disease
cancer NN O I-Disease
. NN O O

We NN O O
have NN O O
reported NN O O
the NN O O
presence NN O O
of NN O O
a NN O O
specific NN O O
mutation NN O O
( NN O O
ATG50 NN O O
- NN O O
- NN O O
> NN O O
AGG NN O O
) NN O O
or NN O O
deletion NN O O
of NN O O
codon NN O O
50 NN O O
of NN O O
the NN O O
ARP NN O O
gene NN O O
in NN O O
different NN O O
tumor NN O B-Disease
types NN O I-Disease
( NN O O
Shridhar NN O O
et NN O O
al NN O O
. NN O O
, NN O O
1996 NN O O
, NN O O
1996a NN O O
) NN O O
. NN O O

In NN O O
the NN O O
present NN O O
study NN O O
, NN O O
we NN O O
have NN O O
observed NN O O
mutations NN O O
involving NN O O
codon NN O O
50 NN O O
in NN O O
11 NN O O
of NN O O
37 NN O O
pancreatic NN O B-Disease
tumors NN O I-Disease
. NN O O

The NN O O
frequency NN O O
of NN O O
codon NN O O
50 NN O O
mutation NN O O
is NN O O
roughly NN O O
the NN O O
same NN O O
in NN O O
pancreatic NN O B-Disease
tumors NN O I-Disease
as NN O O
in NN O O
the NN O O
other NN O O
types NN O O
of NN O O
tumors NN O B-Disease
previously NN O O
examined NN O O
. NN O O

In NN O O
addition NN O O
, NN O O
we NN O O
have NN O O
detected NN O O
mutations NN O O
at NN O O
codon NN O O
51 NN O O
in NN O O
multiple NN O O
PCR NN O O
subclones NN O O
in NN O O
two NN O O
other NN O O
pancreatic NN O B-Disease
tumors NN O I-Disease
. NN O O

Mutations NN O O
in NN O O
the NN O O
ARP NN O O
gene NN O O
are NN O O
thus NN O O
commonly NN O O
observed NN O O
in NN O O
pancreatic NN O B-Disease
cancer NN O I-Disease
, NN O O
as NN O O
well NN O O
as NN O O
many NN O O
other NN O O
cancers NN O B-Disease
. NN O O

Difficulties NN O O
in NN O O
the NN O O
ascertainment NN O O
of NN O O
C9 NN O B-Disease
deficiency NN O I-Disease
: NN O O
lessons NN O O
to NN O O
be NN O O
drawn NN O O
from NN O O
a NN O O
compound NN O O
heterozygote NN O O
C9 NN O B-Disease
- NN O I-Disease
deficient NN O I-Disease
subject NN O O
. NN O O

A NN O O
group NN O O
of NN O O
patients NN O O
with NN O O
long NN O O
- NN O O
surviving NN O O
mismatched NN O O
kidney NN O O
allografts NN O O
were NN O O
investigated NN O O
for NN O O
complement NN O O
function NN O O
using NN O O
haemolytic NN O O
assays NN O O
in NN O O
agarose NN O O
gels NN O O
. NN O O

One NN O O
patient NN O O
was NN O O
found NN O O
to NN O O
have NN O O
no NN O O
alternative NN O O
pathway NN O O
activity NN O O
but NN O O
a NN O O
low NN O O
normal NN O O
classical NN O O
pathway NN O O
. NN O O

Surprisingly NN O O
, NN O O
investigation NN O O
revealed NN O O
that NN O O
the NN O O
patients NN O O
complement NN O O
was NN O O
normal NN O O
for NN O O
all NN O O
components NN O O
except NN O O
C9 NN O O
, NN O O
which NN O O
was NN O O
functionally NN O O
absent NN O O
. NN O O

The NN O O
patient NN O O
was NN O O
shown NN O O
to NN O O
be NN O O
heterozygous NN O O
for NN O O
DNA NN O O
markers NN O O
in NN O O
the NN O O
C6 NN O O
, NN O O
C7 NN O O
and NN O O
C9 NN O O
region NN O O
of NN O O
chromosome NN O O
5 NN O O
and NN O O
therefore NN O O
appears NN O O
to NN O O
be NN O O
a NN O O
compound NN O O
heterozygote NN O O
for NN O O
two NN O O
uncharacterized NN O O
C9 NN O B-Disease
deficiency NN O I-Disease
genes NN O O
. NN O O

Serological NN O O
analysis NN O O
by NN O O
ELISA NN O O
revealed NN O O
that NN O O
he NN O O
has NN O O
trace NN O O
concentrations NN O O
of NN O O
a NN O O
non NN O O
- NN O O
functional NN O O
C9 NN O O
molecule NN O O
. NN O O

Western NN O O
blot NN O O
analysis NN O O
was NN O O
not NN O O
sufficiently NN O O
sensitive NN O O
to NN O O
permit NN O O
detection NN O O
of NN O O
this NN O O
molecule NN O O
. NN O O

We NN O O
hypothesize NN O O
that NN O O
the NN O O
patient NN O O
is NN O O
heterozygous NN O O
for NN O O
a NN O O
complete NN O B-Disease
deficiency NN O I-Disease
of NN O I-Disease
C9 NN O I-Disease
and NN O O
for NN O O
a NN O O
gene NN O O
directing NN O O
hyposynthesis NN O O
of NN O O
a NN O O
defective NN O O
C9 NN O O
. NN O O

We NN O O
also NN O O
suggest NN O O
that NN O O
C9 NN O B-Disease
deficiency NN O I-Disease
may NN O O
be NN O O
more NN O O
common NN O O
among NN O O
Caucasians NN O O
than NN O O
has NN O O
been NN O O
reported NN O O
. NN O O
. NN O O

Screening NN O O
for NN O O
ESR NN O O
mutations NN O O
in NN O O
breast NN O B-Disease
and NN O I-Disease
ovarian NN O I-Disease
cancer NN O I-Disease
patients NN O O
. NN O O

In NN O O
the NN O O
present NN O O
study NN O O
, NN O O
leukocyte NN O O
DNA NN O O
from NN O O
143 NN O O
patients NN O O
with NN O O
familial NN O O
clustering NN O O
of NN O O
breast NN O B-Disease
and NN O I-Disease
/ NN O I-Disease
or NN O I-Disease
ovarian NN O I-Disease
cancer NN O I-Disease
and NN O O
tumour NN O B-Disease
DNA NN O O
from NN O O
96 NN O O
breast NN O B-Disease
carcinomas NN O I-Disease
were NN O O
screened NN O O
for NN O O
base NN O O
mutations NN O O
in NN O O
the NN O O
estrogen NN O O
receptor NN O O
gene NN O O
( NN O O
ESR NN O O
) NN O O
. NN O O

Three NN O O
patients NN O O
with NN O O
a NN O O
family NN O O
history NN O O
of NN O O
cancer NN O B-Disease
were NN O O
carrying NN O O
a NN O O
Gly160Cys NN O O
germline NN O O
substitution NN O O
. NN O O

This NN O O
alteration NN O O
was NN O O
also NN O O
detected NN O O
in NN O O
eight NN O O
( NN O O
four NN O O
females NN O O
and NN O O
four NN O O
males NN O O
) NN O O
of NN O O
729 NN O O
controls NN O O
( NN O O
366 NN O O
female NN O O
, NN O O
363 NN O O
males NN O O
) NN O O
, NN O O
indicating NN O O
that NN O O
the NN O O
substitution NN O O
probably NN O O
represents NN O O
a NN O O
polymorphism NN O O
. NN O O

However NN O O
, NN O O
in NN O O
the NN O O
229 NN O O
female NN O O
controls NN O O
in NN O O
whom NN O O
family NN O O
history NN O O
of NN O O
cancer NN O B-Disease
was NN O O
known NN O O
, NN O O
one NN O O
of NN O O
two NN O O
who NN O O
had NN O O
a NN O O
sister NN O O
with NN O O
breast NN O B-Disease
cancer NN O I-Disease
was NN O O
carrying NN O O
the NN O O
variant NN O O
allele NN O O
. NN O O

Hence NN O O
, NN O O
a NN O O
possible NN O O
clinical NN O O
significance NN O O
of NN O O
the NN O O
glycine NN O O
into NN O O
cysteine NN O O
cannot NN O O
be NN O O
completely NN O O
ruled NN O O
out NN O O
and NN O O
should NN O O
be NN O O
further NN O O
investigated NN O O
. NN O O

Somatic NN O O
mutations NN O O
were NN O O
not NN O O
detected NN O O
in NN O O
any NN O O
of NN O O
the NN O O
tumours NN O B-Disease
studied NN O O
, NN O O
and NN O O
the NN O O
present NN O O
data NN O O
do NN O O
not NN O O
provide NN O O
support NN O O
for NN O O
somatic NN O O
ESR NN O O
base NN O O
mutations NN O O
as NN O O
an NN O O
important NN O O
mechanism NN O O
for NN O O
hormonal NN O O
therapy NN O O
resistance NN O O
in NN O O
estrogen NN O B-Disease
receptor NN O I-Disease
- NN O I-Disease
positive NN O I-Disease
breast NN O I-Disease
carcinomas NN O I-Disease
. NN O O
. NN O O

Molecular NN O O
bases NN O O
of NN O O
C7 NN O B-Disease
deficiency NN O I-Disease
: NN O O
three NN O O
different NN O O
defects NN O O
. NN O O

The NN O O
molecular NN O O
basis NN O O
of NN O O
C7 NN O B-Disease
deficiency NN O I-Disease
has NN O O
been NN O O
investigated NN O O
in NN O O
two NN O O
Irish NN O O
families NN O O
and NN O O
a NN O O
number NN O O
of NN O O
Israeli NN O O
families NN O O
of NN O O
Moroccan NN O O
Sephardic NN O O
Jewish NN O O
origin NN O O
. NN O O

Exon NN O O
PCR NN O O
and NN O O
sequencing NN O O
revealed NN O O
a NN O O
heterozygous NN O O
point NN O O
mutation NN O O
at NN O O
the NN O O
3 NN O O
splice NN O O
acceptor NN O O
site NN O O
of NN O O
intron NN O O
1 NN O O
in NN O O
one NN O O
Irish NN O O
family NN O O
. NN O O

In NN O O
the NN O O
other NN O O
Irish NN O O
family NN O O
, NN O O
exons NN O O
7 NN O O
and NN O O
8 NN O O
failed NN O O
to NN O O
amplify NN O O
and NN O O
they NN O O
were NN O O
shown NN O O
to NN O O
be NN O O
deleted NN O O
. NN O O

Marker NN O O
haplotype NN O O
studies NN O O
of NN O O
the NN O O
C6 NN O O
and NN O O
C7 NN O O
gene NN O O
region NN O O
and NN O O
Southern NN O O
blots NN O O
show NN O O
that NN O O
the NN O O
Irish NN O O
family NN O O
with NN O O
the NN O O
splice NN O O
defect NN O O
also NN O O
segregate NN O O
for NN O O
the NN O O
deletion NN O O
, NN O O
which NN O O
is NN O O
not NN O O
easily NN O O
detected NN O O
in NN O O
heterozygotes NN O O
. NN O O

The NN O O
Israeli NN O O
C7 NN O B-Disease
- NN O I-Disease
deficient NN O I-Disease
cases NN O O
all NN O O
share NN O O
a NN O O
C7 NN O O
haplotype NN O O
and NN O O
are NN O O
homozygous NN O O
for NN O O
a NN O O
mis NN O O
- NN O O
sense NN O O
mutation NN O O
in NN O O
exon NN O O
9 NN O O
. NN O O

However NN O O
, NN O O
one NN O O
individual NN O O
is NN O O
heterozygous NN O O
for NN O O
markers NN O O
at NN O O
adjacent NN O O
C6 NN O O
loci NN O O
, NN O O
showing NN O O
that NN O O
there NN O O
has NN O O
been NN O O
an NN O O
intergenic NN O O
recombination NN O O
and NN O O
suggesting NN O O
that NN O O
the NN O O
deficiency NN O O
mutation NN O O
is NN O O
of NN O O
appreciable NN O O
antiquity NN O O
. NN O O
. NN O O

Molecular NN O O
heterogeneity NN O O
of NN O O
classical NN O B-Disease
and NN O I-Disease
Duarte NN O I-Disease
galactosemia NN O I-Disease
: NN O O
mutation NN O O
analysis NN O O
by NN O O
denaturing NN O O
gradient NN O O
gel NN O O
electrophoresis NN O O
. NN O O

Classical NN O B-Disease
galactosemia NN O I-Disease
is NN O O
caused NN O O
by NN O O
one NN O O
common NN O O
missense NN O O
mutation NN O O
( NN O O
Q188R NN O O
) NN O O
and NN O O
by NN O O
several NN O O
rare NN O O
mutations NN O O
in NN O O
the NN O O
galactose NN O O
- NN O O
1 NN O O
- NN O O
phosphate NN O O
uridyltransferase NN O O
( NN O O
GALT NN O O
) NN O O
gene NN O O
. NN O O

The NN O O
most NN O O
common NN O O
variant NN O O
of NN O O
GALT NN O O
, NN O O
the NN O O
Duarte NN O O
variant NN O O
, NN O O
occurs NN O O
as NN O O
two NN O O
types NN O O
, NN O O
Duarte NN O O
- NN O O
1 NN O O
( NN O O
D NN O O
- NN O O
1 NN O O
) NN O O
and NN O O
Duarte NN O O
- NN O O
2 NN O O
( NN O O
D NN O O
- NN O O
2 NN O O
) NN O O
, NN O O
both NN O O
of NN O O
which NN O O
carry NN O O
the NN O O
sequence NN O O
change NN O O
N314D NN O O
. NN O O

D NN O O
- NN O O
1 NN O O
increases NN O O
, NN O O
whereas NN O O
D NN O O
- NN O O
2 NN O O
decreases NN O O
GALT NN O O
activity NN O O
. NN O O

To NN O O
study NN O O
the NN O O
molecular NN O O
genetics NN O O
of NN O O
classical NN O B-Disease
and NN O I-Disease
Duarte NN O I-Disease
galactosemia NN O I-Disease
, NN O O
we NN O O
analyzed NN O O
the NN O O
GALT NN O O
mutations NN O O
in NN O O
30 NN O O
families NN O O
with NN O O
classical NN O B-Disease
galactosemia NN O I-Disease
, NN O O
in NN O O
10 NN O O
families NN O O
with NN O O
the NN O O
D NN O O
- NN O O
2 NN O O
variant NN O O
and NN O O
in NN O O
3 NN O O
individuals NN O O
carrying NN O O
the NN O O
D NN O O
- NN O O
1 NN O O
allele NN O O
by NN O O
denaturing NN O O
gradient NN O O
gel NN O O
electrophoresis NN O O
( NN O O
DGGE NN O O
) NN O O
. NN O O

DGGE NN O O
detected NN O O
59 NN O O
of NN O O
the NN O O
60 NN O O
classical NN O O
galactosemia NN O B-Disease
alleles NN O O
. NN O O

Q188R NN O O
accounted NN O O
for NN O O
60 NN O O
% NN O O
, NN O O
K285N NN O O
accounted NN O O
for NN O O
28 NN O O
% NN O O
of NN O O
these NN O O
alleles NN O O
. NN O O

Eight NN O O
novel NN O O
candidate NN O O
galactosemia NN O B-Disease
mutations NN O O
were NN O O
found NN O O
. NN O O

On NN O O
all NN O O
D NN O O
- NN O O
2 NN O O
alleles NN O O
N314D NN O O
occurred NN O O
in NN O O
cis NN O O
with NN O O
two NN O O
intronic NN O O
sequence NN O O
changes NN O O
, NN O O
on NN O O
the NN O O
D NN O O
- NN O O
1 NN O O
alleles NN O O
in NN O O
cis NN O O
with NN O O
a NN O O
neutral NN O O
mutation NN O O
in NN O O
exon NN O O
7 NN O O
. NN O O

We NN O O
conclude NN O O
that NN O O
the NN O O
mutations NN O O
causing NN O O
galactosemia NN O B-Disease
are NN O O
highly NN O O
heterogeneous NN O O
and NN O O
that NN O O
K285N NN O O
is NN O O
a NN O O
second NN O O
common NN O O
galactosemia NN O B-Disease
mutation NN O O
in NN O O
our NN O O
population NN O O
. NN O O
. NN O O

Isolation NN O O
of NN O O
full NN O O
- NN O O
length NN O O
ATM NN O O
cDNA NN O O
and NN O O
correction NN O O
of NN O O
the NN O O
ataxia NN O B-Disease
- NN O I-Disease
telangiectasia NN O I-Disease
cellular NN O O
phenotype NN O O
. NN O O

A NN O O
gene NN O O
mutated NN O O
in NN O O
the NN O O
human NN O O
genetic NN O B-Disease
disorder NN O I-Disease
ataxia NN O B-Disease
- NN O I-Disease
telangiectasia NN O I-Disease
( NN O O
A NN O B-Disease
- NN O I-Disease
T NN O I-Disease
) NN O O
, NN O O
ATM NN O O
, NN O O
was NN O O
recently NN O O
identified NN O O
by NN O O
positional NN O O
cloning NN O O
. NN O O

ATM NN O O
is NN O O
a NN O O
member NN O O
of NN O O
the NN O O
phosphatidylinositol NN O O
- NN O O
3 NN O O
- NN O O
kinase NN O O
superfamily NN O O
, NN O O
some NN O O
of NN O O
which NN O O
are NN O O
protein NN O O
kinases NN O O
and NN O O
appear NN O O
to NN O O
have NN O O
important NN O O
roles NN O O
in NN O O
cell NN O O
cycle NN O O
control NN O O
and NN O O
radiation NN O O
signal NN O O
transduction NN O O
. NN O O

We NN O O
describe NN O O
herein NN O O
, NN O O
to NN O O
our NN O O
knowledge NN O O
, NN O O
for NN O O
the NN O O
first NN O O
time NN O O
, NN O O
the NN O O
cloning NN O O
of NN O O
a NN O O
full NN O O
- NN O O
length NN O O
cDNA NN O O
for NN O O
ATM NN O O
and NN O O
correction NN O O
of NN O O
multiple NN O O
aspects NN O O
of NN O O
the NN O O
radio NN O O
- NN O O
sensitive NN O O
phenotype NN O O
of NN O O
A NN O B-Disease
- NN O I-Disease
T NN O I-Disease
cells NN O O
by NN O O
transfection NN O O
with NN O O
this NN O O
cDNA NN O O
. NN O O

Overexpression NN O O
of NN O O
ATM NN O O
cDNA NN O O
in NN O O
A NN O B-Disease
- NN O I-Disease
T NN O I-Disease
cells NN O O
enhanced NN O O
the NN O O
survival NN O O
of NN O O
these NN O O
cells NN O O
in NN O O
response NN O O
to NN O O
radiation NN O O
exposure NN O O
, NN O O
decreased NN O O
radiation NN O O
- NN O O
induced NN O O
chromosome NN O O
aberrations NN O O
, NN O O
reduced NN O O
radio NN O O
- NN O O
resistant NN O O
DNA NN O O
synthesis NN O O
, NN O O
and NN O O
partially NN O O
corrected NN O O
defective NN O O
cell NN O O
cycle NN O O
checkpoints NN O O
and NN O O
induction NN O O
of NN O O
stress NN O O
- NN O O
activated NN O O
protein NN O O
kinase NN O O
. NN O O

This NN O O
correction NN O O
of NN O O
the NN O O
defects NN O O
in NN O O
A NN O B-Disease
- NN O I-Disease
T NN O I-Disease
cells NN O O
provides NN O O
further NN O O
evidence NN O O
of NN O O
the NN O O
multiplicity NN O O
of NN O O
effector NN O O
functions NN O O
of NN O O
the NN O O
ATM NN O O
protein NN O O
and NN O O
suggests NN O O
possible NN O O
approaches NN O O
to NN O O
gene NN O O
therapy NN O O
. NN O O
. NN O O

Fusion NN O O
genes NN O O
resulting NN O O
from NN O O
alternative NN O O
chromosomal NN O O
translocations NN O O
are NN O O
overexpressed NN O O
by NN O O
gene NN O O
- NN O O
specific NN O O
mechanisms NN O O
in NN O O
alveolar NN O B-Disease
rhabdomyosarcoma NN O I-Disease
. NN O O

Chromosomal NN O O
translocations NN O O
identified NN O O
in NN O O
hematopoietic NN O B-Disease
and NN O I-Disease
solid NN O I-Disease
tumors NN O I-Disease
result NN O O
in NN O O
deregulated NN O O
expression NN O O
of NN O O
protooncogenes NN O O
or NN O O
creation NN O O
of NN O O
chimeric NN O O
proteins NN O O
with NN O O
tumorigenic NN O O
potential NN O O
. NN O O

In NN O O
the NN O O
pediatric NN O O
solid NN O B-Disease
tumor NN O I-Disease
alveolar NN O B-Disease
rhabdomyosarcoma NN O I-Disease
, NN O O
a NN O O
consistent NN O O
t NN O O
( NN O O
2 NN O O
; NN O O
13 NN O O
) NN O O
( NN O O
q35 NN O O
; NN O O
q14 NN O O
) NN O O
or NN O O
variant NN O O
t NN O O
( NN O O
1 NN O O
; NN O O
13 NN O O
) NN O O
( NN O O
p36 NN O O
; NN O O
q14 NN O O
) NN O O
translocation NN O O
generates NN O O
PAX3 NN O O
- NN O O
FKHR NN O O
or NN O O
PAX7 NN O O
- NN O O
FKHR NN O O
fusion NN O O
proteins NN O O
, NN O O
respectively NN O O
. NN O O

In NN O O
this NN O O
report NN O O
, NN O O
we NN O O
demonstrate NN O O
that NN O O
in NN O O
addition NN O O
to NN O O
functional NN O O
alterations NN O O
these NN O O
translocations NN O O
are NN O O
associated NN O O
with NN O O
fusion NN O O
product NN O O
overexpression NN O O
. NN O O

Furthermore NN O O
, NN O O
PAX3 NN O O
- NN O O
FKHR NN O O
and NN O O
PAX7 NN O O
- NN O O
FKHR NN O O
overexpression NN O O
occurs NN O O
by NN O O
distinct NN O O
mechanisms NN O O
. NN O O

Transcription NN O O
of NN O O
PAX3 NN O O
- NN O O
FKHR NN O O
is NN O O
increased NN O O
relative NN O O
to NN O O
wild NN O O
- NN O O
type NN O O
PAX3 NN O O
by NN O O
a NN O O
copy NN O O
number NN O O
- NN O O
independent NN O O
process NN O O
. NN O O

In NN O O
contrast NN O O
, NN O O
PAX7 NN O O
- NN O O
FKHR NN O O
overexpression NN O O
results NN O O
from NN O O
fusion NN O O
gene NN O O
amplification NN O O
. NN O O

Thus NN O O
, NN O O
gene NN O O
- NN O O
specific NN O O
mechanisms NN O O
were NN O O
selected NN O O
to NN O O
overexpress NN O O
PAX3 NN O O
- NN O O
FKHR NN O O
and NN O O
PAX7 NN O O
- NN O O
FKHR NN O O
in NN O O
alveolar NN O B-Disease
rhabdomyosarcoma NN O I-Disease
, NN O O
presumably NN O O
due NN O O
to NN O O
differences NN O O
in NN O O
regulation NN O O
between NN O O
the NN O O
wild NN O O
- NN O O
type NN O O
loci NN O O
. NN O O

We NN O O
postulate NN O O
that NN O O
these NN O O
overexpression NN O O
mechanisms NN O O
ensure NN O O
a NN O O
critical NN O O
level NN O O
of NN O O
gene NN O O
product NN O O
for NN O O
the NN O O
oncogenic NN O O
effects NN O O
of NN O O
these NN O O
fusions NN O O
. NN O O
. NN O O

atm NN O O
and NN O O
p53 NN O O
cooperate NN O O
in NN O O
apoptosis NN O O
and NN O O
suppression NN O O
of NN O O
tumorigenesis NN O O
, NN O O
but NN O O
not NN O O
in NN O O
resistance NN O O
to NN O O
acute NN O B-Disease
radiation NN O I-Disease
toxicity NN O I-Disease
. NN O O

Mutations NN O O
in NN O O
atm NN O O
and NN O O
p53 NN O O
cause NN O O
the NN O O
human NN O O
cancer NN O B-Disease
- NN O I-Disease
associated NN O I-Disease
diseases NN O I-Disease
ataxia NN O B-Disease
- NN O I-Disease
telangiectasia NN O I-Disease
and NN O O
Li NN O B-Disease
- NN O I-Disease
Fraumeni NN O I-Disease
syndrome NN O I-Disease
, NN O O
respectively NN O O
. NN O O

The NN O O
two NN O O
genes NN O O
are NN O O
believed NN O O
to NN O O
interact NN O O
in NN O O
a NN O O
number NN O O
of NN O O
pathways NN O O
, NN O O
including NN O O
regulation NN O O
of NN O O
DNA NN O O
damage NN O O
- NN O O
induced NN O O
cell NN O O
- NN O O
cycle NN O O
checkpoints NN O O
, NN O O
apoptosis NN O O
and NN O O
radiation NN O O
sensitivity NN O O
, NN O O
and NN O O
cellular NN O O
proliferation NN O O
. NN O O

Atm NN O O
- NN O O
null NN O O
mice NN O O
, NN O O
as NN O O
well NN O O
as NN O O
those NN O O
null NN O O
for NN O O
p53 NN O O
, NN O O
develop NN O O
mainly NN O O
T NN O B-Disease
- NN O I-Disease
cell NN O I-Disease
lymphomas NN O I-Disease
, NN O O
supporting NN O O
the NN O O
view NN O O
that NN O O
these NN O O
genes NN O O
have NN O O
similar NN O O
roles NN O O
in NN O O
thymocyte NN O O
development NN O O
. NN O O

To NN O O
study NN O O
the NN O O
interactions NN O O
of NN O O
these NN O O
two NN O O
genes NN O O
on NN O O
an NN O O
organismal NN O O
level NN O O
, NN O O
we NN O O
bred NN O O
mice NN O O
heterozygous NN O O
for NN O O
null NN O O
alleles NN O O
of NN O O
both NN O O
atm NN O O
and NN O O
p53 NN O O
to NN O O
produce NN O O
all NN O O
genotypic NN O O
combinations NN O O
. NN O O

Mice NN O O
doubly NN O O
null NN O O
for NN O O
atm NN O O
and NN O O
p53 NN O O
exhibited NN O O
a NN O O
dramatic NN O O
acceleration NN O O
of NN O O
tumour NN O B-Disease
formation NN O O
relative NN O O
to NN O O
singly NN O O
null NN O O
mice NN O O
, NN O O
indicating NN O O
that NN O O
both NN O O
genes NN O O
collaborate NN O O
in NN O O
a NN O O
significant NN O O
manner NN O O
to NN O O
prevent NN O O
tumorigenesis NN O O
. NN O O

With NN O O
respect NN O O
to NN O O
their NN O O
roles NN O O
in NN O O
apoptosis NN O O
, NN O O
loss NN O O
of NN O O
atm NN O O
rendered NN O O
thymocytes NN O O
only NN O O
partly NN O O
resistant NN O O
to NN O O
irradiation NN O O
- NN O O
induced NN O O
apoptosis NN O O
, NN O O
whereas NN O O
additional NN O O
loss NN O O
of NN O O
p53 NN O O
engendered NN O O
complete NN O O
resistance NN O O
. NN O O

This NN O O
implies NN O O
that NN O O
the NN O O
irradiation NN O O
- NN O O
induced NN O O
atm NN O O
and NN O O
p53 NN O O
apoptotic NN O O
pathways NN O O
are NN O O
not NN O O
completely NN O O
congruent NN O O
. NN O O

Finally NN O O
- NN O O
and NN O O
in NN O O
contrast NN O O
to NN O O
prior NN O O
predictions NN O O
- NN O O
atm NN O O
and NN O O
p53 NN O O
do NN O O
not NN O O
appear NN O O
to NN O O
interact NN O O
in NN O O
acute NN O B-Disease
radiation NN O I-Disease
toxicity NN O I-Disease
, NN O O
suggesting NN O O
a NN O O
separate NN O O
atm NN O O
effector NN O O
pathway NN O O
for NN O O
this NN O O
DNA NN O O
damage NN O O
response NN O O
and NN O O
having NN O O
implications NN O O
for NN O O
the NN O O
prognosis NN O O
and NN O O
treatment NN O O
of NN O O
human NN O O
tumours NN O B-Disease
. NN O O
. NN O O

Trinucleotide NN O O
repeat NN O O
expansion NN O O
at NN O O
the NN O O
myotonic NN O B-Disease
dystrophy NN O I-Disease
locus NN O O
reduces NN O O
expression NN O O
of NN O O
DMAHP NN O O
. NN O O

Myotonic NN O B-Disease
dystrophy NN O I-Disease
, NN O O
or NN O O
dystrophia NN O B-Disease
myotonica NN O I-Disease
( NN O O
DM NN O B-Disease
) NN O O
, NN O O
is NN O O
an NN O O
autosomal NN O B-Disease
dominant NN O I-Disease
multisystem NN O I-Disease
disorder NN O I-Disease
caused NN O O
by NN O O
the NN O O
expansion NN O O
of NN O O
a NN O O
CTG NN O O
trinucleotide NN O O
repeat NN O O
in NN O O
the NN O O
3 NN O O
untranslated NN O O
region NN O O
of NN O O
the NN O O
DMPK NN O O
protein NN O O
kinase NN O O
gene NN O O
on NN O O
chromosome NN O O
19q13 NN O O
. NN O O

3 NN O O
( NN O O
refs NN O O
1 NN O O
- NN O O
3 NN O O
) NN O O
. NN O O

Although NN O O
the NN O O
DM NN O B-Disease
mutation NN O O
was NN O O
identified NN O O
more NN O O
than NN O O
five NN O O
years NN O O
ago NN O O
, NN O O
the NN O O
pathogenic NN O O
mechanisms NN O O
underlying NN O O
this NN O O
most NN O O
prevalent NN O O
form NN O O
of NN O O
hereditary NN O O
adult NN O O
neuromuscular NN O B-Disease
disease NN O I-Disease
remain NN O O
elusive NN O O
. NN O O

Previous NN O O
work NN O O
from NN O O
our NN O O
laboratory NN O O
demonstrated NN O O
that NN O O
a NN O O
DNase NN O O
l NN O O
- NN O O
hypersensitive NN O O
site NN O O
located NN O O
adjacent NN O O
to NN O O
the NN O O
repeats NN O O
on NN O O
the NN O O
wild NN O O
- NN O O
type NN O O
allele NN O O
is NN O O
eliminated NN O O
by NN O O
repeat NN O O
expansion NN O O
, NN O O
indicating NN O O
that NN O O
large NN O O
CTG NN O O
- NN O O
repeat NN O O
arrays NN O O
may NN O O
be NN O O
associated NN O O
with NN O O
a NN O O
local NN O O
chromatin NN O O
environment NN O O
that NN O O
represses NN O O
gene NN O O
expression NN O O
. NN O O

Here NN O O
we NN O O
report NN O O
that NN O O
the NN O O
hypersensitive NN O O
site NN O O
contains NN O O
an NN O O
enhancer NN O O
element NN O O
that NN O O
regulates NN O O
transcription NN O O
of NN O O
the NN O O
adjacent NN O O
DMAHP NN O O
homeobox NN O O
gene NN O O
. NN O O

Analysis NN O O
of NN O O
DMAHP NN O O
expression NN O O
in NN O O
the NN O O
cells NN O O
of NN O O
DM NN O B-Disease
patients NN O O
with NN O O
loss NN O O
of NN O O
the NN O O
hypersensitive NN O O
site NN O O
revealed NN O O
a NN O O
two NN O O
- NN O O
to NN O O
fourfold NN O O
reduction NN O O
in NN O O
steady NN O O
- NN O O
state NN O O
DMAHP NN O O
transcript NN O O
levels NN O O
relative NN O O
to NN O O
wild NN O O
- NN O O
type NN O O
controls NN O O
. NN O O

Allele NN O O
- NN O O
specific NN O O
analysis NN O O
of NN O O
DMAHP NN O O
expression NN O O
showed NN O O
that NN O O
steady NN O O
- NN O O
state NN O O
transcript NN O O
levels NN O O
from NN O O
the NN O O
expanded NN O O
allele NN O O
were NN O O
greatly NN O O
reduced NN O O
in NN O O
comparison NN O O
to NN O O
those NN O O
from NN O O
the NN O O
wild NN O O
- NN O O
type NN O O
allele NN O O
. NN O O

Together NN O O
, NN O O
these NN O O
results NN O O
demonstrate NN O O
that NN O O
CTG NN O O
- NN O O
repeat NN O O
expansions NN O O
can NN O O
suppress NN O O
local NN O O
gene NN O O
expression NN O O
and NN O O
implicate NN O O
DMAHP NN O O
in NN O O
DM NN O B-Disease
pathogenesis NN O O
. NN O O

Constitutively NN O O
methylated NN O O
CpG NN O O
dinucleotides NN O O
as NN O O
mutation NN O O
hot NN O O
spots NN O O
in NN O O
the NN O O
retinoblastoma NN O B-Disease
gene NN O O
( NN O O
RB1 NN O O
) NN O O
. NN O O

A NN O O
wide NN O O
spectrum NN O O
of NN O O
mutations NN O O
, NN O O
ranging NN O O
from NN O O
point NN O O
mutations NN O O
to NN O O
large NN O O
deletions NN O O
, NN O O
have NN O O
been NN O O
described NN O O
in NN O O
the NN O O
retinoblastoma NN O B-Disease
gene NN O O
( NN O O
RB1 NN O O
) NN O O
. NN O O

Mutations NN O O
have NN O O
been NN O O
found NN O O
throughout NN O O
the NN O O
gene NN O O
; NN O O
however NN O O
, NN O O
these NN O O
genetic NN O O
alterations NN O O
do NN O O
not NN O O
appear NN O O
to NN O O
be NN O O
homogeneously NN O O
distributed NN O O
. NN O O

In NN O O
particular NN O O
, NN O O
a NN O O
significant NN O O
proportion NN O O
of NN O O
disease NN O O
- NN O O
causing NN O O
mutations NN O O
results NN O O
in NN O O
the NN O O
premature NN O O
termination NN O O
of NN O O
protein NN O O
synthesis NN O O
, NN O O
and NN O O
the NN O O
majority NN O O
of NN O O
these NN O O
mutations NN O O
occur NN O O
as NN O O
C NN O O
- NN O O
- NN O O
> NN O O
T NN O O
transitions NN O O
at NN O O
CpG NN O O
dinucleotides NN O O
( NN O O
CpGs NN O O
) NN O O
. NN O O

Such NN O O
recurrent NN O O
CpG NN O O
mutations NN O O
, NN O O
including NN O O
those NN O O
found NN O O
in NN O O
RB1 NN O O
, NN O O
are NN O O
likely NN O O
the NN O O
result NN O O
of NN O O
the NN O O
deamination NN O O
of NN O O
5 NN O O
- NN O O
methylcytosine NN O O
within NN O O
these NN O O
CpGs NN O O
. NN O O

In NN O O
the NN O O
present NN O O
study NN O O
, NN O O
we NN O O
used NN O O
the NN O O
sodiumbisulfite NN O O
conversion NN O O
method NN O O
to NN O O
detect NN O O
cytosine NN O O
methylation NN O O
in NN O O
representative NN O O
exons NN O O
of NN O O
RB1 NN O O
. NN O O

We NN O O
analyzed NN O O
DNA NN O O
from NN O O
a NN O O
variety NN O O
of NN O O
tissues NN O O
and NN O O
specifically NN O O
targeted NN O O
CGA NN O O
codons NN O O
in NN O O
RB1 NN O O
, NN O O
where NN O O
recurrent NN O O
premature NN O O
termination NN O O
mutations NN O O
have NN O O
been NN O O
reported NN O O
. NN O O

We NN O O
found NN O O
that NN O O
DNA NN O O
methylation NN O O
within NN O O
RB1 NN O O
exons NN O O
8 NN O O
, NN O O
14 NN O O
, NN O O
25 NN O O
, NN O O
and NN O O
27 NN O O
appeared NN O O
to NN O O
be NN O O
restricted NN O O
to NN O O
CpGs NN O O
, NN O O
including NN O O
six NN O O
CGA NN O O
codons NN O O
. NN O O

Other NN O O
codons NN O O
containing NN O O
methylated NN O O
cytosines NN O O
have NN O O
not NN O O
been NN O O
reported NN O O
to NN O O
be NN O O
mutated NN O O
. NN O O

Therefore NN O O
, NN O O
disease NN O O
- NN O O
causing NN O O
mutations NN O O
at NN O O
CpGs NN O O
in NN O O
RB1 NN O O
appear NN O O
to NN O O
be NN O O
determined NN O O
by NN O O
several NN O O
factors NN O O
, NN O O
including NN O O
the NN O O
constitutive NN O O
presence NN O O
of NN O O
DNA NN O O
methylation NN O O
at NN O O
cytosines NN O O
within NN O O
CpGs NN O O
, NN O O
the NN O O
specific NN O O
codon NN O O
within NN O O
which NN O O
the NN O O
methylated NN O O
cytosine NN O O
is NN O O
located NN O O
, NN O O
and NN O O
the NN O O
particular NN O O
region NN O O
of NN O O
the NN O O
gene NN O O
within NN O O
which NN O O
that NN O O
codon NN O O
resides NN O O
. NN O O
. NN O O

The NN O O
von NN O B-Disease
Hippel NN O I-Disease
- NN O I-Disease
Lindau NN O I-Disease
tumor NN O I-Disease
suppressor NN O O
gene NN O O
product NN O O
interacts NN O O
with NN O O
Sp1 NN O O
to NN O O
repress NN O O
vascular NN O O
endothelial NN O O
growth NN O O
factor NN O O
promoter NN O O
activity NN O O
. NN O O

The NN O O
von NN O B-Disease
Hippel NN O I-Disease
- NN O I-Disease
Lindau NN O I-Disease
tumor NN O I-Disease
suppressor NN O O
gene NN O O
( NN O O
VHL NN O O
) NN O O
has NN O O
a NN O O
critical NN O O
role NN O O
in NN O O
the NN O O
pathogenesis NN O O
of NN O O
clear NN O B-Disease
- NN O I-Disease
cell NN O I-Disease
renal NN O I-Disease
cell NN O I-Disease
carcinoma NN O I-Disease
( NN O O
RCC NN O B-Disease
) NN O O
, NN O O
as NN O O
VHL NN O O
mutations NN O O
have NN O O
been NN O O
found NN O O
in NN O O
both NN O O
von NN O B-Disease
Hippel NN O I-Disease
- NN O I-Disease
Lindau NN O I-Disease
disease NN O I-Disease
- NN O I-Disease
associated NN O I-Disease
and NN O I-Disease
sporadic NN O I-Disease
RCCs NN O I-Disease
. NN O O

Recent NN O O
studies NN O O
suggest NN O O
that NN O O
vascular NN O O
endothelial NN O O
growth NN O O
factor NN O O
( NN O O
VEGF NN O O
) NN O O
mRNA NN O O
is NN O O
upregulated NN O O
in NN O O
RCC NN O B-Disease
- NN O I-Disease
and NN O I-Disease
von NN O I-Disease
Hippel NN O I-Disease
- NN O I-Disease
Lindau NN O I-Disease
disease NN O I-Disease
- NN O I-Disease
associated NN O I-Disease
tumors NN O I-Disease
. NN O O

We NN O O
have NN O O
therefore NN O O
assessed NN O O
the NN O O
effect NN O O
of NN O O
the NN O O
VHL NN O O
gene NN O O
product NN O O
on NN O O
VEGF NN O O
expression NN O O
. NN O O

VEGF NN O O
promoter NN O O
- NN O O
luciferase NN O O
constructs NN O O
were NN O O
transiently NN O O
cotransfected NN O O
with NN O O
a NN O O
wild NN O O
- NN O O
type NN O O
VHL NN O O
( NN O O
wt NN O O
- NN O O
VHL NN O O
) NN O O
vector NN O O
in NN O O
several NN O O
cell NN O O
lines NN O O
, NN O O
including NN O O
293 NN O O
embryonic NN O O
kidney NN O O
and NN O O
RCC NN O B-Disease
cell NN O O
lines NN O O
. NN O O

wt NN O O
- NN O O
VHL NN O O
protein NN O O
inhibited NN O O
VEGF NN O O
promoter NN O O
activity NN O O
in NN O O
a NN O O
dose NN O O
- NN O O
dependent NN O O
manner NN O O
up NN O O
to NN O O
5 NN O O
- NN O O
to NN O O
10 NN O O
- NN O O
fold NN O O
. NN O O

Deletion NN O O
analysis NN O O
defined NN O O
a NN O O
144 NN O O
- NN O O
bp NN O O
region NN O O
of NN O O
the NN O O
VEGF NN O O
promoter NN O O
necessary NN O O
for NN O O
VHL NN O O
repression NN O O
. NN O O

This NN O O
VHL NN O O
- NN O O
responsive NN O O
element NN O O
is NN O O
GC NN O O
rich NN O O
and NN O O
specifically NN O O
binds NN O O
the NN O O
transcription NN O O
factor NN O O
Sp1 NN O O
in NN O O
crude NN O O
nuclear NN O O
extracts NN O O
. NN O O

In NN O O
Drosophila NN O O
cells NN O O
, NN O O
cotransfected NN O O
VHL NN O O
represses NN O O
Sp1 NN O O
- NN O O
mediated NN O O
activation NN O O
but NN O O
not NN O O
basal NN O O
activity NN O O
of NN O O
the NN O O
VEGF NN O O
promoter NN O O
. NN O O

We NN O O
next NN O O
demonstrated NN O O
in NN O O
coimmunoprecipitates NN O O
that NN O O
VHL NN O O
and NN O O
Sp1 NN O O
were NN O O
part NN O O
of NN O O
the NN O O
same NN O O
complex NN O O
and NN O O
, NN O O
by NN O O
using NN O O
a NN O O
glutathione NN O O
- NN O O
S NN O O
- NN O O
transferase NN O O
- NN O O
VHL NN O O
fusion NN O O
protein NN O O
and NN O O
purified NN O O
Sp1 NN O O
, NN O O
that NN O O
VHL NN O O
and NN O O
Sp1 NN O O
directly NN O O
interact NN O O
. NN O O

Furthermore NN O O
, NN O O
endogenous NN O O
VEGF NN O O
mRNA NN O O
levels NN O O
were NN O O
suppressed NN O O
in NN O O
permanent NN O O
RCC NN O B-Disease
cell NN O O
lines NN O O
expressing NN O O
wt NN O O
- NN O O
VHL NN O O
, NN O O
and NN O O
nuclear NN O O
run NN O O
- NN O O
on NN O O
studies NN O O
indicated NN O O
that NN O O
VHL NN O O
regulation NN O O
of NN O O
VEGF NN O O
occurs NN O O
at NN O O
least NN O O
partly NN O O
at NN O O
the NN O O
transcriptional NN O O
level NN O O
. NN O O

These NN O O
observations NN O O
support NN O O
a NN O O
new NN O O
mechanism NN O O
for NN O O
VHL NN O O
- NN O O
mediated NN O O
transcriptional NN O O
repression NN O O
via NN O O
a NN O O
direct NN O O
inhibitory NN O O
action NN O O
on NN O O
Sp1 NN O O
and NN O O
suggest NN O O
that NN O O
loss NN O O
of NN O O
Sp1 NN O O
inhibition NN O O
may NN O O
be NN O O
important NN O O
in NN O O
the NN O O
pathogenesis NN O O
of NN O O
von NN O B-Disease
Hippel NN O I-Disease
- NN O I-Disease
Lindau NN O I-Disease
disease NN O I-Disease
and NN O O
RCC NN O B-Disease
. NN O O
. NN O O

Adult NN O B-Disease
onset NN O I-Disease
globoid NN O I-Disease
cell NN O I-Disease
leukodystrophy NN O I-Disease
( NN O O
Krabbe NN O B-Disease
disease NN O I-Disease
) NN O O
: NN O O
analysis NN O O
of NN O O
galactosylceramidase NN O O
cDNA NN O O
from NN O O
four NN O O
Japanese NN O O
patients NN O O
. NN O O

We NN O O
examined NN O O
galactosylceramidase NN O O
( NN O O
GALC NN O O
) NN O O
cDNA NN O O
in NN O O
four NN O O
Japanese NN O O
patients NN O O
with NN O O
adult NN O B-Disease
onset NN O I-Disease
globoid NN O I-Disease
cell NN O I-Disease
leukodystrophy NN O I-Disease
( NN O O
Krabbe NN O B-Disease
disease NN O I-Disease
; NN O O
AO NN O B-Disease
- NN O I-Disease
GLD NN O I-Disease
) NN O O
by NN O O
polymerase NN O O
chain NN O O
reaction NN O O
/ NN O O
single NN O O
- NN O O
strand NN O O
conformation NN O O
polymorphism NN O O
( NN O O
PCR NN O O
- NN O O
SSCP NN O O
) NN O O
analysis NN O O
, NN O O
subsequent NN O O
sequence NN O O
determination NN O O
, NN O O
and NN O O
restriction NN O O
enzyme NN O O
digestion NN O O
of NN O O
PCR NN O O
products NN O O
, NN O O
initial NN O O
symptoms NN O O
were NN O O
the NN O O
onset NN O O
of NN O O
slowly NN O O
progressive NN O O
spastic NN O B-Disease
paraplegia NN O I-Disease
from NN O O
the NN O O
middle NN O O
of NN O O
the NN O O
second NN O O
decade NN O O
, NN O O
and NN O O
all NN O O
patients NN O O
had NN O O
diminished NN O B-Disease
GALC NN O I-Disease
activity NN O I-Disease
in NN O O
their NN O O
leukocytes NN O O
. NN O O

We NN O O
identified NN O O
three NN O O
missense NN O O
mutations NN O O
( NN O O
I66M NN O O
, NN O O
G270D NN O O
, NN O O
L618S NN O O
) NN O O
and NN O O
one NN O O
exon NN O O
- NN O O
6 NN O O
skipping NN O O
( NN O O
535 NN O O
- NN O O
573del NN O O
) NN O O
. NN O O

Two NN O O
of NN O O
the NN O O
patients NN O O
had NN O O
only NN O O
the NN O O
I66M NN O O
mutant NN O O
mRNA NN O O
, NN O O
and NN O O
one NN O O
only NN O O
the NN O O
G27OD NN O O
mutant NN O O
mRNA NN O O
. NN O O

The NN O O
fourth NN O O
patient NN O O
carried NN O O
a NN O O
compound NN O O
heterozygous NN O O
mutation NN O O
of NN O O
535 NN O O
- NN O O
573del NN O O
and NN O O
L618S NN O O
. NN O O

To NN O O
determine NN O O
the NN O O
enzymatic NN O O
activities NN O O
produced NN O O
by NN O O
these NN O O
mutations NN O O
, NN O O
we NN O O
constructed NN O O
mutated NN O O
GALC NN O O
cDNAs NN O O
and NN O O
expressed NN O O
them NN O O
in NN O O
COS NN O O
- NN O O
1 NN O O
cells NN O O
. NN O O

Three NN O O
mutations NN O O
, NN O O
viz NN O O
. NN O O
, NN O O
G270D NN O O
, NN O O
L618S NN O O
, NN O O
and NN O O
exon NN O O
- NN O O
6 NN O O
skipping NN O O
( NN O O
535 NN O O
- NN O O
573del NN O O
) NN O O
, NN O O
produced NN O O
diminished NN O B-Disease
GALC NN O I-Disease
activity NN O I-Disease
as NN O O
expected NN O O
. NN O O

The NN O O
I66M NN O O
mutation NN O O
in NN O O
the NN O O
wild NN O O
- NN O O
type NN O O
GALC NN O O
cDNA NN O O
( NN O O
I289 NN O O
) NN O O
had NN O O
normal NN O O
activity NN O O
, NN O O
but NN O O
when NN O O
this NN O O
mutation NN O O
and NN O O
the NN O O
V289 NN O O
polymorphism NN O O
were NN O O
introduced NN O O
into NN O O
the NN O O
same NN O O
allele NN O O
, NN O O
it NN O O
had NN O O
decreased NN O O
activity NN O O
. NN O O

Thus NN O O
, NN O O
the NN O O
combination NN O O
of NN O O
a NN O O
unique NN O O
mutation NN O O
and NN O O
polymorphism NN O O
causes NN O O
conformational NN O O
change NN O O
in NN O O
the NN O O
GALC NN O O
enzyme NN O O
, NN O O
resulting NN O O
in NN O O
low NN O O
enzymatic NN O O
activity NN O O
. NN O O

AO NN O B-Disease
- NN O I-Disease
GLD NN O I-Disease
mutations NN O O
, NN O O
including NN O O
those NN O O
found NN O O
here NN O O
, NN O O
are NN O O
located NN O O
in NN O O
the NN O O
N NN O O
- NN O O
terminus NN O O
( NN O O
I66M NN O O
, NN O O
G270D NN O O
, NN O O
535 NN O O
- NN O O
573del NN O O
) NN O O
or NN O O
C NN O O
- NN O O
terminus NN O O
( NN O O
L618S NN O O
) NN O O
of NN O O
the NN O O
GALC NN O O
enzyme NN O O
, NN O O
whereas NN O O
the NN O O
reported NN O O
mutations NN O O
in NN O O
the NN O O
infantile NN O O
form NN O O
( NN O O
IF NN O B-Disease
- NN O I-Disease
GLD NN O I-Disease
) NN O O
are NN O O
in NN O O
the NN O O
central NN O O
domain NN O O
. NN O O

This NN O O
difference NN O O
in NN O O
mutation NN O O
sites NN O O
may NN O O
affect NN O O
the NN O O
clinical NN O O
features NN O O
of NN O O
GLD NN O B-Disease
. NN O O


